data_2k4m_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2k4m _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 75.6 m95 . . . . . 0 N--CA 1.457 -0.105 0 CA-C-O 120.975 0.417 . . . . 0.0 110.457 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 23.9 t-20 -58.04 -52.74 64.29 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.354 -176.762 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.478 ' HB3' ' HD2' ' A' ' 138' ' ' TYR . 6.0 m-20 -59.14 -35.48 73.57 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.344 -179.489 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 61.6 tp -58.38 -47.63 83.25 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.331 178.481 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -61.34 -47.52 85.54 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.909 178.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.556 ' HA ' HD12 ' A' ' 30' ' ' ILE . 58.0 t -58.13 -43.97 86.55 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.162 0 CA-C-O 120.955 0.407 . . . . 0.0 110.83 179.82 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 68.4 t80 -56.0 -47.47 77.68 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.736 -0.665 . . . . 0.0 110.487 178.819 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.502 HG21 HD11 ' A' ' 92' ' ' LEU . 77.6 mt -63.37 -42.63 97.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.731 179.022 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.556 HD12 ' HA ' ' A' ' 27' ' ' VAL . 83.1 mt -56.26 -44.23 78.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.482 -0.781 . . . . 0.0 111.05 178.39 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . 0.465 ' HG3' ' O ' ' A' ' 27' ' ' VAL . 81.8 mtp180 -70.29 -30.34 67.31 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.959 -177.354 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 74.3 m -75.58 -29.89 59.46 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.213 -178.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 22.3 p -112.67 -97.4 0.43 Allowed 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.532 -0.303 . . . . 0.0 111.336 -178.876 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 113.81 -178.96 18.66 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.993 -0.622 . . . . 0.0 112.037 -178.03 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 10.6 Cg_exo -71.05 150.36 60.21 Favored 'Trans proline' 0 C--O 1.234 0.292 0 C-N-CA 122.932 2.421 . . . . 0.0 112.222 -179.412 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 84.93 41.94 7.38 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.831 -0.699 . . . . 0.0 112.86 179.257 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 14.6 t -168.65 -178.64 3.51 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 177.137 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 66.9 mtp85 -114.67 136.08 53.45 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 120.711 0.291 . . . . 0.0 111.082 -178.433 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.888 ' HB ' HD22 ' A' ' 62' ' ' LEU . 40.2 t -124.06 132.11 71.86 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 N-CA-C 108.914 -0.772 . . . . 0.0 108.914 173.47 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.414 HG11 ' CD1' ' A' ' 87' ' ' TYR . 62.0 t -105.79 124.22 60.76 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 C-N-CA 120.87 -0.332 . . . . 0.0 111.246 -175.939 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . 0.4 ' OE1' HD23 ' A' ' 64' ' ' LEU . 44.9 tt0 -103.59 109.47 21.16 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.931 -0.577 . . . . 0.0 109.852 176.583 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.539 HG13 HD22 ' A' ' 106' ' ' LEU . 47.0 t -96.65 132.99 39.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 115.947 -0.569 . . . . 0.0 109.954 179.707 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 87.12 20.48 52.81 Favored Glycine 0 N--CA 1.447 -0.613 0 C-N-CA 120.474 -0.87 . . . . 0.0 111.811 -178.637 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . 0.438 ' HB3' ' CD2' ' A' ' 48' ' ' LEU . . . -55.81 -68.0 0.24 Allowed 'General case' 0 C--N 1.331 -0.201 0 O-C-N 123.744 0.32 . . . . 0.0 110.253 178.695 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 58.22 -93.05 0.04 OUTLIER Glycine 0 N--CA 1.452 -0.284 0 CA-C-N 115.572 -0.74 . . . . 0.0 114.1 173.06 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . 0.427 HH11 ' HD3' ' A' ' 46' ' ' ARG . 32.7 ttt-85 -126.58 11.24 7.32 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 121.351 0.596 . . . . 0.0 110.571 -172.181 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 59.0 t80 -133.04 97.96 4.15 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 109.529 -0.545 . . . . 0.0 109.529 178.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . 0.708 HD21 HD11 ' A' ' 64' ' ' LEU . 67.1 mt -113.4 24.37 12.3 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.952 -172.278 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 56.8 t80 -64.65 -50.86 65.42 Favored 'General case' 0 C--N 1.329 -0.292 0 C-N-CA 120.928 -0.309 . . . . 0.0 111.781 -176.908 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.476 ' O ' HG13 ' A' ' 54' ' ' ILE . 44.1 t -60.92 -55.47 24.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.559 -0.291 . . . . 0.0 111.011 -173.013 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 10.9 p -56.93 -43.12 81.17 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.975 179.538 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.457 ' HA ' ' HG2' ' A' ' 55' ' ' ARG . 36.7 t70 -64.99 -42.88 94.12 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.728 0.299 . . . . 0.0 110.905 -179.466 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 74.6 t80 -61.11 -42.02 97.75 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.062 0.458 . . . . 0.0 110.341 177.281 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.518 HG22 HG12 ' A' ' 30' ' ' ILE . 86.3 mt -64.61 -49.13 81.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.294 179.21 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' ARG . . . . . 0.457 ' HG2' ' HA ' ' A' ' 52' ' ' ASP . 40.8 ptt180 -67.96 -18.74 64.83 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-O 120.862 0.363 . . . . 0.0 111.401 -176.05 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 84.6 mttt -84.51 -34.11 23.39 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.828 0.346 . . . . 0.0 110.971 176.104 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.6 OUTLIER -79.85 -33.6 40.05 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.253 178.76 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 70.6 m -141.78 135.95 30.2 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.5 178.063 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 7.6 tmtt? -76.15 64.77 2.03 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.888 0.852 . . . . 0.0 109.378 176.755 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.503 HG22 HG22 ' A' ' 39' ' ' VAL . 8.3 p -95.18 148.2 5.27 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.964 0 CA-C-N 114.727 -1.124 . . . . 0.0 109.118 173.834 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 25.9 t0 -78.91 88.58 4.71 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 121.34 0.59 . . . . 0.0 109.437 -179.808 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . 0.888 HD22 ' HB ' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -82.99 115.12 21.69 Favored 'General case' 0 N--CA 1.448 -0.549 0 CA-C-N 115.532 -0.758 . . . . 0.0 110.1 -177.578 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 45.3 t -103.56 114.73 43.96 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-N 115.462 -0.79 . . . . 0.0 110.081 -177.54 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . 0.708 HD11 HD21 ' A' ' 48' ' ' LEU . 20.1 mt -91.61 135.95 33.49 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-N 115.671 -0.695 . . . . 0.0 109.607 -179.696 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 14.5 p -130.76 128.96 41.83 Favored 'General case' 0 C--N 1.319 -0.723 0 C-N-CA 121.045 -0.262 . . . . 0.0 111.271 -179.074 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 5.8 t70 -171.0 155.34 4.45 Favored 'General case' 0 CA--C 1.519 -0.246 0 N-CA-C 109.371 -0.603 . . . . 0.0 109.371 175.839 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . 0.608 HG23 ' HG2' ' A' ' 68' ' ' LYS . 58.1 mt -78.1 131.2 35.06 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 CA-C-N 116.642 -0.254 . . . . 0.0 110.606 -177.942 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' LYS . . . . . 0.608 ' HG2' HG23 ' A' ' 67' ' ' ILE . 7.9 ptmm? 42.31 71.73 1.31 Allowed Pre-proline 0 N--CA 1.471 0.586 0 O-C-N 124.152 0.908 . . . . 0.0 112.915 179.265 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo . . . . . 0 N--CA 1.463 -0.319 0 C-N-CA 122.549 2.166 . . . . 0.0 112.168 177.768 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . 0.653 ' HA ' ' HB2' ' A' ' 64' ' ' LEU . 50.6 mt . . . . . 0 N--CA 1.452 -0.35 0 CA-C-O 120.574 0.226 . . . . 0.0 110.441 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.416 HG11 HD11 ' A' ' 86' ' ' ILE . 61.5 t -64.45 116.91 4.29 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 N-CA-C 109.631 -0.507 . . . . 0.0 109.631 176.875 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 16.2 mtt180 -84.48 53.69 2.75 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.679 -0.692 . . . . 0.0 110.432 -175.417 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 2.0 t70 -98.83 -162.36 0.95 Allowed 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 116.307 -0.406 . . . . 0.0 109.972 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' ASP . . . . . 0.494 ' OD1' HG21 ' A' ' 80' ' ' THR . 11.8 t0 -119.38 146.17 45.57 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 120.773 0.321 . . . . 0.0 111.251 -175.475 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' ILE . . . . . 0.539 HG22 HD11 ' A' ' 67' ' ' ILE . 10.7 tp -107.96 -20.59 6.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.292 -176.266 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.494 HG21 ' OD1' ' A' ' 78' ' ' ASP . 13.3 t -79.82 -25.06 40.97 Favored 'General case' 0 CA--C 1.529 0.167 0 CA-C-O 121.616 0.722 . . . . 0.0 109.322 178.913 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 23.2 m -132.54 79.86 63.83 Favored Pre-proline 0 C--N 1.322 -0.613 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 166.048 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' PRO . . . . . 0.405 ' HA ' ' O ' ' A' ' 78' ' ' ASP . 74.2 Cg_endo -74.97 146.15 32.44 Favored 'Trans proline' 0 N--CA 1.462 -0.364 0 C-N-CA 122.799 2.332 . . . . 0.0 112.991 -171.954 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' ARG . . . . . 0.508 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 82.9 mtt180 -94.58 107.92 19.89 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.542 -0.754 . . . . 0.0 110.22 175.845 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' MET . . . . . 0.54 ' HA ' ' HD2' ' A' ' 87' ' ' TYR . 95.3 mmm -59.56 -24.41 63.71 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.587 -0.733 . . . . 0.0 111.571 -176.087 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . 0.508 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 9.4 pt-20 -55.45 -29.56 58.89 Favored 'General case' 0 C--N 1.33 -0.272 0 O-C-N 123.245 0.341 . . . . 0.0 111.415 179.465 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.416 HD11 HG11 ' A' ' 75' ' ' VAL . 64.9 mt -78.52 -35.59 19.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.81 -178.403 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . 0.54 ' HD2' ' HA ' ' A' ' 84' ' ' MET . 49.4 m-85 -85.86 -25.86 25.98 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.209 -175.327 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . 0.609 ' HG2' HG11 ' A' ' 113' ' ' VAL . 81.6 mtp180 -70.35 138.29 51.29 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 121.36 0.6 . . . . 0.0 110.666 -178.553 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 92.92 -1.19 70.51 Favored Glycine 0 C--N 1.317 -0.478 0 CA-C-N 115.11 -0.95 . . . . 0.0 111.993 -176.652 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -86.7 147.64 25.79 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.905 0.383 . . . . 0.0 110.664 178.596 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -91.05 -27.08 18.84 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.801 179.306 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . 0.502 HD11 HG21 ' A' ' 29' ' ' ILE . 6.2 tt -152.35 143.24 22.99 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.143 -177.935 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.564 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 72.3 mt -131.46 122.74 51.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 N-CA-C 109.473 -0.566 . . . . 0.0 109.473 178.547 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 15.1 p90 -129.77 157.89 40.93 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 120.917 0.389 . . . . 0.0 110.883 -178.691 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' SER . . . . . 0.47 ' HA ' ' O ' ' A' ' 42' ' ' VAL . 16.5 m -128.04 128.37 44.85 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.958 -0.564 . . . . 0.0 110.974 -176.731 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 50.6 mm -91.71 106.67 17.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.437 -179.806 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 11.1 tpp180 57.06 69.87 1.55 Allowed Pre-proline 0 CA--C 1.535 0.389 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.071 178.821 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' PRO . . . . . 0.538 ' HG2' HG23 ' A' ' 119' ' ' ILE . 5.6 Cg_endo -87.05 135.69 3.95 Favored 'Trans proline' 0 N--CA 1.455 -0.762 0 C-N-CA 122.799 2.332 . . . . 0.0 112.31 -179.09 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . 0.537 ' HD2' HD12 ' A' ' 102' ' ' ILE . 32.3 Cg_exo -59.12 142.51 99.38 Favored 'Trans proline' 0 C--O 1.236 0.411 0 C-N-CA 122.464 2.11 . . . . 0.0 111.7 174.627 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -76.97 43.01 0.33 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.763 -176.092 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 101' ' ' GLU . . . . . 0.487 ' HG3' HG23 ' A' ' 102' ' ' ILE . 12.0 pt-20 -140.27 -34.45 0.53 Allowed 'General case' 0 N--CA 1.45 -0.472 0 CA-C-N 115.902 -0.59 . . . . 0.0 111.541 178.797 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.537 HD12 ' HD2' ' A' ' 99' ' ' PRO . 45.8 pt -95.56 -0.78 10.62 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.211 0 CA-C-O 120.837 0.351 . . . . 0.0 111.597 -176.53 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 103' ' ' HIS . . . . . 0.531 ' O ' ' HG3' ' A' ' 107' ' ' MET . 41.8 p-80 -55.92 -36.93 68.25 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.932 -0.576 . . . . 0.0 111.303 -178.863 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 6.7 m -60.93 -39.32 88.97 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.0 -179.4 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.559 ' O ' HG23 ' A' ' 109' ' ' VAL . 14.2 m -66.58 -35.37 80.05 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.976 -0.556 . . . . 0.0 109.88 -179.752 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . 0.539 HD22 HG13 ' A' ' 42' ' ' VAL . 96.3 mt -69.91 -41.06 75.19 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.704 -0.68 . . . . 0.0 111.138 -179.676 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 107' ' ' MET . . . . . 0.682 ' HE2' ' HB2' ' A' ' 132' ' ' LYS . 70.0 mtp -62.5 -42.37 99.45 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.813 -0.63 . . . . 0.0 111.487 -177.24 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 14.1 ptm180 -69.54 -29.87 67.56 Favored 'General case' 0 C--N 1.33 -0.261 0 C-N-CA 120.762 -0.375 . . . . 0.0 111.158 -179.572 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.559 HG23 ' O ' ' A' ' 105' ' ' SER . 75.4 t -66.75 -48.69 79.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 C-N-CA 120.933 -0.307 . . . . 0.0 110.56 178.399 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -57.55 -46.25 84.15 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.262 177.676 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . 0.537 ' HA ' ' HB3' ' A' ' 148' ' ' ALA . 12.3 t70 -63.43 -34.37 77.59 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.553 -0.749 . . . . 0.0 110.729 -177.868 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -70.31 -46.97 63.19 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.801 -0.636 . . . . 0.0 111.797 -179.773 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.609 HG11 ' HG2' ' A' ' 88' ' ' ARG . 23.1 m -84.95 -26.28 6.76 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-N 116.416 -0.356 . . . . 0.0 111.811 -173.769 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 89.67 43.18 5.23 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.092 179.468 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -124.1 154.34 40.12 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.668 0.27 . . . . 0.0 110.503 -178.524 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 116' ' ' ARG . . . . . 0.449 ' HD3' ' OE1' ' A' ' 145' ' ' GLU . 14.5 ttm180 -73.95 124.48 26.27 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 178.13 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . 0.564 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 56.1 tp -93.46 121.39 34.81 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.246 -0.434 . . . . 0.0 109.977 178.562 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 67.8 mt -119.12 120.18 63.1 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 CA-C-O 121.321 0.581 . . . . 0.0 110.907 179.435 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 119' ' ' ILE . . . . . 0.538 HG23 ' HG2' ' A' ' 98' ' ' PRO . 14.2 mt -112.68 130.6 66.16 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.674 178.874 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 2.6 tmtm? -106.34 94.71 10.16 Favored Pre-proline 0 C--N 1.323 -0.545 0 N-CA-C 109.287 -0.634 . . . . 0.0 109.287 174.926 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 91.1 Cg_endo -85.67 -162.69 0.16 Allowed 'Trans proline' 0 N--CA 1.46 -0.464 0 C-N-CA 122.749 2.299 . . . . 0.0 112.588 -179.539 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 122' ' ' LEU . . . . . 0.908 ' HB2' ' HB3' ' A' ' 125' ' ' GLU . 9.9 mp -86.15 159.57 19.48 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.45 179.681 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 4.0 p -64.13 -33.72 76.42 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.915 -0.584 . . . . 0.0 111.617 -178.529 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -132.18 43.74 1.26 Allowed Glycine 0 N--CA 1.447 -0.579 0 C-N-CA 120.935 -0.65 . . . . 0.0 112.135 179.824 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . 0.908 ' HB3' ' HB2' ' A' ' 122' ' ' LEU . 34.3 tt0 -145.32 129.23 17.39 Favored 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 110.044 -0.354 . . . . 0.0 110.044 179.274 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -85.41 167.59 15.38 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.605 -175.902 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 35.7 mt . . . . . 0 C--N 1.326 -0.455 0 CA-C-O 121.084 0.469 . . . . 0.0 110.218 -178.513 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 132' ' ' LYS . . . . . 0.682 ' HB2' ' HE2' ' A' ' 107' ' ' MET . 28.1 mmmt . . . . . 0 N--CA 1.453 -0.29 0 CA-C-O 121.0 0.429 . . . . 0.0 110.462 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 133' ' ' MET . . . . . . . . . . . . . 75.9 mtp -90.83 156.9 17.69 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.055 -0.521 . . . . 0.0 111.014 -175.525 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 16.1 ptmt -120.54 141.11 50.55 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 115.535 -0.757 . . . . 0.0 110.93 -175.582 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . 0.431 HD12 ' HD2' ' A' ' 142' ' ' TYR . 51.2 tp -83.12 120.65 26.03 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.108 178.042 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -119.19 146.01 24.48 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.743 -178.114 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 8.3 m120 -118.84 119.24 33.8 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.535 -0.543 . . . . 0.0 109.535 -179.233 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . 0.478 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 40.6 t80 -123.52 117.42 25.05 Favored 'General case' 0 C--N 1.321 -0.641 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 178.511 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 70.34 -87.29 0.33 Allowed Glycine 0 N--CA 1.443 -0.865 0 CA-C-N 115.604 -0.725 . . . . 0.0 111.43 -175.546 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 14.2 tpp180 -139.1 -13.09 1.21 Allowed 'General case' 0 C--N 1.317 -0.83 0 CA-C-O 121.259 0.552 . . . . 0.0 110.241 -179.147 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 5.8 t -97.99 141.17 31.29 Favored 'General case' 0 N--CA 1.448 -0.538 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.261 -176.608 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 142' ' ' TYR . . . . . 0.431 ' HD2' HD12 ' A' ' 135' ' ' LEU . 52.0 p90 -118.88 147.12 44.32 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 121.117 0.484 . . . . 0.0 110.545 177.432 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 15.2 p90 -155.24 -176.97 6.21 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.322 -0.854 . . . . 0.0 109.778 -176.292 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 31.7 m-85 -115.32 125.49 53.31 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-O 120.454 0.168 . . . . 0.0 110.76 179.699 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 145' ' ' GLU . . . . . 0.449 ' OE1' ' HD3' ' A' ' 116' ' ' ARG . 15.5 pt-20 -114.72 160.0 19.89 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 121.081 0.467 . . . . 0.0 109.813 175.847 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 26.4 t80 -143.87 122.18 12.32 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-N 115.714 -0.675 . . . . 0.0 109.566 175.158 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 147' ' ' ILE . . . . . 0.425 ' N ' HD12 ' A' ' 147' ' ' ILE . 3.2 mp -90.31 102.34 13.19 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 -178.973 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . 0.537 ' HB3' ' HA ' ' A' ' 111' ' ' ASP . . . -72.53 114.17 10.37 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.839 -0.619 . . . . 0.0 109.903 177.381 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 8.1 pt-20 . . . . . 0 C--N 1.322 -0.62 0 CA-C-O 121.332 0.586 . . . . 0.0 110.886 -176.348 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' TRP . . . . . 0.411 ' HB3' HG22 ' A' ' 50' ' ' VAL . 50.2 m95 . . . . . 0 N--CA 1.454 -0.268 0 CA-C-O 120.884 0.373 . . . . 0.0 110.286 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 25.8 t-20 -72.57 -43.32 63.58 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.98 -0.555 . . . . 0.0 109.691 177.801 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 42.5 m-20 -57.42 -51.03 71.07 Favored 'General case' 0 N--CA 1.463 0.205 0 CA-C-N 115.949 -0.568 . . . . 0.0 109.712 176.927 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.406 ' O ' HG13 ' A' ' 29' ' ' ILE . 58.2 tp -55.01 -47.78 74.22 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.44 -0.8 . . . . 0.0 110.954 179.035 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -55.3 -52.11 64.53 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.223 179.763 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.487 ' HA ' HD11 ' A' ' 30' ' ' ILE . 98.4 t -59.51 -40.51 82.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.975 -179.523 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 84.9 t80 -60.11 -43.54 95.53 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.494 178.428 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.406 HG13 ' O ' ' A' ' 25' ' ' LEU . 82.6 mt -64.84 -43.67 96.36 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.595 177.909 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.635 HG12 HG21 ' A' ' 54' ' ' ILE . 85.8 mt -56.75 -38.84 60.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.901 178.206 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 32.8 mtp85 -70.62 -35.13 72.78 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.082 179.852 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 78.9 m -87.61 0.79 55.15 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.674 -174.047 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 15.5 p -122.01 -71.73 0.72 Allowed 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 120.977 0.418 . . . . 0.0 111.175 178.026 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 97.38 145.23 18.71 Favored Glycine 0 N--CA 1.446 -0.666 0 C-N-CA 120.804 -0.712 . . . . 0.0 111.586 -177.895 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -59.18 130.55 36.7 Favored 'Trans proline' 0 C--O 1.233 0.266 0 C-N-CA 122.852 2.368 . . . . 0.0 112.671 -177.433 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 105.37 24.97 6.87 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.467 -0.873 . . . . 0.0 112.978 177.474 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 13.8 t -131.71 -171.55 2.64 Favored 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 177.312 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -119.35 131.47 55.7 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 120.897 0.379 . . . . 0.0 110.433 177.866 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.422 ' O ' ' HA ' ' A' ' 62' ' ' LEU . 95.9 t -128.14 130.44 69.62 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 176.578 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 46.5 t -107.21 126.04 63.36 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.674 0 CA-C-O 120.91 0.386 . . . . 0.0 111.036 -176.38 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . 0.404 ' HB3' HD21 ' A' ' 64' ' ' LEU . 39.2 tt0 -104.18 114.82 29.32 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.686 175.841 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 62.1 t -98.13 125.75 51.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.691 -177.668 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 88.03 28.66 22.63 Favored Glycine 0 N--CA 1.452 -0.261 0 CA-C-N 115.989 -0.551 . . . . 0.0 112.015 179.603 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . 0.417 ' HB3' ' CD2' ' A' ' 48' ' ' LEU . . . -55.79 -76.58 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.35 0 C-N-CA 123.045 0.538 . . . . 0.0 112.356 -176.503 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 64.09 -102.04 0.55 Allowed Glycine 0 CA--C 1.519 0.301 0 C-N-CA 121.185 -0.531 . . . . 0.0 113.188 179.408 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -107.59 -1.89 20.79 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.655 0.264 . . . . 0.0 111.547 -178.082 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.838 ' HD1' ' HH ' ' A' ' 49' ' ' TYR . 99.4 m-85 -87.72 23.56 1.96 Allowed 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.933 0.397 . . . . 0.0 111.408 -174.957 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . 0.758 HD21 HD12 ' A' ' 64' ' ' LEU . 37.8 mt -66.42 -7.74 21.29 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.691 -0.686 . . . . 0.0 112.831 -172.928 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . 0.838 ' HH ' ' HD1' ' A' ' 47' ' ' PHE . 23.4 p90 -62.0 -25.72 67.81 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.576 0.227 . . . . 0.0 111.361 -179.905 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.411 HG22 ' HB3' ' A' ' 22' ' ' TRP . 61.9 t -74.24 -54.88 13.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.924 0.393 . . . . 0.0 110.381 175.935 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -66.22 -40.13 90.08 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.9 -0.591 . . . . 0.0 112.294 -177.21 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.554 ' O ' ' HG2' ' A' ' 56' ' ' LYS . 38.7 t70 -67.23 -27.75 67.49 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.863 0.363 . . . . 0.0 110.502 -178.688 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 78.5 t80 -69.53 -41.88 75.38 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.892 0.377 . . . . 0.0 110.293 176.014 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.635 HG21 HG12 ' A' ' 30' ' ' ILE . 77.1 mt -63.65 -40.7 90.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 115.946 -0.57 . . . . 0.0 111.231 -178.493 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' ARG . . . . . 0.507 ' HG2' ' HA ' ' A' ' 52' ' ' ASP . 5.8 ptp180 -70.11 -16.57 63.13 Favored 'General case' 0 CA--C 1.534 0.365 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.985 -176.492 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . 0.554 ' HG2' ' O ' ' A' ' 52' ' ' ASP . 67.1 mmtt -72.17 -42.86 65.4 Favored 'General case' 0 N--CA 1.462 0.143 0 CA-C-O 121.186 0.517 . . . . 0.0 110.377 179.645 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 45.4 m-70 -92.36 -46.87 7.47 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.48 -0.782 . . . . 0.0 111.884 -173.002 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' SER . . . . . 0.454 ' HB2' HG21 ' A' ' 60' ' ' VAL . 12.0 p -112.3 134.18 53.99 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 116.609 -0.269 . . . . 0.0 111.163 -176.798 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 25.4 tptp -80.24 65.85 5.53 Favored 'General case' 0 N--CA 1.448 -0.541 0 CA-C-O 122.246 1.022 . . . . 0.0 109.612 174.532 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.454 HG21 ' HB2' ' A' ' 58' ' ' SER . 92.3 t -98.39 130.86 46.58 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.192 0 CA-C-N 114.4 -1.273 . . . . 0.0 109.113 172.662 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 62.2 m-20 -75.67 86.56 2.72 Favored 'General case' 0 C--N 1.317 -0.83 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 178.981 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . 0.422 ' HA ' ' O ' ' A' ' 39' ' ' VAL . 2.8 tt -87.02 115.55 24.48 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 115.45 -0.796 . . . . 0.0 109.933 -177.054 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 48.0 t -97.54 119.16 45.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.055 -177.252 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . 0.758 HD12 HD21 ' A' ' 48' ' ' LEU . 39.2 mt -92.85 121.54 34.33 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-N 115.913 -0.585 . . . . 0.0 109.762 179.102 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 19.4 p -121.74 124.89 45.29 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-O 121.054 0.454 . . . . 0.0 110.485 178.903 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 27.3 t0 -160.72 152.29 19.49 Favored 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 109.612 -0.514 . . . . 0.0 109.612 -179.294 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . 0.675 HG12 ' HA ' ' A' ' 78' ' ' ASP . 49.6 mt -73.12 108.9 4.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 N-CA-C 110.124 -0.325 . . . . 0.0 110.124 -177.935 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' LYS . . . . . 0.434 ' HA ' ' HD2' ' A' ' 69' ' ' PRO . 45.3 mtpt 65.2 88.86 0.11 Allowed Pre-proline 0 C--N 1.328 -0.365 0 CA-C-N 115.157 -0.929 . . . . 0.0 110.627 -178.963 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . 0.746 ' HB3' ' HB ' ' A' ' 74' ' ' ILE . 11.0 Cg_endo . . . . . 0 C--N 1.343 0.27 0 C-N-CA 123.558 2.839 . . . . 0.0 113.229 -177.498 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . 0.746 ' HB ' ' HB3' ' A' ' 69' ' ' PRO . 53.3 mt . . . . . 0 N--CA 1.453 -0.307 0 N-CA-C 110.124 -0.324 . . . . 0.0 110.124 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 45.3 t -78.48 135.84 25.19 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.716 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 177.089 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' ARG . . . . . 0.518 ' HA ' ' HD3' ' A' ' 69' ' ' PRO . 3.3 ptm180 -79.92 25.24 0.37 Allowed 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.638 -0.256 . . . . 0.0 111.389 -176.441 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 38.2 t70 -64.59 103.8 0.72 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.37 0.605 . . . . 0.0 110.277 -177.192 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' ASP . . . . . 0.675 ' HA ' HG12 ' A' ' 67' ' ' ILE . 3.3 m-20 -68.25 123.46 20.79 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.241 -0.89 . . . . 0.0 110.201 -176.335 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 10.6 tp -64.08 -19.02 23.81 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.48 0 CA-C-O 121.132 0.492 . . . . 0.0 111.066 179.665 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 10.2 t -77.45 -14.81 59.61 Favored 'General case' 0 CA--C 1.532 0.288 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.784 178.431 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 33.6 t -158.68 70.53 3.69 Favored Pre-proline 0 C--N 1.326 -0.424 0 N-CA-C 108.353 -0.981 . . . . 0.0 108.353 177.593 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 90.0 Cg_endo -88.24 162.09 7.01 Favored 'Trans proline' 0 N--CA 1.458 -0.615 0 C-N-CA 122.956 2.437 . . . . 0.0 113.591 -168.56 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' ARG . . . . . 0.823 ' HB2' HD11 ' A' ' 86' ' ' ILE . 3.9 mmt180 -98.24 107.68 20.21 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 115.58 -0.736 . . . . 0.0 111.095 175.825 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' MET . . . . . 0.505 ' O ' ' HG3' ' A' ' 88' ' ' ARG . 91.0 mmm -62.17 -23.65 66.72 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.278 177.276 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . 0.413 ' OE2' ' HD2' ' A' ' 83' ' ' ARG . 11.0 pt-20 -69.55 -22.58 63.54 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.638 -178.189 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.823 HD11 ' HB2' ' A' ' 83' ' ' ARG . 95.6 mt -81.04 -36.08 14.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.204 178.342 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 22.8 m-85 -77.76 -31.21 51.92 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.72 -179.369 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . 0.505 ' HG3' ' O ' ' A' ' 84' ' ' MET . 38.2 mtp180 -63.67 123.08 17.94 Favored 'General case' 0 CA--C 1.516 -0.361 0 CA-C-O 121.331 0.586 . . . . 0.0 111.024 179.837 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 109.99 -9.5 31.71 Favored Glycine 0 N--CA 1.446 -0.639 0 CA-C-N 115.321 -0.854 . . . . 0.0 111.706 -178.506 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -81.93 143.8 31.39 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 110.349 -0.241 . . . . 0.0 110.349 178.389 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -92.89 -19.88 21.23 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 121.063 0.458 . . . . 0.0 110.627 -179.881 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . 0.453 HD23 ' N ' ' A' ' 93' ' ' ILE . 3.2 tt -152.09 140.66 20.73 Favored 'General case' 0 N--CA 1.449 -0.487 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.625 -179.062 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.457 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 72.3 mt -132.28 126.91 56.57 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 115.934 -0.576 . . . . 0.0 109.569 178.486 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 8.1 p90 -134.7 162.84 31.21 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 120.812 0.339 . . . . 0.0 110.688 178.563 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 6.8 p -141.97 143.16 33.08 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.1 -176.392 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' ILE . . . . . 0.44 HG23 ' CG ' ' A' ' 47' ' ' PHE . 40.5 mm -90.47 93.11 4.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.632 179.675 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' ARG . . . . . 0.442 ' HG2' ' HA ' ' A' ' 121' ' ' PRO . 1.2 tmm_? 49.44 80.86 0.28 Allowed Pre-proline 0 N--CA 1.464 0.261 0 CA-C-N 115.18 -0.918 . . . . 0.0 111.757 178.552 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' PRO . . . . . 0.507 ' HG2' ' CD2' ' A' ' 103' ' ' HIS . 98.8 Cg_endo -84.98 152.32 11.11 Favored 'Trans proline' 0 N--CA 1.457 -0.63 0 C-N-CA 122.556 2.17 . . . . 0.0 111.874 176.195 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . 0.563 ' HD2' HD12 ' A' ' 102' ' ' ILE . 24.2 Cg_exo -64.15 155.45 64.98 Favored 'Trans proline' 0 C--N 1.343 0.28 0 C-N-CA 122.857 2.371 . . . . 0.0 112.089 175.066 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . 0.633 ' HA ' ' ND1' ' A' ' 103' ' ' HIS . . . -64.17 -16.12 61.26 Favored 'General case' 0 C--N 1.33 -0.257 0 N-CA-C 112.328 0.492 . . . . 0.0 112.328 -176.195 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 101' ' ' GLU . . . . . 0.604 ' HG3' HG23 ' A' ' 102' ' ' ILE . 12.9 pt-20 -76.14 -22.25 55.67 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.781 -0.19 . . . . 0.0 111.509 -177.519 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.604 HG23 ' HG3' ' A' ' 101' ' ' GLU . 43.1 pt -114.91 3.13 7.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 N-CA-C 112.438 0.533 . . . . 0.0 112.438 -176.177 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 103' ' ' HIS . . . . . 0.633 ' ND1' ' HA ' ' A' ' 100' ' ' ALA . 41.8 m170 -58.03 -51.57 69.13 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.002 0.43 . . . . 0.0 110.428 176.92 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 8.8 m -64.46 -29.82 70.86 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.892 -0.594 . . . . 0.0 110.59 178.03 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.544 ' O ' HG23 ' A' ' 109' ' ' VAL . 3.6 m -71.11 -43.9 66.73 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.577 -178.434 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 79.5 mt -60.77 -38.92 86.87 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.818 178.63 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 107' ' ' MET . . . . . 0.426 ' HA ' HD22 ' A' ' 117' ' ' LEU . 76.3 mtp -62.19 -45.54 92.93 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.081 179.841 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 108' ' ' ARG . . . . . 0.528 ' HG2' ' O ' ' A' ' 105' ' ' SER . 12.9 ptm180 -72.01 -22.8 61.36 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.633 -0.258 . . . . 0.0 111.073 -178.26 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.544 HG23 ' O ' ' A' ' 105' ' ' SER . 70.1 t -70.39 -49.94 49.77 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 173.985 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -58.15 -45.54 87.23 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.074 -0.512 . . . . 0.0 109.88 176.67 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . 0.435 ' HA ' ' HB3' ' A' ' 148' ' ' ALA . 21.0 t70 -59.23 -36.15 74.92 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.329 -0.851 . . . . 0.0 111.372 179.387 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -71.95 -45.19 61.98 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.641 -0.709 . . . . 0.0 111.951 -179.269 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 23.2 m -86.94 -28.24 5.78 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 N-CA-C 111.996 0.369 . . . . 0.0 111.996 -174.627 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 87.92 58.96 1.73 Allowed Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.268 -178.65 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -137.47 162.29 34.07 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.752 0.311 . . . . 0.0 110.776 179.37 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 116' ' ' ARG . . . . . 0.435 ' HD3' ' OE1' ' A' ' 145' ' ' GLU . 12.5 ttm180 -79.72 120.27 23.78 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 175.857 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . 0.457 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 52.5 tp -91.99 125.79 36.82 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.089 178.895 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 65.0 mt -118.57 115.02 46.8 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-O 121.176 0.512 . . . . 0.0 110.514 176.889 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 69.8 mt -116.62 120.73 65.87 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.144 179.55 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 120' ' ' LYS . . . . . 0.439 ' HG3' ' HB3' ' A' ' 143' ' ' PHE . 12.1 ttpp -113.58 99.94 50.82 Favored Pre-proline 0 C--N 1.324 -0.525 0 C-N-CA 120.819 -0.353 . . . . 0.0 110.27 175.928 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 121' ' ' PRO . . . . . 0.442 ' HA ' ' HG2' ' A' ' 97' ' ' ARG . 98.9 Cg_endo -81.93 -153.59 0.05 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.609 0 C-N-CA 122.594 2.196 . . . . 0.0 111.079 174.305 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 122' ' ' LEU . . . . . 0.547 ' HB2' ' CG ' ' A' ' 125' ' ' GLU . 3.6 mm? -81.49 -176.98 6.31 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 175.075 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 10.0 t -79.88 1.02 28.68 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.272 0.558 . . . . 0.0 110.602 178.491 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -156.83 71.74 0.25 Allowed Glycine 0 N--CA 1.446 -0.687 0 N-CA-C 111.325 -0.71 . . . . 0.0 111.325 178.081 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . 0.547 ' CG ' ' HB2' ' A' ' 122' ' ' LEU . 9.9 mm-40 -138.01 167.93 20.76 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 109.122 -0.695 . . . . 0.0 109.122 -177.824 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 8.7 t70 -120.68 163.22 18.4 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.046 178.128 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 20.8 mt . . . . . 0 C--N 1.326 -0.441 0 CA-C-O 120.965 0.412 . . . . 0.0 110.716 -175.724 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 46.4 mtmt . . . . . 0 CA--C 1.521 -0.16 0 CA-C-O 120.802 0.334 . . . . 0.0 111.173 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 133' ' ' MET . . . . . 0.565 ' HG2' ' HB2' ' A' ' 146' ' ' TYR . 73.5 mtp -90.12 151.29 21.66 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 179.144 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . 0.753 ' HB3' ' HZ1' ' A' ' 134' ' ' LYS . 0.3 OUTLIER -121.1 143.05 49.29 Favored 'General case' 0 C--N 1.315 -0.924 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.959 -173.655 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . 0.781 HD13 ' HD2' ' A' ' 142' ' ' TYR . 43.4 tp -86.13 119.11 26.07 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.977 -0.556 . . . . 0.0 109.694 178.98 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 136' ' ' VAL . . . . . 0.441 ' CG2' ' HG2' ' A' ' 145' ' ' GLU . 0.0 OUTLIER -117.63 144.52 25.35 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.695 -176.271 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 9.8 m120 -114.96 123.77 49.95 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.41 -179.663 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 58.3 t80 -137.57 123.36 19.99 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 109.932 -0.395 . . . . 0.0 109.932 175.213 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 72.12 -85.98 0.49 Allowed Glycine 0 N--CA 1.449 -0.476 0 N-CA-C 110.838 -0.905 . . . . 0.0 110.838 -175.051 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 7.1 mtt180 -153.73 -5.55 0.18 Allowed 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 115.443 -0.378 . . . . 0.0 111.388 173.569 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 15.3 t -87.91 143.68 26.98 Favored 'General case' 0 N--CA 1.445 -0.701 0 N-CA-C 109.039 -0.726 . . . . 0.0 109.039 176.24 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 142' ' ' TYR . . . . . 0.781 ' HD2' HD13 ' A' ' 135' ' ' LEU . 48.3 p90 -127.1 129.72 48.51 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-O 121.485 0.66 . . . . 0.0 110.214 178.506 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 143' ' ' PHE . . . . . 0.439 ' HB3' ' HG3' ' A' ' 120' ' ' LYS . 9.6 p90 -139.29 175.77 9.28 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-N 114.838 -1.074 . . . . 0.0 109.962 -173.512 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 144' ' ' TYR . . . . . 0.415 ' HA ' ' O ' ' A' ' 134' ' ' LYS . 93.9 m-85 -110.72 122.51 48.0 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.317 179.889 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 145' ' ' GLU . . . . . 0.443 ' O ' ' HG2' ' A' ' 134' ' ' LYS . 19.7 pt-20 -114.68 160.42 19.37 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-O 121.155 0.503 . . . . 0.0 109.805 175.92 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . 0.565 ' HB2' ' HG2' ' A' ' 133' ' ' MET . 46.5 t80 -142.02 125.24 16.42 Favored 'General case' 0 C--N 1.313 -0.993 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.627 175.811 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 147' ' ' ILE . . . . . 0.437 ' N ' HD12 ' A' ' 147' ' ' ILE . 3.5 mp -92.89 108.67 20.63 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.792 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 179.71 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . 0.435 ' HB3' ' HA ' ' A' ' 111' ' ' ASP . . . -74.41 128.77 36.37 Favored 'General case' 0 N--CA 1.442 -0.837 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 173.983 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 19.7 mm-40 . . . . . 0 C--N 1.319 -0.735 0 CA-C-O 121.787 0.803 . . . . 0.0 112.169 -178.23 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 88.3 m95 . . . . . 0 N--CA 1.455 -0.187 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 12.8 m120 -66.06 -48.17 71.9 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.626 -0.716 . . . . 0.0 110.411 177.739 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.699 ' HB3' ' HA3' ' A' ' 139' ' ' GLY . 0.7 OUTLIER -67.51 -35.3 78.84 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.298 179.323 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.692 HD23 ' HD2' ' A' ' 120' ' ' LYS . 50.7 tp -51.79 -49.77 62.06 Favored 'General case' 0 C--O 1.231 0.131 0 CA-C-O 121.15 0.5 . . . . 0.0 109.901 173.576 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . 0.442 ' O ' HG13 ' A' ' 30' ' ' ILE . . . -60.26 -45.75 92.2 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.439 -0.8 . . . . 0.0 111.098 177.825 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 76.0 t -55.45 -43.7 73.09 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 CA-C-N 116.389 -0.369 . . . . 0.0 110.896 178.887 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . 0.446 ' HB2' ' CD2' ' A' ' 138' ' ' TYR . 54.3 t80 -59.49 -43.12 93.39 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.428 179.339 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 65.2 mt -65.68 -44.4 93.43 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.427 178.668 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.694 HG12 HG21 ' A' ' 54' ' ' ILE . 85.5 mt -57.63 -45.82 86.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.969 178.378 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 62.6 mtt180 -68.39 -28.59 67.23 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.193 0.521 . . . . 0.0 111.474 -177.74 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 74.6 m -88.84 -0.4 57.32 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.555 -178.566 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 24.3 p -128.11 -83.73 0.59 Allowed 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.805 0.336 . . . . 0.0 111.01 177.517 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 108.34 160.88 20.4 Favored Glycine 0 N--CA 1.449 -0.477 0 C-N-CA 120.975 -0.631 . . . . 0.0 112.228 -179.891 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 24.5 Cg_exo -63.14 146.0 94.02 Favored 'Trans proline' 0 C--O 1.233 0.269 0 C-N-CA 122.893 2.395 . . . . 0.0 112.178 178.877 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 94.1 -23.05 33.2 Favored Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 120.925 -0.655 . . . . 0.0 112.621 179.001 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 15.7 p -81.62 -171.85 3.54 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 -179.313 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' ARG . . . . . 1.058 ' HG3' ' HA ' ' A' ' 90' ' ' ALA . 17.5 ptm180 -131.2 130.77 43.39 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 121.036 0.446 . . . . 0.0 110.222 173.895 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.418 HG21 HG21 ' A' ' 60' ' ' VAL . 86.7 t -129.73 134.15 63.72 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 CA-C-N 115.804 -0.635 . . . . 0.0 109.351 -177.983 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.431 HG23 ' HB ' ' A' ' 63' ' ' VAL . 45.3 t -109.86 125.45 67.05 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-O 120.952 0.406 . . . . 0.0 111.433 -175.431 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 45.1 tt0 -101.64 120.53 40.48 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.927 -0.579 . . . . 0.0 109.711 175.091 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.475 ' HB ' ' OG ' ' A' ' 95' ' ' SER . 41.8 t -98.22 123.34 50.67 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.265 -179.418 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 97.37 27.31 9.33 Favored Glycine 0 N--CA 1.45 -0.43 0 N-CA-C 111.224 -0.751 . . . . 0.0 111.224 -176.777 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -85.25 76.43 10.16 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.09 0.471 . . . . 0.0 110.863 -177.814 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -111.0 -70.4 0.61 Allowed Glycine 0 N--CA 1.444 -0.807 0 C-N-CA 120.45 -0.881 . . . . 0.0 112.538 -179.421 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -119.03 11.17 12.38 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 120.694 0.283 . . . . 0.0 111.118 -175.872 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 42.2 t80 -130.0 70.75 1.43 Allowed 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 121.275 0.56 . . . . 0.0 109.93 178.519 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 82.1 mt -93.36 20.12 7.49 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.771 -178.656 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 44.9 t80 -63.54 -39.58 94.79 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.955 -177.881 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.467 ' O ' HG13 ' A' ' 54' ' ' ILE . 59.7 t -75.58 -54.4 13.96 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.546 -179.159 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 1.5 p -60.92 -46.77 89.36 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.8 -0.636 . . . . 0.0 112.638 -175.751 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.407 ' O ' ' HG2' ' A' ' 56' ' ' LYS . 38.9 t70 -63.75 -38.1 89.82 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.847 0.356 . . . . 0.0 110.393 -178.131 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 65.6 t80 -61.21 -45.62 93.83 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.376 177.78 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.694 HG21 HG12 ' A' ' 30' ' ' ILE . 83.3 mt -58.64 -48.41 85.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 115.903 -0.59 . . . . 0.0 111.465 -179.033 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 39.1 ptt180 -72.85 -16.77 61.59 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 111.776 0.287 . . . . 0.0 111.776 -175.888 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . 0.905 ' HA ' ' HE2' ' A' ' 56' ' ' LYS . 8.1 mmpt? -73.01 -41.87 63.81 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.798 0.333 . . . . 0.0 110.27 174.882 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 31.0 m-70 -84.44 -52.52 6.11 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.213 -178.837 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 10.5 p -111.65 129.42 56.09 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.153 -178.492 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -82.39 62.34 6.02 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.991 0.901 . . . . 0.0 109.745 176.146 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.418 HG21 HG21 ' A' ' 39' ' ' VAL . 2.3 p -87.43 143.92 10.31 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.935 0 CA-C-N 114.573 -1.194 . . . . 0.0 108.357 171.442 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . 0.459 ' O ' ' HA ' ' A' ' 38' ' ' ARG . 22.8 t0 -75.57 86.99 2.67 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-O 121.647 0.737 . . . . 0.0 109.427 177.706 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 1.5 tt -85.64 122.93 30.45 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.432 -0.804 . . . . 0.0 110.027 -176.208 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.431 ' HB ' HG23 ' A' ' 40' ' ' VAL . 47.6 t -103.75 118.14 50.38 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.698 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.753 -179.276 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . 0.572 ' CB ' HG22 ' A' ' 74' ' ' ILE . 77.8 mt -95.69 133.22 40.03 Favored 'General case' 0 C--N 1.315 -0.906 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.067 -179.053 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.494 HG23 ' HB ' ' A' ' 75' ' ' VAL . 23.7 p -129.61 135.01 48.04 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 120.45 0.167 . . . . 0.0 111.188 179.704 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . 0.787 ' HB3' ' HG3' ' A' ' 69' ' ' PRO . 25.3 t70 -165.25 173.61 11.1 Favored 'General case' 0 C--O 1.234 0.278 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 178.746 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . 0.512 HD13 HG21 ' A' ' 79' ' ' ILE . 39.2 mm -81.26 96.64 3.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-O 120.958 0.408 . . . . 0.0 110.78 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 70.3 mmtt 53.1 66.9 4.25 Favored Pre-proline 0 N--CA 1.467 0.407 0 CA-C-N 115.277 -0.874 . . . . 0.0 111.513 177.481 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . 0.787 ' HG3' ' HB3' ' A' ' 66' ' ' ASP . 17.1 Cg_exo . . . . . 0 C--O 1.234 0.281 0 C-N-CA 123.164 2.576 . . . . 0.0 112.172 -178.09 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . 0.572 HG22 ' CB ' ' A' ' 64' ' ' LEU . 39.7 mt . . . . . 0 C--O 1.233 0.187 0 N-CA-C 110.188 -0.301 . . . . 0.0 110.188 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.618 HG11 HD13 ' A' ' 86' ' ' ILE . 61.0 t -64.45 129.95 28.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 121.031 0.444 . . . . 0.0 110.563 -179.15 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' ARG . . . . . 0.425 HH11 ' HD2' ' A' ' 76' ' ' ARG . 5.4 ptp180 -104.12 28.97 6.29 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.655 -173.883 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . 0.436 ' H ' HG13 ' A' ' 75' ' ' VAL . 11.3 t70 -69.94 -84.74 0.03 OUTLIER 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.851 -0.613 . . . . 0.0 111.272 -172.88 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 7.5 t70 -163.24 -169.64 2.05 Favored 'General case' 0 C--N 1.325 -0.5 0 N-CA-C 109.091 -0.707 . . . . 0.0 109.091 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' ILE . . . . . 0.512 HG21 HD13 ' A' ' 67' ' ' ILE . 13.0 tt -144.19 -28.04 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-O 121.013 0.435 . . . . 0.0 110.749 -179.118 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.506 ' HA ' HG22 ' A' ' 102' ' ' ILE . 14.7 t -103.3 -24.52 13.51 Favored 'General case' 0 N--CA 1.45 -0.44 0 CA-C-O 121.288 0.566 . . . . 0.0 110.058 -178.047 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 68.0 m -150.13 75.17 9.0 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.27 172.871 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' PRO . . . . . 0.461 ' HB2' ' HE2' ' A' ' 87' ' ' TYR . 9.1 Cg_endo -89.64 174.04 3.53 Favored 'Trans proline' 0 N--CA 1.454 -0.824 0 C-N-CA 123.267 2.645 . . . . 0.0 112.887 -177.08 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' ARG . . . . . 0.663 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 81.6 mtt85 -78.3 118.01 20.09 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.152 176.663 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' MET . . . . . 0.483 ' HE2' HG11 ' A' ' 109' ' ' VAL . 91.7 mmm -61.64 -23.77 66.28 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.302 -0.863 . . . . 0.0 111.565 -178.183 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . 0.663 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 8.6 pt-20 -56.9 -29.34 62.93 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.842 0.354 . . . . 0.0 111.417 179.692 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.618 HD13 HG11 ' A' ' 75' ' ' VAL . 54.9 mt -79.28 -24.87 12.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-O 121.199 0.523 . . . . 0.0 110.858 -176.227 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . 0.461 ' HE2' ' HB2' ' A' ' 82' ' ' PRO . 91.5 m-85 -94.51 -27.67 15.85 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.934 -0.576 . . . . 0.0 111.193 -177.159 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . 0.441 ' HG3' ' O ' ' A' ' 84' ' ' MET . 78.1 mtp180 -65.77 131.46 46.37 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.509 0.671 . . . . 0.0 111.454 -176.552 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 93.17 -5.78 75.44 Favored Glycine 0 N--CA 1.448 -0.521 0 CA-C-N 114.798 -1.092 . . . . 0.0 112.36 -179.899 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . 1.058 ' HA ' ' HG3' ' A' ' 38' ' ' ARG . . . -73.6 153.39 40.22 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.888 0.375 . . . . 0.0 110.63 179.432 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -93.85 -20.72 19.79 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.807 -179.415 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . 0.509 ' HG ' ' HB3' ' A' ' 116' ' ' ARG . 3.7 tt -160.89 142.87 12.33 Favored 'General case' 0 N--CA 1.452 -0.365 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.64 -176.809 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.522 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 66.8 mt -132.31 126.72 56.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 177.188 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 19.7 p90 -137.38 160.78 38.11 Favored 'General case' 0 C--N 1.323 -0.579 0 C-N-CA 120.52 -0.472 . . . . 0.0 111.625 -178.155 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' SER . . . . . 0.475 ' OG ' ' HB ' ' A' ' 42' ' ' VAL . 15.7 m -146.5 140.52 26.25 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.777 -178.565 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' ILE . . . . . 0.409 ' N ' HD12 ' A' ' 96' ' ' ILE . 3.6 mp -99.31 97.1 5.52 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 N-CA-C 110.026 -0.361 . . . . 0.0 110.026 178.728 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' ARG . . . . . 0.587 ' HG2' ' HA ' ' A' ' 121' ' ' PRO . 42.8 mtm105 53.77 77.25 0.45 Allowed Pre-proline 0 N--CA 1.468 0.467 0 CA-C-N 115.413 -0.812 . . . . 0.0 111.825 179.612 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 95.7 Cg_endo -88.46 159.42 6.64 Favored 'Trans proline' 0 N--CA 1.459 -0.514 0 C-N-CA 122.733 2.288 . . . . 0.0 112.417 179.775 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . 0.618 ' HD2' HD12 ' A' ' 102' ' ' ILE . 51.1 Cg_exo -53.85 147.8 40.11 Favored 'Trans proline' 0 C--N 1.348 0.507 0 C-N-CA 122.92 2.414 . . . . 0.0 112.115 175.955 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -66.92 -19.74 65.78 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.712 -173.164 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 101' ' ' GLU . . . . . 0.561 ' HG3' HG23 ' A' ' 102' ' ' ILE . 11.7 pt-20 -73.34 -22.47 60.3 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.881 -177.334 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.618 HD12 ' HD2' ' A' ' 99' ' ' PRO . 44.1 pt -109.31 5.51 9.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 N-CA-C 112.505 0.557 . . . . 0.0 112.505 -174.711 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 103' ' ' HIS . . . . . . . . . . . . . 46.9 m170 -58.33 -45.22 88.51 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 120.998 0.427 . . . . 0.0 110.624 178.812 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 17.6 m -75.35 -27.79 59.33 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.518 177.31 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.514 ' O ' HG23 ' A' ' 109' ' ' VAL . 10.2 m -69.98 -45.15 67.95 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.896 -177.896 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 84.2 mt -56.78 -38.28 72.29 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.037 0.446 . . . . 0.0 110.822 178.717 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 107' ' ' MET . . . . . . . . . . . . . 52.0 ttm -68.4 -42.59 78.79 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.473 -178.92 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 108' ' ' ARG . . . . . 0.422 ' HG2' ' HA ' ' A' ' 105' ' ' SER . 2.5 ptm180 -68.71 -29.92 68.46 Favored 'General case' 0 N--CA 1.462 0.137 0 C-N-CA 120.471 -0.492 . . . . 0.0 110.482 179.482 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.514 HG23 ' O ' ' A' ' 105' ' ' SER . 74.5 t -66.12 -47.6 84.28 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.182 0 CA-C-N 116.453 -0.34 . . . . 0.0 110.274 176.165 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -57.74 -43.74 85.59 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.393 177.553 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . 0.417 ' HA ' ' HB1' ' A' ' 148' ' ' ALA . 18.7 t70 -61.83 -40.43 95.24 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.625 -0.716 . . . . 0.0 110.793 179.777 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -69.4 -39.6 77.86 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.551 -0.749 . . . . 0.0 112.059 -177.859 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.432 HG21 HD11 ' A' ' 93' ' ' ILE . 15.8 m -92.39 -27.42 4.7 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 116.552 -0.294 . . . . 0.0 111.709 -174.556 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 86.47 51.56 3.45 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.827 -0.701 . . . . 0.0 112.535 -179.782 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . 0.425 ' O ' ' HB2' ' A' ' 148' ' ' ALA . . . -131.67 165.55 23.46 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.064 0.459 . . . . 0.0 111.162 -178.683 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 116' ' ' ARG . . . . . 0.509 ' HB3' ' HG ' ' A' ' 92' ' ' LEU . 15.3 ttm180 -81.87 128.74 34.35 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.037 176.485 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . 0.522 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 49.8 tp -99.18 127.85 45.22 Favored 'General case' 0 C--N 1.32 -0.704 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 177.859 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 72.4 mt -128.25 125.51 64.34 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-O 120.903 0.382 . . . . 0.0 110.591 179.347 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 61.4 mt -130.27 130.45 65.56 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-O 120.811 0.339 . . . . 0.0 110.263 178.051 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 120' ' ' LYS . . . . . 0.692 ' HD2' HD23 ' A' ' 25' ' ' LEU . 49.9 tttm -116.16 94.23 41.4 Favored Pre-proline 0 C--N 1.324 -0.51 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.227 179.176 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 121' ' ' PRO . . . . . 0.587 ' HA ' ' HG2' ' A' ' 97' ' ' ARG . 89.1 Cg_endo -89.98 -159.7 0.09 OUTLIER 'Trans proline' 0 N--CA 1.459 -0.532 0 C-N-CA 122.799 2.333 . . . . 0.0 112.694 178.101 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 122' ' ' LEU . . . . . 0.511 ' HB3' ' HB3' ' A' ' 125' ' ' GLU . 11.9 tp -76.0 164.2 26.4 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.525 -0.762 . . . . 0.0 110.354 177.365 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 11.4 t -72.73 -28.58 62.73 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.008 0.432 . . . . 0.0 110.366 178.854 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -109.34 44.56 1.47 Allowed Glycine 0 N--CA 1.449 -0.469 0 N-CA-C 110.967 -0.853 . . . . 0.0 110.967 177.105 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . 0.511 ' HB3' ' HB3' ' A' ' 122' ' ' LEU . 31.8 tt0 -147.72 139.25 23.81 Favored 'General case' 0 C--N 1.321 -0.667 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 -174.539 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 17.2 t70 -118.82 161.7 19.7 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 121.068 0.461 . . . . 0.0 111.076 -178.667 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 60.7 mt . . . . . 0 C--N 1.319 -0.717 0 CA-C-N 115.353 -0.839 . . . . 0.0 109.311 177.606 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 132' ' ' LYS . . . . . 0.425 ' HG2' ' N ' ' A' ' 133' ' ' MET . 0.0 OUTLIER . . . . . 0 N--CA 1.465 0.303 0 CA-C-O 121.614 0.721 . . . . 0.0 111.898 . . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 133' ' ' MET . . . . . 0.425 ' N ' ' HG2' ' A' ' 132' ' ' LYS . 90.2 mtp -109.58 160.74 16.0 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.458 -0.792 . . . . 0.0 109.93 -178.759 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . 0.404 ' NZ ' ' HB2' ' A' ' 134' ' ' LYS . 0.0 OUTLIER -95.83 142.7 27.78 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.088 0.471 . . . . 0.0 110.793 -176.062 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . 0.745 HD12 ' HD2' ' A' ' 142' ' ' TYR . 43.5 tp -75.35 131.35 40.2 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-N 115.45 -0.795 . . . . 0.0 110.317 178.833 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 136' ' ' VAL . . . . . 0.401 HG13 ' HE3' ' A' ' 134' ' ' LYS . 0.0 OUTLIER -128.22 137.73 56.63 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.755 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.542 178.564 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 19.5 m-80 -112.28 106.55 15.14 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 115.652 -0.704 . . . . 0.0 110.105 -179.941 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . 0.446 ' CD2' ' HB2' ' A' ' 28' ' ' TYR . 59.8 t80 -148.77 127.62 12.61 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.909 -178.41 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . 0.699 ' HA3' ' HB3' ' A' ' 24' ' ' ASP . . . 67.78 57.8 8.41 Favored Glycine 0 N--CA 1.445 -0.745 0 CA-C-N 115.807 -0.633 . . . . 0.0 114.166 171.223 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 140' ' ' ARG . . . . . 0.52 ' HD2' ' N ' ' A' ' 140' ' ' ARG . 2.4 mpt_? 62.6 10.91 4.4 Favored 'General case' 0 N--CA 1.465 0.316 0 C-N-CA 122.692 0.397 . . . . 0.0 112.059 173.84 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 10.6 t -145.7 153.01 40.52 Favored 'General case' 0 N--CA 1.447 -0.592 0 CA-C-O 120.973 0.416 . . . . 0.0 110.326 -179.813 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 142' ' ' TYR . . . . . 0.745 ' HD2' HD12 ' A' ' 135' ' ' LEU . 5.0 p90 -122.26 137.73 54.74 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 116.052 -0.522 . . . . 0.0 109.716 174.518 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 143' ' ' PHE . . . . . 0.413 ' O ' HD11 ' A' ' 135' ' ' LEU . 21.4 p90 -145.43 -169.64 3.26 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.466 -0.788 . . . . 0.0 109.796 -174.024 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 83.4 m-85 -117.54 137.27 52.68 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 120.754 0.311 . . . . 0.0 110.932 179.903 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 145' ' ' GLU . . . . . 0.4 ' OE1' ' HD3' ' A' ' 116' ' ' ARG . 15.8 pt-20 -130.36 162.42 29.12 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.157 -0.474 . . . . 0.0 109.731 173.737 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 40.7 t80 -142.38 124.24 15.18 Favored 'General case' 0 C--N 1.317 -0.831 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 174.672 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 147' ' ' ILE . . . . . 0.409 HD12 ' N ' ' A' ' 147' ' ' ILE . 2.7 mp -93.93 98.69 8.49 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.68 0 N-CA-C 109.52 -0.548 . . . . 0.0 109.52 -179.366 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . 0.425 ' HB2' ' O ' ' A' ' 115' ' ' ALA . . . -86.89 108.74 18.91 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.625 176.663 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 . . . . . 0 C--N 1.319 -0.719 0 CA-C-O 121.136 0.493 . . . . 0.0 110.601 -179.372 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 89.3 m95 . . . . . 0 N--CA 1.454 -0.243 0 CA-C-O 120.626 0.25 . . . . 0.0 111.057 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 21.0 t-20 -52.34 -50.47 62.25 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.889 -178.776 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 11.3 m-20 -60.5 -33.49 72.69 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.476 -0.329 . . . . 0.0 111.42 -178.22 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.525 HD23 ' HG3' ' A' ' 120' ' ' LYS . 50.6 tp -59.17 -50.65 73.21 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.926 0.393 . . . . 0.0 110.28 176.955 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . 0.407 ' O ' HG13 ' A' ' 30' ' ' ILE . . . -58.49 -49.66 76.54 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.639 179.47 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.43 ' O ' ' HG3' ' A' ' 31' ' ' ARG . 86.4 t -52.74 -46.51 50.8 Favored 'Isoleucine or valine' 0 C--O 1.233 0.209 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.949 177.893 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 86.0 t80 -56.29 -46.18 79.88 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.882 179.417 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 71.1 mt -66.78 -43.08 90.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.972 -179.484 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.407 HG13 ' O ' ' A' ' 26' ' ' ALA . 88.9 mt -56.4 -48.79 79.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 115.817 -0.628 . . . . 0.0 111.067 179.216 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . 0.43 ' HG3' ' O ' ' A' ' 27' ' ' VAL . 61.9 mtp180 -63.25 -36.41 83.58 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.904 -0.589 . . . . 0.0 111.072 -178.808 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 46.6 t -77.29 -25.92 51.83 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.333 -175.338 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 13.7 p -97.03 -76.63 0.51 Allowed 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.785 0.326 . . . . 0.0 111.301 -177.865 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.496 ' O ' HG21 ' A' ' 37' ' ' THR . . . 98.22 167.54 31.54 Favored Glycine 0 N--CA 1.449 -0.452 0 C-N-CA 120.951 -0.642 . . . . 0.0 112.13 -178.601 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 6.7 Cg_exo -73.42 143.54 34.98 Favored 'Trans proline' 0 N--CA 1.462 -0.327 0 C-N-CA 122.878 2.385 . . . . 0.0 112.379 -179.36 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 97.19 -11.29 65.6 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.67 -0.776 . . . . 0.0 113.441 176.218 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' THR . . . . . 0.496 HG21 ' O ' ' A' ' 34' ' ' GLY . 12.6 t -103.52 -179.02 3.83 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 177.501 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' ARG . . . . . 0.661 ' HB2' ' HA ' ' A' ' 90' ' ' ALA . 62.5 mtp180 -115.11 136.63 52.91 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.809 0.338 . . . . 0.0 110.763 -179.227 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.426 ' HB ' HD22 ' A' ' 62' ' ' LEU . 47.5 t -130.9 138.18 54.16 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 177.913 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.425 HG12 ' CE1' ' A' ' 87' ' ' TYR . 33.4 t -118.95 125.45 74.5 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 CA-C-O 120.837 0.351 . . . . 0.0 111.336 -177.254 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . 0.414 ' HB3' ' CD2' ' A' ' 64' ' ' LEU . 43.4 tt0 -99.57 112.15 24.4 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.954 -0.566 . . . . 0.0 109.645 175.462 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 60.5 t -97.45 121.16 47.69 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-N 116.0 -0.546 . . . . 0.0 110.385 -179.143 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 90.35 46.04 4.19 Favored Glycine 0 N--CA 1.444 -0.795 0 C-N-CA 120.539 -0.839 . . . . 0.0 111.861 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . 0.432 ' HB1' ' CD2' ' A' ' 48' ' ' LEU . . . -59.22 -32.94 70.41 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-O 121.328 0.585 . . . . 0.0 110.932 179.292 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 63.88 -123.57 28.74 Favored Glycine 0 N--CA 1.445 -0.701 0 CA-C-N 115.714 -0.675 . . . . 0.0 112.597 177.104 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 30.5 mmt-85 -122.96 9.77 9.41 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 120.847 0.356 . . . . 0.0 110.498 -177.005 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 19.0 p90 -137.36 113.24 9.69 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 121.289 0.566 . . . . 0.0 110.82 -176.845 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . 0.432 ' CD2' ' HB1' ' A' ' 44' ' ' ALA . 68.8 mt -104.64 60.87 0.7 Allowed 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.56 -177.164 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 72.1 t80 -75.56 -52.84 9.68 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.938 0.399 . . . . 0.0 110.88 -179.559 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.452 ' O ' HG13 ' A' ' 54' ' ' ILE . 49.1 t -67.87 -52.78 36.15 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-N 115.868 -0.606 . . . . 0.0 110.722 -176.562 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' SER . . . . . 0.521 ' HB3' HD22 ' A' ' 64' ' ' LEU . 0.2 OUTLIER -54.84 -43.15 72.76 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.767 -0.651 . . . . 0.0 112.491 -178.933 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.425 ' O ' ' HG3' ' A' ' 56' ' ' LYS . 20.7 t70 -67.73 -42.96 81.05 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.834 0.349 . . . . 0.0 110.591 -179.104 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 75.9 t80 -63.99 -40.08 95.57 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.153 -179.009 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.452 HG13 ' O ' ' A' ' 50' ' ' VAL . 80.0 mt -63.01 -45.78 97.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.474 -0.33 . . . . 0.0 111.367 -179.709 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 33.2 ptt180 -72.04 -16.84 62.05 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.89 0.376 . . . . 0.0 110.871 -178.785 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . 0.425 ' HG3' ' O ' ' A' ' 52' ' ' ASP . 24.2 mtpp -73.08 -30.55 63.75 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.318 176.882 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 28.0 m-70 -102.51 -56.61 2.21 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.891 -177.434 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 6.8 p -100.46 135.4 41.95 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 120.982 0.42 . . . . 0.0 112.057 -174.399 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . 0.518 ' HB2' ' HZ2' ' A' ' 59' ' ' LYS . 0.2 OUTLIER -81.39 65.05 6.36 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 122.196 0.998 . . . . 0.0 108.969 171.053 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.42 HG22 HG22 ' A' ' 39' ' ' VAL . 8.8 p -100.54 148.54 6.77 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.09 0 CA-C-N 114.322 -1.308 . . . . 0.0 110.111 178.78 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . 0.556 ' HB3' ' HG2' ' A' ' 38' ' ' ARG . 9.3 t70 -74.77 84.89 2.16 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 176.773 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . 0.426 HD22 ' HB ' ' A' ' 39' ' ' VAL . 3.1 tm? -94.57 116.83 29.24 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 115.441 -0.799 . . . . 0.0 110.287 -173.92 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 60.1 t -113.61 139.09 40.89 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 CA-C-N 115.604 -0.725 . . . . 0.0 110.561 -176.524 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . 0.521 HD22 ' HB3' ' A' ' 51' ' ' SER . 31.6 mt -112.37 136.12 52.23 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 110.171 -0.307 . . . . 0.0 110.171 178.735 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 15.9 p -118.81 125.43 49.55 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.102 0.477 . . . . 0.0 110.706 175.366 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . 0.485 ' HB3' HG21 ' A' ' 74' ' ' ILE . 23.9 t70 -154.82 140.46 17.98 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.532 -0.758 . . . . 0.0 109.247 -179.853 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . 0.489 HG23 ' HG2' ' A' ' 68' ' ' LYS . 59.3 mt -74.44 124.17 31.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-N 116.519 -0.31 . . . . 0.0 110.315 -177.964 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' LYS . . . . . 0.489 ' HG2' HG23 ' A' ' 67' ' ' ILE . 59.8 pttt 39.72 69.72 1.66 Allowed Pre-proline 0 N--CA 1.469 0.499 0 O-C-N 124.29 0.994 . . . . 0.0 111.684 -174.296 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . 0.548 ' CB ' ' HB ' ' A' ' 74' ' ' ILE . 44.1 Cg_endo . . . . . 0 C--O 1.232 0.218 0 C-N-CA 122.856 2.371 . . . . 0.0 113.017 -174.345 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . 0.548 ' HB ' ' CB ' ' A' ' 69' ' ' PRO . 55.3 mt . . . . . 0 N--CA 1.453 -0.291 0 N-CA-C 109.713 -0.477 . . . . 0.0 109.713 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.542 HG11 HD11 ' A' ' 86' ' ' ILE . 66.3 t -66.27 123.72 19.85 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-O 120.884 0.374 . . . . 0.0 110.266 -179.344 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 18.7 ptp180 -85.9 48.61 1.63 Allowed 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.44 0.638 . . . . 0.0 110.695 -176.251 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . 0.425 ' HB2' HG13 ' A' ' 75' ' ' VAL . 2.7 t70 -89.17 -154.56 0.31 Allowed 'General case' 0 C--N 1.321 -0.641 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 179.214 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' ASP . . . . . 0.497 ' OD1' HG22 ' A' ' 80' ' ' THR . 4.9 t70 -136.25 -176.42 4.32 Favored 'General case' 0 C--N 1.321 -0.633 0 C-N-CA 120.737 -0.385 . . . . 0.0 110.251 -178.916 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 8.9 tp -127.37 -28.18 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-O 120.822 0.344 . . . . 0.0 110.502 179.71 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.497 HG22 ' OD1' ' A' ' 78' ' ' ASP . 15.0 t -89.06 -25.75 21.77 Favored 'General case' 0 N--CA 1.451 -0.387 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 177.006 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 34.2 t -135.34 70.5 67.91 Favored Pre-proline 0 C--N 1.326 -0.442 0 CA-C-N 115.33 -0.85 . . . . 0.0 108.997 170.822 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_endo -87.32 157.01 8.11 Favored 'Trans proline' 0 N--CA 1.453 -0.909 0 C-N-CA 122.496 2.131 . . . . 0.0 112.518 -176.146 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' ARG . . . . . 0.741 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 50.0 mtt180 -89.12 111.92 22.79 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.199 173.058 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' MET . . . . . 0.521 ' HE2' HG12 ' A' ' 109' ' ' VAL . 95.2 mmm -66.83 -17.65 64.99 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.5 -177.62 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . 0.741 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 9.9 pt-20 -62.35 -23.35 66.74 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.628 -0.714 . . . . 0.0 111.508 179.078 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.542 HD11 HG11 ' A' ' 75' ' ' VAL . 67.3 mt -84.36 -39.54 14.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-O 121.117 0.484 . . . . 0.0 110.363 179.724 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . 0.425 ' CE1' HG12 ' A' ' 40' ' ' VAL . 90.7 m-85 -78.86 -32.19 45.9 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.756 -0.657 . . . . 0.0 111.322 -177.881 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . 0.412 ' HG3' HG13 ' A' ' 113' ' ' VAL . 57.9 mtt180 -67.01 115.33 6.6 Favored 'General case' 0 CA--C 1.516 -0.339 0 CA-C-O 121.317 0.58 . . . . 0.0 110.633 -179.933 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 119.44 -12.05 11.23 Favored Glycine 0 N--CA 1.448 -0.522 0 CA-C-N 115.037 -0.983 . . . . 0.0 111.455 -175.213 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . 0.661 ' HA ' ' HB2' ' A' ' 38' ' ' ARG . . . -82.94 147.74 28.06 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.881 0.372 . . . . 0.0 110.898 178.346 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -96.73 -22.26 17.09 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.811 179.529 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . 0.465 ' HG ' ' HB3' ' A' ' 116' ' ' ARG . 5.3 tt -150.85 139.79 20.95 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.682 -178.442 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.56 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 67.5 mt -131.57 125.37 56.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.688 -0.687 . . . . 0.0 109.258 178.69 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 19.0 p90 -128.42 155.48 44.69 Favored 'General case' 0 C--N 1.321 -0.645 0 C-N-CA 120.618 -0.433 . . . . 0.0 110.965 -178.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 18.3 m -132.74 130.41 39.94 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.554 -178.436 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 65.4 mt -93.55 103.14 14.37 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.682 -178.894 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 70.6 mtp180 54.38 67.36 3.45 Favored Pre-proline 0 N--CA 1.466 0.329 0 CA-C-N 115.489 -0.778 . . . . 0.0 111.998 -178.517 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -76.91 140.58 20.53 Favored 'Trans proline' 0 N--CA 1.461 -0.402 0 C-N-CA 122.244 1.963 . . . . 0.0 112.251 179.615 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . 0.585 ' HD2' HD11 ' A' ' 102' ' ' ILE . 38.1 Cg_exo -60.2 147.56 93.01 Favored 'Trans proline' 0 C--O 1.235 0.331 0 C-N-CA 122.741 2.294 . . . . 0.0 111.942 176.606 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . 0.639 ' HA ' ' NE2' ' A' ' 103' ' ' HIS . . . -78.54 31.15 0.19 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.227 0.537 . . . . 0.0 111.331 -175.542 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 101' ' ' GLU . . . . . 0.528 ' HG2' ' HB2' ' A' ' 99' ' ' PRO . 7.7 pt-20 -127.55 -1.63 6.16 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-N 115.967 -0.561 . . . . 0.0 111.164 -176.908 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.585 HD11 ' HD2' ' A' ' 99' ' ' PRO . 30.9 pt -131.41 10.33 1.83 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 N-CA-C 112.118 0.414 . . . . 0.0 112.118 -178.308 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 103' ' ' HIS . . . . . 0.639 ' NE2' ' HA ' ' A' ' 100' ' ' ALA . 9.7 m-70 -54.77 -51.65 65.06 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.244 -0.435 . . . . 0.0 112.006 -176.738 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 15.5 m -62.54 -32.49 73.44 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.498 -0.319 . . . . 0.0 111.007 -177.939 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.577 ' O ' HG21 ' A' ' 109' ' ' VAL . 21.0 m -67.45 -42.3 83.32 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.329 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 73.9 mt -64.78 -43.96 91.54 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.493 179.56 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 107' ' ' MET . . . . . 0.403 ' HE2' ' HB2' ' A' ' 132' ' ' LYS . 77.0 mtp -63.18 -41.8 99.27 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.55 -176.244 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 2.9 ptp180 -70.27 -30.78 67.89 Favored 'General case' 0 C--N 1.332 -0.189 0 C-N-CA 120.879 -0.329 . . . . 0.0 111.145 -178.497 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.577 HG21 ' O ' ' A' ' 105' ' ' SER . 75.3 t -63.87 -45.2 97.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.889 0.376 . . . . 0.0 110.062 177.466 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -58.42 -44.4 89.07 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.619 177.71 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . 0.471 ' HA ' ' HB3' ' A' ' 148' ' ' ALA . 13.6 t70 -64.84 -42.48 94.88 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.059 179.586 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -64.8 -41.74 95.56 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.712 -0.676 . . . . 0.0 112.055 -177.488 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.412 HG13 ' HG3' ' A' ' 88' ' ' ARG . 12.2 m -92.57 -24.78 5.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 CA-C-N 116.506 -0.315 . . . . 0.0 111.694 -174.983 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 88.43 49.33 3.71 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.764 -0.731 . . . . 0.0 111.997 179.731 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -129.07 156.5 43.76 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 120.738 0.304 . . . . 0.0 111.142 -177.689 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 116' ' ' ARG . . . . . 0.514 ' HD3' ' OE1' ' A' ' 145' ' ' GLU . 16.4 ttm180 -80.26 125.16 29.52 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.158 -0.474 . . . . 0.0 109.728 177.549 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . 0.56 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 48.7 tp -94.47 119.31 32.99 Favored 'General case' 0 C--N 1.322 -0.619 0 N-CA-C 110.158 -0.312 . . . . 0.0 110.158 179.815 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 63.9 mt -114.91 117.97 57.31 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-O 121.183 0.516 . . . . 0.0 110.732 179.398 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 64.6 mt -112.03 132.22 61.28 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 115.923 -0.581 . . . . 0.0 110.564 179.829 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 120' ' ' LYS . . . . . 0.908 ' HD2' ' HB3' ' A' ' 143' ' ' PHE . 23.1 mmmt -102.58 99.97 14.8 Favored Pre-proline 0 C--N 1.328 -0.347 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.229 174.419 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 121' ' ' PRO . . . . . 0.415 ' HG3' ' HD2' ' A' ' 144' ' ' TYR . 88.4 Cg_endo -82.78 -158.95 0.1 OUTLIER 'Trans proline' 0 N--CA 1.459 -0.535 0 C-N-CA 122.563 2.175 . . . . 0.0 111.351 171.861 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 122' ' ' LEU . . . . . 0.819 ' HB2' ' HB2' ' A' ' 125' ' ' GLU . 3.6 mm? -99.88 -171.04 1.98 Allowed 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 110.267 -0.272 . . . . 0.0 110.267 179.916 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 8.7 t -88.76 -35.11 16.85 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.708 0.289 . . . . 0.0 111.19 -176.719 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -114.78 12.61 20.48 Favored Glycine 0 N--CA 1.449 -0.499 0 C-N-CA 120.436 -0.887 . . . . 0.0 111.296 178.53 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . 0.819 ' HB2' ' HB2' ' A' ' 122' ' ' LEU . 28.2 mt-10 -131.52 126.52 35.12 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.248 -0.476 . . . . 0.0 110.075 -176.342 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 11.3 t70 -87.01 179.28 6.71 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.679 -0.692 . . . . 0.0 109.885 -177.504 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . 0.574 HD13 ' HB2' ' A' ' 144' ' ' TYR . 56.5 mt . . . . . 0 C--N 1.326 -0.438 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 178.799 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 132' ' ' LYS . . . . . 0.403 ' HB2' ' HE2' ' A' ' 107' ' ' MET . 33.5 mttp . . . . . 0 CA--C 1.519 -0.212 0 CA-C-O 121.119 0.485 . . . . 0.0 111.03 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 133' ' ' MET . . . . . 0.537 ' HG2' ' HB2' ' A' ' 146' ' ' TYR . 84.8 mtp -111.14 165.63 11.74 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.857 -0.611 . . . . 0.0 109.405 176.144 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 6.9 pttp -130.51 140.23 50.5 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.09 0.472 . . . . 0.0 111.754 -175.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . 0.577 HD13 ' HD2' ' A' ' 142' ' ' TYR . 39.2 tp -76.93 122.36 24.76 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.585 -0.734 . . . . 0.0 110.777 -179.645 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 136' ' ' VAL . . . . . 0.453 HG22 ' CD1' ' A' ' 143' ' ' PHE . 0.0 OUTLIER -117.95 142.25 33.23 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.761 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.437 178.426 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 137' ' ' ASN . . . . . 0.583 ' ND2' ' HB3' ' A' ' 142' ' ' TYR . 13.8 m120 -117.9 110.32 17.6 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.442 -176.022 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . 0.437 ' O ' HG22 ' A' ' 141' ' ' THR . 76.0 t80 -135.23 130.09 34.69 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.248 -0.433 . . . . 0.0 109.877 -179.434 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 63.75 26.36 69.87 Favored Glycine 0 N--CA 1.453 -0.217 0 C-N-CA 120.54 -0.838 . . . . 0.0 111.702 -176.784 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 21.2 mtp180 66.67 7.69 5.34 Favored 'General case' 0 C--N 1.33 -0.274 0 C-N-CA 123.304 0.641 . . . . 0.0 112.436 -178.731 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 141' ' ' THR . . . . . 0.437 HG22 ' O ' ' A' ' 138' ' ' TYR . 10.8 t -107.48 139.71 41.57 Favored 'General case' 0 N--CA 1.446 -0.659 0 N-CA-C 108.663 -0.866 . . . . 0.0 108.663 169.84 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 142' ' ' TYR . . . . . 0.583 ' HB3' ' ND2' ' A' ' 137' ' ' ASN . 17.0 p90 -113.86 149.08 35.59 Favored 'General case' 0 C--N 1.315 -0.892 0 CA-C-O 121.69 0.757 . . . . 0.0 111.513 -177.581 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 143' ' ' PHE . . . . . 0.908 ' HB3' ' HD2' ' A' ' 120' ' ' LYS . 3.5 p90 -151.41 178.96 8.76 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 114.238 -1.347 . . . . 0.0 108.83 -178.98 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 144' ' ' TYR . . . . . 0.574 ' HB2' HD13 ' A' ' 127' ' ' ILE . 80.6 m-85 -115.58 119.72 37.06 Favored 'General case' 0 C--N 1.313 -0.98 0 C-N-CA 120.62 -0.432 . . . . 0.0 110.529 179.82 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 145' ' ' GLU . . . . . 0.514 ' OE1' ' HD3' ' A' ' 116' ' ' ARG . 18.3 pt-20 -108.15 156.96 18.73 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 176.2 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . 0.537 ' HB2' ' HG2' ' A' ' 133' ' ' MET . 22.7 t80 -137.13 120.68 17.17 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-N 115.626 -0.715 . . . . 0.0 109.66 176.647 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 147' ' ' ILE . . . . . 0.419 HD13 ' N ' ' A' ' 147' ' ' ILE . 3.2 mp -89.05 101.5 12.05 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 -178.481 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . 0.471 ' HB3' ' HA ' ' A' ' 111' ' ' ASP . . . -74.37 96.43 2.86 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 121.225 0.536 . . . . 0.0 109.76 177.19 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 11.6 pt-20 . . . . . 0 C--N 1.314 -0.941 0 CA-C-N 115.155 -0.93 . . . . 0.0 109.752 178.89 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 40.2 m95 . . . . . 0 N--CA 1.461 0.122 0 CA-C-O 121.033 0.444 . . . . 0.0 110.533 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 25.5 t-20 -65.18 -45.55 84.39 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.553 -0.749 . . . . 0.0 110.28 -178.024 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -57.24 -46.29 83.13 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.679 -0.691 . . . . 0.0 110.255 177.953 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 62.2 tp -61.52 -46.96 87.74 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.238 -0.892 . . . . 0.0 110.958 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . 0.49 ' O ' HG13 ' A' ' 30' ' ' ILE . . . -56.19 -52.47 64.28 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.164 -179.742 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.415 ' HA ' HD12 ' A' ' 30' ' ' ILE . 84.0 t -56.12 -42.25 71.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.206 179.131 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 57.4 t80 -57.41 -45.99 83.98 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.574 179.733 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 67.0 mt -67.28 -40.23 84.48 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.785 179.783 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.547 HG12 HG22 ' A' ' 54' ' ' ILE . 95.4 mt -58.85 -38.42 72.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 115.969 -0.56 . . . . 0.0 111.125 179.401 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 40.1 mtp-105 -71.99 -30.32 65.13 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.839 -0.619 . . . . 0.0 111.332 -178.855 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 42.9 t -89.2 -17.41 29.17 Favored 'General case' 0 C--N 1.324 -0.513 0 N-CA-C 111.956 0.354 . . . . 0.0 111.956 -176.489 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 11.5 p -94.68 -79.17 0.43 Allowed 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 111.961 0.356 . . . . 0.0 111.961 -176.086 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.463 ' O ' HG21 ' A' ' 37' ' ' THR . . . 101.16 136.73 9.45 Favored Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.812 -0.709 . . . . 0.0 111.847 -176.698 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . 0.4 ' HD3' ' HA2' ' A' ' 34' ' ' GLY . 48.4 Cg_exo -55.84 126.48 22.55 Favored 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 123.076 2.518 . . . . 0.0 112.767 -176.066 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 112.73 -18.51 22.21 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.294 -0.955 . . . . 0.0 113.48 175.278 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' THR . . . . . 0.463 HG21 ' O ' ' A' ' 34' ' ' GLY . 11.1 t -86.76 -173.6 4.56 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.995 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' ARG . . . . . 0.494 ' HG2' ' CB ' ' A' ' 61' ' ' ASP . 92.1 mtm-85 -118.45 135.2 54.5 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 120.932 0.396 . . . . 0.0 110.735 176.634 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.461 HG22 HG11 ' A' ' 60' ' ' VAL . 90.7 t -130.19 127.44 63.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 176.904 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.427 HG11 ' CE1' ' A' ' 87' ' ' TYR . 35.4 t -109.06 128.79 64.67 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-O 120.937 0.399 . . . . 0.0 111.915 -173.02 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . 0.708 ' HB3' HD21 ' A' ' 64' ' ' LEU . 6.3 tp10 -103.3 127.92 50.5 Favored 'General case' 0 C--O 1.237 0.416 0 CA-C-N 115.379 -0.828 . . . . 0.0 109.452 174.092 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.54 ' HB ' ' HB3' ' A' ' 95' ' ' SER . 35.2 t -106.05 98.91 7.49 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-O 120.974 0.416 . . . . 0.0 110.535 -179.178 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 101.08 84.8 1.83 Allowed Glycine 0 N--CA 1.451 -0.333 0 N-CA-C 111.471 -0.651 . . . . 0.0 111.471 -176.778 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . 0.419 ' HB1' HD22 ' A' ' 48' ' ' LEU . . . -83.07 -40.83 19.35 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 112.106 0.41 . . . . 0.0 112.106 -172.107 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 57.3 -127.55 45.19 Favored Glycine 0 CA--C 1.521 0.447 0 C-N-CA 121.077 -0.582 . . . . 0.0 112.713 179.824 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 52.4 mtp180 -120.42 2.49 10.77 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.866 0.365 . . . . 0.0 111.21 179.071 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.552 ' CE1' ' HB ' ' A' ' 96' ' ' ILE . 6.3 p90 -96.85 58.29 1.61 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.379 0.609 . . . . 0.0 111.088 -176.166 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . 0.419 HD22 ' HB1' ' A' ' 44' ' ' ALA . 83.8 mt -81.68 8.43 9.92 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.79 -0.641 . . . . 0.0 112.12 -174.425 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 75.7 t80 -57.95 -48.75 79.04 Favored 'General case' 0 N--CA 1.463 0.201 0 CA-C-O 120.589 0.233 . . . . 0.0 111.195 -179.802 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.453 ' O ' HG13 ' A' ' 54' ' ' ILE . 85.3 t -58.96 -51.73 69.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.892 -178.398 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' SER . . . . . 0.492 ' CB ' HD23 ' A' ' 64' ' ' LEU . 3.9 p -69.79 -25.76 63.94 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.004 -0.544 . . . . 0.0 112.346 -174.418 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.502 ' O ' ' HG2' ' A' ' 55' ' ' ARG . 17.5 t70 -83.06 -41.46 18.6 Favored 'General case' 0 C--N 1.325 -0.462 0 C-N-CA 120.806 -0.358 . . . . 0.0 110.3 177.232 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 66.4 t80 -58.16 -43.75 87.55 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.545 178.839 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.547 HG22 HG12 ' A' ' 30' ' ' ILE . 89.0 mt -60.2 -47.6 91.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.192 178.326 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' ARG . . . . . 0.502 ' HG2' ' O ' ' A' ' 52' ' ' ASP . 7.9 ptp180 -71.98 -16.31 62.08 Favored 'General case' 0 CA--C 1.532 0.27 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.381 -174.725 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 44.2 mmtm -77.1 -37.57 54.03 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.839 0.352 . . . . 0.0 110.569 176.316 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 13.3 m-70 -83.79 -55.32 4.32 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.67 179.694 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 68.0 m -117.13 127.97 54.66 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.169 -179.025 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 1.3 mptm? -77.5 63.36 2.63 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-O 121.925 0.869 . . . . 0.0 110.475 176.712 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.461 HG11 HG22 ' A' ' 39' ' ' VAL . 66.1 t -82.84 142.35 13.7 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.922 0 CA-C-N 114.444 -1.253 . . . . 0.0 109.09 173.888 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . 0.494 ' CB ' ' HG2' ' A' ' 38' ' ' ARG . 0.3 OUTLIER -73.19 80.08 1.29 Allowed 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.3 0.571 . . . . 0.0 109.5 175.27 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . 0.498 HD22 ' HH ' ' A' ' 94' ' ' TYR . 3.1 tt -84.08 114.88 22.07 Favored 'General case' 0 N--CA 1.444 -0.755 0 CA-C-N 115.598 -0.728 . . . . 0.0 109.378 -178.074 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 58.2 t -99.28 119.52 47.4 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.706 0 CA-C-N 115.296 -0.865 . . . . 0.0 110.229 -177.381 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . 0.708 HD21 ' HB3' ' A' ' 41' ' ' GLU . 65.8 mt -98.3 131.37 44.67 Favored 'General case' 0 C--N 1.316 -0.87 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 176.964 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.401 ' OG1' ' HA ' ' A' ' 42' ' ' VAL . 36.2 p -116.87 130.56 56.79 Favored 'General case' 0 C--N 1.318 -0.799 0 N-CA-C 109.973 -0.38 . . . . 0.0 109.973 177.021 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 5.8 t70 -157.56 161.93 38.78 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 -178.72 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . 0.684 HD13 HG22 ' A' ' 79' ' ' ILE . 48.7 mm -76.63 95.37 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-O 120.835 0.35 . . . . 0.0 110.145 -177.716 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 56.8 mtpt 50.36 70.29 2.12 Favored Pre-proline 0 CA--C 1.535 0.373 0 CA-C-N 115.192 -0.913 . . . . 0.0 111.68 177.437 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . 0.68 ' HD2' ' HG2' ' A' ' 76' ' ' ARG . 37.0 Cg_endo . . . . . 0 C--N 1.345 0.361 0 C-N-CA 123.455 2.77 . . . . 0.0 112.865 -179.121 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . 0.443 HG22 ' CB ' ' A' ' 64' ' ' LEU . 41.0 mt . . . . . 0 N--CA 1.449 -0.488 0 N-CA-C 109.606 -0.516 . . . . 0.0 109.606 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.459 HG12 ' H ' ' A' ' 77' ' ' ASP . 64.3 t -74.12 135.32 27.73 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-O 120.866 0.365 . . . . 0.0 110.029 179.95 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' ARG . . . . . 0.68 ' HG2' ' HD2' ' A' ' 69' ' ' PRO . 26.6 mtp85 -89.74 21.03 3.71 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.907 -0.588 . . . . 0.0 111.856 -174.096 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . 0.459 ' H ' HG12 ' A' ' 75' ' ' VAL . 1.1 m-20 -80.19 160.62 25.57 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.785 0.326 . . . . 0.0 110.843 -179.396 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 11.0 t70 -75.22 152.93 38.29 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.934 -173.789 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' ILE . . . . . 0.684 HG22 HD13 ' A' ' 67' ' ' ILE . 12.4 tt -91.15 -31.42 5.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.883 -175.475 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 11.1 t -99.73 -24.47 14.69 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.291 0.567 . . . . 0.0 109.98 -177.184 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 27.9 m -126.6 74.66 74.74 Favored Pre-proline 0 C--N 1.328 -0.362 0 CA-C-N 115.942 -0.572 . . . . 0.0 109.876 172.472 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 98.1 Cg_endo -90.93 -162.27 0.11 Allowed 'Trans proline' 0 N--CA 1.459 -0.541 0 C-N-CA 123.379 2.72 . . . . 0.0 113.219 -174.071 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 94.8 mtt180 -126.2 116.45 21.33 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.348 178.319 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' MET . . . . . 0.814 ' HA ' ' HD2' ' A' ' 87' ' ' TYR . 25.3 mtp -66.14 -18.5 65.39 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 112.252 0.464 . . . . 0.0 112.252 -177.259 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . 0.402 ' HA ' ' HD3' ' A' ' 88' ' ' ARG . 10.8 pt-20 -65.63 -25.78 67.52 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.094 0.473 . . . . 0.0 110.406 179.335 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 68.3 mt -73.54 -36.74 48.55 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 115.77 -0.65 . . . . 0.0 109.922 177.06 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . 0.814 ' HD2' ' HA ' ' A' ' 84' ' ' MET . 74.2 m-85 -77.92 -30.56 50.65 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.633 -0.712 . . . . 0.0 110.754 -178.242 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . 0.402 ' HD3' ' HA ' ' A' ' 85' ' ' GLU . 69.9 mtp180 -58.17 125.25 22.39 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.964 178.81 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . 0.49 ' HA3' ' NH2' ' A' ' 38' ' ' ARG . . . 97.71 -8.68 63.88 Favored Glycine 0 N--CA 1.447 -0.605 0 C-N-CA 120.821 -0.704 . . . . 0.0 112.45 179.016 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -74.82 142.63 44.19 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 120.777 0.322 . . . . 0.0 110.373 178.277 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -94.39 -18.02 21.96 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.513 179.333 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . 0.413 HD21 ' N ' ' A' ' 93' ' ' ILE . 3.6 tt -153.72 140.05 18.59 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.337 -179.154 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.569 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 71.6 mt -132.24 126.17 55.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 N-CA-C 109.032 -0.729 . . . . 0.0 109.032 178.139 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' TYR . . . . . 0.498 ' HH ' HD22 ' A' ' 62' ' ' LEU . 2.0 p90 -135.29 167.18 21.5 Favored 'General case' 0 C--N 1.32 -0.699 0 C-N-CA 120.663 -0.415 . . . . 0.0 110.535 -178.258 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' SER . . . . . 0.626 ' HA ' ' OE1' ' A' ' 41' ' ' GLU . 4.8 p -153.93 120.32 5.47 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.632 -178.447 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' ILE . . . . . 0.552 ' HB ' ' CE1' ' A' ' 47' ' ' PHE . 46.8 mm -80.81 97.23 3.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.684 179.374 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 2.2 tmt_? 52.66 76.91 0.48 Allowed Pre-proline 0 CA--C 1.534 0.353 0 CA-C-N 114.997 -1.001 . . . . 0.0 111.393 177.921 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 69.1 Cg_endo -89.85 161.99 5.06 Favored 'Trans proline' 0 N--CA 1.457 -0.655 0 C-N-CA 122.856 2.371 . . . . 0.0 112.343 177.589 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . 0.411 ' HB2' ' HG2' ' A' ' 101' ' ' GLU . 14.6 Cg_endo -60.12 147.64 92.51 Favored 'Trans proline' 0 C--N 1.345 0.367 0 C-N-CA 122.275 1.983 . . . . 0.0 111.858 174.64 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -78.13 33.55 0.19 Allowed 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.928 -176.34 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 101' ' ' GLU . . . . . 0.639 ' HG3' HG23 ' A' ' 102' ' ' ILE . 9.7 pt-20 -116.09 -23.35 8.52 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.685 0.278 . . . . 0.0 110.712 176.549 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.639 HG23 ' HG3' ' A' ' 101' ' ' GLU . 30.1 pt -109.83 -0.26 9.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 N-CA-C 112.006 0.373 . . . . 0.0 112.006 -174.667 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 103' ' ' HIS . . . . . . . . . . . . . 22.1 p-80 -60.66 -43.4 97.67 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 121.093 0.473 . . . . 0.0 110.817 -178.228 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 4.0 p -73.78 -29.41 62.17 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.987 -0.552 . . . . 0.0 110.742 179.094 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.501 ' O ' HG21 ' A' ' 109' ' ' VAL . 2.4 m -71.49 -45.47 62.39 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.224 -179.555 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 74.5 mt -60.91 -39.77 90.61 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.229 -179.846 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 107' ' ' MET . . . . . 0.443 ' HA ' HD21 ' A' ' 117' ' ' LEU . 51.7 ttm -60.45 -45.61 93.06 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.49 -179.23 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 108' ' ' ARG . . . . . 0.441 ' HG2' ' O ' ' A' ' 105' ' ' SER . 15.1 ptm180 -74.21 -24.1 59.29 Favored 'General case' 0 C--N 1.327 -0.409 0 C-N-CA 120.978 -0.289 . . . . 0.0 110.89 -177.384 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.66 HG11 ' HE2' ' A' ' 84' ' ' MET . 81.1 t -72.34 -43.61 64.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 173.954 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -58.24 -42.2 85.85 Favored 'General case' 0 CA--C 1.52 -0.197 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.551 177.926 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . 0.779 ' HA ' ' HB2' ' A' ' 148' ' ' ALA . 35.2 t70 -65.61 -40.27 92.43 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.965 -179.769 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -68.21 -37.47 80.9 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.551 -0.75 . . . . 0.0 112.12 -178.218 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 21.5 m -92.99 -22.82 5.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-O 120.794 0.33 . . . . 0.0 111.549 -177.044 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 85.91 54.41 2.77 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.971 -0.633 . . . . 0.0 112.172 178.935 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -132.73 155.87 48.07 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 120.739 0.304 . . . . 0.0 110.917 -178.975 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 23.9 ttm180 -81.53 127.6 33.01 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 176.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . 0.569 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 55.8 tp -93.3 123.94 36.93 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.022 179.348 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 66.5 mt -120.16 120.32 62.64 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 CA-C-O 120.939 0.4 . . . . 0.0 110.641 178.376 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 69.3 mt -120.13 126.57 75.42 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.165 179.331 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 120' ' ' LYS . . . . . 0.732 ' HG2' ' HB3' ' A' ' 143' ' ' PHE . 5.9 tmtt? -120.97 96.33 48.63 Favored Pre-proline 0 C--N 1.325 -0.49 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.118 178.379 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -88.8 -163.62 0.15 Allowed 'Trans proline' 0 C--O 1.238 0.497 0 C-N-CA 122.928 2.419 . . . . 0.0 112.33 177.098 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -70.54 -178.72 1.86 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.29 -0.413 . . . . 0.0 110.901 177.311 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 9.6 t -81.4 -35.26 30.96 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.904 0.383 . . . . 0.0 110.95 -176.39 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -113.74 52.54 0.64 Allowed Glycine 0 N--CA 1.448 -0.556 0 N-CA-C 110.629 -0.988 . . . . 0.0 110.629 175.852 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 36.4 tt0 -138.14 116.61 12.03 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.466 -0.367 . . . . 0.0 110.114 -173.354 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 8.1 t70 -91.71 163.19 14.18 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.987 -0.552 . . . . 0.0 110.117 -177.264 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 15.9 mt . . . . . 0 C--N 1.327 -0.398 0 N-CA-C 110.176 -0.305 . . . . 0.0 110.176 -177.716 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 8.3 tppt? . . . . . 0 N--CA 1.448 -0.527 0 CA-C-O 121.453 0.644 . . . . 0.0 109.302 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 133' ' ' MET . . . . . 0.806 ' HG2' ' HB2' ' A' ' 146' ' ' TYR . 83.4 mtp -87.17 171.75 10.44 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.247 -0.888 . . . . 0.0 110.459 -177.64 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 14.2 ptmt -131.16 146.66 52.42 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.953 -175.268 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . 0.475 HD11 ' HD2' ' A' ' 142' ' ' TYR . 56.7 tp -79.75 129.84 34.82 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.454 176.715 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 136' ' ' VAL . . . . . 0.404 HG23 ' CD1' ' A' ' 143' ' ' PHE . 0.0 OUTLIER -127.66 129.8 70.23 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.702 0 CA-C-O 121.162 0.506 . . . . 0.0 111.162 178.811 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 15.4 m120 -109.85 122.25 47.11 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.31 -0.859 . . . . 0.0 109.234 177.739 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 61.4 t80 -137.67 125.35 22.32 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 120.535 0.207 . . . . 0.0 110.67 -177.475 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 69.26 -88.92 0.25 Allowed Glycine 0 N--CA 1.448 -0.547 0 N-CA-C 111.626 -0.589 . . . . 0.0 111.626 179.225 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 140' ' ' ARG . . . . . 0.633 ' HA ' ' NE ' ' A' ' 140' ' ' ARG . 2.1 mmp_? -143.72 9.96 1.58 Allowed 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 115.446 -0.377 . . . . 0.0 111.182 175.91 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 15.2 t -118.6 155.23 31.31 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.801 0.334 . . . . 0.0 110.611 -179.678 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 142' ' ' TYR . . . . . 0.475 ' HD2' HD11 ' A' ' 135' ' ' LEU . 32.4 p90 -133.58 141.22 47.59 Favored 'General case' 0 N--CA 1.448 -0.533 0 CA-C-O 121.086 0.469 . . . . 0.0 109.992 176.704 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 143' ' ' PHE . . . . . 0.732 ' HB3' ' HG2' ' A' ' 120' ' ' LYS . 11.6 p90 -153.89 -175.98 5.63 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 115.429 -0.805 . . . . 0.0 109.733 -177.006 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 95.7 m-85 -116.98 125.36 51.29 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 110.308 -0.256 . . . . 0.0 110.308 179.375 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 145' ' ' GLU . . . . . . . . . . . . . 21.6 pt-20 -114.05 160.92 18.36 Favored 'General case' 0 C--N 1.321 -0.649 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 176.626 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . 0.806 ' HB2' ' HG2' ' A' ' 133' ' ' MET . 42.3 t80 -141.87 123.44 15.03 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-N 115.971 -0.558 . . . . 0.0 109.693 175.617 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 147' ' ' ILE . . . . . 0.443 HD13 ' N ' ' A' ' 147' ' ' ILE . 3.1 mp -93.03 100.94 12.07 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.834 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 -178.653 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . 0.779 ' HB2' ' HA ' ' A' ' 111' ' ' ASP . . . -67.99 120.16 13.8 Favored 'General case' 0 N--CA 1.447 -0.6 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 174.378 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 . . . . . 0 C--N 1.322 -0.623 0 CA-C-O 121.27 0.557 . . . . 0.0 110.188 -176.06 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 72.5 m95 . . . . . 0 N--CA 1.453 -0.314 0 CA-C-O 120.683 0.277 . . . . 0.0 111.119 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . 0.438 ' O ' HG21 ' A' ' 27' ' ' VAL . 14.6 m120 -60.78 -36.99 80.37 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.522 175.528 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 43.9 m-20 -64.49 -45.16 88.53 Favored 'General case' 0 CA--C 1.52 -0.2 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.38 178.907 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 61.2 tp -55.13 -50.9 68.07 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.75 179.011 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -55.55 -47.03 77.0 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.912 -0.585 . . . . 0.0 111.639 -178.702 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.554 ' HA ' HD13 ' A' ' 30' ' ' ILE . 92.2 t -58.58 -37.09 62.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.471 -179.732 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 59.8 t80 -60.01 -45.89 91.27 Favored 'General case' 0 CA--C 1.534 0.339 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.042 -178.039 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.446 HG13 HD12 ' A' ' 118' ' ' ILE . 3.2 mp -64.09 -41.56 92.83 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.17 0 CA-C-O 120.973 0.416 . . . . 0.0 110.468 176.345 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.588 HG22 ' HB2' ' A' ' 58' ' ' SER . 90.6 mt -58.42 -44.67 89.22 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 115.739 -0.664 . . . . 0.0 111.357 -177.92 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 49.7 mtp180 -66.51 -33.82 76.55 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.463 -177.617 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 44.5 t -82.29 -25.81 33.67 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.416 -174.936 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 15.4 p -95.82 -81.82 0.4 Allowed 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.85 0.357 . . . . 0.0 111.746 -174.056 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 104.56 158.34 23.75 Favored Glycine 0 N--CA 1.447 -0.597 0 C-N-CA 120.937 -0.649 . . . . 0.0 111.8 -176.666 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 15.8 Cg_exo -68.67 139.58 44.61 Favored 'Trans proline' 0 N--CA 1.465 -0.164 0 C-N-CA 122.876 2.384 . . . . 0.0 112.415 -179.426 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 96.1 -4.67 65.32 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.577 -0.821 . . . . 0.0 112.568 178.502 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 29.6 p -96.48 -170.76 2.14 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 109.983 -0.377 . . . . 0.0 109.983 -179.892 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' ARG . . . . . 0.753 ' HB2' ' HA ' ' A' ' 90' ' ' ALA . 99.3 mtt180 -123.21 129.68 51.73 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.704 0.287 . . . . 0.0 110.661 174.429 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.752 HG22 HG22 ' A' ' 60' ' ' VAL . 98.7 t -129.41 121.9 54.39 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 N-CA-C 109.203 -0.665 . . . . 0.0 109.203 175.218 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 34.0 t -106.0 130.83 56.93 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 CA-C-O 120.755 0.312 . . . . 0.0 111.502 -174.293 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . 0.719 ' HB3' HD22 ' A' ' 64' ' ' LEU . 7.8 tp10 -114.15 122.03 45.59 Favored 'General case' 0 C--O 1.239 0.5 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.012 175.24 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.479 HG13 HD23 ' A' ' 106' ' ' LEU . 24.2 t -100.8 89.0 1.55 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 115.773 -0.648 . . . . 0.0 110.489 179.842 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 148.11 55.94 0.02 OUTLIER Glycine 0 N--CA 1.448 -0.538 0 CA-C-N 115.54 -0.754 . . . . 0.0 111.366 -177.879 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . 0.574 ' HB3' ' HB3' ' A' ' 64' ' ' LEU . . . -84.97 76.94 10.21 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.986 0.422 . . . . 0.0 111.961 -173.962 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . 0.599 ' O ' ' HG ' ' A' ' 48' ' ' LEU . . . -89.5 -157.02 32.59 Favored Glycine 0 C--O 1.226 -0.367 0 C-N-CA 120.88 -0.676 . . . . 0.0 111.781 175.823 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . 0.436 HH11 ' HD3' ' A' ' 46' ' ' ARG . 0.0 OUTLIER -74.89 -15.44 60.7 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.984 0.421 . . . . 0.0 110.811 178.802 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 32.0 p90 -85.66 41.16 0.89 Allowed 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.53 -175.122 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . 0.768 HD11 HD11 ' A' ' 74' ' ' ILE . 94.2 mt -80.96 19.16 0.9 Allowed 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 112.379 0.511 . . . . 0.0 112.379 -176.42 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 32.7 p90 -61.29 -27.39 68.44 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.712 0.291 . . . . 0.0 110.918 179.313 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 98.6 t -69.02 -51.28 45.64 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.237 175.43 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' SER . . . . . 0.415 ' O ' ' HG2' ' A' ' 55' ' ' ARG . 1.7 m -61.75 -45.3 94.51 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 121.384 0.612 . . . . 0.0 110.201 -179.868 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.431 ' CG ' ' HZ1' ' A' ' 56' ' ' LYS . 25.6 t70 -58.8 -41.12 85.99 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 114.7 -1.137 . . . . 0.0 111.119 -179.454 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 80.6 t80 -66.99 -52.01 47.93 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.693 178.295 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.528 HG21 HG12 ' A' ' 30' ' ' ILE . 83.8 mt -58.23 -47.27 87.85 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-N 115.981 -0.554 . . . . 0.0 112.075 -176.041 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' ARG . . . . . 0.415 ' HG2' ' O ' ' A' ' 51' ' ' SER . 15.6 ptm180 -68.64 -20.7 64.48 Favored 'General case' 0 CA--C 1.533 0.289 0 N-CA-C 112.535 0.569 . . . . 0.0 112.535 -172.649 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . 0.431 ' HZ1' ' CG ' ' A' ' 52' ' ' ASP . 23.0 mtmm -84.74 -29.93 25.11 Favored 'General case' 0 C--N 1.328 -0.345 0 C-N-CA 120.705 -0.398 . . . . 0.0 111.251 179.28 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 16.4 m-70 -86.48 -54.2 4.55 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.235 0.54 . . . . 0.0 109.586 177.744 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' SER . . . . . 0.588 ' HB2' HG22 ' A' ' 30' ' ' ILE . 10.9 t -104.22 121.63 43.7 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 115.677 -0.692 . . . . 0.0 109.532 179.052 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 3.0 mppt? -84.79 61.45 6.79 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-O 121.897 0.856 . . . . 0.0 110.241 178.951 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.752 HG22 HG22 ' A' ' 39' ' ' VAL . 2.5 p -93.62 153.34 3.39 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.792 0 CA-C-N 114.167 -1.379 . . . . 0.0 109.299 177.232 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 43.9 m-20 -73.33 82.23 1.39 Allowed 'General case' 0 CA--C 1.518 -0.254 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 172.598 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . 0.543 HD23 ' HH ' ' A' ' 94' ' ' TYR . 2.7 tt -80.93 105.45 12.17 Favored 'General case' 0 C--N 1.321 -0.651 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 179.549 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 48.8 t -96.96 117.14 40.95 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.439 -175.829 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . 0.719 HD22 ' HB3' ' A' ' 41' ' ' GLU . 80.0 mt -99.77 130.27 45.96 Favored 'General case' 0 C--N 1.314 -0.954 0 CA-C-N 115.58 -0.737 . . . . 0.0 109.185 177.249 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 22.9 p -117.86 129.4 55.63 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 120.555 0.217 . . . . 0.0 111.047 179.334 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 25.5 t70 -165.05 153.72 12.19 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.917 -0.583 . . . . 0.0 109.931 178.527 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . 0.488 HG22 ' HE3' ' A' ' 68' ' ' LYS . 54.3 mt -76.98 100.39 2.57 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-O 120.93 0.395 . . . . 0.0 110.605 -178.289 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' LYS . . . . . 0.824 ' HZ3' ' HB2' ' A' ' 68' ' ' LYS . 7.4 mtmp? 70.33 83.97 0.15 Allowed Pre-proline 0 C--O 1.233 0.214 0 CA-C-N 115.119 -0.946 . . . . 0.0 110.53 -179.687 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . 0.929 ' HB3' ' HB ' ' A' ' 74' ' ' ILE . 11.2 Cg_endo . . . . . 0 C--O 1.232 0.205 0 C-N-CA 123.714 2.942 . . . . 0.0 113.968 -175.653 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . 0.929 ' HB ' ' HB3' ' A' ' 69' ' ' PRO . 55.8 mt . . . . . 0 C--O 1.234 0.263 0 CA-C-O 120.763 0.316 . . . . 0.0 110.724 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 57.3 t -85.16 126.64 40.35 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 176.126 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' ARG . . . . . 0.463 ' HA ' ' HD3' ' A' ' 69' ' ' PRO . 1.6 ppt_? -77.68 28.08 0.17 Allowed 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 112.491 0.552 . . . . 0.0 112.491 -176.344 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 16.1 t70 -75.71 157.24 33.84 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 110.117 -0.327 . . . . 0.0 110.117 -177.579 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' ASP . . . . . 0.535 ' OD1' HG22 ' A' ' 80' ' ' THR . 5.9 t70 -88.47 161.41 17.03 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 120.691 0.281 . . . . 0.0 110.875 -171.984 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 8.5 tp -98.47 -28.23 3.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-O 120.829 0.347 . . . . 0.0 111.029 -177.926 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.535 HG22 ' OD1' ' A' ' 78' ' ' ASP . 15.0 t -90.02 -1.35 57.95 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.637 0.732 . . . . 0.0 109.165 176.868 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 34.5 t -152.12 72.32 7.78 Favored Pre-proline 0 C--N 1.322 -0.594 0 CA-C-N 114.738 -1.119 . . . . 0.0 108.984 175.069 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' PRO . . . . . 0.523 ' HB2' ' HE2' ' A' ' 87' ' ' TYR . 91.1 Cg_endo -89.47 141.55 4.01 Favored 'Trans proline' 0 N--CA 1.457 -0.633 0 C-N-CA 122.829 2.353 . . . . 0.0 112.798 -177.521 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' ARG . . . . . 0.74 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 56.7 mtt-85 -83.49 113.38 20.75 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.047 178.305 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' MET . . . . . 0.7 ' HA ' ' HD2' ' A' ' 87' ' ' TYR . 29.6 mtp -68.06 -17.4 64.38 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.551 -0.295 . . . . 0.0 110.995 178.168 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . 0.74 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 9.8 pt-20 -61.89 -23.81 66.54 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.934 0.397 . . . . 0.0 110.653 176.592 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 72.6 mt -85.11 -34.48 8.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.48 178.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . 0.7 ' HD2' ' HA ' ' A' ' 84' ' ' MET . 75.0 m-85 -78.23 -30.75 48.91 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.429 -177.243 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . 0.423 ' HG2' HG13 ' A' ' 113' ' ' VAL . 53.2 mtp180 -65.68 140.58 58.48 Favored 'General case' 0 CA--C 1.516 -0.362 0 CA-C-O 121.403 0.621 . . . . 0.0 110.882 178.701 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 91.08 1.73 72.29 Favored Glycine 0 N--CA 1.447 -0.61 0 CA-C-N 115.199 -0.909 . . . . 0.0 111.894 -178.044 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . 0.753 ' HA ' ' HB2' ' A' ' 38' ' ' ARG . . . -85.16 138.77 32.16 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.995 0.426 . . . . 0.0 110.75 178.88 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -89.16 -24.67 22.14 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.079 178.379 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . 0.509 HD22 ' N ' ' A' ' 93' ' ' ILE . 4.7 tt -153.49 143.15 21.85 Favored 'General case' 0 N--CA 1.45 -0.448 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.206 -178.345 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.509 ' N ' HD22 ' A' ' 92' ' ' LEU . 72.7 mt -132.03 133.73 60.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 N-CA-C 109.111 -0.7 . . . . 0.0 109.111 176.551 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' TYR . . . . . 0.543 ' HH ' HD23 ' A' ' 62' ' ' LEU . 1.2 p90 -138.37 161.24 37.46 Favored 'General case' 0 C--N 1.321 -0.636 0 C-N-CA 120.707 -0.397 . . . . 0.0 110.119 -178.693 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' SER . . . . . 0.629 ' HA ' ' OE2' ' A' ' 41' ' ' GLU . 19.4 m -146.87 115.65 6.82 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.058 -178.91 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 78.9 mt -77.23 94.35 1.31 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.752 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.619 179.45 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' ARG . . . . . 0.526 ' HG3' ' OE1' ' A' ' 125' ' ' GLU . 19.6 ttp85 58.61 82.64 0.23 Allowed Pre-proline 0 CA--C 1.531 0.244 0 CA-C-N 114.608 -1.178 . . . . 0.0 111.66 -177.628 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 88.3 Cg_endo -83.74 136.66 7.36 Favored 'Trans proline' 0 N--CA 1.456 -0.724 0 C-N-CA 122.467 2.111 . . . . 0.0 111.638 176.136 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . 0.735 ' HB2' ' HG2' ' A' ' 101' ' ' GLU . 22.4 Cg_exo -63.32 149.94 89.9 Favored 'Trans proline' 0 C--O 1.238 0.478 0 C-N-CA 122.581 2.187 . . . . 0.0 111.733 177.951 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -73.76 42.22 0.13 Allowed 'General case' 0 N--CA 1.465 0.284 0 CA-C-O 121.304 0.573 . . . . 0.0 111.812 -178.216 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 101' ' ' GLU . . . . . 0.735 ' HG2' ' HB2' ' A' ' 99' ' ' PRO . 11.0 pt-20 -132.15 -26.24 1.93 Allowed 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.607 179.303 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.729 HG22 ' HG3' ' A' ' 101' ' ' GLU . 40.1 pt -119.88 -11.64 10.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.55 -175.062 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 103' ' ' HIS . . . . . 0.479 ' O ' ' HG3' ' A' ' 107' ' ' MET . 4.8 p-80 -56.72 -45.24 82.0 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.989 -0.551 . . . . 0.0 111.612 -175.147 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 8.5 m -61.35 -35.05 76.36 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.002 0.43 . . . . 0.0 110.908 179.529 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.795 ' HA ' ' HE ' ' A' ' 108' ' ' ARG . 67.1 m -73.3 -36.71 66.32 Favored 'General case' 0 N--CA 1.451 -0.408 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.39 179.703 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . 0.479 HD23 HG13 ' A' ' 42' ' ' VAL . 85.0 mt -64.39 -42.08 96.31 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.73 178.914 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 107' ' ' MET . . . . . 0.506 ' HA ' HD23 ' A' ' 117' ' ' LEU . 81.4 mtp -60.5 -44.27 96.17 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.539 -179.292 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 108' ' ' ARG . . . . . 0.795 ' HE ' ' HA ' ' A' ' 105' ' ' SER . 31.6 ptt180 -74.73 -20.77 59.69 Favored 'General case' 0 CA--C 1.53 0.205 0 C-N-CA 121.048 -0.261 . . . . 0.0 111.555 -178.263 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.523 HG23 ' O ' ' A' ' 105' ' ' SER . 55.9 t -74.06 -43.47 51.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.749 0.309 . . . . 0.0 110.333 175.421 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -57.24 -45.66 83.73 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.972 -179.822 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . 0.945 ' HA ' ' HB3' ' A' ' 148' ' ' ALA . 4.0 t70 -71.72 -28.71 63.87 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 121.174 0.511 . . . . 0.0 110.254 -177.284 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -74.49 -33.01 62.74 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.953 -0.567 . . . . 0.0 111.809 -179.64 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.423 HG13 ' HG2' ' A' ' 88' ' ' ARG . 34.0 m -95.52 -24.78 4.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 C-N-CA 121.088 -0.245 . . . . 0.0 111.097 179.578 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . 0.431 ' HA2' ' O ' ' A' ' 149' ' ' GLU . . . 89.87 46.5 4.2 Favored Glycine 0 N--CA 1.453 -0.226 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.993 176.303 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -124.66 150.25 46.29 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 120.533 0.206 . . . . 0.0 110.85 -178.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 116' ' ' ARG . . . . . 0.491 ' HD3' ' OE1' ' A' ' 145' ' ' GLU . 14.7 ttm180 -70.65 119.92 15.5 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 177.93 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . 0.506 HD23 ' HA ' ' A' ' 107' ' ' MET . 57.6 tp -90.58 118.59 30.15 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 -179.765 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . 0.446 HD12 HG13 ' A' ' 29' ' ' ILE . 61.9 mt -115.98 112.71 40.77 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.654 0 CA-C-O 121.289 0.566 . . . . 0.0 110.594 179.455 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 62.8 mt -110.97 119.03 58.71 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.845 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.029 178.474 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 120' ' ' LYS . . . . . 0.629 ' HG2' ' HB3' ' A' ' 143' ' ' PHE . 9.0 tmtm? -116.33 96.97 48.99 Favored Pre-proline 0 C--N 1.322 -0.616 0 CA-C-N 116.162 -0.472 . . . . 0.0 109.994 178.885 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 0.9 OUTLIER -77.65 -178.71 4.81 Favored 'Trans proline' 0 N--CA 1.459 -0.522 0 C-N-CA 122.652 2.235 . . . . 0.0 111.442 174.373 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 5.7 mp -63.87 177.68 0.73 Allowed 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.957 -179.439 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 15.2 m -49.45 -65.15 0.61 Allowed 'General case' 0 CA--C 1.53 0.194 0 CA-C-N 115.71 -0.677 . . . . 0.0 111.888 -175.357 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -106.54 64.86 0.27 Allowed Glycine 0 N--CA 1.448 -0.531 0 C-N-CA 120.669 -0.777 . . . . 0.0 111.173 175.452 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . 0.526 ' OE1' ' HG3' ' A' ' 97' ' ' ARG . 40.8 tt0 -140.11 145.48 37.65 Favored 'General case' 0 N--CA 1.448 -0.558 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 -174.712 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 10.3 t70 -123.02 174.67 7.05 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.356 -179.169 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 6.9 mt . . . . . 0 C--N 1.328 -0.334 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.055 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 132' ' ' LYS . . . . . 0.424 ' HB3' ' HE2' ' A' ' 107' ' ' MET . 16.5 tppt? . . . . . 0 C--O 1.232 0.155 0 CA-C-O 121.029 0.442 . . . . 0.0 110.59 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 133' ' ' MET . . . . . 0.777 ' HG2' ' HB2' ' A' ' 146' ' ' TYR . 93.4 mtp -104.86 155.76 18.63 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.578 -177.533 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 12.9 ptmt -106.12 139.73 40.19 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.446 -175.789 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . 0.824 HD11 ' HD2' ' A' ' 142' ' ' TYR . 55.2 tp -78.81 125.27 29.14 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 115.861 -0.608 . . . . 0.0 110.428 177.709 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -119.81 147.16 23.64 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.808 179.059 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 137' ' ' ASN . . . . . 0.55 ' ND2' ' HB3' ' A' ' 142' ' ' TYR . 18.2 m120 -120.72 119.1 31.82 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.92 -0.582 . . . . 0.0 109.63 178.411 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 67.7 t80 -131.74 130.98 42.6 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 109.916 -0.401 . . . . 0.0 109.916 179.289 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 71.66 -91.21 0.49 Allowed Glycine 0 N--CA 1.441 -1.0 0 N-CA-C 111.21 -0.756 . . . . 0.0 111.21 -176.821 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 140' ' ' ARG . . . . . 0.439 ' HD3' ' HA ' ' A' ' 140' ' ' ARG . 29.1 mmt180 -150.21 12.81 0.75 Allowed 'General case' 0 C--N 1.32 -0.708 0 CA-C-O 120.807 0.337 . . . . 0.0 110.556 179.308 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 7.1 t -125.15 160.64 28.67 Favored 'General case' 0 C--N 1.322 -0.606 0 N-CA-C 109.865 -0.42 . . . . 0.0 109.865 -178.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 142' ' ' TYR . . . . . 0.824 ' HD2' HD11 ' A' ' 135' ' ' LEU . 20.8 p90 -126.83 149.64 49.6 Favored 'General case' 0 N--CA 1.449 -0.523 0 CA-C-O 121.405 0.621 . . . . 0.0 111.176 179.494 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 143' ' ' PHE . . . . . 0.629 ' HB3' ' HG2' ' A' ' 120' ' ' LYS . 19.5 p90 -156.39 179.3 9.39 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 114.823 -1.08 . . . . 0.0 109.417 -177.37 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -113.2 127.85 56.3 Favored 'General case' 0 C--N 1.319 -0.752 0 C-N-CA 120.963 -0.295 . . . . 0.0 110.451 -179.738 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 145' ' ' GLU . . . . . 0.491 ' OE1' ' HD3' ' A' ' 116' ' ' ARG . 17.5 pt-20 -114.85 157.04 23.84 Favored 'General case' 0 C--N 1.32 -0.681 0 N-CA-C 109.041 -0.726 . . . . 0.0 109.041 173.189 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . 0.777 ' HB2' ' HG2' ' A' ' 133' ' ' MET . 19.5 t80 -137.77 122.75 19.01 Favored 'General case' 0 C--N 1.31 -1.133 0 CA-C-N 116.054 -0.521 . . . . 0.0 109.638 176.07 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 2.2 mp -79.49 95.76 2.18 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.813 0 N-CA-C 108.442 -0.947 . . . . 0.0 108.442 174.91 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . 0.945 ' HB3' ' HA ' ' A' ' 111' ' ' ASP . . . -74.87 130.3 39.17 Favored 'General case' 0 N--CA 1.437 -1.083 0 CA-C-N 115.462 -0.79 . . . . 0.0 109.739 178.679 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . 0.431 ' O ' ' HA2' ' A' ' 114' ' ' GLY . 74.4 mm-40 . . . . . 0 C--N 1.315 -0.904 0 CA-C-O 122.032 0.92 . . . . 0.0 111.558 178.861 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 95.5 m95 . . . . . 0 CA--C 1.528 0.122 0 N-CA-C 111.58 0.215 . . . . 0.0 111.58 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . 0.435 ' O ' HG21 ' A' ' 27' ' ' VAL . 4.4 m-20 -66.49 -40.72 89.42 Favored 'General case' 0 C--N 1.328 -0.348 0 C-N-CA 121.224 -0.19 . . . . 0.0 111.487 -177.015 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 38.8 m-20 -61.41 -39.44 90.78 Favored 'General case' 0 N--CA 1.466 0.35 0 CA-C-O 121.071 0.462 . . . . 0.0 110.411 177.644 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.57 HD23 ' HD3' ' A' ' 120' ' ' LYS . 25.0 tp -63.33 -42.95 98.99 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.648 -0.705 . . . . 0.0 110.59 176.863 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -59.68 -46.95 87.5 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.738 178.258 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.435 HG21 ' O ' ' A' ' 23' ' ' ASN . 90.3 t -55.59 -42.26 67.9 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.192 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.069 178.803 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 69.2 t80 -59.33 -45.16 92.11 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 121.024 0.44 . . . . 0.0 110.637 179.598 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 57.9 mt -67.07 -39.91 84.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.62 179.751 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.655 HG12 HG22 ' A' ' 54' ' ' ILE . 98.1 mt -59.9 -41.87 87.35 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.453 -0.794 . . . . 0.0 110.941 178.915 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 79.2 mtp180 -66.49 -37.64 85.51 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.882 -178.407 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 81.2 m -76.76 -18.0 58.72 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.214 -176.068 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 11.9 p -104.26 -84.37 0.48 Allowed 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.433 -178.556 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 99.69 160.47 28.82 Favored Glycine 0 N--CA 1.447 -0.626 0 C-N-CA 121.089 -0.577 . . . . 0.0 111.902 -176.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 11.5 Cg_exo -70.95 152.74 63.4 Favored 'Trans proline' 0 C--O 1.235 0.33 0 C-N-CA 122.743 2.296 . . . . 0.0 111.976 179.57 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 99.61 -26.35 24.73 Favored Glycine 0 N--CA 1.453 -0.228 0 C-N-CA 120.827 -0.701 . . . . 0.0 112.752 176.624 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 14.0 t -100.5 -166.99 1.38 Allowed 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 -178.846 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' ARG . . . . . 1.004 ' HG2' ' HA ' ' A' ' 90' ' ' ALA . 0.1 OUTLIER -130.94 136.53 48.65 Favored 'General case' 0 N--CA 1.446 -0.657 0 CA-C-O 121.113 0.483 . . . . 0.0 111.021 -176.767 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.47 HG21 HG22 ' A' ' 60' ' ' VAL . 95.9 t -129.16 135.82 61.04 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.603 0 CA-C-N 115.48 -0.782 . . . . 0.0 109.486 -179.916 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.489 HG12 ' CE2' ' A' ' 87' ' ' TYR . 38.7 t -108.11 128.19 63.72 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 CA-C-O 120.927 0.394 . . . . 0.0 111.31 -176.479 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . 0.571 ' HB3' HD22 ' A' ' 64' ' ' LEU . 41.1 tt0 -106.49 118.23 36.1 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.924 -0.58 . . . . 0.0 109.778 175.826 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.575 ' HB ' ' HG ' ' A' ' 95' ' ' SER . 62.9 t -97.21 120.48 46.6 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.671 -179.173 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 92.5 48.7 2.94 Favored Glycine 0 N--CA 1.447 -0.621 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.139 179.567 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -80.36 41.09 0.52 Allowed 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.063 0.459 . . . . 0.0 111.446 -176.861 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . 0.426 ' O ' ' HB2' ' A' ' 46' ' ' ARG . . . -81.29 81.58 1.62 Allowed Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.954 -0.641 . . . . 0.0 112.27 -178.332 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . 0.426 ' HB2' ' O ' ' A' ' 45' ' ' GLY . 82.9 mtm180 71.08 13.56 6.86 Favored 'General case' 0 N--CA 1.469 0.498 0 C-N-CA 123.238 0.615 . . . . 0.0 111.271 -179.44 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 74.6 m-85 -98.51 17.05 19.94 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.357 0.598 . . . . 0.0 109.706 176.864 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . 0.448 HD23 HD11 ' A' ' 74' ' ' ILE . 82.2 mt -62.14 -10.1 9.44 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 114.793 -1.094 . . . . 0.0 112.388 -174.655 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 73.9 t80 -57.85 -38.35 75.53 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 120.715 0.293 . . . . 0.0 110.837 179.167 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 60.4 t -73.54 -54.63 14.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.435 -179.093 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -59.75 -38.33 81.47 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.852 -179.437 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.549 ' HA ' ' HG2' ' A' ' 55' ' ' ARG . 33.5 t70 -71.44 -35.85 71.06 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.629 0.252 . . . . 0.0 111.181 179.527 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 56.7 t80 -61.36 -49.03 78.57 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 109.503 -0.554 . . . . 0.0 109.503 175.027 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.655 HG22 HG12 ' A' ' 30' ' ' ILE . 77.6 mt -60.85 -51.83 68.61 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-N 115.727 -0.669 . . . . 0.0 111.85 -179.236 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' ARG . . . . . 0.549 ' HG2' ' HA ' ' A' ' 52' ' ' ASP . 40.1 ptt180 -65.29 -19.93 66.18 Favored 'General case' 0 N--CA 1.467 0.392 0 N-CA-C 112.382 0.512 . . . . 0.0 112.382 -173.464 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 3.1 mtmp? -87.33 -38.61 16.07 Favored 'General case' 0 C--N 1.327 -0.372 0 C-N-CA 120.723 -0.391 . . . . 0.0 111.588 178.668 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 31.0 m-70 -76.03 -32.73 59.5 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 120.662 0.268 . . . . 0.0 110.693 179.651 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 67.6 m -138.63 128.0 24.46 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 116.264 -0.425 . . . . 0.0 109.863 174.581 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . 0.405 ' HD3' ' HA ' ' A' ' 59' ' ' LYS . 1.3 tppp? -78.58 63.42 3.38 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 122.096 0.95 . . . . 0.0 110.901 -177.375 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.47 HG22 HG21 ' A' ' 39' ' ' VAL . 7.3 p -86.29 142.21 13.4 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.957 0 CA-C-N 114.349 -1.296 . . . . 0.0 109.387 172.721 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . 0.43 ' O ' ' HA ' ' A' ' 38' ' ' ARG . 33.0 t70 -76.51 89.25 3.27 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 179.228 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 2.3 tt -90.0 122.91 33.44 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.78 -0.646 . . . . 0.0 110.496 -173.93 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 43.8 t -102.29 121.76 53.74 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-N 115.523 -0.762 . . . . 0.0 109.899 -178.234 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . 0.571 HD22 ' HB3' ' A' ' 41' ' ' GLU . 50.8 mt -100.15 131.01 46.34 Favored 'General case' 0 C--N 1.316 -0.858 0 CA-C-N 116.214 -0.448 . . . . 0.0 109.919 179.766 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.562 HG21 ' HB ' ' A' ' 75' ' ' VAL . 17.0 p -132.23 137.37 47.52 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.951 0.405 . . . . 0.0 111.18 178.383 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 30.3 t70 -165.28 158.4 16.27 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.518 177.529 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 40.7 mm -72.09 96.83 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-O 120.759 0.314 . . . . 0.0 110.429 -178.76 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 65.3 mttm 63.56 90.16 0.09 OUTLIER Pre-proline 0 N--CA 1.465 0.309 0 CA-C-N 115.393 -0.821 . . . . 0.0 111.514 178.682 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 97.3 Cg_endo . . . . . 0 N--CA 1.459 -0.506 0 C-N-CA 122.867 2.378 . . . . 0.0 112.726 -179.273 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . 0.448 HD11 HD23 ' A' ' 48' ' ' LEU . 63.6 mt . . . . . 0 N--CA 1.451 -0.393 0 CA-C-O 120.756 0.312 . . . . 0.0 110.358 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.562 ' HB ' HG21 ' A' ' 65' ' ' THR . 53.8 t -72.71 133.37 31.89 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.093 179.321 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 6.7 ptp180 -86.9 32.48 0.67 Allowed 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.855 -176.471 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . 0.504 ' HB2' HG13 ' A' ' 75' ' ' VAL . 1.6 t70 -77.11 -159.16 0.12 Allowed 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.653 -174.329 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' ASP . . . . . 0.434 ' OD1' HG23 ' A' ' 80' ' ' THR . 4.9 t70 -125.15 -174.16 2.98 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 120.733 0.301 . . . . 0.0 110.25 -174.374 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 9.2 tp -139.9 -30.89 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-O 120.877 0.37 . . . . 0.0 110.406 178.951 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.434 HG23 ' OD1' ' A' ' 78' ' ' ASP . 8.9 t -86.38 -20.8 27.71 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.516 0.674 . . . . 0.0 109.247 177.127 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 13.6 t -150.67 72.57 8.92 Favored Pre-proline 0 C--N 1.325 -0.489 0 CA-C-N 115.154 -0.93 . . . . 0.0 108.577 171.721 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' PRO . . . . . 0.43 ' HB3' ' O ' ' A' ' 78' ' ' ASP . 89.6 Cg_endo -89.77 171.3 4.16 Favored 'Trans proline' 0 N--CA 1.457 -0.674 0 C-N-CA 123.007 2.472 . . . . 0.0 113.149 -173.96 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' ARG . . . . . 0.57 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 63.6 mtt180 -88.9 111.36 21.99 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.671 -0.695 . . . . 0.0 109.536 171.432 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' MET . . . . . 0.52 ' O ' ' HG3' ' A' ' 88' ' ' ARG . 92.7 mmm -67.36 -20.04 65.51 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.395 -176.991 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . 0.57 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 9.3 pt-20 -60.49 -27.29 67.47 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.309 -179.664 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 67.4 mt -79.93 -40.24 20.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-O 120.98 0.419 . . . . 0.0 111.07 -178.571 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . 0.489 ' CE2' HG12 ' A' ' 40' ' ' VAL . 73.0 m-85 -81.98 -31.14 31.29 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.632 -176.889 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . 0.706 ' HG2' HG12 ' A' ' 113' ' ' VAL . 16.1 mtp180 -69.42 116.78 10.24 Favored 'General case' 0 CA--C 1.509 -0.606 0 CA-C-O 121.906 0.86 . . . . 0.0 111.462 -175.957 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . 0.424 ' O ' ' HD3' ' A' ' 38' ' ' ARG . . . 116.38 -18.9 13.37 Favored Glycine 0 C--N 1.31 -0.897 0 CA-C-N 114.07 -1.423 . . . . 0.0 111.765 -177.727 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . 1.004 ' HA ' ' HG2' ' A' ' 38' ' ' ARG . . . -66.24 143.09 57.44 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.604 0.24 . . . . 0.0 110.553 179.075 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -82.57 -29.22 30.43 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 120.831 0.348 . . . . 0.0 110.807 -178.624 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . 0.475 ' HG ' ' HB3' ' A' ' 116' ' ' ARG . 5.8 tt -149.71 143.44 25.46 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.15 -0.477 . . . . 0.0 109.96 -177.412 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.603 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 62.8 mt -130.65 127.46 62.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 N-CA-C 109.098 -0.705 . . . . 0.0 109.098 177.019 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' TYR . . . . . 0.612 ' HD2' ' HZ3' ' A' ' 120' ' ' LYS . 20.7 p90 -138.71 142.84 38.91 Favored 'General case' 0 C--N 1.321 -0.664 0 C-N-CA 120.208 -0.597 . . . . 0.0 111.407 -179.039 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' SER . . . . . 0.575 ' HG ' ' HB ' ' A' ' 42' ' ' VAL . 8.0 m -118.08 144.96 45.19 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 115.497 -0.774 . . . . 0.0 110.047 -177.814 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' ILE . . . . . 0.804 HG12 ' HD2' ' A' ' 120' ' ' LYS . 42.9 mt -111.69 106.84 21.55 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-O 120.759 0.314 . . . . 0.0 110.46 179.804 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' ARG . . . . . 0.577 ' HD3' ' O ' ' A' ' 97' ' ' ARG . 0.0 OUTLIER 50.88 76.43 0.55 Allowed Pre-proline 0 CA--C 1.536 0.439 0 CA-C-N 115.099 -0.955 . . . . 0.0 111.173 -177.381 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_endo -96.3 159.61 1.29 Allowed 'Trans proline' 0 N--CA 1.453 -0.886 0 C-N-CA 123.211 2.607 . . . . 0.0 112.698 178.887 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . 0.667 ' HD2' HD13 ' A' ' 102' ' ' ILE . 17.5 Cg_exo -64.16 136.37 51.55 Favored 'Trans proline' 0 N--CA 1.462 -0.353 0 C-N-CA 122.32 2.014 . . . . 0.0 111.306 174.55 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . 0.57 ' HA ' ' CD2' ' A' ' 103' ' ' HIS . . . -68.98 -15.46 63.49 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 120.971 0.415 . . . . 0.0 111.833 -174.977 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 101' ' ' GLU . . . . . . . . . . . . . 1.7 pm0 -75.86 -18.51 59.4 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.888 178.582 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.667 HD13 ' HD2' ' A' ' 99' ' ' PRO . 2.6 pp -113.48 8.1 7.89 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.178 0 N-CA-C 112.567 0.58 . . . . 0.0 112.567 -177.341 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 103' ' ' HIS . . . . . 0.57 ' CD2' ' HA ' ' A' ' 100' ' ' ALA . 4.7 m-70 -57.57 -42.64 83.47 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 121.063 0.459 . . . . 0.0 110.777 176.361 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 6.9 p -69.86 -26.85 64.4 Favored 'General case' 0 C--O 1.236 0.372 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.095 -179.114 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.563 ' O ' HG23 ' A' ' 109' ' ' VAL . 74.8 m -70.52 -44.79 66.85 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 109.757 -0.461 . . . . 0.0 109.757 174.519 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 96.0 mt -56.84 -41.81 78.54 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 121.067 0.46 . . . . 0.0 110.354 175.676 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 107' ' ' MET . . . . . 0.446 ' HE1' ' HG3' ' A' ' 133' ' ' MET . 46.6 tpp -55.59 -52.59 63.25 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.28 -0.873 . . . . 0.0 111.365 178.497 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 4.8 ptp180 -71.3 -22.56 61.93 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 111.889 0.329 . . . . 0.0 111.889 -177.303 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.563 HG23 ' O ' ' A' ' 105' ' ' SER . 82.5 t -70.19 -48.37 61.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 C-N-CA 120.731 -0.388 . . . . 0.0 109.981 175.012 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -60.96 -44.53 97.16 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 177.049 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 22.7 t70 -60.68 -34.06 73.77 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.36 -0.836 . . . . 0.0 111.036 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -74.75 -44.44 49.74 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.795 -0.639 . . . . 0.0 111.813 -179.271 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.706 HG12 ' HG2' ' A' ' 88' ' ' ARG . 13.1 m -87.46 -29.29 5.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.981 -172.549 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 87.32 53.77 2.71 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.852 -0.69 . . . . 0.0 112.392 -178.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -131.97 160.44 35.79 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.737 0.303 . . . . 0.0 111.086 -178.192 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 116' ' ' ARG . . . . . 0.475 ' HB3' ' HG ' ' A' ' 92' ' ' LEU . 13.5 ttm180 -79.0 123.88 27.72 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 109.565 -0.532 . . . . 0.0 109.565 175.923 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . 0.603 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 58.3 tp -98.14 118.32 34.49 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.181 -179.429 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 55.7 mt -117.19 115.13 47.81 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-O 121.197 0.522 . . . . 0.0 110.629 178.861 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 40.6 mt -107.78 135.78 45.3 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.631 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.032 -178.032 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 120' ' ' LYS . . . . . 0.804 ' HD2' HG12 ' A' ' 96' ' ' ILE . 4.5 ptpp? -130.51 91.96 36.47 Favored Pre-proline 0 C--N 1.324 -0.518 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.238 -179.147 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 78.5 Cg_endo -96.77 -164.28 0.09 OUTLIER 'Trans proline' 0 N--CA 1.455 -0.765 0 C-N-CA 123.308 2.672 . . . . 0.0 112.647 179.344 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 122' ' ' LEU . . . . . 0.657 ' HB2' ' HB2' ' A' ' 125' ' ' GLU . 4.2 mm? -74.67 159.32 32.23 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.481 174.796 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 27.3 m -57.96 -43.68 86.57 Favored 'General case' 0 CA--C 1.53 0.2 0 CA-C-O 120.981 0.419 . . . . 0.0 110.959 -178.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -100.76 38.2 3.25 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.8 -0.714 . . . . 0.0 111.595 178.288 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . 0.657 ' HB2' ' HB2' ' A' ' 122' ' ' LEU . 27.4 tt0 -123.09 116.83 24.12 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.586 -0.524 . . . . 0.0 109.586 -177.515 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -88.55 164.71 15.28 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 121.544 0.688 . . . . 0.0 111.544 -172.903 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . 0.484 ' HA ' ' CD2' ' A' ' 103' ' ' HIS . 52.1 mt . . . . . 0 C--N 1.317 -0.827 0 CA-C-N 115.06 -0.973 . . . . 0.0 108.586 172.71 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 25.6 mtpp . . . . . 0 N--CA 1.453 -0.296 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 133' ' ' MET . . . . . 0.799 ' HG2' ' HB2' ' A' ' 146' ' ' TYR . 82.1 mtp -84.05 -179.0 7.14 Favored 'General case' 0 C--O 1.232 0.176 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.294 179.874 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 19.1 ptmt -142.52 135.09 27.99 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 120.985 0.422 . . . . 0.0 111.091 -179.449 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . 0.554 HD11 ' HD2' ' A' ' 142' ' ' TYR . 50.3 tp -71.63 124.14 24.07 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.543 -0.753 . . . . 0.0 110.307 175.743 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -121.78 137.22 56.12 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.145 -179.818 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 12.9 m120 -110.13 126.38 54.0 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 109.136 -0.69 . . . . 0.0 109.136 177.676 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 52.8 t80 -142.12 116.72 9.72 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 121.112 0.482 . . . . 0.0 111.277 -179.39 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 77.45 -92.34 1.08 Allowed Glycine 0 N--CA 1.447 -0.618 0 CA-C-N 115.74 -0.664 . . . . 0.0 112.159 176.045 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 50.4 mtm180 -139.52 16.37 2.55 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-O 121.047 0.451 . . . . 0.0 110.831 -179.372 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 13.8 t -138.15 158.72 43.74 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.269 -179.104 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 142' ' ' TYR . . . . . 0.554 ' HD2' HD11 ' A' ' 135' ' ' LEU . 35.2 p90 -134.33 139.62 45.79 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 178.135 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 9.2 p90 -148.9 -172.83 4.2 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.116 -173.185 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 99.1 m-85 -119.42 128.63 54.22 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 120.486 0.184 . . . . 0.0 110.633 -179.086 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 145' ' ' GLU . . . . . . . . . . . . . 19.1 pt-20 -120.31 159.88 24.13 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.044 0.45 . . . . 0.0 109.916 174.78 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . 0.799 ' HB2' ' HG2' ' A' ' 133' ' ' MET . 49.7 t80 -140.63 127.95 21.14 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 115.904 -0.589 . . . . 0.0 109.816 176.471 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 147' ' ' ILE . . . . . 0.436 ' N ' HD12 ' A' ' 147' ' ' ILE . 3.1 mp -94.63 100.66 11.47 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 N-CA-C 109.679 -0.489 . . . . 0.0 109.679 178.752 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -91.38 125.75 36.24 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.869 -0.605 . . . . 0.0 109.796 177.115 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 . . . . . 0 C--N 1.32 -0.696 0 CA-C-O 121.038 0.447 . . . . 0.0 110.186 -179.533 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 90.8 m95 . . . . . 0 N--CA 1.452 -0.368 0 CA-C-O 120.539 0.209 . . . . 0.0 110.696 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . 0.411 ' O ' HG22 ' A' ' 27' ' ' VAL . 4.7 m-20 -68.99 -47.61 65.13 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.515 -0.311 . . . . 0.0 110.905 177.729 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 15.6 m-20 -60.6 -39.48 88.28 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.81 0.338 . . . . 0.0 110.579 178.59 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 60.5 tp -57.76 -49.53 76.27 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.424 176.204 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -55.71 -47.17 77.31 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.542 -0.753 . . . . 0.0 110.904 178.859 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.411 HG22 ' O ' ' A' ' 23' ' ' ASN . 84.9 t -56.73 -42.9 78.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.938 178.479 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 86.6 t80 -61.32 -45.48 94.28 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.724 0.297 . . . . 0.0 110.383 178.436 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 72.9 mt -63.21 -43.2 98.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.45 178.799 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 86.8 mt -56.83 -42.66 78.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 115.451 -0.795 . . . . 0.0 111.265 177.126 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 21.4 mtp180 -69.06 -32.37 71.79 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.804 -178.816 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 77.0 m -88.33 2.51 52.36 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.794 -0.639 . . . . 0.0 111.758 -175.874 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 22.0 p -129.7 -80.54 0.56 Allowed 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 120.816 0.341 . . . . 0.0 111.004 178.018 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 95.61 160.13 33.08 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.934 -0.65 . . . . 0.0 112.408 -179.616 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -73.25 141.68 32.62 Favored 'Trans proline' 0 N--CA 1.462 -0.347 0 C-N-CA 122.785 2.323 . . . . 0.0 111.438 178.022 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 113.13 3.71 24.39 Favored Glycine 0 N--CA 1.449 -0.452 0 C-N-CA 120.348 -0.929 . . . . 0.0 112.16 -177.226 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 14.7 t -139.42 -169.57 2.71 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 110.001 -0.37 . . . . 0.0 110.001 177.812 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 47.0 mtp180 -121.75 135.84 54.94 Favored 'General case' 0 N--CA 1.45 -0.45 0 CA-C-O 120.906 0.384 . . . . 0.0 110.637 -178.738 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 52.3 t -122.56 134.67 65.07 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 177.463 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 50.3 t -108.04 124.36 64.21 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-O 120.733 0.301 . . . . 0.0 110.678 -177.813 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . 0.504 ' HB2' HD21 ' A' ' 62' ' ' LEU . 35.6 tt0 -102.04 106.68 17.61 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.066 179.004 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.586 ' O ' ' HA ' ' A' ' 95' ' ' SER . 60.3 t -94.04 124.39 46.49 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.603 0 CA-C-N 116.031 -0.531 . . . . 0.0 109.846 179.779 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 96.27 37.63 4.79 Favored Glycine 0 N--CA 1.445 -0.751 0 C-N-CA 120.337 -0.935 . . . . 0.0 111.297 -175.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -81.21 24.61 0.52 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.018 0.437 . . . . 0.0 111.413 -177.822 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -73.89 79.09 0.87 Allowed Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 121.212 -0.518 . . . . 0.0 112.08 -178.924 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 26.7 ttt180 75.67 7.72 3.8 Favored 'General case' 0 N--CA 1.468 0.436 0 C-N-CA 123.418 0.687 . . . . 0.0 110.968 177.14 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 65.8 m-85 -95.96 31.01 2.22 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.39 0.614 . . . . 0.0 110.413 178.06 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . 0.627 HD22 HD11 ' A' ' 64' ' ' LEU . 61.6 mt -74.35 14.65 0.42 Allowed 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.075 -0.966 . . . . 0.0 112.376 -172.931 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 87.8 t80 -70.3 -37.26 74.74 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 121.068 0.461 . . . . 0.0 110.375 179.665 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 47.2 t -74.76 -48.81 32.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-N 115.936 -0.574 . . . . 0.0 110.372 -179.326 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -58.67 -39.77 81.63 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.997 -0.547 . . . . 0.0 111.369 179.526 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.425 ' O ' ' HE2' ' A' ' 56' ' ' LYS . 30.6 t70 -62.06 -45.07 95.16 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.792 0.33 . . . . 0.0 110.531 177.826 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . 0.437 ' HA ' ' HE2' ' A' ' 56' ' ' LYS . 81.5 t80 -63.53 -42.98 98.4 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.927 -179.248 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 80.8 mt -66.22 -47.73 83.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.889 -178.941 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 22.4 ptt180 -62.77 -24.57 67.78 Favored 'General case' 0 N--CA 1.467 0.401 0 N-CA-C 111.856 0.317 . . . . 0.0 111.856 -175.344 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . 0.437 ' HE2' ' HA ' ' A' ' 53' ' ' TYR . 42.2 mtmt -77.2 -31.22 55.17 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.727 0.299 . . . . 0.0 111.692 -177.611 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 20.4 t60 -99.18 -48.56 4.79 Favored 'General case' 0 N--CA 1.448 -0.562 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.518 -177.384 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 38.1 m -95.22 155.51 16.7 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.068 0.461 . . . . 0.0 111.053 -178.024 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 28.5 mmmt -105.17 19.26 20.9 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.938 -0.574 . . . . 0.0 109.704 178.242 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 15.0 p -68.63 153.27 9.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 115.404 -0.816 . . . . 0.0 110.522 -178.78 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -86.58 103.34 14.99 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 120.832 0.349 . . . . 0.0 110.16 178.521 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . 0.504 HD21 ' HB2' ' A' ' 41' ' ' GLU . 1.8 tt -101.36 119.08 38.22 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 115.942 -0.572 . . . . 0.0 109.935 -176.42 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 46.2 t -100.22 119.14 47.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.365 -179.15 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . 0.627 HD11 HD22 ' A' ' 48' ' ' LEU . 32.3 mt -95.42 122.44 38.14 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.935 -0.575 . . . . 0.0 109.73 178.785 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 37.9 p -118.34 142.27 47.69 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 120.567 0.222 . . . . 0.0 111.189 -178.374 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 30.9 t70 -165.32 154.97 12.81 Favored 'General case' 0 C--N 1.33 -0.259 0 N-CA-C 110.124 -0.325 . . . . 0.0 110.124 179.788 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . 0.562 HD13 ' HA ' ' A' ' 78' ' ' ASP . 37.4 mm -69.61 94.33 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.853 0.359 . . . . 0.0 110.163 179.144 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' LYS . . . . . 0.69 ' HD3' ' HB2' ' A' ' 76' ' ' ARG . 40.9 mmtm 44.46 70.66 1.81 Allowed Pre-proline 0 CA--C 1.533 0.296 0 CA-C-N 115.279 -0.873 . . . . 0.0 110.835 -178.304 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . 0.699 ' HD2' ' HA ' ' A' ' 76' ' ' ARG . 10.3 Cg_endo . . . . . 0 C--N 1.344 0.341 0 C-N-CA 123.896 3.064 . . . . 0.0 113.762 -172.495 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . 0.493 ' HB ' ' HG3' ' A' ' 69' ' ' PRO . 35.9 mt . . . . . 0 C--O 1.234 0.276 0 N-CA-C 110.38 -0.23 . . . . 0.0 110.38 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 60.3 t -68.62 128.62 32.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 178.767 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' ARG . . . . . 0.699 ' HA ' ' HD2' ' A' ' 69' ' ' PRO . 32.1 ptt180 -91.43 54.46 2.54 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.453 0.644 . . . . 0.0 110.976 -179.43 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 9.7 p-10 -83.34 -156.54 0.2 Allowed 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.039 -0.982 . . . . 0.0 109.955 178.129 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' ASP . . . . . 0.562 ' HA ' HD13 ' A' ' 67' ' ' ILE . 20.3 m-20 -143.85 108.75 4.94 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 110.297 -0.26 . . . . 0.0 110.297 -179.391 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 9.3 tp -73.66 -24.51 19.99 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.37 0 CA-C-O 120.819 0.343 . . . . 0.0 110.737 178.758 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 10.0 t -69.19 -26.95 65.09 Favored 'General case' 0 CA--C 1.531 0.241 0 CA-C-O 121.219 0.533 . . . . 0.0 110.547 178.077 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 22.7 t -134.28 78.74 57.24 Favored Pre-proline 0 C--N 1.323 -0.569 0 N-CA-C 108.153 -1.055 . . . . 0.0 108.153 173.292 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' PRO . . . . . 0.431 ' HB2' ' HE2' ' A' ' 87' ' ' TYR . 59.1 Cg_endo -71.13 133.44 23.06 Favored 'Trans proline' 0 N--CA 1.461 -0.426 0 C-N-CA 122.762 2.308 . . . . 0.0 113.625 -168.592 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' ARG . . . . . 0.513 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 70.7 mtt85 -84.98 106.27 16.36 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.453 -0.794 . . . . 0.0 109.27 171.871 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' MET . . . . . . . . . . . . . 89.5 mmm -58.21 -26.45 62.85 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.987 -0.551 . . . . 0.0 111.142 -177.235 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . 0.513 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 11.3 pt-20 -62.14 -26.78 68.51 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.672 -179.558 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 73.6 mt -79.46 -41.11 22.16 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-O 121.04 0.447 . . . . 0.0 110.531 -179.339 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . 0.431 ' HE2' ' HB2' ' A' ' 82' ' ' PRO . 44.9 m-85 -79.65 -25.51 41.32 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.789 -176.795 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 52.0 mtp180 -66.23 131.58 46.47 Favored 'General case' 0 CA--C 1.517 -0.304 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.373 176.276 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 98.23 8.72 54.81 Favored Glycine 0 N--CA 1.444 -0.811 0 C-N-CA 120.627 -0.797 . . . . 0.0 111.699 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -100.77 144.6 29.53 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 110.204 -0.295 . . . . 0.0 110.204 177.689 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -92.78 -23.73 18.77 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.078 0.466 . . . . 0.0 110.939 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . 0.455 HD22 ' N ' ' A' ' 93' ' ' ILE . 4.6 tt -150.1 140.74 22.58 Favored 'General case' 0 N--CA 1.449 -0.516 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.434 -178.225 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.513 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 62.8 mt -130.68 119.27 45.15 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 115.784 -0.644 . . . . 0.0 109.419 177.937 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 13.2 p90 -126.18 155.21 42.11 Favored 'General case' 0 C--N 1.32 -0.701 0 C-N-CA 120.553 -0.459 . . . . 0.0 110.544 179.277 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' SER . . . . . 0.586 ' HA ' ' O ' ' A' ' 42' ' ' VAL . 10.6 p -135.81 143.63 45.28 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.752 -0.658 . . . . 0.0 111.424 -175.189 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 74.5 mt -114.86 112.59 40.67 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 115.577 -0.738 . . . . 0.0 110.249 178.763 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 61.6 mtp180 57.59 70.36 1.34 Allowed Pre-proline 0 N--CA 1.466 0.331 0 CA-C-N 115.593 -0.73 . . . . 0.0 112.279 -178.459 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_endo -87.31 131.72 3.05 Favored 'Trans proline' 0 N--CA 1.451 -1.005 0 C-N-CA 122.536 2.157 . . . . 0.0 111.78 175.699 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . 0.614 ' HD2' HD13 ' A' ' 102' ' ' ILE . 52.2 Cg_exo -55.98 148.9 55.3 Favored 'Trans proline' 0 C--O 1.235 0.36 0 C-N-CA 122.464 2.11 . . . . 0.0 111.564 172.267 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . 0.699 ' HA ' ' ND1' ' A' ' 103' ' ' HIS . . . -60.71 -22.91 64.45 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.918 0.39 . . . . 0.0 111.763 -175.337 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 101' ' ' GLU . . . . . 0.679 ' HG3' HG22 ' A' ' 102' ' ' ILE . 10.5 pt-20 -66.65 -31.22 71.75 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.983 -179.958 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.679 HG22 ' HG3' ' A' ' 101' ' ' GLU . 48.3 pt -107.42 -1.05 9.92 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.148 0 N-CA-C 112.482 0.549 . . . . 0.0 112.482 -173.004 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 103' ' ' HIS . . . . . 0.699 ' ND1' ' HA ' ' A' ' 100' ' ' ALA . 13.1 m170 -53.54 -55.61 24.08 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 121.118 0.485 . . . . 0.0 111.162 178.235 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 19.0 m -70.2 -25.59 63.48 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 121.184 0.516 . . . . 0.0 110.689 179.503 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.689 ' O ' ' HG2' ' A' ' 108' ' ' ARG . 1.7 m -71.83 -37.65 70.27 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.502 -177.955 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 86.1 mt -63.62 -39.15 93.64 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.709 177.531 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 107' ' ' MET . . . . . . . . . . . . . 49.7 ttm -64.54 -42.33 95.78 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.208 179.447 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 108' ' ' ARG . . . . . 0.689 ' HG2' ' O ' ' A' ' 105' ' ' SER . 1.7 ptm180 -66.37 -26.84 67.45 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.836 0.35 . . . . 0.0 110.628 -178.225 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 82.2 t -75.3 -49.15 28.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.155 175.374 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -57.69 -42.63 84.05 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.494 177.458 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . 0.483 ' HA ' ' HB2' ' A' ' 148' ' ' ALA . 16.8 t70 -62.45 -32.08 72.9 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.581 -0.736 . . . . 0.0 110.746 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -79.09 -41.74 27.97 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.585 -0.734 . . . . 0.0 111.955 -178.634 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 29.0 m -87.83 -26.14 5.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 N-CA-C 111.907 0.336 . . . . 0.0 111.907 -175.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 82.5 64.86 1.66 Allowed Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.884 -0.674 . . . . 0.0 112.052 -178.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -139.58 155.41 47.49 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 120.815 0.341 . . . . 0.0 110.702 -179.909 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 116' ' ' ARG . . . . . 0.449 ' HB3' ' HG ' ' A' ' 92' ' ' LEU . 20.0 ttm-85 -75.1 121.59 22.27 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 177.416 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . 0.513 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 65.9 tp -94.02 125.28 38.56 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.171 -179.928 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 71.4 mt -124.25 120.51 59.46 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.654 0 CA-C-O 120.899 0.38 . . . . 0.0 110.146 177.488 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 30.2 mt -114.04 131.21 66.64 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.217 -178.348 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 120' ' ' LYS . . . . . 0.594 ' CD ' ' HB3' ' A' ' 143' ' ' PHE . 10.9 mmmm -110.86 98.08 36.61 Favored Pre-proline 0 C--O 1.235 0.308 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.881 172.946 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 85.7 Cg_endo -92.42 -157.89 0.06 OUTLIER 'Trans proline' 0 N--CA 1.453 -0.889 0 C-N-CA 123.177 2.585 . . . . 0.0 111.162 173.729 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 8.0 mp -111.38 150.42 29.79 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 120.635 0.255 . . . . 0.0 110.607 178.205 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 38.1 m -65.57 110.42 2.72 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.064 0.459 . . . . 0.0 110.655 178.916 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 108.36 -10.76 36.34 Favored Glycine 0 N--CA 1.445 -0.71 0 N-CA-C 111.084 -0.806 . . . . 0.0 111.084 -176.461 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 4.7 tp10 -106.39 100.5 10.02 Favored 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 109.08 -0.711 . . . . 0.0 109.08 178.49 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 15.8 t70 -85.22 165.05 17.69 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.427 -0.351 . . . . 0.0 110.958 -174.033 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . 0.43 HG21 ' CG ' ' A' ' 103' ' ' HIS . 52.3 mt . . . . . 0 C--N 1.323 -0.548 0 CA-C-N 115.767 -0.652 . . . . 0.0 110.55 -177.628 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 132' ' ' LYS . . . . . 0.467 ' HE3' ' HB2' ' A' ' 132' ' ' LYS . 35.5 mtmt . . . . . 0 CA--C 1.52 -0.189 0 CA-C-O 120.518 0.199 . . . . 0.0 111.282 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 133' ' ' MET . . . . . . . . . . . . . 79.7 mtp -146.08 150.59 36.23 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 170.789 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 1.5 ptpp? -114.83 141.27 48.12 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 121.322 0.582 . . . . 0.0 111.301 -177.501 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . 0.55 HD11 ' HD2' ' A' ' 142' ' ' TYR . 60.0 tp -82.24 129.23 34.8 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.141 -0.936 . . . . 0.0 109.883 178.666 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -126.35 148.47 31.05 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.885 -177.852 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 13.3 m120 -124.23 125.73 44.89 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.05 -0.523 . . . . 0.0 109.865 179.827 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . 0.599 ' O ' HG21 ' A' ' 141' ' ' THR . 42.7 t80 -149.19 104.79 3.44 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.746 0.307 . . . . 0.0 111.049 177.562 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . 0.438 ' C ' ' H ' ' A' ' 141' ' ' THR . . . 59.93 67.28 2.23 Favored Glycine 0 CA--C 1.521 0.417 0 CA-C-N 116.212 -0.449 . . . . 0.0 113.736 175.878 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 21.9 mmt180 69.54 -21.64 0.16 Allowed 'General case' 0 N--CA 1.47 0.547 0 N-CA-C 113.176 0.806 . . . . 0.0 113.176 176.339 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 141' ' ' THR . . . . . 0.599 HG21 ' O ' ' A' ' 138' ' ' TYR . 1.0 OUTLIER -98.0 131.47 44.4 Favored 'General case' 0 N--CA 1.444 -0.77 0 CA-C-O 121.33 0.586 . . . . 0.0 109.91 -179.359 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 142' ' ' TYR . . . . . 0.55 ' HD2' HD11 ' A' ' 135' ' ' LEU . 21.6 p90 -115.99 147.28 41.37 Favored 'General case' 0 N--CA 1.445 -0.713 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 174.872 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 143' ' ' PHE . . . . . 0.594 ' HB3' ' CD ' ' A' ' 120' ' ' LYS . 12.2 p90 -155.81 171.82 19.38 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.61 -175.308 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -107.93 121.43 44.77 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.899 -0.591 . . . . 0.0 109.568 175.845 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 145' ' ' GLU . . . . . . . . . . . . . 15.3 pt-20 -112.32 156.06 23.06 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-O 121.267 0.556 . . . . 0.0 109.578 177.125 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 34.7 t80 -138.88 124.23 19.28 Favored 'General case' 0 C--N 1.311 -1.092 0 CA-C-N 115.646 -0.706 . . . . 0.0 109.468 176.322 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 147' ' ' ILE . . . . . 0.441 ' N ' HD12 ' A' ' 147' ' ' ILE . 3.1 mp -88.44 96.07 5.72 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.739 0 N-CA-C 109.18 -0.674 . . . . 0.0 109.18 178.078 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . 0.483 ' HB2' ' HA ' ' A' ' 111' ' ' ASP . . . -76.49 118.03 18.75 Favored 'General case' 0 C--N 1.317 -0.819 0 CA-C-N 115.369 -0.832 . . . . 0.0 109.061 177.042 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 31.3 mt-10 . . . . . 0 C--N 1.322 -0.604 0 CA-C-O 121.814 0.816 . . . . 0.0 111.094 -175.206 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 83.2 m95 . . . . . 0 N--CA 1.451 -0.407 0 N-CA-C 109.596 -0.52 . . . . 0.0 109.596 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 4.6 m-20 -62.51 -56.02 21.94 Favored 'General case' 0 CA--C 1.521 -0.171 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.508 176.418 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.54 ' HB3' ' HA3' ' A' ' 139' ' ' GLY . 44.7 m-20 -60.61 -36.64 79.09 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.617 179.766 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 64.6 tp -55.83 -49.74 72.45 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.177 175.027 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . 0.533 ' HB1' HG13 ' A' ' 50' ' ' VAL . . . -62.14 -46.69 87.89 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.582 -0.736 . . . . 0.0 111.024 179.029 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 71.4 t -53.17 -47.32 55.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 121.102 0.477 . . . . 0.0 110.664 176.8 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . 0.476 ' HB2' ' CD1' ' A' ' 138' ' ' TYR . 69.7 t80 -56.2 -41.64 75.9 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.891 178.491 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.473 HG21 HD21 ' A' ' 92' ' ' LEU . 75.8 mt -69.83 -44.81 78.63 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.82 178.88 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.627 HD13 ' HA ' ' A' ' 54' ' ' ILE . 83.6 mt -57.77 -43.77 84.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 115.891 -0.595 . . . . 0.0 111.507 -178.98 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 17.9 mtp180 -64.81 -32.76 74.6 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.902 -178.569 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 81.4 m -88.95 -18.67 26.99 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 115.501 -0.772 . . . . 0.0 111.995 -174.006 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 14.0 p -101.54 -82.1 0.47 Allowed 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 120.797 0.332 . . . . 0.0 111.556 -178.54 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 101.81 161.42 26.77 Favored Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 121.014 -0.612 . . . . 0.0 112.187 -178.328 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 7.6 Cg_exo -72.8 144.48 39.12 Favored 'Trans proline' 0 C--O 1.233 0.269 0 C-N-CA 123.083 2.522 . . . . 0.0 112.383 -179.163 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 111.89 -28.76 9.06 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.533 -0.842 . . . . 0.0 112.813 177.897 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 12.6 t -99.86 -169.45 1.74 Allowed 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 -178.551 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' ARG . . . . . 0.612 ' HB2' ' HA ' ' A' ' 90' ' ' ALA . 66.2 mtp180 -118.6 136.51 53.84 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.954 0.407 . . . . 0.0 111.134 -178.346 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.637 HG23 HG22 ' A' ' 60' ' ' VAL . 95.5 t -129.97 131.11 66.38 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-N 115.83 -0.623 . . . . 0.0 109.369 176.699 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.568 HG23 ' HB ' ' A' ' 63' ' ' VAL . 40.6 t -112.12 129.0 68.4 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 CA-C-O 120.765 0.317 . . . . 0.0 111.759 -173.178 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . 0.447 ' HG2' ' HB3' ' A' ' 44' ' ' ALA . 44.8 tt0 -103.11 107.76 18.7 Favored 'General case' 0 C--O 1.235 0.319 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 174.693 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 44.1 t -89.68 127.78 42.09 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.647 -178.16 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 94.14 23.98 20.82 Favored Glycine 0 N--CA 1.448 -0.523 0 N-CA-C 110.955 -0.858 . . . . 0.0 110.955 -176.375 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . 0.593 ' HB1' HD22 ' A' ' 48' ' ' LEU . . . -93.47 80.38 4.36 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.247 -0.476 . . . . 0.0 110.858 -177.044 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -108.42 -60.61 0.54 Allowed Glycine 0 N--CA 1.446 -0.664 0 C-N-CA 120.824 -0.703 . . . . 0.0 112.015 178.607 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 57.6 mtp180 -125.47 4.44 7.63 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.933 0.397 . . . . 0.0 110.814 -179.171 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.517 ' HE2' HG22 ' A' ' 50' ' ' VAL . 64.7 t80 -86.69 -79.45 0.26 Allowed 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 176.712 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . 0.593 HD22 ' HB1' ' A' ' 44' ' ' ALA . 59.4 mt 62.71 9.35 3.51 Favored 'General case' 0 N--CA 1.467 0.41 0 CA-C-N 115.156 -0.929 . . . . 0.0 112.795 171.006 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . 0.433 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 81.2 t80 -71.08 -45.42 63.77 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 111.791 0.293 . . . . 0.0 111.791 -171.431 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.533 HG13 ' HB1' ' A' ' 26' ' ' ALA . 56.2 t -69.98 -48.57 62.35 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-N 116.599 -0.273 . . . . 0.0 110.597 -177.946 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 50.9 p -58.77 -41.15 85.92 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.453 -0.339 . . . . 0.0 111.037 176.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.728 ' HA ' ' HE ' ' A' ' 55' ' ' ARG . 24.4 t70 -61.13 -37.97 84.72 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.8 0.333 . . . . 0.0 110.712 176.55 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 47.3 t80 -69.19 -45.6 69.55 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.308 178.041 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.627 ' HA ' HD13 ' A' ' 30' ' ' ILE . 88.0 mt -63.45 -44.83 99.02 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.823 -178.347 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' ARG . . . . . 0.728 ' HE ' ' HA ' ' A' ' 52' ' ' ASP . 12.1 ptp180 -63.37 -16.42 60.42 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-O 120.791 0.329 . . . . 0.0 111.584 -175.77 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . 0.463 ' HG3' ' O ' ' A' ' 52' ' ' ASP . 97.7 mttt -81.39 -36.04 30.03 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.599 -179.602 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 81.6 m-70 -103.67 -18.11 14.85 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.817 -175.021 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 6.4 t -135.63 128.9 31.98 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-O 120.794 0.331 . . . . 0.0 110.566 -177.356 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -89.39 51.42 2.12 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.871 0.843 . . . . 0.0 110.126 175.532 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.637 HG22 HG23 ' A' ' 39' ' ' VAL . 8.3 p -83.59 147.21 5.96 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 CA-C-N 114.845 -1.07 . . . . 0.0 108.908 175.434 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . 0.557 ' HB3' ' HG2' ' A' ' 38' ' ' ARG . 19.0 t70 -72.68 95.52 1.88 Allowed 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 109.248 -0.649 . . . . 0.0 109.248 179.269 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 2.1 tt -94.77 128.45 41.49 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.407 -172.318 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.568 ' HB ' HG23 ' A' ' 40' ' ' VAL . 33.3 t -108.71 126.7 65.58 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.45 -178.92 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . 0.698 HD11 HH22 ' A' ' 55' ' ' ARG . 66.7 mt -108.61 131.18 55.13 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 116.039 -0.528 . . . . 0.0 109.63 176.4 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 49.9 p -129.3 127.91 42.11 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.721 0.296 . . . . 0.0 111.319 179.389 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 3.7 t70 -165.74 175.88 8.43 Favored 'General case' 0 C--O 1.233 0.215 0 CA-C-N 116.082 -0.508 . . . . 0.0 109.732 176.964 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 53.0 mt -87.68 114.57 26.72 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-O 120.634 0.254 . . . . 0.0 110.657 -176.391 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 55.3 mtpt 61.17 79.93 0.27 Allowed Pre-proline 0 C--N 1.331 -0.226 0 CA-C-N 115.646 -0.707 . . . . 0.0 110.9 178.287 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . 1.014 ' HB3' ' HB ' ' A' ' 74' ' ' ILE . 18.9 Cg_endo . . . . . 0 C--N 1.342 0.223 0 C-N-CA 123.281 2.654 . . . . 0.0 113.08 -176.092 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . 1.014 ' HB ' ' HB3' ' A' ' 69' ' ' PRO . 65.4 mt . . . . . 0 N--CA 1.451 -0.394 0 N-CA-C 109.996 -0.372 . . . . 0.0 109.996 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.612 HG11 HD11 ' A' ' 86' ' ' ILE . 48.3 t -80.78 135.89 24.32 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 N-CA-C 109.778 -0.452 . . . . 0.0 109.778 176.805 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 11.4 ptt180 -75.98 25.71 0.12 Allowed 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.867 -0.606 . . . . 0.0 111.876 -177.177 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . 0.435 ' H ' ' C ' ' A' ' 75' ' ' VAL . 12.7 t70 -83.35 113.82 20.99 Favored 'General case' 0 C--N 1.324 -0.536 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 -177.753 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 2.2 p30 -70.67 168.97 15.37 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.033 0.444 . . . . 0.0 111.257 -172.697 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' ILE . . . . . 0.415 HD11 HD11 ' A' ' 102' ' ' ILE . 7.1 tp -83.98 -30.27 7.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 N-CA-C 112.936 0.717 . . . . 0.0 112.936 -169.569 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 12.2 t -94.23 -21.01 19.31 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.169 0.509 . . . . 0.0 110.712 -174.017 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 4.5 t -130.64 69.03 82.22 Favored Pre-proline 0 C--N 1.323 -0.585 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.05 -179.807 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -78.64 163.48 26.59 Favored 'Trans proline' 0 N--CA 1.46 -0.443 0 C-N-CA 122.98 2.453 . . . . 0.0 112.619 -175.834 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' ARG . . . . . 0.61 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 88.6 mtm180 -108.92 118.17 36.1 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.291 178.305 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' MET . . . . . 0.522 ' SD ' HG23 ' A' ' 109' ' ' VAL . 92.0 mmm -61.13 -28.61 69.23 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.267 -0.879 . . . . 0.0 111.343 -179.037 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . 0.61 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 10.7 pt-20 -57.69 -24.27 55.9 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.711 -179.975 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.612 HD11 HG11 ' A' ' 75' ' ' VAL . 76.5 mt -86.48 -43.75 16.29 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.089 -177.478 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . 0.422 ' CE1' HG12 ' A' ' 40' ' ' VAL . 88.3 m-85 -72.13 -27.15 62.44 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.37 -178.593 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 27.0 mtp180 -66.06 116.66 7.4 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 121.409 0.623 . . . . 0.0 111.26 -179.482 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 118.61 -15.99 11.44 Favored Glycine 0 N--CA 1.447 -0.597 0 CA-C-N 115.189 -0.914 . . . . 0.0 111.243 -176.065 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . 0.612 ' HA ' ' HB2' ' A' ' 38' ' ' ARG . . . -75.48 145.63 41.25 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.897 0.379 . . . . 0.0 110.545 178.837 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -98.51 -20.76 16.89 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.125 177.659 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . 0.473 HD21 HG21 ' A' ' 29' ' ' ILE . 5.1 tt -153.33 138.24 17.17 Favored 'General case' 0 N--CA 1.447 -0.604 0 CA-C-N 115.688 -0.687 . . . . 0.0 109.967 -179.306 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.527 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 63.6 mt -130.64 131.16 64.96 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 115.987 -0.551 . . . . 0.0 109.629 -178.748 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' TYR . . . . . 0.439 ' HE1' HG12 ' A' ' 39' ' ' VAL . 26.6 p90 -134.15 156.05 49.01 Favored 'General case' 0 C--N 1.322 -0.626 0 C-N-CA 120.625 -0.43 . . . . 0.0 110.811 179.57 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 17.3 m -131.86 139.76 48.91 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.76 -177.651 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 42.3 mm -85.94 86.98 2.5 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.363 -179.259 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' ARG . . . . . 0.422 ' NH1' HD12 ' A' ' 122' ' ' LEU . 39.1 ttp180 44.32 79.56 0.33 Allowed Pre-proline 0 N--CA 1.47 0.558 0 O-C-N 124.126 0.891 . . . . 0.0 112.364 -179.313 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 91.2 Cg_endo -83.83 154.13 13.26 Favored 'Trans proline' 0 N--CA 1.456 -0.704 0 C-N-CA 122.918 2.412 . . . . 0.0 112.042 178.892 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . 0.613 ' HD2' HD12 ' A' ' 102' ' ' ILE . 51.3 Cg_exo -55.35 150.66 40.32 Favored 'Trans proline' 0 C--N 1.346 0.417 0 C-N-CA 122.605 2.204 . . . . 0.0 112.112 175.53 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -79.68 30.31 0.25 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.727 -174.205 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 101' ' ' GLU . . . . . . . . . . . . . 10.4 pt-20 -124.95 -23.46 4.26 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 120.742 0.306 . . . . 0.0 110.954 176.507 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.613 HD12 ' HD2' ' A' ' 99' ' ' PRO . 46.6 pt -98.9 -2.4 9.83 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-O 120.752 0.31 . . . . 0.0 111.316 -177.173 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 103' ' ' HIS . . . . . 0.564 ' O ' ' HG2' ' A' ' 107' ' ' MET . 31.4 p-80 -60.16 -40.09 88.71 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.138 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 8.1 p -63.21 -35.85 81.68 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.913 178.604 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.489 ' O ' HG22 ' A' ' 109' ' ' VAL . 16.3 m -67.42 -45.91 74.72 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.735 -0.666 . . . . 0.0 109.69 177.976 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 96.0 mt -59.86 -42.17 93.1 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.909 178.124 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 107' ' ' MET . . . . . 0.564 ' HG2' ' O ' ' A' ' 103' ' ' HIS . 98.2 mmm -56.71 -49.59 74.71 Favored 'General case' 0 C--O 1.233 0.234 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.537 -179.939 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 33.7 ptt85 -70.77 -30.57 67.09 Favored 'General case' 0 C--N 1.332 -0.188 0 C-N-CA 120.727 -0.389 . . . . 0.0 111.108 -177.403 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.522 HG23 ' SD ' ' A' ' 84' ' ' MET . 69.5 t -67.78 -48.49 75.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 120.575 0.226 . . . . 0.0 110.647 177.029 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -59.08 -41.64 88.5 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.708 179.626 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . 0.655 ' HA ' ' HB1' ' A' ' 148' ' ' ALA . 23.3 t70 -65.6 -42.29 91.8 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.701 -0.682 . . . . 0.0 110.815 178.489 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -62.54 -43.46 98.77 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.964 -0.562 . . . . 0.0 111.645 -178.364 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 20.2 m -85.38 -28.14 6.42 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-O 120.928 0.394 . . . . 0.0 111.022 -177.59 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 87.35 51.85 3.2 Favored Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 120.596 -0.812 . . . . 0.0 111.918 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -130.15 155.47 46.16 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 120.831 0.348 . . . . 0.0 110.901 -178.799 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 116' ' ' ARG . . . . . 0.675 HH21 HD12 ' A' ' 118' ' ' ILE . 50.2 ttp180 -79.21 117.56 20.34 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 178.037 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . 0.527 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 60.3 tp -88.14 118.84 27.99 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.0 -0.546 . . . . 0.0 110.086 -179.535 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . 0.675 HD12 HH21 ' A' ' 116' ' ' ARG . 66.6 mt -114.52 117.42 55.54 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-O 121.28 0.562 . . . . 0.0 110.842 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 71.7 mt -116.52 116.9 53.72 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.323 179.308 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 57.6 tttp -102.76 104.4 38.78 Favored Pre-proline 0 C--N 1.322 -0.598 0 C-N-CA 120.656 -0.418 . . . . 0.0 110.005 172.351 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 121' ' ' PRO . . . . . 0.575 ' HB2' ' O ' ' A' ' 125' ' ' GLU . 70.5 Cg_endo -78.68 -139.58 0.02 OUTLIER 'Trans proline' 0 N--CA 1.457 -0.673 0 C-N-CA 122.522 2.148 . . . . 0.0 111.531 172.673 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 122' ' ' LEU . . . . . 0.857 ' HB3' ' HB3' ' A' ' 125' ' ' GLU . 14.4 tp -126.82 156.94 40.52 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.383 -178.789 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 123' ' ' THR . . . . . 0.458 ' HA ' ' OH ' ' A' ' 142' ' ' TYR . 25.4 m -69.94 102.04 1.9 Allowed 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 177.368 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 100.88 2.88 55.1 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.967 -0.635 . . . . 0.0 111.737 -175.533 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . 0.857 ' HB3' ' HB3' ' A' ' 122' ' ' LEU . 37.7 tt0 -132.38 97.12 4.02 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 177.827 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 14.2 t70 -99.9 173.06 6.85 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.403 -0.817 . . . . 0.0 110.455 -170.227 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 5.3 mt . . . . . 0 C--N 1.33 -0.254 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 178.12 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 132' ' ' LYS . . . . . 0.533 ' HE3' ' HE1' ' A' ' 146' ' ' TYR . 31.7 ttpt . . . . . 0 N--CA 1.465 0.285 0 CA-C-O 121.361 0.601 . . . . 0.0 112.038 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 133' ' ' MET . . . . . . . . . . . . . 46.7 mtp -69.06 170.5 9.81 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.764 176.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . 0.724 ' HB3' ' HZ1' ' A' ' 134' ' ' LYS . 0.5 OUTLIER -139.68 151.65 46.09 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.942 -179.43 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . 0.431 HD12 ' HD2' ' A' ' 142' ' ' TYR . 57.4 tp -89.74 123.46 33.77 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.252 178.206 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 136' ' ' VAL . . . . . 0.46 ' CG2' ' HG2' ' A' ' 145' ' ' GLU . 0.1 OUTLIER -121.74 149.05 24.92 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.445 -179.658 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 12.3 m120 -125.86 112.62 16.2 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.2 -176.214 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . 0.476 ' CD1' ' HB2' ' A' ' 28' ' ' TYR . 53.3 t80 -147.96 123.31 10.29 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.554 0.216 . . . . 0.0 110.947 -179.723 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . 0.54 ' HA3' ' HB3' ' A' ' 24' ' ' ASP . . . 62.93 71.69 0.78 Allowed Glycine 0 N--CA 1.451 -0.317 0 CA-C-N 115.716 -0.674 . . . . 0.0 113.726 173.045 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 6.1 mpt_? 70.99 -39.5 0.45 Allowed 'General case' 0 N--CA 1.473 0.684 0 C-N-CA 123.356 0.662 . . . . 0.0 112.628 175.171 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 141' ' ' THR . . . . . 0.417 ' H ' ' C ' ' A' ' 139' ' ' GLY . 8.8 t -101.87 154.5 18.87 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 121.487 0.66 . . . . 0.0 111.696 -173.817 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 142' ' ' TYR . . . . . 0.458 ' OH ' ' HA ' ' A' ' 123' ' ' THR . 45.8 p90 -112.68 155.02 25.2 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 115.031 -0.986 . . . . 0.0 108.592 169.249 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 18.0 p90 -160.27 179.03 9.03 Favored 'General case' 0 C--N 1.319 -0.744 0 N-CA-C 110.151 -0.315 . . . . 0.0 110.151 -178.348 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 86.5 m-85 -116.27 125.42 52.17 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 120.724 0.297 . . . . 0.0 110.525 -179.505 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 145' ' ' GLU . . . . . 0.46 ' HG2' ' CG2' ' A' ' 136' ' ' VAL . 23.7 pt-20 -117.28 162.1 18.43 Favored 'General case' 0 C--N 1.317 -0.807 0 N-CA-C 109.557 -0.534 . . . . 0.0 109.557 175.235 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . 0.533 ' HE1' ' HE3' ' A' ' 132' ' ' LYS . 14.8 t80 -138.28 117.3 12.51 Favored 'General case' 0 C--N 1.311 -1.102 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.744 175.623 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 147' ' ' ILE . . . . . 0.452 HD11 ' N ' ' A' ' 147' ' ' ILE . 2.4 mp -85.41 99.43 7.39 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.874 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 174.643 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . 0.655 ' HB1' ' HA ' ' A' ' 111' ' ' ASP . . . -58.42 104.48 0.22 Allowed 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 108.933 -0.765 . . . . 0.0 108.933 176.432 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 36.7 mt-10 . . . . . 0 CA--C 1.506 -0.717 0 CA-C-O 122.092 0.948 . . . . 0.0 110.76 -175.329 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' TRP . . . . . 0.576 ' CH2' HG23 ' A' ' 96' ' ' ILE . 99.4 m95 . . . . . 0 C--O 1.232 0.152 0 CA-C-O 120.833 0.349 . . . . 0.0 111.677 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 24.3 t-20 -56.45 -41.06 75.86 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.765 -0.652 . . . . 0.0 111.606 -176.659 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -60.33 -50.82 72.08 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.963 -0.562 . . . . 0.0 112.042 -179.909 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 58.5 tp -56.28 -45.44 80.13 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.195 -178.474 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . 0.503 ' O ' HG13 ' A' ' 30' ' ' ILE . . . -54.74 -52.03 63.81 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.322 -179.157 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 83.2 t -51.4 -47.64 34.91 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.78 178.887 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 74.4 t80 -59.06 -44.59 91.84 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.921 0.391 . . . . 0.0 110.491 -179.054 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 72.5 mt -64.77 -45.53 94.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.918 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.577 HG12 HG21 ' A' ' 54' ' ' ILE . 85.8 mt -57.24 -44.36 83.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.88 179.911 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 55.5 mtt180 -71.36 -20.72 62.12 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.693 -0.685 . . . . 0.0 111.697 -175.224 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 72.8 m -88.98 -21.33 23.58 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.408 -0.36 . . . . 0.0 111.256 179.788 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 12.4 p -106.23 -80.16 0.56 Allowed 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 120.765 0.317 . . . . 0.0 111.255 -176.652 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 95.92 172.82 36.01 Favored Glycine 0 N--CA 1.449 -0.468 0 C-N-CA 120.822 -0.704 . . . . 0.0 112.427 -179.888 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 12.5 Cg_exo -69.68 143.39 51.08 Favored 'Trans proline' 0 N--CA 1.465 -0.189 0 C-N-CA 122.955 2.437 . . . . 0.0 112.335 -179.197 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 91.12 7.27 65.89 Favored Glycine 0 N--CA 1.454 -0.128 0 C-N-CA 120.613 -0.803 . . . . 0.0 112.694 176.413 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 29.9 p -110.43 -174.09 2.4 Favored 'General case' 0 C--N 1.321 -0.671 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 179.848 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' ARG . . . . . 0.613 ' NH2' ' HA3' ' A' ' 89' ' ' GLY . 56.6 mtm180 -129.72 126.91 39.36 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 120.771 0.319 . . . . 0.0 110.647 176.709 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.62 HG23 HG22 ' A' ' 60' ' ' VAL . 41.5 t -122.81 134.51 65.75 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 177.703 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.487 HG12 ' CE1' ' A' ' 87' ' ' TYR . 32.2 t -114.02 122.38 68.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-O 120.955 0.407 . . . . 0.0 110.436 -178.416 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . 0.797 ' HG3' HD22 ' A' ' 64' ' ' LEU . 0.1 OUTLIER -93.07 121.59 34.58 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.71 -174.706 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.495 ' O ' ' HA ' ' A' ' 95' ' ' SER . 48.5 t -102.55 113.65 39.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 N-CA-C 109.566 -0.531 . . . . 0.0 109.566 173.825 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 111.77 44.9 0.86 Allowed Glycine 0 N--CA 1.45 -0.37 0 N-CA-C 111.134 -0.786 . . . . 0.0 111.134 -176.032 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -95.85 14.73 22.41 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.102 0.477 . . . . 0.0 111.044 -175.892 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -72.74 -7.73 70.48 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.946 -0.645 . . . . 0.0 112.947 -178.153 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 74.0 ttt180 -166.18 -34.14 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.94 0.4 . . . . 0.0 110.934 -179.915 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 40.7 m-85 -82.86 83.39 7.77 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 121.116 0.484 . . . . 0.0 111.056 -175.685 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 88.2 mt -109.35 9.3 25.71 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.144 -179.514 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 39.3 t80 -72.54 -50.97 21.96 Favored 'General case' 0 C--N 1.33 -0.267 0 C-N-CA 121.023 -0.271 . . . . 0.0 110.968 178.259 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.527 ' O ' HG13 ' A' ' 54' ' ' ILE . 33.6 t -57.73 -49.0 82.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.463 -176.448 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 1.9 p -60.01 -44.07 94.81 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.93 -0.577 . . . . 0.0 111.787 -179.783 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.529 ' O ' ' HG2' ' A' ' 56' ' ' LYS . 28.8 t70 -64.99 -39.76 93.95 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 120.856 0.36 . . . . 0.0 110.601 -179.907 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 59.5 t80 -65.97 -39.47 90.41 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.563 -179.218 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.577 HG21 HG12 ' A' ' 30' ' ' ILE . 82.3 mt -64.88 -48.71 83.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.613 -179.852 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 39.7 ptt180 -67.28 -17.13 64.66 Favored 'General case' 0 N--CA 1.466 0.348 0 N-CA-C 111.586 0.217 . . . . 0.0 111.586 -175.649 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . 0.529 ' HG2' ' O ' ' A' ' 52' ' ' ASP . 33.1 mmtp -75.04 -36.07 61.87 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.822 0.344 . . . . 0.0 110.747 177.591 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 53.8 m-70 -94.6 -31.11 14.01 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.818 -175.785 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 73.3 m -136.75 132.89 35.41 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 120.759 0.314 . . . . 0.0 111.474 -178.27 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 3.1 tmtp? -81.51 60.97 4.75 Favored 'General case' 0 C--O 1.234 0.256 0 CA-C-O 121.831 0.824 . . . . 0.0 109.708 177.051 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.62 HG22 HG23 ' A' ' 39' ' ' VAL . 2.6 p -84.59 144.61 9.45 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.037 0 CA-C-N 114.975 -1.011 . . . . 0.0 108.869 172.816 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . 0.418 ' O ' ' HA ' ' A' ' 38' ' ' ARG . 24.7 m-20 -79.0 100.36 7.27 Favored 'General case' 0 CA--C 1.515 -0.378 0 CA-C-O 121.605 0.717 . . . . 0.0 109.441 176.328 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . 0.521 HD12 ' OE2' ' A' ' 41' ' ' GLU . 8.5 tt -99.28 129.14 45.48 Favored 'General case' 0 C--N 1.316 -0.854 0 CA-C-N 114.8 -1.091 . . . . 0.0 110.599 -171.653 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 57.7 t -117.45 116.06 50.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.987 -177.895 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . 0.797 HD22 ' HG3' ' A' ' 41' ' ' GLU . 33.1 mt -87.39 128.21 35.2 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 115.966 -0.561 . . . . 0.0 109.828 178.17 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.506 HG23 ' HB ' ' A' ' 75' ' ' VAL . 25.2 p -130.57 134.36 46.95 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 120.488 0.185 . . . . 0.0 110.629 178.965 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -171.74 153.73 3.43 Favored 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 178.395 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . 0.531 HG21 ' HG3' ' A' ' 68' ' ' LYS . 60.8 mt -77.42 122.66 32.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 N-CA-C 110.152 -0.314 . . . . 0.0 110.152 179.483 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' LYS . . . . . 0.531 ' HG3' HG21 ' A' ' 67' ' ' ILE . 91.9 mttt 60.83 80.65 0.26 Allowed Pre-proline 0 C--O 1.234 0.267 0 O-C-N 123.734 0.646 . . . . 0.0 110.485 -177.413 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . 0.652 ' HB3' ' HB ' ' A' ' 74' ' ' ILE . 29.0 Cg_endo . . . . . 0 N--CA 1.464 -0.243 0 C-N-CA 122.799 2.333 . . . . 0.0 112.515 -178.636 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . 0.652 ' HB ' ' HB3' ' A' ' 69' ' ' PRO . 71.2 mt . . . . . 0 N--CA 1.453 -0.301 0 N-CA-C 110.122 -0.325 . . . . 0.0 110.122 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.506 ' HB ' HG23 ' A' ' 65' ' ' THR . 61.2 t -71.28 119.18 17.16 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-O 121.199 0.523 . . . . 0.0 110.343 178.61 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 16.5 ptm180 -81.66 34.5 0.39 Allowed 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.379 -0.828 . . . . 0.0 111.96 -176.27 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 35.2 t70 -78.72 145.02 34.73 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 120.892 0.377 . . . . 0.0 110.392 -177.857 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' ASP . . . . . 0.488 ' HB3' HG22 ' A' ' 80' ' ' THR . 10.4 m-20 -81.15 110.86 17.05 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.696 -176.744 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' ILE . . . . . 0.486 HG22 HD12 ' A' ' 67' ' ' ILE . 10.6 tp -63.96 -19.9 25.51 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.519 0 CA-C-O 120.909 0.385 . . . . 0.0 111.022 179.75 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.488 HG22 ' HB3' ' A' ' 78' ' ' ASP . 7.0 t -68.52 -26.33 65.38 Favored 'General case' 0 CA--C 1.533 0.301 0 CA-C-O 121.13 0.49 . . . . 0.0 110.572 177.73 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 44.3 m -152.0 73.42 7.82 Favored Pre-proline 0 C--N 1.322 -0.607 0 N-CA-C 108.37 -0.974 . . . . 0.0 108.37 176.738 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' PRO . . . . . 0.453 ' HB2' ' HE2' ' A' ' 87' ' ' TYR . 75.8 Cg_endo -76.01 162.8 34.08 Favored 'Trans proline' 0 C--O 1.237 0.429 0 C-N-CA 122.817 2.344 . . . . 0.0 114.044 -166.121 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' ARG . . . . . 0.854 ' HG3' ' HG2' ' A' ' 85' ' ' GLU . 0.2 OUTLIER -81.72 99.99 9.24 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 114.855 -1.066 . . . . 0.0 109.201 174.929 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' MET . . . . . 0.409 ' O ' ' HG3' ' A' ' 88' ' ' ARG . 83.8 mmm -59.08 -31.16 68.64 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 116.596 -0.274 . . . . 0.0 111.186 -177.187 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . 0.854 ' HG2' ' HG3' ' A' ' 83' ' ' ARG . 8.2 pt-20 -66.94 -24.72 66.1 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.495 -0.32 . . . . 0.0 111.397 -179.789 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 69.0 mt -73.62 -32.29 35.17 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 C-N-CA 120.515 -0.474 . . . . 0.0 110.429 177.282 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . 0.487 ' CE1' HG12 ' A' ' 40' ' ' VAL . 98.3 m-85 -85.91 -28.63 24.21 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.974 -0.557 . . . . 0.0 111.22 179.022 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . 0.409 ' HG3' ' O ' ' A' ' 84' ' ' MET . 69.6 mtp180 -61.72 117.95 6.49 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.33 0.586 . . . . 0.0 111.691 -177.639 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . 0.613 ' HA3' ' NH2' ' A' ' 38' ' ' ARG . . . 106.36 -5.19 38.13 Favored Glycine 0 N--CA 1.444 -0.779 0 CA-C-N 115.222 -0.899 . . . . 0.0 112.383 179.906 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -69.85 146.97 50.91 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.801 0.334 . . . . 0.0 110.495 177.733 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -91.5 -30.8 16.23 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.368 -179.766 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . 0.43 ' HG ' ' HB3' ' A' ' 116' ' ' ARG . 5.3 tt -153.25 144.19 22.88 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.182 -178.361 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.669 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 70.1 mt -133.07 129.04 57.04 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 177.31 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' TYR . . . . . 0.472 ' HE2' HD12 ' A' ' 96' ' ' ILE . 51.0 p90 -134.01 162.88 30.85 Favored 'General case' 0 C--N 1.32 -0.715 0 C-N-CA 120.053 -0.659 . . . . 0.0 111.274 179.604 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' SER . . . . . 0.738 ' HB3' ' HG3' ' A' ' 98' ' ' PRO . 15.8 m -137.83 137.83 38.54 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.999 -175.682 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' ILE . . . . . 0.576 HG23 ' CH2' ' A' ' 22' ' ' TRP . 5.0 mp -106.74 93.87 2.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.349 177.866 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 54.1 ttp85 48.29 72.68 1.18 Allowed Pre-proline 0 CA--C 1.54 0.574 0 CA-C-N 115.527 -0.761 . . . . 0.0 112.472 177.242 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' PRO . . . . . 0.738 ' HG3' ' HB3' ' A' ' 95' ' ' SER . 14.8 Cg_endo -91.97 162.81 3.28 Favored 'Trans proline' 0 N--CA 1.454 -0.823 0 C-N-CA 123.228 2.619 . . . . 0.0 111.905 176.798 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . 0.438 ' HB2' ' HG2' ' A' ' 101' ' ' GLU . 2.4 Cg_endo -48.97 139.64 25.3 Favored 'Trans proline' 0 C--N 1.349 0.599 0 C-N-CA 123.181 2.587 . . . . 0.0 112.597 177.159 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . 0.741 ' HA ' ' CE1' ' A' ' 103' ' ' HIS . . . -79.28 19.36 0.59 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.188 -0.46 . . . . 0.0 112.098 -172.528 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 101' ' ' GLU . . . . . 0.438 ' HG2' ' HB2' ' A' ' 99' ' ' PRO . 9.3 pt-20 -115.82 -16.62 11.17 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 115.991 -0.549 . . . . 0.0 111.367 -177.572 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.604 HD13 ' HB2' ' A' ' 98' ' ' PRO . 2.5 pp -112.04 3.44 8.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 N-CA-C 112.258 0.466 . . . . 0.0 112.258 -175.546 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 103' ' ' HIS . . . . . 0.741 ' CE1' ' HA ' ' A' ' 100' ' ' ALA . 33.5 m170 -62.27 -40.79 97.4 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.181 -179.15 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 22.4 m -61.81 -31.46 71.69 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.987 0.422 . . . . 0.0 110.899 178.903 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.547 ' O ' HG22 ' A' ' 109' ' ' VAL . 14.5 m -72.84 -40.68 65.55 Favored 'General case' 0 N--CA 1.448 -0.538 0 CA-C-N 116.045 -0.525 . . . . 0.0 109.897 178.302 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 90.4 mt -61.38 -42.17 98.28 Favored 'General case' 0 C--O 1.233 0.224 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.944 178.289 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 107' ' ' MET . . . . . . . . . . . . . 91.3 mmm -55.37 -48.09 74.81 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.619 -0.719 . . . . 0.0 111.768 -179.598 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 4.1 ptp180 -74.01 -26.89 60.68 Favored 'General case' 0 C--N 1.329 -0.32 0 C-N-CA 120.875 -0.33 . . . . 0.0 111.512 -177.697 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.547 HG22 ' O ' ' A' ' 105' ' ' SER . 70.2 t -66.31 -46.87 85.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 N-CA-C 110.192 -0.299 . . . . 0.0 110.192 175.813 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -59.01 -45.57 90.36 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.292 178.527 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . 0.524 ' HA ' ' HB1' ' A' ' 148' ' ' ALA . 24.4 t70 -64.9 -36.83 85.63 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.885 -0.598 . . . . 0.0 111.026 179.557 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -68.53 -35.56 77.64 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.717 -0.674 . . . . 0.0 112.17 -178.372 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.472 HG11 ' CB ' ' A' ' 87' ' ' TYR . 22.5 m -97.04 -23.77 4.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-O 120.745 0.307 . . . . 0.0 111.65 -177.787 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 89.43 36.4 7.5 Favored Glycine 0 N--CA 1.452 -0.235 0 C-N-CA 120.933 -0.651 . . . . 0.0 112.645 176.792 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -114.24 147.47 38.93 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 121.003 0.43 . . . . 0.0 111.416 -177.187 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 116' ' ' ARG . . . . . 0.43 ' HB3' ' HG ' ' A' ' 92' ' ' LEU . 27.8 ttt180 -70.96 120.06 15.98 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.687 -0.688 . . . . 0.0 109.836 178.876 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . 0.669 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 60.0 tp -94.72 126.83 40.28 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 -179.038 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 64.1 mt -129.02 122.79 57.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-O 120.827 0.346 . . . . 0.0 110.44 -179.223 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 119' ' ' ILE . . . . . 0.525 HG12 ' HB2' ' A' ' 95' ' ' SER . 66.7 mt -130.05 119.85 48.0 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-O 120.777 0.323 . . . . 0.0 110.755 -179.018 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 34.3 ttpt -116.27 98.38 51.31 Favored Pre-proline 0 C--N 1.326 -0.441 0 N-CA-C 109.622 -0.511 . . . . 0.0 109.622 173.085 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 89.6 Cg_endo -87.17 -156.08 0.06 OUTLIER 'Trans proline' 0 N--CA 1.457 -0.631 0 C-N-CA 122.862 2.375 . . . . 0.0 112.471 179.325 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 122' ' ' LEU . . . . . 0.442 HD13 ' HA ' ' A' ' 122' ' ' LEU . 9.3 tp -74.35 161.56 29.75 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.302 177.899 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 12.9 t -69.3 -24.65 63.97 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.064 0.459 . . . . 0.0 110.979 -177.927 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -114.32 27.14 9.17 Favored Glycine 0 N--CA 1.448 -0.519 0 C-N-CA 120.837 -0.696 . . . . 0.0 111.385 176.686 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 35.6 tt0 -128.04 125.93 40.29 Favored 'General case' 0 C--N 1.319 -0.756 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 -177.167 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -108.22 166.86 10.43 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.001 -179.935 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 42.6 mt . . . . . 0 C--N 1.323 -0.551 0 CA-C-O 121.095 0.474 . . . . 0.0 110.207 -178.805 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 55.7 tttp . . . . . 0 CA--C 1.534 0.341 0 N-CA-C 112.836 0.68 . . . . 0.0 112.836 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 133' ' ' MET . . . . . . . . . . . . . 76.0 mtp -96.24 168.72 10.41 Favored 'General case' 0 C--N 1.328 -0.356 0 C-N-CA 120.69 -0.404 . . . . 0.0 111.098 -176.952 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . 0.433 ' HG3' ' HG2' ' A' ' 145' ' ' GLU . 15.8 ptmt -130.62 148.59 52.43 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.911 -178.088 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . 0.606 HD11 ' HD2' ' A' ' 142' ' ' TYR . 39.7 tp -94.62 126.21 39.77 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.395 -179.747 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -123.86 147.19 28.35 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.692 -179.577 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 9.8 m-80 -116.98 119.0 33.95 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.999 0.428 . . . . 0.0 110.299 177.344 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . 0.489 ' O ' HG23 ' A' ' 141' ' ' THR . 71.3 t80 -146.49 128.11 15.15 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.142 -0.481 . . . . 0.0 109.932 -177.038 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . 0.43 ' O ' ' HB2' ' A' ' 140' ' ' ARG . . . 66.37 38.9 94.0 Favored Glycine 0 N--CA 1.449 -0.469 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.238 177.904 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 140' ' ' ARG . . . . . 0.43 ' HB2' ' O ' ' A' ' 139' ' ' GLY . 13.0 mmt85 76.47 -12.54 1.02 Allowed 'General case' 0 N--CA 1.469 0.497 0 C-N-CA 123.438 0.695 . . . . 0.0 112.392 177.804 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 141' ' ' THR . . . . . 0.489 HG23 ' O ' ' A' ' 138' ' ' TYR . 4.6 t -105.21 166.1 10.64 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 120.851 0.358 . . . . 0.0 110.575 -178.972 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 142' ' ' TYR . . . . . 0.606 ' HD2' HD11 ' A' ' 135' ' ' LEU . 14.4 p90 -130.06 141.12 50.75 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.125 -0.488 . . . . 0.0 109.807 178.945 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -150.3 168.43 24.1 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.687 -177.58 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 85.8 m-85 -99.88 125.12 45.81 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 177.499 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 145' ' ' GLU . . . . . 0.433 ' HG2' ' HG3' ' A' ' 134' ' ' LYS . 7.5 pt-20 -116.26 162.84 16.88 Favored 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 109.558 -0.534 . . . . 0.0 109.558 175.596 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . 0.553 ' HB3' ' HB3' ' A' ' 117' ' ' LEU . 15.0 t80 -145.3 123.44 12.16 Favored 'General case' 0 C--N 1.314 -0.946 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.275 178.894 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 3.4 mp -91.92 100.27 10.98 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 177.545 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . 0.524 ' HB1' ' HA ' ' A' ' 111' ' ' ASP . . . -71.68 125.74 27.9 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.896 176.312 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 . . . . . 0 C--N 1.319 -0.751 0 CA-C-N 115.798 -0.637 . . . . 0.0 111.518 177.682 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 78.7 m95 . . . . . 0 CA--C 1.53 0.206 0 CA-C-O 120.854 0.359 . . . . 0.0 110.639 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 27.1 t-20 -56.35 -52.52 64.26 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.779 -0.646 . . . . 0.0 111.492 -177.514 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -63.81 -33.71 76.29 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.138 -178.901 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 56.7 tp -58.08 -49.52 76.64 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.084 175.725 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . 0.409 ' O ' HG13 ' A' ' 30' ' ' ILE . . . -58.57 -48.45 80.88 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.763 178.655 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.435 ' HA ' HD12 ' A' ' 30' ' ' ILE . 87.4 t -54.85 -44.48 72.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.177 178.553 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . 0.416 ' HB2' ' CD2' ' A' ' 138' ' ' TYR . 84.6 t80 -60.77 -46.83 88.97 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.715 179.041 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 83.1 mt -60.9 -42.83 94.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.51 178.332 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.52 HG12 HG23 ' A' ' 54' ' ' ILE . 87.7 mt -56.65 -45.32 82.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 115.704 -0.68 . . . . 0.0 111.066 177.418 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . 0.405 ' HG3' ' O ' ' A' ' 27' ' ' VAL . 81.0 mtp180 -69.33 -27.34 65.27 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 121.147 0.499 . . . . 0.0 110.899 -177.729 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 80.4 m -88.9 -2.88 58.81 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.925 -0.579 . . . . 0.0 111.639 -178.538 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 16.6 p -121.84 -76.76 0.58 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.505 0.193 . . . . 0.0 110.977 -179.387 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.502 ' O ' HG22 ' A' ' 37' ' ' THR . . . 101.03 161.82 27.58 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 121.087 -0.578 . . . . 0.0 112.409 179.597 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_exo -74.36 146.34 35.35 Favored 'Trans proline' 0 N--CA 1.462 -0.351 0 C-N-CA 122.84 2.36 . . . . 0.0 111.986 179.076 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 98.02 -15.82 61.04 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.868 -0.682 . . . . 0.0 113.046 177.357 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' THR . . . . . 0.502 HG22 ' O ' ' A' ' 34' ' ' GLY . 13.6 t -102.42 -172.14 2.08 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 117.039 0.419 . . . . 0.0 110.544 -179.091 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' ARG . . . . . 0.505 ' HB2' ' HA ' ' A' ' 90' ' ' ALA . 68.7 mtp180 -115.42 135.8 53.74 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.565 -0.289 . . . . 0.0 110.976 -177.276 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.482 HG22 HG21 ' A' ' 60' ' ' VAL . 61.7 t -131.59 138.86 52.02 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 175.575 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.562 ' O ' ' HA ' ' A' ' 93' ' ' ILE . 23.4 t -126.92 139.13 52.76 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 178.259 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . 0.615 ' OE2' ' HA ' ' A' ' 64' ' ' LEU . 0.5 OUTLIER -116.12 156.25 26.76 Favored 'General case' 0 C--N 1.32 -0.678 0 C-N-CA 120.123 -0.631 . . . . 0.0 109.959 171.49 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.438 HG23 HD22 ' A' ' 106' ' ' LEU . 62.1 t -110.84 103.23 15.14 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.851 0 CA-C-N 115.755 -0.657 . . . . 0.0 109.79 176.385 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 115.28 56.04 0.36 Allowed Glycine 0 N--CA 1.448 -0.538 0 C-N-CA 120.309 -0.948 . . . . 0.0 112.7 178.707 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . 0.441 ' HB2' ' OE2' ' A' ' 41' ' ' GLU . . . -80.73 77.04 7.61 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.254 0.549 . . . . 0.0 110.424 178.029 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -82.75 -154.89 16.59 Favored Glycine 0 N--CA 1.447 -0.625 0 CA-C-N 115.564 -0.744 . . . . 0.0 112.846 -179.55 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 49.9 ttt180 -70.37 -15.12 62.82 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 121.264 0.554 . . . . 0.0 110.555 -177.46 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 7.7 p90 -88.94 58.71 4.7 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.792 -0.64 . . . . 0.0 111.204 -178.707 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 95.0 mt -78.23 35.09 0.21 Allowed 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.008 -0.542 . . . . 0.0 112.15 -176.848 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 84.3 t80 -71.91 -53.83 11.92 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.602 0.239 . . . . 0.0 110.995 -179.45 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.432 ' O ' HG13 ' A' ' 54' ' ' ILE . 56.7 t -57.72 -50.8 76.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.024 -0.534 . . . . 0.0 111.134 -176.404 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 2.7 p -59.98 -42.33 93.93 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.627 -178.829 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.487 ' O ' ' HG2' ' A' ' 56' ' ' LYS . 27.5 t70 -67.73 -43.23 80.44 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.385 -0.371 . . . . 0.0 110.651 -179.647 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 61.9 t80 -63.01 -44.63 95.45 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.92 -178.405 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.52 HG23 HG12 ' A' ' 30' ' ' ILE . 84.3 mt -61.32 -46.05 97.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.864 179.508 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 2.5 ptm180 -72.92 -16.48 61.55 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.358 -176.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . 0.487 ' HG2' ' O ' ' A' ' 52' ' ' ASP . 36.0 mmtm -72.82 -34.82 67.1 Favored 'General case' 0 C--O 1.234 0.287 0 CA-C-O 120.848 0.356 . . . . 0.0 110.486 175.016 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 29.3 m-70 -93.55 -60.4 1.78 Allowed 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.379 -177.039 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 52.8 m -106.78 133.22 51.77 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 121.233 0.54 . . . . 0.0 111.717 -174.878 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 1.3 tmmm? -76.56 65.76 2.44 Favored 'General case' 0 N--CA 1.451 -0.38 0 CA-C-O 121.769 0.795 . . . . 0.0 108.909 174.318 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.482 HG21 HG22 ' A' ' 39' ' ' VAL . 14.9 p -97.06 147.83 6.03 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.983 0 CA-C-N 115.235 -0.893 . . . . 0.0 109.927 176.115 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 13.2 t70 -81.09 89.6 5.98 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 178.865 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 3.3 tm? -93.97 131.86 39.01 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.481 -0.781 . . . . 0.0 109.27 -178.096 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 42.4 t -115.36 117.92 57.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-O 120.457 0.17 . . . . 0.0 110.842 -177.604 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . 0.615 ' HA ' ' OE2' ' A' ' 41' ' ' GLU . 84.8 mt -86.89 128.07 35.05 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.913 -178.574 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 70.1 p -116.23 123.57 48.09 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.879 177.475 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . 0.641 ' HB3' HG21 ' A' ' 74' ' ' ILE . 17.9 t70 -149.03 136.12 19.95 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.126 -179.841 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . 0.444 HG12 ' HB2' ' A' ' 78' ' ' ASP . 46.2 mt -69.12 110.61 2.63 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 178.189 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' LYS . . . . . 0.421 ' HG2' HG21 ' A' ' 67' ' ' ILE . 31.1 mmtp 63.25 85.37 0.17 Allowed Pre-proline 0 C--N 1.33 -0.269 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 -172.297 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . 0.651 ' HD3' ' HA ' ' A' ' 76' ' ' ARG . 4.2 Cg_endo . . . . . 0 C--N 1.351 0.698 0 C-N-CA 123.805 3.004 . . . . 0.0 112.52 -173.948 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . 0.641 HG21 ' HB3' ' A' ' 66' ' ' ASP . 97.2 mt . . . . . 0 N--CA 1.45 -0.471 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 44.2 t -79.31 137.77 21.17 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 178.935 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' ARG . . . . . 0.651 ' HA ' ' HD3' ' A' ' 69' ' ' PRO . 0.0 OUTLIER -75.57 13.67 0.75 Allowed 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.046 -0.525 . . . . 0.0 111.75 -176.91 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . 0.466 ' OD1' ' HG2' ' A' ' 83' ' ' ARG . 12.7 t70 -70.08 121.89 18.34 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -175.893 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' ASP . . . . . 0.444 ' HB2' HG12 ' A' ' 67' ' ' ILE . 3.3 p30 -101.24 169.53 8.85 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 121.276 0.56 . . . . 0.0 111.526 -172.213 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 8.5 tt -77.46 -15.46 14.37 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 115.328 -0.851 . . . . 0.0 112.518 -171.276 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 7.8 p -93.41 -23.44 18.42 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 121.657 0.742 . . . . 0.0 109.69 -178.902 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' SER . . . . . 0.474 ' N ' ' HD3' ' A' ' 82' ' ' PRO . 23.0 t -139.23 58.22 12.13 Favored Pre-proline 0 N--CA 1.441 -0.897 0 CA-C-N 114.677 -1.147 . . . . 0.0 110.574 -170.596 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' PRO . . . . . 0.474 ' HD3' ' N ' ' A' ' 81' ' ' SER . 5.1 Cg_exo -77.79 140.07 18.19 Favored 'Trans proline' 0 N--CA 1.458 -0.609 0 C-N-CA 122.656 2.237 . . . . 0.0 112.14 -174.736 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' ARG . . . . . 0.842 ' HB2' HD12 ' A' ' 86' ' ' ILE . 55.9 mmt-85 -80.35 113.52 18.59 Favored 'General case' 0 CA--C 1.507 -0.673 0 CA-C-O 121.14 0.495 . . . . 0.0 110.67 178.259 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' MET . . . . . 0.49 ' HA ' ' HD2' ' A' ' 87' ' ' TYR . 22.0 mtp -72.61 -13.12 61.3 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.09 178.553 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . 0.656 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 11.3 pt-20 -70.16 -22.72 62.94 Favored 'General case' 0 C--O 1.232 0.133 0 CA-C-O 121.485 0.659 . . . . 0.0 109.579 175.259 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.842 HD12 ' HB2' ' A' ' 83' ' ' ARG . 96.3 mt -83.34 -33.94 10.47 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 115.251 -0.886 . . . . 0.0 110.172 178.859 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . 0.49 ' HD2' ' HA ' ' A' ' 84' ' ' MET . 95.3 m-85 -82.33 -37.87 25.1 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.572 -178.888 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 23.6 mtp180 -62.55 116.17 4.9 Favored 'General case' 0 CA--C 1.514 -0.44 0 CA-C-O 121.367 0.603 . . . . 0.0 111.401 -178.908 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 111.74 -10.33 27.78 Favored Glycine 0 N--CA 1.447 -0.619 0 CA-C-N 114.914 -1.039 . . . . 0.0 112.054 -178.249 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . 0.505 ' HA ' ' HB2' ' A' ' 38' ' ' ARG . . . -78.72 149.15 32.81 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.057 0.456 . . . . 0.0 110.613 179.649 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -94.38 -21.09 19.18 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.776 -179.245 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . 0.482 HD23 ' N ' ' A' ' 93' ' ' ILE . 4.7 tt -155.12 144.24 20.96 Favored 'General case' 0 N--CA 1.451 -0.376 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.719 -177.864 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.562 ' HA ' ' O ' ' A' ' 40' ' ' VAL . 63.3 mt -130.86 127.18 61.15 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 177.203 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 94' ' ' TYR . . . . . 0.409 ' O ' ' HA ' ' A' ' 41' ' ' GLU . 32.3 p90 -129.24 161.96 28.98 Favored 'General case' 0 C--N 1.322 -0.6 0 C-N-CA 120.578 -0.449 . . . . 0.0 110.897 -179.503 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 14.2 m -144.94 145.72 31.67 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.918 0.39 . . . . 0.0 110.816 -179.333 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 72.6 mt -114.09 109.26 27.85 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.15 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 97' ' ' ARG . . . . . 0.434 HH11 ' HD2' ' A' ' 97' ' ' ARG . 42.0 ttm180 59.48 80.84 0.26 Allowed Pre-proline 0 CA--C 1.534 0.358 0 O-C-N 123.849 0.718 . . . . 0.0 111.35 -178.331 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 96.0 Cg_endo -88.52 133.38 2.68 Favored 'Trans proline' 0 N--CA 1.456 -0.724 0 C-N-CA 122.677 2.251 . . . . 0.0 112.642 179.078 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . 0.621 ' HD2' HD12 ' A' ' 102' ' ' ILE . 32.8 Cg_exo -58.98 141.23 98.1 Favored 'Trans proline' 0 N--CA 1.464 -0.238 0 C-N-CA 122.678 2.252 . . . . 0.0 111.465 175.048 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . 0.722 ' HA ' ' NE2' ' A' ' 103' ' ' HIS . . . -72.07 4.45 3.5 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 112.154 0.428 . . . . 0.0 112.154 -173.737 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 101' ' ' GLU . . . . . 0.595 ' HG3' HG22 ' A' ' 102' ' ' ILE . 9.2 pt-20 -96.33 -21.09 18.02 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.643 -0.253 . . . . 0.0 111.64 -179.928 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.621 HD12 ' HD2' ' A' ' 99' ' ' PRO . 2.5 pp -115.68 10.49 7.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 N-CA-C 113.108 0.781 . . . . 0.0 113.108 -170.331 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 103' ' ' HIS . . . . . 0.722 ' NE2' ' HA ' ' A' ' 100' ' ' ALA . 22.1 m-70 -54.71 -50.22 68.84 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 121.042 0.449 . . . . 0.0 111.13 -179.959 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 5.1 m -64.62 -26.27 68.32 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.96 -177.296 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.522 ' O ' HG21 ' A' ' 109' ' ' VAL . 19.4 m -72.06 -38.98 69.34 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.079 -178.797 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . 0.438 HD22 HG23 ' A' ' 42' ' ' VAL . 77.5 mt -73.42 -41.85 62.78 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.854 179.651 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 107' ' ' MET . . . . . 0.553 ' HG2' ' O ' ' A' ' 103' ' ' HIS . 90.5 mmm -56.44 -41.28 76.19 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.753 -0.658 . . . . 0.0 111.881 -177.981 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 11.2 ptp180 -73.42 -29.42 62.57 Favored 'General case' 0 C--N 1.328 -0.347 0 C-N-CA 120.79 -0.364 . . . . 0.0 111.277 -178.382 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.522 HG21 ' O ' ' A' ' 105' ' ' SER . 81.0 t -68.72 -45.75 80.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 C-N-CA 121.083 -0.247 . . . . 0.0 110.515 -179.777 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -61.77 -44.5 96.76 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.274 178.717 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . 0.706 ' HA ' ' HB3' ' A' ' 148' ' ' ALA . 17.3 t70 -63.85 -34.44 77.94 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.66 -0.7 . . . . 0.0 110.984 179.82 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . 0.406 ' HB2' ' HE2' ' A' ' 84' ' ' MET . . . -70.85 -43.36 68.64 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.825 -0.625 . . . . 0.0 111.955 -178.675 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 21.6 m -89.02 -24.05 6.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 N-CA-C 111.848 0.314 . . . . 0.0 111.848 -175.093 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 84.71 53.68 3.14 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.309 178.691 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -129.83 160.41 33.57 Favored 'General case' 0 C--N 1.323 -0.566 0 O-C-N 122.842 -0.21 . . . . 0.0 110.695 -179.227 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 116' ' ' ARG . . . . . 0.416 ' HD3' ' OE1' ' A' ' 145' ' ' GLU . 10.1 ttm180 -79.53 123.53 27.66 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 109.278 -0.638 . . . . 0.0 109.278 176.013 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . 0.562 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 58.5 tp -95.04 118.01 31.14 Favored 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 109.585 -0.524 . . . . 0.0 109.585 178.812 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 60.2 mt -115.49 114.79 47.37 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.654 0 CA-C-O 121.278 0.561 . . . . 0.0 110.696 -179.773 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 63.1 mt -115.34 123.96 71.41 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.907 0 CA-C-N 116.151 -0.477 . . . . 0.0 109.972 178.908 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 120' ' ' LYS . . . . . 0.502 ' HG2' ' HB3' ' A' ' 143' ' ' PHE . 9.5 tmtm? -110.22 97.92 32.97 Favored Pre-proline 0 C--N 1.321 -0.647 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 176.728 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 80.1 Cg_endo -87.93 -178.18 2.14 Favored 'Trans proline' 0 N--CA 1.453 -0.873 0 C-N-CA 122.794 2.329 . . . . 0.0 111.866 176.433 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 122' ' ' LEU . . . . . 0.732 ' HB2' ' HB3' ' A' ' 125' ' ' GLU . 8.1 mp -108.29 166.93 10.39 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.243 -178.85 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 24.8 m -64.19 111.97 2.82 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 120.942 0.401 . . . . 0.0 110.726 179.147 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 91.66 -32.75 5.14 Favored Glycine 0 N--CA 1.45 -0.379 0 N-CA-C 111.314 -0.714 . . . . 0.0 111.314 -176.8 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . 0.732 ' HB3' ' HB2' ' A' ' 122' ' ' LEU . 20.9 tt0 -92.09 74.68 5.49 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 176.22 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 23.6 t70 -113.62 -178.53 3.4 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 114.788 -1.096 . . . . 0.0 110.948 -166.626 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 4.7 mt . . . . . 0 C--O 1.234 0.268 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 176.201 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 132' ' ' LYS . . . . . 0.421 ' HB3' ' HE1' ' A' ' 107' ' ' MET . 30.9 mmtt . . . . . 0 CA--C 1.524 -0.051 0 N-CA-C 112.152 0.427 . . . . 0.0 112.152 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 133' ' ' MET . . . . . 0.492 ' HG2' ' HB2' ' A' ' 146' ' ' TYR . 77.2 mtp -87.89 154.03 20.85 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.15 0.5 . . . . 0.0 111.616 -173.371 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 14.8 ptmt -112.72 142.66 45.08 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 115.197 -0.91 . . . . 0.0 110.376 -177.305 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . 0.545 HD12 ' HD2' ' A' ' 142' ' ' TYR . 47.2 tp -84.33 123.05 29.76 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.428 -179.957 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -121.68 144.6 30.32 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.935 -179.516 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -111.2 130.53 55.61 Favored 'General case' 0 C--N 1.325 -0.482 0 N-CA-C 109.526 -0.546 . . . . 0.0 109.526 175.002 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . 0.416 ' CD2' ' HB2' ' A' ' 28' ' ' TYR . 57.5 t80 -148.52 111.55 4.87 Favored 'General case' 0 C--N 1.322 -0.629 0 N-CA-C 110.018 -0.364 . . . . 0.0 110.018 176.139 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 69.49 49.2 39.4 Favored Glycine 0 N--CA 1.446 -0.683 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.02 179.826 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 20.9 mmm-85 76.48 -40.66 0.39 Allowed 'General case' 0 N--CA 1.467 0.397 0 C-N-CA 123.729 0.812 . . . . 0.0 112.057 177.446 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 13.8 t -76.73 146.94 37.66 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.192 0.52 . . . . 0.0 110.64 -177.941 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 142' ' ' TYR . . . . . 0.545 ' HD2' HD12 ' A' ' 135' ' ' LEU . 47.4 p90 -117.28 142.94 46.45 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.776 179.194 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 143' ' ' PHE . . . . . 0.502 ' HB3' ' HG2' ' A' ' 120' ' ' LYS . 11.4 p90 -152.48 179.79 8.26 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.58 -0.736 . . . . 0.0 109.748 -178.476 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 89.3 m-85 -115.33 138.07 51.36 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 120.669 0.271 . . . . 0.0 110.595 -179.858 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 145' ' ' GLU . . . . . 0.416 ' OE1' ' HD3' ' A' ' 116' ' ' ARG . 17.9 pt-20 -123.81 160.05 28.22 Favored 'General case' 0 C--N 1.319 -0.737 0 N-CA-C 109.161 -0.681 . . . . 0.0 109.161 173.878 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . 0.492 ' HB2' ' HG2' ' A' ' 133' ' ' MET . 45.7 t80 -142.26 126.36 17.39 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-O 121.07 0.462 . . . . 0.0 110.374 176.78 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 2.1 mp -92.82 108.11 19.91 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.762 0 CA-C-N 115.696 -0.684 . . . . 0.0 109.389 176.683 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . 0.706 ' HB3' ' HA ' ' A' ' 111' ' ' ASP . . . -70.93 129.12 38.22 Favored 'General case' 0 N--CA 1.444 -0.774 0 CA-C-N 115.693 -0.685 . . . . 0.0 110.151 176.353 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 22.4 mm-40 . . . . . 0 C--N 1.321 -0.642 0 CA-C-O 121.768 0.794 . . . . 0.0 111.395 177.779 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 81.7 m95 . . . . . 0 C--O 1.232 0.148 0 CA-C-O 120.792 0.329 . . . . 0.0 111.145 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . 0.499 ' O ' HG21 ' A' ' 27' ' ' VAL . 6.7 m-20 -65.5 -29.85 70.55 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.006 -179.547 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -75.04 -34.07 61.81 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 179.696 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 45.1 tp -60.31 -43.13 96.62 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 115.914 -0.585 . . . . 0.0 109.651 172.846 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -59.05 -47.33 85.62 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.458 -0.792 . . . . 0.0 110.655 176.661 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.499 HG21 ' O ' ' A' ' 23' ' ' ASN . 99.2 t -56.21 -43.25 75.86 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.188 0 CA-C-N 116.361 -0.381 . . . . 0.0 111.111 177.987 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 88.0 t80 -59.44 -48.71 80.59 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.819 0.342 . . . . 0.0 110.461 178.401 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 71.6 mt -58.48 -41.83 82.77 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.251 178.553 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.581 HG12 HG23 ' A' ' 54' ' ' ILE . 83.2 mt -60.32 -38.44 77.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 115.473 -0.785 . . . . 0.0 111.061 177.639 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 22.1 mtp180 -70.78 -30.13 66.52 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.154 -179.22 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 75.6 m -87.03 -8.91 56.67 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.576 -178.501 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 26.0 p -122.84 -80.83 0.63 Allowed 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 120.747 0.308 . . . . 0.0 111.08 179.01 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.446 ' O ' HG21 ' A' ' 37' ' ' THR . . . 88.21 168.51 44.33 Favored Glycine 0 N--CA 1.447 -0.633 0 C-N-CA 121.141 -0.552 . . . . 0.0 112.446 -179.901 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_exo -65.67 140.33 61.69 Favored 'Trans proline' 0 C--O 1.232 0.204 0 C-N-CA 122.644 2.229 . . . . 0.0 111.759 178.225 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 109.98 -8.21 31.41 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.364 -0.922 . . . . 0.0 112.507 178.978 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' THR . . . . . 0.446 HG21 ' O ' ' A' ' 34' ' ' GLY . 11.5 t -125.04 -171.31 2.33 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.306 -0.627 . . . . 0.0 109.306 178.299 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' ARG . . . . . 0.817 ' HG3' ' HA ' ' A' ' 90' ' ' ALA . 1.7 ptm180 -132.48 136.94 47.02 Favored 'General case' 0 N--CA 1.447 -0.604 0 CA-C-O 121.075 0.464 . . . . 0.0 111.418 -179.619 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.472 ' O ' ' HA ' ' A' ' 62' ' ' LEU . 58.2 t -125.91 139.43 51.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 115.611 -0.722 . . . . 0.0 109.747 -178.223 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.465 ' HB ' HG12 ' A' ' 93' ' ' ILE . 39.6 t -116.34 134.47 59.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-O 120.854 0.359 . . . . 0.0 111.164 -178.026 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 44.1 tt0 -108.23 120.56 42.72 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.143 177.02 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.598 ' HB ' ' HB3' ' A' ' 95' ' ' SER . 85.7 t -95.91 123.49 48.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.387 -179.603 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 98.19 25.16 10.53 Favored Glycine 0 N--CA 1.447 -0.567 0 C-N-CA 120.686 -0.769 . . . . 0.0 111.789 -179.366 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -79.32 54.13 1.63 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 121.321 0.582 . . . . 0.0 111.128 -178.281 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -94.25 -64.82 1.02 Allowed Glycine 0 N--CA 1.444 -0.789 0 C-N-CA 120.854 -0.689 . . . . 0.0 111.823 178.674 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -105.07 -8.22 18.63 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.059 0.457 . . . . 0.0 110.306 175.373 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.488 ' HD1' ' HE1' ' A' ' 49' ' ' TYR . 87.4 m-85 -106.76 102.54 11.91 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.909 -0.587 . . . . 0.0 109.981 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . 0.522 HD23 HD12 ' A' ' 64' ' ' LEU . 84.5 mt -129.7 -10.81 4.45 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.448 -0.342 . . . . 0.0 111.002 179.997 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . 0.488 ' HE1' ' HD1' ' A' ' 47' ' ' PHE . 30.6 p90 -59.06 -30.97 68.45 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 112.59 0.589 . . . . 0.0 112.59 -173.917 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 80.5 t -75.81 -58.01 5.26 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-O 120.795 0.331 . . . . 0.0 110.744 178.831 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' SER . . . . . 0.431 ' CB ' HD21 ' A' ' 64' ' ' LEU . 15.5 p -60.32 -39.18 86.12 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.939 -177.983 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.503 ' O ' ' HG3' ' A' ' 56' ' ' LYS . 29.7 t70 -65.11 -33.65 76.53 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.64 -178.38 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 71.0 t80 -71.25 -44.71 64.77 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.545 177.499 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.581 HG23 HG12 ' A' ' 30' ' ' ILE . 79.2 mt -57.48 -46.42 85.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.868 -176.602 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' ARG . . . . . 0.482 HH12 HD11 ' A' ' 64' ' ' LEU . 9.0 ptp85 -69.03 -16.12 63.63 Favored 'General case' 0 N--CA 1.467 0.383 0 N-CA-C 112.164 0.431 . . . . 0.0 112.164 -176.889 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . 0.503 ' HG3' ' O ' ' A' ' 52' ' ' ASP . 67.9 mttm -82.54 -33.08 28.31 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 120.807 0.337 . . . . 0.0 111.392 -179.753 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 13.9 t60 -95.11 -39.65 10.02 Favored 'General case' 0 N--CA 1.448 -0.529 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.357 -177.699 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 8.1 p -118.51 132.07 56.23 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.449 -0.341 . . . . 0.0 111.13 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . 0.402 ' HA ' ' HD2' ' A' ' 59' ' ' LYS . 26.9 mmmt -80.97 61.2 4.47 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.696 0.76 . . . . 0.0 110.603 176.062 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 7.7 p -98.07 144.65 10.92 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.725 0 CA-C-N 114.901 -1.045 . . . . 0.0 109.509 175.508 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -73.12 89.61 1.5 Allowed 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 177.561 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . 0.472 ' HA ' ' O ' ' A' ' 39' ' ' VAL . 3.5 tt -96.39 118.4 32.84 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.014 0.435 . . . . 0.0 110.363 -176.611 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 58.1 t -102.19 128.98 54.31 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.463 0 CA-C-N 115.588 -0.733 . . . . 0.0 110.72 -176.141 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . 0.522 HD12 HD23 ' A' ' 48' ' ' LEU . 66.1 mt -108.66 133.26 52.99 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.936 -0.574 . . . . 0.0 109.999 176.404 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 12.5 p -119.12 132.03 55.96 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.724 0.297 . . . . 0.0 110.71 176.194 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . 0.422 ' HB3' HG21 ' A' ' 74' ' ' ILE . 24.5 t70 -156.96 146.85 20.81 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.426 -177.843 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . 0.592 HG12 ' HB2' ' A' ' 78' ' ' ASP . 34.5 mt -73.9 103.91 2.44 Favored 'Isoleucine or valine' 0 C--O 1.238 0.491 0 N-CA-C 110.114 -0.328 . . . . 0.0 110.114 179.419 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' LYS . . . . . 0.4 ' HA ' ' HD2' ' A' ' 69' ' ' PRO . 30.7 mtpt 56.92 80.08 0.3 Allowed Pre-proline 0 C--N 1.33 -0.276 0 CA-C-N 115.191 -0.913 . . . . 0.0 109.798 -177.091 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . 0.85 ' HB3' ' HB ' ' A' ' 74' ' ' ILE . 9.1 Cg_endo . . . . . 0 C--O 1.234 0.275 0 C-N-CA 123.895 3.064 . . . . 0.0 113.7 -173.077 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . 0.85 ' HB ' ' HB3' ' A' ' 69' ' ' PRO . 43.4 mt . . . . . 0 N--CA 1.453 -0.318 0 N-CA-C 110.164 -0.31 . . . . 0.0 110.164 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.464 HG13 ' H ' ' A' ' 77' ' ' ASP . 63.3 t -79.41 141.94 14.66 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.093 178.764 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' ARG . . . . . 0.548 ' HG2' ' HD2' ' A' ' 69' ' ' PRO . 89.1 mtm180 -82.87 16.41 2.28 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.913 -176.148 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . 0.464 ' H ' HG13 ' A' ' 75' ' ' VAL . 35.9 t70 -87.03 138.01 31.86 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 179.001 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' ASP . . . . . 0.592 ' HB2' HG12 ' A' ' 67' ' ' ILE . 0.7 OUTLIER -103.32 177.92 4.7 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.73 0.3 . . . . 0.0 111.257 -173.362 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 9.3 tp -94.03 -24.66 4.95 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.444 0 N-CA-C 112.601 0.593 . . . . 0.0 112.601 -170.401 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.519 HG22 ' OD1' ' A' ' 78' ' ' ASP . 6.3 t -91.1 -20.5 21.96 Favored 'General case' 0 C--N 1.325 -0.47 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 -178.319 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' SER . . . . . 0.501 ' HB2' ' OD2' ' A' ' 78' ' ' ASP . 34.0 m -129.42 62.85 65.23 Favored Pre-proline 0 CA--C 1.535 0.391 0 CA-C-N 115.48 -0.782 . . . . 0.0 110.081 172.822 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 87.9 Cg_endo -85.7 150.28 9.98 Favored 'Trans proline' 0 N--CA 1.459 -0.515 0 C-N-CA 122.375 2.05 . . . . 0.0 113.525 -171.847 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 77.8 mtt-85 -88.95 112.51 23.41 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.416 -0.811 . . . . 0.0 110.413 175.147 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' MET . . . . . . . . . . . . . 93.6 mmm -66.05 -23.38 66.53 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.449 -0.341 . . . . 0.0 111.057 -179.264 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 6.7 pm0 -67.62 -19.32 65.21 Favored 'General case' 0 N--CA 1.464 0.246 0 CA-C-O 120.889 0.376 . . . . 0.0 111.01 179.61 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 62.1 mt -83.81 -39.34 14.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.345 179.017 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . 0.404 ' CB ' HG13 ' A' ' 113' ' ' VAL . 93.3 m-85 -80.65 -34.07 35.17 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.209 -178.557 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . 0.528 ' HA ' ' HB ' ' A' ' 113' ' ' VAL . 62.2 mtp85 -65.15 132.93 50.42 Favored 'General case' 0 CA--C 1.515 -0.384 0 CA-C-O 121.329 0.585 . . . . 0.0 110.856 -178.509 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 102.4 -19.41 48.33 Favored Glycine 0 N--CA 1.446 -0.683 0 CA-C-N 115.053 -0.976 . . . . 0.0 111.641 -176.803 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . 0.817 ' HA ' ' HG3' ' A' ' 38' ' ' ARG . . . -71.46 145.3 49.32 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.837 0.351 . . . . 0.0 110.705 -179.772 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -92.52 -21.98 19.81 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.041 -179.188 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . 0.524 ' HG ' ' HB3' ' A' ' 116' ' ' ARG . 3.5 tt -150.81 138.4 19.68 Favored 'General case' 0 N--CA 1.449 -0.497 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.912 -176.28 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.63 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 85.5 mt -133.03 124.05 49.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 115.719 -0.673 . . . . 0.0 109.326 176.955 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 94' ' ' TYR . . . . . 0.405 ' HB3' ' HB ' ' A' ' 118' ' ' ILE . 10.2 p90 -130.01 158.84 38.49 Favored 'General case' 0 C--N 1.32 -0.696 0 C-N-CA 120.808 -0.357 . . . . 0.0 110.802 -179.524 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 95' ' ' SER . . . . . 0.598 ' HB3' ' HB ' ' A' ' 42' ' ' VAL . 11.5 p -145.07 137.71 26.18 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.594 -177.749 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 63.7 mt -104.7 111.51 34.55 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.293 -179.212 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 6.1 tpm_? 61.32 75.67 0.44 Allowed Pre-proline 0 CA--C 1.534 0.355 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.188 -179.763 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 0.9 OUTLIER -84.32 150.86 12.01 Favored 'Trans proline' 0 N--CA 1.457 -0.629 0 C-N-CA 122.788 2.325 . . . . 0.0 111.589 176.449 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -59.39 155.16 42.64 Favored 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.703 2.269 . . . . 0.0 111.619 175.727 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . 0.634 ' HA ' ' CE1' ' A' ' 103' ' ' HIS . . . -79.26 7.19 8.17 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 112.144 0.424 . . . . 0.0 112.144 -174.118 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 101' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -111.75 -14.03 13.64 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 111.804 0.298 . . . . 0.0 111.804 179.597 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.417 HG13 ' O ' ' A' ' 102' ' ' ILE . 32.2 pt -123.51 77.46 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 121.821 0.82 . . . . 0.0 111.661 -179.281 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 103' ' ' HIS . . . . . 0.634 ' CE1' ' HA ' ' A' ' 100' ' ' ALA . 44.9 m80 -112.99 -50.25 2.89 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.418 -0.81 . . . . 0.0 109.331 174.983 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 18.9 t -74.9 -23.76 58.42 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 176.353 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.523 ' O ' ' HG2' ' A' ' 108' ' ' ARG . 3.3 m -67.87 -38.96 83.76 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.459 -0.791 . . . . 0.0 109.754 177.272 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 69.2 mt -73.2 -38.76 65.99 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.129 175.701 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 107' ' ' MET . . . . . . . . . . . . . 47.9 ttm -62.1 -39.82 93.75 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.685 -0.689 . . . . 0.0 111.129 -179.819 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 108' ' ' ARG . . . . . 0.523 ' HG2' ' O ' ' A' ' 105' ' ' SER . 7.9 ptp180 -68.56 -25.35 64.86 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.629 0.252 . . . . 0.0 110.795 -179.816 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.479 HG22 ' O ' ' A' ' 105' ' ' SER . 94.2 t -72.32 -48.18 49.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 175.697 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -59.63 -41.59 90.8 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.167 176.164 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 18.0 t70 -61.95 -38.28 87.89 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.412 -0.813 . . . . 0.0 111.164 178.232 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -72.74 -40.37 66.11 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.612 -0.722 . . . . 0.0 111.957 -178.377 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.528 ' HB ' ' HA ' ' A' ' 88' ' ' ARG . 13.7 m -91.01 -24.57 5.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-O 120.895 0.378 . . . . 0.0 111.741 -174.339 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 88.69 42.13 5.83 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 121.009 -0.615 . . . . 0.0 112.421 178.916 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -119.41 156.5 30.03 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 121.101 0.477 . . . . 0.0 111.407 -177.177 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 116' ' ' ARG . . . . . 0.524 ' HB3' ' HG ' ' A' ' 92' ' ' LEU . 21.5 ttm180 -79.59 121.37 25.18 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.793 -0.639 . . . . 0.0 109.654 176.793 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . 0.63 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 53.3 tp -92.71 118.83 31.47 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.383 -178.579 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . 0.405 ' HB ' ' HB3' ' A' ' 94' ' ' TYR . 64.1 mt -113.38 121.72 66.12 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.61 0 CA-C-O 121.024 0.44 . . . . 0.0 110.425 178.101 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 56.4 mt -120.46 134.31 64.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.375 -179.809 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 45.2 tptt -110.14 98.2 33.94 Favored Pre-proline 0 C--N 1.323 -0.549 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.524 175.43 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 82.0 Cg_endo -91.47 174.62 2.42 Favored 'Trans proline' 0 N--CA 1.456 -0.721 0 C-N-CA 123.068 2.512 . . . . 0.0 112.005 173.961 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -99.01 163.79 12.44 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.467 178.984 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 14.5 t -65.06 -21.78 66.88 Favored 'General case' 0 CA--C 1.534 0.363 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.429 -179.162 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -104.13 18.04 46.74 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.308 179.871 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 22.7 mm-40 -119.6 -173.84 2.62 Favored 'General case' 0 N--CA 1.449 -0.487 0 CA-C-O 121.209 0.528 . . . . 0.0 110.334 -178.489 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -148.87 170.01 19.25 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 115.381 -0.827 . . . . 0.0 108.791 176.548 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 7.5 mt . . . . . 0 C--N 1.322 -0.591 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 179.484 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 29.5 mmmt . . . . . 0 N--CA 1.456 -0.125 0 CA-C-O 120.845 0.355 . . . . 0.0 111.447 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 133' ' ' MET . . . . . 0.719 ' HG2' ' HB2' ' A' ' 146' ' ' TYR . 82.5 mtp -92.38 164.94 13.31 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.929 -174.431 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 13.2 ptmm? -127.08 140.47 52.26 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.971 -177.503 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . 0.513 HD12 ' HD2' ' A' ' 142' ' ' TYR . 51.6 tp -80.7 129.19 34.38 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.338 -179.091 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -123.3 139.04 51.18 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.68 178.751 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 16.8 m120 -114.83 108.25 16.5 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 115.801 -0.636 . . . . 0.0 109.868 179.557 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 54.1 t80 -131.65 106.01 7.89 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-O 120.929 0.395 . . . . 0.0 110.323 -178.275 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . 0.461 ' O ' ' HB2' ' A' ' 140' ' ' ARG . . . 80.0 34.16 31.07 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.094 178.922 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 140' ' ' ARG . . . . . 0.461 ' HB2' ' O ' ' A' ' 139' ' ' GLY . 0.0 OUTLIER 75.32 -14.57 0.75 Allowed 'General case' 0 N--CA 1.468 0.471 0 C-N-CA 123.279 0.632 . . . . 0.0 111.921 178.097 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 8.3 t -93.9 141.62 28.31 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 175.562 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 142' ' ' TYR . . . . . 0.513 ' HD2' HD12 ' A' ' 135' ' ' LEU . 43.0 p90 -119.07 143.54 47.07 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 121.364 0.602 . . . . 0.0 110.825 -176.052 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 15.0 p90 -152.01 173.88 14.34 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 115.119 -0.946 . . . . 0.0 109.413 -178.512 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 76.8 m-85 -112.94 129.47 56.46 Favored 'General case' 0 C--N 1.322 -0.611 0 C-N-CA 121.058 -0.257 . . . . 0.0 110.691 -179.624 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 145' ' ' GLU . . . . . 0.481 ' OE1' ' HD3' ' A' ' 116' ' ' ARG . 19.2 pt-20 -115.33 157.19 24.18 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 174.667 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . 0.719 ' HB2' ' HG2' ' A' ' 133' ' ' MET . 32.9 t80 -139.24 124.19 18.77 Favored 'General case' 0 C--N 1.315 -0.913 0 CA-C-N 115.752 -0.658 . . . . 0.0 109.904 176.656 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 3.1 mp -93.54 105.93 17.41 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.859 0 N-CA-C 109.726 -0.472 . . . . 0.0 109.726 -179.168 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -62.3 114.94 3.76 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-O 121.139 0.495 . . . . 0.0 110.756 178.054 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 8.1 mm-40 . . . . . 0 C--N 1.32 -0.683 0 CA-C-N 115.346 -0.843 . . . . 0.0 111.194 179.22 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 51.4 m95 . . . . . 0 C--O 1.232 0.167 0 CA-C-O 120.677 0.275 . . . . 0.0 111.22 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . 0.415 ' O ' HG22 ' A' ' 27' ' ' VAL . 25.1 t-20 -66.19 -58.96 4.26 Favored 'General case' 0 N--CA 1.463 0.198 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.674 -172.285 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.452 ' CB ' ' HA3' ' A' ' 139' ' ' GLY . 4.5 m-20 -58.12 -32.68 68.36 Favored 'General case' 0 N--CA 1.464 0.27 0 CA-C-O 120.631 0.253 . . . . 0.0 111.333 -178.892 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 45.7 tp -57.16 -51.22 70.2 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-O 120.932 0.396 . . . . 0.0 110.262 175.291 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . 0.416 ' HB3' HG13 ' A' ' 50' ' ' VAL . . . -63.48 -43.56 96.94 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.601 179.887 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.415 HG22 ' O ' ' A' ' 23' ' ' ASN . 95.5 t -52.13 -47.85 43.09 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.153 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.076 177.454 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 56.4 t80 -57.81 -43.31 85.62 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.539 179.88 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 70.8 mt -67.91 -43.97 85.51 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.791 179.247 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.457 HG12 HG23 ' A' ' 54' ' ' ILE . 92.1 mt -58.27 -45.54 89.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 115.61 -0.723 . . . . 0.0 111.0 178.303 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 84.0 mtt-85 -65.56 -27.72 68.63 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.666 -0.697 . . . . 0.0 111.761 -177.848 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 53.5 t -84.79 -27.35 26.9 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.596 -0.275 . . . . 0.0 111.186 -179.011 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 12.4 p -94.21 -76.96 0.47 Allowed 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 120.797 0.332 . . . . 0.0 111.202 -177.041 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 95.75 142.81 13.42 Favored Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 120.85 -0.69 . . . . 0.0 112.162 -178.843 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . 0.505 ' HG3' ' HA ' ' A' ' 58' ' ' SER . 58.1 Cg_exo -51.68 126.4 19.6 Favored 'Trans proline' 0 C--N 1.343 0.284 0 C-N-CA 123.283 2.655 . . . . 0.0 113.001 -176.795 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 104.32 53.93 0.81 Allowed Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.514 179.517 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 15.1 t -166.74 -175.84 3.27 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 179.624 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 63.1 mtt85 -122.11 132.51 54.51 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 121.08 0.467 . . . . 0.0 110.775 -179.911 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.89 ' HB ' HD21 ' A' ' 62' ' ' LEU . 60.6 t -123.85 131.76 72.45 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 N-CA-C 108.763 -0.828 . . . . 0.0 108.763 176.76 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.407 HG11 ' CE1' ' A' ' 87' ' ' TYR . 35.6 t -106.7 126.56 62.57 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-O 120.817 0.342 . . . . 0.0 110.887 -177.679 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 46.4 tt0 -108.22 124.12 49.81 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.144 178.368 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.892 ' HB ' ' HB3' ' A' ' 95' ' ' SER . 95.1 t -97.37 121.72 48.17 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.593 -179.876 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 89.68 34.13 8.67 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.855 -0.688 . . . . 0.0 111.519 -179.64 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -81.09 14.15 2.44 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 112.432 0.53 . . . . 0.0 112.432 -173.185 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -54.41 -38.04 61.59 Favored Glycine 0 CA--C 1.519 0.32 0 C-N-CA 121.201 -0.524 . . . . 0.0 113.807 -176.887 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 19.4 mtp180 -139.2 13.28 2.61 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 117.129 0.465 . . . . 0.0 111.997 -177.144 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 73.4 m-85 -112.15 29.03 8.24 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 121.254 0.55 . . . . 0.0 110.619 -177.519 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . 0.542 HD22 HD13 ' A' ' 74' ' ' ILE . 87.0 mt -59.26 -15.66 16.89 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 114.868 -1.06 . . . . 0.0 113.074 -175.342 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 81.5 t80 -59.13 -45.26 91.39 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.583 0.23 . . . . 0.0 111.313 -179.249 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.418 ' O ' HG13 ' A' ' 54' ' ' ILE . 42.8 t -65.41 -54.64 26.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.672 -175.224 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' SER . . . . . 0.436 ' CB ' HD22 ' A' ' 64' ' ' LEU . 0.2 OUTLIER -59.52 -41.96 91.17 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.701 -179.796 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.587 ' HA ' ' HG2' ' A' ' 55' ' ' ARG . 38.7 t70 -69.08 -37.92 78.72 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 120.857 -0.337 . . . . 0.0 110.865 -179.224 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 89.4 t80 -60.26 -37.06 79.26 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.875 0.369 . . . . 0.0 110.034 177.925 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.457 HG23 HG12 ' A' ' 30' ' ' ILE . 76.0 mt -63.29 -54.78 28.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.949 -0.568 . . . . 0.0 110.673 176.044 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' ARG . . . . . 0.587 ' HG2' ' HA ' ' A' ' 52' ' ' ASP . 3.7 ptp180 -69.77 -16.44 63.3 Favored 'General case' 0 N--CA 1.465 0.318 0 N-CA-C 112.072 0.397 . . . . 0.0 112.072 -177.083 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . 0.691 ' HA ' ' HE3' ' A' ' 56' ' ' LYS . 0.0 OUTLIER -64.04 -39.24 93.66 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.693 0.282 . . . . 0.0 110.843 176.378 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 29.9 m-70 -107.27 -50.51 3.07 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.746 -178.61 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' SER . . . . . 0.505 ' HA ' ' HG3' ' A' ' 35' ' ' PRO . 57.6 m -88.38 132.99 34.22 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.851 -178.289 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . 0.557 ' N ' ' HD2' ' A' ' 59' ' ' LYS . 3.3 mptp? -80.19 57.06 2.61 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.684 0.754 . . . . 0.0 109.825 178.661 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.483 HG12 HG22 ' A' ' 39' ' ' VAL . 54.0 t -101.22 139.32 22.76 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-N 114.998 -1.001 . . . . 0.0 111.043 -178.11 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -80.02 98.61 7.28 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.866 -0.606 . . . . 0.0 109.524 174.819 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . 0.89 HD21 ' HB ' ' A' ' 39' ' ' VAL . 0.2 OUTLIER -87.54 121.02 29.43 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 115.934 -0.575 . . . . 0.0 109.593 -178.827 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 40.9 t -100.49 113.77 37.26 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.661 0 CA-C-N 115.738 -0.665 . . . . 0.0 109.786 -179.757 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . 0.726 ' HB2' ' HA ' ' A' ' 74' ' ' ILE . 54.5 mt -97.37 139.8 32.78 Favored 'General case' 0 C--N 1.312 -1.04 0 CA-C-N 115.628 -0.714 . . . . 0.0 110.338 -177.507 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.407 ' OG1' ' HA ' ' A' ' 42' ' ' VAL . 38.0 p -131.23 137.92 49.12 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.301 0.096 . . . . 0.0 110.91 178.547 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 4.7 t70 -171.19 170.81 5.93 Favored 'General case' 0 N--CA 1.466 0.33 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 175.759 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 49.5 mm -85.96 104.74 13.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 120.813 0.34 . . . . 0.0 110.865 -175.898 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 35.4 mtmt 56.21 77.52 0.42 Allowed Pre-proline 0 C--N 1.33 -0.278 0 CA-C-N 115.324 -0.853 . . . . 0.0 111.894 -179.575 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . 0.797 ' HD2' ' HG2' ' A' ' 76' ' ' ARG . 70.1 Cg_endo . . . . . 0 N--CA 1.459 -0.505 0 C-N-CA 122.334 2.023 . . . . 0.0 112.139 175.613 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . 0.726 ' HA ' ' HB2' ' A' ' 64' ' ' LEU . 44.6 mt . . . . . 0 N--CA 1.451 -0.415 0 CA-C-O 120.94 0.4 . . . . 0.0 110.531 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 97.8 t -77.53 139.04 19.3 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 CA-C-N 116.065 -0.516 . . . . 0.0 109.807 176.43 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' ARG . . . . . 0.797 ' HG2' ' HD2' ' A' ' 69' ' ' PRO . 65.7 mtm180 -84.62 38.77 0.71 Allowed 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 120.762 0.315 . . . . 0.0 110.807 -177.73 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 28.1 t70 -76.68 126.73 31.49 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 121.024 0.44 . . . . 0.0 110.447 -178.649 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' ASP . . . . . 0.486 ' HB3' HG21 ' A' ' 80' ' ' THR . 3.3 m-20 -71.13 97.28 1.47 Allowed 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.891 -0.595 . . . . 0.0 109.971 175.808 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 9.7 tp -58.56 -17.31 9.92 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.388 0 CA-C-O 121.273 0.559 . . . . 0.0 111.663 -178.255 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.486 HG21 ' HB3' ' A' ' 78' ' ' ASP . 8.8 t -66.39 -24.08 66.42 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.027 0.442 . . . . 0.0 110.442 176.246 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 36.6 m -154.42 70.18 6.08 Favored Pre-proline 0 C--N 1.329 -0.32 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 177.514 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' PRO . . . . . 0.535 ' HB2' ' HE2' ' A' ' 87' ' ' TYR . 74.0 Cg_endo -73.27 159.28 47.37 Favored 'Trans proline' 0 C--O 1.236 0.387 0 C-N-CA 123.011 2.474 . . . . 0.0 113.516 -169.691 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' ARG . . . . . 0.681 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 1.9 mtm180 -93.99 126.39 39.18 Favored 'General case' 0 C--N 1.323 -0.543 0 CA-C-N 115.793 -0.639 . . . . 0.0 110.921 177.958 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' MET . . . . . . . . . . . . . 89.3 mmm -64.56 -23.93 67.43 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.252 -178.066 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . 0.681 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 12.0 pt-20 -62.52 -20.53 64.72 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.607 -179.112 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 63.8 mt -86.2 -29.47 6.08 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-O 121.167 0.508 . . . . 0.0 110.541 -178.802 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . 0.535 ' HE2' ' HB2' ' A' ' 82' ' ' PRO . 84.6 m-85 -93.34 -30.62 15.03 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.734 -176.259 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 81.8 mtp180 -66.75 114.14 5.4 Favored 'General case' 0 CA--C 1.514 -0.416 0 CA-C-O 121.485 0.659 . . . . 0.0 111.484 -176.889 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 116.09 -17.51 14.84 Favored Glycine 0 N--CA 1.446 -0.684 0 CA-C-N 114.902 -1.044 . . . . 0.0 111.982 -177.593 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -71.86 147.71 46.87 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.769 0.318 . . . . 0.0 110.665 178.835 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -91.34 -26.37 18.96 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-O 121.035 0.445 . . . . 0.0 110.856 -179.665 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . 0.486 ' HG ' ' HB3' ' A' ' 116' ' ' ARG . 5.0 tt -149.55 142.71 25.03 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.653 -177.715 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.591 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 63.2 mt -131.45 123.09 51.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 N-CA-C 109.117 -0.697 . . . . 0.0 109.117 178.269 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 94' ' ' TYR . . . . . 0.407 ' HE1' HG13 ' A' ' 39' ' ' VAL . 10.7 p90 -136.24 161.3 36.14 Favored 'General case' 0 C--N 1.321 -0.659 0 C-N-CA 120.403 -0.519 . . . . 0.0 111.375 -178.119 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 95' ' ' SER . . . . . 0.892 ' HB3' ' HB ' ' A' ' 42' ' ' VAL . 5.4 p -147.87 147.58 29.92 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.824 -0.626 . . . . 0.0 110.447 -178.268 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 4.3 mp -114.45 121.89 67.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-N 116.668 -0.242 . . . . 0.0 110.567 -179.184 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 50.85 67.28 4.46 Favored Pre-proline 0 N--CA 1.467 0.4 0 O-C-N 123.815 0.697 . . . . 0.0 111.201 179.328 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 85.5 Cg_endo -87.18 143.84 6.81 Favored 'Trans proline' 0 N--CA 1.456 -0.706 0 C-N-CA 122.861 2.374 . . . . 0.0 113.19 -174.772 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . 0.544 ' HD2' HD11 ' A' ' 102' ' ' ILE . 24.3 Cg_exo -63.7 144.51 89.47 Favored 'Trans proline' 0 C--O 1.234 0.317 0 C-N-CA 122.737 2.291 . . . . 0.0 111.573 175.611 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -78.22 44.17 0.48 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.177 0.513 . . . . 0.0 111.289 -177.708 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 101' ' ' GLU . . . . . 0.588 ' HG3' HG23 ' A' ' 102' ' ' ILE . 11.2 pt-20 -132.49 -11.4 3.15 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.439 175.795 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.588 HG23 ' HG3' ' A' ' 101' ' ' GLU . 35.1 pt -122.85 -6.86 8.25 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.449 -0.341 . . . . 0.0 111.636 -177.542 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 103' ' ' HIS . . . . . . . . . . . . . 16.1 p-80 -62.97 -39.31 94.29 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.083 -176.256 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 32.2 t -71.78 -32.93 68.17 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 121.309 0.576 . . . . 0.0 110.086 178.487 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.58 ' O ' ' HG3' ' A' ' 108' ' ' ARG . 31.0 m -70.68 -33.28 70.75 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.314 179.898 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . 0.499 ' HG ' ' O ' ' A' ' 102' ' ' ILE . 85.2 mt -61.34 -40.27 93.66 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.831 177.606 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 107' ' ' MET . . . . . 0.418 ' HE1' ' O ' ' A' ' 132' ' ' LYS . 39.7 tpp -56.67 -54.4 46.54 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.344 178.036 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 108' ' ' ARG . . . . . 0.58 ' HG3' ' O ' ' A' ' 105' ' ' SER . 1.6 ptm180 -65.09 -30.94 71.93 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.492 -0.322 . . . . 0.0 111.624 -177.28 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.481 HG22 ' O ' ' A' ' 105' ' ' SER . 83.4 t -73.27 -45.86 51.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 C-N-CA 120.972 -0.291 . . . . 0.0 110.917 179.194 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -59.31 -47.74 84.26 Favored 'General case' 0 CA--C 1.516 -0.355 0 CA-C-O 120.759 0.314 . . . . 0.0 110.163 178.8 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . 0.712 ' HA ' ' HB3' ' A' ' 148' ' ' ALA . 17.3 t70 -66.73 -29.17 69.08 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.984 -176.679 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -71.54 -43.57 66.18 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.547 178.727 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 16.2 m -88.08 -27.01 5.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.456 -0.338 . . . . 0.0 111.758 -175.7 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 89.31 46.27 4.44 Favored Glycine 0 N--CA 1.449 -0.452 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.42 179.016 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -122.5 160.92 24.6 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 121.096 0.474 . . . . 0.0 111.201 -178.233 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 116' ' ' ARG . . . . . 0.486 ' HB3' ' HG ' ' A' ' 92' ' ' LEU . 29.5 ttt180 -81.92 116.42 21.55 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.859 -0.61 . . . . 0.0 109.604 178.542 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . 0.591 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 56.0 tp -90.9 118.5 30.35 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.09 -179.401 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 66.3 mt -119.5 126.04 74.96 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-O 121.121 0.486 . . . . 0.0 110.362 179.07 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 119' ' ' ILE . . . . . 0.484 ' O ' ' HD3' ' A' ' 121' ' ' PRO . 63.8 mt -112.93 127.49 70.14 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.055 178.167 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 48.3 tptt -105.65 91.8 5.42 Favored Pre-proline 0 C--N 1.325 -0.463 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.067 178.507 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 121' ' ' PRO . . . . . 0.517 ' HB2' ' CG ' ' A' ' 125' ' ' GLU . 75.9 Cg_endo -92.68 -177.86 0.82 Allowed 'Trans proline' 0 N--CA 1.455 -0.751 0 C-N-CA 122.622 2.215 . . . . 0.0 111.951 175.049 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -72.81 146.02 46.59 Favored 'General case' 0 C--N 1.327 -0.37 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 173.26 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 123' ' ' THR . . . . . 0.458 ' O ' HG22 ' A' ' 123' ' ' THR . 6.2 t -68.61 96.09 0.69 Allowed 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 121.668 0.747 . . . . 0.0 109.475 175.83 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 138.13 -17.58 3.37 Favored Glycine 0 N--CA 1.449 -0.485 0 CA-C-N 115.458 -0.792 . . . . 0.0 112.482 -178.117 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . 0.517 ' CG ' ' HB2' ' A' ' 121' ' ' PRO . 7.5 pt-20 -97.64 164.75 12.28 Favored 'General case' 0 N--CA 1.445 -0.7 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 178.402 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -128.66 162.17 27.96 Favored 'General case' 0 C--N 1.312 -1.044 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.426 -178.71 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . 0.435 HD11 HD11 ' A' ' 119' ' ' ILE . 19.8 mt . . . . . 0 C--N 1.321 -0.674 0 N-CA-C 108.546 -0.909 . . . . 0.0 108.546 174.464 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 132' ' ' LYS . . . . . 0.418 ' O ' ' HE1' ' A' ' 107' ' ' MET . 0.0 OUTLIER . . . . . 0 N--CA 1.457 -0.125 0 CA-C-O 121.816 0.817 . . . . 0.0 112.777 . . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 133' ' ' MET . . . . . . . . . . . . . 85.7 mtp -139.55 170.7 15.43 Favored 'General case' 0 C--N 1.313 -1.005 0 CA-C-N 114.929 -1.032 . . . . 0.0 109.266 176.919 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . 0.46 ' NZ ' ' HB2' ' A' ' 134' ' ' LYS . 0.0 OUTLIER -128.29 146.01 50.88 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-O 120.988 0.423 . . . . 0.0 111.396 -178.367 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . 0.487 HD11 ' CD1' ' A' ' 142' ' ' TYR . 53.0 tp -80.88 139.26 36.02 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.718 -0.673 . . . . 0.0 109.554 177.165 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 136' ' ' VAL . . . . . 0.406 HG23 ' CD1' ' A' ' 143' ' ' PHE . 0.0 OUTLIER -134.66 134.46 54.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-O 120.971 0.415 . . . . 0.0 110.765 177.267 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 137' ' ' ASN . . . . . 0.43 ' ND2' ' HB3' ' A' ' 142' ' ' TYR . 16.0 m120 -107.41 114.59 28.7 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.35 178.915 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 53.2 t80 -148.75 122.28 9.14 Favored 'General case' 0 C--N 1.326 -0.445 0 C-N-CA 120.959 -0.297 . . . . 0.0 110.91 -178.766 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . 0.452 ' HA3' ' CB ' ' A' ' 24' ' ' ASP . . . 64.44 62.68 4.89 Favored Glycine 0 N--CA 1.452 -0.273 0 CA-C-N 115.797 -0.638 . . . . 0.0 113.231 174.867 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 35.3 mmt180 71.41 -38.28 0.42 Allowed 'General case' 0 N--CA 1.47 0.544 0 C-N-CA 123.647 0.779 . . . . 0.0 112.168 175.731 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 141' ' ' THR . . . . . 0.444 ' H ' ' C ' ' A' ' 139' ' ' GLY . 9.9 t -96.34 156.82 16.18 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 121.133 0.492 . . . . 0.0 110.831 -178.025 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 142' ' ' TYR . . . . . 0.487 ' CD1' HD11 ' A' ' 135' ' ' LEU . 44.0 p90 -121.58 154.19 37.05 Favored 'General case' 0 C--N 1.32 -0.699 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 169.415 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 143' ' ' PHE . . . . . 0.417 ' O ' HD13 ' A' ' 135' ' ' LEU . 8.9 p90 -153.37 -177.64 6.47 Favored 'General case' 0 C--N 1.316 -0.858 0 CA-C-N 116.129 -0.487 . . . . 0.0 109.777 -177.536 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 86.9 m-85 -116.41 131.97 56.8 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 116.724 -0.216 . . . . 0.0 110.699 -178.083 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 145' ' ' GLU . . . . . 0.444 ' CD ' HH21 ' A' ' 116' ' ' ARG . 17.1 pt-20 -128.91 162.3 27.86 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.044 0.45 . . . . 0.0 110.626 178.832 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 38.9 t80 -142.56 127.01 17.78 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 115.604 -0.725 . . . . 0.0 109.665 173.561 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 147' ' ' ILE . . . . . 0.427 ' N ' HD12 ' A' ' 147' ' ' ILE . 3.8 mp -95.07 100.27 10.77 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.842 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 178.854 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . 0.712 ' HB3' ' HA ' ' A' ' 111' ' ' ASP . . . -76.39 96.29 3.99 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.953 -0.567 . . . . 0.0 109.659 176.569 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 . . . . . 0 C--N 1.314 -0.966 0 CA-C-N 115.662 -0.699 . . . . 0.0 111.165 -174.929 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' TRP . . . . . 0.616 ' HB3' HG23 ' A' ' 50' ' ' VAL . 77.0 m95 . . . . . 0 N--CA 1.452 -0.335 0 CA-C-O 120.57 0.224 . . . . 0.0 110.824 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 6.4 m120 -56.33 -52.09 65.84 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.098 177.36 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.411 ' OD2' ' HA3' ' A' ' 139' ' ' GLY . 1.3 t70 -76.77 -28.98 55.89 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.423 -177.152 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 58.5 tp -59.29 -45.98 89.79 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-O 121.049 0.452 . . . . 0.0 109.907 174.516 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . 0.446 ' O ' HG13 ' A' ' 30' ' ' ILE . . . -56.18 -44.46 79.38 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.46 -0.791 . . . . 0.0 110.667 178.629 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 88.5 t -54.4 -46.85 70.34 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.244 0 O-C-N 123.264 0.352 . . . . 0.0 110.857 177.38 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . 0.538 ' HB2' ' CD2' ' A' ' 138' ' ' TYR . 87.2 t80 -58.48 -45.73 88.07 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.332 177.877 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 74.5 mt -63.09 -46.12 96.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.719 178.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.762 HG12 HG23 ' A' ' 54' ' ' ILE . 83.0 mt -57.48 -44.07 84.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 115.692 -0.685 . . . . 0.0 110.919 178.211 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 75.1 mtt180 -72.8 -21.26 61.01 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.263 -176.28 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 73.3 m -88.54 -14.01 38.75 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.345 -0.389 . . . . 0.0 111.339 177.753 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 22.0 p -126.53 -86.11 0.61 Allowed 'General case' 0 CA--C 1.534 0.328 0 CA-C-O 120.678 0.275 . . . . 0.0 111.358 179.315 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 99.77 -176.25 28.36 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 121.167 -0.539 . . . . 0.0 112.595 178.459 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -71.93 155.37 57.71 Favored 'Trans proline' 0 C--O 1.233 0.26 0 C-N-CA 122.534 2.156 . . . . 0.0 112.247 -179.35 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 98.02 -11.76 64.01 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.681 -0.771 . . . . 0.0 113.081 176.345 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 14.0 t -121.7 -166.61 1.4 Allowed 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.382 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' ARG . . . . . 0.629 ' HG2' ' HB2' ' A' ' 61' ' ' ASP . 84.3 mtt180 -128.03 136.36 51.13 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.891 0.377 . . . . 0.0 110.877 -179.218 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.873 ' HB ' HD23 ' A' ' 62' ' ' LEU . 20.9 t -125.47 140.63 47.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 177.182 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 40.4 t -112.41 128.93 68.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-O 120.941 0.401 . . . . 0.0 111.282 -177.469 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . 0.409 ' OE1' HD22 ' A' ' 64' ' ' LEU . 42.5 tt0 -105.06 110.2 22.5 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.659 -0.7 . . . . 0.0 109.549 176.887 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.415 ' HB ' ' HB3' ' A' ' 95' ' ' SER . 58.5 t -94.11 113.76 29.39 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.399 -179.462 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 103.8 42.87 1.89 Allowed Glycine 0 N--CA 1.446 -0.657 0 C-N-CA 120.524 -0.846 . . . . 0.0 111.612 -178.679 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -85.99 -127.01 0.04 OUTLIER 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 110.37 -0.233 . . . . 0.0 110.37 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 67.77 -90.23 0.2 Allowed Glycine 0 C--N 1.33 0.203 0 C-N-CA 121.281 -0.485 . . . . 0.0 112.589 177.873 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -71.9 -23.47 61.49 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 109.705 -0.479 . . . . 0.0 109.705 176.67 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 50.2 m-85 -110.18 109.59 20.14 Favored 'General case' 0 C--O 1.224 -0.277 0 CA-C-N 115.971 -0.558 . . . . 0.0 110.048 178.236 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 96.9 mt -131.35 0.81 4.11 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.706 0.289 . . . . 0.0 111.084 179.722 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 9.2 p90 -69.08 -26.97 65.21 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 112.211 0.449 . . . . 0.0 112.211 -174.936 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.616 HG23 ' HB3' ' A' ' 22' ' ' TRP . 40.9 t -76.02 -58.69 4.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-O 120.93 0.395 . . . . 0.0 110.763 179.734 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 3.3 p -60.77 -42.59 97.78 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.748 -0.66 . . . . 0.0 112.484 -176.703 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.515 ' O ' ' HG2' ' A' ' 56' ' ' LYS . 30.3 t70 -66.53 -27.54 67.84 Favored 'General case' 0 C--N 1.33 -0.256 0 C-N-CA 120.917 -0.313 . . . . 0.0 110.885 -179.359 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 88.1 t80 -70.44 -42.49 71.48 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 120.974 0.416 . . . . 0.0 110.34 175.819 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.762 HG23 HG12 ' A' ' 30' ' ' ILE . 77.3 mt -61.9 -43.58 97.66 Favored 'Isoleucine or valine' 0 C--O 1.236 0.353 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.119 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' ARG . . . . . 0.505 ' HG2' ' HA ' ' A' ' 52' ' ' ASP . 4.1 ptm180 -68.76 -16.09 63.7 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.952 -0.567 . . . . 0.0 111.794 -176.534 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . 0.515 ' HG2' ' O ' ' A' ' 52' ' ' ASP . 69.5 mmtt -65.34 -42.05 93.28 Favored 'General case' 0 C--O 1.233 0.192 0 CA-C-O 121.058 0.456 . . . . 0.0 110.349 177.401 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 33.2 m170 -94.17 -57.5 2.5 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.762 -0.654 . . . . 0.0 111.483 -174.519 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 69.0 m -102.72 130.65 49.73 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.11 0.481 . . . . 0.0 111.618 -175.589 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . 0.526 ' HE3' ' C ' ' A' ' 59' ' ' LYS . 0.1 OUTLIER -80.42 65.52 5.59 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 121.99 0.9 . . . . 0.0 109.224 173.676 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.576 HG23 HG21 ' A' ' 39' ' ' VAL . 7.3 p -97.16 143.5 12.37 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.025 0 CA-C-N 114.606 -1.179 . . . . 0.0 109.003 174.3 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . 0.629 ' HB2' ' HG2' ' A' ' 38' ' ' ARG . 19.7 m-20 -76.32 96.11 3.91 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-O 121.243 0.544 . . . . 0.0 109.68 178.081 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . 0.873 HD23 ' HB ' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -86.88 118.1 26.05 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 115.476 -0.784 . . . . 0.0 109.506 -178.936 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.506 HG12 HG22 ' A' ' 75' ' ' VAL . 61.9 t -97.94 114.76 36.19 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.849 0 CA-C-N 115.683 -0.689 . . . . 0.0 110.127 -179.996 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . 0.455 HD13 HG12 ' A' ' 74' ' ' ILE . 31.8 mt -96.77 124.0 40.63 Favored 'General case' 0 C--N 1.315 -0.93 0 CA-C-N 115.616 -0.72 . . . . 0.0 109.646 -179.915 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 33.1 p -108.34 124.96 51.16 Favored 'General case' 0 C--N 1.315 -0.924 0 CA-C-O 120.933 0.397 . . . . 0.0 110.278 177.276 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 25.6 t70 -156.17 144.58 19.98 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.202 -176.676 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . 0.433 HG23 ' HG3' ' A' ' 68' ' ' LYS . 53.7 mt -73.42 113.71 11.78 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 116.343 -0.389 . . . . 0.0 110.208 178.676 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' LYS . . . . . 0.433 ' HG3' HG23 ' A' ' 67' ' ' ILE . 5.8 mtpm? 59.76 82.01 0.24 Allowed Pre-proline 0 C--O 1.233 0.212 0 CA-C-N 115.54 -0.754 . . . . 0.0 110.568 179.483 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo . . . . . 0 C--O 1.232 0.198 0 C-N-CA 122.742 2.295 . . . . 0.0 113.008 -175.535 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . 0.455 HG12 HD13 ' A' ' 64' ' ' LEU . 56.8 mt . . . . . 0 N--CA 1.45 -0.445 0 N-CA-C 108.673 -0.862 . . . . 0.0 108.673 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.508 HG11 HD13 ' A' ' 86' ' ' ILE . 63.5 t -86.47 130.21 37.05 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.711 0 CA-C-O 120.942 0.401 . . . . 0.0 110.611 -176.539 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 15.3 ptm180 -75.15 49.19 0.44 Allowed 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.502 -0.772 . . . . 0.0 111.54 179.809 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 22.6 t70 -108.14 117.96 35.51 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 116.083 -0.508 . . . . 0.0 109.779 179.411 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' ASP . . . . . 0.461 ' OD2' HG23 ' A' ' 80' ' ' THR . 5.5 p-10 -92.18 132.15 36.86 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.361 -0.382 . . . . 0.0 110.548 -179.423 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 10.7 tp -62.95 -18.05 20.55 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.476 0 CA-C-N 116.155 -0.475 . . . . 0.0 112.185 -173.62 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.461 HG23 ' OD2' ' A' ' 78' ' ' ASP . 0.7 OUTLIER -77.75 -27.71 50.47 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.877 0.37 . . . . 0.0 110.66 177.483 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 22.2 t -140.81 66.42 26.65 Favored Pre-proline 0 C--N 1.326 -0.416 0 N-CA-C 109.636 -0.505 . . . . 0.0 109.636 177.996 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 76.0 Cg_endo -89.93 151.75 4.91 Favored 'Trans proline' 0 N--CA 1.456 -0.732 0 C-N-CA 122.62 2.213 . . . . 0.0 113.436 -171.817 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' ARG . . . . . 0.689 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 53.0 mtt-85 -93.19 115.26 27.89 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.481 174.589 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' MET . . . . . 0.513 ' HE2' HG11 ' A' ' 109' ' ' VAL . 93.4 mmm -62.05 -22.48 65.78 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.926 -0.579 . . . . 0.0 111.055 -178.981 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . 0.689 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 12.9 pt-20 -62.27 -21.68 65.4 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-O 120.913 0.387 . . . . 0.0 111.137 178.692 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.508 HD13 HG11 ' A' ' 75' ' ' VAL . 82.2 mt -83.76 -43.21 17.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.621 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 70.7 m-85 -76.27 -31.5 58.3 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.841 -178.004 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . 0.7 ' HG3' HG12 ' A' ' 113' ' ' VAL . 31.9 mtp85 -66.91 119.86 12.62 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.615 177.737 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 115.11 -8.74 20.96 Favored Glycine 0 N--CA 1.449 -0.499 0 CA-C-N 115.737 -0.665 . . . . 0.0 111.538 -175.748 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -89.35 140.87 29.07 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 120.884 0.374 . . . . 0.0 110.633 179.227 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -88.09 -22.24 24.26 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.968 -178.927 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . 0.467 HD22 ' N ' ' A' ' 93' ' ' ILE . 3.3 tt -151.62 141.97 22.45 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.272 -176.733 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.535 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 65.4 mt -132.43 123.35 49.72 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-N 115.986 -0.552 . . . . 0.0 109.701 179.149 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 94' ' ' TYR . . . . . 0.527 ' HH ' HD13 ' A' ' 62' ' ' LEU . 23.3 p90 -125.03 150.95 46.22 Favored 'General case' 0 C--N 1.322 -0.612 0 C-N-CA 120.709 -0.396 . . . . 0.0 110.402 177.906 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 95' ' ' SER . . . . . 0.415 ' HB3' ' HB ' ' A' ' 42' ' ' VAL . 11.7 p -131.52 140.58 49.54 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.692 -178.089 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 96' ' ' ILE . . . . . 0.458 HG23 ' CH2' ' A' ' 22' ' ' TRP . 81.1 mt -98.45 90.2 2.07 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-O 121.425 0.631 . . . . 0.0 110.775 -177.467 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 50.8 ttt-85 56.4 95.81 0.04 OUTLIER Pre-proline 0 N--CA 1.469 0.498 0 CA-C-N 114.304 -1.316 . . . . 0.0 111.99 -177.999 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 96.8 Cg_endo -88.97 137.14 3.14 Favored 'Trans proline' 0 N--CA 1.455 -0.739 0 C-N-CA 122.647 2.232 . . . . 0.0 112.612 177.722 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . 0.681 ' HD2' HD13 ' A' ' 102' ' ' ILE . 50.5 Cg_exo -53.95 156.63 12.16 Favored 'Trans proline' 0 C--O 1.236 0.393 0 C-N-CA 122.797 2.331 . . . . 0.0 112.079 175.534 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . 0.671 ' HA ' ' CE1' ' A' ' 103' ' ' HIS . . . -75.49 29.51 0.1 Allowed 'General case' 0 C--N 1.328 -0.351 0 N-CA-C 112.57 0.582 . . . . 0.0 112.57 -172.67 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 101' ' ' GLU . . . . . 0.553 ' HG3' HG22 ' A' ' 102' ' ' ILE . 12.5 pt-20 -129.89 -23.71 2.76 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 111.937 0.347 . . . . 0.0 111.937 -178.386 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.681 HD13 ' HD2' ' A' ' 99' ' ' PRO . 41.2 pt -106.78 14.4 7.85 Favored 'Isoleucine or valine' 0 C--O 1.234 0.258 0 N-CA-C 112.45 0.537 . . . . 0.0 112.45 -172.949 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 103' ' ' HIS . . . . . 0.671 ' CE1' ' HA ' ' A' ' 100' ' ' ALA . 28.9 m170 -53.78 -54.06 43.51 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.245 0.545 . . . . 0.0 110.334 177.79 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 104' ' ' SER . . . . . 0.52 ' O ' ' HG2' ' A' ' 108' ' ' ARG . 8.8 m -59.89 -34.59 73.37 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.294 -0.866 . . . . 0.0 110.871 -177.722 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.565 ' O ' HG22 ' A' ' 109' ' ' VAL . 16.7 m -63.52 -56.07 18.97 Favored 'General case' 0 N--CA 1.452 -0.329 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.198 -177.556 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 72.2 mt -56.56 -41.16 76.42 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.657 -0.701 . . . . 0.0 111.08 -178.839 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 107' ' ' MET . . . . . . . . . . . . . 96.5 mmm -62.0 -46.89 87.22 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.889 -0.596 . . . . 0.0 111.138 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 108' ' ' ARG . . . . . 0.52 ' HG2' ' O ' ' A' ' 104' ' ' SER . 3.1 ptp180 -77.08 -22.23 53.14 Favored 'General case' 0 C--N 1.331 -0.238 0 C-N-CA 120.679 -0.409 . . . . 0.0 111.847 -178.4 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.565 HG22 ' O ' ' A' ' 105' ' ' SER . 76.2 t -68.31 -48.75 71.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 173.866 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -61.34 -37.2 82.45 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.043 177.944 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 11.2 t70 -66.01 -40.73 91.33 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.144 -0.934 . . . . 0.0 110.904 177.911 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -69.54 -43.14 73.59 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.837 -0.619 . . . . 0.0 111.987 -176.961 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.7 HG12 ' HG3' ' A' ' 88' ' ' ARG . 20.0 m -87.21 -25.16 6.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-O 120.722 0.296 . . . . 0.0 111.585 -175.561 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 82.29 59.82 2.22 Favored Glycine 0 N--CA 1.447 -0.621 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.21 179.944 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -135.43 173.96 11.14 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-O 120.854 0.359 . . . . 0.0 110.441 -179.922 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 116' ' ' ARG . . . . . 0.435 ' HD3' ' OE1' ' A' ' 145' ' ' GLU . 13.8 ttm180 -92.7 124.29 36.6 Favored 'General case' 0 C--N 1.323 -0.576 0 N-CA-C 109.66 -0.496 . . . . 0.0 109.66 175.616 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . 0.535 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 61.6 tp -92.66 132.75 36.63 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 116.175 -0.466 . . . . 0.0 109.803 178.945 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 64.6 mt -126.18 122.65 62.02 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-O 121.078 0.466 . . . . 0.0 110.645 177.698 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 66.8 mt -121.43 122.9 68.43 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.016 177.599 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 23.3 ttmm -114.76 104.24 54.36 Favored Pre-proline 0 C--N 1.321 -0.645 0 CA-C-O 120.829 0.347 . . . . 0.0 110.881 176.296 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -80.63 170.78 15.34 Favored 'Trans proline' 0 N--CA 1.455 -0.78 0 C-N-CA 122.211 1.941 . . . . 0.0 110.912 169.737 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 122' ' ' LEU . . . . . 0.728 ' HB2' ' HG3' ' A' ' 125' ' ' GLU . 41.0 mt -70.17 155.29 40.83 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 116.494 -0.321 . . . . 0.0 110.378 179.473 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 123' ' ' THR . . . . . 0.682 ' HA ' ' HE1' ' A' ' 142' ' ' TYR . 46.1 m -64.8 109.9 2.22 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 109.992 -0.373 . . . . 0.0 109.992 175.629 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 107.36 -1.31 34.84 Favored Glycine 0 N--CA 1.446 -0.663 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.141 -178.536 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . 0.728 ' HG3' ' HB2' ' A' ' 122' ' ' LEU . 5.1 mt-10 -96.27 -169.21 1.87 Allowed 'General case' 0 N--CA 1.449 -0.501 0 CA-C-O 121.261 0.553 . . . . 0.0 110.8 177.538 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 126' ' ' ASP . . . . . 0.408 ' H ' ' HB3' ' A' ' 125' ' ' GLU . 5.8 t70 -149.35 165.43 32.03 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-N 115.193 -0.912 . . . . 0.0 109.116 -178.345 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 32.6 mt . . . . . 0 C--N 1.325 -0.475 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 176.328 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 90.1 mttt . . . . . 0 N--CA 1.454 -0.236 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 133' ' ' MET . . . . . . . . . . . . . 71.0 mtp 68.95 -178.93 0.22 Allowed 'General case' 0 N--CA 1.467 0.383 0 O-C-N 123.791 0.682 . . . . 0.0 110.668 -179.333 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 17.5 ptmt -136.85 144.07 43.41 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.95 179.9 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . 0.544 HD11 ' HD2' ' A' ' 142' ' ' TYR . 53.6 tp -87.63 127.77 35.28 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.655 -179.405 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 136' ' ' VAL . . . . . 0.421 ' C ' HD21 ' A' ' 137' ' ' ASN . 0.0 OUTLIER -130.14 140.66 48.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.902 179.493 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 137' ' ' ASN . . . . . 0.421 HD21 ' C ' ' A' ' 136' ' ' VAL . 0.9 OUTLIER -120.13 105.5 11.05 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.04 178.001 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . 0.538 ' CD2' ' HB2' ' A' ' 28' ' ' TYR . 73.4 t80 -117.83 112.06 19.89 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.585 -0.524 . . . . 0.0 109.585 178.778 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . 0.411 ' HA3' ' OD2' ' A' ' 24' ' ' ASP . . . 81.44 26.97 49.8 Favored Glycine 0 N--CA 1.447 -0.567 0 C-N-CA 120.743 -0.741 . . . . 0.0 111.797 -178.536 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 140' ' ' ARG . . . . . 0.466 ' HD3' ' HA ' ' A' ' 140' ' ' ARG . 26.5 mmt180 67.6 8.45 6.36 Favored 'General case' 0 N--CA 1.463 0.224 0 C-N-CA 123.248 0.619 . . . . 0.0 111.927 -179.807 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 141' ' ' THR . . . . . 0.441 HG22 ' O ' ' A' ' 138' ' ' TYR . 14.0 t -107.03 135.62 48.27 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 170.926 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 142' ' ' TYR . . . . . 0.682 ' HE1' ' HA ' ' A' ' 123' ' ' THR . 6.7 p90 -101.18 147.58 26.09 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-O 121.019 0.438 . . . . 0.0 110.789 -172.947 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 20.9 p90 -156.08 170.4 22.27 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-N 115.639 -0.71 . . . . 0.0 109.321 175.962 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 96.3 m-85 -113.51 124.27 51.99 Favored 'General case' 0 C--N 1.318 -0.797 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 179.266 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 145' ' ' GLU . . . . . 0.435 ' OE1' ' HD3' ' A' ' 116' ' ' ARG . 19.1 pt-20 -112.73 161.66 16.63 Favored 'General case' 0 C--N 1.316 -0.874 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 178.4 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . 0.401 ' HB3' ' HB3' ' A' ' 117' ' ' LEU . 63.8 t80 -141.36 129.06 21.58 Favored 'General case' 0 C--N 1.315 -0.928 0 CA-C-N 115.938 -0.573 . . . . 0.0 109.897 175.511 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 147' ' ' ILE . . . . . 0.416 ' N ' HD12 ' A' ' 147' ' ' ILE . 3.5 mp -101.68 120.21 50.99 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.96 0 N-CA-C 107.956 -1.128 . . . . 0.0 107.956 176.327 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -63.31 92.62 0.06 Allowed 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.503 0.668 . . . . 0.0 110.377 179.112 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 . . . . . 0 N--CA 1.445 -0.687 0 CA-C-N 114.675 -1.148 . . . . 0.0 111.014 -175.582 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 61.8 m95 . . . . . 0 N--CA 1.455 -0.19 0 CA-C-O 120.916 0.389 . . . . 0.0 110.38 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . 0.433 ' O ' HG21 ' A' ' 27' ' ' VAL . 9.6 m120 -72.32 -36.03 68.76 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 174.337 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.47 ' HB3' ' HA3' ' A' ' 139' ' ' GLY . 5.4 m-20 -64.55 -38.15 90.01 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.283 174.772 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 53.8 tp -53.23 -50.31 65.01 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.161 -0.472 . . . . 0.0 109.958 173.016 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . 0.41 ' O ' HG13 ' A' ' 30' ' ' ILE . . . -58.61 -48.72 80.02 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.884 177.269 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.433 HG21 ' O ' ' A' ' 23' ' ' ASN . 79.0 t -52.52 -45.82 47.33 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.22 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.175 177.102 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . 0.475 ' HB2' ' CD2' ' A' ' 138' ' ' TYR . 78.1 t80 -58.03 -47.12 84.06 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.535 178.629 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.434 HG12 HD12 ' A' ' 118' ' ' ILE . 78.5 mt -60.43 -44.18 95.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.542 178.311 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.63 HD13 ' HA ' ' A' ' 54' ' ' ILE . 83.7 mt -61.99 -41.09 89.65 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 115.601 -0.727 . . . . 0.0 111.455 -179.505 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 41.5 mtp-105 -71.78 -29.86 64.93 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.888 -177.541 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 76.5 m -80.92 -27.32 36.21 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.381 -0.372 . . . . 0.0 111.426 -178.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 14.0 p -93.77 -75.35 0.5 Allowed 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 120.752 0.31 . . . . 0.0 111.291 -177.673 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 109.43 134.6 7.03 Favored Glycine 0 N--CA 1.448 -0.543 0 C-N-CA 121.072 -0.585 . . . . 0.0 111.694 -176.399 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 32.8 Cg_exo -57.53 133.0 53.89 Favored 'Trans proline' 0 C--O 1.232 0.206 0 C-N-CA 122.925 2.417 . . . . 0.0 112.421 -179.155 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 102.24 62.76 0.73 Allowed Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.434 -0.888 . . . . 0.0 111.731 -177.948 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 15.0 t -178.31 -166.96 0.12 Allowed 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 108.545 -0.909 . . . . 0.0 108.545 -178.191 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' ARG . . . . . 0.808 ' HG2' ' HB3' ' A' ' 61' ' ' ASP . 48.5 mtt180 -124.58 136.61 54.1 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 121.045 0.45 . . . . 0.0 111.055 176.96 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.757 HG22 HG12 ' A' ' 60' ' ' VAL . 86.1 t -125.65 121.96 61.24 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 N-CA-C 109.16 -0.681 . . . . 0.0 109.16 175.342 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.404 HG21 ' HB ' ' A' ' 63' ' ' VAL . 26.4 t -101.37 132.64 46.8 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-O 120.743 0.306 . . . . 0.0 110.79 -175.261 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . 0.685 ' HB3' HD21 ' A' ' 64' ' ' LEU . 10.7 tt0 -108.72 126.0 52.53 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.154 -0.476 . . . . 0.0 109.972 176.252 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.703 HG12 HD13 ' A' ' 79' ' ' ILE . 64.8 t -94.12 106.62 18.29 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.774 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 174.644 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 156.75 -66.54 0.3 Allowed Glycine 0 N--CA 1.44 -1.1 0 C-N-CA 120.283 -0.96 . . . . 0.0 111.753 -178.671 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . 0.984 ' HB1' HD12 ' A' ' 74' ' ' ILE . . . 53.38 34.36 17.87 Favored 'General case' 0 C--O 1.233 0.187 0 CA-C-O 121.132 0.491 . . . . 0.0 111.774 176.832 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -91.34 -144.85 13.52 Favored Glycine 0 N--CA 1.445 -0.742 0 C-N-CA 120.623 -0.798 . . . . 0.0 112.847 -177.541 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 39.1 mtp180 -92.6 29.81 1.67 Allowed 'General case' 0 C--N 1.321 -0.667 0 CA-C-O 121.251 0.548 . . . . 0.0 110.523 -176.026 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 5.1 p90 -129.91 30.17 4.88 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.93 -176.675 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . 0.557 HD22 ' HA ' ' A' ' 44' ' ' ALA . 94.1 mt -72.75 7.92 1.73 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.993 -0.549 . . . . 0.0 112.147 -174.318 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 5.7 p90 -65.95 -26.37 67.54 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.819 0.342 . . . . 0.0 110.931 177.025 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.47 ' O ' HG13 ' A' ' 54' ' ' ILE . 93.6 t -72.35 -54.37 16.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.19 175.513 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -61.86 -41.33 97.72 Favored 'General case' 0 N--CA 1.449 -0.479 0 CA-C-N 115.795 -0.638 . . . . 0.0 111.592 -179.099 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 22.1 t70 -65.49 -42.78 91.77 Favored 'General case' 0 C--N 1.329 -0.306 0 C-N-CA 121.033 -0.267 . . . . 0.0 110.756 179.128 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 89.7 t80 -59.56 -36.66 76.64 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.864 0.364 . . . . 0.0 110.533 178.64 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.63 ' HA ' HD13 ' A' ' 30' ' ' ILE . 81.3 mt -61.27 -46.85 95.79 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.386 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.017 178.205 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 36.8 ptt180 -75.33 -16.71 60.38 Favored 'General case' 0 C--O 1.234 0.25 0 CA-C-O 120.843 0.354 . . . . 0.0 111.078 -178.201 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 43.4 mmtm -75.62 -35.39 60.5 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.56 -0.291 . . . . 0.0 110.986 177.234 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . 0.461 ' CD2' HG21 ' A' ' 30' ' ' ILE . 13.1 t60 -103.94 -38.31 7.04 Favored 'General case' 0 N--CA 1.451 -0.418 0 CA-C-O 120.953 0.406 . . . . 0.0 110.75 -175.13 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 7.9 t -110.08 140.82 43.74 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 121.03 0.443 . . . . 0.0 110.302 -177.697 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . 0.494 ' N ' ' HD2' ' A' ' 59' ' ' LYS . 4.1 mptp? -92.22 60.59 3.74 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.783 0.802 . . . . 0.0 109.888 178.378 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.757 HG12 HG22 ' A' ' 39' ' ' VAL . 73.7 t -106.26 139.46 27.54 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-N 114.623 -1.171 . . . . 0.0 110.67 177.985 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . 0.808 ' HB3' ' HG2' ' A' ' 38' ' ' ARG . 18.0 t70 -74.98 90.75 2.46 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 109.168 -0.678 . . . . 0.0 109.168 175.823 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 5.5 tt -84.89 126.85 33.83 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.163 -176.529 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.404 ' HB ' HG21 ' A' ' 40' ' ' VAL . 51.5 t -106.82 127.94 61.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.828 -176.256 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . 0.685 HD21 ' HB3' ' A' ' 41' ' ' GLU . 82.3 mt -111.76 133.87 53.7 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 109.535 -0.543 . . . . 0.0 109.535 176.61 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 3.4 p -127.47 130.22 48.85 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 120.47 0.176 . . . . 0.0 111.024 178.566 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . 0.787 ' HB2' ' HB2' ' A' ' 44' ' ' ALA . 19.4 t0 -162.22 157.58 23.22 Favored 'General case' 0 C--O 1.234 0.268 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.675 -179.355 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 63.7 mt -82.58 122.01 36.55 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 116.115 -0.493 . . . . 0.0 109.79 178.926 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 18.1 ptpt 41.52 69.46 2.04 Favored Pre-proline 0 N--CA 1.474 0.77 0 O-C-N 124.003 0.814 . . . . 0.0 112.346 -175.604 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . 0.503 ' CB ' ' HB ' ' A' ' 74' ' ' ILE . 5.8 Cg_exo . . . . . 0 N--CA 1.46 -0.467 0 C-N-CA 122.898 2.399 . . . . 0.0 111.923 179.072 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . 0.984 HD12 ' HB1' ' A' ' 44' ' ' ALA . 62.5 mt . . . . . 0 C--O 1.235 0.33 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.411 HG11 ' H ' ' A' ' 77' ' ' ASP . 61.6 t -61.18 136.16 25.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-O 120.832 0.348 . . . . 0.0 110.364 -177.908 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 17.1 mmt85 -86.3 15.16 5.55 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.969 -0.559 . . . . 0.0 111.31 -171.947 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . 0.411 ' H ' HG11 ' A' ' 75' ' ' VAL . 26.2 t70 -77.21 136.54 38.56 Favored 'General case' 0 C--N 1.325 -0.5 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 -177.019 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -58.99 116.06 3.55 Favored 'General case' 0 C--O 1.221 -0.439 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.141 -177.145 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' ILE . . . . . 0.703 HD13 HG12 ' A' ' 42' ' ' VAL . 10.6 tp -69.63 -16.28 20.29 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-O 121.344 0.592 . . . . 0.0 110.399 178.551 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 9.0 t -86.99 -11.31 50.87 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.477 178.225 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 45.0 t -157.2 64.86 3.4 Favored Pre-proline 0 C--N 1.326 -0.424 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 179.879 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' PRO . . . . . 0.544 ' HB2' ' HE2' ' A' ' 87' ' ' TYR . 90.1 Cg_endo -85.07 153.26 11.06 Favored 'Trans proline' 0 N--CA 1.458 -0.564 0 C-N-CA 122.717 2.278 . . . . 0.0 113.206 -170.187 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' ARG . . . . . 0.654 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 35.2 mtt180 -87.56 119.82 28.24 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.784 177.292 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' MET . . . . . 0.72 ' HE3' HG12 ' A' ' 109' ' ' VAL . 36.7 mtp -67.94 -9.32 44.24 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.567 -0.742 . . . . 0.0 112.362 -175.302 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . 0.654 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 8.0 pt-20 -61.51 -30.13 70.43 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 121.085 0.469 . . . . 0.0 110.088 175.374 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 69.2 mt -75.07 -40.01 44.31 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 115.47 -0.786 . . . . 0.0 110.514 -179.472 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . 0.637 ' HD2' ' HA ' ' A' ' 84' ' ' MET . 91.5 m-85 -75.27 -34.5 61.37 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.947 -0.57 . . . . 0.0 111.216 -177.717 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 34.0 mtp180 -64.41 114.48 4.34 Favored 'General case' 0 C--O 1.235 0.328 0 CA-C-O 121.572 0.701 . . . . 0.0 110.765 177.71 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 124.21 -12.53 8.03 Favored Glycine 0 N--CA 1.443 -0.864 0 CA-C-N 114.868 -1.06 . . . . 0.0 111.492 -175.825 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -84.21 152.19 24.38 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.838 0.352 . . . . 0.0 110.872 -179.815 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -99.75 -22.16 15.48 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.407 177.546 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . 0.486 ' HG ' ' HB3' ' A' ' 116' ' ' ARG . 4.9 tt -152.53 142.01 21.69 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.298 -177.981 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.571 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 68.3 mt -131.89 122.96 50.48 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 178.807 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 23.4 p90 -130.61 162.33 29.59 Favored 'General case' 0 C--N 1.321 -0.643 0 C-N-CA 120.614 -0.434 . . . . 0.0 111.007 -178.023 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 95' ' ' SER . . . . . 0.558 ' OG ' ' HB ' ' A' ' 42' ' ' VAL . 4.2 m -143.73 145.41 32.39 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.768 -179.126 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 76.7 mt -116.17 111.17 34.29 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.116 177.988 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 97' ' ' ARG . . . . . 0.413 HH11 ' HD2' ' A' ' 97' ' ' ARG . 12.9 ttp180 59.17 73.49 0.68 Allowed Pre-proline 0 N--CA 1.466 0.349 0 CA-C-N 115.701 -0.681 . . . . 0.0 111.331 -177.548 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_endo -88.2 134.8 3.08 Favored 'Trans proline' 0 N--CA 1.455 -0.749 0 C-N-CA 122.826 2.35 . . . . 0.0 111.917 176.953 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . 0.528 ' HG2' HD12 ' A' ' 102' ' ' ILE . 2.9 Cg_endo -47.48 142.49 13.09 Favored 'Trans proline' 0 C--N 1.35 0.606 0 C-N-CA 123.422 2.748 . . . . 0.0 112.807 175.659 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . 0.813 ' HA ' ' CE1' ' A' ' 103' ' ' HIS . . . -75.09 42.84 0.19 Allowed 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.848 -0.615 . . . . 0.0 112.46 -176.168 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 101' ' ' GLU . . . . . 0.429 ' HG3' HG23 ' A' ' 102' ' ' ILE . 10.0 pt-20 -135.6 -24.56 1.35 Allowed 'General case' 0 C--N 1.326 -0.423 0 N-CA-C 112.325 0.491 . . . . 0.0 112.325 177.425 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.528 HD12 ' HG2' ' A' ' 99' ' ' PRO . 6.5 pt -114.55 3.55 7.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 N-CA-C 112.848 0.685 . . . . 0.0 112.848 -172.521 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 103' ' ' HIS . . . . . 0.813 ' CE1' ' HA ' ' A' ' 100' ' ' ALA . 35.7 m80 -47.12 -56.49 6.49 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 112.156 0.428 . . . . 0.0 112.156 179.731 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 40.1 t -66.29 -26.1 67.17 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.069 0.462 . . . . 0.0 110.771 -179.794 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.429 ' O ' HG23 ' A' ' 109' ' ' VAL . 14.2 m -67.86 -33.3 74.49 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.109 179.446 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . 0.418 HD21 HG21 ' A' ' 42' ' ' VAL . 82.0 mt -72.13 -38.37 69.25 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.954 178.448 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 107' ' ' MET . . . . . 0.528 ' HA ' HD22 ' A' ' 117' ' ' LEU . 53.6 ttm -59.18 -43.34 92.15 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.186 -178.991 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 27.3 ptt85 -66.59 -31.58 72.37 Favored 'General case' 0 C--N 1.331 -0.207 0 C-N-CA 120.88 -0.328 . . . . 0.0 110.532 -177.704 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.72 HG12 ' HE3' ' A' ' 84' ' ' MET . 94.0 t -68.94 -46.86 78.37 Favored 'Isoleucine or valine' 0 C--O 1.234 0.243 0 CA-C-N 116.549 -0.296 . . . . 0.0 110.47 179.88 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -58.74 -43.83 90.34 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.512 177.872 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . 0.448 ' HA ' ' HB3' ' A' ' 148' ' ' ALA . 22.5 t70 -65.29 -39.94 93.21 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.012 179.629 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . 0.642 ' HB3' ' HE2' ' A' ' 84' ' ' MET . . . -66.92 -42.94 84.55 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.835 -0.621 . . . . 0.0 111.879 -178.253 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 25.8 m -87.15 -24.41 6.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 120.894 0.378 . . . . 0.0 111.486 -177.393 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 91.11 44.29 4.46 Favored Glycine 0 N--CA 1.449 -0.462 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.27 178.203 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -124.37 156.56 36.85 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 120.723 0.296 . . . . 0.0 110.834 -177.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 116' ' ' ARG . . . . . 0.486 ' HB3' ' HG ' ' A' ' 92' ' ' LEU . 14.3 ttm180 -78.57 127.28 31.91 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 177.015 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . 0.571 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 51.1 tp -95.89 121.93 38.14 Favored 'General case' 0 C--N 1.322 -0.589 0 N-CA-C 109.892 -0.411 . . . . 0.0 109.892 -179.946 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . 0.434 HD12 HG12 ' A' ' 29' ' ' ILE . 69.3 mt -119.77 112.69 38.07 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-O 121.023 0.439 . . . . 0.0 110.617 178.729 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 50.6 mt -111.61 121.18 63.66 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.797 0 CA-C-O 120.919 0.39 . . . . 0.0 110.32 178.94 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 63.6 tttp -111.11 103.31 54.72 Favored Pre-proline 0 C--N 1.32 -0.699 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.489 174.878 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 93.0 Cg_endo -82.9 -166.86 0.41 Allowed 'Trans proline' 0 N--CA 1.455 -0.773 0 C-N-CA 122.591 2.194 . . . . 0.0 110.829 171.185 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 7.1 mp -88.81 166.92 13.69 Favored 'General case' 0 C--N 1.319 -0.72 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 177.103 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 4.7 t -68.61 -9.39 49.5 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.153 0.501 . . . . 0.0 111.219 -177.68 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -117.49 24.7 8.99 Favored Glycine 0 N--CA 1.446 -0.676 0 N-CA-C 111.587 -0.605 . . . . 0.0 111.587 175.5 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 26.9 mm-40 -129.38 172.75 11.19 Favored 'General case' 0 N--CA 1.45 -0.46 0 CA-C-O 121.209 0.528 . . . . 0.0 110.754 -176.774 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 8.4 t70 -143.79 -170.82 3.4 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-N 115.05 -0.977 . . . . 0.0 108.58 175.358 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . 0.569 HD12 ' HB2' ' A' ' 144' ' ' TYR . 18.3 mt . . . . . 0 C--N 1.318 -0.764 0 CA-C-O 120.667 0.27 . . . . 0.0 110.337 179.49 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 28.7 mtpp . . . . . 0 C--O 1.23 0.059 0 CA-C-O 120.838 0.351 . . . . 0.0 111.399 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 133' ' ' MET . . . . . 0.4 ' HG2' ' HB2' ' A' ' 146' ' ' TYR . 88.9 mtp -98.77 151.51 20.71 Favored 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 178.405 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 16.2 ptmt -100.42 134.62 43.1 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 121.222 0.534 . . . . 0.0 111.353 -174.795 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . 0.479 HD12 ' HD2' ' A' ' 142' ' ' TYR . 54.6 tp -78.58 126.7 31.11 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.334 -0.848 . . . . 0.0 110.154 177.438 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -123.43 135.12 64.32 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.712 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.909 179.869 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 137' ' ' ASN . . . . . 0.497 ' ND2' ' HB3' ' A' ' 142' ' ' TYR . 14.5 m120 -111.52 112.35 24.02 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.662 -0.699 . . . . 0.0 109.442 178.217 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . 0.475 ' CD2' ' HB2' ' A' ' 28' ' ' TYR . 61.1 t80 -144.73 128.77 17.55 Favored 'General case' 0 C--N 1.318 -0.773 0 N-CA-C 110.348 -0.241 . . . . 0.0 110.348 -178.001 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . 0.47 ' HA3' ' HB3' ' A' ' 24' ' ' ASP . . . 68.79 35.94 81.08 Favored Glycine 0 N--CA 1.447 -0.61 0 C-N-CA 120.944 -0.646 . . . . 0.0 112.907 176.169 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 140' ' ' ARG . . . . . 0.419 ' HB2' ' O ' ' A' ' 139' ' ' GLY . 69.0 mtt85 72.97 4.51 4.98 Favored 'General case' 0 N--CA 1.463 0.223 0 C-N-CA 122.772 0.429 . . . . 0.0 112.081 175.723 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 14.9 t -124.57 154.09 41.15 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 176.296 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 142' ' ' TYR . . . . . 0.497 ' HB3' ' ND2' ' A' ' 137' ' ' ASN . 45.4 p90 -123.21 147.81 46.49 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-O 121.162 0.506 . . . . 0.0 110.653 178.539 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 14.0 p90 -154.01 179.59 8.77 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-N 115.064 -0.971 . . . . 0.0 109.056 -177.676 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 144' ' ' TYR . . . . . 0.569 ' HB2' HD12 ' A' ' 127' ' ' ILE . 97.3 m-85 -115.79 127.79 55.35 Favored 'General case' 0 C--N 1.32 -0.709 0 N-CA-C 110.19 -0.3 . . . . 0.0 110.19 179.452 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 145' ' ' GLU . . . . . 0.473 ' OE1' ' HD3' ' A' ' 116' ' ' ARG . 18.2 pt-20 -115.48 161.75 18.14 Favored 'General case' 0 C--N 1.32 -0.691 0 N-CA-C 109.715 -0.476 . . . . 0.0 109.715 176.1 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . 0.452 ' HB3' ' HB3' ' A' ' 117' ' ' LEU . 51.0 t80 -141.33 126.9 18.91 Favored 'General case' 0 C--N 1.313 -0.997 0 CA-C-N 115.604 -0.725 . . . . 0.0 109.741 177.532 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 147' ' ' ILE . . . . . 0.405 HD13 ' N ' ' A' ' 147' ' ' ILE . 3.1 mp -95.57 109.33 22.38 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.81 0 N-CA-C 109.585 -0.524 . . . . 0.0 109.585 -179.249 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . 0.448 ' HB3' ' HA ' ' A' ' 111' ' ' ASP . . . -63.0 111.24 2.08 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.392 -0.596 . . . . 0.0 109.392 175.114 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 . . . . . 0 C--N 1.322 -0.595 0 CA-C-O 121.859 0.838 . . . . 0.0 111.946 -173.756 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' TRP . . . . . 0.565 ' HB3' HG23 ' A' ' 50' ' ' VAL . 83.1 m95 . . . . . 0 N--CA 1.456 -0.157 0 CA-C-O 120.528 0.204 . . . . 0.0 111.385 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . 0.485 ' O ' HG21 ' A' ' 27' ' ' VAL . 2.1 m-20 -60.8 -48.79 80.22 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.811 -172.605 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -60.89 -39.55 89.7 Favored 'General case' 0 N--CA 1.468 0.44 0 CA-C-O 120.735 0.302 . . . . 0.0 111.477 -179.08 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.731 HD23 ' HD2' ' A' ' 120' ' ' LYS . 54.0 tp -58.08 -50.8 72.2 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.458 177.574 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . 0.479 ' O ' HG13 ' A' ' 30' ' ' ILE . . . -59.46 -46.38 88.95 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.618 -0.719 . . . . 0.0 111.18 -179.029 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.554 ' HA ' HD12 ' A' ' 30' ' ' ILE . 87.5 t -55.64 -44.29 76.25 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.915 179.912 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 72.7 t80 -59.8 -46.19 89.98 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.584 179.003 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.541 HG22 HD22 ' A' ' 92' ' ' LEU . 75.9 mt -59.69 -43.02 90.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.47 178.246 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.782 HG12 HG23 ' A' ' 54' ' ' ILE . 82.2 mt -59.05 -47.08 91.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 115.642 -0.708 . . . . 0.0 111.78 -179.622 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . 0.52 ' HG3' ' O ' ' A' ' 27' ' ' VAL . 35.6 mtp180 -73.44 -22.6 60.16 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 121.03 0.443 . . . . 0.0 111.02 -174.156 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 69.5 m -88.59 -8.92 53.89 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.262 -179.563 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 13.5 p -112.88 -70.01 0.83 Allowed 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.76 0.314 . . . . 0.0 111.154 -178.943 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 93.49 166.12 37.73 Favored Glycine 0 N--CA 1.449 -0.492 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.277 179.793 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 69.8 Cg_endo -75.99 156.31 38.62 Favored 'Trans proline' 0 CA--C 1.532 0.376 0 C-N-CA 122.7 2.267 . . . . 0.0 112.597 -179.831 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 84.07 39.3 9.39 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.888 178.491 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 12.5 t -164.4 -170.19 1.99 Allowed 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 177.8 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' ARG . . . . . 0.424 ' HA ' ' O ' ' A' ' 61' ' ' ASP . 49.0 mtm180 -119.3 136.23 54.34 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.945 0.402 . . . . 0.0 110.882 179.789 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.68 HG22 HG23 ' A' ' 60' ' ' VAL . 91.6 t -119.76 113.16 39.89 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 N-CA-C 109.034 -0.728 . . . . 0.0 109.034 173.806 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.587 ' O ' ' HA ' ' A' ' 93' ' ' ILE . 46.9 t -97.12 134.23 35.68 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.853 0 CA-C-O 120.931 0.396 . . . . 0.0 110.916 -175.703 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . 0.442 ' HA ' ' O ' ' A' ' 94' ' ' TYR . 0.4 OUTLIER -114.6 157.18 23.41 Favored 'General case' 0 C--N 1.318 -0.793 0 N-CA-C 109.036 -0.728 . . . . 0.0 109.036 173.521 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.524 ' HB ' ' HB3' ' A' ' 95' ' ' SER . 54.7 t -124.76 112.34 31.6 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.733 0 CA-C-N 116.512 -0.313 . . . . 0.0 110.954 178.334 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 112.3 32.82 2.26 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.665 -0.778 . . . . 0.0 113.602 173.74 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -50.44 -58.64 5.27 Favored 'General case' 0 N--CA 1.466 0.345 0 N-CA-C 112.378 0.51 . . . . 0.0 112.378 -178.24 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 63.66 -108.14 2.07 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 121.052 -0.594 . . . . 0.0 112.677 179.519 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 16.7 ptt180 -127.11 5.71 6.47 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.678 0.275 . . . . 0.0 111.333 -179.58 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.506 ' HE2' HG13 ' A' ' 96' ' ' ILE . 14.4 p90 -112.46 90.99 3.49 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.959 0.885 . . . . 0.0 110.496 179.186 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . 0.414 HD22 HD12 ' A' ' 64' ' ' LEU . 74.6 mt -102.07 16.45 26.03 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.217 -0.901 . . . . 0.0 110.629 -175.877 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 78.0 t80 -60.69 -50.07 74.96 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.368 -0.378 . . . . 0.0 111.322 -177.054 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.565 HG23 ' HB3' ' A' ' 22' ' ' TRP . 59.6 t -62.38 -48.76 86.83 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-O 121.039 0.447 . . . . 0.0 110.726 -178.981 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' SER . . . . . 0.427 ' CB ' HD23 ' A' ' 64' ' ' LEU . 0.0 OUTLIER -63.98 -45.63 88.2 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.622 -177.166 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.613 ' O ' ' HG3' ' A' ' 56' ' ' LYS . 26.4 t70 -70.88 -30.32 66.65 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 120.641 0.258 . . . . 0.0 110.662 -179.042 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 45.4 t80 -61.73 -42.48 99.02 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.06 0.457 . . . . 0.0 109.961 175.97 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.782 HG23 HG12 ' A' ' 30' ' ' ILE . 80.5 mt -63.61 -48.01 88.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 115.815 -0.63 . . . . 0.0 111.437 -179.883 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' ARG . . . . . 0.571 ' HG2' ' HA ' ' A' ' 52' ' ' ASP . 0.1 OUTLIER -69.51 -18.88 63.72 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 111.898 0.333 . . . . 0.0 111.898 -177.149 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . 0.613 ' HG3' ' O ' ' A' ' 52' ' ' ASP . 56.7 mttm -67.57 -37.79 83.15 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.115 0.483 . . . . 0.0 110.575 176.084 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . 0.497 ' CD2' HG21 ' A' ' 30' ' ' ILE . 16.8 t60 -101.72 -39.42 7.44 Favored 'General case' 0 N--CA 1.444 -0.746 0 CA-C-N 115.879 -0.6 . . . . 0.0 111.034 -172.111 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' SER . . . . . 0.57 ' HB2' HG22 ' A' ' 30' ' ' ILE . 8.8 t -109.78 139.58 44.68 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.75 0.31 . . . . 0.0 110.393 -177.379 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 14.4 mmmm -91.35 59.99 4.04 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 121.85 0.833 . . . . 0.0 109.981 177.184 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.68 HG23 HG22 ' A' ' 39' ' ' VAL . 13.6 p -110.72 145.05 17.57 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.814 0 CA-C-N 114.817 -1.083 . . . . 0.0 110.098 177.38 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . 0.424 ' O ' ' HA ' ' A' ' 38' ' ' ARG . 21.6 t70 -78.79 101.63 7.71 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.062 0.458 . . . . 0.0 109.897 178.656 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 3.6 tt -91.93 119.02 31.3 Favored 'General case' 0 C--N 1.315 -0.925 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 -178.864 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.416 HG12 ' CG2' ' A' ' 86' ' ' ILE . 47.1 t -96.62 119.16 44.31 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-N 115.605 -0.725 . . . . 0.0 110.503 -176.822 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . 0.593 ' HB2' ' HA ' ' A' ' 74' ' ' ILE . 51.1 mt -94.39 138.34 32.46 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.553 -0.749 . . . . 0.0 109.722 179.629 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.499 ' OG1' ' HA ' ' A' ' 42' ' ' VAL . 70.2 p -128.56 130.7 47.78 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 120.875 0.369 . . . . 0.0 110.759 178.141 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 31.3 t70 -160.78 146.42 14.65 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.165 -0.47 . . . . 0.0 109.823 179.172 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . 0.72 HD12 HG23 ' A' ' 79' ' ' ILE . 50.6 mt -75.85 106.42 5.67 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-O 121.111 0.482 . . . . 0.0 110.662 179.526 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' LYS . . . . . 0.434 ' N ' ' HD3' ' A' ' 69' ' ' PRO . 45.6 mtmt 65.73 65.47 0.87 Allowed Pre-proline 0 CA--C 1.533 0.307 0 CA-C-N 115.197 -0.911 . . . . 0.0 111.814 177.723 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . 0.94 ' HD2' ' HG3' ' A' ' 76' ' ' ARG . 2.6 Cg_exo . . . . . 0 C--O 1.234 0.324 0 C-N-CA 122.976 2.45 . . . . 0.0 111.739 177.055 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . 0.593 ' HA ' ' HB2' ' A' ' 64' ' ' LEU . 35.5 mt . . . . . 0 N--CA 1.449 -0.486 0 N-CA-C 108.892 -0.781 . . . . 0.0 108.892 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 98.7 t -78.84 136.39 23.91 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.715 0 CA-C-O 121.437 0.637 . . . . 0.0 110.178 -179.16 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' ARG . . . . . 0.94 ' HG3' ' HD2' ' A' ' 69' ' ' PRO . 1.3 mpp_? -90.83 34.17 0.92 Allowed 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 115.032 -0.985 . . . . 0.0 110.841 -173.0 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 22.6 t0 -89.86 136.94 32.74 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.082 -0.71 . . . . 0.0 109.082 177.888 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 7.0 p-10 -95.85 153.05 17.95 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-O 121.166 0.508 . . . . 0.0 111.353 -172.043 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' ILE . . . . . 0.72 HG23 HD12 ' A' ' 67' ' ' ILE . 10.4 tp -71.36 -27.09 27.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 115.648 -0.705 . . . . 0.0 112.478 -170.873 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 14.3 t -89.19 6.34 40.57 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.34 0.591 . . . . 0.0 110.326 -179.11 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 32.8 t -152.29 58.5 2.59 Favored Pre-proline 0 C--N 1.325 -0.495 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.909 174.428 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' PRO . . . . . 0.484 ' HB2' ' HE2' ' A' ' 87' ' ' TYR . 65.4 Cg_endo -74.99 131.13 13.95 Favored 'Trans proline' 0 C--O 1.238 0.503 0 C-N-CA 122.192 1.928 . . . . 0.0 112.092 -175.105 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' ARG . . . . . 0.572 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 37.1 mtp85 -85.51 120.52 27.05 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.141 0.496 . . . . 0.0 111.063 -179.12 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' MET . . . . . 0.508 ' O ' ' HG3' ' A' ' 88' ' ' ARG . 96.1 mmm -62.5 -21.4 65.47 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.415 -0.811 . . . . 0.0 110.516 179.699 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . 0.572 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 11.1 pt-20 -66.29 -21.62 66.27 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-O 121.195 0.522 . . . . 0.0 110.799 -178.834 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.416 ' CG2' HG12 ' A' ' 63' ' ' VAL . 66.5 mt -85.85 -31.2 6.5 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.497 -179.41 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . 0.484 ' HE2' ' HB2' ' A' ' 82' ' ' PRO . 79.9 m-85 -88.96 -26.06 21.72 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.432 -176.578 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . 0.55 ' HG2' HG12 ' A' ' 113' ' ' VAL . 81.8 mtp180 -71.97 143.82 49.09 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 121.142 0.496 . . . . 0.0 111.041 -178.912 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 80.54 11.2 84.37 Favored Glycine 0 C--N 1.319 -0.414 0 CA-C-N 115.274 -0.875 . . . . 0.0 112.042 -178.606 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -96.0 154.92 16.98 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.847 0.355 . . . . 0.0 110.355 178.627 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -98.34 -23.65 15.54 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 116.108 -0.497 . . . . 0.0 111.025 179.928 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . 0.541 HD22 HG22 ' A' ' 29' ' ' ILE . 4.1 tt -156.99 145.11 19.4 Favored 'General case' 0 N--CA 1.452 -0.373 0 CA-C-O 120.873 0.368 . . . . 0.0 110.81 -177.33 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.587 ' HA ' ' O ' ' A' ' 40' ' ' VAL . 61.6 mt -132.77 131.04 59.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 N-CA-C 109.031 -0.729 . . . . 0.0 109.031 178.193 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 94' ' ' TYR . . . . . 0.442 ' O ' ' HA ' ' A' ' 41' ' ' GLU . 32.4 p90 -139.68 155.74 47.21 Favored 'General case' 0 C--N 1.326 -0.414 0 C-N-CA 120.709 -0.396 . . . . 0.0 110.644 -179.508 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 95' ' ' SER . . . . . 0.524 ' HB3' ' HB ' ' A' ' 42' ' ' VAL . 10.2 p -142.48 148.16 37.24 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-O 120.748 0.309 . . . . 0.0 111.095 -176.964 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 96' ' ' ILE . . . . . 0.506 HG13 ' HE2' ' A' ' 47' ' ' PHE . 38.2 mm -99.03 92.82 2.83 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.585 -179.744 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 97' ' ' ARG . . . . . 0.58 ' NH2' ' HA ' ' A' ' 122' ' ' LEU . 98.8 mtt180 54.08 76.51 0.51 Allowed Pre-proline 0 N--CA 1.468 0.446 0 CA-C-N 115.7 -0.682 . . . . 0.0 112.429 177.995 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 98.9 Cg_endo -80.7 157.4 21.48 Favored 'Trans proline' 0 N--CA 1.46 -0.47 0 C-N-CA 122.539 2.159 . . . . 0.0 112.259 179.1 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . 0.759 ' HD2' HD11 ' A' ' 102' ' ' ILE . 32.4 Cg_exo -57.44 142.19 95.14 Favored 'Trans proline' 0 C--N 1.345 0.394 0 C-N-CA 122.817 2.345 . . . . 0.0 111.683 174.604 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . 0.564 ' HA ' ' NE2' ' A' ' 103' ' ' HIS . . . -63.03 -22.84 67.14 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.329 -0.396 . . . . 0.0 112.035 -175.784 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 101' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -74.86 -10.65 59.7 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 112.072 0.397 . . . . 0.0 112.072 -176.703 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.759 HD11 ' HD2' ' A' ' 99' ' ' PRO . 45.6 pt -120.62 8.92 6.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 N-CA-C 112.502 0.556 . . . . 0.0 112.502 -177.776 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 103' ' ' HIS . . . . . 0.564 ' NE2' ' HA ' ' A' ' 100' ' ' ALA . 5.3 m-70 -53.98 -51.2 64.64 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-O 121.053 0.454 . . . . 0.0 110.902 178.04 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 41.1 t -68.25 -28.43 67.21 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.351 -179.743 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.526 ' O ' HG21 ' A' ' 109' ' ' VAL . 29.9 t -68.88 -45.52 70.76 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.962 -0.563 . . . . 0.0 109.908 -179.69 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 72.0 mt -64.37 -40.3 95.57 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.389 -0.369 . . . . 0.0 111.03 178.793 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 107' ' ' MET . . . . . 0.495 ' HE1' ' HB2' ' A' ' 132' ' ' LYS . 66.3 mtp -65.54 -42.48 91.9 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.25 -179.667 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 108' ' ' ARG . . . . . 0.503 ' HG2' ' O ' ' A' ' 105' ' ' SER . 8.0 ptm180 -67.93 -31.87 71.92 Favored 'General case' 0 N--CA 1.462 0.154 0 C-N-CA 120.942 -0.303 . . . . 0.0 110.858 -178.847 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.526 HG21 ' O ' ' A' ' 105' ' ' SER . 76.1 t -66.54 -46.65 85.78 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.193 0 CA-C-O 120.71 0.29 . . . . 0.0 110.279 176.798 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -57.34 -45.84 83.89 Favored 'General case' 0 CA--C 1.514 -0.406 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.123 177.419 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . 0.835 ' HA ' ' HB1' ' A' ' 148' ' ' ALA . 5.0 t70 -66.46 -34.09 77.16 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.668 -177.497 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -70.24 -36.29 74.4 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.94 -179.659 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.55 HG12 ' HG2' ' A' ' 88' ' ' ARG . 18.7 m -93.53 -25.96 4.76 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 116.446 -0.343 . . . . 0.0 111.509 -178.172 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 87.97 41.47 6.29 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.863 -0.684 . . . . 0.0 112.634 178.296 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -120.02 158.69 26.27 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.854 0.359 . . . . 0.0 110.918 -178.471 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 116' ' ' ARG . . . . . 0.471 ' HD3' ' OE1' ' A' ' 145' ' ' GLU . 13.2 ttm180 -78.77 123.87 27.62 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 178.434 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . 0.555 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 52.0 tp -97.0 123.11 40.63 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.141 179.123 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . 0.421 HD11 HG12 ' A' ' 29' ' ' ILE . 53.6 mt -118.39 128.78 75.34 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 CA-C-O 120.976 0.417 . . . . 0.0 110.572 179.437 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 66.0 mt -128.04 134.58 64.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.36 -179.813 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 120' ' ' LYS . . . . . 0.731 ' HD2' HD23 ' A' ' 25' ' ' LEU . 10.4 mttm -113.43 104.25 55.47 Favored Pre-proline 0 C--N 1.324 -0.516 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.481 173.163 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 121' ' ' PRO . . . . . 0.41 ' HD2' ' HA ' ' A' ' 120' ' ' LYS . 58.5 Cg_endo -72.28 -146.47 0.02 OUTLIER 'Trans proline' 0 CA--C 1.535 0.547 0 C-N-CA 123.208 2.605 . . . . 0.0 112.758 176.971 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 122' ' ' LEU . . . . . 0.703 ' HB2' ' HB3' ' A' ' 125' ' ' GLU . 7.1 mp -87.59 -176.24 5.49 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.433 -0.349 . . . . 0.0 111.18 -175.884 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 21.7 m -61.23 -39.36 89.99 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.965 -0.562 . . . . 0.0 111.878 -177.533 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -145.14 42.05 1.02 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.996 -0.621 . . . . 0.0 111.602 178.477 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . 0.703 ' HB3' ' HB2' ' A' ' 122' ' ' LEU . 5.6 tp10 -131.98 136.17 47.1 Favored 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 -176.268 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 126' ' ' ASP . . . . . 0.41 ' CG ' ' H ' ' A' ' 127' ' ' ILE . 21.1 t70 -76.49 -179.31 5.13 Favored 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 109.838 -0.431 . . . . 0.0 109.838 178.373 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . 0.41 ' H ' ' CG ' ' A' ' 126' ' ' ASP . 9.3 mt . . . . . 0 C--N 1.325 -0.499 0 N-CA-C 109.17 -0.678 . . . . 0.0 109.17 177.616 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 132' ' ' LYS . . . . . 0.495 ' HB2' ' HE1' ' A' ' 107' ' ' MET . 23.2 mmmt . . . . . 0 CA--C 1.52 -0.201 0 CA-C-O 121.454 0.645 . . . . 0.0 109.727 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 133' ' ' MET . . . . . 0.662 ' HG2' ' HB2' ' A' ' 146' ' ' TYR . 88.0 mtp -100.28 176.18 5.46 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.017 -0.992 . . . . 0.0 109.907 -179.543 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 14.9 ptmt -121.35 142.1 50.3 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 120.939 0.399 . . . . 0.0 110.635 -178.398 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . 0.722 HD11 ' HD2' ' A' ' 142' ' ' TYR . 50.1 tp -86.14 124.43 32.54 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.394 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 136' ' ' VAL . . . . . 0.437 HG23 ' CD1' ' A' ' 143' ' ' PHE . 0.0 OUTLIER -121.02 137.48 54.61 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.161 -179.724 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 137' ' ' ASN . . . . . 0.466 ' N ' HD21 ' A' ' 137' ' ' ASN . 0.9 OUTLIER -107.34 123.78 48.85 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 109.254 -0.647 . . . . 0.0 109.254 174.807 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 57.8 t80 -143.02 116.71 9.24 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 179.427 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . 0.406 ' C ' ' H ' ' A' ' 141' ' ' THR . . . 69.38 39.18 81.05 Favored Glycine 0 N--CA 1.447 -0.613 0 C-N-CA 120.575 -0.821 . . . . 0.0 111.95 -177.755 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 140' ' ' ARG . . . . . 0.434 HH11 ' HD3' ' A' ' 140' ' ' ARG . 22.8 ttp-105 73.24 -21.08 0.26 Allowed 'General case' 0 CA--C 1.531 0.229 0 C-N-CA 123.665 0.786 . . . . 0.0 112.561 177.802 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 141' ' ' THR . . . . . 0.406 ' H ' ' C ' ' A' ' 139' ' ' GLY . 6.5 t -92.15 141.71 28.29 Favored 'General case' 0 C--N 1.323 -0.562 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 177.355 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 142' ' ' TYR . . . . . 0.722 ' HD2' HD11 ' A' ' 135' ' ' LEU . 44.4 p90 -110.27 152.43 26.16 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.076 0.465 . . . . 0.0 110.917 -178.742 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 143' ' ' PHE . . . . . 0.454 ' O ' HD13 ' A' ' 135' ' ' LEU . 5.4 p90 -157.7 176.22 12.88 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.837 178.632 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 73.6 m-85 -111.03 132.02 54.57 Favored 'General case' 0 C--N 1.319 -0.745 0 C-N-CA 121.011 -0.276 . . . . 0.0 110.81 -179.54 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 145' ' ' GLU . . . . . 0.471 ' OE1' ' HD3' ' A' ' 116' ' ' ARG . 21.0 pt-20 -120.72 160.85 22.48 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 109.33 -0.619 . . . . 0.0 109.33 174.288 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . 0.662 ' HB2' ' HG2' ' A' ' 133' ' ' MET . 32.3 t80 -140.3 124.2 17.4 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-N 116.12 -0.491 . . . . 0.0 109.742 178.017 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 147' ' ' ILE . . . . . 0.435 HD13 ' N ' ' A' ' 147' ' ' ILE . 2.8 mp -91.8 100.54 11.38 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 N-CA-C 109.624 -0.51 . . . . 0.0 109.624 179.702 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . 0.835 ' HB1' ' HA ' ' A' ' 111' ' ' ASP . . . -82.57 122.02 27.55 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.446 -0.797 . . . . 0.0 109.959 177.448 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 15.5 pt-20 . . . . . 0 C--N 1.321 -0.667 0 CA-C-O 120.801 0.334 . . . . 0.0 110.684 -179.419 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 95.8 m95 . . . . . 0 CA--C 1.522 -0.127 0 CA-C-O 120.967 0.413 . . . . 0.0 110.585 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . 0.468 ' O ' HG21 ' A' ' 27' ' ' VAL . 12.3 m120 -62.74 -45.82 90.94 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.813 -178.172 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 13.0 m-20 -62.85 -41.12 99.23 Favored 'General case' 0 N--CA 1.464 0.256 0 CA-C-O 120.549 0.214 . . . . 0.0 110.897 178.418 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 58.3 tp -57.43 -48.03 80.23 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 121.021 0.438 . . . . 0.0 109.993 176.423 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . 0.486 ' O ' HG13 ' A' ' 30' ' ' ILE . . . -60.82 -46.78 89.22 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.954 178.225 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.481 ' HA ' HD13 ' A' ' 30' ' ' ILE . 53.1 t -56.96 -41.62 77.31 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.199 0 CA-C-N 116.559 -0.291 . . . . 0.0 111.234 179.842 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 61.1 t80 -58.44 -42.79 88.13 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.081 0.467 . . . . 0.0 110.35 178.174 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 66.5 mt -70.2 -40.92 78.67 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.489 178.732 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.701 HG12 HG22 ' A' ' 54' ' ' ILE . 97.0 mt -57.45 -44.63 84.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 115.4 -0.818 . . . . 0.0 111.068 178.838 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . 0.41 ' HG3' ' O ' ' A' ' 27' ' ' VAL . 73.4 mtp180 -65.95 -28.99 69.33 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.035 -0.529 . . . . 0.0 111.614 -178.237 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 46.0 t -88.7 -20.59 24.65 Favored 'General case' 0 C--N 1.324 -0.514 0 C-N-CA 121.104 -0.238 . . . . 0.0 111.496 -176.034 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 12.6 p -100.7 -78.99 0.51 Allowed 'General case' 0 C--N 1.327 -0.398 0 C-N-CA 121.172 -0.211 . . . . 0.0 111.537 -177.386 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 106.27 164.3 22.85 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.986 -0.626 . . . . 0.0 112.267 -179.801 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 8.6 Cg_exo -71.88 144.57 43.59 Favored 'Trans proline' 0 C--O 1.234 0.296 0 C-N-CA 123.121 2.548 . . . . 0.0 112.631 -179.286 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 83.65 2.03 89.97 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 121.19 -0.528 . . . . 0.0 112.846 177.83 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 26.1 p -96.82 -172.38 2.46 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' ARG . . . . . 0.408 ' HA ' ' O ' ' A' ' 61' ' ' ASP . 20.6 mtp180 -123.92 130.66 52.96 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 110.244 -0.28 . . . . 0.0 110.244 176.764 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.503 HG21 HG22 ' A' ' 60' ' ' VAL . 83.9 t -130.09 138.53 53.75 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 178.659 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 39.8 t -111.95 121.15 63.88 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-O 120.778 0.323 . . . . 0.0 110.936 -176.275 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 44.7 tt0 -99.99 108.64 20.89 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 176.053 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.5 ' HB ' ' OG ' ' A' ' 95' ' ' SER . 46.1 t -97.21 125.49 50.26 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.058 -178.681 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 100.65 20.59 14.39 Favored Glycine 0 N--CA 1.447 -0.605 0 C-N-CA 120.483 -0.865 . . . . 0.0 111.804 -176.927 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . 0.444 ' O ' HD13 ' A' ' 74' ' ' ILE . . . -79.09 78.62 5.54 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.19 0.519 . . . . 0.0 110.044 -179.091 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -94.01 -67.85 1.06 Allowed Glycine 0 N--CA 1.443 -0.836 0 CA-C-N 115.67 -0.696 . . . . 0.0 112.907 -178.445 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 61.3 mtt85 -113.66 -45.91 3.08 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 111.778 0.288 . . . . 0.0 111.778 -174.524 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 13.3 p90 -89.1 97.83 11.42 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.549 0.69 . . . . 0.0 111.048 -177.483 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . 0.521 HD22 HD11 ' A' ' 64' ' ' LEU . 79.9 mt -100.0 28.61 4.72 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.533 -0.758 . . . . 0.0 110.277 -179.957 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 74.2 t80 -72.52 -44.89 61.58 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.338 -175.29 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.43 ' O ' HG13 ' A' ' 54' ' ' ILE . 40.9 t -62.05 -55.56 23.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.727 0.299 . . . . 0.0 110.649 -175.459 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' SER . . . . . 0.405 ' CB ' HD21 ' A' ' 64' ' ' LEU . 1.6 p -54.74 -46.82 74.32 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.802 -0.636 . . . . 0.0 112.074 179.396 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.67 ' O ' ' HG2' ' A' ' 56' ' ' LYS . 33.7 t70 -68.95 -31.11 69.75 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.651 0.262 . . . . 0.0 111.127 -177.966 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 77.4 t80 -71.59 -37.11 71.02 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 120.869 0.366 . . . . 0.0 110.756 179.833 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.701 HG22 HG12 ' A' ' 30' ' ' ILE . 88.3 mt -63.73 -44.54 98.37 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-N 116.48 -0.327 . . . . 0.0 111.098 -179.559 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' ARG . . . . . 0.404 ' HA ' ' O ' ' A' ' 58' ' ' SER . 4.9 ptm180 -68.38 -15.56 63.6 Favored 'General case' 0 CA--C 1.533 0.319 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.321 -178.758 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . 0.67 ' HG2' ' O ' ' A' ' 52' ' ' ASP . 32.2 mmmt -73.77 -34.77 64.83 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.989 0.423 . . . . 0.0 110.779 177.183 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 56.7 m-70 -93.2 -47.11 7.1 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.395 -178.622 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' SER . . . . . 0.404 ' O ' ' HA ' ' A' ' 55' ' ' ARG . 67.2 m -121.55 135.19 55.03 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.381 179.546 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 29.3 mmmt -80.08 57.78 2.78 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.707 0.765 . . . . 0.0 110.435 -179.641 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.503 HG22 HG21 ' A' ' 39' ' ' VAL . 3.6 p -85.57 146.05 7.06 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 CA-C-N 114.89 -1.05 . . . . 0.0 109.859 176.705 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . 0.408 ' O ' ' HA ' ' A' ' 38' ' ' ARG . 30.4 t70 -84.72 100.27 11.38 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 177.314 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 2.3 tt -99.62 129.6 45.78 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.134 -176.542 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 48.5 t -106.08 122.12 59.36 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.635 -178.633 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . 0.521 HD11 HD22 ' A' ' 48' ' ' LEU . 42.8 mt -94.19 135.3 35.72 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.127 -0.488 . . . . 0.0 109.746 178.055 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 18.9 p -128.44 130.8 48.13 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.593 0.235 . . . . 0.0 111.407 -178.994 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 25.3 t0 -162.89 146.87 11.29 Favored 'General case' 0 C--N 1.333 -0.142 0 CA-C-N 116.11 -0.495 . . . . 0.0 109.842 177.889 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . 0.622 HD11 ' H ' ' A' ' 79' ' ' ILE . 48.5 mm -73.81 104.89 2.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 N-CA-C 110.169 -0.308 . . . . 0.0 110.169 179.425 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 31.4 mtmm 49.66 78.75 0.38 Allowed Pre-proline 0 N--CA 1.466 0.345 0 CA-C-N 115.576 -0.738 . . . . 0.0 111.381 -175.214 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . 0.696 ' HD2' ' HG2' ' A' ' 76' ' ' ARG . 11.7 Cg_endo . . . . . 0 C--N 1.344 0.3 0 C-N-CA 123.294 2.662 . . . . 0.0 112.901 -178.777 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . 0.444 HD13 ' O ' ' A' ' 44' ' ' ALA . 60.0 mt . . . . . 0 N--CA 1.454 -0.25 0 N-CA-C 110.367 -0.234 . . . . 0.0 110.367 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.441 HG13 ' HB2' ' A' ' 77' ' ' ASP . 98.8 t -74.03 129.09 36.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-O 120.922 0.391 . . . . 0.0 110.329 179.821 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' ARG . . . . . 0.696 ' HG2' ' HD2' ' A' ' 69' ' ' PRO . 88.9 mtt180 -86.68 35.0 0.66 Allowed 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.185 -175.903 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . 0.441 ' HB2' HG13 ' A' ' 75' ' ' VAL . 1.0 OUTLIER -77.63 173.76 11.67 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 109.711 -0.477 . . . . 0.0 109.711 -178.182 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 19.1 m-20 -103.42 122.52 45.04 Favored 'General case' 0 C--N 1.323 -0.566 0 C-N-CA 120.931 -0.307 . . . . 0.0 110.372 -173.89 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' ILE . . . . . 0.622 ' H ' HD11 ' A' ' 67' ' ' ILE . 10.8 tt -75.56 -26.79 18.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 CA-C-O 121.091 0.472 . . . . 0.0 111.018 178.023 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 15.0 t -84.1 -9.83 58.29 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.572 0.701 . . . . 0.0 110.386 -179.584 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 50.9 m -147.62 70.1 11.41 Favored Pre-proline 0 C--N 1.323 -0.585 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 174.421 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' PRO . . . . . 0.685 ' HB2' ' HE2' ' A' ' 87' ' ' TYR . 72.0 Cg_endo -76.95 141.31 21.11 Favored 'Trans proline' 0 N--CA 1.461 -0.436 0 C-N-CA 122.559 2.173 . . . . 0.0 113.49 -169.092 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 83' ' ' ARG . . . . . 0.613 ' HG2' ' HG2' ' A' ' 85' ' ' GLU . 0.0 OUTLIER -79.02 117.31 19.96 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.487 -0.779 . . . . 0.0 109.328 174.11 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' MET . . . . . . . . . . . . . 5.4 mtp -66.08 -25.42 67.01 Favored 'General case' 0 C--N 1.324 -0.534 0 C-N-CA 120.878 -0.329 . . . . 0.0 111.243 -177.475 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . 0.613 ' HG2' ' HG2' ' A' ' 83' ' ' ARG . 10.9 pt-20 -60.87 -26.12 67.17 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.825 0.345 . . . . 0.0 111.235 177.614 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 72.6 mt -74.67 -41.21 48.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.786 0.327 . . . . 0.0 110.856 178.358 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . 0.685 ' HE2' ' HB2' ' A' ' 82' ' ' PRO . 91.4 m-85 -82.09 -34.27 29.42 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.482 -178.359 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . 0.416 HH11 ' HD2' ' A' ' 88' ' ' ARG . 22.4 mtp180 -68.83 125.58 27.06 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.198 0.523 . . . . 0.0 110.398 179.296 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 101.72 3.07 52.75 Favored Glycine 0 N--CA 1.446 -0.675 0 CA-C-N 115.376 -0.829 . . . . 0.0 111.634 -176.488 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -85.63 144.05 28.08 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.084 0.468 . . . . 0.0 110.731 178.808 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -89.31 -19.62 25.07 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.594 179.215 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . 0.471 HD21 ' N ' ' A' ' 93' ' ' ILE . 5.6 tt -166.59 141.27 4.23 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.064 -0.517 . . . . 0.0 109.865 -178.038 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.586 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 58.6 mt -124.95 126.33 71.06 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 N-CA-C 109.433 -0.58 . . . . 0.0 109.433 177.285 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 18.8 p90 -134.21 156.18 48.82 Favored 'General case' 0 C--N 1.322 -0.619 0 C-N-CA 120.226 -0.59 . . . . 0.0 111.511 -178.877 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 95' ' ' SER . . . . . 0.5 ' OG ' ' HB ' ' A' ' 42' ' ' VAL . 14.4 m -148.06 130.52 15.77 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.457 -0.792 . . . . 0.0 110.196 -178.571 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 96' ' ' ILE . . . . . 0.42 HD11 ' N ' ' A' ' 96' ' ' ILE . 4.0 mp -87.99 103.32 13.47 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 177.123 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 97' ' ' ARG . . . . . 1.081 ' HB3' ' HA ' ' A' ' 121' ' ' PRO . 8.9 ptm180 40.11 89.61 0.08 OUTLIER Pre-proline 0 N--CA 1.475 0.809 0 C-N-CA 124.685 1.194 . . . . 0.0 113.269 -176.279 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 89.9 Cg_endo -79.96 154.33 22.69 Favored 'Trans proline' 0 N--CA 1.459 -0.525 0 C-N-CA 122.472 2.115 . . . . 0.0 112.191 178.581 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . 0.788 ' HD2' HD13 ' A' ' 102' ' ' ILE . 51.4 Cg_exo -54.27 158.28 9.89 Favored 'Trans proline' 0 C--O 1.234 0.313 0 C-N-CA 122.8 2.334 . . . . 0.0 112.288 173.936 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -80.37 25.86 0.39 Allowed 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.147 -0.479 . . . . 0.0 112.046 -172.997 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 101' ' ' GLU . . . . . 0.642 ' HG3' HG23 ' A' ' 102' ' ' ILE . 12.2 pt-20 -124.3 -21.29 5.0 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.76 -0.2 . . . . 0.0 111.276 178.113 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.788 HD13 ' HD2' ' A' ' 99' ' ' PRO . 45.2 pt -110.38 -1.62 9.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 N-CA-C 112.031 0.382 . . . . 0.0 112.031 -174.646 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 103' ' ' HIS . . . . . 0.513 ' O ' ' HG2' ' A' ' 107' ' ' MET . 23.7 p-80 -61.68 -41.77 98.02 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.798 0.333 . . . . 0.0 110.46 -179.258 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 20.6 t -71.25 -30.21 66.04 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.16 0.505 . . . . 0.0 110.056 177.895 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.545 ' O ' HG22 ' A' ' 109' ' ' VAL . 4.6 m -68.82 -46.08 69.54 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.046 -179.626 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 92.3 mt -58.18 -40.46 81.55 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.168 179.76 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 107' ' ' MET . . . . . 0.616 ' HE2' ' HB3' ' A' ' 132' ' ' LYS . 94.2 mmm -60.92 -43.85 98.0 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.43 -178.839 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 108' ' ' ARG . . . . . 0.435 ' HG2' ' O ' ' A' ' 105' ' ' SER . 13.1 ptp180 -76.9 -27.09 54.81 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.663 -0.244 . . . . 0.0 111.2 -177.786 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.545 HG22 ' O ' ' A' ' 105' ' ' SER . 73.6 t -70.9 -44.52 75.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 C-N-CA 121.158 -0.217 . . . . 0.0 110.674 177.744 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -59.46 -41.24 89.25 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 121.106 0.479 . . . . 0.0 110.323 178.466 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . 0.453 ' HA ' ' HB3' ' A' ' 148' ' ' ALA . 16.2 t70 -65.4 -34.92 79.45 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.779 -178.565 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -72.46 -45.13 60.94 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.866 -0.606 . . . . 0.0 111.739 -178.263 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.406 HG13 ' CG ' ' A' ' 88' ' ' ARG . 31.1 m -85.88 -25.63 6.52 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-N 116.533 -0.303 . . . . 0.0 111.771 -176.102 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 84.96 59.3 1.99 Allowed Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.039 179.797 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . 0.456 ' O ' ' HB1' ' A' ' 148' ' ' ALA . . . -140.44 149.5 42.65 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 120.927 0.394 . . . . 0.0 110.791 -179.241 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 116' ' ' ARG . . . . . 0.515 ' HD3' ' OE1' ' A' ' 145' ' ' GLU . 14.9 ttm180 -70.98 129.75 39.8 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.893 -0.594 . . . . 0.0 109.999 177.318 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . 0.586 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 58.1 tp -100.16 118.66 36.97 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 116.049 -0.523 . . . . 0.0 109.709 178.645 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 60.0 mt -112.66 117.85 56.36 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-O 120.914 0.388 . . . . 0.0 110.569 179.702 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 119' ' ' ILE . . . . . 0.437 ' HA ' ' O ' ' A' ' 95' ' ' SER . 73.3 mt -120.35 120.23 62.2 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.672 -179.646 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 62.2 tttm -115.8 100.9 54.01 Favored Pre-proline 0 C--N 1.32 -0.674 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.208 175.533 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 121' ' ' PRO . . . . . 1.081 ' HA ' ' HB3' ' A' ' 97' ' ' ARG . 86.8 Cg_endo -78.96 -165.46 0.34 Allowed 'Trans proline' 0 N--CA 1.459 -0.503 0 C-N-CA 122.59 2.193 . . . . 0.0 111.792 175.696 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 122' ' ' LEU . . . . . 0.563 ' HB2' ' HB2' ' A' ' 125' ' ' GLU . 31.3 mt -66.54 152.72 44.68 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.872 175.924 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 19.9 m -64.71 106.0 1.1 Allowed 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.02 -0.536 . . . . 0.0 109.569 175.081 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 92.06 30.72 9.86 Favored Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 120.935 -0.65 . . . . 0.0 111.653 -175.118 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . 0.563 ' HB2' ' HB2' ' A' ' 122' ' ' LEU . 43.6 tt0 -126.6 145.19 50.64 Favored 'General case' 0 N--CA 1.448 -0.564 0 CA-C-O 121.032 0.444 . . . . 0.0 110.053 -179.408 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -101.15 167.08 10.45 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.471 -178.566 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 6.4 mt . . . . . 0 C--N 1.328 -0.341 0 N-CA-C 110.02 -0.363 . . . . 0.0 110.02 -178.852 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 132' ' ' LYS . . . . . 0.616 ' HB3' ' HE2' ' A' ' 107' ' ' MET . 46.8 mmtm . . . . . 0 N--CA 1.458 -0.068 0 CA-C-O 120.845 0.355 . . . . 0.0 110.899 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 133' ' ' MET . . . . . 0.483 ' HG2' ' HB2' ' A' ' 146' ' ' TYR . 85.7 mtp -133.62 170.56 15.35 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.411 -177.179 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -118.38 145.37 45.21 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.689 179.862 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . 0.482 HD12 ' HD2' ' A' ' 142' ' ' TYR . 57.7 tp -80.74 134.24 35.79 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.121 178.26 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -129.54 138.59 53.88 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-O 121.193 0.521 . . . . 0.0 111.577 -179.958 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 14.3 m120 -110.23 120.17 41.6 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.005 177.323 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 59.5 t80 -148.64 123.4 9.9 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 110.201 -0.296 . . . . 0.0 110.201 177.894 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . 0.412 ' C ' ' H ' ' A' ' 141' ' ' THR . . . 66.79 42.72 92.89 Favored Glycine 0 N--CA 1.448 -0.563 0 C-N-CA 121.029 -0.605 . . . . 0.0 112.801 177.461 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 55.5 ttt180 73.75 -19.87 0.33 Allowed 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 123.325 0.65 . . . . 0.0 112.361 175.455 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 141' ' ' THR . . . . . 0.412 ' H ' ' C ' ' A' ' 139' ' ' GLY . 5.2 t -97.63 163.21 12.93 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 178.58 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 142' ' ' TYR . . . . . 0.482 ' HD2' HD12 ' A' ' 135' ' ' LEU . 37.6 p90 -131.98 148.93 52.54 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 121.237 0.541 . . . . 0.0 110.886 -179.664 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 8.7 p90 -155.23 177.69 11.06 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 115.26 -0.882 . . . . 0.0 109.4 -179.104 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -113.13 134.34 54.6 Favored 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 110.068 -0.345 . . . . 0.0 110.068 179.419 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 145' ' ' GLU . . . . . 0.515 ' OE1' ' HD3' ' A' ' 116' ' ' ARG . 20.1 pt-20 -126.8 158.47 36.51 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 121.265 0.555 . . . . 0.0 110.385 177.237 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . 0.483 ' HB2' ' HG2' ' A' ' 133' ' ' MET . 35.6 t80 -134.76 126.26 28.58 Favored 'General case' 0 C--N 1.316 -0.89 0 CA-C-N 115.465 -0.789 . . . . 0.0 109.265 175.241 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 147' ' ' ILE . . . . . 0.409 ' N ' HD13 ' A' ' 147' ' ' ILE . 3.1 mp -92.24 100.23 10.92 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 CA-C-O 121.19 0.519 . . . . 0.0 109.739 -178.661 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . 0.456 ' HB1' ' O ' ' A' ' 115' ' ' ALA . . . -91.73 107.4 19.18 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.61 -0.723 . . . . 0.0 109.064 174.499 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 . . . . . 0 C--O 1.236 0.368 0 CA-C-O 121.199 0.523 . . . . 0.0 110.28 -177.884 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 80.6 m95 . . . . . 0 N--CA 1.453 -0.297 0 CA-C-O 121.022 0.439 . . . . 0.0 110.45 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . 0.41 ' O ' HG22 ' A' ' 27' ' ' VAL . 2.7 t-20 -72.57 -45.23 60.2 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.118 178.752 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -59.77 -42.07 92.49 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.234 178.024 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 62.2 tp -55.76 -49.01 74.27 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.297 176.697 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . 0.488 ' O ' HG13 ' A' ' 30' ' ' ILE . . . -58.91 -52.25 66.55 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.891 179.081 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.41 HG22 ' O ' ' A' ' 23' ' ' ASN . 91.6 t -55.03 -43.32 69.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.321 -0.4 . . . . 0.0 111.188 -179.933 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 67.5 t80 -58.98 -47.32 85.6 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.957 0.408 . . . . 0.0 110.467 179.094 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.501 HG22 HD11 ' A' ' 92' ' ' LEU . 91.2 mt -61.89 -42.95 96.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.589 179.017 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.643 HG12 HG23 ' A' ' 54' ' ' ILE . 95.8 mt -58.23 -39.82 75.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 115.696 -0.683 . . . . 0.0 111.348 179.818 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . 0.401 ' HG3' ' O ' ' A' ' 27' ' ' VAL . 44.3 mtp-105 -74.55 -24.0 58.88 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.153 -178.558 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 85.0 m -88.99 -19.29 25.89 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.702 -177.926 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 13.9 p -106.6 -77.6 0.59 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.624 -177.801 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 95.36 163.33 34.43 Favored Glycine 0 N--CA 1.446 -0.635 0 C-N-CA 121.082 -0.58 . . . . 0.0 112.203 -178.467 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -66.09 143.08 70.48 Favored 'Trans proline' 0 C--O 1.233 0.26 0 C-N-CA 122.794 2.329 . . . . 0.0 112.64 -179.79 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 109.57 -32.62 6.64 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.894 177.091 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 11.3 t -98.02 -170.97 2.06 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 110.005 -0.368 . . . . 0.0 110.005 -176.467 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' ARG . . . . . 0.816 ' HG2' ' HB3' ' A' ' 61' ' ' ASP . 45.0 mtt180 -124.28 136.66 54.29 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.004 0.431 . . . . 0.0 111.673 -176.533 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.455 HG22 HG22 ' A' ' 60' ' ' VAL . 63.4 t -121.44 125.34 73.49 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-N 115.528 -0.76 . . . . 0.0 109.318 175.852 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 47.2 t -103.72 128.27 57.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-O 120.811 0.339 . . . . 0.0 111.406 -175.193 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . 0.469 ' HB3' HD21 ' A' ' 64' ' ' LEU . 34.3 tt0 -105.13 118.54 36.8 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 173.972 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.493 ' HA ' ' OG1' ' A' ' 65' ' ' THR . 58.5 t -95.54 121.05 45.73 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.362 -179.864 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 96.61 43.24 3.2 Favored Glycine 0 N--CA 1.446 -0.671 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.103 -179.817 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -77.01 82.77 3.53 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.351 0.596 . . . . 0.0 110.519 -178.292 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -69.64 -98.37 0.05 OUTLIER Glycine 0 N--CA 1.447 -0.593 0 CA-C-N 115.01 -0.995 . . . . 0.0 112.903 179.889 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . 0.535 ' HD2' ' O ' ' A' ' 46' ' ' ARG . 8.2 tmm_? -136.82 -7.19 1.88 Allowed 'General case' 0 C--N 1.327 -0.4 0 C-N-CA 120.904 -0.318 . . . . 0.0 111.27 -177.199 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 9.0 p90 -61.98 -63.01 1.39 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.808 0.337 . . . . 0.0 111.011 179.688 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . 0.408 HD21 HD12 ' A' ' 64' ' ' LEU . 59.7 mt 55.85 22.23 5.45 Favored 'General case' 0 C--N 1.323 -0.552 0 C-N-CA 123.684 0.794 . . . . 0.0 112.59 173.81 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 86.4 t80 -74.97 -56.85 4.33 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.781 0.324 . . . . 0.0 110.984 -178.075 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.47 ' O ' HG13 ' A' ' 54' ' ' ILE . 52.5 t -63.49 -52.78 53.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.074 -175.816 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' SER . . . . . 0.546 ' CB ' HD23 ' A' ' 64' ' ' LEU . 0.2 OUTLIER -59.47 -46.88 87.52 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.695 -0.684 . . . . 0.0 112.491 -176.587 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 35.6 t70 -68.07 -27.2 66.29 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.729 0.3 . . . . 0.0 110.948 -177.689 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 89.3 t80 -73.81 -45.62 50.29 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 120.699 0.285 . . . . 0.0 110.798 176.916 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.643 HG23 HG12 ' A' ' 30' ' ' ILE . 78.3 mt -59.92 -43.24 91.78 Favored 'Isoleucine or valine' 0 C--O 1.234 0.253 0 CA-C-N 116.403 -0.362 . . . . 0.0 111.307 -178.079 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 2.0 ptm180 -67.83 -16.73 64.24 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.479 -178.84 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 67.2 mttm -88.05 -42.85 12.12 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.116 0.484 . . . . 0.0 110.454 177.002 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.9 OUTLIER -65.53 -41.68 92.83 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.633 -0.712 . . . . 0.0 110.932 -177.559 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' SER . . . . . 0.415 ' C ' ' H ' ' A' ' 60' ' ' VAL . 74.1 m -132.41 153.51 50.75 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.348 -179.507 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -76.71 38.84 0.2 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.908 177.846 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.455 HG22 HG22 ' A' ' 39' ' ' VAL . 7.2 p -84.03 138.76 18.66 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 CA-C-N 116.047 -0.524 . . . . 0.0 109.624 179.13 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . 0.816 ' HB3' ' HG2' ' A' ' 38' ' ' ARG . 13.9 t70 -84.86 93.76 8.59 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 -178.232 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 4.2 tt -90.38 127.8 36.29 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.005 -175.424 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 59.4 t -106.36 121.91 59.5 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 115.773 -0.649 . . . . 0.0 111.016 -176.674 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . 0.546 HD23 ' CB ' ' A' ' 51' ' ' SER . 90.5 mt -98.93 141.33 31.83 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.05 -0.523 . . . . 0.0 109.816 176.65 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.493 ' OG1' ' HA ' ' A' ' 42' ' ' VAL . 28.8 p -121.28 127.18 51.11 Favored 'General case' 0 C--O 1.238 0.487 0 CA-C-O 120.608 0.242 . . . . 0.0 111.627 -178.738 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 32.0 t70 -166.27 139.01 3.93 Favored 'General case' 0 N--CA 1.463 0.218 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.364 178.117 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 58.6 mt -75.97 112.04 13.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 N-CA-C 110.249 -0.278 . . . . 0.0 110.249 -179.511 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 47.1 mtmt 56.47 75.04 0.61 Allowed Pre-proline 0 C--N 1.33 -0.249 0 O-C-N 123.598 0.561 . . . . 0.0 109.839 -178.179 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . 0.563 ' CB ' ' HB ' ' A' ' 74' ' ' ILE . 8.1 Cg_exo . . . . . 0 N--CA 1.465 -0.178 0 C-N-CA 123.249 2.633 . . . . 0.0 112.815 -171.195 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . 0.563 ' HB ' ' CB ' ' A' ' 69' ' ' PRO . 67.7 mt . . . . . 0 N--CA 1.45 -0.461 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.46 HG13 ' H ' ' A' ' 77' ' ' ASP . 91.1 t -73.91 122.56 27.3 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 120.865 0.364 . . . . 0.0 110.24 178.858 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -78.34 16.55 0.77 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.696 -0.684 . . . . 0.0 112.645 -175.232 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . 0.46 ' H ' HG13 ' A' ' 75' ' ' VAL . 2.6 m-20 -76.14 155.44 34.63 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 121.496 0.665 . . . . 0.0 111.887 -175.478 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 16.9 t0 -78.88 143.78 35.57 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 114.88 -1.054 . . . . 0.0 111.276 -174.237 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 7.6 tp -96.59 -26.59 4.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.375 -177.206 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 5.0 t -78.22 -25.66 47.09 Favored 'General case' 0 C--O 1.234 0.247 0 N-CA-C 109.376 -0.602 . . . . 0.0 109.376 179.759 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 1.2 m -124.38 76.03 61.74 Favored Pre-proline 0 C--N 1.329 -0.3 0 N-CA-C 108.45 -0.944 . . . . 0.0 108.45 169.027 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -79.07 131.55 9.96 Favored 'Trans proline' 0 N--CA 1.461 -0.405 0 C-N-CA 122.671 2.247 . . . . 0.0 113.453 -170.887 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 83' ' ' ARG . . . . . 0.681 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 64.5 mtt180 -70.57 109.5 4.89 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.651 -0.704 . . . . 0.0 110.016 174.303 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' MET . . . . . 0.715 ' HA ' ' HD2' ' A' ' 87' ' ' TYR . 31.5 mtp -73.31 -10.23 59.53 Favored 'General case' 0 C--N 1.323 -0.572 0 C-N-CA 120.816 -0.354 . . . . 0.0 110.58 178.66 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . 0.681 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 10.5 pt-20 -66.94 -21.98 65.96 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.542 173.908 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 71.9 mt -81.8 -34.59 12.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-O 121.351 0.596 . . . . 0.0 110.042 178.145 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . 0.715 ' HD2' ' HA ' ' A' ' 84' ' ' MET . 85.3 m-85 -82.39 -33.9 28.54 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.585 -0.734 . . . . 0.0 110.687 -178.487 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 50.6 mtp180 -64.07 122.46 16.61 Favored 'General case' 0 CA--C 1.516 -0.345 0 CA-C-O 121.227 0.536 . . . . 0.0 111.01 177.626 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 104.06 -12.28 52.37 Favored Glycine 0 N--CA 1.444 -0.767 0 CA-C-N 115.299 -0.864 . . . . 0.0 111.921 -178.976 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -78.79 142.5 36.91 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 110.015 -0.365 . . . . 0.0 110.015 177.767 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -90.71 -19.9 23.04 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-O 121.127 0.489 . . . . 0.0 110.453 -179.415 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . 0.591 ' HG ' ' HB3' ' A' ' 116' ' ' ARG . 3.4 tt -153.92 139.78 18.14 Favored 'General case' 0 N--CA 1.447 -0.596 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.929 -176.943 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.569 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 70.0 mt -131.33 124.64 55.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 177.791 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 94' ' ' TYR . . . . . 0.438 ' HE1' HG13 ' A' ' 39' ' ' VAL . 13.9 p90 -134.72 164.9 26.48 Favored 'General case' 0 C--N 1.321 -0.661 0 C-N-CA 120.717 -0.393 . . . . 0.0 111.08 -178.809 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 6.9 p -140.58 131.14 25.46 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.523 -178.884 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 38.5 mm -92.03 98.31 8.23 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.098 179.262 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 63.0 mtm180 59.3 76.46 0.44 Allowed Pre-proline 0 C--N 1.332 -0.182 0 CA-C-N 115.401 -0.818 . . . . 0.0 111.54 -179.242 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 98' ' ' PRO . . . . . 0.424 ' HA ' ' HD3' ' A' ' 99' ' ' PRO . 93.4 Cg_endo -87.97 152.61 7.13 Favored 'Trans proline' 0 N--CA 1.455 -0.747 0 C-N-CA 122.593 2.195 . . . . 0.0 112.1 177.294 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . 0.652 ' HB2' ' HG2' ' A' ' 101' ' ' GLU . 6.3 Cg_exo -73.07 148.71 45.24 Favored 'Trans proline' 0 N--CA 1.461 -0.405 0 C-N-CA 122.524 2.149 . . . . 0.0 111.461 176.019 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -76.45 39.75 0.21 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.173 0.511 . . . . 0.0 111.735 -177.475 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 101' ' ' GLU . . . . . 0.652 ' HG2' ' HB2' ' A' ' 99' ' ' PRO . 11.6 pt-20 -121.51 -28.74 4.54 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.205 177.615 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.595 HG23 ' HG3' ' A' ' 101' ' ' GLU . 34.8 pt -110.67 5.28 8.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.359 -175.976 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 103' ' ' HIS . . . . . . . . . . . . . 9.6 p-80 -60.99 -48.17 83.07 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 115.62 -0.718 . . . . 0.0 111.392 -177.043 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 47.1 m -70.97 -23.07 62.14 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.177 0.513 . . . . 0.0 110.658 178.689 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.545 ' O ' ' HG2' ' A' ' 108' ' ' ARG . 8.7 m -73.96 -37.92 64.37 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.242 178.542 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . 0.407 ' HG ' ' O ' ' A' ' 102' ' ' ILE . 94.0 mt -63.61 -41.08 98.34 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.722 178.014 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 107' ' ' MET . . . . . . . . . . . . . 97.7 mmm -57.33 -47.02 82.66 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.759 -0.655 . . . . 0.0 111.316 -179.281 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 108' ' ' ARG . . . . . 0.545 ' HG2' ' O ' ' A' ' 105' ' ' SER . 6.6 ptp180 -67.6 -31.48 71.55 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.505 -0.316 . . . . 0.0 111.178 -176.941 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.571 HG13 ' HE2' ' A' ' 84' ' ' MET . 92.1 t -74.29 -46.0 45.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.486 -0.325 . . . . 0.0 110.659 -178.862 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -58.3 -49.99 75.2 Favored 'General case' 0 CA--C 1.516 -0.347 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 176.946 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 15.3 t70 -55.16 -40.83 71.08 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.093 -0.958 . . . . 0.0 111.028 179.565 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . 0.47 ' HB3' ' HE1' ' A' ' 84' ' ' MET . . . -68.5 -44.94 73.62 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.918 -0.583 . . . . 0.0 112.196 -176.995 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 31.1 m -84.83 -27.63 6.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 C-N-CA 120.766 -0.374 . . . . 0.0 111.759 -175.29 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 98.04 22.53 15.15 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.631 -0.795 . . . . 0.0 112.654 177.578 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -99.09 163.46 12.56 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 121.505 0.669 . . . . 0.0 111.844 -176.483 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 116' ' ' ARG . . . . . 0.591 ' HB3' ' HG ' ' A' ' 92' ' ' LEU . 23.2 ttt180 -85.08 116.23 23.34 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 115.181 -0.918 . . . . 0.0 109.591 178.181 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . 0.569 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 52.2 tp -90.13 128.01 36.23 Favored 'General case' 0 C--N 1.32 -0.693 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 -178.261 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 72.2 mt -129.02 119.72 50.0 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 CA-C-O 121.178 0.513 . . . . 0.0 110.891 179.683 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 64.6 mt -119.75 125.1 73.98 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.437 179.88 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 8.9 tmtm? -108.48 98.23 26.94 Favored Pre-proline 0 C--N 1.325 -0.474 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 175.22 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -77.52 -174.26 2.14 Favored 'Trans proline' 0 C--O 1.236 0.386 0 C-N-CA 122.796 2.33 . . . . 0.0 112.944 -179.507 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 122' ' ' LEU . . . . . 0.407 ' HB2' ' HB3' ' A' ' 125' ' ' GLU . 91.7 mt -75.59 176.04 8.0 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.753 -0.658 . . . . 0.0 111.463 -175.967 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 4.1 p -74.86 102.83 4.87 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.725 -0.671 . . . . 0.0 111.002 179.317 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 82.11 30.23 35.21 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.156 179.547 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . 0.407 ' HB3' ' HB2' ' A' ' 122' ' ' LEU . 8.8 tp10 -133.26 136.78 45.75 Favored 'General case' 0 N--CA 1.448 -0.574 0 N-CA-C 109.143 -0.688 . . . . 0.0 109.143 178.049 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -107.25 166.99 10.23 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.043 -173.481 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 45.2 mt . . . . . 0 C--N 1.327 -0.378 0 CA-C-N 115.958 -0.564 . . . . 0.0 109.998 179.642 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 3.9 mppt? . . . . . 0 CA--C 1.515 -0.399 0 CA-C-O 121.279 0.562 . . . . 0.0 111.84 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 133' ' ' MET . . . . . . . . . . . . . 85.0 mtp -137.77 160.63 38.73 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 115.056 -0.975 . . . . 0.0 108.971 174.405 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . 0.655 ' HG3' ' HG2' ' A' ' 145' ' ' GLU . 1.4 ptmt -111.93 133.07 54.36 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-O 121.039 0.447 . . . . 0.0 110.866 -178.123 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . 0.631 HD13 ' HD2' ' A' ' 142' ' ' TYR . 51.9 tp -81.67 121.4 26.32 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.067 179.244 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -116.21 141.95 31.7 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.65 -178.014 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -115.33 111.35 20.74 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.737 -0.665 . . . . 0.0 109.351 176.226 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . 0.604 ' O ' HG21 ' A' ' 141' ' ' THR . 57.0 t80 -124.85 104.68 8.74 Favored 'General case' 0 C--N 1.319 -0.734 0 N-CA-C 109.49 -0.559 . . . . 0.0 109.49 -178.761 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 68.27 40.96 87.24 Favored Glycine 0 CA--C 1.519 0.299 0 C-N-CA 120.55 -0.833 . . . . 0.0 111.609 -175.575 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 75.83 -25.89 0.2 Allowed 'General case' 0 N--CA 1.472 0.63 0 C-N-CA 123.681 0.792 . . . . 0.0 113.073 178.464 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 141' ' ' THR . . . . . 0.604 HG21 ' O ' ' A' ' 138' ' ' TYR . 13.9 t -75.26 142.68 43.31 Favored 'General case' 0 C--O 1.236 0.38 0 N-CA-C 109.338 -0.616 . . . . 0.0 109.338 177.262 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 142' ' ' TYR . . . . . 0.631 ' HD2' HD13 ' A' ' 135' ' ' LEU . 26.4 p90 -121.41 141.55 50.87 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 121.394 0.616 . . . . 0.0 111.229 -176.452 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 25.1 p90 -154.32 170.21 21.86 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 114.975 -1.011 . . . . 0.0 109.515 -179.968 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 75.5 m-85 -107.5 126.4 52.47 Favored 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 110.227 -0.286 . . . . 0.0 110.227 179.474 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 145' ' ' GLU . . . . . 0.655 ' HG2' ' HG3' ' A' ' 134' ' ' LYS . 10.0 pt-20 -115.41 164.12 14.74 Favored 'General case' 0 C--N 1.32 -0.677 0 N-CA-C 109.685 -0.487 . . . . 0.0 109.685 177.594 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . 0.54 ' HB3' ' HB3' ' A' ' 117' ' ' LEU . 50.8 t80 -147.03 127.74 14.28 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.352 177.382 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 147' ' ' ILE . . . . . 0.425 HD13 ' N ' ' A' ' 147' ' ' ILE . 3.1 mp -96.73 104.92 16.43 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.706 0 CA-C-N 115.779 -0.646 . . . . 0.0 109.366 179.506 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -70.25 117.44 11.81 Favored 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 175.974 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 30.3 mt-10 . . . . . 0 C--N 1.32 -0.692 0 CA-C-O 121.702 0.763 . . . . 0.0 111.795 -176.743 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' TRP . . . . . 0.55 ' HB3' HG23 ' A' ' 50' ' ' VAL . 98.2 m95 . . . . . 0 N--CA 1.454 -0.229 0 CA-C-O 120.836 0.35 . . . . 0.0 110.675 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 13.9 m120 -66.01 -41.0 91.58 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.987 -179.638 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 26.2 m-20 -59.17 -46.78 87.49 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.049 178.905 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 66.6 tp -59.6 -47.86 83.94 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.402 -0.817 . . . . 0.0 110.672 178.721 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . 0.417 ' O ' HG13 ' A' ' 30' ' ' ILE . . . -54.71 -51.98 63.87 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.474 -179.399 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.431 ' HA ' HD12 ' A' ' 30' ' ' ILE . 88.4 t -56.02 -43.11 74.29 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-O 120.9 0.381 . . . . 0.0 111.136 -179.717 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 83.5 t80 -59.17 -45.56 90.69 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.576 179.222 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.433 HD13 ' CD1' ' A' ' 94' ' ' TYR . 79.8 mt -65.36 -42.59 93.99 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.626 179.192 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.609 HG12 HG23 ' A' ' 54' ' ' ILE . 96.2 mt -56.62 -45.38 82.46 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-N 115.593 -0.73 . . . . 0.0 111.001 178.654 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 83.7 mtp180 -64.98 -28.27 69.4 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.629 -178.106 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 44.2 t -86.93 -24.53 24.75 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.669 0.271 . . . . 0.0 111.298 -177.316 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 11.3 p -98.48 -77.11 0.52 Allowed 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 120.745 0.307 . . . . 0.0 111.421 -176.774 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 90.57 172.22 44.1 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.943 -0.646 . . . . 0.0 112.307 -178.493 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 63.0 Cg_endo -74.29 153.68 45.71 Favored 'Trans proline' 0 C--O 1.235 0.33 0 C-N-CA 122.571 2.18 . . . . 0.0 112.121 179.391 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 82.35 30.05 34.9 Favored Glycine 0 CA--C 1.518 0.238 0 C-N-CA 120.675 -0.774 . . . . 0.0 113.073 177.772 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 14.2 t -150.07 -176.53 5.49 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 176.199 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' ARG . . . . . 0.52 ' HB2' ' HA ' ' A' ' 90' ' ' ALA . 17.4 mtp180 -117.34 135.56 53.77 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 120.856 0.36 . . . . 0.0 111.389 -176.697 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.439 HG12 ' OE1' ' A' ' 41' ' ' GLU . 16.7 t -123.98 125.03 70.28 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 172.843 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 47.1 t -109.71 117.59 54.94 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 121.191 0.52 . . . . 0.0 110.59 -177.887 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . 0.535 ' HB2' HD22 ' A' ' 64' ' ' LEU . 0.1 OUTLIER -90.98 120.32 31.88 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.309 -0.86 . . . . 0.0 110.29 -175.927 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.647 HG11 HD22 ' A' ' 106' ' ' LEU . 59.4 t -94.33 110.26 23.38 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.701 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 175.992 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 98.91 97.78 2.1 Favored Glycine 0 N--CA 1.446 -0.696 0 N-CA-C 110.988 -0.845 . . . . 0.0 110.988 -175.353 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -111.53 -53.24 2.72 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.652 0.263 . . . . 0.0 110.913 -176.256 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 48.53 -121.14 7.35 Favored Glycine 0 N--CA 1.449 -0.451 0 CA-C-N 115.788 -0.642 . . . . 0.0 112.311 -176.523 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 94.7 mtt180 -118.1 3.23 12.07 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 120.903 0.382 . . . . 0.0 110.256 175.77 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 12.4 p90 -98.05 63.34 1.6 Allowed 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.621 0.724 . . . . 0.0 111.143 -175.891 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 55.2 mt -85.33 22.74 1.44 Allowed 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.694 -0.685 . . . . 0.0 110.869 -178.713 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 80.6 t80 -63.33 -41.43 98.89 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.332 -176.512 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.55 HG23 ' HB3' ' A' ' 22' ' ' TRP . 42.6 t -75.32 -50.48 24.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.659 -178.957 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 3.0 p -62.35 -45.78 91.65 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.556 -0.747 . . . . 0.0 112.306 -174.225 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.525 ' O ' ' HG2' ' A' ' 56' ' ' LYS . 35.5 t70 -70.07 -35.67 74.4 Favored 'General case' 0 C--N 1.33 -0.275 0 C-N-CA 120.655 -0.418 . . . . 0.0 110.646 -177.011 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 88.6 t80 -58.72 -40.48 83.88 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.944 0.402 . . . . 0.0 110.299 178.079 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.609 HG23 HG12 ' A' ' 30' ' ' ILE . 79.6 mt -65.62 -49.23 79.1 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.338 -179.921 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' ARG . . . . . 0.455 ' HG2' ' HA ' ' A' ' 52' ' ' ASP . 5.7 ptm180 -69.29 -19.98 63.9 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-N 116.476 -0.329 . . . . 0.0 111.598 -176.55 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . 0.532 ' HZ2' ' HB3' ' A' ' 56' ' ' LYS . 4.6 mmmp? -82.09 -35.61 28.44 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.713 0.292 . . . . 0.0 111.192 177.697 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 14.4 t60 -84.55 -41.24 16.67 Favored 'General case' 0 N--CA 1.446 -0.674 0 CA-C-O 121.037 0.446 . . . . 0.0 109.966 -177.595 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 74.6 m -122.9 133.44 54.4 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.355 176.519 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -78.17 63.94 3.22 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 121.862 0.839 . . . . 0.0 110.086 179.47 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.411 HG23 HG22 ' A' ' 39' ' ' VAL . 7.1 p -94.85 149.57 4.42 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.883 0 CA-C-N 114.489 -1.232 . . . . 0.0 109.873 175.913 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 52.3 t0 -74.77 96.05 3.0 Favored 'General case' 0 C--O 1.234 0.268 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 178.093 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . 0.487 HD21 ' OE2' ' A' ' 41' ' ' GLU . 1.1 tm? -93.14 126.01 38.03 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 115.233 -0.894 . . . . 0.0 110.262 -173.379 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 41.7 t -125.85 119.61 55.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.043 -177.13 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . 0.535 HD22 ' HB2' ' A' ' 41' ' ' GLU . 12.7 mt -96.48 148.99 22.24 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 116.175 -0.466 . . . . 0.0 109.97 178.601 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.515 HG21 ' HB ' ' A' ' 75' ' ' VAL . 15.3 p -134.48 127.8 32.16 Favored 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 110.566 -0.161 . . . . 0.0 110.566 176.827 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 3.4 t70 -163.4 175.61 10.63 Favored 'General case' 0 N--CA 1.464 0.236 0 N-CA-C 110.062 -0.347 . . . . 0.0 110.062 -178.619 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 48.9 mm -88.5 107.84 18.12 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 116.652 -0.249 . . . . 0.0 110.398 -178.62 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 55.0 mtmt 60.11 90.0 0.1 OUTLIER Pre-proline 0 N--CA 1.466 0.329 0 O-C-N 123.674 0.608 . . . . 0.0 111.118 -177.987 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . 0.953 ' HB3' ' HB ' ' A' ' 74' ' ' ILE . 32.9 Cg_endo . . . . . 0 C--O 1.233 0.268 0 C-N-CA 123.127 2.551 . . . . 0.0 113.177 -177.462 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . 0.953 ' HB ' ' HB3' ' A' ' 69' ' ' PRO . 40.3 mt . . . . . 0 N--CA 1.449 -0.478 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.606 HG11 HD13 ' A' ' 86' ' ' ILE . 55.8 t -78.12 131.17 35.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 176.959 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' ARG . . . . . 0.431 ' HA ' ' HD3' ' A' ' 69' ' ' PRO . 36.2 ptt180 -82.88 29.49 0.46 Allowed 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.762 -0.654 . . . . 0.0 111.939 -175.902 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 31.9 t0 -84.02 160.42 21.0 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 110.024 -0.362 . . . . 0.0 110.024 -178.944 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -79.61 104.02 9.92 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-O 120.849 0.357 . . . . 0.0 110.268 -177.646 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' ILE . . . . . 0.538 HD11 HG12 ' A' ' 42' ' ' VAL . 12.8 tt -57.67 -23.33 19.98 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.501 0 CA-C-N 115.692 -0.685 . . . . 0.0 112.478 -176.379 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 5.1 t -87.9 -6.56 58.01 Favored 'General case' 0 CA--C 1.539 0.534 0 CA-C-O 121.141 0.496 . . . . 0.0 110.869 -178.1 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 32.9 t -154.63 60.09 2.64 Favored Pre-proline 0 C--N 1.328 -0.336 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 178.177 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' PRO . . . . . 0.777 ' HB2' ' HE2' ' A' ' 87' ' ' TYR . 84.3 Cg_endo -79.24 155.34 25.4 Favored 'Trans proline' 0 N--CA 1.461 -0.405 0 C-N-CA 122.676 2.251 . . . . 0.0 113.784 -166.01 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 83' ' ' ARG . . . . . 0.825 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 94.1 mtt180 -76.28 132.99 40.17 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.11 -0.95 . . . . 0.0 110.995 177.929 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' MET . . . . . 0.429 ' HE3' HG12 ' A' ' 109' ' ' VAL . 87.5 mmm -70.77 -22.42 62.39 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.119 176.812 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . 0.825 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 10.3 pt-20 -66.0 -13.93 60.74 Favored 'General case' 0 CA--C 1.532 0.282 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.823 179.865 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.606 HD13 HG11 ' A' ' 75' ' ' VAL . 66.7 mt -93.25 -40.02 11.51 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-O 121.06 0.457 . . . . 0.0 110.846 -179.346 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . 0.777 ' HE2' ' HB2' ' A' ' 82' ' ' PRO . 99.0 m-85 -80.04 -28.76 39.25 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.322 -176.872 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 30.5 mtt-85 -61.7 120.75 11.24 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 121.045 0.45 . . . . 0.0 111.222 179.598 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 109.39 -2.44 31.0 Favored Glycine 0 N--CA 1.446 -0.637 0 CA-C-N 115.607 -0.724 . . . . 0.0 111.872 -177.896 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . 0.52 ' HA ' ' HB2' ' A' ' 38' ' ' ARG . . . -90.5 143.16 27.02 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.738 0.304 . . . . 0.0 110.594 178.162 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -88.52 -28.02 21.06 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.624 -179.505 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . 0.517 ' HG ' ' HB3' ' A' ' 116' ' ' ARG . 6.8 tt -149.5 143.14 25.45 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.052 -177.019 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.569 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 68.0 mt -133.36 119.42 35.02 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 N-CA-C 109.432 -0.581 . . . . 0.0 109.432 178.36 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 94' ' ' TYR . . . . . 0.433 ' CD1' HD13 ' A' ' 29' ' ' ILE . 47.7 p90 -124.58 158.59 32.65 Favored 'General case' 0 C--N 1.321 -0.664 0 C-N-CA 120.219 -0.593 . . . . 0.0 110.823 177.976 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 14.2 m -126.62 125.98 42.83 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.795 -0.638 . . . . 0.0 110.715 -176.847 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 54.2 mt -94.52 97.13 6.55 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.089 -179.672 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 97' ' ' ARG . . . . . 0.419 HH11 ' HD3' ' A' ' 97' ' ' ARG . 7.7 ttm180 59.91 73.46 0.65 Allowed Pre-proline 0 CA--C 1.533 0.295 0 CA-C-N 115.494 -0.776 . . . . 0.0 110.87 -179.028 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_endo -85.64 137.71 5.87 Favored 'Trans proline' 0 N--CA 1.458 -0.57 0 C-N-CA 122.529 2.153 . . . . 0.0 112.775 -179.302 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 32.8 Cg_endo -67.36 163.05 36.06 Favored 'Trans proline' 0 C--O 1.234 0.307 0 C-N-CA 122.685 2.256 . . . . 0.0 112.182 175.441 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -85.61 36.21 0.64 Allowed 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.959 -177.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 101' ' ' GLU . . . . . 0.439 ' HG3' HG22 ' A' ' 102' ' ' ILE . 11.7 pt-20 -117.63 -10.96 10.48 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 121.156 0.503 . . . . 0.0 110.47 175.482 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.572 ' O ' ' HG ' ' A' ' 106' ' ' LEU . 20.8 pt -129.49 9.11 2.48 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.96 -178.184 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 103' ' ' HIS . . . . . . . . . . . . . 8.8 p-80 -55.28 -56.39 20.62 Favored 'General case' 0 C--N 1.316 -0.851 0 CA-C-N 115.505 -0.771 . . . . 0.0 112.31 -174.969 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 31.5 t -76.23 -26.16 55.77 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 121.112 0.482 . . . . 0.0 109.999 179.128 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.517 ' O ' HG23 ' A' ' 109' ' ' VAL . 6.5 m -66.21 -42.73 88.33 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.204 -178.433 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . 0.647 HD22 HG11 ' A' ' 42' ' ' VAL . 82.2 mt -61.32 -41.49 97.1 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.838 -0.619 . . . . 0.0 111.259 179.205 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 107' ' ' MET . . . . . 0.405 ' HA ' HD21 ' A' ' 117' ' ' LEU . 45.5 mtp -65.29 -42.01 93.55 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.229 -178.926 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 16.7 ptm180 -73.32 -22.94 60.21 Favored 'General case' 0 C--N 1.332 -0.183 0 C-N-CA 120.976 -0.29 . . . . 0.0 111.462 -178.907 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.517 HG23 ' O ' ' A' ' 105' ' ' SER . 73.2 t -76.15 -46.46 33.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 N-CA-C 110.235 -0.283 . . . . 0.0 110.235 175.573 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -57.18 -50.16 73.7 Favored 'General case' 0 CA--C 1.517 -0.324 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.022 176.46 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . 0.419 ' HA ' ' HB3' ' A' ' 148' ' ' ALA . 16.3 t70 -59.54 -34.16 72.31 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.459 -0.791 . . . . 0.0 111.038 -178.565 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -70.73 -46.46 63.0 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.837 -178.708 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 33.6 m -84.67 -27.88 6.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 C-N-CA 121.0 -0.28 . . . . 0.0 111.624 -176.127 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 93.41 38.05 5.43 Favored Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 120.697 -0.764 . . . . 0.0 112.475 179.548 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -114.14 149.82 35.07 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.039 0.447 . . . . 0.0 111.093 -179.059 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 116' ' ' ARG . . . . . 0.517 ' HB3' ' HG ' ' A' ' 92' ' ' LEU . 19.8 ttt180 -71.38 116.17 11.39 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.725 -0.67 . . . . 0.0 109.803 179.321 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . 0.569 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 62.2 tp -88.53 120.43 29.9 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 116.034 -0.53 . . . . 0.0 109.968 -179.517 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 71.0 mt -121.52 114.94 44.99 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 CA-C-O 121.16 0.505 . . . . 0.0 110.363 179.233 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 51.0 mt -112.77 121.27 64.73 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.761 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.55 -179.379 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 1.6 tmtp? -109.99 95.33 20.51 Favored Pre-proline 0 C--N 1.322 -0.614 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 173.503 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 121' ' ' PRO . . . . . 0.419 ' HB2' ' HB3' ' A' ' 125' ' ' GLU . 88.7 Cg_endo -89.02 -161.95 0.12 Allowed 'Trans proline' 0 N--CA 1.454 -0.839 0 C-N-CA 122.998 2.465 . . . . 0.0 112.244 179.997 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 122' ' ' LEU . . . . . 0.85 ' HB2' ' HB2' ' A' ' 125' ' ' GLU . 10.3 mp -83.53 168.14 16.72 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.987 -0.552 . . . . 0.0 110.391 179.65 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 123' ' ' THR . . . . . 0.437 ' HA ' ' HH ' ' A' ' 142' ' ' TYR . 3.9 m -59.91 -32.05 70.39 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.546 -176.86 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -125.43 38.84 2.19 Favored Glycine 0 N--CA 1.452 -0.245 0 C-N-CA 120.711 -0.756 . . . . 0.0 111.844 177.756 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . 0.85 ' HB2' ' HB2' ' A' ' 122' ' ' LEU . 6.0 tp10 -110.5 118.01 35.11 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 120.696 0.284 . . . . 0.0 110.267 -176.104 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -84.69 167.77 15.87 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.137 0.494 . . . . 0.0 111.014 179.007 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 85.7 mt . . . . . 0 C--N 1.325 -0.477 0 CA-C-N 115.609 -0.723 . . . . 0.0 110.55 -178.407 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 132' ' ' LYS . . . . . 0.59 ' HD3' ' H ' ' A' ' 132' ' ' LYS . 0.0 OUTLIER . . . . . 0 N--CA 1.465 0.313 0 CA-C-O 121.134 0.492 . . . . 0.0 112.024 . . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 133' ' ' MET . . . . . 0.511 ' HG2' ' HB2' ' A' ' 146' ' ' TYR . 86.0 mtp -148.46 162.19 40.11 Favored 'General case' 0 C--N 1.314 -0.949 0 N-CA-C 107.994 -1.113 . . . . 0.0 107.994 173.272 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . 0.529 ' HG3' ' HG2' ' A' ' 145' ' ' GLU . 13.1 ptmm? -126.36 133.1 51.42 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-O 120.956 0.408 . . . . 0.0 111.21 -176.899 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . 0.785 HD11 ' HD2' ' A' ' 142' ' ' TYR . 55.6 tp -84.38 121.16 27.16 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.023 -179.662 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -116.77 149.98 18.87 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.598 -177.334 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 10.5 m120 -116.29 125.82 52.7 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 177.584 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 34.4 t80 -138.27 130.79 29.18 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 109.565 -0.532 . . . . 0.0 109.565 176.239 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 72.03 -87.75 0.48 Allowed Glycine 0 N--CA 1.443 -0.837 0 N-CA-C 110.681 -0.967 . . . . 0.0 110.681 -174.428 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 140' ' ' ARG . . . . . 0.705 ' HA ' ' NE ' ' A' ' 140' ' ' ARG . 2.0 mmp_? -156.53 14.61 0.3 Allowed 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.423 -0.388 . . . . 0.0 110.75 174.346 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 11.2 t -113.98 154.95 26.75 Favored 'General case' 0 N--CA 1.448 -0.57 0 CA-C-N 116.33 -0.395 . . . . 0.0 109.948 179.035 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 142' ' ' TYR . . . . . 0.785 ' HD2' HD11 ' A' ' 135' ' ' LEU . 14.7 p90 -122.86 138.11 54.75 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 121.042 0.449 . . . . 0.0 110.36 -179.875 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 143' ' ' PHE . . . . . 0.414 ' O ' HD13 ' A' ' 135' ' ' LEU . 12.4 p90 -146.85 162.34 38.85 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-N 115.562 -0.745 . . . . 0.0 110.146 -177.238 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 96.3 m-85 -101.04 122.53 43.71 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 116.429 -0.351 . . . . 0.0 110.294 -179.447 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 145' ' ' GLU . . . . . 0.529 ' HG2' ' HG3' ' A' ' 134' ' ' LYS . 11.5 pt-20 -113.37 156.77 22.84 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 121.086 0.47 . . . . 0.0 110.036 177.522 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . 0.511 ' HB2' ' HG2' ' A' ' 133' ' ' MET . 41.7 t80 -141.91 124.47 15.83 Favored 'General case' 0 C--N 1.314 -0.969 0 CA-C-N 115.493 -0.776 . . . . 0.0 109.659 176.833 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 3.7 mp -93.0 101.37 12.55 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.88 0 N-CA-C 109.596 -0.52 . . . . 0.0 109.596 -177.63 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . 0.419 ' HB3' ' HA ' ' A' ' 111' ' ' ASP . . . -69.91 108.59 4.07 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 108.57 -0.9 . . . . 0.0 108.57 172.717 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 40.6 mt-10 . . . . . 0 C--N 1.321 -0.661 0 CA-C-O 122.04 0.924 . . . . 0.0 112.424 -170.762 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 95.4 m95 . . . . . 0 C--O 1.232 0.175 0 CA-C-O 121.046 0.45 . . . . 0.0 110.677 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . 0.424 ' O ' HG22 ' A' ' 27' ' ' VAL . 2.7 t-20 -68.26 -37.74 81.06 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.205 -179.555 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.415 ' HB3' ' HD2' ' A' ' 138' ' ' TYR . 44.0 m-20 -61.61 -43.28 99.16 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.279 -0.418 . . . . 0.0 110.389 179.392 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.474 HD23 ' HD3' ' A' ' 120' ' ' LYS . 61.9 tp -58.16 -50.07 74.78 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.305 178.241 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . 0.406 ' O ' HG13 ' A' ' 30' ' ' ILE . . . -55.76 -51.78 66.22 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.876 179.049 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.424 HG22 ' O ' ' A' ' 23' ' ' ASN . 96.7 t -57.04 -43.89 81.93 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.221 179.42 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 52.2 t80 -58.18 -48.63 79.71 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.861 0.363 . . . . 0.0 110.265 178.684 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.406 HG13 ' O ' ' A' ' 25' ' ' LEU . 81.7 mt -60.81 -42.67 93.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.486 178.904 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.406 HG13 ' O ' ' A' ' 26' ' ' ALA . 90.8 mt -58.15 -41.86 81.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.123 179.118 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 63.0 mtp180 -69.05 -35.07 76.16 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.076 0.465 . . . . 0.0 111.295 -179.654 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.409 ' SG ' HD12 ' A' ' 92' ' ' LEU . 48.3 t -81.37 -25.95 35.88 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.98 -0.555 . . . . 0.0 111.512 -175.509 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 20.8 p -93.56 -81.93 0.36 Allowed 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 111.851 0.315 . . . . 0.0 111.851 -174.92 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.408 ' O ' HG21 ' A' ' 37' ' ' THR . . . 107.22 168.19 22.12 Favored Glycine 0 N--CA 1.449 -0.476 0 N-CA-C 111.384 -0.686 . . . . 0.0 111.384 -175.158 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 71.0 Cg_endo -76.77 145.96 26.1 Favored 'Trans proline' 0 N--CA 1.464 -0.26 0 C-N-CA 122.32 2.013 . . . . 0.0 112.801 -178.769 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 91.75 -20.34 42.64 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.876 -0.678 . . . . 0.0 113.602 175.22 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' THR . . . . . 0.408 HG21 ' O ' ' A' ' 34' ' ' GLY . 14.7 t -92.06 178.85 5.75 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 117.115 0.457 . . . . 0.0 110.011 -179.08 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' ARG . . . . . 0.497 ' HA ' ' O ' ' A' ' 61' ' ' ASP . 0.1 OUTLIER -111.81 136.06 51.59 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-O 120.967 0.413 . . . . 0.0 111.351 -176.239 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 62.3 t -126.22 117.27 48.15 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 N-CA-C 108.997 -0.742 . . . . 0.0 108.997 173.836 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.511 HG21 ' HB ' ' A' ' 63' ' ' VAL . 40.9 t -103.13 128.86 55.73 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-O 120.999 0.428 . . . . 0.0 111.703 -173.176 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . 0.616 ' HB3' HD22 ' A' ' 64' ' ' LEU . 21.7 tp10 -105.22 127.41 52.91 Favored 'General case' 0 C--O 1.24 0.569 0 CA-C-N 115.606 -0.724 . . . . 0.0 109.991 174.377 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.467 ' HB ' ' OG ' ' A' ' 95' ' ' SER . 59.0 t -93.57 89.95 2.79 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 CA-C-N 115.976 -0.557 . . . . 0.0 110.235 179.816 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 121.18 120.83 2.75 Favored Glycine 0 N--CA 1.443 -0.837 0 CA-C-N 115.662 -0.699 . . . . 0.0 111.505 -175.201 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . 0.608 ' HB2' HD22 ' A' ' 48' ' ' LEU . . . -110.59 -57.98 2.15 Favored 'General case' 0 C--N 1.321 -0.668 0 O-C-N 122.399 -0.471 . . . . 0.0 111.047 -177.198 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 52.72 -118.67 8.21 Favored Glycine 0 CA--C 1.519 0.317 0 C-N-CA 121.085 -0.579 . . . . 0.0 112.693 -178.707 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 65.2 mtp180 -134.52 14.61 3.74 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.827 0.346 . . . . 0.0 111.264 -179.669 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 21.8 p90 -103.52 35.19 2.67 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.369 0.604 . . . . 0.0 110.553 -178.298 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . 0.608 HD22 ' HB2' ' A' ' 44' ' ' ALA . 94.5 mt -76.13 13.43 0.9 Allowed 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.484 -0.78 . . . . 0.0 112.569 -173.963 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 42.2 p90 -67.62 -26.45 66.25 Favored 'General case' 0 C--N 1.324 -0.509 0 C-N-CA 120.713 -0.395 . . . . 0.0 110.454 177.02 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.421 ' O ' HG13 ' A' ' 54' ' ' ILE . 54.0 t -68.72 -54.5 20.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.439 176.407 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 7.3 p -62.51 -46.78 86.85 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.847 -176.134 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -70.66 -27.55 64.13 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.569 -176.328 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 82.9 t80 -68.74 -46.65 68.33 Favored 'General case' 0 C--N 1.328 -0.346 0 C-N-CA 120.783 -0.367 . . . . 0.0 110.443 176.291 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.421 HG13 ' O ' ' A' ' 50' ' ' VAL . 77.9 mt -59.15 -45.79 92.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.385 -176.824 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 6.9 ptp180 -71.76 -16.48 62.2 Favored 'General case' 0 C--O 1.236 0.39 0 CA-C-O 120.893 0.378 . . . . 0.0 111.499 -179.111 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 8.3 mtpm? -83.7 -21.8 32.24 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.861 0.362 . . . . 0.0 111.566 177.618 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 11.8 t60 -103.16 -43.02 5.58 Favored 'General case' 0 N--CA 1.445 -0.69 0 CA-C-O 121.01 0.433 . . . . 0.0 109.863 -178.143 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 9.1 t -120.09 144.08 47.8 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 109.202 -0.666 . . . . 0.0 109.202 178.336 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . 0.44 ' HD3' ' HA ' ' A' ' 59' ' ' LYS . 6.1 tppt? -89.25 58.15 4.34 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 122.11 0.957 . . . . 0.0 110.332 -179.459 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 7.6 p -94.97 145.53 8.02 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.817 0 CA-C-N 114.41 -1.268 . . . . 0.0 109.677 175.564 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . 0.497 ' O ' ' HA ' ' A' ' 38' ' ' ARG . 25.6 t70 -84.62 93.46 8.39 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 179.278 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 4.6 tt -89.86 120.17 30.87 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.67 -176.192 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.511 ' HB ' HG21 ' A' ' 40' ' ' VAL . 47.8 t -103.91 122.51 56.75 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.653 0 CA-C-N 115.674 -0.694 . . . . 0.0 110.493 -174.721 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . 0.616 HD22 ' HB3' ' A' ' 41' ' ' GLU . 41.6 mt -99.55 133.43 43.89 Favored 'General case' 0 C--N 1.316 -0.889 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 176.575 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.407 HG23 ' HB ' ' A' ' 75' ' ' VAL . 13.0 p -125.73 124.04 40.18 Favored 'General case' 0 C--N 1.317 -0.813 0 N-CA-C 110.048 -0.353 . . . . 0.0 110.048 176.544 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 39.2 t0 -170.36 172.01 6.34 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -175.712 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . 0.656 HG23 ' HG2' ' A' ' 68' ' ' LYS . 26.0 mm -73.67 129.83 36.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.073 -179.709 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' LYS . . . . . 0.656 ' HG2' HG23 ' A' ' 67' ' ' ILE . 19.6 pttp 38.71 90.32 0.07 OUTLIER Pre-proline 0 N--CA 1.476 0.837 0 O-C-N 124.247 0.967 . . . . 0.0 113.278 178.933 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . 0.949 ' HB3' ' HB ' ' A' ' 74' ' ' ILE . 4.9 Cg_endo . . . . . 0 C--N 1.346 0.395 0 C-N-CA 123.875 3.05 . . . . 0.0 113.202 179.534 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . 0.949 ' HB ' ' HB3' ' A' ' 69' ' ' PRO . 56.1 mt . . . . . 0 N--CA 1.447 -0.61 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.502 HG11 HD13 ' A' ' 86' ' ' ILE . 91.2 t -76.04 132.09 33.72 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 176.369 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 9.8 ptp180 -79.3 21.14 0.48 Allowed 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 120.987 0.422 . . . . 0.0 111.371 -175.967 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . 0.486 ' HB2' HG13 ' A' ' 75' ' ' VAL . 6.1 t70 -83.48 112.49 20.01 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 109.615 -0.513 . . . . 0.0 109.615 -176.385 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 10.7 p-10 -70.87 142.21 51.2 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 121.426 0.632 . . . . 0.0 111.444 -174.055 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 6.9 tp -66.77 -21.95 29.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.367 -0.833 . . . . 0.0 112.345 -173.66 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 10.2 t -90.05 -0.54 57.64 Favored 'General case' 0 C--N 1.322 -0.626 0 C-N-CA 120.274 -0.571 . . . . 0.0 110.492 -178.801 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' SER . . . . . 0.417 ' N ' ' HD3' ' A' ' 82' ' ' PRO . 4.9 m -148.24 46.58 0.46 Allowed Pre-proline 0 CA--C 1.538 0.505 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.883 177.421 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' PRO . . . . . 0.417 ' HA ' ' OD2' ' A' ' 77' ' ' ASP . 93.3 Cg_endo -81.23 149.45 17.17 Favored 'Trans proline' 0 C--N 1.352 0.711 0 C-N-CA 122.287 1.992 . . . . 0.0 113.174 -169.01 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 83' ' ' ARG . . . . . 0.482 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 73.1 mtp85 -96.36 125.22 40.71 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.82 -0.627 . . . . 0.0 111.061 177.222 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 84' ' ' MET . . . . . 0.501 ' HE2' HG11 ' A' ' 109' ' ' VAL . 91.3 mmm -63.92 -20.02 65.54 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.678 -0.692 . . . . 0.0 111.296 -179.314 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . 0.482 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 11.0 pt-20 -69.81 -16.65 63.31 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.506 -176.451 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.502 HD13 HG11 ' A' ' 75' ' ' VAL . 70.4 mt -85.23 -36.14 10.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 121.298 0.571 . . . . 0.0 109.963 178.154 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 99.2 m-85 -80.59 -31.85 36.61 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.865 -178.73 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . 0.412 ' HG3' HG13 ' A' ' 113' ' ' VAL . 23.3 mtp85 -64.07 119.61 10.47 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-O 121.142 0.496 . . . . 0.0 110.795 179.259 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 115.65 -17.21 16.08 Favored Glycine 0 N--CA 1.444 -0.805 0 CA-C-N 115.44 -0.8 . . . . 0.0 111.557 -177.739 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -73.38 144.55 46.39 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.83 0.348 . . . . 0.0 110.769 179.052 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -88.94 -25.66 21.95 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 121.27 0.557 . . . . 0.0 110.142 178.093 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . 0.475 HD21 ' N ' ' A' ' 93' ' ' ILE . 4.7 tt -150.86 141.09 22.26 Favored 'General case' 0 N--CA 1.448 -0.559 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.409 -177.136 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 93' ' ' ILE . . . . . 0.54 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 61.2 mt -130.58 128.14 63.06 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.187 177.226 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -136.88 169.69 17.35 Favored 'General case' 0 C--N 1.318 -0.781 0 C-N-CA 120.786 -0.366 . . . . 0.0 110.117 -179.074 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 95' ' ' SER . . . . . 0.614 ' HB2' ' HG3' ' A' ' 98' ' ' PRO . 7.1 m -152.07 123.08 7.57 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.346 178.901 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 96' ' ' ILE . . . . . 0.731 HG21 ' HG2' ' A' ' 97' ' ' ARG . 2.3 mp -73.37 114.94 13.6 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-N 116.3 -0.409 . . . . 0.0 109.907 174.771 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 97' ' ' ARG . . . . . 0.731 ' HG2' HG21 ' A' ' 96' ' ' ILE . 13.6 ptt180 43.54 76.27 0.55 Allowed Pre-proline 0 N--CA 1.472 0.668 0 C-N-CA 124.376 1.071 . . . . 0.0 113.17 177.41 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 98' ' ' PRO . . . . . 0.614 ' HG3' ' HB2' ' A' ' 95' ' ' SER . 12.8 Cg_endo -90.07 146.54 4.52 Favored 'Trans proline' 0 N--CA 1.453 -0.909 0 C-N-CA 122.583 2.189 . . . . 0.0 111.889 175.689 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . 0.526 ' HD2' HD12 ' A' ' 102' ' ' ILE . 32.2 Cg_exo -61.05 140.37 89.43 Favored 'Trans proline' 0 C--N 1.344 0.34 0 C-N-CA 122.492 2.128 . . . . 0.0 111.991 177.483 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -79.74 30.85 0.25 Allowed 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 121.101 0.477 . . . . 0.0 111.805 -174.871 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 101' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -122.2 -6.89 8.84 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.812 178.614 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.526 HD12 ' HD2' ' A' ' 99' ' ' PRO . 30.8 pt -120.25 8.53 6.37 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 120.907 0.384 . . . . 0.0 111.163 -179.021 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 103' ' ' HIS . . . . . 0.452 ' O ' ' HG2' ' A' ' 107' ' ' MET . 44.7 p-80 -60.82 -40.06 91.31 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.373 -177.149 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 23.3 m -61.75 -29.58 70.22 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.861 0.362 . . . . 0.0 111.016 178.749 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.519 ' O ' HG22 ' A' ' 109' ' ' VAL . 19.3 m -75.61 -38.29 59.13 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.079 178.518 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 94.5 mt -69.14 -41.7 76.98 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.953 179.6 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 107' ' ' MET . . . . . 0.452 ' HG2' ' O ' ' A' ' 103' ' ' HIS . 94.9 mmm -57.38 -47.53 81.44 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.804 -0.634 . . . . 0.0 111.535 -179.281 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 6.7 ptp85 -66.96 -31.74 72.51 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.578 -0.283 . . . . 0.0 111.608 -178.186 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.519 HG22 ' O ' ' A' ' 105' ' ' SER . 76.3 t -66.7 -47.93 81.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 C-N-CA 121.115 -0.234 . . . . 0.0 110.897 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -57.98 -46.27 85.44 Favored 'General case' 0 CA--C 1.518 -0.286 0 CA-C-N 116.515 -0.311 . . . . 0.0 110.641 179.853 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 17.8 t70 -67.73 -36.21 80.16 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.783 -178.599 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -65.43 -43.25 91.06 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.65 -179.843 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.412 HG13 ' HG3' ' A' ' 88' ' ' ARG . 18.6 m -88.22 -30.09 5.46 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.537 -175.912 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 91.41 51.63 2.5 Favored Glycine 0 N--CA 1.448 -0.554 0 C-N-CA 120.596 -0.811 . . . . 0.0 112.15 -178.856 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -132.0 157.6 43.67 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.906 0.384 . . . . 0.0 110.879 -179.424 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 116' ' ' ARG . . . . . 0.67 ' HD3' ' OE1' ' A' ' 145' ' ' GLU . 12.5 ttm180 -78.58 123.22 26.86 Favored 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 109.569 -0.53 . . . . 0.0 109.569 177.163 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . 0.54 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 57.3 tp -94.12 118.9 32.19 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 116.179 -0.464 . . . . 0.0 109.947 -179.553 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 59.7 mt -114.39 115.06 48.45 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 CA-C-O 121.32 0.581 . . . . 0.0 110.807 179.654 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 53.5 mt -122.52 118.62 55.77 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.953 -179.249 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 120' ' ' LYS . . . . . 0.526 ' HB3' ' HB3' ' A' ' 143' ' ' PHE . 0.6 OUTLIER -118.81 101.74 50.11 Favored Pre-proline 0 C--N 1.319 -0.722 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 169.759 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 121' ' ' PRO . . . . . 0.478 ' HA ' ' HA ' ' A' ' 97' ' ' ARG . 96.6 Cg_endo -80.04 -161.95 0.17 Allowed 'Trans proline' 0 N--CA 1.461 -0.438 0 C-N-CA 122.902 2.401 . . . . 0.0 112.425 -176.658 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 122' ' ' LEU . . . . . 0.672 ' HB2' ' HB2' ' A' ' 125' ' ' GLU . 3.0 mm? -65.31 150.08 48.87 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.929 -0.578 . . . . 0.0 109.977 178.162 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 23.2 m -68.28 -25.82 65.35 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.119 -0.491 . . . . 0.0 112.005 -171.246 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -105.67 1.64 39.25 Favored Glycine 0 N--CA 1.453 -0.233 0 C-N-CA 120.095 -1.05 . . . . 0.0 112.694 -179.563 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . 0.672 ' HB2' ' HB2' ' A' ' 122' ' ' LEU . 1.6 mp0 -105.79 -170.28 1.71 Allowed 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.239 0.542 . . . . 0.0 111.401 -173.595 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 16.8 t70 -143.99 171.53 14.13 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 115.147 -0.933 . . . . 0.0 108.846 179.18 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 39.1 mt . . . . . 0 C--N 1.325 -0.488 0 CA-C-O 121.048 0.451 . . . . 0.0 110.24 179.655 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 30.8 mmmt . . . . . 0 N--CA 1.454 -0.24 0 CA-C-O 121.122 0.487 . . . . 0.0 110.1 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 133' ' ' MET . . . . . 0.513 ' HG2' ' HB2' ' A' ' 146' ' ' TYR . 79.4 mtp -114.4 170.12 8.53 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.56 -0.746 . . . . 0.0 110.195 -176.311 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 134' ' ' LYS . . . . . 0.418 ' HG3' ' HG2' ' A' ' 145' ' ' GLU . 18.8 ptmt -121.75 134.07 54.93 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.815 -178.591 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . 0.533 HD11 ' HD2' ' A' ' 142' ' ' TYR . 60.0 tp -82.75 122.39 28.12 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 120.932 0.396 . . . . 0.0 110.537 178.223 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -118.16 147.04 21.87 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.355 179.84 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 13.4 m120 -124.18 96.94 5.12 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 109.416 -0.587 . . . . 0.0 109.416 -179.666 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . 0.415 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 64.1 t80 -104.42 109.1 20.83 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.272 -175.172 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 72.71 -82.08 0.61 Allowed Glycine 0 N--CA 1.45 -0.392 0 CA-C-N 115.768 -0.651 . . . . 0.0 111.832 179.875 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 140' ' ' ARG . . . . . 0.401 ' HD3' ' HA ' ' A' ' 140' ' ' ARG . 16.3 mmt180 -141.36 -7.43 1.01 Allowed 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 115.477 -0.362 . . . . 0.0 111.109 177.08 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 3.4 t -99.17 135.82 40.03 Favored 'General case' 0 N--CA 1.446 -0.637 0 CA-C-O 121.279 0.561 . . . . 0.0 110.083 -179.229 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 142' ' ' TYR . . . . . 0.533 ' HD2' HD11 ' A' ' 135' ' ' LEU . 27.0 p90 -114.06 144.22 43.48 Favored 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 176.193 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 143' ' ' PHE . . . . . 0.526 ' HB3' ' HB3' ' A' ' 120' ' ' LYS . 23.7 p90 -157.25 162.77 39.24 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.556 -178.854 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 87.1 m-85 -100.93 118.3 36.69 Favored 'General case' 0 C--N 1.314 -0.949 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 175.177 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 145' ' ' GLU . . . . . 0.67 ' OE1' ' HD3' ' A' ' 116' ' ' ARG . 11.5 pt-20 -110.0 155.17 22.15 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-O 121.321 0.581 . . . . 0.0 109.695 178.701 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . 0.513 ' HB2' ' HG2' ' A' ' 133' ' ' MET . 32.4 t80 -137.39 123.81 20.76 Favored 'General case' 0 C--N 1.307 -1.259 0 CA-C-N 115.498 -0.774 . . . . 0.0 109.382 176.493 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 147' ' ' ILE . . . . . 0.44 ' N ' HD12 ' A' ' 147' ' ' ILE . 3.3 mp -94.36 103.79 15.07 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.799 0 CA-C-N 116.111 -0.495 . . . . 0.0 109.932 -177.621 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -68.37 119.3 12.66 Favored 'General case' 0 N--CA 1.443 -0.783 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 171.358 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 . . . . . 0 C--N 1.322 -0.593 0 CA-C-O 121.121 0.486 . . . . 0.0 110.3 -177.363 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.7 mpt? . . . . . 0 N--CA 1.479 1.014 0 N-CA-C 110.453 -0.203 . . . . 0.0 110.453 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 79.56 165.05 29.89 Favored Glycine 0 N--CA 1.448 -0.559 0 C-N-CA 120.846 -0.693 . . . . 0.0 113.045 176.857 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 58.7 m -132.79 128.1 36.02 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 120.901 0.381 . . . . 0.0 110.167 175.436 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 21.6 m -102.99 23.45 12.26 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 121.291 0.567 . . . . 0.0 110.538 -178.345 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 48.8 m80 -95.9 80.45 3.34 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.722 177.879 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 30.2 p-80 -100.9 107.13 18.57 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.887 -0.597 . . . . 0.0 109.719 174.66 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 95.6 m-70 -88.35 88.91 7.78 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 121.296 0.569 . . . . 0.0 110.814 -175.818 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 35.2 m-70 -108.9 112.27 24.41 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.219 -0.9 . . . . 0.0 109.869 176.486 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 4.4 p-80 -141.35 46.01 1.72 Allowed 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.304 -179.507 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 81.6 m-70 -67.76 98.44 0.71 Allowed 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.662 -0.699 . . . . 0.0 109.873 179.586 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 11.3 p -158.83 127.38 5.3 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.764 -174.669 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 17.3 t -84.95 107.29 17.02 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 109.365 -0.605 . . . . 0.0 109.365 177.216 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -80.77 72.22 2.74 Favored Glycine 0 N--CA 1.448 -0.564 0 C-N-CA 121.173 -0.537 . . . . 0.0 112.973 -175.456 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 87.4 mt -105.14 105.16 15.08 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-O 121.164 0.507 . . . . 0.0 109.773 174.644 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 7.7 m -118.6 116.27 35.0 Favored Pre-proline 0 C--N 1.317 -0.812 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.796 -177.684 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -62.32 126.79 19.33 Favored 'Trans proline' 0 N--CA 1.461 -0.433 0 C-N-CA 122.528 2.152 . . . . 0.0 112.693 -179.026 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 18.3 ptt180 -91.19 -176.36 4.56 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 115.131 -0.94 . . . . 0.0 110.066 -179.626 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 82.17 0.85 90.1 Favored Glycine 0 N--CA 1.449 -0.487 0 C-N-CA 120.396 -0.907 . . . . 0.0 111.074 -176.299 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 1.9 p -85.3 45.03 1.14 Allowed 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 121.324 0.583 . . . . 0.0 110.649 -179.701 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 71.8 m-70 -60.95 -37.97 84.24 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.482 -0.781 . . . . 0.0 110.576 -177.822 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' MET . . . . . . . . . . . . . 66.2 mtt -70.66 -15.57 62.74 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.821 -179.318 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 75.6 m95 -95.63 -18.84 20.21 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.457 178.738 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 23.9 t-20 -58.04 -52.74 64.29 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.354 -176.762 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.478 ' HB3' ' HD2' ' A' ' 138' ' ' TYR . 6.0 m-20 -59.14 -35.48 73.57 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.344 -179.489 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 61.6 tp -58.38 -47.63 83.25 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.331 178.481 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -61.34 -47.52 85.54 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.909 178.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.556 ' HA ' HD12 ' A' ' 30' ' ' ILE . 58.0 t -58.13 -43.97 86.55 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.162 0 CA-C-O 120.955 0.407 . . . . 0.0 110.83 179.82 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 68.4 t80 -56.0 -47.47 77.68 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.736 -0.665 . . . . 0.0 110.487 178.819 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.502 HG21 HD11 ' A' ' 92' ' ' LEU . 77.6 mt -63.37 -42.63 97.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.731 179.022 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.556 HD12 ' HA ' ' A' ' 27' ' ' VAL . 83.1 mt -56.26 -44.23 78.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.482 -0.781 . . . . 0.0 111.05 178.39 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . 0.465 ' HG3' ' O ' ' A' ' 27' ' ' VAL . 81.8 mtp180 -70.29 -30.34 67.31 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.959 -177.354 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 74.3 m -75.58 -29.89 59.46 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.213 -178.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 22.3 p -112.67 -97.4 0.43 Allowed 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.532 -0.303 . . . . 0.0 111.336 -178.876 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 113.81 -178.96 18.66 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.993 -0.622 . . . . 0.0 112.037 -178.03 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 10.6 Cg_exo -71.05 150.36 60.21 Favored 'Trans proline' 0 C--O 1.234 0.292 0 C-N-CA 122.932 2.421 . . . . 0.0 112.222 -179.412 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 84.93 41.94 7.38 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.831 -0.699 . . . . 0.0 112.86 179.257 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 14.6 t -168.65 -178.64 3.51 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 177.137 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 66.9 mtp85 -114.67 136.08 53.45 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 120.711 0.291 . . . . 0.0 111.082 -178.433 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.888 ' HB ' HD22 ' A' ' 62' ' ' LEU . 40.2 t -124.06 132.11 71.86 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 N-CA-C 108.914 -0.772 . . . . 0.0 108.914 173.47 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.414 HG11 ' CD1' ' A' ' 87' ' ' TYR . 62.0 t -105.79 124.22 60.76 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 C-N-CA 120.87 -0.332 . . . . 0.0 111.246 -175.939 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . 0.4 ' OE1' HD23 ' A' ' 64' ' ' LEU . 44.9 tt0 -103.59 109.47 21.16 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.931 -0.577 . . . . 0.0 109.852 176.583 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.539 HG13 HD22 ' A' ' 106' ' ' LEU . 47.0 t -96.65 132.99 39.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 115.947 -0.569 . . . . 0.0 109.954 179.707 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 87.12 20.48 52.81 Favored Glycine 0 N--CA 1.447 -0.613 0 C-N-CA 120.474 -0.87 . . . . 0.0 111.811 -178.637 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . 0.438 ' HB3' ' CD2' ' A' ' 48' ' ' LEU . . . -55.81 -68.0 0.24 Allowed 'General case' 0 C--N 1.331 -0.201 0 O-C-N 123.744 0.32 . . . . 0.0 110.253 178.695 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 58.22 -93.05 0.04 OUTLIER Glycine 0 N--CA 1.452 -0.284 0 CA-C-N 115.572 -0.74 . . . . 0.0 114.1 173.06 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . 0.427 HH11 ' HD3' ' A' ' 46' ' ' ARG . 32.7 ttt-85 -126.58 11.24 7.32 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 121.351 0.596 . . . . 0.0 110.571 -172.181 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 59.0 t80 -133.04 97.96 4.15 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 109.529 -0.545 . . . . 0.0 109.529 178.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . 0.708 HD21 HD11 ' A' ' 64' ' ' LEU . 67.1 mt -113.4 24.37 12.3 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.952 -172.278 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 56.8 t80 -64.65 -50.86 65.42 Favored 'General case' 0 C--N 1.329 -0.292 0 C-N-CA 120.928 -0.309 . . . . 0.0 111.781 -176.908 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.476 ' O ' HG13 ' A' ' 54' ' ' ILE . 44.1 t -60.92 -55.47 24.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.559 -0.291 . . . . 0.0 111.011 -173.013 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 10.9 p -56.93 -43.12 81.17 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.975 179.538 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.457 ' HA ' ' HG2' ' A' ' 55' ' ' ARG . 36.7 t70 -64.99 -42.88 94.12 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.728 0.299 . . . . 0.0 110.905 -179.466 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 74.6 t80 -61.11 -42.02 97.75 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.062 0.458 . . . . 0.0 110.341 177.281 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.518 HG22 HG12 ' A' ' 30' ' ' ILE . 86.3 mt -64.61 -49.13 81.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.294 179.21 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . 0.457 ' HG2' ' HA ' ' A' ' 52' ' ' ASP . 40.8 ptt180 -67.96 -18.74 64.83 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-O 120.862 0.363 . . . . 0.0 111.401 -176.05 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 84.6 mttt -84.51 -34.11 23.39 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.828 0.346 . . . . 0.0 110.971 176.104 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.6 OUTLIER -79.85 -33.6 40.05 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.253 178.76 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 70.6 m -141.78 135.95 30.2 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.5 178.063 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 7.6 tmtt? -76.15 64.77 2.03 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.888 0.852 . . . . 0.0 109.378 176.755 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.503 HG22 HG22 ' A' ' 39' ' ' VAL . 8.3 p -95.18 148.2 5.27 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.964 0 CA-C-N 114.727 -1.124 . . . . 0.0 109.118 173.834 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 25.9 t0 -78.91 88.58 4.71 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 121.34 0.59 . . . . 0.0 109.437 -179.808 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . 0.888 HD22 ' HB ' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -82.99 115.12 21.69 Favored 'General case' 0 N--CA 1.448 -0.549 0 CA-C-N 115.532 -0.758 . . . . 0.0 110.1 -177.578 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 45.3 t -103.56 114.73 43.96 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-N 115.462 -0.79 . . . . 0.0 110.081 -177.54 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . 0.708 HD11 HD21 ' A' ' 48' ' ' LEU . 20.1 mt -91.61 135.95 33.49 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-N 115.671 -0.695 . . . . 0.0 109.607 -179.696 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 14.5 p -130.76 128.96 41.83 Favored 'General case' 0 C--N 1.319 -0.723 0 C-N-CA 121.045 -0.262 . . . . 0.0 111.271 -179.074 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 5.8 t70 -171.0 155.34 4.45 Favored 'General case' 0 CA--C 1.519 -0.246 0 N-CA-C 109.371 -0.603 . . . . 0.0 109.371 175.839 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . 0.608 HG23 ' HG2' ' A' ' 68' ' ' LYS . 58.1 mt -78.1 131.2 35.06 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 CA-C-N 116.642 -0.254 . . . . 0.0 110.606 -177.942 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' LYS . . . . . 0.608 ' HG2' HG23 ' A' ' 67' ' ' ILE . 7.9 ptmm? 42.31 71.73 1.31 Allowed Pre-proline 0 N--CA 1.471 0.586 0 O-C-N 124.152 0.908 . . . . 0.0 112.915 179.265 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -78.91 167.15 22.5 Favored 'Trans proline' 0 N--CA 1.463 -0.319 0 C-N-CA 122.549 2.166 . . . . 0.0 112.168 177.768 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 12.6 t -120.49 6.7 10.58 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 121.359 0.599 . . . . 0.0 109.629 179.009 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 79.1 m80 -117.99 131.76 56.45 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.641 -0.709 . . . . 0.0 110.747 -175.504 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -68.12 107.75 2.18 Favored Glycine 0 N--CA 1.45 -0.386 0 CA-C-N 115.822 -0.627 . . . . 0.0 112.223 179.836 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 142.62 -24.65 2.31 Favored Glycine 0 N--CA 1.448 -0.534 0 C-N-CA 120.954 -0.641 . . . . 0.0 111.928 -179.456 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . 0.653 ' HA ' ' HB2' ' A' ' 64' ' ' LEU . 50.6 mt -84.92 125.84 40.33 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-O 120.574 0.226 . . . . 0.0 110.441 -179.823 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.416 HG11 HD11 ' A' ' 86' ' ' ILE . 61.5 t -64.45 116.91 4.29 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 N-CA-C 109.631 -0.507 . . . . 0.0 109.631 176.875 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 16.2 mtt180 -84.48 53.69 2.75 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.679 -0.692 . . . . 0.0 110.432 -175.417 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 2.0 t70 -98.83 -162.36 0.95 Allowed 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 116.307 -0.406 . . . . 0.0 109.972 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . 0.494 ' OD1' HG21 ' A' ' 80' ' ' THR . 11.8 t0 -119.38 146.17 45.57 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 120.773 0.321 . . . . 0.0 111.251 -175.475 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . 0.539 HG22 HD11 ' A' ' 67' ' ' ILE . 10.7 tp -107.96 -20.59 6.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.292 -176.266 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.494 HG21 ' OD1' ' A' ' 78' ' ' ASP . 13.3 t -79.82 -25.06 40.97 Favored 'General case' 0 CA--C 1.529 0.167 0 CA-C-O 121.616 0.722 . . . . 0.0 109.322 178.913 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 23.2 m -132.54 79.86 63.83 Favored Pre-proline 0 C--N 1.322 -0.613 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 166.048 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.405 ' HA ' ' O ' ' A' ' 78' ' ' ASP . 74.2 Cg_endo -74.97 146.15 32.44 Favored 'Trans proline' 0 N--CA 1.462 -0.364 0 C-N-CA 122.799 2.332 . . . . 0.0 112.991 -171.954 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' ARG . . . . . 0.508 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 82.9 mtt180 -94.58 107.92 19.89 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.542 -0.754 . . . . 0.0 110.22 175.845 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' MET . . . . . 0.54 ' HA ' ' HD2' ' A' ' 87' ' ' TYR . 95.3 mmm -59.56 -24.41 63.71 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.587 -0.733 . . . . 0.0 111.571 -176.087 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.508 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 9.4 pt-20 -55.45 -29.56 58.89 Favored 'General case' 0 C--N 1.33 -0.272 0 O-C-N 123.245 0.341 . . . . 0.0 111.415 179.465 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.416 HD11 HG11 ' A' ' 75' ' ' VAL . 64.9 mt -78.52 -35.59 19.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.81 -178.403 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . 0.54 ' HD2' ' HA ' ' A' ' 84' ' ' MET . 49.4 m-85 -85.86 -25.86 25.98 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.209 -175.327 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . 0.609 ' HG2' HG11 ' A' ' 113' ' ' VAL . 81.6 mtp180 -70.35 138.29 51.29 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 121.36 0.6 . . . . 0.0 110.666 -178.553 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 92.92 -1.19 70.51 Favored Glycine 0 C--N 1.317 -0.478 0 CA-C-N 115.11 -0.95 . . . . 0.0 111.993 -176.652 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -86.7 147.64 25.79 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.905 0.383 . . . . 0.0 110.664 178.596 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -91.05 -27.08 18.84 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.801 179.306 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . 0.502 HD11 HG21 ' A' ' 29' ' ' ILE . 6.2 tt -152.35 143.24 22.99 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.143 -177.935 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.564 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 72.3 mt -131.46 122.74 51.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 N-CA-C 109.473 -0.566 . . . . 0.0 109.473 178.547 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 15.1 p90 -129.77 157.89 40.93 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 120.917 0.389 . . . . 0.0 110.883 -178.691 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' SER . . . . . 0.47 ' HA ' ' O ' ' A' ' 42' ' ' VAL . 16.5 m -128.04 128.37 44.85 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.958 -0.564 . . . . 0.0 110.974 -176.731 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 50.6 mm -91.71 106.67 17.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.437 -179.806 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 11.1 tpp180 57.06 69.87 1.55 Allowed Pre-proline 0 CA--C 1.535 0.389 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.071 178.821 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' PRO . . . . . 0.538 ' HG2' HG23 ' A' ' 119' ' ' ILE . 5.6 Cg_endo -87.05 135.69 3.95 Favored 'Trans proline' 0 N--CA 1.455 -0.762 0 C-N-CA 122.799 2.332 . . . . 0.0 112.31 -179.09 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . 0.537 ' HD2' HD12 ' A' ' 102' ' ' ILE . 32.3 Cg_exo -59.12 142.51 99.38 Favored 'Trans proline' 0 C--O 1.236 0.411 0 C-N-CA 122.464 2.11 . . . . 0.0 111.7 174.627 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -76.97 43.01 0.33 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.763 -176.092 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' GLU . . . . . 0.487 ' HG3' HG23 ' A' ' 102' ' ' ILE . 12.0 pt-20 -140.27 -34.45 0.53 Allowed 'General case' 0 N--CA 1.45 -0.472 0 CA-C-N 115.902 -0.59 . . . . 0.0 111.541 178.797 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.537 HD12 ' HD2' ' A' ' 99' ' ' PRO . 45.8 pt -95.56 -0.78 10.62 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.211 0 CA-C-O 120.837 0.351 . . . . 0.0 111.597 -176.53 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' HIS . . . . . 0.531 ' O ' ' HG3' ' A' ' 107' ' ' MET . 41.8 p-80 -55.92 -36.93 68.25 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.932 -0.576 . . . . 0.0 111.303 -178.863 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 6.7 m -60.93 -39.32 88.97 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.0 -179.4 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.559 ' O ' HG23 ' A' ' 109' ' ' VAL . 14.2 m -66.58 -35.37 80.05 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.976 -0.556 . . . . 0.0 109.88 -179.752 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . 0.539 HD22 HG13 ' A' ' 42' ' ' VAL . 96.3 mt -69.91 -41.06 75.19 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.704 -0.68 . . . . 0.0 111.138 -179.676 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' MET . . . . . 0.682 ' HE2' ' HB2' ' A' ' 132' ' ' LYS . 70.0 mtp -62.5 -42.37 99.45 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.813 -0.63 . . . . 0.0 111.487 -177.24 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 14.1 ptm180 -69.54 -29.87 67.56 Favored 'General case' 0 C--N 1.33 -0.261 0 C-N-CA 120.762 -0.375 . . . . 0.0 111.158 -179.572 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.559 HG23 ' O ' ' A' ' 105' ' ' SER . 75.4 t -66.75 -48.69 79.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 C-N-CA 120.933 -0.307 . . . . 0.0 110.56 178.399 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -57.55 -46.25 84.15 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.262 177.676 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.537 ' HA ' ' HB3' ' A' ' 148' ' ' ALA . 12.3 t70 -63.43 -34.37 77.59 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.553 -0.749 . . . . 0.0 110.729 -177.868 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -70.31 -46.97 63.19 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.801 -0.636 . . . . 0.0 111.797 -179.773 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.609 HG11 ' HG2' ' A' ' 88' ' ' ARG . 23.1 m -84.95 -26.28 6.76 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-N 116.416 -0.356 . . . . 0.0 111.811 -173.769 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 89.67 43.18 5.23 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.092 179.468 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -124.1 154.34 40.12 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.668 0.27 . . . . 0.0 110.503 -178.524 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' ARG . . . . . 0.449 ' HD3' ' OE1' ' A' ' 145' ' ' GLU . 14.5 ttm180 -73.95 124.48 26.27 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 178.13 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . 0.564 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 56.1 tp -93.46 121.39 34.81 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.246 -0.434 . . . . 0.0 109.977 178.562 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 67.8 mt -119.12 120.18 63.1 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 CA-C-O 121.321 0.581 . . . . 0.0 110.907 179.435 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 119' ' ' ILE . . . . . 0.538 HG23 ' HG2' ' A' ' 98' ' ' PRO . 14.2 mt -112.68 130.6 66.16 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.674 178.874 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 2.6 tmtm? -106.34 94.71 10.16 Favored Pre-proline 0 C--N 1.323 -0.545 0 N-CA-C 109.287 -0.634 . . . . 0.0 109.287 174.926 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 91.1 Cg_endo -85.67 -162.69 0.16 Allowed 'Trans proline' 0 N--CA 1.46 -0.464 0 C-N-CA 122.749 2.299 . . . . 0.0 112.588 -179.539 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 122' ' ' LEU . . . . . 0.908 ' HB2' ' HB3' ' A' ' 125' ' ' GLU . 9.9 mp -86.15 159.57 19.48 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.45 179.681 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 4.0 p -64.13 -33.72 76.42 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.915 -0.584 . . . . 0.0 111.617 -178.529 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -132.18 43.74 1.26 Allowed Glycine 0 N--CA 1.447 -0.579 0 C-N-CA 120.935 -0.65 . . . . 0.0 112.135 179.824 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . 0.908 ' HB3' ' HB2' ' A' ' 122' ' ' LEU . 34.3 tt0 -145.32 129.23 17.39 Favored 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 110.044 -0.354 . . . . 0.0 110.044 179.274 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -85.41 167.59 15.38 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.605 -175.902 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 35.7 mt -87.0 -21.64 7.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-O 121.084 0.469 . . . . 0.0 110.218 -178.513 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 19.8 t 60.21 65.22 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.233 0 CA-C-O 122.11 0.957 . . . . 0.0 110.126 -177.256 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 129' ' ' THR . . . . . 0.529 ' HB ' ' CD2' ' A' ' 103' ' ' HIS . 12.9 t -138.65 -179.25 5.71 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 115.128 -0.942 . . . . 0.0 109.558 -178.989 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 3.0 mp0 -74.24 161.29 30.07 Favored 'General case' 0 C--N 1.319 -0.72 0 N-CA-C 109.492 -0.559 . . . . 0.0 109.492 176.894 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 131' ' ' ARG . . . . . . . . . . . . . 34.9 ttm180 -74.39 82.26 1.92 Allowed 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 121.402 0.62 . . . . 0.0 110.176 -179.181 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 132' ' ' LYS . . . . . 0.682 ' HB2' ' HE2' ' A' ' 107' ' ' MET . 28.1 mmmt -126.98 -38.99 1.98 Allowed 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.231 -0.895 . . . . 0.0 110.462 -176.968 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 133' ' ' MET . . . . . . . . . . . . . 75.9 mtp -90.83 156.9 17.69 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.055 -0.521 . . . . 0.0 111.014 -175.525 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 16.1 ptmt -120.54 141.11 50.55 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 115.535 -0.757 . . . . 0.0 110.93 -175.582 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . 0.431 HD12 ' HD2' ' A' ' 142' ' ' TYR . 51.2 tp -83.12 120.65 26.03 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.108 178.042 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -119.19 146.01 24.48 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.743 -178.114 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 8.3 m120 -118.84 119.24 33.8 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.535 -0.543 . . . . 0.0 109.535 -179.233 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . 0.478 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 40.6 t80 -123.52 117.42 25.05 Favored 'General case' 0 C--N 1.321 -0.641 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 178.511 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 70.34 -87.29 0.33 Allowed Glycine 0 N--CA 1.443 -0.865 0 CA-C-N 115.604 -0.725 . . . . 0.0 111.43 -175.546 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 14.2 tpp180 -139.1 -13.09 1.21 Allowed 'General case' 0 C--N 1.317 -0.83 0 CA-C-O 121.259 0.552 . . . . 0.0 110.241 -179.147 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 5.8 t -97.99 141.17 31.29 Favored 'General case' 0 N--CA 1.448 -0.538 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.261 -176.608 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 142' ' ' TYR . . . . . 0.431 ' HD2' HD12 ' A' ' 135' ' ' LEU . 52.0 p90 -118.88 147.12 44.32 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 121.117 0.484 . . . . 0.0 110.545 177.432 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 15.2 p90 -155.24 -176.97 6.21 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.322 -0.854 . . . . 0.0 109.778 -176.292 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 31.7 m-85 -115.32 125.49 53.31 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-O 120.454 0.168 . . . . 0.0 110.76 179.699 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 145' ' ' GLU . . . . . 0.449 ' OE1' ' HD3' ' A' ' 116' ' ' ARG . 15.5 pt-20 -114.72 160.0 19.89 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 121.081 0.467 . . . . 0.0 109.813 175.847 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 26.4 t80 -143.87 122.18 12.32 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-N 115.714 -0.675 . . . . 0.0 109.566 175.158 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 147' ' ' ILE . . . . . 0.425 ' N ' HD12 ' A' ' 147' ' ' ILE . 3.2 mp -90.31 102.34 13.19 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 -178.973 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . 0.537 ' HB3' ' HA ' ' A' ' 111' ' ' ASP . . . -72.53 114.17 10.37 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.839 -0.619 . . . . 0.0 109.903 177.381 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 8.1 pt-20 -72.63 150.19 43.25 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.332 0.586 . . . . 0.0 110.886 -176.348 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 26.3 t -86.19 150.74 3.79 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.818 0 CA-C-N 115.464 -0.789 . . . . 0.0 109.434 -177.599 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 151' ' ' ARG . . . . . . . . . . . . . 5.6 mmp_? -69.56 154.2 42.35 Favored 'General case' 0 C--N 1.328 -0.334 0 N-CA-C 110.346 -0.242 . . . . 0.0 110.346 -179.805 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 23.1 t -63.36 149.34 46.05 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 176.21 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 99.1 mtt180 . . . . . 0 C--O 1.249 1.04 0 CA-C-O 118.506 -0.759 . . . . 0.0 110.171 -177.869 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.6 mpt? . . . . . 0 N--CA 1.481 1.11 0 CA-C-O 120.666 0.27 . . . . 0.0 110.44 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -138.63 44.89 1.07 Allowed Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.201 -178.804 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 20.1 m -85.11 41.88 0.9 Allowed 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 121.251 0.548 . . . . 0.0 111.003 -179.204 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 6.1 p -101.34 -169.66 1.72 Allowed 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.202 177.865 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 54.7 p-80 -134.84 133.86 40.18 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.02 0.438 . . . . 0.0 110.618 177.353 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 30.4 t60 -156.42 165.4 36.45 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 -178.714 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 94.1 m-70 67.75 14.82 9.57 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 123.065 0.546 . . . . 0.0 110.874 -177.136 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 9.6 m-70 -81.35 60.84 4.59 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-O 121.209 0.528 . . . . 0.0 112.189 -175.911 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 29.1 m80 -136.1 99.67 4.2 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.808 -0.633 . . . . 0.0 109.831 174.915 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 13.8 p80 -79.48 163.71 24.52 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 116.013 -0.539 . . . . 0.0 110.363 -178.641 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 4.1 t -154.96 44.11 0.49 Allowed 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 108.477 -0.935 . . . . 0.0 108.477 178.735 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 38.1 t -78.13 92.87 4.46 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.316 -0.856 . . . . 0.0 110.966 -175.375 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -138.46 42.19 1.29 Allowed Glycine 0 N--CA 1.448 -0.536 0 C-N-CA 120.807 -0.711 . . . . 0.0 111.761 177.532 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . 0.672 HD23 ' H ' ' A' ' 14' ' ' LEU . 2.5 pt? -106.78 153.77 21.97 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 120.806 0.336 . . . . 0.0 110.783 -177.52 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 29.9 m -91.71 136.76 26.09 Favored Pre-proline 0 C--N 1.323 -0.55 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.948 178.423 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -77.23 156.99 33.55 Favored 'Trans proline' 0 C--O 1.236 0.4 0 C-N-CA 122.839 2.36 . . . . 0.0 112.189 -179.893 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 33.7 mtp180 -108.9 141.79 40.46 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.937 -179.671 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -76.95 104.05 1.86 Allowed Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 121.201 -0.524 . . . . 0.0 112.939 -176.606 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' SER . . . . . 0.415 ' CB ' ' HB2' ' A' ' 22' ' ' TRP . 12.6 p -99.74 164.86 11.86 Favored 'General case' 0 C--N 1.323 -0.548 0 C-N-CA 122.399 0.28 . . . . 0.0 110.475 177.961 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 37.8 t-80 -95.6 -83.85 0.35 Allowed 'General case' 0 C--N 1.325 -0.466 0 C-N-CA 120.973 -0.291 . . . . 0.0 110.775 -178.878 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' MET . . . . . 0.414 ' HB3' ' HB ' ' A' ' 141' ' ' THR . 56.7 mtt -64.14 -29.52 70.64 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-O 121.089 0.471 . . . . 0.0 111.214 -178.688 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' TRP . . . . . 0.415 ' HB2' ' CB ' ' A' ' 19' ' ' SER . 50.2 m95 -69.28 -26.79 64.92 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.286 -178.611 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 25.8 t-20 -72.57 -43.32 63.58 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.98 -0.555 . . . . 0.0 109.691 177.801 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 42.5 m-20 -57.42 -51.03 71.07 Favored 'General case' 0 N--CA 1.463 0.205 0 CA-C-N 115.949 -0.568 . . . . 0.0 109.712 176.927 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.406 ' O ' HG13 ' A' ' 29' ' ' ILE . 58.2 tp -55.01 -47.78 74.22 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.44 -0.8 . . . . 0.0 110.954 179.035 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -55.3 -52.11 64.53 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.223 179.763 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.487 ' HA ' HD11 ' A' ' 30' ' ' ILE . 98.4 t -59.51 -40.51 82.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.975 -179.523 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 84.9 t80 -60.11 -43.54 95.53 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.494 178.428 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.406 HG13 ' O ' ' A' ' 25' ' ' LEU . 82.6 mt -64.84 -43.67 96.36 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.595 177.909 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.635 HG12 HG21 ' A' ' 54' ' ' ILE . 85.8 mt -56.75 -38.84 60.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.901 178.206 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 32.8 mtp85 -70.62 -35.13 72.78 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.082 179.852 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 78.9 m -87.61 0.79 55.15 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.674 -174.047 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 15.5 p -122.01 -71.73 0.72 Allowed 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 120.977 0.418 . . . . 0.0 111.175 178.026 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 97.38 145.23 18.71 Favored Glycine 0 N--CA 1.446 -0.666 0 C-N-CA 120.804 -0.712 . . . . 0.0 111.586 -177.895 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -59.18 130.55 36.7 Favored 'Trans proline' 0 C--O 1.233 0.266 0 C-N-CA 122.852 2.368 . . . . 0.0 112.671 -177.433 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 105.37 24.97 6.87 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.467 -0.873 . . . . 0.0 112.978 177.474 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 13.8 t -131.71 -171.55 2.64 Favored 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 177.312 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -119.35 131.47 55.7 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 120.897 0.379 . . . . 0.0 110.433 177.866 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.422 ' O ' ' HA ' ' A' ' 62' ' ' LEU . 95.9 t -128.14 130.44 69.62 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 176.578 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 46.5 t -107.21 126.04 63.36 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.674 0 CA-C-O 120.91 0.386 . . . . 0.0 111.036 -176.38 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . 0.404 ' HB3' HD21 ' A' ' 64' ' ' LEU . 39.2 tt0 -104.18 114.82 29.32 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.686 175.841 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 62.1 t -98.13 125.75 51.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.691 -177.668 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 88.03 28.66 22.63 Favored Glycine 0 N--CA 1.452 -0.261 0 CA-C-N 115.989 -0.551 . . . . 0.0 112.015 179.603 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . 0.417 ' HB3' ' CD2' ' A' ' 48' ' ' LEU . . . -55.79 -76.58 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.35 0 C-N-CA 123.045 0.538 . . . . 0.0 112.356 -176.503 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 64.09 -102.04 0.55 Allowed Glycine 0 CA--C 1.519 0.301 0 C-N-CA 121.185 -0.531 . . . . 0.0 113.188 179.408 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -107.59 -1.89 20.79 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.655 0.264 . . . . 0.0 111.547 -178.082 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.838 ' HD1' ' HH ' ' A' ' 49' ' ' TYR . 99.4 m-85 -87.72 23.56 1.96 Allowed 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.933 0.397 . . . . 0.0 111.408 -174.957 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . 0.758 HD21 HD12 ' A' ' 64' ' ' LEU . 37.8 mt -66.42 -7.74 21.29 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.691 -0.686 . . . . 0.0 112.831 -172.928 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . 0.838 ' HH ' ' HD1' ' A' ' 47' ' ' PHE . 23.4 p90 -62.0 -25.72 67.81 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.576 0.227 . . . . 0.0 111.361 -179.905 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.411 HG22 ' HB3' ' A' ' 22' ' ' TRP . 61.9 t -74.24 -54.88 13.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.924 0.393 . . . . 0.0 110.381 175.935 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -66.22 -40.13 90.08 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.9 -0.591 . . . . 0.0 112.294 -177.21 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.554 ' O ' ' HG2' ' A' ' 56' ' ' LYS . 38.7 t70 -67.23 -27.75 67.49 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.863 0.363 . . . . 0.0 110.502 -178.688 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 78.5 t80 -69.53 -41.88 75.38 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.892 0.377 . . . . 0.0 110.293 176.014 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.635 HG21 HG12 ' A' ' 30' ' ' ILE . 77.1 mt -63.65 -40.7 90.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 115.946 -0.57 . . . . 0.0 111.231 -178.493 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . 0.507 ' HG2' ' HA ' ' A' ' 52' ' ' ASP . 5.8 ptp180 -70.11 -16.57 63.13 Favored 'General case' 0 CA--C 1.534 0.365 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.985 -176.492 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . 0.554 ' HG2' ' O ' ' A' ' 52' ' ' ASP . 67.1 mmtt -72.17 -42.86 65.4 Favored 'General case' 0 N--CA 1.462 0.143 0 CA-C-O 121.186 0.517 . . . . 0.0 110.377 179.645 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 45.4 m-70 -92.36 -46.87 7.47 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.48 -0.782 . . . . 0.0 111.884 -173.002 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' SER . . . . . 0.454 ' HB2' HG21 ' A' ' 60' ' ' VAL . 12.0 p -112.3 134.18 53.99 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 116.609 -0.269 . . . . 0.0 111.163 -176.798 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 25.4 tptp -80.24 65.85 5.53 Favored 'General case' 0 N--CA 1.448 -0.541 0 CA-C-O 122.246 1.022 . . . . 0.0 109.612 174.532 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.454 HG21 ' HB2' ' A' ' 58' ' ' SER . 92.3 t -98.39 130.86 46.58 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.192 0 CA-C-N 114.4 -1.273 . . . . 0.0 109.113 172.662 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 62.2 m-20 -75.67 86.56 2.72 Favored 'General case' 0 C--N 1.317 -0.83 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 178.981 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . 0.422 ' HA ' ' O ' ' A' ' 39' ' ' VAL . 2.8 tt -87.02 115.55 24.48 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 115.45 -0.796 . . . . 0.0 109.933 -177.054 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 48.0 t -97.54 119.16 45.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.055 -177.252 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . 0.758 HD12 HD21 ' A' ' 48' ' ' LEU . 39.2 mt -92.85 121.54 34.33 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-N 115.913 -0.585 . . . . 0.0 109.762 179.102 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 19.4 p -121.74 124.89 45.29 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-O 121.054 0.454 . . . . 0.0 110.485 178.903 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 27.3 t0 -160.72 152.29 19.49 Favored 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 109.612 -0.514 . . . . 0.0 109.612 -179.294 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . 0.675 HG12 ' HA ' ' A' ' 78' ' ' ASP . 49.6 mt -73.12 108.9 4.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 N-CA-C 110.124 -0.325 . . . . 0.0 110.124 -177.935 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' LYS . . . . . 0.434 ' HA ' ' HD2' ' A' ' 69' ' ' PRO . 45.3 mtpt 65.2 88.86 0.11 Allowed Pre-proline 0 C--N 1.328 -0.365 0 CA-C-N 115.157 -0.929 . . . . 0.0 110.627 -178.963 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . 0.746 ' HB3' ' HB ' ' A' ' 74' ' ' ILE . 11.0 Cg_endo -57.44 140.08 92.09 Favored 'Trans proline' 0 C--N 1.343 0.27 0 C-N-CA 123.558 2.839 . . . . 0.0 113.229 -177.498 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 35.8 m -97.48 -12.16 22.96 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.695 -0.684 . . . . 0.0 111.156 178.716 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . 0.482 ' HB2' HD12 ' A' ' 48' ' ' LEU . 38.0 m-70 -135.23 179.85 6.07 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.368 -179.83 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -88.62 144.33 18.24 Favored Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 120.92 -0.657 . . . . 0.0 111.931 178.593 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 95.21 1.03 62.94 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.131 -179.797 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . 0.746 ' HB ' ' HB3' ' A' ' 69' ' ' PRO . 53.3 mt -100.72 128.0 53.27 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 N-CA-C 110.124 -0.324 . . . . 0.0 110.124 179.177 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 45.3 t -78.48 135.84 25.19 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.716 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 177.089 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' ARG . . . . . 0.518 ' HA ' ' HD3' ' A' ' 69' ' ' PRO . 3.3 ptm180 -79.92 25.24 0.37 Allowed 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.638 -0.256 . . . . 0.0 111.389 -176.441 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 38.2 t70 -64.59 103.8 0.72 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.37 0.605 . . . . 0.0 110.277 -177.192 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . 0.675 ' HA ' HG12 ' A' ' 67' ' ' ILE . 3.3 m-20 -68.25 123.46 20.79 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.241 -0.89 . . . . 0.0 110.201 -176.335 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 10.6 tp -64.08 -19.02 23.81 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.48 0 CA-C-O 121.132 0.492 . . . . 0.0 111.066 179.665 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 10.2 t -77.45 -14.81 59.61 Favored 'General case' 0 CA--C 1.532 0.288 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.784 178.431 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 33.6 t -158.68 70.53 3.69 Favored Pre-proline 0 C--N 1.326 -0.424 0 N-CA-C 108.353 -0.981 . . . . 0.0 108.353 177.593 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 90.0 Cg_endo -88.24 162.09 7.01 Favored 'Trans proline' 0 N--CA 1.458 -0.615 0 C-N-CA 122.956 2.437 . . . . 0.0 113.591 -168.56 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' ARG . . . . . 0.823 ' HB2' HD11 ' A' ' 86' ' ' ILE . 3.9 mmt180 -98.24 107.68 20.21 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 115.58 -0.736 . . . . 0.0 111.095 175.825 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' MET . . . . . 0.505 ' O ' ' HG3' ' A' ' 88' ' ' ARG . 91.0 mmm -62.17 -23.65 66.72 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.278 177.276 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.413 ' OE2' ' HD2' ' A' ' 83' ' ' ARG . 11.0 pt-20 -69.55 -22.58 63.54 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.638 -178.189 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.823 HD11 ' HB2' ' A' ' 83' ' ' ARG . 95.6 mt -81.04 -36.08 14.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.204 178.342 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 22.8 m-85 -77.76 -31.21 51.92 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.72 -179.369 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . 0.505 ' HG3' ' O ' ' A' ' 84' ' ' MET . 38.2 mtp180 -63.67 123.08 17.94 Favored 'General case' 0 CA--C 1.516 -0.361 0 CA-C-O 121.331 0.586 . . . . 0.0 111.024 179.837 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 109.99 -9.5 31.71 Favored Glycine 0 N--CA 1.446 -0.639 0 CA-C-N 115.321 -0.854 . . . . 0.0 111.706 -178.506 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -81.93 143.8 31.39 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 110.349 -0.241 . . . . 0.0 110.349 178.389 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -92.89 -19.88 21.23 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 121.063 0.458 . . . . 0.0 110.627 -179.881 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . 0.453 HD23 ' N ' ' A' ' 93' ' ' ILE . 3.2 tt -152.09 140.66 20.73 Favored 'General case' 0 N--CA 1.449 -0.487 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.625 -179.062 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.457 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 72.3 mt -132.28 126.91 56.57 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 115.934 -0.576 . . . . 0.0 109.569 178.486 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 8.1 p90 -134.7 162.84 31.21 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 120.812 0.339 . . . . 0.0 110.688 178.563 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 6.8 p -141.97 143.16 33.08 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.1 -176.392 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' ILE . . . . . 0.44 HG23 ' CG ' ' A' ' 47' ' ' PHE . 40.5 mm -90.47 93.11 4.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.632 179.675 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . 0.442 ' HG2' ' HA ' ' A' ' 121' ' ' PRO . 1.2 tmm_? 49.44 80.86 0.28 Allowed Pre-proline 0 N--CA 1.464 0.261 0 CA-C-N 115.18 -0.918 . . . . 0.0 111.757 178.552 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' PRO . . . . . 0.507 ' HG2' ' CD2' ' A' ' 103' ' ' HIS . 98.8 Cg_endo -84.98 152.32 11.11 Favored 'Trans proline' 0 N--CA 1.457 -0.63 0 C-N-CA 122.556 2.17 . . . . 0.0 111.874 176.195 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . 0.563 ' HD2' HD12 ' A' ' 102' ' ' ILE . 24.2 Cg_exo -64.15 155.45 64.98 Favored 'Trans proline' 0 C--N 1.343 0.28 0 C-N-CA 122.857 2.371 . . . . 0.0 112.089 175.066 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.633 ' HA ' ' ND1' ' A' ' 103' ' ' HIS . . . -64.17 -16.12 61.26 Favored 'General case' 0 C--N 1.33 -0.257 0 N-CA-C 112.328 0.492 . . . . 0.0 112.328 -176.195 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' GLU . . . . . 0.604 ' HG3' HG23 ' A' ' 102' ' ' ILE . 12.9 pt-20 -76.14 -22.25 55.67 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.781 -0.19 . . . . 0.0 111.509 -177.519 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.604 HG23 ' HG3' ' A' ' 101' ' ' GLU . 43.1 pt -114.91 3.13 7.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 N-CA-C 112.438 0.533 . . . . 0.0 112.438 -176.177 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' HIS . . . . . 0.633 ' ND1' ' HA ' ' A' ' 100' ' ' ALA . 41.8 m170 -58.03 -51.57 69.13 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.002 0.43 . . . . 0.0 110.428 176.92 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 8.8 m -64.46 -29.82 70.86 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.892 -0.594 . . . . 0.0 110.59 178.03 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.544 ' O ' HG23 ' A' ' 109' ' ' VAL . 3.6 m -71.11 -43.9 66.73 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.577 -178.434 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 79.5 mt -60.77 -38.92 86.87 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.818 178.63 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' MET . . . . . 0.426 ' HA ' HD22 ' A' ' 117' ' ' LEU . 76.3 mtp -62.19 -45.54 92.93 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.081 179.841 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' ARG . . . . . 0.528 ' HG2' ' O ' ' A' ' 105' ' ' SER . 12.9 ptm180 -72.01 -22.8 61.36 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.633 -0.258 . . . . 0.0 111.073 -178.26 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.544 HG23 ' O ' ' A' ' 105' ' ' SER . 70.1 t -70.39 -49.94 49.77 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 173.985 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -58.15 -45.54 87.23 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.074 -0.512 . . . . 0.0 109.88 176.67 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.435 ' HA ' ' HB3' ' A' ' 148' ' ' ALA . 21.0 t70 -59.23 -36.15 74.92 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.329 -0.851 . . . . 0.0 111.372 179.387 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -71.95 -45.19 61.98 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.641 -0.709 . . . . 0.0 111.951 -179.269 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 23.2 m -86.94 -28.24 5.78 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 N-CA-C 111.996 0.369 . . . . 0.0 111.996 -174.627 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 87.92 58.96 1.73 Allowed Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.268 -178.65 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -137.47 162.29 34.07 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.752 0.311 . . . . 0.0 110.776 179.37 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 116' ' ' ARG . . . . . 0.435 ' HD3' ' OE1' ' A' ' 145' ' ' GLU . 12.5 ttm180 -79.72 120.27 23.78 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 175.857 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . 0.457 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 52.5 tp -91.99 125.79 36.82 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.089 178.895 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 65.0 mt -118.57 115.02 46.8 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-O 121.176 0.512 . . . . 0.0 110.514 176.889 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 69.8 mt -116.62 120.73 65.87 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.144 179.55 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 120' ' ' LYS . . . . . 0.439 ' HG3' ' HB3' ' A' ' 143' ' ' PHE . 12.1 ttpp -113.58 99.94 50.82 Favored Pre-proline 0 C--N 1.324 -0.525 0 C-N-CA 120.819 -0.353 . . . . 0.0 110.27 175.928 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 121' ' ' PRO . . . . . 0.442 ' HA ' ' HG2' ' A' ' 97' ' ' ARG . 98.9 Cg_endo -81.93 -153.59 0.05 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.609 0 C-N-CA 122.594 2.196 . . . . 0.0 111.079 174.305 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 122' ' ' LEU . . . . . 0.547 ' HB2' ' CG ' ' A' ' 125' ' ' GLU . 3.6 mm? -81.49 -176.98 6.31 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 175.075 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 10.0 t -79.88 1.02 28.68 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.272 0.558 . . . . 0.0 110.602 178.491 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -156.83 71.74 0.25 Allowed Glycine 0 N--CA 1.446 -0.687 0 N-CA-C 111.325 -0.71 . . . . 0.0 111.325 178.081 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . 0.547 ' CG ' ' HB2' ' A' ' 122' ' ' LEU . 9.9 mm-40 -138.01 167.93 20.76 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 109.122 -0.695 . . . . 0.0 109.122 -177.824 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 8.7 t70 -120.68 163.22 18.4 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.046 178.128 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.517 ' HB ' HG22 ' A' ' 129' ' ' THR . 20.8 mt -109.86 -15.4 9.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-O 120.965 0.412 . . . . 0.0 110.716 -175.724 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 18.3 t 51.87 65.06 0.18 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.285 0 CA-C-O 121.651 0.739 . . . . 0.0 110.215 -176.065 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 129' ' ' THR . . . . . 0.517 HG22 ' HB ' ' A' ' 127' ' ' ILE . 9.0 t -144.04 177.21 8.73 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.876 -176.125 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 130' ' ' GLU . . . . . 0.66 ' HG3' ' HG3' ' A' ' 132' ' ' LYS . 9.8 pt-20 -88.86 28.54 1.15 Allowed 'General case' 0 CA--C 1.532 0.26 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.648 -175.158 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 131' ' ' ARG . . . . . . . . . . . . . 86.0 mtt180 63.8 24.31 13.74 Favored 'General case' 0 N--CA 1.47 0.535 0 N-CA-C 112.718 0.636 . . . . 0.0 112.718 171.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 132' ' ' LYS . . . . . 0.66 ' HG3' ' HG3' ' A' ' 130' ' ' GLU . 46.4 mtmt -83.36 -9.35 59.11 Favored 'General case' 0 C--N 1.327 -0.383 0 C-N-CA 120.667 -0.413 . . . . 0.0 111.173 177.845 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 133' ' ' MET . . . . . 0.565 ' HG2' ' HB2' ' A' ' 146' ' ' TYR . 73.5 mtp -90.12 151.29 21.66 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 179.144 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . 0.753 ' HB3' ' HZ1' ' A' ' 134' ' ' LYS . 0.3 OUTLIER -121.1 143.05 49.29 Favored 'General case' 0 C--N 1.315 -0.924 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.959 -173.655 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . 0.781 HD13 ' HD2' ' A' ' 142' ' ' TYR . 43.4 tp -86.13 119.11 26.07 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.977 -0.556 . . . . 0.0 109.694 178.98 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 136' ' ' VAL . . . . . 0.441 ' CG2' ' HG2' ' A' ' 145' ' ' GLU . 0.0 OUTLIER -117.63 144.52 25.35 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.695 -176.271 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 9.8 m120 -114.96 123.77 49.95 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.41 -179.663 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 58.3 t80 -137.57 123.36 19.99 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 109.932 -0.395 . . . . 0.0 109.932 175.213 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 72.12 -85.98 0.49 Allowed Glycine 0 N--CA 1.449 -0.476 0 N-CA-C 110.838 -0.905 . . . . 0.0 110.838 -175.051 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 7.1 mtt180 -153.73 -5.55 0.18 Allowed 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 115.443 -0.378 . . . . 0.0 111.388 173.569 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 141' ' ' THR . . . . . 0.414 ' HB ' ' HB3' ' A' ' 21' ' ' MET . 15.3 t -87.91 143.68 26.98 Favored 'General case' 0 N--CA 1.445 -0.701 0 N-CA-C 109.039 -0.726 . . . . 0.0 109.039 176.24 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 142' ' ' TYR . . . . . 0.781 ' HD2' HD13 ' A' ' 135' ' ' LEU . 48.3 p90 -127.1 129.72 48.51 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-O 121.485 0.66 . . . . 0.0 110.214 178.506 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 143' ' ' PHE . . . . . 0.439 ' HB3' ' HG3' ' A' ' 120' ' ' LYS . 9.6 p90 -139.29 175.77 9.28 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-N 114.838 -1.074 . . . . 0.0 109.962 -173.512 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 144' ' ' TYR . . . . . 0.415 ' HA ' ' O ' ' A' ' 134' ' ' LYS . 93.9 m-85 -110.72 122.51 48.0 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.317 179.889 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 145' ' ' GLU . . . . . 0.443 ' O ' ' HG2' ' A' ' 134' ' ' LYS . 19.7 pt-20 -114.68 160.42 19.37 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-O 121.155 0.503 . . . . 0.0 109.805 175.92 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . 0.565 ' HB2' ' HG2' ' A' ' 133' ' ' MET . 46.5 t80 -142.02 125.24 16.42 Favored 'General case' 0 C--N 1.313 -0.993 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.627 175.811 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 147' ' ' ILE . . . . . 0.437 ' N ' HD12 ' A' ' 147' ' ' ILE . 3.5 mp -92.89 108.67 20.63 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.792 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 179.71 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . 0.435 ' HB3' ' HA ' ' A' ' 111' ' ' ASP . . . -74.41 128.77 36.37 Favored 'General case' 0 N--CA 1.442 -0.837 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 173.983 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 19.7 mm-40 -61.12 165.74 4.12 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-O 121.787 0.803 . . . . 0.0 112.169 -178.23 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 41.1 t -71.94 131.47 34.61 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.8 0 CA-C-N 114.621 -1.172 . . . . 0.0 109.772 -178.644 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 151' ' ' ARG . . . . . 0.494 ' HA ' ' HD3' ' A' ' 151' ' ' ARG . 23.7 mmt180 -92.73 164.49 13.36 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.548 -176.115 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 42.1 t -88.56 150.2 23.2 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.564 -0.743 . . . . 0.0 110.873 -174.387 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 7.9 tpm_? . . . . . 0 C--O 1.249 1.047 0 CA-C-O 118.298 -0.858 . . . . 0.0 109.512 177.326 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 17.1 tpt . . . . . 0 N--CA 1.479 1.016 0 N-CA-C 110.313 -0.254 . . . . 0.0 110.313 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 139.95 -93.22 0.19 Allowed Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 120.637 -0.792 . . . . 0.0 112.466 177.67 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 33.4 t -78.27 123.39 26.89 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 120.925 0.393 . . . . 0.0 110.592 -178.21 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 19.4 m -103.35 117.58 34.81 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.236 -0.438 . . . . 0.0 109.965 178.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 85.4 m-70 -102.55 141.63 35.06 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.497 -177.224 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 79.2 m-70 -99.0 122.35 42.14 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.751 -179.829 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 83.2 t60 -76.31 -39.15 54.84 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.385 178.053 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 22.7 t60 -116.12 132.51 56.64 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.245 -177.943 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 56.8 m-70 -120.73 159.89 24.46 Favored 'General case' 0 C--N 1.324 -0.513 0 N-CA-C 109.449 -0.574 . . . . 0.0 109.449 -179.715 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 17.9 p80 -126.04 172.54 9.88 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.034 0.445 . . . . 0.0 111.134 -175.119 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 35.8 t -134.61 100.67 4.7 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.612 -0.722 . . . . 0.0 109.512 177.735 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 14.8 m -59.69 -36.4 76.41 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.135 -179.018 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -87.16 110.1 3.52 Favored Glycine 0 N--CA 1.443 -0.896 0 C-N-CA 120.574 -0.822 . . . . 0.0 111.12 176.107 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . 0.67 ' H ' HD22 ' A' ' 14' ' ' LEU . 2.3 pt? -70.25 138.65 51.83 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 120.9 0.381 . . . . 0.0 110.371 179.142 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 27.3 m -87.22 152.92 53.53 Favored Pre-proline 0 C--N 1.323 -0.572 0 CA-C-N 116.037 -0.528 . . . . 0.0 110.259 179.476 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -68.36 157.59 61.19 Favored 'Trans proline' 0 C--O 1.236 0.398 0 C-N-CA 122.438 2.092 . . . . 0.0 111.834 178.67 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . 0.479 ' HD2' ' H ' ' A' ' 17' ' ' ARG . 1.1 mpt_? -79.36 75.92 5.95 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.385 0.612 . . . . 0.0 109.946 179.544 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . 0.401 ' O ' ' HG2' ' A' ' 21' ' ' MET . . . -96.83 89.91 1.1 Allowed Glycine 0 N--CA 1.443 -0.874 0 CA-C-N 115.474 -0.785 . . . . 0.0 112.377 -177.907 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 13.0 m -87.96 -28.34 21.53 Favored 'General case' 0 C--N 1.32 -0.71 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 175.57 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 19.2 t-160 -61.38 -30.62 70.65 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 114.867 -1.06 . . . . 0.0 111.162 -177.679 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' MET . . . . . 0.695 ' HB2' ' HB ' ' A' ' 141' ' ' THR . 21.2 ptt? -67.28 -17.2 64.69 Favored 'General case' 0 CA--C 1.53 0.21 0 CA-C-O 120.681 0.277 . . . . 0.0 111.436 -178.4 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 88.3 m95 -87.42 -32.55 19.47 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 176.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 12.8 m120 -66.06 -48.17 71.9 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.626 -0.716 . . . . 0.0 110.411 177.739 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.699 ' HB3' ' HA3' ' A' ' 139' ' ' GLY . 0.7 OUTLIER -67.51 -35.3 78.84 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.298 179.323 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.692 HD23 ' HD2' ' A' ' 120' ' ' LYS . 50.7 tp -51.79 -49.77 62.06 Favored 'General case' 0 C--O 1.231 0.131 0 CA-C-O 121.15 0.5 . . . . 0.0 109.901 173.576 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . 0.442 ' O ' HG13 ' A' ' 30' ' ' ILE . . . -60.26 -45.75 92.2 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.439 -0.8 . . . . 0.0 111.098 177.825 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 76.0 t -55.45 -43.7 73.09 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 CA-C-N 116.389 -0.369 . . . . 0.0 110.896 178.887 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . 0.446 ' HB2' ' CD2' ' A' ' 138' ' ' TYR . 54.3 t80 -59.49 -43.12 93.39 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.428 179.339 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 65.2 mt -65.68 -44.4 93.43 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.427 178.668 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.694 HG12 HG21 ' A' ' 54' ' ' ILE . 85.5 mt -57.63 -45.82 86.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.969 178.378 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 62.6 mtt180 -68.39 -28.59 67.23 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.193 0.521 . . . . 0.0 111.474 -177.74 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 74.6 m -88.84 -0.4 57.32 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.555 -178.566 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 24.3 p -128.11 -83.73 0.59 Allowed 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.805 0.336 . . . . 0.0 111.01 177.517 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 108.34 160.88 20.4 Favored Glycine 0 N--CA 1.449 -0.477 0 C-N-CA 120.975 -0.631 . . . . 0.0 112.228 -179.891 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 24.5 Cg_exo -63.14 146.0 94.02 Favored 'Trans proline' 0 C--O 1.233 0.269 0 C-N-CA 122.893 2.395 . . . . 0.0 112.178 178.877 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 94.1 -23.05 33.2 Favored Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 120.925 -0.655 . . . . 0.0 112.621 179.001 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 15.7 p -81.62 -171.85 3.54 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 -179.313 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . 1.058 ' HG3' ' HA ' ' A' ' 90' ' ' ALA . 17.5 ptm180 -131.2 130.77 43.39 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 121.036 0.446 . . . . 0.0 110.222 173.895 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.418 HG21 HG21 ' A' ' 60' ' ' VAL . 86.7 t -129.73 134.15 63.72 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 CA-C-N 115.804 -0.635 . . . . 0.0 109.351 -177.983 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.431 HG23 ' HB ' ' A' ' 63' ' ' VAL . 45.3 t -109.86 125.45 67.05 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-O 120.952 0.406 . . . . 0.0 111.433 -175.431 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 45.1 tt0 -101.64 120.53 40.48 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.927 -0.579 . . . . 0.0 109.711 175.091 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.475 ' HB ' ' OG ' ' A' ' 95' ' ' SER . 41.8 t -98.22 123.34 50.67 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.265 -179.418 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 97.37 27.31 9.33 Favored Glycine 0 N--CA 1.45 -0.43 0 N-CA-C 111.224 -0.751 . . . . 0.0 111.224 -176.777 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -85.25 76.43 10.16 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.09 0.471 . . . . 0.0 110.863 -177.814 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -111.0 -70.4 0.61 Allowed Glycine 0 N--CA 1.444 -0.807 0 C-N-CA 120.45 -0.881 . . . . 0.0 112.538 -179.421 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -119.03 11.17 12.38 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 120.694 0.283 . . . . 0.0 111.118 -175.872 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 42.2 t80 -130.0 70.75 1.43 Allowed 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 121.275 0.56 . . . . 0.0 109.93 178.519 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 82.1 mt -93.36 20.12 7.49 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.771 -178.656 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 44.9 t80 -63.54 -39.58 94.79 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.955 -177.881 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.467 ' O ' HG13 ' A' ' 54' ' ' ILE . 59.7 t -75.58 -54.4 13.96 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.546 -179.159 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 1.5 p -60.92 -46.77 89.36 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.8 -0.636 . . . . 0.0 112.638 -175.751 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.407 ' O ' ' HG2' ' A' ' 56' ' ' LYS . 38.9 t70 -63.75 -38.1 89.82 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.847 0.356 . . . . 0.0 110.393 -178.131 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 65.6 t80 -61.21 -45.62 93.83 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.376 177.78 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.694 HG21 HG12 ' A' ' 30' ' ' ILE . 83.3 mt -58.64 -48.41 85.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 115.903 -0.59 . . . . 0.0 111.465 -179.033 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 39.1 ptt180 -72.85 -16.77 61.59 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 111.776 0.287 . . . . 0.0 111.776 -175.888 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . 0.905 ' HA ' ' HE2' ' A' ' 56' ' ' LYS . 8.1 mmpt? -73.01 -41.87 63.81 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.798 0.333 . . . . 0.0 110.27 174.882 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 31.0 m-70 -84.44 -52.52 6.11 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.213 -178.837 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 10.5 p -111.65 129.42 56.09 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.153 -178.492 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -82.39 62.34 6.02 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.991 0.901 . . . . 0.0 109.745 176.146 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.418 HG21 HG21 ' A' ' 39' ' ' VAL . 2.3 p -87.43 143.92 10.31 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.935 0 CA-C-N 114.573 -1.194 . . . . 0.0 108.357 171.442 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . 0.459 ' O ' ' HA ' ' A' ' 38' ' ' ARG . 22.8 t0 -75.57 86.99 2.67 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-O 121.647 0.737 . . . . 0.0 109.427 177.706 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 1.5 tt -85.64 122.93 30.45 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.432 -0.804 . . . . 0.0 110.027 -176.208 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.431 ' HB ' HG23 ' A' ' 40' ' ' VAL . 47.6 t -103.75 118.14 50.38 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.698 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.753 -179.276 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . 0.572 ' CB ' HG22 ' A' ' 74' ' ' ILE . 77.8 mt -95.69 133.22 40.03 Favored 'General case' 0 C--N 1.315 -0.906 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.067 -179.053 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.494 HG23 ' HB ' ' A' ' 75' ' ' VAL . 23.7 p -129.61 135.01 48.04 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 120.45 0.167 . . . . 0.0 111.188 179.704 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . 0.787 ' HB3' ' HG3' ' A' ' 69' ' ' PRO . 25.3 t70 -165.25 173.61 11.1 Favored 'General case' 0 C--O 1.234 0.278 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 178.746 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . 0.512 HD13 HG21 ' A' ' 79' ' ' ILE . 39.2 mm -81.26 96.64 3.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-O 120.958 0.408 . . . . 0.0 110.78 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 70.3 mmtt 53.1 66.9 4.25 Favored Pre-proline 0 N--CA 1.467 0.407 0 CA-C-N 115.277 -0.874 . . . . 0.0 111.513 177.481 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . 0.787 ' HG3' ' HB3' ' A' ' 66' ' ' ASP . 17.1 Cg_exo -69.34 146.62 63.38 Favored 'Trans proline' 0 C--O 1.234 0.281 0 C-N-CA 123.164 2.576 . . . . 0.0 112.172 -178.09 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 12.3 p -95.7 11.25 34.08 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.782 -175.477 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 27.6 t60 -99.8 11.32 39.55 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 121.009 0.433 . . . . 0.0 110.233 -178.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 78.63 -78.04 1.69 Allowed Glycine 0 CA--C 1.518 0.256 0 C-N-CA 121.278 -0.487 . . . . 0.0 114.004 172.152 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -70.19 -11.15 66.94 Favored Glycine 0 CA--C 1.519 0.305 0 C-N-CA 121.4 -0.428 . . . . 0.0 114.04 -171.852 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . 0.572 HG22 ' CB ' ' A' ' 64' ' ' LEU . 39.7 mt -72.37 138.16 22.08 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 116.939 0.369 . . . . 0.0 110.188 179.917 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.618 HG11 HD13 ' A' ' 86' ' ' ILE . 61.0 t -64.45 129.95 28.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 121.031 0.444 . . . . 0.0 110.563 -179.15 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' ARG . . . . . 0.425 HH11 ' HD2' ' A' ' 76' ' ' ARG . 5.4 ptp180 -104.12 28.97 6.29 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.655 -173.883 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . 0.436 ' H ' HG13 ' A' ' 75' ' ' VAL . 11.3 t70 -69.94 -84.74 0.03 OUTLIER 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.851 -0.613 . . . . 0.0 111.272 -172.88 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 7.5 t70 -163.24 -169.64 2.05 Favored 'General case' 0 C--N 1.325 -0.5 0 N-CA-C 109.091 -0.707 . . . . 0.0 109.091 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . 0.512 HG21 HD13 ' A' ' 67' ' ' ILE . 13.0 tt -144.19 -28.04 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-O 121.013 0.435 . . . . 0.0 110.749 -179.118 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.506 ' HA ' HG22 ' A' ' 102' ' ' ILE . 14.7 t -103.3 -24.52 13.51 Favored 'General case' 0 N--CA 1.45 -0.44 0 CA-C-O 121.288 0.566 . . . . 0.0 110.058 -178.047 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 68.0 m -150.13 75.17 9.0 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.27 172.871 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.461 ' HB2' ' HE2' ' A' ' 87' ' ' TYR . 9.1 Cg_endo -89.64 174.04 3.53 Favored 'Trans proline' 0 N--CA 1.454 -0.824 0 C-N-CA 123.267 2.645 . . . . 0.0 112.887 -177.08 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' ARG . . . . . 0.663 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 81.6 mtt85 -78.3 118.01 20.09 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.152 176.663 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' MET . . . . . 0.483 ' HE2' HG11 ' A' ' 109' ' ' VAL . 91.7 mmm -61.64 -23.77 66.28 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.302 -0.863 . . . . 0.0 111.565 -178.183 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.663 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 8.6 pt-20 -56.9 -29.34 62.93 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.842 0.354 . . . . 0.0 111.417 179.692 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.618 HD13 HG11 ' A' ' 75' ' ' VAL . 54.9 mt -79.28 -24.87 12.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-O 121.199 0.523 . . . . 0.0 110.858 -176.227 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . 0.461 ' HE2' ' HB2' ' A' ' 82' ' ' PRO . 91.5 m-85 -94.51 -27.67 15.85 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.934 -0.576 . . . . 0.0 111.193 -177.159 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . 0.441 ' HG3' ' O ' ' A' ' 84' ' ' MET . 78.1 mtp180 -65.77 131.46 46.37 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.509 0.671 . . . . 0.0 111.454 -176.552 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 93.17 -5.78 75.44 Favored Glycine 0 N--CA 1.448 -0.521 0 CA-C-N 114.798 -1.092 . . . . 0.0 112.36 -179.899 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . 1.058 ' HA ' ' HG3' ' A' ' 38' ' ' ARG . . . -73.6 153.39 40.22 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.888 0.375 . . . . 0.0 110.63 179.432 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -93.85 -20.72 19.79 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.807 -179.415 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . 0.509 ' HG ' ' HB3' ' A' ' 116' ' ' ARG . 3.7 tt -160.89 142.87 12.33 Favored 'General case' 0 N--CA 1.452 -0.365 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.64 -176.809 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.522 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 66.8 mt -132.31 126.72 56.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 177.188 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 19.7 p90 -137.38 160.78 38.11 Favored 'General case' 0 C--N 1.323 -0.579 0 C-N-CA 120.52 -0.472 . . . . 0.0 111.625 -178.155 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' SER . . . . . 0.475 ' OG ' ' HB ' ' A' ' 42' ' ' VAL . 15.7 m -146.5 140.52 26.25 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.777 -178.565 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' ILE . . . . . 0.409 ' N ' HD12 ' A' ' 96' ' ' ILE . 3.6 mp -99.31 97.1 5.52 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 N-CA-C 110.026 -0.361 . . . . 0.0 110.026 178.728 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . 0.587 ' HG2' ' HA ' ' A' ' 121' ' ' PRO . 42.8 mtm105 53.77 77.25 0.45 Allowed Pre-proline 0 N--CA 1.468 0.467 0 CA-C-N 115.413 -0.812 . . . . 0.0 111.825 179.612 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 95.7 Cg_endo -88.46 159.42 6.64 Favored 'Trans proline' 0 N--CA 1.459 -0.514 0 C-N-CA 122.733 2.288 . . . . 0.0 112.417 179.775 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . 0.618 ' HD2' HD12 ' A' ' 102' ' ' ILE . 51.1 Cg_exo -53.85 147.8 40.11 Favored 'Trans proline' 0 C--N 1.348 0.507 0 C-N-CA 122.92 2.414 . . . . 0.0 112.115 175.955 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -66.92 -19.74 65.78 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.712 -173.164 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' GLU . . . . . 0.561 ' HG3' HG23 ' A' ' 102' ' ' ILE . 11.7 pt-20 -73.34 -22.47 60.3 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.881 -177.334 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.618 HD12 ' HD2' ' A' ' 99' ' ' PRO . 44.1 pt -109.31 5.51 9.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 N-CA-C 112.505 0.557 . . . . 0.0 112.505 -174.711 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' HIS . . . . . . . . . . . . . 46.9 m170 -58.33 -45.22 88.51 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 120.998 0.427 . . . . 0.0 110.624 178.812 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 17.6 m -75.35 -27.79 59.33 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.518 177.31 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.514 ' O ' HG23 ' A' ' 109' ' ' VAL . 10.2 m -69.98 -45.15 67.95 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.896 -177.896 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 84.2 mt -56.78 -38.28 72.29 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.037 0.446 . . . . 0.0 110.822 178.717 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' MET . . . . . 0.564 ' SD ' ' HB2' ' A' ' 131' ' ' ARG . 52.0 ttm -68.4 -42.59 78.79 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.473 -178.92 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' ARG . . . . . 0.422 ' HG2' ' HA ' ' A' ' 105' ' ' SER . 2.5 ptm180 -68.71 -29.92 68.46 Favored 'General case' 0 N--CA 1.462 0.137 0 C-N-CA 120.471 -0.492 . . . . 0.0 110.482 179.482 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.514 HG23 ' O ' ' A' ' 105' ' ' SER . 74.5 t -66.12 -47.6 84.28 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.182 0 CA-C-N 116.453 -0.34 . . . . 0.0 110.274 176.165 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -57.74 -43.74 85.59 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.393 177.553 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.417 ' HA ' ' HB1' ' A' ' 148' ' ' ALA . 18.7 t70 -61.83 -40.43 95.24 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.625 -0.716 . . . . 0.0 110.793 179.777 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -69.4 -39.6 77.86 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.551 -0.749 . . . . 0.0 112.059 -177.859 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.432 HG21 HD11 ' A' ' 93' ' ' ILE . 15.8 m -92.39 -27.42 4.7 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 116.552 -0.294 . . . . 0.0 111.709 -174.556 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . 0.643 ' HA3' HG22 ' A' ' 150' ' ' VAL . . . 86.47 51.56 3.45 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.827 -0.701 . . . . 0.0 112.535 -179.782 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . 0.425 ' O ' ' HB2' ' A' ' 148' ' ' ALA . . . -131.67 165.55 23.46 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.064 0.459 . . . . 0.0 111.162 -178.683 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 116' ' ' ARG . . . . . 0.509 ' HB3' ' HG ' ' A' ' 92' ' ' LEU . 15.3 ttm180 -81.87 128.74 34.35 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.037 176.485 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . 0.522 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 49.8 tp -99.18 127.85 45.22 Favored 'General case' 0 C--N 1.32 -0.704 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 177.859 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 72.4 mt -128.25 125.51 64.34 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-O 120.903 0.382 . . . . 0.0 110.591 179.347 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 61.4 mt -130.27 130.45 65.56 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-O 120.811 0.339 . . . . 0.0 110.263 178.051 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 120' ' ' LYS . . . . . 0.692 ' HD2' HD23 ' A' ' 25' ' ' LEU . 49.9 tttm -116.16 94.23 41.4 Favored Pre-proline 0 C--N 1.324 -0.51 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.227 179.176 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 121' ' ' PRO . . . . . 0.587 ' HA ' ' HG2' ' A' ' 97' ' ' ARG . 89.1 Cg_endo -89.98 -159.7 0.09 OUTLIER 'Trans proline' 0 N--CA 1.459 -0.532 0 C-N-CA 122.799 2.333 . . . . 0.0 112.694 178.101 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 122' ' ' LEU . . . . . 0.511 ' HB3' ' HB3' ' A' ' 125' ' ' GLU . 11.9 tp -76.0 164.2 26.4 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.525 -0.762 . . . . 0.0 110.354 177.365 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 11.4 t -72.73 -28.58 62.73 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.008 0.432 . . . . 0.0 110.366 178.854 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -109.34 44.56 1.47 Allowed Glycine 0 N--CA 1.449 -0.469 0 N-CA-C 110.967 -0.853 . . . . 0.0 110.967 177.105 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . 0.511 ' HB3' ' HB3' ' A' ' 122' ' ' LEU . 31.8 tt0 -147.72 139.25 23.81 Favored 'General case' 0 C--N 1.321 -0.667 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 -174.539 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 17.2 t70 -118.82 161.7 19.7 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 121.068 0.461 . . . . 0.0 111.076 -178.667 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 60.7 mt -97.42 109.33 23.16 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.717 0 CA-C-N 115.353 -0.839 . . . . 0.0 109.311 177.606 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 17.3 m -83.08 47.7 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-O 121.737 0.779 . . . . 0.0 111.015 -176.108 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 129' ' ' THR . . . . . 0.509 HG23 ' HG3' ' A' ' 133' ' ' MET . 12.1 t -78.08 -179.85 6.38 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 114.868 -1.06 . . . . 0.0 110.722 -178.075 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 7.9 tp10 -79.67 -63.75 1.34 Allowed 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 112.254 0.465 . . . . 0.0 112.254 -169.093 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 131' ' ' ARG . . . . . 0.564 ' HB2' ' SD ' ' A' ' 107' ' ' MET . 94.7 mtt180 -89.26 -2.49 58.49 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.776 -0.193 . . . . 0.0 111.183 -175.469 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 132' ' ' LYS . . . . . 0.425 ' HG2' ' N ' ' A' ' 133' ' ' MET . 0.0 OUTLIER 71.77 147.79 0.08 Allowed 'General case' 0 N--CA 1.465 0.303 0 O-C-N 123.89 0.743 . . . . 0.0 111.898 -178.026 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 133' ' ' MET . . . . . 0.509 ' HG3' HG23 ' A' ' 129' ' ' THR . 90.2 mtp -109.58 160.74 16.0 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.458 -0.792 . . . . 0.0 109.93 -178.759 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . 0.404 ' NZ ' ' HB2' ' A' ' 134' ' ' LYS . 0.0 OUTLIER -95.83 142.7 27.78 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.088 0.471 . . . . 0.0 110.793 -176.062 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . 0.745 HD12 ' HD2' ' A' ' 142' ' ' TYR . 43.5 tp -75.35 131.35 40.2 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-N 115.45 -0.795 . . . . 0.0 110.317 178.833 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 136' ' ' VAL . . . . . 0.401 HG13 ' HE3' ' A' ' 134' ' ' LYS . 0.0 OUTLIER -128.22 137.73 56.63 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.755 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.542 178.564 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 19.5 m-80 -112.28 106.55 15.14 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 115.652 -0.704 . . . . 0.0 110.105 -179.941 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . 0.446 ' CD2' ' HB2' ' A' ' 28' ' ' TYR . 59.8 t80 -148.77 127.62 12.61 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.909 -178.41 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . 0.699 ' HA3' ' HB3' ' A' ' 24' ' ' ASP . . . 67.78 57.8 8.41 Favored Glycine 0 N--CA 1.445 -0.745 0 CA-C-N 115.807 -0.633 . . . . 0.0 114.166 171.223 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 140' ' ' ARG . . . . . 0.52 ' HD2' ' N ' ' A' ' 140' ' ' ARG . 2.4 mpt_? 62.6 10.91 4.4 Favored 'General case' 0 N--CA 1.465 0.316 0 C-N-CA 122.692 0.397 . . . . 0.0 112.059 173.84 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 141' ' ' THR . . . . . 0.695 ' HB ' ' HB2' ' A' ' 21' ' ' MET . 10.6 t -145.7 153.01 40.52 Favored 'General case' 0 N--CA 1.447 -0.592 0 CA-C-O 120.973 0.416 . . . . 0.0 110.326 -179.813 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 142' ' ' TYR . . . . . 0.745 ' HD2' HD12 ' A' ' 135' ' ' LEU . 5.0 p90 -122.26 137.73 54.74 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 116.052 -0.522 . . . . 0.0 109.716 174.518 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 143' ' ' PHE . . . . . 0.413 ' O ' HD11 ' A' ' 135' ' ' LEU . 21.4 p90 -145.43 -169.64 3.26 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.466 -0.788 . . . . 0.0 109.796 -174.024 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 83.4 m-85 -117.54 137.27 52.68 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 120.754 0.311 . . . . 0.0 110.932 179.903 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 145' ' ' GLU . . . . . 0.4 ' OE1' ' HD3' ' A' ' 116' ' ' ARG . 15.8 pt-20 -130.36 162.42 29.12 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.157 -0.474 . . . . 0.0 109.731 173.737 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 40.7 t80 -142.38 124.24 15.18 Favored 'General case' 0 C--N 1.317 -0.831 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 174.672 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 147' ' ' ILE . . . . . 0.409 HD12 ' N ' ' A' ' 147' ' ' ILE . 2.7 mp -93.93 98.69 8.49 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.68 0 N-CA-C 109.52 -0.548 . . . . 0.0 109.52 -179.366 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . 0.425 ' HB2' ' O ' ' A' ' 115' ' ' ALA . . . -86.89 108.74 18.91 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.625 176.663 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -75.15 166.06 24.24 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 121.136 0.493 . . . . 0.0 110.601 -179.372 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 150' ' ' VAL . . . . . 0.643 HG22 ' HA3' ' A' ' 114' ' ' GLY . 14.6 t -104.01 126.2 58.64 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.878 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 175.851 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 151' ' ' ARG . . . . . . . . . . . . . 48.0 mtp180 -77.07 94.24 3.99 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-O 121.155 0.502 . . . . 0.0 110.525 -178.678 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 12.3 p -101.16 99.42 9.83 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 115.651 -0.704 . . . . 0.0 110.316 178.261 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 153' ' ' ARG . . . . . 0.404 ' HD2' ' O ' ' A' ' 153' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--O 1.247 0.955 0 CA-C-O 118.829 -0.605 . . . . 0.0 109.539 178.488 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 4.2 mpp? . . . . . 0 N--CA 1.481 1.11 0 CA-C-O 120.727 0.299 . . . . 0.0 110.281 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 171.29 46.23 0.04 OUTLIER Glycine 0 N--CA 1.448 -0.538 0 C-N-CA 120.847 -0.692 . . . . 0.0 111.972 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 13.0 m -122.86 10.12 9.51 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.13 0.49 . . . . 0.0 110.425 -179.85 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 14.5 m -97.74 -50.27 4.52 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.914 -0.584 . . . . 0.0 109.907 179.774 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 28.3 m80 -100.38 164.68 11.82 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.694 -0.685 . . . . 0.0 110.071 -178.148 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 22.0 m-70 -108.04 101.79 11.01 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 120.906 0.384 . . . . 0.0 110.745 -179.753 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . 0.455 ' CG ' ' H ' ' A' ' 8' ' ' HIS . 35.8 t-80 -160.69 -177.28 6.07 Favored 'General case' 0 C--N 1.325 -0.482 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 179.353 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . 0.455 ' H ' ' CG ' ' A' ' 7' ' ' HIS . 56.1 m80 63.92 27.35 14.4 Favored 'General case' 0 N--CA 1.468 0.466 0 C-N-CA 122.796 0.438 . . . . 0.0 111.505 179.061 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 52.7 m80 -73.49 130.35 39.92 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.49 178.079 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' HIS . . . . . 0.403 ' CD2' ' HA3' ' A' ' 73' ' ' GLY . 54.9 p-80 -104.55 164.91 11.42 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.254 0.55 . . . . 0.0 111.012 -178.18 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 17.8 m -114.16 130.64 56.6 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.652 -0.704 . . . . 0.0 109.525 175.453 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 29.5 p -153.37 96.53 2.05 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.984 0.421 . . . . 0.0 111.305 -178.018 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -106.1 82.56 0.33 Allowed Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 120.678 -0.772 . . . . 0.0 112.022 178.499 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 93.1 mt -97.88 169.93 9.31 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 120.756 0.312 . . . . 0.0 110.836 -178.085 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 4.4 p -151.38 104.84 2.93 Favored Pre-proline 0 C--N 1.323 -0.547 0 CA-C-O 121.381 0.61 . . . . 0.0 110.027 177.036 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.443 ' HB2' ' HD1' ' A' ' 49' ' ' TYR . 93.6 Cg_endo -85.85 145.96 9.04 Favored 'Trans proline' 0 N--CA 1.456 -0.687 0 C-N-CA 122.614 2.209 . . . . 0.0 113.128 -177.994 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -127.39 156.38 42.13 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.726 174.051 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 65.94 -161.71 43.53 Favored Glycine 0 N--CA 1.45 -0.43 0 C-N-CA 120.463 -0.875 . . . . 0.0 110.983 -173.932 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 35.1 t 63.07 26.72 15.53 Favored 'General case' 0 CA--C 1.534 0.338 0 CA-C-O 121.105 0.479 . . . . 0.0 110.689 175.67 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 33.9 m-70 -63.65 -24.3 67.73 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-N 115.975 -0.557 . . . . 0.0 111.573 -174.717 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' MET . . . . . . . . . . . . . 28.1 ttt -66.68 -20.18 65.92 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 121.166 0.508 . . . . 0.0 110.992 179.712 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 89.3 m95 -88.72 -16.8 31.33 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.974 -0.557 . . . . 0.0 111.057 -179.538 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 21.0 t-20 -52.34 -50.47 62.25 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.889 -178.776 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 11.3 m-20 -60.5 -33.49 72.69 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.476 -0.329 . . . . 0.0 111.42 -178.22 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.525 HD23 ' HG3' ' A' ' 120' ' ' LYS . 50.6 tp -59.17 -50.65 73.21 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.926 0.393 . . . . 0.0 110.28 176.955 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . 0.407 ' O ' HG13 ' A' ' 30' ' ' ILE . . . -58.49 -49.66 76.54 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.639 179.47 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.43 ' O ' ' HG3' ' A' ' 31' ' ' ARG . 86.4 t -52.74 -46.51 50.8 Favored 'Isoleucine or valine' 0 C--O 1.233 0.209 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.949 177.893 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 86.0 t80 -56.29 -46.18 79.88 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.882 179.417 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 71.1 mt -66.78 -43.08 90.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.972 -179.484 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.407 HG13 ' O ' ' A' ' 26' ' ' ALA . 88.9 mt -56.4 -48.79 79.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 115.817 -0.628 . . . . 0.0 111.067 179.216 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . 0.43 ' HG3' ' O ' ' A' ' 27' ' ' VAL . 61.9 mtp180 -63.25 -36.41 83.58 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.904 -0.589 . . . . 0.0 111.072 -178.808 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 46.6 t -77.29 -25.92 51.83 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.333 -175.338 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 13.7 p -97.03 -76.63 0.51 Allowed 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.785 0.326 . . . . 0.0 111.301 -177.865 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.496 ' O ' HG21 ' A' ' 37' ' ' THR . . . 98.22 167.54 31.54 Favored Glycine 0 N--CA 1.449 -0.452 0 C-N-CA 120.951 -0.642 . . . . 0.0 112.13 -178.601 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 6.7 Cg_exo -73.42 143.54 34.98 Favored 'Trans proline' 0 N--CA 1.462 -0.327 0 C-N-CA 122.878 2.385 . . . . 0.0 112.379 -179.36 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 97.19 -11.29 65.6 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.67 -0.776 . . . . 0.0 113.441 176.218 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' THR . . . . . 0.496 HG21 ' O ' ' A' ' 34' ' ' GLY . 12.6 t -103.52 -179.02 3.83 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 177.501 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . 0.661 ' HB2' ' HA ' ' A' ' 90' ' ' ALA . 62.5 mtp180 -115.11 136.63 52.91 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.809 0.338 . . . . 0.0 110.763 -179.227 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.426 ' HB ' HD22 ' A' ' 62' ' ' LEU . 47.5 t -130.9 138.18 54.16 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 177.913 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.425 HG12 ' CE1' ' A' ' 87' ' ' TYR . 33.4 t -118.95 125.45 74.5 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 CA-C-O 120.837 0.351 . . . . 0.0 111.336 -177.254 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . 0.414 ' HB3' ' CD2' ' A' ' 64' ' ' LEU . 43.4 tt0 -99.57 112.15 24.4 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.954 -0.566 . . . . 0.0 109.645 175.462 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 60.5 t -97.45 121.16 47.69 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-N 116.0 -0.546 . . . . 0.0 110.385 -179.143 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 90.35 46.04 4.19 Favored Glycine 0 N--CA 1.444 -0.795 0 C-N-CA 120.539 -0.839 . . . . 0.0 111.861 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . 0.432 ' HB1' ' CD2' ' A' ' 48' ' ' LEU . . . -59.22 -32.94 70.41 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-O 121.328 0.585 . . . . 0.0 110.932 179.292 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 63.88 -123.57 28.74 Favored Glycine 0 N--CA 1.445 -0.701 0 CA-C-N 115.714 -0.675 . . . . 0.0 112.597 177.104 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . 0.468 ' HA ' ' HE1' ' A' ' 71' ' ' HIS . 30.5 mmt-85 -122.96 9.77 9.41 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 120.847 0.356 . . . . 0.0 110.498 -177.005 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 19.0 p90 -137.36 113.24 9.69 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 121.289 0.566 . . . . 0.0 110.82 -176.845 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . 0.432 ' CD2' ' HB1' ' A' ' 44' ' ' ALA . 68.8 mt -104.64 60.87 0.7 Allowed 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.56 -177.164 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . 0.443 ' HD1' ' HB2' ' A' ' 16' ' ' PRO . 72.1 t80 -75.56 -52.84 9.68 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.938 0.399 . . . . 0.0 110.88 -179.559 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.452 ' O ' HG13 ' A' ' 54' ' ' ILE . 49.1 t -67.87 -52.78 36.15 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-N 115.868 -0.606 . . . . 0.0 110.722 -176.562 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' SER . . . . . 0.521 ' HB3' HD22 ' A' ' 64' ' ' LEU . 0.2 OUTLIER -54.84 -43.15 72.76 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.767 -0.651 . . . . 0.0 112.491 -178.933 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.425 ' O ' ' HG3' ' A' ' 56' ' ' LYS . 20.7 t70 -67.73 -42.96 81.05 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.834 0.349 . . . . 0.0 110.591 -179.104 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 75.9 t80 -63.99 -40.08 95.57 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.153 -179.009 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.452 HG13 ' O ' ' A' ' 50' ' ' VAL . 80.0 mt -63.01 -45.78 97.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.474 -0.33 . . . . 0.0 111.367 -179.709 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 33.2 ptt180 -72.04 -16.84 62.05 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.89 0.376 . . . . 0.0 110.871 -178.785 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . 0.425 ' HG3' ' O ' ' A' ' 52' ' ' ASP . 24.2 mtpp -73.08 -30.55 63.75 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.318 176.882 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 28.0 m-70 -102.51 -56.61 2.21 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.891 -177.434 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 6.8 p -100.46 135.4 41.95 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 120.982 0.42 . . . . 0.0 112.057 -174.399 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . 0.518 ' HB2' ' HZ2' ' A' ' 59' ' ' LYS . 0.2 OUTLIER -81.39 65.05 6.36 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 122.196 0.998 . . . . 0.0 108.969 171.053 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.42 HG22 HG22 ' A' ' 39' ' ' VAL . 8.8 p -100.54 148.54 6.77 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.09 0 CA-C-N 114.322 -1.308 . . . . 0.0 110.111 178.78 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . 0.556 ' HB3' ' HG2' ' A' ' 38' ' ' ARG . 9.3 t70 -74.77 84.89 2.16 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 176.773 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . 0.426 HD22 ' HB ' ' A' ' 39' ' ' VAL . 3.1 tm? -94.57 116.83 29.24 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 115.441 -0.799 . . . . 0.0 110.287 -173.92 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 60.1 t -113.61 139.09 40.89 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 CA-C-N 115.604 -0.725 . . . . 0.0 110.561 -176.524 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . 0.521 HD22 ' HB3' ' A' ' 51' ' ' SER . 31.6 mt -112.37 136.12 52.23 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 110.171 -0.307 . . . . 0.0 110.171 178.735 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 15.9 p -118.81 125.43 49.55 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.102 0.477 . . . . 0.0 110.706 175.366 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . 0.485 ' HB3' HG21 ' A' ' 74' ' ' ILE . 23.9 t70 -154.82 140.46 17.98 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.532 -0.758 . . . . 0.0 109.247 -179.853 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . 0.489 HG23 ' HG2' ' A' ' 68' ' ' LYS . 59.3 mt -74.44 124.17 31.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-N 116.519 -0.31 . . . . 0.0 110.315 -177.964 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' LYS . . . . . 0.489 ' HG2' HG23 ' A' ' 67' ' ' ILE . 59.8 pttt 39.72 69.72 1.66 Allowed Pre-proline 0 N--CA 1.469 0.499 0 O-C-N 124.29 0.994 . . . . 0.0 111.684 -174.296 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . 0.548 ' CB ' ' HB ' ' A' ' 74' ' ' ILE . 44.1 Cg_endo -67.64 141.88 56.56 Favored 'Trans proline' 0 C--O 1.232 0.218 0 C-N-CA 122.856 2.371 . . . . 0.0 113.017 -174.345 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 11.7 t -88.37 -16.19 33.6 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.27 -178.874 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . 0.468 ' HE1' ' HA ' ' A' ' 46' ' ' ARG . 71.6 m80 -80.52 -12.29 59.55 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.883 -179.604 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 80.98 -53.1 4.58 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 121.039 -0.601 . . . . 0.0 113.419 175.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.403 ' HA3' ' CD2' ' A' ' 10' ' ' HIS . . . -76.21 -10.26 85.43 Favored Glycine 0 C--O 1.228 -0.259 0 C-N-CA 121.348 -0.453 . . . . 0.0 113.585 -175.957 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . 0.548 ' HB ' ' CB ' ' A' ' 69' ' ' PRO . 55.3 mt -75.3 142.3 14.73 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 N-CA-C 109.713 -0.477 . . . . 0.0 109.713 177.254 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.542 HG11 HD11 ' A' ' 86' ' ' ILE . 66.3 t -66.27 123.72 19.85 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-O 120.884 0.374 . . . . 0.0 110.266 -179.344 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 18.7 ptp180 -85.9 48.61 1.63 Allowed 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.44 0.638 . . . . 0.0 110.695 -176.251 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . 0.425 ' HB2' HG13 ' A' ' 75' ' ' VAL . 2.7 t70 -89.17 -154.56 0.31 Allowed 'General case' 0 C--N 1.321 -0.641 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 179.214 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . 0.497 ' OD1' HG22 ' A' ' 80' ' ' THR . 4.9 t70 -136.25 -176.42 4.32 Favored 'General case' 0 C--N 1.321 -0.633 0 C-N-CA 120.737 -0.385 . . . . 0.0 110.251 -178.916 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 8.9 tp -127.37 -28.18 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-O 120.822 0.344 . . . . 0.0 110.502 179.71 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.497 HG22 ' OD1' ' A' ' 78' ' ' ASP . 15.0 t -89.06 -25.75 21.77 Favored 'General case' 0 N--CA 1.451 -0.387 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 177.006 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 34.2 t -135.34 70.5 67.91 Favored Pre-proline 0 C--N 1.326 -0.442 0 CA-C-N 115.33 -0.85 . . . . 0.0 108.997 170.822 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_endo -87.32 157.01 8.11 Favored 'Trans proline' 0 N--CA 1.453 -0.909 0 C-N-CA 122.496 2.131 . . . . 0.0 112.518 -176.146 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' ARG . . . . . 0.741 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 50.0 mtt180 -89.12 111.92 22.79 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.199 173.058 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' MET . . . . . 0.521 ' HE2' HG12 ' A' ' 109' ' ' VAL . 95.2 mmm -66.83 -17.65 64.99 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.5 -177.62 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.741 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 9.9 pt-20 -62.35 -23.35 66.74 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.628 -0.714 . . . . 0.0 111.508 179.078 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.542 HD11 HG11 ' A' ' 75' ' ' VAL . 67.3 mt -84.36 -39.54 14.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-O 121.117 0.484 . . . . 0.0 110.363 179.724 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . 0.425 ' CE1' HG12 ' A' ' 40' ' ' VAL . 90.7 m-85 -78.86 -32.19 45.9 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.756 -0.657 . . . . 0.0 111.322 -177.881 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . 0.412 ' HG3' HG13 ' A' ' 113' ' ' VAL . 57.9 mtt180 -67.01 115.33 6.6 Favored 'General case' 0 CA--C 1.516 -0.339 0 CA-C-O 121.317 0.58 . . . . 0.0 110.633 -179.933 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 119.44 -12.05 11.23 Favored Glycine 0 N--CA 1.448 -0.522 0 CA-C-N 115.037 -0.983 . . . . 0.0 111.455 -175.213 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . 0.661 ' HA ' ' HB2' ' A' ' 38' ' ' ARG . . . -82.94 147.74 28.06 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.881 0.372 . . . . 0.0 110.898 178.346 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -96.73 -22.26 17.09 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.811 179.529 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . 0.465 ' HG ' ' HB3' ' A' ' 116' ' ' ARG . 5.3 tt -150.85 139.79 20.95 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.682 -178.442 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.56 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 67.5 mt -131.57 125.37 56.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.688 -0.687 . . . . 0.0 109.258 178.69 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 19.0 p90 -128.42 155.48 44.69 Favored 'General case' 0 C--N 1.321 -0.645 0 C-N-CA 120.618 -0.433 . . . . 0.0 110.965 -178.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 18.3 m -132.74 130.41 39.94 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.554 -178.436 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 65.4 mt -93.55 103.14 14.37 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.682 -178.894 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 70.6 mtp180 54.38 67.36 3.45 Favored Pre-proline 0 N--CA 1.466 0.329 0 CA-C-N 115.489 -0.778 . . . . 0.0 111.998 -178.517 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -76.91 140.58 20.53 Favored 'Trans proline' 0 N--CA 1.461 -0.402 0 C-N-CA 122.244 1.963 . . . . 0.0 112.251 179.615 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . 0.585 ' HD2' HD11 ' A' ' 102' ' ' ILE . 38.1 Cg_exo -60.2 147.56 93.01 Favored 'Trans proline' 0 C--O 1.235 0.331 0 C-N-CA 122.741 2.294 . . . . 0.0 111.942 176.606 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.639 ' HA ' ' NE2' ' A' ' 103' ' ' HIS . . . -78.54 31.15 0.19 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.227 0.537 . . . . 0.0 111.331 -175.542 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' GLU . . . . . 0.528 ' HG2' ' HB2' ' A' ' 99' ' ' PRO . 7.7 pt-20 -127.55 -1.63 6.16 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-N 115.967 -0.561 . . . . 0.0 111.164 -176.908 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.585 HD11 ' HD2' ' A' ' 99' ' ' PRO . 30.9 pt -131.41 10.33 1.83 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 N-CA-C 112.118 0.414 . . . . 0.0 112.118 -178.308 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' HIS . . . . . 0.639 ' NE2' ' HA ' ' A' ' 100' ' ' ALA . 9.7 m-70 -54.77 -51.65 65.06 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.244 -0.435 . . . . 0.0 112.006 -176.738 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 15.5 m -62.54 -32.49 73.44 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.498 -0.319 . . . . 0.0 111.007 -177.939 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.577 ' O ' HG21 ' A' ' 109' ' ' VAL . 21.0 m -67.45 -42.3 83.32 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.329 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 73.9 mt -64.78 -43.96 91.54 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.493 179.56 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' MET . . . . . 0.403 ' HE2' ' HB2' ' A' ' 132' ' ' LYS . 77.0 mtp -63.18 -41.8 99.27 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.55 -176.244 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 2.9 ptp180 -70.27 -30.78 67.89 Favored 'General case' 0 C--N 1.332 -0.189 0 C-N-CA 120.879 -0.329 . . . . 0.0 111.145 -178.497 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.577 HG21 ' O ' ' A' ' 105' ' ' SER . 75.3 t -63.87 -45.2 97.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.889 0.376 . . . . 0.0 110.062 177.466 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -58.42 -44.4 89.07 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.619 177.71 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.471 ' HA ' ' HB3' ' A' ' 148' ' ' ALA . 13.6 t70 -64.84 -42.48 94.88 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.059 179.586 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -64.8 -41.74 95.56 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.712 -0.676 . . . . 0.0 112.055 -177.488 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.412 HG13 ' HG3' ' A' ' 88' ' ' ARG . 12.2 m -92.57 -24.78 5.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 CA-C-N 116.506 -0.315 . . . . 0.0 111.694 -174.983 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 88.43 49.33 3.71 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.764 -0.731 . . . . 0.0 111.997 179.731 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -129.07 156.5 43.76 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 120.738 0.304 . . . . 0.0 111.142 -177.689 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 116' ' ' ARG . . . . . 0.514 ' HD3' ' OE1' ' A' ' 145' ' ' GLU . 16.4 ttm180 -80.26 125.16 29.52 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.158 -0.474 . . . . 0.0 109.728 177.549 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . 0.56 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 48.7 tp -94.47 119.31 32.99 Favored 'General case' 0 C--N 1.322 -0.619 0 N-CA-C 110.158 -0.312 . . . . 0.0 110.158 179.815 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 63.9 mt -114.91 117.97 57.31 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-O 121.183 0.516 . . . . 0.0 110.732 179.398 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 64.6 mt -112.03 132.22 61.28 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 115.923 -0.581 . . . . 0.0 110.564 179.829 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 120' ' ' LYS . . . . . 0.908 ' HD2' ' HB3' ' A' ' 143' ' ' PHE . 23.1 mmmt -102.58 99.97 14.8 Favored Pre-proline 0 C--N 1.328 -0.347 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.229 174.419 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 121' ' ' PRO . . . . . 0.415 ' HG3' ' HD2' ' A' ' 144' ' ' TYR . 88.4 Cg_endo -82.78 -158.95 0.1 OUTLIER 'Trans proline' 0 N--CA 1.459 -0.535 0 C-N-CA 122.563 2.175 . . . . 0.0 111.351 171.861 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 122' ' ' LEU . . . . . 0.819 ' HB2' ' HB2' ' A' ' 125' ' ' GLU . 3.6 mm? -99.88 -171.04 1.98 Allowed 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 110.267 -0.272 . . . . 0.0 110.267 179.916 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 8.7 t -88.76 -35.11 16.85 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.708 0.289 . . . . 0.0 111.19 -176.719 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -114.78 12.61 20.48 Favored Glycine 0 N--CA 1.449 -0.499 0 C-N-CA 120.436 -0.887 . . . . 0.0 111.296 178.53 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . 0.819 ' HB2' ' HB2' ' A' ' 122' ' ' LEU . 28.2 mt-10 -131.52 126.52 35.12 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.248 -0.476 . . . . 0.0 110.075 -176.342 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 11.3 t70 -87.01 179.28 6.71 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.679 -0.692 . . . . 0.0 109.885 -177.504 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.574 HD13 ' HB2' ' A' ' 144' ' ' TYR . 56.5 mt -71.64 -33.72 49.92 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 178.799 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 55.6 t 68.71 79.53 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.333 -0.148 0 CA-C-N 115.313 -0.858 . . . . 0.0 109.582 -174.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 13.2 t -165.65 -168.95 1.43 Allowed 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.438 -0.801 . . . . 0.0 109.635 -176.514 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -73.92 148.86 41.84 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 110.01 -0.367 . . . . 0.0 110.01 179.452 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 131' ' ' ARG . . . . . 0.413 HH11 ' HD3' ' A' ' 131' ' ' ARG . 10.0 mmm180 -79.24 63.63 3.93 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.222 0.534 . . . . 0.0 110.881 -177.699 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 132' ' ' LYS . . . . . 0.403 ' HB2' ' HE2' ' A' ' 107' ' ' MET . 33.5 mttp -117.36 -1.25 11.8 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.03 179.92 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 133' ' ' MET . . . . . 0.537 ' HG2' ' HB2' ' A' ' 146' ' ' TYR . 84.8 mtp -111.14 165.63 11.74 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.857 -0.611 . . . . 0.0 109.405 176.144 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 6.9 pttp -130.51 140.23 50.5 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.09 0.472 . . . . 0.0 111.754 -175.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . 0.577 HD13 ' HD2' ' A' ' 142' ' ' TYR . 39.2 tp -76.93 122.36 24.76 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.585 -0.734 . . . . 0.0 110.777 -179.645 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 136' ' ' VAL . . . . . 0.453 HG22 ' CD1' ' A' ' 143' ' ' PHE . 0.0 OUTLIER -117.95 142.25 33.23 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.761 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.437 178.426 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 137' ' ' ASN . . . . . 0.583 ' ND2' ' HB3' ' A' ' 142' ' ' TYR . 13.8 m120 -117.9 110.32 17.6 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.442 -176.022 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . 0.437 ' O ' HG22 ' A' ' 141' ' ' THR . 76.0 t80 -135.23 130.09 34.69 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.248 -0.433 . . . . 0.0 109.877 -179.434 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 63.75 26.36 69.87 Favored Glycine 0 N--CA 1.453 -0.217 0 C-N-CA 120.54 -0.838 . . . . 0.0 111.702 -176.784 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 21.2 mtp180 66.67 7.69 5.34 Favored 'General case' 0 C--N 1.33 -0.274 0 C-N-CA 123.304 0.641 . . . . 0.0 112.436 -178.731 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 141' ' ' THR . . . . . 0.437 HG22 ' O ' ' A' ' 138' ' ' TYR . 10.8 t -107.48 139.71 41.57 Favored 'General case' 0 N--CA 1.446 -0.659 0 N-CA-C 108.663 -0.866 . . . . 0.0 108.663 169.84 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 142' ' ' TYR . . . . . 0.583 ' HB3' ' ND2' ' A' ' 137' ' ' ASN . 17.0 p90 -113.86 149.08 35.59 Favored 'General case' 0 C--N 1.315 -0.892 0 CA-C-O 121.69 0.757 . . . . 0.0 111.513 -177.581 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 143' ' ' PHE . . . . . 0.908 ' HB3' ' HD2' ' A' ' 120' ' ' LYS . 3.5 p90 -151.41 178.96 8.76 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 114.238 -1.347 . . . . 0.0 108.83 -178.98 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 144' ' ' TYR . . . . . 0.574 ' HB2' HD13 ' A' ' 127' ' ' ILE . 80.6 m-85 -115.58 119.72 37.06 Favored 'General case' 0 C--N 1.313 -0.98 0 C-N-CA 120.62 -0.432 . . . . 0.0 110.529 179.82 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 145' ' ' GLU . . . . . 0.514 ' OE1' ' HD3' ' A' ' 116' ' ' ARG . 18.3 pt-20 -108.15 156.96 18.73 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 176.2 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . 0.537 ' HB2' ' HG2' ' A' ' 133' ' ' MET . 22.7 t80 -137.13 120.68 17.17 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-N 115.626 -0.715 . . . . 0.0 109.66 176.647 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 147' ' ' ILE . . . . . 0.419 HD13 ' N ' ' A' ' 147' ' ' ILE . 3.2 mp -89.05 101.5 12.05 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 -178.481 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . 0.471 ' HB3' ' HA ' ' A' ' 111' ' ' ASP . . . -74.37 96.43 2.86 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 121.225 0.536 . . . . 0.0 109.76 177.19 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 11.6 pt-20 -75.54 164.67 26.1 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-N 115.155 -0.93 . . . . 0.0 109.752 178.89 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 34.5 t -68.18 127.58 30.15 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 N-CA-C 109.248 -0.649 . . . . 0.0 109.248 177.846 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 151' ' ' ARG . . . . . . . . . . . . . 13.6 ptt180 -81.44 66.93 7.2 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-O 121.691 0.757 . . . . 0.0 110.633 -176.597 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 10.8 t -164.7 -176.28 4.2 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 114.912 -1.04 . . . . 0.0 108.918 179.008 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.247 0.933 0 CA-C-O 118.503 -0.761 . . . . 0.0 109.714 178.847 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 23.9 ptt? . . . . . 0 N--CA 1.479 1.002 0 CA-C-O 121.498 0.666 . . . . 0.0 110.545 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 157.36 135.22 1.88 Allowed Glycine 0 N--CA 1.444 -0.829 0 CA-C-N 115.556 -0.747 . . . . 0.0 111.479 179.687 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 27.6 m -66.63 98.0 0.48 Allowed 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.301 0.572 . . . . 0.0 111.025 -177.353 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 15.5 m -94.32 53.0 1.64 Allowed 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.73 -0.668 . . . . 0.0 109.322 178.412 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 8.5 p80 -74.16 162.98 28.41 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.243 -0.889 . . . . 0.0 111.084 -175.238 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 27.1 m-70 -98.36 118.78 35.8 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.91 -0.587 . . . . 0.0 110.517 -179.624 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 70.3 m80 -69.13 -28.83 66.81 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 121.396 0.617 . . . . 0.0 109.388 175.016 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 26.9 m-70 -116.03 115.53 26.29 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.226 -0.897 . . . . 0.0 109.61 173.718 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 74.9 t60 -71.28 -33.82 70.1 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 107.845 -1.168 . . . . 0.0 107.845 173.094 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 32.1 p-80 -129.85 122.48 28.78 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 114.457 -1.247 . . . . 0.0 108.427 169.303 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 10.7 t -66.64 98.6 0.53 Allowed 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.098 0.475 . . . . 0.0 110.748 -177.265 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 33.6 t -128.95 132.35 47.6 Favored 'General case' 0 N--CA 1.45 -0.445 0 CA-C-N 115.724 -0.671 . . . . 0.0 110.081 -179.015 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 153.5 -177.31 31.12 Favored Glycine 0 N--CA 1.446 -0.691 0 C-N-CA 121.028 -0.606 . . . . 0.0 111.916 -179.813 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . 0.641 ' H ' HD22 ' A' ' 14' ' ' LEU . 2.4 pt? -112.37 147.34 36.6 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 110.238 -0.282 . . . . 0.0 110.238 179.241 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 16.3 m -93.21 114.58 63.18 Favored Pre-proline 0 C--N 1.326 -0.455 0 CA-C-O 121.112 0.482 . . . . 0.0 110.563 178.13 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 89.5 Cg_endo -80.07 166.77 20.58 Favored 'Trans proline' 0 N--CA 1.459 -0.54 0 C-N-CA 122.62 2.213 . . . . 0.0 112.406 -179.173 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 23.0 mmt180 -87.13 -15.35 38.68 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.926 178.21 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 72.88 35.64 58.11 Favored Glycine 0 N--CA 1.448 -0.534 0 C-N-CA 120.75 -0.738 . . . . 0.0 111.941 179.847 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 12.7 p -83.61 108.26 16.59 Favored 'General case' 0 N--CA 1.447 -0.601 0 CA-C-O 121.307 0.575 . . . . 0.0 110.495 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' HIS . . . . . 0.562 ' CG ' ' H ' ' A' ' 21' ' ' MET . 58.0 t60 -164.35 -152.26 0.18 Allowed 'General case' 0 C--N 1.32 -0.68 0 N-CA-C 107.302 -1.37 . . . . 0.0 107.302 -176.322 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' MET . . . . . 0.582 ' HB3' ' HB ' ' A' ' 141' ' ' THR . 0.0 OUTLIER -56.87 -14.68 3.68 Favored 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 112.212 0.449 . . . . 0.0 112.212 178.06 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' TRP . . . . . 0.521 ' CD1' ' HB3' ' A' ' 20' ' ' HIS . 40.2 m95 -54.63 -33.35 60.44 Favored 'General case' 0 N--CA 1.461 0.122 0 CA-C-O 121.033 0.444 . . . . 0.0 110.533 175.321 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 25.5 t-20 -65.18 -45.55 84.39 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.553 -0.749 . . . . 0.0 110.28 -178.024 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -57.24 -46.29 83.13 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.679 -0.691 . . . . 0.0 110.255 177.953 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 62.2 tp -61.52 -46.96 87.74 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.238 -0.892 . . . . 0.0 110.958 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . 0.49 ' O ' HG13 ' A' ' 30' ' ' ILE . . . -56.19 -52.47 64.28 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.164 -179.742 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.415 ' HA ' HD12 ' A' ' 30' ' ' ILE . 84.0 t -56.12 -42.25 71.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.206 179.131 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 57.4 t80 -57.41 -45.99 83.98 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.574 179.733 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 67.0 mt -67.28 -40.23 84.48 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.785 179.783 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.547 HG12 HG22 ' A' ' 54' ' ' ILE . 95.4 mt -58.85 -38.42 72.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 115.969 -0.56 . . . . 0.0 111.125 179.401 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 40.1 mtp-105 -71.99 -30.32 65.13 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.839 -0.619 . . . . 0.0 111.332 -178.855 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 42.9 t -89.2 -17.41 29.17 Favored 'General case' 0 C--N 1.324 -0.513 0 N-CA-C 111.956 0.354 . . . . 0.0 111.956 -176.489 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 11.5 p -94.68 -79.17 0.43 Allowed 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 111.961 0.356 . . . . 0.0 111.961 -176.086 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.463 ' O ' HG21 ' A' ' 37' ' ' THR . . . 101.16 136.73 9.45 Favored Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.812 -0.709 . . . . 0.0 111.847 -176.698 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . 0.4 ' HD3' ' HA2' ' A' ' 34' ' ' GLY . 48.4 Cg_exo -55.84 126.48 22.55 Favored 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 123.076 2.518 . . . . 0.0 112.767 -176.066 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 112.73 -18.51 22.21 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.294 -0.955 . . . . 0.0 113.48 175.278 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' THR . . . . . 0.463 HG21 ' O ' ' A' ' 34' ' ' GLY . 11.1 t -86.76 -173.6 4.56 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.995 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . 0.494 ' HG2' ' CB ' ' A' ' 61' ' ' ASP . 92.1 mtm-85 -118.45 135.2 54.5 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 120.932 0.396 . . . . 0.0 110.735 176.634 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.461 HG22 HG11 ' A' ' 60' ' ' VAL . 90.7 t -130.19 127.44 63.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 176.904 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.427 HG11 ' CE1' ' A' ' 87' ' ' TYR . 35.4 t -109.06 128.79 64.67 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-O 120.937 0.399 . . . . 0.0 111.915 -173.02 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . 0.708 ' HB3' HD21 ' A' ' 64' ' ' LEU . 6.3 tp10 -103.3 127.92 50.5 Favored 'General case' 0 C--O 1.237 0.416 0 CA-C-N 115.379 -0.828 . . . . 0.0 109.452 174.092 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.54 ' HB ' ' HB3' ' A' ' 95' ' ' SER . 35.2 t -106.05 98.91 7.49 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-O 120.974 0.416 . . . . 0.0 110.535 -179.178 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 101.08 84.8 1.83 Allowed Glycine 0 N--CA 1.451 -0.333 0 N-CA-C 111.471 -0.651 . . . . 0.0 111.471 -176.778 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . 0.419 ' HB1' HD22 ' A' ' 48' ' ' LEU . . . -83.07 -40.83 19.35 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 112.106 0.41 . . . . 0.0 112.106 -172.107 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 57.3 -127.55 45.19 Favored Glycine 0 CA--C 1.521 0.447 0 C-N-CA 121.077 -0.582 . . . . 0.0 112.713 179.824 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 52.4 mtp180 -120.42 2.49 10.77 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.866 0.365 . . . . 0.0 111.21 179.071 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.552 ' CE1' ' HB ' ' A' ' 96' ' ' ILE . 6.3 p90 -96.85 58.29 1.61 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.379 0.609 . . . . 0.0 111.088 -176.166 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . 0.419 HD22 ' HB1' ' A' ' 44' ' ' ALA . 83.8 mt -81.68 8.43 9.92 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.79 -0.641 . . . . 0.0 112.12 -174.425 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 75.7 t80 -57.95 -48.75 79.04 Favored 'General case' 0 N--CA 1.463 0.201 0 CA-C-O 120.589 0.233 . . . . 0.0 111.195 -179.802 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.453 ' O ' HG13 ' A' ' 54' ' ' ILE . 85.3 t -58.96 -51.73 69.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.892 -178.398 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' SER . . . . . 0.492 ' CB ' HD23 ' A' ' 64' ' ' LEU . 3.9 p -69.79 -25.76 63.94 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.004 -0.544 . . . . 0.0 112.346 -174.418 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.502 ' O ' ' HG2' ' A' ' 55' ' ' ARG . 17.5 t70 -83.06 -41.46 18.6 Favored 'General case' 0 C--N 1.325 -0.462 0 C-N-CA 120.806 -0.358 . . . . 0.0 110.3 177.232 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 66.4 t80 -58.16 -43.75 87.55 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.545 178.839 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.547 HG22 HG12 ' A' ' 30' ' ' ILE . 89.0 mt -60.2 -47.6 91.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.192 178.326 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . 0.502 ' HG2' ' O ' ' A' ' 52' ' ' ASP . 7.9 ptp180 -71.98 -16.31 62.08 Favored 'General case' 0 CA--C 1.532 0.27 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.381 -174.725 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 44.2 mmtm -77.1 -37.57 54.03 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.839 0.352 . . . . 0.0 110.569 176.316 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 13.3 m-70 -83.79 -55.32 4.32 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.67 179.694 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 68.0 m -117.13 127.97 54.66 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.169 -179.025 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 1.3 mptm? -77.5 63.36 2.63 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-O 121.925 0.869 . . . . 0.0 110.475 176.712 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.461 HG11 HG22 ' A' ' 39' ' ' VAL . 66.1 t -82.84 142.35 13.7 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.922 0 CA-C-N 114.444 -1.253 . . . . 0.0 109.09 173.888 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . 0.494 ' CB ' ' HG2' ' A' ' 38' ' ' ARG . 0.3 OUTLIER -73.19 80.08 1.29 Allowed 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.3 0.571 . . . . 0.0 109.5 175.27 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . 0.498 HD22 ' HH ' ' A' ' 94' ' ' TYR . 3.1 tt -84.08 114.88 22.07 Favored 'General case' 0 N--CA 1.444 -0.755 0 CA-C-N 115.598 -0.728 . . . . 0.0 109.378 -178.074 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 58.2 t -99.28 119.52 47.4 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.706 0 CA-C-N 115.296 -0.865 . . . . 0.0 110.229 -177.381 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . 0.708 HD21 ' HB3' ' A' ' 41' ' ' GLU . 65.8 mt -98.3 131.37 44.67 Favored 'General case' 0 C--N 1.316 -0.87 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 176.964 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.401 ' OG1' ' HA ' ' A' ' 42' ' ' VAL . 36.2 p -116.87 130.56 56.79 Favored 'General case' 0 C--N 1.318 -0.799 0 N-CA-C 109.973 -0.38 . . . . 0.0 109.973 177.021 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 5.8 t70 -157.56 161.93 38.78 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 -178.72 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . 0.684 HD13 HG22 ' A' ' 79' ' ' ILE . 48.7 mm -76.63 95.37 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-O 120.835 0.35 . . . . 0.0 110.145 -177.716 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 56.8 mtpt 50.36 70.29 2.12 Favored Pre-proline 0 CA--C 1.535 0.373 0 CA-C-N 115.192 -0.913 . . . . 0.0 111.68 177.437 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . 0.68 ' HD2' ' HG2' ' A' ' 76' ' ' ARG . 37.0 Cg_endo -64.76 155.61 66.32 Favored 'Trans proline' 0 C--N 1.345 0.361 0 C-N-CA 123.455 2.77 . . . . 0.0 112.865 -179.121 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 11.4 p -89.52 -34.37 16.42 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.705 -0.679 . . . . 0.0 110.742 177.792 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 88.8 m-70 -81.09 131.27 35.29 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.376 -177.902 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -68.46 128.05 24.08 Favored Glycine 0 N--CA 1.449 -0.473 0 CA-C-N 115.763 -0.653 . . . . 0.0 111.483 176.121 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 127.22 -23.36 5.5 Favored Glycine 0 N--CA 1.447 -0.614 0 N-CA-C 111.248 -0.741 . . . . 0.0 111.248 -176.632 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . 0.443 HG22 ' CB ' ' A' ' 64' ' ' LEU . 41.0 mt -93.83 136.62 24.89 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 109.606 -0.516 . . . . 0.0 109.606 176.64 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.459 HG12 ' H ' ' A' ' 77' ' ' ASP . 64.3 t -74.12 135.32 27.73 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-O 120.866 0.365 . . . . 0.0 110.029 179.95 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' ARG . . . . . 0.68 ' HG2' ' HD2' ' A' ' 69' ' ' PRO . 26.6 mtp85 -89.74 21.03 3.71 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.907 -0.588 . . . . 0.0 111.856 -174.096 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . 0.459 ' H ' HG12 ' A' ' 75' ' ' VAL . 1.1 m-20 -80.19 160.62 25.57 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.785 0.326 . . . . 0.0 110.843 -179.396 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 11.0 t70 -75.22 152.93 38.29 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.934 -173.789 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . 0.684 HG22 HD13 ' A' ' 67' ' ' ILE . 12.4 tt -91.15 -31.42 5.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.883 -175.475 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 11.1 t -99.73 -24.47 14.69 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.291 0.567 . . . . 0.0 109.98 -177.184 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 27.9 m -126.6 74.66 74.74 Favored Pre-proline 0 C--N 1.328 -0.362 0 CA-C-N 115.942 -0.572 . . . . 0.0 109.876 172.472 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 98.1 Cg_endo -90.93 -162.27 0.11 Allowed 'Trans proline' 0 N--CA 1.459 -0.541 0 C-N-CA 123.379 2.72 . . . . 0.0 113.219 -174.071 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 94.8 mtt180 -126.2 116.45 21.33 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.348 178.319 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' MET . . . . . 0.814 ' HA ' ' HD2' ' A' ' 87' ' ' TYR . 25.3 mtp -66.14 -18.5 65.39 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 112.252 0.464 . . . . 0.0 112.252 -177.259 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.402 ' HA ' ' HD3' ' A' ' 88' ' ' ARG . 10.8 pt-20 -65.63 -25.78 67.52 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.094 0.473 . . . . 0.0 110.406 179.335 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 68.3 mt -73.54 -36.74 48.55 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 115.77 -0.65 . . . . 0.0 109.922 177.06 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . 0.814 ' HD2' ' HA ' ' A' ' 84' ' ' MET . 74.2 m-85 -77.92 -30.56 50.65 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.633 -0.712 . . . . 0.0 110.754 -178.242 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . 0.402 ' HD3' ' HA ' ' A' ' 85' ' ' GLU . 69.9 mtp180 -58.17 125.25 22.39 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.964 178.81 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . 0.49 ' HA3' ' NH2' ' A' ' 38' ' ' ARG . . . 97.71 -8.68 63.88 Favored Glycine 0 N--CA 1.447 -0.605 0 C-N-CA 120.821 -0.704 . . . . 0.0 112.45 179.016 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -74.82 142.63 44.19 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 120.777 0.322 . . . . 0.0 110.373 178.277 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -94.39 -18.02 21.96 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.513 179.333 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . 0.413 HD21 ' N ' ' A' ' 93' ' ' ILE . 3.6 tt -153.72 140.05 18.59 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.337 -179.154 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.569 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 71.6 mt -132.24 126.17 55.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 N-CA-C 109.032 -0.729 . . . . 0.0 109.032 178.139 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' TYR . . . . . 0.498 ' HH ' HD22 ' A' ' 62' ' ' LEU . 2.0 p90 -135.29 167.18 21.5 Favored 'General case' 0 C--N 1.32 -0.699 0 C-N-CA 120.663 -0.415 . . . . 0.0 110.535 -178.258 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' SER . . . . . 0.626 ' HA ' ' OE1' ' A' ' 41' ' ' GLU . 4.8 p -153.93 120.32 5.47 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.632 -178.447 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' ILE . . . . . 0.552 ' HB ' ' CE1' ' A' ' 47' ' ' PHE . 46.8 mm -80.81 97.23 3.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.684 179.374 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 2.2 tmt_? 52.66 76.91 0.48 Allowed Pre-proline 0 CA--C 1.534 0.353 0 CA-C-N 114.997 -1.001 . . . . 0.0 111.393 177.921 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 69.1 Cg_endo -89.85 161.99 5.06 Favored 'Trans proline' 0 N--CA 1.457 -0.655 0 C-N-CA 122.856 2.371 . . . . 0.0 112.343 177.589 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . 0.411 ' HB2' ' HG2' ' A' ' 101' ' ' GLU . 14.6 Cg_endo -60.12 147.64 92.51 Favored 'Trans proline' 0 C--N 1.345 0.367 0 C-N-CA 122.275 1.983 . . . . 0.0 111.858 174.64 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -78.13 33.55 0.19 Allowed 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.928 -176.34 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' GLU . . . . . 0.639 ' HG3' HG23 ' A' ' 102' ' ' ILE . 9.7 pt-20 -116.09 -23.35 8.52 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.685 0.278 . . . . 0.0 110.712 176.549 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.639 HG23 ' HG3' ' A' ' 101' ' ' GLU . 30.1 pt -109.83 -0.26 9.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 N-CA-C 112.006 0.373 . . . . 0.0 112.006 -174.667 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' HIS . . . . . 0.716 ' HD2' ' HB ' ' A' ' 129' ' ' THR . 22.1 p-80 -60.66 -43.4 97.67 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 121.093 0.473 . . . . 0.0 110.817 -178.228 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 4.0 p -73.78 -29.41 62.17 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.987 -0.552 . . . . 0.0 110.742 179.094 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.501 ' O ' HG21 ' A' ' 109' ' ' VAL . 2.4 m -71.49 -45.47 62.39 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.224 -179.555 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 74.5 mt -60.91 -39.77 90.61 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.229 -179.846 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' MET . . . . . 0.443 ' HA ' HD21 ' A' ' 117' ' ' LEU . 51.7 ttm -60.45 -45.61 93.06 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.49 -179.23 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' ARG . . . . . 0.441 ' HG2' ' O ' ' A' ' 105' ' ' SER . 15.1 ptm180 -74.21 -24.1 59.29 Favored 'General case' 0 C--N 1.327 -0.409 0 C-N-CA 120.978 -0.289 . . . . 0.0 110.89 -177.384 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.66 HG11 ' HE2' ' A' ' 84' ' ' MET . 81.1 t -72.34 -43.61 64.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 173.954 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -58.24 -42.2 85.85 Favored 'General case' 0 CA--C 1.52 -0.197 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.551 177.926 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.779 ' HA ' ' HB2' ' A' ' 148' ' ' ALA . 35.2 t70 -65.61 -40.27 92.43 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.965 -179.769 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -68.21 -37.47 80.9 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.551 -0.75 . . . . 0.0 112.12 -178.218 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 21.5 m -92.99 -22.82 5.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-O 120.794 0.33 . . . . 0.0 111.549 -177.044 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 85.91 54.41 2.77 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.971 -0.633 . . . . 0.0 112.172 178.935 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -132.73 155.87 48.07 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 120.739 0.304 . . . . 0.0 110.917 -178.975 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 23.9 ttm180 -81.53 127.6 33.01 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 176.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . 0.569 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 55.8 tp -93.3 123.94 36.93 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.022 179.348 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 66.5 mt -120.16 120.32 62.64 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 CA-C-O 120.939 0.4 . . . . 0.0 110.641 178.376 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 69.3 mt -120.13 126.57 75.42 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.165 179.331 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 120' ' ' LYS . . . . . 0.732 ' HG2' ' HB3' ' A' ' 143' ' ' PHE . 5.9 tmtt? -120.97 96.33 48.63 Favored Pre-proline 0 C--N 1.325 -0.49 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.118 178.379 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -88.8 -163.62 0.15 Allowed 'Trans proline' 0 C--O 1.238 0.497 0 C-N-CA 122.928 2.419 . . . . 0.0 112.33 177.098 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -70.54 -178.72 1.86 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.29 -0.413 . . . . 0.0 110.901 177.311 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 9.6 t -81.4 -35.26 30.96 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.904 0.383 . . . . 0.0 110.95 -176.39 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -113.74 52.54 0.64 Allowed Glycine 0 N--CA 1.448 -0.556 0 N-CA-C 110.629 -0.988 . . . . 0.0 110.629 175.852 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 36.4 tt0 -138.14 116.61 12.03 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.466 -0.367 . . . . 0.0 110.114 -173.354 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 8.1 t70 -91.71 163.19 14.18 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.987 -0.552 . . . . 0.0 110.117 -177.264 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 15.9 mt -93.2 -10.98 9.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 N-CA-C 110.176 -0.305 . . . . 0.0 110.176 -177.716 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 19.2 m 47.41 32.08 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.764 0 C-N-CA 124.167 0.987 . . . . 0.0 112.533 179.664 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 129' ' ' THR . . . . . 0.716 ' HB ' ' HD2' ' A' ' 103' ' ' HIS . 14.9 t -109.05 157.99 18.17 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.405 -179.843 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 130' ' ' GLU . . . . . 0.4 ' OE2' ' HD2' ' A' ' 131' ' ' ARG . 1.1 tm-20 -58.08 122.75 13.83 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 108.763 -0.829 . . . . 0.0 108.763 176.086 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 131' ' ' ARG . . . . . 0.4 ' HD2' ' OE2' ' A' ' 130' ' ' GLU . 0.0 OUTLIER -52.87 112.11 0.79 Allowed 'General case' 0 N--CA 1.464 0.24 0 CA-C-O 122.148 0.975 . . . . 0.0 111.921 -171.848 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 8.3 tppt? -144.13 -32.8 0.42 Allowed 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 114.582 -1.19 . . . . 0.0 109.302 -177.734 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 133' ' ' MET . . . . . 0.806 ' HG2' ' HB2' ' A' ' 146' ' ' TYR . 83.4 mtp -87.17 171.75 10.44 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.247 -0.888 . . . . 0.0 110.459 -177.64 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 14.2 ptmt -131.16 146.66 52.42 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.953 -175.268 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . 0.475 HD11 ' HD2' ' A' ' 142' ' ' TYR . 56.7 tp -79.75 129.84 34.82 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.454 176.715 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 136' ' ' VAL . . . . . 0.404 HG23 ' CD1' ' A' ' 143' ' ' PHE . 0.0 OUTLIER -127.66 129.8 70.23 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.702 0 CA-C-O 121.162 0.506 . . . . 0.0 111.162 178.811 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 15.4 m120 -109.85 122.25 47.11 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.31 -0.859 . . . . 0.0 109.234 177.739 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 61.4 t80 -137.67 125.35 22.32 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 120.535 0.207 . . . . 0.0 110.67 -177.475 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 69.26 -88.92 0.25 Allowed Glycine 0 N--CA 1.448 -0.547 0 N-CA-C 111.626 -0.589 . . . . 0.0 111.626 179.225 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 140' ' ' ARG . . . . . 0.633 ' HA ' ' NE ' ' A' ' 140' ' ' ARG . 2.1 mmp_? -143.72 9.96 1.58 Allowed 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 115.446 -0.377 . . . . 0.0 111.182 175.91 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 141' ' ' THR . . . . . 0.582 ' HB ' ' HB3' ' A' ' 21' ' ' MET . 15.2 t -118.6 155.23 31.31 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.801 0.334 . . . . 0.0 110.611 -179.678 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 142' ' ' TYR . . . . . 0.475 ' HD2' HD11 ' A' ' 135' ' ' LEU . 32.4 p90 -133.58 141.22 47.59 Favored 'General case' 0 N--CA 1.448 -0.533 0 CA-C-O 121.086 0.469 . . . . 0.0 109.992 176.704 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 143' ' ' PHE . . . . . 0.732 ' HB3' ' HG2' ' A' ' 120' ' ' LYS . 11.6 p90 -153.89 -175.98 5.63 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 115.429 -0.805 . . . . 0.0 109.733 -177.006 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 95.7 m-85 -116.98 125.36 51.29 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 110.308 -0.256 . . . . 0.0 110.308 179.375 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 145' ' ' GLU . . . . . . . . . . . . . 21.6 pt-20 -114.05 160.92 18.36 Favored 'General case' 0 C--N 1.321 -0.649 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 176.626 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . 0.806 ' HB2' ' HG2' ' A' ' 133' ' ' MET . 42.3 t80 -141.87 123.44 15.03 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-N 115.971 -0.558 . . . . 0.0 109.693 175.617 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 147' ' ' ILE . . . . . 0.443 HD13 ' N ' ' A' ' 147' ' ' ILE . 3.1 mp -93.03 100.94 12.07 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.834 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 -178.653 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . 0.779 ' HB2' ' HA ' ' A' ' 111' ' ' ASP . . . -67.99 120.16 13.8 Favored 'General case' 0 N--CA 1.447 -0.6 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 174.378 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -62.03 143.1 57.06 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.27 0.557 . . . . 0.0 110.188 -176.06 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 8.2 t -96.15 126.34 48.78 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.901 0 CA-C-N 115.608 -0.723 . . . . 0.0 110.339 -174.779 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 151' ' ' ARG . . . . . . . . . . . . . 12.5 ptm180 -72.52 163.41 28.08 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 115.518 -0.764 . . . . 0.0 110.656 177.728 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 3.8 p -72.9 161.68 30.42 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 115.976 -0.557 . . . . 0.0 110.207 173.48 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 11.9 mmt180 . . . . . 0 C--O 1.25 1.08 0 CA-C-O 118.511 -0.756 . . . . 0.0 111.007 -178.046 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 13.5 tpt . . . . . 0 N--CA 1.478 0.967 0 N-CA-C 110.044 -0.354 . . . . 0.0 110.044 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -172.0 -117.45 0.44 Allowed Glycine 0 N--CA 1.447 -0.595 0 N-CA-C 111.179 -0.768 . . . . 0.0 111.179 179.684 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 48.7 m 53.6 37.42 25.9 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.156 0.503 . . . . 0.0 111.525 177.113 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 16.2 m -94.31 125.56 39.02 Favored 'General case' 0 N--CA 1.45 -0.465 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.148 179.786 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 71.4 m-70 -86.45 85.87 7.33 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.209 0.528 . . . . 0.0 110.315 -178.929 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 26.7 t-80 -114.66 86.13 2.38 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.506 -0.77 . . . . 0.0 109.942 -179.874 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 11.3 p-80 -154.63 172.81 17.26 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.838 -0.619 . . . . 0.0 109.718 177.522 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 46.0 m80 -103.71 116.69 32.79 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 120.912 0.387 . . . . 0.0 110.749 -175.455 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 20.0 p80 -105.95 164.64 11.8 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.133 179.968 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 47.6 t-80 64.35 101.98 0.04 OUTLIER 'General case' 0 N--CA 1.466 0.332 0 O-C-N 123.878 0.736 . . . . 0.0 111.635 179.109 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 10.1 t -107.04 138.83 42.46 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.026 -0.534 . . . . 0.0 109.561 176.241 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 3.8 p -73.03 128.99 37.09 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 120.735 0.303 . . . . 0.0 110.529 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -90.88 151.55 21.24 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.878 -0.677 . . . . 0.0 112.526 -178.188 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 96.3 mt -125.17 115.27 20.17 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 110.034 -0.358 . . . . 0.0 110.034 179.493 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 31.7 m -92.48 145.49 30.63 Favored Pre-proline 0 C--N 1.32 -0.681 0 CA-C-N 116.53 -0.305 . . . . 0.0 111.039 -179.295 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 16.6 Cg_exo -68.61 156.8 64.32 Favored 'Trans proline' 0 C--O 1.234 0.279 0 C-N-CA 122.716 2.278 . . . . 0.0 111.661 176.03 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -141.74 59.95 1.48 Allowed 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 121.225 0.536 . . . . 0.0 110.894 -177.085 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -89.92 0.94 80.03 Favored Glycine 0 N--CA 1.451 -0.305 0 CA-C-N 115.698 -0.683 . . . . 0.0 111.868 178.265 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' SER . . . . . 0.648 ' HB3' ' CD1' ' A' ' 22' ' ' TRP . 51.0 m -86.06 76.48 9.79 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.147 0.499 . . . . 0.0 110.119 177.405 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 54.7 m80 -62.98 -31.38 72.49 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.469 -0.787 . . . . 0.0 112.039 -174.022 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' MET . . . . . 0.458 ' CG ' ' HB ' ' A' ' 141' ' ' THR . 50.1 ttm -69.96 -28.54 65.63 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.239 0.543 . . . . 0.0 110.469 179.605 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' TRP . . . . . 0.648 ' CD1' ' HB3' ' A' ' 19' ' ' SER . 72.5 m95 -82.61 -19.25 38.71 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.748 -0.66 . . . . 0.0 111.119 -174.928 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . 0.438 ' O ' HG21 ' A' ' 27' ' ' VAL . 14.6 m120 -60.78 -36.99 80.37 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.522 175.528 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 43.9 m-20 -64.49 -45.16 88.53 Favored 'General case' 0 CA--C 1.52 -0.2 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.38 178.907 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 61.2 tp -55.13 -50.9 68.07 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.75 179.011 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -55.55 -47.03 77.0 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.912 -0.585 . . . . 0.0 111.639 -178.702 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.554 ' HA ' HD13 ' A' ' 30' ' ' ILE . 92.2 t -58.58 -37.09 62.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.471 -179.732 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 59.8 t80 -60.01 -45.89 91.27 Favored 'General case' 0 CA--C 1.534 0.339 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.042 -178.039 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.446 HG13 HD12 ' A' ' 118' ' ' ILE . 3.2 mp -64.09 -41.56 92.83 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.17 0 CA-C-O 120.973 0.416 . . . . 0.0 110.468 176.345 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.588 HG22 ' HB2' ' A' ' 58' ' ' SER . 90.6 mt -58.42 -44.67 89.22 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 115.739 -0.664 . . . . 0.0 111.357 -177.92 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 49.7 mtp180 -66.51 -33.82 76.55 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.463 -177.617 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 44.5 t -82.29 -25.81 33.67 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.416 -174.936 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 15.4 p -95.82 -81.82 0.4 Allowed 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.85 0.357 . . . . 0.0 111.746 -174.056 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 104.56 158.34 23.75 Favored Glycine 0 N--CA 1.447 -0.597 0 C-N-CA 120.937 -0.649 . . . . 0.0 111.8 -176.666 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 15.8 Cg_exo -68.67 139.58 44.61 Favored 'Trans proline' 0 N--CA 1.465 -0.164 0 C-N-CA 122.876 2.384 . . . . 0.0 112.415 -179.426 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 96.1 -4.67 65.32 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.577 -0.821 . . . . 0.0 112.568 178.502 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 29.6 p -96.48 -170.76 2.14 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 109.983 -0.377 . . . . 0.0 109.983 -179.892 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . 0.753 ' HB2' ' HA ' ' A' ' 90' ' ' ALA . 99.3 mtt180 -123.21 129.68 51.73 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.704 0.287 . . . . 0.0 110.661 174.429 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.752 HG22 HG22 ' A' ' 60' ' ' VAL . 98.7 t -129.41 121.9 54.39 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 N-CA-C 109.203 -0.665 . . . . 0.0 109.203 175.218 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 34.0 t -106.0 130.83 56.93 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 CA-C-O 120.755 0.312 . . . . 0.0 111.502 -174.293 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . 0.719 ' HB3' HD22 ' A' ' 64' ' ' LEU . 7.8 tp10 -114.15 122.03 45.59 Favored 'General case' 0 C--O 1.239 0.5 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.012 175.24 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.479 HG13 HD23 ' A' ' 106' ' ' LEU . 24.2 t -100.8 89.0 1.55 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 115.773 -0.648 . . . . 0.0 110.489 179.842 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 148.11 55.94 0.02 OUTLIER Glycine 0 N--CA 1.448 -0.538 0 CA-C-N 115.54 -0.754 . . . . 0.0 111.366 -177.879 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . 0.574 ' HB3' ' HB3' ' A' ' 64' ' ' LEU . . . -84.97 76.94 10.21 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.986 0.422 . . . . 0.0 111.961 -173.962 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . 0.599 ' O ' ' HG ' ' A' ' 48' ' ' LEU . . . -89.5 -157.02 32.59 Favored Glycine 0 C--O 1.226 -0.367 0 C-N-CA 120.88 -0.676 . . . . 0.0 111.781 175.823 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . 0.436 HH11 ' HD3' ' A' ' 46' ' ' ARG . 0.0 OUTLIER -74.89 -15.44 60.7 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.984 0.421 . . . . 0.0 110.811 178.802 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 32.0 p90 -85.66 41.16 0.89 Allowed 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.53 -175.122 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . 0.768 HD11 HD11 ' A' ' 74' ' ' ILE . 94.2 mt -80.96 19.16 0.9 Allowed 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 112.379 0.511 . . . . 0.0 112.379 -176.42 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 32.7 p90 -61.29 -27.39 68.44 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.712 0.291 . . . . 0.0 110.918 179.313 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 98.6 t -69.02 -51.28 45.64 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.237 175.43 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' SER . . . . . 0.415 ' O ' ' HG2' ' A' ' 55' ' ' ARG . 1.7 m -61.75 -45.3 94.51 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 121.384 0.612 . . . . 0.0 110.201 -179.868 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.431 ' CG ' ' HZ1' ' A' ' 56' ' ' LYS . 25.6 t70 -58.8 -41.12 85.99 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 114.7 -1.137 . . . . 0.0 111.119 -179.454 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 80.6 t80 -66.99 -52.01 47.93 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.693 178.295 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.528 HG21 HG12 ' A' ' 30' ' ' ILE . 83.8 mt -58.23 -47.27 87.85 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-N 115.981 -0.554 . . . . 0.0 112.075 -176.041 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . 0.415 ' HG2' ' O ' ' A' ' 51' ' ' SER . 15.6 ptm180 -68.64 -20.7 64.48 Favored 'General case' 0 CA--C 1.533 0.289 0 N-CA-C 112.535 0.569 . . . . 0.0 112.535 -172.649 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . 0.431 ' HZ1' ' CG ' ' A' ' 52' ' ' ASP . 23.0 mtmm -84.74 -29.93 25.11 Favored 'General case' 0 C--N 1.328 -0.345 0 C-N-CA 120.705 -0.398 . . . . 0.0 111.251 179.28 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 16.4 m-70 -86.48 -54.2 4.55 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.235 0.54 . . . . 0.0 109.586 177.744 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' SER . . . . . 0.588 ' HB2' HG22 ' A' ' 30' ' ' ILE . 10.9 t -104.22 121.63 43.7 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 115.677 -0.692 . . . . 0.0 109.532 179.052 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 3.0 mppt? -84.79 61.45 6.79 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-O 121.897 0.856 . . . . 0.0 110.241 178.951 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.752 HG22 HG22 ' A' ' 39' ' ' VAL . 2.5 p -93.62 153.34 3.39 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.792 0 CA-C-N 114.167 -1.379 . . . . 0.0 109.299 177.232 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 43.9 m-20 -73.33 82.23 1.39 Allowed 'General case' 0 CA--C 1.518 -0.254 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 172.598 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . 0.543 HD23 ' HH ' ' A' ' 94' ' ' TYR . 2.7 tt -80.93 105.45 12.17 Favored 'General case' 0 C--N 1.321 -0.651 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 179.549 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 48.8 t -96.96 117.14 40.95 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.439 -175.829 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . 0.719 HD22 ' HB3' ' A' ' 41' ' ' GLU . 80.0 mt -99.77 130.27 45.96 Favored 'General case' 0 C--N 1.314 -0.954 0 CA-C-N 115.58 -0.737 . . . . 0.0 109.185 177.249 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 22.9 p -117.86 129.4 55.63 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 120.555 0.217 . . . . 0.0 111.047 179.334 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 25.5 t70 -165.05 153.72 12.19 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.917 -0.583 . . . . 0.0 109.931 178.527 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . 0.488 HG22 ' HE3' ' A' ' 68' ' ' LYS . 54.3 mt -76.98 100.39 2.57 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-O 120.93 0.395 . . . . 0.0 110.605 -178.289 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' LYS . . . . . 0.824 ' HZ3' ' HB2' ' A' ' 68' ' ' LYS . 7.4 mtmp? 70.33 83.97 0.15 Allowed Pre-proline 0 C--O 1.233 0.214 0 CA-C-N 115.119 -0.946 . . . . 0.0 110.53 -179.687 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . 0.929 ' HB3' ' HB ' ' A' ' 74' ' ' ILE . 11.2 Cg_endo -56.78 140.09 90.35 Favored 'Trans proline' 0 C--O 1.232 0.205 0 C-N-CA 123.714 2.942 . . . . 0.0 113.968 -175.653 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 28.6 m -103.12 16.88 25.43 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.483 -0.78 . . . . 0.0 110.267 174.837 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 22.3 t-80 -146.35 174.44 11.36 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 -179.279 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -99.89 119.14 6.4 Favored Glycine 0 N--CA 1.449 -0.457 0 C-N-CA 120.823 -0.703 . . . . 0.0 112.535 -175.837 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 120.86 -13.62 9.81 Favored Glycine 0 N--CA 1.454 -0.136 0 C-N-CA 120.904 -0.665 . . . . 0.0 112.004 179.393 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . 0.929 ' HB ' ' HB3' ' A' ' 69' ' ' PRO . 55.8 mt -79.09 139.4 18.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-O 120.763 0.316 . . . . 0.0 110.724 -179.746 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 57.3 t -85.16 126.64 40.35 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 176.126 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' ARG . . . . . 0.463 ' HA ' ' HD3' ' A' ' 69' ' ' PRO . 1.6 ppt_? -77.68 28.08 0.17 Allowed 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 112.491 0.552 . . . . 0.0 112.491 -176.344 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 16.1 t70 -75.71 157.24 33.84 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 110.117 -0.327 . . . . 0.0 110.117 -177.579 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . 0.535 ' OD1' HG22 ' A' ' 80' ' ' THR . 5.9 t70 -88.47 161.41 17.03 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 120.691 0.281 . . . . 0.0 110.875 -171.984 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 8.5 tp -98.47 -28.23 3.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-O 120.829 0.347 . . . . 0.0 111.029 -177.926 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.535 HG22 ' OD1' ' A' ' 78' ' ' ASP . 15.0 t -90.02 -1.35 57.95 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.637 0.732 . . . . 0.0 109.165 176.868 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 34.5 t -152.12 72.32 7.78 Favored Pre-proline 0 C--N 1.322 -0.594 0 CA-C-N 114.738 -1.119 . . . . 0.0 108.984 175.069 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.523 ' HB2' ' HE2' ' A' ' 87' ' ' TYR . 91.1 Cg_endo -89.47 141.55 4.01 Favored 'Trans proline' 0 N--CA 1.457 -0.633 0 C-N-CA 122.829 2.353 . . . . 0.0 112.798 -177.521 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' ARG . . . . . 0.74 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 56.7 mtt-85 -83.49 113.38 20.75 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.047 178.305 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' MET . . . . . 0.7 ' HA ' ' HD2' ' A' ' 87' ' ' TYR . 29.6 mtp -68.06 -17.4 64.38 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.551 -0.295 . . . . 0.0 110.995 178.168 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.74 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 9.8 pt-20 -61.89 -23.81 66.54 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.934 0.397 . . . . 0.0 110.653 176.592 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 72.6 mt -85.11 -34.48 8.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.48 178.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . 0.7 ' HD2' ' HA ' ' A' ' 84' ' ' MET . 75.0 m-85 -78.23 -30.75 48.91 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.429 -177.243 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . 0.423 ' HG2' HG13 ' A' ' 113' ' ' VAL . 53.2 mtp180 -65.68 140.58 58.48 Favored 'General case' 0 CA--C 1.516 -0.362 0 CA-C-O 121.403 0.621 . . . . 0.0 110.882 178.701 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 91.08 1.73 72.29 Favored Glycine 0 N--CA 1.447 -0.61 0 CA-C-N 115.199 -0.909 . . . . 0.0 111.894 -178.044 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . 0.753 ' HA ' ' HB2' ' A' ' 38' ' ' ARG . . . -85.16 138.77 32.16 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.995 0.426 . . . . 0.0 110.75 178.88 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -89.16 -24.67 22.14 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.079 178.379 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . 0.509 HD22 ' N ' ' A' ' 93' ' ' ILE . 4.7 tt -153.49 143.15 21.85 Favored 'General case' 0 N--CA 1.45 -0.448 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.206 -178.345 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.509 ' N ' HD22 ' A' ' 92' ' ' LEU . 72.7 mt -132.03 133.73 60.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 N-CA-C 109.111 -0.7 . . . . 0.0 109.111 176.551 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' TYR . . . . . 0.543 ' HH ' HD23 ' A' ' 62' ' ' LEU . 1.2 p90 -138.37 161.24 37.46 Favored 'General case' 0 C--N 1.321 -0.636 0 C-N-CA 120.707 -0.397 . . . . 0.0 110.119 -178.693 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' SER . . . . . 0.629 ' HA ' ' OE2' ' A' ' 41' ' ' GLU . 19.4 m -146.87 115.65 6.82 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.058 -178.91 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 78.9 mt -77.23 94.35 1.31 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.752 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.619 179.45 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . 0.526 ' HG3' ' OE1' ' A' ' 125' ' ' GLU . 19.6 ttp85 58.61 82.64 0.23 Allowed Pre-proline 0 CA--C 1.531 0.244 0 CA-C-N 114.608 -1.178 . . . . 0.0 111.66 -177.628 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 88.3 Cg_endo -83.74 136.66 7.36 Favored 'Trans proline' 0 N--CA 1.456 -0.724 0 C-N-CA 122.467 2.111 . . . . 0.0 111.638 176.136 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . 0.735 ' HB2' ' HG2' ' A' ' 101' ' ' GLU . 22.4 Cg_exo -63.32 149.94 89.9 Favored 'Trans proline' 0 C--O 1.238 0.478 0 C-N-CA 122.581 2.187 . . . . 0.0 111.733 177.951 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -73.76 42.22 0.13 Allowed 'General case' 0 N--CA 1.465 0.284 0 CA-C-O 121.304 0.573 . . . . 0.0 111.812 -178.216 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' GLU . . . . . 0.735 ' HG2' ' HB2' ' A' ' 99' ' ' PRO . 11.0 pt-20 -132.15 -26.24 1.93 Allowed 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.607 179.303 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.729 HG22 ' HG3' ' A' ' 101' ' ' GLU . 40.1 pt -119.88 -11.64 10.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.55 -175.062 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' HIS . . . . . 0.724 ' HD2' ' HB ' ' A' ' 129' ' ' THR . 4.8 p-80 -56.72 -45.24 82.0 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.989 -0.551 . . . . 0.0 111.612 -175.147 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 8.5 m -61.35 -35.05 76.36 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.002 0.43 . . . . 0.0 110.908 179.529 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.795 ' HA ' ' HE ' ' A' ' 108' ' ' ARG . 67.1 m -73.3 -36.71 66.32 Favored 'General case' 0 N--CA 1.451 -0.408 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.39 179.703 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . 0.479 HD23 HG13 ' A' ' 42' ' ' VAL . 85.0 mt -64.39 -42.08 96.31 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.73 178.914 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' MET . . . . . 0.506 ' HA ' HD23 ' A' ' 117' ' ' LEU . 81.4 mtp -60.5 -44.27 96.17 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.539 -179.292 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' ARG . . . . . 0.795 ' HE ' ' HA ' ' A' ' 105' ' ' SER . 31.6 ptt180 -74.73 -20.77 59.69 Favored 'General case' 0 CA--C 1.53 0.205 0 C-N-CA 121.048 -0.261 . . . . 0.0 111.555 -178.263 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.523 HG23 ' O ' ' A' ' 105' ' ' SER . 55.9 t -74.06 -43.47 51.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.749 0.309 . . . . 0.0 110.333 175.421 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -57.24 -45.66 83.73 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.972 -179.822 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.945 ' HA ' ' HB3' ' A' ' 148' ' ' ALA . 4.0 t70 -71.72 -28.71 63.87 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 121.174 0.511 . . . . 0.0 110.254 -177.284 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -74.49 -33.01 62.74 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.953 -0.567 . . . . 0.0 111.809 -179.64 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.423 HG13 ' HG2' ' A' ' 88' ' ' ARG . 34.0 m -95.52 -24.78 4.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 C-N-CA 121.088 -0.245 . . . . 0.0 111.097 179.578 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . 0.431 ' HA2' ' O ' ' A' ' 149' ' ' GLU . . . 89.87 46.5 4.2 Favored Glycine 0 N--CA 1.453 -0.226 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.993 176.303 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -124.66 150.25 46.29 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 120.533 0.206 . . . . 0.0 110.85 -178.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 116' ' ' ARG . . . . . 0.491 ' HD3' ' OE1' ' A' ' 145' ' ' GLU . 14.7 ttm180 -70.65 119.92 15.5 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 177.93 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . 0.506 HD23 ' HA ' ' A' ' 107' ' ' MET . 57.6 tp -90.58 118.59 30.15 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 -179.765 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . 0.446 HD12 HG13 ' A' ' 29' ' ' ILE . 61.9 mt -115.98 112.71 40.77 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.654 0 CA-C-O 121.289 0.566 . . . . 0.0 110.594 179.455 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 62.8 mt -110.97 119.03 58.71 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.845 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.029 178.474 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 120' ' ' LYS . . . . . 0.629 ' HG2' ' HB3' ' A' ' 143' ' ' PHE . 9.0 tmtm? -116.33 96.97 48.99 Favored Pre-proline 0 C--N 1.322 -0.616 0 CA-C-N 116.162 -0.472 . . . . 0.0 109.994 178.885 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 0.9 OUTLIER -77.65 -178.71 4.81 Favored 'Trans proline' 0 N--CA 1.459 -0.522 0 C-N-CA 122.652 2.235 . . . . 0.0 111.442 174.373 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 5.7 mp -63.87 177.68 0.73 Allowed 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.957 -179.439 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 15.2 m -49.45 -65.15 0.61 Allowed 'General case' 0 CA--C 1.53 0.194 0 CA-C-N 115.71 -0.677 . . . . 0.0 111.888 -175.357 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -106.54 64.86 0.27 Allowed Glycine 0 N--CA 1.448 -0.531 0 C-N-CA 120.669 -0.777 . . . . 0.0 111.173 175.452 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . 0.526 ' OE1' ' HG3' ' A' ' 97' ' ' ARG . 40.8 tt0 -140.11 145.48 37.65 Favored 'General case' 0 N--CA 1.448 -0.558 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 -174.712 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 10.3 t70 -123.02 174.67 7.05 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.356 -179.169 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.535 ' HB ' HG23 ' A' ' 129' ' ' THR . 6.9 mt -93.6 -19.85 6.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.055 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . 0.432 HG22 ' O ' ' A' ' 127' ' ' ILE . 5.9 m 53.22 24.07 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.666 0 C-N-CA 124.628 1.171 . . . . 0.0 112.686 179.179 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 129' ' ' THR . . . . . 0.786 HG22 ' H ' ' A' ' 130' ' ' GLU . 1.7 t -82.07 -69.68 0.6 Allowed 'General case' 0 CA--C 1.536 0.412 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.139 174.747 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 130' ' ' GLU . . . . . 0.786 ' H ' HG22 ' A' ' 129' ' ' THR . 6.9 pt-20 -176.78 -174.68 0.57 Allowed 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 108.6 -0.889 . . . . 0.0 108.6 174.637 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 131' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -91.91 27.07 2.21 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 121.213 0.53 . . . . 0.0 110.699 -177.299 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 132' ' ' LYS . . . . . 0.535 ' H ' ' HG3' ' A' ' 130' ' ' GLU . 16.5 tppt? -66.99 -24.49 66.04 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.59 178.045 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 133' ' ' MET . . . . . 0.777 ' HG2' ' HB2' ' A' ' 146' ' ' TYR . 93.4 mtp -104.86 155.76 18.63 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.578 -177.533 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 12.9 ptmt -106.12 139.73 40.19 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.446 -175.789 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . 0.824 HD11 ' HD2' ' A' ' 142' ' ' TYR . 55.2 tp -78.81 125.27 29.14 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 115.861 -0.608 . . . . 0.0 110.428 177.709 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -119.81 147.16 23.64 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.808 179.059 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 137' ' ' ASN . . . . . 0.55 ' ND2' ' HB3' ' A' ' 142' ' ' TYR . 18.2 m120 -120.72 119.1 31.82 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.92 -0.582 . . . . 0.0 109.63 178.411 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 67.7 t80 -131.74 130.98 42.6 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 109.916 -0.401 . . . . 0.0 109.916 179.289 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 71.66 -91.21 0.49 Allowed Glycine 0 N--CA 1.441 -1.0 0 N-CA-C 111.21 -0.756 . . . . 0.0 111.21 -176.821 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 140' ' ' ARG . . . . . 0.439 ' HD3' ' HA ' ' A' ' 140' ' ' ARG . 29.1 mmt180 -150.21 12.81 0.75 Allowed 'General case' 0 C--N 1.32 -0.708 0 CA-C-O 120.807 0.337 . . . . 0.0 110.556 179.308 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 141' ' ' THR . . . . . 0.458 ' HB ' ' CG ' ' A' ' 21' ' ' MET . 7.1 t -125.15 160.64 28.67 Favored 'General case' 0 C--N 1.322 -0.606 0 N-CA-C 109.865 -0.42 . . . . 0.0 109.865 -178.991 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 142' ' ' TYR . . . . . 0.824 ' HD2' HD11 ' A' ' 135' ' ' LEU . 20.8 p90 -126.83 149.64 49.6 Favored 'General case' 0 N--CA 1.449 -0.523 0 CA-C-O 121.405 0.621 . . . . 0.0 111.176 179.494 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 143' ' ' PHE . . . . . 0.629 ' HB3' ' HG2' ' A' ' 120' ' ' LYS . 19.5 p90 -156.39 179.3 9.39 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 114.823 -1.08 . . . . 0.0 109.417 -177.37 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -113.2 127.85 56.3 Favored 'General case' 0 C--N 1.319 -0.752 0 C-N-CA 120.963 -0.295 . . . . 0.0 110.451 -179.738 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 145' ' ' GLU . . . . . 0.491 ' OE1' ' HD3' ' A' ' 116' ' ' ARG . 17.5 pt-20 -114.85 157.04 23.84 Favored 'General case' 0 C--N 1.32 -0.681 0 N-CA-C 109.041 -0.726 . . . . 0.0 109.041 173.189 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . 0.777 ' HB2' ' HG2' ' A' ' 133' ' ' MET . 19.5 t80 -137.77 122.75 19.01 Favored 'General case' 0 C--N 1.31 -1.133 0 CA-C-N 116.054 -0.521 . . . . 0.0 109.638 176.07 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 2.2 mp -79.49 95.76 2.18 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.813 0 N-CA-C 108.442 -0.947 . . . . 0.0 108.442 174.91 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . 0.945 ' HB3' ' HA ' ' A' ' 111' ' ' ASP . . . -74.87 130.3 39.17 Favored 'General case' 0 N--CA 1.437 -1.083 0 CA-C-N 115.462 -0.79 . . . . 0.0 109.739 178.679 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . 0.581 ' OE1' ' HD3' ' A' ' 153' ' ' ARG . 74.4 mm-40 -65.16 179.56 0.7 Allowed 'General case' 0 C--N 1.315 -0.904 0 CA-C-O 122.032 0.92 . . . . 0.0 111.558 178.861 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 150' ' ' VAL . . . . . 0.608 ' HB ' ' HA ' ' A' ' 153' ' ' ARG . 39.2 t -116.08 135.27 56.78 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.111 0 CA-C-N 114.511 -1.222 . . . . 0.0 107.95 176.144 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 151' ' ' ARG . . . . . . . . . . . . . 26.3 mtp180 -62.49 106.74 0.81 Allowed 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 120.827 0.346 . . . . 0.0 110.077 -176.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 16.2 m 67.79 24.09 8.34 Favored 'General case' 0 C--N 1.333 -0.151 0 CA-C-N 115.001 -0.999 . . . . 0.0 110.811 -177.801 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 153' ' ' ARG . . . . . 0.608 ' HA ' ' HB ' ' A' ' 150' ' ' VAL . 21.1 mtm180 . . . . . 0 C--O 1.25 1.106 0 O-C-N 125.088 1.493 . . . . 0.0 114.247 -178.674 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 66.1 mtt . . . . . 0 N--CA 1.479 1.001 0 N-CA-C 110.097 -0.334 . . . . 0.0 110.097 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 81.01 -142.77 23.57 Favored Glycine 0 N--CA 1.448 -0.54 0 C-N-CA 120.933 -0.651 . . . . 0.0 111.932 178.281 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 43.0 t -132.78 135.35 45.65 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-O 121.025 0.44 . . . . 0.0 110.597 177.657 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 24.2 m -95.16 6.4 49.17 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 121.475 0.655 . . . . 0.0 109.555 176.503 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 62.0 t60 -112.8 110.32 20.35 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.185 -0.916 . . . . 0.0 110.142 179.401 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 48.5 t-80 -94.44 122.25 36.81 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 109.721 -0.474 . . . . 0.0 109.721 176.475 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 81.2 t60 -127.9 117.81 22.47 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.316 -177.405 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 5.9 p80 -76.37 128.18 34.32 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.169 -0.469 . . . . 0.0 109.893 176.598 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 20.1 t-80 -77.05 153.83 34.0 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.216 -177.577 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 15.6 p-80 -68.77 105.29 2.27 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.6 0.714 . . . . 0.0 109.809 175.855 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 23.1 t -145.04 162.05 37.91 Favored 'General case' 0 N--CA 1.446 -0.63 0 CA-C-N 115.393 -0.821 . . . . 0.0 110.192 -173.068 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 27.8 t -108.66 121.25 44.63 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 177.352 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -82.98 179.45 52.96 Favored Glycine 0 N--CA 1.446 -0.685 0 C-N-CA 120.618 -0.801 . . . . 0.0 112.223 -178.394 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . 0.488 HD12 HH12 ' A' ' 17' ' ' ARG . 2.7 pt? -71.49 152.94 42.59 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 120.665 0.269 . . . . 0.0 110.457 178.633 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 24.5 m -83.33 127.51 68.32 Favored Pre-proline 0 C--N 1.323 -0.558 0 CA-C-O 121.027 0.441 . . . . 0.0 110.859 179.291 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 30.7 Cg_endo -66.54 133.34 31.82 Favored 'Trans proline' 0 N--CA 1.46 -0.464 0 C-N-CA 121.951 1.767 . . . . 0.0 111.51 176.628 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . 0.564 ' HB2' ' CE1' ' A' ' 20' ' ' HIS . 11.1 mpt_? -81.01 63.09 5.24 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 116.421 -0.354 . . . . 0.0 111.028 -178.432 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . 0.474 ' O ' ' HG2' ' A' ' 21' ' ' MET . . . 64.62 -93.2 0.14 Allowed Glycine 0 C--N 1.331 0.266 0 CA-C-N 115.773 -0.649 . . . . 0.0 113.716 175.352 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 19.9 m -54.83 -24.92 25.22 Favored 'General case' 0 C--N 1.326 -0.431 0 N-CA-C 112.957 0.725 . . . . 0.0 112.957 -172.982 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' HIS . . . . . 0.564 ' CE1' ' HB2' ' A' ' 17' ' ' ARG . 51.6 m170 -54.52 -40.07 68.25 Favored 'General case' 0 N--CA 1.465 0.302 0 N-CA-C 111.784 0.29 . . . . 0.0 111.784 -177.668 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' MET . . . . . 0.474 ' HG2' ' O ' ' A' ' 18' ' ' GLY . 27.2 ptm -83.73 -16.75 43.68 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 120.746 0.307 . . . . 0.0 111.38 -177.513 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 95.5 m95 -91.19 -31.56 16.14 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.545 -0.298 . . . . 0.0 111.58 -176.943 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . 0.435 ' O ' HG21 ' A' ' 27' ' ' VAL . 4.4 m-20 -66.49 -40.72 89.42 Favored 'General case' 0 C--N 1.328 -0.348 0 C-N-CA 121.224 -0.19 . . . . 0.0 111.487 -177.015 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 38.8 m-20 -61.41 -39.44 90.78 Favored 'General case' 0 N--CA 1.466 0.35 0 CA-C-O 121.071 0.462 . . . . 0.0 110.411 177.644 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.57 HD23 ' HD3' ' A' ' 120' ' ' LYS . 25.0 tp -63.33 -42.95 98.99 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.648 -0.705 . . . . 0.0 110.59 176.863 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -59.68 -46.95 87.5 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.738 178.258 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.435 HG21 ' O ' ' A' ' 23' ' ' ASN . 90.3 t -55.59 -42.26 67.9 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.192 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.069 178.803 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 69.2 t80 -59.33 -45.16 92.11 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 121.024 0.44 . . . . 0.0 110.637 179.598 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 57.9 mt -67.07 -39.91 84.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.62 179.751 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.655 HG12 HG22 ' A' ' 54' ' ' ILE . 98.1 mt -59.9 -41.87 87.35 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.453 -0.794 . . . . 0.0 110.941 178.915 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 79.2 mtp180 -66.49 -37.64 85.51 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.882 -178.407 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 81.2 m -76.76 -18.0 58.72 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.214 -176.068 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 11.9 p -104.26 -84.37 0.48 Allowed 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.433 -178.556 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 99.69 160.47 28.82 Favored Glycine 0 N--CA 1.447 -0.626 0 C-N-CA 121.089 -0.577 . . . . 0.0 111.902 -176.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 11.5 Cg_exo -70.95 152.74 63.4 Favored 'Trans proline' 0 C--O 1.235 0.33 0 C-N-CA 122.743 2.296 . . . . 0.0 111.976 179.57 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 99.61 -26.35 24.73 Favored Glycine 0 N--CA 1.453 -0.228 0 C-N-CA 120.827 -0.701 . . . . 0.0 112.752 176.624 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 14.0 t -100.5 -166.99 1.38 Allowed 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 -178.846 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . 1.004 ' HG2' ' HA ' ' A' ' 90' ' ' ALA . 0.1 OUTLIER -130.94 136.53 48.65 Favored 'General case' 0 N--CA 1.446 -0.657 0 CA-C-O 121.113 0.483 . . . . 0.0 111.021 -176.767 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.47 HG21 HG22 ' A' ' 60' ' ' VAL . 95.9 t -129.16 135.82 61.04 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.603 0 CA-C-N 115.48 -0.782 . . . . 0.0 109.486 -179.916 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.489 HG12 ' CE2' ' A' ' 87' ' ' TYR . 38.7 t -108.11 128.19 63.72 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 CA-C-O 120.927 0.394 . . . . 0.0 111.31 -176.479 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . 0.571 ' HB3' HD22 ' A' ' 64' ' ' LEU . 41.1 tt0 -106.49 118.23 36.1 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.924 -0.58 . . . . 0.0 109.778 175.826 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.575 ' HB ' ' HG ' ' A' ' 95' ' ' SER . 62.9 t -97.21 120.48 46.6 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.671 -179.173 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 92.5 48.7 2.94 Favored Glycine 0 N--CA 1.447 -0.621 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.139 179.567 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -80.36 41.09 0.52 Allowed 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.063 0.459 . . . . 0.0 111.446 -176.861 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . 0.426 ' O ' ' HB2' ' A' ' 46' ' ' ARG . . . -81.29 81.58 1.62 Allowed Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.954 -0.641 . . . . 0.0 112.27 -178.332 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . 0.426 ' HB2' ' O ' ' A' ' 45' ' ' GLY . 82.9 mtm180 71.08 13.56 6.86 Favored 'General case' 0 N--CA 1.469 0.498 0 C-N-CA 123.238 0.615 . . . . 0.0 111.271 -179.44 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 74.6 m-85 -98.51 17.05 19.94 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.357 0.598 . . . . 0.0 109.706 176.864 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . 0.448 HD23 HD11 ' A' ' 74' ' ' ILE . 82.2 mt -62.14 -10.1 9.44 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 114.793 -1.094 . . . . 0.0 112.388 -174.655 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 73.9 t80 -57.85 -38.35 75.53 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 120.715 0.293 . . . . 0.0 110.837 179.167 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 60.4 t -73.54 -54.63 14.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.435 -179.093 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -59.75 -38.33 81.47 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.852 -179.437 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.549 ' HA ' ' HG2' ' A' ' 55' ' ' ARG . 33.5 t70 -71.44 -35.85 71.06 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.629 0.252 . . . . 0.0 111.181 179.527 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 56.7 t80 -61.36 -49.03 78.57 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 109.503 -0.554 . . . . 0.0 109.503 175.027 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.655 HG22 HG12 ' A' ' 30' ' ' ILE . 77.6 mt -60.85 -51.83 68.61 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-N 115.727 -0.669 . . . . 0.0 111.85 -179.236 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . 0.549 ' HG2' ' HA ' ' A' ' 52' ' ' ASP . 40.1 ptt180 -65.29 -19.93 66.18 Favored 'General case' 0 N--CA 1.467 0.392 0 N-CA-C 112.382 0.512 . . . . 0.0 112.382 -173.464 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 3.1 mtmp? -87.33 -38.61 16.07 Favored 'General case' 0 C--N 1.327 -0.372 0 C-N-CA 120.723 -0.391 . . . . 0.0 111.588 178.668 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 31.0 m-70 -76.03 -32.73 59.5 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 120.662 0.268 . . . . 0.0 110.693 179.651 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 67.6 m -138.63 128.0 24.46 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 116.264 -0.425 . . . . 0.0 109.863 174.581 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . 0.405 ' HD3' ' HA ' ' A' ' 59' ' ' LYS . 1.3 tppp? -78.58 63.42 3.38 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 122.096 0.95 . . . . 0.0 110.901 -177.375 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.47 HG22 HG21 ' A' ' 39' ' ' VAL . 7.3 p -86.29 142.21 13.4 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.957 0 CA-C-N 114.349 -1.296 . . . . 0.0 109.387 172.721 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . 0.43 ' O ' ' HA ' ' A' ' 38' ' ' ARG . 33.0 t70 -76.51 89.25 3.27 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 179.228 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 2.3 tt -90.0 122.91 33.44 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.78 -0.646 . . . . 0.0 110.496 -173.93 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 43.8 t -102.29 121.76 53.74 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-N 115.523 -0.762 . . . . 0.0 109.899 -178.234 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . 0.571 HD22 ' HB3' ' A' ' 41' ' ' GLU . 50.8 mt -100.15 131.01 46.34 Favored 'General case' 0 C--N 1.316 -0.858 0 CA-C-N 116.214 -0.448 . . . . 0.0 109.919 179.766 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.562 HG21 ' HB ' ' A' ' 75' ' ' VAL . 17.0 p -132.23 137.37 47.52 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.951 0.405 . . . . 0.0 111.18 178.383 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 30.3 t70 -165.28 158.4 16.27 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.518 177.529 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 40.7 mm -72.09 96.83 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-O 120.759 0.314 . . . . 0.0 110.429 -178.76 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 65.3 mttm 63.56 90.16 0.09 OUTLIER Pre-proline 0 N--CA 1.465 0.309 0 CA-C-N 115.393 -0.821 . . . . 0.0 111.514 178.682 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 97.3 Cg_endo -83.84 170.35 11.32 Favored 'Trans proline' 0 N--CA 1.459 -0.506 0 C-N-CA 122.867 2.378 . . . . 0.0 112.726 -179.273 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 14.8 t -156.64 34.48 0.31 Allowed 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.844 0.831 . . . . 0.0 108.868 178.686 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . 0.44 ' HB3' HD13 ' A' ' 48' ' ' LEU . 20.2 m80 -115.88 -66.58 1.07 Allowed 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.114 -0.948 . . . . 0.0 110.883 -173.11 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -160.16 -126.7 0.85 Allowed Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.1 -179.154 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -81.93 61.4 4.67 Favored Glycine 0 N--CA 1.452 -0.241 0 C-N-CA 121.076 -0.583 . . . . 0.0 112.273 -178.572 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . 0.448 HD11 HD23 ' A' ' 48' ' ' LEU . 63.6 mt -107.53 134.83 48.1 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-O 120.756 0.312 . . . . 0.0 110.358 179.299 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.562 ' HB ' HG21 ' A' ' 65' ' ' THR . 53.8 t -72.71 133.37 31.89 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.093 179.321 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 6.7 ptp180 -86.9 32.48 0.67 Allowed 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.855 -176.471 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . 0.504 ' HB2' HG13 ' A' ' 75' ' ' VAL . 1.6 t70 -77.11 -159.16 0.12 Allowed 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.653 -174.329 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . 0.434 ' OD1' HG23 ' A' ' 80' ' ' THR . 4.9 t70 -125.15 -174.16 2.98 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 120.733 0.301 . . . . 0.0 110.25 -174.374 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 9.2 tp -139.9 -30.89 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-O 120.877 0.37 . . . . 0.0 110.406 178.951 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.434 HG23 ' OD1' ' A' ' 78' ' ' ASP . 8.9 t -86.38 -20.8 27.71 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.516 0.674 . . . . 0.0 109.247 177.127 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 13.6 t -150.67 72.57 8.92 Favored Pre-proline 0 C--N 1.325 -0.489 0 CA-C-N 115.154 -0.93 . . . . 0.0 108.577 171.721 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.43 ' HB3' ' O ' ' A' ' 78' ' ' ASP . 89.6 Cg_endo -89.77 171.3 4.16 Favored 'Trans proline' 0 N--CA 1.457 -0.674 0 C-N-CA 123.007 2.472 . . . . 0.0 113.149 -173.96 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' ARG . . . . . 0.57 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 63.6 mtt180 -88.9 111.36 21.99 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.671 -0.695 . . . . 0.0 109.536 171.432 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' MET . . . . . 0.52 ' O ' ' HG3' ' A' ' 88' ' ' ARG . 92.7 mmm -67.36 -20.04 65.51 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.395 -176.991 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.57 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 9.3 pt-20 -60.49 -27.29 67.47 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.309 -179.664 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 67.4 mt -79.93 -40.24 20.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-O 120.98 0.419 . . . . 0.0 111.07 -178.571 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . 0.489 ' CE2' HG12 ' A' ' 40' ' ' VAL . 73.0 m-85 -81.98 -31.14 31.29 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.632 -176.889 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . 0.706 ' HG2' HG12 ' A' ' 113' ' ' VAL . 16.1 mtp180 -69.42 116.78 10.24 Favored 'General case' 0 CA--C 1.509 -0.606 0 CA-C-O 121.906 0.86 . . . . 0.0 111.462 -175.957 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . 0.424 ' O ' ' HD3' ' A' ' 38' ' ' ARG . . . 116.38 -18.9 13.37 Favored Glycine 0 C--N 1.31 -0.897 0 CA-C-N 114.07 -1.423 . . . . 0.0 111.765 -177.727 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . 1.004 ' HA ' ' HG2' ' A' ' 38' ' ' ARG . . . -66.24 143.09 57.44 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.604 0.24 . . . . 0.0 110.553 179.075 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -82.57 -29.22 30.43 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 120.831 0.348 . . . . 0.0 110.807 -178.624 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . 0.475 ' HG ' ' HB3' ' A' ' 116' ' ' ARG . 5.8 tt -149.71 143.44 25.46 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.15 -0.477 . . . . 0.0 109.96 -177.412 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.603 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 62.8 mt -130.65 127.46 62.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 N-CA-C 109.098 -0.705 . . . . 0.0 109.098 177.019 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' TYR . . . . . 0.612 ' HD2' ' HZ3' ' A' ' 120' ' ' LYS . 20.7 p90 -138.71 142.84 38.91 Favored 'General case' 0 C--N 1.321 -0.664 0 C-N-CA 120.208 -0.597 . . . . 0.0 111.407 -179.039 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' SER . . . . . 0.575 ' HG ' ' HB ' ' A' ' 42' ' ' VAL . 8.0 m -118.08 144.96 45.19 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 115.497 -0.774 . . . . 0.0 110.047 -177.814 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' ILE . . . . . 0.804 HG12 ' HD2' ' A' ' 120' ' ' LYS . 42.9 mt -111.69 106.84 21.55 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-O 120.759 0.314 . . . . 0.0 110.46 179.804 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . 0.577 ' HD3' ' O ' ' A' ' 97' ' ' ARG . 0.0 OUTLIER 50.88 76.43 0.55 Allowed Pre-proline 0 CA--C 1.536 0.439 0 CA-C-N 115.099 -0.955 . . . . 0.0 111.173 -177.381 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_endo -96.3 159.61 1.29 Allowed 'Trans proline' 0 N--CA 1.453 -0.886 0 C-N-CA 123.211 2.607 . . . . 0.0 112.698 178.887 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . 0.667 ' HD2' HD13 ' A' ' 102' ' ' ILE . 17.5 Cg_exo -64.16 136.37 51.55 Favored 'Trans proline' 0 N--CA 1.462 -0.353 0 C-N-CA 122.32 2.014 . . . . 0.0 111.306 174.55 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.57 ' HA ' ' CD2' ' A' ' 103' ' ' HIS . . . -68.98 -15.46 63.49 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 120.971 0.415 . . . . 0.0 111.833 -174.977 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' GLU . . . . . . . . . . . . . 1.7 pm0 -75.86 -18.51 59.4 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.888 178.582 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.667 HD13 ' HD2' ' A' ' 99' ' ' PRO . 2.6 pp -113.48 8.1 7.89 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.178 0 N-CA-C 112.567 0.58 . . . . 0.0 112.567 -177.341 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' HIS . . . . . 0.57 ' CD2' ' HA ' ' A' ' 100' ' ' ALA . 4.7 m-70 -57.57 -42.64 83.47 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 121.063 0.459 . . . . 0.0 110.777 176.361 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 6.9 p -69.86 -26.85 64.4 Favored 'General case' 0 C--O 1.236 0.372 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.095 -179.114 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.563 ' O ' HG23 ' A' ' 109' ' ' VAL . 74.8 m -70.52 -44.79 66.85 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 109.757 -0.461 . . . . 0.0 109.757 174.519 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 96.0 mt -56.84 -41.81 78.54 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 121.067 0.46 . . . . 0.0 110.354 175.676 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' MET . . . . . 0.446 ' HE1' ' HG3' ' A' ' 133' ' ' MET . 46.6 tpp -55.59 -52.59 63.25 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.28 -0.873 . . . . 0.0 111.365 178.497 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 4.8 ptp180 -71.3 -22.56 61.93 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 111.889 0.329 . . . . 0.0 111.889 -177.303 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.563 HG23 ' O ' ' A' ' 105' ' ' SER . 82.5 t -70.19 -48.37 61.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 C-N-CA 120.731 -0.388 . . . . 0.0 109.981 175.012 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -60.96 -44.53 97.16 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 177.049 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 22.7 t70 -60.68 -34.06 73.77 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.36 -0.836 . . . . 0.0 111.036 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -74.75 -44.44 49.74 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.795 -0.639 . . . . 0.0 111.813 -179.271 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.706 HG12 ' HG2' ' A' ' 88' ' ' ARG . 13.1 m -87.46 -29.29 5.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.981 -172.549 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 87.32 53.77 2.71 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.852 -0.69 . . . . 0.0 112.392 -178.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -131.97 160.44 35.79 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.737 0.303 . . . . 0.0 111.086 -178.192 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 116' ' ' ARG . . . . . 0.475 ' HB3' ' HG ' ' A' ' 92' ' ' LEU . 13.5 ttm180 -79.0 123.88 27.72 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 109.565 -0.532 . . . . 0.0 109.565 175.923 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . 0.603 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 58.3 tp -98.14 118.32 34.49 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.181 -179.429 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 55.7 mt -117.19 115.13 47.81 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-O 121.197 0.522 . . . . 0.0 110.629 178.861 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 40.6 mt -107.78 135.78 45.3 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.631 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.032 -178.032 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 120' ' ' LYS . . . . . 0.804 ' HD2' HG12 ' A' ' 96' ' ' ILE . 4.5 ptpp? -130.51 91.96 36.47 Favored Pre-proline 0 C--N 1.324 -0.518 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.238 -179.147 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 78.5 Cg_endo -96.77 -164.28 0.09 OUTLIER 'Trans proline' 0 N--CA 1.455 -0.765 0 C-N-CA 123.308 2.672 . . . . 0.0 112.647 179.344 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 122' ' ' LEU . . . . . 0.657 ' HB2' ' HB2' ' A' ' 125' ' ' GLU . 4.2 mm? -74.67 159.32 32.23 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.481 174.796 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 27.3 m -57.96 -43.68 86.57 Favored 'General case' 0 CA--C 1.53 0.2 0 CA-C-O 120.981 0.419 . . . . 0.0 110.959 -178.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -100.76 38.2 3.25 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.8 -0.714 . . . . 0.0 111.595 178.288 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . 0.657 ' HB2' ' HB2' ' A' ' 122' ' ' LEU . 27.4 tt0 -123.09 116.83 24.12 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.586 -0.524 . . . . 0.0 109.586 -177.515 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -88.55 164.71 15.28 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 121.544 0.688 . . . . 0.0 111.544 -172.903 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.554 HG21 ' HB ' ' A' ' 129' ' ' THR . 52.1 mt -101.6 103.25 14.65 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.827 0 CA-C-N 115.06 -0.973 . . . . 0.0 108.586 172.71 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 39.0 t -73.72 72.99 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 121.994 0.902 . . . . 0.0 109.754 -179.49 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 129' ' ' THR . . . . . 0.554 ' HB ' HG21 ' A' ' 127' ' ' ILE . 2.8 m -160.9 133.46 6.16 Favored 'General case' 0 N--CA 1.434 -1.256 0 CA-C-N 114.275 -1.33 . . . . 0.0 108.275 -179.179 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 6.3 mt-10 -58.69 156.87 10.22 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.947 0.403 . . . . 0.0 111.818 -176.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 131' ' ' ARG . . . . . . . . . . . . . 62.4 mtm-85 -61.47 106.15 0.61 Allowed 'General case' 0 C--O 1.234 0.289 0 CA-C-N 115.412 -0.813 . . . . 0.0 113.114 -169.197 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 25.6 mtpp -137.33 -29.0 0.9 Allowed 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 114.404 -1.271 . . . . 0.0 109.759 172.816 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 133' ' ' MET . . . . . 0.799 ' HG2' ' HB2' ' A' ' 146' ' ' TYR . 82.1 mtp -84.05 -179.0 7.14 Favored 'General case' 0 C--O 1.232 0.176 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.294 179.874 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 19.1 ptmt -142.52 135.09 27.99 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 120.985 0.422 . . . . 0.0 111.091 -179.449 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . 0.554 HD11 ' HD2' ' A' ' 142' ' ' TYR . 50.3 tp -71.63 124.14 24.07 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.543 -0.753 . . . . 0.0 110.307 175.743 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -121.78 137.22 56.12 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.145 -179.818 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 12.9 m120 -110.13 126.38 54.0 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 109.136 -0.69 . . . . 0.0 109.136 177.676 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 52.8 t80 -142.12 116.72 9.72 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 121.112 0.482 . . . . 0.0 111.277 -179.39 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 77.45 -92.34 1.08 Allowed Glycine 0 N--CA 1.447 -0.618 0 CA-C-N 115.74 -0.664 . . . . 0.0 112.159 176.045 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 50.4 mtm180 -139.52 16.37 2.55 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-O 121.047 0.451 . . . . 0.0 110.831 -179.372 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 13.8 t -138.15 158.72 43.74 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.269 -179.104 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 142' ' ' TYR . . . . . 0.554 ' HD2' HD11 ' A' ' 135' ' ' LEU . 35.2 p90 -134.33 139.62 45.79 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 178.135 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 9.2 p90 -148.9 -172.83 4.2 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.116 -173.185 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 99.1 m-85 -119.42 128.63 54.22 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 120.486 0.184 . . . . 0.0 110.633 -179.086 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 145' ' ' GLU . . . . . . . . . . . . . 19.1 pt-20 -120.31 159.88 24.13 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.044 0.45 . . . . 0.0 109.916 174.78 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . 0.799 ' HB2' ' HG2' ' A' ' 133' ' ' MET . 49.7 t80 -140.63 127.95 21.14 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 115.904 -0.589 . . . . 0.0 109.816 176.471 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 147' ' ' ILE . . . . . 0.436 ' N ' HD12 ' A' ' 147' ' ' ILE . 3.1 mp -94.63 100.66 11.47 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 N-CA-C 109.679 -0.489 . . . . 0.0 109.679 178.752 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -91.38 125.75 36.24 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.869 -0.605 . . . . 0.0 109.796 177.115 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 -79.69 160.89 26.12 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-O 121.038 0.447 . . . . 0.0 110.186 -179.533 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 40.5 t -84.3 140.65 15.81 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-N 116.0 -0.545 . . . . 0.0 109.555 179.783 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 151' ' ' ARG . . . . . 0.501 ' HD3' ' O ' ' A' ' 151' ' ' ARG . 0.1 OUTLIER -56.68 131.25 48.51 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.967 0.413 . . . . 0.0 110.237 178.67 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 4.9 m -60.93 122.43 14.87 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.618 -0.719 . . . . 0.0 112.028 -171.859 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 153' ' ' ARG . . . . . 0.427 ' HB2' HH11 ' A' ' 151' ' ' ARG . 50.4 ttp85 . . . . . 0 C--O 1.249 1.052 0 CA-C-O 118.289 -0.862 . . . . 0.0 109.103 173.14 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 26.6 ptt? . . . . . 0 N--CA 1.483 1.222 0 N-CA-C 111.525 0.194 . . . . 0.0 111.525 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 75.85 -157.88 49.3 Favored Glycine 0 N--CA 1.449 -0.495 0 C-N-CA 120.631 -0.795 . . . . 0.0 112.322 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 29.4 m -97.99 174.34 6.61 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 120.961 0.41 . . . . 0.0 110.733 -178.036 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 10.7 t -141.78 75.3 1.49 Allowed 'General case' 0 C--N 1.322 -0.612 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 175.106 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 28.6 t-80 -146.91 153.7 40.43 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.436 -173.281 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 2.0 t-80 71.77 20.56 4.54 Favored 'General case' 0 N--CA 1.464 0.264 0 O-C-N 124.089 0.868 . . . . 0.0 109.79 -177.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 80.7 m80 -92.49 6.32 47.55 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.304 -0.862 . . . . 0.0 109.472 172.928 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 62.9 m80 -73.93 142.38 45.93 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.248 -0.887 . . . . 0.0 110.497 -178.107 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 20.5 m80 -89.66 84.99 6.35 Favored 'General case' 0 C--N 1.32 -0.683 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 -178.072 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 52.0 p-80 -95.24 126.07 40.31 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 121.185 0.516 . . . . 0.0 110.552 178.55 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 21.4 m -149.26 111.53 4.68 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.907 -0.588 . . . . 0.0 109.777 179.042 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 5.3 t -108.43 179.37 4.22 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 116.455 -0.339 . . . . 0.0 110.465 -176.678 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -131.04 166.42 22.71 Favored Glycine 0 N--CA 1.446 -0.661 0 N-CA-C 111.276 -0.73 . . . . 0.0 111.276 177.548 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . 0.42 HD13 ' O ' ' A' ' 14' ' ' LEU . 2.9 pp -136.46 152.61 50.76 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.863 0.331 . . . . 0.0 110.785 178.97 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.489 ' HA ' ' HD3' ' A' ' 16' ' ' PRO . 14.2 m -115.46 115.48 42.12 Favored Pre-proline 0 C--N 1.322 -0.624 0 CA-C-O 121.296 0.569 . . . . 0.0 111.027 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.489 ' HD3' ' HA ' ' A' ' 15' ' ' VAL . 3.9 Cg_exo -82.33 142.04 11.73 Favored 'Trans proline' 0 N--CA 1.458 -0.587 0 C-N-CA 123.245 2.63 . . . . 0.0 112.101 178.663 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 34.4 mmt180 -87.2 -33.26 19.4 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 121.354 0.597 . . . . 0.0 109.939 177.276 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 123.54 99.7 1.4 Allowed Glycine 0 N--CA 1.446 -0.669 0 N-CA-C 110.716 -0.954 . . . . 0.0 110.716 -174.897 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' SER . . . . . 0.774 ' HB3' ' HD1' ' A' ' 22' ' ' TRP . 37.6 m -119.21 94.94 4.6 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-O 121.111 0.482 . . . . 0.0 111.274 -173.936 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 9.7 m80 -60.32 -45.84 92.01 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.506 -0.77 . . . . 0.0 110.491 -178.55 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -65.62 -15.52 62.82 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.43 -0.805 . . . . 0.0 111.763 -177.028 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' TRP . . . . . 0.774 ' HD1' ' HB3' ' A' ' 19' ' ' SER . 90.8 m95 -94.83 -29.55 14.67 Favored 'General case' 0 C--N 1.322 -0.598 0 C-N-CA 121.013 -0.275 . . . . 0.0 110.696 177.891 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . 0.411 ' O ' HG22 ' A' ' 27' ' ' VAL . 4.7 m-20 -68.99 -47.61 65.13 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.515 -0.311 . . . . 0.0 110.905 177.729 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 15.6 m-20 -60.6 -39.48 88.28 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.81 0.338 . . . . 0.0 110.579 178.59 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 60.5 tp -57.76 -49.53 76.27 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.424 176.204 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -55.71 -47.17 77.31 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.542 -0.753 . . . . 0.0 110.904 178.859 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.411 HG22 ' O ' ' A' ' 23' ' ' ASN . 84.9 t -56.73 -42.9 78.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.938 178.479 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 86.6 t80 -61.32 -45.48 94.28 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.724 0.297 . . . . 0.0 110.383 178.436 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 72.9 mt -63.21 -43.2 98.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.45 178.799 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 86.8 mt -56.83 -42.66 78.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 115.451 -0.795 . . . . 0.0 111.265 177.126 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 21.4 mtp180 -69.06 -32.37 71.79 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.804 -178.816 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 77.0 m -88.33 2.51 52.36 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.794 -0.639 . . . . 0.0 111.758 -175.874 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 22.0 p -129.7 -80.54 0.56 Allowed 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 120.816 0.341 . . . . 0.0 111.004 178.018 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 95.61 160.13 33.08 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.934 -0.65 . . . . 0.0 112.408 -179.616 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -73.25 141.68 32.62 Favored 'Trans proline' 0 N--CA 1.462 -0.347 0 C-N-CA 122.785 2.323 . . . . 0.0 111.438 178.022 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 113.13 3.71 24.39 Favored Glycine 0 N--CA 1.449 -0.452 0 C-N-CA 120.348 -0.929 . . . . 0.0 112.16 -177.226 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 14.7 t -139.42 -169.57 2.71 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 110.001 -0.37 . . . . 0.0 110.001 177.812 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 47.0 mtp180 -121.75 135.84 54.94 Favored 'General case' 0 N--CA 1.45 -0.45 0 CA-C-O 120.906 0.384 . . . . 0.0 110.637 -178.738 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 52.3 t -122.56 134.67 65.07 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 177.463 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 50.3 t -108.04 124.36 64.21 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-O 120.733 0.301 . . . . 0.0 110.678 -177.813 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . 0.504 ' HB2' HD21 ' A' ' 62' ' ' LEU . 35.6 tt0 -102.04 106.68 17.61 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.066 179.004 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.586 ' O ' ' HA ' ' A' ' 95' ' ' SER . 60.3 t -94.04 124.39 46.49 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.603 0 CA-C-N 116.031 -0.531 . . . . 0.0 109.846 179.779 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 96.27 37.63 4.79 Favored Glycine 0 N--CA 1.445 -0.751 0 C-N-CA 120.337 -0.935 . . . . 0.0 111.297 -175.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -81.21 24.61 0.52 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.018 0.437 . . . . 0.0 111.413 -177.822 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -73.89 79.09 0.87 Allowed Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 121.212 -0.518 . . . . 0.0 112.08 -178.924 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 26.7 ttt180 75.67 7.72 3.8 Favored 'General case' 0 N--CA 1.468 0.436 0 C-N-CA 123.418 0.687 . . . . 0.0 110.968 177.14 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 65.8 m-85 -95.96 31.01 2.22 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.39 0.614 . . . . 0.0 110.413 178.06 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . 0.627 HD22 HD11 ' A' ' 64' ' ' LEU . 61.6 mt -74.35 14.65 0.42 Allowed 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.075 -0.966 . . . . 0.0 112.376 -172.931 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . 0.479 ' CE2' ' HB2' ' A' ' 19' ' ' SER . 87.8 t80 -70.3 -37.26 74.74 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 121.068 0.461 . . . . 0.0 110.375 179.665 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 47.2 t -74.76 -48.81 32.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-N 115.936 -0.574 . . . . 0.0 110.372 -179.326 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -58.67 -39.77 81.63 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.997 -0.547 . . . . 0.0 111.369 179.526 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.425 ' O ' ' HE2' ' A' ' 56' ' ' LYS . 30.6 t70 -62.06 -45.07 95.16 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.792 0.33 . . . . 0.0 110.531 177.826 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . 0.437 ' HA ' ' HE2' ' A' ' 56' ' ' LYS . 81.5 t80 -63.53 -42.98 98.4 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.927 -179.248 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 80.8 mt -66.22 -47.73 83.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.889 -178.941 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 22.4 ptt180 -62.77 -24.57 67.78 Favored 'General case' 0 N--CA 1.467 0.401 0 N-CA-C 111.856 0.317 . . . . 0.0 111.856 -175.344 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . 0.437 ' HE2' ' HA ' ' A' ' 53' ' ' TYR . 42.2 mtmt -77.2 -31.22 55.17 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.727 0.299 . . . . 0.0 111.692 -177.611 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 20.4 t60 -99.18 -48.56 4.79 Favored 'General case' 0 N--CA 1.448 -0.562 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.518 -177.384 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 38.1 m -95.22 155.51 16.7 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.068 0.461 . . . . 0.0 111.053 -178.024 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 28.5 mmmt -105.17 19.26 20.9 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.938 -0.574 . . . . 0.0 109.704 178.242 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 15.0 p -68.63 153.27 9.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 115.404 -0.816 . . . . 0.0 110.522 -178.78 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -86.58 103.34 14.99 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 120.832 0.349 . . . . 0.0 110.16 178.521 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . 0.504 HD21 ' HB2' ' A' ' 41' ' ' GLU . 1.8 tt -101.36 119.08 38.22 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 115.942 -0.572 . . . . 0.0 109.935 -176.42 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 46.2 t -100.22 119.14 47.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.365 -179.15 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . 0.627 HD11 HD22 ' A' ' 48' ' ' LEU . 32.3 mt -95.42 122.44 38.14 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.935 -0.575 . . . . 0.0 109.73 178.785 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 37.9 p -118.34 142.27 47.69 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 120.567 0.222 . . . . 0.0 111.189 -178.374 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 30.9 t70 -165.32 154.97 12.81 Favored 'General case' 0 C--N 1.33 -0.259 0 N-CA-C 110.124 -0.325 . . . . 0.0 110.124 179.788 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . 0.562 HD13 ' HA ' ' A' ' 78' ' ' ASP . 37.4 mm -69.61 94.33 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.853 0.359 . . . . 0.0 110.163 179.144 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' LYS . . . . . 0.69 ' HD3' ' HB2' ' A' ' 76' ' ' ARG . 40.9 mmtm 44.46 70.66 1.81 Allowed Pre-proline 0 CA--C 1.533 0.296 0 CA-C-N 115.279 -0.873 . . . . 0.0 110.835 -178.304 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . 0.699 ' HD2' ' HA ' ' A' ' 76' ' ' ARG . 10.3 Cg_endo -51.45 142.25 39.03 Favored 'Trans proline' 0 C--N 1.344 0.341 0 C-N-CA 123.896 3.064 . . . . 0.0 113.762 -172.495 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 22.6 t -96.82 -8.4 31.14 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 114.961 -1.018 . . . . 0.0 109.944 -178.769 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 60.5 t-80 -79.79 -46.46 16.93 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.204 -178.443 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 109.37 144.09 10.41 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.96 -0.638 . . . . 0.0 111.918 -177.842 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 86.95 -41.11 3.08 Favored Glycine 0 CA--C 1.516 0.148 0 C-N-CA 120.901 -0.666 . . . . 0.0 112.187 179.493 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . 0.493 ' HB ' ' HG3' ' A' ' 69' ' ' PRO . 35.9 mt -58.76 149.08 5.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 C-N-CA 122.809 0.444 . . . . 0.0 110.38 177.072 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 60.3 t -68.62 128.62 32.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 178.767 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' ARG . . . . . 0.699 ' HA ' ' HD2' ' A' ' 69' ' ' PRO . 32.1 ptt180 -91.43 54.46 2.54 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.453 0.644 . . . . 0.0 110.976 -179.43 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 9.7 p-10 -83.34 -156.54 0.2 Allowed 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.039 -0.982 . . . . 0.0 109.955 178.129 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . 0.562 ' HA ' HD13 ' A' ' 67' ' ' ILE . 20.3 m-20 -143.85 108.75 4.94 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 110.297 -0.26 . . . . 0.0 110.297 -179.391 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 9.3 tp -73.66 -24.51 19.99 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.37 0 CA-C-O 120.819 0.343 . . . . 0.0 110.737 178.758 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 10.0 t -69.19 -26.95 65.09 Favored 'General case' 0 CA--C 1.531 0.241 0 CA-C-O 121.219 0.533 . . . . 0.0 110.547 178.077 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 22.7 t -134.28 78.74 57.24 Favored Pre-proline 0 C--N 1.323 -0.569 0 N-CA-C 108.153 -1.055 . . . . 0.0 108.153 173.292 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.431 ' HB2' ' HE2' ' A' ' 87' ' ' TYR . 59.1 Cg_endo -71.13 133.44 23.06 Favored 'Trans proline' 0 N--CA 1.461 -0.426 0 C-N-CA 122.762 2.308 . . . . 0.0 113.625 -168.592 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' ARG . . . . . 0.513 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 70.7 mtt85 -84.98 106.27 16.36 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.453 -0.794 . . . . 0.0 109.27 171.871 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' MET . . . . . . . . . . . . . 89.5 mmm -58.21 -26.45 62.85 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.987 -0.551 . . . . 0.0 111.142 -177.235 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.513 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 11.3 pt-20 -62.14 -26.78 68.51 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.672 -179.558 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 73.6 mt -79.46 -41.11 22.16 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-O 121.04 0.447 . . . . 0.0 110.531 -179.339 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . 0.431 ' HE2' ' HB2' ' A' ' 82' ' ' PRO . 44.9 m-85 -79.65 -25.51 41.32 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.789 -176.795 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 52.0 mtp180 -66.23 131.58 46.47 Favored 'General case' 0 CA--C 1.517 -0.304 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.373 176.276 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 98.23 8.72 54.81 Favored Glycine 0 N--CA 1.444 -0.811 0 C-N-CA 120.627 -0.797 . . . . 0.0 111.699 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -100.77 144.6 29.53 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 110.204 -0.295 . . . . 0.0 110.204 177.689 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -92.78 -23.73 18.77 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.078 0.466 . . . . 0.0 110.939 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . 0.455 HD22 ' N ' ' A' ' 93' ' ' ILE . 4.6 tt -150.1 140.74 22.58 Favored 'General case' 0 N--CA 1.449 -0.516 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.434 -178.225 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.513 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 62.8 mt -130.68 119.27 45.15 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 115.784 -0.644 . . . . 0.0 109.419 177.937 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 13.2 p90 -126.18 155.21 42.11 Favored 'General case' 0 C--N 1.32 -0.701 0 C-N-CA 120.553 -0.459 . . . . 0.0 110.544 179.277 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' SER . . . . . 0.586 ' HA ' ' O ' ' A' ' 42' ' ' VAL . 10.6 p -135.81 143.63 45.28 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.752 -0.658 . . . . 0.0 111.424 -175.189 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 74.5 mt -114.86 112.59 40.67 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 115.577 -0.738 . . . . 0.0 110.249 178.763 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 61.6 mtp180 57.59 70.36 1.34 Allowed Pre-proline 0 N--CA 1.466 0.331 0 CA-C-N 115.593 -0.73 . . . . 0.0 112.279 -178.459 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_endo -87.31 131.72 3.05 Favored 'Trans proline' 0 N--CA 1.451 -1.005 0 C-N-CA 122.536 2.157 . . . . 0.0 111.78 175.699 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . 0.614 ' HD2' HD13 ' A' ' 102' ' ' ILE . 52.2 Cg_exo -55.98 148.9 55.3 Favored 'Trans proline' 0 C--O 1.235 0.36 0 C-N-CA 122.464 2.11 . . . . 0.0 111.564 172.267 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.699 ' HA ' ' ND1' ' A' ' 103' ' ' HIS . . . -60.71 -22.91 64.45 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.918 0.39 . . . . 0.0 111.763 -175.337 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' GLU . . . . . 0.679 ' HG3' HG22 ' A' ' 102' ' ' ILE . 10.5 pt-20 -66.65 -31.22 71.75 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.983 -179.958 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.679 HG22 ' HG3' ' A' ' 101' ' ' GLU . 48.3 pt -107.42 -1.05 9.92 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.148 0 N-CA-C 112.482 0.549 . . . . 0.0 112.482 -173.004 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' HIS . . . . . 0.699 ' ND1' ' HA ' ' A' ' 100' ' ' ALA . 13.1 m170 -53.54 -55.61 24.08 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 121.118 0.485 . . . . 0.0 111.162 178.235 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 19.0 m -70.2 -25.59 63.48 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 121.184 0.516 . . . . 0.0 110.689 179.503 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.689 ' O ' ' HG2' ' A' ' 108' ' ' ARG . 1.7 m -71.83 -37.65 70.27 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.502 -177.955 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 86.1 mt -63.62 -39.15 93.64 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.709 177.531 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' MET . . . . . 0.441 ' SD ' ' HB3' ' A' ' 131' ' ' ARG . 49.7 ttm -64.54 -42.33 95.78 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.208 179.447 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' ARG . . . . . 0.689 ' HG2' ' O ' ' A' ' 105' ' ' SER . 1.7 ptm180 -66.37 -26.84 67.45 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.836 0.35 . . . . 0.0 110.628 -178.225 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 82.2 t -75.3 -49.15 28.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.155 175.374 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -57.69 -42.63 84.05 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.494 177.458 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.483 ' HA ' ' HB2' ' A' ' 148' ' ' ALA . 16.8 t70 -62.45 -32.08 72.9 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.581 -0.736 . . . . 0.0 110.746 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -79.09 -41.74 27.97 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.585 -0.734 . . . . 0.0 111.955 -178.634 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 29.0 m -87.83 -26.14 5.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 N-CA-C 111.907 0.336 . . . . 0.0 111.907 -175.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 82.5 64.86 1.66 Allowed Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.884 -0.674 . . . . 0.0 112.052 -178.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -139.58 155.41 47.49 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 120.815 0.341 . . . . 0.0 110.702 -179.909 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 116' ' ' ARG . . . . . 0.449 ' HB3' ' HG ' ' A' ' 92' ' ' LEU . 20.0 ttm-85 -75.1 121.59 22.27 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 177.416 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . 0.513 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 65.9 tp -94.02 125.28 38.56 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.171 -179.928 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 71.4 mt -124.25 120.51 59.46 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.654 0 CA-C-O 120.899 0.38 . . . . 0.0 110.146 177.488 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 30.2 mt -114.04 131.21 66.64 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.217 -178.348 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 120' ' ' LYS . . . . . 0.594 ' CD ' ' HB3' ' A' ' 143' ' ' PHE . 10.9 mmmm -110.86 98.08 36.61 Favored Pre-proline 0 C--O 1.235 0.308 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.881 172.946 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 85.7 Cg_endo -92.42 -157.89 0.06 OUTLIER 'Trans proline' 0 N--CA 1.453 -0.889 0 C-N-CA 123.177 2.585 . . . . 0.0 111.162 173.729 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 8.0 mp -111.38 150.42 29.79 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 120.635 0.255 . . . . 0.0 110.607 178.205 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 38.1 m -65.57 110.42 2.72 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.064 0.459 . . . . 0.0 110.655 178.916 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 108.36 -10.76 36.34 Favored Glycine 0 N--CA 1.445 -0.71 0 N-CA-C 111.084 -0.806 . . . . 0.0 111.084 -176.461 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 4.7 tp10 -106.39 100.5 10.02 Favored 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 109.08 -0.711 . . . . 0.0 109.08 178.49 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 15.8 t70 -85.22 165.05 17.69 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.427 -0.351 . . . . 0.0 110.958 -174.033 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.43 HG21 ' CG ' ' A' ' 103' ' ' HIS . 52.3 mt -83.2 -21.72 8.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-N 115.767 -0.652 . . . . 0.0 110.55 -177.628 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 17.4 m 47.6 26.87 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.931 0 C-N-CA 124.444 1.098 . . . . 0.0 112.926 179.77 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 13.7 t -92.89 145.44 24.38 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 109.97 -0.381 . . . . 0.0 109.97 177.831 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -91.08 32.02 1.05 Allowed 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.271 0.558 . . . . 0.0 109.915 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 131' ' ' ARG . . . . . 0.441 ' HB3' ' SD ' ' A' ' 107' ' ' MET . 4.0 mmp_? -110.65 -177.8 3.32 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.579 -178.272 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 132' ' ' LYS . . . . . 0.467 ' HE3' ' HB2' ' A' ' 132' ' ' LYS . 35.5 mtmt -99.49 124.32 44.56 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.282 -178.918 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 133' ' ' MET . . . . . . . . . . . . . 79.7 mtp -146.08 150.59 36.23 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 170.789 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 1.5 ptpp? -114.83 141.27 48.12 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 121.322 0.582 . . . . 0.0 111.301 -177.501 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . 0.55 HD11 ' HD2' ' A' ' 142' ' ' TYR . 60.0 tp -82.24 129.23 34.8 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.141 -0.936 . . . . 0.0 109.883 178.666 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -126.35 148.47 31.05 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.885 -177.852 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 13.3 m120 -124.23 125.73 44.89 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.05 -0.523 . . . . 0.0 109.865 179.827 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . 0.599 ' O ' HG21 ' A' ' 141' ' ' THR . 42.7 t80 -149.19 104.79 3.44 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.746 0.307 . . . . 0.0 111.049 177.562 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . 0.438 ' C ' ' H ' ' A' ' 141' ' ' THR . . . 59.93 67.28 2.23 Favored Glycine 0 CA--C 1.521 0.417 0 CA-C-N 116.212 -0.449 . . . . 0.0 113.736 175.878 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 21.9 mmt180 69.54 -21.64 0.16 Allowed 'General case' 0 N--CA 1.47 0.547 0 N-CA-C 113.176 0.806 . . . . 0.0 113.176 176.339 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 141' ' ' THR . . . . . 0.599 HG21 ' O ' ' A' ' 138' ' ' TYR . 1.0 OUTLIER -98.0 131.47 44.4 Favored 'General case' 0 N--CA 1.444 -0.77 0 CA-C-O 121.33 0.586 . . . . 0.0 109.91 -179.359 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 142' ' ' TYR . . . . . 0.55 ' HD2' HD11 ' A' ' 135' ' ' LEU . 21.6 p90 -115.99 147.28 41.37 Favored 'General case' 0 N--CA 1.445 -0.713 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 174.872 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 143' ' ' PHE . . . . . 0.594 ' HB3' ' CD ' ' A' ' 120' ' ' LYS . 12.2 p90 -155.81 171.82 19.38 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.61 -175.308 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -107.93 121.43 44.77 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.899 -0.591 . . . . 0.0 109.568 175.845 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 145' ' ' GLU . . . . . . . . . . . . . 15.3 pt-20 -112.32 156.06 23.06 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-O 121.267 0.556 . . . . 0.0 109.578 177.125 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 34.7 t80 -138.88 124.23 19.28 Favored 'General case' 0 C--N 1.311 -1.092 0 CA-C-N 115.646 -0.706 . . . . 0.0 109.468 176.322 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 147' ' ' ILE . . . . . 0.441 ' N ' HD12 ' A' ' 147' ' ' ILE . 3.1 mp -88.44 96.07 5.72 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.739 0 N-CA-C 109.18 -0.674 . . . . 0.0 109.18 178.078 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . 0.483 ' HB2' ' HA ' ' A' ' 111' ' ' ASP . . . -76.49 118.03 18.75 Favored 'General case' 0 C--N 1.317 -0.819 0 CA-C-N 115.369 -0.832 . . . . 0.0 109.061 177.042 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 31.3 mt-10 -61.48 129.59 41.92 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 121.814 0.816 . . . . 0.0 111.094 -175.206 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 9.3 t -83.49 118.28 30.73 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.008 0 CA-C-N 114.387 -1.279 . . . . 0.0 110.557 -171.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 151' ' ' ARG . . . . . . . . . . . . . 13.0 ptp180 -87.54 80.56 8.01 Favored 'General case' 0 C--N 1.314 -0.961 0 CA-C-N 115.174 -0.921 . . . . 0.0 109.379 177.701 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 44.7 t -140.4 151.15 44.7 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.547 -0.751 . . . . 0.0 110.986 -173.846 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 37.2 tpt85 . . . . . 0 N--CA 1.44 -0.932 0 CA-C-O 118.266 -0.873 . . . . 0.0 109.055 172.78 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.479 0.985 0 N-CA-C 109.702 -0.481 . . . . 0.0 109.702 . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -82.88 100.48 2.2 Favored Glycine 0 N--CA 1.446 -0.683 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.481 -178.685 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 27.9 t -65.59 126.95 29.95 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 109.36 -0.607 . . . . 0.0 109.36 177.192 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 8.6 p -80.92 49.77 1.27 Allowed 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 112.264 0.468 . . . . 0.0 112.264 -172.156 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 26.1 t-80 -121.61 85.87 2.48 Favored 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 171.813 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 7.6 p-80 -136.62 17.13 3.11 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.518 -0.764 . . . . 0.0 110.632 -177.407 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 10.7 p80 -101.44 17.48 22.61 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 121.387 0.613 . . . . 0.0 110.105 178.617 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 43.0 p-80 -74.6 -7.25 52.56 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.506 -0.77 . . . . 0.0 112.048 -175.123 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 15.7 p-80 -79.69 163.36 24.59 Favored 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 176.119 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 54.3 p-80 -132.41 169.33 16.68 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 121.015 0.436 . . . . 0.0 111.331 -175.901 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 42.9 t -133.7 156.03 48.67 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.585 -0.734 . . . . 0.0 109.644 175.303 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 20.8 m -127.82 0.92 6.04 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 120.782 0.325 . . . . 0.0 110.592 178.688 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 68.27 82.35 0.17 Allowed Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 120.837 -0.697 . . . . 0.0 112.26 -177.277 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . 0.657 ' H ' HD22 ' A' ' 14' ' ' LEU . 2.5 pt? -84.37 142.06 30.43 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 120.872 0.368 . . . . 0.0 110.422 -178.607 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 46.4 t -117.65 106.68 45.84 Favored Pre-proline 0 C--N 1.32 -0.698 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.06 179.372 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_endo -81.58 163.51 18.97 Favored 'Trans proline' 0 N--CA 1.456 -0.7 0 C-N-CA 122.983 2.455 . . . . 0.0 112.038 179.225 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . 0.476 ' HA ' ' NE ' ' A' ' 17' ' ' ARG . 5.0 mmp_? -110.92 143.71 41.13 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.261 178.381 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 140.58 -165.69 26.05 Favored Glycine 0 N--CA 1.448 -0.505 0 C-N-CA 120.68 -0.772 . . . . 0.0 112.241 178.81 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' SER . . . . . 0.481 ' HB3' ' HD1' ' A' ' 22' ' ' TRP . 15.3 m -80.89 44.83 0.77 Allowed 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 120.757 0.313 . . . . 0.0 111.237 -178.532 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' HIS . . . . . 0.429 ' HA ' ' HB2' ' A' ' 23' ' ' ASN . 61.8 m-70 -66.68 -20.39 65.97 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 111.83 0.307 . . . . 0.0 111.83 -177.023 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' MET . . . . . . . . . . . . . 56.9 mtt -68.22 -18.05 64.47 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.214 0.531 . . . . 0.0 110.271 174.737 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' TRP . . . . . 0.481 ' HD1' ' HB3' ' A' ' 19' ' ' SER . 83.2 m95 -96.54 -30.38 13.34 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.914 -0.585 . . . . 0.0 109.596 175.431 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . 0.429 ' HB2' ' HA ' ' A' ' 20' ' ' HIS . 4.6 m-20 -62.51 -56.02 21.94 Favored 'General case' 0 CA--C 1.521 -0.171 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.508 176.418 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.54 ' HB3' ' HA3' ' A' ' 139' ' ' GLY . 44.7 m-20 -60.61 -36.64 79.09 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.617 179.766 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 64.6 tp -55.83 -49.74 72.45 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.177 175.027 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . 0.533 ' HB1' HG13 ' A' ' 50' ' ' VAL . . . -62.14 -46.69 87.89 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.582 -0.736 . . . . 0.0 111.024 179.029 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 71.4 t -53.17 -47.32 55.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 121.102 0.477 . . . . 0.0 110.664 176.8 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . 0.476 ' HB2' ' CD1' ' A' ' 138' ' ' TYR . 69.7 t80 -56.2 -41.64 75.9 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.891 178.491 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.473 HG21 HD21 ' A' ' 92' ' ' LEU . 75.8 mt -69.83 -44.81 78.63 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.82 178.88 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.627 HD13 ' HA ' ' A' ' 54' ' ' ILE . 83.6 mt -57.77 -43.77 84.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 115.891 -0.595 . . . . 0.0 111.507 -178.98 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 17.9 mtp180 -64.81 -32.76 74.6 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.902 -178.569 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 81.4 m -88.95 -18.67 26.99 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 115.501 -0.772 . . . . 0.0 111.995 -174.006 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 14.0 p -101.54 -82.1 0.47 Allowed 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 120.797 0.332 . . . . 0.0 111.556 -178.54 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 101.81 161.42 26.77 Favored Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 121.014 -0.612 . . . . 0.0 112.187 -178.328 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 7.6 Cg_exo -72.8 144.48 39.12 Favored 'Trans proline' 0 C--O 1.233 0.269 0 C-N-CA 123.083 2.522 . . . . 0.0 112.383 -179.163 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 111.89 -28.76 9.06 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.533 -0.842 . . . . 0.0 112.813 177.897 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 12.6 t -99.86 -169.45 1.74 Allowed 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 -178.551 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . 0.612 ' HB2' ' HA ' ' A' ' 90' ' ' ALA . 66.2 mtp180 -118.6 136.51 53.84 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.954 0.407 . . . . 0.0 111.134 -178.346 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.637 HG23 HG22 ' A' ' 60' ' ' VAL . 95.5 t -129.97 131.11 66.38 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-N 115.83 -0.623 . . . . 0.0 109.369 176.699 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.568 HG23 ' HB ' ' A' ' 63' ' ' VAL . 40.6 t -112.12 129.0 68.4 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 CA-C-O 120.765 0.317 . . . . 0.0 111.759 -173.178 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . 0.447 ' HG2' ' HB3' ' A' ' 44' ' ' ALA . 44.8 tt0 -103.11 107.76 18.7 Favored 'General case' 0 C--O 1.235 0.319 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 174.693 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 44.1 t -89.68 127.78 42.09 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.647 -178.16 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 94.14 23.98 20.82 Favored Glycine 0 N--CA 1.448 -0.523 0 N-CA-C 110.955 -0.858 . . . . 0.0 110.955 -176.375 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . 0.593 ' HB1' HD22 ' A' ' 48' ' ' LEU . . . -93.47 80.38 4.36 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.247 -0.476 . . . . 0.0 110.858 -177.044 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -108.42 -60.61 0.54 Allowed Glycine 0 N--CA 1.446 -0.664 0 C-N-CA 120.824 -0.703 . . . . 0.0 112.015 178.607 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 57.6 mtp180 -125.47 4.44 7.63 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.933 0.397 . . . . 0.0 110.814 -179.171 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.517 ' HE2' HG22 ' A' ' 50' ' ' VAL . 64.7 t80 -86.69 -79.45 0.26 Allowed 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 176.712 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . 0.593 HD22 ' HB1' ' A' ' 44' ' ' ALA . 59.4 mt 62.71 9.35 3.51 Favored 'General case' 0 N--CA 1.467 0.41 0 CA-C-N 115.156 -0.929 . . . . 0.0 112.795 171.006 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . 0.433 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 81.2 t80 -71.08 -45.42 63.77 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 111.791 0.293 . . . . 0.0 111.791 -171.431 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.533 HG13 ' HB1' ' A' ' 26' ' ' ALA . 56.2 t -69.98 -48.57 62.35 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-N 116.599 -0.273 . . . . 0.0 110.597 -177.946 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 50.9 p -58.77 -41.15 85.92 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.453 -0.339 . . . . 0.0 111.037 176.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.728 ' HA ' ' HE ' ' A' ' 55' ' ' ARG . 24.4 t70 -61.13 -37.97 84.72 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.8 0.333 . . . . 0.0 110.712 176.55 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 47.3 t80 -69.19 -45.6 69.55 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.308 178.041 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.627 ' HA ' HD13 ' A' ' 30' ' ' ILE . 88.0 mt -63.45 -44.83 99.02 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.823 -178.347 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . 0.728 ' HE ' ' HA ' ' A' ' 52' ' ' ASP . 12.1 ptp180 -63.37 -16.42 60.42 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-O 120.791 0.329 . . . . 0.0 111.584 -175.77 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . 0.463 ' HG3' ' O ' ' A' ' 52' ' ' ASP . 97.7 mttt -81.39 -36.04 30.03 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.599 -179.602 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 81.6 m-70 -103.67 -18.11 14.85 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.817 -175.021 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 6.4 t -135.63 128.9 31.98 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-O 120.794 0.331 . . . . 0.0 110.566 -177.356 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -89.39 51.42 2.12 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.871 0.843 . . . . 0.0 110.126 175.532 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.637 HG22 HG23 ' A' ' 39' ' ' VAL . 8.3 p -83.59 147.21 5.96 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 CA-C-N 114.845 -1.07 . . . . 0.0 108.908 175.434 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . 0.557 ' HB3' ' HG2' ' A' ' 38' ' ' ARG . 19.0 t70 -72.68 95.52 1.88 Allowed 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 109.248 -0.649 . . . . 0.0 109.248 179.269 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 2.1 tt -94.77 128.45 41.49 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.407 -172.318 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.568 ' HB ' HG23 ' A' ' 40' ' ' VAL . 33.3 t -108.71 126.7 65.58 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.45 -178.92 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . 0.698 HD11 HH22 ' A' ' 55' ' ' ARG . 66.7 mt -108.61 131.18 55.13 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 116.039 -0.528 . . . . 0.0 109.63 176.4 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 49.9 p -129.3 127.91 42.11 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.721 0.296 . . . . 0.0 111.319 179.389 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 3.7 t70 -165.74 175.88 8.43 Favored 'General case' 0 C--O 1.233 0.215 0 CA-C-N 116.082 -0.508 . . . . 0.0 109.732 176.964 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 53.0 mt -87.68 114.57 26.72 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-O 120.634 0.254 . . . . 0.0 110.657 -176.391 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 55.3 mtpt 61.17 79.93 0.27 Allowed Pre-proline 0 C--N 1.331 -0.226 0 CA-C-N 115.646 -0.707 . . . . 0.0 110.9 178.287 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . 1.014 ' HB3' ' HB ' ' A' ' 74' ' ' ILE . 18.9 Cg_endo -58.21 114.84 2.15 Favored 'Trans proline' 0 C--N 1.342 0.223 0 C-N-CA 123.281 2.654 . . . . 0.0 113.08 -176.092 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 5.9 p -80.56 -30.54 37.04 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.932 178.911 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 46.1 t-80 -64.5 -59.11 4.7 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.797 178.826 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 132.33 -41.58 1.48 Allowed Glycine 0 N--CA 1.447 -0.575 0 C-N-CA 120.877 -0.678 . . . . 0.0 111.992 -179.164 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -93.6 24.54 25.37 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 121.004 -0.617 . . . . 0.0 112.031 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . 1.014 ' HB ' ' HB3' ' A' ' 69' ' ' PRO . 65.4 mt -104.91 146.47 12.06 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 N-CA-C 109.996 -0.372 . . . . 0.0 109.996 -179.71 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.612 HG11 HD11 ' A' ' 86' ' ' ILE . 48.3 t -80.78 135.89 24.32 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 N-CA-C 109.778 -0.452 . . . . 0.0 109.778 176.805 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 11.4 ptt180 -75.98 25.71 0.12 Allowed 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.867 -0.606 . . . . 0.0 111.876 -177.177 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . 0.435 ' H ' ' C ' ' A' ' 75' ' ' VAL . 12.7 t70 -83.35 113.82 20.99 Favored 'General case' 0 C--N 1.324 -0.536 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 -177.753 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 2.2 p30 -70.67 168.97 15.37 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.033 0.444 . . . . 0.0 111.257 -172.697 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . 0.415 HD11 HD11 ' A' ' 102' ' ' ILE . 7.1 tp -83.98 -30.27 7.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 N-CA-C 112.936 0.717 . . . . 0.0 112.936 -169.569 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 12.2 t -94.23 -21.01 19.31 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.169 0.509 . . . . 0.0 110.712 -174.017 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 4.5 t -130.64 69.03 82.22 Favored Pre-proline 0 C--N 1.323 -0.585 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.05 -179.807 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -78.64 163.48 26.59 Favored 'Trans proline' 0 N--CA 1.46 -0.443 0 C-N-CA 122.98 2.453 . . . . 0.0 112.619 -175.834 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' ARG . . . . . 0.61 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 88.6 mtm180 -108.92 118.17 36.1 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.291 178.305 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' MET . . . . . 0.522 ' SD ' HG23 ' A' ' 109' ' ' VAL . 92.0 mmm -61.13 -28.61 69.23 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.267 -0.879 . . . . 0.0 111.343 -179.037 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.61 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 10.7 pt-20 -57.69 -24.27 55.9 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.711 -179.975 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.612 HD11 HG11 ' A' ' 75' ' ' VAL . 76.5 mt -86.48 -43.75 16.29 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.089 -177.478 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . 0.422 ' CE1' HG12 ' A' ' 40' ' ' VAL . 88.3 m-85 -72.13 -27.15 62.44 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.37 -178.593 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 27.0 mtp180 -66.06 116.66 7.4 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 121.409 0.623 . . . . 0.0 111.26 -179.482 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 118.61 -15.99 11.44 Favored Glycine 0 N--CA 1.447 -0.597 0 CA-C-N 115.189 -0.914 . . . . 0.0 111.243 -176.065 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . 0.612 ' HA ' ' HB2' ' A' ' 38' ' ' ARG . . . -75.48 145.63 41.25 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.897 0.379 . . . . 0.0 110.545 178.837 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -98.51 -20.76 16.89 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.125 177.659 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . 0.473 HD21 HG21 ' A' ' 29' ' ' ILE . 5.1 tt -153.33 138.24 17.17 Favored 'General case' 0 N--CA 1.447 -0.604 0 CA-C-N 115.688 -0.687 . . . . 0.0 109.967 -179.306 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.527 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 63.6 mt -130.64 131.16 64.96 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 115.987 -0.551 . . . . 0.0 109.629 -178.748 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' TYR . . . . . 0.439 ' HE1' HG12 ' A' ' 39' ' ' VAL . 26.6 p90 -134.15 156.05 49.01 Favored 'General case' 0 C--N 1.322 -0.626 0 C-N-CA 120.625 -0.43 . . . . 0.0 110.811 179.57 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 17.3 m -131.86 139.76 48.91 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.76 -177.651 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 42.3 mm -85.94 86.98 2.5 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.363 -179.259 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . 0.422 ' NH1' HD12 ' A' ' 122' ' ' LEU . 39.1 ttp180 44.32 79.56 0.33 Allowed Pre-proline 0 N--CA 1.47 0.558 0 O-C-N 124.126 0.891 . . . . 0.0 112.364 -179.313 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 91.2 Cg_endo -83.83 154.13 13.26 Favored 'Trans proline' 0 N--CA 1.456 -0.704 0 C-N-CA 122.918 2.412 . . . . 0.0 112.042 178.892 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . 0.613 ' HD2' HD12 ' A' ' 102' ' ' ILE . 51.3 Cg_exo -55.35 150.66 40.32 Favored 'Trans proline' 0 C--N 1.346 0.417 0 C-N-CA 122.605 2.204 . . . . 0.0 112.112 175.53 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -79.68 30.31 0.25 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.727 -174.205 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' GLU . . . . . . . . . . . . . 10.4 pt-20 -124.95 -23.46 4.26 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 120.742 0.306 . . . . 0.0 110.954 176.507 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.613 HD12 ' HD2' ' A' ' 99' ' ' PRO . 46.6 pt -98.9 -2.4 9.83 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-O 120.752 0.31 . . . . 0.0 111.316 -177.173 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' HIS . . . . . 0.564 ' O ' ' HG2' ' A' ' 107' ' ' MET . 31.4 p-80 -60.16 -40.09 88.71 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.138 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 8.1 p -63.21 -35.85 81.68 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.913 178.604 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.489 ' O ' HG22 ' A' ' 109' ' ' VAL . 16.3 m -67.42 -45.91 74.72 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.735 -0.666 . . . . 0.0 109.69 177.976 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 96.0 mt -59.86 -42.17 93.1 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.909 178.124 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' MET . . . . . 0.564 ' HG2' ' O ' ' A' ' 103' ' ' HIS . 98.2 mmm -56.71 -49.59 74.71 Favored 'General case' 0 C--O 1.233 0.234 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.537 -179.939 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 33.7 ptt85 -70.77 -30.57 67.09 Favored 'General case' 0 C--N 1.332 -0.188 0 C-N-CA 120.727 -0.389 . . . . 0.0 111.108 -177.403 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.522 HG23 ' SD ' ' A' ' 84' ' ' MET . 69.5 t -67.78 -48.49 75.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 120.575 0.226 . . . . 0.0 110.647 177.029 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -59.08 -41.64 88.5 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.708 179.626 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.655 ' HA ' ' HB1' ' A' ' 148' ' ' ALA . 23.3 t70 -65.6 -42.29 91.8 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.701 -0.682 . . . . 0.0 110.815 178.489 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -62.54 -43.46 98.77 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.964 -0.562 . . . . 0.0 111.645 -178.364 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 20.2 m -85.38 -28.14 6.42 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-O 120.928 0.394 . . . . 0.0 111.022 -177.59 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 87.35 51.85 3.2 Favored Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 120.596 -0.812 . . . . 0.0 111.918 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -130.15 155.47 46.16 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 120.831 0.348 . . . . 0.0 110.901 -178.799 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 116' ' ' ARG . . . . . 0.675 HH21 HD12 ' A' ' 118' ' ' ILE . 50.2 ttp180 -79.21 117.56 20.34 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 178.037 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . 0.527 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 60.3 tp -88.14 118.84 27.99 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.0 -0.546 . . . . 0.0 110.086 -179.535 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . 0.675 HD12 HH21 ' A' ' 116' ' ' ARG . 66.6 mt -114.52 117.42 55.54 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-O 121.28 0.562 . . . . 0.0 110.842 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 71.7 mt -116.52 116.9 53.72 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.323 179.308 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 57.6 tttp -102.76 104.4 38.78 Favored Pre-proline 0 C--N 1.322 -0.598 0 C-N-CA 120.656 -0.418 . . . . 0.0 110.005 172.351 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 121' ' ' PRO . . . . . 0.575 ' HB2' ' O ' ' A' ' 125' ' ' GLU . 70.5 Cg_endo -78.68 -139.58 0.02 OUTLIER 'Trans proline' 0 N--CA 1.457 -0.673 0 C-N-CA 122.522 2.148 . . . . 0.0 111.531 172.673 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 122' ' ' LEU . . . . . 0.857 ' HB3' ' HB3' ' A' ' 125' ' ' GLU . 14.4 tp -126.82 156.94 40.52 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.383 -178.789 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 123' ' ' THR . . . . . 0.458 ' HA ' ' OH ' ' A' ' 142' ' ' TYR . 25.4 m -69.94 102.04 1.9 Allowed 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 177.368 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 100.88 2.88 55.1 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.967 -0.635 . . . . 0.0 111.737 -175.533 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . 0.857 ' HB3' ' HB3' ' A' ' 122' ' ' LEU . 37.7 tt0 -132.38 97.12 4.02 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 177.827 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 14.2 t70 -99.9 173.06 6.85 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.403 -0.817 . . . . 0.0 110.455 -170.227 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 5.3 mt -78.62 -14.98 13.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 178.12 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 27.6 m 48.21 35.7 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.556 0 C-N-CA 124.669 1.188 . . . . 0.0 112.263 -178.962 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 15.2 t -115.19 144.03 44.32 Favored 'General case' 0 N--CA 1.452 -0.33 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.743 179.393 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 6.9 mp0 -102.19 63.75 0.91 Allowed 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 121.021 0.439 . . . . 0.0 109.923 177.893 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 131' ' ' ARG . . . . . 0.486 ' HA ' ' HE ' ' A' ' 131' ' ' ARG . 0.0 OUTLIER -108.96 -170.16 1.61 Allowed 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.38 -176.569 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 132' ' ' LYS . . . . . 0.533 ' HE3' ' HE1' ' A' ' 146' ' ' TYR . 31.7 ttpt -84.72 11.0 9.83 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-O 121.361 0.601 . . . . 0.0 112.038 -172.165 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 133' ' ' MET . . . . . . . . . . . . . 46.7 mtp -69.06 170.5 9.81 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.764 176.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . 0.724 ' HB3' ' HZ1' ' A' ' 134' ' ' LYS . 0.5 OUTLIER -139.68 151.65 46.09 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.942 -179.43 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . 0.431 HD12 ' HD2' ' A' ' 142' ' ' TYR . 57.4 tp -89.74 123.46 33.77 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.252 178.206 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 136' ' ' VAL . . . . . 0.46 ' CG2' ' HG2' ' A' ' 145' ' ' GLU . 0.1 OUTLIER -121.74 149.05 24.92 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.445 -179.658 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 12.3 m120 -125.86 112.62 16.2 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.2 -176.214 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . 0.476 ' CD1' ' HB2' ' A' ' 28' ' ' TYR . 53.3 t80 -147.96 123.31 10.29 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.554 0.216 . . . . 0.0 110.947 -179.723 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . 0.54 ' HA3' ' HB3' ' A' ' 24' ' ' ASP . . . 62.93 71.69 0.78 Allowed Glycine 0 N--CA 1.451 -0.317 0 CA-C-N 115.716 -0.674 . . . . 0.0 113.726 173.045 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 6.1 mpt_? 70.99 -39.5 0.45 Allowed 'General case' 0 N--CA 1.473 0.684 0 C-N-CA 123.356 0.662 . . . . 0.0 112.628 175.171 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 141' ' ' THR . . . . . 0.417 ' H ' ' C ' ' A' ' 139' ' ' GLY . 8.8 t -101.87 154.5 18.87 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 121.487 0.66 . . . . 0.0 111.696 -173.817 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 142' ' ' TYR . . . . . 0.458 ' OH ' ' HA ' ' A' ' 123' ' ' THR . 45.8 p90 -112.68 155.02 25.2 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 115.031 -0.986 . . . . 0.0 108.592 169.249 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 18.0 p90 -160.27 179.03 9.03 Favored 'General case' 0 C--N 1.319 -0.744 0 N-CA-C 110.151 -0.315 . . . . 0.0 110.151 -178.348 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 86.5 m-85 -116.27 125.42 52.17 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 120.724 0.297 . . . . 0.0 110.525 -179.505 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 145' ' ' GLU . . . . . 0.46 ' HG2' ' CG2' ' A' ' 136' ' ' VAL . 23.7 pt-20 -117.28 162.1 18.43 Favored 'General case' 0 C--N 1.317 -0.807 0 N-CA-C 109.557 -0.534 . . . . 0.0 109.557 175.235 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . 0.533 ' HE1' ' HE3' ' A' ' 132' ' ' LYS . 14.8 t80 -138.28 117.3 12.51 Favored 'General case' 0 C--N 1.311 -1.102 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.744 175.623 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 147' ' ' ILE . . . . . 0.452 HD11 ' N ' ' A' ' 147' ' ' ILE . 2.4 mp -85.41 99.43 7.39 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.874 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 174.643 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . 0.655 ' HB1' ' HA ' ' A' ' 111' ' ' ASP . . . -58.42 104.48 0.22 Allowed 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 108.933 -0.765 . . . . 0.0 108.933 176.432 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 36.7 mt-10 -50.91 121.32 5.81 Favored 'General case' 0 CA--C 1.506 -0.717 0 CA-C-O 122.092 0.948 . . . . 0.0 110.76 -175.329 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 150' ' ' VAL . . . . . 0.512 HG12 ' H ' ' A' ' 152' ' ' SER . 3.5 t -64.64 118.35 6.78 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.12 0 CA-C-N 113.326 -1.761 . . . . 0.0 111.425 -164.226 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 151' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.31 25.48 2.21 Favored 'General case' 0 C--N 1.315 -0.906 0 CA-C-N 114.786 -1.097 . . . . 0.0 110.152 176.432 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 152' ' ' SER . . . . . 0.512 ' H ' HG12 ' A' ' 150' ' ' VAL . 15.6 m -138.84 157.6 45.76 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 114.747 -1.115 . . . . 0.0 108.907 177.632 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 99.1 mtt180 . . . . . 0 C--O 1.246 0.889 0 CA-C-O 118.718 -0.658 . . . . 0.0 110.246 178.525 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 27.5 ttt . . . . . 0 N--CA 1.478 0.943 0 CA-C-O 120.747 0.308 . . . . 0.0 110.447 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 87.52 -69.27 2.98 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.584 176.17 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 15.1 m -72.38 85.05 1.1 Allowed 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.975 0.417 . . . . 0.0 110.465 179.774 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 48.8 m -154.23 86.12 1.16 Allowed 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.238 177.879 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 49.4 m80 -92.31 118.99 31.45 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 109.503 -0.554 . . . . 0.0 109.503 179.17 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 88.0 m-70 -91.76 81.83 5.23 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.504 0.669 . . . . 0.0 111.121 -173.806 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 52.6 t-80 -135.49 100.41 4.5 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.188 -0.915 . . . . 0.0 109.222 175.414 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 8.6 p-80 -119.77 34.46 5.21 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.113 -178.249 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 38.2 t60 -60.16 126.48 27.69 Favored 'General case' 0 C--N 1.327 -0.388 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 176.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 30.7 m170 -69.04 145.02 53.86 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.922 -177.607 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 33.9 t -124.68 144.21 50.33 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 116.076 -0.511 . . . . 0.0 109.922 -179.069 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 71.2 m -100.22 100.37 11.18 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 120.959 0.409 . . . . 0.0 110.683 178.264 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -118.52 151.33 17.84 Favored Glycine 0 N--CA 1.446 -0.699 0 C-N-CA 120.8 -0.715 . . . . 0.0 111.656 179.502 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 94.6 mt -99.54 167.2 10.75 Favored 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 110.172 -0.307 . . . . 0.0 110.172 -179.86 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 7.6 p -83.83 127.95 65.25 Favored Pre-proline 0 C--N 1.322 -0.605 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 176.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 23.1 Cg_exo -63.63 125.88 16.4 Favored 'Trans proline' 0 N--CA 1.461 -0.416 0 C-N-CA 122.323 2.015 . . . . 0.0 112.135 179.146 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -97.54 150.92 20.57 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-N 115.463 -0.79 . . . . 0.0 109.938 -179.313 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 80.6 28.47 47.28 Favored Glycine 0 N--CA 1.446 -0.692 0 N-CA-C 110.798 -0.921 . . . . 0.0 110.798 -171.526 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 11.7 p -104.56 17.16 24.66 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 120.891 0.377 . . . . 0.0 111.17 -175.062 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 36.7 m-70 -58.89 -24.41 62.23 Favored 'General case' 0 N--CA 1.464 0.268 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.325 179.664 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' MET . . . . . . . . . . . . . 22.8 mmt -77.13 -16.91 58.99 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.966 -178.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' TRP . . . . . 0.576 ' CH2' HG23 ' A' ' 96' ' ' ILE . 99.4 m95 -98.81 -18.1 18.11 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.351 -0.386 . . . . 0.0 111.677 -179.882 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 24.3 t-20 -56.45 -41.06 75.86 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.765 -0.652 . . . . 0.0 111.606 -176.659 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -60.33 -50.82 72.08 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.963 -0.562 . . . . 0.0 112.042 -179.909 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 58.5 tp -56.28 -45.44 80.13 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.195 -178.474 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . 0.503 ' O ' HG13 ' A' ' 30' ' ' ILE . . . -54.74 -52.03 63.81 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.322 -179.157 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 83.2 t -51.4 -47.64 34.91 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.78 178.887 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 74.4 t80 -59.06 -44.59 91.84 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.921 0.391 . . . . 0.0 110.491 -179.054 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 72.5 mt -64.77 -45.53 94.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.918 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.577 HG12 HG21 ' A' ' 54' ' ' ILE . 85.8 mt -57.24 -44.36 83.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.88 179.911 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 55.5 mtt180 -71.36 -20.72 62.12 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.693 -0.685 . . . . 0.0 111.697 -175.224 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 72.8 m -88.98 -21.33 23.58 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.408 -0.36 . . . . 0.0 111.256 179.788 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 12.4 p -106.23 -80.16 0.56 Allowed 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 120.765 0.317 . . . . 0.0 111.255 -176.652 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 95.92 172.82 36.01 Favored Glycine 0 N--CA 1.449 -0.468 0 C-N-CA 120.822 -0.704 . . . . 0.0 112.427 -179.888 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 12.5 Cg_exo -69.68 143.39 51.08 Favored 'Trans proline' 0 N--CA 1.465 -0.189 0 C-N-CA 122.955 2.437 . . . . 0.0 112.335 -179.197 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 91.12 7.27 65.89 Favored Glycine 0 N--CA 1.454 -0.128 0 C-N-CA 120.613 -0.803 . . . . 0.0 112.694 176.413 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 29.9 p -110.43 -174.09 2.4 Favored 'General case' 0 C--N 1.321 -0.671 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 179.848 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . 0.613 ' NH2' ' HA3' ' A' ' 89' ' ' GLY . 56.6 mtm180 -129.72 126.91 39.36 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 120.771 0.319 . . . . 0.0 110.647 176.709 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.62 HG23 HG22 ' A' ' 60' ' ' VAL . 41.5 t -122.81 134.51 65.75 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 177.703 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.487 HG12 ' CE1' ' A' ' 87' ' ' TYR . 32.2 t -114.02 122.38 68.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-O 120.955 0.407 . . . . 0.0 110.436 -178.416 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . 0.797 ' HG3' HD22 ' A' ' 64' ' ' LEU . 0.1 OUTLIER -93.07 121.59 34.58 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.71 -174.706 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.495 ' O ' ' HA ' ' A' ' 95' ' ' SER . 48.5 t -102.55 113.65 39.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 N-CA-C 109.566 -0.531 . . . . 0.0 109.566 173.825 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 111.77 44.9 0.86 Allowed Glycine 0 N--CA 1.45 -0.37 0 N-CA-C 111.134 -0.786 . . . . 0.0 111.134 -176.032 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -95.85 14.73 22.41 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.102 0.477 . . . . 0.0 111.044 -175.892 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -72.74 -7.73 70.48 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.946 -0.645 . . . . 0.0 112.947 -178.153 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 74.0 ttt180 -166.18 -34.14 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.94 0.4 . . . . 0.0 110.934 -179.915 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 40.7 m-85 -82.86 83.39 7.77 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 121.116 0.484 . . . . 0.0 111.056 -175.685 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 88.2 mt -109.35 9.3 25.71 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.144 -179.514 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 39.3 t80 -72.54 -50.97 21.96 Favored 'General case' 0 C--N 1.33 -0.267 0 C-N-CA 121.023 -0.271 . . . . 0.0 110.968 178.259 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.527 ' O ' HG13 ' A' ' 54' ' ' ILE . 33.6 t -57.73 -49.0 82.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.463 -176.448 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 1.9 p -60.01 -44.07 94.81 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.93 -0.577 . . . . 0.0 111.787 -179.783 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.529 ' O ' ' HG2' ' A' ' 56' ' ' LYS . 28.8 t70 -64.99 -39.76 93.95 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 120.856 0.36 . . . . 0.0 110.601 -179.907 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 59.5 t80 -65.97 -39.47 90.41 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.563 -179.218 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.577 HG21 HG12 ' A' ' 30' ' ' ILE . 82.3 mt -64.88 -48.71 83.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.613 -179.852 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 39.7 ptt180 -67.28 -17.13 64.66 Favored 'General case' 0 N--CA 1.466 0.348 0 N-CA-C 111.586 0.217 . . . . 0.0 111.586 -175.649 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . 0.529 ' HG2' ' O ' ' A' ' 52' ' ' ASP . 33.1 mmtp -75.04 -36.07 61.87 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.822 0.344 . . . . 0.0 110.747 177.591 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 53.8 m-70 -94.6 -31.11 14.01 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.818 -175.785 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 73.3 m -136.75 132.89 35.41 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 120.759 0.314 . . . . 0.0 111.474 -178.27 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 3.1 tmtp? -81.51 60.97 4.75 Favored 'General case' 0 C--O 1.234 0.256 0 CA-C-O 121.831 0.824 . . . . 0.0 109.708 177.051 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.62 HG22 HG23 ' A' ' 39' ' ' VAL . 2.6 p -84.59 144.61 9.45 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.037 0 CA-C-N 114.975 -1.011 . . . . 0.0 108.869 172.816 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . 0.418 ' O ' ' HA ' ' A' ' 38' ' ' ARG . 24.7 m-20 -79.0 100.36 7.27 Favored 'General case' 0 CA--C 1.515 -0.378 0 CA-C-O 121.605 0.717 . . . . 0.0 109.441 176.328 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . 0.521 HD12 ' OE2' ' A' ' 41' ' ' GLU . 8.5 tt -99.28 129.14 45.48 Favored 'General case' 0 C--N 1.316 -0.854 0 CA-C-N 114.8 -1.091 . . . . 0.0 110.599 -171.653 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 57.7 t -117.45 116.06 50.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.987 -177.895 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . 0.797 HD22 ' HG3' ' A' ' 41' ' ' GLU . 33.1 mt -87.39 128.21 35.2 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 115.966 -0.561 . . . . 0.0 109.828 178.17 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.506 HG23 ' HB ' ' A' ' 75' ' ' VAL . 25.2 p -130.57 134.36 46.95 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 120.488 0.185 . . . . 0.0 110.629 178.965 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -171.74 153.73 3.43 Favored 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 178.395 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . 0.531 HG21 ' HG3' ' A' ' 68' ' ' LYS . 60.8 mt -77.42 122.66 32.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 N-CA-C 110.152 -0.314 . . . . 0.0 110.152 179.483 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' LYS . . . . . 0.531 ' HG3' HG21 ' A' ' 67' ' ' ILE . 91.9 mttt 60.83 80.65 0.26 Allowed Pre-proline 0 C--O 1.234 0.267 0 O-C-N 123.734 0.646 . . . . 0.0 110.485 -177.413 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . 0.652 ' HB3' ' HB ' ' A' ' 74' ' ' ILE . 29.0 Cg_endo -64.71 122.39 10.23 Favored 'Trans proline' 0 N--CA 1.464 -0.243 0 C-N-CA 122.799 2.333 . . . . 0.0 112.515 -178.636 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 8.0 t -87.96 7.07 32.77 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.914 -178.266 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 50.7 t-80 -112.43 -73.43 0.67 Allowed 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.46 -179.758 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 145.32 -35.15 1.47 Allowed Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.01 -179.534 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -92.55 23.23 29.01 Favored Glycine 0 C--O 1.228 -0.238 0 C-N-CA 120.979 -0.629 . . . . 0.0 111.825 177.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . 0.652 ' HB ' ' HB3' ' A' ' 69' ' ' PRO . 71.2 mt -109.99 140.34 29.39 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-N 115.518 -0.341 . . . . 0.0 110.122 -178.478 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.506 ' HB ' HG23 ' A' ' 65' ' ' THR . 61.2 t -71.28 119.18 17.16 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-O 121.199 0.523 . . . . 0.0 110.343 178.61 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 16.5 ptm180 -81.66 34.5 0.39 Allowed 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.379 -0.828 . . . . 0.0 111.96 -176.27 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 35.2 t70 -78.72 145.02 34.73 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 120.892 0.377 . . . . 0.0 110.392 -177.857 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . 0.488 ' HB3' HG22 ' A' ' 80' ' ' THR . 10.4 m-20 -81.15 110.86 17.05 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.696 -176.744 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . 0.486 HG22 HD12 ' A' ' 67' ' ' ILE . 10.6 tp -63.96 -19.9 25.51 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.519 0 CA-C-O 120.909 0.385 . . . . 0.0 111.022 179.75 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.488 HG22 ' HB3' ' A' ' 78' ' ' ASP . 7.0 t -68.52 -26.33 65.38 Favored 'General case' 0 CA--C 1.533 0.301 0 CA-C-O 121.13 0.49 . . . . 0.0 110.572 177.73 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 44.3 m -152.0 73.42 7.82 Favored Pre-proline 0 C--N 1.322 -0.607 0 N-CA-C 108.37 -0.974 . . . . 0.0 108.37 176.738 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.453 ' HB2' ' HE2' ' A' ' 87' ' ' TYR . 75.8 Cg_endo -76.01 162.8 34.08 Favored 'Trans proline' 0 C--O 1.237 0.429 0 C-N-CA 122.817 2.344 . . . . 0.0 114.044 -166.121 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' ARG . . . . . 0.854 ' HG3' ' HG2' ' A' ' 85' ' ' GLU . 0.2 OUTLIER -81.72 99.99 9.24 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 114.855 -1.066 . . . . 0.0 109.201 174.929 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' MET . . . . . 0.409 ' O ' ' HG3' ' A' ' 88' ' ' ARG . 83.8 mmm -59.08 -31.16 68.64 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 116.596 -0.274 . . . . 0.0 111.186 -177.187 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.854 ' HG2' ' HG3' ' A' ' 83' ' ' ARG . 8.2 pt-20 -66.94 -24.72 66.1 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.495 -0.32 . . . . 0.0 111.397 -179.789 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 69.0 mt -73.62 -32.29 35.17 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 C-N-CA 120.515 -0.474 . . . . 0.0 110.429 177.282 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . 0.487 ' CE1' HG12 ' A' ' 40' ' ' VAL . 98.3 m-85 -85.91 -28.63 24.21 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.974 -0.557 . . . . 0.0 111.22 179.022 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . 0.409 ' HG3' ' O ' ' A' ' 84' ' ' MET . 69.6 mtp180 -61.72 117.95 6.49 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.33 0.586 . . . . 0.0 111.691 -177.639 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . 0.613 ' HA3' ' NH2' ' A' ' 38' ' ' ARG . . . 106.36 -5.19 38.13 Favored Glycine 0 N--CA 1.444 -0.779 0 CA-C-N 115.222 -0.899 . . . . 0.0 112.383 179.906 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -69.85 146.97 50.91 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.801 0.334 . . . . 0.0 110.495 177.733 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -91.5 -30.8 16.23 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.368 -179.766 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . 0.43 ' HG ' ' HB3' ' A' ' 116' ' ' ARG . 5.3 tt -153.25 144.19 22.88 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.182 -178.361 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.669 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 70.1 mt -133.07 129.04 57.04 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 177.31 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' TYR . . . . . 0.472 ' HE2' HD12 ' A' ' 96' ' ' ILE . 51.0 p90 -134.01 162.88 30.85 Favored 'General case' 0 C--N 1.32 -0.715 0 C-N-CA 120.053 -0.659 . . . . 0.0 111.274 179.604 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' SER . . . . . 0.738 ' HB3' ' HG3' ' A' ' 98' ' ' PRO . 15.8 m -137.83 137.83 38.54 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.999 -175.682 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' ILE . . . . . 0.576 HG23 ' CH2' ' A' ' 22' ' ' TRP . 5.0 mp -106.74 93.87 2.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.349 177.866 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 54.1 ttp85 48.29 72.68 1.18 Allowed Pre-proline 0 CA--C 1.54 0.574 0 CA-C-N 115.527 -0.761 . . . . 0.0 112.472 177.242 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' PRO . . . . . 0.738 ' HG3' ' HB3' ' A' ' 95' ' ' SER . 14.8 Cg_endo -91.97 162.81 3.28 Favored 'Trans proline' 0 N--CA 1.454 -0.823 0 C-N-CA 123.228 2.619 . . . . 0.0 111.905 176.798 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . 0.438 ' HB2' ' HG2' ' A' ' 101' ' ' GLU . 2.4 Cg_endo -48.97 139.64 25.3 Favored 'Trans proline' 0 C--N 1.349 0.599 0 C-N-CA 123.181 2.587 . . . . 0.0 112.597 177.159 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.741 ' HA ' ' CE1' ' A' ' 103' ' ' HIS . . . -79.28 19.36 0.59 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.188 -0.46 . . . . 0.0 112.098 -172.528 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' GLU . . . . . 0.438 ' HG2' ' HB2' ' A' ' 99' ' ' PRO . 9.3 pt-20 -115.82 -16.62 11.17 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 115.991 -0.549 . . . . 0.0 111.367 -177.572 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.604 HD13 ' HB2' ' A' ' 98' ' ' PRO . 2.5 pp -112.04 3.44 8.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 N-CA-C 112.258 0.466 . . . . 0.0 112.258 -175.546 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' HIS . . . . . 0.741 ' CE1' ' HA ' ' A' ' 100' ' ' ALA . 33.5 m170 -62.27 -40.79 97.4 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.181 -179.15 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 22.4 m -61.81 -31.46 71.69 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.987 0.422 . . . . 0.0 110.899 178.903 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.547 ' O ' HG22 ' A' ' 109' ' ' VAL . 14.5 m -72.84 -40.68 65.55 Favored 'General case' 0 N--CA 1.448 -0.538 0 CA-C-N 116.045 -0.525 . . . . 0.0 109.897 178.302 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 90.4 mt -61.38 -42.17 98.28 Favored 'General case' 0 C--O 1.233 0.224 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.944 178.289 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' MET . . . . . . . . . . . . . 91.3 mmm -55.37 -48.09 74.81 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.619 -0.719 . . . . 0.0 111.768 -179.598 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 4.1 ptp180 -74.01 -26.89 60.68 Favored 'General case' 0 C--N 1.329 -0.32 0 C-N-CA 120.875 -0.33 . . . . 0.0 111.512 -177.697 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.547 HG22 ' O ' ' A' ' 105' ' ' SER . 70.2 t -66.31 -46.87 85.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 N-CA-C 110.192 -0.299 . . . . 0.0 110.192 175.813 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -59.01 -45.57 90.36 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.292 178.527 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.524 ' HA ' ' HB1' ' A' ' 148' ' ' ALA . 24.4 t70 -64.9 -36.83 85.63 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.885 -0.598 . . . . 0.0 111.026 179.557 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -68.53 -35.56 77.64 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.717 -0.674 . . . . 0.0 112.17 -178.372 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.472 HG11 ' CB ' ' A' ' 87' ' ' TYR . 22.5 m -97.04 -23.77 4.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-O 120.745 0.307 . . . . 0.0 111.65 -177.787 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 89.43 36.4 7.5 Favored Glycine 0 N--CA 1.452 -0.235 0 C-N-CA 120.933 -0.651 . . . . 0.0 112.645 176.792 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -114.24 147.47 38.93 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 121.003 0.43 . . . . 0.0 111.416 -177.187 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 116' ' ' ARG . . . . . 0.43 ' HB3' ' HG ' ' A' ' 92' ' ' LEU . 27.8 ttt180 -70.96 120.06 15.98 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.687 -0.688 . . . . 0.0 109.836 178.876 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . 0.669 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 60.0 tp -94.72 126.83 40.28 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 -179.038 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 64.1 mt -129.02 122.79 57.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-O 120.827 0.346 . . . . 0.0 110.44 -179.223 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 119' ' ' ILE . . . . . 0.525 HG12 ' HB2' ' A' ' 95' ' ' SER . 66.7 mt -130.05 119.85 48.0 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-O 120.777 0.323 . . . . 0.0 110.755 -179.018 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 34.3 ttpt -116.27 98.38 51.31 Favored Pre-proline 0 C--N 1.326 -0.441 0 N-CA-C 109.622 -0.511 . . . . 0.0 109.622 173.085 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 89.6 Cg_endo -87.17 -156.08 0.06 OUTLIER 'Trans proline' 0 N--CA 1.457 -0.631 0 C-N-CA 122.862 2.375 . . . . 0.0 112.471 179.325 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 122' ' ' LEU . . . . . 0.442 HD13 ' HA ' ' A' ' 122' ' ' LEU . 9.3 tp -74.35 161.56 29.75 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.302 177.899 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 12.9 t -69.3 -24.65 63.97 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.064 0.459 . . . . 0.0 110.979 -177.927 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -114.32 27.14 9.17 Favored Glycine 0 N--CA 1.448 -0.519 0 C-N-CA 120.837 -0.696 . . . . 0.0 111.385 176.686 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 35.6 tt0 -128.04 125.93 40.29 Favored 'General case' 0 C--N 1.319 -0.756 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 -177.167 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -108.22 166.86 10.43 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.001 -179.935 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 42.6 mt -83.83 -22.78 8.15 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-O 121.095 0.474 . . . . 0.0 110.207 -178.805 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 11.1 t 61.75 39.12 0.18 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.228 0 CA-C-O 122.027 0.917 . . . . 0.0 109.714 -178.908 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 6.1 t -131.02 20.91 4.92 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.417 -0.811 . . . . 0.0 108.939 176.134 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 6.0 tp10 -54.34 105.41 0.15 Allowed 'General case' 0 C--O 1.233 0.212 0 CA-C-N 114.797 -1.092 . . . . 0.0 111.131 -173.183 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 131' ' ' ARG . . . . . . . . . . . . . 5.2 ttm105 179.53 -37.38 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.47 -0.786 . . . . 0.0 110.942 -172.901 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 55.7 tttp -134.65 -17.57 1.96 Allowed 'General case' 0 CA--C 1.534 0.341 0 N-CA-C 112.836 0.68 . . . . 0.0 112.836 -165.698 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 133' ' ' MET . . . . . . . . . . . . . 76.0 mtp -96.24 168.72 10.41 Favored 'General case' 0 C--N 1.328 -0.356 0 C-N-CA 120.69 -0.404 . . . . 0.0 111.098 -176.952 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . 0.433 ' HG3' ' HG2' ' A' ' 145' ' ' GLU . 15.8 ptmt -130.62 148.59 52.43 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.911 -178.088 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . 0.606 HD11 ' HD2' ' A' ' 142' ' ' TYR . 39.7 tp -94.62 126.21 39.77 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.395 -179.747 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -123.86 147.19 28.35 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.692 -179.577 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 9.8 m-80 -116.98 119.0 33.95 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.999 0.428 . . . . 0.0 110.299 177.344 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . 0.489 ' O ' HG23 ' A' ' 141' ' ' THR . 71.3 t80 -146.49 128.11 15.15 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.142 -0.481 . . . . 0.0 109.932 -177.038 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . 0.43 ' O ' ' HB2' ' A' ' 140' ' ' ARG . . . 66.37 38.9 94.0 Favored Glycine 0 N--CA 1.449 -0.469 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.238 177.904 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 140' ' ' ARG . . . . . 0.43 ' HB2' ' O ' ' A' ' 139' ' ' GLY . 13.0 mmt85 76.47 -12.54 1.02 Allowed 'General case' 0 N--CA 1.469 0.497 0 C-N-CA 123.438 0.695 . . . . 0.0 112.392 177.804 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 141' ' ' THR . . . . . 0.489 HG23 ' O ' ' A' ' 138' ' ' TYR . 4.6 t -105.21 166.1 10.64 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 120.851 0.358 . . . . 0.0 110.575 -178.972 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 142' ' ' TYR . . . . . 0.606 ' HD2' HD11 ' A' ' 135' ' ' LEU . 14.4 p90 -130.06 141.12 50.75 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.125 -0.488 . . . . 0.0 109.807 178.945 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -150.3 168.43 24.1 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.687 -177.58 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 85.8 m-85 -99.88 125.12 45.81 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 177.499 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 145' ' ' GLU . . . . . 0.433 ' HG2' ' HG3' ' A' ' 134' ' ' LYS . 7.5 pt-20 -116.26 162.84 16.88 Favored 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 109.558 -0.534 . . . . 0.0 109.558 175.596 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . 0.553 ' HB3' ' HB3' ' A' ' 117' ' ' LEU . 15.0 t80 -145.3 123.44 12.16 Favored 'General case' 0 C--N 1.314 -0.946 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.275 178.894 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 3.4 mp -91.92 100.27 10.98 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 177.545 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . 0.524 ' HB1' ' HA ' ' A' ' 111' ' ' ASP . . . -71.68 125.74 27.9 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.896 176.312 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -59.4 149.95 27.82 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.798 -0.637 . . . . 0.0 111.518 177.682 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 25.1 t -85.0 128.85 38.61 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.911 0 CA-C-N 115.021 -0.991 . . . . 0.0 109.404 179.268 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 151' ' ' ARG . . . . . . . . . . . . . 44.7 mtp85 -78.69 152.28 31.7 Favored 'General case' 0 C--N 1.317 -0.848 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.369 -178.222 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 18.8 t -80.67 147.07 30.8 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.624 -174.828 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 8.6 ptt180 . . . . . 0 C--O 1.248 1.025 0 CA-C-O 118.165 -0.922 . . . . 0.0 110.044 178.998 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 25.0 mmt . . . . . 0 N--CA 1.48 1.062 0 N-CA-C 110.192 -0.299 . . . . 0.0 110.192 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -54.84 110.99 1.92 Allowed Glycine 0 C--N 1.332 0.321 0 C-N-CA 121.361 -0.447 . . . . 0.0 112.688 -177.822 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 16.1 m -115.87 123.14 47.39 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 120.727 0.299 . . . . 0.0 110.239 -179.2 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 15.9 m -90.58 131.47 36.28 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.495 -178.365 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 51.2 p-80 -99.85 146.11 26.99 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 109.962 -0.384 . . . . 0.0 109.962 178.621 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 38.9 m80 -104.52 178.26 4.61 Favored 'General case' 0 C--N 1.316 -0.878 0 CA-C-N 116.173 -0.467 . . . . 0.0 109.77 177.928 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 41.8 m80 -80.49 94.51 6.24 Favored 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 109.377 -0.601 . . . . 0.0 109.377 179.191 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 12.3 t-80 -111.22 126.42 54.85 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.347 -0.842 . . . . 0.0 110.076 -173.667 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 29.9 m170 61.84 77.94 0.31 Allowed 'General case' 0 N--CA 1.464 0.244 0 CA-C-O 121.453 0.644 . . . . 0.0 110.992 -176.552 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 56.3 t-80 -139.77 146.97 40.16 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.505 -0.771 . . . . 0.0 109.284 178.029 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 21.6 t -160.96 172.54 16.74 Favored 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 178.441 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 32.5 t -154.33 161.73 41.59 Favored 'General case' 0 C--N 1.32 -0.705 0 N-CA-C 109.557 -0.534 . . . . 0.0 109.557 -179.069 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -94.54 100.66 2.62 Favored Glycine 0 N--CA 1.447 -0.608 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.037 -179.298 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 94.1 mt -73.21 136.37 44.68 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.052 0.454 . . . . 0.0 110.319 -179.416 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 28.9 m -93.32 152.75 41.35 Favored Pre-proline 0 C--N 1.321 -0.655 0 CA-C-N 115.979 -0.555 . . . . 0.0 111.015 -178.911 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -70.41 159.09 54.09 Favored 'Trans proline' 0 C--O 1.234 0.3 0 C-N-CA 122.427 2.085 . . . . 0.0 111.465 175.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . 0.519 ' HD3' ' H ' ' A' ' 17' ' ' ARG . 0.0 OUTLIER -111.29 114.13 27.09 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 121.126 0.488 . . . . 0.0 110.694 -177.869 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -65.17 101.94 0.61 Allowed Glycine 0 N--CA 1.449 -0.453 0 CA-C-N 115.674 -0.694 . . . . 0.0 111.964 179.31 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 3.3 p -160.84 118.54 2.42 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 120.801 0.334 . . . . 0.0 110.215 -177.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 91.2 m-70 -125.04 -52.48 1.65 Allowed 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.463 -0.335 . . . . 0.0 111.234 -176.646 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -72.83 -15.8 61.61 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 121.039 0.447 . . . . 0.0 111.175 -177.303 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 78.7 m95 -66.59 -18.45 65.37 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.639 176.655 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 27.1 t-20 -56.35 -52.52 64.26 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.779 -0.646 . . . . 0.0 111.492 -177.514 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -63.81 -33.71 76.29 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.138 -178.901 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 56.7 tp -58.08 -49.52 76.64 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.084 175.725 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . 0.409 ' O ' HG13 ' A' ' 30' ' ' ILE . . . -58.57 -48.45 80.88 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.763 178.655 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.435 ' HA ' HD12 ' A' ' 30' ' ' ILE . 87.4 t -54.85 -44.48 72.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.177 178.553 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . 0.416 ' HB2' ' CD2' ' A' ' 138' ' ' TYR . 84.6 t80 -60.77 -46.83 88.97 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.715 179.041 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 83.1 mt -60.9 -42.83 94.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.51 178.332 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.52 HG12 HG23 ' A' ' 54' ' ' ILE . 87.7 mt -56.65 -45.32 82.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 115.704 -0.68 . . . . 0.0 111.066 177.418 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . 0.405 ' HG3' ' O ' ' A' ' 27' ' ' VAL . 81.0 mtp180 -69.33 -27.34 65.27 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 121.147 0.499 . . . . 0.0 110.899 -177.729 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 80.4 m -88.9 -2.88 58.81 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.925 -0.579 . . . . 0.0 111.639 -178.538 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 16.6 p -121.84 -76.76 0.58 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.505 0.193 . . . . 0.0 110.977 -179.387 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.502 ' O ' HG22 ' A' ' 37' ' ' THR . . . 101.03 161.82 27.58 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 121.087 -0.578 . . . . 0.0 112.409 179.597 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_exo -74.36 146.34 35.35 Favored 'Trans proline' 0 N--CA 1.462 -0.351 0 C-N-CA 122.84 2.36 . . . . 0.0 111.986 179.076 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 98.02 -15.82 61.04 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.868 -0.682 . . . . 0.0 113.046 177.357 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' THR . . . . . 0.502 HG22 ' O ' ' A' ' 34' ' ' GLY . 13.6 t -102.42 -172.14 2.08 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 117.039 0.419 . . . . 0.0 110.544 -179.091 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . 0.505 ' HB2' ' HA ' ' A' ' 90' ' ' ALA . 68.7 mtp180 -115.42 135.8 53.74 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.565 -0.289 . . . . 0.0 110.976 -177.276 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.482 HG22 HG21 ' A' ' 60' ' ' VAL . 61.7 t -131.59 138.86 52.02 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 175.575 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.562 ' O ' ' HA ' ' A' ' 93' ' ' ILE . 23.4 t -126.92 139.13 52.76 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 178.259 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . 0.615 ' OE2' ' HA ' ' A' ' 64' ' ' LEU . 0.5 OUTLIER -116.12 156.25 26.76 Favored 'General case' 0 C--N 1.32 -0.678 0 C-N-CA 120.123 -0.631 . . . . 0.0 109.959 171.49 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.438 HG23 HD22 ' A' ' 106' ' ' LEU . 62.1 t -110.84 103.23 15.14 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.851 0 CA-C-N 115.755 -0.657 . . . . 0.0 109.79 176.385 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 115.28 56.04 0.36 Allowed Glycine 0 N--CA 1.448 -0.538 0 C-N-CA 120.309 -0.948 . . . . 0.0 112.7 178.707 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . 0.441 ' HB2' ' OE2' ' A' ' 41' ' ' GLU . . . -80.73 77.04 7.61 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.254 0.549 . . . . 0.0 110.424 178.029 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -82.75 -154.89 16.59 Favored Glycine 0 N--CA 1.447 -0.625 0 CA-C-N 115.564 -0.744 . . . . 0.0 112.846 -179.55 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 49.9 ttt180 -70.37 -15.12 62.82 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 121.264 0.554 . . . . 0.0 110.555 -177.46 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 7.7 p90 -88.94 58.71 4.7 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.792 -0.64 . . . . 0.0 111.204 -178.707 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 95.0 mt -78.23 35.09 0.21 Allowed 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.008 -0.542 . . . . 0.0 112.15 -176.848 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . 0.511 ' HB2' ' HG3' ' A' ' 17' ' ' ARG . 84.3 t80 -71.91 -53.83 11.92 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.602 0.239 . . . . 0.0 110.995 -179.45 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.432 ' O ' HG13 ' A' ' 54' ' ' ILE . 56.7 t -57.72 -50.8 76.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.024 -0.534 . . . . 0.0 111.134 -176.404 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 2.7 p -59.98 -42.33 93.93 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.627 -178.829 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.487 ' O ' ' HG2' ' A' ' 56' ' ' LYS . 27.5 t70 -67.73 -43.23 80.44 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.385 -0.371 . . . . 0.0 110.651 -179.647 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 61.9 t80 -63.01 -44.63 95.45 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.92 -178.405 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.52 HG23 HG12 ' A' ' 30' ' ' ILE . 84.3 mt -61.32 -46.05 97.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.864 179.508 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 2.5 ptm180 -72.92 -16.48 61.55 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.358 -176.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . 0.487 ' HG2' ' O ' ' A' ' 52' ' ' ASP . 36.0 mmtm -72.82 -34.82 67.1 Favored 'General case' 0 C--O 1.234 0.287 0 CA-C-O 120.848 0.356 . . . . 0.0 110.486 175.016 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 29.3 m-70 -93.55 -60.4 1.78 Allowed 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.379 -177.039 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 52.8 m -106.78 133.22 51.77 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 121.233 0.54 . . . . 0.0 111.717 -174.878 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 1.3 tmmm? -76.56 65.76 2.44 Favored 'General case' 0 N--CA 1.451 -0.38 0 CA-C-O 121.769 0.795 . . . . 0.0 108.909 174.318 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.482 HG21 HG22 ' A' ' 39' ' ' VAL . 14.9 p -97.06 147.83 6.03 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.983 0 CA-C-N 115.235 -0.893 . . . . 0.0 109.927 176.115 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 13.2 t70 -81.09 89.6 5.98 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 178.865 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 3.3 tm? -93.97 131.86 39.01 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.481 -0.781 . . . . 0.0 109.27 -178.096 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 42.4 t -115.36 117.92 57.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-O 120.457 0.17 . . . . 0.0 110.842 -177.604 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . 0.615 ' HA ' ' OE2' ' A' ' 41' ' ' GLU . 84.8 mt -86.89 128.07 35.05 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.913 -178.574 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 70.1 p -116.23 123.57 48.09 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.879 177.475 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . 0.641 ' HB3' HG21 ' A' ' 74' ' ' ILE . 17.9 t70 -149.03 136.12 19.95 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.126 -179.841 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . 0.444 HG12 ' HB2' ' A' ' 78' ' ' ASP . 46.2 mt -69.12 110.61 2.63 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 178.189 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' LYS . . . . . 0.421 ' HG2' HG21 ' A' ' 67' ' ' ILE . 31.1 mmtp 63.25 85.37 0.17 Allowed Pre-proline 0 C--N 1.33 -0.269 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 -172.297 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . 0.651 ' HD3' ' HA ' ' A' ' 76' ' ' ARG . 4.2 Cg_endo -44.47 108.01 0.12 Allowed 'Trans proline' 0 C--N 1.351 0.698 0 C-N-CA 123.805 3.004 . . . . 0.0 112.52 -173.948 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 17.4 m -65.77 -33.24 75.41 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 114.835 -1.075 . . . . 0.0 111.801 -176.482 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . 0.488 ' H ' HD13 ' A' ' 74' ' ' ILE . 71.7 t60 -141.87 96.59 2.99 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 112.942 0.719 . . . . 0.0 112.942 -170.574 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 57.74 -113.13 4.34 Favored Glycine 0 CA--C 1.519 0.313 0 CA-C-N 115.553 -0.749 . . . . 0.0 114.799 167.454 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -82.35 58.72 4.96 Favored Glycine 0 C--N 1.332 0.361 0 C-N-CA 121.615 -0.326 . . . . 0.0 113.772 -170.9 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . 0.641 HG21 ' HB3' ' A' ' 66' ' ' ASP . 97.2 mt -115.83 141.89 31.32 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 174.403 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 44.2 t -79.31 137.77 21.17 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 178.935 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' ARG . . . . . 0.651 ' HA ' ' HD3' ' A' ' 69' ' ' PRO . 0.0 OUTLIER -75.57 13.67 0.75 Allowed 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.046 -0.525 . . . . 0.0 111.75 -176.91 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . 0.466 ' OD1' ' HG2' ' A' ' 83' ' ' ARG . 12.7 t70 -70.08 121.89 18.34 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -175.893 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . 0.444 ' HB2' HG12 ' A' ' 67' ' ' ILE . 3.3 p30 -101.24 169.53 8.85 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 121.276 0.56 . . . . 0.0 111.526 -172.213 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 8.5 tt -77.46 -15.46 14.37 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 115.328 -0.851 . . . . 0.0 112.518 -171.276 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 7.8 p -93.41 -23.44 18.42 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 121.657 0.742 . . . . 0.0 109.69 -178.902 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' SER . . . . . 0.474 ' N ' ' HD3' ' A' ' 82' ' ' PRO . 23.0 t -139.23 58.22 12.13 Favored Pre-proline 0 N--CA 1.441 -0.897 0 CA-C-N 114.677 -1.147 . . . . 0.0 110.574 -170.596 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.474 ' HD3' ' N ' ' A' ' 81' ' ' SER . 5.1 Cg_exo -77.79 140.07 18.19 Favored 'Trans proline' 0 N--CA 1.458 -0.609 0 C-N-CA 122.656 2.237 . . . . 0.0 112.14 -174.736 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' ARG . . . . . 0.842 ' HB2' HD12 ' A' ' 86' ' ' ILE . 55.9 mmt-85 -80.35 113.52 18.59 Favored 'General case' 0 CA--C 1.507 -0.673 0 CA-C-O 121.14 0.495 . . . . 0.0 110.67 178.259 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' MET . . . . . 0.49 ' HA ' ' HD2' ' A' ' 87' ' ' TYR . 22.0 mtp -72.61 -13.12 61.3 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.09 178.553 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.656 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 11.3 pt-20 -70.16 -22.72 62.94 Favored 'General case' 0 C--O 1.232 0.133 0 CA-C-O 121.485 0.659 . . . . 0.0 109.579 175.259 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.842 HD12 ' HB2' ' A' ' 83' ' ' ARG . 96.3 mt -83.34 -33.94 10.47 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 115.251 -0.886 . . . . 0.0 110.172 178.859 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . 0.49 ' HD2' ' HA ' ' A' ' 84' ' ' MET . 95.3 m-85 -82.33 -37.87 25.1 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.572 -178.888 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 23.6 mtp180 -62.55 116.17 4.9 Favored 'General case' 0 CA--C 1.514 -0.44 0 CA-C-O 121.367 0.603 . . . . 0.0 111.401 -178.908 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 111.74 -10.33 27.78 Favored Glycine 0 N--CA 1.447 -0.619 0 CA-C-N 114.914 -1.039 . . . . 0.0 112.054 -178.249 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . 0.505 ' HA ' ' HB2' ' A' ' 38' ' ' ARG . . . -78.72 149.15 32.81 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.057 0.456 . . . . 0.0 110.613 179.649 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -94.38 -21.09 19.18 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.776 -179.245 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . 0.482 HD23 ' N ' ' A' ' 93' ' ' ILE . 4.7 tt -155.12 144.24 20.96 Favored 'General case' 0 N--CA 1.451 -0.376 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.719 -177.864 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.562 ' HA ' ' O ' ' A' ' 40' ' ' VAL . 63.3 mt -130.86 127.18 61.15 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 177.203 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' TYR . . . . . 0.409 ' O ' ' HA ' ' A' ' 41' ' ' GLU . 32.3 p90 -129.24 161.96 28.98 Favored 'General case' 0 C--N 1.322 -0.6 0 C-N-CA 120.578 -0.449 . . . . 0.0 110.897 -179.503 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 14.2 m -144.94 145.72 31.67 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.918 0.39 . . . . 0.0 110.816 -179.333 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 72.6 mt -114.09 109.26 27.85 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.15 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . 0.434 HH11 ' HD2' ' A' ' 97' ' ' ARG . 42.0 ttm180 59.48 80.84 0.26 Allowed Pre-proline 0 CA--C 1.534 0.358 0 O-C-N 123.849 0.718 . . . . 0.0 111.35 -178.331 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 96.0 Cg_endo -88.52 133.38 2.68 Favored 'Trans proline' 0 N--CA 1.456 -0.724 0 C-N-CA 122.677 2.251 . . . . 0.0 112.642 179.078 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . 0.621 ' HD2' HD12 ' A' ' 102' ' ' ILE . 32.8 Cg_exo -58.98 141.23 98.1 Favored 'Trans proline' 0 N--CA 1.464 -0.238 0 C-N-CA 122.678 2.252 . . . . 0.0 111.465 175.048 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.722 ' HA ' ' NE2' ' A' ' 103' ' ' HIS . . . -72.07 4.45 3.5 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 112.154 0.428 . . . . 0.0 112.154 -173.737 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' GLU . . . . . 0.595 ' HG3' HG22 ' A' ' 102' ' ' ILE . 9.2 pt-20 -96.33 -21.09 18.02 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.643 -0.253 . . . . 0.0 111.64 -179.928 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.621 HD12 ' HD2' ' A' ' 99' ' ' PRO . 2.5 pp -115.68 10.49 7.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 N-CA-C 113.108 0.781 . . . . 0.0 113.108 -170.331 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 103' ' ' HIS . . . . . 0.722 ' NE2' ' HA ' ' A' ' 100' ' ' ALA . 22.1 m-70 -54.71 -50.22 68.84 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 121.042 0.449 . . . . 0.0 111.13 -179.959 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 5.1 m -64.62 -26.27 68.32 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.96 -177.296 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.522 ' O ' HG21 ' A' ' 109' ' ' VAL . 19.4 m -72.06 -38.98 69.34 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.079 -178.797 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . 0.438 HD22 HG23 ' A' ' 42' ' ' VAL . 77.5 mt -73.42 -41.85 62.78 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.854 179.651 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 107' ' ' MET . . . . . 0.553 ' HG2' ' O ' ' A' ' 103' ' ' HIS . 90.5 mmm -56.44 -41.28 76.19 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.753 -0.658 . . . . 0.0 111.881 -177.981 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 11.2 ptp180 -73.42 -29.42 62.57 Favored 'General case' 0 C--N 1.328 -0.347 0 C-N-CA 120.79 -0.364 . . . . 0.0 111.277 -178.382 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.522 HG21 ' O ' ' A' ' 105' ' ' SER . 81.0 t -68.72 -45.75 80.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 C-N-CA 121.083 -0.247 . . . . 0.0 110.515 -179.777 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -61.77 -44.5 96.76 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.274 178.717 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.706 ' HA ' ' HB3' ' A' ' 148' ' ' ALA . 17.3 t70 -63.85 -34.44 77.94 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.66 -0.7 . . . . 0.0 110.984 179.82 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . 0.406 ' HB2' ' HE2' ' A' ' 84' ' ' MET . . . -70.85 -43.36 68.64 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.825 -0.625 . . . . 0.0 111.955 -178.675 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 21.6 m -89.02 -24.05 6.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 N-CA-C 111.848 0.314 . . . . 0.0 111.848 -175.093 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 84.71 53.68 3.14 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.309 178.691 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -129.83 160.41 33.57 Favored 'General case' 0 C--N 1.323 -0.566 0 O-C-N 122.842 -0.21 . . . . 0.0 110.695 -179.227 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 116' ' ' ARG . . . . . 0.416 ' HD3' ' OE1' ' A' ' 145' ' ' GLU . 10.1 ttm180 -79.53 123.53 27.66 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 109.278 -0.638 . . . . 0.0 109.278 176.013 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . 0.562 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 58.5 tp -95.04 118.01 31.14 Favored 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 109.585 -0.524 . . . . 0.0 109.585 178.812 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 60.2 mt -115.49 114.79 47.37 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.654 0 CA-C-O 121.278 0.561 . . . . 0.0 110.696 -179.773 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 63.1 mt -115.34 123.96 71.41 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.907 0 CA-C-N 116.151 -0.477 . . . . 0.0 109.972 178.908 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 120' ' ' LYS . . . . . 0.502 ' HG2' ' HB3' ' A' ' 143' ' ' PHE . 9.5 tmtm? -110.22 97.92 32.97 Favored Pre-proline 0 C--N 1.321 -0.647 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 176.728 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 80.1 Cg_endo -87.93 -178.18 2.14 Favored 'Trans proline' 0 N--CA 1.453 -0.873 0 C-N-CA 122.794 2.329 . . . . 0.0 111.866 176.433 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 122' ' ' LEU . . . . . 0.732 ' HB2' ' HB3' ' A' ' 125' ' ' GLU . 8.1 mp -108.29 166.93 10.39 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.243 -178.85 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 24.8 m -64.19 111.97 2.82 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 120.942 0.401 . . . . 0.0 110.726 179.147 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 91.66 -32.75 5.14 Favored Glycine 0 N--CA 1.45 -0.379 0 N-CA-C 111.314 -0.714 . . . . 0.0 111.314 -176.8 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . 0.732 ' HB3' ' HB2' ' A' ' 122' ' ' LEU . 20.9 tt0 -92.09 74.68 5.49 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 176.22 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 23.6 t70 -113.62 -178.53 3.4 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 114.788 -1.096 . . . . 0.0 110.948 -166.626 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.569 ' HB ' ' HG1' ' A' ' 129' ' ' THR . 4.7 mt -71.51 -27.28 28.14 Favored 'Isoleucine or valine' 0 C--O 1.234 0.268 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 176.201 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 3.3 t 63.35 33.92 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.261 0 CA-C-O 121.911 0.862 . . . . 0.0 109.453 -179.158 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 129' ' ' THR . . . . . 0.569 ' HG1' ' HB ' ' A' ' 127' ' ' ILE . 20.2 p -117.66 -72.63 0.68 Allowed 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.482 -0.781 . . . . 0.0 111.822 -173.482 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 58.8 80.4 0.19 Allowed 'General case' 0 C--O 1.233 0.215 0 O-C-N 123.682 0.614 . . . . 0.0 110.535 -176.571 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 131' ' ' ARG . . . . . . . . . . . . . 19.1 tpp180 -165.68 -71.97 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.213 0.53 . . . . 0.0 110.412 -177.672 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 132' ' ' LYS . . . . . 0.421 ' HB3' ' HE1' ' A' ' 107' ' ' MET . 30.9 mmtt -77.89 -49.9 13.29 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.45 -0.795 . . . . 0.0 112.152 -176.699 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 133' ' ' MET . . . . . 0.492 ' HG2' ' HB2' ' A' ' 146' ' ' TYR . 77.2 mtp -87.89 154.03 20.85 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.15 0.5 . . . . 0.0 111.616 -173.371 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 14.8 ptmt -112.72 142.66 45.08 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 115.197 -0.91 . . . . 0.0 110.376 -177.305 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . 0.545 HD12 ' HD2' ' A' ' 142' ' ' TYR . 47.2 tp -84.33 123.05 29.76 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.428 -179.957 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -121.68 144.6 30.32 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.935 -179.516 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -111.2 130.53 55.61 Favored 'General case' 0 C--N 1.325 -0.482 0 N-CA-C 109.526 -0.546 . . . . 0.0 109.526 175.002 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . 0.416 ' CD2' ' HB2' ' A' ' 28' ' ' TYR . 57.5 t80 -148.52 111.55 4.87 Favored 'General case' 0 C--N 1.322 -0.629 0 N-CA-C 110.018 -0.364 . . . . 0.0 110.018 176.139 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 69.49 49.2 39.4 Favored Glycine 0 N--CA 1.446 -0.683 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.02 179.826 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 20.9 mmm-85 76.48 -40.66 0.39 Allowed 'General case' 0 N--CA 1.467 0.397 0 C-N-CA 123.729 0.812 . . . . 0.0 112.057 177.446 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 13.8 t -76.73 146.94 37.66 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.192 0.52 . . . . 0.0 110.64 -177.941 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 142' ' ' TYR . . . . . 0.545 ' HD2' HD12 ' A' ' 135' ' ' LEU . 47.4 p90 -117.28 142.94 46.45 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.776 179.194 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 143' ' ' PHE . . . . . 0.502 ' HB3' ' HG2' ' A' ' 120' ' ' LYS . 11.4 p90 -152.48 179.79 8.26 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.58 -0.736 . . . . 0.0 109.748 -178.476 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 89.3 m-85 -115.33 138.07 51.36 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 120.669 0.271 . . . . 0.0 110.595 -179.858 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 145' ' ' GLU . . . . . 0.416 ' OE1' ' HD3' ' A' ' 116' ' ' ARG . 17.9 pt-20 -123.81 160.05 28.22 Favored 'General case' 0 C--N 1.319 -0.737 0 N-CA-C 109.161 -0.681 . . . . 0.0 109.161 173.878 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . 0.492 ' HB2' ' HG2' ' A' ' 133' ' ' MET . 45.7 t80 -142.26 126.36 17.39 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-O 121.07 0.462 . . . . 0.0 110.374 176.78 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 2.1 mp -92.82 108.11 19.91 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.762 0 CA-C-N 115.696 -0.684 . . . . 0.0 109.389 176.683 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . 0.706 ' HB3' ' HA ' ' A' ' 111' ' ' ASP . . . -70.93 129.12 38.22 Favored 'General case' 0 N--CA 1.444 -0.774 0 CA-C-N 115.693 -0.685 . . . . 0.0 110.151 176.353 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 22.4 mm-40 -64.18 167.95 6.01 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 121.768 0.794 . . . . 0.0 111.395 177.779 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 16.5 t -90.4 117.7 34.2 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.953 0 CA-C-N 114.836 -1.074 . . . . 0.0 109.525 179.346 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 151' ' ' ARG . . . . . . . . . . . . . 30.2 mmm180 -87.59 90.04 8.22 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 115.727 -0.67 . . . . 0.0 109.979 -179.499 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 20.9 t -143.19 148.07 35.9 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.508 -178.662 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 9.2 tpt180 . . . . . 0 C--O 1.251 1.153 0 CA-C-O 118.293 -0.861 . . . . 0.0 109.114 178.278 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 22.0 ptm . . . . . 0 N--CA 1.482 1.163 0 N-CA-C 110.032 -0.359 . . . . 0.0 110.032 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -79.63 53.18 4.25 Favored Glycine 0 N--CA 1.453 -0.216 0 C-N-CA 121.265 -0.493 . . . . 0.0 113.195 -174.045 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 16.3 m -79.68 -20.77 45.8 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.162 0.506 . . . . 0.0 110.243 177.236 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 33.9 m -114.98 89.05 3.01 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.94 -0.573 . . . . 0.0 109.997 176.504 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 41.1 p-80 -93.12 7.6 43.53 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.406 0.622 . . . . 0.0 110.239 178.484 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 21.1 m-70 -92.01 35.51 0.98 Allowed 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.328 178.214 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 28.1 p-80 -81.29 137.67 35.78 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.681 178.835 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 76.5 t60 -129.34 128.48 43.2 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 109.563 -0.532 . . . . 0.0 109.563 -179.078 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 81.6 t60 -81.39 -32.38 32.83 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.46 -172.578 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 94.1 m-70 -87.23 16.76 4.87 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.793 0.33 . . . . 0.0 111.302 -175.979 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 19.6 m -65.8 111.01 3.04 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.144 177.112 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 19.7 t -94.09 -47.32 6.73 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 115.915 -0.584 . . . . 0.0 109.757 -178.791 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 83.22 113.47 0.53 Allowed Glycine 0 N--CA 1.448 -0.512 0 CA-C-N 115.739 -0.664 . . . . 0.0 112.175 -178.921 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -77.48 126.02 30.25 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-O 120.919 0.39 . . . . 0.0 110.54 -178.73 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 60.9 t -102.83 111.11 64.65 Favored Pre-proline 0 C--N 1.323 -0.55 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.709 -178.107 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -79.51 179.26 6.51 Favored 'Trans proline' 0 N--CA 1.46 -0.467 0 C-N-CA 123.051 2.5 . . . . 0.0 111.117 174.932 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 35.2 ptt180 -81.0 -19.18 44.55 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.267 0.556 . . . . 0.0 110.241 -179.86 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -179.0 164.37 32.61 Favored Glycine 0 N--CA 1.444 -0.783 0 CA-C-N 115.689 -0.687 . . . . 0.0 111.507 178.297 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 12.2 p -87.81 148.24 24.77 Favored 'General case' 0 C--N 1.32 -0.704 0 N-CA-C 110.095 -0.335 . . . . 0.0 110.095 177.77 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 64.1 m80 -131.1 -46.49 1.01 Allowed 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.974 0.416 . . . . 0.0 110.393 179.498 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' MET . . . . . . . . . . . . . 65.5 mtt -71.5 -40.79 69.94 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.022 179.394 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 81.7 m95 -69.57 -19.99 63.66 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.497 -0.774 . . . . 0.0 111.145 -178.567 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . 0.499 ' O ' HG21 ' A' ' 27' ' ' VAL . 6.7 m-20 -65.5 -29.85 70.55 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.006 -179.547 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -75.04 -34.07 61.81 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 179.696 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 45.1 tp -60.31 -43.13 96.62 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 115.914 -0.585 . . . . 0.0 109.651 172.846 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -59.05 -47.33 85.62 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.458 -0.792 . . . . 0.0 110.655 176.661 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.499 HG21 ' O ' ' A' ' 23' ' ' ASN . 99.2 t -56.21 -43.25 75.86 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.188 0 CA-C-N 116.361 -0.381 . . . . 0.0 111.111 177.987 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 88.0 t80 -59.44 -48.71 80.59 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.819 0.342 . . . . 0.0 110.461 178.401 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 71.6 mt -58.48 -41.83 82.77 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.251 178.553 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.581 HG12 HG23 ' A' ' 54' ' ' ILE . 83.2 mt -60.32 -38.44 77.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 115.473 -0.785 . . . . 0.0 111.061 177.639 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 22.1 mtp180 -70.78 -30.13 66.52 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.154 -179.22 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 75.6 m -87.03 -8.91 56.67 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.576 -178.501 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 26.0 p -122.84 -80.83 0.63 Allowed 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 120.747 0.308 . . . . 0.0 111.08 179.01 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.446 ' O ' HG21 ' A' ' 37' ' ' THR . . . 88.21 168.51 44.33 Favored Glycine 0 N--CA 1.447 -0.633 0 C-N-CA 121.141 -0.552 . . . . 0.0 112.446 -179.901 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_exo -65.67 140.33 61.69 Favored 'Trans proline' 0 C--O 1.232 0.204 0 C-N-CA 122.644 2.229 . . . . 0.0 111.759 178.225 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 109.98 -8.21 31.41 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.364 -0.922 . . . . 0.0 112.507 178.978 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' THR . . . . . 0.446 HG21 ' O ' ' A' ' 34' ' ' GLY . 11.5 t -125.04 -171.31 2.33 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.306 -0.627 . . . . 0.0 109.306 178.299 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . 0.817 ' HG3' ' HA ' ' A' ' 90' ' ' ALA . 1.7 ptm180 -132.48 136.94 47.02 Favored 'General case' 0 N--CA 1.447 -0.604 0 CA-C-O 121.075 0.464 . . . . 0.0 111.418 -179.619 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.472 ' O ' ' HA ' ' A' ' 62' ' ' LEU . 58.2 t -125.91 139.43 51.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 115.611 -0.722 . . . . 0.0 109.747 -178.223 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.465 ' HB ' HG12 ' A' ' 93' ' ' ILE . 39.6 t -116.34 134.47 59.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-O 120.854 0.359 . . . . 0.0 111.164 -178.026 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 44.1 tt0 -108.23 120.56 42.72 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.143 177.02 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.598 ' HB ' ' HB3' ' A' ' 95' ' ' SER . 85.7 t -95.91 123.49 48.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.387 -179.603 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 98.19 25.16 10.53 Favored Glycine 0 N--CA 1.447 -0.567 0 C-N-CA 120.686 -0.769 . . . . 0.0 111.789 -179.366 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -79.32 54.13 1.63 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 121.321 0.582 . . . . 0.0 111.128 -178.281 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -94.25 -64.82 1.02 Allowed Glycine 0 N--CA 1.444 -0.789 0 C-N-CA 120.854 -0.689 . . . . 0.0 111.823 178.674 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -105.07 -8.22 18.63 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.059 0.457 . . . . 0.0 110.306 175.373 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.488 ' HD1' ' HE1' ' A' ' 49' ' ' TYR . 87.4 m-85 -106.76 102.54 11.91 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.909 -0.587 . . . . 0.0 109.981 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . 0.522 HD23 HD12 ' A' ' 64' ' ' LEU . 84.5 mt -129.7 -10.81 4.45 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.448 -0.342 . . . . 0.0 111.002 179.997 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . 0.488 ' HE1' ' HD1' ' A' ' 47' ' ' PHE . 30.6 p90 -59.06 -30.97 68.45 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 112.59 0.589 . . . . 0.0 112.59 -173.917 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 80.5 t -75.81 -58.01 5.26 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-O 120.795 0.331 . . . . 0.0 110.744 178.831 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' SER . . . . . 0.431 ' CB ' HD21 ' A' ' 64' ' ' LEU . 15.5 p -60.32 -39.18 86.12 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.939 -177.983 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.503 ' O ' ' HG3' ' A' ' 56' ' ' LYS . 29.7 t70 -65.11 -33.65 76.53 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.64 -178.38 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 71.0 t80 -71.25 -44.71 64.77 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.545 177.499 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.581 HG23 HG12 ' A' ' 30' ' ' ILE . 79.2 mt -57.48 -46.42 85.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.868 -176.602 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . 0.482 HH12 HD11 ' A' ' 64' ' ' LEU . 9.0 ptp85 -69.03 -16.12 63.63 Favored 'General case' 0 N--CA 1.467 0.383 0 N-CA-C 112.164 0.431 . . . . 0.0 112.164 -176.889 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . 0.503 ' HG3' ' O ' ' A' ' 52' ' ' ASP . 67.9 mttm -82.54 -33.08 28.31 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 120.807 0.337 . . . . 0.0 111.392 -179.753 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 13.9 t60 -95.11 -39.65 10.02 Favored 'General case' 0 N--CA 1.448 -0.529 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.357 -177.699 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 8.1 p -118.51 132.07 56.23 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.449 -0.341 . . . . 0.0 111.13 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . 0.402 ' HA ' ' HD2' ' A' ' 59' ' ' LYS . 26.9 mmmt -80.97 61.2 4.47 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.696 0.76 . . . . 0.0 110.603 176.062 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 7.7 p -98.07 144.65 10.92 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.725 0 CA-C-N 114.901 -1.045 . . . . 0.0 109.509 175.508 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -73.12 89.61 1.5 Allowed 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 177.561 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . 0.472 ' HA ' ' O ' ' A' ' 39' ' ' VAL . 3.5 tt -96.39 118.4 32.84 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.014 0.435 . . . . 0.0 110.363 -176.611 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 58.1 t -102.19 128.98 54.31 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.463 0 CA-C-N 115.588 -0.733 . . . . 0.0 110.72 -176.141 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . 0.522 HD12 HD23 ' A' ' 48' ' ' LEU . 66.1 mt -108.66 133.26 52.99 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.936 -0.574 . . . . 0.0 109.999 176.404 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 12.5 p -119.12 132.03 55.96 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.724 0.297 . . . . 0.0 110.71 176.194 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . 0.422 ' HB3' HG21 ' A' ' 74' ' ' ILE . 24.5 t70 -156.96 146.85 20.81 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.426 -177.843 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . 0.592 HG12 ' HB2' ' A' ' 78' ' ' ASP . 34.5 mt -73.9 103.91 2.44 Favored 'Isoleucine or valine' 0 C--O 1.238 0.491 0 N-CA-C 110.114 -0.328 . . . . 0.0 110.114 179.419 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' LYS . . . . . 0.4 ' HA ' ' HD2' ' A' ' 69' ' ' PRO . 30.7 mtpt 56.92 80.08 0.3 Allowed Pre-proline 0 C--N 1.33 -0.276 0 CA-C-N 115.191 -0.913 . . . . 0.0 109.798 -177.091 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . 0.85 ' HB3' ' HB ' ' A' ' 74' ' ' ILE . 9.1 Cg_endo -49.8 133.16 33.0 Favored 'Trans proline' 0 C--O 1.234 0.275 0 C-N-CA 123.895 3.064 . . . . 0.0 113.7 -173.077 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 39.5 t -87.75 -5.7 58.53 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.438 -0.801 . . . . 0.0 110.053 177.51 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 68.7 m-70 -136.43 165.53 25.59 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.354 -179.559 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -86.53 138.76 16.02 Favored Glycine 0 N--CA 1.448 -0.558 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.263 -179.131 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 106.55 -2.26 36.76 Favored Glycine 0 N--CA 1.449 -0.456 0 C-N-CA 120.76 -0.733 . . . . 0.0 111.753 179.303 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . 0.85 ' HB ' ' HB3' ' A' ' 69' ' ' PRO . 43.4 mt -98.91 140.28 18.83 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 N-CA-C 110.164 -0.31 . . . . 0.0 110.164 -179.754 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.464 HG13 ' H ' ' A' ' 77' ' ' ASP . 63.3 t -79.41 141.94 14.66 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.093 178.764 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' ARG . . . . . 0.548 ' HG2' ' HD2' ' A' ' 69' ' ' PRO . 89.1 mtm180 -82.87 16.41 2.28 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.913 -176.148 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . 0.464 ' H ' HG13 ' A' ' 75' ' ' VAL . 35.9 t70 -87.03 138.01 31.86 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 179.001 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . 0.592 ' HB2' HG12 ' A' ' 67' ' ' ILE . 0.7 OUTLIER -103.32 177.92 4.7 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.73 0.3 . . . . 0.0 111.257 -173.362 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 9.3 tp -94.03 -24.66 4.95 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.444 0 N-CA-C 112.601 0.593 . . . . 0.0 112.601 -170.401 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.519 HG22 ' OD1' ' A' ' 78' ' ' ASP . 6.3 t -91.1 -20.5 21.96 Favored 'General case' 0 C--N 1.325 -0.47 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 -178.319 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' SER . . . . . 0.501 ' HB2' ' OD2' ' A' ' 78' ' ' ASP . 34.0 m -129.42 62.85 65.23 Favored Pre-proline 0 CA--C 1.535 0.391 0 CA-C-N 115.48 -0.782 . . . . 0.0 110.081 172.822 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 87.9 Cg_endo -85.7 150.28 9.98 Favored 'Trans proline' 0 N--CA 1.459 -0.515 0 C-N-CA 122.375 2.05 . . . . 0.0 113.525 -171.847 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 77.8 mtt-85 -88.95 112.51 23.41 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.416 -0.811 . . . . 0.0 110.413 175.147 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' MET . . . . . . . . . . . . . 93.6 mmm -66.05 -23.38 66.53 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.449 -0.341 . . . . 0.0 111.057 -179.264 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 6.7 pm0 -67.62 -19.32 65.21 Favored 'General case' 0 N--CA 1.464 0.246 0 CA-C-O 120.889 0.376 . . . . 0.0 111.01 179.61 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 62.1 mt -83.81 -39.34 14.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.345 179.017 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . 0.404 ' CB ' HG13 ' A' ' 113' ' ' VAL . 93.3 m-85 -80.65 -34.07 35.17 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.209 -178.557 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . 0.528 ' HA ' ' HB ' ' A' ' 113' ' ' VAL . 62.2 mtp85 -65.15 132.93 50.42 Favored 'General case' 0 CA--C 1.515 -0.384 0 CA-C-O 121.329 0.585 . . . . 0.0 110.856 -178.509 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 102.4 -19.41 48.33 Favored Glycine 0 N--CA 1.446 -0.683 0 CA-C-N 115.053 -0.976 . . . . 0.0 111.641 -176.803 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . 0.817 ' HA ' ' HG3' ' A' ' 38' ' ' ARG . . . -71.46 145.3 49.32 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.837 0.351 . . . . 0.0 110.705 -179.772 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -92.52 -21.98 19.81 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.041 -179.188 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . 0.524 ' HG ' ' HB3' ' A' ' 116' ' ' ARG . 3.5 tt -150.81 138.4 19.68 Favored 'General case' 0 N--CA 1.449 -0.497 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.912 -176.28 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.63 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 85.5 mt -133.03 124.05 49.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 115.719 -0.673 . . . . 0.0 109.326 176.955 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' TYR . . . . . 0.405 ' HB3' ' HB ' ' A' ' 118' ' ' ILE . 10.2 p90 -130.01 158.84 38.49 Favored 'General case' 0 C--N 1.32 -0.696 0 C-N-CA 120.808 -0.357 . . . . 0.0 110.802 -179.524 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' SER . . . . . 0.598 ' HB3' ' HB ' ' A' ' 42' ' ' VAL . 11.5 p -145.07 137.71 26.18 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.594 -177.749 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 63.7 mt -104.7 111.51 34.55 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.293 -179.212 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 6.1 tpm_? 61.32 75.67 0.44 Allowed Pre-proline 0 CA--C 1.534 0.355 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.188 -179.763 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 0.9 OUTLIER -84.32 150.86 12.01 Favored 'Trans proline' 0 N--CA 1.457 -0.629 0 C-N-CA 122.788 2.325 . . . . 0.0 111.589 176.449 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -59.39 155.16 42.64 Favored 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.703 2.269 . . . . 0.0 111.619 175.727 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.634 ' HA ' ' CE1' ' A' ' 103' ' ' HIS . . . -79.26 7.19 8.17 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 112.144 0.424 . . . . 0.0 112.144 -174.118 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -111.75 -14.03 13.64 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 111.804 0.298 . . . . 0.0 111.804 179.597 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.417 HG13 ' O ' ' A' ' 102' ' ' ILE . 32.2 pt -123.51 77.46 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 121.821 0.82 . . . . 0.0 111.661 -179.281 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 103' ' ' HIS . . . . . 0.634 ' CE1' ' HA ' ' A' ' 100' ' ' ALA . 44.9 m80 -112.99 -50.25 2.89 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.418 -0.81 . . . . 0.0 109.331 174.983 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 18.9 t -74.9 -23.76 58.42 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 176.353 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.523 ' O ' ' HG2' ' A' ' 108' ' ' ARG . 3.3 m -67.87 -38.96 83.76 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.459 -0.791 . . . . 0.0 109.754 177.272 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 69.2 mt -73.2 -38.76 65.99 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.129 175.701 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 107' ' ' MET . . . . . . . . . . . . . 47.9 ttm -62.1 -39.82 93.75 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.685 -0.689 . . . . 0.0 111.129 -179.819 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 108' ' ' ARG . . . . . 0.523 ' HG2' ' O ' ' A' ' 105' ' ' SER . 7.9 ptp180 -68.56 -25.35 64.86 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.629 0.252 . . . . 0.0 110.795 -179.816 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.479 HG22 ' O ' ' A' ' 105' ' ' SER . 94.2 t -72.32 -48.18 49.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 175.697 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -59.63 -41.59 90.8 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.167 176.164 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 18.0 t70 -61.95 -38.28 87.89 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.412 -0.813 . . . . 0.0 111.164 178.232 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -72.74 -40.37 66.11 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.612 -0.722 . . . . 0.0 111.957 -178.377 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.528 ' HB ' ' HA ' ' A' ' 88' ' ' ARG . 13.7 m -91.01 -24.57 5.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-O 120.895 0.378 . . . . 0.0 111.741 -174.339 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 88.69 42.13 5.83 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 121.009 -0.615 . . . . 0.0 112.421 178.916 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -119.41 156.5 30.03 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 121.101 0.477 . . . . 0.0 111.407 -177.177 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 116' ' ' ARG . . . . . 0.524 ' HB3' ' HG ' ' A' ' 92' ' ' LEU . 21.5 ttm180 -79.59 121.37 25.18 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.793 -0.639 . . . . 0.0 109.654 176.793 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . 0.63 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 53.3 tp -92.71 118.83 31.47 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.383 -178.579 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . 0.405 ' HB ' ' HB3' ' A' ' 94' ' ' TYR . 64.1 mt -113.38 121.72 66.12 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.61 0 CA-C-O 121.024 0.44 . . . . 0.0 110.425 178.101 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 56.4 mt -120.46 134.31 64.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.375 -179.809 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 45.2 tptt -110.14 98.2 33.94 Favored Pre-proline 0 C--N 1.323 -0.549 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.524 175.43 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 82.0 Cg_endo -91.47 174.62 2.42 Favored 'Trans proline' 0 N--CA 1.456 -0.721 0 C-N-CA 123.068 2.512 . . . . 0.0 112.005 173.961 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -99.01 163.79 12.44 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.467 178.984 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 14.5 t -65.06 -21.78 66.88 Favored 'General case' 0 CA--C 1.534 0.363 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.429 -179.162 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -104.13 18.04 46.74 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.308 179.871 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 22.7 mm-40 -119.6 -173.84 2.62 Favored 'General case' 0 N--CA 1.449 -0.487 0 CA-C-O 121.209 0.528 . . . . 0.0 110.334 -178.489 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -148.87 170.01 19.25 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 115.381 -0.827 . . . . 0.0 108.791 176.548 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.486 ' C ' ' H ' ' A' ' 129' ' ' THR . 7.5 mt -101.1 -18.19 6.47 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 179.484 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 27.8 t 68.72 -13.32 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.541 0.611 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.572 179.213 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 129' ' ' THR . . . . . 0.486 ' H ' ' C ' ' A' ' 127' ' ' ILE . 7.7 t -79.47 -176.97 5.54 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.931 0.396 . . . . 0.0 110.582 179.915 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 130' ' ' GLU . . . . . 0.485 ' HB2' ' HG2' ' A' ' 132' ' ' LYS . 33.2 mt-10 -87.22 -166.6 1.62 Allowed 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.982 -0.553 . . . . 0.0 110.537 -178.89 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 131' ' ' ARG . . . . . 0.754 ' HD2' ' H ' ' A' ' 131' ' ' ARG . 0.0 OUTLIER -77.55 37.67 0.23 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 121.107 0.48 . . . . 0.0 110.598 177.609 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 132' ' ' LYS . . . . . 0.485 ' HG2' ' HB2' ' A' ' 130' ' ' GLU . 29.5 mmmt -79.27 -41.29 28.49 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.844 -0.616 . . . . 0.0 111.447 -176.03 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 133' ' ' MET . . . . . 0.719 ' HG2' ' HB2' ' A' ' 146' ' ' TYR . 82.5 mtp -92.38 164.94 13.31 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.929 -174.431 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 13.2 ptmm? -127.08 140.47 52.26 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.971 -177.503 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . 0.513 HD12 ' HD2' ' A' ' 142' ' ' TYR . 51.6 tp -80.7 129.19 34.38 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.338 -179.091 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -123.3 139.04 51.18 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.68 178.751 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 16.8 m120 -114.83 108.25 16.5 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 115.801 -0.636 . . . . 0.0 109.868 179.557 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 54.1 t80 -131.65 106.01 7.89 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-O 120.929 0.395 . . . . 0.0 110.323 -178.275 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . 0.461 ' O ' ' HB2' ' A' ' 140' ' ' ARG . . . 80.0 34.16 31.07 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.094 178.922 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 140' ' ' ARG . . . . . 0.461 ' HB2' ' O ' ' A' ' 139' ' ' GLY . 0.0 OUTLIER 75.32 -14.57 0.75 Allowed 'General case' 0 N--CA 1.468 0.471 0 C-N-CA 123.279 0.632 . . . . 0.0 111.921 178.097 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 8.3 t -93.9 141.62 28.31 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 175.562 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 142' ' ' TYR . . . . . 0.513 ' HD2' HD12 ' A' ' 135' ' ' LEU . 43.0 p90 -119.07 143.54 47.07 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 121.364 0.602 . . . . 0.0 110.825 -176.052 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 15.0 p90 -152.01 173.88 14.34 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 115.119 -0.946 . . . . 0.0 109.413 -178.512 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 76.8 m-85 -112.94 129.47 56.46 Favored 'General case' 0 C--N 1.322 -0.611 0 C-N-CA 121.058 -0.257 . . . . 0.0 110.691 -179.624 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 145' ' ' GLU . . . . . 0.481 ' OE1' ' HD3' ' A' ' 116' ' ' ARG . 19.2 pt-20 -115.33 157.19 24.18 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 174.667 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . 0.719 ' HB2' ' HG2' ' A' ' 133' ' ' MET . 32.9 t80 -139.24 124.19 18.77 Favored 'General case' 0 C--N 1.315 -0.913 0 CA-C-N 115.752 -0.658 . . . . 0.0 109.904 176.656 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 3.1 mp -93.54 105.93 17.41 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.859 0 N-CA-C 109.726 -0.472 . . . . 0.0 109.726 -179.168 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -62.3 114.94 3.76 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-O 121.139 0.495 . . . . 0.0 110.756 178.054 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 8.1 mm-40 -76.28 -175.53 3.24 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.346 -0.843 . . . . 0.0 111.194 179.22 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 21.5 t -87.55 135.55 25.11 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.92 0 CA-C-N 114.824 -1.08 . . . . 0.0 109.07 177.591 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 151' ' ' ARG . . . . . . . . . . . . . 3.9 ppt_? -59.37 135.92 57.81 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.872 0.368 . . . . 0.0 110.198 -178.474 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 34.8 m -128.95 114.7 16.78 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.786 -176.935 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 62.0 ttt-85 . . . . . 0 C--O 1.245 0.856 0 CA-C-O 118.519 -0.753 . . . . 0.0 109.707 179.588 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 64.9 mtt . . . . . 0 N--CA 1.482 1.134 0 N-CA-C 110.108 -0.331 . . . . 0.0 110.108 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -129.58 -164.24 11.37 Favored Glycine 0 N--CA 1.446 -0.69 0 C-N-CA 120.852 -0.69 . . . . 0.0 111.835 178.388 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 22.7 m -128.11 -174.57 3.25 Favored 'General case' 0 C--N 1.32 -0.68 0 N-CA-C 109.708 -0.479 . . . . 0.0 109.708 177.588 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 33.0 m -67.15 135.69 53.92 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.871 0.367 . . . . 0.0 110.618 179.257 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 37.6 p-80 -122.92 144.82 48.97 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.526 179.467 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 8.1 p80 -140.69 117.73 11.19 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 115.953 -0.567 . . . . 0.0 109.705 176.058 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 18.2 m-70 -120.12 117.11 27.08 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.349 -173.344 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 43.6 m80 56.74 43.34 25.39 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-N 115.733 -0.667 . . . . 0.0 112.214 173.908 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 45.5 t60 -132.92 23.87 4.25 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 122.162 0.982 . . . . 0.0 108.433 174.549 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 22.5 p-80 -98.73 158.21 15.77 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 114.799 -1.091 . . . . 0.0 111.169 -177.421 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 38.7 m 65.51 18.72 11.37 Favored 'General case' 0 CA--C 1.533 0.311 0 CA-C-N 115.492 -0.776 . . . . 0.0 112.144 174.676 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 14.6 p -82.13 77.37 8.94 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.572 0.701 . . . . 0.0 111.06 -179.345 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -165.59 69.01 0.19 Allowed Glycine 0 N--CA 1.448 -0.561 0 CA-C-N 115.436 -0.802 . . . . 0.0 111.222 179.252 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 82.8 mt -81.49 138.67 35.46 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.901 0.381 . . . . 0.0 111.137 -175.666 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 47.3 t -112.27 98.84 44.6 Favored Pre-proline 0 C--N 1.323 -0.564 0 CA-C-N 115.824 -0.626 . . . . 0.0 109.65 176.363 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 77.1 Cg_endo -86.36 -175.12 1.65 Allowed 'Trans proline' 0 N--CA 1.458 -0.592 0 C-N-CA 123.138 2.558 . . . . 0.0 112.94 -176.602 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . 0.431 ' HA ' ' HB2' ' A' ' 20' ' ' HIS . 16.0 mtt-85 -92.21 -166.02 1.46 Allowed 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.779 -0.646 . . . . 0.0 111.287 179.185 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . 0.417 ' H ' ' HB3' ' A' ' 17' ' ' ARG . . . 92.55 -54.67 2.72 Favored Glycine 0 N--CA 1.446 -0.664 0 N-CA-C 111.178 -0.769 . . . . 0.0 111.178 -174.704 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' SER . . . . . 0.432 ' HB2' ' CZ ' ' A' ' 49' ' ' TYR . 36.5 p -110.42 8.45 23.21 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 121.065 0.46 . . . . 0.0 110.21 176.793 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' HIS . . . . . 0.431 ' HB2' ' HA ' ' A' ' 17' ' ' ARG . 21.7 t-80 -57.37 -42.22 81.67 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.525 -0.762 . . . . 0.0 111.433 -178.244 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -60.33 -24.95 65.44 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 121.342 0.591 . . . . 0.0 110.738 -177.829 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 51.4 m95 -97.29 -19.35 18.61 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.22 -178.764 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . 0.415 ' O ' HG22 ' A' ' 27' ' ' VAL . 25.1 t-20 -66.19 -58.96 4.26 Favored 'General case' 0 N--CA 1.463 0.198 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.674 -172.285 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.452 ' CB ' ' HA3' ' A' ' 139' ' ' GLY . 4.5 m-20 -58.12 -32.68 68.36 Favored 'General case' 0 N--CA 1.464 0.27 0 CA-C-O 120.631 0.253 . . . . 0.0 111.333 -178.892 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 45.7 tp -57.16 -51.22 70.2 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-O 120.932 0.396 . . . . 0.0 110.262 175.291 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . 0.416 ' HB3' HG13 ' A' ' 50' ' ' VAL . . . -63.48 -43.56 96.94 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.601 179.887 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.415 HG22 ' O ' ' A' ' 23' ' ' ASN . 95.5 t -52.13 -47.85 43.09 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.153 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.076 177.454 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 56.4 t80 -57.81 -43.31 85.62 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.539 179.88 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 70.8 mt -67.91 -43.97 85.51 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.791 179.247 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.457 HG12 HG23 ' A' ' 54' ' ' ILE . 92.1 mt -58.27 -45.54 89.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 115.61 -0.723 . . . . 0.0 111.0 178.303 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 84.0 mtt-85 -65.56 -27.72 68.63 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.666 -0.697 . . . . 0.0 111.761 -177.848 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 53.5 t -84.79 -27.35 26.9 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.596 -0.275 . . . . 0.0 111.186 -179.011 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 12.4 p -94.21 -76.96 0.47 Allowed 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 120.797 0.332 . . . . 0.0 111.202 -177.041 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 95.75 142.81 13.42 Favored Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 120.85 -0.69 . . . . 0.0 112.162 -178.843 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . 0.505 ' HG3' ' HA ' ' A' ' 58' ' ' SER . 58.1 Cg_exo -51.68 126.4 19.6 Favored 'Trans proline' 0 C--N 1.343 0.284 0 C-N-CA 123.283 2.655 . . . . 0.0 113.001 -176.795 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 104.32 53.93 0.81 Allowed Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.514 179.517 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 15.1 t -166.74 -175.84 3.27 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 179.624 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 63.1 mtt85 -122.11 132.51 54.51 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 121.08 0.467 . . . . 0.0 110.775 -179.911 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.89 ' HB ' HD21 ' A' ' 62' ' ' LEU . 60.6 t -123.85 131.76 72.45 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 N-CA-C 108.763 -0.828 . . . . 0.0 108.763 176.76 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.407 HG11 ' CE1' ' A' ' 87' ' ' TYR . 35.6 t -106.7 126.56 62.57 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-O 120.817 0.342 . . . . 0.0 110.887 -177.679 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 46.4 tt0 -108.22 124.12 49.81 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.144 178.368 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.892 ' HB ' ' HB3' ' A' ' 95' ' ' SER . 95.1 t -97.37 121.72 48.17 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.593 -179.876 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 89.68 34.13 8.67 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.855 -0.688 . . . . 0.0 111.519 -179.64 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -81.09 14.15 2.44 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 112.432 0.53 . . . . 0.0 112.432 -173.185 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -54.41 -38.04 61.59 Favored Glycine 0 CA--C 1.519 0.32 0 C-N-CA 121.201 -0.524 . . . . 0.0 113.807 -176.887 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 19.4 mtp180 -139.2 13.28 2.61 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 117.129 0.465 . . . . 0.0 111.997 -177.144 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 73.4 m-85 -112.15 29.03 8.24 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 121.254 0.55 . . . . 0.0 110.619 -177.519 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . 0.542 HD22 HD13 ' A' ' 74' ' ' ILE . 87.0 mt -59.26 -15.66 16.89 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 114.868 -1.06 . . . . 0.0 113.074 -175.342 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . 0.432 ' CZ ' ' HB2' ' A' ' 19' ' ' SER . 81.5 t80 -59.13 -45.26 91.39 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.583 0.23 . . . . 0.0 111.313 -179.249 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.418 ' O ' HG13 ' A' ' 54' ' ' ILE . 42.8 t -65.41 -54.64 26.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.672 -175.224 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' SER . . . . . 0.436 ' CB ' HD22 ' A' ' 64' ' ' LEU . 0.2 OUTLIER -59.52 -41.96 91.17 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.701 -179.796 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.587 ' HA ' ' HG2' ' A' ' 55' ' ' ARG . 38.7 t70 -69.08 -37.92 78.72 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 120.857 -0.337 . . . . 0.0 110.865 -179.224 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 89.4 t80 -60.26 -37.06 79.26 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.875 0.369 . . . . 0.0 110.034 177.925 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.457 HG23 HG12 ' A' ' 30' ' ' ILE . 76.0 mt -63.29 -54.78 28.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.949 -0.568 . . . . 0.0 110.673 176.044 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . 0.587 ' HG2' ' HA ' ' A' ' 52' ' ' ASP . 3.7 ptp180 -69.77 -16.44 63.3 Favored 'General case' 0 N--CA 1.465 0.318 0 N-CA-C 112.072 0.397 . . . . 0.0 112.072 -177.083 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . 0.691 ' HA ' ' HE3' ' A' ' 56' ' ' LYS . 0.0 OUTLIER -64.04 -39.24 93.66 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.693 0.282 . . . . 0.0 110.843 176.378 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 29.9 m-70 -107.27 -50.51 3.07 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.746 -178.61 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' SER . . . . . 0.505 ' HA ' ' HG3' ' A' ' 35' ' ' PRO . 57.6 m -88.38 132.99 34.22 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.851 -178.289 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . 0.557 ' N ' ' HD2' ' A' ' 59' ' ' LYS . 3.3 mptp? -80.19 57.06 2.61 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.684 0.754 . . . . 0.0 109.825 178.661 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.483 HG12 HG22 ' A' ' 39' ' ' VAL . 54.0 t -101.22 139.32 22.76 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-N 114.998 -1.001 . . . . 0.0 111.043 -178.11 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -80.02 98.61 7.28 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.866 -0.606 . . . . 0.0 109.524 174.819 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . 0.89 HD21 ' HB ' ' A' ' 39' ' ' VAL . 0.2 OUTLIER -87.54 121.02 29.43 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 115.934 -0.575 . . . . 0.0 109.593 -178.827 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 40.9 t -100.49 113.77 37.26 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.661 0 CA-C-N 115.738 -0.665 . . . . 0.0 109.786 -179.757 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . 0.726 ' HB2' ' HA ' ' A' ' 74' ' ' ILE . 54.5 mt -97.37 139.8 32.78 Favored 'General case' 0 C--N 1.312 -1.04 0 CA-C-N 115.628 -0.714 . . . . 0.0 110.338 -177.507 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.407 ' OG1' ' HA ' ' A' ' 42' ' ' VAL . 38.0 p -131.23 137.92 49.12 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.301 0.096 . . . . 0.0 110.91 178.547 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 4.7 t70 -171.19 170.81 5.93 Favored 'General case' 0 N--CA 1.466 0.33 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 175.759 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 49.5 mm -85.96 104.74 13.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 120.813 0.34 . . . . 0.0 110.865 -175.898 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 35.4 mtmt 56.21 77.52 0.42 Allowed Pre-proline 0 C--N 1.33 -0.278 0 CA-C-N 115.324 -0.853 . . . . 0.0 111.894 -179.575 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . 0.797 ' HD2' ' HG2' ' A' ' 76' ' ' ARG . 70.1 Cg_endo -76.57 154.96 35.63 Favored 'Trans proline' 0 N--CA 1.459 -0.505 0 C-N-CA 122.334 2.023 . . . . 0.0 112.139 175.613 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 29.5 m -140.81 0.16 1.57 Allowed 'General case' 0 C--N 1.32 -0.697 0 CA-C-O 121.171 0.51 . . . . 0.0 110.333 178.155 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 80.7 t60 -143.26 116.55 9.02 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.69 -0.686 . . . . 0.0 109.831 -179.685 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 101.52 166.34 27.46 Favored Glycine 0 N--CA 1.449 -0.488 0 C-N-CA 121.028 -0.606 . . . . 0.0 111.991 -179.248 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -81.18 60.99 4.64 Favored Glycine 0 N--CA 1.452 -0.261 0 N-CA-C 111.727 -0.549 . . . . 0.0 111.727 177.303 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . 0.726 ' HA ' ' HB2' ' A' ' 64' ' ' LEU . 44.6 mt -96.85 135.67 30.2 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-O 120.94 0.4 . . . . 0.0 110.531 -177.844 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 97.8 t -77.53 139.04 19.3 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 CA-C-N 116.065 -0.516 . . . . 0.0 109.807 176.43 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' ARG . . . . . 0.797 ' HG2' ' HD2' ' A' ' 69' ' ' PRO . 65.7 mtm180 -84.62 38.77 0.71 Allowed 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 120.762 0.315 . . . . 0.0 110.807 -177.73 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 28.1 t70 -76.68 126.73 31.49 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 121.024 0.44 . . . . 0.0 110.447 -178.649 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . 0.486 ' HB3' HG21 ' A' ' 80' ' ' THR . 3.3 m-20 -71.13 97.28 1.47 Allowed 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.891 -0.595 . . . . 0.0 109.971 175.808 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 9.7 tp -58.56 -17.31 9.92 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.388 0 CA-C-O 121.273 0.559 . . . . 0.0 111.663 -178.255 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.486 HG21 ' HB3' ' A' ' 78' ' ' ASP . 8.8 t -66.39 -24.08 66.42 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.027 0.442 . . . . 0.0 110.442 176.246 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 36.6 m -154.42 70.18 6.08 Favored Pre-proline 0 C--N 1.329 -0.32 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 177.514 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.535 ' HB2' ' HE2' ' A' ' 87' ' ' TYR . 74.0 Cg_endo -73.27 159.28 47.37 Favored 'Trans proline' 0 C--O 1.236 0.387 0 C-N-CA 123.011 2.474 . . . . 0.0 113.516 -169.691 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' ARG . . . . . 0.681 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 1.9 mtm180 -93.99 126.39 39.18 Favored 'General case' 0 C--N 1.323 -0.543 0 CA-C-N 115.793 -0.639 . . . . 0.0 110.921 177.958 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' MET . . . . . . . . . . . . . 89.3 mmm -64.56 -23.93 67.43 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.252 -178.066 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.681 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 12.0 pt-20 -62.52 -20.53 64.72 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.607 -179.112 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 63.8 mt -86.2 -29.47 6.08 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-O 121.167 0.508 . . . . 0.0 110.541 -178.802 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . 0.535 ' HE2' ' HB2' ' A' ' 82' ' ' PRO . 84.6 m-85 -93.34 -30.62 15.03 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.734 -176.259 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 81.8 mtp180 -66.75 114.14 5.4 Favored 'General case' 0 CA--C 1.514 -0.416 0 CA-C-O 121.485 0.659 . . . . 0.0 111.484 -176.889 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 116.09 -17.51 14.84 Favored Glycine 0 N--CA 1.446 -0.684 0 CA-C-N 114.902 -1.044 . . . . 0.0 111.982 -177.593 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -71.86 147.71 46.87 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.769 0.318 . . . . 0.0 110.665 178.835 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -91.34 -26.37 18.96 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-O 121.035 0.445 . . . . 0.0 110.856 -179.665 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . 0.486 ' HG ' ' HB3' ' A' ' 116' ' ' ARG . 5.0 tt -149.55 142.71 25.03 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.653 -177.715 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.591 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 63.2 mt -131.45 123.09 51.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 N-CA-C 109.117 -0.697 . . . . 0.0 109.117 178.269 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' TYR . . . . . 0.407 ' HE1' HG13 ' A' ' 39' ' ' VAL . 10.7 p90 -136.24 161.3 36.14 Favored 'General case' 0 C--N 1.321 -0.659 0 C-N-CA 120.403 -0.519 . . . . 0.0 111.375 -178.119 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' SER . . . . . 0.892 ' HB3' ' HB ' ' A' ' 42' ' ' VAL . 5.4 p -147.87 147.58 29.92 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.824 -0.626 . . . . 0.0 110.447 -178.268 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 4.3 mp -114.45 121.89 67.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-N 116.668 -0.242 . . . . 0.0 110.567 -179.184 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 50.85 67.28 4.46 Favored Pre-proline 0 N--CA 1.467 0.4 0 O-C-N 123.815 0.697 . . . . 0.0 111.201 179.328 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 85.5 Cg_endo -87.18 143.84 6.81 Favored 'Trans proline' 0 N--CA 1.456 -0.706 0 C-N-CA 122.861 2.374 . . . . 0.0 113.19 -174.772 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . 0.544 ' HD2' HD11 ' A' ' 102' ' ' ILE . 24.3 Cg_exo -63.7 144.51 89.47 Favored 'Trans proline' 0 C--O 1.234 0.317 0 C-N-CA 122.737 2.291 . . . . 0.0 111.573 175.611 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -78.22 44.17 0.48 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.177 0.513 . . . . 0.0 111.289 -177.708 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' GLU . . . . . 0.588 ' HG3' HG23 ' A' ' 102' ' ' ILE . 11.2 pt-20 -132.49 -11.4 3.15 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.439 175.795 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.588 HG23 ' HG3' ' A' ' 101' ' ' GLU . 35.1 pt -122.85 -6.86 8.25 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.449 -0.341 . . . . 0.0 111.636 -177.542 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 103' ' ' HIS . . . . . 0.739 ' HD2' ' HB ' ' A' ' 129' ' ' THR . 16.1 p-80 -62.97 -39.31 94.29 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.083 -176.256 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 32.2 t -71.78 -32.93 68.17 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 121.309 0.576 . . . . 0.0 110.086 178.487 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.58 ' O ' ' HG3' ' A' ' 108' ' ' ARG . 31.0 m -70.68 -33.28 70.75 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.314 179.898 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . 0.499 ' HG ' ' O ' ' A' ' 102' ' ' ILE . 85.2 mt -61.34 -40.27 93.66 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.831 177.606 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 107' ' ' MET . . . . . 0.569 ' HG2' ' HD3' ' A' ' 131' ' ' ARG . 39.7 tpp -56.67 -54.4 46.54 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.344 178.036 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 108' ' ' ARG . . . . . 0.58 ' HG3' ' O ' ' A' ' 105' ' ' SER . 1.6 ptm180 -65.09 -30.94 71.93 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.492 -0.322 . . . . 0.0 111.624 -177.28 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.481 HG22 ' O ' ' A' ' 105' ' ' SER . 83.4 t -73.27 -45.86 51.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 C-N-CA 120.972 -0.291 . . . . 0.0 110.917 179.194 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -59.31 -47.74 84.26 Favored 'General case' 0 CA--C 1.516 -0.355 0 CA-C-O 120.759 0.314 . . . . 0.0 110.163 178.8 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.712 ' HA ' ' HB3' ' A' ' 148' ' ' ALA . 17.3 t70 -66.73 -29.17 69.08 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.984 -176.679 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -71.54 -43.57 66.18 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.547 178.727 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 16.2 m -88.08 -27.01 5.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.456 -0.338 . . . . 0.0 111.758 -175.7 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 89.31 46.27 4.44 Favored Glycine 0 N--CA 1.449 -0.452 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.42 179.016 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -122.5 160.92 24.6 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 121.096 0.474 . . . . 0.0 111.201 -178.233 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 116' ' ' ARG . . . . . 0.486 ' HB3' ' HG ' ' A' ' 92' ' ' LEU . 29.5 ttt180 -81.92 116.42 21.55 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.859 -0.61 . . . . 0.0 109.604 178.542 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . 0.591 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 56.0 tp -90.9 118.5 30.35 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.09 -179.401 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 66.3 mt -119.5 126.04 74.96 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-O 121.121 0.486 . . . . 0.0 110.362 179.07 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 119' ' ' ILE . . . . . 0.484 ' O ' ' HD3' ' A' ' 121' ' ' PRO . 63.8 mt -112.93 127.49 70.14 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.055 178.167 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 48.3 tptt -105.65 91.8 5.42 Favored Pre-proline 0 C--N 1.325 -0.463 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.067 178.507 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 121' ' ' PRO . . . . . 0.517 ' HB2' ' CG ' ' A' ' 125' ' ' GLU . 75.9 Cg_endo -92.68 -177.86 0.82 Allowed 'Trans proline' 0 N--CA 1.455 -0.751 0 C-N-CA 122.622 2.215 . . . . 0.0 111.951 175.049 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -72.81 146.02 46.59 Favored 'General case' 0 C--N 1.327 -0.37 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 173.26 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 123' ' ' THR . . . . . 0.458 ' O ' HG22 ' A' ' 123' ' ' THR . 6.2 t -68.61 96.09 0.69 Allowed 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 121.668 0.747 . . . . 0.0 109.475 175.83 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 138.13 -17.58 3.37 Favored Glycine 0 N--CA 1.449 -0.485 0 CA-C-N 115.458 -0.792 . . . . 0.0 112.482 -178.117 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . 0.517 ' CG ' ' HB2' ' A' ' 121' ' ' PRO . 7.5 pt-20 -97.64 164.75 12.28 Favored 'General case' 0 N--CA 1.445 -0.7 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 178.402 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -128.66 162.17 27.96 Favored 'General case' 0 C--N 1.312 -1.044 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.426 -178.71 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.435 HD11 HD11 ' A' ' 119' ' ' ILE . 19.8 mt -90.85 106.58 17.63 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.674 0 N-CA-C 108.546 -0.909 . . . . 0.0 108.546 174.464 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 14.0 m -73.76 78.9 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.825 0 CA-C-O 121.982 0.896 . . . . 0.0 110.738 -179.75 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 129' ' ' THR . . . . . 0.739 ' HB ' ' HD2' ' A' ' 103' ' ' HIS . 6.4 t -144.2 155.69 44.0 Favored 'General case' 0 N--CA 1.447 -0.596 0 CA-C-N 115.024 -0.989 . . . . 0.0 110.579 -175.821 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -88.62 -19.13 26.65 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 121.289 0.566 . . . . 0.0 109.759 172.349 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 131' ' ' ARG . . . . . 0.569 ' HD3' ' HG2' ' A' ' 107' ' ' MET . 6.1 mmp_? -61.94 141.24 58.13 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.511 -176.877 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 132' ' ' LYS . . . . . 0.418 ' O ' ' HE1' ' A' ' 107' ' ' MET . 0.0 OUTLIER -83.89 122.9 29.34 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.816 0.817 . . . . 0.0 112.777 -171.652 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 133' ' ' MET . . . . . . . . . . . . . 85.7 mtp -139.55 170.7 15.43 Favored 'General case' 0 C--N 1.313 -1.005 0 CA-C-N 114.929 -1.032 . . . . 0.0 109.266 176.919 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . 0.46 ' NZ ' ' HB2' ' A' ' 134' ' ' LYS . 0.0 OUTLIER -128.29 146.01 50.88 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-O 120.988 0.423 . . . . 0.0 111.396 -178.367 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . 0.487 HD11 ' CD1' ' A' ' 142' ' ' TYR . 53.0 tp -80.88 139.26 36.02 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.718 -0.673 . . . . 0.0 109.554 177.165 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 136' ' ' VAL . . . . . 0.406 HG23 ' CD1' ' A' ' 143' ' ' PHE . 0.0 OUTLIER -134.66 134.46 54.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-O 120.971 0.415 . . . . 0.0 110.765 177.267 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 137' ' ' ASN . . . . . 0.43 ' ND2' ' HB3' ' A' ' 142' ' ' TYR . 16.0 m120 -107.41 114.59 28.7 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.35 178.915 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 53.2 t80 -148.75 122.28 9.14 Favored 'General case' 0 C--N 1.326 -0.445 0 C-N-CA 120.959 -0.297 . . . . 0.0 110.91 -178.766 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . 0.452 ' HA3' ' CB ' ' A' ' 24' ' ' ASP . . . 64.44 62.68 4.89 Favored Glycine 0 N--CA 1.452 -0.273 0 CA-C-N 115.797 -0.638 . . . . 0.0 113.231 174.867 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 35.3 mmt180 71.41 -38.28 0.42 Allowed 'General case' 0 N--CA 1.47 0.544 0 C-N-CA 123.647 0.779 . . . . 0.0 112.168 175.731 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 141' ' ' THR . . . . . 0.444 ' H ' ' C ' ' A' ' 139' ' ' GLY . 9.9 t -96.34 156.82 16.18 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 121.133 0.492 . . . . 0.0 110.831 -178.025 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 142' ' ' TYR . . . . . 0.487 ' CD1' HD11 ' A' ' 135' ' ' LEU . 44.0 p90 -121.58 154.19 37.05 Favored 'General case' 0 C--N 1.32 -0.699 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 169.415 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 143' ' ' PHE . . . . . 0.417 ' O ' HD13 ' A' ' 135' ' ' LEU . 8.9 p90 -153.37 -177.64 6.47 Favored 'General case' 0 C--N 1.316 -0.858 0 CA-C-N 116.129 -0.487 . . . . 0.0 109.777 -177.536 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 86.9 m-85 -116.41 131.97 56.8 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 116.724 -0.216 . . . . 0.0 110.699 -178.083 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 145' ' ' GLU . . . . . 0.444 ' CD ' HH21 ' A' ' 116' ' ' ARG . 17.1 pt-20 -128.91 162.3 27.86 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.044 0.45 . . . . 0.0 110.626 178.832 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 38.9 t80 -142.56 127.01 17.78 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 115.604 -0.725 . . . . 0.0 109.665 173.561 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 147' ' ' ILE . . . . . 0.427 ' N ' HD12 ' A' ' 147' ' ' ILE . 3.8 mp -95.07 100.27 10.77 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.842 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 178.854 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . 0.712 ' HB3' ' HA ' ' A' ' 111' ' ' ASP . . . -76.39 96.29 3.99 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.953 -0.567 . . . . 0.0 109.659 176.569 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -77.32 154.79 32.51 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-N 115.662 -0.699 . . . . 0.0 111.165 -174.929 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 59.7 t -76.79 147.66 7.4 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-N 115.411 -0.813 . . . . 0.0 109.356 178.845 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 151' ' ' ARG . . . . . . . . . . . . . 59.7 mtm-85 -67.13 152.1 46.37 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.724 0.297 . . . . 0.0 110.222 -178.976 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 18.5 m -80.78 94.78 6.48 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-O 121.181 0.515 . . . . 0.0 110.842 -176.464 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 26.9 mmm180 . . . . . 0 C--O 1.245 0.853 0 CA-C-O 118.376 -0.821 . . . . 0.0 109.809 176.729 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 2.1 mpt? . . . . . 0 N--CA 1.483 1.205 0 N-CA-C 110.222 -0.288 . . . . 0.0 110.222 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -170.04 -93.07 0.09 OUTLIER Glycine 0 N--CA 1.448 -0.547 0 N-CA-C 111.548 -0.621 . . . . 0.0 111.548 179.925 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 34.5 m 58.3 63.41 1.74 Allowed 'General case' 0 C--O 1.235 0.303 0 CA-C-O 121.21 0.528 . . . . 0.0 111.114 178.391 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 13.5 t -94.16 154.95 17.31 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.639 -0.71 . . . . 0.0 110.247 -179.487 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 19.4 t-80 -142.54 150.69 40.75 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 178.655 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 36.9 m80 -65.06 101.24 0.5 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.047 0.451 . . . . 0.0 110.397 178.473 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 51.4 t60 -148.97 136.21 20.1 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.684 -0.689 . . . . 0.0 109.766 -176.402 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 17.5 p80 -115.8 131.45 56.93 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-O 121.061 0.458 . . . . 0.0 109.89 176.917 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 45.8 m80 -75.6 153.03 37.57 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.944 -0.571 . . . . 0.0 111.197 -178.964 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 18.5 p80 -77.4 161.5 27.96 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.424 -0.807 . . . . 0.0 110.62 -179.224 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 3.9 p -107.73 106.65 17.07 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.241 175.229 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 68.3 m -142.0 169.04 18.34 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.835 -0.621 . . . . 0.0 110.449 -179.199 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -78.19 78.65 1.56 Allowed Glycine 0 N--CA 1.447 -0.581 0 C-N-CA 121.083 -0.579 . . . . 0.0 111.748 178.527 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 86.8 mt -74.52 145.37 43.53 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 120.719 0.295 . . . . 0.0 110.381 -178.702 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.407 ' HA ' ' HD3' ' A' ' 16' ' ' PRO . 45.1 t -86.72 117.31 68.47 Favored Pre-proline 0 C--N 1.325 -0.47 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.661 -178.06 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.407 ' HD3' ' HA ' ' A' ' 15' ' ' VAL . 2.8 Cg_exo -76.08 154.79 37.77 Favored 'Trans proline' 0 N--CA 1.463 -0.299 0 C-N-CA 123.063 2.508 . . . . 0.0 111.953 178.668 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -95.12 -156.19 0.5 Allowed 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.285 -0.416 . . . . 0.0 109.986 -179.361 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -77.49 167.62 54.05 Favored Glycine 0 N--CA 1.447 -0.609 0 C-N-CA 120.987 -0.625 . . . . 0.0 112.014 176.594 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 2.4 p -95.38 28.68 2.81 Favored 'General case' 0 C--N 1.321 -0.661 0 N-CA-C 111.88 0.326 . . . . 0.0 111.88 -175.709 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 40.6 t60 -53.7 -44.54 69.87 Favored 'General case' 0 N--CA 1.466 0.364 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.53 -177.394 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' MET . . . . . . . . . . . . . 67.2 mtt -71.94 -16.95 62.11 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 120.926 0.393 . . . . 0.0 111.521 -177.455 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' TRP . . . . . 0.616 ' HB3' HG23 ' A' ' 50' ' ' VAL . 77.0 m95 -96.03 -27.37 15.14 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.824 -176.888 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 6.4 m120 -56.33 -52.09 65.84 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.098 177.36 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.411 ' OD2' ' HA3' ' A' ' 139' ' ' GLY . 1.3 t70 -76.77 -28.98 55.89 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.423 -177.152 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 58.5 tp -59.29 -45.98 89.79 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-O 121.049 0.452 . . . . 0.0 109.907 174.516 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . 0.446 ' O ' HG13 ' A' ' 30' ' ' ILE . . . -56.18 -44.46 79.38 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.46 -0.791 . . . . 0.0 110.667 178.629 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 88.5 t -54.4 -46.85 70.34 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.244 0 O-C-N 123.264 0.352 . . . . 0.0 110.857 177.38 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . 0.538 ' HB2' ' CD2' ' A' ' 138' ' ' TYR . 87.2 t80 -58.48 -45.73 88.07 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.332 177.877 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 74.5 mt -63.09 -46.12 96.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.719 178.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.762 HG12 HG23 ' A' ' 54' ' ' ILE . 83.0 mt -57.48 -44.07 84.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 115.692 -0.685 . . . . 0.0 110.919 178.211 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 75.1 mtt180 -72.8 -21.26 61.01 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.263 -176.28 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 73.3 m -88.54 -14.01 38.75 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.345 -0.389 . . . . 0.0 111.339 177.753 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 22.0 p -126.53 -86.11 0.61 Allowed 'General case' 0 CA--C 1.534 0.328 0 CA-C-O 120.678 0.275 . . . . 0.0 111.358 179.315 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 99.77 -176.25 28.36 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 121.167 -0.539 . . . . 0.0 112.595 178.459 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -71.93 155.37 57.71 Favored 'Trans proline' 0 C--O 1.233 0.26 0 C-N-CA 122.534 2.156 . . . . 0.0 112.247 -179.35 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 98.02 -11.76 64.01 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.681 -0.771 . . . . 0.0 113.081 176.345 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 14.0 t -121.7 -166.61 1.4 Allowed 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.382 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . 0.629 ' HG2' ' HB2' ' A' ' 61' ' ' ASP . 84.3 mtt180 -128.03 136.36 51.13 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.891 0.377 . . . . 0.0 110.877 -179.218 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.873 ' HB ' HD23 ' A' ' 62' ' ' LEU . 20.9 t -125.47 140.63 47.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 177.182 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 40.4 t -112.41 128.93 68.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-O 120.941 0.401 . . . . 0.0 111.282 -177.469 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . 0.409 ' OE1' HD22 ' A' ' 64' ' ' LEU . 42.5 tt0 -105.06 110.2 22.5 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.659 -0.7 . . . . 0.0 109.549 176.887 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.415 ' HB ' ' HB3' ' A' ' 95' ' ' SER . 58.5 t -94.11 113.76 29.39 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.399 -179.462 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 103.8 42.87 1.89 Allowed Glycine 0 N--CA 1.446 -0.657 0 C-N-CA 120.524 -0.846 . . . . 0.0 111.612 -178.679 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -85.99 -127.01 0.04 OUTLIER 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 110.37 -0.233 . . . . 0.0 110.37 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 67.77 -90.23 0.2 Allowed Glycine 0 C--N 1.33 0.203 0 C-N-CA 121.281 -0.485 . . . . 0.0 112.589 177.873 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -71.9 -23.47 61.49 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 109.705 -0.479 . . . . 0.0 109.705 176.67 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 50.2 m-85 -110.18 109.59 20.14 Favored 'General case' 0 C--O 1.224 -0.277 0 CA-C-N 115.971 -0.558 . . . . 0.0 110.048 178.236 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 96.9 mt -131.35 0.81 4.11 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.706 0.289 . . . . 0.0 111.084 179.722 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 9.2 p90 -69.08 -26.97 65.21 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 112.211 0.449 . . . . 0.0 112.211 -174.936 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.616 HG23 ' HB3' ' A' ' 22' ' ' TRP . 40.9 t -76.02 -58.69 4.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-O 120.93 0.395 . . . . 0.0 110.763 179.734 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 3.3 p -60.77 -42.59 97.78 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.748 -0.66 . . . . 0.0 112.484 -176.703 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.515 ' O ' ' HG2' ' A' ' 56' ' ' LYS . 30.3 t70 -66.53 -27.54 67.84 Favored 'General case' 0 C--N 1.33 -0.256 0 C-N-CA 120.917 -0.313 . . . . 0.0 110.885 -179.359 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 88.1 t80 -70.44 -42.49 71.48 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 120.974 0.416 . . . . 0.0 110.34 175.819 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.762 HG23 HG12 ' A' ' 30' ' ' ILE . 77.3 mt -61.9 -43.58 97.66 Favored 'Isoleucine or valine' 0 C--O 1.236 0.353 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.119 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . 0.505 ' HG2' ' HA ' ' A' ' 52' ' ' ASP . 4.1 ptm180 -68.76 -16.09 63.7 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.952 -0.567 . . . . 0.0 111.794 -176.534 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . 0.515 ' HG2' ' O ' ' A' ' 52' ' ' ASP . 69.5 mmtt -65.34 -42.05 93.28 Favored 'General case' 0 C--O 1.233 0.192 0 CA-C-O 121.058 0.456 . . . . 0.0 110.349 177.401 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 33.2 m170 -94.17 -57.5 2.5 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.762 -0.654 . . . . 0.0 111.483 -174.519 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 69.0 m -102.72 130.65 49.73 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.11 0.481 . . . . 0.0 111.618 -175.589 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . 0.526 ' HE3' ' C ' ' A' ' 59' ' ' LYS . 0.1 OUTLIER -80.42 65.52 5.59 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 121.99 0.9 . . . . 0.0 109.224 173.676 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.576 HG23 HG21 ' A' ' 39' ' ' VAL . 7.3 p -97.16 143.5 12.37 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.025 0 CA-C-N 114.606 -1.179 . . . . 0.0 109.003 174.3 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . 0.629 ' HB2' ' HG2' ' A' ' 38' ' ' ARG . 19.7 m-20 -76.32 96.11 3.91 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-O 121.243 0.544 . . . . 0.0 109.68 178.081 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . 0.873 HD23 ' HB ' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -86.88 118.1 26.05 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 115.476 -0.784 . . . . 0.0 109.506 -178.936 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.506 HG12 HG22 ' A' ' 75' ' ' VAL . 61.9 t -97.94 114.76 36.19 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.849 0 CA-C-N 115.683 -0.689 . . . . 0.0 110.127 -179.996 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . 0.455 HD13 HG12 ' A' ' 74' ' ' ILE . 31.8 mt -96.77 124.0 40.63 Favored 'General case' 0 C--N 1.315 -0.93 0 CA-C-N 115.616 -0.72 . . . . 0.0 109.646 -179.915 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 33.1 p -108.34 124.96 51.16 Favored 'General case' 0 C--N 1.315 -0.924 0 CA-C-O 120.933 0.397 . . . . 0.0 110.278 177.276 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 25.6 t70 -156.17 144.58 19.98 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.202 -176.676 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . 0.433 HG23 ' HG3' ' A' ' 68' ' ' LYS . 53.7 mt -73.42 113.71 11.78 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 116.343 -0.389 . . . . 0.0 110.208 178.676 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' LYS . . . . . 0.433 ' HG3' HG23 ' A' ' 67' ' ' ILE . 5.8 mtpm? 59.76 82.01 0.24 Allowed Pre-proline 0 C--O 1.233 0.212 0 CA-C-N 115.54 -0.754 . . . . 0.0 110.568 179.483 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -71.06 137.61 32.05 Favored 'Trans proline' 0 C--O 1.232 0.198 0 C-N-CA 122.742 2.295 . . . . 0.0 113.008 -175.535 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 46.3 m -85.98 -37.43 19.01 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.957 177.043 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 71.3 m-70 -96.33 132.86 41.38 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.928 -177.084 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -66.89 102.77 0.81 Allowed Glycine 0 N--CA 1.448 -0.524 0 N-CA-C 111.449 -0.66 . . . . 0.0 111.449 175.59 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 147.88 -23.13 1.46 Allowed Glycine 0 N--CA 1.446 -0.663 0 N-CA-C 110.716 -0.954 . . . . 0.0 110.716 -175.548 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . 0.455 HG12 HD13 ' A' ' 64' ' ' LEU . 56.8 mt -83.67 140.16 16.62 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 N-CA-C 108.673 -0.862 . . . . 0.0 108.673 173.169 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.508 HG11 HD13 ' A' ' 86' ' ' ILE . 63.5 t -86.47 130.21 37.05 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.711 0 CA-C-O 120.942 0.401 . . . . 0.0 110.611 -176.539 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 15.3 ptm180 -75.15 49.19 0.44 Allowed 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.502 -0.772 . . . . 0.0 111.54 179.809 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 22.6 t70 -108.14 117.96 35.51 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 116.083 -0.508 . . . . 0.0 109.779 179.411 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . 0.461 ' OD2' HG23 ' A' ' 80' ' ' THR . 5.5 p-10 -92.18 132.15 36.86 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.361 -0.382 . . . . 0.0 110.548 -179.423 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 10.7 tp -62.95 -18.05 20.55 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.476 0 CA-C-N 116.155 -0.475 . . . . 0.0 112.185 -173.62 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.461 HG23 ' OD2' ' A' ' 78' ' ' ASP . 0.7 OUTLIER -77.75 -27.71 50.47 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.877 0.37 . . . . 0.0 110.66 177.483 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 22.2 t -140.81 66.42 26.65 Favored Pre-proline 0 C--N 1.326 -0.416 0 N-CA-C 109.636 -0.505 . . . . 0.0 109.636 177.996 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 76.0 Cg_endo -89.93 151.75 4.91 Favored 'Trans proline' 0 N--CA 1.456 -0.732 0 C-N-CA 122.62 2.213 . . . . 0.0 113.436 -171.817 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' ARG . . . . . 0.689 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 53.0 mtt-85 -93.19 115.26 27.89 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.481 174.589 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' MET . . . . . 0.513 ' HE2' HG11 ' A' ' 109' ' ' VAL . 93.4 mmm -62.05 -22.48 65.78 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.926 -0.579 . . . . 0.0 111.055 -178.981 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.689 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 12.9 pt-20 -62.27 -21.68 65.4 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-O 120.913 0.387 . . . . 0.0 111.137 178.692 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.508 HD13 HG11 ' A' ' 75' ' ' VAL . 82.2 mt -83.76 -43.21 17.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.621 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 70.7 m-85 -76.27 -31.5 58.3 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.841 -178.004 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . 0.7 ' HG3' HG12 ' A' ' 113' ' ' VAL . 31.9 mtp85 -66.91 119.86 12.62 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.615 177.737 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 115.11 -8.74 20.96 Favored Glycine 0 N--CA 1.449 -0.499 0 CA-C-N 115.737 -0.665 . . . . 0.0 111.538 -175.748 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -89.35 140.87 29.07 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 120.884 0.374 . . . . 0.0 110.633 179.227 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -88.09 -22.24 24.26 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.968 -178.927 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . 0.467 HD22 ' N ' ' A' ' 93' ' ' ILE . 3.3 tt -151.62 141.97 22.45 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.272 -176.733 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.535 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 65.4 mt -132.43 123.35 49.72 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-N 115.986 -0.552 . . . . 0.0 109.701 179.149 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' TYR . . . . . 0.527 ' HH ' HD13 ' A' ' 62' ' ' LEU . 23.3 p90 -125.03 150.95 46.22 Favored 'General case' 0 C--N 1.322 -0.612 0 C-N-CA 120.709 -0.396 . . . . 0.0 110.402 177.906 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' SER . . . . . 0.415 ' HB3' ' HB ' ' A' ' 42' ' ' VAL . 11.7 p -131.52 140.58 49.54 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.692 -178.089 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' ILE . . . . . 0.458 HG23 ' CH2' ' A' ' 22' ' ' TRP . 81.1 mt -98.45 90.2 2.07 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-O 121.425 0.631 . . . . 0.0 110.775 -177.467 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 50.8 ttt-85 56.4 95.81 0.04 OUTLIER Pre-proline 0 N--CA 1.469 0.498 0 CA-C-N 114.304 -1.316 . . . . 0.0 111.99 -177.999 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 96.8 Cg_endo -88.97 137.14 3.14 Favored 'Trans proline' 0 N--CA 1.455 -0.739 0 C-N-CA 122.647 2.232 . . . . 0.0 112.612 177.722 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . 0.681 ' HD2' HD13 ' A' ' 102' ' ' ILE . 50.5 Cg_exo -53.95 156.63 12.16 Favored 'Trans proline' 0 C--O 1.236 0.393 0 C-N-CA 122.797 2.331 . . . . 0.0 112.079 175.534 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.671 ' HA ' ' CE1' ' A' ' 103' ' ' HIS . . . -75.49 29.51 0.1 Allowed 'General case' 0 C--N 1.328 -0.351 0 N-CA-C 112.57 0.582 . . . . 0.0 112.57 -172.67 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' GLU . . . . . 0.553 ' HG3' HG22 ' A' ' 102' ' ' ILE . 12.5 pt-20 -129.89 -23.71 2.76 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 111.937 0.347 . . . . 0.0 111.937 -178.386 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.681 HD13 ' HD2' ' A' ' 99' ' ' PRO . 41.2 pt -106.78 14.4 7.85 Favored 'Isoleucine or valine' 0 C--O 1.234 0.258 0 N-CA-C 112.45 0.537 . . . . 0.0 112.45 -172.949 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 103' ' ' HIS . . . . . 0.671 ' CE1' ' HA ' ' A' ' 100' ' ' ALA . 28.9 m170 -53.78 -54.06 43.51 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.245 0.545 . . . . 0.0 110.334 177.79 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 104' ' ' SER . . . . . 0.52 ' O ' ' HG2' ' A' ' 108' ' ' ARG . 8.8 m -59.89 -34.59 73.37 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.294 -0.866 . . . . 0.0 110.871 -177.722 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.565 ' O ' HG22 ' A' ' 109' ' ' VAL . 16.7 m -63.52 -56.07 18.97 Favored 'General case' 0 N--CA 1.452 -0.329 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.198 -177.556 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 72.2 mt -56.56 -41.16 76.42 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.657 -0.701 . . . . 0.0 111.08 -178.839 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 107' ' ' MET . . . . . . . . . . . . . 96.5 mmm -62.0 -46.89 87.22 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.889 -0.596 . . . . 0.0 111.138 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 108' ' ' ARG . . . . . 0.52 ' HG2' ' O ' ' A' ' 104' ' ' SER . 3.1 ptp180 -77.08 -22.23 53.14 Favored 'General case' 0 C--N 1.331 -0.238 0 C-N-CA 120.679 -0.409 . . . . 0.0 111.847 -178.4 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.565 HG22 ' O ' ' A' ' 105' ' ' SER . 76.2 t -68.31 -48.75 71.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 173.866 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -61.34 -37.2 82.45 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.043 177.944 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 11.2 t70 -66.01 -40.73 91.33 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.144 -0.934 . . . . 0.0 110.904 177.911 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -69.54 -43.14 73.59 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.837 -0.619 . . . . 0.0 111.987 -176.961 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.7 HG12 ' HG3' ' A' ' 88' ' ' ARG . 20.0 m -87.21 -25.16 6.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-O 120.722 0.296 . . . . 0.0 111.585 -175.561 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 82.29 59.82 2.22 Favored Glycine 0 N--CA 1.447 -0.621 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.21 179.944 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -135.43 173.96 11.14 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-O 120.854 0.359 . . . . 0.0 110.441 -179.922 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 116' ' ' ARG . . . . . 0.435 ' HD3' ' OE1' ' A' ' 145' ' ' GLU . 13.8 ttm180 -92.7 124.29 36.6 Favored 'General case' 0 C--N 1.323 -0.576 0 N-CA-C 109.66 -0.496 . . . . 0.0 109.66 175.616 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . 0.535 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 61.6 tp -92.66 132.75 36.63 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 116.175 -0.466 . . . . 0.0 109.803 178.945 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 64.6 mt -126.18 122.65 62.02 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-O 121.078 0.466 . . . . 0.0 110.645 177.698 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 66.8 mt -121.43 122.9 68.43 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.016 177.599 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 23.3 ttmm -114.76 104.24 54.36 Favored Pre-proline 0 C--N 1.321 -0.645 0 CA-C-O 120.829 0.347 . . . . 0.0 110.881 176.296 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -80.63 170.78 15.34 Favored 'Trans proline' 0 N--CA 1.455 -0.78 0 C-N-CA 122.211 1.941 . . . . 0.0 110.912 169.737 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 122' ' ' LEU . . . . . 0.728 ' HB2' ' HG3' ' A' ' 125' ' ' GLU . 41.0 mt -70.17 155.29 40.83 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 116.494 -0.321 . . . . 0.0 110.378 179.473 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 123' ' ' THR . . . . . 0.682 ' HA ' ' HE1' ' A' ' 142' ' ' TYR . 46.1 m -64.8 109.9 2.22 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 109.992 -0.373 . . . . 0.0 109.992 175.629 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 107.36 -1.31 34.84 Favored Glycine 0 N--CA 1.446 -0.663 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.141 -178.536 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . 0.728 ' HG3' ' HB2' ' A' ' 122' ' ' LEU . 5.1 mt-10 -96.27 -169.21 1.87 Allowed 'General case' 0 N--CA 1.449 -0.501 0 CA-C-O 121.261 0.553 . . . . 0.0 110.8 177.538 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 126' ' ' ASP . . . . . 0.408 ' H ' ' HB3' ' A' ' 125' ' ' GLU . 5.8 t70 -149.35 165.43 32.03 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-N 115.193 -0.912 . . . . 0.0 109.116 -178.345 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 32.6 mt -93.54 -19.53 6.64 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 176.328 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 22.8 m 41.0 69.5 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.469 0.502 0 CA-C-O 121.988 0.899 . . . . 0.0 111.882 -175.122 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 9.8 t -146.23 -172.26 3.9 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.324 -0.853 . . . . 0.0 110.315 -175.831 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 42.9 tt0 -65.13 136.13 56.33 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 109.641 -0.503 . . . . 0.0 109.641 176.744 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 131' ' ' ARG . . . . . . . . . . . . . 97.7 mtt180 -63.54 92.32 0.06 Allowed 'General case' 0 N--CA 1.463 0.222 0 CA-C-O 121.317 0.579 . . . . 0.0 112.125 -175.105 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 90.1 mttt -148.42 -167.25 2.76 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.401 -0.818 . . . . 0.0 109.789 178.056 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 133' ' ' MET . . . . . . . . . . . . . 71.0 mtp 68.95 -178.93 0.22 Allowed 'General case' 0 N--CA 1.467 0.383 0 O-C-N 123.791 0.682 . . . . 0.0 110.668 -179.333 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 17.5 ptmt -136.85 144.07 43.41 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.95 179.9 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . 0.544 HD11 ' HD2' ' A' ' 142' ' ' TYR . 53.6 tp -87.63 127.77 35.28 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.655 -179.405 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 136' ' ' VAL . . . . . 0.421 ' C ' HD21 ' A' ' 137' ' ' ASN . 0.0 OUTLIER -130.14 140.66 48.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.902 179.493 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 137' ' ' ASN . . . . . 0.421 HD21 ' C ' ' A' ' 136' ' ' VAL . 0.9 OUTLIER -120.13 105.5 11.05 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.04 178.001 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . 0.538 ' CD2' ' HB2' ' A' ' 28' ' ' TYR . 73.4 t80 -117.83 112.06 19.89 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.585 -0.524 . . . . 0.0 109.585 178.778 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . 0.411 ' HA3' ' OD2' ' A' ' 24' ' ' ASP . . . 81.44 26.97 49.8 Favored Glycine 0 N--CA 1.447 -0.567 0 C-N-CA 120.743 -0.741 . . . . 0.0 111.797 -178.536 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 140' ' ' ARG . . . . . 0.466 ' HD3' ' HA ' ' A' ' 140' ' ' ARG . 26.5 mmt180 67.6 8.45 6.36 Favored 'General case' 0 N--CA 1.463 0.224 0 C-N-CA 123.248 0.619 . . . . 0.0 111.927 -179.807 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 141' ' ' THR . . . . . 0.441 HG22 ' O ' ' A' ' 138' ' ' TYR . 14.0 t -107.03 135.62 48.27 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 170.926 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 142' ' ' TYR . . . . . 0.682 ' HE1' ' HA ' ' A' ' 123' ' ' THR . 6.7 p90 -101.18 147.58 26.09 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-O 121.019 0.438 . . . . 0.0 110.789 -172.947 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 20.9 p90 -156.08 170.4 22.27 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-N 115.639 -0.71 . . . . 0.0 109.321 175.962 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 96.3 m-85 -113.51 124.27 51.99 Favored 'General case' 0 C--N 1.318 -0.797 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 179.266 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 145' ' ' GLU . . . . . 0.435 ' OE1' ' HD3' ' A' ' 116' ' ' ARG . 19.1 pt-20 -112.73 161.66 16.63 Favored 'General case' 0 C--N 1.316 -0.874 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 178.4 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . 0.401 ' HB3' ' HB3' ' A' ' 117' ' ' LEU . 63.8 t80 -141.36 129.06 21.58 Favored 'General case' 0 C--N 1.315 -0.928 0 CA-C-N 115.938 -0.573 . . . . 0.0 109.897 175.511 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 147' ' ' ILE . . . . . 0.416 ' N ' HD12 ' A' ' 147' ' ' ILE . 3.5 mp -101.68 120.21 50.99 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.96 0 N-CA-C 107.956 -1.128 . . . . 0.0 107.956 176.327 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -63.31 92.62 0.06 Allowed 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.503 0.668 . . . . 0.0 110.377 179.112 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -81.71 171.27 14.78 Favored 'General case' 0 N--CA 1.445 -0.687 0 CA-C-N 114.675 -1.148 . . . . 0.0 111.014 -175.582 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 19.5 t -68.54 132.06 33.15 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 115.79 -0.641 . . . . 0.0 109.966 -179.943 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 151' ' ' ARG . . . . . 0.41 HH11 ' HD3' ' A' ' 151' ' ' ARG . 13.5 ptt-85 -60.19 115.53 3.56 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.899 -0.591 . . . . 0.0 111.093 179.728 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 28.1 t -113.23 143.1 44.98 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-N 115.416 -0.811 . . . . 0.0 109.419 178.912 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 153' ' ' ARG . . . . . 0.425 ' O ' ' HG3' ' A' ' 153' ' ' ARG . 32.4 ptt180 . . . . . 0 C--O 1.25 1.107 0 CA-C-O 118.865 -0.588 . . . . 0.0 110.21 178.656 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 16.2 tpt . . . . . 0 N--CA 1.48 1.072 0 CA-C-O 120.712 0.291 . . . . 0.0 110.566 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 109.63 -161.05 13.16 Favored Glycine 0 N--CA 1.451 -0.349 0 N-CA-C 111.758 -0.537 . . . . 0.0 111.758 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.0 p -88.52 96.81 10.77 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 121.244 0.545 . . . . 0.0 109.969 177.221 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 13.6 t -95.97 99.93 11.65 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.791 -0.641 . . . . 0.0 110.316 -174.361 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 26.9 m170 -111.01 110.56 21.16 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.047 179.009 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 88.7 m-70 -127.72 139.53 52.64 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 121.081 0.467 . . . . 0.0 111.095 -179.703 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 74.9 m80 -95.66 102.77 14.6 Favored 'General case' 0 C--N 1.321 -0.667 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 174.378 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 86.9 m-70 -86.02 92.03 8.57 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.897 -0.592 . . . . 0.0 111.323 -172.095 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 78.1 t60 -96.86 127.2 42.6 Favored 'General case' 0 C--N 1.322 -0.612 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 173.62 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 37.9 p-80 -90.21 132.47 35.47 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 121.136 0.494 . . . . 0.0 111.146 -177.831 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 34.5 t -100.13 169.29 9.26 Favored 'General case' 0 C--N 1.32 -0.697 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 176.365 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 9.2 m -67.06 118.69 10.85 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 178.613 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -72.16 120.04 7.63 Favored Glycine 0 N--CA 1.446 -0.669 0 C-N-CA 120.375 -0.917 . . . . 0.0 112.359 -179.309 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -82.55 111.63 18.72 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 120.941 0.4 . . . . 0.0 110.409 179.644 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.427 ' HA ' ' HD3' ' A' ' 16' ' ' PRO . 28.3 m -124.32 131.68 24.22 Favored Pre-proline 0 C--N 1.324 -0.537 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.738 179.899 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.552 ' HD2' ' HD2' ' A' ' 49' ' ' TYR . 56.6 Cg_endo -89.84 141.75 3.82 Favored 'Trans proline' 0 N--CA 1.454 -0.838 0 C-N-CA 122.855 2.37 . . . . 0.0 112.403 177.013 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . 0.412 HH11 ' HD2' ' A' ' 17' ' ' ARG . 40.4 mtm105 -91.87 98.07 11.37 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.035 179.042 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -176.95 34.85 0.08 OUTLIER Glycine 0 N--CA 1.447 -0.604 0 C-N-CA 120.859 -0.686 . . . . 0.0 111.46 178.3 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' SER . . . . . 0.956 ' HB2' ' HB2' ' A' ' 22' ' ' TRP . 48.6 p -132.53 80.05 1.88 Allowed 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 120.668 0.27 . . . . 0.0 110.709 -175.915 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 41.9 m-70 -65.82 -62.58 1.42 Allowed 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.407 -0.36 . . . . 0.0 111.194 -177.183 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' MET . . . . . 0.732 ' HB2' ' HB ' ' A' ' 141' ' ' THR . 1.2 pmm? -66.3 -20.55 66.13 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.168 -177.456 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' TRP . . . . . 0.956 ' HB2' ' HB2' ' A' ' 19' ' ' SER . 61.8 m95 -76.18 -29.56 57.73 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 120.916 0.389 . . . . 0.0 110.38 178.38 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . 0.433 ' O ' HG21 ' A' ' 27' ' ' VAL . 9.6 m120 -72.32 -36.03 68.76 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 174.337 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.47 ' HB3' ' HA3' ' A' ' 139' ' ' GLY . 5.4 m-20 -64.55 -38.15 90.01 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.283 174.772 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 53.8 tp -53.23 -50.31 65.01 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.161 -0.472 . . . . 0.0 109.958 173.016 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . 0.41 ' O ' HG13 ' A' ' 30' ' ' ILE . . . -58.61 -48.72 80.02 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.884 177.269 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.433 HG21 ' O ' ' A' ' 23' ' ' ASN . 79.0 t -52.52 -45.82 47.33 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.22 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.175 177.102 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . 0.475 ' HB2' ' CD2' ' A' ' 138' ' ' TYR . 78.1 t80 -58.03 -47.12 84.06 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.535 178.629 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.434 HG12 HD12 ' A' ' 118' ' ' ILE . 78.5 mt -60.43 -44.18 95.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.542 178.311 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.63 HD13 ' HA ' ' A' ' 54' ' ' ILE . 83.7 mt -61.99 -41.09 89.65 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 115.601 -0.727 . . . . 0.0 111.455 -179.505 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 41.5 mtp-105 -71.78 -29.86 64.93 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.888 -177.541 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 76.5 m -80.92 -27.32 36.21 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.381 -0.372 . . . . 0.0 111.426 -178.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 14.0 p -93.77 -75.35 0.5 Allowed 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 120.752 0.31 . . . . 0.0 111.291 -177.673 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 109.43 134.6 7.03 Favored Glycine 0 N--CA 1.448 -0.543 0 C-N-CA 121.072 -0.585 . . . . 0.0 111.694 -176.399 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 32.8 Cg_exo -57.53 133.0 53.89 Favored 'Trans proline' 0 C--O 1.232 0.206 0 C-N-CA 122.925 2.417 . . . . 0.0 112.421 -179.155 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 102.24 62.76 0.73 Allowed Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.434 -0.888 . . . . 0.0 111.731 -177.948 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 15.0 t -178.31 -166.96 0.12 Allowed 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 108.545 -0.909 . . . . 0.0 108.545 -178.191 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . 0.808 ' HG2' ' HB3' ' A' ' 61' ' ' ASP . 48.5 mtt180 -124.58 136.61 54.1 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 121.045 0.45 . . . . 0.0 111.055 176.96 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.757 HG22 HG12 ' A' ' 60' ' ' VAL . 86.1 t -125.65 121.96 61.24 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 N-CA-C 109.16 -0.681 . . . . 0.0 109.16 175.342 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.404 HG21 ' HB ' ' A' ' 63' ' ' VAL . 26.4 t -101.37 132.64 46.8 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-O 120.743 0.306 . . . . 0.0 110.79 -175.261 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . 0.685 ' HB3' HD21 ' A' ' 64' ' ' LEU . 10.7 tt0 -108.72 126.0 52.53 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.154 -0.476 . . . . 0.0 109.972 176.252 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.703 HG12 HD13 ' A' ' 79' ' ' ILE . 64.8 t -94.12 106.62 18.29 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.774 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 174.644 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 156.75 -66.54 0.3 Allowed Glycine 0 N--CA 1.44 -1.1 0 C-N-CA 120.283 -0.96 . . . . 0.0 111.753 -178.671 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . 0.984 ' HB1' HD12 ' A' ' 74' ' ' ILE . . . 53.38 34.36 17.87 Favored 'General case' 0 C--O 1.233 0.187 0 CA-C-O 121.132 0.491 . . . . 0.0 111.774 176.832 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -91.34 -144.85 13.52 Favored Glycine 0 N--CA 1.445 -0.742 0 C-N-CA 120.623 -0.798 . . . . 0.0 112.847 -177.541 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 39.1 mtp180 -92.6 29.81 1.67 Allowed 'General case' 0 C--N 1.321 -0.667 0 CA-C-O 121.251 0.548 . . . . 0.0 110.523 -176.026 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 5.1 p90 -129.91 30.17 4.88 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.93 -176.675 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . 0.557 HD22 ' HA ' ' A' ' 44' ' ' ALA . 94.1 mt -72.75 7.92 1.73 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.993 -0.549 . . . . 0.0 112.147 -174.318 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . 0.552 ' HD2' ' HD2' ' A' ' 16' ' ' PRO . 5.7 p90 -65.95 -26.37 67.54 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.819 0.342 . . . . 0.0 110.931 177.025 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.47 ' O ' HG13 ' A' ' 54' ' ' ILE . 93.6 t -72.35 -54.37 16.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.19 175.513 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -61.86 -41.33 97.72 Favored 'General case' 0 N--CA 1.449 -0.479 0 CA-C-N 115.795 -0.638 . . . . 0.0 111.592 -179.099 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 22.1 t70 -65.49 -42.78 91.77 Favored 'General case' 0 C--N 1.329 -0.306 0 C-N-CA 121.033 -0.267 . . . . 0.0 110.756 179.128 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 89.7 t80 -59.56 -36.66 76.64 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.864 0.364 . . . . 0.0 110.533 178.64 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.63 ' HA ' HD13 ' A' ' 30' ' ' ILE . 81.3 mt -61.27 -46.85 95.79 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.386 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.017 178.205 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 36.8 ptt180 -75.33 -16.71 60.38 Favored 'General case' 0 C--O 1.234 0.25 0 CA-C-O 120.843 0.354 . . . . 0.0 111.078 -178.201 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 43.4 mmtm -75.62 -35.39 60.5 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.56 -0.291 . . . . 0.0 110.986 177.234 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . 0.461 ' CD2' HG21 ' A' ' 30' ' ' ILE . 13.1 t60 -103.94 -38.31 7.04 Favored 'General case' 0 N--CA 1.451 -0.418 0 CA-C-O 120.953 0.406 . . . . 0.0 110.75 -175.13 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 7.9 t -110.08 140.82 43.74 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 121.03 0.443 . . . . 0.0 110.302 -177.697 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . 0.494 ' N ' ' HD2' ' A' ' 59' ' ' LYS . 4.1 mptp? -92.22 60.59 3.74 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.783 0.802 . . . . 0.0 109.888 178.378 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.757 HG12 HG22 ' A' ' 39' ' ' VAL . 73.7 t -106.26 139.46 27.54 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-N 114.623 -1.171 . . . . 0.0 110.67 177.985 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . 0.808 ' HB3' ' HG2' ' A' ' 38' ' ' ARG . 18.0 t70 -74.98 90.75 2.46 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 109.168 -0.678 . . . . 0.0 109.168 175.823 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 5.5 tt -84.89 126.85 33.83 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.163 -176.529 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.404 ' HB ' HG21 ' A' ' 40' ' ' VAL . 51.5 t -106.82 127.94 61.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.828 -176.256 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . 0.685 HD21 ' HB3' ' A' ' 41' ' ' GLU . 82.3 mt -111.76 133.87 53.7 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 109.535 -0.543 . . . . 0.0 109.535 176.61 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 3.4 p -127.47 130.22 48.85 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 120.47 0.176 . . . . 0.0 111.024 178.566 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . 0.787 ' HB2' ' HB2' ' A' ' 44' ' ' ALA . 19.4 t0 -162.22 157.58 23.22 Favored 'General case' 0 C--O 1.234 0.268 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.675 -179.355 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 63.7 mt -82.58 122.01 36.55 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 116.115 -0.493 . . . . 0.0 109.79 178.926 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 18.1 ptpt 41.52 69.46 2.04 Favored Pre-proline 0 N--CA 1.474 0.77 0 O-C-N 124.003 0.814 . . . . 0.0 112.346 -175.604 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . 0.503 ' CB ' ' HB ' ' A' ' 74' ' ' ILE . 5.8 Cg_exo -74.51 132.61 16.32 Favored 'Trans proline' 0 N--CA 1.46 -0.467 0 C-N-CA 122.898 2.399 . . . . 0.0 111.923 179.072 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 34.0 t -78.29 -17.62 56.36 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.13 -176.759 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 64.5 m80 -80.54 -11.69 59.63 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.385 -0.371 . . . . 0.0 111.649 -176.325 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 81.24 -52.34 4.5 Favored Glycine 0 CA--C 1.52 0.401 0 C-N-CA 120.92 -0.657 . . . . 0.0 113.765 173.774 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -74.36 -3.87 67.3 Favored Glycine 0 CA--C 1.518 0.25 0 C-N-CA 121.141 -0.552 . . . . 0.0 113.23 -175.468 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . 0.984 HD12 ' HB1' ' A' ' 44' ' ' ALA . 62.5 mt -85.91 135.51 24.84 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.713 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 178.345 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.411 HG11 ' H ' ' A' ' 77' ' ' ASP . 61.6 t -61.18 136.16 25.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-O 120.832 0.348 . . . . 0.0 110.364 -177.908 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 17.1 mmt85 -86.3 15.16 5.55 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.969 -0.559 . . . . 0.0 111.31 -171.947 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . 0.411 ' H ' HG11 ' A' ' 75' ' ' VAL . 26.2 t70 -77.21 136.54 38.56 Favored 'General case' 0 C--N 1.325 -0.5 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 -177.019 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -58.99 116.06 3.55 Favored 'General case' 0 C--O 1.221 -0.439 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.141 -177.145 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . 0.703 HD13 HG12 ' A' ' 42' ' ' VAL . 10.6 tp -69.63 -16.28 20.29 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-O 121.344 0.592 . . . . 0.0 110.399 178.551 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 9.0 t -86.99 -11.31 50.87 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.477 178.225 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 45.0 t -157.2 64.86 3.4 Favored Pre-proline 0 C--N 1.326 -0.424 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 179.879 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.544 ' HB2' ' HE2' ' A' ' 87' ' ' TYR . 90.1 Cg_endo -85.07 153.26 11.06 Favored 'Trans proline' 0 N--CA 1.458 -0.564 0 C-N-CA 122.717 2.278 . . . . 0.0 113.206 -170.187 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' ARG . . . . . 0.654 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 35.2 mtt180 -87.56 119.82 28.24 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.784 177.292 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' MET . . . . . 0.72 ' HE3' HG12 ' A' ' 109' ' ' VAL . 36.7 mtp -67.94 -9.32 44.24 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.567 -0.742 . . . . 0.0 112.362 -175.302 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.654 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 8.0 pt-20 -61.51 -30.13 70.43 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 121.085 0.469 . . . . 0.0 110.088 175.374 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 69.2 mt -75.07 -40.01 44.31 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 115.47 -0.786 . . . . 0.0 110.514 -179.472 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . 0.637 ' HD2' ' HA ' ' A' ' 84' ' ' MET . 91.5 m-85 -75.27 -34.5 61.37 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.947 -0.57 . . . . 0.0 111.216 -177.717 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 34.0 mtp180 -64.41 114.48 4.34 Favored 'General case' 0 C--O 1.235 0.328 0 CA-C-O 121.572 0.701 . . . . 0.0 110.765 177.71 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 124.21 -12.53 8.03 Favored Glycine 0 N--CA 1.443 -0.864 0 CA-C-N 114.868 -1.06 . . . . 0.0 111.492 -175.825 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -84.21 152.19 24.38 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.838 0.352 . . . . 0.0 110.872 -179.815 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -99.75 -22.16 15.48 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.407 177.546 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . 0.486 ' HG ' ' HB3' ' A' ' 116' ' ' ARG . 4.9 tt -152.53 142.01 21.69 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.298 -177.981 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.571 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 68.3 mt -131.89 122.96 50.48 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 178.807 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 23.4 p90 -130.61 162.33 29.59 Favored 'General case' 0 C--N 1.321 -0.643 0 C-N-CA 120.614 -0.434 . . . . 0.0 111.007 -178.023 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' SER . . . . . 0.558 ' OG ' ' HB ' ' A' ' 42' ' ' VAL . 4.2 m -143.73 145.41 32.39 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.768 -179.126 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 76.7 mt -116.17 111.17 34.29 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.116 177.988 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . 0.413 HH11 ' HD2' ' A' ' 97' ' ' ARG . 12.9 ttp180 59.17 73.49 0.68 Allowed Pre-proline 0 N--CA 1.466 0.349 0 CA-C-N 115.701 -0.681 . . . . 0.0 111.331 -177.548 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_endo -88.2 134.8 3.08 Favored 'Trans proline' 0 N--CA 1.455 -0.749 0 C-N-CA 122.826 2.35 . . . . 0.0 111.917 176.953 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . 0.528 ' HG2' HD12 ' A' ' 102' ' ' ILE . 2.9 Cg_endo -47.48 142.49 13.09 Favored 'Trans proline' 0 C--N 1.35 0.606 0 C-N-CA 123.422 2.748 . . . . 0.0 112.807 175.659 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.813 ' HA ' ' CE1' ' A' ' 103' ' ' HIS . . . -75.09 42.84 0.19 Allowed 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.848 -0.615 . . . . 0.0 112.46 -176.168 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' GLU . . . . . 0.429 ' HG3' HG23 ' A' ' 102' ' ' ILE . 10.0 pt-20 -135.6 -24.56 1.35 Allowed 'General case' 0 C--N 1.326 -0.423 0 N-CA-C 112.325 0.491 . . . . 0.0 112.325 177.425 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.528 HD12 ' HG2' ' A' ' 99' ' ' PRO . 6.5 pt -114.55 3.55 7.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 N-CA-C 112.848 0.685 . . . . 0.0 112.848 -172.521 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 103' ' ' HIS . . . . . 0.813 ' CE1' ' HA ' ' A' ' 100' ' ' ALA . 35.7 m80 -47.12 -56.49 6.49 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 112.156 0.428 . . . . 0.0 112.156 179.731 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 40.1 t -66.29 -26.1 67.17 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.069 0.462 . . . . 0.0 110.771 -179.794 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.429 ' O ' HG23 ' A' ' 109' ' ' VAL . 14.2 m -67.86 -33.3 74.49 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.109 179.446 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . 0.418 HD21 HG21 ' A' ' 42' ' ' VAL . 82.0 mt -72.13 -38.37 69.25 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.954 178.448 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 107' ' ' MET . . . . . 0.528 ' HA ' HD22 ' A' ' 117' ' ' LEU . 53.6 ttm -59.18 -43.34 92.15 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.186 -178.991 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 27.3 ptt85 -66.59 -31.58 72.37 Favored 'General case' 0 C--N 1.331 -0.207 0 C-N-CA 120.88 -0.328 . . . . 0.0 110.532 -177.704 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.72 HG12 ' HE3' ' A' ' 84' ' ' MET . 94.0 t -68.94 -46.86 78.37 Favored 'Isoleucine or valine' 0 C--O 1.234 0.243 0 CA-C-N 116.549 -0.296 . . . . 0.0 110.47 179.88 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -58.74 -43.83 90.34 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.512 177.872 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.448 ' HA ' ' HB3' ' A' ' 148' ' ' ALA . 22.5 t70 -65.29 -39.94 93.21 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.012 179.629 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . 0.642 ' HB3' ' HE2' ' A' ' 84' ' ' MET . . . -66.92 -42.94 84.55 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.835 -0.621 . . . . 0.0 111.879 -178.253 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 25.8 m -87.15 -24.41 6.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 120.894 0.378 . . . . 0.0 111.486 -177.393 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 91.11 44.29 4.46 Favored Glycine 0 N--CA 1.449 -0.462 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.27 178.203 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -124.37 156.56 36.85 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 120.723 0.296 . . . . 0.0 110.834 -177.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 116' ' ' ARG . . . . . 0.486 ' HB3' ' HG ' ' A' ' 92' ' ' LEU . 14.3 ttm180 -78.57 127.28 31.91 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 177.015 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . 0.571 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 51.1 tp -95.89 121.93 38.14 Favored 'General case' 0 C--N 1.322 -0.589 0 N-CA-C 109.892 -0.411 . . . . 0.0 109.892 -179.946 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . 0.434 HD12 HG12 ' A' ' 29' ' ' ILE . 69.3 mt -119.77 112.69 38.07 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-O 121.023 0.439 . . . . 0.0 110.617 178.729 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 50.6 mt -111.61 121.18 63.66 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.797 0 CA-C-O 120.919 0.39 . . . . 0.0 110.32 178.94 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 63.6 tttp -111.11 103.31 54.72 Favored Pre-proline 0 C--N 1.32 -0.699 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.489 174.878 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 93.0 Cg_endo -82.9 -166.86 0.41 Allowed 'Trans proline' 0 N--CA 1.455 -0.773 0 C-N-CA 122.591 2.194 . . . . 0.0 110.829 171.185 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 7.1 mp -88.81 166.92 13.69 Favored 'General case' 0 C--N 1.319 -0.72 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 177.103 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 4.7 t -68.61 -9.39 49.5 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.153 0.501 . . . . 0.0 111.219 -177.68 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -117.49 24.7 8.99 Favored Glycine 0 N--CA 1.446 -0.676 0 N-CA-C 111.587 -0.605 . . . . 0.0 111.587 175.5 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 26.9 mm-40 -129.38 172.75 11.19 Favored 'General case' 0 N--CA 1.45 -0.46 0 CA-C-O 121.209 0.528 . . . . 0.0 110.754 -176.774 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 8.4 t70 -143.79 -170.82 3.4 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-N 115.05 -0.977 . . . . 0.0 108.58 175.358 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.569 HD12 ' HB2' ' A' ' 144' ' ' TYR . 18.3 mt -110.42 -22.61 4.91 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.764 0 CA-C-O 120.667 0.27 . . . . 0.0 110.337 179.49 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 17.4 m 46.77 24.88 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.038 0 C-N-CA 124.218 1.007 . . . . 0.0 113.044 179.401 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 129' ' ' THR . . . . . 0.423 ' O ' ' HB3' ' A' ' 130' ' ' GLU . 15.1 t -94.94 30.68 2.04 Favored 'General case' 0 C--O 1.237 0.401 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.022 179.032 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 130' ' ' GLU . . . . . 0.423 ' HB3' ' O ' ' A' ' 129' ' ' THR . 8.4 tp10 75.94 153.6 0.14 Allowed 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 115.145 -0.934 . . . . 0.0 109.758 -171.363 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 131' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -79.55 40.58 0.45 Allowed 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 120.992 0.425 . . . . 0.0 111.255 -175.139 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 28.7 mtpp -89.87 -10.2 46.17 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.399 -178.01 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 133' ' ' MET . . . . . 0.4 ' HG2' ' HB2' ' A' ' 146' ' ' TYR . 88.9 mtp -98.77 151.51 20.71 Favored 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 178.405 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 16.2 ptmt -100.42 134.62 43.1 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 121.222 0.534 . . . . 0.0 111.353 -174.795 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . 0.479 HD12 ' HD2' ' A' ' 142' ' ' TYR . 54.6 tp -78.58 126.7 31.11 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.334 -0.848 . . . . 0.0 110.154 177.438 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -123.43 135.12 64.32 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.712 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.909 179.869 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 137' ' ' ASN . . . . . 0.497 ' ND2' ' HB3' ' A' ' 142' ' ' TYR . 14.5 m120 -111.52 112.35 24.02 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.662 -0.699 . . . . 0.0 109.442 178.217 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . 0.475 ' CD2' ' HB2' ' A' ' 28' ' ' TYR . 61.1 t80 -144.73 128.77 17.55 Favored 'General case' 0 C--N 1.318 -0.773 0 N-CA-C 110.348 -0.241 . . . . 0.0 110.348 -178.001 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . 0.47 ' HA3' ' HB3' ' A' ' 24' ' ' ASP . . . 68.79 35.94 81.08 Favored Glycine 0 N--CA 1.447 -0.61 0 C-N-CA 120.944 -0.646 . . . . 0.0 112.907 176.169 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 140' ' ' ARG . . . . . 0.419 ' HB2' ' O ' ' A' ' 139' ' ' GLY . 69.0 mtt85 72.97 4.51 4.98 Favored 'General case' 0 N--CA 1.463 0.223 0 C-N-CA 122.772 0.429 . . . . 0.0 112.081 175.723 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 141' ' ' THR . . . . . 0.732 ' HB ' ' HB2' ' A' ' 21' ' ' MET . 14.9 t -124.57 154.09 41.15 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 176.296 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 142' ' ' TYR . . . . . 0.497 ' HB3' ' ND2' ' A' ' 137' ' ' ASN . 45.4 p90 -123.21 147.81 46.49 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-O 121.162 0.506 . . . . 0.0 110.653 178.539 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 14.0 p90 -154.01 179.59 8.77 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-N 115.064 -0.971 . . . . 0.0 109.056 -177.676 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 144' ' ' TYR . . . . . 0.569 ' HB2' HD12 ' A' ' 127' ' ' ILE . 97.3 m-85 -115.79 127.79 55.35 Favored 'General case' 0 C--N 1.32 -0.709 0 N-CA-C 110.19 -0.3 . . . . 0.0 110.19 179.452 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 145' ' ' GLU . . . . . 0.473 ' OE1' ' HD3' ' A' ' 116' ' ' ARG . 18.2 pt-20 -115.48 161.75 18.14 Favored 'General case' 0 C--N 1.32 -0.691 0 N-CA-C 109.715 -0.476 . . . . 0.0 109.715 176.1 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . 0.452 ' HB3' ' HB3' ' A' ' 117' ' ' LEU . 51.0 t80 -141.33 126.9 18.91 Favored 'General case' 0 C--N 1.313 -0.997 0 CA-C-N 115.604 -0.725 . . . . 0.0 109.741 177.532 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 147' ' ' ILE . . . . . 0.405 HD13 ' N ' ' A' ' 147' ' ' ILE . 3.1 mp -95.57 109.33 22.38 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.81 0 N-CA-C 109.585 -0.524 . . . . 0.0 109.585 -179.249 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . 0.448 ' HB3' ' HA ' ' A' ' 111' ' ' ASP . . . -63.0 111.24 2.08 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.392 -0.596 . . . . 0.0 109.392 175.114 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 -64.37 154.37 35.67 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 121.859 0.838 . . . . 0.0 111.946 -173.756 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 40.7 t -108.46 149.24 11.86 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.957 0 CA-C-N 114.77 -1.105 . . . . 0.0 108.94 179.978 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 151' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -58.01 145.65 35.42 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.667 0.27 . . . . 0.0 110.623 178.162 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 3.7 m -62.33 110.55 1.68 Allowed 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.845 -0.616 . . . . 0.0 109.853 179.477 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 10.1 ptm180 . . . . . 0 C--O 1.248 0.974 0 CA-C-O 118.133 -0.937 . . . . 0.0 110.63 -177.254 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 22.0 mmt . . . . . 0 N--CA 1.479 0.997 0 CA-C-O 120.757 0.313 . . . . 0.0 110.326 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 127.0 141.05 5.32 Favored Glycine 0 N--CA 1.445 -0.759 0 C-N-CA 120.827 -0.702 . . . . 0.0 111.815 -179.714 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 16.1 m -140.46 108.79 5.82 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 120.699 0.285 . . . . 0.0 110.313 179.838 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 33.1 m -76.44 113.98 14.64 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.386 179.322 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 2.0 p80 -111.57 101.78 10.16 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 121.555 0.693 . . . . 0.0 109.872 179.165 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . 0.448 ' HB3' ' CD2' ' A' ' 8' ' ' HIS . 60.7 m80 -91.97 100.93 13.49 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.578 -0.737 . . . . 0.0 110.717 -176.025 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 62.4 m-70 -89.31 100.57 13.33 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 116.127 -0.488 . . . . 0.0 109.993 177.632 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . 0.448 ' CD2' ' HB3' ' A' ' 6' ' ' HIS . 97.2 m-70 -131.55 98.03 4.39 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.723 -179.886 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 56.6 t-80 -99.53 98.96 9.79 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 109.091 -0.707 . . . . 0.0 109.091 173.588 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 40.3 m80 -76.43 94.64 3.69 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.927 -0.578 . . . . 0.0 110.528 -177.815 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 19.5 m -86.3 44.33 1.13 Allowed 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.454 -0.794 . . . . 0.0 110.265 -179.716 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 22.6 t -109.07 118.34 36.52 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.732 -0.667 . . . . 0.0 109.755 -178.62 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -78.69 87.46 1.14 Allowed Glycine 0 N--CA 1.448 -0.56 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.581 -177.771 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . 0.729 ' H ' HD22 ' A' ' 14' ' ' LEU . 2.4 pt? -81.64 147.33 29.61 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 110.067 -0.346 . . . . 0.0 110.067 176.203 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 7.2 p -89.98 125.16 61.51 Favored Pre-proline 0 C--N 1.325 -0.469 0 CA-C-O 120.999 0.428 . . . . 0.0 110.272 -179.376 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -81.81 -178.89 4.44 Favored 'Trans proline' 0 N--CA 1.46 -0.468 0 C-N-CA 122.749 2.3 . . . . 0.0 112.993 -177.731 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 27.3 mmt180 -92.59 173.9 7.55 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.813 -0.631 . . . . 0.0 110.465 178.464 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -62.59 135.19 44.55 Favored Glycine 0 N--CA 1.448 -0.54 0 C-N-CA 121.191 -0.528 . . . . 0.0 112.016 178.188 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 48.9 m -74.52 78.99 1.94 Allowed 'General case' 0 C--N 1.323 -0.587 0 CA-C-O 121.275 0.56 . . . . 0.0 111.34 -178.751 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 43.1 m80 -131.62 -26.83 1.98 Allowed 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.467 -0.788 . . . . 0.0 109.698 173.236 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' MET . . . . . . . . . . . . . 25.4 ptm -69.25 -15.81 63.45 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.324 -0.853 . . . . 0.0 111.12 178.824 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' TRP . . . . . 0.565 ' HB3' HG23 ' A' ' 50' ' ' VAL . 83.1 m95 -80.71 -19.51 44.92 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.385 -176.142 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . 0.485 ' O ' HG21 ' A' ' 27' ' ' VAL . 2.1 m-20 -60.8 -48.79 80.22 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.811 -172.605 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -60.89 -39.55 89.7 Favored 'General case' 0 N--CA 1.468 0.44 0 CA-C-O 120.735 0.302 . . . . 0.0 111.477 -179.08 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.731 HD23 ' HD2' ' A' ' 120' ' ' LYS . 54.0 tp -58.08 -50.8 72.2 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.458 177.574 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . 0.479 ' O ' HG13 ' A' ' 30' ' ' ILE . . . -59.46 -46.38 88.95 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.618 -0.719 . . . . 0.0 111.18 -179.029 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.554 ' HA ' HD12 ' A' ' 30' ' ' ILE . 87.5 t -55.64 -44.29 76.25 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.915 179.912 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 72.7 t80 -59.8 -46.19 89.98 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.584 179.003 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.541 HG22 HD22 ' A' ' 92' ' ' LEU . 75.9 mt -59.69 -43.02 90.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.47 178.246 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.782 HG12 HG23 ' A' ' 54' ' ' ILE . 82.2 mt -59.05 -47.08 91.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 115.642 -0.708 . . . . 0.0 111.78 -179.622 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . 0.52 ' HG3' ' O ' ' A' ' 27' ' ' VAL . 35.6 mtp180 -73.44 -22.6 60.16 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 121.03 0.443 . . . . 0.0 111.02 -174.156 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 69.5 m -88.59 -8.92 53.89 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.262 -179.563 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 13.5 p -112.88 -70.01 0.83 Allowed 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.76 0.314 . . . . 0.0 111.154 -178.943 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 93.49 166.12 37.73 Favored Glycine 0 N--CA 1.449 -0.492 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.277 179.793 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 69.8 Cg_endo -75.99 156.31 38.62 Favored 'Trans proline' 0 CA--C 1.532 0.376 0 C-N-CA 122.7 2.267 . . . . 0.0 112.597 -179.831 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 84.07 39.3 9.39 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.888 178.491 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 12.5 t -164.4 -170.19 1.99 Allowed 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 177.8 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . 0.424 ' HA ' ' O ' ' A' ' 61' ' ' ASP . 49.0 mtm180 -119.3 136.23 54.34 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.945 0.402 . . . . 0.0 110.882 179.789 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.68 HG22 HG23 ' A' ' 60' ' ' VAL . 91.6 t -119.76 113.16 39.89 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 N-CA-C 109.034 -0.728 . . . . 0.0 109.034 173.806 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.587 ' O ' ' HA ' ' A' ' 93' ' ' ILE . 46.9 t -97.12 134.23 35.68 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.853 0 CA-C-O 120.931 0.396 . . . . 0.0 110.916 -175.703 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . 0.442 ' HA ' ' O ' ' A' ' 94' ' ' TYR . 0.4 OUTLIER -114.6 157.18 23.41 Favored 'General case' 0 C--N 1.318 -0.793 0 N-CA-C 109.036 -0.728 . . . . 0.0 109.036 173.521 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.524 ' HB ' ' HB3' ' A' ' 95' ' ' SER . 54.7 t -124.76 112.34 31.6 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.733 0 CA-C-N 116.512 -0.313 . . . . 0.0 110.954 178.334 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 112.3 32.82 2.26 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.665 -0.778 . . . . 0.0 113.602 173.74 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -50.44 -58.64 5.27 Favored 'General case' 0 N--CA 1.466 0.345 0 N-CA-C 112.378 0.51 . . . . 0.0 112.378 -178.24 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 63.66 -108.14 2.07 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 121.052 -0.594 . . . . 0.0 112.677 179.519 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 16.7 ptt180 -127.11 5.71 6.47 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.678 0.275 . . . . 0.0 111.333 -179.58 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.506 ' HE2' HG13 ' A' ' 96' ' ' ILE . 14.4 p90 -112.46 90.99 3.49 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.959 0.885 . . . . 0.0 110.496 179.186 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . 0.414 HD22 HD12 ' A' ' 64' ' ' LEU . 74.6 mt -102.07 16.45 26.03 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.217 -0.901 . . . . 0.0 110.629 -175.877 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 78.0 t80 -60.69 -50.07 74.96 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.368 -0.378 . . . . 0.0 111.322 -177.054 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.565 HG23 ' HB3' ' A' ' 22' ' ' TRP . 59.6 t -62.38 -48.76 86.83 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-O 121.039 0.447 . . . . 0.0 110.726 -178.981 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' SER . . . . . 0.427 ' CB ' HD23 ' A' ' 64' ' ' LEU . 0.0 OUTLIER -63.98 -45.63 88.2 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.622 -177.166 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.613 ' O ' ' HG3' ' A' ' 56' ' ' LYS . 26.4 t70 -70.88 -30.32 66.65 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 120.641 0.258 . . . . 0.0 110.662 -179.042 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 45.4 t80 -61.73 -42.48 99.02 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.06 0.457 . . . . 0.0 109.961 175.97 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.782 HG23 HG12 ' A' ' 30' ' ' ILE . 80.5 mt -63.61 -48.01 88.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 115.815 -0.63 . . . . 0.0 111.437 -179.883 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . 0.571 ' HG2' ' HA ' ' A' ' 52' ' ' ASP . 0.1 OUTLIER -69.51 -18.88 63.72 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 111.898 0.333 . . . . 0.0 111.898 -177.149 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . 0.613 ' HG3' ' O ' ' A' ' 52' ' ' ASP . 56.7 mttm -67.57 -37.79 83.15 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.115 0.483 . . . . 0.0 110.575 176.084 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . 0.497 ' CD2' HG21 ' A' ' 30' ' ' ILE . 16.8 t60 -101.72 -39.42 7.44 Favored 'General case' 0 N--CA 1.444 -0.746 0 CA-C-N 115.879 -0.6 . . . . 0.0 111.034 -172.111 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' SER . . . . . 0.57 ' HB2' HG22 ' A' ' 30' ' ' ILE . 8.8 t -109.78 139.58 44.68 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.75 0.31 . . . . 0.0 110.393 -177.379 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 14.4 mmmm -91.35 59.99 4.04 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 121.85 0.833 . . . . 0.0 109.981 177.184 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.68 HG23 HG22 ' A' ' 39' ' ' VAL . 13.6 p -110.72 145.05 17.57 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.814 0 CA-C-N 114.817 -1.083 . . . . 0.0 110.098 177.38 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . 0.424 ' O ' ' HA ' ' A' ' 38' ' ' ARG . 21.6 t70 -78.79 101.63 7.71 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.062 0.458 . . . . 0.0 109.897 178.656 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 3.6 tt -91.93 119.02 31.3 Favored 'General case' 0 C--N 1.315 -0.925 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 -178.864 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.416 HG12 ' CG2' ' A' ' 86' ' ' ILE . 47.1 t -96.62 119.16 44.31 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-N 115.605 -0.725 . . . . 0.0 110.503 -176.822 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . 0.593 ' HB2' ' HA ' ' A' ' 74' ' ' ILE . 51.1 mt -94.39 138.34 32.46 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.553 -0.749 . . . . 0.0 109.722 179.629 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.499 ' OG1' ' HA ' ' A' ' 42' ' ' VAL . 70.2 p -128.56 130.7 47.78 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 120.875 0.369 . . . . 0.0 110.759 178.141 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 31.3 t70 -160.78 146.42 14.65 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.165 -0.47 . . . . 0.0 109.823 179.172 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . 0.72 HD12 HG23 ' A' ' 79' ' ' ILE . 50.6 mt -75.85 106.42 5.67 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-O 121.111 0.482 . . . . 0.0 110.662 179.526 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' LYS . . . . . 0.434 ' N ' ' HD3' ' A' ' 69' ' ' PRO . 45.6 mtmt 65.73 65.47 0.87 Allowed Pre-proline 0 CA--C 1.533 0.307 0 CA-C-N 115.197 -0.911 . . . . 0.0 111.814 177.723 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . 0.94 ' HD2' ' HG3' ' A' ' 76' ' ' ARG . 2.6 Cg_exo -76.69 149.42 30.02 Favored 'Trans proline' 0 C--O 1.234 0.324 0 C-N-CA 122.976 2.45 . . . . 0.0 111.739 177.055 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 25.3 m -100.45 -1.48 35.71 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.422 -0.354 . . . . 0.0 111.248 -178.173 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 84.5 t60 -117.66 121.35 40.66 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.493 -0.321 . . . . 0.0 110.97 -175.413 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -58.24 124.89 37.8 Favored Glycine 0 N--CA 1.45 -0.431 0 CA-C-N 115.919 -0.582 . . . . 0.0 111.759 175.049 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 128.86 -24.82 4.77 Favored Glycine 0 N--CA 1.446 -0.665 0 N-CA-C 110.752 -0.939 . . . . 0.0 110.752 -174.377 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . 0.593 ' HA ' ' HB2' ' A' ' 64' ' ' LEU . 35.5 mt -95.7 135.81 28.63 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 N-CA-C 108.892 -0.781 . . . . 0.0 108.892 174.145 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 98.7 t -78.84 136.39 23.91 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.715 0 CA-C-O 121.437 0.637 . . . . 0.0 110.178 -179.16 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' ARG . . . . . 0.94 ' HG3' ' HD2' ' A' ' 69' ' ' PRO . 1.3 mpp_? -90.83 34.17 0.92 Allowed 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 115.032 -0.985 . . . . 0.0 110.841 -173.0 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 22.6 t0 -89.86 136.94 32.74 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.082 -0.71 . . . . 0.0 109.082 177.888 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 7.0 p-10 -95.85 153.05 17.95 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-O 121.166 0.508 . . . . 0.0 111.353 -172.043 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . 0.72 HG23 HD12 ' A' ' 67' ' ' ILE . 10.4 tp -71.36 -27.09 27.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 115.648 -0.705 . . . . 0.0 112.478 -170.873 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 14.3 t -89.19 6.34 40.57 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.34 0.591 . . . . 0.0 110.326 -179.11 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 32.8 t -152.29 58.5 2.59 Favored Pre-proline 0 C--N 1.325 -0.495 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.909 174.428 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.484 ' HB2' ' HE2' ' A' ' 87' ' ' TYR . 65.4 Cg_endo -74.99 131.13 13.95 Favored 'Trans proline' 0 C--O 1.238 0.503 0 C-N-CA 122.192 1.928 . . . . 0.0 112.092 -175.105 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' ARG . . . . . 0.572 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 37.1 mtp85 -85.51 120.52 27.05 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.141 0.496 . . . . 0.0 111.063 -179.12 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' MET . . . . . 0.508 ' O ' ' HG3' ' A' ' 88' ' ' ARG . 96.1 mmm -62.5 -21.4 65.47 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.415 -0.811 . . . . 0.0 110.516 179.699 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.572 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 11.1 pt-20 -66.29 -21.62 66.27 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-O 121.195 0.522 . . . . 0.0 110.799 -178.834 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.416 ' CG2' HG12 ' A' ' 63' ' ' VAL . 66.5 mt -85.85 -31.2 6.5 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.497 -179.41 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . 0.484 ' HE2' ' HB2' ' A' ' 82' ' ' PRO . 79.9 m-85 -88.96 -26.06 21.72 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.432 -176.578 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . 0.55 ' HG2' HG12 ' A' ' 113' ' ' VAL . 81.8 mtp180 -71.97 143.82 49.09 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 121.142 0.496 . . . . 0.0 111.041 -178.912 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 80.54 11.2 84.37 Favored Glycine 0 C--N 1.319 -0.414 0 CA-C-N 115.274 -0.875 . . . . 0.0 112.042 -178.606 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -96.0 154.92 16.98 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.847 0.355 . . . . 0.0 110.355 178.627 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -98.34 -23.65 15.54 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 116.108 -0.497 . . . . 0.0 111.025 179.928 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . 0.541 HD22 HG22 ' A' ' 29' ' ' ILE . 4.1 tt -156.99 145.11 19.4 Favored 'General case' 0 N--CA 1.452 -0.373 0 CA-C-O 120.873 0.368 . . . . 0.0 110.81 -177.33 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.587 ' HA ' ' O ' ' A' ' 40' ' ' VAL . 61.6 mt -132.77 131.04 59.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 N-CA-C 109.031 -0.729 . . . . 0.0 109.031 178.193 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' TYR . . . . . 0.442 ' O ' ' HA ' ' A' ' 41' ' ' GLU . 32.4 p90 -139.68 155.74 47.21 Favored 'General case' 0 C--N 1.326 -0.414 0 C-N-CA 120.709 -0.396 . . . . 0.0 110.644 -179.508 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' SER . . . . . 0.524 ' HB3' ' HB ' ' A' ' 42' ' ' VAL . 10.2 p -142.48 148.16 37.24 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-O 120.748 0.309 . . . . 0.0 111.095 -176.964 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' ILE . . . . . 0.506 HG13 ' HE2' ' A' ' 47' ' ' PHE . 38.2 mm -99.03 92.82 2.83 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.585 -179.744 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . 0.58 ' NH2' ' HA ' ' A' ' 122' ' ' LEU . 98.8 mtt180 54.08 76.51 0.51 Allowed Pre-proline 0 N--CA 1.468 0.446 0 CA-C-N 115.7 -0.682 . . . . 0.0 112.429 177.995 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 98.9 Cg_endo -80.7 157.4 21.48 Favored 'Trans proline' 0 N--CA 1.46 -0.47 0 C-N-CA 122.539 2.159 . . . . 0.0 112.259 179.1 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . 0.759 ' HD2' HD11 ' A' ' 102' ' ' ILE . 32.4 Cg_exo -57.44 142.19 95.14 Favored 'Trans proline' 0 C--N 1.345 0.394 0 C-N-CA 122.817 2.345 . . . . 0.0 111.683 174.604 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.564 ' HA ' ' NE2' ' A' ' 103' ' ' HIS . . . -63.03 -22.84 67.14 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.329 -0.396 . . . . 0.0 112.035 -175.784 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 101' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -74.86 -10.65 59.7 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 112.072 0.397 . . . . 0.0 112.072 -176.703 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.759 HD11 ' HD2' ' A' ' 99' ' ' PRO . 45.6 pt -120.62 8.92 6.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 N-CA-C 112.502 0.556 . . . . 0.0 112.502 -177.776 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 103' ' ' HIS . . . . . 0.564 ' NE2' ' HA ' ' A' ' 100' ' ' ALA . 5.3 m-70 -53.98 -51.2 64.64 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-O 121.053 0.454 . . . . 0.0 110.902 178.04 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 41.1 t -68.25 -28.43 67.21 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.351 -179.743 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.526 ' O ' HG21 ' A' ' 109' ' ' VAL . 29.9 t -68.88 -45.52 70.76 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.962 -0.563 . . . . 0.0 109.908 -179.69 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 72.0 mt -64.37 -40.3 95.57 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.389 -0.369 . . . . 0.0 111.03 178.793 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 107' ' ' MET . . . . . 0.495 ' HE1' ' HB2' ' A' ' 132' ' ' LYS . 66.3 mtp -65.54 -42.48 91.9 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.25 -179.667 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 108' ' ' ARG . . . . . 0.503 ' HG2' ' O ' ' A' ' 105' ' ' SER . 8.0 ptm180 -67.93 -31.87 71.92 Favored 'General case' 0 N--CA 1.462 0.154 0 C-N-CA 120.942 -0.303 . . . . 0.0 110.858 -178.847 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.526 HG21 ' O ' ' A' ' 105' ' ' SER . 76.1 t -66.54 -46.65 85.78 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.193 0 CA-C-O 120.71 0.29 . . . . 0.0 110.279 176.798 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -57.34 -45.84 83.89 Favored 'General case' 0 CA--C 1.514 -0.406 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.123 177.419 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.835 ' HA ' ' HB1' ' A' ' 148' ' ' ALA . 5.0 t70 -66.46 -34.09 77.16 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.668 -177.497 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -70.24 -36.29 74.4 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.94 -179.659 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.55 HG12 ' HG2' ' A' ' 88' ' ' ARG . 18.7 m -93.53 -25.96 4.76 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 116.446 -0.343 . . . . 0.0 111.509 -178.172 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 87.97 41.47 6.29 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.863 -0.684 . . . . 0.0 112.634 178.296 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -120.02 158.69 26.27 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.854 0.359 . . . . 0.0 110.918 -178.471 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 116' ' ' ARG . . . . . 0.471 ' HD3' ' OE1' ' A' ' 145' ' ' GLU . 13.2 ttm180 -78.77 123.87 27.62 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 178.434 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . 0.555 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 52.0 tp -97.0 123.11 40.63 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.141 179.123 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . 0.421 HD11 HG12 ' A' ' 29' ' ' ILE . 53.6 mt -118.39 128.78 75.34 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 CA-C-O 120.976 0.417 . . . . 0.0 110.572 179.437 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 66.0 mt -128.04 134.58 64.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.36 -179.813 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 120' ' ' LYS . . . . . 0.731 ' HD2' HD23 ' A' ' 25' ' ' LEU . 10.4 mttm -113.43 104.25 55.47 Favored Pre-proline 0 C--N 1.324 -0.516 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.481 173.163 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 121' ' ' PRO . . . . . 0.41 ' HD2' ' HA ' ' A' ' 120' ' ' LYS . 58.5 Cg_endo -72.28 -146.47 0.02 OUTLIER 'Trans proline' 0 CA--C 1.535 0.547 0 C-N-CA 123.208 2.605 . . . . 0.0 112.758 176.971 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 122' ' ' LEU . . . . . 0.703 ' HB2' ' HB3' ' A' ' 125' ' ' GLU . 7.1 mp -87.59 -176.24 5.49 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.433 -0.349 . . . . 0.0 111.18 -175.884 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 21.7 m -61.23 -39.36 89.99 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.965 -0.562 . . . . 0.0 111.878 -177.533 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -145.14 42.05 1.02 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.996 -0.621 . . . . 0.0 111.602 178.477 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . 0.703 ' HB3' ' HB2' ' A' ' 122' ' ' LEU . 5.6 tp10 -131.98 136.17 47.1 Favored 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 -176.268 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 126' ' ' ASP . . . . . 0.41 ' CG ' ' H ' ' A' ' 127' ' ' ILE . 21.1 t70 -76.49 -179.31 5.13 Favored 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 109.838 -0.431 . . . . 0.0 109.838 178.373 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.467 ' HB ' HG21 ' A' ' 129' ' ' THR . 9.3 mt -84.59 7.25 1.82 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 N-CA-C 109.17 -0.678 . . . . 0.0 109.17 177.616 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . 0.408 HG23 ' O ' ' A' ' 127' ' ' ILE . 15.2 m 51.58 27.98 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 C-N-CA 124.802 1.241 . . . . 0.0 112.225 178.394 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 129' ' ' THR . . . . . 0.58 HG23 ' H ' ' A' ' 131' ' ' ARG . 9.9 t -105.49 178.58 4.52 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 115.295 -0.866 . . . . 0.0 109.073 176.996 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 29.9 mt-10 -80.27 7.51 9.34 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.317 0.58 . . . . 0.0 110.131 178.741 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 131' ' ' ARG . . . . . 0.58 ' H ' HG23 ' A' ' 129' ' ' THR . 25.0 mtp180 60.19 75.63 0.4 Allowed 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 114.648 -1.16 . . . . 0.0 112.392 170.008 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 132' ' ' LYS . . . . . 0.495 ' HB2' ' HE1' ' A' ' 107' ' ' MET . 23.2 mmmt -92.77 -1.2 57.0 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.454 -0.794 . . . . 0.0 109.727 172.22 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 133' ' ' MET . . . . . 0.662 ' HG2' ' HB2' ' A' ' 146' ' ' TYR . 88.0 mtp -100.28 176.18 5.46 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.017 -0.992 . . . . 0.0 109.907 -179.543 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 14.9 ptmt -121.35 142.1 50.3 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 120.939 0.399 . . . . 0.0 110.635 -178.398 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . 0.722 HD11 ' HD2' ' A' ' 142' ' ' TYR . 50.1 tp -86.14 124.43 32.54 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.394 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 136' ' ' VAL . . . . . 0.437 HG23 ' CD1' ' A' ' 143' ' ' PHE . 0.0 OUTLIER -121.02 137.48 54.61 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.161 -179.724 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 137' ' ' ASN . . . . . 0.466 ' N ' HD21 ' A' ' 137' ' ' ASN . 0.9 OUTLIER -107.34 123.78 48.85 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 109.254 -0.647 . . . . 0.0 109.254 174.807 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 57.8 t80 -143.02 116.71 9.24 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 179.427 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . 0.406 ' C ' ' H ' ' A' ' 141' ' ' THR . . . 69.38 39.18 81.05 Favored Glycine 0 N--CA 1.447 -0.613 0 C-N-CA 120.575 -0.821 . . . . 0.0 111.95 -177.755 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 140' ' ' ARG . . . . . 0.434 HH11 ' HD3' ' A' ' 140' ' ' ARG . 22.8 ttp-105 73.24 -21.08 0.26 Allowed 'General case' 0 CA--C 1.531 0.229 0 C-N-CA 123.665 0.786 . . . . 0.0 112.561 177.802 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 141' ' ' THR . . . . . 0.406 ' H ' ' C ' ' A' ' 139' ' ' GLY . 6.5 t -92.15 141.71 28.29 Favored 'General case' 0 C--N 1.323 -0.562 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 177.355 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 142' ' ' TYR . . . . . 0.722 ' HD2' HD11 ' A' ' 135' ' ' LEU . 44.4 p90 -110.27 152.43 26.16 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.076 0.465 . . . . 0.0 110.917 -178.742 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 143' ' ' PHE . . . . . 0.454 ' O ' HD13 ' A' ' 135' ' ' LEU . 5.4 p90 -157.7 176.22 12.88 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.837 178.632 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 73.6 m-85 -111.03 132.02 54.57 Favored 'General case' 0 C--N 1.319 -0.745 0 C-N-CA 121.011 -0.276 . . . . 0.0 110.81 -179.54 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 145' ' ' GLU . . . . . 0.471 ' OE1' ' HD3' ' A' ' 116' ' ' ARG . 21.0 pt-20 -120.72 160.85 22.48 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 109.33 -0.619 . . . . 0.0 109.33 174.288 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . 0.662 ' HB2' ' HG2' ' A' ' 133' ' ' MET . 32.3 t80 -140.3 124.2 17.4 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-N 116.12 -0.491 . . . . 0.0 109.742 178.017 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 147' ' ' ILE . . . . . 0.435 HD13 ' N ' ' A' ' 147' ' ' ILE . 2.8 mp -91.8 100.54 11.38 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 N-CA-C 109.624 -0.51 . . . . 0.0 109.624 179.702 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . 0.835 ' HB1' ' HA ' ' A' ' 111' ' ' ASP . . . -82.57 122.02 27.55 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.446 -0.797 . . . . 0.0 109.959 177.448 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 15.5 pt-20 -78.27 163.79 25.44 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-O 120.801 0.334 . . . . 0.0 110.684 -179.419 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 42.9 t -84.03 131.74 33.19 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 N-CA-C 109.426 -0.583 . . . . 0.0 109.426 175.928 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 151' ' ' ARG . . . . . . . . . . . . . 30.5 ptt85 -72.84 149.47 43.52 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.997 -176.138 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 5.3 p -79.38 132.89 36.54 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.892 -0.594 . . . . 0.0 111.05 179.773 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 53.3 mtp180 . . . . . 0 C--O 1.249 1.053 0 CA-C-O 118.282 -0.866 . . . . 0.0 109.791 176.414 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 93.8 mtp . . . . . 0 N--CA 1.481 1.084 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 98.49 139.23 10.69 Favored Glycine 0 N--CA 1.444 -0.801 0 C-N-CA 120.809 -0.71 . . . . 0.0 111.892 -179.308 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 14.9 m -76.09 103.25 6.05 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-O 121.131 0.491 . . . . 0.0 109.915 179.355 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 24.5 p -101.46 34.7 2.5 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.787 -177.303 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 48.0 m80 -72.64 92.75 1.55 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.512 178.926 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 7.8 p80 -87.63 143.09 27.36 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 177.62 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 29.4 m-70 -99.63 114.15 27.02 Favored 'General case' 0 C--N 1.316 -0.851 0 CA-C-O 120.877 0.37 . . . . 0.0 110.07 179.854 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 45.0 t-80 -75.53 111.12 10.5 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.098 -179.296 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 57.0 t-80 -87.88 108.4 19.15 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.365 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 10.2 p80 -94.91 154.29 17.28 Favored 'General case' 0 C--N 1.32 -0.712 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 172.519 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 44.7 m -66.59 95.3 0.33 Allowed 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.332 0.587 . . . . 0.0 112.316 -172.79 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 43.2 m -116.7 100.0 7.51 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.572 -0.74 . . . . 0.0 109.273 173.637 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -108.35 159.08 14.45 Favored Glycine 0 N--CA 1.446 -0.672 0 C-N-CA 120.541 -0.837 . . . . 0.0 112.608 -175.712 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -70.02 119.62 14.5 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 110.269 -0.271 . . . . 0.0 110.269 179.087 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 20.9 m -70.93 129.49 89.51 Favored Pre-proline 0 C--N 1.326 -0.435 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.506 177.638 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 16.6 Cg_exo -67.63 131.01 23.33 Favored 'Trans proline' 0 N--CA 1.463 -0.307 0 C-N-CA 122.974 2.449 . . . . 0.0 112.429 -178.296 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 27.9 mmm180 -89.72 -178.66 5.58 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.54 177.754 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -67.8 86.53 0.16 Allowed Glycine 0 C--N 1.331 0.279 0 N-CA-C 111.043 -0.823 . . . . 0.0 111.043 174.327 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 16.2 m -94.47 25.12 4.08 Favored 'General case' 0 C--N 1.323 -0.576 0 N-CA-C 111.946 0.35 . . . . 0.0 111.946 -169.608 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' HIS . . . . . 0.467 ' HA ' ' OD1' ' A' ' 23' ' ' ASN . 24.4 t-80 -62.47 -32.61 73.52 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.847 0.356 . . . . 0.0 110.324 179.474 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' MET . . . . . . . . . . . . . 23.8 ptp -63.2 -27.77 69.59 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.982 178.053 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 95.8 m95 -80.95 -19.37 44.31 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.967 0.413 . . . . 0.0 110.585 -178.535 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . 0.468 ' O ' HG21 ' A' ' 27' ' ' VAL . 12.3 m120 -62.74 -45.82 90.94 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.813 -178.172 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 13.0 m-20 -62.85 -41.12 99.23 Favored 'General case' 0 N--CA 1.464 0.256 0 CA-C-O 120.549 0.214 . . . . 0.0 110.897 178.418 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 58.3 tp -57.43 -48.03 80.23 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 121.021 0.438 . . . . 0.0 109.993 176.423 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . 0.486 ' O ' HG13 ' A' ' 30' ' ' ILE . . . -60.82 -46.78 89.22 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.954 178.225 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.481 ' HA ' HD13 ' A' ' 30' ' ' ILE . 53.1 t -56.96 -41.62 77.31 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.199 0 CA-C-N 116.559 -0.291 . . . . 0.0 111.234 179.842 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 61.1 t80 -58.44 -42.79 88.13 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.081 0.467 . . . . 0.0 110.35 178.174 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 66.5 mt -70.2 -40.92 78.67 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.489 178.732 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.701 HG12 HG22 ' A' ' 54' ' ' ILE . 97.0 mt -57.45 -44.63 84.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 115.4 -0.818 . . . . 0.0 111.068 178.838 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . 0.41 ' HG3' ' O ' ' A' ' 27' ' ' VAL . 73.4 mtp180 -65.95 -28.99 69.33 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.035 -0.529 . . . . 0.0 111.614 -178.237 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 46.0 t -88.7 -20.59 24.65 Favored 'General case' 0 C--N 1.324 -0.514 0 C-N-CA 121.104 -0.238 . . . . 0.0 111.496 -176.034 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 12.6 p -100.7 -78.99 0.51 Allowed 'General case' 0 C--N 1.327 -0.398 0 C-N-CA 121.172 -0.211 . . . . 0.0 111.537 -177.386 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 106.27 164.3 22.85 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.986 -0.626 . . . . 0.0 112.267 -179.801 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 8.6 Cg_exo -71.88 144.57 43.59 Favored 'Trans proline' 0 C--O 1.234 0.296 0 C-N-CA 123.121 2.548 . . . . 0.0 112.631 -179.286 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 83.65 2.03 89.97 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 121.19 -0.528 . . . . 0.0 112.846 177.83 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 26.1 p -96.82 -172.38 2.46 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . 0.408 ' HA ' ' O ' ' A' ' 61' ' ' ASP . 20.6 mtp180 -123.92 130.66 52.96 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 110.244 -0.28 . . . . 0.0 110.244 176.764 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.503 HG21 HG22 ' A' ' 60' ' ' VAL . 83.9 t -130.09 138.53 53.75 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 178.659 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 39.8 t -111.95 121.15 63.88 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-O 120.778 0.323 . . . . 0.0 110.936 -176.275 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 44.7 tt0 -99.99 108.64 20.89 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 176.053 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.5 ' HB ' ' OG ' ' A' ' 95' ' ' SER . 46.1 t -97.21 125.49 50.26 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.058 -178.681 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 100.65 20.59 14.39 Favored Glycine 0 N--CA 1.447 -0.605 0 C-N-CA 120.483 -0.865 . . . . 0.0 111.804 -176.927 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . 0.444 ' O ' HD13 ' A' ' 74' ' ' ILE . . . -79.09 78.62 5.54 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.19 0.519 . . . . 0.0 110.044 -179.091 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -94.01 -67.85 1.06 Allowed Glycine 0 N--CA 1.443 -0.836 0 CA-C-N 115.67 -0.696 . . . . 0.0 112.907 -178.445 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 61.3 mtt85 -113.66 -45.91 3.08 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 111.778 0.288 . . . . 0.0 111.778 -174.524 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 13.3 p90 -89.1 97.83 11.42 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.549 0.69 . . . . 0.0 111.048 -177.483 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . 0.521 HD22 HD11 ' A' ' 64' ' ' LEU . 79.9 mt -100.0 28.61 4.72 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.533 -0.758 . . . . 0.0 110.277 -179.957 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 74.2 t80 -72.52 -44.89 61.58 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.338 -175.29 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.43 ' O ' HG13 ' A' ' 54' ' ' ILE . 40.9 t -62.05 -55.56 23.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.727 0.299 . . . . 0.0 110.649 -175.459 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' SER . . . . . 0.405 ' CB ' HD21 ' A' ' 64' ' ' LEU . 1.6 p -54.74 -46.82 74.32 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.802 -0.636 . . . . 0.0 112.074 179.396 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.67 ' O ' ' HG2' ' A' ' 56' ' ' LYS . 33.7 t70 -68.95 -31.11 69.75 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.651 0.262 . . . . 0.0 111.127 -177.966 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 77.4 t80 -71.59 -37.11 71.02 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 120.869 0.366 . . . . 0.0 110.756 179.833 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.701 HG22 HG12 ' A' ' 30' ' ' ILE . 88.3 mt -63.73 -44.54 98.37 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-N 116.48 -0.327 . . . . 0.0 111.098 -179.559 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . 0.404 ' HA ' ' O ' ' A' ' 58' ' ' SER . 4.9 ptm180 -68.38 -15.56 63.6 Favored 'General case' 0 CA--C 1.533 0.319 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.321 -178.758 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . 0.67 ' HG2' ' O ' ' A' ' 52' ' ' ASP . 32.2 mmmt -73.77 -34.77 64.83 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.989 0.423 . . . . 0.0 110.779 177.183 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 56.7 m-70 -93.2 -47.11 7.1 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.395 -178.622 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' SER . . . . . 0.404 ' O ' ' HA ' ' A' ' 55' ' ' ARG . 67.2 m -121.55 135.19 55.03 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.381 179.546 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 29.3 mmmt -80.08 57.78 2.78 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.707 0.765 . . . . 0.0 110.435 -179.641 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.503 HG22 HG21 ' A' ' 39' ' ' VAL . 3.6 p -85.57 146.05 7.06 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 CA-C-N 114.89 -1.05 . . . . 0.0 109.859 176.705 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . 0.408 ' O ' ' HA ' ' A' ' 38' ' ' ARG . 30.4 t70 -84.72 100.27 11.38 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 177.314 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 2.3 tt -99.62 129.6 45.78 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.134 -176.542 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 48.5 t -106.08 122.12 59.36 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.635 -178.633 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . 0.521 HD11 HD22 ' A' ' 48' ' ' LEU . 42.8 mt -94.19 135.3 35.72 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.127 -0.488 . . . . 0.0 109.746 178.055 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 18.9 p -128.44 130.8 48.13 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.593 0.235 . . . . 0.0 111.407 -178.994 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 25.3 t0 -162.89 146.87 11.29 Favored 'General case' 0 C--N 1.333 -0.142 0 CA-C-N 116.11 -0.495 . . . . 0.0 109.842 177.889 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . 0.622 HD11 ' H ' ' A' ' 79' ' ' ILE . 48.5 mm -73.81 104.89 2.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 N-CA-C 110.169 -0.308 . . . . 0.0 110.169 179.425 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 31.4 mtmm 49.66 78.75 0.38 Allowed Pre-proline 0 N--CA 1.466 0.345 0 CA-C-N 115.576 -0.738 . . . . 0.0 111.381 -175.214 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . 0.696 ' HD2' ' HG2' ' A' ' 76' ' ' ARG . 11.7 Cg_endo -56.32 137.03 78.58 Favored 'Trans proline' 0 C--N 1.344 0.3 0 C-N-CA 123.294 2.662 . . . . 0.0 112.901 -178.777 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 12.8 m -97.22 -0.62 46.45 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.903 -0.59 . . . . 0.0 111.246 -178.197 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 25.0 t60 -105.38 -81.63 0.53 Allowed 'General case' 0 C--N 1.327 -0.37 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 178.206 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 156.85 163.09 12.02 Favored Glycine 0 N--CA 1.448 -0.521 0 C-N-CA 120.994 -0.622 . . . . 0.0 111.79 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 72.59 2.47 55.88 Favored Glycine 0 CA--C 1.518 0.266 0 C-N-CA 121.462 -0.399 . . . . 0.0 113.092 179.725 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . 0.444 HD13 ' O ' ' A' ' 44' ' ' ALA . 60.0 mt -100.37 142.77 14.98 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 N-CA-C 110.367 -0.234 . . . . 0.0 110.367 -176.868 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.441 HG13 ' HB2' ' A' ' 77' ' ' ASP . 98.8 t -74.03 129.09 36.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-O 120.922 0.391 . . . . 0.0 110.329 179.821 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' ARG . . . . . 0.696 ' HG2' ' HD2' ' A' ' 69' ' ' PRO . 88.9 mtt180 -86.68 35.0 0.66 Allowed 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.185 -175.903 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . 0.441 ' HB2' HG13 ' A' ' 75' ' ' VAL . 1.0 OUTLIER -77.63 173.76 11.67 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 109.711 -0.477 . . . . 0.0 109.711 -178.182 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 19.1 m-20 -103.42 122.52 45.04 Favored 'General case' 0 C--N 1.323 -0.566 0 C-N-CA 120.931 -0.307 . . . . 0.0 110.372 -173.89 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . 0.622 ' H ' HD11 ' A' ' 67' ' ' ILE . 10.8 tt -75.56 -26.79 18.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 CA-C-O 121.091 0.472 . . . . 0.0 111.018 178.023 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 15.0 t -84.1 -9.83 58.29 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.572 0.701 . . . . 0.0 110.386 -179.584 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 50.9 m -147.62 70.1 11.41 Favored Pre-proline 0 C--N 1.323 -0.585 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 174.421 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.685 ' HB2' ' HE2' ' A' ' 87' ' ' TYR . 72.0 Cg_endo -76.95 141.31 21.11 Favored 'Trans proline' 0 N--CA 1.461 -0.436 0 C-N-CA 122.559 2.173 . . . . 0.0 113.49 -169.092 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' ARG . . . . . 0.613 ' HG2' ' HG2' ' A' ' 85' ' ' GLU . 0.0 OUTLIER -79.02 117.31 19.96 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.487 -0.779 . . . . 0.0 109.328 174.11 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' MET . . . . . . . . . . . . . 5.4 mtp -66.08 -25.42 67.01 Favored 'General case' 0 C--N 1.324 -0.534 0 C-N-CA 120.878 -0.329 . . . . 0.0 111.243 -177.475 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.613 ' HG2' ' HG2' ' A' ' 83' ' ' ARG . 10.9 pt-20 -60.87 -26.12 67.17 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.825 0.345 . . . . 0.0 111.235 177.614 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 72.6 mt -74.67 -41.21 48.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.786 0.327 . . . . 0.0 110.856 178.358 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . 0.685 ' HE2' ' HB2' ' A' ' 82' ' ' PRO . 91.4 m-85 -82.09 -34.27 29.42 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.482 -178.359 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . 0.416 HH11 ' HD2' ' A' ' 88' ' ' ARG . 22.4 mtp180 -68.83 125.58 27.06 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.198 0.523 . . . . 0.0 110.398 179.296 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 101.72 3.07 52.75 Favored Glycine 0 N--CA 1.446 -0.675 0 CA-C-N 115.376 -0.829 . . . . 0.0 111.634 -176.488 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -85.63 144.05 28.08 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.084 0.468 . . . . 0.0 110.731 178.808 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -89.31 -19.62 25.07 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.594 179.215 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . 0.471 HD21 ' N ' ' A' ' 93' ' ' ILE . 5.6 tt -166.59 141.27 4.23 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.064 -0.517 . . . . 0.0 109.865 -178.038 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.586 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 58.6 mt -124.95 126.33 71.06 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 N-CA-C 109.433 -0.58 . . . . 0.0 109.433 177.285 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 18.8 p90 -134.21 156.18 48.82 Favored 'General case' 0 C--N 1.322 -0.619 0 C-N-CA 120.226 -0.59 . . . . 0.0 111.511 -178.877 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' SER . . . . . 0.5 ' OG ' ' HB ' ' A' ' 42' ' ' VAL . 14.4 m -148.06 130.52 15.77 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.457 -0.792 . . . . 0.0 110.196 -178.571 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' ILE . . . . . 0.42 HD11 ' N ' ' A' ' 96' ' ' ILE . 4.0 mp -87.99 103.32 13.47 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 177.123 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . 1.081 ' HB3' ' HA ' ' A' ' 121' ' ' PRO . 8.9 ptm180 40.11 89.61 0.08 OUTLIER Pre-proline 0 N--CA 1.475 0.809 0 C-N-CA 124.685 1.194 . . . . 0.0 113.269 -176.279 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 89.9 Cg_endo -79.96 154.33 22.69 Favored 'Trans proline' 0 N--CA 1.459 -0.525 0 C-N-CA 122.472 2.115 . . . . 0.0 112.191 178.581 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . 0.788 ' HD2' HD13 ' A' ' 102' ' ' ILE . 51.4 Cg_exo -54.27 158.28 9.89 Favored 'Trans proline' 0 C--O 1.234 0.313 0 C-N-CA 122.8 2.334 . . . . 0.0 112.288 173.936 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -80.37 25.86 0.39 Allowed 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.147 -0.479 . . . . 0.0 112.046 -172.997 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 101' ' ' GLU . . . . . 0.642 ' HG3' HG23 ' A' ' 102' ' ' ILE . 12.2 pt-20 -124.3 -21.29 5.0 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.76 -0.2 . . . . 0.0 111.276 178.113 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.788 HD13 ' HD2' ' A' ' 99' ' ' PRO . 45.2 pt -110.38 -1.62 9.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 N-CA-C 112.031 0.382 . . . . 0.0 112.031 -174.646 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 103' ' ' HIS . . . . . 0.513 ' O ' ' HG2' ' A' ' 107' ' ' MET . 23.7 p-80 -61.68 -41.77 98.02 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.798 0.333 . . . . 0.0 110.46 -179.258 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 20.6 t -71.25 -30.21 66.04 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.16 0.505 . . . . 0.0 110.056 177.895 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.545 ' O ' HG22 ' A' ' 109' ' ' VAL . 4.6 m -68.82 -46.08 69.54 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.046 -179.626 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 92.3 mt -58.18 -40.46 81.55 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.168 179.76 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 107' ' ' MET . . . . . 0.616 ' HE2' ' HB3' ' A' ' 132' ' ' LYS . 94.2 mmm -60.92 -43.85 98.0 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.43 -178.839 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 108' ' ' ARG . . . . . 0.435 ' HG2' ' O ' ' A' ' 105' ' ' SER . 13.1 ptp180 -76.9 -27.09 54.81 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.663 -0.244 . . . . 0.0 111.2 -177.786 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.545 HG22 ' O ' ' A' ' 105' ' ' SER . 73.6 t -70.9 -44.52 75.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 C-N-CA 121.158 -0.217 . . . . 0.0 110.674 177.744 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -59.46 -41.24 89.25 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 121.106 0.479 . . . . 0.0 110.323 178.466 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.453 ' HA ' ' HB3' ' A' ' 148' ' ' ALA . 16.2 t70 -65.4 -34.92 79.45 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.779 -178.565 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -72.46 -45.13 60.94 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.866 -0.606 . . . . 0.0 111.739 -178.263 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.406 HG13 ' CG ' ' A' ' 88' ' ' ARG . 31.1 m -85.88 -25.63 6.52 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-N 116.533 -0.303 . . . . 0.0 111.771 -176.102 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 84.96 59.3 1.99 Allowed Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.039 179.797 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . 0.456 ' O ' ' HB1' ' A' ' 148' ' ' ALA . . . -140.44 149.5 42.65 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 120.927 0.394 . . . . 0.0 110.791 -179.241 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 116' ' ' ARG . . . . . 0.515 ' HD3' ' OE1' ' A' ' 145' ' ' GLU . 14.9 ttm180 -70.98 129.75 39.8 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.893 -0.594 . . . . 0.0 109.999 177.318 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . 0.586 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 58.1 tp -100.16 118.66 36.97 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 116.049 -0.523 . . . . 0.0 109.709 178.645 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 60.0 mt -112.66 117.85 56.36 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-O 120.914 0.388 . . . . 0.0 110.569 179.702 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 119' ' ' ILE . . . . . 0.437 ' HA ' ' O ' ' A' ' 95' ' ' SER . 73.3 mt -120.35 120.23 62.2 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.672 -179.646 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 62.2 tttm -115.8 100.9 54.01 Favored Pre-proline 0 C--N 1.32 -0.674 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.208 175.533 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 121' ' ' PRO . . . . . 1.081 ' HA ' ' HB3' ' A' ' 97' ' ' ARG . 86.8 Cg_endo -78.96 -165.46 0.34 Allowed 'Trans proline' 0 N--CA 1.459 -0.503 0 C-N-CA 122.59 2.193 . . . . 0.0 111.792 175.696 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 122' ' ' LEU . . . . . 0.563 ' HB2' ' HB2' ' A' ' 125' ' ' GLU . 31.3 mt -66.54 152.72 44.68 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.872 175.924 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 19.9 m -64.71 106.0 1.1 Allowed 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.02 -0.536 . . . . 0.0 109.569 175.081 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 92.06 30.72 9.86 Favored Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 120.935 -0.65 . . . . 0.0 111.653 -175.118 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . 0.563 ' HB2' ' HB2' ' A' ' 122' ' ' LEU . 43.6 tt0 -126.6 145.19 50.64 Favored 'General case' 0 N--CA 1.448 -0.564 0 CA-C-O 121.032 0.444 . . . . 0.0 110.053 -179.408 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -101.15 167.08 10.45 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.471 -178.566 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.545 ' HB ' HG23 ' A' ' 129' ' ' THR . 6.4 mt -108.13 11.17 8.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 N-CA-C 110.02 -0.363 . . . . 0.0 110.02 -178.852 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 20.1 m 48.45 35.54 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.837 0 C-N-CA 124.147 0.979 . . . . 0.0 111.918 -179.45 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 129' ' ' THR . . . . . 0.545 HG23 ' HB ' ' A' ' 127' ' ' ILE . 13.5 t -123.16 136.97 55.0 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 114.984 -1.007 . . . . 0.0 108.94 178.082 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -88.42 101.03 13.5 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 120.76 0.314 . . . . 0.0 111.335 -173.096 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 131' ' ' ARG . . . . . . . . . . . . . 2.7 ptp180 42.02 36.76 0.71 Allowed 'General case' 0 N--CA 1.476 0.844 0 C-N-CA 124.673 1.189 . . . . 0.0 113.642 175.383 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 132' ' ' LYS . . . . . 0.616 ' HB3' ' HE2' ' A' ' 107' ' ' MET . 46.8 mmtm -84.94 -12.3 53.64 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.845 0.355 . . . . 0.0 110.899 177.795 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 133' ' ' MET . . . . . 0.483 ' HG2' ' HB2' ' A' ' 146' ' ' TYR . 85.7 mtp -133.62 170.56 15.35 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.411 -177.179 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -118.38 145.37 45.21 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.689 179.862 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . 0.482 HD12 ' HD2' ' A' ' 142' ' ' TYR . 57.7 tp -80.74 134.24 35.79 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.121 178.26 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -129.54 138.59 53.88 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-O 121.193 0.521 . . . . 0.0 111.577 -179.958 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 14.3 m120 -110.23 120.17 41.6 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.005 177.323 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 59.5 t80 -148.64 123.4 9.9 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 110.201 -0.296 . . . . 0.0 110.201 177.894 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . 0.412 ' C ' ' H ' ' A' ' 141' ' ' THR . . . 66.79 42.72 92.89 Favored Glycine 0 N--CA 1.448 -0.563 0 C-N-CA 121.029 -0.605 . . . . 0.0 112.801 177.461 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 55.5 ttt180 73.75 -19.87 0.33 Allowed 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 123.325 0.65 . . . . 0.0 112.361 175.455 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 141' ' ' THR . . . . . 0.412 ' H ' ' C ' ' A' ' 139' ' ' GLY . 5.2 t -97.63 163.21 12.93 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 178.58 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 142' ' ' TYR . . . . . 0.482 ' HD2' HD12 ' A' ' 135' ' ' LEU . 37.6 p90 -131.98 148.93 52.54 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 121.237 0.541 . . . . 0.0 110.886 -179.664 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 8.7 p90 -155.23 177.69 11.06 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 115.26 -0.882 . . . . 0.0 109.4 -179.104 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -113.13 134.34 54.6 Favored 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 110.068 -0.345 . . . . 0.0 110.068 179.419 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 145' ' ' GLU . . . . . 0.515 ' OE1' ' HD3' ' A' ' 116' ' ' ARG . 20.1 pt-20 -126.8 158.47 36.51 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 121.265 0.555 . . . . 0.0 110.385 177.237 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . 0.483 ' HB2' ' HG2' ' A' ' 133' ' ' MET . 35.6 t80 -134.76 126.26 28.58 Favored 'General case' 0 C--N 1.316 -0.89 0 CA-C-N 115.465 -0.789 . . . . 0.0 109.265 175.241 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 147' ' ' ILE . . . . . 0.409 ' N ' HD13 ' A' ' 147' ' ' ILE . 3.1 mp -92.24 100.23 10.92 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 CA-C-O 121.19 0.519 . . . . 0.0 109.739 -178.661 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . 0.456 ' HB1' ' O ' ' A' ' 115' ' ' ALA . . . -91.73 107.4 19.18 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.61 -0.723 . . . . 0.0 109.064 174.499 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -63.44 156.5 25.96 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-O 121.199 0.523 . . . . 0.0 110.28 -177.884 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 11.6 t -83.19 123.23 38.47 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.91 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 177.251 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 151' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -56.76 107.43 0.39 Allowed 'General case' 0 C--N 1.322 -0.595 0 O-C-N 123.599 0.562 . . . . 0.0 111.088 -178.391 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 18.1 m -61.51 119.96 9.61 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.121 -0.945 . . . . 0.0 111.084 -176.678 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 3.5 mmp_? . . . . . 0 C--O 1.247 0.966 0 CA-C-N 115.307 -0.86 . . . . 0.0 109.916 -179.36 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 51.9 tpp . . . . . 0 N--CA 1.479 0.98 0 CA-C-O 120.685 0.279 . . . . 0.0 110.471 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -176.48 55.88 0.11 Allowed Glycine 0 N--CA 1.449 -0.466 0 N-CA-C 111.425 -0.67 . . . . 0.0 111.425 178.161 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 39.0 m -92.98 128.94 39.02 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.927 0.394 . . . . 0.0 111.245 -177.346 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 43.4 m -103.68 74.8 1.26 Allowed 'General case' 0 C--N 1.323 -0.548 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 171.237 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 56.5 p-80 -84.7 -171.45 3.64 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.897 -175.748 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 21.0 m-70 -81.98 83.77 7.16 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 121.396 0.617 . . . . 0.0 110.435 179.786 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . 0.555 ' CE1' ' HB3' ' A' ' 9' ' ' HIS . 50.9 t-80 -107.4 -70.55 0.79 Allowed 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 115.101 -0.954 . . . . 0.0 108.76 176.951 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 38.8 m80 60.5 23.73 13.38 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 115.515 -0.766 . . . . 0.0 112.4 172.657 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . 0.555 ' HB3' ' CE1' ' A' ' 7' ' ' HIS . 15.6 t-80 -101.64 97.31 7.75 Favored 'General case' 0 C--N 1.32 -0.676 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 172.293 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 39.1 m80 -81.78 74.69 8.75 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 121.696 0.76 . . . . 0.0 110.69 -174.631 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 41.3 t -157.36 137.8 12.92 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 114.785 -1.098 . . . . 0.0 108.948 179.311 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 22.5 m -72.81 -19.49 61.32 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 120.9 0.381 . . . . 0.0 110.355 178.705 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 79.61 -61.33 4.26 Favored Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 120.913 -0.661 . . . . 0.0 111.489 -177.623 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . 0.415 ' O ' ' HD3' ' A' ' 16' ' ' PRO . 86.7 mt -134.4 123.51 24.2 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.51 -0.552 . . . . 0.0 109.51 175.86 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.437 ' HA ' ' HD3' ' A' ' 16' ' ' PRO . 48.6 t -87.69 108.32 19.9 Favored Pre-proline 0 C--N 1.322 -0.611 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 174.702 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.437 ' HD3' ' HA ' ' A' ' 15' ' ' VAL . 1.5 Cg_endo -84.31 -172.35 1.25 Allowed 'Trans proline' 0 N--CA 1.454 -0.837 0 C-N-CA 123.145 2.563 . . . . 0.0 111.793 -179.033 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 49.4 mtp85 -83.7 79.81 9.34 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.377 0.608 . . . . 0.0 109.841 178.528 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -95.15 60.88 1.6 Allowed Glycine 0 N--CA 1.448 -0.51 0 CA-C-N 115.478 -0.783 . . . . 0.0 112.665 -177.392 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' SER . . . . . 0.646 ' HA ' ' HD1' ' A' ' 22' ' ' TRP . 2.4 p -94.49 10.46 34.49 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 121.113 0.482 . . . . 0.0 110.915 178.823 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 35.7 t60 -63.91 -52.91 57.66 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.998 -176.575 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' MET . . . . . . . . . . . . . 21.3 ptp -64.12 -20.32 65.89 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-O 120.99 0.424 . . . . 0.0 111.568 -176.296 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' TRP . . . . . 0.646 ' HD1' ' HA ' ' A' ' 19' ' ' SER . 80.6 m95 -81.89 -22.55 36.81 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.022 0.439 . . . . 0.0 110.45 -178.448 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . 0.41 ' O ' HG22 ' A' ' 27' ' ' VAL . 2.7 t-20 -72.57 -45.23 60.2 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.118 178.752 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -59.77 -42.07 92.49 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.234 178.024 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 62.2 tp -55.76 -49.01 74.27 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.297 176.697 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . 0.488 ' O ' HG13 ' A' ' 30' ' ' ILE . . . -58.91 -52.25 66.55 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.891 179.081 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.41 HG22 ' O ' ' A' ' 23' ' ' ASN . 91.6 t -55.03 -43.32 69.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.321 -0.4 . . . . 0.0 111.188 -179.933 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 67.5 t80 -58.98 -47.32 85.6 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.957 0.408 . . . . 0.0 110.467 179.094 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.501 HG22 HD11 ' A' ' 92' ' ' LEU . 91.2 mt -61.89 -42.95 96.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.589 179.017 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.643 HG12 HG23 ' A' ' 54' ' ' ILE . 95.8 mt -58.23 -39.82 75.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 115.696 -0.683 . . . . 0.0 111.348 179.818 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . 0.401 ' HG3' ' O ' ' A' ' 27' ' ' VAL . 44.3 mtp-105 -74.55 -24.0 58.88 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.153 -178.558 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 85.0 m -88.99 -19.29 25.89 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.702 -177.926 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 13.9 p -106.6 -77.6 0.59 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.624 -177.801 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 95.36 163.33 34.43 Favored Glycine 0 N--CA 1.446 -0.635 0 C-N-CA 121.082 -0.58 . . . . 0.0 112.203 -178.467 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -66.09 143.08 70.48 Favored 'Trans proline' 0 C--O 1.233 0.26 0 C-N-CA 122.794 2.329 . . . . 0.0 112.64 -179.79 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 109.57 -32.62 6.64 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.894 177.091 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 11.3 t -98.02 -170.97 2.06 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 110.005 -0.368 . . . . 0.0 110.005 -176.467 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . 0.816 ' HG2' ' HB3' ' A' ' 61' ' ' ASP . 45.0 mtt180 -124.28 136.66 54.29 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.004 0.431 . . . . 0.0 111.673 -176.533 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.455 HG22 HG22 ' A' ' 60' ' ' VAL . 63.4 t -121.44 125.34 73.49 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-N 115.528 -0.76 . . . . 0.0 109.318 175.852 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 47.2 t -103.72 128.27 57.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-O 120.811 0.339 . . . . 0.0 111.406 -175.193 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . 0.469 ' HB3' HD21 ' A' ' 64' ' ' LEU . 34.3 tt0 -105.13 118.54 36.8 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 173.972 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.493 ' HA ' ' OG1' ' A' ' 65' ' ' THR . 58.5 t -95.54 121.05 45.73 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.362 -179.864 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 96.61 43.24 3.2 Favored Glycine 0 N--CA 1.446 -0.671 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.103 -179.817 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -77.01 82.77 3.53 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.351 0.596 . . . . 0.0 110.519 -178.292 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -69.64 -98.37 0.05 OUTLIER Glycine 0 N--CA 1.447 -0.593 0 CA-C-N 115.01 -0.995 . . . . 0.0 112.903 179.889 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . 0.535 ' HD2' ' O ' ' A' ' 46' ' ' ARG . 8.2 tmm_? -136.82 -7.19 1.88 Allowed 'General case' 0 C--N 1.327 -0.4 0 C-N-CA 120.904 -0.318 . . . . 0.0 111.27 -177.199 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 9.0 p90 -61.98 -63.01 1.39 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.808 0.337 . . . . 0.0 111.011 179.688 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . 0.408 HD21 HD12 ' A' ' 64' ' ' LEU . 59.7 mt 55.85 22.23 5.45 Favored 'General case' 0 C--N 1.323 -0.552 0 C-N-CA 123.684 0.794 . . . . 0.0 112.59 173.81 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 86.4 t80 -74.97 -56.85 4.33 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.781 0.324 . . . . 0.0 110.984 -178.075 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.47 ' O ' HG13 ' A' ' 54' ' ' ILE . 52.5 t -63.49 -52.78 53.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.074 -175.816 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' SER . . . . . 0.546 ' CB ' HD23 ' A' ' 64' ' ' LEU . 0.2 OUTLIER -59.47 -46.88 87.52 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.695 -0.684 . . . . 0.0 112.491 -176.587 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 35.6 t70 -68.07 -27.2 66.29 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.729 0.3 . . . . 0.0 110.948 -177.689 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 89.3 t80 -73.81 -45.62 50.29 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 120.699 0.285 . . . . 0.0 110.798 176.916 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.643 HG23 HG12 ' A' ' 30' ' ' ILE . 78.3 mt -59.92 -43.24 91.78 Favored 'Isoleucine or valine' 0 C--O 1.234 0.253 0 CA-C-N 116.403 -0.362 . . . . 0.0 111.307 -178.079 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 2.0 ptm180 -67.83 -16.73 64.24 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.479 -178.84 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 67.2 mttm -88.05 -42.85 12.12 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.116 0.484 . . . . 0.0 110.454 177.002 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.9 OUTLIER -65.53 -41.68 92.83 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.633 -0.712 . . . . 0.0 110.932 -177.559 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' SER . . . . . 0.415 ' C ' ' H ' ' A' ' 60' ' ' VAL . 74.1 m -132.41 153.51 50.75 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.348 -179.507 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -76.71 38.84 0.2 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.908 177.846 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.455 HG22 HG22 ' A' ' 39' ' ' VAL . 7.2 p -84.03 138.76 18.66 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 CA-C-N 116.047 -0.524 . . . . 0.0 109.624 179.13 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . 0.816 ' HB3' ' HG2' ' A' ' 38' ' ' ARG . 13.9 t70 -84.86 93.76 8.59 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 -178.232 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 4.2 tt -90.38 127.8 36.29 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.005 -175.424 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 59.4 t -106.36 121.91 59.5 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 115.773 -0.649 . . . . 0.0 111.016 -176.674 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . 0.546 HD23 ' CB ' ' A' ' 51' ' ' SER . 90.5 mt -98.93 141.33 31.83 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.05 -0.523 . . . . 0.0 109.816 176.65 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.493 ' OG1' ' HA ' ' A' ' 42' ' ' VAL . 28.8 p -121.28 127.18 51.11 Favored 'General case' 0 C--O 1.238 0.487 0 CA-C-O 120.608 0.242 . . . . 0.0 111.627 -178.738 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 32.0 t70 -166.27 139.01 3.93 Favored 'General case' 0 N--CA 1.463 0.218 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.364 178.117 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 58.6 mt -75.97 112.04 13.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 N-CA-C 110.249 -0.278 . . . . 0.0 110.249 -179.511 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 47.1 mtmt 56.47 75.04 0.61 Allowed Pre-proline 0 C--N 1.33 -0.249 0 O-C-N 123.598 0.561 . . . . 0.0 109.839 -178.179 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . 0.563 ' CB ' ' HB ' ' A' ' 74' ' ' ILE . 8.1 Cg_exo -71.99 148.73 51.67 Favored 'Trans proline' 0 N--CA 1.465 -0.178 0 C-N-CA 123.249 2.633 . . . . 0.0 112.815 -171.195 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 23.8 p -82.88 -32.98 27.1 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.903 -179.477 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 27.7 t60 -74.62 -37.72 62.73 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.16 -177.904 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . 0.414 ' C ' ' H ' ' A' ' 74' ' ' ILE . . . 94.85 -35.78 4.08 Favored Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 120.542 -0.837 . . . . 0.0 111.978 -177.881 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -79.8 21.34 4.76 Favored Glycine 0 C--N 1.332 0.311 0 C-N-CA 120.995 -0.622 . . . . 0.0 111.988 177.455 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . 0.563 ' HB ' ' CB ' ' A' ' 69' ' ' PRO . 67.7 mt -117.3 147.93 20.38 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 179.652 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.46 HG13 ' H ' ' A' ' 77' ' ' ASP . 91.1 t -73.91 122.56 27.3 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 120.865 0.364 . . . . 0.0 110.24 178.858 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -78.34 16.55 0.77 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.696 -0.684 . . . . 0.0 112.645 -175.232 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . 0.46 ' H ' HG13 ' A' ' 75' ' ' VAL . 2.6 m-20 -76.14 155.44 34.63 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 121.496 0.665 . . . . 0.0 111.887 -175.478 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 16.9 t0 -78.88 143.78 35.57 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 114.88 -1.054 . . . . 0.0 111.276 -174.237 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 7.6 tp -96.59 -26.59 4.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.375 -177.206 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 5.0 t -78.22 -25.66 47.09 Favored 'General case' 0 C--O 1.234 0.247 0 N-CA-C 109.376 -0.602 . . . . 0.0 109.376 179.759 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 1.2 m -124.38 76.03 61.74 Favored Pre-proline 0 C--N 1.329 -0.3 0 N-CA-C 108.45 -0.944 . . . . 0.0 108.45 169.027 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -79.07 131.55 9.96 Favored 'Trans proline' 0 N--CA 1.461 -0.405 0 C-N-CA 122.671 2.247 . . . . 0.0 113.453 -170.887 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' ARG . . . . . 0.681 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 64.5 mtt180 -70.57 109.5 4.89 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.651 -0.704 . . . . 0.0 110.016 174.303 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' MET . . . . . 0.715 ' HA ' ' HD2' ' A' ' 87' ' ' TYR . 31.5 mtp -73.31 -10.23 59.53 Favored 'General case' 0 C--N 1.323 -0.572 0 C-N-CA 120.816 -0.354 . . . . 0.0 110.58 178.66 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.681 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 10.5 pt-20 -66.94 -21.98 65.96 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.542 173.908 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 71.9 mt -81.8 -34.59 12.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-O 121.351 0.596 . . . . 0.0 110.042 178.145 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . 0.715 ' HD2' ' HA ' ' A' ' 84' ' ' MET . 85.3 m-85 -82.39 -33.9 28.54 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.585 -0.734 . . . . 0.0 110.687 -178.487 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 50.6 mtp180 -64.07 122.46 16.61 Favored 'General case' 0 CA--C 1.516 -0.345 0 CA-C-O 121.227 0.536 . . . . 0.0 111.01 177.626 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 104.06 -12.28 52.37 Favored Glycine 0 N--CA 1.444 -0.767 0 CA-C-N 115.299 -0.864 . . . . 0.0 111.921 -178.976 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -78.79 142.5 36.91 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 110.015 -0.365 . . . . 0.0 110.015 177.767 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -90.71 -19.9 23.04 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-O 121.127 0.489 . . . . 0.0 110.453 -179.415 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . 0.591 ' HG ' ' HB3' ' A' ' 116' ' ' ARG . 3.4 tt -153.92 139.78 18.14 Favored 'General case' 0 N--CA 1.447 -0.596 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.929 -176.943 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.569 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 70.0 mt -131.33 124.64 55.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 177.791 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' TYR . . . . . 0.438 ' HE1' HG13 ' A' ' 39' ' ' VAL . 13.9 p90 -134.72 164.9 26.48 Favored 'General case' 0 C--N 1.321 -0.661 0 C-N-CA 120.717 -0.393 . . . . 0.0 111.08 -178.809 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 6.9 p -140.58 131.14 25.46 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.523 -178.884 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 38.5 mm -92.03 98.31 8.23 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.098 179.262 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 63.0 mtm180 59.3 76.46 0.44 Allowed Pre-proline 0 C--N 1.332 -0.182 0 CA-C-N 115.401 -0.818 . . . . 0.0 111.54 -179.242 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' PRO . . . . . 0.424 ' HA ' ' HD3' ' A' ' 99' ' ' PRO . 93.4 Cg_endo -87.97 152.61 7.13 Favored 'Trans proline' 0 N--CA 1.455 -0.747 0 C-N-CA 122.593 2.195 . . . . 0.0 112.1 177.294 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . 0.652 ' HB2' ' HG2' ' A' ' 101' ' ' GLU . 6.3 Cg_exo -73.07 148.71 45.24 Favored 'Trans proline' 0 N--CA 1.461 -0.405 0 C-N-CA 122.524 2.149 . . . . 0.0 111.461 176.019 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -76.45 39.75 0.21 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.173 0.511 . . . . 0.0 111.735 -177.475 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 101' ' ' GLU . . . . . 0.652 ' HG2' ' HB2' ' A' ' 99' ' ' PRO . 11.6 pt-20 -121.51 -28.74 4.54 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.205 177.615 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.595 HG23 ' HG3' ' A' ' 101' ' ' GLU . 34.8 pt -110.67 5.28 8.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.359 -175.976 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 103' ' ' HIS . . . . . 0.798 ' HD2' ' HB ' ' A' ' 129' ' ' THR . 9.6 p-80 -60.99 -48.17 83.07 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 115.62 -0.718 . . . . 0.0 111.392 -177.043 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 47.1 m -70.97 -23.07 62.14 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.177 0.513 . . . . 0.0 110.658 178.689 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.545 ' O ' ' HG2' ' A' ' 108' ' ' ARG . 8.7 m -73.96 -37.92 64.37 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.242 178.542 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . 0.407 ' HG ' ' O ' ' A' ' 102' ' ' ILE . 94.0 mt -63.61 -41.08 98.34 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.722 178.014 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 107' ' ' MET . . . . . 0.518 ' HE3' ' HB3' ' A' ' 131' ' ' ARG . 97.7 mmm -57.33 -47.02 82.66 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.759 -0.655 . . . . 0.0 111.316 -179.281 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 108' ' ' ARG . . . . . 0.545 ' HG2' ' O ' ' A' ' 105' ' ' SER . 6.6 ptp180 -67.6 -31.48 71.55 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.505 -0.316 . . . . 0.0 111.178 -176.941 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.571 HG13 ' HE2' ' A' ' 84' ' ' MET . 92.1 t -74.29 -46.0 45.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.486 -0.325 . . . . 0.0 110.659 -178.862 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -58.3 -49.99 75.2 Favored 'General case' 0 CA--C 1.516 -0.347 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 176.946 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 15.3 t70 -55.16 -40.83 71.08 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.093 -0.958 . . . . 0.0 111.028 179.565 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . 0.47 ' HB3' ' HE1' ' A' ' 84' ' ' MET . . . -68.5 -44.94 73.62 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.918 -0.583 . . . . 0.0 112.196 -176.995 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 31.1 m -84.83 -27.63 6.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 C-N-CA 120.766 -0.374 . . . . 0.0 111.759 -175.29 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 98.04 22.53 15.15 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.631 -0.795 . . . . 0.0 112.654 177.578 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -99.09 163.46 12.56 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 121.505 0.669 . . . . 0.0 111.844 -176.483 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 116' ' ' ARG . . . . . 0.591 ' HB3' ' HG ' ' A' ' 92' ' ' LEU . 23.2 ttt180 -85.08 116.23 23.34 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 115.181 -0.918 . . . . 0.0 109.591 178.181 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . 0.569 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 52.2 tp -90.13 128.01 36.23 Favored 'General case' 0 C--N 1.32 -0.693 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 -178.261 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 72.2 mt -129.02 119.72 50.0 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 CA-C-O 121.178 0.513 . . . . 0.0 110.891 179.683 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 64.6 mt -119.75 125.1 73.98 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.437 179.88 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 8.9 tmtm? -108.48 98.23 26.94 Favored Pre-proline 0 C--N 1.325 -0.474 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 175.22 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -77.52 -174.26 2.14 Favored 'Trans proline' 0 C--O 1.236 0.386 0 C-N-CA 122.796 2.33 . . . . 0.0 112.944 -179.507 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 122' ' ' LEU . . . . . 0.407 ' HB2' ' HB3' ' A' ' 125' ' ' GLU . 91.7 mt -75.59 176.04 8.0 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.753 -0.658 . . . . 0.0 111.463 -175.967 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 4.1 p -74.86 102.83 4.87 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.725 -0.671 . . . . 0.0 111.002 179.317 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 82.11 30.23 35.21 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.156 179.547 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . 0.407 ' HB3' ' HB2' ' A' ' 122' ' ' LEU . 8.8 tp10 -133.26 136.78 45.75 Favored 'General case' 0 N--CA 1.448 -0.574 0 N-CA-C 109.143 -0.688 . . . . 0.0 109.143 178.049 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -107.25 166.99 10.23 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.043 -173.481 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 45.2 mt -77.66 -21.18 13.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 115.958 -0.564 . . . . 0.0 109.998 179.642 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 28.4 m 45.86 40.19 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.604 0 C-N-CA 124.263 1.025 . . . . 0.0 112.828 176.317 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 129' ' ' THR . . . . . 0.798 ' HB ' ' HD2' ' A' ' 103' ' ' HIS . 11.9 t -95.98 169.67 9.81 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.381 -179.877 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 46.5 mt-10 -90.5 -11.28 40.71 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.111 0.481 . . . . 0.0 109.931 176.329 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 131' ' ' ARG . . . . . 0.518 ' HB3' ' HE3' ' A' ' 107' ' ' MET . 19.9 mmt180 -83.02 166.84 18.45 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.434 -0.803 . . . . 0.0 109.99 -179.244 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 3.9 mppt? -106.3 130.76 54.08 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.279 0.562 . . . . 0.0 111.84 -175.497 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 133' ' ' MET . . . . . . . . . . . . . 85.0 mtp -137.77 160.63 38.73 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 115.056 -0.975 . . . . 0.0 108.971 174.405 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . 0.655 ' HG3' ' HG2' ' A' ' 145' ' ' GLU . 1.4 ptmt -111.93 133.07 54.36 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-O 121.039 0.447 . . . . 0.0 110.866 -178.123 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . 0.631 HD13 ' HD2' ' A' ' 142' ' ' TYR . 51.9 tp -81.67 121.4 26.32 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.067 179.244 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -116.21 141.95 31.7 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.65 -178.014 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -115.33 111.35 20.74 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.737 -0.665 . . . . 0.0 109.351 176.226 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . 0.604 ' O ' HG21 ' A' ' 141' ' ' THR . 57.0 t80 -124.85 104.68 8.74 Favored 'General case' 0 C--N 1.319 -0.734 0 N-CA-C 109.49 -0.559 . . . . 0.0 109.49 -178.761 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 68.27 40.96 87.24 Favored Glycine 0 CA--C 1.519 0.299 0 C-N-CA 120.55 -0.833 . . . . 0.0 111.609 -175.575 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 75.83 -25.89 0.2 Allowed 'General case' 0 N--CA 1.472 0.63 0 C-N-CA 123.681 0.792 . . . . 0.0 113.073 178.464 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 141' ' ' THR . . . . . 0.604 HG21 ' O ' ' A' ' 138' ' ' TYR . 13.9 t -75.26 142.68 43.31 Favored 'General case' 0 C--O 1.236 0.38 0 N-CA-C 109.338 -0.616 . . . . 0.0 109.338 177.262 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 142' ' ' TYR . . . . . 0.631 ' HD2' HD13 ' A' ' 135' ' ' LEU . 26.4 p90 -121.41 141.55 50.87 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 121.394 0.616 . . . . 0.0 111.229 -176.452 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 25.1 p90 -154.32 170.21 21.86 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 114.975 -1.011 . . . . 0.0 109.515 -179.968 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 75.5 m-85 -107.5 126.4 52.47 Favored 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 110.227 -0.286 . . . . 0.0 110.227 179.474 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 145' ' ' GLU . . . . . 0.655 ' HG2' ' HG3' ' A' ' 134' ' ' LYS . 10.0 pt-20 -115.41 164.12 14.74 Favored 'General case' 0 C--N 1.32 -0.677 0 N-CA-C 109.685 -0.487 . . . . 0.0 109.685 177.594 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . 0.54 ' HB3' ' HB3' ' A' ' 117' ' ' LEU . 50.8 t80 -147.03 127.74 14.28 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.352 177.382 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 147' ' ' ILE . . . . . 0.425 HD13 ' N ' ' A' ' 147' ' ' ILE . 3.1 mp -96.73 104.92 16.43 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.706 0 CA-C-N 115.779 -0.646 . . . . 0.0 109.366 179.506 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -70.25 117.44 11.81 Favored 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 175.974 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 30.3 mt-10 -73.4 133.69 43.83 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 121.702 0.763 . . . . 0.0 111.795 -176.743 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 25.8 t -106.05 132.87 52.04 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.07 0 CA-C-N 114.442 -1.254 . . . . 0.0 108.75 176.166 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 151' ' ' ARG . . . . . . . . . . . . . 33.1 ptt180 -64.72 127.94 33.66 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 121.14 0.495 . . . . 0.0 110.37 -178.806 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 8.2 t -83.82 144.73 29.08 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.682 -0.69 . . . . 0.0 109.752 -178.604 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 23.4 mtm180 . . . . . 0 C--O 1.247 0.97 0 CA-C-O 118.365 -0.826 . . . . 0.0 110.461 -179.9 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 4.0 mpp? . . . . . 0 N--CA 1.481 1.094 0 N-CA-C 110.214 -0.291 . . . . 0.0 110.214 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -117.79 143.18 17.67 Favored Glycine 0 N--CA 1.447 -0.604 0 C-N-CA 120.886 -0.673 . . . . 0.0 112.159 179.819 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 36.9 t -97.53 -48.26 5.34 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.873 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 41.5 m -124.6 111.35 15.54 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.552 179.864 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 96.4 m-70 -94.22 94.55 8.4 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.001 0.429 . . . . 0.0 110.046 176.228 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 33.8 p-80 -101.0 168.87 9.33 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.958 -0.564 . . . . 0.0 111.218 -177.31 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 12.3 m-70 -112.14 -178.39 3.41 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.744 -0.662 . . . . 0.0 109.563 175.742 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 54.6 m80 -96.92 13.87 27.35 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 121.179 0.514 . . . . 0.0 109.955 177.152 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 29.1 m80 -115.07 150.57 35.73 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.373 -175.683 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 57.7 m80 -94.06 -28.46 15.72 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 177.67 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 13.7 p -162.98 171.55 16.36 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.088 -0.96 . . . . 0.0 109.674 178.005 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 16.4 m -63.33 109.22 1.51 Allowed 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 120.905 0.384 . . . . 0.0 110.51 178.834 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -87.43 141.45 17.4 Favored Glycine 0 N--CA 1.445 -0.743 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.444 -178.405 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 93.7 mt -96.26 -159.95 0.76 Allowed 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 109.573 -0.529 . . . . 0.0 109.573 176.078 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 15.0 m -61.14 128.61 89.69 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 120.898 0.38 . . . . 0.0 110.479 176.931 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -77.44 -176.14 3.05 Favored 'Trans proline' 0 N--CA 1.462 -0.35 0 C-N-CA 122.678 2.252 . . . . 0.0 112.25 -177.886 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . 0.461 ' O ' ' HD2' ' A' ' 17' ' ' ARG . 0.6 OUTLIER -120.18 136.57 54.58 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 121.055 0.455 . . . . 0.0 110.756 177.13 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 105.83 -42.15 1.98 Allowed Glycine 0 N--CA 1.449 -0.458 0 C-N-CA 121.017 -0.611 . . . . 0.0 112.564 -176.88 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 54.4 m -82.12 7.35 13.69 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 112.394 0.516 . . . . 0.0 112.394 -175.945 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' HIS . . . . . 0.417 ' HA ' ' OD1' ' A' ' 23' ' ' ASN . 31.7 m-70 -65.08 -16.91 63.99 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.706 0.288 . . . . 0.0 111.253 179.424 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' MET . . . . . . . . . . . . . 24.8 ptp -64.84 -17.48 64.29 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.174 177.679 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' TRP . . . . . 0.55 ' HB3' HG23 ' A' ' 50' ' ' VAL . 98.2 m95 -94.7 -22.31 18.2 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.675 179.854 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . 0.417 ' OD1' ' HA ' ' A' ' 20' ' ' HIS . 13.9 m120 -66.01 -41.0 91.58 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.987 -179.638 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 26.2 m-20 -59.17 -46.78 87.49 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.049 178.905 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 66.6 tp -59.6 -47.86 83.94 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.402 -0.817 . . . . 0.0 110.672 178.721 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . 0.417 ' O ' HG13 ' A' ' 30' ' ' ILE . . . -54.71 -51.98 63.87 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.474 -179.399 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.431 ' HA ' HD12 ' A' ' 30' ' ' ILE . 88.4 t -56.02 -43.11 74.29 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-O 120.9 0.381 . . . . 0.0 111.136 -179.717 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 83.5 t80 -59.17 -45.56 90.69 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.576 179.222 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.433 HD13 ' CD1' ' A' ' 94' ' ' TYR . 79.8 mt -65.36 -42.59 93.99 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.626 179.192 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.609 HG12 HG23 ' A' ' 54' ' ' ILE . 96.2 mt -56.62 -45.38 82.46 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-N 115.593 -0.73 . . . . 0.0 111.001 178.654 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 83.7 mtp180 -64.98 -28.27 69.4 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.629 -178.106 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 44.2 t -86.93 -24.53 24.75 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.669 0.271 . . . . 0.0 111.298 -177.316 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 11.3 p -98.48 -77.11 0.52 Allowed 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 120.745 0.307 . . . . 0.0 111.421 -176.774 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 90.57 172.22 44.1 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.943 -0.646 . . . . 0.0 112.307 -178.493 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 63.0 Cg_endo -74.29 153.68 45.71 Favored 'Trans proline' 0 C--O 1.235 0.33 0 C-N-CA 122.571 2.18 . . . . 0.0 112.121 179.391 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 82.35 30.05 34.9 Favored Glycine 0 CA--C 1.518 0.238 0 C-N-CA 120.675 -0.774 . . . . 0.0 113.073 177.772 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 14.2 t -150.07 -176.53 5.49 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 176.199 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . 0.52 ' HB2' ' HA ' ' A' ' 90' ' ' ALA . 17.4 mtp180 -117.34 135.56 53.77 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 120.856 0.36 . . . . 0.0 111.389 -176.697 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.439 HG12 ' OE1' ' A' ' 41' ' ' GLU . 16.7 t -123.98 125.03 70.28 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 172.843 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 47.1 t -109.71 117.59 54.94 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 121.191 0.52 . . . . 0.0 110.59 -177.887 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . 0.535 ' HB2' HD22 ' A' ' 64' ' ' LEU . 0.1 OUTLIER -90.98 120.32 31.88 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.309 -0.86 . . . . 0.0 110.29 -175.927 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.647 HG11 HD22 ' A' ' 106' ' ' LEU . 59.4 t -94.33 110.26 23.38 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.701 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 175.992 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 98.91 97.78 2.1 Favored Glycine 0 N--CA 1.446 -0.696 0 N-CA-C 110.988 -0.845 . . . . 0.0 110.988 -175.353 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -111.53 -53.24 2.72 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.652 0.263 . . . . 0.0 110.913 -176.256 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 48.53 -121.14 7.35 Favored Glycine 0 N--CA 1.449 -0.451 0 CA-C-N 115.788 -0.642 . . . . 0.0 112.311 -176.523 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 94.7 mtt180 -118.1 3.23 12.07 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 120.903 0.382 . . . . 0.0 110.256 175.77 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 12.4 p90 -98.05 63.34 1.6 Allowed 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.621 0.724 . . . . 0.0 111.143 -175.891 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 55.2 mt -85.33 22.74 1.44 Allowed 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.694 -0.685 . . . . 0.0 110.869 -178.713 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 80.6 t80 -63.33 -41.43 98.89 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.332 -176.512 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.55 HG23 ' HB3' ' A' ' 22' ' ' TRP . 42.6 t -75.32 -50.48 24.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.659 -178.957 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 3.0 p -62.35 -45.78 91.65 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.556 -0.747 . . . . 0.0 112.306 -174.225 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.525 ' O ' ' HG2' ' A' ' 56' ' ' LYS . 35.5 t70 -70.07 -35.67 74.4 Favored 'General case' 0 C--N 1.33 -0.275 0 C-N-CA 120.655 -0.418 . . . . 0.0 110.646 -177.011 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 88.6 t80 -58.72 -40.48 83.88 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.944 0.402 . . . . 0.0 110.299 178.079 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.609 HG23 HG12 ' A' ' 30' ' ' ILE . 79.6 mt -65.62 -49.23 79.1 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.338 -179.921 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . 0.455 ' HG2' ' HA ' ' A' ' 52' ' ' ASP . 5.7 ptm180 -69.29 -19.98 63.9 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-N 116.476 -0.329 . . . . 0.0 111.598 -176.55 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . 0.532 ' HZ2' ' HB3' ' A' ' 56' ' ' LYS . 4.6 mmmp? -82.09 -35.61 28.44 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.713 0.292 . . . . 0.0 111.192 177.697 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 14.4 t60 -84.55 -41.24 16.67 Favored 'General case' 0 N--CA 1.446 -0.674 0 CA-C-O 121.037 0.446 . . . . 0.0 109.966 -177.595 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 74.6 m -122.9 133.44 54.4 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.355 176.519 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -78.17 63.94 3.22 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 121.862 0.839 . . . . 0.0 110.086 179.47 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.411 HG23 HG22 ' A' ' 39' ' ' VAL . 7.1 p -94.85 149.57 4.42 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.883 0 CA-C-N 114.489 -1.232 . . . . 0.0 109.873 175.913 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 52.3 t0 -74.77 96.05 3.0 Favored 'General case' 0 C--O 1.234 0.268 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 178.093 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . 0.487 HD21 ' OE2' ' A' ' 41' ' ' GLU . 1.1 tm? -93.14 126.01 38.03 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 115.233 -0.894 . . . . 0.0 110.262 -173.379 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 41.7 t -125.85 119.61 55.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.043 -177.13 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . 0.535 HD22 ' HB2' ' A' ' 41' ' ' GLU . 12.7 mt -96.48 148.99 22.24 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 116.175 -0.466 . . . . 0.0 109.97 178.601 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.515 HG21 ' HB ' ' A' ' 75' ' ' VAL . 15.3 p -134.48 127.8 32.16 Favored 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 110.566 -0.161 . . . . 0.0 110.566 176.827 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 3.4 t70 -163.4 175.61 10.63 Favored 'General case' 0 N--CA 1.464 0.236 0 N-CA-C 110.062 -0.347 . . . . 0.0 110.062 -178.619 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 48.9 mm -88.5 107.84 18.12 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 116.652 -0.249 . . . . 0.0 110.398 -178.62 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 55.0 mtmt 60.11 90.0 0.1 OUTLIER Pre-proline 0 N--CA 1.466 0.329 0 O-C-N 123.674 0.608 . . . . 0.0 111.118 -177.987 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . 0.953 ' HB3' ' HB ' ' A' ' 74' ' ' ILE . 32.9 Cg_endo -66.25 141.6 63.39 Favored 'Trans proline' 0 C--O 1.233 0.268 0 C-N-CA 123.127 2.551 . . . . 0.0 113.177 -177.462 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 14.8 m -95.09 -14.78 23.93 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.693 -0.685 . . . . 0.0 110.444 175.923 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 89.7 m-70 -124.33 150.52 45.38 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.354 -179.211 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -77.42 57.59 3.73 Favored Glycine 0 CA--C 1.52 0.348 0 C-N-CA 121.421 -0.418 . . . . 0.0 112.924 179.925 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -157.85 8.12 0.2 Allowed Glycine 0 N--CA 1.449 -0.474 0 N-CA-C 111.397 -0.681 . . . . 0.0 111.397 177.373 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . 0.953 ' HB ' ' HB3' ' A' ' 69' ' ' PRO . 40.3 mt -117.44 134.44 61.02 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 -177.78 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.606 HG11 HD13 ' A' ' 86' ' ' ILE . 55.8 t -78.12 131.17 35.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 176.959 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' ARG . . . . . 0.431 ' HA ' ' HD3' ' A' ' 69' ' ' PRO . 36.2 ptt180 -82.88 29.49 0.46 Allowed 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.762 -0.654 . . . . 0.0 111.939 -175.902 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 31.9 t0 -84.02 160.42 21.0 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 110.024 -0.362 . . . . 0.0 110.024 -178.944 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -79.61 104.02 9.92 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-O 120.849 0.357 . . . . 0.0 110.268 -177.646 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . 0.538 HD11 HG12 ' A' ' 42' ' ' VAL . 12.8 tt -57.67 -23.33 19.98 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.501 0 CA-C-N 115.692 -0.685 . . . . 0.0 112.478 -176.379 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 5.1 t -87.9 -6.56 58.01 Favored 'General case' 0 CA--C 1.539 0.534 0 CA-C-O 121.141 0.496 . . . . 0.0 110.869 -178.1 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 32.9 t -154.63 60.09 2.64 Favored Pre-proline 0 C--N 1.328 -0.336 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 178.177 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.777 ' HB2' ' HE2' ' A' ' 87' ' ' TYR . 84.3 Cg_endo -79.24 155.34 25.4 Favored 'Trans proline' 0 N--CA 1.461 -0.405 0 C-N-CA 122.676 2.251 . . . . 0.0 113.784 -166.01 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' ARG . . . . . 0.825 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 94.1 mtt180 -76.28 132.99 40.17 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.11 -0.95 . . . . 0.0 110.995 177.929 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' MET . . . . . 0.429 ' HE3' HG12 ' A' ' 109' ' ' VAL . 87.5 mmm -70.77 -22.42 62.39 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.119 176.812 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.825 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 10.3 pt-20 -66.0 -13.93 60.74 Favored 'General case' 0 CA--C 1.532 0.282 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.823 179.865 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.606 HD13 HG11 ' A' ' 75' ' ' VAL . 66.7 mt -93.25 -40.02 11.51 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-O 121.06 0.457 . . . . 0.0 110.846 -179.346 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . 0.777 ' HE2' ' HB2' ' A' ' 82' ' ' PRO . 99.0 m-85 -80.04 -28.76 39.25 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.322 -176.872 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 30.5 mtt-85 -61.7 120.75 11.24 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 121.045 0.45 . . . . 0.0 111.222 179.598 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 109.39 -2.44 31.0 Favored Glycine 0 N--CA 1.446 -0.637 0 CA-C-N 115.607 -0.724 . . . . 0.0 111.872 -177.896 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . 0.52 ' HA ' ' HB2' ' A' ' 38' ' ' ARG . . . -90.5 143.16 27.02 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.738 0.304 . . . . 0.0 110.594 178.162 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -88.52 -28.02 21.06 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.624 -179.505 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . 0.517 ' HG ' ' HB3' ' A' ' 116' ' ' ARG . 6.8 tt -149.5 143.14 25.45 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.052 -177.019 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.569 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 68.0 mt -133.36 119.42 35.02 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 N-CA-C 109.432 -0.581 . . . . 0.0 109.432 178.36 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' TYR . . . . . 0.433 ' CD1' HD13 ' A' ' 29' ' ' ILE . 47.7 p90 -124.58 158.59 32.65 Favored 'General case' 0 C--N 1.321 -0.664 0 C-N-CA 120.219 -0.593 . . . . 0.0 110.823 177.976 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 14.2 m -126.62 125.98 42.83 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.795 -0.638 . . . . 0.0 110.715 -176.847 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 54.2 mt -94.52 97.13 6.55 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.089 -179.672 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . 0.419 HH11 ' HD3' ' A' ' 97' ' ' ARG . 7.7 ttm180 59.91 73.46 0.65 Allowed Pre-proline 0 CA--C 1.533 0.295 0 CA-C-N 115.494 -0.776 . . . . 0.0 110.87 -179.028 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_endo -85.64 137.71 5.87 Favored 'Trans proline' 0 N--CA 1.458 -0.57 0 C-N-CA 122.529 2.153 . . . . 0.0 112.775 -179.302 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 32.8 Cg_endo -67.36 163.05 36.06 Favored 'Trans proline' 0 C--O 1.234 0.307 0 C-N-CA 122.685 2.256 . . . . 0.0 112.182 175.441 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -85.61 36.21 0.64 Allowed 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.959 -177.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 101' ' ' GLU . . . . . 0.439 ' HG3' HG22 ' A' ' 102' ' ' ILE . 11.7 pt-20 -117.63 -10.96 10.48 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 121.156 0.503 . . . . 0.0 110.47 175.482 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.572 ' O ' ' HG ' ' A' ' 106' ' ' LEU . 20.8 pt -129.49 9.11 2.48 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.96 -178.184 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 103' ' ' HIS . . . . . . . . . . . . . 8.8 p-80 -55.28 -56.39 20.62 Favored 'General case' 0 C--N 1.316 -0.851 0 CA-C-N 115.505 -0.771 . . . . 0.0 112.31 -174.969 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 31.5 t -76.23 -26.16 55.77 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 121.112 0.482 . . . . 0.0 109.999 179.128 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.517 ' O ' HG23 ' A' ' 109' ' ' VAL . 6.5 m -66.21 -42.73 88.33 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.204 -178.433 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . 0.647 HD22 HG11 ' A' ' 42' ' ' VAL . 82.2 mt -61.32 -41.49 97.1 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.838 -0.619 . . . . 0.0 111.259 179.205 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 107' ' ' MET . . . . . 0.485 ' SD ' ' HB3' ' A' ' 131' ' ' ARG . 45.5 mtp -65.29 -42.01 93.55 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.229 -178.926 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 16.7 ptm180 -73.32 -22.94 60.21 Favored 'General case' 0 C--N 1.332 -0.183 0 C-N-CA 120.976 -0.29 . . . . 0.0 111.462 -178.907 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.517 HG23 ' O ' ' A' ' 105' ' ' SER . 73.2 t -76.15 -46.46 33.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 N-CA-C 110.235 -0.283 . . . . 0.0 110.235 175.573 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -57.18 -50.16 73.7 Favored 'General case' 0 CA--C 1.517 -0.324 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.022 176.46 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.419 ' HA ' ' HB3' ' A' ' 148' ' ' ALA . 16.3 t70 -59.54 -34.16 72.31 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.459 -0.791 . . . . 0.0 111.038 -178.565 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -70.73 -46.46 63.0 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.837 -178.708 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 33.6 m -84.67 -27.88 6.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 C-N-CA 121.0 -0.28 . . . . 0.0 111.624 -176.127 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 93.41 38.05 5.43 Favored Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 120.697 -0.764 . . . . 0.0 112.475 179.548 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -114.14 149.82 35.07 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.039 0.447 . . . . 0.0 111.093 -179.059 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 116' ' ' ARG . . . . . 0.517 ' HB3' ' HG ' ' A' ' 92' ' ' LEU . 19.8 ttt180 -71.38 116.17 11.39 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.725 -0.67 . . . . 0.0 109.803 179.321 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . 0.569 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 62.2 tp -88.53 120.43 29.9 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 116.034 -0.53 . . . . 0.0 109.968 -179.517 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 71.0 mt -121.52 114.94 44.99 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 CA-C-O 121.16 0.505 . . . . 0.0 110.363 179.233 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 51.0 mt -112.77 121.27 64.73 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.761 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.55 -179.379 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 1.6 tmtp? -109.99 95.33 20.51 Favored Pre-proline 0 C--N 1.322 -0.614 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 173.503 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 121' ' ' PRO . . . . . 0.419 ' HB2' ' HB3' ' A' ' 125' ' ' GLU . 88.7 Cg_endo -89.02 -161.95 0.12 Allowed 'Trans proline' 0 N--CA 1.454 -0.839 0 C-N-CA 122.998 2.465 . . . . 0.0 112.244 179.997 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 122' ' ' LEU . . . . . 0.85 ' HB2' ' HB2' ' A' ' 125' ' ' GLU . 10.3 mp -83.53 168.14 16.72 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.987 -0.552 . . . . 0.0 110.391 179.65 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 123' ' ' THR . . . . . 0.437 ' HA ' ' HH ' ' A' ' 142' ' ' TYR . 3.9 m -59.91 -32.05 70.39 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.546 -176.86 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -125.43 38.84 2.19 Favored Glycine 0 N--CA 1.452 -0.245 0 C-N-CA 120.711 -0.756 . . . . 0.0 111.844 177.756 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . 0.85 ' HB2' ' HB2' ' A' ' 122' ' ' LEU . 6.0 tp10 -110.5 118.01 35.11 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 120.696 0.284 . . . . 0.0 110.267 -176.104 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -84.69 167.77 15.87 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.137 0.494 . . . . 0.0 111.014 179.007 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.433 HG21 ' HB ' ' A' ' 129' ' ' THR . 85.7 mt -92.15 -26.47 4.91 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 CA-C-N 115.609 -0.723 . . . . 0.0 110.55 -178.407 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . 0.412 ' HB ' ' O ' ' A' ' 127' ' ' ILE . 91.2 t 75.57 -40.1 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.471 0.582 0 C-N-CA 123.022 0.529 . . . . 0.0 110.562 178.912 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 129' ' ' THR . . . . . 0.433 ' HB ' HG21 ' A' ' 127' ' ' ILE . 15.3 m -56.25 -48.32 76.77 Favored 'General case' 0 N--CA 1.444 -0.748 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.277 171.282 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 19.7 mm-40 58.9 19.66 7.29 Favored 'General case' 0 CA--C 1.533 0.307 0 CA-C-N 115.068 -0.969 . . . . 0.0 111.67 178.145 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 131' ' ' ARG . . . . . 0.485 ' HB3' ' SD ' ' A' ' 107' ' ' MET . 52.3 ttt180 -76.21 161.86 28.44 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 109.349 -0.611 . . . . 0.0 109.349 177.388 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 132' ' ' LYS . . . . . 0.59 ' HD3' ' H ' ' A' ' 132' ' ' LYS . 0.0 OUTLIER -48.2 115.1 1.08 Allowed 'General case' 0 N--CA 1.465 0.313 0 CA-C-O 121.134 0.492 . . . . 0.0 112.024 -179.087 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 133' ' ' MET . . . . . 0.511 ' HG2' ' HB2' ' A' ' 146' ' ' TYR . 86.0 mtp -148.46 162.19 40.11 Favored 'General case' 0 C--N 1.314 -0.949 0 N-CA-C 107.994 -1.113 . . . . 0.0 107.994 173.272 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . 0.529 ' HG3' ' HG2' ' A' ' 145' ' ' GLU . 13.1 ptmm? -126.36 133.1 51.42 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-O 120.956 0.408 . . . . 0.0 111.21 -176.899 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . 0.785 HD11 ' HD2' ' A' ' 142' ' ' TYR . 55.6 tp -84.38 121.16 27.16 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.023 -179.662 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -116.77 149.98 18.87 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.598 -177.334 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 10.5 m120 -116.29 125.82 52.7 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 177.584 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 34.4 t80 -138.27 130.79 29.18 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 109.565 -0.532 . . . . 0.0 109.565 176.239 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 72.03 -87.75 0.48 Allowed Glycine 0 N--CA 1.443 -0.837 0 N-CA-C 110.681 -0.967 . . . . 0.0 110.681 -174.428 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 140' ' ' ARG . . . . . 0.705 ' HA ' ' NE ' ' A' ' 140' ' ' ARG . 2.0 mmp_? -156.53 14.61 0.3 Allowed 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.423 -0.388 . . . . 0.0 110.75 174.346 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 11.2 t -113.98 154.95 26.75 Favored 'General case' 0 N--CA 1.448 -0.57 0 CA-C-N 116.33 -0.395 . . . . 0.0 109.948 179.035 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 142' ' ' TYR . . . . . 0.785 ' HD2' HD11 ' A' ' 135' ' ' LEU . 14.7 p90 -122.86 138.11 54.75 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 121.042 0.449 . . . . 0.0 110.36 -179.875 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 143' ' ' PHE . . . . . 0.414 ' O ' HD13 ' A' ' 135' ' ' LEU . 12.4 p90 -146.85 162.34 38.85 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-N 115.562 -0.745 . . . . 0.0 110.146 -177.238 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 96.3 m-85 -101.04 122.53 43.71 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 116.429 -0.351 . . . . 0.0 110.294 -179.447 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 145' ' ' GLU . . . . . 0.529 ' HG2' ' HG3' ' A' ' 134' ' ' LYS . 11.5 pt-20 -113.37 156.77 22.84 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 121.086 0.47 . . . . 0.0 110.036 177.522 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . 0.511 ' HB2' ' HG2' ' A' ' 133' ' ' MET . 41.7 t80 -141.91 124.47 15.83 Favored 'General case' 0 C--N 1.314 -0.969 0 CA-C-N 115.493 -0.776 . . . . 0.0 109.659 176.833 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 3.7 mp -93.0 101.37 12.55 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.88 0 N-CA-C 109.596 -0.52 . . . . 0.0 109.596 -177.63 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . 0.419 ' HB3' ' HA ' ' A' ' 111' ' ' ASP . . . -69.91 108.59 4.07 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 108.57 -0.9 . . . . 0.0 108.57 172.717 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 40.6 mt-10 -64.5 133.82 53.2 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 122.04 0.924 . . . . 0.0 112.424 -170.762 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 23.0 t -103.91 145.48 12.75 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.884 0 CA-C-N 113.888 -1.506 . . . . 0.0 109.614 179.666 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 151' ' ' ARG . . . . . . . . . . . . . 26.8 mmm180 -61.05 159.99 10.74 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 121.148 0.499 . . . . 0.0 110.898 176.729 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 1.1 p -73.2 141.2 47.34 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.553 -177.735 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.249 1.028 0 CA-C-O 118.507 -0.759 . . . . 0.0 109.426 177.067 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.479 0.983 0 CA-C-O 121.004 0.43 . . . . 0.0 110.185 . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -102.98 96.81 1.41 Allowed Glycine 0 N--CA 1.448 -0.564 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.527 -176.52 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 31.4 t -85.05 136.72 33.45 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 176.401 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 31.9 p -137.65 174.4 10.62 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.662 -0.245 . . . . 0.0 110.77 -177.209 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 66.6 m-70 -80.1 121.72 25.89 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 121.009 0.433 . . . . 0.0 110.577 -178.314 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 17.7 p80 -97.47 13.52 29.57 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-O 121.265 0.555 . . . . 0.0 110.509 179.591 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 66.4 m80 -75.68 104.4 6.21 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.617 -179.188 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 51.0 p-80 -83.81 149.77 26.2 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.456 -0.338 . . . . 0.0 110.325 177.946 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 36.8 m80 -97.54 89.81 4.81 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.432 -177.908 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 29.4 p-80 -62.04 -46.94 86.95 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.036 177.52 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 5.1 t 57.87 23.24 9.52 Favored 'General case' 0 CA--C 1.532 0.264 0 CA-C-N 115.749 -0.66 . . . . 0.0 111.249 174.47 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 5.2 p -94.01 109.4 21.14 Favored 'General case' 0 N--CA 1.448 -0.526 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.102 -177.638 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -76.53 127.39 8.63 Favored Glycine 0 N--CA 1.445 -0.732 0 C-N-CA 120.696 -0.764 . . . . 0.0 111.358 175.396 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . 0.421 HD12 ' HE2' ' A' ' 56' ' ' LYS . 88.3 mt -67.07 140.44 57.62 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.739 0.304 . . . . 0.0 110.698 -178.484 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.432 ' HA ' ' HD3' ' A' ' 16' ' ' PRO . 33.2 m -58.85 149.04 66.78 Favored Pre-proline 0 C--N 1.326 -0.456 0 CA-C-N 115.368 -0.833 . . . . 0.0 112.816 -172.855 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.432 ' HD3' ' HA ' ' A' ' 15' ' ' VAL . 3.7 Cg_exo -77.62 128.18 9.29 Favored 'Trans proline' 0 N--CA 1.457 -0.666 0 C-N-CA 123.036 2.491 . . . . 0.0 110.504 169.65 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . 0.652 ' HD3' ' O ' ' A' ' 17' ' ' ARG . 0.0 OUTLIER -100.13 102.68 14.06 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-O 121.17 0.51 . . . . 0.0 111.547 -172.696 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 67.32 5.25 34.31 Favored Glycine 0 CA--C 1.518 0.273 0 CA-C-N 115.787 -0.642 . . . . 0.0 113.085 176.252 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' SER . . . . . 0.522 ' O ' ' HB2' ' A' ' 23' ' ' ASN . 19.5 p -97.41 101.15 12.62 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-O 120.816 0.341 . . . . 0.0 110.583 -178.35 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 30.4 m80 -111.92 -63.64 1.39 Allowed 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 177.467 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' MET . . . . . . . . . . . . . 15.6 tmm? -73.52 -36.36 65.71 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.836 -0.62 . . . . 0.0 109.784 175.247 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 95.4 m95 -72.08 -19.39 61.82 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.899 -0.591 . . . . 0.0 110.677 177.164 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . 0.522 ' HB2' ' O ' ' A' ' 19' ' ' SER . 2.7 t-20 -68.26 -37.74 81.06 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.205 -179.555 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.415 ' HB3' ' HD2' ' A' ' 138' ' ' TYR . 44.0 m-20 -61.61 -43.28 99.16 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.279 -0.418 . . . . 0.0 110.389 179.392 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.474 HD23 ' HD3' ' A' ' 120' ' ' LYS . 61.9 tp -58.16 -50.07 74.78 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.305 178.241 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . 0.406 ' O ' HG13 ' A' ' 30' ' ' ILE . . . -55.76 -51.78 66.22 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.876 179.049 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.424 HG22 ' O ' ' A' ' 23' ' ' ASN . 96.7 t -57.04 -43.89 81.93 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.221 179.42 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 52.2 t80 -58.18 -48.63 79.71 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.861 0.363 . . . . 0.0 110.265 178.684 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.406 HG13 ' O ' ' A' ' 25' ' ' LEU . 81.7 mt -60.81 -42.67 93.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.486 178.904 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.406 HG13 ' O ' ' A' ' 26' ' ' ALA . 90.8 mt -58.15 -41.86 81.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.123 179.118 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 63.0 mtp180 -69.05 -35.07 76.16 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.076 0.465 . . . . 0.0 111.295 -179.654 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.409 ' SG ' HD12 ' A' ' 92' ' ' LEU . 48.3 t -81.37 -25.95 35.88 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.98 -0.555 . . . . 0.0 111.512 -175.509 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 20.8 p -93.56 -81.93 0.36 Allowed 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 111.851 0.315 . . . . 0.0 111.851 -174.92 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.408 ' O ' HG21 ' A' ' 37' ' ' THR . . . 107.22 168.19 22.12 Favored Glycine 0 N--CA 1.449 -0.476 0 N-CA-C 111.384 -0.686 . . . . 0.0 111.384 -175.158 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 71.0 Cg_endo -76.77 145.96 26.1 Favored 'Trans proline' 0 N--CA 1.464 -0.26 0 C-N-CA 122.32 2.013 . . . . 0.0 112.801 -178.769 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 91.75 -20.34 42.64 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.876 -0.678 . . . . 0.0 113.602 175.22 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' THR . . . . . 0.408 HG21 ' O ' ' A' ' 34' ' ' GLY . 14.7 t -92.06 178.85 5.75 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 117.115 0.457 . . . . 0.0 110.011 -179.08 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' ARG . . . . . 0.497 ' HA ' ' O ' ' A' ' 61' ' ' ASP . 0.1 OUTLIER -111.81 136.06 51.59 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-O 120.967 0.413 . . . . 0.0 111.351 -176.239 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 62.3 t -126.22 117.27 48.15 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 N-CA-C 108.997 -0.742 . . . . 0.0 108.997 173.836 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.511 HG21 ' HB ' ' A' ' 63' ' ' VAL . 40.9 t -103.13 128.86 55.73 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-O 120.999 0.428 . . . . 0.0 111.703 -173.176 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . 0.616 ' HB3' HD22 ' A' ' 64' ' ' LEU . 21.7 tp10 -105.22 127.41 52.91 Favored 'General case' 0 C--O 1.24 0.569 0 CA-C-N 115.606 -0.724 . . . . 0.0 109.991 174.377 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.467 ' HB ' ' OG ' ' A' ' 95' ' ' SER . 59.0 t -93.57 89.95 2.79 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 CA-C-N 115.976 -0.557 . . . . 0.0 110.235 179.816 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 121.18 120.83 2.75 Favored Glycine 0 N--CA 1.443 -0.837 0 CA-C-N 115.662 -0.699 . . . . 0.0 111.505 -175.201 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . 0.608 ' HB2' HD22 ' A' ' 48' ' ' LEU . . . -110.59 -57.98 2.15 Favored 'General case' 0 C--N 1.321 -0.668 0 O-C-N 122.399 -0.471 . . . . 0.0 111.047 -177.198 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 52.72 -118.67 8.21 Favored Glycine 0 CA--C 1.519 0.317 0 C-N-CA 121.085 -0.579 . . . . 0.0 112.693 -178.707 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 65.2 mtp180 -134.52 14.61 3.74 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.827 0.346 . . . . 0.0 111.264 -179.669 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 21.8 p90 -103.52 35.19 2.67 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.369 0.604 . . . . 0.0 110.553 -178.298 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . 0.608 HD22 ' HB2' ' A' ' 44' ' ' ALA . 94.5 mt -76.13 13.43 0.9 Allowed 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.484 -0.78 . . . . 0.0 112.569 -173.963 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 42.2 p90 -67.62 -26.45 66.25 Favored 'General case' 0 C--N 1.324 -0.509 0 C-N-CA 120.713 -0.395 . . . . 0.0 110.454 177.02 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.421 ' O ' HG13 ' A' ' 54' ' ' ILE . 54.0 t -68.72 -54.5 20.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.439 176.407 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 7.3 p -62.51 -46.78 86.85 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.847 -176.134 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -70.66 -27.55 64.13 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.569 -176.328 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 82.9 t80 -68.74 -46.65 68.33 Favored 'General case' 0 C--N 1.328 -0.346 0 C-N-CA 120.783 -0.367 . . . . 0.0 110.443 176.291 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.421 HG13 ' O ' ' A' ' 50' ' ' VAL . 77.9 mt -59.15 -45.79 92.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.385 -176.824 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 6.9 ptp180 -71.76 -16.48 62.2 Favored 'General case' 0 C--O 1.236 0.39 0 CA-C-O 120.893 0.378 . . . . 0.0 111.499 -179.111 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . 0.421 ' HE2' HD12 ' A' ' 14' ' ' LEU . 8.3 mtpm? -83.7 -21.8 32.24 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.861 0.362 . . . . 0.0 111.566 177.618 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 11.8 t60 -103.16 -43.02 5.58 Favored 'General case' 0 N--CA 1.445 -0.69 0 CA-C-O 121.01 0.433 . . . . 0.0 109.863 -178.143 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 9.1 t -120.09 144.08 47.8 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 109.202 -0.666 . . . . 0.0 109.202 178.336 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . 0.44 ' HD3' ' HA ' ' A' ' 59' ' ' LYS . 6.1 tppt? -89.25 58.15 4.34 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 122.11 0.957 . . . . 0.0 110.332 -179.459 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 7.6 p -94.97 145.53 8.02 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.817 0 CA-C-N 114.41 -1.268 . . . . 0.0 109.677 175.564 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . 0.497 ' O ' ' HA ' ' A' ' 38' ' ' ARG . 25.6 t70 -84.62 93.46 8.39 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 179.278 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 4.6 tt -89.86 120.17 30.87 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.67 -176.192 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.511 ' HB ' HG21 ' A' ' 40' ' ' VAL . 47.8 t -103.91 122.51 56.75 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.653 0 CA-C-N 115.674 -0.694 . . . . 0.0 110.493 -174.721 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . 0.616 HD22 ' HB3' ' A' ' 41' ' ' GLU . 41.6 mt -99.55 133.43 43.89 Favored 'General case' 0 C--N 1.316 -0.889 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 176.575 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.407 HG23 ' HB ' ' A' ' 75' ' ' VAL . 13.0 p -125.73 124.04 40.18 Favored 'General case' 0 C--N 1.317 -0.813 0 N-CA-C 110.048 -0.353 . . . . 0.0 110.048 176.544 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 39.2 t0 -170.36 172.01 6.34 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -175.712 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . 0.656 HG23 ' HG2' ' A' ' 68' ' ' LYS . 26.0 mm -73.67 129.83 36.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.073 -179.709 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' LYS . . . . . 0.656 ' HG2' HG23 ' A' ' 67' ' ' ILE . 19.6 pttp 38.71 90.32 0.07 OUTLIER Pre-proline 0 N--CA 1.476 0.837 0 O-C-N 124.247 0.967 . . . . 0.0 113.278 178.933 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . 0.949 ' HB3' ' HB ' ' A' ' 74' ' ' ILE . 4.9 Cg_endo -48.39 137.58 24.79 Favored 'Trans proline' 0 C--N 1.346 0.395 0 C-N-CA 123.875 3.05 . . . . 0.0 113.202 179.534 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 4.7 m -122.6 20.6 10.26 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.895 -0.593 . . . . 0.0 111.065 -178.054 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 64.4 t60 -138.75 -89.07 0.22 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.808 0.337 . . . . 0.0 110.678 -175.389 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -164.71 -72.63 0.03 OUTLIER Glycine 0 N--CA 1.447 -0.61 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.002 -179.752 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -81.04 48.65 3.82 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 121.013 -0.613 . . . . 0.0 112.665 -179.884 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . 0.949 ' HB ' ' HB3' ' A' ' 69' ' ' PRO . 56.1 mt -113.94 123.15 69.32 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.61 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 177.069 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.502 HG11 HD13 ' A' ' 86' ' ' ILE . 91.2 t -76.04 132.09 33.72 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 176.369 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 9.8 ptp180 -79.3 21.14 0.48 Allowed 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 120.987 0.422 . . . . 0.0 111.371 -175.967 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . 0.486 ' HB2' HG13 ' A' ' 75' ' ' VAL . 6.1 t70 -83.48 112.49 20.01 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 109.615 -0.513 . . . . 0.0 109.615 -176.385 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 10.7 p-10 -70.87 142.21 51.2 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 121.426 0.632 . . . . 0.0 111.444 -174.055 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 6.9 tp -66.77 -21.95 29.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.367 -0.833 . . . . 0.0 112.345 -173.66 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 10.2 t -90.05 -0.54 57.64 Favored 'General case' 0 C--N 1.322 -0.626 0 C-N-CA 120.274 -0.571 . . . . 0.0 110.492 -178.801 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' SER . . . . . 0.417 ' N ' ' HD3' ' A' ' 82' ' ' PRO . 4.9 m -148.24 46.58 0.46 Allowed Pre-proline 0 CA--C 1.538 0.505 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.883 177.421 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.417 ' HA ' ' OD2' ' A' ' 77' ' ' ASP . 93.3 Cg_endo -81.23 149.45 17.17 Favored 'Trans proline' 0 C--N 1.352 0.711 0 C-N-CA 122.287 1.992 . . . . 0.0 113.174 -169.01 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' ARG . . . . . 0.482 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 73.1 mtp85 -96.36 125.22 40.71 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.82 -0.627 . . . . 0.0 111.061 177.222 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' MET . . . . . 0.501 ' HE2' HG11 ' A' ' 109' ' ' VAL . 91.3 mmm -63.92 -20.02 65.54 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.678 -0.692 . . . . 0.0 111.296 -179.314 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.482 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 11.0 pt-20 -69.81 -16.65 63.31 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.506 -176.451 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.502 HD13 HG11 ' A' ' 75' ' ' VAL . 70.4 mt -85.23 -36.14 10.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 121.298 0.571 . . . . 0.0 109.963 178.154 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 99.2 m-85 -80.59 -31.85 36.61 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.865 -178.73 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . 0.412 ' HG3' HG13 ' A' ' 113' ' ' VAL . 23.3 mtp85 -64.07 119.61 10.47 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-O 121.142 0.496 . . . . 0.0 110.795 179.259 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 115.65 -17.21 16.08 Favored Glycine 0 N--CA 1.444 -0.805 0 CA-C-N 115.44 -0.8 . . . . 0.0 111.557 -177.739 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -73.38 144.55 46.39 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.83 0.348 . . . . 0.0 110.769 179.052 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -88.94 -25.66 21.95 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 121.27 0.557 . . . . 0.0 110.142 178.093 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . 0.475 HD21 ' N ' ' A' ' 93' ' ' ILE . 4.7 tt -150.86 141.09 22.26 Favored 'General case' 0 N--CA 1.448 -0.559 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.409 -177.136 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' ILE . . . . . 0.54 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 61.2 mt -130.58 128.14 63.06 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.187 177.226 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -136.88 169.69 17.35 Favored 'General case' 0 C--N 1.318 -0.781 0 C-N-CA 120.786 -0.366 . . . . 0.0 110.117 -179.074 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' SER . . . . . 0.614 ' HB2' ' HG3' ' A' ' 98' ' ' PRO . 7.1 m -152.07 123.08 7.57 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.346 178.901 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 96' ' ' ILE . . . . . 0.731 HG21 ' HG2' ' A' ' 97' ' ' ARG . 2.3 mp -73.37 114.94 13.6 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-N 116.3 -0.409 . . . . 0.0 109.907 174.771 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . 0.731 ' HG2' HG21 ' A' ' 96' ' ' ILE . 13.6 ptt180 43.54 76.27 0.55 Allowed Pre-proline 0 N--CA 1.472 0.668 0 C-N-CA 124.376 1.071 . . . . 0.0 113.17 177.41 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 98' ' ' PRO . . . . . 0.614 ' HG3' ' HB2' ' A' ' 95' ' ' SER . 12.8 Cg_endo -90.07 146.54 4.52 Favored 'Trans proline' 0 N--CA 1.453 -0.909 0 C-N-CA 122.583 2.189 . . . . 0.0 111.889 175.689 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . 0.526 ' HD2' HD12 ' A' ' 102' ' ' ILE . 32.2 Cg_exo -61.05 140.37 89.43 Favored 'Trans proline' 0 C--N 1.344 0.34 0 C-N-CA 122.492 2.128 . . . . 0.0 111.991 177.483 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -79.74 30.85 0.25 Allowed 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 121.101 0.477 . . . . 0.0 111.805 -174.871 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 101' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -122.2 -6.89 8.84 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.812 178.614 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.526 HD12 ' HD2' ' A' ' 99' ' ' PRO . 30.8 pt -120.25 8.53 6.37 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 120.907 0.384 . . . . 0.0 111.163 -179.021 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 103' ' ' HIS . . . . . 0.452 ' O ' ' HG2' ' A' ' 107' ' ' MET . 44.7 p-80 -60.82 -40.06 91.31 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.373 -177.149 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 23.3 m -61.75 -29.58 70.22 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.861 0.362 . . . . 0.0 111.016 178.749 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.519 ' O ' HG22 ' A' ' 109' ' ' VAL . 19.3 m -75.61 -38.29 59.13 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.079 178.518 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 94.5 mt -69.14 -41.7 76.98 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.953 179.6 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 107' ' ' MET . . . . . 0.452 ' HG2' ' O ' ' A' ' 103' ' ' HIS . 94.9 mmm -57.38 -47.53 81.44 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.804 -0.634 . . . . 0.0 111.535 -179.281 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 6.7 ptp85 -66.96 -31.74 72.51 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.578 -0.283 . . . . 0.0 111.608 -178.186 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.519 HG22 ' O ' ' A' ' 105' ' ' SER . 76.3 t -66.7 -47.93 81.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 C-N-CA 121.115 -0.234 . . . . 0.0 110.897 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -57.98 -46.27 85.44 Favored 'General case' 0 CA--C 1.518 -0.286 0 CA-C-N 116.515 -0.311 . . . . 0.0 110.641 179.853 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 17.8 t70 -67.73 -36.21 80.16 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.783 -178.599 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -65.43 -43.25 91.06 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.65 -179.843 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.412 HG13 ' HG3' ' A' ' 88' ' ' ARG . 18.6 m -88.22 -30.09 5.46 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.537 -175.912 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 91.41 51.63 2.5 Favored Glycine 0 N--CA 1.448 -0.554 0 C-N-CA 120.596 -0.811 . . . . 0.0 112.15 -178.856 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -132.0 157.6 43.67 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.906 0.384 . . . . 0.0 110.879 -179.424 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 116' ' ' ARG . . . . . 0.67 ' HD3' ' OE1' ' A' ' 145' ' ' GLU . 12.5 ttm180 -78.58 123.22 26.86 Favored 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 109.569 -0.53 . . . . 0.0 109.569 177.163 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . 0.54 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 57.3 tp -94.12 118.9 32.19 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 116.179 -0.464 . . . . 0.0 109.947 -179.553 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 59.7 mt -114.39 115.06 48.45 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 CA-C-O 121.32 0.581 . . . . 0.0 110.807 179.654 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 53.5 mt -122.52 118.62 55.77 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.953 -179.249 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 120' ' ' LYS . . . . . 0.526 ' HB3' ' HB3' ' A' ' 143' ' ' PHE . 0.6 OUTLIER -118.81 101.74 50.11 Favored Pre-proline 0 C--N 1.319 -0.722 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 169.759 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 121' ' ' PRO . . . . . 0.478 ' HA ' ' HA ' ' A' ' 97' ' ' ARG . 96.6 Cg_endo -80.04 -161.95 0.17 Allowed 'Trans proline' 0 N--CA 1.461 -0.438 0 C-N-CA 122.902 2.401 . . . . 0.0 112.425 -176.658 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 122' ' ' LEU . . . . . 0.672 ' HB2' ' HB2' ' A' ' 125' ' ' GLU . 3.0 mm? -65.31 150.08 48.87 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.929 -0.578 . . . . 0.0 109.977 178.162 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 23.2 m -68.28 -25.82 65.35 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.119 -0.491 . . . . 0.0 112.005 -171.246 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -105.67 1.64 39.25 Favored Glycine 0 N--CA 1.453 -0.233 0 C-N-CA 120.095 -1.05 . . . . 0.0 112.694 -179.563 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . 0.672 ' HB2' ' HB2' ' A' ' 122' ' ' LEU . 1.6 mp0 -105.79 -170.28 1.71 Allowed 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.239 0.542 . . . . 0.0 111.401 -173.595 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 16.8 t70 -143.99 171.53 14.13 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 115.147 -0.933 . . . . 0.0 108.846 179.18 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.551 ' HB ' HG23 ' A' ' 129' ' ' THR . 39.1 mt -88.83 -15.22 9.1 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-O 121.048 0.451 . . . . 0.0 110.24 179.655 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 48.9 t 73.82 -5.62 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.469 0.506 0 CA-C-O 121.346 0.593 . . . . 0.0 111.022 178.142 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 129' ' ' THR . . . . . 0.551 HG23 ' HB ' ' A' ' 127' ' ' ILE . 8.8 t -71.01 153.07 42.93 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 174.964 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 39.4 tt0 -60.19 -82.68 0.02 OUTLIER 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.819 -179.025 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 131' ' ' ARG . . . . . 0.402 HH11 ' HD2' ' A' ' 131' ' ' ARG . 0.0 OUTLIER -169.09 84.99 0.15 Allowed 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 175.561 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 30.8 mmmt -121.16 -15.92 8.09 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 115.245 -0.889 . . . . 0.0 110.1 -178.467 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 133' ' ' MET . . . . . 0.513 ' HG2' ' HB2' ' A' ' 146' ' ' TYR . 79.4 mtp -114.4 170.12 8.53 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.56 -0.746 . . . . 0.0 110.195 -176.311 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 134' ' ' LYS . . . . . 0.418 ' HG3' ' HG2' ' A' ' 145' ' ' GLU . 18.8 ptmt -121.75 134.07 54.93 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.815 -178.591 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . 0.533 HD11 ' HD2' ' A' ' 142' ' ' TYR . 60.0 tp -82.75 122.39 28.12 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 120.932 0.396 . . . . 0.0 110.537 178.223 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -118.16 147.04 21.87 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.355 179.84 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 13.4 m120 -124.18 96.94 5.12 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 109.416 -0.587 . . . . 0.0 109.416 -179.666 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . 0.415 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 64.1 t80 -104.42 109.1 20.83 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.272 -175.172 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 72.71 -82.08 0.61 Allowed Glycine 0 N--CA 1.45 -0.392 0 CA-C-N 115.768 -0.651 . . . . 0.0 111.832 179.875 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 140' ' ' ARG . . . . . 0.401 ' HD3' ' HA ' ' A' ' 140' ' ' ARG . 16.3 mmt180 -141.36 -7.43 1.01 Allowed 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 115.477 -0.362 . . . . 0.0 111.109 177.08 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 3.4 t -99.17 135.82 40.03 Favored 'General case' 0 N--CA 1.446 -0.637 0 CA-C-O 121.279 0.561 . . . . 0.0 110.083 -179.229 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 142' ' ' TYR . . . . . 0.533 ' HD2' HD11 ' A' ' 135' ' ' LEU . 27.0 p90 -114.06 144.22 43.48 Favored 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 176.193 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 143' ' ' PHE . . . . . 0.526 ' HB3' ' HB3' ' A' ' 120' ' ' LYS . 23.7 p90 -157.25 162.77 39.24 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.556 -178.854 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 87.1 m-85 -100.93 118.3 36.69 Favored 'General case' 0 C--N 1.314 -0.949 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 175.177 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 145' ' ' GLU . . . . . 0.67 ' OE1' ' HD3' ' A' ' 116' ' ' ARG . 11.5 pt-20 -110.0 155.17 22.15 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-O 121.321 0.581 . . . . 0.0 109.695 178.701 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . 0.513 ' HB2' ' HG2' ' A' ' 133' ' ' MET . 32.4 t80 -137.39 123.81 20.76 Favored 'General case' 0 C--N 1.307 -1.259 0 CA-C-N 115.498 -0.774 . . . . 0.0 109.382 176.493 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 147' ' ' ILE . . . . . 0.44 ' N ' HD12 ' A' ' 147' ' ' ILE . 3.3 mp -94.36 103.79 15.07 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.799 0 CA-C-N 116.111 -0.495 . . . . 0.0 109.932 -177.621 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -68.37 119.3 12.66 Favored 'General case' 0 N--CA 1.443 -0.783 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 171.358 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 -63.08 155.81 26.74 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 121.121 0.486 . . . . 0.0 110.3 -177.363 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 16.3 t -70.09 122.95 22.85 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.788 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.938 -170.401 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 151' ' ' ARG . . . . . . . . . . . . . 27.7 mmm180 -78.71 150.38 32.54 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-N 115.025 -0.989 . . . . 0.0 109.132 -179.909 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 50.0 m -71.08 91.15 0.89 Allowed 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.277 0.561 . . . . 0.0 111.36 -176.706 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 2.8 tmt_? . . . . . 0 C--O 1.249 1.056 0 CA-C-O 118.196 -0.907 . . . . 0.0 109.184 176.282 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 75.6 m95 . . . . . 0 N--CA 1.457 -0.105 0 CA-C-O 120.975 0.417 . . . . 0.0 110.457 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 23.9 t-20 -58.04 -52.74 64.29 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.354 -176.762 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.482 ' HB3' ' HD2' ' A' ' 138' ' ' TYR . 6.0 m-20 -59.14 -35.48 73.57 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.344 -179.489 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 61.6 tp -58.38 -47.63 83.25 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.331 178.481 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -61.34 -47.52 85.54 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.909 178.961 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.579 ' HA ' HD12 ' A' ' 30' ' ' ILE . 58.0 t -58.13 -43.97 86.55 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.162 0 CA-C-O 120.955 0.407 . . . . 0.0 110.83 179.82 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 68.4 t80 -56.0 -47.47 77.68 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.736 -0.665 . . . . 0.0 110.487 178.819 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.509 HG23 HD13 ' A' ' 92' ' ' LEU . 77.6 mt -63.37 -42.63 97.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.731 179.022 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.579 HD12 ' HA ' ' A' ' 27' ' ' VAL . 83.1 mt -56.26 -44.23 78.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.482 -0.781 . . . . 0.0 111.05 178.39 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 31' ' ' ARG . . . . . 0.468 ' HG3' ' O ' ' A' ' 27' ' ' VAL . 81.8 mtp180 -70.29 -30.34 67.31 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.959 -177.354 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 74.3 m -75.58 -29.89 59.46 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.213 -178.995 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 22.3 p -112.67 -97.4 0.43 Allowed 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.532 -0.303 . . . . 0.0 111.336 -178.876 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 113.81 -178.96 18.66 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.993 -0.622 . . . . 0.0 112.037 -178.03 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 10.6 Cg_exo -71.05 150.36 60.21 Favored 'Trans proline' 0 C--O 1.234 0.292 0 C-N-CA 122.932 2.421 . . . . 0.0 112.222 -179.412 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 84.93 41.94 7.38 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.831 -0.699 . . . . 0.0 112.86 179.257 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 14.6 t -168.65 -178.64 3.51 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 177.137 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 66.9 mtp85 -114.67 136.08 53.45 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 120.711 0.291 . . . . 0.0 111.082 -178.433 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.9 ' HB ' HD22 ' A' ' 62' ' ' LEU . 40.2 t -124.06 132.11 71.86 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 N-CA-C 108.914 -0.772 . . . . 0.0 108.914 173.47 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.423 HG11 ' CD1' ' A' ' 87' ' ' TYR . 62.0 t -105.79 124.22 60.76 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 C-N-CA 120.87 -0.332 . . . . 0.0 111.246 -175.939 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 41' ' ' GLU . . . . . 0.411 ' OE1' HD22 ' A' ' 64' ' ' LEU . 44.9 tt0 -103.59 109.47 21.16 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.931 -0.577 . . . . 0.0 109.852 176.583 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.573 HG11 HD21 ' A' ' 106' ' ' LEU . 47.0 t -96.65 132.99 39.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 115.947 -0.569 . . . . 0.0 109.954 179.707 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 87.12 20.48 52.81 Favored Glycine 0 N--CA 1.447 -0.613 0 C-N-CA 120.474 -0.87 . . . . 0.0 111.811 -178.637 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.452 ' HB1' ' CD2' ' A' ' 48' ' ' LEU . . . -55.81 -68.0 0.24 Allowed 'General case' 0 C--N 1.331 -0.201 0 O-C-N 123.744 0.32 . . . . 0.0 110.253 178.695 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 58.22 -93.05 0.04 OUTLIER Glycine 0 N--CA 1.452 -0.284 0 CA-C-N 115.572 -0.74 . . . . 0.0 114.1 173.06 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 46' ' ' ARG . . . . . 0.44 HH11 ' HD3' ' A' ' 46' ' ' ARG . 32.7 ttt-85 -126.58 11.24 7.32 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 121.351 0.596 . . . . 0.0 110.571 -172.181 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 59.0 t80 -133.04 97.96 4.15 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 109.529 -0.545 . . . . 0.0 109.529 178.995 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.72 HD22 HD13 ' A' ' 64' ' ' LEU . 67.1 mt -113.4 24.37 12.3 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.952 -172.278 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 56.8 t80 -64.65 -50.86 65.42 Favored 'General case' 0 C--N 1.329 -0.292 0 C-N-CA 120.928 -0.309 . . . . 0.0 111.781 -176.908 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.476 ' O ' HG13 ' A' ' 54' ' ' ILE . 44.1 t -60.92 -55.47 24.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.559 -0.291 . . . . 0.0 111.011 -173.013 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 10.9 p -56.93 -43.12 81.17 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.975 179.538 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.469 ' HA ' ' HG2' ' A' ' 55' ' ' ARG . 36.7 t70 -64.99 -42.88 94.12 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.728 0.299 . . . . 0.0 110.905 -179.466 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 74.6 t80 -61.11 -42.02 97.75 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.062 0.458 . . . . 0.0 110.341 177.281 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.552 HG23 HG12 ' A' ' 30' ' ' ILE . 86.3 mt -64.61 -49.13 81.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.294 179.21 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 55' ' ' ARG . . . . . 0.469 ' HG2' ' HA ' ' A' ' 52' ' ' ASP . 40.8 ptt180 -67.96 -18.74 64.83 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-O 120.862 0.363 . . . . 0.0 111.401 -176.05 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 84.6 mttt -84.51 -34.11 23.39 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.828 0.346 . . . . 0.0 110.971 176.104 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.6 OUTLIER -79.85 -33.6 40.05 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.253 178.76 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 70.6 m -141.78 135.95 30.2 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.5 178.063 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 7.6 tmtt? -76.15 64.77 2.03 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.888 0.852 . . . . 0.0 109.378 176.755 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.515 HG21 HG23 ' A' ' 39' ' ' VAL . 8.3 p -95.18 148.2 5.27 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.964 0 CA-C-N 114.727 -1.124 . . . . 0.0 109.118 173.834 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 25.9 t0 -78.91 88.58 4.71 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 121.34 0.59 . . . . 0.0 109.437 -179.808 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 62' ' ' LEU . . . . . 0.9 HD22 ' HB ' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -82.99 115.12 21.69 Favored 'General case' 0 N--CA 1.448 -0.549 0 CA-C-N 115.532 -0.758 . . . . 0.0 110.1 -177.578 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 45.3 t -103.56 114.73 43.96 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-N 115.462 -0.79 . . . . 0.0 110.081 -177.54 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 64' ' ' LEU . . . . . 0.72 HD13 HD22 ' A' ' 48' ' ' LEU . 20.1 mt -91.61 135.95 33.49 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-N 115.671 -0.695 . . . . 0.0 109.607 -179.696 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 14.5 p -130.76 128.96 41.83 Favored 'General case' 0 C--N 1.319 -0.723 0 C-N-CA 121.045 -0.262 . . . . 0.0 111.271 -179.074 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 5.8 t70 -171.0 155.34 4.45 Favored 'General case' 0 CA--C 1.519 -0.246 0 N-CA-C 109.371 -0.603 . . . . 0.0 109.371 175.839 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.625 HG22 ' HG2' ' A' ' 68' ' ' LYS . 58.1 mt -78.1 131.2 35.06 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 CA-C-N 116.642 -0.254 . . . . 0.0 110.606 -177.942 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 68' ' ' LYS . . . . . 0.625 ' HG2' HG22 ' A' ' 67' ' ' ILE . 7.9 ptmm? 42.31 71.73 1.31 Allowed Pre-proline 0 N--CA 1.471 0.586 0 O-C-N 124.152 0.908 . . . . 0.0 112.915 179.265 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo . . . . . 0 N--CA 1.463 -0.319 0 C-N-CA 122.549 2.166 . . . . 0.0 112.168 177.768 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.673 ' HA ' ' HB2' ' A' ' 64' ' ' LEU . 50.6 mt . . . . . 0 N--CA 1.452 -0.35 0 CA-C-O 120.574 0.226 . . . . 0.0 110.441 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.441 HG11 HD13 ' A' ' 86' ' ' ILE . 61.5 t -64.45 116.91 4.29 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 N-CA-C 109.631 -0.507 . . . . 0.0 109.631 176.875 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 16.2 mtt180 -84.48 53.69 2.75 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.679 -0.692 . . . . 0.0 110.432 -175.417 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 77' ' ' ASP . . . . . 0.421 ' HB2' HG12 ' A' ' 75' ' ' VAL . 2.0 t70 -98.83 -162.36 0.95 Allowed 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 116.307 -0.406 . . . . 0.0 109.972 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 78' ' ' ASP . . . . . 0.503 ' OD1' HG22 ' A' ' 80' ' ' THR . 11.8 t0 -119.38 146.17 45.57 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 120.773 0.321 . . . . 0.0 111.251 -175.475 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 79' ' ' ILE . . . . . 0.558 HG22 HD11 ' A' ' 67' ' ' ILE . 10.7 tp -107.96 -20.59 6.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.292 -176.266 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.503 HG22 ' OD1' ' A' ' 78' ' ' ASP . 13.3 t -79.82 -25.06 40.97 Favored 'General case' 0 CA--C 1.529 0.167 0 CA-C-O 121.616 0.722 . . . . 0.0 109.322 178.913 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 23.2 m -132.54 79.86 63.83 Favored Pre-proline 0 C--N 1.322 -0.613 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 166.048 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -74.97 146.15 32.44 Favored 'Trans proline' 0 N--CA 1.462 -0.364 0 C-N-CA 122.799 2.332 . . . . 0.0 112.991 -171.954 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 83' ' ' ARG . . . . . 0.537 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 82.9 mtt180 -94.58 107.92 19.89 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.542 -0.754 . . . . 0.0 110.22 175.845 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 84' ' ' MET . . . . . 0.554 ' HA ' ' HD2' ' A' ' 87' ' ' TYR . 95.3 mmm -59.56 -24.41 63.71 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.587 -0.733 . . . . 0.0 111.571 -176.087 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.537 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 9.4 pt-20 -55.45 -29.56 58.89 Favored 'General case' 0 C--N 1.33 -0.272 0 O-C-N 123.245 0.341 . . . . 0.0 111.415 179.465 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.441 HD13 HG11 ' A' ' 75' ' ' VAL . 64.9 mt -78.52 -35.59 19.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.81 -178.403 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 87' ' ' TYR . . . . . 0.554 ' HD2' ' HA ' ' A' ' 84' ' ' MET . 49.4 m-85 -85.86 -25.86 25.98 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.209 -175.327 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 88' ' ' ARG . . . . . 0.645 ' HG2' HG12 ' A' ' 113' ' ' VAL . 81.6 mtp180 -70.35 138.29 51.29 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 121.36 0.6 . . . . 0.0 110.666 -178.553 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 92.92 -1.19 70.51 Favored Glycine 0 C--N 1.317 -0.478 0 CA-C-N 115.11 -0.95 . . . . 0.0 111.993 -176.652 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -86.7 147.64 25.79 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.905 0.383 . . . . 0.0 110.664 178.596 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -91.05 -27.08 18.84 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.801 179.306 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 92' ' ' LEU . . . . . 0.509 HD13 HG23 ' A' ' 29' ' ' ILE . 6.2 tt -152.35 143.24 22.99 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.143 -177.935 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.572 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 72.3 mt -131.46 122.74 51.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 N-CA-C 109.473 -0.566 . . . . 0.0 109.473 178.547 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 15.1 p90 -129.77 157.89 40.93 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 120.917 0.389 . . . . 0.0 110.883 -178.691 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 95' ' ' SER . . . . . 0.487 ' HA ' ' O ' ' A' ' 42' ' ' VAL . 16.5 m -128.04 128.37 44.85 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.958 -0.564 . . . . 0.0 110.974 -176.731 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 50.6 mm -91.71 106.67 17.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.437 -179.806 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 11.1 tpp180 57.06 69.87 1.55 Allowed Pre-proline 0 CA--C 1.535 0.389 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.071 178.821 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 98' ' ' PRO . . . . . 0.56 ' HG2' HG23 ' A' ' 119' ' ' ILE . 5.6 Cg_endo -87.05 135.69 3.95 Favored 'Trans proline' 0 N--CA 1.455 -0.762 0 C-N-CA 122.799 2.332 . . . . 0.0 112.31 -179.09 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 99' ' ' PRO . . . . . 0.559 ' HD2' HD11 ' A' ' 102' ' ' ILE . 32.3 Cg_exo -59.12 142.51 99.38 Favored 'Trans proline' 0 C--O 1.236 0.411 0 C-N-CA 122.464 2.11 . . . . 0.0 111.7 174.627 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -76.97 43.01 0.33 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.763 -176.092 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 101' ' ' GLU . . . . . 0.506 ' HG3' HG23 ' A' ' 102' ' ' ILE . 12.0 pt-20 -140.27 -34.45 0.53 Allowed 'General case' 0 N--CA 1.45 -0.472 0 CA-C-N 115.902 -0.59 . . . . 0.0 111.541 178.797 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.559 HD11 ' HD2' ' A' ' 99' ' ' PRO . 45.8 pt -95.56 -0.78 10.62 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.211 0 CA-C-O 120.837 0.351 . . . . 0.0 111.597 -176.53 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 103' ' ' HIS . . . . . 0.539 ' O ' ' HG3' ' A' ' 107' ' ' MET . 41.8 p-80 -55.92 -36.93 68.25 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.932 -0.576 . . . . 0.0 111.303 -178.863 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 6.7 m -60.93 -39.32 88.97 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.0 -179.4 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.558 ' O ' HG23 ' A' ' 109' ' ' VAL . 14.2 m -66.58 -35.37 80.05 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.976 -0.556 . . . . 0.0 109.88 -179.752 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.573 HD21 HG11 ' A' ' 42' ' ' VAL . 96.3 mt -69.91 -41.06 75.19 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.704 -0.68 . . . . 0.0 111.138 -179.676 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 107' ' ' MET . . . . . 0.539 ' HG3' ' O ' ' A' ' 103' ' ' HIS . 70.0 mtp -62.5 -42.37 99.45 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.813 -0.63 . . . . 0.0 111.487 -177.24 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 14.1 ptm180 -69.54 -29.87 67.56 Favored 'General case' 0 C--N 1.33 -0.261 0 C-N-CA 120.762 -0.375 . . . . 0.0 111.158 -179.572 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.558 HG23 ' O ' ' A' ' 105' ' ' SER . 75.4 t -66.75 -48.69 79.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 C-N-CA 120.933 -0.307 . . . . 0.0 110.56 178.399 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -57.55 -46.25 84.15 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.262 177.676 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.548 ' HA ' ' HB1' ' A' ' 148' ' ' ALA . 12.3 t70 -63.43 -34.37 77.59 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.553 -0.749 . . . . 0.0 110.729 -177.868 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -70.31 -46.97 63.19 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.801 -0.636 . . . . 0.0 111.797 -179.773 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.645 HG12 ' HG2' ' A' ' 88' ' ' ARG . 23.1 m -84.95 -26.28 6.76 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-N 116.416 -0.356 . . . . 0.0 111.811 -173.769 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 89.67 43.18 5.23 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.092 179.468 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -124.1 154.34 40.12 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.668 0.27 . . . . 0.0 110.503 -178.524 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 116' ' ' ARG . . . . . 0.463 ' HD3' ' OE1' ' A' ' 145' ' ' GLU . 14.5 ttm180 -73.95 124.48 26.27 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 178.13 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 117' ' ' LEU . . . . . 0.572 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 56.1 tp -93.46 121.39 34.81 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.246 -0.434 . . . . 0.0 109.977 178.562 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 118' ' ' ILE . . . . . 0.406 HD12 HG12 ' A' ' 29' ' ' ILE . 67.8 mt -119.12 120.18 63.1 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 CA-C-O 121.321 0.581 . . . . 0.0 110.907 179.435 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 119' ' ' ILE . . . . . 0.56 HG23 ' HG2' ' A' ' 98' ' ' PRO . 14.2 mt -112.68 130.6 66.16 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.674 178.874 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 2.6 tmtm? -106.34 94.71 10.16 Favored Pre-proline 0 C--N 1.323 -0.545 0 N-CA-C 109.287 -0.634 . . . . 0.0 109.287 174.926 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 91.1 Cg_endo -85.67 -162.69 0.16 Allowed 'Trans proline' 0 N--CA 1.46 -0.464 0 C-N-CA 122.749 2.299 . . . . 0.0 112.588 -179.539 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 122' ' ' LEU . . . . . 0.943 ' HB2' ' HB3' ' A' ' 125' ' ' GLU . 9.9 mp -86.15 159.57 19.48 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.45 179.681 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 4.0 p -64.13 -33.72 76.42 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.915 -0.584 . . . . 0.0 111.617 -178.529 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -132.18 43.74 1.26 Allowed Glycine 0 N--CA 1.447 -0.579 0 C-N-CA 120.935 -0.65 . . . . 0.0 112.135 179.824 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 125' ' ' GLU . . . . . 0.943 ' HB3' ' HB2' ' A' ' 122' ' ' LEU . 34.3 tt0 -145.32 129.23 17.39 Favored 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 110.044 -0.354 . . . . 0.0 110.044 179.274 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -85.41 167.59 15.38 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.605 -175.902 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 35.7 mt . . . . . 0 C--N 1.326 -0.455 0 CA-C-O 121.084 0.469 . . . . 0.0 110.218 -178.513 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 28.1 mmmt . . . . . 0 N--CA 1.453 -0.29 0 CA-C-O 121.0 0.429 . . . . 0.0 110.462 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 133' ' ' MET . . . . . . . . . . . . . 75.9 mtp -90.83 156.9 17.69 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.055 -0.521 . . . . 0.0 111.014 -175.525 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 16.1 ptmt -120.54 141.11 50.55 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 115.535 -0.757 . . . . 0.0 110.93 -175.582 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 135' ' ' LEU . . . . . 0.431 HD11 ' HD2' ' A' ' 142' ' ' TYR . 51.2 tp -83.12 120.65 26.03 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.108 178.042 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -119.19 146.01 24.48 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.743 -178.114 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 9.3 m-80 -118.84 119.24 33.8 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.535 -0.543 . . . . 0.0 109.535 -179.233 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 138' ' ' TYR . . . . . 0.482 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 40.6 t80 -123.52 117.42 25.05 Favored 'General case' 0 C--N 1.321 -0.641 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 178.511 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 70.34 -87.29 0.33 Allowed Glycine 0 N--CA 1.443 -0.865 0 CA-C-N 115.604 -0.725 . . . . 0.0 111.43 -175.546 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 14.2 tpp180 -139.1 -13.09 1.21 Allowed 'General case' 0 C--N 1.317 -0.83 0 CA-C-O 121.259 0.552 . . . . 0.0 110.241 -179.147 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 5.8 t -97.99 141.17 31.29 Favored 'General case' 0 N--CA 1.448 -0.538 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.261 -176.608 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 142' ' ' TYR . . . . . 0.431 ' HD2' HD11 ' A' ' 135' ' ' LEU . 52.0 p90 -118.88 147.12 44.32 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 121.117 0.484 . . . . 0.0 110.545 177.432 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 15.2 p90 -155.24 -176.97 6.21 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.322 -0.854 . . . . 0.0 109.778 -176.292 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 31.7 m-85 -115.32 125.49 53.31 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-O 120.454 0.168 . . . . 0.0 110.76 179.699 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 145' ' ' GLU . . . . . 0.463 ' OE1' ' HD3' ' A' ' 116' ' ' ARG . 15.5 pt-20 -114.72 160.0 19.89 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 121.081 0.467 . . . . 0.0 109.813 175.847 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 146' ' ' TYR . . . . . 0.406 ' HB3' ' HB3' ' A' ' 117' ' ' LEU . 26.4 t80 -143.87 122.18 12.32 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-N 115.714 -0.675 . . . . 0.0 109.566 175.158 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 147' ' ' ILE . . . . . 0.439 ' N ' HD12 ' A' ' 147' ' ' ILE . 3.2 mp -90.31 102.34 13.19 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 -178.973 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 148' ' ' ALA . . . . . 0.548 ' HB1' ' HA ' ' A' ' 111' ' ' ASP . . . -72.53 114.17 10.37 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.839 -0.619 . . . . 0.0 109.903 177.381 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 8.1 pt-20 . . . . . 0 C--N 1.322 -0.62 0 CA-C-O 121.332 0.586 . . . . 0.0 110.886 -176.348 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 22' ' ' TRP . . . . . 0.434 ' HB3' HG22 ' A' ' 50' ' ' VAL . 50.2 m95 . . . . . 0 N--CA 1.454 -0.268 0 CA-C-O 120.884 0.373 . . . . 0.0 110.286 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 25.8 t-20 -72.57 -43.32 63.58 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.98 -0.555 . . . . 0.0 109.691 177.801 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 42.5 m-20 -57.42 -51.03 71.07 Favored 'General case' 0 N--CA 1.463 0.205 0 CA-C-N 115.949 -0.568 . . . . 0.0 109.712 176.927 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.402 ' O ' HG13 ' A' ' 29' ' ' ILE . 58.2 tp -55.01 -47.78 74.22 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.44 -0.8 . . . . 0.0 110.954 179.035 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -55.3 -52.11 64.53 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.223 179.763 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.523 ' HA ' HD12 ' A' ' 30' ' ' ILE . 98.4 t -59.51 -40.51 82.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.975 -179.523 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 84.9 t80 -60.11 -43.54 95.53 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.494 178.428 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.404 HG23 HD13 ' A' ' 92' ' ' LEU . 82.6 mt -64.84 -43.67 96.36 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.595 177.909 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.662 HG12 HG23 ' A' ' 54' ' ' ILE . 85.8 mt -56.75 -38.84 60.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.901 178.206 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 32.8 mtp85 -70.62 -35.13 72.78 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.082 179.852 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 78.9 m -87.61 0.79 55.15 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.674 -174.047 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 15.5 p -122.01 -71.73 0.72 Allowed 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 120.977 0.418 . . . . 0.0 111.175 178.026 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 97.38 145.23 18.71 Favored Glycine 0 N--CA 1.446 -0.666 0 C-N-CA 120.804 -0.712 . . . . 0.0 111.586 -177.895 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -59.18 130.55 36.7 Favored 'Trans proline' 0 C--O 1.233 0.266 0 C-N-CA 122.852 2.368 . . . . 0.0 112.671 -177.433 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 105.37 24.97 6.87 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.467 -0.873 . . . . 0.0 112.978 177.474 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 13.8 t -131.71 -171.55 2.64 Favored 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 177.312 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -119.35 131.47 55.7 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 120.897 0.379 . . . . 0.0 110.433 177.866 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.45 ' O ' ' HA ' ' A' ' 62' ' ' LEU . 95.9 t -128.14 130.44 69.62 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 176.578 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.403 HG11 ' CD1' ' A' ' 87' ' ' TYR . 46.5 t -107.21 126.04 63.36 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.674 0 CA-C-O 120.91 0.386 . . . . 0.0 111.036 -176.38 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 41' ' ' GLU . . . . . 0.445 ' HB3' HD23 ' A' ' 64' ' ' LEU . 39.2 tt0 -104.18 114.82 29.32 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.686 175.841 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 62.1 t -98.13 125.75 51.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.691 -177.668 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 88.03 28.66 22.63 Favored Glycine 0 N--CA 1.452 -0.261 0 CA-C-N 115.989 -0.551 . . . . 0.0 112.015 179.603 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.436 ' HB1' ' CD2' ' A' ' 48' ' ' LEU . . . -55.79 -76.58 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.35 0 C-N-CA 123.045 0.538 . . . . 0.0 112.356 -176.503 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 64.09 -102.04 0.55 Allowed Glycine 0 CA--C 1.519 0.301 0 C-N-CA 121.185 -0.531 . . . . 0.0 113.188 179.408 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -107.59 -1.89 20.79 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.655 0.264 . . . . 0.0 111.547 -178.082 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.445 ' CG ' HG21 ' A' ' 96' ' ' ILE . 99.4 m-85 -87.72 23.56 1.96 Allowed 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.933 0.397 . . . . 0.0 111.408 -174.957 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.762 HD22 HD13 ' A' ' 64' ' ' LEU . 37.8 mt -66.42 -7.74 21.29 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.691 -0.686 . . . . 0.0 112.831 -172.928 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 49' ' ' TYR . . . . . 0.438 ' CE2' ' HA ' ' A' ' 47' ' ' PHE . 23.4 p90 -62.0 -25.72 67.81 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.576 0.227 . . . . 0.0 111.361 -179.905 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.434 HG22 ' HB3' ' A' ' 22' ' ' TRP . 61.9 t -74.24 -54.88 13.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.924 0.393 . . . . 0.0 110.381 175.935 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -66.22 -40.13 90.08 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.9 -0.591 . . . . 0.0 112.294 -177.21 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.558 ' O ' ' HG2' ' A' ' 56' ' ' LYS . 38.7 t70 -67.23 -27.75 67.49 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.863 0.363 . . . . 0.0 110.502 -178.688 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 78.5 t80 -69.53 -41.88 75.38 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.892 0.377 . . . . 0.0 110.293 176.014 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.662 HG23 HG12 ' A' ' 30' ' ' ILE . 77.1 mt -63.65 -40.7 90.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 115.946 -0.57 . . . . 0.0 111.231 -178.493 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 55' ' ' ARG . . . . . 0.505 ' HG2' ' HA ' ' A' ' 52' ' ' ASP . 5.8 ptp180 -70.11 -16.57 63.13 Favored 'General case' 0 CA--C 1.534 0.365 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.985 -176.492 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 56' ' ' LYS . . . . . 0.558 ' HG2' ' O ' ' A' ' 52' ' ' ASP . 67.1 mmtt -72.17 -42.86 65.4 Favored 'General case' 0 N--CA 1.462 0.143 0 CA-C-O 121.186 0.517 . . . . 0.0 110.377 179.645 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 45.4 m-70 -92.36 -46.87 7.47 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.48 -0.782 . . . . 0.0 111.884 -173.002 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 58' ' ' SER . . . . . 0.448 ' HB2' HG23 ' A' ' 60' ' ' VAL . 12.0 p -112.3 134.18 53.99 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 116.609 -0.269 . . . . 0.0 111.163 -176.798 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 25.4 tptp -80.24 65.85 5.53 Favored 'General case' 0 N--CA 1.448 -0.541 0 CA-C-O 122.246 1.022 . . . . 0.0 109.612 174.532 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.448 HG23 ' HB2' ' A' ' 58' ' ' SER . 92.3 t -98.39 130.86 46.58 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.192 0 CA-C-N 114.4 -1.273 . . . . 0.0 109.113 172.662 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 62.2 m-20 -75.67 86.56 2.72 Favored 'General case' 0 C--N 1.317 -0.83 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 178.981 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 62' ' ' LEU . . . . . 0.45 ' HA ' ' O ' ' A' ' 39' ' ' VAL . 2.8 tt -87.02 115.55 24.48 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 115.45 -0.796 . . . . 0.0 109.933 -177.054 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 48.0 t -97.54 119.16 45.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.055 -177.252 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 64' ' ' LEU . . . . . 0.762 HD13 HD22 ' A' ' 48' ' ' LEU . 39.2 mt -92.85 121.54 34.33 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-N 115.913 -0.585 . . . . 0.0 109.762 179.102 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 19.4 p -121.74 124.89 45.29 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-O 121.054 0.454 . . . . 0.0 110.485 178.903 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 27.3 t0 -160.72 152.29 19.49 Favored 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 109.612 -0.514 . . . . 0.0 109.612 -179.294 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.694 HG12 ' HA ' ' A' ' 78' ' ' ASP . 49.6 mt -73.12 108.9 4.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 N-CA-C 110.124 -0.325 . . . . 0.0 110.124 -177.935 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 68' ' ' LYS . . . . . 0.452 ' HA ' ' HD2' ' A' ' 69' ' ' PRO . 45.3 mtpt 65.2 88.86 0.11 Allowed Pre-proline 0 C--N 1.328 -0.365 0 CA-C-N 115.157 -0.929 . . . . 0.0 110.627 -178.963 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 69' ' ' PRO . . . . . 0.756 ' HB3' ' HB ' ' A' ' 74' ' ' ILE . 11.0 Cg_endo . . . . . 0 C--N 1.343 0.27 0 C-N-CA 123.558 2.839 . . . . 0.0 113.229 -177.498 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.756 ' HB ' ' HB3' ' A' ' 69' ' ' PRO . 53.3 mt . . . . . 0 N--CA 1.453 -0.307 0 N-CA-C 110.124 -0.324 . . . . 0.0 110.124 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 45.3 t -78.48 135.84 25.19 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.716 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 177.089 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 76' ' ' ARG . . . . . 0.529 ' HA ' ' HD3' ' A' ' 69' ' ' PRO . 3.3 ptm180 -79.92 25.24 0.37 Allowed 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.638 -0.256 . . . . 0.0 111.389 -176.441 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 38.2 t70 -64.59 103.8 0.72 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.37 0.605 . . . . 0.0 110.277 -177.192 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 78' ' ' ASP . . . . . 0.694 ' HA ' HG12 ' A' ' 67' ' ' ILE . 3.3 m-20 -68.25 123.46 20.79 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.241 -0.89 . . . . 0.0 110.201 -176.335 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 10.6 tp -64.08 -19.02 23.81 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.48 0 CA-C-O 121.132 0.492 . . . . 0.0 111.066 179.665 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 10.2 t -77.45 -14.81 59.61 Favored 'General case' 0 CA--C 1.532 0.288 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.784 178.431 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 33.6 t -158.68 70.53 3.69 Favored Pre-proline 0 C--N 1.326 -0.424 0 N-CA-C 108.353 -0.981 . . . . 0.0 108.353 177.593 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 90.0 Cg_endo -88.24 162.09 7.01 Favored 'Trans proline' 0 N--CA 1.458 -0.615 0 C-N-CA 122.956 2.437 . . . . 0.0 113.591 -168.56 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 83' ' ' ARG . . . . . 0.745 ' HB2' HD12 ' A' ' 86' ' ' ILE . 3.9 mmt180 -98.24 107.68 20.21 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 115.58 -0.736 . . . . 0.0 111.095 175.825 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 84' ' ' MET . . . . . 0.503 ' O ' ' HG3' ' A' ' 88' ' ' ARG . 91.0 mmm -62.17 -23.65 66.72 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.278 177.276 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.428 ' OE2' ' HD2' ' A' ' 83' ' ' ARG . 11.0 pt-20 -69.55 -22.58 63.54 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.638 -178.189 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.745 HD12 ' HB2' ' A' ' 83' ' ' ARG . 95.6 mt -81.04 -36.08 14.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.204 178.342 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 87' ' ' TYR . . . . . 0.403 ' CD1' HG11 ' A' ' 40' ' ' VAL . 22.8 m-85 -77.76 -31.21 51.92 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.72 -179.369 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 88' ' ' ARG . . . . . 0.503 ' HG3' ' O ' ' A' ' 84' ' ' MET . 38.2 mtp180 -63.67 123.08 17.94 Favored 'General case' 0 CA--C 1.516 -0.361 0 CA-C-O 121.331 0.586 . . . . 0.0 111.024 179.837 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 109.99 -9.5 31.71 Favored Glycine 0 N--CA 1.446 -0.639 0 CA-C-N 115.321 -0.854 . . . . 0.0 111.706 -178.506 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -81.93 143.8 31.39 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 110.349 -0.241 . . . . 0.0 110.349 178.389 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -92.89 -19.88 21.23 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 121.063 0.458 . . . . 0.0 110.627 -179.881 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 92' ' ' LEU . . . . . 0.45 HD23 ' N ' ' A' ' 93' ' ' ILE . 3.2 tt -152.09 140.66 20.73 Favored 'General case' 0 N--CA 1.449 -0.487 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.625 -179.062 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.467 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 72.3 mt -132.28 126.91 56.57 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 115.934 -0.576 . . . . 0.0 109.569 178.486 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 94' ' ' TYR . . . . . 0.4 ' HB3' ' HB ' ' A' ' 118' ' ' ILE . 8.1 p90 -134.7 162.84 31.21 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 120.812 0.339 . . . . 0.0 110.688 178.563 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 6.8 p -141.97 143.16 33.08 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.1 -176.392 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 96' ' ' ILE . . . . . 0.445 HG21 ' CG ' ' A' ' 47' ' ' PHE . 40.5 mm -90.47 93.11 4.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.632 179.675 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 97' ' ' ARG . . . . . 0.499 ' HG2' ' HA ' ' A' ' 121' ' ' PRO . 1.2 tmm_? 49.44 80.86 0.28 Allowed Pre-proline 0 N--CA 1.464 0.261 0 CA-C-N 115.18 -0.918 . . . . 0.0 111.757 178.552 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 98' ' ' PRO . . . . . 0.518 ' HG2' ' CD2' ' A' ' 103' ' ' HIS . 98.8 Cg_endo -84.98 152.32 11.11 Favored 'Trans proline' 0 N--CA 1.457 -0.63 0 C-N-CA 122.556 2.17 . . . . 0.0 111.874 176.195 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 99' ' ' PRO . . . . . 0.591 ' HD2' HD11 ' A' ' 102' ' ' ILE . 24.2 Cg_exo -64.15 155.45 64.98 Favored 'Trans proline' 0 C--N 1.343 0.28 0 C-N-CA 122.857 2.371 . . . . 0.0 112.089 175.066 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 100' ' ' ALA . . . . . 0.641 ' HA ' ' ND1' ' A' ' 103' ' ' HIS . . . -64.17 -16.12 61.26 Favored 'General case' 0 C--N 1.33 -0.257 0 N-CA-C 112.328 0.492 . . . . 0.0 112.328 -176.195 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 101' ' ' GLU . . . . . 0.626 ' HG3' HG23 ' A' ' 102' ' ' ILE . 12.9 pt-20 -76.14 -22.25 55.67 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.781 -0.19 . . . . 0.0 111.509 -177.519 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.626 HG23 ' HG3' ' A' ' 101' ' ' GLU . 43.1 pt -114.91 3.13 7.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 N-CA-C 112.438 0.533 . . . . 0.0 112.438 -176.177 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 103' ' ' HIS . . . . . 0.641 ' ND1' ' HA ' ' A' ' 100' ' ' ALA . 41.8 m170 -58.03 -51.57 69.13 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.002 0.43 . . . . 0.0 110.428 176.92 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 8.8 m -64.46 -29.82 70.86 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.892 -0.594 . . . . 0.0 110.59 178.03 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.554 ' O ' HG23 ' A' ' 109' ' ' VAL . 3.6 m -71.11 -43.9 66.73 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.577 -178.434 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 79.5 mt -60.77 -38.92 86.87 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.818 178.63 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 107' ' ' MET . . . . . 0.451 ' HA ' HD22 ' A' ' 117' ' ' LEU . 76.3 mtp -62.19 -45.54 92.93 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.081 179.841 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 108' ' ' ARG . . . . . 0.549 ' HG2' ' O ' ' A' ' 105' ' ' SER . 12.9 ptm180 -72.01 -22.8 61.36 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.633 -0.258 . . . . 0.0 111.073 -178.26 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.554 HG23 ' O ' ' A' ' 105' ' ' SER . 70.1 t -70.39 -49.94 49.77 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 173.985 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -58.15 -45.54 87.23 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.074 -0.512 . . . . 0.0 109.88 176.67 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.476 ' HA ' ' HB1' ' A' ' 148' ' ' ALA . 21.0 t70 -59.23 -36.15 74.92 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.329 -0.851 . . . . 0.0 111.372 179.387 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -71.95 -45.19 61.98 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.641 -0.709 . . . . 0.0 111.951 -179.269 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 23.2 m -86.94 -28.24 5.78 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 N-CA-C 111.996 0.369 . . . . 0.0 111.996 -174.627 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 87.92 58.96 1.73 Allowed Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.268 -178.65 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -137.47 162.29 34.07 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.752 0.311 . . . . 0.0 110.776 179.37 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 116' ' ' ARG . . . . . 0.446 ' HD3' ' OE1' ' A' ' 145' ' ' GLU . 12.5 ttm180 -79.72 120.27 23.78 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 175.857 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 117' ' ' LEU . . . . . 0.467 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 52.5 tp -91.99 125.79 36.82 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.089 178.895 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 118' ' ' ILE . . . . . 0.4 ' HB ' ' HB3' ' A' ' 94' ' ' TYR . 65.0 mt -118.57 115.02 46.8 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-O 121.176 0.512 . . . . 0.0 110.514 176.889 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 69.8 mt -116.62 120.73 65.87 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.144 179.55 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 120' ' ' LYS . . . . . 0.456 ' HG3' ' HB3' ' A' ' 143' ' ' PHE . 12.1 ttpp -113.58 99.94 50.82 Favored Pre-proline 0 C--N 1.324 -0.525 0 C-N-CA 120.819 -0.353 . . . . 0.0 110.27 175.928 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 121' ' ' PRO . . . . . 0.499 ' HA ' ' HG2' ' A' ' 97' ' ' ARG . 98.9 Cg_endo -81.93 -153.59 0.05 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.609 0 C-N-CA 122.594 2.196 . . . . 0.0 111.079 174.305 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 122' ' ' LEU . . . . . 0.579 ' HB2' ' HG2' ' A' ' 125' ' ' GLU . 3.6 mm? -81.49 -176.98 6.31 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 175.075 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 10.0 t -79.88 1.02 28.68 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.272 0.558 . . . . 0.0 110.602 178.491 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -156.83 71.74 0.25 Allowed Glycine 0 N--CA 1.446 -0.687 0 N-CA-C 111.325 -0.71 . . . . 0.0 111.325 178.081 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 125' ' ' GLU . . . . . 0.579 ' HG2' ' HB2' ' A' ' 122' ' ' LEU . 9.9 mm-40 -138.01 167.93 20.76 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 109.122 -0.695 . . . . 0.0 109.122 -177.824 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 8.7 t70 -120.68 163.22 18.4 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.046 178.128 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 20.8 mt . . . . . 0 C--N 1.326 -0.441 0 CA-C-O 120.965 0.412 . . . . 0.0 110.716 -175.724 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 46.4 mtmt . . . . . 0 CA--C 1.521 -0.16 0 CA-C-O 120.802 0.334 . . . . 0.0 111.173 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 133' ' ' MET . . . . . 0.569 ' HG2' ' HB2' ' A' ' 146' ' ' TYR . 73.5 mtp -90.12 151.29 21.66 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 179.144 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 134' ' ' LYS . . . . . 0.546 ' HB3' ' NZ ' ' A' ' 134' ' ' LYS . 0.3 OUTLIER -121.1 143.05 49.29 Favored 'General case' 0 C--N 1.315 -0.924 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.959 -173.655 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 135' ' ' LEU . . . . . 0.781 HD11 ' HD2' ' A' ' 142' ' ' TYR . 43.4 tp -86.13 119.11 26.07 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.977 -0.556 . . . . 0.0 109.694 178.98 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 136' ' ' VAL . . . . . 0.441 ' CG2' ' HG2' ' A' ' 145' ' ' GLU . 0.0 OUTLIER -117.63 144.52 25.35 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.695 -176.271 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 52.3 m-20 -114.96 123.77 49.95 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.41 -179.663 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 58.3 t80 -137.57 123.36 19.99 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 109.932 -0.395 . . . . 0.0 109.932 175.213 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 72.12 -85.98 0.49 Allowed Glycine 0 N--CA 1.449 -0.476 0 N-CA-C 110.838 -0.905 . . . . 0.0 110.838 -175.051 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 7.1 mtt180 -153.73 -5.55 0.18 Allowed 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 115.443 -0.378 . . . . 0.0 111.388 173.569 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 15.3 t -87.91 143.68 26.98 Favored 'General case' 0 N--CA 1.445 -0.701 0 N-CA-C 109.039 -0.726 . . . . 0.0 109.039 176.24 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 142' ' ' TYR . . . . . 0.781 ' HD2' HD11 ' A' ' 135' ' ' LEU . 48.3 p90 -127.1 129.72 48.51 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-O 121.485 0.66 . . . . 0.0 110.214 178.506 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 143' ' ' PHE . . . . . 0.456 ' HB3' ' HG3' ' A' ' 120' ' ' LYS . 9.6 p90 -139.29 175.77 9.28 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-N 114.838 -1.074 . . . . 0.0 109.962 -173.512 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 144' ' ' TYR . . . . . 0.42 ' HA ' ' O ' ' A' ' 134' ' ' LYS . 93.9 m-85 -110.72 122.51 48.0 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.317 179.889 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 145' ' ' GLU . . . . . 0.459 ' O ' ' HG2' ' A' ' 134' ' ' LYS . 19.7 pt-20 -114.68 160.42 19.37 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-O 121.155 0.503 . . . . 0.0 109.805 175.92 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 146' ' ' TYR . . . . . 0.569 ' HB2' ' HG2' ' A' ' 133' ' ' MET . 46.5 t80 -142.02 125.24 16.42 Favored 'General case' 0 C--N 1.313 -0.993 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.627 175.811 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 147' ' ' ILE . . . . . 0.421 ' N ' HD12 ' A' ' 147' ' ' ILE . 3.5 mp -92.89 108.67 20.63 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.792 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 179.71 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 148' ' ' ALA . . . . . 0.476 ' HB1' ' HA ' ' A' ' 111' ' ' ASP . . . -74.41 128.77 36.37 Favored 'General case' 0 N--CA 1.442 -0.837 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 173.983 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 19.7 mm-40 . . . . . 0 C--N 1.319 -0.735 0 CA-C-O 121.787 0.803 . . . . 0.0 112.169 -178.23 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 22' ' ' TRP . . . . . 0.413 ' HB2' ' HE2' ' A' ' 49' ' ' TYR . 88.3 m95 . . . . . 0 N--CA 1.455 -0.187 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 12.8 m120 -66.06 -48.17 71.9 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.626 -0.716 . . . . 0.0 110.411 177.739 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.714 ' HB3' ' HA3' ' A' ' 139' ' ' GLY . 0.7 OUTLIER -67.51 -35.3 78.84 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.298 179.323 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.716 HD22 ' HD2' ' A' ' 120' ' ' LYS . 50.7 tp -51.79 -49.77 62.06 Favored 'General case' 0 C--O 1.231 0.131 0 CA-C-O 121.15 0.5 . . . . 0.0 109.901 173.576 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 26' ' ' ALA . . . . . 0.433 ' O ' HG13 ' A' ' 30' ' ' ILE . . . -60.26 -45.75 92.2 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.439 -0.8 . . . . 0.0 111.098 177.825 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.438 ' HA ' HD12 ' A' ' 30' ' ' ILE . 76.0 t -55.45 -43.7 73.09 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 CA-C-N 116.389 -0.369 . . . . 0.0 110.896 178.887 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 28' ' ' TYR . . . . . 0.446 ' HB2' ' CD2' ' A' ' 138' ' ' TYR . 54.3 t80 -59.49 -43.12 93.39 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.428 179.339 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 65.2 mt -65.68 -44.4 93.43 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.427 178.668 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.713 HG12 HG23 ' A' ' 54' ' ' ILE . 85.5 mt -57.63 -45.82 86.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.969 178.378 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 62.6 mtt180 -68.39 -28.59 67.23 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.193 0.521 . . . . 0.0 111.474 -177.74 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 74.6 m -88.84 -0.4 57.32 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.555 -178.566 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 24.3 p -128.11 -83.73 0.59 Allowed 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.805 0.336 . . . . 0.0 111.01 177.517 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 108.34 160.88 20.4 Favored Glycine 0 N--CA 1.449 -0.477 0 C-N-CA 120.975 -0.631 . . . . 0.0 112.228 -179.891 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 24.5 Cg_exo -63.14 146.0 94.02 Favored 'Trans proline' 0 C--O 1.233 0.269 0 C-N-CA 122.893 2.395 . . . . 0.0 112.178 178.877 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 94.1 -23.05 33.2 Favored Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 120.925 -0.655 . . . . 0.0 112.621 179.001 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 15.7 p -81.62 -171.85 3.54 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 -179.313 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 38' ' ' ARG . . . . . 1.085 ' HG3' ' HA ' ' A' ' 90' ' ' ALA . 17.5 ptm180 -131.2 130.77 43.39 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 121.036 0.446 . . . . 0.0 110.222 173.895 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.429 HG13 ' HB3' ' A' ' 92' ' ' LEU . 86.7 t -129.73 134.15 63.72 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 CA-C-N 115.804 -0.635 . . . . 0.0 109.351 -177.983 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.45 HG22 ' HB ' ' A' ' 63' ' ' VAL . 45.3 t -109.86 125.45 67.05 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-O 120.952 0.406 . . . . 0.0 111.433 -175.431 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 45.1 tt0 -101.64 120.53 40.48 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.927 -0.579 . . . . 0.0 109.711 175.091 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.484 ' HB ' ' OG ' ' A' ' 95' ' ' SER . 41.8 t -98.22 123.34 50.67 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.265 -179.418 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 97.37 27.31 9.33 Favored Glycine 0 N--CA 1.45 -0.43 0 N-CA-C 111.224 -0.751 . . . . 0.0 111.224 -176.777 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -85.25 76.43 10.16 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.09 0.471 . . . . 0.0 110.863 -177.814 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -111.0 -70.4 0.61 Allowed Glycine 0 N--CA 1.444 -0.807 0 C-N-CA 120.45 -0.881 . . . . 0.0 112.538 -179.421 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -119.03 11.17 12.38 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 120.694 0.283 . . . . 0.0 111.118 -175.872 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 42.2 t80 -130.0 70.75 1.43 Allowed 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 121.275 0.56 . . . . 0.0 109.93 178.519 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 82.1 mt -93.36 20.12 7.49 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.771 -178.656 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 49' ' ' TYR . . . . . 0.413 ' HE2' ' HB2' ' A' ' 22' ' ' TRP . 44.9 t80 -63.54 -39.58 94.79 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.955 -177.881 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.463 ' O ' HG13 ' A' ' 54' ' ' ILE . 59.7 t -75.58 -54.4 13.96 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.546 -179.159 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 1.5 p -60.92 -46.77 89.36 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.8 -0.636 . . . . 0.0 112.638 -175.751 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.426 ' O ' ' HG2' ' A' ' 56' ' ' LYS . 38.9 t70 -63.75 -38.1 89.82 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.847 0.356 . . . . 0.0 110.393 -178.131 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 65.6 t80 -61.21 -45.62 93.83 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.376 177.78 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.713 HG23 HG12 ' A' ' 30' ' ' ILE . 83.3 mt -58.64 -48.41 85.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 115.903 -0.59 . . . . 0.0 111.465 -179.033 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 39.1 ptt180 -72.85 -16.77 61.59 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 111.776 0.287 . . . . 0.0 111.776 -175.888 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 56' ' ' LYS . . . . . 0.935 ' HA ' ' HE2' ' A' ' 56' ' ' LYS . 8.1 mmpt? -73.01 -41.87 63.81 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.798 0.333 . . . . 0.0 110.27 174.882 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 31.0 m-70 -84.44 -52.52 6.11 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.213 -178.837 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 10.5 p -111.65 129.42 56.09 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.153 -178.492 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -82.39 62.34 6.02 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.991 0.901 . . . . 0.0 109.745 176.146 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.41 HG21 HG23 ' A' ' 39' ' ' VAL . 2.3 p -87.43 143.92 10.31 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.935 0 CA-C-N 114.573 -1.194 . . . . 0.0 108.357 171.442 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 61' ' ' ASP . . . . . 0.48 ' O ' ' HA ' ' A' ' 38' ' ' ARG . 22.8 t0 -75.57 86.99 2.67 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-O 121.647 0.737 . . . . 0.0 109.427 177.706 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 1.5 tt -85.64 122.93 30.45 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.432 -0.804 . . . . 0.0 110.027 -176.208 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.45 ' HB ' HG22 ' A' ' 40' ' ' VAL . 47.6 t -103.75 118.14 50.38 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.698 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.753 -179.276 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 64' ' ' LEU . . . . . 0.579 ' CB ' HG23 ' A' ' 74' ' ' ILE . 77.8 mt -95.69 133.22 40.03 Favored 'General case' 0 C--N 1.315 -0.906 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.067 -179.053 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.493 HG22 ' HB ' ' A' ' 75' ' ' VAL . 23.7 p -129.61 135.01 48.04 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 120.45 0.167 . . . . 0.0 111.188 179.704 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 66' ' ' ASP . . . . . 0.804 ' HB3' ' HG3' ' A' ' 69' ' ' PRO . 25.3 t70 -165.25 173.61 11.1 Favored 'General case' 0 C--O 1.234 0.278 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 178.746 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.533 HD11 HG22 ' A' ' 79' ' ' ILE . 39.2 mm -81.26 96.64 3.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-O 120.958 0.408 . . . . 0.0 110.78 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 68' ' ' LYS . . . . . 0.408 ' HD3' ' HB2' ' A' ' 76' ' ' ARG . 70.3 mmtt 53.1 66.9 4.25 Favored Pre-proline 0 N--CA 1.467 0.407 0 CA-C-N 115.277 -0.874 . . . . 0.0 111.513 177.481 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 69' ' ' PRO . . . . . 0.804 ' HG3' ' HB3' ' A' ' 66' ' ' ASP . 17.1 Cg_exo . . . . . 0 C--O 1.234 0.281 0 C-N-CA 123.164 2.576 . . . . 0.0 112.172 -178.09 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.579 HG23 ' CB ' ' A' ' 64' ' ' LEU . 39.7 mt . . . . . 0 C--O 1.233 0.187 0 N-CA-C 110.188 -0.301 . . . . 0.0 110.188 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.635 HG11 HD13 ' A' ' 86' ' ' ILE . 61.0 t -64.45 129.95 28.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 121.031 0.444 . . . . 0.0 110.563 -179.15 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 76' ' ' ARG . . . . . 0.454 ' HA ' ' HD3' ' A' ' 69' ' ' PRO . 5.4 ptp180 -104.12 28.97 6.29 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.655 -173.883 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 77' ' ' ASP . . . . . 0.5 ' H ' HG12 ' A' ' 75' ' ' VAL . 11.3 t70 -69.94 -84.74 0.03 OUTLIER 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.851 -0.613 . . . . 0.0 111.272 -172.88 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 78' ' ' ASP . . . . . 0.4 ' H ' ' HB3' ' A' ' 77' ' ' ASP . 7.5 t70 -163.24 -169.64 2.05 Favored 'General case' 0 C--N 1.325 -0.5 0 N-CA-C 109.091 -0.707 . . . . 0.0 109.091 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 79' ' ' ILE . . . . . 0.533 HG22 HD11 ' A' ' 67' ' ' ILE . 13.0 tt -144.19 -28.04 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-O 121.013 0.435 . . . . 0.0 110.749 -179.118 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.517 ' HA ' HG21 ' A' ' 102' ' ' ILE . 14.7 t -103.3 -24.52 13.51 Favored 'General case' 0 N--CA 1.45 -0.44 0 CA-C-O 121.288 0.566 . . . . 0.0 110.058 -178.047 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 68.0 m -150.13 75.17 9.0 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.27 172.871 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 82' ' ' PRO . . . . . 0.476 ' HB2' ' HE2' ' A' ' 87' ' ' TYR . 9.1 Cg_endo -89.64 174.04 3.53 Favored 'Trans proline' 0 N--CA 1.454 -0.824 0 C-N-CA 123.267 2.645 . . . . 0.0 112.887 -177.08 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 83' ' ' ARG . . . . . 0.692 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 81.6 mtt85 -78.3 118.01 20.09 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.152 176.663 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 84' ' ' MET . . . . . 0.463 ' HE1' ' HA ' ' A' ' 109' ' ' VAL . 91.7 mmm -61.64 -23.77 66.28 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.302 -0.863 . . . . 0.0 111.565 -178.183 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.692 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 8.6 pt-20 -56.9 -29.34 62.93 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.842 0.354 . . . . 0.0 111.417 179.692 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.635 HD13 HG11 ' A' ' 75' ' ' VAL . 54.9 mt -79.28 -24.87 12.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-O 121.199 0.523 . . . . 0.0 110.858 -176.227 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 87' ' ' TYR . . . . . 0.476 ' HE2' ' HB2' ' A' ' 82' ' ' PRO . 91.5 m-85 -94.51 -27.67 15.85 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.934 -0.576 . . . . 0.0 111.193 -177.159 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 88' ' ' ARG . . . . . 0.446 ' HG3' ' O ' ' A' ' 84' ' ' MET . 78.1 mtp180 -65.77 131.46 46.37 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.509 0.671 . . . . 0.0 111.454 -176.552 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 93.17 -5.78 75.44 Favored Glycine 0 N--CA 1.448 -0.521 0 CA-C-N 114.798 -1.092 . . . . 0.0 112.36 -179.899 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 90' ' ' ALA . . . . . 1.085 ' HA ' ' HG3' ' A' ' 38' ' ' ARG . . . -73.6 153.39 40.22 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.888 0.375 . . . . 0.0 110.63 179.432 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -93.85 -20.72 19.79 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.807 -179.415 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 92' ' ' LEU . . . . . 0.513 ' HG ' ' HB3' ' A' ' 116' ' ' ARG . 3.7 tt -160.89 142.87 12.33 Favored 'General case' 0 N--CA 1.452 -0.365 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.64 -176.809 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.533 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 66.8 mt -132.31 126.72 56.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 177.188 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 19.7 p90 -137.38 160.78 38.11 Favored 'General case' 0 C--N 1.323 -0.579 0 C-N-CA 120.52 -0.472 . . . . 0.0 111.625 -178.155 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 95' ' ' SER . . . . . 0.484 ' OG ' ' HB ' ' A' ' 42' ' ' VAL . 15.7 m -146.5 140.52 26.25 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.777 -178.565 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 96' ' ' ILE . . . . . 0.426 ' N ' HD12 ' A' ' 96' ' ' ILE . 3.6 mp -99.31 97.1 5.52 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 N-CA-C 110.026 -0.361 . . . . 0.0 110.026 178.728 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 97' ' ' ARG . . . . . 0.644 ' HG2' ' HA ' ' A' ' 121' ' ' PRO . 42.8 mtm105 53.77 77.25 0.45 Allowed Pre-proline 0 N--CA 1.468 0.467 0 CA-C-N 115.413 -0.812 . . . . 0.0 111.825 179.612 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 95.7 Cg_endo -88.46 159.42 6.64 Favored 'Trans proline' 0 N--CA 1.459 -0.514 0 C-N-CA 122.733 2.288 . . . . 0.0 112.417 179.775 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 99' ' ' PRO . . . . . 0.626 ' HD2' HD11 ' A' ' 102' ' ' ILE . 51.1 Cg_exo -53.85 147.8 40.11 Favored 'Trans proline' 0 C--N 1.348 0.507 0 C-N-CA 122.92 2.414 . . . . 0.0 112.115 175.955 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -66.92 -19.74 65.78 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.712 -173.164 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 101' ' ' GLU . . . . . 0.586 ' HG3' HG23 ' A' ' 102' ' ' ILE . 11.7 pt-20 -73.34 -22.47 60.3 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.881 -177.334 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.626 HD11 ' HD2' ' A' ' 99' ' ' PRO . 44.1 pt -109.31 5.51 9.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 N-CA-C 112.505 0.557 . . . . 0.0 112.505 -174.711 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 103' ' ' HIS . . . . . . . . . . . . . 46.9 m170 -58.33 -45.22 88.51 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 120.998 0.427 . . . . 0.0 110.624 178.812 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 17.6 m -75.35 -27.79 59.33 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.518 177.31 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.511 ' O ' HG23 ' A' ' 109' ' ' VAL . 10.2 m -69.98 -45.15 67.95 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.896 -177.896 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 84.2 mt -56.78 -38.28 72.29 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.037 0.446 . . . . 0.0 110.822 178.717 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 107' ' ' MET . . . . . 0.408 ' HA ' HD22 ' A' ' 117' ' ' LEU . 52.0 ttm -68.4 -42.59 78.79 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.473 -178.92 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 108' ' ' ARG . . . . . 0.445 ' HG2' ' HA ' ' A' ' 105' ' ' SER . 2.5 ptm180 -68.71 -29.92 68.46 Favored 'General case' 0 N--CA 1.462 0.137 0 C-N-CA 120.471 -0.492 . . . . 0.0 110.482 179.482 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.511 HG23 ' O ' ' A' ' 105' ' ' SER . 74.5 t -66.12 -47.6 84.28 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.182 0 CA-C-N 116.453 -0.34 . . . . 0.0 110.274 176.165 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -57.74 -43.74 85.59 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.393 177.553 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.418 ' HA ' ' HB1' ' A' ' 148' ' ' ALA . 18.7 t70 -61.83 -40.43 95.24 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.625 -0.716 . . . . 0.0 110.793 179.777 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -69.4 -39.6 77.86 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.551 -0.749 . . . . 0.0 112.059 -177.859 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.462 HG21 HD11 ' A' ' 93' ' ' ILE . 15.8 m -92.39 -27.42 4.7 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 116.552 -0.294 . . . . 0.0 111.709 -174.556 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 86.47 51.56 3.45 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.827 -0.701 . . . . 0.0 112.535 -179.782 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 115' ' ' ALA . . . . . 0.449 ' O ' ' HB3' ' A' ' 148' ' ' ALA . . . -131.67 165.55 23.46 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.064 0.459 . . . . 0.0 111.162 -178.683 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 116' ' ' ARG . . . . . 0.513 ' HB3' ' HG ' ' A' ' 92' ' ' LEU . 15.3 ttm180 -81.87 128.74 34.35 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.037 176.485 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 117' ' ' LEU . . . . . 0.533 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 49.8 tp -99.18 127.85 45.22 Favored 'General case' 0 C--N 1.32 -0.704 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 177.859 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 72.4 mt -128.25 125.51 64.34 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-O 120.903 0.382 . . . . 0.0 110.591 179.347 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 61.4 mt -130.27 130.45 65.56 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-O 120.811 0.339 . . . . 0.0 110.263 178.051 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 120' ' ' LYS . . . . . 0.716 ' HD2' HD22 ' A' ' 25' ' ' LEU . 49.9 tttm -116.16 94.23 41.4 Favored Pre-proline 0 C--N 1.324 -0.51 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.227 179.176 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 121' ' ' PRO . . . . . 0.644 ' HA ' ' HG2' ' A' ' 97' ' ' ARG . 89.1 Cg_endo -89.98 -159.7 0.09 OUTLIER 'Trans proline' 0 N--CA 1.459 -0.532 0 C-N-CA 122.799 2.333 . . . . 0.0 112.694 178.101 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 122' ' ' LEU . . . . . 0.54 ' HB3' ' HB3' ' A' ' 125' ' ' GLU . 11.9 tp -76.0 164.2 26.4 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.525 -0.762 . . . . 0.0 110.354 177.365 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 11.4 t -72.73 -28.58 62.73 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.008 0.432 . . . . 0.0 110.366 178.854 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -109.34 44.56 1.47 Allowed Glycine 0 N--CA 1.449 -0.469 0 N-CA-C 110.967 -0.853 . . . . 0.0 110.967 177.105 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 125' ' ' GLU . . . . . 0.54 ' HB3' ' HB3' ' A' ' 122' ' ' LEU . 31.8 tt0 -147.72 139.25 23.81 Favored 'General case' 0 C--N 1.321 -0.667 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 -174.539 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 17.2 t70 -118.82 161.7 19.7 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 121.068 0.461 . . . . 0.0 111.076 -178.667 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 60.7 mt . . . . . 0 C--N 1.319 -0.717 0 CA-C-N 115.353 -0.839 . . . . 0.0 109.311 177.606 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 132' ' ' LYS . . . . . 0.414 ' HG2' ' N ' ' A' ' 133' ' ' MET . 0.0 OUTLIER . . . . . 0 N--CA 1.465 0.303 0 CA-C-O 121.614 0.721 . . . . 0.0 111.898 . . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 133' ' ' MET . . . . . 0.414 ' N ' ' HG2' ' A' ' 132' ' ' LYS . 90.2 mtp -109.58 160.74 16.0 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.458 -0.792 . . . . 0.0 109.93 -178.759 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 134' ' ' LYS . . . . . 0.413 ' HE3' HG13 ' A' ' 136' ' ' VAL . 0.0 OUTLIER -95.83 142.7 27.78 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.088 0.471 . . . . 0.0 110.793 -176.062 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 135' ' ' LEU . . . . . 0.754 HD11 ' HD2' ' A' ' 142' ' ' TYR . 43.5 tp -75.35 131.35 40.2 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-N 115.45 -0.795 . . . . 0.0 110.317 178.833 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 136' ' ' VAL . . . . . 0.413 HG13 ' HE3' ' A' ' 134' ' ' LYS . 0.0 OUTLIER -128.22 137.73 56.63 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.755 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.542 178.564 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 19.5 m-80 -112.28 106.55 15.14 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 115.652 -0.704 . . . . 0.0 110.105 -179.941 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 138' ' ' TYR . . . . . 0.446 ' CD2' ' HB2' ' A' ' 28' ' ' TYR . 59.8 t80 -148.77 127.62 12.61 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.909 -178.41 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 139' ' ' GLY . . . . . 0.714 ' HA3' ' HB3' ' A' ' 24' ' ' ASP . . . 67.78 57.8 8.41 Favored Glycine 0 N--CA 1.445 -0.745 0 CA-C-N 115.807 -0.633 . . . . 0.0 114.166 171.223 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 140' ' ' ARG . . . . . 0.52 ' HD2' ' N ' ' A' ' 140' ' ' ARG . 2.4 mpt_? 62.6 10.91 4.4 Favored 'General case' 0 N--CA 1.465 0.316 0 C-N-CA 122.692 0.397 . . . . 0.0 112.059 173.84 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 10.6 t -145.7 153.01 40.52 Favored 'General case' 0 N--CA 1.447 -0.592 0 CA-C-O 120.973 0.416 . . . . 0.0 110.326 -179.813 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 142' ' ' TYR . . . . . 0.754 ' HD2' HD11 ' A' ' 135' ' ' LEU . 5.0 p90 -122.26 137.73 54.74 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 116.052 -0.522 . . . . 0.0 109.716 174.518 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 143' ' ' PHE . . . . . 0.423 ' O ' HD12 ' A' ' 135' ' ' LEU . 21.4 p90 -145.43 -169.64 3.26 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.466 -0.788 . . . . 0.0 109.796 -174.024 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 83.4 m-85 -117.54 137.27 52.68 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 120.754 0.311 . . . . 0.0 110.932 179.903 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 145' ' ' GLU . . . . . 0.407 ' OE1' ' HD3' ' A' ' 116' ' ' ARG . 15.8 pt-20 -130.36 162.42 29.12 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.157 -0.474 . . . . 0.0 109.731 173.737 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 40.7 t80 -142.38 124.24 15.18 Favored 'General case' 0 C--N 1.317 -0.831 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 174.672 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 147' ' ' ILE . . . . . 0.417 HD12 ' N ' ' A' ' 147' ' ' ILE . 2.7 mp -93.93 98.69 8.49 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.68 0 N-CA-C 109.52 -0.548 . . . . 0.0 109.52 -179.366 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 148' ' ' ALA . . . . . 0.449 ' HB3' ' O ' ' A' ' 115' ' ' ALA . . . -86.89 108.74 18.91 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.625 176.663 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 . . . . . 0 C--N 1.319 -0.719 0 CA-C-O 121.136 0.493 . . . . 0.0 110.601 -179.372 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 22' ' ' TRP . . . . . 0.404 ' O ' ' HB3' ' A' ' 25' ' ' LEU . 89.3 m95 . . . . . 0 N--CA 1.454 -0.243 0 CA-C-O 120.626 0.25 . . . . 0.0 111.057 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 21.0 t-20 -52.34 -50.47 62.25 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.889 -178.776 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 11.3 m-20 -60.5 -33.49 72.69 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.476 -0.329 . . . . 0.0 111.42 -178.22 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.567 HD22 ' HG3' ' A' ' 120' ' ' LYS . 50.6 tp -59.17 -50.65 73.21 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.926 0.393 . . . . 0.0 110.28 176.955 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 26' ' ' ALA . . . . . 0.403 ' HB2' HG13 ' A' ' 50' ' ' VAL . . . -58.49 -49.66 76.54 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.639 179.47 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.427 ' O ' ' HG3' ' A' ' 31' ' ' ARG . 86.4 t -52.74 -46.51 50.8 Favored 'Isoleucine or valine' 0 C--O 1.233 0.209 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.949 177.893 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 86.0 t80 -56.29 -46.18 79.88 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.882 179.417 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 71.1 mt -66.78 -43.08 90.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.972 -179.484 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.422 HG12 HG23 ' A' ' 54' ' ' ILE . 88.9 mt -56.4 -48.79 79.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 115.817 -0.628 . . . . 0.0 111.067 179.216 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 31' ' ' ARG . . . . . 0.427 ' HG3' ' O ' ' A' ' 27' ' ' VAL . 61.9 mtp180 -63.25 -36.41 83.58 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.904 -0.589 . . . . 0.0 111.072 -178.808 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 46.6 t -77.29 -25.92 51.83 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.333 -175.338 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 13.7 p -97.03 -76.63 0.51 Allowed 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.785 0.326 . . . . 0.0 111.301 -177.865 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.505 ' O ' HG22 ' A' ' 37' ' ' THR . . . 98.22 167.54 31.54 Favored Glycine 0 N--CA 1.449 -0.452 0 C-N-CA 120.951 -0.642 . . . . 0.0 112.13 -178.601 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 6.7 Cg_exo -73.42 143.54 34.98 Favored 'Trans proline' 0 N--CA 1.462 -0.327 0 C-N-CA 122.878 2.385 . . . . 0.0 112.379 -179.36 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 97.19 -11.29 65.6 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.67 -0.776 . . . . 0.0 113.441 176.218 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 37' ' ' THR . . . . . 0.505 HG22 ' O ' ' A' ' 34' ' ' GLY . 12.6 t -103.52 -179.02 3.83 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 177.501 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 38' ' ' ARG . . . . . 0.681 ' HB2' ' HA ' ' A' ' 90' ' ' ALA . 62.5 mtp180 -115.11 136.63 52.91 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.809 0.338 . . . . 0.0 110.763 -179.227 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.429 HG23 HG21 ' A' ' 60' ' ' VAL . 47.5 t -130.9 138.18 54.16 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 177.913 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.454 HG11 ' CE1' ' A' ' 87' ' ' TYR . 33.4 t -118.95 125.45 74.5 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 CA-C-O 120.837 0.351 . . . . 0.0 111.336 -177.254 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 41' ' ' GLU . . . . . 0.436 ' HB3' HD23 ' A' ' 64' ' ' LEU . 43.4 tt0 -99.57 112.15 24.4 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.954 -0.566 . . . . 0.0 109.645 175.462 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 60.5 t -97.45 121.16 47.69 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-N 116.0 -0.546 . . . . 0.0 110.385 -179.143 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 90.35 46.04 4.19 Favored Glycine 0 N--CA 1.444 -0.795 0 C-N-CA 120.539 -0.839 . . . . 0.0 111.861 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.442 ' HB1' ' CD2' ' A' ' 48' ' ' LEU . . . -59.22 -32.94 70.41 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-O 121.328 0.585 . . . . 0.0 110.932 179.292 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 63.88 -123.57 28.74 Favored Glycine 0 N--CA 1.445 -0.701 0 CA-C-N 115.714 -0.675 . . . . 0.0 112.597 177.104 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 30.5 mmt-85 -122.96 9.77 9.41 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 120.847 0.356 . . . . 0.0 110.498 -177.005 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 19.0 p90 -137.36 113.24 9.69 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 121.289 0.566 . . . . 0.0 110.82 -176.845 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.442 ' CD2' ' HB1' ' A' ' 44' ' ' ALA . 68.8 mt -104.64 60.87 0.7 Allowed 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.56 -177.164 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 72.1 t80 -75.56 -52.84 9.68 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.938 0.399 . . . . 0.0 110.88 -179.559 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.45 ' O ' HG13 ' A' ' 54' ' ' ILE . 49.1 t -67.87 -52.78 36.15 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-N 115.868 -0.606 . . . . 0.0 110.722 -176.562 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 51' ' ' SER . . . . . 0.529 ' HB3' HD21 ' A' ' 64' ' ' LEU . 0.2 OUTLIER -54.84 -43.15 72.76 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.767 -0.651 . . . . 0.0 112.491 -178.933 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.417 ' O ' ' HG3' ' A' ' 56' ' ' LYS . 20.7 t70 -67.73 -42.96 81.05 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.834 0.349 . . . . 0.0 110.591 -179.104 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 75.9 t80 -63.99 -40.08 95.57 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.153 -179.009 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.45 HG13 ' O ' ' A' ' 50' ' ' VAL . 80.0 mt -63.01 -45.78 97.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.474 -0.33 . . . . 0.0 111.367 -179.709 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 33.2 ptt180 -72.04 -16.84 62.05 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.89 0.376 . . . . 0.0 110.871 -178.785 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 56' ' ' LYS . . . . . 0.417 ' HG3' ' O ' ' A' ' 52' ' ' ASP . 24.2 mtpp -73.08 -30.55 63.75 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.318 176.882 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 28.0 m-70 -102.51 -56.61 2.21 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.891 -177.434 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 6.8 p -100.46 135.4 41.95 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 120.982 0.42 . . . . 0.0 112.057 -174.399 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -81.39 65.05 6.36 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 122.196 0.998 . . . . 0.0 108.969 171.053 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.429 HG21 HG23 ' A' ' 39' ' ' VAL . 8.8 p -100.54 148.54 6.77 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.09 0 CA-C-N 114.322 -1.308 . . . . 0.0 110.111 178.78 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 61' ' ' ASP . . . . . 0.563 ' HB3' ' HG2' ' A' ' 38' ' ' ARG . 9.3 t70 -74.77 84.89 2.16 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 176.773 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 62' ' ' LEU . . . . . 0.425 HD23 ' HB ' ' A' ' 39' ' ' VAL . 3.1 tm? -94.57 116.83 29.24 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 115.441 -0.799 . . . . 0.0 110.287 -173.92 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 60.1 t -113.61 139.09 40.89 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 CA-C-N 115.604 -0.725 . . . . 0.0 110.561 -176.524 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 64' ' ' LEU . . . . . 0.529 HD21 ' HB3' ' A' ' 51' ' ' SER . 31.6 mt -112.37 136.12 52.23 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 110.171 -0.307 . . . . 0.0 110.171 178.735 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 15.9 p -118.81 125.43 49.55 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.102 0.477 . . . . 0.0 110.706 175.366 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 66' ' ' ASP . . . . . 0.478 ' HB3' HG21 ' A' ' 74' ' ' ILE . 23.9 t70 -154.82 140.46 17.98 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.532 -0.758 . . . . 0.0 109.247 -179.853 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.496 HG22 ' HG2' ' A' ' 68' ' ' LYS . 59.3 mt -74.44 124.17 31.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-N 116.519 -0.31 . . . . 0.0 110.315 -177.964 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 68' ' ' LYS . . . . . 0.496 ' HG2' HG22 ' A' ' 67' ' ' ILE . 59.8 pttt 39.72 69.72 1.66 Allowed Pre-proline 0 N--CA 1.469 0.499 0 O-C-N 124.29 0.994 . . . . 0.0 111.684 -174.296 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 69' ' ' PRO . . . . . 0.561 ' CB ' ' HB ' ' A' ' 74' ' ' ILE . 44.1 Cg_endo . . . . . 0 C--O 1.232 0.218 0 C-N-CA 122.856 2.371 . . . . 0.0 113.017 -174.345 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.561 ' HB ' ' CB ' ' A' ' 69' ' ' PRO . 55.3 mt . . . . . 0 N--CA 1.453 -0.291 0 N-CA-C 109.713 -0.477 . . . . 0.0 109.713 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.555 HG11 HD13 ' A' ' 86' ' ' ILE . 66.3 t -66.27 123.72 19.85 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-O 120.884 0.374 . . . . 0.0 110.266 -179.344 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 18.7 ptp180 -85.9 48.61 1.63 Allowed 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.44 0.638 . . . . 0.0 110.695 -176.251 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 77' ' ' ASP . . . . . 0.43 ' HB2' HG12 ' A' ' 75' ' ' VAL . 2.7 t70 -89.17 -154.56 0.31 Allowed 'General case' 0 C--N 1.321 -0.641 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 179.214 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 78' ' ' ASP . . . . . 0.521 ' OD1' HG22 ' A' ' 80' ' ' THR . 4.9 t70 -136.25 -176.42 4.32 Favored 'General case' 0 C--N 1.321 -0.633 0 C-N-CA 120.737 -0.385 . . . . 0.0 110.251 -178.916 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 8.9 tp -127.37 -28.18 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-O 120.822 0.344 . . . . 0.0 110.502 179.71 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.521 HG22 ' OD1' ' A' ' 78' ' ' ASP . 15.0 t -89.06 -25.75 21.77 Favored 'General case' 0 N--CA 1.451 -0.387 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 177.006 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 34.2 t -135.34 70.5 67.91 Favored Pre-proline 0 C--N 1.326 -0.442 0 CA-C-N 115.33 -0.85 . . . . 0.0 108.997 170.822 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_endo -87.32 157.01 8.11 Favored 'Trans proline' 0 N--CA 1.453 -0.909 0 C-N-CA 122.496 2.131 . . . . 0.0 112.518 -176.146 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 83' ' ' ARG . . . . . 0.765 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 50.0 mtt180 -89.12 111.92 22.79 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.199 173.058 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 84' ' ' MET . . . . . 0.523 ' HE1' ' HA ' ' A' ' 109' ' ' VAL . 95.2 mmm -66.83 -17.65 64.99 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.5 -177.62 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.765 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 9.9 pt-20 -62.35 -23.35 66.74 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.628 -0.714 . . . . 0.0 111.508 179.078 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.555 HD13 HG11 ' A' ' 75' ' ' VAL . 67.3 mt -84.36 -39.54 14.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-O 121.117 0.484 . . . . 0.0 110.363 179.724 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 87' ' ' TYR . . . . . 0.454 ' CE1' HG11 ' A' ' 40' ' ' VAL . 90.7 m-85 -78.86 -32.19 45.9 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.756 -0.657 . . . . 0.0 111.322 -177.881 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 88' ' ' ARG . . . . . 0.438 ' HG3' HG12 ' A' ' 113' ' ' VAL . 57.9 mtt180 -67.01 115.33 6.6 Favored 'General case' 0 CA--C 1.516 -0.339 0 CA-C-O 121.317 0.58 . . . . 0.0 110.633 -179.933 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 119.44 -12.05 11.23 Favored Glycine 0 N--CA 1.448 -0.522 0 CA-C-N 115.037 -0.983 . . . . 0.0 111.455 -175.213 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 90' ' ' ALA . . . . . 0.681 ' HA ' ' HB2' ' A' ' 38' ' ' ARG . . . -82.94 147.74 28.06 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.881 0.372 . . . . 0.0 110.898 178.346 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -96.73 -22.26 17.09 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.811 179.529 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 92' ' ' LEU . . . . . 0.462 ' HG ' ' HB3' ' A' ' 116' ' ' ARG . 5.3 tt -150.85 139.79 20.95 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.682 -178.442 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.569 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 67.5 mt -131.57 125.37 56.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.688 -0.687 . . . . 0.0 109.258 178.69 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 19.0 p90 -128.42 155.48 44.69 Favored 'General case' 0 C--N 1.321 -0.645 0 C-N-CA 120.618 -0.433 . . . . 0.0 110.965 -178.961 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 18.3 m -132.74 130.41 39.94 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.554 -178.436 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 65.4 mt -93.55 103.14 14.37 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.682 -178.894 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 70.6 mtp180 54.38 67.36 3.45 Favored Pre-proline 0 N--CA 1.466 0.329 0 CA-C-N 115.489 -0.778 . . . . 0.0 111.998 -178.517 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 98' ' ' PRO . . . . . 0.447 ' HA ' ' HD3' ' A' ' 99' ' ' PRO . 72.5 Cg_endo -76.91 140.58 20.53 Favored 'Trans proline' 0 N--CA 1.461 -0.402 0 C-N-CA 122.244 1.963 . . . . 0.0 112.251 179.615 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 99' ' ' PRO . . . . . 0.626 ' HD2' HD11 ' A' ' 102' ' ' ILE . 38.1 Cg_exo -60.2 147.56 93.01 Favored 'Trans proline' 0 C--O 1.235 0.331 0 C-N-CA 122.741 2.294 . . . . 0.0 111.942 176.606 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 100' ' ' ALA . . . . . 0.64 ' HA ' ' NE2' ' A' ' 103' ' ' HIS . . . -78.54 31.15 0.19 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.227 0.537 . . . . 0.0 111.331 -175.542 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 101' ' ' GLU . . . . . 0.565 ' HG2' ' HB2' ' A' ' 99' ' ' PRO . 7.7 pt-20 -127.55 -1.63 6.16 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-N 115.967 -0.561 . . . . 0.0 111.164 -176.908 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.626 HD11 ' HD2' ' A' ' 99' ' ' PRO . 30.9 pt -131.41 10.33 1.83 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 N-CA-C 112.118 0.414 . . . . 0.0 112.118 -178.308 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 103' ' ' HIS . . . . . 0.64 ' NE2' ' HA ' ' A' ' 100' ' ' ALA . 9.7 m-70 -54.77 -51.65 65.06 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.244 -0.435 . . . . 0.0 112.006 -176.738 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 15.5 m -62.54 -32.49 73.44 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.498 -0.319 . . . . 0.0 111.007 -177.939 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.592 ' O ' HG23 ' A' ' 109' ' ' VAL . 21.0 m -67.45 -42.3 83.32 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.329 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 73.9 mt -64.78 -43.96 91.54 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.493 179.56 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 107' ' ' MET . . . . . 0.4 ' HG3' ' O ' ' A' ' 103' ' ' HIS . 77.0 mtp -63.18 -41.8 99.27 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.55 -176.244 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 2.9 ptp180 -70.27 -30.78 67.89 Favored 'General case' 0 C--N 1.332 -0.189 0 C-N-CA 120.879 -0.329 . . . . 0.0 111.145 -178.497 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.592 HG23 ' O ' ' A' ' 105' ' ' SER . 75.3 t -63.87 -45.2 97.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.889 0.376 . . . . 0.0 110.062 177.466 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -58.42 -44.4 89.07 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.619 177.71 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.455 ' HA ' ' HB1' ' A' ' 148' ' ' ALA . 13.6 t70 -64.84 -42.48 94.88 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.059 179.586 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -64.8 -41.74 95.56 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.712 -0.676 . . . . 0.0 112.055 -177.488 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.438 HG12 ' HG3' ' A' ' 88' ' ' ARG . 12.2 m -92.57 -24.78 5.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 CA-C-N 116.506 -0.315 . . . . 0.0 111.694 -174.983 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 88.43 49.33 3.71 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.764 -0.731 . . . . 0.0 111.997 179.731 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -129.07 156.5 43.76 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 120.738 0.304 . . . . 0.0 111.142 -177.689 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 116' ' ' ARG . . . . . 0.534 ' HD3' ' OE1' ' A' ' 145' ' ' GLU . 16.4 ttm180 -80.26 125.16 29.52 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.158 -0.474 . . . . 0.0 109.728 177.549 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 117' ' ' LEU . . . . . 0.569 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 48.7 tp -94.47 119.31 32.99 Favored 'General case' 0 C--N 1.322 -0.619 0 N-CA-C 110.158 -0.312 . . . . 0.0 110.158 179.815 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 63.9 mt -114.91 117.97 57.31 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-O 121.183 0.516 . . . . 0.0 110.732 179.398 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 64.6 mt -112.03 132.22 61.28 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 115.923 -0.581 . . . . 0.0 110.564 179.829 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 120' ' ' LYS . . . . . 0.953 ' HD2' ' HB3' ' A' ' 143' ' ' PHE . 23.1 mmmt -102.58 99.97 14.8 Favored Pre-proline 0 C--N 1.328 -0.347 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.229 174.419 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 121' ' ' PRO . . . . . 0.425 ' HG3' ' HD2' ' A' ' 144' ' ' TYR . 88.4 Cg_endo -82.78 -158.95 0.1 OUTLIER 'Trans proline' 0 N--CA 1.459 -0.535 0 C-N-CA 122.563 2.175 . . . . 0.0 111.351 171.861 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 122' ' ' LEU . . . . . 0.829 ' HB2' ' HB2' ' A' ' 125' ' ' GLU . 3.6 mm? -99.88 -171.04 1.98 Allowed 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 110.267 -0.272 . . . . 0.0 110.267 179.916 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 8.7 t -88.76 -35.11 16.85 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.708 0.289 . . . . 0.0 111.19 -176.719 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -114.78 12.61 20.48 Favored Glycine 0 N--CA 1.449 -0.499 0 C-N-CA 120.436 -0.887 . . . . 0.0 111.296 178.53 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 125' ' ' GLU . . . . . 0.829 ' HB2' ' HB2' ' A' ' 122' ' ' LEU . 28.2 mt-10 -131.52 126.52 35.12 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.248 -0.476 . . . . 0.0 110.075 -176.342 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 11.3 t70 -87.01 179.28 6.71 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.679 -0.692 . . . . 0.0 109.885 -177.504 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 127' ' ' ILE . . . . . 0.58 HD11 ' HB2' ' A' ' 144' ' ' TYR . 56.5 mt . . . . . 0 C--N 1.326 -0.438 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 178.799 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 33.5 mttp . . . . . 0 CA--C 1.519 -0.212 0 CA-C-O 121.119 0.485 . . . . 0.0 111.03 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 133' ' ' MET . . . . . 0.55 ' HG2' ' HB2' ' A' ' 146' ' ' TYR . 84.8 mtp -111.14 165.63 11.74 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.857 -0.611 . . . . 0.0 109.405 176.144 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 134' ' ' LYS . . . . . 0.408 ' HE3' ' OE2' ' A' ' 145' ' ' GLU . 6.9 pttp -130.51 140.23 50.5 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.09 0.472 . . . . 0.0 111.754 -175.974 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 135' ' ' LEU . . . . . 0.57 HD11 ' HD2' ' A' ' 142' ' ' TYR . 39.2 tp -76.93 122.36 24.76 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.585 -0.734 . . . . 0.0 110.777 -179.645 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 136' ' ' VAL . . . . . 0.433 HG23 ' CD1' ' A' ' 143' ' ' PHE . 0.0 OUTLIER -117.95 142.25 33.23 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.761 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.437 178.426 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 137' ' ' ASN . . . . . 0.441 ' OD1' ' HB3' ' A' ' 142' ' ' TYR . 15.6 m-80 -117.9 110.32 17.6 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.442 -176.022 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 138' ' ' TYR . . . . . 0.436 ' O ' HG22 ' A' ' 141' ' ' THR . 76.0 t80 -135.23 130.09 34.69 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.248 -0.433 . . . . 0.0 109.877 -179.434 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 63.75 26.36 69.87 Favored Glycine 0 N--CA 1.453 -0.217 0 C-N-CA 120.54 -0.838 . . . . 0.0 111.702 -176.784 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 21.2 mtp180 66.67 7.69 5.34 Favored 'General case' 0 C--N 1.33 -0.274 0 C-N-CA 123.304 0.641 . . . . 0.0 112.436 -178.731 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 141' ' ' THR . . . . . 0.436 HG22 ' O ' ' A' ' 138' ' ' TYR . 10.8 t -107.48 139.71 41.57 Favored 'General case' 0 N--CA 1.446 -0.659 0 N-CA-C 108.663 -0.866 . . . . 0.0 108.663 169.84 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 142' ' ' TYR . . . . . 0.57 ' HD2' HD11 ' A' ' 135' ' ' LEU . 17.0 p90 -113.86 149.08 35.59 Favored 'General case' 0 C--N 1.315 -0.892 0 CA-C-O 121.69 0.757 . . . . 0.0 111.513 -177.581 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 143' ' ' PHE . . . . . 0.953 ' HB3' ' HD2' ' A' ' 120' ' ' LYS . 3.5 p90 -151.41 178.96 8.76 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 114.238 -1.347 . . . . 0.0 108.83 -178.98 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 144' ' ' TYR . . . . . 0.58 ' HB2' HD11 ' A' ' 127' ' ' ILE . 80.6 m-85 -115.58 119.72 37.06 Favored 'General case' 0 C--N 1.313 -0.98 0 C-N-CA 120.62 -0.432 . . . . 0.0 110.529 179.82 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 145' ' ' GLU . . . . . 0.534 ' OE1' ' HD3' ' A' ' 116' ' ' ARG . 18.3 pt-20 -108.15 156.96 18.73 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 176.2 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 146' ' ' TYR . . . . . 0.55 ' HB2' ' HG2' ' A' ' 133' ' ' MET . 22.7 t80 -137.13 120.68 17.17 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-N 115.626 -0.715 . . . . 0.0 109.66 176.647 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 147' ' ' ILE . . . . . 0.434 ' N ' HD12 ' A' ' 147' ' ' ILE . 3.2 mp -89.05 101.5 12.05 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 -178.481 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 148' ' ' ALA . . . . . 0.455 ' HB1' ' HA ' ' A' ' 111' ' ' ASP . . . -74.37 96.43 2.86 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 121.225 0.536 . . . . 0.0 109.76 177.19 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 11.6 pt-20 . . . . . 0 C--N 1.314 -0.941 0 CA-C-N 115.155 -0.93 . . . . 0.0 109.752 178.89 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 40.2 m95 . . . . . 0 N--CA 1.461 0.122 0 CA-C-O 121.033 0.444 . . . . 0.0 110.533 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 25.5 t-20 -65.18 -45.55 84.39 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.553 -0.749 . . . . 0.0 110.28 -178.024 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -57.24 -46.29 83.13 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.679 -0.691 . . . . 0.0 110.255 177.953 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 62.2 tp -61.52 -46.96 87.74 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.238 -0.892 . . . . 0.0 110.958 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' ALA . . . . . 0.487 ' O ' HG13 ' A' ' 30' ' ' ILE . . . -56.19 -52.47 64.28 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.164 -179.742 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.448 ' HA ' HD12 ' A' ' 30' ' ' ILE . 84.0 t -56.12 -42.25 71.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.206 179.131 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 57.4 t80 -57.41 -45.99 83.98 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.574 179.733 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 67.0 mt -67.28 -40.23 84.48 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.785 179.783 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.576 HG12 HG23 ' A' ' 54' ' ' ILE . 95.4 mt -58.85 -38.42 72.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 115.969 -0.56 . . . . 0.0 111.125 179.401 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 40.1 mtp-105 -71.99 -30.32 65.13 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.839 -0.619 . . . . 0.0 111.332 -178.855 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 42.9 t -89.2 -17.41 29.17 Favored 'General case' 0 C--N 1.324 -0.513 0 N-CA-C 111.956 0.354 . . . . 0.0 111.956 -176.489 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 11.5 p -94.68 -79.17 0.43 Allowed 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 111.961 0.356 . . . . 0.0 111.961 -176.086 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.48 ' O ' HG22 ' A' ' 37' ' ' THR . . . 101.16 136.73 9.45 Favored Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.812 -0.709 . . . . 0.0 111.847 -176.698 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 35' ' ' PRO . . . . . 0.411 ' HD3' ' HA2' ' A' ' 34' ' ' GLY . 48.4 Cg_exo -55.84 126.48 22.55 Favored 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 123.076 2.518 . . . . 0.0 112.767 -176.066 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 112.73 -18.51 22.21 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.294 -0.955 . . . . 0.0 113.48 175.278 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 37' ' ' THR . . . . . 0.48 HG22 ' O ' ' A' ' 34' ' ' GLY . 11.1 t -86.76 -173.6 4.56 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.995 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 38' ' ' ARG . . . . . 0.505 ' HG2' ' CB ' ' A' ' 61' ' ' ASP . 92.1 mtm-85 -118.45 135.2 54.5 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 120.932 0.396 . . . . 0.0 110.735 176.634 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.497 HG23 HG11 ' A' ' 60' ' ' VAL . 90.7 t -130.19 127.44 63.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 176.904 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.433 HG11 ' CE1' ' A' ' 87' ' ' TYR . 35.4 t -109.06 128.79 64.67 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-O 120.937 0.399 . . . . 0.0 111.915 -173.02 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 41' ' ' GLU . . . . . 0.723 ' HB3' HD23 ' A' ' 64' ' ' LEU . 6.3 tp10 -103.3 127.92 50.5 Favored 'General case' 0 C--O 1.237 0.416 0 CA-C-N 115.379 -0.828 . . . . 0.0 109.452 174.092 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.567 ' HB ' ' HB3' ' A' ' 95' ' ' SER . 35.2 t -106.05 98.91 7.49 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-O 120.974 0.416 . . . . 0.0 110.535 -179.178 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 101.08 84.8 1.83 Allowed Glycine 0 N--CA 1.451 -0.333 0 N-CA-C 111.471 -0.651 . . . . 0.0 111.471 -176.778 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.448 ' HB1' HD21 ' A' ' 48' ' ' LEU . . . -83.07 -40.83 19.35 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 112.106 0.41 . . . . 0.0 112.106 -172.107 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 57.3 -127.55 45.19 Favored Glycine 0 CA--C 1.521 0.447 0 C-N-CA 121.077 -0.582 . . . . 0.0 112.713 179.824 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 52.4 mtp180 -120.42 2.49 10.77 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.866 0.365 . . . . 0.0 111.21 179.071 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.566 ' CE1' ' HB ' ' A' ' 96' ' ' ILE . 6.3 p90 -96.85 58.29 1.61 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.379 0.609 . . . . 0.0 111.088 -176.166 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.448 HD21 ' HB1' ' A' ' 44' ' ' ALA . 83.8 mt -81.68 8.43 9.92 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.79 -0.641 . . . . 0.0 112.12 -174.425 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 75.7 t80 -57.95 -48.75 79.04 Favored 'General case' 0 N--CA 1.463 0.201 0 CA-C-O 120.589 0.233 . . . . 0.0 111.195 -179.802 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.45 ' O ' HG13 ' A' ' 54' ' ' ILE . 85.3 t -58.96 -51.73 69.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.892 -178.398 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 51' ' ' SER . . . . . 0.503 ' CB ' HD21 ' A' ' 64' ' ' LEU . 3.9 p -69.79 -25.76 63.94 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.004 -0.544 . . . . 0.0 112.346 -174.418 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.522 ' O ' ' HG2' ' A' ' 55' ' ' ARG . 17.5 t70 -83.06 -41.46 18.6 Favored 'General case' 0 C--N 1.325 -0.462 0 C-N-CA 120.806 -0.358 . . . . 0.0 110.3 177.232 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 66.4 t80 -58.16 -43.75 87.55 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.545 178.839 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.576 HG23 HG12 ' A' ' 30' ' ' ILE . 89.0 mt -60.2 -47.6 91.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.192 178.326 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 55' ' ' ARG . . . . . 0.522 ' HG2' ' O ' ' A' ' 52' ' ' ASP . 7.9 ptp180 -71.98 -16.31 62.08 Favored 'General case' 0 CA--C 1.532 0.27 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.381 -174.725 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 44.2 mmtm -77.1 -37.57 54.03 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.839 0.352 . . . . 0.0 110.569 176.316 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 13.3 m-70 -83.79 -55.32 4.32 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.67 179.694 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 68.0 m -117.13 127.97 54.66 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.169 -179.025 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 1.3 mptm? -77.5 63.36 2.63 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-O 121.925 0.869 . . . . 0.0 110.475 176.712 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.497 HG11 HG23 ' A' ' 39' ' ' VAL . 66.1 t -82.84 142.35 13.7 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.922 0 CA-C-N 114.444 -1.253 . . . . 0.0 109.09 173.888 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 61' ' ' ASP . . . . . 0.505 ' CB ' ' HG2' ' A' ' 38' ' ' ARG . 0.3 OUTLIER -73.19 80.08 1.29 Allowed 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.3 0.571 . . . . 0.0 109.5 175.27 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 62' ' ' LEU . . . . . 0.402 ' HA ' ' O ' ' A' ' 39' ' ' VAL . 3.1 tt -84.08 114.88 22.07 Favored 'General case' 0 N--CA 1.444 -0.755 0 CA-C-N 115.598 -0.728 . . . . 0.0 109.378 -178.074 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.401 HG11 ' CG2' ' A' ' 86' ' ' ILE . 58.2 t -99.28 119.52 47.4 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.706 0 CA-C-N 115.296 -0.865 . . . . 0.0 110.229 -177.381 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 64' ' ' LEU . . . . . 0.723 HD23 ' HB3' ' A' ' 41' ' ' GLU . 65.8 mt -98.3 131.37 44.67 Favored 'General case' 0 C--N 1.316 -0.87 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 176.964 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.41 ' OG1' ' HA ' ' A' ' 42' ' ' VAL . 36.2 p -116.87 130.56 56.79 Favored 'General case' 0 C--N 1.318 -0.799 0 N-CA-C 109.973 -0.38 . . . . 0.0 109.973 177.021 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 5.8 t70 -157.56 161.93 38.78 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 -178.72 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.698 HD11 HG22 ' A' ' 79' ' ' ILE . 48.7 mm -76.63 95.37 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-O 120.835 0.35 . . . . 0.0 110.145 -177.716 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 56.8 mtpt 50.36 70.29 2.12 Favored Pre-proline 0 CA--C 1.535 0.373 0 CA-C-N 115.192 -0.913 . . . . 0.0 111.68 177.437 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 69' ' ' PRO . . . . . 0.676 ' HD2' ' HG2' ' A' ' 76' ' ' ARG . 37.0 Cg_endo . . . . . 0 C--N 1.345 0.361 0 C-N-CA 123.455 2.77 . . . . 0.0 112.865 -179.121 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.452 HG23 ' CB ' ' A' ' 64' ' ' LEU . 41.0 mt . . . . . 0 N--CA 1.449 -0.488 0 N-CA-C 109.606 -0.516 . . . . 0.0 109.606 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.526 HG12 ' H ' ' A' ' 77' ' ' ASP . 64.3 t -74.12 135.32 27.73 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-O 120.866 0.365 . . . . 0.0 110.029 179.95 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 76' ' ' ARG . . . . . 0.676 ' HG2' ' HD2' ' A' ' 69' ' ' PRO . 26.6 mtp85 -89.74 21.03 3.71 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.907 -0.588 . . . . 0.0 111.856 -174.096 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 77' ' ' ASP . . . . . 0.526 ' H ' HG12 ' A' ' 75' ' ' VAL . 1.1 m-20 -80.19 160.62 25.57 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.785 0.326 . . . . 0.0 110.843 -179.396 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 78' ' ' ASP . . . . . 0.406 ' HB3' ' O ' ' A' ' 81' ' ' SER . 11.0 t70 -75.22 152.93 38.29 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.934 -173.789 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 79' ' ' ILE . . . . . 0.698 HG22 HD11 ' A' ' 67' ' ' ILE . 12.4 tt -91.15 -31.42 5.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.883 -175.475 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 11.1 t -99.73 -24.47 14.69 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.291 0.567 . . . . 0.0 109.98 -177.184 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 81' ' ' SER . . . . . 0.406 ' O ' ' HB3' ' A' ' 78' ' ' ASP . 27.9 m -126.6 74.66 74.74 Favored Pre-proline 0 C--N 1.328 -0.362 0 CA-C-N 115.942 -0.572 . . . . 0.0 109.876 172.472 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 98.1 Cg_endo -90.93 -162.27 0.11 Allowed 'Trans proline' 0 N--CA 1.459 -0.541 0 C-N-CA 123.379 2.72 . . . . 0.0 113.219 -174.071 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 94.8 mtt180 -126.2 116.45 21.33 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.348 178.319 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 84' ' ' MET . . . . . 0.835 ' HA ' ' HD2' ' A' ' 87' ' ' TYR . 25.3 mtp -66.14 -18.5 65.39 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 112.252 0.464 . . . . 0.0 112.252 -177.259 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.417 ' HA ' ' HD3' ' A' ' 88' ' ' ARG . 10.8 pt-20 -65.63 -25.78 67.52 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.094 0.473 . . . . 0.0 110.406 179.335 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.401 ' CG2' HG11 ' A' ' 63' ' ' VAL . 68.3 mt -73.54 -36.74 48.55 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 115.77 -0.65 . . . . 0.0 109.922 177.06 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 87' ' ' TYR . . . . . 0.835 ' HD2' ' HA ' ' A' ' 84' ' ' MET . 74.2 m-85 -77.92 -30.56 50.65 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.633 -0.712 . . . . 0.0 110.754 -178.242 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 88' ' ' ARG . . . . . 0.417 ' HD3' ' HA ' ' A' ' 85' ' ' GLU . 69.9 mtp180 -58.17 125.25 22.39 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.964 178.81 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 89' ' ' GLY . . . . . 0.494 ' HA3' ' NH2' ' A' ' 38' ' ' ARG . . . 97.71 -8.68 63.88 Favored Glycine 0 N--CA 1.447 -0.605 0 C-N-CA 120.821 -0.704 . . . . 0.0 112.45 179.016 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -74.82 142.63 44.19 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 120.777 0.322 . . . . 0.0 110.373 178.277 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -94.39 -18.02 21.96 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.513 179.333 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 92' ' ' LEU . . . . . 0.417 HD23 ' N ' ' A' ' 93' ' ' ILE . 3.6 tt -153.72 140.05 18.59 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.337 -179.154 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.574 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 71.6 mt -132.24 126.17 55.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 N-CA-C 109.032 -0.729 . . . . 0.0 109.032 178.139 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 94' ' ' TYR . . . . . 0.409 ' HE1' HG12 ' A' ' 39' ' ' VAL . 2.0 p90 -135.29 167.18 21.5 Favored 'General case' 0 C--N 1.32 -0.699 0 C-N-CA 120.663 -0.415 . . . . 0.0 110.535 -178.258 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 95' ' ' SER . . . . . 0.633 ' HA ' ' OE1' ' A' ' 41' ' ' GLU . 4.8 p -153.93 120.32 5.47 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.632 -178.447 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 96' ' ' ILE . . . . . 0.566 ' HB ' ' CE1' ' A' ' 47' ' ' PHE . 46.8 mm -80.81 97.23 3.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.684 179.374 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 2.2 tmt_? 52.66 76.91 0.48 Allowed Pre-proline 0 CA--C 1.534 0.353 0 CA-C-N 114.997 -1.001 . . . . 0.0 111.393 177.921 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 69.1 Cg_endo -89.85 161.99 5.06 Favored 'Trans proline' 0 N--CA 1.457 -0.655 0 C-N-CA 122.856 2.371 . . . . 0.0 112.343 177.589 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 99' ' ' PRO . . . . . 0.438 ' HB2' ' HG2' ' A' ' 101' ' ' GLU . 14.6 Cg_endo -60.12 147.64 92.51 Favored 'Trans proline' 0 C--N 1.345 0.367 0 C-N-CA 122.275 1.983 . . . . 0.0 111.858 174.64 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -78.13 33.55 0.19 Allowed 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.928 -176.34 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 101' ' ' GLU . . . . . 0.663 ' HG3' HG23 ' A' ' 102' ' ' ILE . 9.7 pt-20 -116.09 -23.35 8.52 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.685 0.278 . . . . 0.0 110.712 176.549 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.663 HG23 ' HG3' ' A' ' 101' ' ' GLU . 30.1 pt -109.83 -0.26 9.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 N-CA-C 112.006 0.373 . . . . 0.0 112.006 -174.667 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 103' ' ' HIS . . . . . . . . . . . . . 22.1 p-80 -60.66 -43.4 97.67 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 121.093 0.473 . . . . 0.0 110.817 -178.228 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 4.0 p -73.78 -29.41 62.17 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.987 -0.552 . . . . 0.0 110.742 179.094 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.492 ' O ' HG23 ' A' ' 109' ' ' VAL . 2.4 m -71.49 -45.47 62.39 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.224 -179.555 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.408 ' HG ' ' O ' ' A' ' 102' ' ' ILE . 74.5 mt -60.91 -39.77 90.61 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.229 -179.846 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 107' ' ' MET . . . . . 0.457 ' HA ' HD22 ' A' ' 117' ' ' LEU . 51.7 ttm -60.45 -45.61 93.06 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.49 -179.23 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 108' ' ' ARG . . . . . 0.467 ' HG2' ' O ' ' A' ' 105' ' ' SER . 15.1 ptm180 -74.21 -24.1 59.29 Favored 'General case' 0 C--N 1.327 -0.409 0 C-N-CA 120.978 -0.289 . . . . 0.0 110.89 -177.384 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.492 HG23 ' O ' ' A' ' 105' ' ' SER . 81.1 t -72.34 -43.61 64.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 173.954 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -58.24 -42.2 85.85 Favored 'General case' 0 CA--C 1.52 -0.197 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.551 177.926 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.784 ' HA ' ' HB1' ' A' ' 148' ' ' ALA . 35.2 t70 -65.61 -40.27 92.43 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.965 -179.769 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -68.21 -37.47 80.9 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.551 -0.75 . . . . 0.0 112.12 -178.218 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 21.5 m -92.99 -22.82 5.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-O 120.794 0.33 . . . . 0.0 111.549 -177.044 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 85.91 54.41 2.77 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.971 -0.633 . . . . 0.0 112.172 178.935 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -132.73 155.87 48.07 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 120.739 0.304 . . . . 0.0 110.917 -178.975 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 23.9 ttm180 -81.53 127.6 33.01 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 176.998 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 117' ' ' LEU . . . . . 0.574 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 55.8 tp -93.3 123.94 36.93 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.022 179.348 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 66.5 mt -120.16 120.32 62.64 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 CA-C-O 120.939 0.4 . . . . 0.0 110.641 178.376 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 69.3 mt -120.13 126.57 75.42 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.165 179.331 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 120' ' ' LYS . . . . . 0.769 ' HG2' ' HB3' ' A' ' 143' ' ' PHE . 5.9 tmtt? -120.97 96.33 48.63 Favored Pre-proline 0 C--N 1.325 -0.49 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.118 178.379 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -88.8 -163.62 0.15 Allowed 'Trans proline' 0 C--O 1.238 0.497 0 C-N-CA 122.928 2.419 . . . . 0.0 112.33 177.098 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -70.54 -178.72 1.86 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.29 -0.413 . . . . 0.0 110.901 177.311 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 9.6 t -81.4 -35.26 30.96 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.904 0.383 . . . . 0.0 110.95 -176.39 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -113.74 52.54 0.64 Allowed Glycine 0 N--CA 1.448 -0.556 0 N-CA-C 110.629 -0.988 . . . . 0.0 110.629 175.852 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 36.4 tt0 -138.14 116.61 12.03 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.466 -0.367 . . . . 0.0 110.114 -173.354 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 8.1 t70 -91.71 163.19 14.18 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.987 -0.552 . . . . 0.0 110.117 -177.264 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 15.9 mt . . . . . 0 C--N 1.327 -0.398 0 N-CA-C 110.176 -0.305 . . . . 0.0 110.176 -177.716 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 8.3 tppt? . . . . . 0 N--CA 1.448 -0.527 0 CA-C-O 121.453 0.644 . . . . 0.0 109.302 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 133' ' ' MET . . . . . 0.806 ' HG2' ' HB2' ' A' ' 146' ' ' TYR . 83.4 mtp -87.17 171.75 10.44 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.247 -0.888 . . . . 0.0 110.459 -177.64 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 134' ' ' LYS . . . . . 0.405 ' HE2' HG13 ' A' ' 136' ' ' VAL . 14.2 ptmt -131.16 146.66 52.42 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.953 -175.268 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 135' ' ' LEU . . . . . 0.484 HD11 ' HD2' ' A' ' 142' ' ' TYR . 56.7 tp -79.75 129.84 34.82 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.454 176.715 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 136' ' ' VAL . . . . . 0.405 HG13 ' HE2' ' A' ' 134' ' ' LYS . 0.0 OUTLIER -127.66 129.8 70.23 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.702 0 CA-C-O 121.162 0.506 . . . . 0.0 111.162 178.811 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 22.3 m-80 -109.85 122.25 47.11 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.31 -0.859 . . . . 0.0 109.234 177.739 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 61.4 t80 -137.67 125.35 22.32 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 120.535 0.207 . . . . 0.0 110.67 -177.475 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 69.26 -88.92 0.25 Allowed Glycine 0 N--CA 1.448 -0.547 0 N-CA-C 111.626 -0.589 . . . . 0.0 111.626 179.225 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 140' ' ' ARG . . . . . 0.638 ' HA ' ' NE ' ' A' ' 140' ' ' ARG . 2.1 mmp_? -143.72 9.96 1.58 Allowed 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 115.446 -0.377 . . . . 0.0 111.182 175.91 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 15.2 t -118.6 155.23 31.31 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.801 0.334 . . . . 0.0 110.611 -179.678 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 142' ' ' TYR . . . . . 0.484 ' HD2' HD11 ' A' ' 135' ' ' LEU . 32.4 p90 -133.58 141.22 47.59 Favored 'General case' 0 N--CA 1.448 -0.533 0 CA-C-O 121.086 0.469 . . . . 0.0 109.992 176.704 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 143' ' ' PHE . . . . . 0.769 ' HB3' ' HG2' ' A' ' 120' ' ' LYS . 11.6 p90 -153.89 -175.98 5.63 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 115.429 -0.805 . . . . 0.0 109.733 -177.006 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 95.7 m-85 -116.98 125.36 51.29 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 110.308 -0.256 . . . . 0.0 110.308 179.375 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 145' ' ' GLU . . . . . . . . . . . . . 21.6 pt-20 -114.05 160.92 18.36 Favored 'General case' 0 C--N 1.321 -0.649 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 176.626 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 146' ' ' TYR . . . . . 0.806 ' HB2' ' HG2' ' A' ' 133' ' ' MET . 42.3 t80 -141.87 123.44 15.03 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-N 115.971 -0.558 . . . . 0.0 109.693 175.617 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 147' ' ' ILE . . . . . 0.439 ' N ' HD12 ' A' ' 147' ' ' ILE . 3.1 mp -93.03 100.94 12.07 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.834 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 -178.653 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 148' ' ' ALA . . . . . 0.784 ' HB1' ' HA ' ' A' ' 111' ' ' ASP . . . -67.99 120.16 13.8 Favored 'General case' 0 N--CA 1.447 -0.6 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 174.378 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 . . . . . 0 C--N 1.322 -0.623 0 CA-C-O 121.27 0.557 . . . . 0.0 110.188 -176.06 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 72.5 m95 . . . . . 0 N--CA 1.453 -0.314 0 CA-C-O 120.683 0.277 . . . . 0.0 111.119 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 23' ' ' ASN . . . . . 0.432 ' O ' HG23 ' A' ' 27' ' ' VAL . 14.6 m120 -60.78 -36.99 80.37 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.522 175.528 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 43.9 m-20 -64.49 -45.16 88.53 Favored 'General case' 0 CA--C 1.52 -0.2 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.38 178.907 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 61.2 tp -55.13 -50.9 68.07 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.75 179.011 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -55.55 -47.03 77.0 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.912 -0.585 . . . . 0.0 111.639 -178.702 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.576 ' HA ' HD12 ' A' ' 30' ' ' ILE . 92.2 t -58.58 -37.09 62.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.471 -179.732 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 59.8 t80 -60.01 -45.89 91.27 Favored 'General case' 0 CA--C 1.534 0.339 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.042 -178.039 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.456 HG13 HD12 ' A' ' 118' ' ' ILE . 3.2 mp -64.09 -41.56 92.83 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.17 0 CA-C-O 120.973 0.416 . . . . 0.0 110.468 176.345 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.607 HG23 ' HB2' ' A' ' 58' ' ' SER . 90.6 mt -58.42 -44.67 89.22 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 115.739 -0.664 . . . . 0.0 111.357 -177.92 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 49.7 mtp180 -66.51 -33.82 76.55 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.463 -177.617 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 44.5 t -82.29 -25.81 33.67 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.416 -174.936 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 15.4 p -95.82 -81.82 0.4 Allowed 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.85 0.357 . . . . 0.0 111.746 -174.056 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 104.56 158.34 23.75 Favored Glycine 0 N--CA 1.447 -0.597 0 C-N-CA 120.937 -0.649 . . . . 0.0 111.8 -176.666 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 15.8 Cg_exo -68.67 139.58 44.61 Favored 'Trans proline' 0 N--CA 1.465 -0.164 0 C-N-CA 122.876 2.384 . . . . 0.0 112.415 -179.426 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 96.1 -4.67 65.32 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.577 -0.821 . . . . 0.0 112.568 178.502 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 29.6 p -96.48 -170.76 2.14 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 109.983 -0.377 . . . . 0.0 109.983 -179.892 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 38' ' ' ARG . . . . . 0.777 ' HB2' ' HA ' ' A' ' 90' ' ' ALA . 99.3 mtt180 -123.21 129.68 51.73 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.704 0.287 . . . . 0.0 110.661 174.429 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.788 HG23 HG21 ' A' ' 60' ' ' VAL . 98.7 t -129.41 121.9 54.39 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 N-CA-C 109.203 -0.665 . . . . 0.0 109.203 175.218 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 34.0 t -106.0 130.83 56.93 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 CA-C-O 120.755 0.312 . . . . 0.0 111.502 -174.293 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 41' ' ' GLU . . . . . 0.749 ' HB3' HD23 ' A' ' 64' ' ' LEU . 7.8 tp10 -114.15 122.03 45.59 Favored 'General case' 0 C--O 1.239 0.5 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.012 175.24 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.495 HG11 HD21 ' A' ' 106' ' ' LEU . 24.2 t -100.8 89.0 1.55 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 115.773 -0.648 . . . . 0.0 110.489 179.842 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 148.11 55.94 0.02 OUTLIER Glycine 0 N--CA 1.448 -0.538 0 CA-C-N 115.54 -0.754 . . . . 0.0 111.366 -177.879 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.624 ' HB2' ' HB3' ' A' ' 64' ' ' LEU . . . -84.97 76.94 10.21 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.986 0.422 . . . . 0.0 111.961 -173.962 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 45' ' ' GLY . . . . . 0.601 ' O ' ' HG ' ' A' ' 48' ' ' LEU . . . -89.5 -157.02 32.59 Favored Glycine 0 C--O 1.226 -0.367 0 C-N-CA 120.88 -0.676 . . . . 0.0 111.781 175.823 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 46' ' ' ARG . . . . . 0.451 HH11 ' HD3' ' A' ' 46' ' ' ARG . 0.0 OUTLIER -74.89 -15.44 60.7 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.984 0.421 . . . . 0.0 110.811 178.802 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 32.0 p90 -85.66 41.16 0.89 Allowed 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.53 -175.122 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.757 HD11 HD11 ' A' ' 74' ' ' ILE . 94.2 mt -80.96 19.16 0.9 Allowed 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 112.379 0.511 . . . . 0.0 112.379 -176.42 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 32.7 p90 -61.29 -27.39 68.44 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.712 0.291 . . . . 0.0 110.918 179.313 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 98.6 t -69.02 -51.28 45.64 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.237 175.43 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 51' ' ' SER . . . . . 0.413 ' O ' ' HG2' ' A' ' 55' ' ' ARG . 1.7 m -61.75 -45.3 94.51 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 121.384 0.612 . . . . 0.0 110.201 -179.868 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 25.6 t70 -58.8 -41.12 85.99 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 114.7 -1.137 . . . . 0.0 111.119 -179.454 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 80.6 t80 -66.99 -52.01 47.93 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.693 178.295 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.558 HG23 HG12 ' A' ' 30' ' ' ILE . 83.8 mt -58.23 -47.27 87.85 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-N 115.981 -0.554 . . . . 0.0 112.075 -176.041 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 55' ' ' ARG . . . . . 0.413 ' HG2' ' O ' ' A' ' 51' ' ' SER . 15.6 ptm180 -68.64 -20.7 64.48 Favored 'General case' 0 CA--C 1.533 0.289 0 N-CA-C 112.535 0.569 . . . . 0.0 112.535 -172.649 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 23.0 mtmm -84.74 -29.93 25.11 Favored 'General case' 0 C--N 1.328 -0.345 0 C-N-CA 120.705 -0.398 . . . . 0.0 111.251 179.28 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 16.4 m-70 -86.48 -54.2 4.55 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.235 0.54 . . . . 0.0 109.586 177.744 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 58' ' ' SER . . . . . 0.607 ' HB2' HG23 ' A' ' 30' ' ' ILE . 10.9 t -104.22 121.63 43.7 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 115.677 -0.692 . . . . 0.0 109.532 179.052 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 3.0 mppt? -84.79 61.45 6.79 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-O 121.897 0.856 . . . . 0.0 110.241 178.951 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.788 HG21 HG23 ' A' ' 39' ' ' VAL . 2.5 p -93.62 153.34 3.39 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.792 0 CA-C-N 114.167 -1.379 . . . . 0.0 109.299 177.232 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 43.9 m-20 -73.33 82.23 1.39 Allowed 'General case' 0 CA--C 1.518 -0.254 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 172.598 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 62' ' ' LEU . . . . . 0.45 ' HA ' ' O ' ' A' ' 39' ' ' VAL . 2.7 tt -80.93 105.45 12.17 Favored 'General case' 0 C--N 1.321 -0.651 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 179.549 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 48.8 t -96.96 117.14 40.95 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.439 -175.829 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 64' ' ' LEU . . . . . 0.749 HD23 ' HB3' ' A' ' 41' ' ' GLU . 80.0 mt -99.77 130.27 45.96 Favored 'General case' 0 C--N 1.314 -0.954 0 CA-C-N 115.58 -0.737 . . . . 0.0 109.185 177.249 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 22.9 p -117.86 129.4 55.63 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 120.555 0.217 . . . . 0.0 111.047 179.334 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 25.5 t70 -165.05 153.72 12.19 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.917 -0.583 . . . . 0.0 109.931 178.527 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.475 HG22 ' HE3' ' A' ' 68' ' ' LYS . 54.3 mt -76.98 100.39 2.57 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-O 120.93 0.395 . . . . 0.0 110.605 -178.289 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 68' ' ' LYS . . . . . 0.581 ' HB2' ' NZ ' ' A' ' 68' ' ' LYS . 7.4 mtmp? 70.33 83.97 0.15 Allowed Pre-proline 0 C--O 1.233 0.214 0 CA-C-N 115.119 -0.946 . . . . 0.0 110.53 -179.687 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 69' ' ' PRO . . . . . 0.96 ' HB3' ' HB ' ' A' ' 74' ' ' ILE . 11.2 Cg_endo . . . . . 0 C--O 1.232 0.205 0 C-N-CA 123.714 2.942 . . . . 0.0 113.968 -175.653 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.96 ' HB ' ' HB3' ' A' ' 69' ' ' PRO . 55.8 mt . . . . . 0 C--O 1.234 0.263 0 CA-C-O 120.763 0.316 . . . . 0.0 110.724 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 57.3 t -85.16 126.64 40.35 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 176.126 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 76' ' ' ARG . . . . . 0.478 ' HB3' ' HD2' ' A' ' 69' ' ' PRO . 1.6 ppt_? -77.68 28.08 0.17 Allowed 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 112.491 0.552 . . . . 0.0 112.491 -176.344 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 16.1 t70 -75.71 157.24 33.84 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 110.117 -0.327 . . . . 0.0 110.117 -177.579 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 78' ' ' ASP . . . . . 0.541 ' OD1' HG22 ' A' ' 80' ' ' THR . 5.9 t70 -88.47 161.41 17.03 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 120.691 0.281 . . . . 0.0 110.875 -171.984 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 8.5 tp -98.47 -28.23 3.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-O 120.829 0.347 . . . . 0.0 111.029 -177.926 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.541 HG22 ' OD1' ' A' ' 78' ' ' ASP . 15.0 t -90.02 -1.35 57.95 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.637 0.732 . . . . 0.0 109.165 176.868 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 34.5 t -152.12 72.32 7.78 Favored Pre-proline 0 C--N 1.322 -0.594 0 CA-C-N 114.738 -1.119 . . . . 0.0 108.984 175.069 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 82' ' ' PRO . . . . . 0.539 ' HB2' ' HE2' ' A' ' 87' ' ' TYR . 91.1 Cg_endo -89.47 141.55 4.01 Favored 'Trans proline' 0 N--CA 1.457 -0.633 0 C-N-CA 122.829 2.353 . . . . 0.0 112.798 -177.521 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 83' ' ' ARG . . . . . 0.771 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 56.7 mtt-85 -83.49 113.38 20.75 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.047 178.305 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 84' ' ' MET . . . . . 0.71 ' HA ' ' HD2' ' A' ' 87' ' ' TYR . 29.6 mtp -68.06 -17.4 64.38 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.551 -0.295 . . . . 0.0 110.995 178.168 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.771 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 9.8 pt-20 -61.89 -23.81 66.54 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.934 0.397 . . . . 0.0 110.653 176.592 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 72.6 mt -85.11 -34.48 8.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.48 178.984 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 87' ' ' TYR . . . . . 0.71 ' HD2' ' HA ' ' A' ' 84' ' ' MET . 75.0 m-85 -78.23 -30.75 48.91 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.429 -177.243 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 88' ' ' ARG . . . . . 0.465 ' HG2' HG12 ' A' ' 113' ' ' VAL . 53.2 mtp180 -65.68 140.58 58.48 Favored 'General case' 0 CA--C 1.516 -0.362 0 CA-C-O 121.403 0.621 . . . . 0.0 110.882 178.701 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 91.08 1.73 72.29 Favored Glycine 0 N--CA 1.447 -0.61 0 CA-C-N 115.199 -0.909 . . . . 0.0 111.894 -178.044 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 90' ' ' ALA . . . . . 0.777 ' HA ' ' HB2' ' A' ' 38' ' ' ARG . . . -85.16 138.77 32.16 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.995 0.426 . . . . 0.0 110.75 178.88 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -89.16 -24.67 22.14 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.079 178.379 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 92' ' ' LEU . . . . . 0.515 HD23 ' N ' ' A' ' 93' ' ' ILE . 4.7 tt -153.49 143.15 21.85 Favored 'General case' 0 N--CA 1.45 -0.448 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.206 -178.345 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.515 ' N ' HD23 ' A' ' 92' ' ' LEU . 72.7 mt -132.03 133.73 60.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 N-CA-C 109.111 -0.7 . . . . 0.0 109.111 176.551 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 94' ' ' TYR . . . . . 0.453 ' O ' ' HA ' ' A' ' 41' ' ' GLU . 1.2 p90 -138.37 161.24 37.46 Favored 'General case' 0 C--N 1.321 -0.636 0 C-N-CA 120.707 -0.397 . . . . 0.0 110.119 -178.693 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 95' ' ' SER . . . . . 0.639 ' HA ' ' OE2' ' A' ' 41' ' ' GLU . 19.4 m -146.87 115.65 6.82 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.058 -178.91 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 78.9 mt -77.23 94.35 1.31 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.752 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.619 179.45 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 97' ' ' ARG . . . . . 0.534 ' HG3' ' OE1' ' A' ' 125' ' ' GLU . 19.6 ttp85 58.61 82.64 0.23 Allowed Pre-proline 0 CA--C 1.531 0.244 0 CA-C-N 114.608 -1.178 . . . . 0.0 111.66 -177.628 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 98' ' ' PRO . . . . . 0.457 ' HA ' ' HD3' ' A' ' 99' ' ' PRO . 88.3 Cg_endo -83.74 136.66 7.36 Favored 'Trans proline' 0 N--CA 1.456 -0.724 0 C-N-CA 122.467 2.111 . . . . 0.0 111.638 176.136 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 99' ' ' PRO . . . . . 0.747 ' HB2' ' HG2' ' A' ' 101' ' ' GLU . 22.4 Cg_exo -63.32 149.94 89.9 Favored 'Trans proline' 0 C--O 1.238 0.478 0 C-N-CA 122.581 2.187 . . . . 0.0 111.733 177.951 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -73.76 42.22 0.13 Allowed 'General case' 0 N--CA 1.465 0.284 0 CA-C-O 121.304 0.573 . . . . 0.0 111.812 -178.216 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 101' ' ' GLU . . . . . 0.757 ' HG3' HG23 ' A' ' 102' ' ' ILE . 11.0 pt-20 -132.15 -26.24 1.93 Allowed 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.607 179.303 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.757 HG23 ' HG3' ' A' ' 101' ' ' GLU . 40.1 pt -119.88 -11.64 10.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.55 -175.062 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 103' ' ' HIS . . . . . 0.485 ' O ' ' HG3' ' A' ' 107' ' ' MET . 4.8 p-80 -56.72 -45.24 82.0 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.989 -0.551 . . . . 0.0 111.612 -175.147 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 8.5 m -61.35 -35.05 76.36 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.002 0.43 . . . . 0.0 110.908 179.529 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.839 ' HA ' ' HE ' ' A' ' 108' ' ' ARG . 67.1 m -73.3 -36.71 66.32 Favored 'General case' 0 N--CA 1.451 -0.408 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.39 179.703 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.495 HD21 HG11 ' A' ' 42' ' ' VAL . 85.0 mt -64.39 -42.08 96.31 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.73 178.914 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 107' ' ' MET . . . . . 0.522 ' HA ' HD22 ' A' ' 117' ' ' LEU . 81.4 mtp -60.5 -44.27 96.17 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.539 -179.292 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 108' ' ' ARG . . . . . 0.839 ' HE ' ' HA ' ' A' ' 105' ' ' SER . 31.6 ptt180 -74.73 -20.77 59.69 Favored 'General case' 0 CA--C 1.53 0.205 0 C-N-CA 121.048 -0.261 . . . . 0.0 111.555 -178.263 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.528 HG23 ' O ' ' A' ' 105' ' ' SER . 55.9 t -74.06 -43.47 51.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.749 0.309 . . . . 0.0 110.333 175.421 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -57.24 -45.66 83.73 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.972 -179.822 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.961 ' HA ' ' HB1' ' A' ' 148' ' ' ALA . 4.0 t70 -71.72 -28.71 63.87 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 121.174 0.511 . . . . 0.0 110.254 -177.284 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -74.49 -33.01 62.74 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.953 -0.567 . . . . 0.0 111.809 -179.64 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.465 HG12 ' HG2' ' A' ' 88' ' ' ARG . 34.0 m -95.52 -24.78 4.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 C-N-CA 121.088 -0.245 . . . . 0.0 111.097 179.578 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 114' ' ' GLY . . . . . 0.446 ' HA2' ' O ' ' A' ' 149' ' ' GLU . . . 89.87 46.5 4.2 Favored Glycine 0 N--CA 1.453 -0.226 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.993 176.303 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 115' ' ' ALA . . . . . 0.405 ' O ' ' HB3' ' A' ' 148' ' ' ALA . . . -124.66 150.25 46.29 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 120.533 0.206 . . . . 0.0 110.85 -178.954 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 116' ' ' ARG . . . . . 0.506 ' HD3' ' OE1' ' A' ' 145' ' ' GLU . 14.7 ttm180 -70.65 119.92 15.5 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 177.93 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 117' ' ' LEU . . . . . 0.522 HD22 ' HA ' ' A' ' 107' ' ' MET . 57.6 tp -90.58 118.59 30.15 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 -179.765 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 118' ' ' ILE . . . . . 0.456 HD12 HG13 ' A' ' 29' ' ' ILE . 61.9 mt -115.98 112.71 40.77 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.654 0 CA-C-O 121.289 0.566 . . . . 0.0 110.594 179.455 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 62.8 mt -110.97 119.03 58.71 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.845 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.029 178.474 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 120' ' ' LYS . . . . . 0.663 ' HG2' ' HB3' ' A' ' 143' ' ' PHE . 9.0 tmtm? -116.33 96.97 48.99 Favored Pre-proline 0 C--N 1.322 -0.616 0 CA-C-N 116.162 -0.472 . . . . 0.0 109.994 178.885 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 0.9 OUTLIER -77.65 -178.71 4.81 Favored 'Trans proline' 0 N--CA 1.459 -0.522 0 C-N-CA 122.652 2.235 . . . . 0.0 111.442 174.373 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 5.7 mp -63.87 177.68 0.73 Allowed 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.957 -179.439 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 15.2 m -49.45 -65.15 0.61 Allowed 'General case' 0 CA--C 1.53 0.194 0 CA-C-N 115.71 -0.677 . . . . 0.0 111.888 -175.357 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -106.54 64.86 0.27 Allowed Glycine 0 N--CA 1.448 -0.531 0 C-N-CA 120.669 -0.777 . . . . 0.0 111.173 175.452 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 125' ' ' GLU . . . . . 0.534 ' OE1' ' HG3' ' A' ' 97' ' ' ARG . 40.8 tt0 -140.11 145.48 37.65 Favored 'General case' 0 N--CA 1.448 -0.558 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 -174.712 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 10.3 t70 -123.02 174.67 7.05 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.356 -179.169 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 6.9 mt . . . . . 0 C--N 1.328 -0.334 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.055 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 16.5 tppt? . . . . . 0 C--O 1.232 0.155 0 CA-C-O 121.029 0.442 . . . . 0.0 110.59 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 133' ' ' MET . . . . . 0.789 ' HG2' ' HB2' ' A' ' 146' ' ' TYR . 93.4 mtp -104.86 155.76 18.63 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.578 -177.533 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 12.9 ptmt -106.12 139.73 40.19 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.446 -175.789 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 135' ' ' LEU . . . . . 0.838 HD11 ' HD2' ' A' ' 142' ' ' TYR . 55.2 tp -78.81 125.27 29.14 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 115.861 -0.608 . . . . 0.0 110.428 177.709 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -119.81 147.16 23.64 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.808 179.059 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 137' ' ' ASN . . . . . 0.415 ' OD1' ' HB3' ' A' ' 142' ' ' TYR . 34.3 m-80 -120.72 119.1 31.82 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.92 -0.582 . . . . 0.0 109.63 178.411 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 67.7 t80 -131.74 130.98 42.6 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 109.916 -0.401 . . . . 0.0 109.916 179.289 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 71.66 -91.21 0.49 Allowed Glycine 0 N--CA 1.441 -1.0 0 N-CA-C 111.21 -0.756 . . . . 0.0 111.21 -176.821 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 140' ' ' ARG . . . . . 0.447 ' HD3' ' HA ' ' A' ' 140' ' ' ARG . 29.1 mmt180 -150.21 12.81 0.75 Allowed 'General case' 0 C--N 1.32 -0.708 0 CA-C-O 120.807 0.337 . . . . 0.0 110.556 179.308 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 7.1 t -125.15 160.64 28.67 Favored 'General case' 0 C--N 1.322 -0.606 0 N-CA-C 109.865 -0.42 . . . . 0.0 109.865 -178.991 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 142' ' ' TYR . . . . . 0.838 ' HD2' HD11 ' A' ' 135' ' ' LEU . 20.8 p90 -126.83 149.64 49.6 Favored 'General case' 0 N--CA 1.449 -0.523 0 CA-C-O 121.405 0.621 . . . . 0.0 111.176 179.494 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 143' ' ' PHE . . . . . 0.663 ' HB3' ' HG2' ' A' ' 120' ' ' LYS . 19.5 p90 -156.39 179.3 9.39 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 114.823 -1.08 . . . . 0.0 109.417 -177.37 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -113.2 127.85 56.3 Favored 'General case' 0 C--N 1.319 -0.752 0 C-N-CA 120.963 -0.295 . . . . 0.0 110.451 -179.738 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 145' ' ' GLU . . . . . 0.506 ' OE1' ' HD3' ' A' ' 116' ' ' ARG . 17.5 pt-20 -114.85 157.04 23.84 Favored 'General case' 0 C--N 1.32 -0.681 0 N-CA-C 109.041 -0.726 . . . . 0.0 109.041 173.189 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 146' ' ' TYR . . . . . 0.789 ' HB2' ' HG2' ' A' ' 133' ' ' MET . 19.5 t80 -137.77 122.75 19.01 Favored 'General case' 0 C--N 1.31 -1.133 0 CA-C-N 116.054 -0.521 . . . . 0.0 109.638 176.07 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 2.2 mp -79.49 95.76 2.18 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.813 0 N-CA-C 108.442 -0.947 . . . . 0.0 108.442 174.91 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 148' ' ' ALA . . . . . 0.961 ' HB1' ' HA ' ' A' ' 111' ' ' ASP . . . -74.87 130.3 39.17 Favored 'General case' 0 N--CA 1.437 -1.083 0 CA-C-N 115.462 -0.79 . . . . 0.0 109.739 178.679 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 149' ' ' GLU . . . . . 0.446 ' O ' ' HA2' ' A' ' 114' ' ' GLY . 74.4 mm-40 . . . . . 0 C--N 1.315 -0.904 0 CA-C-O 122.032 0.92 . . . . 0.0 111.558 178.861 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 95.5 m95 . . . . . 0 CA--C 1.528 0.122 0 N-CA-C 111.58 0.215 . . . . 0.0 111.58 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 23' ' ' ASN . . . . . 0.446 ' O ' HG23 ' A' ' 27' ' ' VAL . 4.4 m-20 -66.49 -40.72 89.42 Favored 'General case' 0 C--N 1.328 -0.348 0 C-N-CA 121.224 -0.19 . . . . 0.0 111.487 -177.015 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 38.8 m-20 -61.41 -39.44 90.78 Favored 'General case' 0 N--CA 1.466 0.35 0 CA-C-O 121.071 0.462 . . . . 0.0 110.411 177.644 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.545 HD21 ' HD3' ' A' ' 120' ' ' LYS . 25.0 tp -63.33 -42.95 98.99 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.648 -0.705 . . . . 0.0 110.59 176.863 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -59.68 -46.95 87.5 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.738 178.258 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.446 HG23 ' O ' ' A' ' 23' ' ' ASN . 90.3 t -55.59 -42.26 67.9 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.192 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.069 178.803 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 69.2 t80 -59.33 -45.16 92.11 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 121.024 0.44 . . . . 0.0 110.637 179.598 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 57.9 mt -67.07 -39.91 84.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.62 179.751 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.683 HG12 HG23 ' A' ' 54' ' ' ILE . 98.1 mt -59.9 -41.87 87.35 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.453 -0.794 . . . . 0.0 110.941 178.915 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 79.2 mtp180 -66.49 -37.64 85.51 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.882 -178.407 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 81.2 m -76.76 -18.0 58.72 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.214 -176.068 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 11.9 p -104.26 -84.37 0.48 Allowed 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.433 -178.556 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.402 ' O ' HG22 ' A' ' 37' ' ' THR . . . 99.69 160.47 28.82 Favored Glycine 0 N--CA 1.447 -0.626 0 C-N-CA 121.089 -0.577 . . . . 0.0 111.902 -176.96 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 11.5 Cg_exo -70.95 152.74 63.4 Favored 'Trans proline' 0 C--O 1.235 0.33 0 C-N-CA 122.743 2.296 . . . . 0.0 111.976 179.57 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 99.61 -26.35 24.73 Favored Glycine 0 N--CA 1.453 -0.228 0 C-N-CA 120.827 -0.701 . . . . 0.0 112.752 176.624 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 37' ' ' THR . . . . . 0.402 HG22 ' O ' ' A' ' 34' ' ' GLY . 14.0 t -100.5 -166.99 1.38 Allowed 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 -178.846 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 38' ' ' ARG . . . . . 0.995 ' HG2' ' HA ' ' A' ' 90' ' ' ALA . 0.1 OUTLIER -130.94 136.53 48.65 Favored 'General case' 0 N--CA 1.446 -0.657 0 CA-C-O 121.113 0.483 . . . . 0.0 111.021 -176.767 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.448 HG23 HG21 ' A' ' 60' ' ' VAL . 95.9 t -129.16 135.82 61.04 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.603 0 CA-C-N 115.48 -0.782 . . . . 0.0 109.486 -179.916 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.517 HG11 ' CE2' ' A' ' 87' ' ' TYR . 38.7 t -108.11 128.19 63.72 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 CA-C-O 120.927 0.394 . . . . 0.0 111.31 -176.479 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 41' ' ' GLU . . . . . 0.58 ' HB3' HD23 ' A' ' 64' ' ' LEU . 41.1 tt0 -106.49 118.23 36.1 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.924 -0.58 . . . . 0.0 109.778 175.826 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 62.9 t -97.21 120.48 46.6 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.671 -179.173 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 92.5 48.7 2.94 Favored Glycine 0 N--CA 1.447 -0.621 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.139 179.567 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -80.36 41.09 0.52 Allowed 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.063 0.459 . . . . 0.0 111.446 -176.861 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 45' ' ' GLY . . . . . 0.425 ' O ' ' HB2' ' A' ' 46' ' ' ARG . . . -81.29 81.58 1.62 Allowed Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.954 -0.641 . . . . 0.0 112.27 -178.332 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 46' ' ' ARG . . . . . 0.425 ' HB2' ' O ' ' A' ' 45' ' ' GLY . 82.9 mtm180 71.08 13.56 6.86 Favored 'General case' 0 N--CA 1.469 0.498 0 C-N-CA 123.238 0.615 . . . . 0.0 111.271 -179.44 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 74.6 m-85 -98.51 17.05 19.94 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.357 0.598 . . . . 0.0 109.706 176.864 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.438 HD21 HD11 ' A' ' 74' ' ' ILE . 82.2 mt -62.14 -10.1 9.44 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 114.793 -1.094 . . . . 0.0 112.388 -174.655 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 73.9 t80 -57.85 -38.35 75.53 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 120.715 0.293 . . . . 0.0 110.837 179.167 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 60.4 t -73.54 -54.63 14.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.435 -179.093 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -59.75 -38.33 81.47 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.852 -179.437 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.565 ' HA ' ' HG2' ' A' ' 55' ' ' ARG . 33.5 t70 -71.44 -35.85 71.06 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.629 0.252 . . . . 0.0 111.181 179.527 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 56.7 t80 -61.36 -49.03 78.57 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 109.503 -0.554 . . . . 0.0 109.503 175.027 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.683 HG23 HG12 ' A' ' 30' ' ' ILE . 77.6 mt -60.85 -51.83 68.61 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-N 115.727 -0.669 . . . . 0.0 111.85 -179.236 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 55' ' ' ARG . . . . . 0.565 ' HG2' ' HA ' ' A' ' 52' ' ' ASP . 40.1 ptt180 -65.29 -19.93 66.18 Favored 'General case' 0 N--CA 1.467 0.392 0 N-CA-C 112.382 0.512 . . . . 0.0 112.382 -173.464 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 3.1 mtmp? -87.33 -38.61 16.07 Favored 'General case' 0 C--N 1.327 -0.372 0 C-N-CA 120.723 -0.391 . . . . 0.0 111.588 178.668 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 42.6 m80 -76.03 -32.73 59.5 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 120.662 0.268 . . . . 0.0 110.693 179.651 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 67.6 m -138.63 128.0 24.46 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 116.264 -0.425 . . . . 0.0 109.863 174.581 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 59' ' ' LYS . . . . . 0.409 ' HA ' ' HD3' ' A' ' 59' ' ' LYS . 1.3 tppp? -78.58 63.42 3.38 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 122.096 0.95 . . . . 0.0 110.901 -177.375 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.448 HG21 HG23 ' A' ' 39' ' ' VAL . 7.3 p -86.29 142.21 13.4 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.957 0 CA-C-N 114.349 -1.296 . . . . 0.0 109.387 172.721 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 61' ' ' ASP . . . . . 0.443 ' O ' ' HA ' ' A' ' 38' ' ' ARG . 33.0 t70 -76.51 89.25 3.27 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 179.228 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 2.3 tt -90.0 122.91 33.44 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.78 -0.646 . . . . 0.0 110.496 -173.93 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 43.8 t -102.29 121.76 53.74 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-N 115.523 -0.762 . . . . 0.0 109.899 -178.234 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 64' ' ' LEU . . . . . 0.58 HD23 ' HB3' ' A' ' 41' ' ' GLU . 50.8 mt -100.15 131.01 46.34 Favored 'General case' 0 C--N 1.316 -0.858 0 CA-C-N 116.214 -0.448 . . . . 0.0 109.919 179.766 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.549 HG22 ' HB ' ' A' ' 75' ' ' VAL . 17.0 p -132.23 137.37 47.52 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.951 0.405 . . . . 0.0 111.18 178.383 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 30.3 t70 -165.28 158.4 16.27 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.518 177.529 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 40.7 mm -72.09 96.83 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-O 120.759 0.314 . . . . 0.0 110.429 -178.76 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 65.3 mttm 63.56 90.16 0.09 OUTLIER Pre-proline 0 N--CA 1.465 0.309 0 CA-C-N 115.393 -0.821 . . . . 0.0 111.514 178.682 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 69' ' ' PRO . . . . . 0.415 ' HD3' ' HA ' ' A' ' 76' ' ' ARG . 97.3 Cg_endo . . . . . 0 N--CA 1.459 -0.506 0 C-N-CA 122.867 2.378 . . . . 0.0 112.726 -179.273 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.438 HD11 HD21 ' A' ' 48' ' ' LEU . 63.6 mt . . . . . 0 N--CA 1.451 -0.393 0 CA-C-O 120.756 0.312 . . . . 0.0 110.358 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.549 ' HB ' HG22 ' A' ' 65' ' ' THR . 53.8 t -72.71 133.37 31.89 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.093 179.321 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 76' ' ' ARG . . . . . 0.415 ' HA ' ' HD3' ' A' ' 69' ' ' PRO . 6.7 ptp180 -86.9 32.48 0.67 Allowed 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.855 -176.471 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 77' ' ' ASP . . . . . 0.498 ' HB2' HG12 ' A' ' 75' ' ' VAL . 1.6 t70 -77.11 -159.16 0.12 Allowed 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.653 -174.329 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 78' ' ' ASP . . . . . 0.457 ' OD1' HG22 ' A' ' 80' ' ' THR . 4.9 t70 -125.15 -174.16 2.98 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 120.733 0.301 . . . . 0.0 110.25 -174.374 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 9.2 tp -139.9 -30.89 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-O 120.877 0.37 . . . . 0.0 110.406 178.951 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.457 HG22 ' OD1' ' A' ' 78' ' ' ASP . 8.9 t -86.38 -20.8 27.71 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.516 0.674 . . . . 0.0 109.247 177.127 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 13.6 t -150.67 72.57 8.92 Favored Pre-proline 0 C--N 1.325 -0.489 0 CA-C-N 115.154 -0.93 . . . . 0.0 108.577 171.721 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 82' ' ' PRO . . . . . 0.442 ' HB3' ' O ' ' A' ' 78' ' ' ASP . 89.6 Cg_endo -89.77 171.3 4.16 Favored 'Trans proline' 0 N--CA 1.457 -0.674 0 C-N-CA 123.007 2.472 . . . . 0.0 113.149 -173.96 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 83' ' ' ARG . . . . . 0.597 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 63.6 mtt180 -88.9 111.36 21.99 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.671 -0.695 . . . . 0.0 109.536 171.432 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 84' ' ' MET . . . . . 0.522 ' O ' ' HG3' ' A' ' 88' ' ' ARG . 92.7 mmm -67.36 -20.04 65.51 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.395 -176.991 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.597 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 9.3 pt-20 -60.49 -27.29 67.47 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.309 -179.664 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 67.4 mt -79.93 -40.24 20.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-O 120.98 0.419 . . . . 0.0 111.07 -178.571 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 87' ' ' TYR . . . . . 0.517 ' CE2' HG11 ' A' ' 40' ' ' VAL . 73.0 m-85 -81.98 -31.14 31.29 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.632 -176.889 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 88' ' ' ARG . . . . . 0.744 ' HG2' HG12 ' A' ' 113' ' ' VAL . 16.1 mtp180 -69.42 116.78 10.24 Favored 'General case' 0 CA--C 1.509 -0.606 0 CA-C-O 121.906 0.86 . . . . 0.0 111.462 -175.957 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 89' ' ' GLY . . . . . 0.439 ' O ' ' HD3' ' A' ' 38' ' ' ARG . . . 116.38 -18.9 13.37 Favored Glycine 0 C--N 1.31 -0.897 0 CA-C-N 114.07 -1.423 . . . . 0.0 111.765 -177.727 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 90' ' ' ALA . . . . . 0.995 ' HA ' ' HG2' ' A' ' 38' ' ' ARG . . . -66.24 143.09 57.44 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.604 0.24 . . . . 0.0 110.553 179.075 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -82.57 -29.22 30.43 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 120.831 0.348 . . . . 0.0 110.807 -178.624 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 92' ' ' LEU . . . . . 0.473 ' HG ' ' HB3' ' A' ' 116' ' ' ARG . 5.8 tt -149.71 143.44 25.46 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.15 -0.477 . . . . 0.0 109.96 -177.412 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.613 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 62.8 mt -130.65 127.46 62.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 N-CA-C 109.098 -0.705 . . . . 0.0 109.098 177.019 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 94' ' ' TYR . . . . . 0.756 ' HD2' ' HZ3' ' A' ' 120' ' ' LYS . 20.7 p90 -138.71 142.84 38.91 Favored 'General case' 0 C--N 1.321 -0.664 0 C-N-CA 120.208 -0.597 . . . . 0.0 111.407 -179.039 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 95' ' ' SER . . . . . 0.416 ' O ' ' HG2' ' A' ' 120' ' ' LYS . 8.0 m -118.08 144.96 45.19 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 115.497 -0.774 . . . . 0.0 110.047 -177.814 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 96' ' ' ILE . . . . . 0.819 HG12 ' HD2' ' A' ' 120' ' ' LYS . 42.9 mt -111.69 106.84 21.55 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-O 120.759 0.314 . . . . 0.0 110.46 179.804 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 97' ' ' ARG . . . . . 0.576 ' HD3' ' O ' ' A' ' 97' ' ' ARG . 0.0 OUTLIER 50.88 76.43 0.55 Allowed Pre-proline 0 CA--C 1.536 0.439 0 CA-C-N 115.099 -0.955 . . . . 0.0 111.173 -177.381 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_endo -96.3 159.61 1.29 Allowed 'Trans proline' 0 N--CA 1.453 -0.886 0 C-N-CA 123.211 2.607 . . . . 0.0 112.698 178.887 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 99' ' ' PRO . . . . . 0.677 ' HD2' HD11 ' A' ' 102' ' ' ILE . 17.5 Cg_exo -64.16 136.37 51.55 Favored 'Trans proline' 0 N--CA 1.462 -0.353 0 C-N-CA 122.32 2.014 . . . . 0.0 111.306 174.55 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 100' ' ' ALA . . . . . 0.69 ' HA ' ' CE1' ' A' ' 103' ' ' HIS . . . -68.98 -15.46 63.49 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 120.971 0.415 . . . . 0.0 111.833 -174.977 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 101' ' ' GLU . . . . . . . . . . . . . 1.7 pm0 -75.86 -18.51 59.4 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.888 178.582 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.677 HD11 ' HD2' ' A' ' 99' ' ' PRO . 2.6 pp -113.48 8.1 7.89 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.178 0 N-CA-C 112.567 0.58 . . . . 0.0 112.567 -177.341 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 103' ' ' HIS . . . . . 0.69 ' CE1' ' HA ' ' A' ' 100' ' ' ALA . 64.9 m170 -57.57 -42.64 83.47 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 121.063 0.459 . . . . 0.0 110.777 176.361 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 6.9 p -69.86 -26.85 64.4 Favored 'General case' 0 C--O 1.236 0.372 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.095 -179.114 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.571 ' O ' HG23 ' A' ' 109' ' ' VAL . 74.8 m -70.52 -44.79 66.85 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 109.757 -0.461 . . . . 0.0 109.757 174.519 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 96.0 mt -56.84 -41.81 78.54 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 121.067 0.46 . . . . 0.0 110.354 175.676 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 107' ' ' MET . . . . . . . . . . . . . 46.6 tpp -55.59 -52.59 63.25 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.28 -0.873 . . . . 0.0 111.365 178.497 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 4.8 ptp180 -71.3 -22.56 61.93 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 111.889 0.329 . . . . 0.0 111.889 -177.303 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.571 HG23 ' O ' ' A' ' 105' ' ' SER . 82.5 t -70.19 -48.37 61.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 C-N-CA 120.731 -0.388 . . . . 0.0 109.981 175.012 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -60.96 -44.53 97.16 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 177.049 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 22.7 t70 -60.68 -34.06 73.77 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.36 -0.836 . . . . 0.0 111.036 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -74.75 -44.44 49.74 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.795 -0.639 . . . . 0.0 111.813 -179.271 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.744 HG12 ' HG2' ' A' ' 88' ' ' ARG . 13.1 m -87.46 -29.29 5.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.981 -172.549 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 87.32 53.77 2.71 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.852 -0.69 . . . . 0.0 112.392 -178.978 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -131.97 160.44 35.79 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.737 0.303 . . . . 0.0 111.086 -178.192 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 116' ' ' ARG . . . . . 0.473 ' HB3' ' HG ' ' A' ' 92' ' ' LEU . 13.5 ttm180 -79.0 123.88 27.72 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 109.565 -0.532 . . . . 0.0 109.565 175.923 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 117' ' ' LEU . . . . . 0.613 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 58.3 tp -98.14 118.32 34.49 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.181 -179.429 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 55.7 mt -117.19 115.13 47.81 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-O 121.197 0.522 . . . . 0.0 110.629 178.861 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 40.6 mt -107.78 135.78 45.3 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.631 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.032 -178.032 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 120' ' ' LYS . . . . . 0.819 ' HD2' HG12 ' A' ' 96' ' ' ILE . 4.5 ptpp? -130.51 91.96 36.47 Favored Pre-proline 0 C--N 1.324 -0.518 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.238 -179.147 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 78.5 Cg_endo -96.77 -164.28 0.09 OUTLIER 'Trans proline' 0 N--CA 1.455 -0.765 0 C-N-CA 123.308 2.672 . . . . 0.0 112.647 179.344 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 122' ' ' LEU . . . . . 0.695 ' HB2' ' HB2' ' A' ' 125' ' ' GLU . 4.2 mm? -74.67 159.32 32.23 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.481 174.796 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 27.3 m -57.96 -43.68 86.57 Favored 'General case' 0 CA--C 1.53 0.2 0 CA-C-O 120.981 0.419 . . . . 0.0 110.959 -178.948 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -100.76 38.2 3.25 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.8 -0.714 . . . . 0.0 111.595 178.288 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 125' ' ' GLU . . . . . 0.695 ' HB2' ' HB2' ' A' ' 122' ' ' LEU . 27.4 tt0 -123.09 116.83 24.12 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.586 -0.524 . . . . 0.0 109.586 -177.515 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -88.55 164.71 15.28 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 121.544 0.688 . . . . 0.0 111.544 -172.903 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 52.1 mt . . . . . 0 C--N 1.317 -0.827 0 CA-C-N 115.06 -0.973 . . . . 0.0 108.586 172.71 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 25.6 mtpp . . . . . 0 N--CA 1.453 -0.296 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 133' ' ' MET . . . . . 0.8 ' HG2' ' HB2' ' A' ' 146' ' ' TYR . 82.1 mtp -84.05 -179.0 7.14 Favored 'General case' 0 C--O 1.232 0.176 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.294 179.874 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 19.1 ptmt -142.52 135.09 27.99 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 120.985 0.422 . . . . 0.0 111.091 -179.449 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 135' ' ' LEU . . . . . 0.563 HD11 ' HD2' ' A' ' 142' ' ' TYR . 50.3 tp -71.63 124.14 24.07 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.543 -0.753 . . . . 0.0 110.307 175.743 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 136' ' ' VAL . . . . . 0.42 HG23 ' CD1' ' A' ' 143' ' ' PHE . 0.0 OUTLIER -121.78 137.22 56.12 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.145 -179.818 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 17.2 m-80 -110.13 126.38 54.0 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 109.136 -0.69 . . . . 0.0 109.136 177.676 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 52.8 t80 -142.12 116.72 9.72 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 121.112 0.482 . . . . 0.0 111.277 -179.39 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 77.45 -92.34 1.08 Allowed Glycine 0 N--CA 1.447 -0.618 0 CA-C-N 115.74 -0.664 . . . . 0.0 112.159 176.045 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 50.4 mtm180 -139.52 16.37 2.55 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-O 121.047 0.451 . . . . 0.0 110.831 -179.372 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 13.8 t -138.15 158.72 43.74 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.269 -179.104 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 142' ' ' TYR . . . . . 0.563 ' HD2' HD11 ' A' ' 135' ' ' LEU . 35.2 p90 -134.33 139.62 45.79 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 178.135 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 143' ' ' PHE . . . . . 0.42 ' CD1' HG23 ' A' ' 136' ' ' VAL . 9.2 p90 -148.9 -172.83 4.2 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.116 -173.185 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 99.1 m-85 -119.42 128.63 54.22 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 120.486 0.184 . . . . 0.0 110.633 -179.086 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 145' ' ' GLU . . . . . . . . . . . . . 19.1 pt-20 -120.31 159.88 24.13 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.044 0.45 . . . . 0.0 109.916 174.78 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 146' ' ' TYR . . . . . 0.8 ' HB2' ' HG2' ' A' ' 133' ' ' MET . 49.7 t80 -140.63 127.95 21.14 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 115.904 -0.589 . . . . 0.0 109.816 176.471 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 147' ' ' ILE . . . . . 0.433 ' N ' HD12 ' A' ' 147' ' ' ILE . 3.1 mp -94.63 100.66 11.47 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 N-CA-C 109.679 -0.489 . . . . 0.0 109.679 178.752 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -91.38 125.75 36.24 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.869 -0.605 . . . . 0.0 109.796 177.115 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 . . . . . 0 C--N 1.32 -0.696 0 CA-C-O 121.038 0.447 . . . . 0.0 110.186 -179.533 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 90.8 m95 . . . . . 0 N--CA 1.452 -0.368 0 CA-C-O 120.539 0.209 . . . . 0.0 110.696 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 23' ' ' ASN . . . . . 0.412 ' O ' HG23 ' A' ' 27' ' ' VAL . 4.7 m-20 -68.99 -47.61 65.13 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.515 -0.311 . . . . 0.0 110.905 177.729 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 15.6 m-20 -60.6 -39.48 88.28 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.81 0.338 . . . . 0.0 110.579 178.59 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 60.5 tp -57.76 -49.53 76.27 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.424 176.204 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -55.71 -47.17 77.31 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.542 -0.753 . . . . 0.0 110.904 178.859 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.412 HG23 ' O ' ' A' ' 23' ' ' ASN . 84.9 t -56.73 -42.9 78.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.938 178.479 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 86.6 t80 -61.32 -45.48 94.28 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.724 0.297 . . . . 0.0 110.383 178.436 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 72.9 mt -63.21 -43.2 98.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.45 178.799 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 86.8 mt -56.83 -42.66 78.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 115.451 -0.795 . . . . 0.0 111.265 177.126 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 21.4 mtp180 -69.06 -32.37 71.79 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.804 -178.816 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 77.0 m -88.33 2.51 52.36 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.794 -0.639 . . . . 0.0 111.758 -175.874 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 22.0 p -129.7 -80.54 0.56 Allowed 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 120.816 0.341 . . . . 0.0 111.004 178.018 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 95.61 160.13 33.08 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.934 -0.65 . . . . 0.0 112.408 -179.616 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -73.25 141.68 32.62 Favored 'Trans proline' 0 N--CA 1.462 -0.347 0 C-N-CA 122.785 2.323 . . . . 0.0 111.438 178.022 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 113.13 3.71 24.39 Favored Glycine 0 N--CA 1.449 -0.452 0 C-N-CA 120.348 -0.929 . . . . 0.0 112.16 -177.226 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 14.7 t -139.42 -169.57 2.71 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 110.001 -0.37 . . . . 0.0 110.001 177.812 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 38' ' ' ARG . . . . . 0.41 ' HD3' HH11 ' A' ' 38' ' ' ARG . 47.0 mtp180 -121.75 135.84 54.94 Favored 'General case' 0 N--CA 1.45 -0.45 0 CA-C-O 120.906 0.384 . . . . 0.0 110.637 -178.738 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 52.3 t -122.56 134.67 65.07 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 177.463 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 50.3 t -108.04 124.36 64.21 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-O 120.733 0.301 . . . . 0.0 110.678 -177.813 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' GLU . . . . . 0.527 ' HB2' HD21 ' A' ' 62' ' ' LEU . 35.6 tt0 -102.04 106.68 17.61 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.066 179.004 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.6 ' O ' ' HA ' ' A' ' 95' ' ' SER . 60.3 t -94.04 124.39 46.49 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.603 0 CA-C-N 116.031 -0.531 . . . . 0.0 109.846 179.779 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 96.27 37.63 4.79 Favored Glycine 0 N--CA 1.445 -0.751 0 C-N-CA 120.337 -0.935 . . . . 0.0 111.297 -175.93 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -81.21 24.61 0.52 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.018 0.437 . . . . 0.0 111.413 -177.822 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -73.89 79.09 0.87 Allowed Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 121.212 -0.518 . . . . 0.0 112.08 -178.924 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 26.7 ttt180 75.67 7.72 3.8 Favored 'General case' 0 N--CA 1.468 0.436 0 C-N-CA 123.418 0.687 . . . . 0.0 110.968 177.14 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 65.8 m-85 -95.96 31.01 2.22 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.39 0.614 . . . . 0.0 110.413 178.06 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.609 HD22 HD13 ' A' ' 64' ' ' LEU . 61.6 mt -74.35 14.65 0.42 Allowed 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.075 -0.966 . . . . 0.0 112.376 -172.931 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 87.8 t80 -70.3 -37.26 74.74 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 121.068 0.461 . . . . 0.0 110.375 179.665 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 47.2 t -74.76 -48.81 32.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-N 115.936 -0.574 . . . . 0.0 110.372 -179.326 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -58.67 -39.77 81.63 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.997 -0.547 . . . . 0.0 111.369 179.526 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.425 ' O ' ' HE2' ' A' ' 56' ' ' LYS . 30.6 t70 -62.06 -45.07 95.16 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.792 0.33 . . . . 0.0 110.531 177.826 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 53' ' ' TYR . . . . . 0.459 ' HA ' ' HE2' ' A' ' 56' ' ' LYS . 81.5 t80 -63.53 -42.98 98.4 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.927 -179.248 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 80.8 mt -66.22 -47.73 83.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.889 -178.941 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 22.4 ptt180 -62.77 -24.57 67.78 Favored 'General case' 0 N--CA 1.467 0.401 0 N-CA-C 111.856 0.317 . . . . 0.0 111.856 -175.344 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 56' ' ' LYS . . . . . 0.459 ' HE2' ' HA ' ' A' ' 53' ' ' TYR . 42.2 mtmt -77.2 -31.22 55.17 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.727 0.299 . . . . 0.0 111.692 -177.611 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 7.7 t-80 -99.18 -48.56 4.79 Favored 'General case' 0 N--CA 1.448 -0.562 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.518 -177.384 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 38.1 m -95.22 155.51 16.7 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.068 0.461 . . . . 0.0 111.053 -178.024 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 28.5 mmmt -105.17 19.26 20.9 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.938 -0.574 . . . . 0.0 109.704 178.242 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 15.0 p -68.63 153.27 9.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 115.404 -0.816 . . . . 0.0 110.522 -178.78 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -86.58 103.34 14.99 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 120.832 0.349 . . . . 0.0 110.16 178.521 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 62' ' ' LEU . . . . . 0.527 HD21 ' HB2' ' A' ' 41' ' ' GLU . 1.8 tt -101.36 119.08 38.22 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 115.942 -0.572 . . . . 0.0 109.935 -176.42 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 46.2 t -100.22 119.14 47.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.365 -179.15 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 64' ' ' LEU . . . . . 0.609 HD13 HD22 ' A' ' 48' ' ' LEU . 32.3 mt -95.42 122.44 38.14 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.935 -0.575 . . . . 0.0 109.73 178.785 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 37.9 p -118.34 142.27 47.69 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 120.567 0.222 . . . . 0.0 111.189 -178.374 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 30.9 t70 -165.32 154.97 12.81 Favored 'General case' 0 C--N 1.33 -0.259 0 N-CA-C 110.124 -0.325 . . . . 0.0 110.124 179.788 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.575 HD13 ' HA ' ' A' ' 78' ' ' ASP . 37.4 mm -69.61 94.33 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.853 0.359 . . . . 0.0 110.163 179.144 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 68' ' ' LYS . . . . . 0.722 ' HD3' ' HB2' ' A' ' 76' ' ' ARG . 40.9 mmtm 44.46 70.66 1.81 Allowed Pre-proline 0 CA--C 1.533 0.296 0 CA-C-N 115.279 -0.873 . . . . 0.0 110.835 -178.304 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 69' ' ' PRO . . . . . 0.742 ' HD2' ' HA ' ' A' ' 76' ' ' ARG . 10.3 Cg_endo . . . . . 0 C--N 1.344 0.341 0 C-N-CA 123.896 3.064 . . . . 0.0 113.762 -172.495 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.495 ' HB ' ' HG3' ' A' ' 69' ' ' PRO . 35.9 mt . . . . . 0 C--O 1.234 0.276 0 N-CA-C 110.38 -0.23 . . . . 0.0 110.38 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 60.3 t -68.62 128.62 32.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 178.767 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 76' ' ' ARG . . . . . 0.742 ' HA ' ' HD2' ' A' ' 69' ' ' PRO . 32.1 ptt180 -91.43 54.46 2.54 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.453 0.644 . . . . 0.0 110.976 -179.43 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 9.7 p-10 -83.34 -156.54 0.2 Allowed 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.039 -0.982 . . . . 0.0 109.955 178.129 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 78' ' ' ASP . . . . . 0.575 ' HA ' HD13 ' A' ' 67' ' ' ILE . 20.3 m-20 -143.85 108.75 4.94 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 110.297 -0.26 . . . . 0.0 110.297 -179.391 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 9.3 tp -73.66 -24.51 19.99 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.37 0 CA-C-O 120.819 0.343 . . . . 0.0 110.737 178.758 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 10.0 t -69.19 -26.95 65.09 Favored 'General case' 0 CA--C 1.531 0.241 0 CA-C-O 121.219 0.533 . . . . 0.0 110.547 178.077 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 22.7 t -134.28 78.74 57.24 Favored Pre-proline 0 C--N 1.323 -0.569 0 N-CA-C 108.153 -1.055 . . . . 0.0 108.153 173.292 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 82' ' ' PRO . . . . . 0.429 ' HB2' ' HE2' ' A' ' 87' ' ' TYR . 59.1 Cg_endo -71.13 133.44 23.06 Favored 'Trans proline' 0 N--CA 1.461 -0.426 0 C-N-CA 122.762 2.308 . . . . 0.0 113.625 -168.592 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 83' ' ' ARG . . . . . 0.537 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 70.7 mtt85 -84.98 106.27 16.36 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.453 -0.794 . . . . 0.0 109.27 171.871 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 84' ' ' MET . . . . . . . . . . . . . 89.5 mmm -58.21 -26.45 62.85 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.987 -0.551 . . . . 0.0 111.142 -177.235 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.537 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 11.3 pt-20 -62.14 -26.78 68.51 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.672 -179.558 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 73.6 mt -79.46 -41.11 22.16 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-O 121.04 0.447 . . . . 0.0 110.531 -179.339 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 87' ' ' TYR . . . . . 0.429 ' HE2' ' HB2' ' A' ' 82' ' ' PRO . 44.9 m-85 -79.65 -25.51 41.32 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.789 -176.795 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 52.0 mtp180 -66.23 131.58 46.47 Favored 'General case' 0 CA--C 1.517 -0.304 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.373 176.276 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 98.23 8.72 54.81 Favored Glycine 0 N--CA 1.444 -0.811 0 C-N-CA 120.627 -0.797 . . . . 0.0 111.699 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -100.77 144.6 29.53 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 110.204 -0.295 . . . . 0.0 110.204 177.689 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -92.78 -23.73 18.77 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.078 0.466 . . . . 0.0 110.939 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 92' ' ' LEU . . . . . 0.464 HD23 ' N ' ' A' ' 93' ' ' ILE . 4.6 tt -150.1 140.74 22.58 Favored 'General case' 0 N--CA 1.449 -0.516 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.434 -178.225 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.524 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 62.8 mt -130.68 119.27 45.15 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 115.784 -0.644 . . . . 0.0 109.419 177.937 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 13.2 p90 -126.18 155.21 42.11 Favored 'General case' 0 C--N 1.32 -0.701 0 C-N-CA 120.553 -0.459 . . . . 0.0 110.544 179.277 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 95' ' ' SER . . . . . 0.6 ' HA ' ' O ' ' A' ' 42' ' ' VAL . 10.6 p -135.81 143.63 45.28 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.752 -0.658 . . . . 0.0 111.424 -175.189 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 74.5 mt -114.86 112.59 40.67 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 115.577 -0.738 . . . . 0.0 110.249 178.763 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 61.6 mtp180 57.59 70.36 1.34 Allowed Pre-proline 0 N--CA 1.466 0.331 0 CA-C-N 115.593 -0.73 . . . . 0.0 112.279 -178.459 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_endo -87.31 131.72 3.05 Favored 'Trans proline' 0 N--CA 1.451 -1.005 0 C-N-CA 122.536 2.157 . . . . 0.0 111.78 175.699 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 99' ' ' PRO . . . . . 0.635 ' HD2' HD11 ' A' ' 102' ' ' ILE . 52.2 Cg_exo -55.98 148.9 55.3 Favored 'Trans proline' 0 C--O 1.235 0.36 0 C-N-CA 122.464 2.11 . . . . 0.0 111.564 172.267 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 100' ' ' ALA . . . . . 0.712 ' HA ' ' ND1' ' A' ' 103' ' ' HIS . . . -60.71 -22.91 64.45 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.918 0.39 . . . . 0.0 111.763 -175.337 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 101' ' ' GLU . . . . . 0.694 ' HG3' HG23 ' A' ' 102' ' ' ILE . 10.5 pt-20 -66.65 -31.22 71.75 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.983 -179.958 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.694 HG23 ' HG3' ' A' ' 101' ' ' GLU . 48.3 pt -107.42 -1.05 9.92 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.148 0 N-CA-C 112.482 0.549 . . . . 0.0 112.482 -173.004 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 103' ' ' HIS . . . . . 0.712 ' ND1' ' HA ' ' A' ' 100' ' ' ALA . 13.1 m170 -53.54 -55.61 24.08 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 121.118 0.485 . . . . 0.0 111.162 178.235 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 19.0 m -70.2 -25.59 63.48 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 121.184 0.516 . . . . 0.0 110.689 179.503 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.705 ' O ' ' HG2' ' A' ' 108' ' ' ARG . 1.7 m -71.83 -37.65 70.27 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.502 -177.955 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 86.1 mt -63.62 -39.15 93.64 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.709 177.531 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 107' ' ' MET . . . . . . . . . . . . . 49.7 ttm -64.54 -42.33 95.78 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.208 179.447 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 108' ' ' ARG . . . . . 0.705 ' HG2' ' O ' ' A' ' 105' ' ' SER . 1.7 ptm180 -66.37 -26.84 67.45 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.836 0.35 . . . . 0.0 110.628 -178.225 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 82.2 t -75.3 -49.15 28.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.155 175.374 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -57.69 -42.63 84.05 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.494 177.458 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.492 ' HA ' ' HB1' ' A' ' 148' ' ' ALA . 16.8 t70 -62.45 -32.08 72.9 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.581 -0.736 . . . . 0.0 110.746 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -79.09 -41.74 27.97 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.585 -0.734 . . . . 0.0 111.955 -178.634 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 29.0 m -87.83 -26.14 5.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 N-CA-C 111.907 0.336 . . . . 0.0 111.907 -175.955 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 82.5 64.86 1.66 Allowed Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.884 -0.674 . . . . 0.0 112.052 -178.955 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 115' ' ' ALA . . . . . 0.4 ' O ' ' HB3' ' A' ' 148' ' ' ALA . . . -139.58 155.41 47.49 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 120.815 0.341 . . . . 0.0 110.702 -179.909 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 116' ' ' ARG . . . . . 0.449 ' HB3' ' HG ' ' A' ' 92' ' ' LEU . 20.0 ttm-85 -75.1 121.59 22.27 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 177.416 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 117' ' ' LEU . . . . . 0.524 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 65.9 tp -94.02 125.28 38.56 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.171 -179.928 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 71.4 mt -124.25 120.51 59.46 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.654 0 CA-C-O 120.899 0.38 . . . . 0.0 110.146 177.488 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 30.2 mt -114.04 131.21 66.64 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.217 -178.348 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 120' ' ' LYS . . . . . 0.616 ' HD3' ' HB3' ' A' ' 143' ' ' PHE . 10.9 mmmm -110.86 98.08 36.61 Favored Pre-proline 0 C--O 1.235 0.308 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.881 172.946 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 85.7 Cg_endo -92.42 -157.89 0.06 OUTLIER 'Trans proline' 0 N--CA 1.453 -0.889 0 C-N-CA 123.177 2.585 . . . . 0.0 111.162 173.729 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 8.0 mp -111.38 150.42 29.79 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 120.635 0.255 . . . . 0.0 110.607 178.205 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 38.1 m -65.57 110.42 2.72 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.064 0.459 . . . . 0.0 110.655 178.916 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 108.36 -10.76 36.34 Favored Glycine 0 N--CA 1.445 -0.71 0 N-CA-C 111.084 -0.806 . . . . 0.0 111.084 -176.461 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 4.7 tp10 -106.39 100.5 10.02 Favored 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 109.08 -0.711 . . . . 0.0 109.08 178.49 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 15.8 t70 -85.22 165.05 17.69 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.427 -0.351 . . . . 0.0 110.958 -174.033 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 127' ' ' ILE . . . . . 0.447 HG23 ' CG ' ' A' ' 103' ' ' HIS . 52.3 mt . . . . . 0 C--N 1.323 -0.548 0 CA-C-N 115.767 -0.652 . . . . 0.0 110.55 -177.628 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 132' ' ' LYS . . . . . 0.468 ' HE3' ' HB2' ' A' ' 132' ' ' LYS . 35.5 mtmt . . . . . 0 CA--C 1.52 -0.189 0 CA-C-O 120.518 0.199 . . . . 0.0 111.282 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 133' ' ' MET . . . . . . . . . . . . . 79.7 mtp -146.08 150.59 36.23 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 170.789 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 1.5 ptpp? -114.83 141.27 48.12 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 121.322 0.582 . . . . 0.0 111.301 -177.501 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 135' ' ' LEU . . . . . 0.558 HD11 ' HD2' ' A' ' 142' ' ' TYR . 60.0 tp -82.24 129.23 34.8 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.141 -0.936 . . . . 0.0 109.883 178.666 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -126.35 148.47 31.05 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.885 -177.852 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 68.2 m-20 -124.23 125.73 44.89 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.05 -0.523 . . . . 0.0 109.865 179.827 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 138' ' ' TYR . . . . . 0.608 ' O ' HG22 ' A' ' 141' ' ' THR . 42.7 t80 -149.19 104.79 3.44 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.746 0.307 . . . . 0.0 111.049 177.562 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 139' ' ' GLY . . . . . 0.402 ' C ' ' H ' ' A' ' 141' ' ' THR . . . 59.93 67.28 2.23 Favored Glycine 0 CA--C 1.521 0.417 0 CA-C-N 116.212 -0.449 . . . . 0.0 113.736 175.878 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 21.9 mmt180 69.54 -21.64 0.16 Allowed 'General case' 0 N--CA 1.47 0.547 0 N-CA-C 113.176 0.806 . . . . 0.0 113.176 176.339 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 141' ' ' THR . . . . . 0.608 HG22 ' O ' ' A' ' 138' ' ' TYR . 1.0 OUTLIER -98.0 131.47 44.4 Favored 'General case' 0 N--CA 1.444 -0.77 0 CA-C-O 121.33 0.586 . . . . 0.0 109.91 -179.359 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 142' ' ' TYR . . . . . 0.558 ' HD2' HD11 ' A' ' 135' ' ' LEU . 21.6 p90 -115.99 147.28 41.37 Favored 'General case' 0 N--CA 1.445 -0.713 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 174.872 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 143' ' ' PHE . . . . . 0.616 ' HB3' ' HD3' ' A' ' 120' ' ' LYS . 12.2 p90 -155.81 171.82 19.38 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.61 -175.308 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -107.93 121.43 44.77 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.899 -0.591 . . . . 0.0 109.568 175.845 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 145' ' ' GLU . . . . . . . . . . . . . 15.3 pt-20 -112.32 156.06 23.06 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-O 121.267 0.556 . . . . 0.0 109.578 177.125 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 34.7 t80 -138.88 124.23 19.28 Favored 'General case' 0 C--N 1.311 -1.092 0 CA-C-N 115.646 -0.706 . . . . 0.0 109.468 176.322 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 147' ' ' ILE . . . . . 0.446 ' N ' HD12 ' A' ' 147' ' ' ILE . 3.1 mp -88.44 96.07 5.72 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.739 0 N-CA-C 109.18 -0.674 . . . . 0.0 109.18 178.078 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 148' ' ' ALA . . . . . 0.492 ' HB1' ' HA ' ' A' ' 111' ' ' ASP . . . -76.49 118.03 18.75 Favored 'General case' 0 C--N 1.317 -0.819 0 CA-C-N 115.369 -0.832 . . . . 0.0 109.061 177.042 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 31.3 mt-10 . . . . . 0 C--N 1.322 -0.604 0 CA-C-O 121.814 0.816 . . . . 0.0 111.094 -175.206 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 83.2 m95 . . . . . 0 N--CA 1.451 -0.407 0 N-CA-C 109.596 -0.52 . . . . 0.0 109.596 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 4.6 m-20 -62.51 -56.02 21.94 Favored 'General case' 0 CA--C 1.521 -0.171 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.508 176.418 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.549 ' HB3' ' HA3' ' A' ' 139' ' ' GLY . 44.7 m-20 -60.61 -36.64 79.09 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.617 179.766 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 64.6 tp -55.83 -49.74 72.45 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.177 175.027 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' ALA . . . . . 0.566 ' HB2' HG13 ' A' ' 50' ' ' VAL . . . -62.14 -46.69 87.89 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.582 -0.736 . . . . 0.0 111.024 179.029 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 71.4 t -53.17 -47.32 55.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 121.102 0.477 . . . . 0.0 110.664 176.8 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' TYR . . . . . 0.481 ' HB2' ' CD1' ' A' ' 138' ' ' TYR . 69.7 t80 -56.2 -41.64 75.9 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.891 178.491 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.499 HG23 HD22 ' A' ' 92' ' ' LEU . 75.8 mt -69.83 -44.81 78.63 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.82 178.88 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.621 HD11 ' HA ' ' A' ' 54' ' ' ILE . 83.6 mt -57.77 -43.77 84.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 115.891 -0.595 . . . . 0.0 111.507 -178.98 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 17.9 mtp180 -64.81 -32.76 74.6 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.902 -178.569 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 81.4 m -88.95 -18.67 26.99 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 115.501 -0.772 . . . . 0.0 111.995 -174.006 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 14.0 p -101.54 -82.1 0.47 Allowed 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 120.797 0.332 . . . . 0.0 111.556 -178.54 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 101.81 161.42 26.77 Favored Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 121.014 -0.612 . . . . 0.0 112.187 -178.328 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 7.6 Cg_exo -72.8 144.48 39.12 Favored 'Trans proline' 0 C--O 1.233 0.269 0 C-N-CA 123.083 2.522 . . . . 0.0 112.383 -179.163 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 111.89 -28.76 9.06 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.533 -0.842 . . . . 0.0 112.813 177.897 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 12.6 t -99.86 -169.45 1.74 Allowed 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 -178.551 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' ARG . . . . . 0.628 ' HB2' ' HA ' ' A' ' 90' ' ' ALA . 66.2 mtp180 -118.6 136.51 53.84 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.954 0.407 . . . . 0.0 111.134 -178.346 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.655 HG23 HG21 ' A' ' 60' ' ' VAL . 95.5 t -129.97 131.11 66.38 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-N 115.83 -0.623 . . . . 0.0 109.369 176.699 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.576 HG22 ' HB ' ' A' ' 63' ' ' VAL . 40.6 t -112.12 129.0 68.4 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 CA-C-O 120.765 0.317 . . . . 0.0 111.759 -173.178 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 41' ' ' GLU . . . . . 0.459 ' HB3' HD23 ' A' ' 64' ' ' LEU . 44.8 tt0 -103.11 107.76 18.7 Favored 'General case' 0 C--O 1.235 0.319 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 174.693 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 44.1 t -89.68 127.78 42.09 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.647 -178.16 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 94.14 23.98 20.82 Favored Glycine 0 N--CA 1.448 -0.523 0 N-CA-C 110.955 -0.858 . . . . 0.0 110.955 -176.375 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.608 ' HB1' HD23 ' A' ' 48' ' ' LEU . . . -93.47 80.38 4.36 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.247 -0.476 . . . . 0.0 110.858 -177.044 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -108.42 -60.61 0.54 Allowed Glycine 0 N--CA 1.446 -0.664 0 C-N-CA 120.824 -0.703 . . . . 0.0 112.015 178.607 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 57.6 mtp180 -125.47 4.44 7.63 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.933 0.397 . . . . 0.0 110.814 -179.171 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.528 ' HE2' HG23 ' A' ' 50' ' ' VAL . 64.7 t80 -86.69 -79.45 0.26 Allowed 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 176.712 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.646 HD22 HD13 ' A' ' 64' ' ' LEU . 59.4 mt 62.71 9.35 3.51 Favored 'General case' 0 N--CA 1.467 0.41 0 CA-C-N 115.156 -0.929 . . . . 0.0 112.795 171.006 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 49' ' ' TYR . . . . . 0.452 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 81.2 t80 -71.08 -45.42 63.77 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 111.791 0.293 . . . . 0.0 111.791 -171.431 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.566 HG13 ' HB2' ' A' ' 26' ' ' ALA . 56.2 t -69.98 -48.57 62.35 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-N 116.599 -0.273 . . . . 0.0 110.597 -177.946 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 50.9 p -58.77 -41.15 85.92 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.453 -0.339 . . . . 0.0 111.037 176.956 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.737 ' HA ' ' HE ' ' A' ' 55' ' ' ARG . 24.4 t70 -61.13 -37.97 84.72 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.8 0.333 . . . . 0.0 110.712 176.55 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 47.3 t80 -69.19 -45.6 69.55 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.308 178.041 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.621 ' HA ' HD11 ' A' ' 30' ' ' ILE . 88.0 mt -63.45 -44.83 99.02 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.823 -178.347 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 55' ' ' ARG . . . . . 0.748 HH22 HD11 ' A' ' 64' ' ' LEU . 12.1 ptp180 -63.37 -16.42 60.42 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-O 120.791 0.329 . . . . 0.0 111.584 -175.77 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 56' ' ' LYS . . . . . 0.459 ' HG3' ' O ' ' A' ' 52' ' ' ASP . 97.7 mttt -81.39 -36.04 30.03 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.599 -179.602 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 81.6 m-70 -103.67 -18.11 14.85 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.817 -175.021 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 58' ' ' SER . . . . . 0.421 ' HB2' HG23 ' A' ' 30' ' ' ILE . 6.4 t -135.63 128.9 31.98 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-O 120.794 0.331 . . . . 0.0 110.566 -177.356 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -89.39 51.42 2.12 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.871 0.843 . . . . 0.0 110.126 175.532 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.655 HG21 HG23 ' A' ' 39' ' ' VAL . 8.3 p -83.59 147.21 5.96 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 CA-C-N 114.845 -1.07 . . . . 0.0 108.908 175.434 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 61' ' ' ASP . . . . . 0.571 ' HB3' ' HG2' ' A' ' 38' ' ' ARG . 19.0 t70 -72.68 95.52 1.88 Allowed 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 109.248 -0.649 . . . . 0.0 109.248 179.269 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 62' ' ' LEU . . . . . 0.411 ' HA ' ' O ' ' A' ' 39' ' ' VAL . 2.1 tt -94.77 128.45 41.49 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.407 -172.318 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.576 ' HB ' HG22 ' A' ' 40' ' ' VAL . 33.3 t -108.71 126.7 65.58 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.45 -178.92 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 64' ' ' LEU . . . . . 0.748 HD11 HH22 ' A' ' 55' ' ' ARG . 66.7 mt -108.61 131.18 55.13 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 116.039 -0.528 . . . . 0.0 109.63 176.4 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 49.9 p -129.3 127.91 42.11 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.721 0.296 . . . . 0.0 111.319 179.389 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 3.7 t70 -165.74 175.88 8.43 Favored 'General case' 0 C--O 1.233 0.215 0 CA-C-N 116.082 -0.508 . . . . 0.0 109.732 176.964 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 53.0 mt -87.68 114.57 26.72 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-O 120.634 0.254 . . . . 0.0 110.657 -176.391 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 55.3 mtpt 61.17 79.93 0.27 Allowed Pre-proline 0 C--N 1.331 -0.226 0 CA-C-N 115.646 -0.707 . . . . 0.0 110.9 178.287 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 69' ' ' PRO . . . . . 1.017 ' HB3' ' HB ' ' A' ' 74' ' ' ILE . 18.9 Cg_endo . . . . . 0 C--N 1.342 0.223 0 C-N-CA 123.281 2.654 . . . . 0.0 113.08 -176.092 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 1.017 ' HB ' ' HB3' ' A' ' 69' ' ' PRO . 65.4 mt . . . . . 0 N--CA 1.451 -0.394 0 N-CA-C 109.996 -0.372 . . . . 0.0 109.996 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.589 HG11 HD13 ' A' ' 86' ' ' ILE . 48.3 t -80.78 135.89 24.32 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 N-CA-C 109.778 -0.452 . . . . 0.0 109.778 176.805 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 11.4 ptt180 -75.98 25.71 0.12 Allowed 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.867 -0.606 . . . . 0.0 111.876 -177.177 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 77' ' ' ASP . . . . . 0.404 ' H ' ' C ' ' A' ' 75' ' ' VAL . 12.7 t70 -83.35 113.82 20.99 Favored 'General case' 0 C--N 1.324 -0.536 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 -177.753 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 2.2 p30 -70.67 168.97 15.37 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.033 0.444 . . . . 0.0 111.257 -172.697 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 79' ' ' ILE . . . . . 0.443 HD11 HD12 ' A' ' 102' ' ' ILE . 7.1 tp -83.98 -30.27 7.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 N-CA-C 112.936 0.717 . . . . 0.0 112.936 -169.569 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 12.2 t -94.23 -21.01 19.31 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.169 0.509 . . . . 0.0 110.712 -174.017 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 4.5 t -130.64 69.03 82.22 Favored Pre-proline 0 C--N 1.323 -0.585 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.05 -179.807 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -78.64 163.48 26.59 Favored 'Trans proline' 0 N--CA 1.46 -0.443 0 C-N-CA 122.98 2.453 . . . . 0.0 112.619 -175.834 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 83' ' ' ARG . . . . . 0.645 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 88.6 mtm180 -108.92 118.17 36.1 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.291 178.305 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 84' ' ' MET . . . . . 0.515 ' SD ' HG22 ' A' ' 109' ' ' VAL . 92.0 mmm -61.13 -28.61 69.23 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.267 -0.879 . . . . 0.0 111.343 -179.037 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.645 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 10.7 pt-20 -57.69 -24.27 55.9 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.711 -179.975 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.589 HD13 HG11 ' A' ' 75' ' ' VAL . 76.5 mt -86.48 -43.75 16.29 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.089 -177.478 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 87' ' ' TYR . . . . . 0.438 ' CE1' HG11 ' A' ' 40' ' ' VAL . 88.3 m-85 -72.13 -27.15 62.44 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.37 -178.593 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 27.0 mtp180 -66.06 116.66 7.4 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 121.409 0.623 . . . . 0.0 111.26 -179.482 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 118.61 -15.99 11.44 Favored Glycine 0 N--CA 1.447 -0.597 0 CA-C-N 115.189 -0.914 . . . . 0.0 111.243 -176.065 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 90' ' ' ALA . . . . . 0.628 ' HA ' ' HB2' ' A' ' 38' ' ' ARG . . . -75.48 145.63 41.25 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.897 0.379 . . . . 0.0 110.545 178.837 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -98.51 -20.76 16.89 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.125 177.659 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 92' ' ' LEU . . . . . 0.499 HD22 HG23 ' A' ' 29' ' ' ILE . 5.1 tt -153.33 138.24 17.17 Favored 'General case' 0 N--CA 1.447 -0.604 0 CA-C-N 115.688 -0.687 . . . . 0.0 109.967 -179.306 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.538 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 63.6 mt -130.64 131.16 64.96 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 115.987 -0.551 . . . . 0.0 109.629 -178.748 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 94' ' ' TYR . . . . . 0.454 ' HE1' HG12 ' A' ' 39' ' ' VAL . 26.6 p90 -134.15 156.05 49.01 Favored 'General case' 0 C--N 1.322 -0.626 0 C-N-CA 120.625 -0.43 . . . . 0.0 110.811 179.57 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 17.3 m -131.86 139.76 48.91 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.76 -177.651 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 42.3 mm -85.94 86.98 2.5 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.363 -179.259 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 97' ' ' ARG . . . . . 0.438 ' NH1' HD13 ' A' ' 122' ' ' LEU . 39.1 ttp180 44.32 79.56 0.33 Allowed Pre-proline 0 N--CA 1.47 0.558 0 O-C-N 124.126 0.891 . . . . 0.0 112.364 -179.313 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 91.2 Cg_endo -83.83 154.13 13.26 Favored 'Trans proline' 0 N--CA 1.456 -0.704 0 C-N-CA 122.918 2.412 . . . . 0.0 112.042 178.892 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 99' ' ' PRO . . . . . 0.605 ' HD2' HD11 ' A' ' 102' ' ' ILE . 51.3 Cg_exo -55.35 150.66 40.32 Favored 'Trans proline' 0 C--N 1.346 0.417 0 C-N-CA 122.605 2.204 . . . . 0.0 112.112 175.53 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -79.68 30.31 0.25 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.727 -174.205 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 101' ' ' GLU . . . . . 0.413 ' HG3' HG23 ' A' ' 102' ' ' ILE . 10.4 pt-20 -124.95 -23.46 4.26 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 120.742 0.306 . . . . 0.0 110.954 176.507 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.605 HD11 ' HD2' ' A' ' 99' ' ' PRO . 46.6 pt -98.9 -2.4 9.83 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-O 120.752 0.31 . . . . 0.0 111.316 -177.173 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 103' ' ' HIS . . . . . 0.576 ' O ' ' HG2' ' A' ' 107' ' ' MET . 31.4 p-80 -60.16 -40.09 88.71 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.138 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 8.1 p -63.21 -35.85 81.68 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.913 178.604 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.514 ' O ' HG23 ' A' ' 109' ' ' VAL . 16.3 m -67.42 -45.91 74.72 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.735 -0.666 . . . . 0.0 109.69 177.976 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 96.0 mt -59.86 -42.17 93.1 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.909 178.124 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 107' ' ' MET . . . . . 0.576 ' HG2' ' O ' ' A' ' 103' ' ' HIS . 98.2 mmm -56.71 -49.59 74.71 Favored 'General case' 0 C--O 1.233 0.234 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.537 -179.939 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 33.7 ptt85 -70.77 -30.57 67.09 Favored 'General case' 0 C--N 1.332 -0.188 0 C-N-CA 120.727 -0.389 . . . . 0.0 111.108 -177.403 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.515 HG22 ' SD ' ' A' ' 84' ' ' MET . 69.5 t -67.78 -48.49 75.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 120.575 0.226 . . . . 0.0 110.647 177.029 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -59.08 -41.64 88.5 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.708 179.626 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.679 ' HA ' ' HB1' ' A' ' 148' ' ' ALA . 23.3 t70 -65.6 -42.29 91.8 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.701 -0.682 . . . . 0.0 110.815 178.489 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -62.54 -43.46 98.77 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.964 -0.562 . . . . 0.0 111.645 -178.364 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.419 HG21 HD11 ' A' ' 93' ' ' ILE . 20.2 m -85.38 -28.14 6.42 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-O 120.928 0.394 . . . . 0.0 111.022 -177.59 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 87.35 51.85 3.2 Favored Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 120.596 -0.812 . . . . 0.0 111.918 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -130.15 155.47 46.16 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 120.831 0.348 . . . . 0.0 110.901 -178.799 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 116' ' ' ARG . . . . . 0.698 HH21 HD11 ' A' ' 118' ' ' ILE . 50.2 ttp180 -79.21 117.56 20.34 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 178.037 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 117' ' ' LEU . . . . . 0.538 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 60.3 tp -88.14 118.84 27.99 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.0 -0.546 . . . . 0.0 110.086 -179.535 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 118' ' ' ILE . . . . . 0.698 HD11 HH21 ' A' ' 116' ' ' ARG . 66.6 mt -114.52 117.42 55.54 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-O 121.28 0.562 . . . . 0.0 110.842 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 71.7 mt -116.52 116.9 53.72 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.323 179.308 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 57.6 tttp -102.76 104.4 38.78 Favored Pre-proline 0 C--N 1.322 -0.598 0 C-N-CA 120.656 -0.418 . . . . 0.0 110.005 172.351 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 121' ' ' PRO . . . . . 0.591 ' HB2' ' O ' ' A' ' 125' ' ' GLU . 70.5 Cg_endo -78.68 -139.58 0.02 OUTLIER 'Trans proline' 0 N--CA 1.457 -0.673 0 C-N-CA 122.522 2.148 . . . . 0.0 111.531 172.673 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 122' ' ' LEU . . . . . 0.888 ' HB3' ' HB3' ' A' ' 125' ' ' GLU . 14.4 tp -126.82 156.94 40.52 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.383 -178.789 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 123' ' ' THR . . . . . 0.472 ' HA ' ' OH ' ' A' ' 142' ' ' TYR . 25.4 m -69.94 102.04 1.9 Allowed 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 177.368 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 100.88 2.88 55.1 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.967 -0.635 . . . . 0.0 111.737 -175.533 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 125' ' ' GLU . . . . . 0.888 ' HB3' ' HB3' ' A' ' 122' ' ' LEU . 37.7 tt0 -132.38 97.12 4.02 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 177.827 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 14.2 t70 -99.9 173.06 6.85 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.403 -0.817 . . . . 0.0 110.455 -170.227 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 5.3 mt . . . . . 0 C--N 1.33 -0.254 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 178.12 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 132' ' ' LYS . . . . . 0.555 ' HE3' ' HE1' ' A' ' 146' ' ' TYR . 31.7 ttpt . . . . . 0 N--CA 1.465 0.285 0 CA-C-O 121.361 0.601 . . . . 0.0 112.038 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 133' ' ' MET . . . . . . . . . . . . . 46.7 mtp -69.06 170.5 9.81 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.764 176.949 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 134' ' ' LYS . . . . . 0.476 ' HB3' ' NZ ' ' A' ' 134' ' ' LYS . 0.5 OUTLIER -139.68 151.65 46.09 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.942 -179.43 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 135' ' ' LEU . . . . . 0.436 HD11 ' HD2' ' A' ' 142' ' ' TYR . 57.4 tp -89.74 123.46 33.77 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.252 178.206 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 136' ' ' VAL . . . . . 0.452 ' CG2' ' HG2' ' A' ' 145' ' ' GLU . 0.1 OUTLIER -121.74 149.05 24.92 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.445 -179.658 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 17.0 m-80 -125.86 112.62 16.2 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.2 -176.214 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 138' ' ' TYR . . . . . 0.481 ' CD1' ' HB2' ' A' ' 28' ' ' TYR . 53.3 t80 -147.96 123.31 10.29 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.554 0.216 . . . . 0.0 110.947 -179.723 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 139' ' ' GLY . . . . . 0.549 ' HA3' ' HB3' ' A' ' 24' ' ' ASP . . . 62.93 71.69 0.78 Allowed Glycine 0 N--CA 1.451 -0.317 0 CA-C-N 115.716 -0.674 . . . . 0.0 113.726 173.045 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 6.1 mpt_? 70.99 -39.5 0.45 Allowed 'General case' 0 N--CA 1.473 0.684 0 C-N-CA 123.356 0.662 . . . . 0.0 112.628 175.171 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 8.8 t -101.87 154.5 18.87 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 121.487 0.66 . . . . 0.0 111.696 -173.817 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 142' ' ' TYR . . . . . 0.472 ' OH ' ' HA ' ' A' ' 123' ' ' THR . 45.8 p90 -112.68 155.02 25.2 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 115.031 -0.986 . . . . 0.0 108.592 169.249 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 18.0 p90 -160.27 179.03 9.03 Favored 'General case' 0 C--N 1.319 -0.744 0 N-CA-C 110.151 -0.315 . . . . 0.0 110.151 -178.348 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 86.5 m-85 -116.27 125.42 52.17 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 120.724 0.297 . . . . 0.0 110.525 -179.505 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 145' ' ' GLU . . . . . 0.452 ' HG2' ' CG2' ' A' ' 136' ' ' VAL . 23.7 pt-20 -117.28 162.1 18.43 Favored 'General case' 0 C--N 1.317 -0.807 0 N-CA-C 109.557 -0.534 . . . . 0.0 109.557 175.235 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 146' ' ' TYR . . . . . 0.555 ' HE1' ' HE3' ' A' ' 132' ' ' LYS . 14.8 t80 -138.28 117.3 12.51 Favored 'General case' 0 C--N 1.311 -1.102 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.744 175.623 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 147' ' ' ILE . . . . . 0.42 ' N ' HD12 ' A' ' 147' ' ' ILE . 2.4 mp -85.41 99.43 7.39 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.874 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 174.643 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 148' ' ' ALA . . . . . 0.679 ' HB1' ' HA ' ' A' ' 111' ' ' ASP . . . -58.42 104.48 0.22 Allowed 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 108.933 -0.765 . . . . 0.0 108.933 176.432 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 36.7 mt-10 . . . . . 0 CA--C 1.506 -0.717 0 CA-C-O 122.092 0.948 . . . . 0.0 110.76 -175.329 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 22' ' ' TRP . . . . . 0.601 ' CH2' HG23 ' A' ' 96' ' ' ILE . 99.4 m95 . . . . . 0 C--O 1.232 0.152 0 CA-C-O 120.833 0.349 . . . . 0.0 111.677 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 24.3 t-20 -56.45 -41.06 75.86 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.765 -0.652 . . . . 0.0 111.606 -176.659 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -60.33 -50.82 72.08 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.963 -0.562 . . . . 0.0 112.042 -179.909 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 58.5 tp -56.28 -45.44 80.13 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.195 -178.474 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' ALA . . . . . 0.5 ' O ' HG13 ' A' ' 30' ' ' ILE . . . -54.74 -52.03 63.81 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.322 -179.157 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 83.2 t -51.4 -47.64 34.91 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.78 178.887 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 74.4 t80 -59.06 -44.59 91.84 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.921 0.391 . . . . 0.0 110.491 -179.054 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 72.5 mt -64.77 -45.53 94.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.918 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.607 HG12 HG23 ' A' ' 54' ' ' ILE . 85.8 mt -57.24 -44.36 83.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.88 179.911 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 55.5 mtt180 -71.36 -20.72 62.12 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.693 -0.685 . . . . 0.0 111.697 -175.224 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 72.8 m -88.98 -21.33 23.58 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.408 -0.36 . . . . 0.0 111.256 179.788 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 12.4 p -106.23 -80.16 0.56 Allowed 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 120.765 0.317 . . . . 0.0 111.255 -176.652 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 95.92 172.82 36.01 Favored Glycine 0 N--CA 1.449 -0.468 0 C-N-CA 120.822 -0.704 . . . . 0.0 112.427 -179.888 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 12.5 Cg_exo -69.68 143.39 51.08 Favored 'Trans proline' 0 N--CA 1.465 -0.189 0 C-N-CA 122.955 2.437 . . . . 0.0 112.335 -179.197 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 91.12 7.27 65.89 Favored Glycine 0 N--CA 1.454 -0.128 0 C-N-CA 120.613 -0.803 . . . . 0.0 112.694 176.413 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 29.9 p -110.43 -174.09 2.4 Favored 'General case' 0 C--N 1.321 -0.671 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 179.848 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 38' ' ' ARG . . . . . 0.619 ' NH2' ' HA3' ' A' ' 89' ' ' GLY . 56.6 mtm180 -129.72 126.91 39.36 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 120.771 0.319 . . . . 0.0 110.647 176.709 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.643 HG23 HG21 ' A' ' 60' ' ' VAL . 41.5 t -122.81 134.51 65.75 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 177.703 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.475 HG11 ' CE1' ' A' ' 87' ' ' TYR . 32.2 t -114.02 122.38 68.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-O 120.955 0.407 . . . . 0.0 110.436 -178.416 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 41' ' ' GLU . . . . . 0.815 ' HG3' HD23 ' A' ' 64' ' ' LEU . 0.1 OUTLIER -93.07 121.59 34.58 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.71 -174.706 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.508 ' O ' ' HA ' ' A' ' 95' ' ' SER . 48.5 t -102.55 113.65 39.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 N-CA-C 109.566 -0.531 . . . . 0.0 109.566 173.825 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 111.77 44.9 0.86 Allowed Glycine 0 N--CA 1.45 -0.37 0 N-CA-C 111.134 -0.786 . . . . 0.0 111.134 -176.032 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -95.85 14.73 22.41 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.102 0.477 . . . . 0.0 111.044 -175.892 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -72.74 -7.73 70.48 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.946 -0.645 . . . . 0.0 112.947 -178.153 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 74.0 ttt180 -166.18 -34.14 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.94 0.4 . . . . 0.0 110.934 -179.915 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 40.7 m-85 -82.86 83.39 7.77 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 121.116 0.484 . . . . 0.0 111.056 -175.685 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 88.2 mt -109.35 9.3 25.71 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.144 -179.514 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 39.3 t80 -72.54 -50.97 21.96 Favored 'General case' 0 C--N 1.33 -0.267 0 C-N-CA 121.023 -0.271 . . . . 0.0 110.968 178.259 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.528 ' O ' HG13 ' A' ' 54' ' ' ILE . 33.6 t -57.73 -49.0 82.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.463 -176.448 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 1.9 p -60.01 -44.07 94.81 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.93 -0.577 . . . . 0.0 111.787 -179.783 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.542 ' O ' ' HG2' ' A' ' 56' ' ' LYS . 28.8 t70 -64.99 -39.76 93.95 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 120.856 0.36 . . . . 0.0 110.601 -179.907 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 59.5 t80 -65.97 -39.47 90.41 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.563 -179.218 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.607 HG23 HG12 ' A' ' 30' ' ' ILE . 82.3 mt -64.88 -48.71 83.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.613 -179.852 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 39.7 ptt180 -67.28 -17.13 64.66 Favored 'General case' 0 N--CA 1.466 0.348 0 N-CA-C 111.586 0.217 . . . . 0.0 111.586 -175.649 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 56' ' ' LYS . . . . . 0.542 ' HG2' ' O ' ' A' ' 52' ' ' ASP . 33.1 mmtp -75.04 -36.07 61.87 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.822 0.344 . . . . 0.0 110.747 177.591 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 53.8 m-70 -94.6 -31.11 14.01 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.818 -175.785 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 73.3 m -136.75 132.89 35.41 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 120.759 0.314 . . . . 0.0 111.474 -178.27 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 3.1 tmtp? -81.51 60.97 4.75 Favored 'General case' 0 C--O 1.234 0.256 0 CA-C-O 121.831 0.824 . . . . 0.0 109.708 177.051 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.643 HG21 HG23 ' A' ' 39' ' ' VAL . 2.6 p -84.59 144.61 9.45 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.037 0 CA-C-N 114.975 -1.011 . . . . 0.0 108.869 172.816 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 61' ' ' ASP . . . . . 0.43 ' O ' ' HA ' ' A' ' 38' ' ' ARG . 24.7 m-20 -79.0 100.36 7.27 Favored 'General case' 0 CA--C 1.515 -0.378 0 CA-C-O 121.605 0.717 . . . . 0.0 109.441 176.328 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 62' ' ' LEU . . . . . 0.516 HD11 ' OE2' ' A' ' 41' ' ' GLU . 8.5 tt -99.28 129.14 45.48 Favored 'General case' 0 C--N 1.316 -0.854 0 CA-C-N 114.8 -1.091 . . . . 0.0 110.599 -171.653 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 57.7 t -117.45 116.06 50.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.987 -177.895 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 64' ' ' LEU . . . . . 0.815 HD23 ' HG3' ' A' ' 41' ' ' GLU . 33.1 mt -87.39 128.21 35.2 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 115.966 -0.561 . . . . 0.0 109.828 178.17 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.512 HG22 ' HB ' ' A' ' 75' ' ' VAL . 25.2 p -130.57 134.36 46.95 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 120.488 0.185 . . . . 0.0 110.629 178.965 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -171.74 153.73 3.43 Favored 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 178.395 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.546 HD11 HG22 ' A' ' 79' ' ' ILE . 60.8 mt -77.42 122.66 32.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 N-CA-C 110.152 -0.314 . . . . 0.0 110.152 179.483 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 68' ' ' LYS . . . . . 0.52 ' HG3' HG22 ' A' ' 67' ' ' ILE . 91.9 mttt 60.83 80.65 0.26 Allowed Pre-proline 0 C--O 1.234 0.267 0 O-C-N 123.734 0.646 . . . . 0.0 110.485 -177.413 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 69' ' ' PRO . . . . . 0.692 ' HB3' ' HB ' ' A' ' 74' ' ' ILE . 29.0 Cg_endo . . . . . 0 N--CA 1.464 -0.243 0 C-N-CA 122.799 2.333 . . . . 0.0 112.515 -178.636 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.692 ' HB ' ' HB3' ' A' ' 69' ' ' PRO . 71.2 mt . . . . . 0 N--CA 1.453 -0.301 0 N-CA-C 110.122 -0.325 . . . . 0.0 110.122 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.512 ' HB ' HG22 ' A' ' 65' ' ' THR . 61.2 t -71.28 119.18 17.16 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-O 121.199 0.523 . . . . 0.0 110.343 178.61 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 76' ' ' ARG . . . . . 0.41 ' H ' ' HG2' ' A' ' 76' ' ' ARG . 16.5 ptm180 -81.66 34.5 0.39 Allowed 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.379 -0.828 . . . . 0.0 111.96 -176.27 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 35.2 t70 -78.72 145.02 34.73 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 120.892 0.377 . . . . 0.0 110.392 -177.857 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 78' ' ' ASP . . . . . 0.51 ' HB3' HG22 ' A' ' 80' ' ' THR . 10.4 m-20 -81.15 110.86 17.05 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.696 -176.744 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 79' ' ' ILE . . . . . 0.546 HG22 HD11 ' A' ' 67' ' ' ILE . 10.6 tp -63.96 -19.9 25.51 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.519 0 CA-C-O 120.909 0.385 . . . . 0.0 111.022 179.75 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.51 HG22 ' HB3' ' A' ' 78' ' ' ASP . 7.0 t -68.52 -26.33 65.38 Favored 'General case' 0 CA--C 1.533 0.301 0 CA-C-O 121.13 0.49 . . . . 0.0 110.572 177.73 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 44.3 m -152.0 73.42 7.82 Favored Pre-proline 0 C--N 1.322 -0.607 0 N-CA-C 108.37 -0.974 . . . . 0.0 108.37 176.738 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 82' ' ' PRO . . . . . 0.469 ' HB2' ' HE2' ' A' ' 87' ' ' TYR . 75.8 Cg_endo -76.01 162.8 34.08 Favored 'Trans proline' 0 C--O 1.237 0.429 0 C-N-CA 122.817 2.344 . . . . 0.0 114.044 -166.121 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 83' ' ' ARG . . . . . 0.872 ' HG3' ' HG2' ' A' ' 85' ' ' GLU . 0.2 OUTLIER -81.72 99.99 9.24 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 114.855 -1.066 . . . . 0.0 109.201 174.929 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 84' ' ' MET . . . . . 0.401 ' O ' ' HG3' ' A' ' 88' ' ' ARG . 83.8 mmm -59.08 -31.16 68.64 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 116.596 -0.274 . . . . 0.0 111.186 -177.187 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.872 ' HG2' ' HG3' ' A' ' 83' ' ' ARG . 8.2 pt-20 -66.94 -24.72 66.1 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.495 -0.32 . . . . 0.0 111.397 -179.789 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 69.0 mt -73.62 -32.29 35.17 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 C-N-CA 120.515 -0.474 . . . . 0.0 110.429 177.282 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 87' ' ' TYR . . . . . 0.483 ' CB ' HG11 ' A' ' 113' ' ' VAL . 98.3 m-85 -85.91 -28.63 24.21 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.974 -0.557 . . . . 0.0 111.22 179.022 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 88' ' ' ARG . . . . . 0.401 ' HG3' ' O ' ' A' ' 84' ' ' MET . 69.6 mtp180 -61.72 117.95 6.49 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.33 0.586 . . . . 0.0 111.691 -177.639 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 89' ' ' GLY . . . . . 0.619 ' HA3' ' NH2' ' A' ' 38' ' ' ARG . . . 106.36 -5.19 38.13 Favored Glycine 0 N--CA 1.444 -0.779 0 CA-C-N 115.222 -0.899 . . . . 0.0 112.383 179.906 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -69.85 146.97 50.91 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.801 0.334 . . . . 0.0 110.495 177.733 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -91.5 -30.8 16.23 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.368 -179.766 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 92' ' ' LEU . . . . . 0.444 ' HG ' ' HB3' ' A' ' 116' ' ' ARG . 5.3 tt -153.25 144.19 22.88 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.182 -178.361 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.679 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 70.1 mt -133.07 129.04 57.04 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 177.31 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 94' ' ' TYR . . . . . 0.474 ' HE2' HD11 ' A' ' 96' ' ' ILE . 51.0 p90 -134.01 162.88 30.85 Favored 'General case' 0 C--N 1.32 -0.715 0 C-N-CA 120.053 -0.659 . . . . 0.0 111.274 179.604 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 95' ' ' SER . . . . . 0.782 ' HB3' ' HG3' ' A' ' 98' ' ' PRO . 15.8 m -137.83 137.83 38.54 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.999 -175.682 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 96' ' ' ILE . . . . . 0.601 HG23 ' CH2' ' A' ' 22' ' ' TRP . 5.0 mp -106.74 93.87 2.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.349 177.866 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 54.1 ttp85 48.29 72.68 1.18 Allowed Pre-proline 0 CA--C 1.54 0.574 0 CA-C-N 115.527 -0.761 . . . . 0.0 112.472 177.242 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 98' ' ' PRO . . . . . 0.782 ' HG3' ' HB3' ' A' ' 95' ' ' SER . 14.8 Cg_endo -91.97 162.81 3.28 Favored 'Trans proline' 0 N--CA 1.454 -0.823 0 C-N-CA 123.228 2.619 . . . . 0.0 111.905 176.798 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 99' ' ' PRO . . . . . 0.461 ' HB2' ' HG2' ' A' ' 101' ' ' GLU . 2.4 Cg_endo -48.97 139.64 25.3 Favored 'Trans proline' 0 C--N 1.349 0.599 0 C-N-CA 123.181 2.587 . . . . 0.0 112.597 177.159 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 100' ' ' ALA . . . . . 0.746 ' HA ' ' CE1' ' A' ' 103' ' ' HIS . . . -79.28 19.36 0.59 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.188 -0.46 . . . . 0.0 112.098 -172.528 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 101' ' ' GLU . . . . . 0.461 ' HG2' ' HB2' ' A' ' 99' ' ' PRO . 9.3 pt-20 -115.82 -16.62 11.17 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 115.991 -0.549 . . . . 0.0 111.367 -177.572 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.634 HD11 ' HB2' ' A' ' 98' ' ' PRO . 2.5 pp -112.04 3.44 8.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 N-CA-C 112.258 0.466 . . . . 0.0 112.258 -175.546 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 103' ' ' HIS . . . . . 0.746 ' CE1' ' HA ' ' A' ' 100' ' ' ALA . 33.5 m170 -62.27 -40.79 97.4 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.181 -179.15 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 22.4 m -61.81 -31.46 71.69 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.987 0.422 . . . . 0.0 110.899 178.903 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.561 ' O ' HG23 ' A' ' 109' ' ' VAL . 14.5 m -72.84 -40.68 65.55 Favored 'General case' 0 N--CA 1.448 -0.538 0 CA-C-N 116.045 -0.525 . . . . 0.0 109.897 178.302 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 90.4 mt -61.38 -42.17 98.28 Favored 'General case' 0 C--O 1.233 0.224 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.944 178.289 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 107' ' ' MET . . . . . . . . . . . . . 91.3 mmm -55.37 -48.09 74.81 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.619 -0.719 . . . . 0.0 111.768 -179.598 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 4.1 ptp180 -74.01 -26.89 60.68 Favored 'General case' 0 C--N 1.329 -0.32 0 C-N-CA 120.875 -0.33 . . . . 0.0 111.512 -177.697 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.561 HG23 ' O ' ' A' ' 105' ' ' SER . 70.2 t -66.31 -46.87 85.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 N-CA-C 110.192 -0.299 . . . . 0.0 110.192 175.813 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -59.01 -45.57 90.36 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.292 178.527 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.504 ' HA ' ' HB1' ' A' ' 148' ' ' ALA . 24.4 t70 -64.9 -36.83 85.63 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.885 -0.598 . . . . 0.0 111.026 179.557 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -68.53 -35.56 77.64 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.717 -0.674 . . . . 0.0 112.17 -178.372 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.483 HG11 ' CB ' ' A' ' 87' ' ' TYR . 22.5 m -97.04 -23.77 4.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-O 120.745 0.307 . . . . 0.0 111.65 -177.787 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 89.43 36.4 7.5 Favored Glycine 0 N--CA 1.452 -0.235 0 C-N-CA 120.933 -0.651 . . . . 0.0 112.645 176.792 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -114.24 147.47 38.93 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 121.003 0.43 . . . . 0.0 111.416 -177.187 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 116' ' ' ARG . . . . . 0.444 ' HB3' ' HG ' ' A' ' 92' ' ' LEU . 27.8 ttt180 -70.96 120.06 15.98 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.687 -0.688 . . . . 0.0 109.836 178.876 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 117' ' ' LEU . . . . . 0.679 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 60.0 tp -94.72 126.83 40.28 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 -179.038 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 64.1 mt -129.02 122.79 57.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-O 120.827 0.346 . . . . 0.0 110.44 -179.223 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 119' ' ' ILE . . . . . 0.519 HG12 ' HB2' ' A' ' 95' ' ' SER . 66.7 mt -130.05 119.85 48.0 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-O 120.777 0.323 . . . . 0.0 110.755 -179.018 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 34.3 ttpt -116.27 98.38 51.31 Favored Pre-proline 0 C--N 1.326 -0.441 0 N-CA-C 109.622 -0.511 . . . . 0.0 109.622 173.085 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 89.6 Cg_endo -87.17 -156.08 0.06 OUTLIER 'Trans proline' 0 N--CA 1.457 -0.631 0 C-N-CA 122.862 2.375 . . . . 0.0 112.471 179.325 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 122' ' ' LEU . . . . . 0.441 HD12 ' HA ' ' A' ' 122' ' ' LEU . 9.3 tp -74.35 161.56 29.75 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.302 177.899 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 12.9 t -69.3 -24.65 63.97 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.064 0.459 . . . . 0.0 110.979 -177.927 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -114.32 27.14 9.17 Favored Glycine 0 N--CA 1.448 -0.519 0 C-N-CA 120.837 -0.696 . . . . 0.0 111.385 176.686 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 125' ' ' GLU . . . . . 0.404 ' CB ' ' HB3' ' A' ' 122' ' ' LEU . 35.6 tt0 -128.04 125.93 40.29 Favored 'General case' 0 C--N 1.319 -0.756 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 -177.167 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -108.22 166.86 10.43 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.001 -179.935 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 42.6 mt . . . . . 0 C--N 1.323 -0.551 0 CA-C-O 121.095 0.474 . . . . 0.0 110.207 -178.805 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 132' ' ' LYS . . . . . 0.406 ' HE3' ' CZ ' ' A' ' 146' ' ' TYR . 55.7 tttp . . . . . 0 CA--C 1.534 0.341 0 N-CA-C 112.836 0.68 . . . . 0.0 112.836 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 133' ' ' MET . . . . . . . . . . . . . 76.0 mtp -96.24 168.72 10.41 Favored 'General case' 0 C--N 1.328 -0.356 0 C-N-CA 120.69 -0.404 . . . . 0.0 111.098 -176.952 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 134' ' ' LYS . . . . . 0.461 ' HG3' ' HG2' ' A' ' 145' ' ' GLU . 15.8 ptmt -130.62 148.59 52.43 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.911 -178.088 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 135' ' ' LEU . . . . . 0.605 HD11 ' HD2' ' A' ' 142' ' ' TYR . 39.7 tp -94.62 126.21 39.77 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.395 -179.747 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -123.86 147.19 28.35 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.692 -179.577 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 9.8 m-80 -116.98 119.0 33.95 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.999 0.428 . . . . 0.0 110.299 177.344 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 138' ' ' TYR . . . . . 0.498 ' O ' HG22 ' A' ' 141' ' ' THR . 71.3 t80 -146.49 128.11 15.15 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.142 -0.481 . . . . 0.0 109.932 -177.038 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 139' ' ' GLY . . . . . 0.424 ' O ' ' HB2' ' A' ' 140' ' ' ARG . . . 66.37 38.9 94.0 Favored Glycine 0 N--CA 1.449 -0.469 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.238 177.904 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 140' ' ' ARG . . . . . 0.424 ' HB2' ' O ' ' A' ' 139' ' ' GLY . 13.0 mmt85 76.47 -12.54 1.02 Allowed 'General case' 0 N--CA 1.469 0.497 0 C-N-CA 123.438 0.695 . . . . 0.0 112.392 177.804 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 141' ' ' THR . . . . . 0.498 HG22 ' O ' ' A' ' 138' ' ' TYR . 4.6 t -105.21 166.1 10.64 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 120.851 0.358 . . . . 0.0 110.575 -178.972 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 142' ' ' TYR . . . . . 0.605 ' HD2' HD11 ' A' ' 135' ' ' LEU . 14.4 p90 -130.06 141.12 50.75 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.125 -0.488 . . . . 0.0 109.807 178.945 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -150.3 168.43 24.1 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.687 -177.58 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 85.8 m-85 -99.88 125.12 45.81 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 177.499 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 145' ' ' GLU . . . . . 0.461 ' HG2' ' HG3' ' A' ' 134' ' ' LYS . 7.5 pt-20 -116.26 162.84 16.88 Favored 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 109.558 -0.534 . . . . 0.0 109.558 175.596 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 146' ' ' TYR . . . . . 0.559 ' HB3' ' HB3' ' A' ' 117' ' ' LEU . 15.0 t80 -145.3 123.44 12.16 Favored 'General case' 0 C--N 1.314 -0.946 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.275 178.894 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 3.4 mp -91.92 100.27 10.98 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 177.545 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 148' ' ' ALA . . . . . 0.504 ' HB1' ' HA ' ' A' ' 111' ' ' ASP . . . -71.68 125.74 27.9 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.896 176.312 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 . . . . . 0 C--N 1.319 -0.751 0 CA-C-N 115.798 -0.637 . . . . 0.0 111.518 177.682 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 78.7 m95 . . . . . 0 CA--C 1.53 0.206 0 CA-C-O 120.854 0.359 . . . . 0.0 110.639 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 27.1 t-20 -56.35 -52.52 64.26 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.779 -0.646 . . . . 0.0 111.492 -177.514 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -63.81 -33.71 76.29 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.138 -178.901 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 56.7 tp -58.08 -49.52 76.64 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.084 175.725 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' ALA . . . . . 0.402 ' O ' HG13 ' A' ' 30' ' ' ILE . . . -58.57 -48.45 80.88 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.763 178.655 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.478 ' HA ' HD12 ' A' ' 30' ' ' ILE . 87.4 t -54.85 -44.48 72.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.177 178.553 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 28' ' ' TYR . . . . . 0.424 ' HB2' ' CD2' ' A' ' 138' ' ' TYR . 84.6 t80 -60.77 -46.83 88.97 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.715 179.041 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 83.1 mt -60.9 -42.83 94.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.51 178.332 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.548 HG12 HG23 ' A' ' 54' ' ' ILE . 87.7 mt -56.65 -45.32 82.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 115.704 -0.68 . . . . 0.0 111.066 177.418 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 31' ' ' ARG . . . . . 0.405 ' HG3' ' O ' ' A' ' 27' ' ' VAL . 81.0 mtp180 -69.33 -27.34 65.27 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 121.147 0.499 . . . . 0.0 110.899 -177.729 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 80.4 m -88.9 -2.88 58.81 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.925 -0.579 . . . . 0.0 111.639 -178.538 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 16.6 p -121.84 -76.76 0.58 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.505 0.193 . . . . 0.0 110.977 -179.387 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.512 ' O ' HG22 ' A' ' 37' ' ' THR . . . 101.03 161.82 27.58 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 121.087 -0.578 . . . . 0.0 112.409 179.597 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_exo -74.36 146.34 35.35 Favored 'Trans proline' 0 N--CA 1.462 -0.351 0 C-N-CA 122.84 2.36 . . . . 0.0 111.986 179.076 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 98.02 -15.82 61.04 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.868 -0.682 . . . . 0.0 113.046 177.357 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 37' ' ' THR . . . . . 0.512 HG22 ' O ' ' A' ' 34' ' ' GLY . 13.6 t -102.42 -172.14 2.08 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 117.039 0.419 . . . . 0.0 110.544 -179.091 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 38' ' ' ARG . . . . . 0.53 ' HB2' ' HA ' ' A' ' 90' ' ' ALA . 68.7 mtp180 -115.42 135.8 53.74 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.565 -0.289 . . . . 0.0 110.976 -177.276 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.496 HG23 HG21 ' A' ' 60' ' ' VAL . 61.7 t -131.59 138.86 52.02 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 175.575 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.566 ' O ' ' HA ' ' A' ' 93' ' ' ILE . 23.4 t -126.92 139.13 52.76 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 178.259 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 41' ' ' GLU . . . . . 0.623 ' OE2' ' HA ' ' A' ' 64' ' ' LEU . 0.5 OUTLIER -116.12 156.25 26.76 Favored 'General case' 0 C--N 1.32 -0.678 0 C-N-CA 120.123 -0.631 . . . . 0.0 109.959 171.49 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.439 HG21 HD22 ' A' ' 106' ' ' LEU . 62.1 t -110.84 103.23 15.14 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.851 0 CA-C-N 115.755 -0.657 . . . . 0.0 109.79 176.385 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 115.28 56.04 0.36 Allowed Glycine 0 N--CA 1.448 -0.538 0 C-N-CA 120.309 -0.948 . . . . 0.0 112.7 178.707 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.434 ' HB2' ' OE2' ' A' ' 41' ' ' GLU . . . -80.73 77.04 7.61 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.254 0.549 . . . . 0.0 110.424 178.029 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -82.75 -154.89 16.59 Favored Glycine 0 N--CA 1.447 -0.625 0 CA-C-N 115.564 -0.744 . . . . 0.0 112.846 -179.55 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 49.9 ttt180 -70.37 -15.12 62.82 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 121.264 0.554 . . . . 0.0 110.555 -177.46 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 7.7 p90 -88.94 58.71 4.7 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.792 -0.64 . . . . 0.0 111.204 -178.707 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 95.0 mt -78.23 35.09 0.21 Allowed 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.008 -0.542 . . . . 0.0 112.15 -176.848 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 84.3 t80 -71.91 -53.83 11.92 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.602 0.239 . . . . 0.0 110.995 -179.45 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.431 ' O ' HG13 ' A' ' 54' ' ' ILE . 56.7 t -57.72 -50.8 76.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.024 -0.534 . . . . 0.0 111.134 -176.404 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 2.7 p -59.98 -42.33 93.93 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.627 -178.829 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.499 ' O ' ' HG2' ' A' ' 56' ' ' LYS . 27.5 t70 -67.73 -43.23 80.44 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.385 -0.371 . . . . 0.0 110.651 -179.647 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 61.9 t80 -63.01 -44.63 95.45 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.92 -178.405 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.548 HG23 HG12 ' A' ' 30' ' ' ILE . 84.3 mt -61.32 -46.05 97.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.864 179.508 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 2.5 ptm180 -72.92 -16.48 61.55 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.358 -176.992 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 56' ' ' LYS . . . . . 0.499 ' HG2' ' O ' ' A' ' 52' ' ' ASP . 36.0 mmtm -72.82 -34.82 67.1 Favored 'General case' 0 C--O 1.234 0.287 0 CA-C-O 120.848 0.356 . . . . 0.0 110.486 175.016 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 29.3 m-70 -93.55 -60.4 1.78 Allowed 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.379 -177.039 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 52.8 m -106.78 133.22 51.77 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 121.233 0.54 . . . . 0.0 111.717 -174.878 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 1.3 tmmm? -76.56 65.76 2.44 Favored 'General case' 0 N--CA 1.451 -0.38 0 CA-C-O 121.769 0.795 . . . . 0.0 108.909 174.318 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.496 HG21 HG23 ' A' ' 39' ' ' VAL . 14.9 p -97.06 147.83 6.03 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.983 0 CA-C-N 115.235 -0.893 . . . . 0.0 109.927 176.115 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 13.2 t70 -81.09 89.6 5.98 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 178.865 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 3.3 tm? -93.97 131.86 39.01 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.481 -0.781 . . . . 0.0 109.27 -178.096 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 42.4 t -115.36 117.92 57.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-O 120.457 0.17 . . . . 0.0 110.842 -177.604 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 64' ' ' LEU . . . . . 0.623 ' HA ' ' OE2' ' A' ' 41' ' ' GLU . 84.8 mt -86.89 128.07 35.05 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.913 -178.574 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 70.1 p -116.23 123.57 48.09 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.879 177.475 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 66' ' ' ASP . . . . . 0.689 ' HB3' HG21 ' A' ' 74' ' ' ILE . 17.9 t70 -149.03 136.12 19.95 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.126 -179.841 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.462 HG12 ' HB2' ' A' ' 78' ' ' ASP . 46.2 mt -69.12 110.61 2.63 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 178.189 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 68' ' ' LYS . . . . . 0.432 ' HG2' HG22 ' A' ' 67' ' ' ILE . 31.1 mmtp 63.25 85.37 0.17 Allowed Pre-proline 0 C--N 1.33 -0.269 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 -172.297 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 69' ' ' PRO . . . . . 0.655 ' HD3' ' HA ' ' A' ' 76' ' ' ARG . 4.2 Cg_endo . . . . . 0 C--N 1.351 0.698 0 C-N-CA 123.805 3.004 . . . . 0.0 112.52 -173.948 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.689 HG21 ' HB3' ' A' ' 66' ' ' ASP . 97.2 mt . . . . . 0 N--CA 1.45 -0.471 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 44.2 t -79.31 137.77 21.17 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 178.935 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 76' ' ' ARG . . . . . 0.655 ' HA ' ' HD3' ' A' ' 69' ' ' PRO . 0.0 OUTLIER -75.57 13.67 0.75 Allowed 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.046 -0.525 . . . . 0.0 111.75 -176.91 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 77' ' ' ASP . . . . . 0.473 ' OD1' ' HG2' ' A' ' 83' ' ' ARG . 12.7 t70 -70.08 121.89 18.34 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -175.893 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 78' ' ' ASP . . . . . 0.462 ' HB2' HG12 ' A' ' 67' ' ' ILE . 3.3 p30 -101.24 169.53 8.85 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 121.276 0.56 . . . . 0.0 111.526 -172.213 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 8.5 tt -77.46 -15.46 14.37 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 115.328 -0.851 . . . . 0.0 112.518 -171.276 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 7.8 p -93.41 -23.44 18.42 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 121.657 0.742 . . . . 0.0 109.69 -178.902 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 81' ' ' SER . . . . . 0.465 ' N ' ' HD3' ' A' ' 82' ' ' PRO . 23.0 t -139.23 58.22 12.13 Favored Pre-proline 0 N--CA 1.441 -0.897 0 CA-C-N 114.677 -1.147 . . . . 0.0 110.574 -170.596 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 82' ' ' PRO . . . . . 0.465 ' HD3' ' N ' ' A' ' 81' ' ' SER . 5.1 Cg_exo -77.79 140.07 18.19 Favored 'Trans proline' 0 N--CA 1.458 -0.609 0 C-N-CA 122.656 2.237 . . . . 0.0 112.14 -174.736 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 83' ' ' ARG . . . . . 0.78 ' HB2' HD12 ' A' ' 86' ' ' ILE . 55.9 mmt-85 -80.35 113.52 18.59 Favored 'General case' 0 CA--C 1.507 -0.673 0 CA-C-O 121.14 0.495 . . . . 0.0 110.67 178.259 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 84' ' ' MET . . . . . 0.483 ' HA ' ' HD2' ' A' ' 87' ' ' TYR . 22.0 mtp -72.61 -13.12 61.3 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.09 178.553 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.684 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 11.3 pt-20 -70.16 -22.72 62.94 Favored 'General case' 0 C--O 1.232 0.133 0 CA-C-O 121.485 0.659 . . . . 0.0 109.579 175.259 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.78 HD12 ' HB2' ' A' ' 83' ' ' ARG . 96.3 mt -83.34 -33.94 10.47 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 115.251 -0.886 . . . . 0.0 110.172 178.859 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 87' ' ' TYR . . . . . 0.483 ' HD2' ' HA ' ' A' ' 84' ' ' MET . 95.3 m-85 -82.33 -37.87 25.1 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.572 -178.888 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 23.6 mtp180 -62.55 116.17 4.9 Favored 'General case' 0 CA--C 1.514 -0.44 0 CA-C-O 121.367 0.603 . . . . 0.0 111.401 -178.908 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 111.74 -10.33 27.78 Favored Glycine 0 N--CA 1.447 -0.619 0 CA-C-N 114.914 -1.039 . . . . 0.0 112.054 -178.249 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 90' ' ' ALA . . . . . 0.53 ' HA ' ' HB2' ' A' ' 38' ' ' ARG . . . -78.72 149.15 32.81 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.057 0.456 . . . . 0.0 110.613 179.649 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -94.38 -21.09 19.18 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.776 -179.245 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 92' ' ' LEU . . . . . 0.486 HD23 ' N ' ' A' ' 93' ' ' ILE . 4.7 tt -155.12 144.24 20.96 Favored 'General case' 0 N--CA 1.451 -0.376 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.719 -177.864 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.57 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 63.3 mt -130.86 127.18 61.15 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 177.203 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 94' ' ' TYR . . . . . 0.428 ' O ' ' HA ' ' A' ' 41' ' ' GLU . 32.3 p90 -129.24 161.96 28.98 Favored 'General case' 0 C--N 1.322 -0.6 0 C-N-CA 120.578 -0.449 . . . . 0.0 110.897 -179.503 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 14.2 m -144.94 145.72 31.67 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.918 0.39 . . . . 0.0 110.816 -179.333 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 72.6 mt -114.09 109.26 27.85 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.15 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 97' ' ' ARG . . . . . 0.441 ' HD2' HH11 ' A' ' 97' ' ' ARG . 42.0 ttm180 59.48 80.84 0.26 Allowed Pre-proline 0 CA--C 1.534 0.358 0 O-C-N 123.849 0.718 . . . . 0.0 111.35 -178.331 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 98' ' ' PRO . . . . . 0.421 ' HA ' ' HD3' ' A' ' 99' ' ' PRO . 96.0 Cg_endo -88.52 133.38 2.68 Favored 'Trans proline' 0 N--CA 1.456 -0.724 0 C-N-CA 122.677 2.251 . . . . 0.0 112.642 179.078 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 99' ' ' PRO . . . . . 0.639 ' HD2' HD11 ' A' ' 102' ' ' ILE . 32.8 Cg_exo -58.98 141.23 98.1 Favored 'Trans proline' 0 N--CA 1.464 -0.238 0 C-N-CA 122.678 2.252 . . . . 0.0 111.465 175.048 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 100' ' ' ALA . . . . . 0.721 ' HA ' ' NE2' ' A' ' 103' ' ' HIS . . . -72.07 4.45 3.5 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 112.154 0.428 . . . . 0.0 112.154 -173.737 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 101' ' ' GLU . . . . . 0.602 ' HG3' HG23 ' A' ' 102' ' ' ILE . 9.2 pt-20 -96.33 -21.09 18.02 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.643 -0.253 . . . . 0.0 111.64 -179.928 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.639 HD11 ' HD2' ' A' ' 99' ' ' PRO . 2.5 pp -115.68 10.49 7.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 N-CA-C 113.108 0.781 . . . . 0.0 113.108 -170.331 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 103' ' ' HIS . . . . . 0.721 ' NE2' ' HA ' ' A' ' 100' ' ' ALA . 22.1 m-70 -54.71 -50.22 68.84 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 121.042 0.449 . . . . 0.0 111.13 -179.959 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 5.1 m -64.62 -26.27 68.32 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.96 -177.296 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.526 ' O ' HG23 ' A' ' 109' ' ' VAL . 19.4 m -72.06 -38.98 69.34 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.079 -178.797 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.439 HD22 HG21 ' A' ' 42' ' ' VAL . 77.5 mt -73.42 -41.85 62.78 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.854 179.651 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 107' ' ' MET . . . . . 0.562 ' HG2' ' O ' ' A' ' 103' ' ' HIS . 90.5 mmm -56.44 -41.28 76.19 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.753 -0.658 . . . . 0.0 111.881 -177.981 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 108' ' ' ARG . . . . . 0.403 HH11 ' HD3' ' A' ' 108' ' ' ARG . 11.2 ptp180 -73.42 -29.42 62.57 Favored 'General case' 0 C--N 1.328 -0.347 0 C-N-CA 120.79 -0.364 . . . . 0.0 111.277 -178.382 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.526 HG23 ' O ' ' A' ' 105' ' ' SER . 81.0 t -68.72 -45.75 80.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 C-N-CA 121.083 -0.247 . . . . 0.0 110.515 -179.777 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -61.77 -44.5 96.76 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.274 178.717 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.708 ' HA ' ' HB1' ' A' ' 148' ' ' ALA . 17.3 t70 -63.85 -34.44 77.94 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.66 -0.7 . . . . 0.0 110.984 179.82 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -70.85 -43.36 68.64 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.825 -0.625 . . . . 0.0 111.955 -178.675 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 21.6 m -89.02 -24.05 6.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 N-CA-C 111.848 0.314 . . . . 0.0 111.848 -175.093 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 84.71 53.68 3.14 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.309 178.691 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -129.83 160.41 33.57 Favored 'General case' 0 C--N 1.323 -0.566 0 O-C-N 122.842 -0.21 . . . . 0.0 110.695 -179.227 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 116' ' ' ARG . . . . . 0.431 ' HD3' ' OE1' ' A' ' 145' ' ' GLU . 10.1 ttm180 -79.53 123.53 27.66 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 109.278 -0.638 . . . . 0.0 109.278 176.013 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 117' ' ' LEU . . . . . 0.57 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 58.5 tp -95.04 118.01 31.14 Favored 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 109.585 -0.524 . . . . 0.0 109.585 178.812 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 60.2 mt -115.49 114.79 47.37 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.654 0 CA-C-O 121.278 0.561 . . . . 0.0 110.696 -179.773 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 63.1 mt -115.34 123.96 71.41 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.907 0 CA-C-N 116.151 -0.477 . . . . 0.0 109.972 178.908 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 120' ' ' LYS . . . . . 0.543 ' HG2' ' HB3' ' A' ' 143' ' ' PHE . 9.5 tmtm? -110.22 97.92 32.97 Favored Pre-proline 0 C--N 1.321 -0.647 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 176.728 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 80.1 Cg_endo -87.93 -178.18 2.14 Favored 'Trans proline' 0 N--CA 1.453 -0.873 0 C-N-CA 122.794 2.329 . . . . 0.0 111.866 176.433 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 122' ' ' LEU . . . . . 0.75 ' HB2' ' HB3' ' A' ' 125' ' ' GLU . 8.1 mp -108.29 166.93 10.39 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.243 -178.85 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 24.8 m -64.19 111.97 2.82 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 120.942 0.401 . . . . 0.0 110.726 179.147 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 91.66 -32.75 5.14 Favored Glycine 0 N--CA 1.45 -0.379 0 N-CA-C 111.314 -0.714 . . . . 0.0 111.314 -176.8 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 125' ' ' GLU . . . . . 0.75 ' HB3' ' HB2' ' A' ' 122' ' ' LEU . 20.9 tt0 -92.09 74.68 5.49 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 176.22 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 23.6 t70 -113.62 -178.53 3.4 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 114.788 -1.096 . . . . 0.0 110.948 -166.626 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 4.7 mt . . . . . 0 C--O 1.234 0.268 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 176.201 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 30.9 mmtt . . . . . 0 CA--C 1.524 -0.051 0 N-CA-C 112.152 0.427 . . . . 0.0 112.152 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 133' ' ' MET . . . . . 0.51 ' HG2' ' HB2' ' A' ' 146' ' ' TYR . 77.2 mtp -87.89 154.03 20.85 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.15 0.5 . . . . 0.0 111.616 -173.371 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 14.8 ptmt -112.72 142.66 45.08 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 115.197 -0.91 . . . . 0.0 110.376 -177.305 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 135' ' ' LEU . . . . . 0.554 HD11 ' HD2' ' A' ' 142' ' ' TYR . 47.2 tp -84.33 123.05 29.76 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.428 -179.957 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -121.68 144.6 30.32 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.935 -179.516 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 4.3 m-20 -111.2 130.53 55.61 Favored 'General case' 0 C--N 1.325 -0.482 0 N-CA-C 109.526 -0.546 . . . . 0.0 109.526 175.002 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 138' ' ' TYR . . . . . 0.424 ' CD2' ' HB2' ' A' ' 28' ' ' TYR . 57.5 t80 -148.52 111.55 4.87 Favored 'General case' 0 C--N 1.322 -0.629 0 N-CA-C 110.018 -0.364 . . . . 0.0 110.018 176.139 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 69.49 49.2 39.4 Favored Glycine 0 N--CA 1.446 -0.683 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.02 179.826 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 20.9 mmm-85 76.48 -40.66 0.39 Allowed 'General case' 0 N--CA 1.467 0.397 0 C-N-CA 123.729 0.812 . . . . 0.0 112.057 177.446 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 13.8 t -76.73 146.94 37.66 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.192 0.52 . . . . 0.0 110.64 -177.941 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 142' ' ' TYR . . . . . 0.554 ' HD2' HD11 ' A' ' 135' ' ' LEU . 47.4 p90 -117.28 142.94 46.45 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.776 179.194 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 143' ' ' PHE . . . . . 0.543 ' HB3' ' HG2' ' A' ' 120' ' ' LYS . 11.4 p90 -152.48 179.79 8.26 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.58 -0.736 . . . . 0.0 109.748 -178.476 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 89.3 m-85 -115.33 138.07 51.36 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 120.669 0.271 . . . . 0.0 110.595 -179.858 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 145' ' ' GLU . . . . . 0.431 ' OE1' ' HD3' ' A' ' 116' ' ' ARG . 17.9 pt-20 -123.81 160.05 28.22 Favored 'General case' 0 C--N 1.319 -0.737 0 N-CA-C 109.161 -0.681 . . . . 0.0 109.161 173.878 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 146' ' ' TYR . . . . . 0.51 ' HB2' ' HG2' ' A' ' 133' ' ' MET . 45.7 t80 -142.26 126.36 17.39 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-O 121.07 0.462 . . . . 0.0 110.374 176.78 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 2.1 mp -92.82 108.11 19.91 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.762 0 CA-C-N 115.696 -0.684 . . . . 0.0 109.389 176.683 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 148' ' ' ALA . . . . . 0.708 ' HB1' ' HA ' ' A' ' 111' ' ' ASP . . . -70.93 129.12 38.22 Favored 'General case' 0 N--CA 1.444 -0.774 0 CA-C-N 115.693 -0.685 . . . . 0.0 110.151 176.353 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 22.4 mm-40 . . . . . 0 C--N 1.321 -0.642 0 CA-C-O 121.768 0.794 . . . . 0.0 111.395 177.779 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 81.7 m95 . . . . . 0 C--O 1.232 0.148 0 CA-C-O 120.792 0.329 . . . . 0.0 111.145 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 23' ' ' ASN . . . . . 0.504 ' O ' HG23 ' A' ' 27' ' ' VAL . 6.7 m-20 -65.5 -29.85 70.55 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.006 -179.547 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -75.04 -34.07 61.81 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 179.696 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 45.1 tp -60.31 -43.13 96.62 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 115.914 -0.585 . . . . 0.0 109.651 172.846 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -59.05 -47.33 85.62 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.458 -0.792 . . . . 0.0 110.655 176.661 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.504 HG23 ' O ' ' A' ' 23' ' ' ASN . 99.2 t -56.21 -43.25 75.86 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.188 0 CA-C-N 116.361 -0.381 . . . . 0.0 111.111 177.987 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 88.0 t80 -59.44 -48.71 80.59 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.819 0.342 . . . . 0.0 110.461 178.401 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 71.6 mt -58.48 -41.83 82.77 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.251 178.553 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.608 HG12 HG23 ' A' ' 54' ' ' ILE . 83.2 mt -60.32 -38.44 77.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 115.473 -0.785 . . . . 0.0 111.061 177.639 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 22.1 mtp180 -70.78 -30.13 66.52 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.154 -179.22 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 75.6 m -87.03 -8.91 56.67 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.576 -178.501 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 26.0 p -122.84 -80.83 0.63 Allowed 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 120.747 0.308 . . . . 0.0 111.08 179.01 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.455 ' O ' HG22 ' A' ' 37' ' ' THR . . . 88.21 168.51 44.33 Favored Glycine 0 N--CA 1.447 -0.633 0 C-N-CA 121.141 -0.552 . . . . 0.0 112.446 -179.901 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_exo -65.67 140.33 61.69 Favored 'Trans proline' 0 C--O 1.232 0.204 0 C-N-CA 122.644 2.229 . . . . 0.0 111.759 178.225 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 109.98 -8.21 31.41 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.364 -0.922 . . . . 0.0 112.507 178.978 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 37' ' ' THR . . . . . 0.455 HG22 ' O ' ' A' ' 34' ' ' GLY . 11.5 t -125.04 -171.31 2.33 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.306 -0.627 . . . . 0.0 109.306 178.299 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 38' ' ' ARG . . . . . 0.841 ' HG3' ' HA ' ' A' ' 90' ' ' ALA . 1.7 ptm180 -132.48 136.94 47.02 Favored 'General case' 0 N--CA 1.447 -0.604 0 CA-C-O 121.075 0.464 . . . . 0.0 111.418 -179.619 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.488 ' O ' ' HA ' ' A' ' 62' ' ' LEU . 58.2 t -125.91 139.43 51.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 115.611 -0.722 . . . . 0.0 109.747 -178.223 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.475 ' HB ' HG12 ' A' ' 93' ' ' ILE . 39.6 t -116.34 134.47 59.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-O 120.854 0.359 . . . . 0.0 111.164 -178.026 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 44.1 tt0 -108.23 120.56 42.72 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.143 177.02 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.626 ' HB ' ' HB3' ' A' ' 95' ' ' SER . 85.7 t -95.91 123.49 48.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.387 -179.603 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 98.19 25.16 10.53 Favored Glycine 0 N--CA 1.447 -0.567 0 C-N-CA 120.686 -0.769 . . . . 0.0 111.789 -179.366 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -79.32 54.13 1.63 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 121.321 0.582 . . . . 0.0 111.128 -178.281 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -94.25 -64.82 1.02 Allowed Glycine 0 N--CA 1.444 -0.789 0 C-N-CA 120.854 -0.689 . . . . 0.0 111.823 178.674 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -105.07 -8.22 18.63 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.059 0.457 . . . . 0.0 110.306 175.373 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.487 ' HD1' ' HE1' ' A' ' 49' ' ' TYR . 87.4 m-85 -106.76 102.54 11.91 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.909 -0.587 . . . . 0.0 109.981 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.533 HD22 HD13 ' A' ' 64' ' ' LEU . 84.5 mt -129.7 -10.81 4.45 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.448 -0.342 . . . . 0.0 111.002 179.997 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 49' ' ' TYR . . . . . 0.487 ' HE1' ' HD1' ' A' ' 47' ' ' PHE . 30.6 p90 -59.06 -30.97 68.45 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 112.59 0.589 . . . . 0.0 112.59 -173.917 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 80.5 t -75.81 -58.01 5.26 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-O 120.795 0.331 . . . . 0.0 110.744 178.831 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 51' ' ' SER . . . . . 0.428 ' CB ' HD21 ' A' ' 64' ' ' LEU . 15.5 p -60.32 -39.18 86.12 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.939 -177.983 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.499 ' O ' ' HG3' ' A' ' 56' ' ' LYS . 29.7 t70 -65.11 -33.65 76.53 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.64 -178.38 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 71.0 t80 -71.25 -44.71 64.77 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.545 177.499 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.608 HG23 HG12 ' A' ' 30' ' ' ILE . 79.2 mt -57.48 -46.42 85.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.868 -176.602 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 55' ' ' ARG . . . . . 0.512 HH12 HD11 ' A' ' 64' ' ' LEU . 9.0 ptp85 -69.03 -16.12 63.63 Favored 'General case' 0 N--CA 1.467 0.383 0 N-CA-C 112.164 0.431 . . . . 0.0 112.164 -176.889 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 56' ' ' LYS . . . . . 0.499 ' HG3' ' O ' ' A' ' 52' ' ' ASP . 67.9 mttm -82.54 -33.08 28.31 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 120.807 0.337 . . . . 0.0 111.392 -179.753 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 5.4 t-80 -95.11 -39.65 10.02 Favored 'General case' 0 N--CA 1.448 -0.529 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.357 -177.699 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 8.1 p -118.51 132.07 56.23 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.449 -0.341 . . . . 0.0 111.13 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 59' ' ' LYS . . . . . 0.463 ' HD2' ' HA ' ' A' ' 59' ' ' LYS . 26.9 mmmt -80.97 61.2 4.47 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.696 0.76 . . . . 0.0 110.603 176.062 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 7.7 p -98.07 144.65 10.92 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.725 0 CA-C-N 114.901 -1.045 . . . . 0.0 109.509 175.508 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -73.12 89.61 1.5 Allowed 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 177.561 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 62' ' ' LEU . . . . . 0.488 ' HA ' ' O ' ' A' ' 39' ' ' VAL . 3.5 tt -96.39 118.4 32.84 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.014 0.435 . . . . 0.0 110.363 -176.611 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 58.1 t -102.19 128.98 54.31 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.463 0 CA-C-N 115.588 -0.733 . . . . 0.0 110.72 -176.141 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 64' ' ' LEU . . . . . 0.533 HD13 HD22 ' A' ' 48' ' ' LEU . 66.1 mt -108.66 133.26 52.99 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.936 -0.574 . . . . 0.0 109.999 176.404 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 12.5 p -119.12 132.03 55.96 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.724 0.297 . . . . 0.0 110.71 176.194 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 66' ' ' ASP . . . . . 0.448 ' HB3' HG21 ' A' ' 74' ' ' ILE . 24.5 t70 -156.96 146.85 20.81 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.426 -177.843 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.614 HG12 ' HB2' ' A' ' 78' ' ' ASP . 34.5 mt -73.9 103.91 2.44 Favored 'Isoleucine or valine' 0 C--O 1.238 0.491 0 N-CA-C 110.114 -0.328 . . . . 0.0 110.114 179.419 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 68' ' ' LYS . . . . . 0.401 ' HE2' ' HB3' ' A' ' 68' ' ' LYS . 30.7 mtpt 56.92 80.08 0.3 Allowed Pre-proline 0 C--N 1.33 -0.276 0 CA-C-N 115.191 -0.913 . . . . 0.0 109.798 -177.091 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 69' ' ' PRO . . . . . 0.877 ' HB3' ' HB ' ' A' ' 74' ' ' ILE . 9.1 Cg_endo . . . . . 0 C--O 1.234 0.275 0 C-N-CA 123.895 3.064 . . . . 0.0 113.7 -173.077 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.877 ' HB ' ' HB3' ' A' ' 69' ' ' PRO . 43.4 mt . . . . . 0 N--CA 1.453 -0.318 0 N-CA-C 110.164 -0.31 . . . . 0.0 110.164 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.525 HG12 ' H ' ' A' ' 77' ' ' ASP . 63.3 t -79.41 141.94 14.66 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.093 178.764 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 76' ' ' ARG . . . . . 0.566 ' HG2' ' HD2' ' A' ' 69' ' ' PRO . 89.1 mtm180 -82.87 16.41 2.28 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.913 -176.148 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 77' ' ' ASP . . . . . 0.525 ' H ' HG12 ' A' ' 75' ' ' VAL . 35.9 t70 -87.03 138.01 31.86 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 179.001 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 78' ' ' ASP . . . . . 0.614 ' HB2' HG12 ' A' ' 67' ' ' ILE . 0.7 OUTLIER -103.32 177.92 4.7 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.73 0.3 . . . . 0.0 111.257 -173.362 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 9.3 tp -94.03 -24.66 4.95 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.444 0 N-CA-C 112.601 0.593 . . . . 0.0 112.601 -170.401 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.51 HG22 ' OD1' ' A' ' 78' ' ' ASP . 6.3 t -91.1 -20.5 21.96 Favored 'General case' 0 C--N 1.325 -0.47 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 -178.319 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 81' ' ' SER . . . . . 0.495 ' HB2' ' OD2' ' A' ' 78' ' ' ASP . 34.0 m -129.42 62.85 65.23 Favored Pre-proline 0 CA--C 1.535 0.391 0 CA-C-N 115.48 -0.782 . . . . 0.0 110.081 172.822 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 87.9 Cg_endo -85.7 150.28 9.98 Favored 'Trans proline' 0 N--CA 1.459 -0.515 0 C-N-CA 122.375 2.05 . . . . 0.0 113.525 -171.847 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 77.8 mtt-85 -88.95 112.51 23.41 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.416 -0.811 . . . . 0.0 110.413 175.147 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 84' ' ' MET . . . . . . . . . . . . . 93.6 mmm -66.05 -23.38 66.53 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.449 -0.341 . . . . 0.0 111.057 -179.264 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 6.7 pm0 -67.62 -19.32 65.21 Favored 'General case' 0 N--CA 1.464 0.246 0 CA-C-O 120.889 0.376 . . . . 0.0 111.01 179.61 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.404 HD13 HG11 ' A' ' 75' ' ' VAL . 62.1 mt -83.81 -39.34 14.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.345 179.017 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 87' ' ' TYR . . . . . 0.417 ' CB ' HG11 ' A' ' 113' ' ' VAL . 93.3 m-85 -80.65 -34.07 35.17 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.209 -178.557 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 88' ' ' ARG . . . . . 0.525 ' HA ' ' HB ' ' A' ' 113' ' ' VAL . 62.2 mtp85 -65.15 132.93 50.42 Favored 'General case' 0 CA--C 1.515 -0.384 0 CA-C-O 121.329 0.585 . . . . 0.0 110.856 -178.509 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 102.4 -19.41 48.33 Favored Glycine 0 N--CA 1.446 -0.683 0 CA-C-N 115.053 -0.976 . . . . 0.0 111.641 -176.803 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 90' ' ' ALA . . . . . 0.841 ' HA ' ' HG3' ' A' ' 38' ' ' ARG . . . -71.46 145.3 49.32 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.837 0.351 . . . . 0.0 110.705 -179.772 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -92.52 -21.98 19.81 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.041 -179.188 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 92' ' ' LEU . . . . . 0.525 ' HG ' ' HB3' ' A' ' 116' ' ' ARG . 3.5 tt -150.81 138.4 19.68 Favored 'General case' 0 N--CA 1.449 -0.497 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.912 -176.28 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.643 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 85.5 mt -133.03 124.05 49.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 115.719 -0.673 . . . . 0.0 109.326 176.955 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 94' ' ' TYR . . . . . 0.437 ' HB3' ' HB ' ' A' ' 118' ' ' ILE . 10.2 p90 -130.01 158.84 38.49 Favored 'General case' 0 C--N 1.32 -0.696 0 C-N-CA 120.808 -0.357 . . . . 0.0 110.802 -179.524 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 95' ' ' SER . . . . . 0.626 ' HB3' ' HB ' ' A' ' 42' ' ' VAL . 11.5 p -145.07 137.71 26.18 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.594 -177.749 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 63.7 mt -104.7 111.51 34.55 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.293 -179.212 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 6.1 tpm_? 61.32 75.67 0.44 Allowed Pre-proline 0 CA--C 1.534 0.355 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.188 -179.763 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 98' ' ' PRO . . . . . 0.42 ' HA ' ' HD3' ' A' ' 99' ' ' PRO . 0.9 OUTLIER -84.32 150.86 12.01 Favored 'Trans proline' 0 N--CA 1.457 -0.629 0 C-N-CA 122.788 2.325 . . . . 0.0 111.589 176.449 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 99' ' ' PRO . . . . . 0.42 ' HD3' ' HA ' ' A' ' 98' ' ' PRO . 31.2 Cg_exo -59.39 155.16 42.64 Favored 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.703 2.269 . . . . 0.0 111.619 175.727 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 100' ' ' ALA . . . . . 0.451 ' HA ' ' NE2' ' A' ' 103' ' ' HIS . . . -79.26 7.19 8.17 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 112.144 0.424 . . . . 0.0 112.144 -174.118 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 101' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -111.75 -14.03 13.64 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 111.804 0.298 . . . . 0.0 111.804 179.597 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.42 HG13 ' O ' ' A' ' 102' ' ' ILE . 32.2 pt -123.51 77.46 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 121.821 0.82 . . . . 0.0 111.661 -179.281 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 103' ' ' HIS . . . . . 0.451 ' NE2' ' HA ' ' A' ' 100' ' ' ALA . 95.5 m-70 -112.99 -50.25 2.89 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.418 -0.81 . . . . 0.0 109.331 174.983 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 18.9 t -74.9 -23.76 58.42 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 176.353 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.546 ' O ' ' HG2' ' A' ' 108' ' ' ARG . 3.3 m -67.87 -38.96 83.76 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.459 -0.791 . . . . 0.0 109.754 177.272 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 69.2 mt -73.2 -38.76 65.99 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.129 175.701 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 107' ' ' MET . . . . . . . . . . . . . 47.9 ttm -62.1 -39.82 93.75 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.685 -0.689 . . . . 0.0 111.129 -179.819 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 108' ' ' ARG . . . . . 0.546 ' HG2' ' O ' ' A' ' 105' ' ' SER . 7.9 ptp180 -68.56 -25.35 64.86 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.629 0.252 . . . . 0.0 110.795 -179.816 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.489 HG23 ' O ' ' A' ' 105' ' ' SER . 94.2 t -72.32 -48.18 49.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 175.697 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -59.63 -41.59 90.8 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.167 176.164 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 18.0 t70 -61.95 -38.28 87.89 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.412 -0.813 . . . . 0.0 111.164 178.232 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -72.74 -40.37 66.11 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.612 -0.722 . . . . 0.0 111.957 -178.377 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.525 ' HB ' ' HA ' ' A' ' 88' ' ' ARG . 13.7 m -91.01 -24.57 5.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-O 120.895 0.378 . . . . 0.0 111.741 -174.339 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 88.69 42.13 5.83 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 121.009 -0.615 . . . . 0.0 112.421 178.916 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -119.41 156.5 30.03 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 121.101 0.477 . . . . 0.0 111.407 -177.177 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 116' ' ' ARG . . . . . 0.525 ' HB3' ' HG ' ' A' ' 92' ' ' LEU . 21.5 ttm180 -79.59 121.37 25.18 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.793 -0.639 . . . . 0.0 109.654 176.793 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 117' ' ' LEU . . . . . 0.643 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 53.3 tp -92.71 118.83 31.47 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.383 -178.579 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 118' ' ' ILE . . . . . 0.437 ' HB ' ' HB3' ' A' ' 94' ' ' TYR . 64.1 mt -113.38 121.72 66.12 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.61 0 CA-C-O 121.024 0.44 . . . . 0.0 110.425 178.101 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 56.4 mt -120.46 134.31 64.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.375 -179.809 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 45.2 tptt -110.14 98.2 33.94 Favored Pre-proline 0 C--N 1.323 -0.549 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.524 175.43 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 82.0 Cg_endo -91.47 174.62 2.42 Favored 'Trans proline' 0 N--CA 1.456 -0.721 0 C-N-CA 123.068 2.512 . . . . 0.0 112.005 173.961 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -99.01 163.79 12.44 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.467 178.984 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 14.5 t -65.06 -21.78 66.88 Favored 'General case' 0 CA--C 1.534 0.363 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.429 -179.162 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -104.13 18.04 46.74 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.308 179.871 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 22.7 mm-40 -119.6 -173.84 2.62 Favored 'General case' 0 N--CA 1.449 -0.487 0 CA-C-O 121.209 0.528 . . . . 0.0 110.334 -178.489 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -148.87 170.01 19.25 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 115.381 -0.827 . . . . 0.0 108.791 176.548 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 7.5 mt . . . . . 0 C--N 1.322 -0.591 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 179.484 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 29.5 mmmt . . . . . 0 N--CA 1.456 -0.125 0 CA-C-O 120.845 0.355 . . . . 0.0 111.447 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 133' ' ' MET . . . . . 0.737 ' HG2' ' HB2' ' A' ' 146' ' ' TYR . 82.5 mtp -92.38 164.94 13.31 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.929 -174.431 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 13.2 ptmm? -127.08 140.47 52.26 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.971 -177.503 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 135' ' ' LEU . . . . . 0.512 HD11 ' HD2' ' A' ' 142' ' ' TYR . 51.6 tp -80.7 129.19 34.38 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.338 -179.091 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -123.3 139.04 51.18 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.68 178.751 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 16.8 m120 -114.83 108.25 16.5 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 115.801 -0.636 . . . . 0.0 109.868 179.557 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 138' ' ' TYR . . . . . 0.4 ' O ' HG22 ' A' ' 141' ' ' THR . 54.1 t80 -131.65 106.01 7.89 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-O 120.929 0.395 . . . . 0.0 110.323 -178.275 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 139' ' ' GLY . . . . . 0.468 ' O ' ' HB2' ' A' ' 140' ' ' ARG . . . 80.0 34.16 31.07 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.094 178.922 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 140' ' ' ARG . . . . . 0.468 ' HB2' ' O ' ' A' ' 139' ' ' GLY . 0.0 OUTLIER 75.32 -14.57 0.75 Allowed 'General case' 0 N--CA 1.468 0.471 0 C-N-CA 123.279 0.632 . . . . 0.0 111.921 178.097 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 141' ' ' THR . . . . . 0.4 HG22 ' O ' ' A' ' 138' ' ' TYR . 8.3 t -93.9 141.62 28.31 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 175.562 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 142' ' ' TYR . . . . . 0.512 ' HD2' HD11 ' A' ' 135' ' ' LEU . 43.0 p90 -119.07 143.54 47.07 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 121.364 0.602 . . . . 0.0 110.825 -176.052 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 15.0 p90 -152.01 173.88 14.34 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 115.119 -0.946 . . . . 0.0 109.413 -178.512 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 76.8 m-85 -112.94 129.47 56.46 Favored 'General case' 0 C--N 1.322 -0.611 0 C-N-CA 121.058 -0.257 . . . . 0.0 110.691 -179.624 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 145' ' ' GLU . . . . . 0.495 ' OE1' ' HD3' ' A' ' 116' ' ' ARG . 19.2 pt-20 -115.33 157.19 24.18 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 174.667 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 146' ' ' TYR . . . . . 0.737 ' HB2' ' HG2' ' A' ' 133' ' ' MET . 32.9 t80 -139.24 124.19 18.77 Favored 'General case' 0 C--N 1.315 -0.913 0 CA-C-N 115.752 -0.658 . . . . 0.0 109.904 176.656 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 3.1 mp -93.54 105.93 17.41 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.859 0 N-CA-C 109.726 -0.472 . . . . 0.0 109.726 -179.168 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -62.3 114.94 3.76 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-O 121.139 0.495 . . . . 0.0 110.756 178.054 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 8.1 mm-40 . . . . . 0 C--N 1.32 -0.683 0 CA-C-N 115.346 -0.843 . . . . 0.0 111.194 179.22 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 51.4 m95 . . . . . 0 C--O 1.232 0.167 0 CA-C-O 120.677 0.275 . . . . 0.0 111.22 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 23' ' ' ASN . . . . . 0.43 ' O ' HG23 ' A' ' 27' ' ' VAL . 25.1 t-20 -66.19 -58.96 4.26 Favored 'General case' 0 N--CA 1.463 0.198 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.674 -172.285 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.462 ' CB ' ' HA3' ' A' ' 139' ' ' GLY . 4.5 m-20 -58.12 -32.68 68.36 Favored 'General case' 0 N--CA 1.464 0.27 0 CA-C-O 120.631 0.253 . . . . 0.0 111.333 -178.892 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 45.7 tp -57.16 -51.22 70.2 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-O 120.932 0.396 . . . . 0.0 110.262 175.291 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' ALA . . . . . 0.426 ' HB2' HG13 ' A' ' 50' ' ' VAL . . . -63.48 -43.56 96.94 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.601 179.887 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.43 HG23 ' O ' ' A' ' 23' ' ' ASN . 95.5 t -52.13 -47.85 43.09 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.153 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.076 177.454 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 56.4 t80 -57.81 -43.31 85.62 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.539 179.88 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.414 HG23 HD13 ' A' ' 92' ' ' LEU . 70.8 mt -67.91 -43.97 85.51 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.791 179.247 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.486 HG12 HG23 ' A' ' 54' ' ' ILE . 92.1 mt -58.27 -45.54 89.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 115.61 -0.723 . . . . 0.0 111.0 178.303 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 84.0 mtt-85 -65.56 -27.72 68.63 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.666 -0.697 . . . . 0.0 111.761 -177.848 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 53.5 t -84.79 -27.35 26.9 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.596 -0.275 . . . . 0.0 111.186 -179.011 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 12.4 p -94.21 -76.96 0.47 Allowed 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 120.797 0.332 . . . . 0.0 111.202 -177.041 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.402 ' HA2' ' HD3' ' A' ' 35' ' ' PRO . . . 95.75 142.81 13.42 Favored Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 120.85 -0.69 . . . . 0.0 112.162 -178.843 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 35' ' ' PRO . . . . . 0.526 ' HG3' ' HA ' ' A' ' 58' ' ' SER . 58.1 Cg_exo -51.68 126.4 19.6 Favored 'Trans proline' 0 C--N 1.343 0.284 0 C-N-CA 123.283 2.655 . . . . 0.0 113.001 -176.795 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 104.32 53.93 0.81 Allowed Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.514 179.517 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 15.1 t -166.74 -175.84 3.27 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 179.624 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 63.1 mtt85 -122.11 132.51 54.51 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 121.08 0.467 . . . . 0.0 110.775 -179.911 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.928 ' HB ' HD22 ' A' ' 62' ' ' LEU . 60.6 t -123.85 131.76 72.45 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 N-CA-C 108.763 -0.828 . . . . 0.0 108.763 176.76 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.446 HG11 ' CE1' ' A' ' 87' ' ' TYR . 35.6 t -106.7 126.56 62.57 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-O 120.817 0.342 . . . . 0.0 110.887 -177.679 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 46.4 tt0 -108.22 124.12 49.81 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.144 178.368 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.911 ' HB ' ' HB3' ' A' ' 95' ' ' SER . 95.1 t -97.37 121.72 48.17 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.593 -179.876 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 89.68 34.13 8.67 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.855 -0.688 . . . . 0.0 111.519 -179.64 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -81.09 14.15 2.44 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 112.432 0.53 . . . . 0.0 112.432 -173.185 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -54.41 -38.04 61.59 Favored Glycine 0 CA--C 1.519 0.32 0 C-N-CA 121.201 -0.524 . . . . 0.0 113.807 -176.887 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 46' ' ' ARG . . . . . 0.416 HH11 ' HD2' ' A' ' 46' ' ' ARG . 19.4 mtp180 -139.2 13.28 2.61 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 117.129 0.465 . . . . 0.0 111.997 -177.144 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 73.4 m-85 -112.15 29.03 8.24 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 121.254 0.55 . . . . 0.0 110.619 -177.519 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.588 HD21 HD11 ' A' ' 74' ' ' ILE . 87.0 mt -59.26 -15.66 16.89 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 114.868 -1.06 . . . . 0.0 113.074 -175.342 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 81.5 t80 -59.13 -45.26 91.39 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.583 0.23 . . . . 0.0 111.313 -179.249 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.426 HG13 ' HB2' ' A' ' 26' ' ' ALA . 42.8 t -65.41 -54.64 26.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.672 -175.224 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 51' ' ' SER . . . . . 0.442 ' CB ' HD21 ' A' ' 64' ' ' LEU . 0.2 OUTLIER -59.52 -41.96 91.17 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.701 -179.796 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.608 ' HA ' ' HG2' ' A' ' 55' ' ' ARG . 38.7 t70 -69.08 -37.92 78.72 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 120.857 -0.337 . . . . 0.0 110.865 -179.224 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 89.4 t80 -60.26 -37.06 79.26 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.875 0.369 . . . . 0.0 110.034 177.925 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.486 HG23 HG12 ' A' ' 30' ' ' ILE . 76.0 mt -63.29 -54.78 28.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.949 -0.568 . . . . 0.0 110.673 176.044 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 55' ' ' ARG . . . . . 0.608 ' HG2' ' HA ' ' A' ' 52' ' ' ASP . 3.7 ptp180 -69.77 -16.44 63.3 Favored 'General case' 0 N--CA 1.465 0.318 0 N-CA-C 112.072 0.397 . . . . 0.0 112.072 -177.083 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 56' ' ' LYS . . . . . 0.7 ' HA ' ' HE3' ' A' ' 56' ' ' LYS . 0.0 OUTLIER -64.04 -39.24 93.66 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.693 0.282 . . . . 0.0 110.843 176.378 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 29.9 m-70 -107.27 -50.51 3.07 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.746 -178.61 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 58' ' ' SER . . . . . 0.526 ' HA ' ' HG3' ' A' ' 35' ' ' PRO . 57.6 m -88.38 132.99 34.22 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.851 -178.289 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 59' ' ' LYS . . . . . 0.562 ' N ' ' HD2' ' A' ' 59' ' ' LYS . 3.3 mptp? -80.19 57.06 2.61 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.684 0.754 . . . . 0.0 109.825 178.661 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.488 HG11 HG23 ' A' ' 39' ' ' VAL . 54.0 t -101.22 139.32 22.76 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-N 114.998 -1.001 . . . . 0.0 111.043 -178.11 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -80.02 98.61 7.28 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.866 -0.606 . . . . 0.0 109.524 174.819 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 62' ' ' LEU . . . . . 0.928 HD22 ' HB ' ' A' ' 39' ' ' VAL . 0.2 OUTLIER -87.54 121.02 29.43 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 115.934 -0.575 . . . . 0.0 109.593 -178.827 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 40.9 t -100.49 113.77 37.26 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.661 0 CA-C-N 115.738 -0.665 . . . . 0.0 109.786 -179.757 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 64' ' ' LEU . . . . . 0.75 ' HB2' ' HA ' ' A' ' 74' ' ' ILE . 54.5 mt -97.37 139.8 32.78 Favored 'General case' 0 C--N 1.312 -1.04 0 CA-C-N 115.628 -0.714 . . . . 0.0 110.338 -177.507 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.417 ' OG1' ' HA ' ' A' ' 42' ' ' VAL . 38.0 p -131.23 137.92 49.12 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.301 0.096 . . . . 0.0 110.91 178.547 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 4.7 t70 -171.19 170.81 5.93 Favored 'General case' 0 N--CA 1.466 0.33 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 175.759 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 49.5 mm -85.96 104.74 13.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 120.813 0.34 . . . . 0.0 110.865 -175.898 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 35.4 mtmt 56.21 77.52 0.42 Allowed Pre-proline 0 C--N 1.33 -0.278 0 CA-C-N 115.324 -0.853 . . . . 0.0 111.894 -179.575 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 69' ' ' PRO . . . . . 0.795 ' HD2' ' HG2' ' A' ' 76' ' ' ARG . 70.1 Cg_endo . . . . . 0 N--CA 1.459 -0.505 0 C-N-CA 122.334 2.023 . . . . 0.0 112.139 175.613 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.75 ' HA ' ' HB2' ' A' ' 64' ' ' LEU . 44.6 mt . . . . . 0 N--CA 1.451 -0.415 0 CA-C-O 120.94 0.4 . . . . 0.0 110.531 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 97.8 t -77.53 139.04 19.3 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 CA-C-N 116.065 -0.516 . . . . 0.0 109.807 176.43 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 76' ' ' ARG . . . . . 0.795 ' HG2' ' HD2' ' A' ' 69' ' ' PRO . 65.7 mtm180 -84.62 38.77 0.71 Allowed 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 120.762 0.315 . . . . 0.0 110.807 -177.73 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 28.1 t70 -76.68 126.73 31.49 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 121.024 0.44 . . . . 0.0 110.447 -178.649 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 78' ' ' ASP . . . . . 0.508 ' HB3' HG22 ' A' ' 80' ' ' THR . 3.3 m-20 -71.13 97.28 1.47 Allowed 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.891 -0.595 . . . . 0.0 109.971 175.808 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 9.7 tp -58.56 -17.31 9.92 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.388 0 CA-C-O 121.273 0.559 . . . . 0.0 111.663 -178.255 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.508 HG22 ' HB3' ' A' ' 78' ' ' ASP . 8.8 t -66.39 -24.08 66.42 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.027 0.442 . . . . 0.0 110.442 176.246 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 36.6 m -154.42 70.18 6.08 Favored Pre-proline 0 C--N 1.329 -0.32 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 177.514 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 82' ' ' PRO . . . . . 0.556 ' HB2' ' HE2' ' A' ' 87' ' ' TYR . 74.0 Cg_endo -73.27 159.28 47.37 Favored 'Trans proline' 0 C--O 1.236 0.387 0 C-N-CA 123.011 2.474 . . . . 0.0 113.516 -169.691 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 83' ' ' ARG . . . . . 0.704 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 1.9 mtm180 -93.99 126.39 39.18 Favored 'General case' 0 C--N 1.323 -0.543 0 CA-C-N 115.793 -0.639 . . . . 0.0 110.921 177.958 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 84' ' ' MET . . . . . . . . . . . . . 89.3 mmm -64.56 -23.93 67.43 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.252 -178.066 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.704 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 12.0 pt-20 -62.52 -20.53 64.72 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.607 -179.112 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 63.8 mt -86.2 -29.47 6.08 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-O 121.167 0.508 . . . . 0.0 110.541 -178.802 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 87' ' ' TYR . . . . . 0.556 ' HE2' ' HB2' ' A' ' 82' ' ' PRO . 84.6 m-85 -93.34 -30.62 15.03 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.734 -176.259 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 81.8 mtp180 -66.75 114.14 5.4 Favored 'General case' 0 CA--C 1.514 -0.416 0 CA-C-O 121.485 0.659 . . . . 0.0 111.484 -176.889 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 116.09 -17.51 14.84 Favored Glycine 0 N--CA 1.446 -0.684 0 CA-C-N 114.902 -1.044 . . . . 0.0 111.982 -177.593 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -71.86 147.71 46.87 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.769 0.318 . . . . 0.0 110.665 178.835 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -91.34 -26.37 18.96 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-O 121.035 0.445 . . . . 0.0 110.856 -179.665 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 92' ' ' LEU . . . . . 0.496 ' HG ' ' HB3' ' A' ' 116' ' ' ARG . 5.0 tt -149.55 142.71 25.03 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.653 -177.715 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.604 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 63.2 mt -131.45 123.09 51.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 N-CA-C 109.117 -0.697 . . . . 0.0 109.117 178.269 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 10.7 p90 -136.24 161.3 36.14 Favored 'General case' 0 C--N 1.321 -0.659 0 C-N-CA 120.403 -0.519 . . . . 0.0 111.375 -178.119 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 95' ' ' SER . . . . . 0.911 ' HB3' ' HB ' ' A' ' 42' ' ' VAL . 5.4 p -147.87 147.58 29.92 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.824 -0.626 . . . . 0.0 110.447 -178.268 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 96' ' ' ILE . . . . . 0.401 HD12 ' N ' ' A' ' 96' ' ' ILE . 4.3 mp -114.45 121.89 67.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-N 116.668 -0.242 . . . . 0.0 110.567 -179.184 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 50.85 67.28 4.46 Favored Pre-proline 0 N--CA 1.467 0.4 0 O-C-N 123.815 0.697 . . . . 0.0 111.201 179.328 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 98' ' ' PRO . . . . . 0.478 ' HA ' ' HD3' ' A' ' 99' ' ' PRO . 85.5 Cg_endo -87.18 143.84 6.81 Favored 'Trans proline' 0 N--CA 1.456 -0.706 0 C-N-CA 122.861 2.374 . . . . 0.0 113.19 -174.772 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 99' ' ' PRO . . . . . 0.555 ' HD2' HD11 ' A' ' 102' ' ' ILE . 24.3 Cg_exo -63.7 144.51 89.47 Favored 'Trans proline' 0 C--O 1.234 0.317 0 C-N-CA 122.737 2.291 . . . . 0.0 111.573 175.611 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -78.22 44.17 0.48 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.177 0.513 . . . . 0.0 111.289 -177.708 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 101' ' ' GLU . . . . . 0.611 ' HG3' HG23 ' A' ' 102' ' ' ILE . 11.2 pt-20 -132.49 -11.4 3.15 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.439 175.795 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.611 HG23 ' HG3' ' A' ' 101' ' ' GLU . 35.1 pt -122.85 -6.86 8.25 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.449 -0.341 . . . . 0.0 111.636 -177.542 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 103' ' ' HIS . . . . . . . . . . . . . 16.1 p-80 -62.97 -39.31 94.29 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.083 -176.256 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 32.2 t -71.78 -32.93 68.17 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 121.309 0.576 . . . . 0.0 110.086 178.487 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.602 ' O ' ' HG3' ' A' ' 108' ' ' ARG . 31.0 m -70.68 -33.28 70.75 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.314 179.898 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.512 ' HG ' ' O ' ' A' ' 102' ' ' ILE . 85.2 mt -61.34 -40.27 93.66 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.831 177.606 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 107' ' ' MET . . . . . . . . . . . . . 39.7 tpp -56.67 -54.4 46.54 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.344 178.036 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 108' ' ' ARG . . . . . 0.602 ' HG3' ' O ' ' A' ' 105' ' ' SER . 1.6 ptm180 -65.09 -30.94 71.93 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.492 -0.322 . . . . 0.0 111.624 -177.28 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.485 HG23 ' O ' ' A' ' 105' ' ' SER . 83.4 t -73.27 -45.86 51.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 C-N-CA 120.972 -0.291 . . . . 0.0 110.917 179.194 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -59.31 -47.74 84.26 Favored 'General case' 0 CA--C 1.516 -0.355 0 CA-C-O 120.759 0.314 . . . . 0.0 110.163 178.8 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.706 ' HA ' ' HB1' ' A' ' 148' ' ' ALA . 17.3 t70 -66.73 -29.17 69.08 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.984 -176.679 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -71.54 -43.57 66.18 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.547 178.727 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 16.2 m -88.08 -27.01 5.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.456 -0.338 . . . . 0.0 111.758 -175.7 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 89.31 46.27 4.44 Favored Glycine 0 N--CA 1.449 -0.452 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.42 179.016 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -122.5 160.92 24.6 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 121.096 0.474 . . . . 0.0 111.201 -178.233 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 116' ' ' ARG . . . . . 0.496 ' HB3' ' HG ' ' A' ' 92' ' ' LEU . 29.5 ttt180 -81.92 116.42 21.55 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.859 -0.61 . . . . 0.0 109.604 178.542 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 117' ' ' LEU . . . . . 0.604 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 56.0 tp -90.9 118.5 30.35 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.09 -179.401 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 66.3 mt -119.5 126.04 74.96 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-O 121.121 0.486 . . . . 0.0 110.362 179.07 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 119' ' ' ILE . . . . . 0.51 ' O ' ' HD3' ' A' ' 121' ' ' PRO . 63.8 mt -112.93 127.49 70.14 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.055 178.167 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 48.3 tptt -105.65 91.8 5.42 Favored Pre-proline 0 C--N 1.325 -0.463 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.067 178.507 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 121' ' ' PRO . . . . . 0.536 ' HB2' ' CG ' ' A' ' 125' ' ' GLU . 75.9 Cg_endo -92.68 -177.86 0.82 Allowed 'Trans proline' 0 N--CA 1.455 -0.751 0 C-N-CA 122.622 2.215 . . . . 0.0 111.951 175.049 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -72.81 146.02 46.59 Favored 'General case' 0 C--N 1.327 -0.37 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 173.26 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 123' ' ' THR . . . . . 0.437 HG23 ' O ' ' A' ' 123' ' ' THR . 6.2 t -68.61 96.09 0.69 Allowed 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 121.668 0.747 . . . . 0.0 109.475 175.83 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 138.13 -17.58 3.37 Favored Glycine 0 N--CA 1.449 -0.485 0 CA-C-N 115.458 -0.792 . . . . 0.0 112.482 -178.117 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 125' ' ' GLU . . . . . 0.536 ' CG ' ' HB2' ' A' ' 121' ' ' PRO . 7.5 pt-20 -97.64 164.75 12.28 Favored 'General case' 0 N--CA 1.445 -0.7 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 178.402 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -128.66 162.17 27.96 Favored 'General case' 0 C--N 1.312 -1.044 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.426 -178.71 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 127' ' ' ILE . . . . . 0.456 HD13 HD12 ' A' ' 119' ' ' ILE . 19.8 mt . . . . . 0 C--N 1.321 -0.674 0 N-CA-C 108.546 -0.909 . . . . 0.0 108.546 174.464 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.457 -0.125 0 CA-C-O 121.816 0.817 . . . . 0.0 112.777 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 133' ' ' MET . . . . . . . . . . . . . 85.7 mtp -139.55 170.7 15.43 Favored 'General case' 0 C--N 1.313 -1.005 0 CA-C-N 114.929 -1.032 . . . . 0.0 109.266 176.919 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 134' ' ' LYS . . . . . 0.456 ' NZ ' ' HB2' ' A' ' 134' ' ' LYS . 0.0 OUTLIER -128.29 146.01 50.88 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-O 120.988 0.423 . . . . 0.0 111.396 -178.367 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 135' ' ' LEU . . . . . 0.493 HD11 ' CD1' ' A' ' 142' ' ' TYR . 53.0 tp -80.88 139.26 36.02 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.718 -0.673 . . . . 0.0 109.554 177.165 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 136' ' ' VAL . . . . . 0.414 HG23 ' CD1' ' A' ' 143' ' ' PHE . 0.0 OUTLIER -134.66 134.46 54.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-O 120.971 0.415 . . . . 0.0 110.765 177.267 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 28.0 m-80 -107.41 114.59 28.7 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.35 178.915 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 53.2 t80 -148.75 122.28 9.14 Favored 'General case' 0 C--N 1.326 -0.445 0 C-N-CA 120.959 -0.297 . . . . 0.0 110.91 -178.766 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 139' ' ' GLY . . . . . 0.462 ' HA3' ' CB ' ' A' ' 24' ' ' ASP . . . 64.44 62.68 4.89 Favored Glycine 0 N--CA 1.452 -0.273 0 CA-C-N 115.797 -0.638 . . . . 0.0 113.231 174.867 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 35.3 mmt180 71.41 -38.28 0.42 Allowed 'General case' 0 N--CA 1.47 0.544 0 C-N-CA 123.647 0.779 . . . . 0.0 112.168 175.731 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 141' ' ' THR . . . . . 0.407 ' H ' ' C ' ' A' ' 139' ' ' GLY . 9.9 t -96.34 156.82 16.18 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 121.133 0.492 . . . . 0.0 110.831 -178.025 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 142' ' ' TYR . . . . . 0.493 ' CD1' HD11 ' A' ' 135' ' ' LEU . 44.0 p90 -121.58 154.19 37.05 Favored 'General case' 0 C--N 1.32 -0.699 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 169.415 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 143' ' ' PHE . . . . . 0.42 ' O ' HD12 ' A' ' 135' ' ' LEU . 8.9 p90 -153.37 -177.64 6.47 Favored 'General case' 0 C--N 1.316 -0.858 0 CA-C-N 116.129 -0.487 . . . . 0.0 109.777 -177.536 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 86.9 m-85 -116.41 131.97 56.8 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 116.724 -0.216 . . . . 0.0 110.699 -178.083 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 145' ' ' GLU . . . . . 0.451 ' CD ' HH21 ' A' ' 116' ' ' ARG . 17.1 pt-20 -128.91 162.3 27.86 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.044 0.45 . . . . 0.0 110.626 178.832 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 38.9 t80 -142.56 127.01 17.78 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 115.604 -0.725 . . . . 0.0 109.665 173.561 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 147' ' ' ILE . . . . . 0.427 ' N ' HD12 ' A' ' 147' ' ' ILE . 3.8 mp -95.07 100.27 10.77 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.842 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 178.854 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 148' ' ' ALA . . . . . 0.706 ' HB1' ' HA ' ' A' ' 111' ' ' ASP . . . -76.39 96.29 3.99 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.953 -0.567 . . . . 0.0 109.659 176.569 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 . . . . . 0 C--N 1.314 -0.966 0 CA-C-N 115.662 -0.699 . . . . 0.0 111.165 -174.929 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 22' ' ' TRP . . . . . 0.642 ' HB3' HG22 ' A' ' 50' ' ' VAL . 77.0 m95 . . . . . 0 N--CA 1.452 -0.335 0 CA-C-O 120.57 0.224 . . . . 0.0 110.824 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 6.4 m120 -56.33 -52.09 65.84 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.098 177.36 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.43 ' OD2' ' HA3' ' A' ' 139' ' ' GLY . 1.3 t70 -76.77 -28.98 55.89 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.423 -177.152 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 58.5 tp -59.29 -45.98 89.79 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-O 121.049 0.452 . . . . 0.0 109.907 174.516 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' ALA . . . . . 0.44 ' O ' HG13 ' A' ' 30' ' ' ILE . . . -56.18 -44.46 79.38 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.46 -0.791 . . . . 0.0 110.667 178.629 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 88.5 t -54.4 -46.85 70.34 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.244 0 O-C-N 123.264 0.352 . . . . 0.0 110.857 177.38 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 28' ' ' TYR . . . . . 0.546 ' HB2' ' CD2' ' A' ' 138' ' ' TYR . 87.2 t80 -58.48 -45.73 88.07 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.332 177.877 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.419 HG12 HD12 ' A' ' 118' ' ' ILE . 74.5 mt -63.09 -46.12 96.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.719 178.988 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.783 HG12 HG23 ' A' ' 54' ' ' ILE . 83.0 mt -57.48 -44.07 84.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 115.692 -0.685 . . . . 0.0 110.919 178.211 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 75.1 mtt180 -72.8 -21.26 61.01 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.263 -176.28 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 73.3 m -88.54 -14.01 38.75 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.345 -0.389 . . . . 0.0 111.339 177.753 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 22.0 p -126.53 -86.11 0.61 Allowed 'General case' 0 CA--C 1.534 0.328 0 CA-C-O 120.678 0.275 . . . . 0.0 111.358 179.315 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 99.77 -176.25 28.36 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 121.167 -0.539 . . . . 0.0 112.595 178.459 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -71.93 155.37 57.71 Favored 'Trans proline' 0 C--O 1.233 0.26 0 C-N-CA 122.534 2.156 . . . . 0.0 112.247 -179.35 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 98.02 -11.76 64.01 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.681 -0.771 . . . . 0.0 113.081 176.345 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 14.0 t -121.7 -166.61 1.4 Allowed 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.382 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 38' ' ' ARG . . . . . 0.675 ' HG2' ' HB2' ' A' ' 61' ' ' ASP . 84.3 mtt180 -128.03 136.36 51.13 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.891 0.377 . . . . 0.0 110.877 -179.218 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.868 ' HB ' HD22 ' A' ' 62' ' ' LEU . 20.9 t -125.47 140.63 47.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 177.182 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 40.4 t -112.41 128.93 68.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-O 120.941 0.401 . . . . 0.0 111.282 -177.469 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 41' ' ' GLU . . . . . 0.415 ' OE1' HD22 ' A' ' 64' ' ' LEU . 42.5 tt0 -105.06 110.2 22.5 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.659 -0.7 . . . . 0.0 109.549 176.887 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.438 ' HB ' ' HB3' ' A' ' 95' ' ' SER . 58.5 t -94.11 113.76 29.39 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.399 -179.462 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 103.8 42.87 1.89 Allowed Glycine 0 N--CA 1.446 -0.657 0 C-N-CA 120.524 -0.846 . . . . 0.0 111.612 -178.679 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -85.99 -127.01 0.04 OUTLIER 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 110.37 -0.233 . . . . 0.0 110.37 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 67.77 -90.23 0.2 Allowed Glycine 0 C--N 1.33 0.203 0 C-N-CA 121.281 -0.485 . . . . 0.0 112.589 177.873 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -71.9 -23.47 61.49 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 109.705 -0.479 . . . . 0.0 109.705 176.67 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 50.2 m-85 -110.18 109.59 20.14 Favored 'General case' 0 C--O 1.224 -0.277 0 CA-C-N 115.971 -0.558 . . . . 0.0 110.048 178.236 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 96.9 mt -131.35 0.81 4.11 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.706 0.289 . . . . 0.0 111.084 179.722 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 9.2 p90 -69.08 -26.97 65.21 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 112.211 0.449 . . . . 0.0 112.211 -174.936 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.642 HG22 ' HB3' ' A' ' 22' ' ' TRP . 40.9 t -76.02 -58.69 4.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-O 120.93 0.395 . . . . 0.0 110.763 179.734 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 3.3 p -60.77 -42.59 97.78 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.748 -0.66 . . . . 0.0 112.484 -176.703 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.517 ' O ' ' HG2' ' A' ' 56' ' ' LYS . 30.3 t70 -66.53 -27.54 67.84 Favored 'General case' 0 C--N 1.33 -0.256 0 C-N-CA 120.917 -0.313 . . . . 0.0 110.885 -179.359 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 88.1 t80 -70.44 -42.49 71.48 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 120.974 0.416 . . . . 0.0 110.34 175.819 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.783 HG23 HG12 ' A' ' 30' ' ' ILE . 77.3 mt -61.9 -43.58 97.66 Favored 'Isoleucine or valine' 0 C--O 1.236 0.353 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.119 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 55' ' ' ARG . . . . . 0.499 ' HG2' ' HA ' ' A' ' 52' ' ' ASP . 4.1 ptm180 -68.76 -16.09 63.7 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.952 -0.567 . . . . 0.0 111.794 -176.534 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 56' ' ' LYS . . . . . 0.517 ' HG2' ' O ' ' A' ' 52' ' ' ASP . 69.5 mmtt -65.34 -42.05 93.28 Favored 'General case' 0 C--O 1.233 0.192 0 CA-C-O 121.058 0.456 . . . . 0.0 110.349 177.401 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 33.2 m170 -94.17 -57.5 2.5 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.762 -0.654 . . . . 0.0 111.483 -174.519 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 69.0 m -102.72 130.65 49.73 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.11 0.481 . . . . 0.0 111.618 -175.589 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 59' ' ' LYS . . . . . 0.526 ' HE3' ' C ' ' A' ' 59' ' ' LYS . 0.1 OUTLIER -80.42 65.52 5.59 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 121.99 0.9 . . . . 0.0 109.224 173.676 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.574 HG21 HG23 ' A' ' 39' ' ' VAL . 7.3 p -97.16 143.5 12.37 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.025 0 CA-C-N 114.606 -1.179 . . . . 0.0 109.003 174.3 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 61' ' ' ASP . . . . . 0.675 ' HB2' ' HG2' ' A' ' 38' ' ' ARG . 19.7 m-20 -76.32 96.11 3.91 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-O 121.243 0.544 . . . . 0.0 109.68 178.081 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 62' ' ' LEU . . . . . 0.868 HD22 ' HB ' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -86.88 118.1 26.05 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 115.476 -0.784 . . . . 0.0 109.506 -178.936 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.498 HG13 HG21 ' A' ' 75' ' ' VAL . 61.9 t -97.94 114.76 36.19 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.849 0 CA-C-N 115.683 -0.689 . . . . 0.0 110.127 -179.996 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 64' ' ' LEU . . . . . 0.496 HD12 HG12 ' A' ' 74' ' ' ILE . 31.8 mt -96.77 124.0 40.63 Favored 'General case' 0 C--N 1.315 -0.93 0 CA-C-N 115.616 -0.72 . . . . 0.0 109.646 -179.915 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 33.1 p -108.34 124.96 51.16 Favored 'General case' 0 C--N 1.315 -0.924 0 CA-C-O 120.933 0.397 . . . . 0.0 110.278 177.276 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 25.6 t70 -156.17 144.58 19.98 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.202 -176.676 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.43 HG22 ' HG3' ' A' ' 68' ' ' LYS . 53.7 mt -73.42 113.71 11.78 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 116.343 -0.389 . . . . 0.0 110.208 178.676 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 68' ' ' LYS . . . . . 0.43 ' HG3' HG22 ' A' ' 67' ' ' ILE . 5.8 mtpm? 59.76 82.01 0.24 Allowed Pre-proline 0 C--O 1.233 0.212 0 CA-C-N 115.54 -0.754 . . . . 0.0 110.568 179.483 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo . . . . . 0 C--O 1.232 0.198 0 C-N-CA 122.742 2.295 . . . . 0.0 113.008 -175.535 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.496 HG12 HD12 ' A' ' 64' ' ' LEU . 56.8 mt . . . . . 0 N--CA 1.45 -0.445 0 N-CA-C 108.673 -0.862 . . . . 0.0 108.673 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.513 HG11 HD13 ' A' ' 86' ' ' ILE . 63.5 t -86.47 130.21 37.05 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.711 0 CA-C-O 120.942 0.401 . . . . 0.0 110.611 -176.539 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 76' ' ' ARG . . . . . 0.422 ' HG2' ' H ' ' A' ' 76' ' ' ARG . 15.3 ptm180 -75.15 49.19 0.44 Allowed 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.502 -0.772 . . . . 0.0 111.54 179.809 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 22.6 t70 -108.14 117.96 35.51 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 116.083 -0.508 . . . . 0.0 109.779 179.411 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 78' ' ' ASP . . . . . 0.446 ' OD2' HG23 ' A' ' 80' ' ' THR . 5.5 p-10 -92.18 132.15 36.86 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.361 -0.382 . . . . 0.0 110.548 -179.423 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 10.7 tp -62.95 -18.05 20.55 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.476 0 CA-C-N 116.155 -0.475 . . . . 0.0 112.185 -173.62 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.446 HG23 ' OD2' ' A' ' 78' ' ' ASP . 0.7 OUTLIER -77.75 -27.71 50.47 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.877 0.37 . . . . 0.0 110.66 177.483 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 22.2 t -140.81 66.42 26.65 Favored Pre-proline 0 C--N 1.326 -0.416 0 N-CA-C 109.636 -0.505 . . . . 0.0 109.636 177.996 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 76.0 Cg_endo -89.93 151.75 4.91 Favored 'Trans proline' 0 N--CA 1.456 -0.732 0 C-N-CA 122.62 2.213 . . . . 0.0 113.436 -171.817 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 83' ' ' ARG . . . . . 0.717 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 53.0 mtt-85 -93.19 115.26 27.89 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.481 174.589 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 84' ' ' MET . . . . . . . . . . . . . 93.4 mmm -62.05 -22.48 65.78 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.926 -0.579 . . . . 0.0 111.055 -178.981 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.717 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 12.9 pt-20 -62.27 -21.68 65.4 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-O 120.913 0.387 . . . . 0.0 111.137 178.692 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.513 HD13 HG11 ' A' ' 75' ' ' VAL . 82.2 mt -83.76 -43.21 17.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.621 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 70.7 m-85 -76.27 -31.5 58.3 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.841 -178.004 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 88' ' ' ARG . . . . . 0.732 ' HG3' HG12 ' A' ' 113' ' ' VAL . 31.9 mtp85 -66.91 119.86 12.62 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.615 177.737 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 115.11 -8.74 20.96 Favored Glycine 0 N--CA 1.449 -0.499 0 CA-C-N 115.737 -0.665 . . . . 0.0 111.538 -175.748 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -89.35 140.87 29.07 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 120.884 0.374 . . . . 0.0 110.633 179.227 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -88.09 -22.24 24.26 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.968 -178.927 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 92' ' ' LEU . . . . . 0.472 HD23 ' N ' ' A' ' 93' ' ' ILE . 3.3 tt -151.62 141.97 22.45 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.272 -176.733 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.549 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 65.4 mt -132.43 123.35 49.72 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-N 115.986 -0.552 . . . . 0.0 109.701 179.149 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 23.3 p90 -125.03 150.95 46.22 Favored 'General case' 0 C--N 1.322 -0.612 0 C-N-CA 120.709 -0.396 . . . . 0.0 110.402 177.906 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 95' ' ' SER . . . . . 0.438 ' HB3' ' HB ' ' A' ' 42' ' ' VAL . 11.7 p -131.52 140.58 49.54 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.692 -178.089 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 96' ' ' ILE . . . . . 0.473 HG23 ' CH2' ' A' ' 22' ' ' TRP . 81.1 mt -98.45 90.2 2.07 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-O 121.425 0.631 . . . . 0.0 110.775 -177.467 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 50.8 ttt-85 56.4 95.81 0.04 OUTLIER Pre-proline 0 N--CA 1.469 0.498 0 CA-C-N 114.304 -1.316 . . . . 0.0 111.99 -177.999 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 98' ' ' PRO . . . . . 0.408 ' HA ' ' HD3' ' A' ' 99' ' ' PRO . 96.8 Cg_endo -88.97 137.14 3.14 Favored 'Trans proline' 0 N--CA 1.455 -0.739 0 C-N-CA 122.647 2.232 . . . . 0.0 112.612 177.722 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 99' ' ' PRO . . . . . 0.662 ' HD2' HD11 ' A' ' 102' ' ' ILE . 50.5 Cg_exo -53.95 156.63 12.16 Favored 'Trans proline' 0 C--O 1.236 0.393 0 C-N-CA 122.797 2.331 . . . . 0.0 112.079 175.534 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 100' ' ' ALA . . . . . 0.68 ' HA ' ' CE1' ' A' ' 103' ' ' HIS . . . -75.49 29.51 0.1 Allowed 'General case' 0 C--N 1.328 -0.351 0 N-CA-C 112.57 0.582 . . . . 0.0 112.57 -172.67 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 101' ' ' GLU . . . . . 0.587 ' HG3' HG23 ' A' ' 102' ' ' ILE . 12.5 pt-20 -129.89 -23.71 2.76 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 111.937 0.347 . . . . 0.0 111.937 -178.386 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.662 HD11 ' HD2' ' A' ' 99' ' ' PRO . 41.2 pt -106.78 14.4 7.85 Favored 'Isoleucine or valine' 0 C--O 1.234 0.258 0 N-CA-C 112.45 0.537 . . . . 0.0 112.45 -172.949 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 103' ' ' HIS . . . . . 0.68 ' CE1' ' HA ' ' A' ' 100' ' ' ALA . 28.9 m170 -53.78 -54.06 43.51 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.245 0.545 . . . . 0.0 110.334 177.79 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 104' ' ' SER . . . . . 0.512 ' O ' ' HG2' ' A' ' 108' ' ' ARG . 8.8 m -59.89 -34.59 73.37 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.294 -0.866 . . . . 0.0 110.871 -177.722 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.58 ' O ' HG23 ' A' ' 109' ' ' VAL . 16.7 m -63.52 -56.07 18.97 Favored 'General case' 0 N--CA 1.452 -0.329 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.198 -177.556 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 72.2 mt -56.56 -41.16 76.42 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.657 -0.701 . . . . 0.0 111.08 -178.839 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 107' ' ' MET . . . . . . . . . . . . . 96.5 mmm -62.0 -46.89 87.22 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.889 -0.596 . . . . 0.0 111.138 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 108' ' ' ARG . . . . . 0.512 ' HG2' ' O ' ' A' ' 104' ' ' SER . 3.1 ptp180 -77.08 -22.23 53.14 Favored 'General case' 0 C--N 1.331 -0.238 0 C-N-CA 120.679 -0.409 . . . . 0.0 111.847 -178.4 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.58 HG23 ' O ' ' A' ' 105' ' ' SER . 76.2 t -68.31 -48.75 71.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 173.866 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -61.34 -37.2 82.45 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.043 177.944 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 11.2 t70 -66.01 -40.73 91.33 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.144 -0.934 . . . . 0.0 110.904 177.911 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -69.54 -43.14 73.59 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.837 -0.619 . . . . 0.0 111.987 -176.961 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.732 HG12 ' HG3' ' A' ' 88' ' ' ARG . 20.0 m -87.21 -25.16 6.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-O 120.722 0.296 . . . . 0.0 111.585 -175.561 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 82.29 59.82 2.22 Favored Glycine 0 N--CA 1.447 -0.621 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.21 179.944 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -135.43 173.96 11.14 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-O 120.854 0.359 . . . . 0.0 110.441 -179.922 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 116' ' ' ARG . . . . . 0.449 ' HD3' ' OE1' ' A' ' 145' ' ' GLU . 13.8 ttm180 -92.7 124.29 36.6 Favored 'General case' 0 C--N 1.323 -0.576 0 N-CA-C 109.66 -0.496 . . . . 0.0 109.66 175.616 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 117' ' ' LEU . . . . . 0.549 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 61.6 tp -92.66 132.75 36.63 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 116.175 -0.466 . . . . 0.0 109.803 178.945 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 118' ' ' ILE . . . . . 0.419 HD12 HG12 ' A' ' 29' ' ' ILE . 64.6 mt -126.18 122.65 62.02 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-O 121.078 0.466 . . . . 0.0 110.645 177.698 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 66.8 mt -121.43 122.9 68.43 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.016 177.599 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 23.3 ttmm -114.76 104.24 54.36 Favored Pre-proline 0 C--N 1.321 -0.645 0 CA-C-O 120.829 0.347 . . . . 0.0 110.881 176.296 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -80.63 170.78 15.34 Favored 'Trans proline' 0 N--CA 1.455 -0.78 0 C-N-CA 122.211 1.941 . . . . 0.0 110.912 169.737 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 122' ' ' LEU . . . . . 0.73 ' HB2' ' HG3' ' A' ' 125' ' ' GLU . 41.0 mt -70.17 155.29 40.83 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 116.494 -0.321 . . . . 0.0 110.378 179.473 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 123' ' ' THR . . . . . 0.698 ' HA ' ' HE1' ' A' ' 142' ' ' TYR . 46.1 m -64.8 109.9 2.22 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 109.992 -0.373 . . . . 0.0 109.992 175.629 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 107.36 -1.31 34.84 Favored Glycine 0 N--CA 1.446 -0.663 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.141 -178.536 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 125' ' ' GLU . . . . . 0.73 ' HG3' ' HB2' ' A' ' 122' ' ' LEU . 5.1 mt-10 -96.27 -169.21 1.87 Allowed 'General case' 0 N--CA 1.449 -0.501 0 CA-C-O 121.261 0.553 . . . . 0.0 110.8 177.538 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 5.8 t70 -149.35 165.43 32.03 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-N 115.193 -0.912 . . . . 0.0 109.116 -178.345 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 32.6 mt . . . . . 0 C--N 1.325 -0.475 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 176.328 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 90.1 mttt . . . . . 0 N--CA 1.454 -0.236 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 133' ' ' MET . . . . . . . . . . . . . 71.0 mtp 68.95 -178.93 0.22 Allowed 'General case' 0 N--CA 1.467 0.383 0 O-C-N 123.791 0.682 . . . . 0.0 110.668 -179.333 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 17.5 ptmt -136.85 144.07 43.41 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.95 179.9 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 135' ' ' LEU . . . . . 0.559 HD11 ' HD2' ' A' ' 142' ' ' TYR . 53.6 tp -87.63 127.77 35.28 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.655 -179.405 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -130.14 140.66 48.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.902 179.493 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 3.2 m-20 -120.13 105.5 11.05 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.04 178.001 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 138' ' ' TYR . . . . . 0.546 ' CD2' ' HB2' ' A' ' 28' ' ' TYR . 73.4 t80 -117.83 112.06 19.89 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.585 -0.524 . . . . 0.0 109.585 178.778 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 139' ' ' GLY . . . . . 0.43 ' HA3' ' OD2' ' A' ' 24' ' ' ASP . . . 81.44 26.97 49.8 Favored Glycine 0 N--CA 1.447 -0.567 0 C-N-CA 120.743 -0.741 . . . . 0.0 111.797 -178.536 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 140' ' ' ARG . . . . . 0.464 ' HD3' ' HA ' ' A' ' 140' ' ' ARG . 26.5 mmt180 67.6 8.45 6.36 Favored 'General case' 0 N--CA 1.463 0.224 0 C-N-CA 123.248 0.619 . . . . 0.0 111.927 -179.807 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 141' ' ' THR . . . . . 0.462 HG22 ' O ' ' A' ' 138' ' ' TYR . 14.0 t -107.03 135.62 48.27 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 170.926 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 142' ' ' TYR . . . . . 0.698 ' HE1' ' HA ' ' A' ' 123' ' ' THR . 6.7 p90 -101.18 147.58 26.09 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-O 121.019 0.438 . . . . 0.0 110.789 -172.947 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 20.9 p90 -156.08 170.4 22.27 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-N 115.639 -0.71 . . . . 0.0 109.321 175.962 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 96.3 m-85 -113.51 124.27 51.99 Favored 'General case' 0 C--N 1.318 -0.797 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 179.266 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 145' ' ' GLU . . . . . 0.449 ' OE1' ' HD3' ' A' ' 116' ' ' ARG . 19.1 pt-20 -112.73 161.66 16.63 Favored 'General case' 0 C--N 1.316 -0.874 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 178.4 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 146' ' ' TYR . . . . . 0.415 ' HB3' ' HB3' ' A' ' 117' ' ' LEU . 63.8 t80 -141.36 129.06 21.58 Favored 'General case' 0 C--N 1.315 -0.928 0 CA-C-N 115.938 -0.573 . . . . 0.0 109.897 175.511 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 147' ' ' ILE . . . . . 0.415 ' N ' HD12 ' A' ' 147' ' ' ILE . 3.5 mp -101.68 120.21 50.99 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.96 0 N-CA-C 107.956 -1.128 . . . . 0.0 107.956 176.327 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -63.31 92.62 0.06 Allowed 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.503 0.668 . . . . 0.0 110.377 179.112 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 . . . . . 0 N--CA 1.445 -0.687 0 CA-C-N 114.675 -1.148 . . . . 0.0 111.014 -175.582 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 61.8 m95 . . . . . 0 N--CA 1.455 -0.19 0 CA-C-O 120.916 0.389 . . . . 0.0 110.38 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 23' ' ' ASN . . . . . 0.45 ' O ' HG23 ' A' ' 27' ' ' VAL . 88.2 m-20 -72.32 -36.03 68.76 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 174.337 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.494 ' HB3' ' HA3' ' A' ' 139' ' ' GLY . 5.4 m-20 -64.55 -38.15 90.01 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.283 174.772 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 53.8 tp -53.23 -50.31 65.01 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.161 -0.472 . . . . 0.0 109.958 173.016 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' ALA . . . . . 0.401 ' O ' HG13 ' A' ' 30' ' ' ILE . . . -58.61 -48.72 80.02 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.884 177.269 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.45 HG23 ' O ' ' A' ' 23' ' ' ASN . 79.0 t -52.52 -45.82 47.33 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.22 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.175 177.102 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 28' ' ' TYR . . . . . 0.481 ' HB2' ' CD2' ' A' ' 138' ' ' TYR . 78.1 t80 -58.03 -47.12 84.06 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.535 178.629 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.448 HG12 HD12 ' A' ' 118' ' ' ILE . 78.5 mt -60.43 -44.18 95.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.542 178.311 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.621 HD11 ' HA ' ' A' ' 54' ' ' ILE . 83.7 mt -61.99 -41.09 89.65 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 115.601 -0.727 . . . . 0.0 111.455 -179.505 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 31' ' ' ARG . . . . . 0.406 HH11 ' HD3' ' A' ' 31' ' ' ARG . 41.5 mtp-105 -71.78 -29.86 64.93 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.888 -177.541 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 76.5 m -80.92 -27.32 36.21 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.381 -0.372 . . . . 0.0 111.426 -178.999 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 14.0 p -93.77 -75.35 0.5 Allowed 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 120.752 0.31 . . . . 0.0 111.291 -177.673 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 109.43 134.6 7.03 Favored Glycine 0 N--CA 1.448 -0.543 0 C-N-CA 121.072 -0.585 . . . . 0.0 111.694 -176.399 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 32.8 Cg_exo -57.53 133.0 53.89 Favored 'Trans proline' 0 C--O 1.232 0.206 0 C-N-CA 122.925 2.417 . . . . 0.0 112.421 -179.155 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 102.24 62.76 0.73 Allowed Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.434 -0.888 . . . . 0.0 111.731 -177.948 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 15.0 t -178.31 -166.96 0.12 Allowed 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 108.545 -0.909 . . . . 0.0 108.545 -178.191 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 38' ' ' ARG . . . . . 0.832 ' HG2' ' HB3' ' A' ' 61' ' ' ASP . 48.5 mtt180 -124.58 136.61 54.1 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 121.045 0.45 . . . . 0.0 111.055 176.96 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.767 HG23 HG11 ' A' ' 60' ' ' VAL . 86.1 t -125.65 121.96 61.24 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 N-CA-C 109.16 -0.681 . . . . 0.0 109.16 175.342 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.419 HG22 ' HB ' ' A' ' 63' ' ' VAL . 26.4 t -101.37 132.64 46.8 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-O 120.743 0.306 . . . . 0.0 110.79 -175.261 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 41' ' ' GLU . . . . . 0.711 ' HB3' HD23 ' A' ' 64' ' ' LEU . 10.7 tt0 -108.72 126.0 52.53 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.154 -0.476 . . . . 0.0 109.972 176.252 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.739 HG13 HD11 ' A' ' 79' ' ' ILE . 64.8 t -94.12 106.62 18.29 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.774 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 174.644 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 156.75 -66.54 0.3 Allowed Glycine 0 N--CA 1.44 -1.1 0 C-N-CA 120.283 -0.96 . . . . 0.0 111.753 -178.671 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.979 ' HB1' HD13 ' A' ' 74' ' ' ILE . . . 53.38 34.36 17.87 Favored 'General case' 0 C--O 1.233 0.187 0 CA-C-O 121.132 0.491 . . . . 0.0 111.774 176.832 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -91.34 -144.85 13.52 Favored Glycine 0 N--CA 1.445 -0.742 0 C-N-CA 120.623 -0.798 . . . . 0.0 112.847 -177.541 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 39.1 mtp180 -92.6 29.81 1.67 Allowed 'General case' 0 C--N 1.321 -0.667 0 CA-C-O 121.251 0.548 . . . . 0.0 110.523 -176.026 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 5.1 p90 -129.91 30.17 4.88 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.93 -176.675 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.596 HD21 ' HA ' ' A' ' 44' ' ' ALA . 94.1 mt -72.75 7.92 1.73 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.993 -0.549 . . . . 0.0 112.147 -174.318 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 5.7 p90 -65.95 -26.37 67.54 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.819 0.342 . . . . 0.0 110.931 177.025 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.47 ' O ' HG13 ' A' ' 54' ' ' ILE . 93.6 t -72.35 -54.37 16.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.19 175.513 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -61.86 -41.33 97.72 Favored 'General case' 0 N--CA 1.449 -0.479 0 CA-C-N 115.795 -0.638 . . . . 0.0 111.592 -179.099 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 22.1 t70 -65.49 -42.78 91.77 Favored 'General case' 0 C--N 1.329 -0.306 0 C-N-CA 121.033 -0.267 . . . . 0.0 110.756 179.128 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 89.7 t80 -59.56 -36.66 76.64 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.864 0.364 . . . . 0.0 110.533 178.64 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.621 ' HA ' HD11 ' A' ' 30' ' ' ILE . 81.3 mt -61.27 -46.85 95.79 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.386 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.017 178.205 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 36.8 ptt180 -75.33 -16.71 60.38 Favored 'General case' 0 C--O 1.234 0.25 0 CA-C-O 120.843 0.354 . . . . 0.0 111.078 -178.201 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 43.4 mmtm -75.62 -35.39 60.5 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.56 -0.291 . . . . 0.0 110.986 177.234 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 7.5 t-80 -103.94 -38.31 7.04 Favored 'General case' 0 N--CA 1.451 -0.418 0 CA-C-O 120.953 0.406 . . . . 0.0 110.75 -175.13 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 7.9 t -110.08 140.82 43.74 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 121.03 0.443 . . . . 0.0 110.302 -177.697 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 59' ' ' LYS . . . . . 0.504 ' N ' ' HD2' ' A' ' 59' ' ' LYS . 4.1 mptp? -92.22 60.59 3.74 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.783 0.802 . . . . 0.0 109.888 178.378 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.767 HG11 HG23 ' A' ' 39' ' ' VAL . 73.7 t -106.26 139.46 27.54 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-N 114.623 -1.171 . . . . 0.0 110.67 177.985 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 61' ' ' ASP . . . . . 0.832 ' HB3' ' HG2' ' A' ' 38' ' ' ARG . 18.0 t70 -74.98 90.75 2.46 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 109.168 -0.678 . . . . 0.0 109.168 175.823 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 5.5 tt -84.89 126.85 33.83 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.163 -176.529 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.419 ' HB ' HG22 ' A' ' 40' ' ' VAL . 51.5 t -106.82 127.94 61.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.828 -176.256 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 64' ' ' LEU . . . . . 0.711 HD23 ' HB3' ' A' ' 41' ' ' GLU . 82.3 mt -111.76 133.87 53.7 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 109.535 -0.543 . . . . 0.0 109.535 176.61 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 3.4 p -127.47 130.22 48.85 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 120.47 0.176 . . . . 0.0 111.024 178.566 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 66' ' ' ASP . . . . . 0.812 ' HB2' ' HB3' ' A' ' 44' ' ' ALA . 19.4 t0 -162.22 157.58 23.22 Favored 'General case' 0 C--O 1.234 0.268 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.675 -179.355 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 63.7 mt -82.58 122.01 36.55 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 116.115 -0.493 . . . . 0.0 109.79 178.926 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 18.1 ptpt 41.52 69.46 2.04 Favored Pre-proline 0 N--CA 1.474 0.77 0 O-C-N 124.003 0.814 . . . . 0.0 112.346 -175.604 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 69' ' ' PRO . . . . . 0.513 ' CB ' ' HB ' ' A' ' 74' ' ' ILE . 5.8 Cg_exo . . . . . 0 N--CA 1.46 -0.467 0 C-N-CA 122.898 2.399 . . . . 0.0 111.923 179.072 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.979 HD13 ' HB1' ' A' ' 44' ' ' ALA . 62.5 mt . . . . . 0 C--O 1.235 0.33 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.49 HG12 ' H ' ' A' ' 77' ' ' ASP . 61.6 t -61.18 136.16 25.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-O 120.832 0.348 . . . . 0.0 110.364 -177.908 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 17.1 mmt85 -86.3 15.16 5.55 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.969 -0.559 . . . . 0.0 111.31 -171.947 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 77' ' ' ASP . . . . . 0.49 ' H ' HG12 ' A' ' 75' ' ' VAL . 26.2 t70 -77.21 136.54 38.56 Favored 'General case' 0 C--N 1.325 -0.5 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 -177.019 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -58.99 116.06 3.55 Favored 'General case' 0 C--O 1.221 -0.439 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.141 -177.145 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 79' ' ' ILE . . . . . 0.739 HD11 HG13 ' A' ' 42' ' ' VAL . 10.6 tp -69.63 -16.28 20.29 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-O 121.344 0.592 . . . . 0.0 110.399 178.551 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 9.0 t -86.99 -11.31 50.87 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.477 178.225 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 45.0 t -157.2 64.86 3.4 Favored Pre-proline 0 C--N 1.326 -0.424 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 179.879 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 82' ' ' PRO . . . . . 0.562 ' HB2' ' HE2' ' A' ' 87' ' ' TYR . 90.1 Cg_endo -85.07 153.26 11.06 Favored 'Trans proline' 0 N--CA 1.458 -0.564 0 C-N-CA 122.717 2.278 . . . . 0.0 113.206 -170.187 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 83' ' ' ARG . . . . . 0.68 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 35.2 mtt180 -87.56 119.82 28.24 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.784 177.292 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 84' ' ' MET . . . . . 0.652 ' HA ' ' HD2' ' A' ' 87' ' ' TYR . 36.7 mtp -67.94 -9.32 44.24 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.567 -0.742 . . . . 0.0 112.362 -175.302 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.68 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 8.0 pt-20 -61.51 -30.13 70.43 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 121.085 0.469 . . . . 0.0 110.088 175.374 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 69.2 mt -75.07 -40.01 44.31 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 115.47 -0.786 . . . . 0.0 110.514 -179.472 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 87' ' ' TYR . . . . . 0.652 ' HD2' ' HA ' ' A' ' 84' ' ' MET . 91.5 m-85 -75.27 -34.5 61.37 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.947 -0.57 . . . . 0.0 111.216 -177.717 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 34.0 mtp180 -64.41 114.48 4.34 Favored 'General case' 0 C--O 1.235 0.328 0 CA-C-O 121.572 0.701 . . . . 0.0 110.765 177.71 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 124.21 -12.53 8.03 Favored Glycine 0 N--CA 1.443 -0.864 0 CA-C-N 114.868 -1.06 . . . . 0.0 111.492 -175.825 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -84.21 152.19 24.38 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.838 0.352 . . . . 0.0 110.872 -179.815 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -99.75 -22.16 15.48 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.407 177.546 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 92' ' ' LEU . . . . . 0.483 ' HG ' ' HB3' ' A' ' 116' ' ' ARG . 4.9 tt -152.53 142.01 21.69 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.298 -177.981 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.576 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 68.3 mt -131.89 122.96 50.48 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 178.807 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 23.4 p90 -130.61 162.33 29.59 Favored 'General case' 0 C--N 1.321 -0.643 0 C-N-CA 120.614 -0.434 . . . . 0.0 111.007 -178.023 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 95' ' ' SER . . . . . 0.569 ' OG ' ' HB ' ' A' ' 42' ' ' VAL . 4.2 m -143.73 145.41 32.39 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.768 -179.126 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 76.7 mt -116.17 111.17 34.29 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.116 177.988 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 97' ' ' ARG . . . . . 0.431 HH11 ' HD2' ' A' ' 97' ' ' ARG . 12.9 ttp180 59.17 73.49 0.68 Allowed Pre-proline 0 N--CA 1.466 0.349 0 CA-C-N 115.701 -0.681 . . . . 0.0 111.331 -177.548 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_endo -88.2 134.8 3.08 Favored 'Trans proline' 0 N--CA 1.455 -0.749 0 C-N-CA 122.826 2.35 . . . . 0.0 111.917 176.953 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 99' ' ' PRO . . . . . 0.525 ' HG2' HD11 ' A' ' 102' ' ' ILE . 2.9 Cg_endo -47.48 142.49 13.09 Favored 'Trans proline' 0 C--N 1.35 0.606 0 C-N-CA 123.422 2.748 . . . . 0.0 112.807 175.659 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 100' ' ' ALA . . . . . 0.813 ' HA ' ' CE1' ' A' ' 103' ' ' HIS . . . -75.09 42.84 0.19 Allowed 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.848 -0.615 . . . . 0.0 112.46 -176.168 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 101' ' ' GLU . . . . . 0.449 ' HG3' HG23 ' A' ' 102' ' ' ILE . 10.0 pt-20 -135.6 -24.56 1.35 Allowed 'General case' 0 C--N 1.326 -0.423 0 N-CA-C 112.325 0.491 . . . . 0.0 112.325 177.425 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.525 HD11 ' HG2' ' A' ' 99' ' ' PRO . 6.5 pt -114.55 3.55 7.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 N-CA-C 112.848 0.685 . . . . 0.0 112.848 -172.521 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 103' ' ' HIS . . . . . 0.813 ' CE1' ' HA ' ' A' ' 100' ' ' ALA . 35.7 m80 -47.12 -56.49 6.49 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 112.156 0.428 . . . . 0.0 112.156 179.731 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 40.1 t -66.29 -26.1 67.17 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.069 0.462 . . . . 0.0 110.771 -179.794 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.427 ' O ' HG23 ' A' ' 109' ' ' VAL . 14.2 m -67.86 -33.3 74.49 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.109 179.446 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.421 HD22 HG21 ' A' ' 42' ' ' VAL . 82.0 mt -72.13 -38.37 69.25 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.954 178.448 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 107' ' ' MET . . . . . 0.547 ' HA ' HD22 ' A' ' 117' ' ' LEU . 53.6 ttm -59.18 -43.34 92.15 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.186 -178.991 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 27.3 ptt85 -66.59 -31.58 72.37 Favored 'General case' 0 C--N 1.331 -0.207 0 C-N-CA 120.88 -0.328 . . . . 0.0 110.532 -177.704 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.427 HG23 ' O ' ' A' ' 105' ' ' SER . 94.0 t -68.94 -46.86 78.37 Favored 'Isoleucine or valine' 0 C--O 1.234 0.243 0 CA-C-N 116.549 -0.296 . . . . 0.0 110.47 179.88 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -58.74 -43.83 90.34 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.512 177.872 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.499 ' HA ' ' HB1' ' A' ' 148' ' ' ALA . 22.5 t70 -65.29 -39.94 93.21 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.012 179.629 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -66.92 -42.94 84.55 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.835 -0.621 . . . . 0.0 111.879 -178.253 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 25.8 m -87.15 -24.41 6.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 120.894 0.378 . . . . 0.0 111.486 -177.393 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 91.11 44.29 4.46 Favored Glycine 0 N--CA 1.449 -0.462 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.27 178.203 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -124.37 156.56 36.85 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 120.723 0.296 . . . . 0.0 110.834 -177.995 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 116' ' ' ARG . . . . . 0.484 ' HD3' ' OE1' ' A' ' 145' ' ' GLU . 14.3 ttm180 -78.57 127.28 31.91 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 177.015 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 117' ' ' LEU . . . . . 0.576 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 51.1 tp -95.89 121.93 38.14 Favored 'General case' 0 C--N 1.322 -0.589 0 N-CA-C 109.892 -0.411 . . . . 0.0 109.892 -179.946 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 118' ' ' ILE . . . . . 0.448 HD12 HG12 ' A' ' 29' ' ' ILE . 69.3 mt -119.77 112.69 38.07 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-O 121.023 0.439 . . . . 0.0 110.617 178.729 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 50.6 mt -111.61 121.18 63.66 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.797 0 CA-C-O 120.919 0.39 . . . . 0.0 110.32 178.94 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 63.6 tttp -111.11 103.31 54.72 Favored Pre-proline 0 C--N 1.32 -0.699 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.489 174.878 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 93.0 Cg_endo -82.9 -166.86 0.41 Allowed 'Trans proline' 0 N--CA 1.455 -0.773 0 C-N-CA 122.591 2.194 . . . . 0.0 110.829 171.185 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 7.1 mp -88.81 166.92 13.69 Favored 'General case' 0 C--N 1.319 -0.72 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 177.103 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 4.7 t -68.61 -9.39 49.5 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.153 0.501 . . . . 0.0 111.219 -177.68 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -117.49 24.7 8.99 Favored Glycine 0 N--CA 1.446 -0.676 0 N-CA-C 111.587 -0.605 . . . . 0.0 111.587 175.5 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 26.9 mm-40 -129.38 172.75 11.19 Favored 'General case' 0 N--CA 1.45 -0.46 0 CA-C-O 121.209 0.528 . . . . 0.0 110.754 -176.774 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 8.4 t70 -143.79 -170.82 3.4 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-N 115.05 -0.977 . . . . 0.0 108.58 175.358 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 127' ' ' ILE . . . . . 0.602 HD11 ' HB2' ' A' ' 144' ' ' TYR . 18.3 mt . . . . . 0 C--N 1.318 -0.764 0 CA-C-O 120.667 0.27 . . . . 0.0 110.337 179.49 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 28.7 mtpp . . . . . 0 C--O 1.23 0.059 0 CA-C-O 120.838 0.351 . . . . 0.0 111.399 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 133' ' ' MET . . . . . 0.4 ' HG2' ' HB2' ' A' ' 146' ' ' TYR . 88.9 mtp -98.77 151.51 20.71 Favored 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 178.405 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 16.2 ptmt -100.42 134.62 43.1 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 121.222 0.534 . . . . 0.0 111.353 -174.795 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 135' ' ' LEU . . . . . 0.488 HD11 ' HD2' ' A' ' 142' ' ' TYR . 54.6 tp -78.58 126.7 31.11 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.334 -0.848 . . . . 0.0 110.154 177.438 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -123.43 135.12 64.32 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.712 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.909 179.869 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 20.9 m-80 -111.52 112.35 24.02 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.662 -0.699 . . . . 0.0 109.442 178.217 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 138' ' ' TYR . . . . . 0.481 ' CD2' ' HB2' ' A' ' 28' ' ' TYR . 61.1 t80 -144.73 128.77 17.55 Favored 'General case' 0 C--N 1.318 -0.773 0 N-CA-C 110.348 -0.241 . . . . 0.0 110.348 -178.001 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 139' ' ' GLY . . . . . 0.494 ' HA3' ' HB3' ' A' ' 24' ' ' ASP . . . 68.79 35.94 81.08 Favored Glycine 0 N--CA 1.447 -0.61 0 C-N-CA 120.944 -0.646 . . . . 0.0 112.907 176.169 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 140' ' ' ARG . . . . . 0.411 ' HB2' ' O ' ' A' ' 139' ' ' GLY . 69.0 mtt85 72.97 4.51 4.98 Favored 'General case' 0 N--CA 1.463 0.223 0 C-N-CA 122.772 0.429 . . . . 0.0 112.081 175.723 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 14.9 t -124.57 154.09 41.15 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 176.296 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 142' ' ' TYR . . . . . 0.488 ' HD2' HD11 ' A' ' 135' ' ' LEU . 45.4 p90 -123.21 147.81 46.49 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-O 121.162 0.506 . . . . 0.0 110.653 178.539 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 14.0 p90 -154.01 179.59 8.77 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-N 115.064 -0.971 . . . . 0.0 109.056 -177.676 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 144' ' ' TYR . . . . . 0.602 ' HB2' HD11 ' A' ' 127' ' ' ILE . 97.3 m-85 -115.79 127.79 55.35 Favored 'General case' 0 C--N 1.32 -0.709 0 N-CA-C 110.19 -0.3 . . . . 0.0 110.19 179.452 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 145' ' ' GLU . . . . . 0.484 ' OE1' ' HD3' ' A' ' 116' ' ' ARG . 18.2 pt-20 -115.48 161.75 18.14 Favored 'General case' 0 C--N 1.32 -0.691 0 N-CA-C 109.715 -0.476 . . . . 0.0 109.715 176.1 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 146' ' ' TYR . . . . . 0.463 ' HB3' ' HB3' ' A' ' 117' ' ' LEU . 51.0 t80 -141.33 126.9 18.91 Favored 'General case' 0 C--N 1.313 -0.997 0 CA-C-N 115.604 -0.725 . . . . 0.0 109.741 177.532 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 3.1 mp -95.57 109.33 22.38 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.81 0 N-CA-C 109.585 -0.524 . . . . 0.0 109.585 -179.249 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 148' ' ' ALA . . . . . 0.499 ' HB1' ' HA ' ' A' ' 111' ' ' ASP . . . -63.0 111.24 2.08 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.392 -0.596 . . . . 0.0 109.392 175.114 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 . . . . . 0 C--N 1.322 -0.595 0 CA-C-O 121.859 0.838 . . . . 0.0 111.946 -173.756 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 22' ' ' TRP . . . . . 0.584 ' HB3' HG22 ' A' ' 50' ' ' VAL . 83.1 m95 . . . . . 0 N--CA 1.456 -0.157 0 CA-C-O 120.528 0.204 . . . . 0.0 111.385 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' ASN . . . . . 0.496 ' O ' HG23 ' A' ' 27' ' ' VAL . 2.1 m-20 -60.8 -48.79 80.22 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.811 -172.605 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -60.89 -39.55 89.7 Favored 'General case' 0 N--CA 1.468 0.44 0 CA-C-O 120.735 0.302 . . . . 0.0 111.477 -179.08 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.769 HD22 ' HD2' ' A' ' 120' ' ' LYS . 54.0 tp -58.08 -50.8 72.2 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.458 177.574 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 26' ' ' ALA . . . . . 0.468 ' O ' HG13 ' A' ' 30' ' ' ILE . . . -59.46 -46.38 88.95 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.618 -0.719 . . . . 0.0 111.18 -179.029 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.592 ' HA ' HD12 ' A' ' 30' ' ' ILE . 87.5 t -55.64 -44.29 76.25 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.915 179.912 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 72.7 t80 -59.8 -46.19 89.98 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.584 179.003 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.53 HG23 HD22 ' A' ' 92' ' ' LEU . 75.9 mt -59.69 -43.02 90.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.47 178.246 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.811 HG12 HG23 ' A' ' 54' ' ' ILE . 82.2 mt -59.05 -47.08 91.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 115.642 -0.708 . . . . 0.0 111.78 -179.622 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 31' ' ' ARG . . . . . 0.522 ' HG3' ' O ' ' A' ' 27' ' ' VAL . 35.6 mtp180 -73.44 -22.6 60.16 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 121.03 0.443 . . . . 0.0 111.02 -174.156 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 69.5 m -88.59 -8.92 53.89 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.262 -179.563 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 13.5 p -112.88 -70.01 0.83 Allowed 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.76 0.314 . . . . 0.0 111.154 -178.943 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 93.49 166.12 37.73 Favored Glycine 0 N--CA 1.449 -0.492 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.277 179.793 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 69.8 Cg_endo -75.99 156.31 38.62 Favored 'Trans proline' 0 CA--C 1.532 0.376 0 C-N-CA 122.7 2.267 . . . . 0.0 112.597 -179.831 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 84.07 39.3 9.39 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.888 178.491 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 12.5 t -164.4 -170.19 1.99 Allowed 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 177.8 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 38' ' ' ARG . . . . . 0.431 ' HA ' ' O ' ' A' ' 61' ' ' ASP . 49.0 mtm180 -119.3 136.23 54.34 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.945 0.402 . . . . 0.0 110.882 179.789 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.683 HG23 HG21 ' A' ' 60' ' ' VAL . 91.6 t -119.76 113.16 39.89 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 N-CA-C 109.034 -0.728 . . . . 0.0 109.034 173.806 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.587 ' O ' ' HA ' ' A' ' 93' ' ' ILE . 46.9 t -97.12 134.23 35.68 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.853 0 CA-C-O 120.931 0.396 . . . . 0.0 110.916 -175.703 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 41' ' ' GLU . . . . . 0.467 ' HA ' ' O ' ' A' ' 94' ' ' TYR . 0.4 OUTLIER -114.6 157.18 23.41 Favored 'General case' 0 C--N 1.318 -0.793 0 N-CA-C 109.036 -0.728 . . . . 0.0 109.036 173.521 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.559 ' HB ' ' HB3' ' A' ' 95' ' ' SER . 54.7 t -124.76 112.34 31.6 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.733 0 CA-C-N 116.512 -0.313 . . . . 0.0 110.954 178.334 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 112.3 32.82 2.26 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.665 -0.778 . . . . 0.0 113.602 173.74 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -50.44 -58.64 5.27 Favored 'General case' 0 N--CA 1.466 0.345 0 N-CA-C 112.378 0.51 . . . . 0.0 112.378 -178.24 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 63.66 -108.14 2.07 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 121.052 -0.594 . . . . 0.0 112.677 179.519 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 16.7 ptt180 -127.11 5.71 6.47 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.678 0.275 . . . . 0.0 111.333 -179.58 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.525 ' HE2' HG13 ' A' ' 96' ' ' ILE . 14.4 p90 -112.46 90.99 3.49 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.959 0.885 . . . . 0.0 110.496 179.186 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.447 HD22 HD13 ' A' ' 64' ' ' LEU . 74.6 mt -102.07 16.45 26.03 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.217 -0.901 . . . . 0.0 110.629 -175.877 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 78.0 t80 -60.69 -50.07 74.96 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.368 -0.378 . . . . 0.0 111.322 -177.054 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.584 HG22 ' HB3' ' A' ' 22' ' ' TRP . 59.6 t -62.38 -48.76 86.83 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-O 121.039 0.447 . . . . 0.0 110.726 -178.981 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 51' ' ' SER . . . . . 0.429 ' CB ' HD21 ' A' ' 64' ' ' LEU . 0.0 OUTLIER -63.98 -45.63 88.2 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.622 -177.166 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.626 ' O ' ' HG3' ' A' ' 56' ' ' LYS . 26.4 t70 -70.88 -30.32 66.65 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 120.641 0.258 . . . . 0.0 110.662 -179.042 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 45.4 t80 -61.73 -42.48 99.02 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.06 0.457 . . . . 0.0 109.961 175.97 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.811 HG23 HG12 ' A' ' 30' ' ' ILE . 80.5 mt -63.61 -48.01 88.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 115.815 -0.63 . . . . 0.0 111.437 -179.883 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 55' ' ' ARG . . . . . 0.601 ' HG2' ' HA ' ' A' ' 52' ' ' ASP . 0.1 OUTLIER -69.51 -18.88 63.72 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 111.898 0.333 . . . . 0.0 111.898 -177.149 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 56' ' ' LYS . . . . . 0.626 ' HG3' ' O ' ' A' ' 52' ' ' ASP . 56.7 mttm -67.57 -37.79 83.15 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.115 0.483 . . . . 0.0 110.575 176.084 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 8.4 t-80 -101.72 -39.42 7.44 Favored 'General case' 0 N--CA 1.444 -0.746 0 CA-C-N 115.879 -0.6 . . . . 0.0 111.034 -172.111 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 58' ' ' SER . . . . . 0.591 ' HB2' HG23 ' A' ' 30' ' ' ILE . 8.8 t -109.78 139.58 44.68 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.75 0.31 . . . . 0.0 110.393 -177.379 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 14.4 mmmm -91.35 59.99 4.04 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 121.85 0.833 . . . . 0.0 109.981 177.184 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.683 HG21 HG23 ' A' ' 39' ' ' VAL . 13.6 p -110.72 145.05 17.57 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.814 0 CA-C-N 114.817 -1.083 . . . . 0.0 110.098 177.38 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 61' ' ' ASP . . . . . 0.431 ' O ' ' HA ' ' A' ' 38' ' ' ARG . 21.6 t70 -78.79 101.63 7.71 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.062 0.458 . . . . 0.0 109.897 178.656 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 62' ' ' LEU . . . . . 0.413 ' HA ' ' O ' ' A' ' 39' ' ' VAL . 3.6 tt -91.93 119.02 31.3 Favored 'General case' 0 C--N 1.315 -0.925 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 -178.864 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.417 HG11 ' CG2' ' A' ' 86' ' ' ILE . 47.1 t -96.62 119.16 44.31 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-N 115.605 -0.725 . . . . 0.0 110.503 -176.822 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 64' ' ' LEU . . . . . 0.623 ' HB2' ' HA ' ' A' ' 74' ' ' ILE . 51.1 mt -94.39 138.34 32.46 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.553 -0.749 . . . . 0.0 109.722 179.629 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.508 ' OG1' ' HA ' ' A' ' 42' ' ' VAL . 70.2 p -128.56 130.7 47.78 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 120.875 0.369 . . . . 0.0 110.759 178.141 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 31.3 t70 -160.78 146.42 14.65 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.165 -0.47 . . . . 0.0 109.823 179.172 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.744 HD11 HG22 ' A' ' 79' ' ' ILE . 50.6 mt -75.85 106.42 5.67 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-O 121.111 0.482 . . . . 0.0 110.662 179.526 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 68' ' ' LYS . . . . . 0.431 ' N ' ' HD3' ' A' ' 69' ' ' PRO . 45.6 mtmt 65.73 65.47 0.87 Allowed Pre-proline 0 CA--C 1.533 0.307 0 CA-C-N 115.197 -0.911 . . . . 0.0 111.814 177.723 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 69' ' ' PRO . . . . . 0.984 ' HD2' ' HG3' ' A' ' 76' ' ' ARG . 2.6 Cg_exo . . . . . 0 C--O 1.234 0.324 0 C-N-CA 122.976 2.45 . . . . 0.0 111.739 177.055 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.623 ' HA ' ' HB2' ' A' ' 64' ' ' LEU . 35.5 mt . . . . . 0 N--CA 1.449 -0.486 0 N-CA-C 108.892 -0.781 . . . . 0.0 108.892 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.413 HG11 HD13 ' A' ' 86' ' ' ILE . 98.7 t -78.84 136.39 23.91 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.715 0 CA-C-O 121.437 0.637 . . . . 0.0 110.178 -179.16 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 76' ' ' ARG . . . . . 0.984 ' HG3' ' HD2' ' A' ' 69' ' ' PRO . 1.3 mpp_? -90.83 34.17 0.92 Allowed 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 115.032 -0.985 . . . . 0.0 110.841 -173.0 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 22.6 t0 -89.86 136.94 32.74 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.082 -0.71 . . . . 0.0 109.082 177.888 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 7.0 p-10 -95.85 153.05 17.95 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-O 121.166 0.508 . . . . 0.0 111.353 -172.043 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 79' ' ' ILE . . . . . 0.744 HG22 HD11 ' A' ' 67' ' ' ILE . 10.4 tp -71.36 -27.09 27.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 115.648 -0.705 . . . . 0.0 112.478 -170.873 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 14.3 t -89.19 6.34 40.57 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.34 0.591 . . . . 0.0 110.326 -179.11 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 32.8 t -152.29 58.5 2.59 Favored Pre-proline 0 C--N 1.325 -0.495 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.909 174.428 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 82' ' ' PRO . . . . . 0.487 ' HB2' ' HE2' ' A' ' 87' ' ' TYR . 65.4 Cg_endo -74.99 131.13 13.95 Favored 'Trans proline' 0 C--O 1.238 0.503 0 C-N-CA 122.192 1.928 . . . . 0.0 112.092 -175.105 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 83' ' ' ARG . . . . . 0.607 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 37.1 mtp85 -85.51 120.52 27.05 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.141 0.496 . . . . 0.0 111.063 -179.12 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 84' ' ' MET . . . . . 0.506 ' O ' ' HG3' ' A' ' 88' ' ' ARG . 96.1 mmm -62.5 -21.4 65.47 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.415 -0.811 . . . . 0.0 110.516 179.699 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.607 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 11.1 pt-20 -66.29 -21.62 66.27 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-O 121.195 0.522 . . . . 0.0 110.799 -178.834 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.417 ' CG2' HG11 ' A' ' 63' ' ' VAL . 66.5 mt -85.85 -31.2 6.5 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.497 -179.41 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 87' ' ' TYR . . . . . 0.487 ' HE2' ' HB2' ' A' ' 82' ' ' PRO . 79.9 m-85 -88.96 -26.06 21.72 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.432 -176.578 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 88' ' ' ARG . . . . . 0.583 ' HG2' HG12 ' A' ' 113' ' ' VAL . 81.8 mtp180 -71.97 143.82 49.09 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 121.142 0.496 . . . . 0.0 111.041 -178.912 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 80.54 11.2 84.37 Favored Glycine 0 C--N 1.319 -0.414 0 CA-C-N 115.274 -0.875 . . . . 0.0 112.042 -178.606 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -96.0 154.92 16.98 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.847 0.355 . . . . 0.0 110.355 178.627 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -98.34 -23.65 15.54 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 116.108 -0.497 . . . . 0.0 111.025 179.928 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 92' ' ' LEU . . . . . 0.53 HD22 HG23 ' A' ' 29' ' ' ILE . 4.1 tt -156.99 145.11 19.4 Favored 'General case' 0 N--CA 1.452 -0.373 0 CA-C-O 120.873 0.368 . . . . 0.0 110.81 -177.33 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.587 ' HA ' ' O ' ' A' ' 40' ' ' VAL . 61.6 mt -132.77 131.04 59.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 N-CA-C 109.031 -0.729 . . . . 0.0 109.031 178.193 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 94' ' ' TYR . . . . . 0.467 ' O ' ' HA ' ' A' ' 41' ' ' GLU . 32.4 p90 -139.68 155.74 47.21 Favored 'General case' 0 C--N 1.326 -0.414 0 C-N-CA 120.709 -0.396 . . . . 0.0 110.644 -179.508 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 95' ' ' SER . . . . . 0.559 ' HB3' ' HB ' ' A' ' 42' ' ' VAL . 10.2 p -142.48 148.16 37.24 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-O 120.748 0.309 . . . . 0.0 111.095 -176.964 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 96' ' ' ILE . . . . . 0.525 HG13 ' HE2' ' A' ' 47' ' ' PHE . 38.2 mm -99.03 92.82 2.83 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.585 -179.744 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 97' ' ' ARG . . . . . 0.589 ' NH2' ' HA ' ' A' ' 122' ' ' LEU . 98.8 mtt180 54.08 76.51 0.51 Allowed Pre-proline 0 N--CA 1.468 0.446 0 CA-C-N 115.7 -0.682 . . . . 0.0 112.429 177.995 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 98.9 Cg_endo -80.7 157.4 21.48 Favored 'Trans proline' 0 N--CA 1.46 -0.47 0 C-N-CA 122.539 2.159 . . . . 0.0 112.259 179.1 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 99' ' ' PRO . . . . . 0.784 ' HD2' HD11 ' A' ' 102' ' ' ILE . 32.4 Cg_exo -57.44 142.19 95.14 Favored 'Trans proline' 0 C--N 1.345 0.394 0 C-N-CA 122.817 2.345 . . . . 0.0 111.683 174.604 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 100' ' ' ALA . . . . . 0.56 ' HA ' ' NE2' ' A' ' 103' ' ' HIS . . . -63.03 -22.84 67.14 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.329 -0.396 . . . . 0.0 112.035 -175.784 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 101' ' ' GLU . . . . . 0.423 ' HG3' HG23 ' A' ' 102' ' ' ILE . 12.4 pt-20 -74.86 -10.65 59.7 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 112.072 0.397 . . . . 0.0 112.072 -176.703 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.784 HD11 ' HD2' ' A' ' 99' ' ' PRO . 45.6 pt -120.62 8.92 6.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 N-CA-C 112.502 0.556 . . . . 0.0 112.502 -177.776 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 103' ' ' HIS . . . . . 0.56 ' NE2' ' HA ' ' A' ' 100' ' ' ALA . 5.3 m-70 -53.98 -51.2 64.64 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-O 121.053 0.454 . . . . 0.0 110.902 178.04 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 41.1 t -68.25 -28.43 67.21 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.351 -179.743 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.539 ' O ' HG23 ' A' ' 109' ' ' VAL . 29.9 t -68.88 -45.52 70.76 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.962 -0.563 . . . . 0.0 109.908 -179.69 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 72.0 mt -64.37 -40.3 95.57 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.389 -0.369 . . . . 0.0 111.03 178.793 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 107' ' ' MET . . . . . 0.41 ' HG3' ' O ' ' A' ' 103' ' ' HIS . 66.3 mtp -65.54 -42.48 91.9 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.25 -179.667 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 108' ' ' ARG . . . . . 0.529 ' HG2' ' O ' ' A' ' 105' ' ' SER . 8.0 ptm180 -67.93 -31.87 71.92 Favored 'General case' 0 N--CA 1.462 0.154 0 C-N-CA 120.942 -0.303 . . . . 0.0 110.858 -178.847 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.539 HG23 ' O ' ' A' ' 105' ' ' SER . 76.1 t -66.54 -46.65 85.78 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.193 0 CA-C-O 120.71 0.29 . . . . 0.0 110.279 176.798 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -57.34 -45.84 83.89 Favored 'General case' 0 CA--C 1.514 -0.406 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.123 177.419 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.834 ' HA ' ' HB1' ' A' ' 148' ' ' ALA . 5.0 t70 -66.46 -34.09 77.16 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.668 -177.497 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -70.24 -36.29 74.4 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.94 -179.659 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.583 HG12 ' HG2' ' A' ' 88' ' ' ARG . 18.7 m -93.53 -25.96 4.76 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 116.446 -0.343 . . . . 0.0 111.509 -178.172 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 87.97 41.47 6.29 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.863 -0.684 . . . . 0.0 112.634 178.296 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -120.02 158.69 26.27 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.854 0.359 . . . . 0.0 110.918 -178.471 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 116' ' ' ARG . . . . . 0.486 ' HD3' ' OE1' ' A' ' 145' ' ' GLU . 13.2 ttm180 -78.77 123.87 27.62 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 178.434 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 117' ' ' LEU . . . . . 0.564 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 52.0 tp -97.0 123.11 40.63 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.141 179.123 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 118' ' ' ILE . . . . . 0.438 HD12 HG12 ' A' ' 29' ' ' ILE . 53.6 mt -118.39 128.78 75.34 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 CA-C-O 120.976 0.417 . . . . 0.0 110.572 179.437 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 66.0 mt -128.04 134.58 64.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.36 -179.813 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 120' ' ' LYS . . . . . 0.769 ' HD2' HD22 ' A' ' 25' ' ' LEU . 10.4 mttm -113.43 104.25 55.47 Favored Pre-proline 0 C--N 1.324 -0.516 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.481 173.163 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 121' ' ' PRO . . . . . 0.433 ' HB2' ' H ' ' A' ' 122' ' ' LEU . 58.5 Cg_endo -72.28 -146.47 0.02 OUTLIER 'Trans proline' 0 CA--C 1.535 0.547 0 C-N-CA 123.208 2.605 . . . . 0.0 112.758 176.971 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 122' ' ' LEU . . . . . 0.727 ' HB2' ' HB3' ' A' ' 125' ' ' GLU . 7.1 mp -87.59 -176.24 5.49 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.433 -0.349 . . . . 0.0 111.18 -175.884 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 21.7 m -61.23 -39.36 89.99 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.965 -0.562 . . . . 0.0 111.878 -177.533 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -145.14 42.05 1.02 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.996 -0.621 . . . . 0.0 111.602 178.477 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 125' ' ' GLU . . . . . 0.727 ' HB3' ' HB2' ' A' ' 122' ' ' LEU . 5.6 tp10 -131.98 136.17 47.1 Favored 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 -176.268 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 21.1 t70 -76.49 -179.31 5.13 Favored 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 109.838 -0.431 . . . . 0.0 109.838 178.373 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 9.3 mt . . . . . 0 C--N 1.325 -0.499 0 N-CA-C 109.17 -0.678 . . . . 0.0 109.17 177.616 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 23.2 mmmt . . . . . 0 CA--C 1.52 -0.201 0 CA-C-O 121.454 0.645 . . . . 0.0 109.727 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 133' ' ' MET . . . . . 0.664 ' HG2' ' HB2' ' A' ' 146' ' ' TYR . 88.0 mtp -100.28 176.18 5.46 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.017 -0.992 . . . . 0.0 109.907 -179.543 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 14.9 ptmt -121.35 142.1 50.3 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 120.939 0.399 . . . . 0.0 110.635 -178.398 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 135' ' ' LEU . . . . . 0.73 HD11 ' HD2' ' A' ' 142' ' ' TYR . 50.1 tp -86.14 124.43 32.54 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.394 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 136' ' ' VAL . . . . . 0.437 HG23 ' CD1' ' A' ' 143' ' ' PHE . 0.0 OUTLIER -121.02 137.48 54.61 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.161 -179.724 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 2.9 m-20 -107.34 123.78 48.85 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 109.254 -0.647 . . . . 0.0 109.254 174.807 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 57.8 t80 -143.02 116.71 9.24 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 179.427 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 69.38 39.18 81.05 Favored Glycine 0 N--CA 1.447 -0.613 0 C-N-CA 120.575 -0.821 . . . . 0.0 111.95 -177.755 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 140' ' ' ARG . . . . . 0.442 HH11 ' HD3' ' A' ' 140' ' ' ARG . 22.8 ttp-105 73.24 -21.08 0.26 Allowed 'General case' 0 CA--C 1.531 0.229 0 C-N-CA 123.665 0.786 . . . . 0.0 112.561 177.802 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 6.5 t -92.15 141.71 28.29 Favored 'General case' 0 C--N 1.323 -0.562 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 177.355 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 142' ' ' TYR . . . . . 0.73 ' HD2' HD11 ' A' ' 135' ' ' LEU . 44.4 p90 -110.27 152.43 26.16 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.076 0.465 . . . . 0.0 110.917 -178.742 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 143' ' ' PHE . . . . . 0.492 ' HB3' ' HG3' ' A' ' 120' ' ' LYS . 5.4 p90 -157.7 176.22 12.88 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.837 178.632 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 73.6 m-85 -111.03 132.02 54.57 Favored 'General case' 0 C--N 1.319 -0.745 0 C-N-CA 121.011 -0.276 . . . . 0.0 110.81 -179.54 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 145' ' ' GLU . . . . . 0.486 ' OE1' ' HD3' ' A' ' 116' ' ' ARG . 21.0 pt-20 -120.72 160.85 22.48 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 109.33 -0.619 . . . . 0.0 109.33 174.288 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 146' ' ' TYR . . . . . 0.664 ' HB2' ' HG2' ' A' ' 133' ' ' MET . 32.3 t80 -140.3 124.2 17.4 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-N 116.12 -0.491 . . . . 0.0 109.742 178.017 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 147' ' ' ILE . . . . . 0.426 ' N ' HD12 ' A' ' 147' ' ' ILE . 2.8 mp -91.8 100.54 11.38 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 N-CA-C 109.624 -0.51 . . . . 0.0 109.624 179.702 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 148' ' ' ALA . . . . . 0.834 ' HB1' ' HA ' ' A' ' 111' ' ' ASP . . . -82.57 122.02 27.55 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.446 -0.797 . . . . 0.0 109.959 177.448 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 15.5 pt-20 . . . . . 0 C--N 1.321 -0.667 0 CA-C-O 120.801 0.334 . . . . 0.0 110.684 -179.419 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 95.8 m95 . . . . . 0 CA--C 1.522 -0.127 0 CA-C-O 120.967 0.413 . . . . 0.0 110.585 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 23' ' ' ASN . . . . . 0.464 ' O ' HG23 ' A' ' 27' ' ' VAL . 88.6 m-20 -62.74 -45.82 90.94 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.813 -178.172 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 13.0 m-20 -62.85 -41.12 99.23 Favored 'General case' 0 N--CA 1.464 0.256 0 CA-C-O 120.549 0.214 . . . . 0.0 110.897 178.418 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 58.3 tp -57.43 -48.03 80.23 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 121.021 0.438 . . . . 0.0 109.993 176.423 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' ALA . . . . . 0.485 ' O ' HG13 ' A' ' 30' ' ' ILE . . . -60.82 -46.78 89.22 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.954 178.225 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.504 ' HA ' HD12 ' A' ' 30' ' ' ILE . 53.1 t -56.96 -41.62 77.31 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.199 0 CA-C-N 116.559 -0.291 . . . . 0.0 111.234 179.842 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 61.1 t80 -58.44 -42.79 88.13 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.081 0.467 . . . . 0.0 110.35 178.174 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 66.5 mt -70.2 -40.92 78.67 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.489 178.732 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.741 HG12 HG23 ' A' ' 54' ' ' ILE . 97.0 mt -57.45 -44.63 84.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 115.4 -0.818 . . . . 0.0 111.068 178.838 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 31' ' ' ARG . . . . . 0.408 ' HG3' ' O ' ' A' ' 27' ' ' VAL . 73.4 mtp180 -65.95 -28.99 69.33 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.035 -0.529 . . . . 0.0 111.614 -178.237 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 46.0 t -88.7 -20.59 24.65 Favored 'General case' 0 C--N 1.324 -0.514 0 C-N-CA 121.104 -0.238 . . . . 0.0 111.496 -176.034 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 12.6 p -100.7 -78.99 0.51 Allowed 'General case' 0 C--N 1.327 -0.398 0 C-N-CA 121.172 -0.211 . . . . 0.0 111.537 -177.386 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 106.27 164.3 22.85 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.986 -0.626 . . . . 0.0 112.267 -179.801 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 8.6 Cg_exo -71.88 144.57 43.59 Favored 'Trans proline' 0 C--O 1.234 0.296 0 C-N-CA 123.121 2.548 . . . . 0.0 112.631 -179.286 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 83.65 2.03 89.97 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 121.19 -0.528 . . . . 0.0 112.846 177.83 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 26.1 p -96.82 -172.38 2.46 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 38' ' ' ARG . . . . . 0.42 ' HA ' ' O ' ' A' ' 61' ' ' ASP . 20.6 mtp180 -123.92 130.66 52.96 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 110.244 -0.28 . . . . 0.0 110.244 176.764 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.543 HG23 HG21 ' A' ' 60' ' ' VAL . 83.9 t -130.09 138.53 53.75 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 178.659 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 39.8 t -111.95 121.15 63.88 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-O 120.778 0.323 . . . . 0.0 110.936 -176.275 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 41' ' ' GLU . . . . . 0.404 ' HB2' HD21 ' A' ' 62' ' ' LEU . 44.7 tt0 -99.99 108.64 20.89 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 176.053 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.509 ' HB ' ' OG ' ' A' ' 95' ' ' SER . 46.1 t -97.21 125.49 50.26 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.058 -178.681 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 100.65 20.59 14.39 Favored Glycine 0 N--CA 1.447 -0.605 0 C-N-CA 120.483 -0.865 . . . . 0.0 111.804 -176.927 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.446 ' O ' HD13 ' A' ' 74' ' ' ILE . . . -79.09 78.62 5.54 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.19 0.519 . . . . 0.0 110.044 -179.091 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -94.01 -67.85 1.06 Allowed Glycine 0 N--CA 1.443 -0.836 0 CA-C-N 115.67 -0.696 . . . . 0.0 112.907 -178.445 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 61.3 mtt85 -113.66 -45.91 3.08 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 111.778 0.288 . . . . 0.0 111.778 -174.524 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 13.3 p90 -89.1 97.83 11.42 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.549 0.69 . . . . 0.0 111.048 -177.483 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.531 HD22 HD13 ' A' ' 64' ' ' LEU . 79.9 mt -100.0 28.61 4.72 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.533 -0.758 . . . . 0.0 110.277 -179.957 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 74.2 t80 -72.52 -44.89 61.58 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.338 -175.29 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.429 ' O ' HG13 ' A' ' 54' ' ' ILE . 40.9 t -62.05 -55.56 23.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.727 0.299 . . . . 0.0 110.649 -175.459 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 51' ' ' SER . . . . . 0.415 ' CB ' HD21 ' A' ' 64' ' ' LEU . 1.6 p -54.74 -46.82 74.32 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.802 -0.636 . . . . 0.0 112.074 179.396 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.689 ' O ' ' HG2' ' A' ' 56' ' ' LYS . 33.7 t70 -68.95 -31.11 69.75 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.651 0.262 . . . . 0.0 111.127 -177.966 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 77.4 t80 -71.59 -37.11 71.02 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 120.869 0.366 . . . . 0.0 110.756 179.833 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.741 HG23 HG12 ' A' ' 30' ' ' ILE . 88.3 mt -63.73 -44.54 98.37 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-N 116.48 -0.327 . . . . 0.0 111.098 -179.559 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 55' ' ' ARG . . . . . 0.414 ' HA ' ' O ' ' A' ' 58' ' ' SER . 4.9 ptm180 -68.38 -15.56 63.6 Favored 'General case' 0 CA--C 1.533 0.319 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.321 -178.758 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 56' ' ' LYS . . . . . 0.689 ' HG2' ' O ' ' A' ' 52' ' ' ASP . 32.2 mmmt -73.77 -34.77 64.83 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.989 0.423 . . . . 0.0 110.779 177.183 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 56.7 m-70 -93.2 -47.11 7.1 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.395 -178.622 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 58' ' ' SER . . . . . 0.414 ' O ' ' HA ' ' A' ' 55' ' ' ARG . 67.2 m -121.55 135.19 55.03 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.381 179.546 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 29.3 mmmt -80.08 57.78 2.78 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.707 0.765 . . . . 0.0 110.435 -179.641 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.543 HG21 HG23 ' A' ' 39' ' ' VAL . 3.6 p -85.57 146.05 7.06 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 CA-C-N 114.89 -1.05 . . . . 0.0 109.859 176.705 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 61' ' ' ASP . . . . . 0.42 ' O ' ' HA ' ' A' ' 38' ' ' ARG . 30.4 t70 -84.72 100.27 11.38 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 177.314 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 62' ' ' LEU . . . . . 0.404 HD21 ' HB2' ' A' ' 41' ' ' GLU . 2.3 tt -99.62 129.6 45.78 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.134 -176.542 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 48.5 t -106.08 122.12 59.36 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.635 -178.633 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 64' ' ' LEU . . . . . 0.531 HD13 HD22 ' A' ' 48' ' ' LEU . 42.8 mt -94.19 135.3 35.72 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.127 -0.488 . . . . 0.0 109.746 178.055 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 18.9 p -128.44 130.8 48.13 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.593 0.235 . . . . 0.0 111.407 -178.994 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 25.3 t0 -162.89 146.87 11.29 Favored 'General case' 0 C--N 1.333 -0.142 0 CA-C-N 116.11 -0.495 . . . . 0.0 109.842 177.889 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.659 HD11 ' H ' ' A' ' 79' ' ' ILE . 48.5 mm -73.81 104.89 2.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 N-CA-C 110.169 -0.308 . . . . 0.0 110.169 179.425 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 31.4 mtmm 49.66 78.75 0.38 Allowed Pre-proline 0 N--CA 1.466 0.345 0 CA-C-N 115.576 -0.738 . . . . 0.0 111.381 -175.214 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 69' ' ' PRO . . . . . 0.707 ' HD2' ' HG2' ' A' ' 76' ' ' ARG . 11.7 Cg_endo . . . . . 0 C--N 1.344 0.3 0 C-N-CA 123.294 2.662 . . . . 0.0 112.901 -178.777 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.454 ' HB ' ' CB ' ' A' ' 69' ' ' PRO . 60.0 mt . . . . . 0 N--CA 1.454 -0.25 0 N-CA-C 110.367 -0.234 . . . . 0.0 110.367 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.408 HG12 ' HB2' ' A' ' 77' ' ' ASP . 98.8 t -74.03 129.09 36.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-O 120.922 0.391 . . . . 0.0 110.329 179.821 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 76' ' ' ARG . . . . . 0.707 ' HG2' ' HD2' ' A' ' 69' ' ' PRO . 88.9 mtt180 -86.68 35.0 0.66 Allowed 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.185 -175.903 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 77' ' ' ASP . . . . . 0.408 ' HB2' HG12 ' A' ' 75' ' ' VAL . 1.0 OUTLIER -77.63 173.76 11.67 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 109.711 -0.477 . . . . 0.0 109.711 -178.182 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 19.1 m-20 -103.42 122.52 45.04 Favored 'General case' 0 C--N 1.323 -0.566 0 C-N-CA 120.931 -0.307 . . . . 0.0 110.372 -173.89 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 79' ' ' ILE . . . . . 0.659 ' H ' HD11 ' A' ' 67' ' ' ILE . 10.8 tt -75.56 -26.79 18.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 CA-C-O 121.091 0.472 . . . . 0.0 111.018 178.023 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 15.0 t -84.1 -9.83 58.29 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.572 0.701 . . . . 0.0 110.386 -179.584 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 50.9 m -147.62 70.1 11.41 Favored Pre-proline 0 C--N 1.323 -0.585 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 174.421 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 82' ' ' PRO . . . . . 0.711 ' HB2' ' HE2' ' A' ' 87' ' ' TYR . 72.0 Cg_endo -76.95 141.31 21.11 Favored 'Trans proline' 0 N--CA 1.461 -0.436 0 C-N-CA 122.559 2.173 . . . . 0.0 113.49 -169.092 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 83' ' ' ARG . . . . . 0.622 ' HG2' ' HG2' ' A' ' 85' ' ' GLU . 0.0 OUTLIER -79.02 117.31 19.96 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.487 -0.779 . . . . 0.0 109.328 174.11 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 84' ' ' MET . . . . . . . . . . . . . 5.4 mtp -66.08 -25.42 67.01 Favored 'General case' 0 C--N 1.324 -0.534 0 C-N-CA 120.878 -0.329 . . . . 0.0 111.243 -177.475 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.622 ' HG2' ' HG2' ' A' ' 83' ' ' ARG . 10.9 pt-20 -60.87 -26.12 67.17 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.825 0.345 . . . . 0.0 111.235 177.614 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.409 HG13 ' HB3' ' A' ' 83' ' ' ARG . 72.6 mt -74.67 -41.21 48.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.786 0.327 . . . . 0.0 110.856 178.358 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 87' ' ' TYR . . . . . 0.711 ' HE2' ' HB2' ' A' ' 82' ' ' PRO . 91.4 m-85 -82.09 -34.27 29.42 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.482 -178.359 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 88' ' ' ARG . . . . . 0.427 HH11 ' HD2' ' A' ' 88' ' ' ARG . 22.4 mtp180 -68.83 125.58 27.06 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.198 0.523 . . . . 0.0 110.398 179.296 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 101.72 3.07 52.75 Favored Glycine 0 N--CA 1.446 -0.675 0 CA-C-N 115.376 -0.829 . . . . 0.0 111.634 -176.488 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -85.63 144.05 28.08 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.084 0.468 . . . . 0.0 110.731 178.808 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -89.31 -19.62 25.07 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.594 179.215 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 92' ' ' LEU . . . . . 0.48 HD23 ' N ' ' A' ' 93' ' ' ILE . 5.6 tt -166.59 141.27 4.23 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.064 -0.517 . . . . 0.0 109.865 -178.038 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.595 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 58.6 mt -124.95 126.33 71.06 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 N-CA-C 109.433 -0.58 . . . . 0.0 109.433 177.285 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 18.8 p90 -134.21 156.18 48.82 Favored 'General case' 0 C--N 1.322 -0.619 0 C-N-CA 120.226 -0.59 . . . . 0.0 111.511 -178.877 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 95' ' ' SER . . . . . 0.509 ' OG ' ' HB ' ' A' ' 42' ' ' VAL . 14.4 m -148.06 130.52 15.77 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.457 -0.792 . . . . 0.0 110.196 -178.571 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 96' ' ' ILE . . . . . 0.435 ' N ' HD12 ' A' ' 96' ' ' ILE . 4.0 mp -87.99 103.32 13.47 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 177.123 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 97' ' ' ARG . . . . . 1.074 ' HB3' ' HA ' ' A' ' 121' ' ' PRO . 8.9 ptm180 40.11 89.61 0.08 OUTLIER Pre-proline 0 N--CA 1.475 0.809 0 C-N-CA 124.685 1.194 . . . . 0.0 113.269 -176.279 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 89.9 Cg_endo -79.96 154.33 22.69 Favored 'Trans proline' 0 N--CA 1.459 -0.525 0 C-N-CA 122.472 2.115 . . . . 0.0 112.191 178.581 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 99' ' ' PRO . . . . . 0.798 ' HD2' HD11 ' A' ' 102' ' ' ILE . 51.4 Cg_exo -54.27 158.28 9.89 Favored 'Trans proline' 0 C--O 1.234 0.313 0 C-N-CA 122.8 2.334 . . . . 0.0 112.288 173.936 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -80.37 25.86 0.39 Allowed 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.147 -0.479 . . . . 0.0 112.046 -172.997 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 101' ' ' GLU . . . . . 0.666 ' HG3' HG23 ' A' ' 102' ' ' ILE . 12.2 pt-20 -124.3 -21.29 5.0 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.76 -0.2 . . . . 0.0 111.276 178.113 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.798 HD11 ' HD2' ' A' ' 99' ' ' PRO . 45.2 pt -110.38 -1.62 9.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 N-CA-C 112.031 0.382 . . . . 0.0 112.031 -174.646 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 103' ' ' HIS . . . . . 0.529 ' O ' ' HG2' ' A' ' 107' ' ' MET . 23.7 p-80 -61.68 -41.77 98.02 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.798 0.333 . . . . 0.0 110.46 -179.258 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 20.6 t -71.25 -30.21 66.04 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.16 0.505 . . . . 0.0 110.056 177.895 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.541 ' O ' HG23 ' A' ' 109' ' ' VAL . 4.6 m -68.82 -46.08 69.54 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.046 -179.626 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 92.3 mt -58.18 -40.46 81.55 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.168 179.76 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 107' ' ' MET . . . . . 0.529 ' HG2' ' O ' ' A' ' 103' ' ' HIS . 94.2 mmm -60.92 -43.85 98.0 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.43 -178.839 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 108' ' ' ARG . . . . . 0.458 ' HG2' ' O ' ' A' ' 105' ' ' SER . 13.1 ptp180 -76.9 -27.09 54.81 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.663 -0.244 . . . . 0.0 111.2 -177.786 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.541 HG23 ' O ' ' A' ' 105' ' ' SER . 73.6 t -70.9 -44.52 75.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 C-N-CA 121.158 -0.217 . . . . 0.0 110.674 177.744 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -59.46 -41.24 89.25 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 121.106 0.479 . . . . 0.0 110.323 178.466 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.467 ' HA ' ' HB1' ' A' ' 148' ' ' ALA . 16.2 t70 -65.4 -34.92 79.45 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.779 -178.565 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -72.46 -45.13 60.94 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.866 -0.606 . . . . 0.0 111.739 -178.263 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.418 HG12 ' CG ' ' A' ' 88' ' ' ARG . 31.1 m -85.88 -25.63 6.52 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-N 116.533 -0.303 . . . . 0.0 111.771 -176.102 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 84.96 59.3 1.99 Allowed Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.039 179.797 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 115' ' ' ALA . . . . . 0.455 ' O ' ' HB3' ' A' ' 148' ' ' ALA . . . -140.44 149.5 42.65 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 120.927 0.394 . . . . 0.0 110.791 -179.241 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 116' ' ' ARG . . . . . 0.529 ' HD3' ' OE1' ' A' ' 145' ' ' GLU . 14.9 ttm180 -70.98 129.75 39.8 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.893 -0.594 . . . . 0.0 109.999 177.318 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 117' ' ' LEU . . . . . 0.595 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 58.1 tp -100.16 118.66 36.97 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 116.049 -0.523 . . . . 0.0 109.709 178.645 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 60.0 mt -112.66 117.85 56.36 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-O 120.914 0.388 . . . . 0.0 110.569 179.702 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 119' ' ' ILE . . . . . 0.436 ' HA ' ' O ' ' A' ' 95' ' ' SER . 73.3 mt -120.35 120.23 62.2 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.672 -179.646 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 62.2 tttm -115.8 100.9 54.01 Favored Pre-proline 0 C--N 1.32 -0.674 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.208 175.533 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 121' ' ' PRO . . . . . 1.074 ' HA ' ' HB3' ' A' ' 97' ' ' ARG . 86.8 Cg_endo -78.96 -165.46 0.34 Allowed 'Trans proline' 0 N--CA 1.459 -0.503 0 C-N-CA 122.59 2.193 . . . . 0.0 111.792 175.696 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 122' ' ' LEU . . . . . 0.598 ' HB2' ' HB2' ' A' ' 125' ' ' GLU . 31.3 mt -66.54 152.72 44.68 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.872 175.924 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 19.9 m -64.71 106.0 1.1 Allowed 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.02 -0.536 . . . . 0.0 109.569 175.081 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 92.06 30.72 9.86 Favored Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 120.935 -0.65 . . . . 0.0 111.653 -175.118 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 125' ' ' GLU . . . . . 0.598 ' HB2' ' HB2' ' A' ' 122' ' ' LEU . 43.6 tt0 -126.6 145.19 50.64 Favored 'General case' 0 N--CA 1.448 -0.564 0 CA-C-O 121.032 0.444 . . . . 0.0 110.053 -179.408 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -101.15 167.08 10.45 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.471 -178.566 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 6.4 mt . . . . . 0 C--N 1.328 -0.341 0 N-CA-C 110.02 -0.363 . . . . 0.0 110.02 -178.852 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 46.8 mmtm . . . . . 0 N--CA 1.458 -0.068 0 CA-C-O 120.845 0.355 . . . . 0.0 110.899 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 133' ' ' MET . . . . . 0.491 ' HG2' ' HB2' ' A' ' 146' ' ' TYR . 85.7 mtp -133.62 170.56 15.35 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.411 -177.179 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -118.38 145.37 45.21 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.689 179.862 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 135' ' ' LEU . . . . . 0.488 HD11 ' HD2' ' A' ' 142' ' ' TYR . 57.7 tp -80.74 134.24 35.79 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.121 178.26 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -129.54 138.59 53.88 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-O 121.193 0.521 . . . . 0.0 111.577 -179.958 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 87.9 m-20 -110.23 120.17 41.6 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.005 177.323 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 59.5 t80 -148.64 123.4 9.9 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 110.201 -0.296 . . . . 0.0 110.201 177.894 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 66.79 42.72 92.89 Favored Glycine 0 N--CA 1.448 -0.563 0 C-N-CA 121.029 -0.605 . . . . 0.0 112.801 177.461 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 55.5 ttt180 73.75 -19.87 0.33 Allowed 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 123.325 0.65 . . . . 0.0 112.361 175.455 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 5.2 t -97.63 163.21 12.93 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 178.58 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 142' ' ' TYR . . . . . 0.488 ' HD2' HD11 ' A' ' 135' ' ' LEU . 37.6 p90 -131.98 148.93 52.54 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 121.237 0.541 . . . . 0.0 110.886 -179.664 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 8.7 p90 -155.23 177.69 11.06 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 115.26 -0.882 . . . . 0.0 109.4 -179.104 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -113.13 134.34 54.6 Favored 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 110.068 -0.345 . . . . 0.0 110.068 179.419 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 145' ' ' GLU . . . . . 0.529 ' OE1' ' HD3' ' A' ' 116' ' ' ARG . 20.1 pt-20 -126.8 158.47 36.51 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 121.265 0.555 . . . . 0.0 110.385 177.237 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 146' ' ' TYR . . . . . 0.491 ' HB2' ' HG2' ' A' ' 133' ' ' MET . 35.6 t80 -134.76 126.26 28.58 Favored 'General case' 0 C--N 1.316 -0.89 0 CA-C-N 115.465 -0.789 . . . . 0.0 109.265 175.241 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 147' ' ' ILE . . . . . 0.408 ' N ' HD12 ' A' ' 147' ' ' ILE . 3.1 mp -92.24 100.23 10.92 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 CA-C-O 121.19 0.519 . . . . 0.0 109.739 -178.661 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 148' ' ' ALA . . . . . 0.467 ' HB1' ' HA ' ' A' ' 111' ' ' ASP . . . -91.73 107.4 19.18 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.61 -0.723 . . . . 0.0 109.064 174.499 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 . . . . . 0 C--O 1.236 0.368 0 CA-C-O 121.199 0.523 . . . . 0.0 110.28 -177.884 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 80.6 m95 . . . . . 0 N--CA 1.453 -0.297 0 CA-C-O 121.022 0.439 . . . . 0.0 110.45 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 23' ' ' ASN . . . . . 0.419 ' O ' HG23 ' A' ' 27' ' ' VAL . 50.6 t30 -72.57 -45.23 60.2 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.118 178.752 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -59.77 -42.07 92.49 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.234 178.024 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 62.2 tp -55.76 -49.01 74.27 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.297 176.697 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' ALA . . . . . 0.508 ' HB2' HG13 ' A' ' 50' ' ' VAL . . . -58.91 -52.25 66.55 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.891 179.081 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.422 ' HA ' HD12 ' A' ' 30' ' ' ILE . 91.6 t -55.03 -43.32 69.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.321 -0.4 . . . . 0.0 111.188 -179.933 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 67.5 t80 -58.98 -47.32 85.6 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.957 0.408 . . . . 0.0 110.467 179.094 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.513 HG23 HD13 ' A' ' 92' ' ' LEU . 91.2 mt -61.89 -42.95 96.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.589 179.017 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.677 HG12 HG23 ' A' ' 54' ' ' ILE . 95.8 mt -58.23 -39.82 75.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 115.696 -0.683 . . . . 0.0 111.348 179.818 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 44.3 mtp-105 -74.55 -24.0 58.88 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.153 -178.558 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 85.0 m -88.99 -19.29 25.89 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.702 -177.926 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 13.9 p -106.6 -77.6 0.59 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.624 -177.801 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 95.36 163.33 34.43 Favored Glycine 0 N--CA 1.446 -0.635 0 C-N-CA 121.082 -0.58 . . . . 0.0 112.203 -178.467 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -66.09 143.08 70.48 Favored 'Trans proline' 0 C--O 1.233 0.26 0 C-N-CA 122.794 2.329 . . . . 0.0 112.64 -179.79 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 109.57 -32.62 6.64 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.894 177.091 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 11.3 t -98.02 -170.97 2.06 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 110.005 -0.368 . . . . 0.0 110.005 -176.467 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 38' ' ' ARG . . . . . 0.834 ' HG2' ' HB3' ' A' ' 61' ' ' ASP . 45.0 mtt180 -124.28 136.66 54.29 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.004 0.431 . . . . 0.0 111.673 -176.533 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.441 HG23 HG21 ' A' ' 60' ' ' VAL . 63.4 t -121.44 125.34 73.49 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-N 115.528 -0.76 . . . . 0.0 109.318 175.852 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 47.2 t -103.72 128.27 57.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-O 120.811 0.339 . . . . 0.0 111.406 -175.193 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 41' ' ' GLU . . . . . 0.493 ' HB3' HD23 ' A' ' 64' ' ' LEU . 34.3 tt0 -105.13 118.54 36.8 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 173.972 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.502 ' HA ' ' OG1' ' A' ' 65' ' ' THR . 58.5 t -95.54 121.05 45.73 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.362 -179.864 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 96.61 43.24 3.2 Favored Glycine 0 N--CA 1.446 -0.671 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.103 -179.817 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -77.01 82.77 3.53 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.351 0.596 . . . . 0.0 110.519 -178.292 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -69.64 -98.37 0.05 OUTLIER Glycine 0 N--CA 1.447 -0.593 0 CA-C-N 115.01 -0.995 . . . . 0.0 112.903 179.889 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 46' ' ' ARG . . . . . 0.534 ' HD2' ' O ' ' A' ' 46' ' ' ARG . 8.2 tmm_? -136.82 -7.19 1.88 Allowed 'General case' 0 C--N 1.327 -0.4 0 C-N-CA 120.904 -0.318 . . . . 0.0 111.27 -177.199 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.411 ' CZ ' ' HB ' ' A' ' 96' ' ' ILE . 9.0 p90 -61.98 -63.01 1.39 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.808 0.337 . . . . 0.0 111.011 179.688 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.417 HD22 HD13 ' A' ' 64' ' ' LEU . 59.7 mt 55.85 22.23 5.45 Favored 'General case' 0 C--N 1.323 -0.552 0 C-N-CA 123.684 0.794 . . . . 0.0 112.59 173.81 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 86.4 t80 -74.97 -56.85 4.33 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.781 0.324 . . . . 0.0 110.984 -178.075 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.508 HG13 ' HB2' ' A' ' 26' ' ' ALA . 52.5 t -63.49 -52.78 53.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.074 -175.816 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 51' ' ' SER . . . . . 0.556 ' CB ' HD21 ' A' ' 64' ' ' LEU . 0.2 OUTLIER -59.47 -46.88 87.52 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.695 -0.684 . . . . 0.0 112.491 -176.587 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 35.6 t70 -68.07 -27.2 66.29 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.729 0.3 . . . . 0.0 110.948 -177.689 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 89.3 t80 -73.81 -45.62 50.29 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 120.699 0.285 . . . . 0.0 110.798 176.916 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.677 HG23 HG12 ' A' ' 30' ' ' ILE . 78.3 mt -59.92 -43.24 91.78 Favored 'Isoleucine or valine' 0 C--O 1.234 0.253 0 CA-C-N 116.403 -0.362 . . . . 0.0 111.307 -178.079 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 2.0 ptm180 -67.83 -16.73 64.24 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.479 -178.84 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 67.2 mttm -88.05 -42.85 12.12 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.116 0.484 . . . . 0.0 110.454 177.002 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.9 OUTLIER -65.53 -41.68 92.83 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.633 -0.712 . . . . 0.0 110.932 -177.559 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 74.1 m -132.41 153.51 50.75 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.348 -179.507 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -76.71 38.84 0.2 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.908 177.846 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.441 HG21 HG23 ' A' ' 39' ' ' VAL . 7.2 p -84.03 138.76 18.66 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 CA-C-N 116.047 -0.524 . . . . 0.0 109.624 179.13 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 61' ' ' ASP . . . . . 0.834 ' HB3' ' HG2' ' A' ' 38' ' ' ARG . 13.9 t70 -84.86 93.76 8.59 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 -178.232 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 4.2 tt -90.38 127.8 36.29 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.005 -175.424 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 59.4 t -106.36 121.91 59.5 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 115.773 -0.649 . . . . 0.0 111.016 -176.674 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 64' ' ' LEU . . . . . 0.556 HD21 ' CB ' ' A' ' 51' ' ' SER . 90.5 mt -98.93 141.33 31.83 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.05 -0.523 . . . . 0.0 109.816 176.65 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.502 ' OG1' ' HA ' ' A' ' 42' ' ' VAL . 28.8 p -121.28 127.18 51.11 Favored 'General case' 0 C--O 1.238 0.487 0 CA-C-O 120.608 0.242 . . . . 0.0 111.627 -178.738 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 32.0 t70 -166.27 139.01 3.93 Favored 'General case' 0 N--CA 1.463 0.218 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.364 178.117 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 58.6 mt -75.97 112.04 13.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 N-CA-C 110.249 -0.278 . . . . 0.0 110.249 -179.511 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 47.1 mtmt 56.47 75.04 0.61 Allowed Pre-proline 0 C--N 1.33 -0.249 0 O-C-N 123.598 0.561 . . . . 0.0 109.839 -178.179 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 69' ' ' PRO . . . . . 0.574 ' CB ' ' HB ' ' A' ' 74' ' ' ILE . 8.1 Cg_exo . . . . . 0 N--CA 1.465 -0.178 0 C-N-CA 123.249 2.633 . . . . 0.0 112.815 -171.195 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.574 ' HB ' ' CB ' ' A' ' 69' ' ' PRO . 67.7 mt . . . . . 0 N--CA 1.45 -0.461 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.541 HG12 ' H ' ' A' ' 77' ' ' ASP . 91.1 t -73.91 122.56 27.3 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 120.865 0.364 . . . . 0.0 110.24 178.858 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -78.34 16.55 0.77 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.696 -0.684 . . . . 0.0 112.645 -175.232 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 77' ' ' ASP . . . . . 0.541 ' H ' HG12 ' A' ' 75' ' ' VAL . 2.6 m-20 -76.14 155.44 34.63 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 121.496 0.665 . . . . 0.0 111.887 -175.478 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 16.9 t0 -78.88 143.78 35.57 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 114.88 -1.054 . . . . 0.0 111.276 -174.237 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 7.6 tp -96.59 -26.59 4.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.375 -177.206 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 5.0 t -78.22 -25.66 47.09 Favored 'General case' 0 C--O 1.234 0.247 0 N-CA-C 109.376 -0.602 . . . . 0.0 109.376 179.759 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 1.2 m -124.38 76.03 61.74 Favored Pre-proline 0 C--N 1.329 -0.3 0 N-CA-C 108.45 -0.944 . . . . 0.0 108.45 169.027 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -79.07 131.55 9.96 Favored 'Trans proline' 0 N--CA 1.461 -0.405 0 C-N-CA 122.671 2.247 . . . . 0.0 113.453 -170.887 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 83' ' ' ARG . . . . . 0.707 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 64.5 mtt180 -70.57 109.5 4.89 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.651 -0.704 . . . . 0.0 110.016 174.303 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 84' ' ' MET . . . . . 0.718 ' HA ' ' HD2' ' A' ' 87' ' ' TYR . 31.5 mtp -73.31 -10.23 59.53 Favored 'General case' 0 C--N 1.323 -0.572 0 C-N-CA 120.816 -0.354 . . . . 0.0 110.58 178.66 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.707 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 10.5 pt-20 -66.94 -21.98 65.96 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.542 173.908 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 71.9 mt -81.8 -34.59 12.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-O 121.351 0.596 . . . . 0.0 110.042 178.145 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 87' ' ' TYR . . . . . 0.718 ' HD2' ' HA ' ' A' ' 84' ' ' MET . 85.3 m-85 -82.39 -33.9 28.54 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.585 -0.734 . . . . 0.0 110.687 -178.487 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 50.6 mtp180 -64.07 122.46 16.61 Favored 'General case' 0 CA--C 1.516 -0.345 0 CA-C-O 121.227 0.536 . . . . 0.0 111.01 177.626 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 104.06 -12.28 52.37 Favored Glycine 0 N--CA 1.444 -0.767 0 CA-C-N 115.299 -0.864 . . . . 0.0 111.921 -178.976 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -78.79 142.5 36.91 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 110.015 -0.365 . . . . 0.0 110.015 177.767 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -90.71 -19.9 23.04 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-O 121.127 0.489 . . . . 0.0 110.453 -179.415 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 92' ' ' LEU . . . . . 0.602 ' HG ' ' HB3' ' A' ' 116' ' ' ARG . 3.4 tt -153.92 139.78 18.14 Favored 'General case' 0 N--CA 1.447 -0.596 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.929 -176.943 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.574 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 70.0 mt -131.33 124.64 55.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 177.791 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 13.9 p90 -134.72 164.9 26.48 Favored 'General case' 0 C--N 1.321 -0.661 0 C-N-CA 120.717 -0.393 . . . . 0.0 111.08 -178.809 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 6.9 p -140.58 131.14 25.46 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.523 -178.884 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 96' ' ' ILE . . . . . 0.411 ' HB ' ' CZ ' ' A' ' 47' ' ' PHE . 38.5 mm -92.03 98.31 8.23 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.098 179.262 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 63.0 mtm180 59.3 76.46 0.44 Allowed Pre-proline 0 C--N 1.332 -0.182 0 CA-C-N 115.401 -0.818 . . . . 0.0 111.54 -179.242 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 98' ' ' PRO . . . . . 0.475 ' HA ' ' HD3' ' A' ' 99' ' ' PRO . 93.4 Cg_endo -87.97 152.61 7.13 Favored 'Trans proline' 0 N--CA 1.455 -0.747 0 C-N-CA 122.593 2.195 . . . . 0.0 112.1 177.294 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 99' ' ' PRO . . . . . 0.657 ' HB2' ' HG2' ' A' ' 101' ' ' GLU . 6.3 Cg_exo -73.07 148.71 45.24 Favored 'Trans proline' 0 N--CA 1.461 -0.405 0 C-N-CA 122.524 2.149 . . . . 0.0 111.461 176.019 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -76.45 39.75 0.21 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.173 0.511 . . . . 0.0 111.735 -177.475 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 101' ' ' GLU . . . . . 0.657 ' HG2' ' HB2' ' A' ' 99' ' ' PRO . 11.6 pt-20 -121.51 -28.74 4.54 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.205 177.615 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.615 HG23 ' HG3' ' A' ' 101' ' ' GLU . 34.8 pt -110.67 5.28 8.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.359 -175.976 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 103' ' ' HIS . . . . . . . . . . . . . 9.6 p-80 -60.99 -48.17 83.07 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 115.62 -0.718 . . . . 0.0 111.392 -177.043 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 47.1 m -70.97 -23.07 62.14 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.177 0.513 . . . . 0.0 110.658 178.689 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.567 ' O ' ' HG2' ' A' ' 108' ' ' ARG . 8.7 m -73.96 -37.92 64.37 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.242 178.542 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.419 ' HG ' ' O ' ' A' ' 102' ' ' ILE . 94.0 mt -63.61 -41.08 98.34 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.722 178.014 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 107' ' ' MET . . . . . . . . . . . . . 97.7 mmm -57.33 -47.02 82.66 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.759 -0.655 . . . . 0.0 111.316 -179.281 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 108' ' ' ARG . . . . . 0.567 ' HG2' ' O ' ' A' ' 105' ' ' SER . 6.6 ptp180 -67.6 -31.48 71.55 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.505 -0.316 . . . . 0.0 111.178 -176.941 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.464 HG23 ' O ' ' A' ' 105' ' ' SER . 92.1 t -74.29 -46.0 45.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.486 -0.325 . . . . 0.0 110.659 -178.862 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -58.3 -49.99 75.2 Favored 'General case' 0 CA--C 1.516 -0.347 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 176.946 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.418 ' HA ' ' HB1' ' A' ' 148' ' ' ALA . 15.3 t70 -55.16 -40.83 71.08 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.093 -0.958 . . . . 0.0 111.028 179.565 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -68.5 -44.94 73.62 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.918 -0.583 . . . . 0.0 112.196 -176.995 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 31.1 m -84.83 -27.63 6.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 C-N-CA 120.766 -0.374 . . . . 0.0 111.759 -175.29 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 98.04 22.53 15.15 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.631 -0.795 . . . . 0.0 112.654 177.578 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -99.09 163.46 12.56 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 121.505 0.669 . . . . 0.0 111.844 -176.483 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 116' ' ' ARG . . . . . 0.602 ' HB3' ' HG ' ' A' ' 92' ' ' LEU . 23.2 ttt180 -85.08 116.23 23.34 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 115.181 -0.918 . . . . 0.0 109.591 178.181 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 117' ' ' LEU . . . . . 0.574 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 52.2 tp -90.13 128.01 36.23 Favored 'General case' 0 C--N 1.32 -0.693 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 -178.261 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 72.2 mt -129.02 119.72 50.0 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 CA-C-O 121.178 0.513 . . . . 0.0 110.891 179.683 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 64.6 mt -119.75 125.1 73.98 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.437 179.88 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 8.9 tmtm? -108.48 98.23 26.94 Favored Pre-proline 0 C--N 1.325 -0.474 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 175.22 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -77.52 -174.26 2.14 Favored 'Trans proline' 0 C--O 1.236 0.386 0 C-N-CA 122.796 2.33 . . . . 0.0 112.944 -179.507 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 122' ' ' LEU . . . . . 0.429 ' HB2' ' HB3' ' A' ' 125' ' ' GLU . 91.7 mt -75.59 176.04 8.0 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.753 -0.658 . . . . 0.0 111.463 -175.967 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 4.1 p -74.86 102.83 4.87 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.725 -0.671 . . . . 0.0 111.002 179.317 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 82.11 30.23 35.21 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.156 179.547 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 125' ' ' GLU . . . . . 0.429 ' HB3' ' HB2' ' A' ' 122' ' ' LEU . 8.8 tp10 -133.26 136.78 45.75 Favored 'General case' 0 N--CA 1.448 -0.574 0 N-CA-C 109.143 -0.688 . . . . 0.0 109.143 178.049 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -107.25 166.99 10.23 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.043 -173.481 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 45.2 mt . . . . . 0 C--N 1.327 -0.378 0 CA-C-N 115.958 -0.564 . . . . 0.0 109.998 179.642 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 3.9 mppt? . . . . . 0 CA--C 1.515 -0.399 0 CA-C-O 121.279 0.562 . . . . 0.0 111.84 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 133' ' ' MET . . . . . . . . . . . . . 85.0 mtp -137.77 160.63 38.73 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 115.056 -0.975 . . . . 0.0 108.971 174.405 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 134' ' ' LYS . . . . . 0.691 ' HG3' ' HG2' ' A' ' 145' ' ' GLU . 1.4 ptmt -111.93 133.07 54.36 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-O 121.039 0.447 . . . . 0.0 110.866 -178.123 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 135' ' ' LEU . . . . . 0.629 HD11 ' HD2' ' A' ' 142' ' ' TYR . 51.9 tp -81.67 121.4 26.32 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.067 179.244 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -116.21 141.95 31.7 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.65 -178.014 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 5.2 m-20 -115.33 111.35 20.74 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.737 -0.665 . . . . 0.0 109.351 176.226 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 138' ' ' TYR . . . . . 0.614 ' O ' HG22 ' A' ' 141' ' ' THR . 57.0 t80 -124.85 104.68 8.74 Favored 'General case' 0 C--N 1.319 -0.734 0 N-CA-C 109.49 -0.559 . . . . 0.0 109.49 -178.761 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 139' ' ' GLY . . . . . 0.4 ' O ' ' HB2' ' A' ' 140' ' ' ARG . . . 68.27 40.96 87.24 Favored Glycine 0 CA--C 1.519 0.299 0 C-N-CA 120.55 -0.833 . . . . 0.0 111.609 -175.575 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 140' ' ' ARG . . . . . 0.4 ' HB2' ' O ' ' A' ' 139' ' ' GLY . 0.0 OUTLIER 75.83 -25.89 0.2 Allowed 'General case' 0 N--CA 1.472 0.63 0 C-N-CA 123.681 0.792 . . . . 0.0 113.073 178.464 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 141' ' ' THR . . . . . 0.614 HG22 ' O ' ' A' ' 138' ' ' TYR . 13.9 t -75.26 142.68 43.31 Favored 'General case' 0 C--O 1.236 0.38 0 N-CA-C 109.338 -0.616 . . . . 0.0 109.338 177.262 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 142' ' ' TYR . . . . . 0.629 ' HD2' HD11 ' A' ' 135' ' ' LEU . 26.4 p90 -121.41 141.55 50.87 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 121.394 0.616 . . . . 0.0 111.229 -176.452 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 25.1 p90 -154.32 170.21 21.86 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 114.975 -1.011 . . . . 0.0 109.515 -179.968 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 75.5 m-85 -107.5 126.4 52.47 Favored 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 110.227 -0.286 . . . . 0.0 110.227 179.474 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 145' ' ' GLU . . . . . 0.691 ' HG2' ' HG3' ' A' ' 134' ' ' LYS . 10.0 pt-20 -115.41 164.12 14.74 Favored 'General case' 0 C--N 1.32 -0.677 0 N-CA-C 109.685 -0.487 . . . . 0.0 109.685 177.594 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 146' ' ' TYR . . . . . 0.563 ' HB3' ' HB3' ' A' ' 117' ' ' LEU . 50.8 t80 -147.03 127.74 14.28 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.352 177.382 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 147' ' ' ILE . . . . . 0.42 ' N ' HD12 ' A' ' 147' ' ' ILE . 3.1 mp -96.73 104.92 16.43 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.706 0 CA-C-N 115.779 -0.646 . . . . 0.0 109.366 179.506 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 148' ' ' ALA . . . . . 0.418 ' HB1' ' HA ' ' A' ' 111' ' ' ASP . . . -70.25 117.44 11.81 Favored 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 175.974 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 30.3 mt-10 . . . . . 0 C--N 1.32 -0.692 0 CA-C-O 121.702 0.763 . . . . 0.0 111.795 -176.743 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 22' ' ' TRP . . . . . 0.572 ' HB3' HG22 ' A' ' 50' ' ' VAL . 98.2 m95 . . . . . 0 N--CA 1.454 -0.229 0 CA-C-O 120.836 0.35 . . . . 0.0 110.675 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 23' ' ' ASN . . . . . 0.404 ' O ' HG23 ' A' ' 27' ' ' VAL . 13.9 m120 -66.01 -41.0 91.58 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.987 -179.638 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 26.2 m-20 -59.17 -46.78 87.49 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.049 178.905 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 66.6 tp -59.6 -47.86 83.94 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.402 -0.817 . . . . 0.0 110.672 178.721 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 26' ' ' ALA . . . . . 0.411 ' O ' HG13 ' A' ' 30' ' ' ILE . . . -54.71 -51.98 63.87 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.474 -179.399 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.463 ' HA ' HD12 ' A' ' 30' ' ' ILE . 88.4 t -56.02 -43.11 74.29 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-O 120.9 0.381 . . . . 0.0 111.136 -179.717 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 83.5 t80 -59.17 -45.56 90.69 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.576 179.222 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.443 HD13 ' CD1' ' A' ' 94' ' ' TYR . 79.8 mt -65.36 -42.59 93.99 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.626 179.192 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.638 HG12 HG23 ' A' ' 54' ' ' ILE . 96.2 mt -56.62 -45.38 82.46 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-N 115.593 -0.73 . . . . 0.0 111.001 178.654 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 83.7 mtp180 -64.98 -28.27 69.4 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.629 -178.106 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 44.2 t -86.93 -24.53 24.75 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.669 0.271 . . . . 0.0 111.298 -177.316 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 11.3 p -98.48 -77.11 0.52 Allowed 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 120.745 0.307 . . . . 0.0 111.421 -176.774 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 90.57 172.22 44.1 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.943 -0.646 . . . . 0.0 112.307 -178.493 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 63.0 Cg_endo -74.29 153.68 45.71 Favored 'Trans proline' 0 C--O 1.235 0.33 0 C-N-CA 122.571 2.18 . . . . 0.0 112.121 179.391 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 82.35 30.05 34.9 Favored Glycine 0 CA--C 1.518 0.238 0 C-N-CA 120.675 -0.774 . . . . 0.0 113.073 177.772 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 14.2 t -150.07 -176.53 5.49 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 176.199 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 38' ' ' ARG . . . . . 0.544 ' HB2' ' HA ' ' A' ' 90' ' ' ALA . 17.4 mtp180 -117.34 135.56 53.77 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 120.856 0.36 . . . . 0.0 111.389 -176.697 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.442 HG12 ' OE1' ' A' ' 41' ' ' GLU . 16.7 t -123.98 125.03 70.28 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 172.843 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 47.1 t -109.71 117.59 54.94 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 121.191 0.52 . . . . 0.0 110.59 -177.887 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 41' ' ' GLU . . . . . 0.535 ' HB2' HD23 ' A' ' 64' ' ' LEU . 0.1 OUTLIER -90.98 120.32 31.88 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.309 -0.86 . . . . 0.0 110.29 -175.927 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.641 HG11 HD21 ' A' ' 106' ' ' LEU . 59.4 t -94.33 110.26 23.38 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.701 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 175.992 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 98.91 97.78 2.1 Favored Glycine 0 N--CA 1.446 -0.696 0 N-CA-C 110.988 -0.845 . . . . 0.0 110.988 -175.353 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -111.53 -53.24 2.72 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.652 0.263 . . . . 0.0 110.913 -176.256 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 48.53 -121.14 7.35 Favored Glycine 0 N--CA 1.449 -0.451 0 CA-C-N 115.788 -0.642 . . . . 0.0 112.311 -176.523 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 94.7 mtt180 -118.1 3.23 12.07 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 120.903 0.382 . . . . 0.0 110.256 175.77 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 12.4 p90 -98.05 63.34 1.6 Allowed 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.621 0.724 . . . . 0.0 111.143 -175.891 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 55.2 mt -85.33 22.74 1.44 Allowed 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.694 -0.685 . . . . 0.0 110.869 -178.713 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 80.6 t80 -63.33 -41.43 98.89 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.332 -176.512 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.572 HG22 ' HB3' ' A' ' 22' ' ' TRP . 42.6 t -75.32 -50.48 24.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.659 -178.957 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 3.0 p -62.35 -45.78 91.65 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.556 -0.747 . . . . 0.0 112.306 -174.225 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.534 ' O ' ' HG2' ' A' ' 56' ' ' LYS . 35.5 t70 -70.07 -35.67 74.4 Favored 'General case' 0 C--N 1.33 -0.275 0 C-N-CA 120.655 -0.418 . . . . 0.0 110.646 -177.011 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 88.6 t80 -58.72 -40.48 83.88 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.944 0.402 . . . . 0.0 110.299 178.079 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.638 HG23 HG12 ' A' ' 30' ' ' ILE . 79.6 mt -65.62 -49.23 79.1 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.338 -179.921 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 55' ' ' ARG . . . . . 0.453 ' HG2' ' O ' ' A' ' 52' ' ' ASP . 5.7 ptm180 -69.29 -19.98 63.9 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-N 116.476 -0.329 . . . . 0.0 111.598 -176.55 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 56' ' ' LYS . . . . . 0.534 ' HG2' ' O ' ' A' ' 52' ' ' ASP . 4.6 mmmp? -82.09 -35.61 28.44 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.713 0.292 . . . . 0.0 111.192 177.697 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 7.9 t-80 -84.55 -41.24 16.67 Favored 'General case' 0 N--CA 1.446 -0.674 0 CA-C-O 121.037 0.446 . . . . 0.0 109.966 -177.595 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 74.6 m -122.9 133.44 54.4 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.355 176.519 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -78.17 63.94 3.22 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 121.862 0.839 . . . . 0.0 110.086 179.47 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.411 HG21 HG23 ' A' ' 39' ' ' VAL . 7.1 p -94.85 149.57 4.42 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.883 0 CA-C-N 114.489 -1.232 . . . . 0.0 109.873 175.913 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 52.3 t0 -74.77 96.05 3.0 Favored 'General case' 0 C--O 1.234 0.268 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 178.093 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 62' ' ' LEU . . . . . 0.488 HD21 ' OE2' ' A' ' 41' ' ' GLU . 1.1 tm? -93.14 126.01 38.03 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 115.233 -0.894 . . . . 0.0 110.262 -173.379 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 41.7 t -125.85 119.61 55.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.043 -177.13 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 64' ' ' LEU . . . . . 0.535 HD23 ' HB2' ' A' ' 41' ' ' GLU . 12.7 mt -96.48 148.99 22.24 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 116.175 -0.466 . . . . 0.0 109.97 178.601 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.525 HG22 ' HB ' ' A' ' 75' ' ' VAL . 15.3 p -134.48 127.8 32.16 Favored 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 110.566 -0.161 . . . . 0.0 110.566 176.827 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 3.4 t70 -163.4 175.61 10.63 Favored 'General case' 0 N--CA 1.464 0.236 0 N-CA-C 110.062 -0.347 . . . . 0.0 110.062 -178.619 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 48.9 mm -88.5 107.84 18.12 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 116.652 -0.249 . . . . 0.0 110.398 -178.62 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 55.0 mtmt 60.11 90.0 0.1 OUTLIER Pre-proline 0 N--CA 1.466 0.329 0 O-C-N 123.674 0.608 . . . . 0.0 111.118 -177.987 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 69' ' ' PRO . . . . . 0.992 ' HB3' ' HB ' ' A' ' 74' ' ' ILE . 32.9 Cg_endo . . . . . 0 C--O 1.233 0.268 0 C-N-CA 123.127 2.551 . . . . 0.0 113.177 -177.462 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.992 ' HB ' ' HB3' ' A' ' 69' ' ' PRO . 40.3 mt . . . . . 0 N--CA 1.449 -0.478 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.617 HG11 HD13 ' A' ' 86' ' ' ILE . 55.8 t -78.12 131.17 35.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 176.959 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 76' ' ' ARG . . . . . 0.423 ' HA ' ' HD3' ' A' ' 69' ' ' PRO . 36.2 ptt180 -82.88 29.49 0.46 Allowed 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.762 -0.654 . . . . 0.0 111.939 -175.902 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 31.9 t0 -84.02 160.42 21.0 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 110.024 -0.362 . . . . 0.0 110.024 -178.944 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -79.61 104.02 9.92 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-O 120.849 0.357 . . . . 0.0 110.268 -177.646 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 79' ' ' ILE . . . . . 0.549 HD11 ' CG1' ' A' ' 42' ' ' VAL . 12.8 tt -57.67 -23.33 19.98 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.501 0 CA-C-N 115.692 -0.685 . . . . 0.0 112.478 -176.379 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 5.1 t -87.9 -6.56 58.01 Favored 'General case' 0 CA--C 1.539 0.534 0 CA-C-O 121.141 0.496 . . . . 0.0 110.869 -178.1 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 32.9 t -154.63 60.09 2.64 Favored Pre-proline 0 C--N 1.328 -0.336 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 178.177 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 82' ' ' PRO . . . . . 0.794 ' HB2' ' HE2' ' A' ' 87' ' ' TYR . 84.3 Cg_endo -79.24 155.34 25.4 Favored 'Trans proline' 0 N--CA 1.461 -0.405 0 C-N-CA 122.676 2.251 . . . . 0.0 113.784 -166.01 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 83' ' ' ARG . . . . . 0.858 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 94.1 mtt180 -76.28 132.99 40.17 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.11 -0.95 . . . . 0.0 110.995 177.929 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 84' ' ' MET . . . . . . . . . . . . . 87.5 mmm -70.77 -22.42 62.39 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.119 176.812 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.858 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 10.3 pt-20 -66.0 -13.93 60.74 Favored 'General case' 0 CA--C 1.532 0.282 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.823 179.865 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.617 HD13 HG11 ' A' ' 75' ' ' VAL . 66.7 mt -93.25 -40.02 11.51 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-O 121.06 0.457 . . . . 0.0 110.846 -179.346 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 87' ' ' TYR . . . . . 0.794 ' HE2' ' HB2' ' A' ' 82' ' ' PRO . 99.0 m-85 -80.04 -28.76 39.25 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.322 -176.872 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 30.5 mtt-85 -61.7 120.75 11.24 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 121.045 0.45 . . . . 0.0 111.222 179.598 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 109.39 -2.44 31.0 Favored Glycine 0 N--CA 1.446 -0.637 0 CA-C-N 115.607 -0.724 . . . . 0.0 111.872 -177.896 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 90' ' ' ALA . . . . . 0.544 ' HA ' ' HB2' ' A' ' 38' ' ' ARG . . . -90.5 143.16 27.02 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.738 0.304 . . . . 0.0 110.594 178.162 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -88.52 -28.02 21.06 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.624 -179.505 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 92' ' ' LEU . . . . . 0.529 ' HG ' ' HB3' ' A' ' 116' ' ' ARG . 6.8 tt -149.5 143.14 25.45 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.052 -177.019 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.578 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 68.0 mt -133.36 119.42 35.02 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 N-CA-C 109.432 -0.581 . . . . 0.0 109.432 178.36 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 94' ' ' TYR . . . . . 0.443 ' CD1' HD13 ' A' ' 29' ' ' ILE . 47.7 p90 -124.58 158.59 32.65 Favored 'General case' 0 C--N 1.321 -0.664 0 C-N-CA 120.219 -0.593 . . . . 0.0 110.823 177.976 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 14.2 m -126.62 125.98 42.83 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.795 -0.638 . . . . 0.0 110.715 -176.847 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 54.2 mt -94.52 97.13 6.55 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.089 -179.672 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 97' ' ' ARG . . . . . 0.434 HH11 ' HD3' ' A' ' 97' ' ' ARG . 7.7 ttm180 59.91 73.46 0.65 Allowed Pre-proline 0 CA--C 1.533 0.295 0 CA-C-N 115.494 -0.776 . . . . 0.0 110.87 -179.028 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_endo -85.64 137.71 5.87 Favored 'Trans proline' 0 N--CA 1.458 -0.57 0 C-N-CA 122.529 2.153 . . . . 0.0 112.775 -179.302 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 32.8 Cg_endo -67.36 163.05 36.06 Favored 'Trans proline' 0 C--O 1.234 0.307 0 C-N-CA 122.685 2.256 . . . . 0.0 112.182 175.441 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -85.61 36.21 0.64 Allowed 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.959 -177.998 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 101' ' ' GLU . . . . . 0.463 ' HG3' HG23 ' A' ' 102' ' ' ILE . 11.7 pt-20 -117.63 -10.96 10.48 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 121.156 0.503 . . . . 0.0 110.47 175.482 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.581 ' O ' ' HG ' ' A' ' 106' ' ' LEU . 20.8 pt -129.49 9.11 2.48 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.96 -178.184 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 103' ' ' HIS . . . . . . . . . . . . . 8.8 p-80 -55.28 -56.39 20.62 Favored 'General case' 0 C--N 1.316 -0.851 0 CA-C-N 115.505 -0.771 . . . . 0.0 112.31 -174.969 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 31.5 t -76.23 -26.16 55.77 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 121.112 0.482 . . . . 0.0 109.999 179.128 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.556 ' O ' HG23 ' A' ' 109' ' ' VAL . 6.5 m -66.21 -42.73 88.33 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.204 -178.433 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.641 HD21 HG11 ' A' ' 42' ' ' VAL . 82.2 mt -61.32 -41.49 97.1 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.838 -0.619 . . . . 0.0 111.259 179.205 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 107' ' ' MET . . . . . 0.425 ' HA ' HD22 ' A' ' 117' ' ' LEU . 45.5 mtp -65.29 -42.01 93.55 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.229 -178.926 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 16.7 ptm180 -73.32 -22.94 60.21 Favored 'General case' 0 C--N 1.332 -0.183 0 C-N-CA 120.976 -0.29 . . . . 0.0 111.462 -178.907 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.556 HG23 ' O ' ' A' ' 105' ' ' SER . 73.2 t -76.15 -46.46 33.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 N-CA-C 110.235 -0.283 . . . . 0.0 110.235 175.573 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -57.18 -50.16 73.7 Favored 'General case' 0 CA--C 1.517 -0.324 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.022 176.46 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.45 ' HA ' ' HB1' ' A' ' 148' ' ' ALA . 16.3 t70 -59.54 -34.16 72.31 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.459 -0.791 . . . . 0.0 111.038 -178.565 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -70.73 -46.46 63.0 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.837 -178.708 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 33.6 m -84.67 -27.88 6.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 C-N-CA 121.0 -0.28 . . . . 0.0 111.624 -176.127 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 93.41 38.05 5.43 Favored Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 120.697 -0.764 . . . . 0.0 112.475 179.548 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -114.14 149.82 35.07 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.039 0.447 . . . . 0.0 111.093 -179.059 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 116' ' ' ARG . . . . . 0.529 ' HB3' ' HG ' ' A' ' 92' ' ' LEU . 19.8 ttt180 -71.38 116.17 11.39 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.725 -0.67 . . . . 0.0 109.803 179.321 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 117' ' ' LEU . . . . . 0.578 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 62.2 tp -88.53 120.43 29.9 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 116.034 -0.53 . . . . 0.0 109.968 -179.517 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 71.0 mt -121.52 114.94 44.99 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 CA-C-O 121.16 0.505 . . . . 0.0 110.363 179.233 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 51.0 mt -112.77 121.27 64.73 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.761 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.55 -179.379 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 120' ' ' LYS . . . . . 0.404 ' C ' ' HD3' ' A' ' 120' ' ' LYS . 1.6 tmtp? -109.99 95.33 20.51 Favored Pre-proline 0 C--N 1.322 -0.614 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 173.503 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 121' ' ' PRO . . . . . 0.428 ' HB2' ' HB3' ' A' ' 125' ' ' GLU . 88.7 Cg_endo -89.02 -161.95 0.12 Allowed 'Trans proline' 0 N--CA 1.454 -0.839 0 C-N-CA 122.998 2.465 . . . . 0.0 112.244 179.997 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 122' ' ' LEU . . . . . 0.882 ' HB2' ' HB2' ' A' ' 125' ' ' GLU . 10.3 mp -83.53 168.14 16.72 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.987 -0.552 . . . . 0.0 110.391 179.65 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 3.9 m -59.91 -32.05 70.39 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.546 -176.86 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -125.43 38.84 2.19 Favored Glycine 0 N--CA 1.452 -0.245 0 C-N-CA 120.711 -0.756 . . . . 0.0 111.844 177.756 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 125' ' ' GLU . . . . . 0.882 ' HB2' ' HB2' ' A' ' 122' ' ' LEU . 6.0 tp10 -110.5 118.01 35.11 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 120.696 0.284 . . . . 0.0 110.267 -176.104 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -84.69 167.77 15.87 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.137 0.494 . . . . 0.0 111.014 179.007 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 85.7 mt . . . . . 0 C--N 1.325 -0.477 0 CA-C-N 115.609 -0.723 . . . . 0.0 110.55 -178.407 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 132' ' ' LYS . . . . . 0.436 ' HB2' ' HE3' ' A' ' 132' ' ' LYS . 0.0 OUTLIER . . . . . 0 N--CA 1.465 0.313 0 CA-C-O 121.134 0.492 . . . . 0.0 112.024 . . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 133' ' ' MET . . . . . 0.512 ' HG2' ' HB2' ' A' ' 146' ' ' TYR . 86.0 mtp -148.46 162.19 40.11 Favored 'General case' 0 C--N 1.314 -0.949 0 N-CA-C 107.994 -1.113 . . . . 0.0 107.994 173.272 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 134' ' ' LYS . . . . . 0.565 ' HG3' ' HG2' ' A' ' 145' ' ' GLU . 13.1 ptmm? -126.36 133.1 51.42 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-O 120.956 0.408 . . . . 0.0 111.21 -176.899 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 135' ' ' LEU . . . . . 0.775 HD11 ' HD2' ' A' ' 142' ' ' TYR . 55.6 tp -84.38 121.16 27.16 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.023 -179.662 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -116.77 149.98 18.87 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.598 -177.334 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 66.4 m-20 -116.29 125.82 52.7 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 177.584 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 34.4 t80 -138.27 130.79 29.18 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 109.565 -0.532 . . . . 0.0 109.565 176.239 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 72.03 -87.75 0.48 Allowed Glycine 0 N--CA 1.443 -0.837 0 N-CA-C 110.681 -0.967 . . . . 0.0 110.681 -174.428 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 140' ' ' ARG . . . . . 0.72 ' HA ' ' NE ' ' A' ' 140' ' ' ARG . 2.0 mmp_? -156.53 14.61 0.3 Allowed 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.423 -0.388 . . . . 0.0 110.75 174.346 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 11.2 t -113.98 154.95 26.75 Favored 'General case' 0 N--CA 1.448 -0.57 0 CA-C-N 116.33 -0.395 . . . . 0.0 109.948 179.035 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 142' ' ' TYR . . . . . 0.775 ' HD2' HD11 ' A' ' 135' ' ' LEU . 14.7 p90 -122.86 138.11 54.75 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 121.042 0.449 . . . . 0.0 110.36 -179.875 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 143' ' ' PHE . . . . . 0.423 ' O ' HD12 ' A' ' 135' ' ' LEU . 12.4 p90 -146.85 162.34 38.85 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-N 115.562 -0.745 . . . . 0.0 110.146 -177.238 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 96.3 m-85 -101.04 122.53 43.71 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 116.429 -0.351 . . . . 0.0 110.294 -179.447 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 145' ' ' GLU . . . . . 0.565 ' HG2' ' HG3' ' A' ' 134' ' ' LYS . 11.5 pt-20 -113.37 156.77 22.84 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 121.086 0.47 . . . . 0.0 110.036 177.522 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 146' ' ' TYR . . . . . 0.512 ' HB2' ' HG2' ' A' ' 133' ' ' MET . 41.7 t80 -141.91 124.47 15.83 Favored 'General case' 0 C--N 1.314 -0.969 0 CA-C-N 115.493 -0.776 . . . . 0.0 109.659 176.833 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 147' ' ' ILE . . . . . 0.409 ' N ' HD12 ' A' ' 147' ' ' ILE . 3.7 mp -93.0 101.37 12.55 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.88 0 N-CA-C 109.596 -0.52 . . . . 0.0 109.596 -177.63 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 148' ' ' ALA . . . . . 0.45 ' HB1' ' HA ' ' A' ' 111' ' ' ASP . . . -69.91 108.59 4.07 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 108.57 -0.9 . . . . 0.0 108.57 172.717 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 40.6 mt-10 . . . . . 0 C--N 1.321 -0.661 0 CA-C-O 122.04 0.924 . . . . 0.0 112.424 -170.762 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 95.4 m95 . . . . . 0 C--O 1.232 0.175 0 CA-C-O 121.046 0.45 . . . . 0.0 110.677 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 23' ' ' ASN . . . . . 0.435 ' O ' HG23 ' A' ' 27' ' ' VAL . 66.9 t30 -68.26 -37.74 81.06 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.205 -179.555 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.427 ' HB3' ' HD2' ' A' ' 138' ' ' TYR . 44.0 m-20 -61.61 -43.28 99.16 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.279 -0.418 . . . . 0.0 110.389 179.392 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.51 HD22 ' HD3' ' A' ' 120' ' ' LYS . 61.9 tp -58.16 -50.07 74.78 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.305 178.241 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -55.76 -51.78 66.22 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.876 179.049 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.435 HG23 ' O ' ' A' ' 23' ' ' ASN . 96.7 t -57.04 -43.89 81.93 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.221 179.42 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 52.2 t80 -58.18 -48.63 79.71 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.861 0.363 . . . . 0.0 110.265 178.684 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.402 HG13 ' O ' ' A' ' 25' ' ' LEU . 81.7 mt -60.81 -42.67 93.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.486 178.904 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 90.8 mt -58.15 -41.86 81.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.123 179.118 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 63.0 mtp180 -69.05 -35.07 76.16 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.076 0.465 . . . . 0.0 111.295 -179.654 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.421 ' SG ' HD12 ' A' ' 92' ' ' LEU . 48.3 t -81.37 -25.95 35.88 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.98 -0.555 . . . . 0.0 111.512 -175.509 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 20.8 p -93.56 -81.93 0.36 Allowed 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 111.851 0.315 . . . . 0.0 111.851 -174.92 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.416 ' O ' HG22 ' A' ' 37' ' ' THR . . . 107.22 168.19 22.12 Favored Glycine 0 N--CA 1.449 -0.476 0 N-CA-C 111.384 -0.686 . . . . 0.0 111.384 -175.158 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 71.0 Cg_endo -76.77 145.96 26.1 Favored 'Trans proline' 0 N--CA 1.464 -0.26 0 C-N-CA 122.32 2.013 . . . . 0.0 112.801 -178.769 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 91.75 -20.34 42.64 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.876 -0.678 . . . . 0.0 113.602 175.22 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 37' ' ' THR . . . . . 0.416 HG22 ' O ' ' A' ' 34' ' ' GLY . 14.7 t -92.06 178.85 5.75 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 117.115 0.457 . . . . 0.0 110.011 -179.08 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 38' ' ' ARG . . . . . 0.503 ' HA ' ' O ' ' A' ' 61' ' ' ASP . 0.1 OUTLIER -111.81 136.06 51.59 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-O 120.967 0.413 . . . . 0.0 111.351 -176.239 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.402 HG23 HG21 ' A' ' 60' ' ' VAL . 62.3 t -126.22 117.27 48.15 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 N-CA-C 108.997 -0.742 . . . . 0.0 108.997 173.836 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.533 HG22 ' HB ' ' A' ' 63' ' ' VAL . 40.9 t -103.13 128.86 55.73 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-O 120.999 0.428 . . . . 0.0 111.703 -173.176 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 41' ' ' GLU . . . . . 0.631 ' HB3' HD23 ' A' ' 64' ' ' LEU . 21.7 tp10 -105.22 127.41 52.91 Favored 'General case' 0 C--O 1.24 0.569 0 CA-C-N 115.606 -0.724 . . . . 0.0 109.991 174.377 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.473 ' HB ' ' OG ' ' A' ' 95' ' ' SER . 59.0 t -93.57 89.95 2.79 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 CA-C-N 115.976 -0.557 . . . . 0.0 110.235 179.816 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 121.18 120.83 2.75 Favored Glycine 0 N--CA 1.443 -0.837 0 CA-C-N 115.662 -0.699 . . . . 0.0 111.505 -175.201 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.598 ' HB1' HD21 ' A' ' 48' ' ' LEU . . . -110.59 -57.98 2.15 Favored 'General case' 0 C--N 1.321 -0.668 0 O-C-N 122.399 -0.471 . . . . 0.0 111.047 -177.198 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 52.72 -118.67 8.21 Favored Glycine 0 CA--C 1.519 0.317 0 C-N-CA 121.085 -0.579 . . . . 0.0 112.693 -178.707 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 65.2 mtp180 -134.52 14.61 3.74 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.827 0.346 . . . . 0.0 111.264 -179.669 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 21.8 p90 -103.52 35.19 2.67 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.369 0.604 . . . . 0.0 110.553 -178.298 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.598 HD21 ' HB1' ' A' ' 44' ' ' ALA . 94.5 mt -76.13 13.43 0.9 Allowed 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.484 -0.78 . . . . 0.0 112.569 -173.963 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 42.2 p90 -67.62 -26.45 66.25 Favored 'General case' 0 C--N 1.324 -0.509 0 C-N-CA 120.713 -0.395 . . . . 0.0 110.454 177.02 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.419 ' O ' HG13 ' A' ' 54' ' ' ILE . 54.0 t -68.72 -54.5 20.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.439 176.407 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 51' ' ' SER . . . . . 0.402 ' HA ' HD13 ' A' ' 62' ' ' LEU . 7.3 p -62.51 -46.78 86.85 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.847 -176.134 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -70.66 -27.55 64.13 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.569 -176.328 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 82.9 t80 -68.74 -46.65 68.33 Favored 'General case' 0 C--N 1.328 -0.346 0 C-N-CA 120.783 -0.367 . . . . 0.0 110.443 176.291 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.419 HG13 ' O ' ' A' ' 50' ' ' VAL . 77.9 mt -59.15 -45.79 92.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.385 -176.824 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 6.9 ptp180 -71.76 -16.48 62.2 Favored 'General case' 0 C--O 1.236 0.39 0 CA-C-O 120.893 0.378 . . . . 0.0 111.499 -179.111 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 8.3 mtpm? -83.7 -21.8 32.24 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.861 0.362 . . . . 0.0 111.566 177.618 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 9.6 t-80 -103.16 -43.02 5.58 Favored 'General case' 0 N--CA 1.445 -0.69 0 CA-C-O 121.01 0.433 . . . . 0.0 109.863 -178.143 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 9.1 t -120.09 144.08 47.8 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 109.202 -0.666 . . . . 0.0 109.202 178.336 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 59' ' ' LYS . . . . . 0.452 ' HA ' ' HD3' ' A' ' 59' ' ' LYS . 6.1 tppt? -89.25 58.15 4.34 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 122.11 0.957 . . . . 0.0 110.332 -179.459 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.402 HG21 HG23 ' A' ' 39' ' ' VAL . 7.6 p -94.97 145.53 8.02 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.817 0 CA-C-N 114.41 -1.268 . . . . 0.0 109.677 175.564 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 61' ' ' ASP . . . . . 0.503 ' O ' ' HA ' ' A' ' 38' ' ' ARG . 25.6 t70 -84.62 93.46 8.39 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 179.278 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 62' ' ' LEU . . . . . 0.402 HD13 ' HA ' ' A' ' 51' ' ' SER . 4.6 tt -89.86 120.17 30.87 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.67 -176.192 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.533 ' HB ' HG22 ' A' ' 40' ' ' VAL . 47.8 t -103.91 122.51 56.75 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.653 0 CA-C-N 115.674 -0.694 . . . . 0.0 110.493 -174.721 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 64' ' ' LEU . . . . . 0.631 HD23 ' HB3' ' A' ' 41' ' ' GLU . 41.6 mt -99.55 133.43 43.89 Favored 'General case' 0 C--N 1.316 -0.889 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 176.575 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.436 HG22 ' HB ' ' A' ' 75' ' ' VAL . 13.0 p -125.73 124.04 40.18 Favored 'General case' 0 C--N 1.317 -0.813 0 N-CA-C 110.048 -0.353 . . . . 0.0 110.048 176.544 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 39.2 t0 -170.36 172.01 6.34 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -175.712 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.671 HG22 ' HG2' ' A' ' 68' ' ' LYS . 26.0 mm -73.67 129.83 36.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.073 -179.709 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 68' ' ' LYS . . . . . 0.671 ' HG2' HG22 ' A' ' 67' ' ' ILE . 19.6 pttp 38.71 90.32 0.07 OUTLIER Pre-proline 0 N--CA 1.476 0.837 0 O-C-N 124.247 0.967 . . . . 0.0 113.278 178.933 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 69' ' ' PRO . . . . . 0.958 ' HB3' ' HB ' ' A' ' 74' ' ' ILE . 4.9 Cg_endo . . . . . 0 C--N 1.346 0.395 0 C-N-CA 123.875 3.05 . . . . 0.0 113.202 179.534 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.958 ' HB ' ' HB3' ' A' ' 69' ' ' PRO . 56.1 mt . . . . . 0 N--CA 1.447 -0.61 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.543 HG11 HD13 ' A' ' 86' ' ' ILE . 91.2 t -76.04 132.09 33.72 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 176.369 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 9.8 ptp180 -79.3 21.14 0.48 Allowed 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 120.987 0.422 . . . . 0.0 111.371 -175.967 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 77' ' ' ASP . . . . . 0.496 ' HB2' HG12 ' A' ' 75' ' ' VAL . 6.1 t70 -83.48 112.49 20.01 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 109.615 -0.513 . . . . 0.0 109.615 -176.385 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 10.7 p-10 -70.87 142.21 51.2 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 121.426 0.632 . . . . 0.0 111.444 -174.055 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 79' ' ' ILE . . . . . 0.404 HD13 HG13 ' A' ' 42' ' ' VAL . 6.9 tp -66.77 -21.95 29.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.367 -0.833 . . . . 0.0 112.345 -173.66 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 10.2 t -90.05 -0.54 57.64 Favored 'General case' 0 C--N 1.322 -0.626 0 C-N-CA 120.274 -0.571 . . . . 0.0 110.492 -178.801 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 81' ' ' SER . . . . . 0.43 ' N ' ' HD3' ' A' ' 82' ' ' PRO . 4.9 m -148.24 46.58 0.46 Allowed Pre-proline 0 CA--C 1.538 0.505 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.883 177.421 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 82' ' ' PRO . . . . . 0.457 ' HA ' ' OD2' ' A' ' 77' ' ' ASP . 93.3 Cg_endo -81.23 149.45 17.17 Favored 'Trans proline' 0 C--N 1.352 0.711 0 C-N-CA 122.287 1.992 . . . . 0.0 113.174 -169.01 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 83' ' ' ARG . . . . . 0.511 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 73.1 mtp85 -96.36 125.22 40.71 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.82 -0.627 . . . . 0.0 111.061 177.222 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 84' ' ' MET . . . . . 0.584 ' HE1' ' HA ' ' A' ' 109' ' ' VAL . 91.3 mmm -63.92 -20.02 65.54 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.678 -0.692 . . . . 0.0 111.296 -179.314 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.511 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 11.0 pt-20 -69.81 -16.65 63.31 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.506 -176.451 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.543 HD13 HG11 ' A' ' 75' ' ' VAL . 70.4 mt -85.23 -36.14 10.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 121.298 0.571 . . . . 0.0 109.963 178.154 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 99.2 m-85 -80.59 -31.85 36.61 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.865 -178.73 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 88' ' ' ARG . . . . . 0.441 ' HG3' HG12 ' A' ' 113' ' ' VAL . 23.3 mtp85 -64.07 119.61 10.47 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-O 121.142 0.496 . . . . 0.0 110.795 179.259 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 115.65 -17.21 16.08 Favored Glycine 0 N--CA 1.444 -0.805 0 CA-C-N 115.44 -0.8 . . . . 0.0 111.557 -177.739 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -73.38 144.55 46.39 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.83 0.348 . . . . 0.0 110.769 179.052 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -88.94 -25.66 21.95 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 121.27 0.557 . . . . 0.0 110.142 178.093 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 92' ' ' LEU . . . . . 0.483 HD23 ' N ' ' A' ' 93' ' ' ILE . 4.7 tt -150.86 141.09 22.26 Favored 'General case' 0 N--CA 1.448 -0.559 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.409 -177.136 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 93' ' ' ILE . . . . . 0.548 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 61.2 mt -130.58 128.14 63.06 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.187 177.226 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -136.88 169.69 17.35 Favored 'General case' 0 C--N 1.318 -0.781 0 C-N-CA 120.786 -0.366 . . . . 0.0 110.117 -179.074 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 95' ' ' SER . . . . . 0.635 ' HB2' ' HG3' ' A' ' 98' ' ' PRO . 7.1 m -152.07 123.08 7.57 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.346 178.901 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 96' ' ' ILE . . . . . 0.748 HG22 ' HG2' ' A' ' 97' ' ' ARG . 2.3 mp -73.37 114.94 13.6 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-N 116.3 -0.409 . . . . 0.0 109.907 174.771 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 97' ' ' ARG . . . . . 0.748 ' HG2' HG22 ' A' ' 96' ' ' ILE . 13.6 ptt180 43.54 76.27 0.55 Allowed Pre-proline 0 N--CA 1.472 0.668 0 C-N-CA 124.376 1.071 . . . . 0.0 113.17 177.41 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 98' ' ' PRO . . . . . 0.635 ' HG3' ' HB2' ' A' ' 95' ' ' SER . 12.8 Cg_endo -90.07 146.54 4.52 Favored 'Trans proline' 0 N--CA 1.453 -0.909 0 C-N-CA 122.583 2.189 . . . . 0.0 111.889 175.689 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 99' ' ' PRO . . . . . 0.526 ' HD2' HD11 ' A' ' 102' ' ' ILE . 32.2 Cg_exo -61.05 140.37 89.43 Favored 'Trans proline' 0 C--N 1.344 0.34 0 C-N-CA 122.492 2.128 . . . . 0.0 111.991 177.483 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -79.74 30.85 0.25 Allowed 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 121.101 0.477 . . . . 0.0 111.805 -174.871 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 101' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -122.2 -6.89 8.84 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.812 178.614 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.526 HD11 ' HD2' ' A' ' 99' ' ' PRO . 30.8 pt -120.25 8.53 6.37 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 120.907 0.384 . . . . 0.0 111.163 -179.021 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 103' ' ' HIS . . . . . 0.465 ' O ' ' HG2' ' A' ' 107' ' ' MET . 44.7 p-80 -60.82 -40.06 91.31 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.373 -177.149 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 23.3 m -61.75 -29.58 70.22 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.861 0.362 . . . . 0.0 111.016 178.749 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.547 ' O ' HG23 ' A' ' 109' ' ' VAL . 19.3 m -75.61 -38.29 59.13 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.079 178.518 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 94.5 mt -69.14 -41.7 76.98 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.953 179.6 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 107' ' ' MET . . . . . 0.465 ' HG2' ' O ' ' A' ' 103' ' ' HIS . 94.9 mmm -57.38 -47.53 81.44 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.804 -0.634 . . . . 0.0 111.535 -179.281 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 6.7 ptp85 -66.96 -31.74 72.51 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.578 -0.283 . . . . 0.0 111.608 -178.186 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.584 ' HA ' ' HE1' ' A' ' 84' ' ' MET . 76.3 t -66.7 -47.93 81.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 C-N-CA 121.115 -0.234 . . . . 0.0 110.897 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -57.98 -46.27 85.44 Favored 'General case' 0 CA--C 1.518 -0.286 0 CA-C-N 116.515 -0.311 . . . . 0.0 110.641 179.853 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 17.8 t70 -67.73 -36.21 80.16 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.783 -178.599 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -65.43 -43.25 91.06 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.65 -179.843 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.441 HG12 ' HG3' ' A' ' 88' ' ' ARG . 18.6 m -88.22 -30.09 5.46 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.537 -175.912 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 91.41 51.63 2.5 Favored Glycine 0 N--CA 1.448 -0.554 0 C-N-CA 120.596 -0.811 . . . . 0.0 112.15 -178.856 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -132.0 157.6 43.67 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.906 0.384 . . . . 0.0 110.879 -179.424 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 116' ' ' ARG . . . . . 0.674 ' HD3' ' OE1' ' A' ' 145' ' ' GLU . 12.5 ttm180 -78.58 123.22 26.86 Favored 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 109.569 -0.53 . . . . 0.0 109.569 177.163 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 117' ' ' LEU . . . . . 0.548 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 57.3 tp -94.12 118.9 32.19 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 116.179 -0.464 . . . . 0.0 109.947 -179.553 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 59.7 mt -114.39 115.06 48.45 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 CA-C-O 121.32 0.581 . . . . 0.0 110.807 179.654 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 53.5 mt -122.52 118.62 55.77 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.953 -179.249 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 120' ' ' LYS . . . . . 0.557 ' HB3' ' HB3' ' A' ' 143' ' ' PHE . 0.6 OUTLIER -118.81 101.74 50.11 Favored Pre-proline 0 C--N 1.319 -0.722 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 169.759 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 121' ' ' PRO . . . . . 0.53 ' HA ' ' HA ' ' A' ' 97' ' ' ARG . 96.6 Cg_endo -80.04 -161.95 0.17 Allowed 'Trans proline' 0 N--CA 1.461 -0.438 0 C-N-CA 122.902 2.401 . . . . 0.0 112.425 -176.658 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 122' ' ' LEU . . . . . 0.681 ' HB2' ' HB2' ' A' ' 125' ' ' GLU . 3.0 mm? -65.31 150.08 48.87 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.929 -0.578 . . . . 0.0 109.977 178.162 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 23.2 m -68.28 -25.82 65.35 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.119 -0.491 . . . . 0.0 112.005 -171.246 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -105.67 1.64 39.25 Favored Glycine 0 N--CA 1.453 -0.233 0 C-N-CA 120.095 -1.05 . . . . 0.0 112.694 -179.563 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 125' ' ' GLU . . . . . 0.681 ' HB2' ' HB2' ' A' ' 122' ' ' LEU . 1.6 mp0 -105.79 -170.28 1.71 Allowed 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.239 0.542 . . . . 0.0 111.401 -173.595 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 16.8 t70 -143.99 171.53 14.13 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 115.147 -0.933 . . . . 0.0 108.846 179.18 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 39.1 mt . . . . . 0 C--N 1.325 -0.488 0 CA-C-O 121.048 0.451 . . . . 0.0 110.24 179.655 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 30.8 mmmt . . . . . 0 N--CA 1.454 -0.24 0 CA-C-O 121.122 0.487 . . . . 0.0 110.1 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 133' ' ' MET . . . . . 0.516 ' HG2' ' HB2' ' A' ' 146' ' ' TYR . 79.4 mtp -114.4 170.12 8.53 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.56 -0.746 . . . . 0.0 110.195 -176.311 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 134' ' ' LYS . . . . . 0.453 ' HG3' ' HG2' ' A' ' 145' ' ' GLU . 18.8 ptmt -121.75 134.07 54.93 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.815 -178.591 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 135' ' ' LEU . . . . . 0.539 HD11 ' HD2' ' A' ' 142' ' ' TYR . 60.0 tp -82.75 122.39 28.12 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 120.932 0.396 . . . . 0.0 110.537 178.223 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -118.16 147.04 21.87 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.355 179.84 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 13.4 m120 -124.18 96.94 5.12 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 109.416 -0.587 . . . . 0.0 109.416 -179.666 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 138' ' ' TYR . . . . . 0.427 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 64.1 t80 -104.42 109.1 20.83 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.272 -175.172 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 72.71 -82.08 0.61 Allowed Glycine 0 N--CA 1.45 -0.392 0 CA-C-N 115.768 -0.651 . . . . 0.0 111.832 179.875 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 140' ' ' ARG . . . . . 0.406 ' HD3' ' HA ' ' A' ' 140' ' ' ARG . 16.3 mmt180 -141.36 -7.43 1.01 Allowed 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 115.477 -0.362 . . . . 0.0 111.109 177.08 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 3.4 t -99.17 135.82 40.03 Favored 'General case' 0 N--CA 1.446 -0.637 0 CA-C-O 121.279 0.561 . . . . 0.0 110.083 -179.229 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 142' ' ' TYR . . . . . 0.539 ' HD2' HD11 ' A' ' 135' ' ' LEU . 27.0 p90 -114.06 144.22 43.48 Favored 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 176.193 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 143' ' ' PHE . . . . . 0.557 ' HB3' ' HB3' ' A' ' 120' ' ' LYS . 23.7 p90 -157.25 162.77 39.24 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.556 -178.854 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 87.1 m-85 -100.93 118.3 36.69 Favored 'General case' 0 C--N 1.314 -0.949 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 175.177 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 145' ' ' GLU . . . . . 0.674 ' OE1' ' HD3' ' A' ' 116' ' ' ARG . 11.5 pt-20 -110.0 155.17 22.15 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-O 121.321 0.581 . . . . 0.0 109.695 178.701 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 146' ' ' TYR . . . . . 0.516 ' HB2' ' HG2' ' A' ' 133' ' ' MET . 32.4 t80 -137.39 123.81 20.76 Favored 'General case' 0 C--N 1.307 -1.259 0 CA-C-N 115.498 -0.774 . . . . 0.0 109.382 176.493 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 147' ' ' ILE . . . . . 0.444 ' N ' HD12 ' A' ' 147' ' ' ILE . 3.3 mp -94.36 103.79 15.07 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.799 0 CA-C-N 116.111 -0.495 . . . . 0.0 109.932 -177.621 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -68.37 119.3 12.66 Favored 'General case' 0 N--CA 1.443 -0.783 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 171.358 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 . . . . . 0 C--N 1.322 -0.593 0 CA-C-O 121.121 0.486 . . . . 0.0 110.3 -177.363 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.7 mpt? . . . . . 0 N--CA 1.479 1.014 0 N-CA-C 110.453 -0.203 . . . . 0.0 110.453 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 79.56 165.05 29.89 Favored Glycine 0 N--CA 1.448 -0.559 0 C-N-CA 120.846 -0.693 . . . . 0.0 113.045 176.857 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 58.7 m -132.79 128.1 36.02 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 120.901 0.381 . . . . 0.0 110.167 175.436 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 21.6 m -102.99 23.45 12.26 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 121.291 0.567 . . . . 0.0 110.538 -178.345 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 48.8 m80 -95.9 80.45 3.34 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.722 177.879 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 30.2 p-80 -100.9 107.13 18.57 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.887 -0.597 . . . . 0.0 109.719 174.66 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 95.6 m-70 -88.35 88.91 7.78 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 121.296 0.569 . . . . 0.0 110.814 -175.818 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 35.2 m-70 -108.9 112.27 24.41 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.219 -0.9 . . . . 0.0 109.869 176.486 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 4.4 p-80 -141.35 46.01 1.72 Allowed 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.304 -179.507 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 81.6 m-70 -67.76 98.44 0.71 Allowed 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.662 -0.699 . . . . 0.0 109.873 179.586 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 11.3 p -158.83 127.38 5.3 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.764 -174.669 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 17.3 t -84.95 107.29 17.02 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 109.365 -0.605 . . . . 0.0 109.365 177.216 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -80.77 72.22 2.74 Favored Glycine 0 N--CA 1.448 -0.564 0 C-N-CA 121.173 -0.537 . . . . 0.0 112.973 -175.456 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 87.4 mt -105.14 105.16 15.08 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-O 121.164 0.507 . . . . 0.0 109.773 174.644 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 7.7 m -118.6 116.27 35.0 Favored Pre-proline 0 C--N 1.317 -0.812 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.796 -177.684 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -62.32 126.79 19.33 Favored 'Trans proline' 0 N--CA 1.461 -0.433 0 C-N-CA 122.528 2.152 . . . . 0.0 112.693 -179.026 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 18.3 ptt180 -91.19 -176.36 4.56 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 115.131 -0.94 . . . . 0.0 110.066 -179.626 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 82.17 0.85 90.1 Favored Glycine 0 N--CA 1.449 -0.487 0 C-N-CA 120.396 -0.907 . . . . 0.0 111.074 -176.299 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 1.9 p -85.3 45.03 1.14 Allowed 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 121.324 0.583 . . . . 0.0 110.649 -179.701 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 71.8 m-70 -60.95 -37.97 84.24 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.482 -0.781 . . . . 0.0 110.576 -177.822 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' MET . . . . . . . . . . . . . 66.2 mtt -70.66 -15.57 62.74 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.821 -179.318 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 75.6 m95 -95.63 -18.84 20.21 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.457 178.738 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 23.9 t-20 -58.04 -52.74 64.29 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.354 -176.762 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.482 ' HB3' ' HD2' ' A' ' 138' ' ' TYR . 6.0 m-20 -59.14 -35.48 73.57 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.344 -179.489 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 61.6 tp -58.38 -47.63 83.25 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.331 178.481 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -61.34 -47.52 85.54 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.909 178.961 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.579 ' HA ' HD12 ' A' ' 30' ' ' ILE . 58.0 t -58.13 -43.97 86.55 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.162 0 CA-C-O 120.955 0.407 . . . . 0.0 110.83 179.82 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 68.4 t80 -56.0 -47.47 77.68 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.736 -0.665 . . . . 0.0 110.487 178.819 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.509 HG23 HD13 ' A' ' 92' ' ' LEU . 77.6 mt -63.37 -42.63 97.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.731 179.022 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.579 HD12 ' HA ' ' A' ' 27' ' ' VAL . 83.1 mt -56.26 -44.23 78.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.482 -0.781 . . . . 0.0 111.05 178.39 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 31' ' ' ARG . . . . . 0.468 ' HG3' ' O ' ' A' ' 27' ' ' VAL . 81.8 mtp180 -70.29 -30.34 67.31 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.959 -177.354 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 74.3 m -75.58 -29.89 59.46 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.213 -178.995 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 22.3 p -112.67 -97.4 0.43 Allowed 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.532 -0.303 . . . . 0.0 111.336 -178.876 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 113.81 -178.96 18.66 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.993 -0.622 . . . . 0.0 112.037 -178.03 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 10.6 Cg_exo -71.05 150.36 60.21 Favored 'Trans proline' 0 C--O 1.234 0.292 0 C-N-CA 122.932 2.421 . . . . 0.0 112.222 -179.412 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 84.93 41.94 7.38 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.831 -0.699 . . . . 0.0 112.86 179.257 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 14.6 t -168.65 -178.64 3.51 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 177.137 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 66.9 mtp85 -114.67 136.08 53.45 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 120.711 0.291 . . . . 0.0 111.082 -178.433 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.9 ' HB ' HD22 ' A' ' 62' ' ' LEU . 40.2 t -124.06 132.11 71.86 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 N-CA-C 108.914 -0.772 . . . . 0.0 108.914 173.47 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.423 HG11 ' CD1' ' A' ' 87' ' ' TYR . 62.0 t -105.79 124.22 60.76 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 C-N-CA 120.87 -0.332 . . . . 0.0 111.246 -175.939 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' GLU . . . . . 0.411 ' OE1' HD22 ' A' ' 64' ' ' LEU . 44.9 tt0 -103.59 109.47 21.16 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.931 -0.577 . . . . 0.0 109.852 176.583 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.573 HG11 HD21 ' A' ' 106' ' ' LEU . 47.0 t -96.65 132.99 39.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 115.947 -0.569 . . . . 0.0 109.954 179.707 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 87.12 20.48 52.81 Favored Glycine 0 N--CA 1.447 -0.613 0 C-N-CA 120.474 -0.87 . . . . 0.0 111.811 -178.637 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.452 ' HB1' ' CD2' ' A' ' 48' ' ' LEU . . . -55.81 -68.0 0.24 Allowed 'General case' 0 C--N 1.331 -0.201 0 O-C-N 123.744 0.32 . . . . 0.0 110.253 178.695 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 58.22 -93.05 0.04 OUTLIER Glycine 0 N--CA 1.452 -0.284 0 CA-C-N 115.572 -0.74 . . . . 0.0 114.1 173.06 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' ARG . . . . . 0.44 HH11 ' HD3' ' A' ' 46' ' ' ARG . 32.7 ttt-85 -126.58 11.24 7.32 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 121.351 0.596 . . . . 0.0 110.571 -172.181 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 59.0 t80 -133.04 97.96 4.15 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 109.529 -0.545 . . . . 0.0 109.529 178.995 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.72 HD22 HD13 ' A' ' 64' ' ' LEU . 67.1 mt -113.4 24.37 12.3 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.952 -172.278 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 56.8 t80 -64.65 -50.86 65.42 Favored 'General case' 0 C--N 1.329 -0.292 0 C-N-CA 120.928 -0.309 . . . . 0.0 111.781 -176.908 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.476 ' O ' HG13 ' A' ' 54' ' ' ILE . 44.1 t -60.92 -55.47 24.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.559 -0.291 . . . . 0.0 111.011 -173.013 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 10.9 p -56.93 -43.12 81.17 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.975 179.538 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.469 ' HA ' ' HG2' ' A' ' 55' ' ' ARG . 36.7 t70 -64.99 -42.88 94.12 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.728 0.299 . . . . 0.0 110.905 -179.466 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 74.6 t80 -61.11 -42.02 97.75 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.062 0.458 . . . . 0.0 110.341 177.281 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.552 HG23 HG12 ' A' ' 30' ' ' ILE . 86.3 mt -64.61 -49.13 81.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.294 179.21 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 55' ' ' ARG . . . . . 0.469 ' HG2' ' HA ' ' A' ' 52' ' ' ASP . 40.8 ptt180 -67.96 -18.74 64.83 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-O 120.862 0.363 . . . . 0.0 111.401 -176.05 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 84.6 mttt -84.51 -34.11 23.39 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.828 0.346 . . . . 0.0 110.971 176.104 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.6 OUTLIER -79.85 -33.6 40.05 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.253 178.76 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 70.6 m -141.78 135.95 30.2 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.5 178.063 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 7.6 tmtt? -76.15 64.77 2.03 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.888 0.852 . . . . 0.0 109.378 176.755 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.515 HG21 HG23 ' A' ' 39' ' ' VAL . 8.3 p -95.18 148.2 5.27 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.964 0 CA-C-N 114.727 -1.124 . . . . 0.0 109.118 173.834 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 25.9 t0 -78.91 88.58 4.71 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 121.34 0.59 . . . . 0.0 109.437 -179.808 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' LEU . . . . . 0.9 HD22 ' HB ' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -82.99 115.12 21.69 Favored 'General case' 0 N--CA 1.448 -0.549 0 CA-C-N 115.532 -0.758 . . . . 0.0 110.1 -177.578 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 45.3 t -103.56 114.73 43.96 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-N 115.462 -0.79 . . . . 0.0 110.081 -177.54 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 64' ' ' LEU . . . . . 0.72 HD13 HD22 ' A' ' 48' ' ' LEU . 20.1 mt -91.61 135.95 33.49 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-N 115.671 -0.695 . . . . 0.0 109.607 -179.696 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 14.5 p -130.76 128.96 41.83 Favored 'General case' 0 C--N 1.319 -0.723 0 C-N-CA 121.045 -0.262 . . . . 0.0 111.271 -179.074 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 5.8 t70 -171.0 155.34 4.45 Favored 'General case' 0 CA--C 1.519 -0.246 0 N-CA-C 109.371 -0.603 . . . . 0.0 109.371 175.839 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.625 HG22 ' HG2' ' A' ' 68' ' ' LYS . 58.1 mt -78.1 131.2 35.06 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 CA-C-N 116.642 -0.254 . . . . 0.0 110.606 -177.942 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 68' ' ' LYS . . . . . 0.625 ' HG2' HG22 ' A' ' 67' ' ' ILE . 7.9 ptmm? 42.31 71.73 1.31 Allowed Pre-proline 0 N--CA 1.471 0.586 0 O-C-N 124.152 0.908 . . . . 0.0 112.915 179.265 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -78.91 167.15 22.5 Favored 'Trans proline' 0 N--CA 1.463 -0.319 0 C-N-CA 122.549 2.166 . . . . 0.0 112.168 177.768 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 12.6 t -120.49 6.7 10.58 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 121.359 0.599 . . . . 0.0 109.629 179.009 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 79.1 m80 -117.99 131.76 56.45 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.641 -0.709 . . . . 0.0 110.747 -175.504 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -68.12 107.75 2.18 Favored Glycine 0 N--CA 1.45 -0.386 0 CA-C-N 115.822 -0.627 . . . . 0.0 112.223 179.836 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 142.62 -24.65 2.31 Favored Glycine 0 N--CA 1.448 -0.534 0 C-N-CA 120.954 -0.641 . . . . 0.0 111.928 -179.456 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.673 ' HA ' ' HB2' ' A' ' 64' ' ' LEU . 50.6 mt -84.92 125.84 40.33 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-O 120.574 0.226 . . . . 0.0 110.441 -179.823 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.441 HG11 HD13 ' A' ' 86' ' ' ILE . 61.5 t -64.45 116.91 4.29 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 N-CA-C 109.631 -0.507 . . . . 0.0 109.631 176.875 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 16.2 mtt180 -84.48 53.69 2.75 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.679 -0.692 . . . . 0.0 110.432 -175.417 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 77' ' ' ASP . . . . . 0.421 ' HB2' HG12 ' A' ' 75' ' ' VAL . 2.0 t70 -98.83 -162.36 0.95 Allowed 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 116.307 -0.406 . . . . 0.0 109.972 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 78' ' ' ASP . . . . . 0.503 ' OD1' HG22 ' A' ' 80' ' ' THR . 11.8 t0 -119.38 146.17 45.57 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 120.773 0.321 . . . . 0.0 111.251 -175.475 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 79' ' ' ILE . . . . . 0.558 HG22 HD11 ' A' ' 67' ' ' ILE . 10.7 tp -107.96 -20.59 6.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.292 -176.266 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.503 HG22 ' OD1' ' A' ' 78' ' ' ASP . 13.3 t -79.82 -25.06 40.97 Favored 'General case' 0 CA--C 1.529 0.167 0 CA-C-O 121.616 0.722 . . . . 0.0 109.322 178.913 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 23.2 m -132.54 79.86 63.83 Favored Pre-proline 0 C--N 1.322 -0.613 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 166.048 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -74.97 146.15 32.44 Favored 'Trans proline' 0 N--CA 1.462 -0.364 0 C-N-CA 122.799 2.332 . . . . 0.0 112.991 -171.954 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 83' ' ' ARG . . . . . 0.537 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 82.9 mtt180 -94.58 107.92 19.89 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.542 -0.754 . . . . 0.0 110.22 175.845 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 84' ' ' MET . . . . . 0.554 ' HA ' ' HD2' ' A' ' 87' ' ' TYR . 95.3 mmm -59.56 -24.41 63.71 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.587 -0.733 . . . . 0.0 111.571 -176.087 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.537 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 9.4 pt-20 -55.45 -29.56 58.89 Favored 'General case' 0 C--N 1.33 -0.272 0 O-C-N 123.245 0.341 . . . . 0.0 111.415 179.465 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.441 HD13 HG11 ' A' ' 75' ' ' VAL . 64.9 mt -78.52 -35.59 19.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.81 -178.403 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 87' ' ' TYR . . . . . 0.554 ' HD2' ' HA ' ' A' ' 84' ' ' MET . 49.4 m-85 -85.86 -25.86 25.98 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.209 -175.327 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 88' ' ' ARG . . . . . 0.645 ' HG2' HG12 ' A' ' 113' ' ' VAL . 81.6 mtp180 -70.35 138.29 51.29 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 121.36 0.6 . . . . 0.0 110.666 -178.553 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 92.92 -1.19 70.51 Favored Glycine 0 C--N 1.317 -0.478 0 CA-C-N 115.11 -0.95 . . . . 0.0 111.993 -176.652 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -86.7 147.64 25.79 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.905 0.383 . . . . 0.0 110.664 178.596 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -91.05 -27.08 18.84 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.801 179.306 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 92' ' ' LEU . . . . . 0.509 HD13 HG23 ' A' ' 29' ' ' ILE . 6.2 tt -152.35 143.24 22.99 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.143 -177.935 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.572 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 72.3 mt -131.46 122.74 51.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 N-CA-C 109.473 -0.566 . . . . 0.0 109.473 178.547 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 15.1 p90 -129.77 157.89 40.93 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 120.917 0.389 . . . . 0.0 110.883 -178.691 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 95' ' ' SER . . . . . 0.487 ' HA ' ' O ' ' A' ' 42' ' ' VAL . 16.5 m -128.04 128.37 44.85 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.958 -0.564 . . . . 0.0 110.974 -176.731 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 50.6 mm -91.71 106.67 17.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.437 -179.806 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 11.1 tpp180 57.06 69.87 1.55 Allowed Pre-proline 0 CA--C 1.535 0.389 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.071 178.821 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 98' ' ' PRO . . . . . 0.56 ' HG2' HG23 ' A' ' 119' ' ' ILE . 5.6 Cg_endo -87.05 135.69 3.95 Favored 'Trans proline' 0 N--CA 1.455 -0.762 0 C-N-CA 122.799 2.332 . . . . 0.0 112.31 -179.09 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.559 ' HD2' HD11 ' A' ' 102' ' ' ILE . 32.3 Cg_exo -59.12 142.51 99.38 Favored 'Trans proline' 0 C--O 1.236 0.411 0 C-N-CA 122.464 2.11 . . . . 0.0 111.7 174.627 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -76.97 43.01 0.33 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.763 -176.092 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 101' ' ' GLU . . . . . 0.506 ' HG3' HG23 ' A' ' 102' ' ' ILE . 12.0 pt-20 -140.27 -34.45 0.53 Allowed 'General case' 0 N--CA 1.45 -0.472 0 CA-C-N 115.902 -0.59 . . . . 0.0 111.541 178.797 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.559 HD11 ' HD2' ' A' ' 99' ' ' PRO . 45.8 pt -95.56 -0.78 10.62 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.211 0 CA-C-O 120.837 0.351 . . . . 0.0 111.597 -176.53 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 103' ' ' HIS . . . . . 0.539 ' O ' ' HG3' ' A' ' 107' ' ' MET . 41.8 p-80 -55.92 -36.93 68.25 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.932 -0.576 . . . . 0.0 111.303 -178.863 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 6.7 m -60.93 -39.32 88.97 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.0 -179.4 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.558 ' O ' HG23 ' A' ' 109' ' ' VAL . 14.2 m -66.58 -35.37 80.05 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.976 -0.556 . . . . 0.0 109.88 -179.752 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.573 HD21 HG11 ' A' ' 42' ' ' VAL . 96.3 mt -69.91 -41.06 75.19 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.704 -0.68 . . . . 0.0 111.138 -179.676 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 107' ' ' MET . . . . . 0.539 ' HG3' ' O ' ' A' ' 103' ' ' HIS . 70.0 mtp -62.5 -42.37 99.45 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.813 -0.63 . . . . 0.0 111.487 -177.24 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 14.1 ptm180 -69.54 -29.87 67.56 Favored 'General case' 0 C--N 1.33 -0.261 0 C-N-CA 120.762 -0.375 . . . . 0.0 111.158 -179.572 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.558 HG23 ' O ' ' A' ' 105' ' ' SER . 75.4 t -66.75 -48.69 79.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 C-N-CA 120.933 -0.307 . . . . 0.0 110.56 178.399 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -57.55 -46.25 84.15 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.262 177.676 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.548 ' HA ' ' HB1' ' A' ' 148' ' ' ALA . 12.3 t70 -63.43 -34.37 77.59 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.553 -0.749 . . . . 0.0 110.729 -177.868 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -70.31 -46.97 63.19 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.801 -0.636 . . . . 0.0 111.797 -179.773 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.645 HG12 ' HG2' ' A' ' 88' ' ' ARG . 23.1 m -84.95 -26.28 6.76 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-N 116.416 -0.356 . . . . 0.0 111.811 -173.769 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 89.67 43.18 5.23 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.092 179.468 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -124.1 154.34 40.12 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.668 0.27 . . . . 0.0 110.503 -178.524 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 116' ' ' ARG . . . . . 0.463 ' HD3' ' OE1' ' A' ' 145' ' ' GLU . 14.5 ttm180 -73.95 124.48 26.27 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 178.13 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 117' ' ' LEU . . . . . 0.572 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 56.1 tp -93.46 121.39 34.81 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.246 -0.434 . . . . 0.0 109.977 178.562 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 118' ' ' ILE . . . . . 0.406 HD12 HG12 ' A' ' 29' ' ' ILE . 67.8 mt -119.12 120.18 63.1 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 CA-C-O 121.321 0.581 . . . . 0.0 110.907 179.435 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 119' ' ' ILE . . . . . 0.56 HG23 ' HG2' ' A' ' 98' ' ' PRO . 14.2 mt -112.68 130.6 66.16 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.674 178.874 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 2.6 tmtm? -106.34 94.71 10.16 Favored Pre-proline 0 C--N 1.323 -0.545 0 N-CA-C 109.287 -0.634 . . . . 0.0 109.287 174.926 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 91.1 Cg_endo -85.67 -162.69 0.16 Allowed 'Trans proline' 0 N--CA 1.46 -0.464 0 C-N-CA 122.749 2.299 . . . . 0.0 112.588 -179.539 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 122' ' ' LEU . . . . . 0.943 ' HB2' ' HB3' ' A' ' 125' ' ' GLU . 9.9 mp -86.15 159.57 19.48 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.45 179.681 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 4.0 p -64.13 -33.72 76.42 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.915 -0.584 . . . . 0.0 111.617 -178.529 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -132.18 43.74 1.26 Allowed Glycine 0 N--CA 1.447 -0.579 0 C-N-CA 120.935 -0.65 . . . . 0.0 112.135 179.824 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 125' ' ' GLU . . . . . 0.943 ' HB3' ' HB2' ' A' ' 122' ' ' LEU . 34.3 tt0 -145.32 129.23 17.39 Favored 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 110.044 -0.354 . . . . 0.0 110.044 179.274 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -85.41 167.59 15.38 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.605 -175.902 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 35.7 mt -87.0 -21.64 7.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-O 121.084 0.469 . . . . 0.0 110.218 -178.513 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 19.8 t 60.21 65.22 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.233 0 CA-C-O 122.11 0.957 . . . . 0.0 110.126 -177.256 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 129' ' ' THR . . . . . 0.536 ' HB ' ' CD2' ' A' ' 103' ' ' HIS . 12.9 t -138.65 -179.25 5.71 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 115.128 -0.942 . . . . 0.0 109.558 -178.989 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 3.0 mp0 -74.24 161.29 30.07 Favored 'General case' 0 C--N 1.319 -0.72 0 N-CA-C 109.492 -0.559 . . . . 0.0 109.492 176.894 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 131' ' ' ARG . . . . . . . . . . . . . 34.9 ttm180 -74.39 82.26 1.92 Allowed 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 121.402 0.62 . . . . 0.0 110.176 -179.181 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 28.1 mmmt -126.98 -38.99 1.98 Allowed 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.231 -0.895 . . . . 0.0 110.462 -176.968 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 133' ' ' MET . . . . . . . . . . . . . 75.9 mtp -90.83 156.9 17.69 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.055 -0.521 . . . . 0.0 111.014 -175.525 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 16.1 ptmt -120.54 141.11 50.55 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 115.535 -0.757 . . . . 0.0 110.93 -175.582 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 135' ' ' LEU . . . . . 0.431 HD11 ' HD2' ' A' ' 142' ' ' TYR . 51.2 tp -83.12 120.65 26.03 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.108 178.042 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -119.19 146.01 24.48 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.743 -178.114 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 9.3 m-80 -118.84 119.24 33.8 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.535 -0.543 . . . . 0.0 109.535 -179.233 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 138' ' ' TYR . . . . . 0.482 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 40.6 t80 -123.52 117.42 25.05 Favored 'General case' 0 C--N 1.321 -0.641 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 178.511 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 70.34 -87.29 0.33 Allowed Glycine 0 N--CA 1.443 -0.865 0 CA-C-N 115.604 -0.725 . . . . 0.0 111.43 -175.546 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 14.2 tpp180 -139.1 -13.09 1.21 Allowed 'General case' 0 C--N 1.317 -0.83 0 CA-C-O 121.259 0.552 . . . . 0.0 110.241 -179.147 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 5.8 t -97.99 141.17 31.29 Favored 'General case' 0 N--CA 1.448 -0.538 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.261 -176.608 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 142' ' ' TYR . . . . . 0.431 ' HD2' HD11 ' A' ' 135' ' ' LEU . 52.0 p90 -118.88 147.12 44.32 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 121.117 0.484 . . . . 0.0 110.545 177.432 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 15.2 p90 -155.24 -176.97 6.21 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.322 -0.854 . . . . 0.0 109.778 -176.292 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 31.7 m-85 -115.32 125.49 53.31 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-O 120.454 0.168 . . . . 0.0 110.76 179.699 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 145' ' ' GLU . . . . . 0.463 ' OE1' ' HD3' ' A' ' 116' ' ' ARG . 15.5 pt-20 -114.72 160.0 19.89 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 121.081 0.467 . . . . 0.0 109.813 175.847 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 146' ' ' TYR . . . . . 0.406 ' HB3' ' HB3' ' A' ' 117' ' ' LEU . 26.4 t80 -143.87 122.18 12.32 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-N 115.714 -0.675 . . . . 0.0 109.566 175.158 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 147' ' ' ILE . . . . . 0.439 ' N ' HD12 ' A' ' 147' ' ' ILE . 3.2 mp -90.31 102.34 13.19 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 -178.973 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 148' ' ' ALA . . . . . 0.548 ' HB1' ' HA ' ' A' ' 111' ' ' ASP . . . -72.53 114.17 10.37 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.839 -0.619 . . . . 0.0 109.903 177.381 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 8.1 pt-20 -72.63 150.19 43.25 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.332 0.586 . . . . 0.0 110.886 -176.348 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 26.3 t -86.19 150.74 3.79 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.818 0 CA-C-N 115.464 -0.789 . . . . 0.0 109.434 -177.599 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 151' ' ' ARG . . . . . . . . . . . . . 5.6 mmp_? -69.56 154.2 42.35 Favored 'General case' 0 C--N 1.328 -0.334 0 N-CA-C 110.346 -0.242 . . . . 0.0 110.346 -179.805 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 23.1 t -63.36 149.34 46.05 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 176.21 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 99.1 mtt180 . . . . . 0 C--O 1.249 1.04 0 CA-C-O 118.506 -0.759 . . . . 0.0 110.171 -177.869 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.6 mpt? . . . . . 0 N--CA 1.481 1.11 0 CA-C-O 120.666 0.27 . . . . 0.0 110.44 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -138.63 44.89 1.07 Allowed Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.201 -178.804 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 20.1 m -85.11 41.88 0.9 Allowed 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 121.251 0.548 . . . . 0.0 111.003 -179.204 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 6.1 p -101.34 -169.66 1.72 Allowed 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.202 177.865 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 54.7 p-80 -134.84 133.86 40.18 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.02 0.438 . . . . 0.0 110.618 177.353 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 30.4 t60 -156.42 165.4 36.45 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 -178.714 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 94.1 m-70 67.75 14.82 9.57 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 123.065 0.546 . . . . 0.0 110.874 -177.136 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 9.6 m-70 -81.35 60.84 4.59 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-O 121.209 0.528 . . . . 0.0 112.189 -175.911 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 29.1 m80 -136.1 99.67 4.2 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.808 -0.633 . . . . 0.0 109.831 174.915 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 13.8 p80 -79.48 163.71 24.52 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 116.013 -0.539 . . . . 0.0 110.363 -178.641 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 4.1 t -154.96 44.11 0.49 Allowed 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 108.477 -0.935 . . . . 0.0 108.477 178.735 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 38.1 t -78.13 92.87 4.46 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.316 -0.856 . . . . 0.0 110.966 -175.375 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -138.46 42.19 1.29 Allowed Glycine 0 N--CA 1.448 -0.536 0 C-N-CA 120.807 -0.711 . . . . 0.0 111.761 177.532 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' LEU . . . . . 0.749 HD23 ' H ' ' A' ' 14' ' ' LEU . 2.5 pt? -106.78 153.77 21.97 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 120.806 0.336 . . . . 0.0 110.783 -177.52 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 29.9 m -91.71 136.76 26.09 Favored Pre-proline 0 C--N 1.323 -0.55 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.948 178.423 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -77.23 156.99 33.55 Favored 'Trans proline' 0 C--O 1.236 0.4 0 C-N-CA 122.839 2.36 . . . . 0.0 112.189 -179.893 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 33.7 mtp180 -108.9 141.79 40.46 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.937 -179.671 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -76.95 104.05 1.86 Allowed Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 121.201 -0.524 . . . . 0.0 112.939 -176.606 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' SER . . . . . 0.412 ' CB ' ' HB2' ' A' ' 22' ' ' TRP . 12.6 p -99.74 164.86 11.86 Favored 'General case' 0 C--N 1.323 -0.548 0 C-N-CA 122.399 0.28 . . . . 0.0 110.475 177.961 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 37.8 t-80 -95.6 -83.85 0.35 Allowed 'General case' 0 C--N 1.325 -0.466 0 C-N-CA 120.973 -0.291 . . . . 0.0 110.775 -178.878 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' MET . . . . . . . . . . . . . 56.7 mtt -64.14 -29.52 70.64 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-O 121.089 0.471 . . . . 0.0 111.214 -178.688 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' TRP . . . . . 0.434 ' HB3' HG22 ' A' ' 50' ' ' VAL . 50.2 m95 -69.28 -26.79 64.92 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.286 -178.611 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 25.8 t-20 -72.57 -43.32 63.58 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.98 -0.555 . . . . 0.0 109.691 177.801 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 42.5 m-20 -57.42 -51.03 71.07 Favored 'General case' 0 N--CA 1.463 0.205 0 CA-C-N 115.949 -0.568 . . . . 0.0 109.712 176.927 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.402 ' O ' HG13 ' A' ' 29' ' ' ILE . 58.2 tp -55.01 -47.78 74.22 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.44 -0.8 . . . . 0.0 110.954 179.035 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -55.3 -52.11 64.53 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.223 179.763 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.523 ' HA ' HD12 ' A' ' 30' ' ' ILE . 98.4 t -59.51 -40.51 82.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.975 -179.523 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 84.9 t80 -60.11 -43.54 95.53 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.494 178.428 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.404 HG23 HD13 ' A' ' 92' ' ' LEU . 82.6 mt -64.84 -43.67 96.36 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.595 177.909 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.662 HG12 HG23 ' A' ' 54' ' ' ILE . 85.8 mt -56.75 -38.84 60.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.901 178.206 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 32.8 mtp85 -70.62 -35.13 72.78 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.082 179.852 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 78.9 m -87.61 0.79 55.15 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.674 -174.047 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 15.5 p -122.01 -71.73 0.72 Allowed 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 120.977 0.418 . . . . 0.0 111.175 178.026 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 97.38 145.23 18.71 Favored Glycine 0 N--CA 1.446 -0.666 0 C-N-CA 120.804 -0.712 . . . . 0.0 111.586 -177.895 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -59.18 130.55 36.7 Favored 'Trans proline' 0 C--O 1.233 0.266 0 C-N-CA 122.852 2.368 . . . . 0.0 112.671 -177.433 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 105.37 24.97 6.87 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.467 -0.873 . . . . 0.0 112.978 177.474 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 13.8 t -131.71 -171.55 2.64 Favored 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 177.312 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -119.35 131.47 55.7 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 120.897 0.379 . . . . 0.0 110.433 177.866 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.45 ' O ' ' HA ' ' A' ' 62' ' ' LEU . 95.9 t -128.14 130.44 69.62 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 176.578 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.403 HG11 ' CD1' ' A' ' 87' ' ' TYR . 46.5 t -107.21 126.04 63.36 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.674 0 CA-C-O 120.91 0.386 . . . . 0.0 111.036 -176.38 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 41' ' ' GLU . . . . . 0.445 ' HB3' HD23 ' A' ' 64' ' ' LEU . 39.2 tt0 -104.18 114.82 29.32 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.686 175.841 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 62.1 t -98.13 125.75 51.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.691 -177.668 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 88.03 28.66 22.63 Favored Glycine 0 N--CA 1.452 -0.261 0 CA-C-N 115.989 -0.551 . . . . 0.0 112.015 179.603 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.436 ' HB1' ' CD2' ' A' ' 48' ' ' LEU . . . -55.79 -76.58 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.35 0 C-N-CA 123.045 0.538 . . . . 0.0 112.356 -176.503 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 64.09 -102.04 0.55 Allowed Glycine 0 CA--C 1.519 0.301 0 C-N-CA 121.185 -0.531 . . . . 0.0 113.188 179.408 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -107.59 -1.89 20.79 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.655 0.264 . . . . 0.0 111.547 -178.082 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.445 ' CG ' HG21 ' A' ' 96' ' ' ILE . 99.4 m-85 -87.72 23.56 1.96 Allowed 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.933 0.397 . . . . 0.0 111.408 -174.957 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.762 HD22 HD13 ' A' ' 64' ' ' LEU . 37.8 mt -66.42 -7.74 21.29 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.691 -0.686 . . . . 0.0 112.831 -172.928 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 49' ' ' TYR . . . . . 0.438 ' CE2' ' HA ' ' A' ' 47' ' ' PHE . 23.4 p90 -62.0 -25.72 67.81 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.576 0.227 . . . . 0.0 111.361 -179.905 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.434 HG22 ' HB3' ' A' ' 22' ' ' TRP . 61.9 t -74.24 -54.88 13.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.924 0.393 . . . . 0.0 110.381 175.935 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -66.22 -40.13 90.08 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.9 -0.591 . . . . 0.0 112.294 -177.21 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.558 ' O ' ' HG2' ' A' ' 56' ' ' LYS . 38.7 t70 -67.23 -27.75 67.49 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.863 0.363 . . . . 0.0 110.502 -178.688 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 78.5 t80 -69.53 -41.88 75.38 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.892 0.377 . . . . 0.0 110.293 176.014 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.662 HG23 HG12 ' A' ' 30' ' ' ILE . 77.1 mt -63.65 -40.7 90.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 115.946 -0.57 . . . . 0.0 111.231 -178.493 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 55' ' ' ARG . . . . . 0.505 ' HG2' ' HA ' ' A' ' 52' ' ' ASP . 5.8 ptp180 -70.11 -16.57 63.13 Favored 'General case' 0 CA--C 1.534 0.365 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.985 -176.492 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 56' ' ' LYS . . . . . 0.558 ' HG2' ' O ' ' A' ' 52' ' ' ASP . 67.1 mmtt -72.17 -42.86 65.4 Favored 'General case' 0 N--CA 1.462 0.143 0 CA-C-O 121.186 0.517 . . . . 0.0 110.377 179.645 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 45.4 m-70 -92.36 -46.87 7.47 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.48 -0.782 . . . . 0.0 111.884 -173.002 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 58' ' ' SER . . . . . 0.448 ' HB2' HG23 ' A' ' 60' ' ' VAL . 12.0 p -112.3 134.18 53.99 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 116.609 -0.269 . . . . 0.0 111.163 -176.798 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 25.4 tptp -80.24 65.85 5.53 Favored 'General case' 0 N--CA 1.448 -0.541 0 CA-C-O 122.246 1.022 . . . . 0.0 109.612 174.532 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.448 HG23 ' HB2' ' A' ' 58' ' ' SER . 92.3 t -98.39 130.86 46.58 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.192 0 CA-C-N 114.4 -1.273 . . . . 0.0 109.113 172.662 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 62.2 m-20 -75.67 86.56 2.72 Favored 'General case' 0 C--N 1.317 -0.83 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 178.981 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 62' ' ' LEU . . . . . 0.45 ' HA ' ' O ' ' A' ' 39' ' ' VAL . 2.8 tt -87.02 115.55 24.48 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 115.45 -0.796 . . . . 0.0 109.933 -177.054 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 48.0 t -97.54 119.16 45.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.055 -177.252 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 64' ' ' LEU . . . . . 0.762 HD13 HD22 ' A' ' 48' ' ' LEU . 39.2 mt -92.85 121.54 34.33 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-N 115.913 -0.585 . . . . 0.0 109.762 179.102 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 19.4 p -121.74 124.89 45.29 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-O 121.054 0.454 . . . . 0.0 110.485 178.903 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 27.3 t0 -160.72 152.29 19.49 Favored 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 109.612 -0.514 . . . . 0.0 109.612 -179.294 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.694 HG12 ' HA ' ' A' ' 78' ' ' ASP . 49.6 mt -73.12 108.9 4.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 N-CA-C 110.124 -0.325 . . . . 0.0 110.124 -177.935 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 68' ' ' LYS . . . . . 0.452 ' HA ' ' HD2' ' A' ' 69' ' ' PRO . 45.3 mtpt 65.2 88.86 0.11 Allowed Pre-proline 0 C--N 1.328 -0.365 0 CA-C-N 115.157 -0.929 . . . . 0.0 110.627 -178.963 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 69' ' ' PRO . . . . . 0.756 ' HB3' ' HB ' ' A' ' 74' ' ' ILE . 11.0 Cg_endo -57.44 140.08 92.09 Favored 'Trans proline' 0 C--N 1.343 0.27 0 C-N-CA 123.558 2.839 . . . . 0.0 113.229 -177.498 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 35.8 m -97.48 -12.16 22.96 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.695 -0.684 . . . . 0.0 111.156 178.716 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 71' ' ' HIS . . . . . 0.496 ' HB2' HD11 ' A' ' 48' ' ' LEU . 38.0 m-70 -135.23 179.85 6.07 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.368 -179.83 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -88.62 144.33 18.24 Favored Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 120.92 -0.657 . . . . 0.0 111.931 178.593 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 95.21 1.03 62.94 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.131 -179.797 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.756 ' HB ' ' HB3' ' A' ' 69' ' ' PRO . 53.3 mt -100.72 128.0 53.27 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 N-CA-C 110.124 -0.324 . . . . 0.0 110.124 179.177 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 45.3 t -78.48 135.84 25.19 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.716 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 177.089 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 76' ' ' ARG . . . . . 0.529 ' HA ' ' HD3' ' A' ' 69' ' ' PRO . 3.3 ptm180 -79.92 25.24 0.37 Allowed 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.638 -0.256 . . . . 0.0 111.389 -176.441 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 38.2 t70 -64.59 103.8 0.72 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.37 0.605 . . . . 0.0 110.277 -177.192 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 78' ' ' ASP . . . . . 0.694 ' HA ' HG12 ' A' ' 67' ' ' ILE . 3.3 m-20 -68.25 123.46 20.79 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.241 -0.89 . . . . 0.0 110.201 -176.335 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 10.6 tp -64.08 -19.02 23.81 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.48 0 CA-C-O 121.132 0.492 . . . . 0.0 111.066 179.665 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 10.2 t -77.45 -14.81 59.61 Favored 'General case' 0 CA--C 1.532 0.288 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.784 178.431 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 33.6 t -158.68 70.53 3.69 Favored Pre-proline 0 C--N 1.326 -0.424 0 N-CA-C 108.353 -0.981 . . . . 0.0 108.353 177.593 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 90.0 Cg_endo -88.24 162.09 7.01 Favored 'Trans proline' 0 N--CA 1.458 -0.615 0 C-N-CA 122.956 2.437 . . . . 0.0 113.591 -168.56 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 83' ' ' ARG . . . . . 0.745 ' HB2' HD12 ' A' ' 86' ' ' ILE . 3.9 mmt180 -98.24 107.68 20.21 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 115.58 -0.736 . . . . 0.0 111.095 175.825 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 84' ' ' MET . . . . . 0.503 ' O ' ' HG3' ' A' ' 88' ' ' ARG . 91.0 mmm -62.17 -23.65 66.72 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.278 177.276 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.428 ' OE2' ' HD2' ' A' ' 83' ' ' ARG . 11.0 pt-20 -69.55 -22.58 63.54 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.638 -178.189 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.745 HD12 ' HB2' ' A' ' 83' ' ' ARG . 95.6 mt -81.04 -36.08 14.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.204 178.342 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 87' ' ' TYR . . . . . 0.403 ' CD1' HG11 ' A' ' 40' ' ' VAL . 22.8 m-85 -77.76 -31.21 51.92 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.72 -179.369 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 88' ' ' ARG . . . . . 0.503 ' HG3' ' O ' ' A' ' 84' ' ' MET . 38.2 mtp180 -63.67 123.08 17.94 Favored 'General case' 0 CA--C 1.516 -0.361 0 CA-C-O 121.331 0.586 . . . . 0.0 111.024 179.837 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 109.99 -9.5 31.71 Favored Glycine 0 N--CA 1.446 -0.639 0 CA-C-N 115.321 -0.854 . . . . 0.0 111.706 -178.506 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -81.93 143.8 31.39 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 110.349 -0.241 . . . . 0.0 110.349 178.389 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -92.89 -19.88 21.23 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 121.063 0.458 . . . . 0.0 110.627 -179.881 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 92' ' ' LEU . . . . . 0.45 HD23 ' N ' ' A' ' 93' ' ' ILE . 3.2 tt -152.09 140.66 20.73 Favored 'General case' 0 N--CA 1.449 -0.487 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.625 -179.062 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.467 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 72.3 mt -132.28 126.91 56.57 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 115.934 -0.576 . . . . 0.0 109.569 178.486 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 94' ' ' TYR . . . . . 0.4 ' HB3' ' HB ' ' A' ' 118' ' ' ILE . 8.1 p90 -134.7 162.84 31.21 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 120.812 0.339 . . . . 0.0 110.688 178.563 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 6.8 p -141.97 143.16 33.08 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.1 -176.392 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 96' ' ' ILE . . . . . 0.445 HG21 ' CG ' ' A' ' 47' ' ' PHE . 40.5 mm -90.47 93.11 4.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.632 179.675 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 97' ' ' ARG . . . . . 0.499 ' HG2' ' HA ' ' A' ' 121' ' ' PRO . 1.2 tmm_? 49.44 80.86 0.28 Allowed Pre-proline 0 N--CA 1.464 0.261 0 CA-C-N 115.18 -0.918 . . . . 0.0 111.757 178.552 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 98' ' ' PRO . . . . . 0.518 ' HG2' ' CD2' ' A' ' 103' ' ' HIS . 98.8 Cg_endo -84.98 152.32 11.11 Favored 'Trans proline' 0 N--CA 1.457 -0.63 0 C-N-CA 122.556 2.17 . . . . 0.0 111.874 176.195 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.591 ' HD2' HD11 ' A' ' 102' ' ' ILE . 24.2 Cg_exo -64.15 155.45 64.98 Favored 'Trans proline' 0 C--N 1.343 0.28 0 C-N-CA 122.857 2.371 . . . . 0.0 112.089 175.066 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.641 ' HA ' ' ND1' ' A' ' 103' ' ' HIS . . . -64.17 -16.12 61.26 Favored 'General case' 0 C--N 1.33 -0.257 0 N-CA-C 112.328 0.492 . . . . 0.0 112.328 -176.195 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 101' ' ' GLU . . . . . 0.626 ' HG3' HG23 ' A' ' 102' ' ' ILE . 12.9 pt-20 -76.14 -22.25 55.67 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.781 -0.19 . . . . 0.0 111.509 -177.519 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.626 HG23 ' HG3' ' A' ' 101' ' ' GLU . 43.1 pt -114.91 3.13 7.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 N-CA-C 112.438 0.533 . . . . 0.0 112.438 -176.177 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 103' ' ' HIS . . . . . 0.641 ' ND1' ' HA ' ' A' ' 100' ' ' ALA . 41.8 m170 -58.03 -51.57 69.13 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.002 0.43 . . . . 0.0 110.428 176.92 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 8.8 m -64.46 -29.82 70.86 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.892 -0.594 . . . . 0.0 110.59 178.03 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.554 ' O ' HG23 ' A' ' 109' ' ' VAL . 3.6 m -71.11 -43.9 66.73 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.577 -178.434 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 79.5 mt -60.77 -38.92 86.87 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.818 178.63 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 107' ' ' MET . . . . . 0.451 ' HA ' HD22 ' A' ' 117' ' ' LEU . 76.3 mtp -62.19 -45.54 92.93 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.081 179.841 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 108' ' ' ARG . . . . . 0.549 ' HG2' ' O ' ' A' ' 105' ' ' SER . 12.9 ptm180 -72.01 -22.8 61.36 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.633 -0.258 . . . . 0.0 111.073 -178.26 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.554 HG23 ' O ' ' A' ' 105' ' ' SER . 70.1 t -70.39 -49.94 49.77 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 173.985 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -58.15 -45.54 87.23 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.074 -0.512 . . . . 0.0 109.88 176.67 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.476 ' HA ' ' HB1' ' A' ' 148' ' ' ALA . 21.0 t70 -59.23 -36.15 74.92 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.329 -0.851 . . . . 0.0 111.372 179.387 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -71.95 -45.19 61.98 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.641 -0.709 . . . . 0.0 111.951 -179.269 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 23.2 m -86.94 -28.24 5.78 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 N-CA-C 111.996 0.369 . . . . 0.0 111.996 -174.627 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 87.92 58.96 1.73 Allowed Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.268 -178.65 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -137.47 162.29 34.07 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.752 0.311 . . . . 0.0 110.776 179.37 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 116' ' ' ARG . . . . . 0.446 ' HD3' ' OE1' ' A' ' 145' ' ' GLU . 12.5 ttm180 -79.72 120.27 23.78 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 175.857 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 117' ' ' LEU . . . . . 0.467 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 52.5 tp -91.99 125.79 36.82 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.089 178.895 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 118' ' ' ILE . . . . . 0.4 ' HB ' ' HB3' ' A' ' 94' ' ' TYR . 65.0 mt -118.57 115.02 46.8 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-O 121.176 0.512 . . . . 0.0 110.514 176.889 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 69.8 mt -116.62 120.73 65.87 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.144 179.55 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 120' ' ' LYS . . . . . 0.456 ' HG3' ' HB3' ' A' ' 143' ' ' PHE . 12.1 ttpp -113.58 99.94 50.82 Favored Pre-proline 0 C--N 1.324 -0.525 0 C-N-CA 120.819 -0.353 . . . . 0.0 110.27 175.928 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 121' ' ' PRO . . . . . 0.499 ' HA ' ' HG2' ' A' ' 97' ' ' ARG . 98.9 Cg_endo -81.93 -153.59 0.05 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.609 0 C-N-CA 122.594 2.196 . . . . 0.0 111.079 174.305 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 122' ' ' LEU . . . . . 0.579 ' HB2' ' HG2' ' A' ' 125' ' ' GLU . 3.6 mm? -81.49 -176.98 6.31 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 175.075 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 10.0 t -79.88 1.02 28.68 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.272 0.558 . . . . 0.0 110.602 178.491 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -156.83 71.74 0.25 Allowed Glycine 0 N--CA 1.446 -0.687 0 N-CA-C 111.325 -0.71 . . . . 0.0 111.325 178.081 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 125' ' ' GLU . . . . . 0.579 ' HG2' ' HB2' ' A' ' 122' ' ' LEU . 9.9 mm-40 -138.01 167.93 20.76 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 109.122 -0.695 . . . . 0.0 109.122 -177.824 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 8.7 t70 -120.68 163.22 18.4 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.046 178.128 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.508 ' HB ' HG22 ' A' ' 129' ' ' THR . 20.8 mt -109.86 -15.4 9.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-O 120.965 0.412 . . . . 0.0 110.716 -175.724 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 18.3 t 51.87 65.06 0.18 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.285 0 CA-C-O 121.651 0.739 . . . . 0.0 110.215 -176.065 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 129' ' ' THR . . . . . 0.508 HG22 ' HB ' ' A' ' 127' ' ' ILE . 9.0 t -144.04 177.21 8.73 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.876 -176.125 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 130' ' ' GLU . . . . . 0.669 ' HG3' ' HG3' ' A' ' 132' ' ' LYS . 9.8 pt-20 -88.86 28.54 1.15 Allowed 'General case' 0 CA--C 1.532 0.26 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.648 -175.158 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 131' ' ' ARG . . . . . . . . . . . . . 86.0 mtt180 63.8 24.31 13.74 Favored 'General case' 0 N--CA 1.47 0.535 0 N-CA-C 112.718 0.636 . . . . 0.0 112.718 171.99 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 132' ' ' LYS . . . . . 0.669 ' HG3' ' HG3' ' A' ' 130' ' ' GLU . 46.4 mtmt -83.36 -9.35 59.11 Favored 'General case' 0 C--N 1.327 -0.383 0 C-N-CA 120.667 -0.413 . . . . 0.0 111.173 177.845 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 133' ' ' MET . . . . . 0.569 ' HG2' ' HB2' ' A' ' 146' ' ' TYR . 73.5 mtp -90.12 151.29 21.66 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 179.144 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 134' ' ' LYS . . . . . 0.546 ' HB3' ' NZ ' ' A' ' 134' ' ' LYS . 0.3 OUTLIER -121.1 143.05 49.29 Favored 'General case' 0 C--N 1.315 -0.924 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.959 -173.655 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 135' ' ' LEU . . . . . 0.781 HD11 ' HD2' ' A' ' 142' ' ' TYR . 43.4 tp -86.13 119.11 26.07 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.977 -0.556 . . . . 0.0 109.694 178.98 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 136' ' ' VAL . . . . . 0.441 ' CG2' ' HG2' ' A' ' 145' ' ' GLU . 0.0 OUTLIER -117.63 144.52 25.35 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.695 -176.271 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 52.3 m-20 -114.96 123.77 49.95 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.41 -179.663 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 58.3 t80 -137.57 123.36 19.99 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 109.932 -0.395 . . . . 0.0 109.932 175.213 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 72.12 -85.98 0.49 Allowed Glycine 0 N--CA 1.449 -0.476 0 N-CA-C 110.838 -0.905 . . . . 0.0 110.838 -175.051 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 7.1 mtt180 -153.73 -5.55 0.18 Allowed 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 115.443 -0.378 . . . . 0.0 111.388 173.569 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 15.3 t -87.91 143.68 26.98 Favored 'General case' 0 N--CA 1.445 -0.701 0 N-CA-C 109.039 -0.726 . . . . 0.0 109.039 176.24 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 142' ' ' TYR . . . . . 0.781 ' HD2' HD11 ' A' ' 135' ' ' LEU . 48.3 p90 -127.1 129.72 48.51 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-O 121.485 0.66 . . . . 0.0 110.214 178.506 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 143' ' ' PHE . . . . . 0.456 ' HB3' ' HG3' ' A' ' 120' ' ' LYS . 9.6 p90 -139.29 175.77 9.28 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-N 114.838 -1.074 . . . . 0.0 109.962 -173.512 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 144' ' ' TYR . . . . . 0.42 ' HA ' ' O ' ' A' ' 134' ' ' LYS . 93.9 m-85 -110.72 122.51 48.0 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.317 179.889 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 145' ' ' GLU . . . . . 0.459 ' O ' ' HG2' ' A' ' 134' ' ' LYS . 19.7 pt-20 -114.68 160.42 19.37 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-O 121.155 0.503 . . . . 0.0 109.805 175.92 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 146' ' ' TYR . . . . . 0.569 ' HB2' ' HG2' ' A' ' 133' ' ' MET . 46.5 t80 -142.02 125.24 16.42 Favored 'General case' 0 C--N 1.313 -0.993 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.627 175.811 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 147' ' ' ILE . . . . . 0.421 ' N ' HD12 ' A' ' 147' ' ' ILE . 3.5 mp -92.89 108.67 20.63 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.792 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 179.71 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 148' ' ' ALA . . . . . 0.476 ' HB1' ' HA ' ' A' ' 111' ' ' ASP . . . -74.41 128.77 36.37 Favored 'General case' 0 N--CA 1.442 -0.837 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 173.983 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 19.7 mm-40 -61.12 165.74 4.12 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-O 121.787 0.803 . . . . 0.0 112.169 -178.23 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 41.1 t -71.94 131.47 34.61 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.8 0 CA-C-N 114.621 -1.172 . . . . 0.0 109.772 -178.644 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 151' ' ' ARG . . . . . 0.501 ' HA ' ' HD3' ' A' ' 151' ' ' ARG . 23.7 mmt180 -92.73 164.49 13.36 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.548 -176.115 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 42.1 t -88.56 150.2 23.2 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.564 -0.743 . . . . 0.0 110.873 -174.387 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 7.9 tpm_? . . . . . 0 C--O 1.249 1.047 0 CA-C-O 118.298 -0.858 . . . . 0.0 109.512 177.326 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 17.1 tpt . . . . . 0 N--CA 1.479 1.016 0 N-CA-C 110.313 -0.254 . . . . 0.0 110.313 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 139.95 -93.22 0.19 Allowed Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 120.637 -0.792 . . . . 0.0 112.466 177.67 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 33.4 t -78.27 123.39 26.89 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 120.925 0.393 . . . . 0.0 110.592 -178.21 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 19.4 m -103.35 117.58 34.81 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.236 -0.438 . . . . 0.0 109.965 178.991 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 85.4 m-70 -102.55 141.63 35.06 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.497 -177.224 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 79.2 m-70 -99.0 122.35 42.14 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.751 -179.829 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 83.2 t60 -76.31 -39.15 54.84 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.385 178.053 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 22.7 t60 -116.12 132.51 56.64 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.245 -177.943 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 56.8 m-70 -120.73 159.89 24.46 Favored 'General case' 0 C--N 1.324 -0.513 0 N-CA-C 109.449 -0.574 . . . . 0.0 109.449 -179.715 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 17.9 p80 -126.04 172.54 9.88 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.034 0.445 . . . . 0.0 111.134 -175.119 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 35.8 t -134.61 100.67 4.7 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.612 -0.722 . . . . 0.0 109.512 177.735 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 14.8 m -59.69 -36.4 76.41 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.135 -179.018 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -87.16 110.1 3.52 Favored Glycine 0 N--CA 1.443 -0.896 0 C-N-CA 120.574 -0.822 . . . . 0.0 111.12 176.107 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' LEU . . . . . 0.674 HD23 ' H ' ' A' ' 14' ' ' LEU . 2.3 pt? -70.25 138.65 51.83 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 120.9 0.381 . . . . 0.0 110.371 179.142 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 27.3 m -87.22 152.92 53.53 Favored Pre-proline 0 C--N 1.323 -0.572 0 CA-C-N 116.037 -0.528 . . . . 0.0 110.259 179.476 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -68.36 157.59 61.19 Favored 'Trans proline' 0 C--O 1.236 0.398 0 C-N-CA 122.438 2.092 . . . . 0.0 111.834 178.67 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' ARG . . . . . 0.537 ' HD2' ' H ' ' A' ' 17' ' ' ARG . 1.1 mpt_? -79.36 75.92 5.95 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.385 0.612 . . . . 0.0 109.946 179.544 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 18' ' ' GLY . . . . . 0.415 ' O ' ' HG2' ' A' ' 21' ' ' MET . . . -96.83 89.91 1.1 Allowed Glycine 0 N--CA 1.443 -0.874 0 CA-C-N 115.474 -0.785 . . . . 0.0 112.377 -177.907 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 13.0 m -87.96 -28.34 21.53 Favored 'General case' 0 C--N 1.32 -0.71 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 175.57 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 19.2 t-160 -61.38 -30.62 70.65 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 114.867 -1.06 . . . . 0.0 111.162 -177.679 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' MET . . . . . 0.709 ' HB2' ' HB ' ' A' ' 141' ' ' THR . 21.2 ptt? -67.28 -17.2 64.69 Favored 'General case' 0 CA--C 1.53 0.21 0 CA-C-O 120.681 0.277 . . . . 0.0 111.436 -178.4 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 22' ' ' TRP . . . . . 0.413 ' HB2' ' HE2' ' A' ' 49' ' ' TYR . 88.3 m95 -87.42 -32.55 19.47 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 176.97 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 12.8 m120 -66.06 -48.17 71.9 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.626 -0.716 . . . . 0.0 110.411 177.739 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.714 ' HB3' ' HA3' ' A' ' 139' ' ' GLY . 0.7 OUTLIER -67.51 -35.3 78.84 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.298 179.323 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.716 HD22 ' HD2' ' A' ' 120' ' ' LYS . 50.7 tp -51.79 -49.77 62.06 Favored 'General case' 0 C--O 1.231 0.131 0 CA-C-O 121.15 0.5 . . . . 0.0 109.901 173.576 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 26' ' ' ALA . . . . . 0.433 ' O ' HG13 ' A' ' 30' ' ' ILE . . . -60.26 -45.75 92.2 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.439 -0.8 . . . . 0.0 111.098 177.825 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.438 ' HA ' HD12 ' A' ' 30' ' ' ILE . 76.0 t -55.45 -43.7 73.09 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 CA-C-N 116.389 -0.369 . . . . 0.0 110.896 178.887 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' TYR . . . . . 0.446 ' HB2' ' CD2' ' A' ' 138' ' ' TYR . 54.3 t80 -59.49 -43.12 93.39 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.428 179.339 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 65.2 mt -65.68 -44.4 93.43 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.427 178.668 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.713 HG12 HG23 ' A' ' 54' ' ' ILE . 85.5 mt -57.63 -45.82 86.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.969 178.378 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 62.6 mtt180 -68.39 -28.59 67.23 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.193 0.521 . . . . 0.0 111.474 -177.74 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 74.6 m -88.84 -0.4 57.32 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.555 -178.566 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 24.3 p -128.11 -83.73 0.59 Allowed 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.805 0.336 . . . . 0.0 111.01 177.517 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 108.34 160.88 20.4 Favored Glycine 0 N--CA 1.449 -0.477 0 C-N-CA 120.975 -0.631 . . . . 0.0 112.228 -179.891 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 24.5 Cg_exo -63.14 146.0 94.02 Favored 'Trans proline' 0 C--O 1.233 0.269 0 C-N-CA 122.893 2.395 . . . . 0.0 112.178 178.877 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 94.1 -23.05 33.2 Favored Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 120.925 -0.655 . . . . 0.0 112.621 179.001 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 15.7 p -81.62 -171.85 3.54 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 -179.313 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' ARG . . . . . 1.085 ' HG3' ' HA ' ' A' ' 90' ' ' ALA . 17.5 ptm180 -131.2 130.77 43.39 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 121.036 0.446 . . . . 0.0 110.222 173.895 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.429 HG13 ' HB3' ' A' ' 92' ' ' LEU . 86.7 t -129.73 134.15 63.72 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 CA-C-N 115.804 -0.635 . . . . 0.0 109.351 -177.983 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.45 HG22 ' HB ' ' A' ' 63' ' ' VAL . 45.3 t -109.86 125.45 67.05 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-O 120.952 0.406 . . . . 0.0 111.433 -175.431 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 45.1 tt0 -101.64 120.53 40.48 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.927 -0.579 . . . . 0.0 109.711 175.091 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.484 ' HB ' ' OG ' ' A' ' 95' ' ' SER . 41.8 t -98.22 123.34 50.67 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.265 -179.418 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 97.37 27.31 9.33 Favored Glycine 0 N--CA 1.45 -0.43 0 N-CA-C 111.224 -0.751 . . . . 0.0 111.224 -176.777 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -85.25 76.43 10.16 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.09 0.471 . . . . 0.0 110.863 -177.814 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -111.0 -70.4 0.61 Allowed Glycine 0 N--CA 1.444 -0.807 0 C-N-CA 120.45 -0.881 . . . . 0.0 112.538 -179.421 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -119.03 11.17 12.38 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 120.694 0.283 . . . . 0.0 111.118 -175.872 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 42.2 t80 -130.0 70.75 1.43 Allowed 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 121.275 0.56 . . . . 0.0 109.93 178.519 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 82.1 mt -93.36 20.12 7.49 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.771 -178.656 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' TYR . . . . . 0.413 ' HE2' ' HB2' ' A' ' 22' ' ' TRP . 44.9 t80 -63.54 -39.58 94.79 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.955 -177.881 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.463 ' O ' HG13 ' A' ' 54' ' ' ILE . 59.7 t -75.58 -54.4 13.96 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.546 -179.159 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 1.5 p -60.92 -46.77 89.36 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.8 -0.636 . . . . 0.0 112.638 -175.751 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.426 ' O ' ' HG2' ' A' ' 56' ' ' LYS . 38.9 t70 -63.75 -38.1 89.82 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.847 0.356 . . . . 0.0 110.393 -178.131 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 65.6 t80 -61.21 -45.62 93.83 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.376 177.78 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.713 HG23 HG12 ' A' ' 30' ' ' ILE . 83.3 mt -58.64 -48.41 85.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 115.903 -0.59 . . . . 0.0 111.465 -179.033 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 39.1 ptt180 -72.85 -16.77 61.59 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 111.776 0.287 . . . . 0.0 111.776 -175.888 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 56' ' ' LYS . . . . . 0.935 ' HA ' ' HE2' ' A' ' 56' ' ' LYS . 8.1 mmpt? -73.01 -41.87 63.81 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.798 0.333 . . . . 0.0 110.27 174.882 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 31.0 m-70 -84.44 -52.52 6.11 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.213 -178.837 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 10.5 p -111.65 129.42 56.09 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.153 -178.492 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -82.39 62.34 6.02 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.991 0.901 . . . . 0.0 109.745 176.146 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.41 HG21 HG23 ' A' ' 39' ' ' VAL . 2.3 p -87.43 143.92 10.31 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.935 0 CA-C-N 114.573 -1.194 . . . . 0.0 108.357 171.442 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 61' ' ' ASP . . . . . 0.48 ' O ' ' HA ' ' A' ' 38' ' ' ARG . 22.8 t0 -75.57 86.99 2.67 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-O 121.647 0.737 . . . . 0.0 109.427 177.706 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 1.5 tt -85.64 122.93 30.45 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.432 -0.804 . . . . 0.0 110.027 -176.208 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.45 ' HB ' HG22 ' A' ' 40' ' ' VAL . 47.6 t -103.75 118.14 50.38 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.698 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.753 -179.276 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 64' ' ' LEU . . . . . 0.579 ' CB ' HG23 ' A' ' 74' ' ' ILE . 77.8 mt -95.69 133.22 40.03 Favored 'General case' 0 C--N 1.315 -0.906 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.067 -179.053 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.493 HG22 ' HB ' ' A' ' 75' ' ' VAL . 23.7 p -129.61 135.01 48.04 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 120.45 0.167 . . . . 0.0 111.188 179.704 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 66' ' ' ASP . . . . . 0.804 ' HB3' ' HG3' ' A' ' 69' ' ' PRO . 25.3 t70 -165.25 173.61 11.1 Favored 'General case' 0 C--O 1.234 0.278 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 178.746 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.533 HD11 HG22 ' A' ' 79' ' ' ILE . 39.2 mm -81.26 96.64 3.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-O 120.958 0.408 . . . . 0.0 110.78 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 68' ' ' LYS . . . . . 0.408 ' HD3' ' HB2' ' A' ' 76' ' ' ARG . 70.3 mmtt 53.1 66.9 4.25 Favored Pre-proline 0 N--CA 1.467 0.407 0 CA-C-N 115.277 -0.874 . . . . 0.0 111.513 177.481 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 69' ' ' PRO . . . . . 0.804 ' HG3' ' HB3' ' A' ' 66' ' ' ASP . 17.1 Cg_exo -69.34 146.62 63.38 Favored 'Trans proline' 0 C--O 1.234 0.281 0 C-N-CA 123.164 2.576 . . . . 0.0 112.172 -178.09 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 12.3 p -95.7 11.25 34.08 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.782 -175.477 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 27.6 t60 -99.8 11.32 39.55 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 121.009 0.433 . . . . 0.0 110.233 -178.954 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 78.63 -78.04 1.69 Allowed Glycine 0 CA--C 1.518 0.256 0 C-N-CA 121.278 -0.487 . . . . 0.0 114.004 172.152 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -70.19 -11.15 66.94 Favored Glycine 0 CA--C 1.519 0.305 0 C-N-CA 121.4 -0.428 . . . . 0.0 114.04 -171.852 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.579 HG23 ' CB ' ' A' ' 64' ' ' LEU . 39.7 mt -72.37 138.16 22.08 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 116.939 0.369 . . . . 0.0 110.188 179.917 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.635 HG11 HD13 ' A' ' 86' ' ' ILE . 61.0 t -64.45 129.95 28.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 121.031 0.444 . . . . 0.0 110.563 -179.15 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 76' ' ' ARG . . . . . 0.454 ' HA ' ' HD3' ' A' ' 69' ' ' PRO . 5.4 ptp180 -104.12 28.97 6.29 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.655 -173.883 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 77' ' ' ASP . . . . . 0.5 ' H ' HG12 ' A' ' 75' ' ' VAL . 11.3 t70 -69.94 -84.74 0.03 OUTLIER 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.851 -0.613 . . . . 0.0 111.272 -172.88 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 78' ' ' ASP . . . . . 0.4 ' H ' ' HB3' ' A' ' 77' ' ' ASP . 7.5 t70 -163.24 -169.64 2.05 Favored 'General case' 0 C--N 1.325 -0.5 0 N-CA-C 109.091 -0.707 . . . . 0.0 109.091 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 79' ' ' ILE . . . . . 0.533 HG22 HD11 ' A' ' 67' ' ' ILE . 13.0 tt -144.19 -28.04 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-O 121.013 0.435 . . . . 0.0 110.749 -179.118 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.517 ' HA ' HG21 ' A' ' 102' ' ' ILE . 14.7 t -103.3 -24.52 13.51 Favored 'General case' 0 N--CA 1.45 -0.44 0 CA-C-O 121.288 0.566 . . . . 0.0 110.058 -178.047 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 68.0 m -150.13 75.17 9.0 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.27 172.871 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.476 ' HB2' ' HE2' ' A' ' 87' ' ' TYR . 9.1 Cg_endo -89.64 174.04 3.53 Favored 'Trans proline' 0 N--CA 1.454 -0.824 0 C-N-CA 123.267 2.645 . . . . 0.0 112.887 -177.08 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 83' ' ' ARG . . . . . 0.692 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 81.6 mtt85 -78.3 118.01 20.09 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.152 176.663 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 84' ' ' MET . . . . . 0.463 ' HE1' ' HA ' ' A' ' 109' ' ' VAL . 91.7 mmm -61.64 -23.77 66.28 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.302 -0.863 . . . . 0.0 111.565 -178.183 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.692 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 8.6 pt-20 -56.9 -29.34 62.93 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.842 0.354 . . . . 0.0 111.417 179.692 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.635 HD13 HG11 ' A' ' 75' ' ' VAL . 54.9 mt -79.28 -24.87 12.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-O 121.199 0.523 . . . . 0.0 110.858 -176.227 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 87' ' ' TYR . . . . . 0.476 ' HE2' ' HB2' ' A' ' 82' ' ' PRO . 91.5 m-85 -94.51 -27.67 15.85 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.934 -0.576 . . . . 0.0 111.193 -177.159 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 88' ' ' ARG . . . . . 0.446 ' HG3' ' O ' ' A' ' 84' ' ' MET . 78.1 mtp180 -65.77 131.46 46.37 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.509 0.671 . . . . 0.0 111.454 -176.552 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 93.17 -5.78 75.44 Favored Glycine 0 N--CA 1.448 -0.521 0 CA-C-N 114.798 -1.092 . . . . 0.0 112.36 -179.899 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 90' ' ' ALA . . . . . 1.085 ' HA ' ' HG3' ' A' ' 38' ' ' ARG . . . -73.6 153.39 40.22 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.888 0.375 . . . . 0.0 110.63 179.432 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -93.85 -20.72 19.79 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.807 -179.415 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 92' ' ' LEU . . . . . 0.513 ' HG ' ' HB3' ' A' ' 116' ' ' ARG . 3.7 tt -160.89 142.87 12.33 Favored 'General case' 0 N--CA 1.452 -0.365 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.64 -176.809 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.533 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 66.8 mt -132.31 126.72 56.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 177.188 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 19.7 p90 -137.38 160.78 38.11 Favored 'General case' 0 C--N 1.323 -0.579 0 C-N-CA 120.52 -0.472 . . . . 0.0 111.625 -178.155 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 95' ' ' SER . . . . . 0.484 ' OG ' ' HB ' ' A' ' 42' ' ' VAL . 15.7 m -146.5 140.52 26.25 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.777 -178.565 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 96' ' ' ILE . . . . . 0.426 ' N ' HD12 ' A' ' 96' ' ' ILE . 3.6 mp -99.31 97.1 5.52 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 N-CA-C 110.026 -0.361 . . . . 0.0 110.026 178.728 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 97' ' ' ARG . . . . . 0.644 ' HG2' ' HA ' ' A' ' 121' ' ' PRO . 42.8 mtm105 53.77 77.25 0.45 Allowed Pre-proline 0 N--CA 1.468 0.467 0 CA-C-N 115.413 -0.812 . . . . 0.0 111.825 179.612 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 95.7 Cg_endo -88.46 159.42 6.64 Favored 'Trans proline' 0 N--CA 1.459 -0.514 0 C-N-CA 122.733 2.288 . . . . 0.0 112.417 179.775 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.626 ' HD2' HD11 ' A' ' 102' ' ' ILE . 51.1 Cg_exo -53.85 147.8 40.11 Favored 'Trans proline' 0 C--N 1.348 0.507 0 C-N-CA 122.92 2.414 . . . . 0.0 112.115 175.955 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -66.92 -19.74 65.78 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.712 -173.164 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 101' ' ' GLU . . . . . 0.586 ' HG3' HG23 ' A' ' 102' ' ' ILE . 11.7 pt-20 -73.34 -22.47 60.3 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.881 -177.334 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.626 HD11 ' HD2' ' A' ' 99' ' ' PRO . 44.1 pt -109.31 5.51 9.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 N-CA-C 112.505 0.557 . . . . 0.0 112.505 -174.711 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 103' ' ' HIS . . . . . . . . . . . . . 46.9 m170 -58.33 -45.22 88.51 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 120.998 0.427 . . . . 0.0 110.624 178.812 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 17.6 m -75.35 -27.79 59.33 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.518 177.31 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.511 ' O ' HG23 ' A' ' 109' ' ' VAL . 10.2 m -69.98 -45.15 67.95 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.896 -177.896 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 84.2 mt -56.78 -38.28 72.29 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.037 0.446 . . . . 0.0 110.822 178.717 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 107' ' ' MET . . . . . 0.556 ' SD ' ' HB2' ' A' ' 131' ' ' ARG . 52.0 ttm -68.4 -42.59 78.79 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.473 -178.92 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 108' ' ' ARG . . . . . 0.445 ' HG2' ' HA ' ' A' ' 105' ' ' SER . 2.5 ptm180 -68.71 -29.92 68.46 Favored 'General case' 0 N--CA 1.462 0.137 0 C-N-CA 120.471 -0.492 . . . . 0.0 110.482 179.482 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.511 HG23 ' O ' ' A' ' 105' ' ' SER . 74.5 t -66.12 -47.6 84.28 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.182 0 CA-C-N 116.453 -0.34 . . . . 0.0 110.274 176.165 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -57.74 -43.74 85.59 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.393 177.553 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.418 ' HA ' ' HB1' ' A' ' 148' ' ' ALA . 18.7 t70 -61.83 -40.43 95.24 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.625 -0.716 . . . . 0.0 110.793 179.777 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -69.4 -39.6 77.86 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.551 -0.749 . . . . 0.0 112.059 -177.859 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.462 HG21 HD11 ' A' ' 93' ' ' ILE . 15.8 m -92.39 -27.42 4.7 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 116.552 -0.294 . . . . 0.0 111.709 -174.556 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 114' ' ' GLY . . . . . 0.655 ' HA3' HG22 ' A' ' 150' ' ' VAL . . . 86.47 51.56 3.45 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.827 -0.701 . . . . 0.0 112.535 -179.782 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 115' ' ' ALA . . . . . 0.449 ' O ' ' HB3' ' A' ' 148' ' ' ALA . . . -131.67 165.55 23.46 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.064 0.459 . . . . 0.0 111.162 -178.683 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 116' ' ' ARG . . . . . 0.513 ' HB3' ' HG ' ' A' ' 92' ' ' LEU . 15.3 ttm180 -81.87 128.74 34.35 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.037 176.485 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 117' ' ' LEU . . . . . 0.533 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 49.8 tp -99.18 127.85 45.22 Favored 'General case' 0 C--N 1.32 -0.704 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 177.859 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 72.4 mt -128.25 125.51 64.34 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-O 120.903 0.382 . . . . 0.0 110.591 179.347 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 61.4 mt -130.27 130.45 65.56 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-O 120.811 0.339 . . . . 0.0 110.263 178.051 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 120' ' ' LYS . . . . . 0.716 ' HD2' HD22 ' A' ' 25' ' ' LEU . 49.9 tttm -116.16 94.23 41.4 Favored Pre-proline 0 C--N 1.324 -0.51 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.227 179.176 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 121' ' ' PRO . . . . . 0.644 ' HA ' ' HG2' ' A' ' 97' ' ' ARG . 89.1 Cg_endo -89.98 -159.7 0.09 OUTLIER 'Trans proline' 0 N--CA 1.459 -0.532 0 C-N-CA 122.799 2.333 . . . . 0.0 112.694 178.101 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 122' ' ' LEU . . . . . 0.54 ' HB3' ' HB3' ' A' ' 125' ' ' GLU . 11.9 tp -76.0 164.2 26.4 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.525 -0.762 . . . . 0.0 110.354 177.365 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 11.4 t -72.73 -28.58 62.73 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.008 0.432 . . . . 0.0 110.366 178.854 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -109.34 44.56 1.47 Allowed Glycine 0 N--CA 1.449 -0.469 0 N-CA-C 110.967 -0.853 . . . . 0.0 110.967 177.105 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 125' ' ' GLU . . . . . 0.54 ' HB3' ' HB3' ' A' ' 122' ' ' LEU . 31.8 tt0 -147.72 139.25 23.81 Favored 'General case' 0 C--N 1.321 -0.667 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 -174.539 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 17.2 t70 -118.82 161.7 19.7 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 121.068 0.461 . . . . 0.0 111.076 -178.667 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 60.7 mt -97.42 109.33 23.16 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.717 0 CA-C-N 115.353 -0.839 . . . . 0.0 109.311 177.606 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 17.3 m -83.08 47.7 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-O 121.737 0.779 . . . . 0.0 111.015 -176.108 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 129' ' ' THR . . . . . 0.527 HG21 ' HG3' ' A' ' 133' ' ' MET . 12.1 t -78.08 -179.85 6.38 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 114.868 -1.06 . . . . 0.0 110.722 -178.075 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 7.9 tp10 -79.67 -63.75 1.34 Allowed 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 112.254 0.465 . . . . 0.0 112.254 -169.093 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 131' ' ' ARG . . . . . 0.556 ' HB2' ' SD ' ' A' ' 107' ' ' MET . 94.7 mtt180 -89.26 -2.49 58.49 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.776 -0.193 . . . . 0.0 111.183 -175.469 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 132' ' ' LYS . . . . . 0.414 ' HG2' ' N ' ' A' ' 133' ' ' MET . 0.0 OUTLIER 71.77 147.79 0.08 Allowed 'General case' 0 N--CA 1.465 0.303 0 O-C-N 123.89 0.743 . . . . 0.0 111.898 -178.026 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 133' ' ' MET . . . . . 0.527 ' HG3' HG21 ' A' ' 129' ' ' THR . 90.2 mtp -109.58 160.74 16.0 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.458 -0.792 . . . . 0.0 109.93 -178.759 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 134' ' ' LYS . . . . . 0.413 ' HE3' HG13 ' A' ' 136' ' ' VAL . 0.0 OUTLIER -95.83 142.7 27.78 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.088 0.471 . . . . 0.0 110.793 -176.062 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 135' ' ' LEU . . . . . 0.754 HD11 ' HD2' ' A' ' 142' ' ' TYR . 43.5 tp -75.35 131.35 40.2 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-N 115.45 -0.795 . . . . 0.0 110.317 178.833 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 136' ' ' VAL . . . . . 0.413 HG13 ' HE3' ' A' ' 134' ' ' LYS . 0.0 OUTLIER -128.22 137.73 56.63 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.755 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.542 178.564 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 19.5 m-80 -112.28 106.55 15.14 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 115.652 -0.704 . . . . 0.0 110.105 -179.941 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 138' ' ' TYR . . . . . 0.446 ' CD2' ' HB2' ' A' ' 28' ' ' TYR . 59.8 t80 -148.77 127.62 12.61 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.909 -178.41 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 139' ' ' GLY . . . . . 0.714 ' HA3' ' HB3' ' A' ' 24' ' ' ASP . . . 67.78 57.8 8.41 Favored Glycine 0 N--CA 1.445 -0.745 0 CA-C-N 115.807 -0.633 . . . . 0.0 114.166 171.223 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 140' ' ' ARG . . . . . 0.52 ' HD2' ' N ' ' A' ' 140' ' ' ARG . 2.4 mpt_? 62.6 10.91 4.4 Favored 'General case' 0 N--CA 1.465 0.316 0 C-N-CA 122.692 0.397 . . . . 0.0 112.059 173.84 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 141' ' ' THR . . . . . 0.709 ' HB ' ' HB2' ' A' ' 21' ' ' MET . 10.6 t -145.7 153.01 40.52 Favored 'General case' 0 N--CA 1.447 -0.592 0 CA-C-O 120.973 0.416 . . . . 0.0 110.326 -179.813 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 142' ' ' TYR . . . . . 0.754 ' HD2' HD11 ' A' ' 135' ' ' LEU . 5.0 p90 -122.26 137.73 54.74 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 116.052 -0.522 . . . . 0.0 109.716 174.518 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 143' ' ' PHE . . . . . 0.423 ' O ' HD12 ' A' ' 135' ' ' LEU . 21.4 p90 -145.43 -169.64 3.26 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.466 -0.788 . . . . 0.0 109.796 -174.024 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 83.4 m-85 -117.54 137.27 52.68 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 120.754 0.311 . . . . 0.0 110.932 179.903 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 145' ' ' GLU . . . . . 0.407 ' OE1' ' HD3' ' A' ' 116' ' ' ARG . 15.8 pt-20 -130.36 162.42 29.12 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.157 -0.474 . . . . 0.0 109.731 173.737 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 40.7 t80 -142.38 124.24 15.18 Favored 'General case' 0 C--N 1.317 -0.831 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 174.672 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 147' ' ' ILE . . . . . 0.417 HD12 ' N ' ' A' ' 147' ' ' ILE . 2.7 mp -93.93 98.69 8.49 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.68 0 N-CA-C 109.52 -0.548 . . . . 0.0 109.52 -179.366 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 148' ' ' ALA . . . . . 0.449 ' HB3' ' O ' ' A' ' 115' ' ' ALA . . . -86.89 108.74 18.91 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.625 176.663 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -75.15 166.06 24.24 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 121.136 0.493 . . . . 0.0 110.601 -179.372 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 150' ' ' VAL . . . . . 0.655 HG22 ' HA3' ' A' ' 114' ' ' GLY . 14.6 t -104.01 126.2 58.64 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.878 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 175.851 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 151' ' ' ARG . . . . . . . . . . . . . 48.0 mtp180 -77.07 94.24 3.99 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-O 121.155 0.502 . . . . 0.0 110.525 -178.678 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 12.3 p -101.16 99.42 9.83 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 115.651 -0.704 . . . . 0.0 110.316 178.261 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.247 0.955 0 CA-C-O 118.829 -0.605 . . . . 0.0 109.539 178.488 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 4.2 mpp? . . . . . 0 N--CA 1.481 1.11 0 CA-C-O 120.727 0.299 . . . . 0.0 110.281 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 171.29 46.23 0.04 OUTLIER Glycine 0 N--CA 1.448 -0.538 0 C-N-CA 120.847 -0.692 . . . . 0.0 111.972 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 13.0 m -122.86 10.12 9.51 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.13 0.49 . . . . 0.0 110.425 -179.85 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 14.5 m -97.74 -50.27 4.52 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.914 -0.584 . . . . 0.0 109.907 179.774 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 28.3 m80 -100.38 164.68 11.82 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.694 -0.685 . . . . 0.0 110.071 -178.148 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 22.0 m-70 -108.04 101.79 11.01 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 120.906 0.384 . . . . 0.0 110.745 -179.753 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' HIS . . . . . 0.421 ' CG ' ' H ' ' A' ' 8' ' ' HIS . 35.8 t-80 -160.69 -177.28 6.07 Favored 'General case' 0 C--N 1.325 -0.482 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 179.353 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 8' ' ' HIS . . . . . 0.421 ' H ' ' CG ' ' A' ' 7' ' ' HIS . 56.1 m80 63.92 27.35 14.4 Favored 'General case' 0 N--CA 1.468 0.466 0 C-N-CA 122.796 0.438 . . . . 0.0 111.505 179.061 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 52.7 m80 -73.49 130.35 39.92 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.49 178.079 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' HIS . . . . . 0.415 ' CD2' ' HA3' ' A' ' 73' ' ' GLY . 54.9 p-80 -104.55 164.91 11.42 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.254 0.55 . . . . 0.0 111.012 -178.18 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 17.8 m -114.16 130.64 56.6 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.652 -0.704 . . . . 0.0 109.525 175.453 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 29.5 p -153.37 96.53 2.05 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.984 0.421 . . . . 0.0 111.305 -178.018 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -106.1 82.56 0.33 Allowed Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 120.678 -0.772 . . . . 0.0 112.022 178.499 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 93.1 mt -97.88 169.93 9.31 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 120.756 0.312 . . . . 0.0 110.836 -178.085 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 4.4 p -151.38 104.84 2.93 Favored Pre-proline 0 C--N 1.323 -0.547 0 CA-C-O 121.381 0.61 . . . . 0.0 110.027 177.036 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.478 ' HB2' ' HD1' ' A' ' 49' ' ' TYR . 93.6 Cg_endo -85.85 145.96 9.04 Favored 'Trans proline' 0 N--CA 1.456 -0.687 0 C-N-CA 122.614 2.209 . . . . 0.0 113.128 -177.994 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -127.39 156.38 42.13 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.726 174.051 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 65.94 -161.71 43.53 Favored Glycine 0 N--CA 1.45 -0.43 0 C-N-CA 120.463 -0.875 . . . . 0.0 110.983 -173.932 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 35.1 t 63.07 26.72 15.53 Favored 'General case' 0 CA--C 1.534 0.338 0 CA-C-O 121.105 0.479 . . . . 0.0 110.689 175.67 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 52.5 m80 -63.65 -24.3 67.73 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-N 115.975 -0.557 . . . . 0.0 111.573 -174.717 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' MET . . . . . . . . . . . . . 28.1 ttt -66.68 -20.18 65.92 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 121.166 0.508 . . . . 0.0 110.992 179.712 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' TRP . . . . . 0.404 ' O ' ' HB3' ' A' ' 25' ' ' LEU . 89.3 m95 -88.72 -16.8 31.33 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.974 -0.557 . . . . 0.0 111.057 -179.538 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 21.0 t-20 -52.34 -50.47 62.25 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.889 -178.776 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 11.3 m-20 -60.5 -33.49 72.69 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.476 -0.329 . . . . 0.0 111.42 -178.22 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.567 HD22 ' HG3' ' A' ' 120' ' ' LYS . 50.6 tp -59.17 -50.65 73.21 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.926 0.393 . . . . 0.0 110.28 176.955 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' ALA . . . . . 0.403 ' HB2' HG13 ' A' ' 50' ' ' VAL . . . -58.49 -49.66 76.54 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.639 179.47 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.427 ' O ' ' HG3' ' A' ' 31' ' ' ARG . 86.4 t -52.74 -46.51 50.8 Favored 'Isoleucine or valine' 0 C--O 1.233 0.209 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.949 177.893 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 86.0 t80 -56.29 -46.18 79.88 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.882 179.417 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 71.1 mt -66.78 -43.08 90.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.972 -179.484 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.422 HG12 HG23 ' A' ' 54' ' ' ILE . 88.9 mt -56.4 -48.79 79.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 115.817 -0.628 . . . . 0.0 111.067 179.216 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 31' ' ' ARG . . . . . 0.427 ' HG3' ' O ' ' A' ' 27' ' ' VAL . 61.9 mtp180 -63.25 -36.41 83.58 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.904 -0.589 . . . . 0.0 111.072 -178.808 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 46.6 t -77.29 -25.92 51.83 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.333 -175.338 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 13.7 p -97.03 -76.63 0.51 Allowed 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.785 0.326 . . . . 0.0 111.301 -177.865 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.505 ' O ' HG22 ' A' ' 37' ' ' THR . . . 98.22 167.54 31.54 Favored Glycine 0 N--CA 1.449 -0.452 0 C-N-CA 120.951 -0.642 . . . . 0.0 112.13 -178.601 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 6.7 Cg_exo -73.42 143.54 34.98 Favored 'Trans proline' 0 N--CA 1.462 -0.327 0 C-N-CA 122.878 2.385 . . . . 0.0 112.379 -179.36 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 97.19 -11.29 65.6 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.67 -0.776 . . . . 0.0 113.441 176.218 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' THR . . . . . 0.505 HG22 ' O ' ' A' ' 34' ' ' GLY . 12.6 t -103.52 -179.02 3.83 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 177.501 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 38' ' ' ARG . . . . . 0.681 ' HB2' ' HA ' ' A' ' 90' ' ' ALA . 62.5 mtp180 -115.11 136.63 52.91 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.809 0.338 . . . . 0.0 110.763 -179.227 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.429 HG23 HG21 ' A' ' 60' ' ' VAL . 47.5 t -130.9 138.18 54.16 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 177.913 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.454 HG11 ' CE1' ' A' ' 87' ' ' TYR . 33.4 t -118.95 125.45 74.5 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 CA-C-O 120.837 0.351 . . . . 0.0 111.336 -177.254 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 41' ' ' GLU . . . . . 0.436 ' HB3' HD23 ' A' ' 64' ' ' LEU . 43.4 tt0 -99.57 112.15 24.4 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.954 -0.566 . . . . 0.0 109.645 175.462 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 60.5 t -97.45 121.16 47.69 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-N 116.0 -0.546 . . . . 0.0 110.385 -179.143 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 90.35 46.04 4.19 Favored Glycine 0 N--CA 1.444 -0.795 0 C-N-CA 120.539 -0.839 . . . . 0.0 111.861 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.442 ' HB1' ' CD2' ' A' ' 48' ' ' LEU . . . -59.22 -32.94 70.41 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-O 121.328 0.585 . . . . 0.0 110.932 179.292 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 63.88 -123.57 28.74 Favored Glycine 0 N--CA 1.445 -0.701 0 CA-C-N 115.714 -0.675 . . . . 0.0 112.597 177.104 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 30.5 mmt-85 -122.96 9.77 9.41 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 120.847 0.356 . . . . 0.0 110.498 -177.005 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 19.0 p90 -137.36 113.24 9.69 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 121.289 0.566 . . . . 0.0 110.82 -176.845 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.442 ' CD2' ' HB1' ' A' ' 44' ' ' ALA . 68.8 mt -104.64 60.87 0.7 Allowed 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.56 -177.164 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 49' ' ' TYR . . . . . 0.478 ' HD1' ' HB2' ' A' ' 16' ' ' PRO . 72.1 t80 -75.56 -52.84 9.68 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.938 0.399 . . . . 0.0 110.88 -179.559 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.45 ' O ' HG13 ' A' ' 54' ' ' ILE . 49.1 t -67.87 -52.78 36.15 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-N 115.868 -0.606 . . . . 0.0 110.722 -176.562 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 51' ' ' SER . . . . . 0.529 ' HB3' HD21 ' A' ' 64' ' ' LEU . 0.2 OUTLIER -54.84 -43.15 72.76 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.767 -0.651 . . . . 0.0 112.491 -178.933 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.417 ' O ' ' HG3' ' A' ' 56' ' ' LYS . 20.7 t70 -67.73 -42.96 81.05 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.834 0.349 . . . . 0.0 110.591 -179.104 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 75.9 t80 -63.99 -40.08 95.57 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.153 -179.009 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.45 HG13 ' O ' ' A' ' 50' ' ' VAL . 80.0 mt -63.01 -45.78 97.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.474 -0.33 . . . . 0.0 111.367 -179.709 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 33.2 ptt180 -72.04 -16.84 62.05 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.89 0.376 . . . . 0.0 110.871 -178.785 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 56' ' ' LYS . . . . . 0.417 ' HG3' ' O ' ' A' ' 52' ' ' ASP . 24.2 mtpp -73.08 -30.55 63.75 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.318 176.882 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 28.0 m-70 -102.51 -56.61 2.21 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.891 -177.434 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 6.8 p -100.46 135.4 41.95 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 120.982 0.42 . . . . 0.0 112.057 -174.399 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -81.39 65.05 6.36 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 122.196 0.998 . . . . 0.0 108.969 171.053 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.429 HG21 HG23 ' A' ' 39' ' ' VAL . 8.8 p -100.54 148.54 6.77 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.09 0 CA-C-N 114.322 -1.308 . . . . 0.0 110.111 178.78 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 61' ' ' ASP . . . . . 0.563 ' HB3' ' HG2' ' A' ' 38' ' ' ARG . 9.3 t70 -74.77 84.89 2.16 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 176.773 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 62' ' ' LEU . . . . . 0.425 HD23 ' HB ' ' A' ' 39' ' ' VAL . 3.1 tm? -94.57 116.83 29.24 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 115.441 -0.799 . . . . 0.0 110.287 -173.92 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 60.1 t -113.61 139.09 40.89 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 CA-C-N 115.604 -0.725 . . . . 0.0 110.561 -176.524 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 64' ' ' LEU . . . . . 0.529 HD21 ' HB3' ' A' ' 51' ' ' SER . 31.6 mt -112.37 136.12 52.23 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 110.171 -0.307 . . . . 0.0 110.171 178.735 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 15.9 p -118.81 125.43 49.55 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.102 0.477 . . . . 0.0 110.706 175.366 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 66' ' ' ASP . . . . . 0.478 ' HB3' HG21 ' A' ' 74' ' ' ILE . 23.9 t70 -154.82 140.46 17.98 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.532 -0.758 . . . . 0.0 109.247 -179.853 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.496 HG22 ' HG2' ' A' ' 68' ' ' LYS . 59.3 mt -74.44 124.17 31.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-N 116.519 -0.31 . . . . 0.0 110.315 -177.964 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 68' ' ' LYS . . . . . 0.496 ' HG2' HG22 ' A' ' 67' ' ' ILE . 59.8 pttt 39.72 69.72 1.66 Allowed Pre-proline 0 N--CA 1.469 0.499 0 O-C-N 124.29 0.994 . . . . 0.0 111.684 -174.296 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 69' ' ' PRO . . . . . 0.561 ' CB ' ' HB ' ' A' ' 74' ' ' ILE . 44.1 Cg_endo -67.64 141.88 56.56 Favored 'Trans proline' 0 C--O 1.232 0.218 0 C-N-CA 122.856 2.371 . . . . 0.0 113.017 -174.345 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 11.7 t -88.37 -16.19 33.6 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.27 -178.874 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 93.1 m-70 -80.52 -12.29 59.55 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.883 -179.604 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 80.98 -53.1 4.58 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 121.039 -0.601 . . . . 0.0 113.419 175.926 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.415 ' HA3' ' CD2' ' A' ' 10' ' ' HIS . . . -76.21 -10.26 85.43 Favored Glycine 0 C--O 1.228 -0.259 0 C-N-CA 121.348 -0.453 . . . . 0.0 113.585 -175.957 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.561 ' HB ' ' CB ' ' A' ' 69' ' ' PRO . 55.3 mt -75.3 142.3 14.73 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 N-CA-C 109.713 -0.477 . . . . 0.0 109.713 177.254 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.555 HG11 HD13 ' A' ' 86' ' ' ILE . 66.3 t -66.27 123.72 19.85 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-O 120.884 0.374 . . . . 0.0 110.266 -179.344 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 18.7 ptp180 -85.9 48.61 1.63 Allowed 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.44 0.638 . . . . 0.0 110.695 -176.251 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 77' ' ' ASP . . . . . 0.43 ' HB2' HG12 ' A' ' 75' ' ' VAL . 2.7 t70 -89.17 -154.56 0.31 Allowed 'General case' 0 C--N 1.321 -0.641 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 179.214 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 78' ' ' ASP . . . . . 0.521 ' OD1' HG22 ' A' ' 80' ' ' THR . 4.9 t70 -136.25 -176.42 4.32 Favored 'General case' 0 C--N 1.321 -0.633 0 C-N-CA 120.737 -0.385 . . . . 0.0 110.251 -178.916 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 8.9 tp -127.37 -28.18 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-O 120.822 0.344 . . . . 0.0 110.502 179.71 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.521 HG22 ' OD1' ' A' ' 78' ' ' ASP . 15.0 t -89.06 -25.75 21.77 Favored 'General case' 0 N--CA 1.451 -0.387 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 177.006 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 34.2 t -135.34 70.5 67.91 Favored Pre-proline 0 C--N 1.326 -0.442 0 CA-C-N 115.33 -0.85 . . . . 0.0 108.997 170.822 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_endo -87.32 157.01 8.11 Favored 'Trans proline' 0 N--CA 1.453 -0.909 0 C-N-CA 122.496 2.131 . . . . 0.0 112.518 -176.146 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 83' ' ' ARG . . . . . 0.765 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 50.0 mtt180 -89.12 111.92 22.79 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.199 173.058 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 84' ' ' MET . . . . . 0.523 ' HE1' ' HA ' ' A' ' 109' ' ' VAL . 95.2 mmm -66.83 -17.65 64.99 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.5 -177.62 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.765 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 9.9 pt-20 -62.35 -23.35 66.74 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.628 -0.714 . . . . 0.0 111.508 179.078 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.555 HD13 HG11 ' A' ' 75' ' ' VAL . 67.3 mt -84.36 -39.54 14.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-O 121.117 0.484 . . . . 0.0 110.363 179.724 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 87' ' ' TYR . . . . . 0.454 ' CE1' HG11 ' A' ' 40' ' ' VAL . 90.7 m-85 -78.86 -32.19 45.9 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.756 -0.657 . . . . 0.0 111.322 -177.881 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 88' ' ' ARG . . . . . 0.438 ' HG3' HG12 ' A' ' 113' ' ' VAL . 57.9 mtt180 -67.01 115.33 6.6 Favored 'General case' 0 CA--C 1.516 -0.339 0 CA-C-O 121.317 0.58 . . . . 0.0 110.633 -179.933 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 119.44 -12.05 11.23 Favored Glycine 0 N--CA 1.448 -0.522 0 CA-C-N 115.037 -0.983 . . . . 0.0 111.455 -175.213 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 90' ' ' ALA . . . . . 0.681 ' HA ' ' HB2' ' A' ' 38' ' ' ARG . . . -82.94 147.74 28.06 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.881 0.372 . . . . 0.0 110.898 178.346 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -96.73 -22.26 17.09 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.811 179.529 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 92' ' ' LEU . . . . . 0.462 ' HG ' ' HB3' ' A' ' 116' ' ' ARG . 5.3 tt -150.85 139.79 20.95 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.682 -178.442 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.569 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 67.5 mt -131.57 125.37 56.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.688 -0.687 . . . . 0.0 109.258 178.69 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 19.0 p90 -128.42 155.48 44.69 Favored 'General case' 0 C--N 1.321 -0.645 0 C-N-CA 120.618 -0.433 . . . . 0.0 110.965 -178.961 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 18.3 m -132.74 130.41 39.94 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.554 -178.436 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 65.4 mt -93.55 103.14 14.37 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.682 -178.894 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 70.6 mtp180 54.38 67.36 3.45 Favored Pre-proline 0 N--CA 1.466 0.329 0 CA-C-N 115.489 -0.778 . . . . 0.0 111.998 -178.517 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 98' ' ' PRO . . . . . 0.447 ' HA ' ' HD3' ' A' ' 99' ' ' PRO . 72.5 Cg_endo -76.91 140.58 20.53 Favored 'Trans proline' 0 N--CA 1.461 -0.402 0 C-N-CA 122.244 1.963 . . . . 0.0 112.251 179.615 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.626 ' HD2' HD11 ' A' ' 102' ' ' ILE . 38.1 Cg_exo -60.2 147.56 93.01 Favored 'Trans proline' 0 C--O 1.235 0.331 0 C-N-CA 122.741 2.294 . . . . 0.0 111.942 176.606 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.64 ' HA ' ' NE2' ' A' ' 103' ' ' HIS . . . -78.54 31.15 0.19 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.227 0.537 . . . . 0.0 111.331 -175.542 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 101' ' ' GLU . . . . . 0.565 ' HG2' ' HB2' ' A' ' 99' ' ' PRO . 7.7 pt-20 -127.55 -1.63 6.16 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-N 115.967 -0.561 . . . . 0.0 111.164 -176.908 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.626 HD11 ' HD2' ' A' ' 99' ' ' PRO . 30.9 pt -131.41 10.33 1.83 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 N-CA-C 112.118 0.414 . . . . 0.0 112.118 -178.308 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 103' ' ' HIS . . . . . 0.64 ' NE2' ' HA ' ' A' ' 100' ' ' ALA . 9.7 m-70 -54.77 -51.65 65.06 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.244 -0.435 . . . . 0.0 112.006 -176.738 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 15.5 m -62.54 -32.49 73.44 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.498 -0.319 . . . . 0.0 111.007 -177.939 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.592 ' O ' HG23 ' A' ' 109' ' ' VAL . 21.0 m -67.45 -42.3 83.32 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.329 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 73.9 mt -64.78 -43.96 91.54 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.493 179.56 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 107' ' ' MET . . . . . 0.4 ' HG3' ' O ' ' A' ' 103' ' ' HIS . 77.0 mtp -63.18 -41.8 99.27 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.55 -176.244 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 2.9 ptp180 -70.27 -30.78 67.89 Favored 'General case' 0 C--N 1.332 -0.189 0 C-N-CA 120.879 -0.329 . . . . 0.0 111.145 -178.497 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.592 HG23 ' O ' ' A' ' 105' ' ' SER . 75.3 t -63.87 -45.2 97.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.889 0.376 . . . . 0.0 110.062 177.466 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -58.42 -44.4 89.07 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.619 177.71 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.455 ' HA ' ' HB1' ' A' ' 148' ' ' ALA . 13.6 t70 -64.84 -42.48 94.88 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.059 179.586 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -64.8 -41.74 95.56 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.712 -0.676 . . . . 0.0 112.055 -177.488 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.438 HG12 ' HG3' ' A' ' 88' ' ' ARG . 12.2 m -92.57 -24.78 5.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 CA-C-N 116.506 -0.315 . . . . 0.0 111.694 -174.983 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 88.43 49.33 3.71 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.764 -0.731 . . . . 0.0 111.997 179.731 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -129.07 156.5 43.76 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 120.738 0.304 . . . . 0.0 111.142 -177.689 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 116' ' ' ARG . . . . . 0.534 ' HD3' ' OE1' ' A' ' 145' ' ' GLU . 16.4 ttm180 -80.26 125.16 29.52 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.158 -0.474 . . . . 0.0 109.728 177.549 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 117' ' ' LEU . . . . . 0.569 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 48.7 tp -94.47 119.31 32.99 Favored 'General case' 0 C--N 1.322 -0.619 0 N-CA-C 110.158 -0.312 . . . . 0.0 110.158 179.815 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 63.9 mt -114.91 117.97 57.31 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-O 121.183 0.516 . . . . 0.0 110.732 179.398 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 64.6 mt -112.03 132.22 61.28 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 115.923 -0.581 . . . . 0.0 110.564 179.829 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 120' ' ' LYS . . . . . 0.953 ' HD2' ' HB3' ' A' ' 143' ' ' PHE . 23.1 mmmt -102.58 99.97 14.8 Favored Pre-proline 0 C--N 1.328 -0.347 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.229 174.419 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 121' ' ' PRO . . . . . 0.425 ' HG3' ' HD2' ' A' ' 144' ' ' TYR . 88.4 Cg_endo -82.78 -158.95 0.1 OUTLIER 'Trans proline' 0 N--CA 1.459 -0.535 0 C-N-CA 122.563 2.175 . . . . 0.0 111.351 171.861 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 122' ' ' LEU . . . . . 0.829 ' HB2' ' HB2' ' A' ' 125' ' ' GLU . 3.6 mm? -99.88 -171.04 1.98 Allowed 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 110.267 -0.272 . . . . 0.0 110.267 179.916 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 8.7 t -88.76 -35.11 16.85 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.708 0.289 . . . . 0.0 111.19 -176.719 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -114.78 12.61 20.48 Favored Glycine 0 N--CA 1.449 -0.499 0 C-N-CA 120.436 -0.887 . . . . 0.0 111.296 178.53 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 125' ' ' GLU . . . . . 0.829 ' HB2' ' HB2' ' A' ' 122' ' ' LEU . 28.2 mt-10 -131.52 126.52 35.12 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.248 -0.476 . . . . 0.0 110.075 -176.342 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 11.3 t70 -87.01 179.28 6.71 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.679 -0.692 . . . . 0.0 109.885 -177.504 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.58 HD11 ' HB2' ' A' ' 144' ' ' TYR . 56.5 mt -71.64 -33.72 49.92 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 178.799 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 55.6 t 68.71 79.53 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.333 -0.148 0 CA-C-N 115.313 -0.858 . . . . 0.0 109.582 -174.991 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 13.2 t -165.65 -168.95 1.43 Allowed 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.438 -0.801 . . . . 0.0 109.635 -176.514 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -73.92 148.86 41.84 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 110.01 -0.367 . . . . 0.0 110.01 179.452 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 131' ' ' ARG . . . . . 0.405 ' HD3' HH11 ' A' ' 131' ' ' ARG . 10.0 mmm180 -79.24 63.63 3.93 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.222 0.534 . . . . 0.0 110.881 -177.699 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 33.5 mttp -117.36 -1.25 11.8 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.03 179.92 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 133' ' ' MET . . . . . 0.55 ' HG2' ' HB2' ' A' ' 146' ' ' TYR . 84.8 mtp -111.14 165.63 11.74 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.857 -0.611 . . . . 0.0 109.405 176.144 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 134' ' ' LYS . . . . . 0.408 ' HE3' ' OE2' ' A' ' 145' ' ' GLU . 6.9 pttp -130.51 140.23 50.5 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.09 0.472 . . . . 0.0 111.754 -175.974 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 135' ' ' LEU . . . . . 0.57 HD11 ' HD2' ' A' ' 142' ' ' TYR . 39.2 tp -76.93 122.36 24.76 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.585 -0.734 . . . . 0.0 110.777 -179.645 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 136' ' ' VAL . . . . . 0.433 HG23 ' CD1' ' A' ' 143' ' ' PHE . 0.0 OUTLIER -117.95 142.25 33.23 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.761 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.437 178.426 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 137' ' ' ASN . . . . . 0.441 ' OD1' ' HB3' ' A' ' 142' ' ' TYR . 15.6 m-80 -117.9 110.32 17.6 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.442 -176.022 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 138' ' ' TYR . . . . . 0.436 ' O ' HG22 ' A' ' 141' ' ' THR . 76.0 t80 -135.23 130.09 34.69 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.248 -0.433 . . . . 0.0 109.877 -179.434 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 63.75 26.36 69.87 Favored Glycine 0 N--CA 1.453 -0.217 0 C-N-CA 120.54 -0.838 . . . . 0.0 111.702 -176.784 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 21.2 mtp180 66.67 7.69 5.34 Favored 'General case' 0 C--N 1.33 -0.274 0 C-N-CA 123.304 0.641 . . . . 0.0 112.436 -178.731 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 141' ' ' THR . . . . . 0.436 HG22 ' O ' ' A' ' 138' ' ' TYR . 10.8 t -107.48 139.71 41.57 Favored 'General case' 0 N--CA 1.446 -0.659 0 N-CA-C 108.663 -0.866 . . . . 0.0 108.663 169.84 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 142' ' ' TYR . . . . . 0.57 ' HD2' HD11 ' A' ' 135' ' ' LEU . 17.0 p90 -113.86 149.08 35.59 Favored 'General case' 0 C--N 1.315 -0.892 0 CA-C-O 121.69 0.757 . . . . 0.0 111.513 -177.581 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 143' ' ' PHE . . . . . 0.953 ' HB3' ' HD2' ' A' ' 120' ' ' LYS . 3.5 p90 -151.41 178.96 8.76 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 114.238 -1.347 . . . . 0.0 108.83 -178.98 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 144' ' ' TYR . . . . . 0.58 ' HB2' HD11 ' A' ' 127' ' ' ILE . 80.6 m-85 -115.58 119.72 37.06 Favored 'General case' 0 C--N 1.313 -0.98 0 C-N-CA 120.62 -0.432 . . . . 0.0 110.529 179.82 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 145' ' ' GLU . . . . . 0.534 ' OE1' ' HD3' ' A' ' 116' ' ' ARG . 18.3 pt-20 -108.15 156.96 18.73 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 176.2 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 146' ' ' TYR . . . . . 0.55 ' HB2' ' HG2' ' A' ' 133' ' ' MET . 22.7 t80 -137.13 120.68 17.17 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-N 115.626 -0.715 . . . . 0.0 109.66 176.647 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 147' ' ' ILE . . . . . 0.434 ' N ' HD12 ' A' ' 147' ' ' ILE . 3.2 mp -89.05 101.5 12.05 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 -178.481 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 148' ' ' ALA . . . . . 0.455 ' HB1' ' HA ' ' A' ' 111' ' ' ASP . . . -74.37 96.43 2.86 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 121.225 0.536 . . . . 0.0 109.76 177.19 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 11.6 pt-20 -75.54 164.67 26.1 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-N 115.155 -0.93 . . . . 0.0 109.752 178.89 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 34.5 t -68.18 127.58 30.15 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 N-CA-C 109.248 -0.649 . . . . 0.0 109.248 177.846 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 151' ' ' ARG . . . . . 0.406 HH11 ' HD2' ' A' ' 151' ' ' ARG . 13.6 ptt180 -81.44 66.93 7.2 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-O 121.691 0.757 . . . . 0.0 110.633 -176.597 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 10.8 t -164.7 -176.28 4.2 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 114.912 -1.04 . . . . 0.0 108.918 179.008 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.247 0.933 0 CA-C-O 118.503 -0.761 . . . . 0.0 109.714 178.847 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.402 ' HG3' ' O ' ' A' ' 1' ' ' MET . 23.9 ptt? . . . . . 0 N--CA 1.479 1.002 0 CA-C-O 121.498 0.666 . . . . 0.0 110.545 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 157.36 135.22 1.88 Allowed Glycine 0 N--CA 1.444 -0.829 0 CA-C-N 115.556 -0.747 . . . . 0.0 111.479 179.687 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 27.6 m -66.63 98.0 0.48 Allowed 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.301 0.572 . . . . 0.0 111.025 -177.353 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 15.5 m -94.32 53.0 1.64 Allowed 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.73 -0.668 . . . . 0.0 109.322 178.412 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 8.5 p80 -74.16 162.98 28.41 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.243 -0.889 . . . . 0.0 111.084 -175.238 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 27.1 m-70 -98.36 118.78 35.8 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.91 -0.587 . . . . 0.0 110.517 -179.624 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 70.3 m80 -69.13 -28.83 66.81 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 121.396 0.617 . . . . 0.0 109.388 175.016 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 26.9 m-70 -116.03 115.53 26.29 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.226 -0.897 . . . . 0.0 109.61 173.718 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 74.9 t60 -71.28 -33.82 70.1 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 107.845 -1.168 . . . . 0.0 107.845 173.094 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 32.1 p-80 -129.85 122.48 28.78 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 114.457 -1.247 . . . . 0.0 108.427 169.303 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 10.7 t -66.64 98.6 0.53 Allowed 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.098 0.475 . . . . 0.0 110.748 -177.265 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 33.6 t -128.95 132.35 47.6 Favored 'General case' 0 N--CA 1.45 -0.445 0 CA-C-N 115.724 -0.671 . . . . 0.0 110.081 -179.015 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 153.5 -177.31 31.12 Favored Glycine 0 N--CA 1.446 -0.691 0 C-N-CA 121.028 -0.606 . . . . 0.0 111.916 -179.813 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' LEU . . . . . 0.72 HD23 ' H ' ' A' ' 14' ' ' LEU . 2.4 pt? -112.37 147.34 36.6 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 110.238 -0.282 . . . . 0.0 110.238 179.241 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 16.3 m -93.21 114.58 63.18 Favored Pre-proline 0 C--N 1.326 -0.455 0 CA-C-O 121.112 0.482 . . . . 0.0 110.563 178.13 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 89.5 Cg_endo -80.07 166.77 20.58 Favored 'Trans proline' 0 N--CA 1.459 -0.54 0 C-N-CA 122.62 2.213 . . . . 0.0 112.406 -179.173 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 23.0 mmt180 -87.13 -15.35 38.68 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.926 178.21 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 72.88 35.64 58.11 Favored Glycine 0 N--CA 1.448 -0.534 0 C-N-CA 120.75 -0.738 . . . . 0.0 111.941 179.847 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 12.7 p -83.61 108.26 16.59 Favored 'General case' 0 N--CA 1.447 -0.601 0 CA-C-O 121.307 0.575 . . . . 0.0 110.495 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' HIS . . . . . 0.538 ' HB3' ' CD1' ' A' ' 22' ' ' TRP . 19.5 t-80 -164.35 -152.26 0.18 Allowed 'General case' 0 C--N 1.32 -0.68 0 N-CA-C 107.302 -1.37 . . . . 0.0 107.302 -176.322 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' MET . . . . . 0.568 ' HB3' ' HB ' ' A' ' 141' ' ' THR . 0.0 OUTLIER -56.87 -14.68 3.68 Favored 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 112.212 0.449 . . . . 0.0 112.212 178.06 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 22' ' ' TRP . . . . . 0.538 ' CD1' ' HB3' ' A' ' 20' ' ' HIS . 40.2 m95 -54.63 -33.35 60.44 Favored 'General case' 0 N--CA 1.461 0.122 0 CA-C-O 121.033 0.444 . . . . 0.0 110.533 175.321 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 25.5 t-20 -65.18 -45.55 84.39 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.553 -0.749 . . . . 0.0 110.28 -178.024 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -57.24 -46.29 83.13 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.679 -0.691 . . . . 0.0 110.255 177.953 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 62.2 tp -61.52 -46.96 87.74 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.238 -0.892 . . . . 0.0 110.958 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' ALA . . . . . 0.487 ' O ' HG13 ' A' ' 30' ' ' ILE . . . -56.19 -52.47 64.28 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.164 -179.742 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.448 ' HA ' HD12 ' A' ' 30' ' ' ILE . 84.0 t -56.12 -42.25 71.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.206 179.131 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 57.4 t80 -57.41 -45.99 83.98 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.574 179.733 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 67.0 mt -67.28 -40.23 84.48 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.785 179.783 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.576 HG12 HG23 ' A' ' 54' ' ' ILE . 95.4 mt -58.85 -38.42 72.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 115.969 -0.56 . . . . 0.0 111.125 179.401 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 40.1 mtp-105 -71.99 -30.32 65.13 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.839 -0.619 . . . . 0.0 111.332 -178.855 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 42.9 t -89.2 -17.41 29.17 Favored 'General case' 0 C--N 1.324 -0.513 0 N-CA-C 111.956 0.354 . . . . 0.0 111.956 -176.489 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 11.5 p -94.68 -79.17 0.43 Allowed 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 111.961 0.356 . . . . 0.0 111.961 -176.086 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.48 ' O ' HG22 ' A' ' 37' ' ' THR . . . 101.16 136.73 9.45 Favored Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.812 -0.709 . . . . 0.0 111.847 -176.698 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 35' ' ' PRO . . . . . 0.411 ' HD3' ' HA2' ' A' ' 34' ' ' GLY . 48.4 Cg_exo -55.84 126.48 22.55 Favored 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 123.076 2.518 . . . . 0.0 112.767 -176.066 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 112.73 -18.51 22.21 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.294 -0.955 . . . . 0.0 113.48 175.278 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' THR . . . . . 0.48 HG22 ' O ' ' A' ' 34' ' ' GLY . 11.1 t -86.76 -173.6 4.56 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.995 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 38' ' ' ARG . . . . . 0.505 ' HG2' ' CB ' ' A' ' 61' ' ' ASP . 92.1 mtm-85 -118.45 135.2 54.5 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 120.932 0.396 . . . . 0.0 110.735 176.634 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.497 HG23 HG11 ' A' ' 60' ' ' VAL . 90.7 t -130.19 127.44 63.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 176.904 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.433 HG11 ' CE1' ' A' ' 87' ' ' TYR . 35.4 t -109.06 128.79 64.67 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-O 120.937 0.399 . . . . 0.0 111.915 -173.02 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 41' ' ' GLU . . . . . 0.723 ' HB3' HD23 ' A' ' 64' ' ' LEU . 6.3 tp10 -103.3 127.92 50.5 Favored 'General case' 0 C--O 1.237 0.416 0 CA-C-N 115.379 -0.828 . . . . 0.0 109.452 174.092 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.567 ' HB ' ' HB3' ' A' ' 95' ' ' SER . 35.2 t -106.05 98.91 7.49 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-O 120.974 0.416 . . . . 0.0 110.535 -179.178 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 101.08 84.8 1.83 Allowed Glycine 0 N--CA 1.451 -0.333 0 N-CA-C 111.471 -0.651 . . . . 0.0 111.471 -176.778 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.448 ' HB1' HD21 ' A' ' 48' ' ' LEU . . . -83.07 -40.83 19.35 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 112.106 0.41 . . . . 0.0 112.106 -172.107 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 57.3 -127.55 45.19 Favored Glycine 0 CA--C 1.521 0.447 0 C-N-CA 121.077 -0.582 . . . . 0.0 112.713 179.824 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 52.4 mtp180 -120.42 2.49 10.77 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.866 0.365 . . . . 0.0 111.21 179.071 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.566 ' CE1' ' HB ' ' A' ' 96' ' ' ILE . 6.3 p90 -96.85 58.29 1.61 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.379 0.609 . . . . 0.0 111.088 -176.166 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.448 HD21 ' HB1' ' A' ' 44' ' ' ALA . 83.8 mt -81.68 8.43 9.92 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.79 -0.641 . . . . 0.0 112.12 -174.425 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 75.7 t80 -57.95 -48.75 79.04 Favored 'General case' 0 N--CA 1.463 0.201 0 CA-C-O 120.589 0.233 . . . . 0.0 111.195 -179.802 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.45 ' O ' HG13 ' A' ' 54' ' ' ILE . 85.3 t -58.96 -51.73 69.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.892 -178.398 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 51' ' ' SER . . . . . 0.503 ' CB ' HD21 ' A' ' 64' ' ' LEU . 3.9 p -69.79 -25.76 63.94 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.004 -0.544 . . . . 0.0 112.346 -174.418 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.522 ' O ' ' HG2' ' A' ' 55' ' ' ARG . 17.5 t70 -83.06 -41.46 18.6 Favored 'General case' 0 C--N 1.325 -0.462 0 C-N-CA 120.806 -0.358 . . . . 0.0 110.3 177.232 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 66.4 t80 -58.16 -43.75 87.55 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.545 178.839 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.576 HG23 HG12 ' A' ' 30' ' ' ILE . 89.0 mt -60.2 -47.6 91.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.192 178.326 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 55' ' ' ARG . . . . . 0.522 ' HG2' ' O ' ' A' ' 52' ' ' ASP . 7.9 ptp180 -71.98 -16.31 62.08 Favored 'General case' 0 CA--C 1.532 0.27 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.381 -174.725 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 44.2 mmtm -77.1 -37.57 54.03 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.839 0.352 . . . . 0.0 110.569 176.316 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 13.3 m-70 -83.79 -55.32 4.32 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.67 179.694 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 68.0 m -117.13 127.97 54.66 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.169 -179.025 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 1.3 mptm? -77.5 63.36 2.63 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-O 121.925 0.869 . . . . 0.0 110.475 176.712 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.497 HG11 HG23 ' A' ' 39' ' ' VAL . 66.1 t -82.84 142.35 13.7 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.922 0 CA-C-N 114.444 -1.253 . . . . 0.0 109.09 173.888 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 61' ' ' ASP . . . . . 0.505 ' CB ' ' HG2' ' A' ' 38' ' ' ARG . 0.3 OUTLIER -73.19 80.08 1.29 Allowed 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.3 0.571 . . . . 0.0 109.5 175.27 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 62' ' ' LEU . . . . . 0.402 ' HA ' ' O ' ' A' ' 39' ' ' VAL . 3.1 tt -84.08 114.88 22.07 Favored 'General case' 0 N--CA 1.444 -0.755 0 CA-C-N 115.598 -0.728 . . . . 0.0 109.378 -178.074 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.401 HG11 ' CG2' ' A' ' 86' ' ' ILE . 58.2 t -99.28 119.52 47.4 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.706 0 CA-C-N 115.296 -0.865 . . . . 0.0 110.229 -177.381 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 64' ' ' LEU . . . . . 0.723 HD23 ' HB3' ' A' ' 41' ' ' GLU . 65.8 mt -98.3 131.37 44.67 Favored 'General case' 0 C--N 1.316 -0.87 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 176.964 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.41 ' OG1' ' HA ' ' A' ' 42' ' ' VAL . 36.2 p -116.87 130.56 56.79 Favored 'General case' 0 C--N 1.318 -0.799 0 N-CA-C 109.973 -0.38 . . . . 0.0 109.973 177.021 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 5.8 t70 -157.56 161.93 38.78 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 -178.72 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.698 HD11 HG22 ' A' ' 79' ' ' ILE . 48.7 mm -76.63 95.37 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-O 120.835 0.35 . . . . 0.0 110.145 -177.716 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 56.8 mtpt 50.36 70.29 2.12 Favored Pre-proline 0 CA--C 1.535 0.373 0 CA-C-N 115.192 -0.913 . . . . 0.0 111.68 177.437 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 69' ' ' PRO . . . . . 0.676 ' HD2' ' HG2' ' A' ' 76' ' ' ARG . 37.0 Cg_endo -64.76 155.61 66.32 Favored 'Trans proline' 0 C--N 1.345 0.361 0 C-N-CA 123.455 2.77 . . . . 0.0 112.865 -179.121 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 11.4 p -89.52 -34.37 16.42 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.705 -0.679 . . . . 0.0 110.742 177.792 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 88.8 m-70 -81.09 131.27 35.29 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.376 -177.902 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -68.46 128.05 24.08 Favored Glycine 0 N--CA 1.449 -0.473 0 CA-C-N 115.763 -0.653 . . . . 0.0 111.483 176.121 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 127.22 -23.36 5.5 Favored Glycine 0 N--CA 1.447 -0.614 0 N-CA-C 111.248 -0.741 . . . . 0.0 111.248 -176.632 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.452 HG23 ' CB ' ' A' ' 64' ' ' LEU . 41.0 mt -93.83 136.62 24.89 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 109.606 -0.516 . . . . 0.0 109.606 176.64 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.526 HG12 ' H ' ' A' ' 77' ' ' ASP . 64.3 t -74.12 135.32 27.73 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-O 120.866 0.365 . . . . 0.0 110.029 179.95 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 76' ' ' ARG . . . . . 0.676 ' HG2' ' HD2' ' A' ' 69' ' ' PRO . 26.6 mtp85 -89.74 21.03 3.71 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.907 -0.588 . . . . 0.0 111.856 -174.096 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 77' ' ' ASP . . . . . 0.526 ' H ' HG12 ' A' ' 75' ' ' VAL . 1.1 m-20 -80.19 160.62 25.57 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.785 0.326 . . . . 0.0 110.843 -179.396 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 78' ' ' ASP . . . . . 0.406 ' HB3' ' O ' ' A' ' 81' ' ' SER . 11.0 t70 -75.22 152.93 38.29 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.934 -173.789 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 79' ' ' ILE . . . . . 0.698 HG22 HD11 ' A' ' 67' ' ' ILE . 12.4 tt -91.15 -31.42 5.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.883 -175.475 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 11.1 t -99.73 -24.47 14.69 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.291 0.567 . . . . 0.0 109.98 -177.184 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 81' ' ' SER . . . . . 0.406 ' O ' ' HB3' ' A' ' 78' ' ' ASP . 27.9 m -126.6 74.66 74.74 Favored Pre-proline 0 C--N 1.328 -0.362 0 CA-C-N 115.942 -0.572 . . . . 0.0 109.876 172.472 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 98.1 Cg_endo -90.93 -162.27 0.11 Allowed 'Trans proline' 0 N--CA 1.459 -0.541 0 C-N-CA 123.379 2.72 . . . . 0.0 113.219 -174.071 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 94.8 mtt180 -126.2 116.45 21.33 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.348 178.319 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 84' ' ' MET . . . . . 0.835 ' HA ' ' HD2' ' A' ' 87' ' ' TYR . 25.3 mtp -66.14 -18.5 65.39 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 112.252 0.464 . . . . 0.0 112.252 -177.259 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.417 ' HA ' ' HD3' ' A' ' 88' ' ' ARG . 10.8 pt-20 -65.63 -25.78 67.52 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.094 0.473 . . . . 0.0 110.406 179.335 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.401 ' CG2' HG11 ' A' ' 63' ' ' VAL . 68.3 mt -73.54 -36.74 48.55 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 115.77 -0.65 . . . . 0.0 109.922 177.06 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 87' ' ' TYR . . . . . 0.835 ' HD2' ' HA ' ' A' ' 84' ' ' MET . 74.2 m-85 -77.92 -30.56 50.65 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.633 -0.712 . . . . 0.0 110.754 -178.242 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 88' ' ' ARG . . . . . 0.417 ' HD3' ' HA ' ' A' ' 85' ' ' GLU . 69.9 mtp180 -58.17 125.25 22.39 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.964 178.81 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 89' ' ' GLY . . . . . 0.494 ' HA3' ' NH2' ' A' ' 38' ' ' ARG . . . 97.71 -8.68 63.88 Favored Glycine 0 N--CA 1.447 -0.605 0 C-N-CA 120.821 -0.704 . . . . 0.0 112.45 179.016 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -74.82 142.63 44.19 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 120.777 0.322 . . . . 0.0 110.373 178.277 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -94.39 -18.02 21.96 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.513 179.333 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 92' ' ' LEU . . . . . 0.417 HD23 ' N ' ' A' ' 93' ' ' ILE . 3.6 tt -153.72 140.05 18.59 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.337 -179.154 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.574 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 71.6 mt -132.24 126.17 55.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 N-CA-C 109.032 -0.729 . . . . 0.0 109.032 178.139 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 94' ' ' TYR . . . . . 0.409 ' HE1' HG12 ' A' ' 39' ' ' VAL . 2.0 p90 -135.29 167.18 21.5 Favored 'General case' 0 C--N 1.32 -0.699 0 C-N-CA 120.663 -0.415 . . . . 0.0 110.535 -178.258 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 95' ' ' SER . . . . . 0.633 ' HA ' ' OE1' ' A' ' 41' ' ' GLU . 4.8 p -153.93 120.32 5.47 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.632 -178.447 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 96' ' ' ILE . . . . . 0.566 ' HB ' ' CE1' ' A' ' 47' ' ' PHE . 46.8 mm -80.81 97.23 3.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.684 179.374 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 2.2 tmt_? 52.66 76.91 0.48 Allowed Pre-proline 0 CA--C 1.534 0.353 0 CA-C-N 114.997 -1.001 . . . . 0.0 111.393 177.921 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 69.1 Cg_endo -89.85 161.99 5.06 Favored 'Trans proline' 0 N--CA 1.457 -0.655 0 C-N-CA 122.856 2.371 . . . . 0.0 112.343 177.589 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.438 ' HB2' ' HG2' ' A' ' 101' ' ' GLU . 14.6 Cg_endo -60.12 147.64 92.51 Favored 'Trans proline' 0 C--N 1.345 0.367 0 C-N-CA 122.275 1.983 . . . . 0.0 111.858 174.64 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -78.13 33.55 0.19 Allowed 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.928 -176.34 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 101' ' ' GLU . . . . . 0.663 ' HG3' HG23 ' A' ' 102' ' ' ILE . 9.7 pt-20 -116.09 -23.35 8.52 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.685 0.278 . . . . 0.0 110.712 176.549 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.663 HG23 ' HG3' ' A' ' 101' ' ' GLU . 30.1 pt -109.83 -0.26 9.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 N-CA-C 112.006 0.373 . . . . 0.0 112.006 -174.667 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 103' ' ' HIS . . . . . 0.446 ' CD2' ' H ' ' A' ' 103' ' ' HIS . 5.7 p80 -60.66 -43.4 97.67 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 121.093 0.473 . . . . 0.0 110.817 -178.228 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 4.0 p -73.78 -29.41 62.17 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.987 -0.552 . . . . 0.0 110.742 179.094 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.492 ' O ' HG23 ' A' ' 109' ' ' VAL . 2.4 m -71.49 -45.47 62.39 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.224 -179.555 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.408 ' HG ' ' O ' ' A' ' 102' ' ' ILE . 74.5 mt -60.91 -39.77 90.61 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.229 -179.846 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 107' ' ' MET . . . . . 0.457 ' HA ' HD22 ' A' ' 117' ' ' LEU . 51.7 ttm -60.45 -45.61 93.06 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.49 -179.23 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 108' ' ' ARG . . . . . 0.467 ' HG2' ' O ' ' A' ' 105' ' ' SER . 15.1 ptm180 -74.21 -24.1 59.29 Favored 'General case' 0 C--N 1.327 -0.409 0 C-N-CA 120.978 -0.289 . . . . 0.0 110.89 -177.384 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.492 HG23 ' O ' ' A' ' 105' ' ' SER . 81.1 t -72.34 -43.61 64.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 173.954 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -58.24 -42.2 85.85 Favored 'General case' 0 CA--C 1.52 -0.197 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.551 177.926 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.784 ' HA ' ' HB1' ' A' ' 148' ' ' ALA . 35.2 t70 -65.61 -40.27 92.43 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.965 -179.769 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -68.21 -37.47 80.9 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.551 -0.75 . . . . 0.0 112.12 -178.218 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 21.5 m -92.99 -22.82 5.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-O 120.794 0.33 . . . . 0.0 111.549 -177.044 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 85.91 54.41 2.77 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.971 -0.633 . . . . 0.0 112.172 178.935 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -132.73 155.87 48.07 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 120.739 0.304 . . . . 0.0 110.917 -178.975 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 23.9 ttm180 -81.53 127.6 33.01 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 176.998 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 117' ' ' LEU . . . . . 0.574 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 55.8 tp -93.3 123.94 36.93 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.022 179.348 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 66.5 mt -120.16 120.32 62.64 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 CA-C-O 120.939 0.4 . . . . 0.0 110.641 178.376 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 69.3 mt -120.13 126.57 75.42 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.165 179.331 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 120' ' ' LYS . . . . . 0.769 ' HG2' ' HB3' ' A' ' 143' ' ' PHE . 5.9 tmtt? -120.97 96.33 48.63 Favored Pre-proline 0 C--N 1.325 -0.49 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.118 178.379 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -88.8 -163.62 0.15 Allowed 'Trans proline' 0 C--O 1.238 0.497 0 C-N-CA 122.928 2.419 . . . . 0.0 112.33 177.098 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -70.54 -178.72 1.86 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.29 -0.413 . . . . 0.0 110.901 177.311 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 9.6 t -81.4 -35.26 30.96 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.904 0.383 . . . . 0.0 110.95 -176.39 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -113.74 52.54 0.64 Allowed Glycine 0 N--CA 1.448 -0.556 0 N-CA-C 110.629 -0.988 . . . . 0.0 110.629 175.852 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 36.4 tt0 -138.14 116.61 12.03 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.466 -0.367 . . . . 0.0 110.114 -173.354 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 8.1 t70 -91.71 163.19 14.18 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.987 -0.552 . . . . 0.0 110.117 -177.264 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 15.9 mt -93.2 -10.98 9.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 N-CA-C 110.176 -0.305 . . . . 0.0 110.176 -177.716 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 19.2 m 47.41 32.08 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.764 0 C-N-CA 124.167 0.987 . . . . 0.0 112.533 179.664 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 14.9 t -109.05 157.99 18.17 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.405 -179.843 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 130' ' ' GLU . . . . . 0.416 ' OE2' ' HD2' ' A' ' 131' ' ' ARG . 1.1 tm-20 -58.08 122.75 13.83 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 108.763 -0.829 . . . . 0.0 108.763 176.086 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 131' ' ' ARG . . . . . 0.425 ' H ' ' CD ' ' A' ' 131' ' ' ARG . 0.0 OUTLIER -52.87 112.11 0.79 Allowed 'General case' 0 N--CA 1.464 0.24 0 CA-C-O 122.148 0.975 . . . . 0.0 111.921 -171.848 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 8.3 tppt? -144.13 -32.8 0.42 Allowed 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 114.582 -1.19 . . . . 0.0 109.302 -177.734 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 133' ' ' MET . . . . . 0.806 ' HG2' ' HB2' ' A' ' 146' ' ' TYR . 83.4 mtp -87.17 171.75 10.44 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.247 -0.888 . . . . 0.0 110.459 -177.64 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 134' ' ' LYS . . . . . 0.405 ' HE2' HG13 ' A' ' 136' ' ' VAL . 14.2 ptmt -131.16 146.66 52.42 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.953 -175.268 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 135' ' ' LEU . . . . . 0.484 HD11 ' HD2' ' A' ' 142' ' ' TYR . 56.7 tp -79.75 129.84 34.82 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.454 176.715 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 136' ' ' VAL . . . . . 0.405 HG13 ' HE2' ' A' ' 134' ' ' LYS . 0.0 OUTLIER -127.66 129.8 70.23 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.702 0 CA-C-O 121.162 0.506 . . . . 0.0 111.162 178.811 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 22.3 m-80 -109.85 122.25 47.11 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.31 -0.859 . . . . 0.0 109.234 177.739 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 61.4 t80 -137.67 125.35 22.32 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 120.535 0.207 . . . . 0.0 110.67 -177.475 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 69.26 -88.92 0.25 Allowed Glycine 0 N--CA 1.448 -0.547 0 N-CA-C 111.626 -0.589 . . . . 0.0 111.626 179.225 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 140' ' ' ARG . . . . . 0.638 ' HA ' ' NE ' ' A' ' 140' ' ' ARG . 2.1 mmp_? -143.72 9.96 1.58 Allowed 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 115.446 -0.377 . . . . 0.0 111.182 175.91 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 141' ' ' THR . . . . . 0.568 ' HB ' ' HB3' ' A' ' 21' ' ' MET . 15.2 t -118.6 155.23 31.31 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.801 0.334 . . . . 0.0 110.611 -179.678 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 142' ' ' TYR . . . . . 0.484 ' HD2' HD11 ' A' ' 135' ' ' LEU . 32.4 p90 -133.58 141.22 47.59 Favored 'General case' 0 N--CA 1.448 -0.533 0 CA-C-O 121.086 0.469 . . . . 0.0 109.992 176.704 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 143' ' ' PHE . . . . . 0.769 ' HB3' ' HG2' ' A' ' 120' ' ' LYS . 11.6 p90 -153.89 -175.98 5.63 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 115.429 -0.805 . . . . 0.0 109.733 -177.006 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 95.7 m-85 -116.98 125.36 51.29 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 110.308 -0.256 . . . . 0.0 110.308 179.375 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 145' ' ' GLU . . . . . . . . . . . . . 21.6 pt-20 -114.05 160.92 18.36 Favored 'General case' 0 C--N 1.321 -0.649 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 176.626 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 146' ' ' TYR . . . . . 0.806 ' HB2' ' HG2' ' A' ' 133' ' ' MET . 42.3 t80 -141.87 123.44 15.03 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-N 115.971 -0.558 . . . . 0.0 109.693 175.617 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 147' ' ' ILE . . . . . 0.439 ' N ' HD12 ' A' ' 147' ' ' ILE . 3.1 mp -93.03 100.94 12.07 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.834 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 -178.653 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 148' ' ' ALA . . . . . 0.784 ' HB1' ' HA ' ' A' ' 111' ' ' ASP . . . -67.99 120.16 13.8 Favored 'General case' 0 N--CA 1.447 -0.6 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 174.378 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -62.03 143.1 57.06 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.27 0.557 . . . . 0.0 110.188 -176.06 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 8.2 t -96.15 126.34 48.78 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.901 0 CA-C-N 115.608 -0.723 . . . . 0.0 110.339 -174.779 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 151' ' ' ARG . . . . . . . . . . . . . 12.5 ptm180 -72.52 163.41 28.08 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 115.518 -0.764 . . . . 0.0 110.656 177.728 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 3.8 p -72.9 161.68 30.42 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 115.976 -0.557 . . . . 0.0 110.207 173.48 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 11.9 mmt180 . . . . . 0 C--O 1.25 1.08 0 CA-C-O 118.511 -0.756 . . . . 0.0 111.007 -178.046 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 13.5 tpt . . . . . 0 N--CA 1.478 0.967 0 N-CA-C 110.044 -0.354 . . . . 0.0 110.044 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -172.0 -117.45 0.44 Allowed Glycine 0 N--CA 1.447 -0.595 0 N-CA-C 111.179 -0.768 . . . . 0.0 111.179 179.684 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 48.7 m 53.6 37.42 25.9 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.156 0.503 . . . . 0.0 111.525 177.113 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 16.2 m -94.31 125.56 39.02 Favored 'General case' 0 N--CA 1.45 -0.465 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.148 179.786 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 71.4 m-70 -86.45 85.87 7.33 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.209 0.528 . . . . 0.0 110.315 -178.929 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 26.7 t-80 -114.66 86.13 2.38 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.506 -0.77 . . . . 0.0 109.942 -179.874 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 11.3 p-80 -154.63 172.81 17.26 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.838 -0.619 . . . . 0.0 109.718 177.522 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 46.0 m80 -103.71 116.69 32.79 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 120.912 0.387 . . . . 0.0 110.749 -175.455 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 20.0 p80 -105.95 164.64 11.8 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.133 179.968 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 47.6 t-80 64.35 101.98 0.04 OUTLIER 'General case' 0 N--CA 1.466 0.332 0 O-C-N 123.878 0.736 . . . . 0.0 111.635 179.109 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 10.1 t -107.04 138.83 42.46 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.026 -0.534 . . . . 0.0 109.561 176.241 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 3.8 p -73.03 128.99 37.09 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 120.735 0.303 . . . . 0.0 110.529 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -90.88 151.55 21.24 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.878 -0.677 . . . . 0.0 112.526 -178.188 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 96.3 mt -125.17 115.27 20.17 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 110.034 -0.358 . . . . 0.0 110.034 179.493 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.408 ' HA ' ' HD3' ' A' ' 16' ' ' PRO . 31.7 m -92.48 145.49 30.63 Favored Pre-proline 0 C--N 1.32 -0.681 0 CA-C-N 116.53 -0.305 . . . . 0.0 111.039 -179.295 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.408 ' HD3' ' HA ' ' A' ' 15' ' ' VAL . 16.6 Cg_exo -68.61 156.8 64.32 Favored 'Trans proline' 0 C--O 1.234 0.279 0 C-N-CA 122.716 2.278 . . . . 0.0 111.661 176.03 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -141.74 59.95 1.48 Allowed 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 121.225 0.536 . . . . 0.0 110.894 -177.085 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -89.92 0.94 80.03 Favored Glycine 0 N--CA 1.451 -0.305 0 CA-C-N 115.698 -0.683 . . . . 0.0 111.868 178.265 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' SER . . . . . 0.661 ' HB3' ' CD1' ' A' ' 22' ' ' TRP . 51.0 m -86.06 76.48 9.79 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.147 0.499 . . . . 0.0 110.119 177.405 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 54.7 m80 -62.98 -31.38 72.49 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.469 -0.787 . . . . 0.0 112.039 -174.022 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' MET . . . . . 0.458 ' CG ' ' HB ' ' A' ' 141' ' ' THR . 50.1 ttm -69.96 -28.54 65.63 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.239 0.543 . . . . 0.0 110.469 179.605 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' TRP . . . . . 0.661 ' CD1' ' HB3' ' A' ' 19' ' ' SER . 72.5 m95 -82.61 -19.25 38.71 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.748 -0.66 . . . . 0.0 111.119 -174.928 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 23' ' ' ASN . . . . . 0.432 ' O ' HG23 ' A' ' 27' ' ' VAL . 14.6 m120 -60.78 -36.99 80.37 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.522 175.528 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 43.9 m-20 -64.49 -45.16 88.53 Favored 'General case' 0 CA--C 1.52 -0.2 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.38 178.907 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 61.2 tp -55.13 -50.9 68.07 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.75 179.011 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -55.55 -47.03 77.0 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.912 -0.585 . . . . 0.0 111.639 -178.702 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.576 ' HA ' HD12 ' A' ' 30' ' ' ILE . 92.2 t -58.58 -37.09 62.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.471 -179.732 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 59.8 t80 -60.01 -45.89 91.27 Favored 'General case' 0 CA--C 1.534 0.339 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.042 -178.039 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.456 HG13 HD12 ' A' ' 118' ' ' ILE . 3.2 mp -64.09 -41.56 92.83 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.17 0 CA-C-O 120.973 0.416 . . . . 0.0 110.468 176.345 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.607 HG23 ' HB2' ' A' ' 58' ' ' SER . 90.6 mt -58.42 -44.67 89.22 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 115.739 -0.664 . . . . 0.0 111.357 -177.92 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 49.7 mtp180 -66.51 -33.82 76.55 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.463 -177.617 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 44.5 t -82.29 -25.81 33.67 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.416 -174.936 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 15.4 p -95.82 -81.82 0.4 Allowed 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.85 0.357 . . . . 0.0 111.746 -174.056 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 104.56 158.34 23.75 Favored Glycine 0 N--CA 1.447 -0.597 0 C-N-CA 120.937 -0.649 . . . . 0.0 111.8 -176.666 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 15.8 Cg_exo -68.67 139.58 44.61 Favored 'Trans proline' 0 N--CA 1.465 -0.164 0 C-N-CA 122.876 2.384 . . . . 0.0 112.415 -179.426 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 96.1 -4.67 65.32 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.577 -0.821 . . . . 0.0 112.568 178.502 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 29.6 p -96.48 -170.76 2.14 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 109.983 -0.377 . . . . 0.0 109.983 -179.892 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' ARG . . . . . 0.777 ' HB2' ' HA ' ' A' ' 90' ' ' ALA . 99.3 mtt180 -123.21 129.68 51.73 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.704 0.287 . . . . 0.0 110.661 174.429 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.788 HG23 HG21 ' A' ' 60' ' ' VAL . 98.7 t -129.41 121.9 54.39 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 N-CA-C 109.203 -0.665 . . . . 0.0 109.203 175.218 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 34.0 t -106.0 130.83 56.93 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 CA-C-O 120.755 0.312 . . . . 0.0 111.502 -174.293 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' GLU . . . . . 0.749 ' HB3' HD23 ' A' ' 64' ' ' LEU . 7.8 tp10 -114.15 122.03 45.59 Favored 'General case' 0 C--O 1.239 0.5 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.012 175.24 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.495 HG11 HD21 ' A' ' 106' ' ' LEU . 24.2 t -100.8 89.0 1.55 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 115.773 -0.648 . . . . 0.0 110.489 179.842 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 148.11 55.94 0.02 OUTLIER Glycine 0 N--CA 1.448 -0.538 0 CA-C-N 115.54 -0.754 . . . . 0.0 111.366 -177.879 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.624 ' HB2' ' HB3' ' A' ' 64' ' ' LEU . . . -84.97 76.94 10.21 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.986 0.422 . . . . 0.0 111.961 -173.962 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 45' ' ' GLY . . . . . 0.601 ' O ' ' HG ' ' A' ' 48' ' ' LEU . . . -89.5 -157.02 32.59 Favored Glycine 0 C--O 1.226 -0.367 0 C-N-CA 120.88 -0.676 . . . . 0.0 111.781 175.823 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 46' ' ' ARG . . . . . 0.451 HH11 ' HD3' ' A' ' 46' ' ' ARG . 0.0 OUTLIER -74.89 -15.44 60.7 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.984 0.421 . . . . 0.0 110.811 178.802 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 32.0 p90 -85.66 41.16 0.89 Allowed 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.53 -175.122 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.757 HD11 HD11 ' A' ' 74' ' ' ILE . 94.2 mt -80.96 19.16 0.9 Allowed 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 112.379 0.511 . . . . 0.0 112.379 -176.42 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 32.7 p90 -61.29 -27.39 68.44 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.712 0.291 . . . . 0.0 110.918 179.313 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 98.6 t -69.02 -51.28 45.64 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.237 175.43 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' SER . . . . . 0.413 ' O ' ' HG2' ' A' ' 55' ' ' ARG . 1.7 m -61.75 -45.3 94.51 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 121.384 0.612 . . . . 0.0 110.201 -179.868 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 25.6 t70 -58.8 -41.12 85.99 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 114.7 -1.137 . . . . 0.0 111.119 -179.454 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 80.6 t80 -66.99 -52.01 47.93 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.693 178.295 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.558 HG23 HG12 ' A' ' 30' ' ' ILE . 83.8 mt -58.23 -47.27 87.85 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-N 115.981 -0.554 . . . . 0.0 112.075 -176.041 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 55' ' ' ARG . . . . . 0.413 ' HG2' ' O ' ' A' ' 51' ' ' SER . 15.6 ptm180 -68.64 -20.7 64.48 Favored 'General case' 0 CA--C 1.533 0.289 0 N-CA-C 112.535 0.569 . . . . 0.0 112.535 -172.649 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 23.0 mtmm -84.74 -29.93 25.11 Favored 'General case' 0 C--N 1.328 -0.345 0 C-N-CA 120.705 -0.398 . . . . 0.0 111.251 179.28 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 16.4 m-70 -86.48 -54.2 4.55 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.235 0.54 . . . . 0.0 109.586 177.744 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' SER . . . . . 0.607 ' HB2' HG23 ' A' ' 30' ' ' ILE . 10.9 t -104.22 121.63 43.7 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 115.677 -0.692 . . . . 0.0 109.532 179.052 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 3.0 mppt? -84.79 61.45 6.79 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-O 121.897 0.856 . . . . 0.0 110.241 178.951 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.788 HG21 HG23 ' A' ' 39' ' ' VAL . 2.5 p -93.62 153.34 3.39 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.792 0 CA-C-N 114.167 -1.379 . . . . 0.0 109.299 177.232 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 43.9 m-20 -73.33 82.23 1.39 Allowed 'General case' 0 CA--C 1.518 -0.254 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 172.598 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' LEU . . . . . 0.45 ' HA ' ' O ' ' A' ' 39' ' ' VAL . 2.7 tt -80.93 105.45 12.17 Favored 'General case' 0 C--N 1.321 -0.651 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 179.549 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 48.8 t -96.96 117.14 40.95 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.439 -175.829 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 64' ' ' LEU . . . . . 0.749 HD23 ' HB3' ' A' ' 41' ' ' GLU . 80.0 mt -99.77 130.27 45.96 Favored 'General case' 0 C--N 1.314 -0.954 0 CA-C-N 115.58 -0.737 . . . . 0.0 109.185 177.249 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 22.9 p -117.86 129.4 55.63 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 120.555 0.217 . . . . 0.0 111.047 179.334 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 25.5 t70 -165.05 153.72 12.19 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.917 -0.583 . . . . 0.0 109.931 178.527 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.475 HG22 ' HE3' ' A' ' 68' ' ' LYS . 54.3 mt -76.98 100.39 2.57 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-O 120.93 0.395 . . . . 0.0 110.605 -178.289 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 68' ' ' LYS . . . . . 0.581 ' HB2' ' NZ ' ' A' ' 68' ' ' LYS . 7.4 mtmp? 70.33 83.97 0.15 Allowed Pre-proline 0 C--O 1.233 0.214 0 CA-C-N 115.119 -0.946 . . . . 0.0 110.53 -179.687 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 69' ' ' PRO . . . . . 0.96 ' HB3' ' HB ' ' A' ' 74' ' ' ILE . 11.2 Cg_endo -56.78 140.09 90.35 Favored 'Trans proline' 0 C--O 1.232 0.205 0 C-N-CA 123.714 2.942 . . . . 0.0 113.968 -175.653 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 28.6 m -103.12 16.88 25.43 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.483 -0.78 . . . . 0.0 110.267 174.837 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 22.3 t-80 -146.35 174.44 11.36 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 -179.279 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -99.89 119.14 6.4 Favored Glycine 0 N--CA 1.449 -0.457 0 C-N-CA 120.823 -0.703 . . . . 0.0 112.535 -175.837 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 120.86 -13.62 9.81 Favored Glycine 0 N--CA 1.454 -0.136 0 C-N-CA 120.904 -0.665 . . . . 0.0 112.004 179.393 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.96 ' HB ' ' HB3' ' A' ' 69' ' ' PRO . 55.8 mt -79.09 139.4 18.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-O 120.763 0.316 . . . . 0.0 110.724 -179.746 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 57.3 t -85.16 126.64 40.35 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 176.126 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 76' ' ' ARG . . . . . 0.478 ' HB3' ' HD2' ' A' ' 69' ' ' PRO . 1.6 ppt_? -77.68 28.08 0.17 Allowed 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 112.491 0.552 . . . . 0.0 112.491 -176.344 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 16.1 t70 -75.71 157.24 33.84 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 110.117 -0.327 . . . . 0.0 110.117 -177.579 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 78' ' ' ASP . . . . . 0.541 ' OD1' HG22 ' A' ' 80' ' ' THR . 5.9 t70 -88.47 161.41 17.03 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 120.691 0.281 . . . . 0.0 110.875 -171.984 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 8.5 tp -98.47 -28.23 3.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-O 120.829 0.347 . . . . 0.0 111.029 -177.926 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.541 HG22 ' OD1' ' A' ' 78' ' ' ASP . 15.0 t -90.02 -1.35 57.95 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.637 0.732 . . . . 0.0 109.165 176.868 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 34.5 t -152.12 72.32 7.78 Favored Pre-proline 0 C--N 1.322 -0.594 0 CA-C-N 114.738 -1.119 . . . . 0.0 108.984 175.069 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.539 ' HB2' ' HE2' ' A' ' 87' ' ' TYR . 91.1 Cg_endo -89.47 141.55 4.01 Favored 'Trans proline' 0 N--CA 1.457 -0.633 0 C-N-CA 122.829 2.353 . . . . 0.0 112.798 -177.521 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 83' ' ' ARG . . . . . 0.771 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 56.7 mtt-85 -83.49 113.38 20.75 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.047 178.305 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 84' ' ' MET . . . . . 0.71 ' HA ' ' HD2' ' A' ' 87' ' ' TYR . 29.6 mtp -68.06 -17.4 64.38 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.551 -0.295 . . . . 0.0 110.995 178.168 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.771 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 9.8 pt-20 -61.89 -23.81 66.54 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.934 0.397 . . . . 0.0 110.653 176.592 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 72.6 mt -85.11 -34.48 8.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.48 178.984 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 87' ' ' TYR . . . . . 0.71 ' HD2' ' HA ' ' A' ' 84' ' ' MET . 75.0 m-85 -78.23 -30.75 48.91 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.429 -177.243 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 88' ' ' ARG . . . . . 0.465 ' HG2' HG12 ' A' ' 113' ' ' VAL . 53.2 mtp180 -65.68 140.58 58.48 Favored 'General case' 0 CA--C 1.516 -0.362 0 CA-C-O 121.403 0.621 . . . . 0.0 110.882 178.701 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 91.08 1.73 72.29 Favored Glycine 0 N--CA 1.447 -0.61 0 CA-C-N 115.199 -0.909 . . . . 0.0 111.894 -178.044 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 90' ' ' ALA . . . . . 0.777 ' HA ' ' HB2' ' A' ' 38' ' ' ARG . . . -85.16 138.77 32.16 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.995 0.426 . . . . 0.0 110.75 178.88 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -89.16 -24.67 22.14 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.079 178.379 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 92' ' ' LEU . . . . . 0.515 HD23 ' N ' ' A' ' 93' ' ' ILE . 4.7 tt -153.49 143.15 21.85 Favored 'General case' 0 N--CA 1.45 -0.448 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.206 -178.345 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.515 ' N ' HD23 ' A' ' 92' ' ' LEU . 72.7 mt -132.03 133.73 60.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 N-CA-C 109.111 -0.7 . . . . 0.0 109.111 176.551 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 94' ' ' TYR . . . . . 0.453 ' O ' ' HA ' ' A' ' 41' ' ' GLU . 1.2 p90 -138.37 161.24 37.46 Favored 'General case' 0 C--N 1.321 -0.636 0 C-N-CA 120.707 -0.397 . . . . 0.0 110.119 -178.693 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 95' ' ' SER . . . . . 0.639 ' HA ' ' OE2' ' A' ' 41' ' ' GLU . 19.4 m -146.87 115.65 6.82 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.058 -178.91 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 78.9 mt -77.23 94.35 1.31 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.752 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.619 179.45 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 97' ' ' ARG . . . . . 0.534 ' HG3' ' OE1' ' A' ' 125' ' ' GLU . 19.6 ttp85 58.61 82.64 0.23 Allowed Pre-proline 0 CA--C 1.531 0.244 0 CA-C-N 114.608 -1.178 . . . . 0.0 111.66 -177.628 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 98' ' ' PRO . . . . . 0.457 ' HA ' ' HD3' ' A' ' 99' ' ' PRO . 88.3 Cg_endo -83.74 136.66 7.36 Favored 'Trans proline' 0 N--CA 1.456 -0.724 0 C-N-CA 122.467 2.111 . . . . 0.0 111.638 176.136 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.747 ' HB2' ' HG2' ' A' ' 101' ' ' GLU . 22.4 Cg_exo -63.32 149.94 89.9 Favored 'Trans proline' 0 C--O 1.238 0.478 0 C-N-CA 122.581 2.187 . . . . 0.0 111.733 177.951 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -73.76 42.22 0.13 Allowed 'General case' 0 N--CA 1.465 0.284 0 CA-C-O 121.304 0.573 . . . . 0.0 111.812 -178.216 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 101' ' ' GLU . . . . . 0.757 ' HG3' HG23 ' A' ' 102' ' ' ILE . 11.0 pt-20 -132.15 -26.24 1.93 Allowed 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.607 179.303 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.757 HG23 ' HG3' ' A' ' 101' ' ' GLU . 40.1 pt -119.88 -11.64 10.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.55 -175.062 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 103' ' ' HIS . . . . . 0.73 ' HD2' ' HB ' ' A' ' 129' ' ' THR . 4.8 p-80 -56.72 -45.24 82.0 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.989 -0.551 . . . . 0.0 111.612 -175.147 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 8.5 m -61.35 -35.05 76.36 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.002 0.43 . . . . 0.0 110.908 179.529 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.839 ' HA ' ' HE ' ' A' ' 108' ' ' ARG . 67.1 m -73.3 -36.71 66.32 Favored 'General case' 0 N--CA 1.451 -0.408 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.39 179.703 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.495 HD21 HG11 ' A' ' 42' ' ' VAL . 85.0 mt -64.39 -42.08 96.31 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.73 178.914 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 107' ' ' MET . . . . . 0.522 ' HA ' HD22 ' A' ' 117' ' ' LEU . 81.4 mtp -60.5 -44.27 96.17 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.539 -179.292 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 108' ' ' ARG . . . . . 0.839 ' HE ' ' HA ' ' A' ' 105' ' ' SER . 31.6 ptt180 -74.73 -20.77 59.69 Favored 'General case' 0 CA--C 1.53 0.205 0 C-N-CA 121.048 -0.261 . . . . 0.0 111.555 -178.263 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.528 HG23 ' O ' ' A' ' 105' ' ' SER . 55.9 t -74.06 -43.47 51.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.749 0.309 . . . . 0.0 110.333 175.421 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -57.24 -45.66 83.73 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.972 -179.822 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.961 ' HA ' ' HB1' ' A' ' 148' ' ' ALA . 4.0 t70 -71.72 -28.71 63.87 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 121.174 0.511 . . . . 0.0 110.254 -177.284 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -74.49 -33.01 62.74 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.953 -0.567 . . . . 0.0 111.809 -179.64 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.465 HG12 ' HG2' ' A' ' 88' ' ' ARG . 34.0 m -95.52 -24.78 4.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 C-N-CA 121.088 -0.245 . . . . 0.0 111.097 179.578 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 114' ' ' GLY . . . . . 0.446 ' HA2' ' O ' ' A' ' 149' ' ' GLU . . . 89.87 46.5 4.2 Favored Glycine 0 N--CA 1.453 -0.226 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.993 176.303 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 115' ' ' ALA . . . . . 0.405 ' O ' ' HB3' ' A' ' 148' ' ' ALA . . . -124.66 150.25 46.29 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 120.533 0.206 . . . . 0.0 110.85 -178.954 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 116' ' ' ARG . . . . . 0.506 ' HD3' ' OE1' ' A' ' 145' ' ' GLU . 14.7 ttm180 -70.65 119.92 15.5 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 177.93 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 117' ' ' LEU . . . . . 0.522 HD22 ' HA ' ' A' ' 107' ' ' MET . 57.6 tp -90.58 118.59 30.15 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 -179.765 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 118' ' ' ILE . . . . . 0.456 HD12 HG13 ' A' ' 29' ' ' ILE . 61.9 mt -115.98 112.71 40.77 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.654 0 CA-C-O 121.289 0.566 . . . . 0.0 110.594 179.455 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 62.8 mt -110.97 119.03 58.71 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.845 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.029 178.474 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 120' ' ' LYS . . . . . 0.663 ' HG2' ' HB3' ' A' ' 143' ' ' PHE . 9.0 tmtm? -116.33 96.97 48.99 Favored Pre-proline 0 C--N 1.322 -0.616 0 CA-C-N 116.162 -0.472 . . . . 0.0 109.994 178.885 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 0.9 OUTLIER -77.65 -178.71 4.81 Favored 'Trans proline' 0 N--CA 1.459 -0.522 0 C-N-CA 122.652 2.235 . . . . 0.0 111.442 174.373 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 5.7 mp -63.87 177.68 0.73 Allowed 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.957 -179.439 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 15.2 m -49.45 -65.15 0.61 Allowed 'General case' 0 CA--C 1.53 0.194 0 CA-C-N 115.71 -0.677 . . . . 0.0 111.888 -175.357 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -106.54 64.86 0.27 Allowed Glycine 0 N--CA 1.448 -0.531 0 C-N-CA 120.669 -0.777 . . . . 0.0 111.173 175.452 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 125' ' ' GLU . . . . . 0.534 ' OE1' ' HG3' ' A' ' 97' ' ' ARG . 40.8 tt0 -140.11 145.48 37.65 Favored 'General case' 0 N--CA 1.448 -0.558 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 -174.712 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 10.3 t70 -123.02 174.67 7.05 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.356 -179.169 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.54 ' HB ' HG22 ' A' ' 129' ' ' THR . 6.9 mt -93.6 -19.85 6.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.055 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.448 HG22 ' O ' ' A' ' 127' ' ' ILE . 5.9 m 53.22 24.07 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.666 0 C-N-CA 124.628 1.171 . . . . 0.0 112.686 179.179 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 129' ' ' THR . . . . . 0.779 HG23 ' H ' ' A' ' 130' ' ' GLU . 1.7 t -82.07 -69.68 0.6 Allowed 'General case' 0 CA--C 1.536 0.412 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.139 174.747 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 130' ' ' GLU . . . . . 0.779 ' H ' HG23 ' A' ' 129' ' ' THR . 6.9 pt-20 -176.78 -174.68 0.57 Allowed 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 108.6 -0.889 . . . . 0.0 108.6 174.637 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 131' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -91.91 27.07 2.21 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 121.213 0.53 . . . . 0.0 110.699 -177.299 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 132' ' ' LYS . . . . . 0.581 ' H ' ' HG3' ' A' ' 130' ' ' GLU . 16.5 tppt? -66.99 -24.49 66.04 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.59 178.045 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 133' ' ' MET . . . . . 0.789 ' HG2' ' HB2' ' A' ' 146' ' ' TYR . 93.4 mtp -104.86 155.76 18.63 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.578 -177.533 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 12.9 ptmt -106.12 139.73 40.19 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.446 -175.789 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 135' ' ' LEU . . . . . 0.838 HD11 ' HD2' ' A' ' 142' ' ' TYR . 55.2 tp -78.81 125.27 29.14 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 115.861 -0.608 . . . . 0.0 110.428 177.709 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -119.81 147.16 23.64 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.808 179.059 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 137' ' ' ASN . . . . . 0.415 ' OD1' ' HB3' ' A' ' 142' ' ' TYR . 34.3 m-80 -120.72 119.1 31.82 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.92 -0.582 . . . . 0.0 109.63 178.411 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 67.7 t80 -131.74 130.98 42.6 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 109.916 -0.401 . . . . 0.0 109.916 179.289 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 71.66 -91.21 0.49 Allowed Glycine 0 N--CA 1.441 -1.0 0 N-CA-C 111.21 -0.756 . . . . 0.0 111.21 -176.821 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 140' ' ' ARG . . . . . 0.447 ' HD3' ' HA ' ' A' ' 140' ' ' ARG . 29.1 mmt180 -150.21 12.81 0.75 Allowed 'General case' 0 C--N 1.32 -0.708 0 CA-C-O 120.807 0.337 . . . . 0.0 110.556 179.308 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 141' ' ' THR . . . . . 0.458 ' HB ' ' CG ' ' A' ' 21' ' ' MET . 7.1 t -125.15 160.64 28.67 Favored 'General case' 0 C--N 1.322 -0.606 0 N-CA-C 109.865 -0.42 . . . . 0.0 109.865 -178.991 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 142' ' ' TYR . . . . . 0.838 ' HD2' HD11 ' A' ' 135' ' ' LEU . 20.8 p90 -126.83 149.64 49.6 Favored 'General case' 0 N--CA 1.449 -0.523 0 CA-C-O 121.405 0.621 . . . . 0.0 111.176 179.494 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 143' ' ' PHE . . . . . 0.663 ' HB3' ' HG2' ' A' ' 120' ' ' LYS . 19.5 p90 -156.39 179.3 9.39 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 114.823 -1.08 . . . . 0.0 109.417 -177.37 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -113.2 127.85 56.3 Favored 'General case' 0 C--N 1.319 -0.752 0 C-N-CA 120.963 -0.295 . . . . 0.0 110.451 -179.738 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 145' ' ' GLU . . . . . 0.506 ' OE1' ' HD3' ' A' ' 116' ' ' ARG . 17.5 pt-20 -114.85 157.04 23.84 Favored 'General case' 0 C--N 1.32 -0.681 0 N-CA-C 109.041 -0.726 . . . . 0.0 109.041 173.189 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 146' ' ' TYR . . . . . 0.789 ' HB2' ' HG2' ' A' ' 133' ' ' MET . 19.5 t80 -137.77 122.75 19.01 Favored 'General case' 0 C--N 1.31 -1.133 0 CA-C-N 116.054 -0.521 . . . . 0.0 109.638 176.07 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 2.2 mp -79.49 95.76 2.18 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.813 0 N-CA-C 108.442 -0.947 . . . . 0.0 108.442 174.91 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 148' ' ' ALA . . . . . 0.961 ' HB1' ' HA ' ' A' ' 111' ' ' ASP . . . -74.87 130.3 39.17 Favored 'General case' 0 N--CA 1.437 -1.083 0 CA-C-N 115.462 -0.79 . . . . 0.0 109.739 178.679 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 149' ' ' GLU . . . . . 0.584 ' OE1' ' HD3' ' A' ' 153' ' ' ARG . 74.4 mm-40 -65.16 179.56 0.7 Allowed 'General case' 0 C--N 1.315 -0.904 0 CA-C-O 122.032 0.92 . . . . 0.0 111.558 178.861 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 150' ' ' VAL . . . . . 0.614 ' HB ' ' HA ' ' A' ' 153' ' ' ARG . 39.2 t -116.08 135.27 56.78 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.111 0 CA-C-N 114.511 -1.222 . . . . 0.0 107.95 176.144 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 151' ' ' ARG . . . . . . . . . . . . . 26.3 mtp180 -62.49 106.74 0.81 Allowed 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 120.827 0.346 . . . . 0.0 110.077 -176.969 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 16.2 m 67.79 24.09 8.34 Favored 'General case' 0 C--N 1.333 -0.151 0 CA-C-N 115.001 -0.999 . . . . 0.0 110.811 -177.801 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 153' ' ' ARG . . . . . 0.614 ' HA ' ' HB ' ' A' ' 150' ' ' VAL . 21.1 mtm180 . . . . . 0 C--O 1.25 1.106 0 O-C-N 125.088 1.493 . . . . 0.0 114.247 -178.674 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 66.1 mtt . . . . . 0 N--CA 1.479 1.001 0 N-CA-C 110.097 -0.334 . . . . 0.0 110.097 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 81.01 -142.77 23.57 Favored Glycine 0 N--CA 1.448 -0.54 0 C-N-CA 120.933 -0.651 . . . . 0.0 111.932 178.281 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 43.0 t -132.78 135.35 45.65 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-O 121.025 0.44 . . . . 0.0 110.597 177.657 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 24.2 m -95.16 6.4 49.17 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 121.475 0.655 . . . . 0.0 109.555 176.503 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 62.0 t60 -112.8 110.32 20.35 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.185 -0.916 . . . . 0.0 110.142 179.401 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 48.5 t-80 -94.44 122.25 36.81 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 109.721 -0.474 . . . . 0.0 109.721 176.475 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 81.2 t60 -127.9 117.81 22.47 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.316 -177.405 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 27.4 p-80 -76.37 128.18 34.32 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.169 -0.469 . . . . 0.0 109.893 176.598 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 20.1 t-80 -77.05 153.83 34.0 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.216 -177.577 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 15.6 p-80 -68.77 105.29 2.27 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.6 0.714 . . . . 0.0 109.809 175.855 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 23.1 t -145.04 162.05 37.91 Favored 'General case' 0 N--CA 1.446 -0.63 0 CA-C-N 115.393 -0.821 . . . . 0.0 110.192 -173.068 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 27.8 t -108.66 121.25 44.63 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 177.352 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -82.98 179.45 52.96 Favored Glycine 0 N--CA 1.446 -0.685 0 C-N-CA 120.618 -0.801 . . . . 0.0 112.223 -178.394 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' LEU . . . . . 0.497 HD12 HH12 ' A' ' 17' ' ' ARG . 2.7 pt? -71.49 152.94 42.59 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 120.665 0.269 . . . . 0.0 110.457 178.633 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 24.5 m -83.33 127.51 68.32 Favored Pre-proline 0 C--N 1.323 -0.558 0 CA-C-O 121.027 0.441 . . . . 0.0 110.859 179.291 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 30.7 Cg_endo -66.54 133.34 31.82 Favored 'Trans proline' 0 N--CA 1.46 -0.464 0 C-N-CA 121.951 1.767 . . . . 0.0 111.51 176.628 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' ARG . . . . . 0.569 ' HB2' ' CE1' ' A' ' 20' ' ' HIS . 11.1 mpt_? -81.01 63.09 5.24 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 116.421 -0.354 . . . . 0.0 111.028 -178.432 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' GLY . . . . . 0.491 ' O ' ' HG2' ' A' ' 21' ' ' MET . . . 64.62 -93.2 0.14 Allowed Glycine 0 C--N 1.331 0.266 0 CA-C-N 115.773 -0.649 . . . . 0.0 113.716 175.352 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' SER . . . . . 0.401 ' HB3' ' OH ' ' A' ' 49' ' ' TYR . 19.9 m -54.83 -24.92 25.22 Favored 'General case' 0 C--N 1.326 -0.431 0 N-CA-C 112.957 0.725 . . . . 0.0 112.957 -172.982 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' HIS . . . . . 0.569 ' CE1' ' HB2' ' A' ' 17' ' ' ARG . 51.6 m170 -54.52 -40.07 68.25 Favored 'General case' 0 N--CA 1.465 0.302 0 N-CA-C 111.784 0.29 . . . . 0.0 111.784 -177.668 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' MET . . . . . 0.491 ' HG2' ' O ' ' A' ' 18' ' ' GLY . 27.2 ptm -83.73 -16.75 43.68 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 120.746 0.307 . . . . 0.0 111.38 -177.513 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 95.5 m95 -91.19 -31.56 16.14 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.545 -0.298 . . . . 0.0 111.58 -176.943 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' ASN . . . . . 0.446 ' O ' HG23 ' A' ' 27' ' ' VAL . 4.4 m-20 -66.49 -40.72 89.42 Favored 'General case' 0 C--N 1.328 -0.348 0 C-N-CA 121.224 -0.19 . . . . 0.0 111.487 -177.015 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 38.8 m-20 -61.41 -39.44 90.78 Favored 'General case' 0 N--CA 1.466 0.35 0 CA-C-O 121.071 0.462 . . . . 0.0 110.411 177.644 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.545 HD21 ' HD3' ' A' ' 120' ' ' LYS . 25.0 tp -63.33 -42.95 98.99 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.648 -0.705 . . . . 0.0 110.59 176.863 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -59.68 -46.95 87.5 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.738 178.258 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.446 HG23 ' O ' ' A' ' 23' ' ' ASN . 90.3 t -55.59 -42.26 67.9 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.192 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.069 178.803 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 69.2 t80 -59.33 -45.16 92.11 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 121.024 0.44 . . . . 0.0 110.637 179.598 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 57.9 mt -67.07 -39.91 84.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.62 179.751 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.683 HG12 HG23 ' A' ' 54' ' ' ILE . 98.1 mt -59.9 -41.87 87.35 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.453 -0.794 . . . . 0.0 110.941 178.915 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 79.2 mtp180 -66.49 -37.64 85.51 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.882 -178.407 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 81.2 m -76.76 -18.0 58.72 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.214 -176.068 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 11.9 p -104.26 -84.37 0.48 Allowed 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.433 -178.556 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.402 ' O ' HG22 ' A' ' 37' ' ' THR . . . 99.69 160.47 28.82 Favored Glycine 0 N--CA 1.447 -0.626 0 C-N-CA 121.089 -0.577 . . . . 0.0 111.902 -176.96 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 11.5 Cg_exo -70.95 152.74 63.4 Favored 'Trans proline' 0 C--O 1.235 0.33 0 C-N-CA 122.743 2.296 . . . . 0.0 111.976 179.57 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 99.61 -26.35 24.73 Favored Glycine 0 N--CA 1.453 -0.228 0 C-N-CA 120.827 -0.701 . . . . 0.0 112.752 176.624 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' THR . . . . . 0.402 HG22 ' O ' ' A' ' 34' ' ' GLY . 14.0 t -100.5 -166.99 1.38 Allowed 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 -178.846 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 38' ' ' ARG . . . . . 0.995 ' HG2' ' HA ' ' A' ' 90' ' ' ALA . 0.1 OUTLIER -130.94 136.53 48.65 Favored 'General case' 0 N--CA 1.446 -0.657 0 CA-C-O 121.113 0.483 . . . . 0.0 111.021 -176.767 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.448 HG23 HG21 ' A' ' 60' ' ' VAL . 95.9 t -129.16 135.82 61.04 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.603 0 CA-C-N 115.48 -0.782 . . . . 0.0 109.486 -179.916 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.517 HG11 ' CE2' ' A' ' 87' ' ' TYR . 38.7 t -108.11 128.19 63.72 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 CA-C-O 120.927 0.394 . . . . 0.0 111.31 -176.479 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 41' ' ' GLU . . . . . 0.58 ' HB3' HD23 ' A' ' 64' ' ' LEU . 41.1 tt0 -106.49 118.23 36.1 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.924 -0.58 . . . . 0.0 109.778 175.826 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 62.9 t -97.21 120.48 46.6 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.671 -179.173 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 92.5 48.7 2.94 Favored Glycine 0 N--CA 1.447 -0.621 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.139 179.567 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -80.36 41.09 0.52 Allowed 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.063 0.459 . . . . 0.0 111.446 -176.861 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 45' ' ' GLY . . . . . 0.425 ' O ' ' HB2' ' A' ' 46' ' ' ARG . . . -81.29 81.58 1.62 Allowed Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.954 -0.641 . . . . 0.0 112.27 -178.332 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 46' ' ' ARG . . . . . 0.425 ' HB2' ' O ' ' A' ' 45' ' ' GLY . 82.9 mtm180 71.08 13.56 6.86 Favored 'General case' 0 N--CA 1.469 0.498 0 C-N-CA 123.238 0.615 . . . . 0.0 111.271 -179.44 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 74.6 m-85 -98.51 17.05 19.94 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.357 0.598 . . . . 0.0 109.706 176.864 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.473 HD11 ' HB3' ' A' ' 71' ' ' HIS . 82.2 mt -62.14 -10.1 9.44 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 114.793 -1.094 . . . . 0.0 112.388 -174.655 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 49' ' ' TYR . . . . . 0.401 ' OH ' ' HB3' ' A' ' 19' ' ' SER . 73.9 t80 -57.85 -38.35 75.53 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 120.715 0.293 . . . . 0.0 110.837 179.167 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 60.4 t -73.54 -54.63 14.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.435 -179.093 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -59.75 -38.33 81.47 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.852 -179.437 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.565 ' HA ' ' HG2' ' A' ' 55' ' ' ARG . 33.5 t70 -71.44 -35.85 71.06 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.629 0.252 . . . . 0.0 111.181 179.527 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 56.7 t80 -61.36 -49.03 78.57 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 109.503 -0.554 . . . . 0.0 109.503 175.027 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.683 HG23 HG12 ' A' ' 30' ' ' ILE . 77.6 mt -60.85 -51.83 68.61 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-N 115.727 -0.669 . . . . 0.0 111.85 -179.236 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 55' ' ' ARG . . . . . 0.565 ' HG2' ' HA ' ' A' ' 52' ' ' ASP . 40.1 ptt180 -65.29 -19.93 66.18 Favored 'General case' 0 N--CA 1.467 0.392 0 N-CA-C 112.382 0.512 . . . . 0.0 112.382 -173.464 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 3.1 mtmp? -87.33 -38.61 16.07 Favored 'General case' 0 C--N 1.327 -0.372 0 C-N-CA 120.723 -0.391 . . . . 0.0 111.588 178.668 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 42.6 m80 -76.03 -32.73 59.5 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 120.662 0.268 . . . . 0.0 110.693 179.651 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 67.6 m -138.63 128.0 24.46 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 116.264 -0.425 . . . . 0.0 109.863 174.581 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 59' ' ' LYS . . . . . 0.409 ' HA ' ' HD3' ' A' ' 59' ' ' LYS . 1.3 tppp? -78.58 63.42 3.38 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 122.096 0.95 . . . . 0.0 110.901 -177.375 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.448 HG21 HG23 ' A' ' 39' ' ' VAL . 7.3 p -86.29 142.21 13.4 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.957 0 CA-C-N 114.349 -1.296 . . . . 0.0 109.387 172.721 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 61' ' ' ASP . . . . . 0.443 ' O ' ' HA ' ' A' ' 38' ' ' ARG . 33.0 t70 -76.51 89.25 3.27 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 179.228 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 2.3 tt -90.0 122.91 33.44 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.78 -0.646 . . . . 0.0 110.496 -173.93 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 43.8 t -102.29 121.76 53.74 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-N 115.523 -0.762 . . . . 0.0 109.899 -178.234 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 64' ' ' LEU . . . . . 0.58 HD23 ' HB3' ' A' ' 41' ' ' GLU . 50.8 mt -100.15 131.01 46.34 Favored 'General case' 0 C--N 1.316 -0.858 0 CA-C-N 116.214 -0.448 . . . . 0.0 109.919 179.766 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.549 HG22 ' HB ' ' A' ' 75' ' ' VAL . 17.0 p -132.23 137.37 47.52 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.951 0.405 . . . . 0.0 111.18 178.383 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 30.3 t70 -165.28 158.4 16.27 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.518 177.529 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 40.7 mm -72.09 96.83 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-O 120.759 0.314 . . . . 0.0 110.429 -178.76 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 65.3 mttm 63.56 90.16 0.09 OUTLIER Pre-proline 0 N--CA 1.465 0.309 0 CA-C-N 115.393 -0.821 . . . . 0.0 111.514 178.682 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 69' ' ' PRO . . . . . 0.415 ' HD3' ' HA ' ' A' ' 76' ' ' ARG . 97.3 Cg_endo -83.84 170.35 11.32 Favored 'Trans proline' 0 N--CA 1.459 -0.506 0 C-N-CA 122.867 2.378 . . . . 0.0 112.726 -179.273 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 14.8 t -156.64 34.48 0.31 Allowed 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.844 0.831 . . . . 0.0 108.868 178.686 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 71' ' ' HIS . . . . . 0.473 ' HB3' HD11 ' A' ' 48' ' ' LEU . 20.2 m80 -115.88 -66.58 1.07 Allowed 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.114 -0.948 . . . . 0.0 110.883 -173.11 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -160.16 -126.7 0.85 Allowed Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.1 -179.154 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -81.93 61.4 4.67 Favored Glycine 0 N--CA 1.452 -0.241 0 C-N-CA 121.076 -0.583 . . . . 0.0 112.273 -178.572 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.438 HD11 HD21 ' A' ' 48' ' ' LEU . 63.6 mt -107.53 134.83 48.1 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-O 120.756 0.312 . . . . 0.0 110.358 179.299 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.549 ' HB ' HG22 ' A' ' 65' ' ' THR . 53.8 t -72.71 133.37 31.89 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.093 179.321 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 76' ' ' ARG . . . . . 0.415 ' HA ' ' HD3' ' A' ' 69' ' ' PRO . 6.7 ptp180 -86.9 32.48 0.67 Allowed 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.855 -176.471 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 77' ' ' ASP . . . . . 0.498 ' HB2' HG12 ' A' ' 75' ' ' VAL . 1.6 t70 -77.11 -159.16 0.12 Allowed 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.653 -174.329 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 78' ' ' ASP . . . . . 0.457 ' OD1' HG22 ' A' ' 80' ' ' THR . 4.9 t70 -125.15 -174.16 2.98 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 120.733 0.301 . . . . 0.0 110.25 -174.374 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 9.2 tp -139.9 -30.89 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-O 120.877 0.37 . . . . 0.0 110.406 178.951 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.457 HG22 ' OD1' ' A' ' 78' ' ' ASP . 8.9 t -86.38 -20.8 27.71 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.516 0.674 . . . . 0.0 109.247 177.127 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 13.6 t -150.67 72.57 8.92 Favored Pre-proline 0 C--N 1.325 -0.489 0 CA-C-N 115.154 -0.93 . . . . 0.0 108.577 171.721 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.442 ' HB3' ' O ' ' A' ' 78' ' ' ASP . 89.6 Cg_endo -89.77 171.3 4.16 Favored 'Trans proline' 0 N--CA 1.457 -0.674 0 C-N-CA 123.007 2.472 . . . . 0.0 113.149 -173.96 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 83' ' ' ARG . . . . . 0.597 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 63.6 mtt180 -88.9 111.36 21.99 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.671 -0.695 . . . . 0.0 109.536 171.432 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 84' ' ' MET . . . . . 0.522 ' O ' ' HG3' ' A' ' 88' ' ' ARG . 92.7 mmm -67.36 -20.04 65.51 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.395 -176.991 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.597 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 9.3 pt-20 -60.49 -27.29 67.47 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.309 -179.664 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 67.4 mt -79.93 -40.24 20.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-O 120.98 0.419 . . . . 0.0 111.07 -178.571 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 87' ' ' TYR . . . . . 0.517 ' CE2' HG11 ' A' ' 40' ' ' VAL . 73.0 m-85 -81.98 -31.14 31.29 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.632 -176.889 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 88' ' ' ARG . . . . . 0.744 ' HG2' HG12 ' A' ' 113' ' ' VAL . 16.1 mtp180 -69.42 116.78 10.24 Favored 'General case' 0 CA--C 1.509 -0.606 0 CA-C-O 121.906 0.86 . . . . 0.0 111.462 -175.957 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 89' ' ' GLY . . . . . 0.439 ' O ' ' HD3' ' A' ' 38' ' ' ARG . . . 116.38 -18.9 13.37 Favored Glycine 0 C--N 1.31 -0.897 0 CA-C-N 114.07 -1.423 . . . . 0.0 111.765 -177.727 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 90' ' ' ALA . . . . . 0.995 ' HA ' ' HG2' ' A' ' 38' ' ' ARG . . . -66.24 143.09 57.44 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.604 0.24 . . . . 0.0 110.553 179.075 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -82.57 -29.22 30.43 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 120.831 0.348 . . . . 0.0 110.807 -178.624 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 92' ' ' LEU . . . . . 0.473 ' HG ' ' HB3' ' A' ' 116' ' ' ARG . 5.8 tt -149.71 143.44 25.46 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.15 -0.477 . . . . 0.0 109.96 -177.412 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.613 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 62.8 mt -130.65 127.46 62.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 N-CA-C 109.098 -0.705 . . . . 0.0 109.098 177.019 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 94' ' ' TYR . . . . . 0.756 ' HD2' ' HZ3' ' A' ' 120' ' ' LYS . 20.7 p90 -138.71 142.84 38.91 Favored 'General case' 0 C--N 1.321 -0.664 0 C-N-CA 120.208 -0.597 . . . . 0.0 111.407 -179.039 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 95' ' ' SER . . . . . 0.416 ' O ' ' HG2' ' A' ' 120' ' ' LYS . 8.0 m -118.08 144.96 45.19 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 115.497 -0.774 . . . . 0.0 110.047 -177.814 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 96' ' ' ILE . . . . . 0.819 HG12 ' HD2' ' A' ' 120' ' ' LYS . 42.9 mt -111.69 106.84 21.55 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-O 120.759 0.314 . . . . 0.0 110.46 179.804 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 97' ' ' ARG . . . . . 0.576 ' HD3' ' O ' ' A' ' 97' ' ' ARG . 0.0 OUTLIER 50.88 76.43 0.55 Allowed Pre-proline 0 CA--C 1.536 0.439 0 CA-C-N 115.099 -0.955 . . . . 0.0 111.173 -177.381 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_endo -96.3 159.61 1.29 Allowed 'Trans proline' 0 N--CA 1.453 -0.886 0 C-N-CA 123.211 2.607 . . . . 0.0 112.698 178.887 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.677 ' HD2' HD11 ' A' ' 102' ' ' ILE . 17.5 Cg_exo -64.16 136.37 51.55 Favored 'Trans proline' 0 N--CA 1.462 -0.353 0 C-N-CA 122.32 2.014 . . . . 0.0 111.306 174.55 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.69 ' HA ' ' CE1' ' A' ' 103' ' ' HIS . . . -68.98 -15.46 63.49 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 120.971 0.415 . . . . 0.0 111.833 -174.977 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 101' ' ' GLU . . . . . . . . . . . . . 1.7 pm0 -75.86 -18.51 59.4 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.888 178.582 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.677 HD11 ' HD2' ' A' ' 99' ' ' PRO . 2.6 pp -113.48 8.1 7.89 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.178 0 N-CA-C 112.567 0.58 . . . . 0.0 112.567 -177.341 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 103' ' ' HIS . . . . . 0.69 ' CE1' ' HA ' ' A' ' 100' ' ' ALA . 64.9 m170 -57.57 -42.64 83.47 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 121.063 0.459 . . . . 0.0 110.777 176.361 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 6.9 p -69.86 -26.85 64.4 Favored 'General case' 0 C--O 1.236 0.372 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.095 -179.114 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.571 ' O ' HG23 ' A' ' 109' ' ' VAL . 74.8 m -70.52 -44.79 66.85 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 109.757 -0.461 . . . . 0.0 109.757 174.519 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 96.0 mt -56.84 -41.81 78.54 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 121.067 0.46 . . . . 0.0 110.354 175.676 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 107' ' ' MET . . . . . . . . . . . . . 46.6 tpp -55.59 -52.59 63.25 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.28 -0.873 . . . . 0.0 111.365 178.497 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 4.8 ptp180 -71.3 -22.56 61.93 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 111.889 0.329 . . . . 0.0 111.889 -177.303 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.571 HG23 ' O ' ' A' ' 105' ' ' SER . 82.5 t -70.19 -48.37 61.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 C-N-CA 120.731 -0.388 . . . . 0.0 109.981 175.012 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -60.96 -44.53 97.16 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 177.049 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 22.7 t70 -60.68 -34.06 73.77 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.36 -0.836 . . . . 0.0 111.036 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -74.75 -44.44 49.74 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.795 -0.639 . . . . 0.0 111.813 -179.271 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.744 HG12 ' HG2' ' A' ' 88' ' ' ARG . 13.1 m -87.46 -29.29 5.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.981 -172.549 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 87.32 53.77 2.71 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.852 -0.69 . . . . 0.0 112.392 -178.978 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -131.97 160.44 35.79 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.737 0.303 . . . . 0.0 111.086 -178.192 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 116' ' ' ARG . . . . . 0.473 ' HB3' ' HG ' ' A' ' 92' ' ' LEU . 13.5 ttm180 -79.0 123.88 27.72 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 109.565 -0.532 . . . . 0.0 109.565 175.923 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 117' ' ' LEU . . . . . 0.613 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 58.3 tp -98.14 118.32 34.49 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.181 -179.429 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 55.7 mt -117.19 115.13 47.81 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-O 121.197 0.522 . . . . 0.0 110.629 178.861 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 40.6 mt -107.78 135.78 45.3 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.631 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.032 -178.032 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 120' ' ' LYS . . . . . 0.819 ' HD2' HG12 ' A' ' 96' ' ' ILE . 4.5 ptpp? -130.51 91.96 36.47 Favored Pre-proline 0 C--N 1.324 -0.518 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.238 -179.147 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 78.5 Cg_endo -96.77 -164.28 0.09 OUTLIER 'Trans proline' 0 N--CA 1.455 -0.765 0 C-N-CA 123.308 2.672 . . . . 0.0 112.647 179.344 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 122' ' ' LEU . . . . . 0.695 ' HB2' ' HB2' ' A' ' 125' ' ' GLU . 4.2 mm? -74.67 159.32 32.23 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.481 174.796 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 27.3 m -57.96 -43.68 86.57 Favored 'General case' 0 CA--C 1.53 0.2 0 CA-C-O 120.981 0.419 . . . . 0.0 110.959 -178.948 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -100.76 38.2 3.25 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.8 -0.714 . . . . 0.0 111.595 178.288 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 125' ' ' GLU . . . . . 0.695 ' HB2' ' HB2' ' A' ' 122' ' ' LEU . 27.4 tt0 -123.09 116.83 24.12 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.586 -0.524 . . . . 0.0 109.586 -177.515 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -88.55 164.71 15.28 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 121.544 0.688 . . . . 0.0 111.544 -172.903 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.557 HG22 ' HB ' ' A' ' 129' ' ' THR . 52.1 mt -101.6 103.25 14.65 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.827 0 CA-C-N 115.06 -0.973 . . . . 0.0 108.586 172.71 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 39.0 t -73.72 72.99 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 121.994 0.902 . . . . 0.0 109.754 -179.49 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 129' ' ' THR . . . . . 0.557 ' HB ' HG22 ' A' ' 127' ' ' ILE . 2.8 m -160.9 133.46 6.16 Favored 'General case' 0 N--CA 1.434 -1.256 0 CA-C-N 114.275 -1.33 . . . . 0.0 108.275 -179.179 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 6.3 mt-10 -58.69 156.87 10.22 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.947 0.403 . . . . 0.0 111.818 -176.993 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 131' ' ' ARG . . . . . . . . . . . . . 62.4 mtm-85 -61.47 106.15 0.61 Allowed 'General case' 0 C--O 1.234 0.289 0 CA-C-N 115.412 -0.813 . . . . 0.0 113.114 -169.197 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 25.6 mtpp -137.33 -29.0 0.9 Allowed 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 114.404 -1.271 . . . . 0.0 109.759 172.816 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 133' ' ' MET . . . . . 0.8 ' HG2' ' HB2' ' A' ' 146' ' ' TYR . 82.1 mtp -84.05 -179.0 7.14 Favored 'General case' 0 C--O 1.232 0.176 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.294 179.874 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 19.1 ptmt -142.52 135.09 27.99 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 120.985 0.422 . . . . 0.0 111.091 -179.449 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 135' ' ' LEU . . . . . 0.563 HD11 ' HD2' ' A' ' 142' ' ' TYR . 50.3 tp -71.63 124.14 24.07 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.543 -0.753 . . . . 0.0 110.307 175.743 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 136' ' ' VAL . . . . . 0.42 HG23 ' CD1' ' A' ' 143' ' ' PHE . 0.0 OUTLIER -121.78 137.22 56.12 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.145 -179.818 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 17.2 m-80 -110.13 126.38 54.0 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 109.136 -0.69 . . . . 0.0 109.136 177.676 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 52.8 t80 -142.12 116.72 9.72 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 121.112 0.482 . . . . 0.0 111.277 -179.39 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 77.45 -92.34 1.08 Allowed Glycine 0 N--CA 1.447 -0.618 0 CA-C-N 115.74 -0.664 . . . . 0.0 112.159 176.045 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 50.4 mtm180 -139.52 16.37 2.55 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-O 121.047 0.451 . . . . 0.0 110.831 -179.372 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 13.8 t -138.15 158.72 43.74 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.269 -179.104 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 142' ' ' TYR . . . . . 0.563 ' HD2' HD11 ' A' ' 135' ' ' LEU . 35.2 p90 -134.33 139.62 45.79 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 178.135 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 143' ' ' PHE . . . . . 0.42 ' CD1' HG23 ' A' ' 136' ' ' VAL . 9.2 p90 -148.9 -172.83 4.2 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.116 -173.185 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 99.1 m-85 -119.42 128.63 54.22 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 120.486 0.184 . . . . 0.0 110.633 -179.086 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 145' ' ' GLU . . . . . . . . . . . . . 19.1 pt-20 -120.31 159.88 24.13 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.044 0.45 . . . . 0.0 109.916 174.78 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 146' ' ' TYR . . . . . 0.8 ' HB2' ' HG2' ' A' ' 133' ' ' MET . 49.7 t80 -140.63 127.95 21.14 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 115.904 -0.589 . . . . 0.0 109.816 176.471 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 147' ' ' ILE . . . . . 0.433 ' N ' HD12 ' A' ' 147' ' ' ILE . 3.1 mp -94.63 100.66 11.47 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 N-CA-C 109.679 -0.489 . . . . 0.0 109.679 178.752 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -91.38 125.75 36.24 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.869 -0.605 . . . . 0.0 109.796 177.115 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 -79.69 160.89 26.12 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-O 121.038 0.447 . . . . 0.0 110.186 -179.533 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 40.5 t -84.3 140.65 15.81 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-N 116.0 -0.545 . . . . 0.0 109.555 179.783 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 151' ' ' ARG . . . . . 0.501 ' HD3' ' O ' ' A' ' 151' ' ' ARG . 0.1 OUTLIER -56.68 131.25 48.51 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.967 0.413 . . . . 0.0 110.237 178.67 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 4.9 m -60.93 122.43 14.87 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.618 -0.719 . . . . 0.0 112.028 -171.859 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 153' ' ' ARG . . . . . 0.436 ' HB2' HH11 ' A' ' 151' ' ' ARG . 50.4 ttp85 . . . . . 0 C--O 1.249 1.052 0 CA-C-O 118.289 -0.862 . . . . 0.0 109.103 173.14 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 26.6 ptt? . . . . . 0 N--CA 1.483 1.222 0 N-CA-C 111.525 0.194 . . . . 0.0 111.525 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 75.85 -157.88 49.3 Favored Glycine 0 N--CA 1.449 -0.495 0 C-N-CA 120.631 -0.795 . . . . 0.0 112.322 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 29.4 m -97.99 174.34 6.61 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 120.961 0.41 . . . . 0.0 110.733 -178.036 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 10.7 t -141.78 75.3 1.49 Allowed 'General case' 0 C--N 1.322 -0.612 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 175.106 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 28.6 t-80 -146.91 153.7 40.43 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.436 -173.281 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 2.0 t-80 71.77 20.56 4.54 Favored 'General case' 0 N--CA 1.464 0.264 0 O-C-N 124.089 0.868 . . . . 0.0 109.79 -177.955 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 80.7 m80 -92.49 6.32 47.55 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.304 -0.862 . . . . 0.0 109.472 172.928 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 62.9 m80 -73.93 142.38 45.93 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.248 -0.887 . . . . 0.0 110.497 -178.107 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 20.5 m80 -89.66 84.99 6.35 Favored 'General case' 0 C--N 1.32 -0.683 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 -178.072 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 52.0 p-80 -95.24 126.07 40.31 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 121.185 0.516 . . . . 0.0 110.552 178.55 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 21.4 m -149.26 111.53 4.68 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.907 -0.588 . . . . 0.0 109.777 179.042 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 5.3 t -108.43 179.37 4.22 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 116.455 -0.339 . . . . 0.0 110.465 -176.678 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -131.04 166.42 22.71 Favored Glycine 0 N--CA 1.446 -0.661 0 N-CA-C 111.276 -0.73 . . . . 0.0 111.276 177.548 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' LEU . . . . . 0.421 ' O ' HD12 ' A' ' 14' ' ' LEU . 2.9 pp -136.46 152.61 50.76 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.863 0.331 . . . . 0.0 110.785 178.97 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.488 ' HA ' ' HD3' ' A' ' 16' ' ' PRO . 14.2 m -115.46 115.48 42.12 Favored Pre-proline 0 C--N 1.322 -0.624 0 CA-C-O 121.296 0.569 . . . . 0.0 111.027 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.488 ' HD3' ' HA ' ' A' ' 15' ' ' VAL . 3.9 Cg_exo -82.33 142.04 11.73 Favored 'Trans proline' 0 N--CA 1.458 -0.587 0 C-N-CA 123.245 2.63 . . . . 0.0 112.101 178.663 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 34.4 mmt180 -87.2 -33.26 19.4 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 121.354 0.597 . . . . 0.0 109.939 177.276 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 123.54 99.7 1.4 Allowed Glycine 0 N--CA 1.446 -0.669 0 N-CA-C 110.716 -0.954 . . . . 0.0 110.716 -174.897 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' SER . . . . . 0.784 ' HB3' ' HD1' ' A' ' 22' ' ' TRP . 37.6 m -119.21 94.94 4.6 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-O 121.111 0.482 . . . . 0.0 111.274 -173.936 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 9.7 m80 -60.32 -45.84 92.01 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.506 -0.77 . . . . 0.0 110.491 -178.55 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -65.62 -15.52 62.82 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.43 -0.805 . . . . 0.0 111.763 -177.028 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 22' ' ' TRP . . . . . 0.784 ' HD1' ' HB3' ' A' ' 19' ' ' SER . 90.8 m95 -94.83 -29.55 14.67 Favored 'General case' 0 C--N 1.322 -0.598 0 C-N-CA 121.013 -0.275 . . . . 0.0 110.696 177.891 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' ASN . . . . . 0.412 ' O ' HG23 ' A' ' 27' ' ' VAL . 4.7 m-20 -68.99 -47.61 65.13 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.515 -0.311 . . . . 0.0 110.905 177.729 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 15.6 m-20 -60.6 -39.48 88.28 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.81 0.338 . . . . 0.0 110.579 178.59 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 60.5 tp -57.76 -49.53 76.27 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.424 176.204 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -55.71 -47.17 77.31 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.542 -0.753 . . . . 0.0 110.904 178.859 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.412 HG23 ' O ' ' A' ' 23' ' ' ASN . 84.9 t -56.73 -42.9 78.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.938 178.479 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 86.6 t80 -61.32 -45.48 94.28 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.724 0.297 . . . . 0.0 110.383 178.436 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 72.9 mt -63.21 -43.2 98.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.45 178.799 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 86.8 mt -56.83 -42.66 78.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 115.451 -0.795 . . . . 0.0 111.265 177.126 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 21.4 mtp180 -69.06 -32.37 71.79 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.804 -178.816 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 77.0 m -88.33 2.51 52.36 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.794 -0.639 . . . . 0.0 111.758 -175.874 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 22.0 p -129.7 -80.54 0.56 Allowed 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 120.816 0.341 . . . . 0.0 111.004 178.018 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 95.61 160.13 33.08 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.934 -0.65 . . . . 0.0 112.408 -179.616 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -73.25 141.68 32.62 Favored 'Trans proline' 0 N--CA 1.462 -0.347 0 C-N-CA 122.785 2.323 . . . . 0.0 111.438 178.022 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 113.13 3.71 24.39 Favored Glycine 0 N--CA 1.449 -0.452 0 C-N-CA 120.348 -0.929 . . . . 0.0 112.16 -177.226 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 14.7 t -139.42 -169.57 2.71 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 110.001 -0.37 . . . . 0.0 110.001 177.812 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' ARG . . . . . 0.41 ' HD3' HH11 ' A' ' 38' ' ' ARG . 47.0 mtp180 -121.75 135.84 54.94 Favored 'General case' 0 N--CA 1.45 -0.45 0 CA-C-O 120.906 0.384 . . . . 0.0 110.637 -178.738 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 52.3 t -122.56 134.67 65.07 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 177.463 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 50.3 t -108.04 124.36 64.21 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-O 120.733 0.301 . . . . 0.0 110.678 -177.813 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' GLU . . . . . 0.527 ' HB2' HD21 ' A' ' 62' ' ' LEU . 35.6 tt0 -102.04 106.68 17.61 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.066 179.004 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.6 ' O ' ' HA ' ' A' ' 95' ' ' SER . 60.3 t -94.04 124.39 46.49 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.603 0 CA-C-N 116.031 -0.531 . . . . 0.0 109.846 179.779 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 96.27 37.63 4.79 Favored Glycine 0 N--CA 1.445 -0.751 0 C-N-CA 120.337 -0.935 . . . . 0.0 111.297 -175.93 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -81.21 24.61 0.52 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.018 0.437 . . . . 0.0 111.413 -177.822 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -73.89 79.09 0.87 Allowed Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 121.212 -0.518 . . . . 0.0 112.08 -178.924 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 26.7 ttt180 75.67 7.72 3.8 Favored 'General case' 0 N--CA 1.468 0.436 0 C-N-CA 123.418 0.687 . . . . 0.0 110.968 177.14 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 65.8 m-85 -95.96 31.01 2.22 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.39 0.614 . . . . 0.0 110.413 178.06 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.609 HD22 HD13 ' A' ' 64' ' ' LEU . 61.6 mt -74.35 14.65 0.42 Allowed 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.075 -0.966 . . . . 0.0 112.376 -172.931 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 49' ' ' TYR . . . . . 0.481 ' CE2' ' HB2' ' A' ' 19' ' ' SER . 87.8 t80 -70.3 -37.26 74.74 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 121.068 0.461 . . . . 0.0 110.375 179.665 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 47.2 t -74.76 -48.81 32.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-N 115.936 -0.574 . . . . 0.0 110.372 -179.326 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -58.67 -39.77 81.63 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.997 -0.547 . . . . 0.0 111.369 179.526 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.425 ' O ' ' HE2' ' A' ' 56' ' ' LYS . 30.6 t70 -62.06 -45.07 95.16 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.792 0.33 . . . . 0.0 110.531 177.826 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 53' ' ' TYR . . . . . 0.459 ' HA ' ' HE2' ' A' ' 56' ' ' LYS . 81.5 t80 -63.53 -42.98 98.4 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.927 -179.248 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 80.8 mt -66.22 -47.73 83.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.889 -178.941 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 22.4 ptt180 -62.77 -24.57 67.78 Favored 'General case' 0 N--CA 1.467 0.401 0 N-CA-C 111.856 0.317 . . . . 0.0 111.856 -175.344 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 56' ' ' LYS . . . . . 0.459 ' HE2' ' HA ' ' A' ' 53' ' ' TYR . 42.2 mtmt -77.2 -31.22 55.17 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.727 0.299 . . . . 0.0 111.692 -177.611 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 7.7 t-80 -99.18 -48.56 4.79 Favored 'General case' 0 N--CA 1.448 -0.562 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.518 -177.384 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 38.1 m -95.22 155.51 16.7 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.068 0.461 . . . . 0.0 111.053 -178.024 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 28.5 mmmt -105.17 19.26 20.9 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.938 -0.574 . . . . 0.0 109.704 178.242 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 15.0 p -68.63 153.27 9.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 115.404 -0.816 . . . . 0.0 110.522 -178.78 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -86.58 103.34 14.99 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 120.832 0.349 . . . . 0.0 110.16 178.521 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 62' ' ' LEU . . . . . 0.527 HD21 ' HB2' ' A' ' 41' ' ' GLU . 1.8 tt -101.36 119.08 38.22 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 115.942 -0.572 . . . . 0.0 109.935 -176.42 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 46.2 t -100.22 119.14 47.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.365 -179.15 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 64' ' ' LEU . . . . . 0.609 HD13 HD22 ' A' ' 48' ' ' LEU . 32.3 mt -95.42 122.44 38.14 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.935 -0.575 . . . . 0.0 109.73 178.785 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 37.9 p -118.34 142.27 47.69 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 120.567 0.222 . . . . 0.0 111.189 -178.374 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 30.9 t70 -165.32 154.97 12.81 Favored 'General case' 0 C--N 1.33 -0.259 0 N-CA-C 110.124 -0.325 . . . . 0.0 110.124 179.788 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.575 HD13 ' HA ' ' A' ' 78' ' ' ASP . 37.4 mm -69.61 94.33 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.853 0.359 . . . . 0.0 110.163 179.144 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 68' ' ' LYS . . . . . 0.722 ' HD3' ' HB2' ' A' ' 76' ' ' ARG . 40.9 mmtm 44.46 70.66 1.81 Allowed Pre-proline 0 CA--C 1.533 0.296 0 CA-C-N 115.279 -0.873 . . . . 0.0 110.835 -178.304 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 69' ' ' PRO . . . . . 0.742 ' HD2' ' HA ' ' A' ' 76' ' ' ARG . 10.3 Cg_endo -51.45 142.25 39.03 Favored 'Trans proline' 0 C--N 1.344 0.341 0 C-N-CA 123.896 3.064 . . . . 0.0 113.762 -172.495 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 22.6 t -96.82 -8.4 31.14 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 114.961 -1.018 . . . . 0.0 109.944 -178.769 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 60.5 t-80 -79.79 -46.46 16.93 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.204 -178.443 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 109.37 144.09 10.41 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.96 -0.638 . . . . 0.0 111.918 -177.842 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 86.95 -41.11 3.08 Favored Glycine 0 CA--C 1.516 0.148 0 C-N-CA 120.901 -0.666 . . . . 0.0 112.187 179.493 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.495 ' HB ' ' HG3' ' A' ' 69' ' ' PRO . 35.9 mt -58.76 149.08 5.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 C-N-CA 122.809 0.444 . . . . 0.0 110.38 177.072 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 60.3 t -68.62 128.62 32.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 178.767 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 76' ' ' ARG . . . . . 0.742 ' HA ' ' HD2' ' A' ' 69' ' ' PRO . 32.1 ptt180 -91.43 54.46 2.54 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.453 0.644 . . . . 0.0 110.976 -179.43 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 9.7 p-10 -83.34 -156.54 0.2 Allowed 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.039 -0.982 . . . . 0.0 109.955 178.129 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 78' ' ' ASP . . . . . 0.575 ' HA ' HD13 ' A' ' 67' ' ' ILE . 20.3 m-20 -143.85 108.75 4.94 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 110.297 -0.26 . . . . 0.0 110.297 -179.391 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 9.3 tp -73.66 -24.51 19.99 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.37 0 CA-C-O 120.819 0.343 . . . . 0.0 110.737 178.758 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 10.0 t -69.19 -26.95 65.09 Favored 'General case' 0 CA--C 1.531 0.241 0 CA-C-O 121.219 0.533 . . . . 0.0 110.547 178.077 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 22.7 t -134.28 78.74 57.24 Favored Pre-proline 0 C--N 1.323 -0.569 0 N-CA-C 108.153 -1.055 . . . . 0.0 108.153 173.292 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.429 ' HB2' ' HE2' ' A' ' 87' ' ' TYR . 59.1 Cg_endo -71.13 133.44 23.06 Favored 'Trans proline' 0 N--CA 1.461 -0.426 0 C-N-CA 122.762 2.308 . . . . 0.0 113.625 -168.592 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 83' ' ' ARG . . . . . 0.537 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 70.7 mtt85 -84.98 106.27 16.36 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.453 -0.794 . . . . 0.0 109.27 171.871 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 84' ' ' MET . . . . . . . . . . . . . 89.5 mmm -58.21 -26.45 62.85 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.987 -0.551 . . . . 0.0 111.142 -177.235 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.537 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 11.3 pt-20 -62.14 -26.78 68.51 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.672 -179.558 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 73.6 mt -79.46 -41.11 22.16 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-O 121.04 0.447 . . . . 0.0 110.531 -179.339 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 87' ' ' TYR . . . . . 0.429 ' HE2' ' HB2' ' A' ' 82' ' ' PRO . 44.9 m-85 -79.65 -25.51 41.32 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.789 -176.795 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 52.0 mtp180 -66.23 131.58 46.47 Favored 'General case' 0 CA--C 1.517 -0.304 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.373 176.276 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 98.23 8.72 54.81 Favored Glycine 0 N--CA 1.444 -0.811 0 C-N-CA 120.627 -0.797 . . . . 0.0 111.699 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -100.77 144.6 29.53 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 110.204 -0.295 . . . . 0.0 110.204 177.689 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -92.78 -23.73 18.77 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.078 0.466 . . . . 0.0 110.939 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 92' ' ' LEU . . . . . 0.464 HD23 ' N ' ' A' ' 93' ' ' ILE . 4.6 tt -150.1 140.74 22.58 Favored 'General case' 0 N--CA 1.449 -0.516 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.434 -178.225 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.524 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 62.8 mt -130.68 119.27 45.15 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 115.784 -0.644 . . . . 0.0 109.419 177.937 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 13.2 p90 -126.18 155.21 42.11 Favored 'General case' 0 C--N 1.32 -0.701 0 C-N-CA 120.553 -0.459 . . . . 0.0 110.544 179.277 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 95' ' ' SER . . . . . 0.6 ' HA ' ' O ' ' A' ' 42' ' ' VAL . 10.6 p -135.81 143.63 45.28 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.752 -0.658 . . . . 0.0 111.424 -175.189 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 74.5 mt -114.86 112.59 40.67 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 115.577 -0.738 . . . . 0.0 110.249 178.763 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 61.6 mtp180 57.59 70.36 1.34 Allowed Pre-proline 0 N--CA 1.466 0.331 0 CA-C-N 115.593 -0.73 . . . . 0.0 112.279 -178.459 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_endo -87.31 131.72 3.05 Favored 'Trans proline' 0 N--CA 1.451 -1.005 0 C-N-CA 122.536 2.157 . . . . 0.0 111.78 175.699 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.635 ' HD2' HD11 ' A' ' 102' ' ' ILE . 52.2 Cg_exo -55.98 148.9 55.3 Favored 'Trans proline' 0 C--O 1.235 0.36 0 C-N-CA 122.464 2.11 . . . . 0.0 111.564 172.267 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.712 ' HA ' ' ND1' ' A' ' 103' ' ' HIS . . . -60.71 -22.91 64.45 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.918 0.39 . . . . 0.0 111.763 -175.337 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 101' ' ' GLU . . . . . 0.694 ' HG3' HG23 ' A' ' 102' ' ' ILE . 10.5 pt-20 -66.65 -31.22 71.75 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.983 -179.958 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.694 HG23 ' HG3' ' A' ' 101' ' ' GLU . 48.3 pt -107.42 -1.05 9.92 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.148 0 N-CA-C 112.482 0.549 . . . . 0.0 112.482 -173.004 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 103' ' ' HIS . . . . . 0.712 ' ND1' ' HA ' ' A' ' 100' ' ' ALA . 13.1 m170 -53.54 -55.61 24.08 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 121.118 0.485 . . . . 0.0 111.162 178.235 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 19.0 m -70.2 -25.59 63.48 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 121.184 0.516 . . . . 0.0 110.689 179.503 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.705 ' O ' ' HG2' ' A' ' 108' ' ' ARG . 1.7 m -71.83 -37.65 70.27 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.502 -177.955 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 86.1 mt -63.62 -39.15 93.64 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.709 177.531 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 107' ' ' MET . . . . . 0.447 ' SD ' ' HB3' ' A' ' 131' ' ' ARG . 49.7 ttm -64.54 -42.33 95.78 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.208 179.447 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 108' ' ' ARG . . . . . 0.705 ' HG2' ' O ' ' A' ' 105' ' ' SER . 1.7 ptm180 -66.37 -26.84 67.45 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.836 0.35 . . . . 0.0 110.628 -178.225 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 82.2 t -75.3 -49.15 28.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.155 175.374 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -57.69 -42.63 84.05 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.494 177.458 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.492 ' HA ' ' HB1' ' A' ' 148' ' ' ALA . 16.8 t70 -62.45 -32.08 72.9 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.581 -0.736 . . . . 0.0 110.746 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -79.09 -41.74 27.97 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.585 -0.734 . . . . 0.0 111.955 -178.634 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 29.0 m -87.83 -26.14 5.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 N-CA-C 111.907 0.336 . . . . 0.0 111.907 -175.955 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 114' ' ' GLY . . . . . 0.412 ' HA3' ' HA ' ' A' ' 150' ' ' VAL . . . 82.5 64.86 1.66 Allowed Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.884 -0.674 . . . . 0.0 112.052 -178.955 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 115' ' ' ALA . . . . . 0.4 ' O ' ' HB3' ' A' ' 148' ' ' ALA . . . -139.58 155.41 47.49 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 120.815 0.341 . . . . 0.0 110.702 -179.909 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 116' ' ' ARG . . . . . 0.449 ' HB3' ' HG ' ' A' ' 92' ' ' LEU . 20.0 ttm-85 -75.1 121.59 22.27 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 177.416 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 117' ' ' LEU . . . . . 0.524 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 65.9 tp -94.02 125.28 38.56 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.171 -179.928 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 71.4 mt -124.25 120.51 59.46 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.654 0 CA-C-O 120.899 0.38 . . . . 0.0 110.146 177.488 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 30.2 mt -114.04 131.21 66.64 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.217 -178.348 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 120' ' ' LYS . . . . . 0.616 ' HD3' ' HB3' ' A' ' 143' ' ' PHE . 10.9 mmmm -110.86 98.08 36.61 Favored Pre-proline 0 C--O 1.235 0.308 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.881 172.946 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 85.7 Cg_endo -92.42 -157.89 0.06 OUTLIER 'Trans proline' 0 N--CA 1.453 -0.889 0 C-N-CA 123.177 2.585 . . . . 0.0 111.162 173.729 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 8.0 mp -111.38 150.42 29.79 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 120.635 0.255 . . . . 0.0 110.607 178.205 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 38.1 m -65.57 110.42 2.72 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.064 0.459 . . . . 0.0 110.655 178.916 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 108.36 -10.76 36.34 Favored Glycine 0 N--CA 1.445 -0.71 0 N-CA-C 111.084 -0.806 . . . . 0.0 111.084 -176.461 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 4.7 tp10 -106.39 100.5 10.02 Favored 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 109.08 -0.711 . . . . 0.0 109.08 178.49 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 15.8 t70 -85.22 165.05 17.69 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.427 -0.351 . . . . 0.0 110.958 -174.033 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.447 HG23 ' CG ' ' A' ' 103' ' ' HIS . 52.3 mt -83.2 -21.72 8.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-N 115.767 -0.652 . . . . 0.0 110.55 -177.628 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 17.4 m 47.6 26.87 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.931 0 C-N-CA 124.444 1.098 . . . . 0.0 112.926 179.77 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 13.7 t -92.89 145.44 24.38 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 109.97 -0.381 . . . . 0.0 109.97 177.831 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -91.08 32.02 1.05 Allowed 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.271 0.558 . . . . 0.0 109.915 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 131' ' ' ARG . . . . . 0.447 ' HB3' ' SD ' ' A' ' 107' ' ' MET . 4.0 mmp_? -110.65 -177.8 3.32 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.579 -178.272 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 132' ' ' LYS . . . . . 0.468 ' HE3' ' HB2' ' A' ' 132' ' ' LYS . 35.5 mtmt -99.49 124.32 44.56 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.282 -178.918 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 133' ' ' MET . . . . . . . . . . . . . 79.7 mtp -146.08 150.59 36.23 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 170.789 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 1.5 ptpp? -114.83 141.27 48.12 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 121.322 0.582 . . . . 0.0 111.301 -177.501 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 135' ' ' LEU . . . . . 0.558 HD11 ' HD2' ' A' ' 142' ' ' TYR . 60.0 tp -82.24 129.23 34.8 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.141 -0.936 . . . . 0.0 109.883 178.666 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -126.35 148.47 31.05 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.885 -177.852 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 68.2 m-20 -124.23 125.73 44.89 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.05 -0.523 . . . . 0.0 109.865 179.827 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 138' ' ' TYR . . . . . 0.608 ' O ' HG22 ' A' ' 141' ' ' THR . 42.7 t80 -149.19 104.79 3.44 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.746 0.307 . . . . 0.0 111.049 177.562 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 139' ' ' GLY . . . . . 0.402 ' C ' ' H ' ' A' ' 141' ' ' THR . . . 59.93 67.28 2.23 Favored Glycine 0 CA--C 1.521 0.417 0 CA-C-N 116.212 -0.449 . . . . 0.0 113.736 175.878 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 21.9 mmt180 69.54 -21.64 0.16 Allowed 'General case' 0 N--CA 1.47 0.547 0 N-CA-C 113.176 0.806 . . . . 0.0 113.176 176.339 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 141' ' ' THR . . . . . 0.608 HG22 ' O ' ' A' ' 138' ' ' TYR . 1.0 OUTLIER -98.0 131.47 44.4 Favored 'General case' 0 N--CA 1.444 -0.77 0 CA-C-O 121.33 0.586 . . . . 0.0 109.91 -179.359 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 142' ' ' TYR . . . . . 0.558 ' HD2' HD11 ' A' ' 135' ' ' LEU . 21.6 p90 -115.99 147.28 41.37 Favored 'General case' 0 N--CA 1.445 -0.713 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 174.872 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 143' ' ' PHE . . . . . 0.616 ' HB3' ' HD3' ' A' ' 120' ' ' LYS . 12.2 p90 -155.81 171.82 19.38 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.61 -175.308 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -107.93 121.43 44.77 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.899 -0.591 . . . . 0.0 109.568 175.845 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 145' ' ' GLU . . . . . . . . . . . . . 15.3 pt-20 -112.32 156.06 23.06 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-O 121.267 0.556 . . . . 0.0 109.578 177.125 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 34.7 t80 -138.88 124.23 19.28 Favored 'General case' 0 C--N 1.311 -1.092 0 CA-C-N 115.646 -0.706 . . . . 0.0 109.468 176.322 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 147' ' ' ILE . . . . . 0.446 ' N ' HD12 ' A' ' 147' ' ' ILE . 3.1 mp -88.44 96.07 5.72 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.739 0 N-CA-C 109.18 -0.674 . . . . 0.0 109.18 178.078 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 148' ' ' ALA . . . . . 0.492 ' HB1' ' HA ' ' A' ' 111' ' ' ASP . . . -76.49 118.03 18.75 Favored 'General case' 0 C--N 1.317 -0.819 0 CA-C-N 115.369 -0.832 . . . . 0.0 109.061 177.042 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 31.3 mt-10 -61.48 129.59 41.92 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 121.814 0.816 . . . . 0.0 111.094 -175.206 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 150' ' ' VAL . . . . . 0.412 ' HA ' ' HA3' ' A' ' 114' ' ' GLY . 9.3 t -83.49 118.28 30.73 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.008 0 CA-C-N 114.387 -1.279 . . . . 0.0 110.557 -171.98 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 151' ' ' ARG . . . . . . . . . . . . . 13.0 ptp180 -87.54 80.56 8.01 Favored 'General case' 0 C--N 1.314 -0.961 0 CA-C-N 115.174 -0.921 . . . . 0.0 109.379 177.701 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 44.7 t -140.4 151.15 44.7 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.547 -0.751 . . . . 0.0 110.986 -173.846 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 37.2 tpt85 . . . . . 0 N--CA 1.44 -0.932 0 CA-C-O 118.266 -0.873 . . . . 0.0 109.055 172.78 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.479 0.985 0 N-CA-C 109.702 -0.481 . . . . 0.0 109.702 . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -82.88 100.48 2.2 Favored Glycine 0 N--CA 1.446 -0.683 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.481 -178.685 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 27.9 t -65.59 126.95 29.95 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 109.36 -0.607 . . . . 0.0 109.36 177.192 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 8.6 p -80.92 49.77 1.27 Allowed 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 112.264 0.468 . . . . 0.0 112.264 -172.156 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 26.1 t-80 -121.61 85.87 2.48 Favored 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 171.813 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 7.6 p-80 -136.62 17.13 3.11 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.518 -0.764 . . . . 0.0 110.632 -177.407 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 10.7 p80 -101.44 17.48 22.61 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 121.387 0.613 . . . . 0.0 110.105 178.617 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 43.0 p-80 -74.6 -7.25 52.56 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.506 -0.77 . . . . 0.0 112.048 -175.123 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 15.7 p-80 -79.69 163.36 24.59 Favored 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 176.119 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 54.3 p-80 -132.41 169.33 16.68 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 121.015 0.436 . . . . 0.0 111.331 -175.901 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 42.9 t -133.7 156.03 48.67 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.585 -0.734 . . . . 0.0 109.644 175.303 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 20.8 m -127.82 0.92 6.04 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 120.782 0.325 . . . . 0.0 110.592 178.688 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 68.27 82.35 0.17 Allowed Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 120.837 -0.697 . . . . 0.0 112.26 -177.277 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' LEU . . . . . 0.734 HD23 ' H ' ' A' ' 14' ' ' LEU . 2.5 pt? -84.37 142.06 30.43 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 120.872 0.368 . . . . 0.0 110.422 -178.607 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.434 ' HA ' ' HD3' ' A' ' 16' ' ' PRO . 46.4 t -117.65 106.68 45.84 Favored Pre-proline 0 C--N 1.32 -0.698 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.06 179.372 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.434 ' HD3' ' HA ' ' A' ' 15' ' ' VAL . 2.7 Cg_endo -81.58 163.51 18.97 Favored 'Trans proline' 0 N--CA 1.456 -0.7 0 C-N-CA 122.983 2.455 . . . . 0.0 112.038 179.225 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' ARG . . . . . 0.487 ' HA ' ' NE ' ' A' ' 17' ' ' ARG . 5.0 mmp_? -110.92 143.71 41.13 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.261 178.381 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 140.58 -165.69 26.05 Favored Glycine 0 N--CA 1.448 -0.505 0 C-N-CA 120.68 -0.772 . . . . 0.0 112.241 178.81 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' SER . . . . . 0.487 ' HB3' ' HD1' ' A' ' 22' ' ' TRP . 15.3 m -80.89 44.83 0.77 Allowed 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 120.757 0.313 . . . . 0.0 111.237 -178.532 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' HIS . . . . . 0.43 ' HA ' ' HB2' ' A' ' 23' ' ' ASN . 61.8 m-70 -66.68 -20.39 65.97 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 111.83 0.307 . . . . 0.0 111.83 -177.023 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 21' ' ' MET . . . . . . . . . . . . . 56.9 mtt -68.22 -18.05 64.47 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.214 0.531 . . . . 0.0 110.271 174.737 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' TRP . . . . . 0.487 ' HD1' ' HB3' ' A' ' 19' ' ' SER . 83.2 m95 -96.54 -30.38 13.34 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.914 -0.585 . . . . 0.0 109.596 175.431 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' ASN . . . . . 0.43 ' HB2' ' HA ' ' A' ' 20' ' ' HIS . 4.6 m-20 -62.51 -56.02 21.94 Favored 'General case' 0 CA--C 1.521 -0.171 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.508 176.418 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.549 ' HB3' ' HA3' ' A' ' 139' ' ' GLY . 44.7 m-20 -60.61 -36.64 79.09 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.617 179.766 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 64.6 tp -55.83 -49.74 72.45 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.177 175.027 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' ALA . . . . . 0.566 ' HB2' HG13 ' A' ' 50' ' ' VAL . . . -62.14 -46.69 87.89 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.582 -0.736 . . . . 0.0 111.024 179.029 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 71.4 t -53.17 -47.32 55.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 121.102 0.477 . . . . 0.0 110.664 176.8 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' TYR . . . . . 0.481 ' HB2' ' CD1' ' A' ' 138' ' ' TYR . 69.7 t80 -56.2 -41.64 75.9 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.891 178.491 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.499 HG23 HD22 ' A' ' 92' ' ' LEU . 75.8 mt -69.83 -44.81 78.63 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.82 178.88 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.621 HD11 ' HA ' ' A' ' 54' ' ' ILE . 83.6 mt -57.77 -43.77 84.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 115.891 -0.595 . . . . 0.0 111.507 -178.98 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 17.9 mtp180 -64.81 -32.76 74.6 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.902 -178.569 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 81.4 m -88.95 -18.67 26.99 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 115.501 -0.772 . . . . 0.0 111.995 -174.006 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 14.0 p -101.54 -82.1 0.47 Allowed 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 120.797 0.332 . . . . 0.0 111.556 -178.54 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 101.81 161.42 26.77 Favored Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 121.014 -0.612 . . . . 0.0 112.187 -178.328 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 7.6 Cg_exo -72.8 144.48 39.12 Favored 'Trans proline' 0 C--O 1.233 0.269 0 C-N-CA 123.083 2.522 . . . . 0.0 112.383 -179.163 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 111.89 -28.76 9.06 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.533 -0.842 . . . . 0.0 112.813 177.897 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 12.6 t -99.86 -169.45 1.74 Allowed 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 -178.551 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' ARG . . . . . 0.628 ' HB2' ' HA ' ' A' ' 90' ' ' ALA . 66.2 mtp180 -118.6 136.51 53.84 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.954 0.407 . . . . 0.0 111.134 -178.346 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.655 HG23 HG21 ' A' ' 60' ' ' VAL . 95.5 t -129.97 131.11 66.38 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-N 115.83 -0.623 . . . . 0.0 109.369 176.699 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.576 HG22 ' HB ' ' A' ' 63' ' ' VAL . 40.6 t -112.12 129.0 68.4 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 CA-C-O 120.765 0.317 . . . . 0.0 111.759 -173.178 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 41' ' ' GLU . . . . . 0.459 ' HB3' HD23 ' A' ' 64' ' ' LEU . 44.8 tt0 -103.11 107.76 18.7 Favored 'General case' 0 C--O 1.235 0.319 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 174.693 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 44.1 t -89.68 127.78 42.09 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.647 -178.16 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 94.14 23.98 20.82 Favored Glycine 0 N--CA 1.448 -0.523 0 N-CA-C 110.955 -0.858 . . . . 0.0 110.955 -176.375 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.608 ' HB1' HD23 ' A' ' 48' ' ' LEU . . . -93.47 80.38 4.36 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.247 -0.476 . . . . 0.0 110.858 -177.044 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -108.42 -60.61 0.54 Allowed Glycine 0 N--CA 1.446 -0.664 0 C-N-CA 120.824 -0.703 . . . . 0.0 112.015 178.607 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 57.6 mtp180 -125.47 4.44 7.63 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.933 0.397 . . . . 0.0 110.814 -179.171 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.528 ' HE2' HG23 ' A' ' 50' ' ' VAL . 64.7 t80 -86.69 -79.45 0.26 Allowed 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 176.712 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.646 HD22 HD13 ' A' ' 64' ' ' LEU . 59.4 mt 62.71 9.35 3.51 Favored 'General case' 0 N--CA 1.467 0.41 0 CA-C-N 115.156 -0.929 . . . . 0.0 112.795 171.006 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 49' ' ' TYR . . . . . 0.452 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 81.2 t80 -71.08 -45.42 63.77 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 111.791 0.293 . . . . 0.0 111.791 -171.431 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.566 HG13 ' HB2' ' A' ' 26' ' ' ALA . 56.2 t -69.98 -48.57 62.35 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-N 116.599 -0.273 . . . . 0.0 110.597 -177.946 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 50.9 p -58.77 -41.15 85.92 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.453 -0.339 . . . . 0.0 111.037 176.956 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.737 ' HA ' ' HE ' ' A' ' 55' ' ' ARG . 24.4 t70 -61.13 -37.97 84.72 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.8 0.333 . . . . 0.0 110.712 176.55 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 47.3 t80 -69.19 -45.6 69.55 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.308 178.041 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.621 ' HA ' HD11 ' A' ' 30' ' ' ILE . 88.0 mt -63.45 -44.83 99.02 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.823 -178.347 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 55' ' ' ARG . . . . . 0.748 HH22 HD11 ' A' ' 64' ' ' LEU . 12.1 ptp180 -63.37 -16.42 60.42 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-O 120.791 0.329 . . . . 0.0 111.584 -175.77 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 56' ' ' LYS . . . . . 0.459 ' HG3' ' O ' ' A' ' 52' ' ' ASP . 97.7 mttt -81.39 -36.04 30.03 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.599 -179.602 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 81.6 m-70 -103.67 -18.11 14.85 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.817 -175.021 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' SER . . . . . 0.421 ' HB2' HG23 ' A' ' 30' ' ' ILE . 6.4 t -135.63 128.9 31.98 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-O 120.794 0.331 . . . . 0.0 110.566 -177.356 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -89.39 51.42 2.12 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.871 0.843 . . . . 0.0 110.126 175.532 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.655 HG21 HG23 ' A' ' 39' ' ' VAL . 8.3 p -83.59 147.21 5.96 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 CA-C-N 114.845 -1.07 . . . . 0.0 108.908 175.434 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 61' ' ' ASP . . . . . 0.571 ' HB3' ' HG2' ' A' ' 38' ' ' ARG . 19.0 t70 -72.68 95.52 1.88 Allowed 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 109.248 -0.649 . . . . 0.0 109.248 179.269 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 62' ' ' LEU . . . . . 0.411 ' HA ' ' O ' ' A' ' 39' ' ' VAL . 2.1 tt -94.77 128.45 41.49 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.407 -172.318 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.576 ' HB ' HG22 ' A' ' 40' ' ' VAL . 33.3 t -108.71 126.7 65.58 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.45 -178.92 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 64' ' ' LEU . . . . . 0.748 HD11 HH22 ' A' ' 55' ' ' ARG . 66.7 mt -108.61 131.18 55.13 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 116.039 -0.528 . . . . 0.0 109.63 176.4 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 49.9 p -129.3 127.91 42.11 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.721 0.296 . . . . 0.0 111.319 179.389 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 3.7 t70 -165.74 175.88 8.43 Favored 'General case' 0 C--O 1.233 0.215 0 CA-C-N 116.082 -0.508 . . . . 0.0 109.732 176.964 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 53.0 mt -87.68 114.57 26.72 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-O 120.634 0.254 . . . . 0.0 110.657 -176.391 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 55.3 mtpt 61.17 79.93 0.27 Allowed Pre-proline 0 C--N 1.331 -0.226 0 CA-C-N 115.646 -0.707 . . . . 0.0 110.9 178.287 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 69' ' ' PRO . . . . . 1.017 ' HB3' ' HB ' ' A' ' 74' ' ' ILE . 18.9 Cg_endo -58.21 114.84 2.15 Favored 'Trans proline' 0 C--N 1.342 0.223 0 C-N-CA 123.281 2.654 . . . . 0.0 113.08 -176.092 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 5.9 p -80.56 -30.54 37.04 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.932 178.911 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 46.1 t-80 -64.5 -59.11 4.7 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.797 178.826 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 132.33 -41.58 1.48 Allowed Glycine 0 N--CA 1.447 -0.575 0 C-N-CA 120.877 -0.678 . . . . 0.0 111.992 -179.164 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -93.6 24.54 25.37 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 121.004 -0.617 . . . . 0.0 112.031 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 1.017 ' HB ' ' HB3' ' A' ' 69' ' ' PRO . 65.4 mt -104.91 146.47 12.06 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 N-CA-C 109.996 -0.372 . . . . 0.0 109.996 -179.71 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.589 HG11 HD13 ' A' ' 86' ' ' ILE . 48.3 t -80.78 135.89 24.32 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 N-CA-C 109.778 -0.452 . . . . 0.0 109.778 176.805 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 11.4 ptt180 -75.98 25.71 0.12 Allowed 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.867 -0.606 . . . . 0.0 111.876 -177.177 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 77' ' ' ASP . . . . . 0.404 ' H ' ' C ' ' A' ' 75' ' ' VAL . 12.7 t70 -83.35 113.82 20.99 Favored 'General case' 0 C--N 1.324 -0.536 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 -177.753 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 2.2 p30 -70.67 168.97 15.37 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.033 0.444 . . . . 0.0 111.257 -172.697 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 79' ' ' ILE . . . . . 0.443 HD11 HD12 ' A' ' 102' ' ' ILE . 7.1 tp -83.98 -30.27 7.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 N-CA-C 112.936 0.717 . . . . 0.0 112.936 -169.569 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 12.2 t -94.23 -21.01 19.31 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.169 0.509 . . . . 0.0 110.712 -174.017 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 4.5 t -130.64 69.03 82.22 Favored Pre-proline 0 C--N 1.323 -0.585 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.05 -179.807 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -78.64 163.48 26.59 Favored 'Trans proline' 0 N--CA 1.46 -0.443 0 C-N-CA 122.98 2.453 . . . . 0.0 112.619 -175.834 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 83' ' ' ARG . . . . . 0.645 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 88.6 mtm180 -108.92 118.17 36.1 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.291 178.305 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 84' ' ' MET . . . . . 0.515 ' SD ' HG22 ' A' ' 109' ' ' VAL . 92.0 mmm -61.13 -28.61 69.23 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.267 -0.879 . . . . 0.0 111.343 -179.037 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.645 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 10.7 pt-20 -57.69 -24.27 55.9 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.711 -179.975 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.589 HD13 HG11 ' A' ' 75' ' ' VAL . 76.5 mt -86.48 -43.75 16.29 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.089 -177.478 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 87' ' ' TYR . . . . . 0.438 ' CE1' HG11 ' A' ' 40' ' ' VAL . 88.3 m-85 -72.13 -27.15 62.44 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.37 -178.593 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 27.0 mtp180 -66.06 116.66 7.4 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 121.409 0.623 . . . . 0.0 111.26 -179.482 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 118.61 -15.99 11.44 Favored Glycine 0 N--CA 1.447 -0.597 0 CA-C-N 115.189 -0.914 . . . . 0.0 111.243 -176.065 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 90' ' ' ALA . . . . . 0.628 ' HA ' ' HB2' ' A' ' 38' ' ' ARG . . . -75.48 145.63 41.25 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.897 0.379 . . . . 0.0 110.545 178.837 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -98.51 -20.76 16.89 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.125 177.659 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 92' ' ' LEU . . . . . 0.499 HD22 HG23 ' A' ' 29' ' ' ILE . 5.1 tt -153.33 138.24 17.17 Favored 'General case' 0 N--CA 1.447 -0.604 0 CA-C-N 115.688 -0.687 . . . . 0.0 109.967 -179.306 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.538 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 63.6 mt -130.64 131.16 64.96 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 115.987 -0.551 . . . . 0.0 109.629 -178.748 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 94' ' ' TYR . . . . . 0.454 ' HE1' HG12 ' A' ' 39' ' ' VAL . 26.6 p90 -134.15 156.05 49.01 Favored 'General case' 0 C--N 1.322 -0.626 0 C-N-CA 120.625 -0.43 . . . . 0.0 110.811 179.57 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 17.3 m -131.86 139.76 48.91 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.76 -177.651 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 42.3 mm -85.94 86.98 2.5 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.363 -179.259 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 97' ' ' ARG . . . . . 0.438 ' NH1' HD13 ' A' ' 122' ' ' LEU . 39.1 ttp180 44.32 79.56 0.33 Allowed Pre-proline 0 N--CA 1.47 0.558 0 O-C-N 124.126 0.891 . . . . 0.0 112.364 -179.313 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 91.2 Cg_endo -83.83 154.13 13.26 Favored 'Trans proline' 0 N--CA 1.456 -0.704 0 C-N-CA 122.918 2.412 . . . . 0.0 112.042 178.892 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.605 ' HD2' HD11 ' A' ' 102' ' ' ILE . 51.3 Cg_exo -55.35 150.66 40.32 Favored 'Trans proline' 0 C--N 1.346 0.417 0 C-N-CA 122.605 2.204 . . . . 0.0 112.112 175.53 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -79.68 30.31 0.25 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.727 -174.205 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 101' ' ' GLU . . . . . 0.413 ' HG3' HG23 ' A' ' 102' ' ' ILE . 10.4 pt-20 -124.95 -23.46 4.26 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 120.742 0.306 . . . . 0.0 110.954 176.507 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.605 HD11 ' HD2' ' A' ' 99' ' ' PRO . 46.6 pt -98.9 -2.4 9.83 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-O 120.752 0.31 . . . . 0.0 111.316 -177.173 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 103' ' ' HIS . . . . . 0.576 ' O ' ' HG2' ' A' ' 107' ' ' MET . 31.4 p-80 -60.16 -40.09 88.71 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.138 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 8.1 p -63.21 -35.85 81.68 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.913 178.604 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.514 ' O ' HG23 ' A' ' 109' ' ' VAL . 16.3 m -67.42 -45.91 74.72 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.735 -0.666 . . . . 0.0 109.69 177.976 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 96.0 mt -59.86 -42.17 93.1 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.909 178.124 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 107' ' ' MET . . . . . 0.576 ' HG2' ' O ' ' A' ' 103' ' ' HIS . 98.2 mmm -56.71 -49.59 74.71 Favored 'General case' 0 C--O 1.233 0.234 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.537 -179.939 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 33.7 ptt85 -70.77 -30.57 67.09 Favored 'General case' 0 C--N 1.332 -0.188 0 C-N-CA 120.727 -0.389 . . . . 0.0 111.108 -177.403 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.515 HG22 ' SD ' ' A' ' 84' ' ' MET . 69.5 t -67.78 -48.49 75.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 120.575 0.226 . . . . 0.0 110.647 177.029 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -59.08 -41.64 88.5 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.708 179.626 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.679 ' HA ' ' HB1' ' A' ' 148' ' ' ALA . 23.3 t70 -65.6 -42.29 91.8 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.701 -0.682 . . . . 0.0 110.815 178.489 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -62.54 -43.46 98.77 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.964 -0.562 . . . . 0.0 111.645 -178.364 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.419 HG21 HD11 ' A' ' 93' ' ' ILE . 20.2 m -85.38 -28.14 6.42 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-O 120.928 0.394 . . . . 0.0 111.022 -177.59 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 87.35 51.85 3.2 Favored Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 120.596 -0.812 . . . . 0.0 111.918 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -130.15 155.47 46.16 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 120.831 0.348 . . . . 0.0 110.901 -178.799 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 116' ' ' ARG . . . . . 0.698 HH21 HD11 ' A' ' 118' ' ' ILE . 50.2 ttp180 -79.21 117.56 20.34 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 178.037 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 117' ' ' LEU . . . . . 0.538 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 60.3 tp -88.14 118.84 27.99 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.0 -0.546 . . . . 0.0 110.086 -179.535 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 118' ' ' ILE . . . . . 0.698 HD11 HH21 ' A' ' 116' ' ' ARG . 66.6 mt -114.52 117.42 55.54 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-O 121.28 0.562 . . . . 0.0 110.842 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 71.7 mt -116.52 116.9 53.72 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.323 179.308 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 57.6 tttp -102.76 104.4 38.78 Favored Pre-proline 0 C--N 1.322 -0.598 0 C-N-CA 120.656 -0.418 . . . . 0.0 110.005 172.351 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 121' ' ' PRO . . . . . 0.591 ' HB2' ' O ' ' A' ' 125' ' ' GLU . 70.5 Cg_endo -78.68 -139.58 0.02 OUTLIER 'Trans proline' 0 N--CA 1.457 -0.673 0 C-N-CA 122.522 2.148 . . . . 0.0 111.531 172.673 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 122' ' ' LEU . . . . . 0.888 ' HB3' ' HB3' ' A' ' 125' ' ' GLU . 14.4 tp -126.82 156.94 40.52 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.383 -178.789 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 123' ' ' THR . . . . . 0.472 ' HA ' ' OH ' ' A' ' 142' ' ' TYR . 25.4 m -69.94 102.04 1.9 Allowed 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 177.368 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 100.88 2.88 55.1 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.967 -0.635 . . . . 0.0 111.737 -175.533 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 125' ' ' GLU . . . . . 0.888 ' HB3' ' HB3' ' A' ' 122' ' ' LEU . 37.7 tt0 -132.38 97.12 4.02 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 177.827 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 14.2 t70 -99.9 173.06 6.85 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.403 -0.817 . . . . 0.0 110.455 -170.227 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.403 ' HB ' HG22 ' A' ' 129' ' ' THR . 5.3 mt -78.62 -14.98 13.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 178.12 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 27.6 m 48.21 35.7 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.556 0 C-N-CA 124.669 1.188 . . . . 0.0 112.263 -178.962 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 129' ' ' THR . . . . . 0.403 HG22 ' HB ' ' A' ' 127' ' ' ILE . 15.2 t -115.19 144.03 44.32 Favored 'General case' 0 N--CA 1.452 -0.33 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.743 179.393 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 6.9 mp0 -102.19 63.75 0.91 Allowed 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 121.021 0.439 . . . . 0.0 109.923 177.893 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 131' ' ' ARG . . . . . 0.505 ' HA ' ' HE ' ' A' ' 131' ' ' ARG . 0.0 OUTLIER -108.96 -170.16 1.61 Allowed 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.38 -176.569 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 132' ' ' LYS . . . . . 0.555 ' HE3' ' HE1' ' A' ' 146' ' ' TYR . 31.7 ttpt -84.72 11.0 9.83 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-O 121.361 0.601 . . . . 0.0 112.038 -172.165 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 133' ' ' MET . . . . . . . . . . . . . 46.7 mtp -69.06 170.5 9.81 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.764 176.949 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 134' ' ' LYS . . . . . 0.476 ' HB3' ' NZ ' ' A' ' 134' ' ' LYS . 0.5 OUTLIER -139.68 151.65 46.09 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.942 -179.43 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 135' ' ' LEU . . . . . 0.436 HD11 ' HD2' ' A' ' 142' ' ' TYR . 57.4 tp -89.74 123.46 33.77 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.252 178.206 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 136' ' ' VAL . . . . . 0.452 ' CG2' ' HG2' ' A' ' 145' ' ' GLU . 0.1 OUTLIER -121.74 149.05 24.92 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.445 -179.658 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 17.0 m-80 -125.86 112.62 16.2 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.2 -176.214 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 138' ' ' TYR . . . . . 0.481 ' CD1' ' HB2' ' A' ' 28' ' ' TYR . 53.3 t80 -147.96 123.31 10.29 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.554 0.216 . . . . 0.0 110.947 -179.723 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 139' ' ' GLY . . . . . 0.549 ' HA3' ' HB3' ' A' ' 24' ' ' ASP . . . 62.93 71.69 0.78 Allowed Glycine 0 N--CA 1.451 -0.317 0 CA-C-N 115.716 -0.674 . . . . 0.0 113.726 173.045 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 6.1 mpt_? 70.99 -39.5 0.45 Allowed 'General case' 0 N--CA 1.473 0.684 0 C-N-CA 123.356 0.662 . . . . 0.0 112.628 175.171 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 8.8 t -101.87 154.5 18.87 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 121.487 0.66 . . . . 0.0 111.696 -173.817 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 142' ' ' TYR . . . . . 0.472 ' OH ' ' HA ' ' A' ' 123' ' ' THR . 45.8 p90 -112.68 155.02 25.2 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 115.031 -0.986 . . . . 0.0 108.592 169.249 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 18.0 p90 -160.27 179.03 9.03 Favored 'General case' 0 C--N 1.319 -0.744 0 N-CA-C 110.151 -0.315 . . . . 0.0 110.151 -178.348 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 86.5 m-85 -116.27 125.42 52.17 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 120.724 0.297 . . . . 0.0 110.525 -179.505 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 145' ' ' GLU . . . . . 0.452 ' HG2' ' CG2' ' A' ' 136' ' ' VAL . 23.7 pt-20 -117.28 162.1 18.43 Favored 'General case' 0 C--N 1.317 -0.807 0 N-CA-C 109.557 -0.534 . . . . 0.0 109.557 175.235 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 146' ' ' TYR . . . . . 0.555 ' HE1' ' HE3' ' A' ' 132' ' ' LYS . 14.8 t80 -138.28 117.3 12.51 Favored 'General case' 0 C--N 1.311 -1.102 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.744 175.623 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 147' ' ' ILE . . . . . 0.42 ' N ' HD12 ' A' ' 147' ' ' ILE . 2.4 mp -85.41 99.43 7.39 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.874 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 174.643 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 148' ' ' ALA . . . . . 0.679 ' HB1' ' HA ' ' A' ' 111' ' ' ASP . . . -58.42 104.48 0.22 Allowed 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 108.933 -0.765 . . . . 0.0 108.933 176.432 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 36.7 mt-10 -50.91 121.32 5.81 Favored 'General case' 0 CA--C 1.506 -0.717 0 CA-C-O 122.092 0.948 . . . . 0.0 110.76 -175.329 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 150' ' ' VAL . . . . . 0.595 HG12 ' H ' ' A' ' 152' ' ' SER . 3.5 t -64.64 118.35 6.78 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.12 0 CA-C-N 113.326 -1.761 . . . . 0.0 111.425 -164.226 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 151' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.31 25.48 2.21 Favored 'General case' 0 C--N 1.315 -0.906 0 CA-C-N 114.786 -1.097 . . . . 0.0 110.152 176.432 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 152' ' ' SER . . . . . 0.595 ' H ' HG12 ' A' ' 150' ' ' VAL . 15.6 m -138.84 157.6 45.76 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 114.747 -1.115 . . . . 0.0 108.907 177.632 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 99.1 mtt180 . . . . . 0 C--O 1.246 0.889 0 CA-C-O 118.718 -0.658 . . . . 0.0 110.246 178.525 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 27.5 ttt . . . . . 0 N--CA 1.478 0.943 0 CA-C-O 120.747 0.308 . . . . 0.0 110.447 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 87.52 -69.27 2.98 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.584 176.17 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 15.1 m -72.38 85.05 1.1 Allowed 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.975 0.417 . . . . 0.0 110.465 179.774 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 48.8 m -154.23 86.12 1.16 Allowed 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.238 177.879 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 49.4 m80 -92.31 118.99 31.45 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 109.503 -0.554 . . . . 0.0 109.503 179.17 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 88.0 m-70 -91.76 81.83 5.23 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.504 0.669 . . . . 0.0 111.121 -173.806 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 52.6 t-80 -135.49 100.41 4.5 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.188 -0.915 . . . . 0.0 109.222 175.414 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 8.6 p-80 -119.77 34.46 5.21 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.113 -178.249 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 38.2 t60 -60.16 126.48 27.69 Favored 'General case' 0 C--N 1.327 -0.388 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 176.989 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 30.7 m170 -69.04 145.02 53.86 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.922 -177.607 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 33.9 t -124.68 144.21 50.33 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 116.076 -0.511 . . . . 0.0 109.922 -179.069 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 71.2 m -100.22 100.37 11.18 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 120.959 0.409 . . . . 0.0 110.683 178.264 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -118.52 151.33 17.84 Favored Glycine 0 N--CA 1.446 -0.699 0 C-N-CA 120.8 -0.715 . . . . 0.0 111.656 179.502 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 94.6 mt -99.54 167.2 10.75 Favored 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 110.172 -0.307 . . . . 0.0 110.172 -179.86 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.41 ' HA ' ' HD3' ' A' ' 16' ' ' PRO . 7.6 p -83.83 127.95 65.25 Favored Pre-proline 0 C--N 1.322 -0.605 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 176.997 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.41 ' HD3' ' HA ' ' A' ' 15' ' ' VAL . 23.1 Cg_exo -63.63 125.88 16.4 Favored 'Trans proline' 0 N--CA 1.461 -0.416 0 C-N-CA 122.323 2.015 . . . . 0.0 112.135 179.146 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -97.54 150.92 20.57 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-N 115.463 -0.79 . . . . 0.0 109.938 -179.313 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 80.6 28.47 47.28 Favored Glycine 0 N--CA 1.446 -0.692 0 N-CA-C 110.798 -0.921 . . . . 0.0 110.798 -171.526 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 11.7 p -104.56 17.16 24.66 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 120.891 0.377 . . . . 0.0 111.17 -175.062 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 36.7 m-70 -58.89 -24.41 62.23 Favored 'General case' 0 N--CA 1.464 0.268 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.325 179.664 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' MET . . . . . . . . . . . . . 22.8 mmt -77.13 -16.91 58.99 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.966 -178.933 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' TRP . . . . . 0.601 ' CH2' HG23 ' A' ' 96' ' ' ILE . 99.4 m95 -98.81 -18.1 18.11 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.351 -0.386 . . . . 0.0 111.677 -179.882 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 24.3 t-20 -56.45 -41.06 75.86 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.765 -0.652 . . . . 0.0 111.606 -176.659 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -60.33 -50.82 72.08 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.963 -0.562 . . . . 0.0 112.042 -179.909 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 58.5 tp -56.28 -45.44 80.13 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.195 -178.474 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' ALA . . . . . 0.5 ' O ' HG13 ' A' ' 30' ' ' ILE . . . -54.74 -52.03 63.81 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.322 -179.157 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 83.2 t -51.4 -47.64 34.91 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.78 178.887 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 74.4 t80 -59.06 -44.59 91.84 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.921 0.391 . . . . 0.0 110.491 -179.054 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 72.5 mt -64.77 -45.53 94.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.918 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.607 HG12 HG23 ' A' ' 54' ' ' ILE . 85.8 mt -57.24 -44.36 83.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.88 179.911 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 55.5 mtt180 -71.36 -20.72 62.12 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.693 -0.685 . . . . 0.0 111.697 -175.224 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 72.8 m -88.98 -21.33 23.58 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.408 -0.36 . . . . 0.0 111.256 179.788 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 12.4 p -106.23 -80.16 0.56 Allowed 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 120.765 0.317 . . . . 0.0 111.255 -176.652 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 95.92 172.82 36.01 Favored Glycine 0 N--CA 1.449 -0.468 0 C-N-CA 120.822 -0.704 . . . . 0.0 112.427 -179.888 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 12.5 Cg_exo -69.68 143.39 51.08 Favored 'Trans proline' 0 N--CA 1.465 -0.189 0 C-N-CA 122.955 2.437 . . . . 0.0 112.335 -179.197 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 91.12 7.27 65.89 Favored Glycine 0 N--CA 1.454 -0.128 0 C-N-CA 120.613 -0.803 . . . . 0.0 112.694 176.413 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 29.9 p -110.43 -174.09 2.4 Favored 'General case' 0 C--N 1.321 -0.671 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 179.848 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' ARG . . . . . 0.619 ' NH2' ' HA3' ' A' ' 89' ' ' GLY . 56.6 mtm180 -129.72 126.91 39.36 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 120.771 0.319 . . . . 0.0 110.647 176.709 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.643 HG23 HG21 ' A' ' 60' ' ' VAL . 41.5 t -122.81 134.51 65.75 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 177.703 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.475 HG11 ' CE1' ' A' ' 87' ' ' TYR . 32.2 t -114.02 122.38 68.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-O 120.955 0.407 . . . . 0.0 110.436 -178.416 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 41' ' ' GLU . . . . . 0.815 ' HG3' HD23 ' A' ' 64' ' ' LEU . 0.1 OUTLIER -93.07 121.59 34.58 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.71 -174.706 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.508 ' O ' ' HA ' ' A' ' 95' ' ' SER . 48.5 t -102.55 113.65 39.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 N-CA-C 109.566 -0.531 . . . . 0.0 109.566 173.825 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 111.77 44.9 0.86 Allowed Glycine 0 N--CA 1.45 -0.37 0 N-CA-C 111.134 -0.786 . . . . 0.0 111.134 -176.032 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -95.85 14.73 22.41 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.102 0.477 . . . . 0.0 111.044 -175.892 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -72.74 -7.73 70.48 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.946 -0.645 . . . . 0.0 112.947 -178.153 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 74.0 ttt180 -166.18 -34.14 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.94 0.4 . . . . 0.0 110.934 -179.915 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 40.7 m-85 -82.86 83.39 7.77 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 121.116 0.484 . . . . 0.0 111.056 -175.685 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 88.2 mt -109.35 9.3 25.71 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.144 -179.514 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 39.3 t80 -72.54 -50.97 21.96 Favored 'General case' 0 C--N 1.33 -0.267 0 C-N-CA 121.023 -0.271 . . . . 0.0 110.968 178.259 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.528 ' O ' HG13 ' A' ' 54' ' ' ILE . 33.6 t -57.73 -49.0 82.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.463 -176.448 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 1.9 p -60.01 -44.07 94.81 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.93 -0.577 . . . . 0.0 111.787 -179.783 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.542 ' O ' ' HG2' ' A' ' 56' ' ' LYS . 28.8 t70 -64.99 -39.76 93.95 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 120.856 0.36 . . . . 0.0 110.601 -179.907 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 59.5 t80 -65.97 -39.47 90.41 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.563 -179.218 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.607 HG23 HG12 ' A' ' 30' ' ' ILE . 82.3 mt -64.88 -48.71 83.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.613 -179.852 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 39.7 ptt180 -67.28 -17.13 64.66 Favored 'General case' 0 N--CA 1.466 0.348 0 N-CA-C 111.586 0.217 . . . . 0.0 111.586 -175.649 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' LYS . . . . . 0.542 ' HG2' ' O ' ' A' ' 52' ' ' ASP . 33.1 mmtp -75.04 -36.07 61.87 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.822 0.344 . . . . 0.0 110.747 177.591 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 53.8 m-70 -94.6 -31.11 14.01 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.818 -175.785 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 73.3 m -136.75 132.89 35.41 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 120.759 0.314 . . . . 0.0 111.474 -178.27 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 3.1 tmtp? -81.51 60.97 4.75 Favored 'General case' 0 C--O 1.234 0.256 0 CA-C-O 121.831 0.824 . . . . 0.0 109.708 177.051 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.643 HG21 HG23 ' A' ' 39' ' ' VAL . 2.6 p -84.59 144.61 9.45 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.037 0 CA-C-N 114.975 -1.011 . . . . 0.0 108.869 172.816 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 61' ' ' ASP . . . . . 0.43 ' O ' ' HA ' ' A' ' 38' ' ' ARG . 24.7 m-20 -79.0 100.36 7.27 Favored 'General case' 0 CA--C 1.515 -0.378 0 CA-C-O 121.605 0.717 . . . . 0.0 109.441 176.328 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 62' ' ' LEU . . . . . 0.516 HD11 ' OE2' ' A' ' 41' ' ' GLU . 8.5 tt -99.28 129.14 45.48 Favored 'General case' 0 C--N 1.316 -0.854 0 CA-C-N 114.8 -1.091 . . . . 0.0 110.599 -171.653 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 57.7 t -117.45 116.06 50.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.987 -177.895 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 64' ' ' LEU . . . . . 0.815 HD23 ' HG3' ' A' ' 41' ' ' GLU . 33.1 mt -87.39 128.21 35.2 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 115.966 -0.561 . . . . 0.0 109.828 178.17 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.512 HG22 ' HB ' ' A' ' 75' ' ' VAL . 25.2 p -130.57 134.36 46.95 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 120.488 0.185 . . . . 0.0 110.629 178.965 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -171.74 153.73 3.43 Favored 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 178.395 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.546 HD11 HG22 ' A' ' 79' ' ' ILE . 60.8 mt -77.42 122.66 32.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 N-CA-C 110.152 -0.314 . . . . 0.0 110.152 179.483 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 68' ' ' LYS . . . . . 0.52 ' HG3' HG22 ' A' ' 67' ' ' ILE . 91.9 mttt 60.83 80.65 0.26 Allowed Pre-proline 0 C--O 1.234 0.267 0 O-C-N 123.734 0.646 . . . . 0.0 110.485 -177.413 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 69' ' ' PRO . . . . . 0.692 ' HB3' ' HB ' ' A' ' 74' ' ' ILE . 29.0 Cg_endo -64.71 122.39 10.23 Favored 'Trans proline' 0 N--CA 1.464 -0.243 0 C-N-CA 122.799 2.333 . . . . 0.0 112.515 -178.636 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 8.0 t -87.96 7.07 32.77 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.914 -178.266 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 50.7 t-80 -112.43 -73.43 0.67 Allowed 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.46 -179.758 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 145.32 -35.15 1.47 Allowed Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.01 -179.534 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -92.55 23.23 29.01 Favored Glycine 0 C--O 1.228 -0.238 0 C-N-CA 120.979 -0.629 . . . . 0.0 111.825 177.899 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.692 ' HB ' ' HB3' ' A' ' 69' ' ' PRO . 71.2 mt -109.99 140.34 29.39 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-N 115.518 -0.341 . . . . 0.0 110.122 -178.478 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.512 ' HB ' HG22 ' A' ' 65' ' ' THR . 61.2 t -71.28 119.18 17.16 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-O 121.199 0.523 . . . . 0.0 110.343 178.61 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 76' ' ' ARG . . . . . 0.41 ' H ' ' HG2' ' A' ' 76' ' ' ARG . 16.5 ptm180 -81.66 34.5 0.39 Allowed 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.379 -0.828 . . . . 0.0 111.96 -176.27 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 35.2 t70 -78.72 145.02 34.73 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 120.892 0.377 . . . . 0.0 110.392 -177.857 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 78' ' ' ASP . . . . . 0.51 ' HB3' HG22 ' A' ' 80' ' ' THR . 10.4 m-20 -81.15 110.86 17.05 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.696 -176.744 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 79' ' ' ILE . . . . . 0.546 HG22 HD11 ' A' ' 67' ' ' ILE . 10.6 tp -63.96 -19.9 25.51 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.519 0 CA-C-O 120.909 0.385 . . . . 0.0 111.022 179.75 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.51 HG22 ' HB3' ' A' ' 78' ' ' ASP . 7.0 t -68.52 -26.33 65.38 Favored 'General case' 0 CA--C 1.533 0.301 0 CA-C-O 121.13 0.49 . . . . 0.0 110.572 177.73 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 44.3 m -152.0 73.42 7.82 Favored Pre-proline 0 C--N 1.322 -0.607 0 N-CA-C 108.37 -0.974 . . . . 0.0 108.37 176.738 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.469 ' HB2' ' HE2' ' A' ' 87' ' ' TYR . 75.8 Cg_endo -76.01 162.8 34.08 Favored 'Trans proline' 0 C--O 1.237 0.429 0 C-N-CA 122.817 2.344 . . . . 0.0 114.044 -166.121 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 83' ' ' ARG . . . . . 0.872 ' HG3' ' HG2' ' A' ' 85' ' ' GLU . 0.2 OUTLIER -81.72 99.99 9.24 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 114.855 -1.066 . . . . 0.0 109.201 174.929 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 84' ' ' MET . . . . . 0.401 ' O ' ' HG3' ' A' ' 88' ' ' ARG . 83.8 mmm -59.08 -31.16 68.64 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 116.596 -0.274 . . . . 0.0 111.186 -177.187 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.872 ' HG2' ' HG3' ' A' ' 83' ' ' ARG . 8.2 pt-20 -66.94 -24.72 66.1 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.495 -0.32 . . . . 0.0 111.397 -179.789 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 69.0 mt -73.62 -32.29 35.17 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 C-N-CA 120.515 -0.474 . . . . 0.0 110.429 177.282 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 87' ' ' TYR . . . . . 0.483 ' CB ' HG11 ' A' ' 113' ' ' VAL . 98.3 m-85 -85.91 -28.63 24.21 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.974 -0.557 . . . . 0.0 111.22 179.022 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 88' ' ' ARG . . . . . 0.401 ' HG3' ' O ' ' A' ' 84' ' ' MET . 69.6 mtp180 -61.72 117.95 6.49 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.33 0.586 . . . . 0.0 111.691 -177.639 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 89' ' ' GLY . . . . . 0.619 ' HA3' ' NH2' ' A' ' 38' ' ' ARG . . . 106.36 -5.19 38.13 Favored Glycine 0 N--CA 1.444 -0.779 0 CA-C-N 115.222 -0.899 . . . . 0.0 112.383 179.906 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -69.85 146.97 50.91 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.801 0.334 . . . . 0.0 110.495 177.733 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -91.5 -30.8 16.23 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.368 -179.766 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 92' ' ' LEU . . . . . 0.444 ' HG ' ' HB3' ' A' ' 116' ' ' ARG . 5.3 tt -153.25 144.19 22.88 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.182 -178.361 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.679 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 70.1 mt -133.07 129.04 57.04 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 177.31 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 94' ' ' TYR . . . . . 0.474 ' HE2' HD11 ' A' ' 96' ' ' ILE . 51.0 p90 -134.01 162.88 30.85 Favored 'General case' 0 C--N 1.32 -0.715 0 C-N-CA 120.053 -0.659 . . . . 0.0 111.274 179.604 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 95' ' ' SER . . . . . 0.782 ' HB3' ' HG3' ' A' ' 98' ' ' PRO . 15.8 m -137.83 137.83 38.54 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.999 -175.682 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 96' ' ' ILE . . . . . 0.601 HG23 ' CH2' ' A' ' 22' ' ' TRP . 5.0 mp -106.74 93.87 2.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.349 177.866 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 54.1 ttp85 48.29 72.68 1.18 Allowed Pre-proline 0 CA--C 1.54 0.574 0 CA-C-N 115.527 -0.761 . . . . 0.0 112.472 177.242 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 98' ' ' PRO . . . . . 0.782 ' HG3' ' HB3' ' A' ' 95' ' ' SER . 14.8 Cg_endo -91.97 162.81 3.28 Favored 'Trans proline' 0 N--CA 1.454 -0.823 0 C-N-CA 123.228 2.619 . . . . 0.0 111.905 176.798 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.461 ' HB2' ' HG2' ' A' ' 101' ' ' GLU . 2.4 Cg_endo -48.97 139.64 25.3 Favored 'Trans proline' 0 C--N 1.349 0.599 0 C-N-CA 123.181 2.587 . . . . 0.0 112.597 177.159 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.746 ' HA ' ' CE1' ' A' ' 103' ' ' HIS . . . -79.28 19.36 0.59 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.188 -0.46 . . . . 0.0 112.098 -172.528 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 101' ' ' GLU . . . . . 0.461 ' HG2' ' HB2' ' A' ' 99' ' ' PRO . 9.3 pt-20 -115.82 -16.62 11.17 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 115.991 -0.549 . . . . 0.0 111.367 -177.572 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.634 HD11 ' HB2' ' A' ' 98' ' ' PRO . 2.5 pp -112.04 3.44 8.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 N-CA-C 112.258 0.466 . . . . 0.0 112.258 -175.546 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 103' ' ' HIS . . . . . 0.746 ' CE1' ' HA ' ' A' ' 100' ' ' ALA . 33.5 m170 -62.27 -40.79 97.4 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.181 -179.15 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 22.4 m -61.81 -31.46 71.69 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.987 0.422 . . . . 0.0 110.899 178.903 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.561 ' O ' HG23 ' A' ' 109' ' ' VAL . 14.5 m -72.84 -40.68 65.55 Favored 'General case' 0 N--CA 1.448 -0.538 0 CA-C-N 116.045 -0.525 . . . . 0.0 109.897 178.302 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 90.4 mt -61.38 -42.17 98.28 Favored 'General case' 0 C--O 1.233 0.224 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.944 178.289 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 107' ' ' MET . . . . . . . . . . . . . 91.3 mmm -55.37 -48.09 74.81 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.619 -0.719 . . . . 0.0 111.768 -179.598 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 4.1 ptp180 -74.01 -26.89 60.68 Favored 'General case' 0 C--N 1.329 -0.32 0 C-N-CA 120.875 -0.33 . . . . 0.0 111.512 -177.697 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.561 HG23 ' O ' ' A' ' 105' ' ' SER . 70.2 t -66.31 -46.87 85.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 N-CA-C 110.192 -0.299 . . . . 0.0 110.192 175.813 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -59.01 -45.57 90.36 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.292 178.527 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.504 ' HA ' ' HB1' ' A' ' 148' ' ' ALA . 24.4 t70 -64.9 -36.83 85.63 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.885 -0.598 . . . . 0.0 111.026 179.557 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -68.53 -35.56 77.64 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.717 -0.674 . . . . 0.0 112.17 -178.372 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.483 HG11 ' CB ' ' A' ' 87' ' ' TYR . 22.5 m -97.04 -23.77 4.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-O 120.745 0.307 . . . . 0.0 111.65 -177.787 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 89.43 36.4 7.5 Favored Glycine 0 N--CA 1.452 -0.235 0 C-N-CA 120.933 -0.651 . . . . 0.0 112.645 176.792 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -114.24 147.47 38.93 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 121.003 0.43 . . . . 0.0 111.416 -177.187 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 116' ' ' ARG . . . . . 0.444 ' HB3' ' HG ' ' A' ' 92' ' ' LEU . 27.8 ttt180 -70.96 120.06 15.98 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.687 -0.688 . . . . 0.0 109.836 178.876 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 117' ' ' LEU . . . . . 0.679 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 60.0 tp -94.72 126.83 40.28 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 -179.038 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 64.1 mt -129.02 122.79 57.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-O 120.827 0.346 . . . . 0.0 110.44 -179.223 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 119' ' ' ILE . . . . . 0.519 HG12 ' HB2' ' A' ' 95' ' ' SER . 66.7 mt -130.05 119.85 48.0 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-O 120.777 0.323 . . . . 0.0 110.755 -179.018 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 34.3 ttpt -116.27 98.38 51.31 Favored Pre-proline 0 C--N 1.326 -0.441 0 N-CA-C 109.622 -0.511 . . . . 0.0 109.622 173.085 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 89.6 Cg_endo -87.17 -156.08 0.06 OUTLIER 'Trans proline' 0 N--CA 1.457 -0.631 0 C-N-CA 122.862 2.375 . . . . 0.0 112.471 179.325 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 122' ' ' LEU . . . . . 0.441 HD12 ' HA ' ' A' ' 122' ' ' LEU . 9.3 tp -74.35 161.56 29.75 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.302 177.899 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 12.9 t -69.3 -24.65 63.97 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.064 0.459 . . . . 0.0 110.979 -177.927 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -114.32 27.14 9.17 Favored Glycine 0 N--CA 1.448 -0.519 0 C-N-CA 120.837 -0.696 . . . . 0.0 111.385 176.686 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 125' ' ' GLU . . . . . 0.404 ' CB ' ' HB3' ' A' ' 122' ' ' LEU . 35.6 tt0 -128.04 125.93 40.29 Favored 'General case' 0 C--N 1.319 -0.756 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 -177.167 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -108.22 166.86 10.43 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.001 -179.935 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 42.6 mt -83.83 -22.78 8.15 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-O 121.095 0.474 . . . . 0.0 110.207 -178.805 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 11.1 t 61.75 39.12 0.18 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.228 0 CA-C-O 122.027 0.917 . . . . 0.0 109.714 -178.908 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 6.1 t -131.02 20.91 4.92 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.417 -0.811 . . . . 0.0 108.939 176.134 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 6.0 tp10 -54.34 105.41 0.15 Allowed 'General case' 0 C--O 1.233 0.212 0 CA-C-N 114.797 -1.092 . . . . 0.0 111.131 -173.183 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 131' ' ' ARG . . . . . . . . . . . . . 5.2 ttm105 179.53 -37.38 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.47 -0.786 . . . . 0.0 110.942 -172.901 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 132' ' ' LYS . . . . . 0.406 ' HE3' ' CZ ' ' A' ' 146' ' ' TYR . 55.7 tttp -134.65 -17.57 1.96 Allowed 'General case' 0 CA--C 1.534 0.341 0 N-CA-C 112.836 0.68 . . . . 0.0 112.836 -165.698 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 133' ' ' MET . . . . . . . . . . . . . 76.0 mtp -96.24 168.72 10.41 Favored 'General case' 0 C--N 1.328 -0.356 0 C-N-CA 120.69 -0.404 . . . . 0.0 111.098 -176.952 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 134' ' ' LYS . . . . . 0.461 ' HG3' ' HG2' ' A' ' 145' ' ' GLU . 15.8 ptmt -130.62 148.59 52.43 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.911 -178.088 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 135' ' ' LEU . . . . . 0.605 HD11 ' HD2' ' A' ' 142' ' ' TYR . 39.7 tp -94.62 126.21 39.77 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.395 -179.747 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -123.86 147.19 28.35 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.692 -179.577 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 9.8 m-80 -116.98 119.0 33.95 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.999 0.428 . . . . 0.0 110.299 177.344 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 138' ' ' TYR . . . . . 0.498 ' O ' HG22 ' A' ' 141' ' ' THR . 71.3 t80 -146.49 128.11 15.15 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.142 -0.481 . . . . 0.0 109.932 -177.038 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 139' ' ' GLY . . . . . 0.424 ' O ' ' HB2' ' A' ' 140' ' ' ARG . . . 66.37 38.9 94.0 Favored Glycine 0 N--CA 1.449 -0.469 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.238 177.904 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 140' ' ' ARG . . . . . 0.424 ' HB2' ' O ' ' A' ' 139' ' ' GLY . 13.0 mmt85 76.47 -12.54 1.02 Allowed 'General case' 0 N--CA 1.469 0.497 0 C-N-CA 123.438 0.695 . . . . 0.0 112.392 177.804 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 141' ' ' THR . . . . . 0.498 HG22 ' O ' ' A' ' 138' ' ' TYR . 4.6 t -105.21 166.1 10.64 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 120.851 0.358 . . . . 0.0 110.575 -178.972 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 142' ' ' TYR . . . . . 0.605 ' HD2' HD11 ' A' ' 135' ' ' LEU . 14.4 p90 -130.06 141.12 50.75 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.125 -0.488 . . . . 0.0 109.807 178.945 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -150.3 168.43 24.1 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.687 -177.58 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 85.8 m-85 -99.88 125.12 45.81 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 177.499 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 145' ' ' GLU . . . . . 0.461 ' HG2' ' HG3' ' A' ' 134' ' ' LYS . 7.5 pt-20 -116.26 162.84 16.88 Favored 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 109.558 -0.534 . . . . 0.0 109.558 175.596 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 146' ' ' TYR . . . . . 0.559 ' HB3' ' HB3' ' A' ' 117' ' ' LEU . 15.0 t80 -145.3 123.44 12.16 Favored 'General case' 0 C--N 1.314 -0.946 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.275 178.894 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 3.4 mp -91.92 100.27 10.98 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 177.545 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 148' ' ' ALA . . . . . 0.504 ' HB1' ' HA ' ' A' ' 111' ' ' ASP . . . -71.68 125.74 27.9 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.896 176.312 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -59.4 149.95 27.82 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.798 -0.637 . . . . 0.0 111.518 177.682 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 25.1 t -85.0 128.85 38.61 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.911 0 CA-C-N 115.021 -0.991 . . . . 0.0 109.404 179.268 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 151' ' ' ARG . . . . . . . . . . . . . 44.7 mtp85 -78.69 152.28 31.7 Favored 'General case' 0 C--N 1.317 -0.848 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.369 -178.222 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 18.8 t -80.67 147.07 30.8 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.624 -174.828 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 153' ' ' ARG . . . . . 0.412 HH11 ' HD3' ' A' ' 153' ' ' ARG . 8.6 ptt180 . . . . . 0 C--O 1.248 1.025 0 CA-C-O 118.165 -0.922 . . . . 0.0 110.044 178.998 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 25.0 mmt . . . . . 0 N--CA 1.48 1.062 0 N-CA-C 110.192 -0.299 . . . . 0.0 110.192 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -54.84 110.99 1.92 Allowed Glycine 0 C--N 1.332 0.321 0 C-N-CA 121.361 -0.447 . . . . 0.0 112.688 -177.822 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 16.1 m -115.87 123.14 47.39 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 120.727 0.299 . . . . 0.0 110.239 -179.2 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 15.9 m -90.58 131.47 36.28 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.495 -178.365 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 51.2 p-80 -99.85 146.11 26.99 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 109.962 -0.384 . . . . 0.0 109.962 178.621 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 38.9 m80 -104.52 178.26 4.61 Favored 'General case' 0 C--N 1.316 -0.878 0 CA-C-N 116.173 -0.467 . . . . 0.0 109.77 177.928 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 41.8 m80 -80.49 94.51 6.24 Favored 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 109.377 -0.601 . . . . 0.0 109.377 179.191 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 12.3 t-80 -111.22 126.42 54.85 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.347 -0.842 . . . . 0.0 110.076 -173.667 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 29.9 m170 61.84 77.94 0.31 Allowed 'General case' 0 N--CA 1.464 0.244 0 CA-C-O 121.453 0.644 . . . . 0.0 110.992 -176.552 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 56.3 t-80 -139.77 146.97 40.16 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.505 -0.771 . . . . 0.0 109.284 178.029 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 21.6 t -160.96 172.54 16.74 Favored 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 178.441 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 32.5 t -154.33 161.73 41.59 Favored 'General case' 0 C--N 1.32 -0.705 0 N-CA-C 109.557 -0.534 . . . . 0.0 109.557 -179.069 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -94.54 100.66 2.62 Favored Glycine 0 N--CA 1.447 -0.608 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.037 -179.298 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 94.1 mt -73.21 136.37 44.68 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.052 0.454 . . . . 0.0 110.319 -179.416 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 28.9 m -93.32 152.75 41.35 Favored Pre-proline 0 C--N 1.321 -0.655 0 CA-C-N 115.979 -0.555 . . . . 0.0 111.015 -178.911 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -70.41 159.09 54.09 Favored 'Trans proline' 0 C--O 1.234 0.3 0 C-N-CA 122.427 2.085 . . . . 0.0 111.465 175.971 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' ARG . . . . . 0.607 ' HD3' ' H ' ' A' ' 17' ' ' ARG . 0.0 OUTLIER -111.29 114.13 27.09 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 121.126 0.488 . . . . 0.0 110.694 -177.869 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -65.17 101.94 0.61 Allowed Glycine 0 N--CA 1.449 -0.453 0 CA-C-N 115.674 -0.694 . . . . 0.0 111.964 179.31 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 3.3 p -160.84 118.54 2.42 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 120.801 0.334 . . . . 0.0 110.215 -177.975 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 91.2 m-70 -125.04 -52.48 1.65 Allowed 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.463 -0.335 . . . . 0.0 111.234 -176.646 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -72.83 -15.8 61.61 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 121.039 0.447 . . . . 0.0 111.175 -177.303 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 78.7 m95 -66.59 -18.45 65.37 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.639 176.655 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 27.1 t-20 -56.35 -52.52 64.26 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.779 -0.646 . . . . 0.0 111.492 -177.514 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -63.81 -33.71 76.29 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.138 -178.901 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 56.7 tp -58.08 -49.52 76.64 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.084 175.725 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' ALA . . . . . 0.402 ' O ' HG13 ' A' ' 30' ' ' ILE . . . -58.57 -48.45 80.88 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.763 178.655 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.478 ' HA ' HD12 ' A' ' 30' ' ' ILE . 87.4 t -54.85 -44.48 72.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.177 178.553 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 28' ' ' TYR . . . . . 0.424 ' HB2' ' CD2' ' A' ' 138' ' ' TYR . 84.6 t80 -60.77 -46.83 88.97 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.715 179.041 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 83.1 mt -60.9 -42.83 94.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.51 178.332 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.548 HG12 HG23 ' A' ' 54' ' ' ILE . 87.7 mt -56.65 -45.32 82.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 115.704 -0.68 . . . . 0.0 111.066 177.418 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 31' ' ' ARG . . . . . 0.405 ' HG3' ' O ' ' A' ' 27' ' ' VAL . 81.0 mtp180 -69.33 -27.34 65.27 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 121.147 0.499 . . . . 0.0 110.899 -177.729 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 80.4 m -88.9 -2.88 58.81 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.925 -0.579 . . . . 0.0 111.639 -178.538 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 16.6 p -121.84 -76.76 0.58 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.505 0.193 . . . . 0.0 110.977 -179.387 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.512 ' O ' HG22 ' A' ' 37' ' ' THR . . . 101.03 161.82 27.58 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 121.087 -0.578 . . . . 0.0 112.409 179.597 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_exo -74.36 146.34 35.35 Favored 'Trans proline' 0 N--CA 1.462 -0.351 0 C-N-CA 122.84 2.36 . . . . 0.0 111.986 179.076 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 98.02 -15.82 61.04 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.868 -0.682 . . . . 0.0 113.046 177.357 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 37' ' ' THR . . . . . 0.512 HG22 ' O ' ' A' ' 34' ' ' GLY . 13.6 t -102.42 -172.14 2.08 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 117.039 0.419 . . . . 0.0 110.544 -179.091 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 38' ' ' ARG . . . . . 0.53 ' HB2' ' HA ' ' A' ' 90' ' ' ALA . 68.7 mtp180 -115.42 135.8 53.74 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.565 -0.289 . . . . 0.0 110.976 -177.276 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.496 HG23 HG21 ' A' ' 60' ' ' VAL . 61.7 t -131.59 138.86 52.02 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 175.575 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.566 ' O ' ' HA ' ' A' ' 93' ' ' ILE . 23.4 t -126.92 139.13 52.76 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 178.259 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 41' ' ' GLU . . . . . 0.623 ' OE2' ' HA ' ' A' ' 64' ' ' LEU . 0.5 OUTLIER -116.12 156.25 26.76 Favored 'General case' 0 C--N 1.32 -0.678 0 C-N-CA 120.123 -0.631 . . . . 0.0 109.959 171.49 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.439 HG21 HD22 ' A' ' 106' ' ' LEU . 62.1 t -110.84 103.23 15.14 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.851 0 CA-C-N 115.755 -0.657 . . . . 0.0 109.79 176.385 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 115.28 56.04 0.36 Allowed Glycine 0 N--CA 1.448 -0.538 0 C-N-CA 120.309 -0.948 . . . . 0.0 112.7 178.707 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.434 ' HB2' ' OE2' ' A' ' 41' ' ' GLU . . . -80.73 77.04 7.61 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.254 0.549 . . . . 0.0 110.424 178.029 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -82.75 -154.89 16.59 Favored Glycine 0 N--CA 1.447 -0.625 0 CA-C-N 115.564 -0.744 . . . . 0.0 112.846 -179.55 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 49.9 ttt180 -70.37 -15.12 62.82 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 121.264 0.554 . . . . 0.0 110.555 -177.46 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 7.7 p90 -88.94 58.71 4.7 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.792 -0.64 . . . . 0.0 111.204 -178.707 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 95.0 mt -78.23 35.09 0.21 Allowed 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.008 -0.542 . . . . 0.0 112.15 -176.848 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' TYR . . . . . 0.543 ' HB2' ' HG3' ' A' ' 17' ' ' ARG . 84.3 t80 -71.91 -53.83 11.92 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.602 0.239 . . . . 0.0 110.995 -179.45 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.431 ' O ' HG13 ' A' ' 54' ' ' ILE . 56.7 t -57.72 -50.8 76.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.024 -0.534 . . . . 0.0 111.134 -176.404 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 2.7 p -59.98 -42.33 93.93 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.627 -178.829 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.499 ' O ' ' HG2' ' A' ' 56' ' ' LYS . 27.5 t70 -67.73 -43.23 80.44 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.385 -0.371 . . . . 0.0 110.651 -179.647 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 61.9 t80 -63.01 -44.63 95.45 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.92 -178.405 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.548 HG23 HG12 ' A' ' 30' ' ' ILE . 84.3 mt -61.32 -46.05 97.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.864 179.508 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 2.5 ptm180 -72.92 -16.48 61.55 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.358 -176.992 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 56' ' ' LYS . . . . . 0.499 ' HG2' ' O ' ' A' ' 52' ' ' ASP . 36.0 mmtm -72.82 -34.82 67.1 Favored 'General case' 0 C--O 1.234 0.287 0 CA-C-O 120.848 0.356 . . . . 0.0 110.486 175.016 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 29.3 m-70 -93.55 -60.4 1.78 Allowed 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.379 -177.039 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 52.8 m -106.78 133.22 51.77 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 121.233 0.54 . . . . 0.0 111.717 -174.878 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 1.3 tmmm? -76.56 65.76 2.44 Favored 'General case' 0 N--CA 1.451 -0.38 0 CA-C-O 121.769 0.795 . . . . 0.0 108.909 174.318 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.496 HG21 HG23 ' A' ' 39' ' ' VAL . 14.9 p -97.06 147.83 6.03 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.983 0 CA-C-N 115.235 -0.893 . . . . 0.0 109.927 176.115 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 13.2 t70 -81.09 89.6 5.98 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 178.865 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 3.3 tm? -93.97 131.86 39.01 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.481 -0.781 . . . . 0.0 109.27 -178.096 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 42.4 t -115.36 117.92 57.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-O 120.457 0.17 . . . . 0.0 110.842 -177.604 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 64' ' ' LEU . . . . . 0.623 ' HA ' ' OE2' ' A' ' 41' ' ' GLU . 84.8 mt -86.89 128.07 35.05 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.913 -178.574 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 70.1 p -116.23 123.57 48.09 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.879 177.475 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 66' ' ' ASP . . . . . 0.689 ' HB3' HG21 ' A' ' 74' ' ' ILE . 17.9 t70 -149.03 136.12 19.95 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.126 -179.841 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.462 HG12 ' HB2' ' A' ' 78' ' ' ASP . 46.2 mt -69.12 110.61 2.63 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 178.189 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 68' ' ' LYS . . . . . 0.432 ' HG2' HG22 ' A' ' 67' ' ' ILE . 31.1 mmtp 63.25 85.37 0.17 Allowed Pre-proline 0 C--N 1.33 -0.269 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 -172.297 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 69' ' ' PRO . . . . . 0.655 ' HD3' ' HA ' ' A' ' 76' ' ' ARG . 4.2 Cg_endo -44.47 108.01 0.12 Allowed 'Trans proline' 0 C--N 1.351 0.698 0 C-N-CA 123.805 3.004 . . . . 0.0 112.52 -173.948 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 17.4 m -65.77 -33.24 75.41 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 114.835 -1.075 . . . . 0.0 111.801 -176.482 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 71' ' ' HIS . . . . . 0.564 ' H ' HD12 ' A' ' 74' ' ' ILE . 71.7 t60 -141.87 96.59 2.99 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 112.942 0.719 . . . . 0.0 112.942 -170.574 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 57.74 -113.13 4.34 Favored Glycine 0 CA--C 1.519 0.313 0 CA-C-N 115.553 -0.749 . . . . 0.0 114.799 167.454 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -82.35 58.72 4.96 Favored Glycine 0 C--N 1.332 0.361 0 C-N-CA 121.615 -0.326 . . . . 0.0 113.772 -170.9 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.689 HG21 ' HB3' ' A' ' 66' ' ' ASP . 97.2 mt -115.83 141.89 31.32 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 174.403 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 44.2 t -79.31 137.77 21.17 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 178.935 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 76' ' ' ARG . . . . . 0.655 ' HA ' ' HD3' ' A' ' 69' ' ' PRO . 0.0 OUTLIER -75.57 13.67 0.75 Allowed 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.046 -0.525 . . . . 0.0 111.75 -176.91 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 77' ' ' ASP . . . . . 0.473 ' OD1' ' HG2' ' A' ' 83' ' ' ARG . 12.7 t70 -70.08 121.89 18.34 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -175.893 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 78' ' ' ASP . . . . . 0.462 ' HB2' HG12 ' A' ' 67' ' ' ILE . 3.3 p30 -101.24 169.53 8.85 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 121.276 0.56 . . . . 0.0 111.526 -172.213 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 8.5 tt -77.46 -15.46 14.37 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 115.328 -0.851 . . . . 0.0 112.518 -171.276 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 7.8 p -93.41 -23.44 18.42 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 121.657 0.742 . . . . 0.0 109.69 -178.902 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 81' ' ' SER . . . . . 0.465 ' N ' ' HD3' ' A' ' 82' ' ' PRO . 23.0 t -139.23 58.22 12.13 Favored Pre-proline 0 N--CA 1.441 -0.897 0 CA-C-N 114.677 -1.147 . . . . 0.0 110.574 -170.596 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.465 ' HD3' ' N ' ' A' ' 81' ' ' SER . 5.1 Cg_exo -77.79 140.07 18.19 Favored 'Trans proline' 0 N--CA 1.458 -0.609 0 C-N-CA 122.656 2.237 . . . . 0.0 112.14 -174.736 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 83' ' ' ARG . . . . . 0.78 ' HB2' HD12 ' A' ' 86' ' ' ILE . 55.9 mmt-85 -80.35 113.52 18.59 Favored 'General case' 0 CA--C 1.507 -0.673 0 CA-C-O 121.14 0.495 . . . . 0.0 110.67 178.259 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 84' ' ' MET . . . . . 0.483 ' HA ' ' HD2' ' A' ' 87' ' ' TYR . 22.0 mtp -72.61 -13.12 61.3 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.09 178.553 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.684 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 11.3 pt-20 -70.16 -22.72 62.94 Favored 'General case' 0 C--O 1.232 0.133 0 CA-C-O 121.485 0.659 . . . . 0.0 109.579 175.259 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.78 HD12 ' HB2' ' A' ' 83' ' ' ARG . 96.3 mt -83.34 -33.94 10.47 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 115.251 -0.886 . . . . 0.0 110.172 178.859 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 87' ' ' TYR . . . . . 0.483 ' HD2' ' HA ' ' A' ' 84' ' ' MET . 95.3 m-85 -82.33 -37.87 25.1 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.572 -178.888 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 23.6 mtp180 -62.55 116.17 4.9 Favored 'General case' 0 CA--C 1.514 -0.44 0 CA-C-O 121.367 0.603 . . . . 0.0 111.401 -178.908 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 111.74 -10.33 27.78 Favored Glycine 0 N--CA 1.447 -0.619 0 CA-C-N 114.914 -1.039 . . . . 0.0 112.054 -178.249 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 90' ' ' ALA . . . . . 0.53 ' HA ' ' HB2' ' A' ' 38' ' ' ARG . . . -78.72 149.15 32.81 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.057 0.456 . . . . 0.0 110.613 179.649 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -94.38 -21.09 19.18 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.776 -179.245 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 92' ' ' LEU . . . . . 0.486 HD23 ' N ' ' A' ' 93' ' ' ILE . 4.7 tt -155.12 144.24 20.96 Favored 'General case' 0 N--CA 1.451 -0.376 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.719 -177.864 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.57 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 63.3 mt -130.86 127.18 61.15 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 177.203 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 94' ' ' TYR . . . . . 0.428 ' O ' ' HA ' ' A' ' 41' ' ' GLU . 32.3 p90 -129.24 161.96 28.98 Favored 'General case' 0 C--N 1.322 -0.6 0 C-N-CA 120.578 -0.449 . . . . 0.0 110.897 -179.503 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 14.2 m -144.94 145.72 31.67 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.918 0.39 . . . . 0.0 110.816 -179.333 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 72.6 mt -114.09 109.26 27.85 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.15 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 97' ' ' ARG . . . . . 0.441 ' HD2' HH11 ' A' ' 97' ' ' ARG . 42.0 ttm180 59.48 80.84 0.26 Allowed Pre-proline 0 CA--C 1.534 0.358 0 O-C-N 123.849 0.718 . . . . 0.0 111.35 -178.331 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 98' ' ' PRO . . . . . 0.421 ' HA ' ' HD3' ' A' ' 99' ' ' PRO . 96.0 Cg_endo -88.52 133.38 2.68 Favored 'Trans proline' 0 N--CA 1.456 -0.724 0 C-N-CA 122.677 2.251 . . . . 0.0 112.642 179.078 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.639 ' HD2' HD11 ' A' ' 102' ' ' ILE . 32.8 Cg_exo -58.98 141.23 98.1 Favored 'Trans proline' 0 N--CA 1.464 -0.238 0 C-N-CA 122.678 2.252 . . . . 0.0 111.465 175.048 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.721 ' HA ' ' NE2' ' A' ' 103' ' ' HIS . . . -72.07 4.45 3.5 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 112.154 0.428 . . . . 0.0 112.154 -173.737 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 101' ' ' GLU . . . . . 0.602 ' HG3' HG23 ' A' ' 102' ' ' ILE . 9.2 pt-20 -96.33 -21.09 18.02 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.643 -0.253 . . . . 0.0 111.64 -179.928 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.639 HD11 ' HD2' ' A' ' 99' ' ' PRO . 2.5 pp -115.68 10.49 7.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 N-CA-C 113.108 0.781 . . . . 0.0 113.108 -170.331 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 103' ' ' HIS . . . . . 0.721 ' NE2' ' HA ' ' A' ' 100' ' ' ALA . 22.1 m-70 -54.71 -50.22 68.84 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 121.042 0.449 . . . . 0.0 111.13 -179.959 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 5.1 m -64.62 -26.27 68.32 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.96 -177.296 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.526 ' O ' HG23 ' A' ' 109' ' ' VAL . 19.4 m -72.06 -38.98 69.34 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.079 -178.797 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.439 HD22 HG21 ' A' ' 42' ' ' VAL . 77.5 mt -73.42 -41.85 62.78 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.854 179.651 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 107' ' ' MET . . . . . 0.562 ' HG2' ' O ' ' A' ' 103' ' ' HIS . 90.5 mmm -56.44 -41.28 76.19 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.753 -0.658 . . . . 0.0 111.881 -177.981 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 108' ' ' ARG . . . . . 0.403 HH11 ' HD3' ' A' ' 108' ' ' ARG . 11.2 ptp180 -73.42 -29.42 62.57 Favored 'General case' 0 C--N 1.328 -0.347 0 C-N-CA 120.79 -0.364 . . . . 0.0 111.277 -178.382 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.526 HG23 ' O ' ' A' ' 105' ' ' SER . 81.0 t -68.72 -45.75 80.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 C-N-CA 121.083 -0.247 . . . . 0.0 110.515 -179.777 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -61.77 -44.5 96.76 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.274 178.717 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.708 ' HA ' ' HB1' ' A' ' 148' ' ' ALA . 17.3 t70 -63.85 -34.44 77.94 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.66 -0.7 . . . . 0.0 110.984 179.82 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -70.85 -43.36 68.64 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.825 -0.625 . . . . 0.0 111.955 -178.675 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 21.6 m -89.02 -24.05 6.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 N-CA-C 111.848 0.314 . . . . 0.0 111.848 -175.093 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 84.71 53.68 3.14 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.309 178.691 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -129.83 160.41 33.57 Favored 'General case' 0 C--N 1.323 -0.566 0 O-C-N 122.842 -0.21 . . . . 0.0 110.695 -179.227 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 116' ' ' ARG . . . . . 0.431 ' HD3' ' OE1' ' A' ' 145' ' ' GLU . 10.1 ttm180 -79.53 123.53 27.66 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 109.278 -0.638 . . . . 0.0 109.278 176.013 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 117' ' ' LEU . . . . . 0.57 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 58.5 tp -95.04 118.01 31.14 Favored 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 109.585 -0.524 . . . . 0.0 109.585 178.812 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 60.2 mt -115.49 114.79 47.37 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.654 0 CA-C-O 121.278 0.561 . . . . 0.0 110.696 -179.773 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 63.1 mt -115.34 123.96 71.41 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.907 0 CA-C-N 116.151 -0.477 . . . . 0.0 109.972 178.908 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 120' ' ' LYS . . . . . 0.543 ' HG2' ' HB3' ' A' ' 143' ' ' PHE . 9.5 tmtm? -110.22 97.92 32.97 Favored Pre-proline 0 C--N 1.321 -0.647 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 176.728 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 80.1 Cg_endo -87.93 -178.18 2.14 Favored 'Trans proline' 0 N--CA 1.453 -0.873 0 C-N-CA 122.794 2.329 . . . . 0.0 111.866 176.433 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 122' ' ' LEU . . . . . 0.75 ' HB2' ' HB3' ' A' ' 125' ' ' GLU . 8.1 mp -108.29 166.93 10.39 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.243 -178.85 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 24.8 m -64.19 111.97 2.82 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 120.942 0.401 . . . . 0.0 110.726 179.147 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 91.66 -32.75 5.14 Favored Glycine 0 N--CA 1.45 -0.379 0 N-CA-C 111.314 -0.714 . . . . 0.0 111.314 -176.8 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 125' ' ' GLU . . . . . 0.75 ' HB3' ' HB2' ' A' ' 122' ' ' LEU . 20.9 tt0 -92.09 74.68 5.49 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 176.22 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 23.6 t70 -113.62 -178.53 3.4 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 114.788 -1.096 . . . . 0.0 110.948 -166.626 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 4.7 mt -71.51 -27.28 28.14 Favored 'Isoleucine or valine' 0 C--O 1.234 0.268 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 176.201 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 3.3 t 63.35 33.92 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.261 0 CA-C-O 121.911 0.862 . . . . 0.0 109.453 -179.158 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 20.2 p -117.66 -72.63 0.68 Allowed 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.482 -0.781 . . . . 0.0 111.822 -173.482 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 58.8 80.4 0.19 Allowed 'General case' 0 C--O 1.233 0.215 0 O-C-N 123.682 0.614 . . . . 0.0 110.535 -176.571 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 131' ' ' ARG . . . . . . . . . . . . . 19.1 tpp180 -165.68 -71.97 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.213 0.53 . . . . 0.0 110.412 -177.672 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 30.9 mmtt -77.89 -49.9 13.29 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.45 -0.795 . . . . 0.0 112.152 -176.699 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 133' ' ' MET . . . . . 0.51 ' HG2' ' HB2' ' A' ' 146' ' ' TYR . 77.2 mtp -87.89 154.03 20.85 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.15 0.5 . . . . 0.0 111.616 -173.371 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 14.8 ptmt -112.72 142.66 45.08 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 115.197 -0.91 . . . . 0.0 110.376 -177.305 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 135' ' ' LEU . . . . . 0.554 HD11 ' HD2' ' A' ' 142' ' ' TYR . 47.2 tp -84.33 123.05 29.76 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.428 -179.957 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -121.68 144.6 30.32 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.935 -179.516 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 4.3 m-20 -111.2 130.53 55.61 Favored 'General case' 0 C--N 1.325 -0.482 0 N-CA-C 109.526 -0.546 . . . . 0.0 109.526 175.002 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 138' ' ' TYR . . . . . 0.424 ' CD2' ' HB2' ' A' ' 28' ' ' TYR . 57.5 t80 -148.52 111.55 4.87 Favored 'General case' 0 C--N 1.322 -0.629 0 N-CA-C 110.018 -0.364 . . . . 0.0 110.018 176.139 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 69.49 49.2 39.4 Favored Glycine 0 N--CA 1.446 -0.683 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.02 179.826 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 20.9 mmm-85 76.48 -40.66 0.39 Allowed 'General case' 0 N--CA 1.467 0.397 0 C-N-CA 123.729 0.812 . . . . 0.0 112.057 177.446 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 13.8 t -76.73 146.94 37.66 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.192 0.52 . . . . 0.0 110.64 -177.941 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 142' ' ' TYR . . . . . 0.554 ' HD2' HD11 ' A' ' 135' ' ' LEU . 47.4 p90 -117.28 142.94 46.45 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.776 179.194 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 143' ' ' PHE . . . . . 0.543 ' HB3' ' HG2' ' A' ' 120' ' ' LYS . 11.4 p90 -152.48 179.79 8.26 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.58 -0.736 . . . . 0.0 109.748 -178.476 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 89.3 m-85 -115.33 138.07 51.36 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 120.669 0.271 . . . . 0.0 110.595 -179.858 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 145' ' ' GLU . . . . . 0.431 ' OE1' ' HD3' ' A' ' 116' ' ' ARG . 17.9 pt-20 -123.81 160.05 28.22 Favored 'General case' 0 C--N 1.319 -0.737 0 N-CA-C 109.161 -0.681 . . . . 0.0 109.161 173.878 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 146' ' ' TYR . . . . . 0.51 ' HB2' ' HG2' ' A' ' 133' ' ' MET . 45.7 t80 -142.26 126.36 17.39 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-O 121.07 0.462 . . . . 0.0 110.374 176.78 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 2.1 mp -92.82 108.11 19.91 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.762 0 CA-C-N 115.696 -0.684 . . . . 0.0 109.389 176.683 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 148' ' ' ALA . . . . . 0.708 ' HB1' ' HA ' ' A' ' 111' ' ' ASP . . . -70.93 129.12 38.22 Favored 'General case' 0 N--CA 1.444 -0.774 0 CA-C-N 115.693 -0.685 . . . . 0.0 110.151 176.353 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 22.4 mm-40 -64.18 167.95 6.01 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 121.768 0.794 . . . . 0.0 111.395 177.779 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 16.5 t -90.4 117.7 34.2 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.953 0 CA-C-N 114.836 -1.074 . . . . 0.0 109.525 179.346 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 151' ' ' ARG . . . . . . . . . . . . . 30.2 mmm180 -87.59 90.04 8.22 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 115.727 -0.67 . . . . 0.0 109.979 -179.499 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 20.9 t -143.19 148.07 35.9 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.508 -178.662 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 9.2 tpt180 . . . . . 0 C--O 1.251 1.153 0 CA-C-O 118.293 -0.861 . . . . 0.0 109.114 178.278 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 22.0 ptm . . . . . 0 N--CA 1.482 1.163 0 N-CA-C 110.032 -0.359 . . . . 0.0 110.032 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -79.63 53.18 4.25 Favored Glycine 0 N--CA 1.453 -0.216 0 C-N-CA 121.265 -0.493 . . . . 0.0 113.195 -174.045 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 16.3 m -79.68 -20.77 45.8 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.162 0.506 . . . . 0.0 110.243 177.236 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 33.9 m -114.98 89.05 3.01 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.94 -0.573 . . . . 0.0 109.997 176.504 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 41.1 p-80 -93.12 7.6 43.53 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.406 0.622 . . . . 0.0 110.239 178.484 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 21.1 m-70 -92.01 35.51 0.98 Allowed 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.328 178.214 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 28.1 p-80 -81.29 137.67 35.78 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.681 178.835 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 76.5 t60 -129.34 128.48 43.2 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 109.563 -0.532 . . . . 0.0 109.563 -179.078 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 81.6 t60 -81.39 -32.38 32.83 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.46 -172.578 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 94.1 m-70 -87.23 16.76 4.87 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.793 0.33 . . . . 0.0 111.302 -175.979 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 19.6 m -65.8 111.01 3.04 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.144 177.112 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 19.7 t -94.09 -47.32 6.73 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 115.915 -0.584 . . . . 0.0 109.757 -178.791 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 83.22 113.47 0.53 Allowed Glycine 0 N--CA 1.448 -0.512 0 CA-C-N 115.739 -0.664 . . . . 0.0 112.175 -178.921 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -77.48 126.02 30.25 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-O 120.919 0.39 . . . . 0.0 110.54 -178.73 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 60.9 t -102.83 111.11 64.65 Favored Pre-proline 0 C--N 1.323 -0.55 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.709 -178.107 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -79.51 179.26 6.51 Favored 'Trans proline' 0 N--CA 1.46 -0.467 0 C-N-CA 123.051 2.5 . . . . 0.0 111.117 174.932 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 35.2 ptt180 -81.0 -19.18 44.55 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.267 0.556 . . . . 0.0 110.241 -179.86 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -179.0 164.37 32.61 Favored Glycine 0 N--CA 1.444 -0.783 0 CA-C-N 115.689 -0.687 . . . . 0.0 111.507 178.297 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 12.2 p -87.81 148.24 24.77 Favored 'General case' 0 C--N 1.32 -0.704 0 N-CA-C 110.095 -0.335 . . . . 0.0 110.095 177.77 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 64.1 m80 -131.1 -46.49 1.01 Allowed 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.974 0.416 . . . . 0.0 110.393 179.498 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' MET . . . . . . . . . . . . . 65.5 mtt -71.5 -40.79 69.94 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.022 179.394 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 81.7 m95 -69.57 -19.99 63.66 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.497 -0.774 . . . . 0.0 111.145 -178.567 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' ASN . . . . . 0.504 ' O ' HG23 ' A' ' 27' ' ' VAL . 6.7 m-20 -65.5 -29.85 70.55 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.006 -179.547 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -75.04 -34.07 61.81 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 179.696 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 45.1 tp -60.31 -43.13 96.62 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 115.914 -0.585 . . . . 0.0 109.651 172.846 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -59.05 -47.33 85.62 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.458 -0.792 . . . . 0.0 110.655 176.661 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.504 HG23 ' O ' ' A' ' 23' ' ' ASN . 99.2 t -56.21 -43.25 75.86 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.188 0 CA-C-N 116.361 -0.381 . . . . 0.0 111.111 177.987 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 88.0 t80 -59.44 -48.71 80.59 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.819 0.342 . . . . 0.0 110.461 178.401 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 71.6 mt -58.48 -41.83 82.77 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.251 178.553 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.608 HG12 HG23 ' A' ' 54' ' ' ILE . 83.2 mt -60.32 -38.44 77.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 115.473 -0.785 . . . . 0.0 111.061 177.639 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 22.1 mtp180 -70.78 -30.13 66.52 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.154 -179.22 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 75.6 m -87.03 -8.91 56.67 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.576 -178.501 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 26.0 p -122.84 -80.83 0.63 Allowed 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 120.747 0.308 . . . . 0.0 111.08 179.01 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.455 ' O ' HG22 ' A' ' 37' ' ' THR . . . 88.21 168.51 44.33 Favored Glycine 0 N--CA 1.447 -0.633 0 C-N-CA 121.141 -0.552 . . . . 0.0 112.446 -179.901 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_exo -65.67 140.33 61.69 Favored 'Trans proline' 0 C--O 1.232 0.204 0 C-N-CA 122.644 2.229 . . . . 0.0 111.759 178.225 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 109.98 -8.21 31.41 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.364 -0.922 . . . . 0.0 112.507 178.978 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 37' ' ' THR . . . . . 0.455 HG22 ' O ' ' A' ' 34' ' ' GLY . 11.5 t -125.04 -171.31 2.33 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.306 -0.627 . . . . 0.0 109.306 178.299 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 38' ' ' ARG . . . . . 0.841 ' HG3' ' HA ' ' A' ' 90' ' ' ALA . 1.7 ptm180 -132.48 136.94 47.02 Favored 'General case' 0 N--CA 1.447 -0.604 0 CA-C-O 121.075 0.464 . . . . 0.0 111.418 -179.619 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.488 ' O ' ' HA ' ' A' ' 62' ' ' LEU . 58.2 t -125.91 139.43 51.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 115.611 -0.722 . . . . 0.0 109.747 -178.223 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.475 ' HB ' HG12 ' A' ' 93' ' ' ILE . 39.6 t -116.34 134.47 59.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-O 120.854 0.359 . . . . 0.0 111.164 -178.026 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 44.1 tt0 -108.23 120.56 42.72 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.143 177.02 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.626 ' HB ' ' HB3' ' A' ' 95' ' ' SER . 85.7 t -95.91 123.49 48.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.387 -179.603 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 98.19 25.16 10.53 Favored Glycine 0 N--CA 1.447 -0.567 0 C-N-CA 120.686 -0.769 . . . . 0.0 111.789 -179.366 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -79.32 54.13 1.63 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 121.321 0.582 . . . . 0.0 111.128 -178.281 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -94.25 -64.82 1.02 Allowed Glycine 0 N--CA 1.444 -0.789 0 C-N-CA 120.854 -0.689 . . . . 0.0 111.823 178.674 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -105.07 -8.22 18.63 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.059 0.457 . . . . 0.0 110.306 175.373 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.487 ' HD1' ' HE1' ' A' ' 49' ' ' TYR . 87.4 m-85 -106.76 102.54 11.91 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.909 -0.587 . . . . 0.0 109.981 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.533 HD22 HD13 ' A' ' 64' ' ' LEU . 84.5 mt -129.7 -10.81 4.45 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.448 -0.342 . . . . 0.0 111.002 179.997 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 49' ' ' TYR . . . . . 0.487 ' HE1' ' HD1' ' A' ' 47' ' ' PHE . 30.6 p90 -59.06 -30.97 68.45 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 112.59 0.589 . . . . 0.0 112.59 -173.917 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 80.5 t -75.81 -58.01 5.26 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-O 120.795 0.331 . . . . 0.0 110.744 178.831 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 51' ' ' SER . . . . . 0.428 ' CB ' HD21 ' A' ' 64' ' ' LEU . 15.5 p -60.32 -39.18 86.12 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.939 -177.983 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.499 ' O ' ' HG3' ' A' ' 56' ' ' LYS . 29.7 t70 -65.11 -33.65 76.53 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.64 -178.38 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 71.0 t80 -71.25 -44.71 64.77 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.545 177.499 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.608 HG23 HG12 ' A' ' 30' ' ' ILE . 79.2 mt -57.48 -46.42 85.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.868 -176.602 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 55' ' ' ARG . . . . . 0.512 HH12 HD11 ' A' ' 64' ' ' LEU . 9.0 ptp85 -69.03 -16.12 63.63 Favored 'General case' 0 N--CA 1.467 0.383 0 N-CA-C 112.164 0.431 . . . . 0.0 112.164 -176.889 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 56' ' ' LYS . . . . . 0.499 ' HG3' ' O ' ' A' ' 52' ' ' ASP . 67.9 mttm -82.54 -33.08 28.31 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 120.807 0.337 . . . . 0.0 111.392 -179.753 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 5.4 t-80 -95.11 -39.65 10.02 Favored 'General case' 0 N--CA 1.448 -0.529 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.357 -177.699 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 8.1 p -118.51 132.07 56.23 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.449 -0.341 . . . . 0.0 111.13 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 59' ' ' LYS . . . . . 0.463 ' HD2' ' HA ' ' A' ' 59' ' ' LYS . 26.9 mmmt -80.97 61.2 4.47 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.696 0.76 . . . . 0.0 110.603 176.062 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 7.7 p -98.07 144.65 10.92 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.725 0 CA-C-N 114.901 -1.045 . . . . 0.0 109.509 175.508 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -73.12 89.61 1.5 Allowed 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 177.561 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 62' ' ' LEU . . . . . 0.488 ' HA ' ' O ' ' A' ' 39' ' ' VAL . 3.5 tt -96.39 118.4 32.84 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.014 0.435 . . . . 0.0 110.363 -176.611 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 58.1 t -102.19 128.98 54.31 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.463 0 CA-C-N 115.588 -0.733 . . . . 0.0 110.72 -176.141 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 64' ' ' LEU . . . . . 0.533 HD13 HD22 ' A' ' 48' ' ' LEU . 66.1 mt -108.66 133.26 52.99 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.936 -0.574 . . . . 0.0 109.999 176.404 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 12.5 p -119.12 132.03 55.96 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.724 0.297 . . . . 0.0 110.71 176.194 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 66' ' ' ASP . . . . . 0.448 ' HB3' HG21 ' A' ' 74' ' ' ILE . 24.5 t70 -156.96 146.85 20.81 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.426 -177.843 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.614 HG12 ' HB2' ' A' ' 78' ' ' ASP . 34.5 mt -73.9 103.91 2.44 Favored 'Isoleucine or valine' 0 C--O 1.238 0.491 0 N-CA-C 110.114 -0.328 . . . . 0.0 110.114 179.419 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 68' ' ' LYS . . . . . 0.401 ' HE2' ' HB3' ' A' ' 68' ' ' LYS . 30.7 mtpt 56.92 80.08 0.3 Allowed Pre-proline 0 C--N 1.33 -0.276 0 CA-C-N 115.191 -0.913 . . . . 0.0 109.798 -177.091 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 69' ' ' PRO . . . . . 0.877 ' HB3' ' HB ' ' A' ' 74' ' ' ILE . 9.1 Cg_endo -49.8 133.16 33.0 Favored 'Trans proline' 0 C--O 1.234 0.275 0 C-N-CA 123.895 3.064 . . . . 0.0 113.7 -173.077 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 39.5 t -87.75 -5.7 58.53 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.438 -0.801 . . . . 0.0 110.053 177.51 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 68.7 m-70 -136.43 165.53 25.59 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.354 -179.559 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -86.53 138.76 16.02 Favored Glycine 0 N--CA 1.448 -0.558 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.263 -179.131 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 106.55 -2.26 36.76 Favored Glycine 0 N--CA 1.449 -0.456 0 C-N-CA 120.76 -0.733 . . . . 0.0 111.753 179.303 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.877 ' HB ' ' HB3' ' A' ' 69' ' ' PRO . 43.4 mt -98.91 140.28 18.83 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 N-CA-C 110.164 -0.31 . . . . 0.0 110.164 -179.754 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.525 HG12 ' H ' ' A' ' 77' ' ' ASP . 63.3 t -79.41 141.94 14.66 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.093 178.764 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 76' ' ' ARG . . . . . 0.566 ' HG2' ' HD2' ' A' ' 69' ' ' PRO . 89.1 mtm180 -82.87 16.41 2.28 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.913 -176.148 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 77' ' ' ASP . . . . . 0.525 ' H ' HG12 ' A' ' 75' ' ' VAL . 35.9 t70 -87.03 138.01 31.86 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 179.001 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 78' ' ' ASP . . . . . 0.614 ' HB2' HG12 ' A' ' 67' ' ' ILE . 0.7 OUTLIER -103.32 177.92 4.7 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.73 0.3 . . . . 0.0 111.257 -173.362 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 9.3 tp -94.03 -24.66 4.95 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.444 0 N-CA-C 112.601 0.593 . . . . 0.0 112.601 -170.401 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.51 HG22 ' OD1' ' A' ' 78' ' ' ASP . 6.3 t -91.1 -20.5 21.96 Favored 'General case' 0 C--N 1.325 -0.47 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 -178.319 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 81' ' ' SER . . . . . 0.495 ' HB2' ' OD2' ' A' ' 78' ' ' ASP . 34.0 m -129.42 62.85 65.23 Favored Pre-proline 0 CA--C 1.535 0.391 0 CA-C-N 115.48 -0.782 . . . . 0.0 110.081 172.822 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 87.9 Cg_endo -85.7 150.28 9.98 Favored 'Trans proline' 0 N--CA 1.459 -0.515 0 C-N-CA 122.375 2.05 . . . . 0.0 113.525 -171.847 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 77.8 mtt-85 -88.95 112.51 23.41 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.416 -0.811 . . . . 0.0 110.413 175.147 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 84' ' ' MET . . . . . . . . . . . . . 93.6 mmm -66.05 -23.38 66.53 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.449 -0.341 . . . . 0.0 111.057 -179.264 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 6.7 pm0 -67.62 -19.32 65.21 Favored 'General case' 0 N--CA 1.464 0.246 0 CA-C-O 120.889 0.376 . . . . 0.0 111.01 179.61 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.404 HD13 HG11 ' A' ' 75' ' ' VAL . 62.1 mt -83.81 -39.34 14.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.345 179.017 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 87' ' ' TYR . . . . . 0.417 ' CB ' HG11 ' A' ' 113' ' ' VAL . 93.3 m-85 -80.65 -34.07 35.17 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.209 -178.557 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 88' ' ' ARG . . . . . 0.525 ' HA ' ' HB ' ' A' ' 113' ' ' VAL . 62.2 mtp85 -65.15 132.93 50.42 Favored 'General case' 0 CA--C 1.515 -0.384 0 CA-C-O 121.329 0.585 . . . . 0.0 110.856 -178.509 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 102.4 -19.41 48.33 Favored Glycine 0 N--CA 1.446 -0.683 0 CA-C-N 115.053 -0.976 . . . . 0.0 111.641 -176.803 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 90' ' ' ALA . . . . . 0.841 ' HA ' ' HG3' ' A' ' 38' ' ' ARG . . . -71.46 145.3 49.32 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.837 0.351 . . . . 0.0 110.705 -179.772 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -92.52 -21.98 19.81 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.041 -179.188 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 92' ' ' LEU . . . . . 0.525 ' HG ' ' HB3' ' A' ' 116' ' ' ARG . 3.5 tt -150.81 138.4 19.68 Favored 'General case' 0 N--CA 1.449 -0.497 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.912 -176.28 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.643 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 85.5 mt -133.03 124.05 49.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 115.719 -0.673 . . . . 0.0 109.326 176.955 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 94' ' ' TYR . . . . . 0.437 ' HB3' ' HB ' ' A' ' 118' ' ' ILE . 10.2 p90 -130.01 158.84 38.49 Favored 'General case' 0 C--N 1.32 -0.696 0 C-N-CA 120.808 -0.357 . . . . 0.0 110.802 -179.524 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 95' ' ' SER . . . . . 0.626 ' HB3' ' HB ' ' A' ' 42' ' ' VAL . 11.5 p -145.07 137.71 26.18 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.594 -177.749 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 63.7 mt -104.7 111.51 34.55 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.293 -179.212 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 6.1 tpm_? 61.32 75.67 0.44 Allowed Pre-proline 0 CA--C 1.534 0.355 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.188 -179.763 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 98' ' ' PRO . . . . . 0.42 ' HA ' ' HD3' ' A' ' 99' ' ' PRO . 0.9 OUTLIER -84.32 150.86 12.01 Favored 'Trans proline' 0 N--CA 1.457 -0.629 0 C-N-CA 122.788 2.325 . . . . 0.0 111.589 176.449 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.42 ' HD3' ' HA ' ' A' ' 98' ' ' PRO . 31.2 Cg_exo -59.39 155.16 42.64 Favored 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.703 2.269 . . . . 0.0 111.619 175.727 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.451 ' HA ' ' NE2' ' A' ' 103' ' ' HIS . . . -79.26 7.19 8.17 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 112.144 0.424 . . . . 0.0 112.144 -174.118 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 101' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -111.75 -14.03 13.64 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 111.804 0.298 . . . . 0.0 111.804 179.597 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.42 HG13 ' O ' ' A' ' 102' ' ' ILE . 32.2 pt -123.51 77.46 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 121.821 0.82 . . . . 0.0 111.661 -179.281 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 103' ' ' HIS . . . . . 0.451 ' NE2' ' HA ' ' A' ' 100' ' ' ALA . 95.5 m-70 -112.99 -50.25 2.89 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.418 -0.81 . . . . 0.0 109.331 174.983 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 18.9 t -74.9 -23.76 58.42 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 176.353 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.546 ' O ' ' HG2' ' A' ' 108' ' ' ARG . 3.3 m -67.87 -38.96 83.76 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.459 -0.791 . . . . 0.0 109.754 177.272 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 69.2 mt -73.2 -38.76 65.99 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.129 175.701 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 107' ' ' MET . . . . . . . . . . . . . 47.9 ttm -62.1 -39.82 93.75 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.685 -0.689 . . . . 0.0 111.129 -179.819 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 108' ' ' ARG . . . . . 0.546 ' HG2' ' O ' ' A' ' 105' ' ' SER . 7.9 ptp180 -68.56 -25.35 64.86 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.629 0.252 . . . . 0.0 110.795 -179.816 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.489 HG23 ' O ' ' A' ' 105' ' ' SER . 94.2 t -72.32 -48.18 49.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 175.697 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -59.63 -41.59 90.8 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.167 176.164 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 18.0 t70 -61.95 -38.28 87.89 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.412 -0.813 . . . . 0.0 111.164 178.232 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -72.74 -40.37 66.11 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.612 -0.722 . . . . 0.0 111.957 -178.377 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.525 ' HB ' ' HA ' ' A' ' 88' ' ' ARG . 13.7 m -91.01 -24.57 5.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-O 120.895 0.378 . . . . 0.0 111.741 -174.339 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 88.69 42.13 5.83 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 121.009 -0.615 . . . . 0.0 112.421 178.916 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -119.41 156.5 30.03 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 121.101 0.477 . . . . 0.0 111.407 -177.177 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 116' ' ' ARG . . . . . 0.525 ' HB3' ' HG ' ' A' ' 92' ' ' LEU . 21.5 ttm180 -79.59 121.37 25.18 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.793 -0.639 . . . . 0.0 109.654 176.793 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 117' ' ' LEU . . . . . 0.643 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 53.3 tp -92.71 118.83 31.47 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.383 -178.579 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 118' ' ' ILE . . . . . 0.437 ' HB ' ' HB3' ' A' ' 94' ' ' TYR . 64.1 mt -113.38 121.72 66.12 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.61 0 CA-C-O 121.024 0.44 . . . . 0.0 110.425 178.101 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 56.4 mt -120.46 134.31 64.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.375 -179.809 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 45.2 tptt -110.14 98.2 33.94 Favored Pre-proline 0 C--N 1.323 -0.549 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.524 175.43 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 82.0 Cg_endo -91.47 174.62 2.42 Favored 'Trans proline' 0 N--CA 1.456 -0.721 0 C-N-CA 123.068 2.512 . . . . 0.0 112.005 173.961 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -99.01 163.79 12.44 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.467 178.984 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 14.5 t -65.06 -21.78 66.88 Favored 'General case' 0 CA--C 1.534 0.363 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.429 -179.162 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -104.13 18.04 46.74 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.308 179.871 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 22.7 mm-40 -119.6 -173.84 2.62 Favored 'General case' 0 N--CA 1.449 -0.487 0 CA-C-O 121.209 0.528 . . . . 0.0 110.334 -178.489 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -148.87 170.01 19.25 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 115.381 -0.827 . . . . 0.0 108.791 176.548 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.443 ' C ' ' H ' ' A' ' 129' ' ' THR . 7.5 mt -101.1 -18.19 6.47 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 179.484 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 27.8 t 68.72 -13.32 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.541 0.611 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.572 179.213 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 129' ' ' THR . . . . . 0.443 ' H ' ' C ' ' A' ' 127' ' ' ILE . 7.7 t -79.47 -176.97 5.54 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.931 0.396 . . . . 0.0 110.582 179.915 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 130' ' ' GLU . . . . . 0.515 ' HB2' ' HG2' ' A' ' 132' ' ' LYS . 33.2 mt-10 -87.22 -166.6 1.62 Allowed 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.982 -0.553 . . . . 0.0 110.537 -178.89 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 131' ' ' ARG . . . . . 0.811 ' HD2' ' H ' ' A' ' 131' ' ' ARG . 0.0 OUTLIER -77.55 37.67 0.23 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 121.107 0.48 . . . . 0.0 110.598 177.609 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 132' ' ' LYS . . . . . 0.515 ' HG2' ' HB2' ' A' ' 130' ' ' GLU . 29.5 mmmt -79.27 -41.29 28.49 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.844 -0.616 . . . . 0.0 111.447 -176.03 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 133' ' ' MET . . . . . 0.737 ' HG2' ' HB2' ' A' ' 146' ' ' TYR . 82.5 mtp -92.38 164.94 13.31 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.929 -174.431 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 13.2 ptmm? -127.08 140.47 52.26 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.971 -177.503 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 135' ' ' LEU . . . . . 0.512 HD11 ' HD2' ' A' ' 142' ' ' TYR . 51.6 tp -80.7 129.19 34.38 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.338 -179.091 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -123.3 139.04 51.18 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.68 178.751 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 16.8 m120 -114.83 108.25 16.5 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 115.801 -0.636 . . . . 0.0 109.868 179.557 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 138' ' ' TYR . . . . . 0.4 ' O ' HG22 ' A' ' 141' ' ' THR . 54.1 t80 -131.65 106.01 7.89 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-O 120.929 0.395 . . . . 0.0 110.323 -178.275 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 139' ' ' GLY . . . . . 0.468 ' O ' ' HB2' ' A' ' 140' ' ' ARG . . . 80.0 34.16 31.07 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.094 178.922 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 140' ' ' ARG . . . . . 0.468 ' HB2' ' O ' ' A' ' 139' ' ' GLY . 0.0 OUTLIER 75.32 -14.57 0.75 Allowed 'General case' 0 N--CA 1.468 0.471 0 C-N-CA 123.279 0.632 . . . . 0.0 111.921 178.097 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 141' ' ' THR . . . . . 0.4 HG22 ' O ' ' A' ' 138' ' ' TYR . 8.3 t -93.9 141.62 28.31 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 175.562 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 142' ' ' TYR . . . . . 0.512 ' HD2' HD11 ' A' ' 135' ' ' LEU . 43.0 p90 -119.07 143.54 47.07 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 121.364 0.602 . . . . 0.0 110.825 -176.052 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 15.0 p90 -152.01 173.88 14.34 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 115.119 -0.946 . . . . 0.0 109.413 -178.512 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 76.8 m-85 -112.94 129.47 56.46 Favored 'General case' 0 C--N 1.322 -0.611 0 C-N-CA 121.058 -0.257 . . . . 0.0 110.691 -179.624 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 145' ' ' GLU . . . . . 0.495 ' OE1' ' HD3' ' A' ' 116' ' ' ARG . 19.2 pt-20 -115.33 157.19 24.18 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 174.667 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 146' ' ' TYR . . . . . 0.737 ' HB2' ' HG2' ' A' ' 133' ' ' MET . 32.9 t80 -139.24 124.19 18.77 Favored 'General case' 0 C--N 1.315 -0.913 0 CA-C-N 115.752 -0.658 . . . . 0.0 109.904 176.656 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 3.1 mp -93.54 105.93 17.41 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.859 0 N-CA-C 109.726 -0.472 . . . . 0.0 109.726 -179.168 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -62.3 114.94 3.76 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-O 121.139 0.495 . . . . 0.0 110.756 178.054 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 8.1 mm-40 -76.28 -175.53 3.24 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.346 -0.843 . . . . 0.0 111.194 179.22 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 21.5 t -87.55 135.55 25.11 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.92 0 CA-C-N 114.824 -1.08 . . . . 0.0 109.07 177.591 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 151' ' ' ARG . . . . . . . . . . . . . 3.9 ppt_? -59.37 135.92 57.81 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.872 0.368 . . . . 0.0 110.198 -178.474 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 34.8 m -128.95 114.7 16.78 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.786 -176.935 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 62.0 ttt-85 . . . . . 0 C--O 1.245 0.856 0 CA-C-O 118.519 -0.753 . . . . 0.0 109.707 179.588 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 64.9 mtt . . . . . 0 N--CA 1.482 1.134 0 N-CA-C 110.108 -0.331 . . . . 0.0 110.108 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -129.58 -164.24 11.37 Favored Glycine 0 N--CA 1.446 -0.69 0 C-N-CA 120.852 -0.69 . . . . 0.0 111.835 178.388 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 22.7 m -128.11 -174.57 3.25 Favored 'General case' 0 C--N 1.32 -0.68 0 N-CA-C 109.708 -0.479 . . . . 0.0 109.708 177.588 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 33.0 m -67.15 135.69 53.92 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.871 0.367 . . . . 0.0 110.618 179.257 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 37.6 p-80 -122.92 144.82 48.97 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.526 179.467 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 8.1 p80 -140.69 117.73 11.19 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 115.953 -0.567 . . . . 0.0 109.705 176.058 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 18.2 m-70 -120.12 117.11 27.08 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.349 -173.344 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 43.6 m80 56.74 43.34 25.39 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-N 115.733 -0.667 . . . . 0.0 112.214 173.908 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 45.5 t60 -132.92 23.87 4.25 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 122.162 0.982 . . . . 0.0 108.433 174.549 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 22.5 p-80 -98.73 158.21 15.77 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 114.799 -1.091 . . . . 0.0 111.169 -177.421 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 38.7 m 65.51 18.72 11.37 Favored 'General case' 0 CA--C 1.533 0.311 0 CA-C-N 115.492 -0.776 . . . . 0.0 112.144 174.676 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 14.6 p -82.13 77.37 8.94 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.572 0.701 . . . . 0.0 111.06 -179.345 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -165.59 69.01 0.19 Allowed Glycine 0 N--CA 1.448 -0.561 0 CA-C-N 115.436 -0.802 . . . . 0.0 111.222 179.252 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 82.8 mt -81.49 138.67 35.46 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.901 0.381 . . . . 0.0 111.137 -175.666 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 47.3 t -112.27 98.84 44.6 Favored Pre-proline 0 C--N 1.323 -0.564 0 CA-C-N 115.824 -0.626 . . . . 0.0 109.65 176.363 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 77.1 Cg_endo -86.36 -175.12 1.65 Allowed 'Trans proline' 0 N--CA 1.458 -0.592 0 C-N-CA 123.138 2.558 . . . . 0.0 112.94 -176.602 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' ARG . . . . . 0.463 ' HA ' ' HB2' ' A' ' 20' ' ' HIS . 16.0 mtt-85 -92.21 -166.02 1.46 Allowed 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.779 -0.646 . . . . 0.0 111.287 179.185 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 92.55 -54.67 2.72 Favored Glycine 0 N--CA 1.446 -0.664 0 N-CA-C 111.178 -0.769 . . . . 0.0 111.178 -174.704 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' SER . . . . . 0.436 ' HB2' ' CZ ' ' A' ' 49' ' ' TYR . 36.5 p -110.42 8.45 23.21 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 121.065 0.46 . . . . 0.0 110.21 176.793 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 20' ' ' HIS . . . . . 0.463 ' HB2' ' HA ' ' A' ' 17' ' ' ARG . 66.7 t60 -57.37 -42.22 81.67 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.525 -0.762 . . . . 0.0 111.433 -178.244 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 21' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -60.33 -24.95 65.44 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 121.342 0.591 . . . . 0.0 110.738 -177.829 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 51.4 m95 -97.29 -19.35 18.61 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.22 -178.764 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' ASN . . . . . 0.43 ' O ' HG23 ' A' ' 27' ' ' VAL . 25.1 t-20 -66.19 -58.96 4.26 Favored 'General case' 0 N--CA 1.463 0.198 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.674 -172.285 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.462 ' CB ' ' HA3' ' A' ' 139' ' ' GLY . 4.5 m-20 -58.12 -32.68 68.36 Favored 'General case' 0 N--CA 1.464 0.27 0 CA-C-O 120.631 0.253 . . . . 0.0 111.333 -178.892 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 45.7 tp -57.16 -51.22 70.2 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-O 120.932 0.396 . . . . 0.0 110.262 175.291 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' ALA . . . . . 0.426 ' HB2' HG13 ' A' ' 50' ' ' VAL . . . -63.48 -43.56 96.94 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.601 179.887 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.43 HG23 ' O ' ' A' ' 23' ' ' ASN . 95.5 t -52.13 -47.85 43.09 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.153 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.076 177.454 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 56.4 t80 -57.81 -43.31 85.62 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.539 179.88 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.414 HG23 HD13 ' A' ' 92' ' ' LEU . 70.8 mt -67.91 -43.97 85.51 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.791 179.247 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.486 HG12 HG23 ' A' ' 54' ' ' ILE . 92.1 mt -58.27 -45.54 89.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 115.61 -0.723 . . . . 0.0 111.0 178.303 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 84.0 mtt-85 -65.56 -27.72 68.63 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.666 -0.697 . . . . 0.0 111.761 -177.848 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 53.5 t -84.79 -27.35 26.9 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.596 -0.275 . . . . 0.0 111.186 -179.011 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 12.4 p -94.21 -76.96 0.47 Allowed 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 120.797 0.332 . . . . 0.0 111.202 -177.041 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.402 ' HA2' ' HD3' ' A' ' 35' ' ' PRO . . . 95.75 142.81 13.42 Favored Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 120.85 -0.69 . . . . 0.0 112.162 -178.843 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 35' ' ' PRO . . . . . 0.526 ' HG3' ' HA ' ' A' ' 58' ' ' SER . 58.1 Cg_exo -51.68 126.4 19.6 Favored 'Trans proline' 0 C--N 1.343 0.284 0 C-N-CA 123.283 2.655 . . . . 0.0 113.001 -176.795 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 104.32 53.93 0.81 Allowed Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.514 179.517 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 15.1 t -166.74 -175.84 3.27 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 179.624 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 63.1 mtt85 -122.11 132.51 54.51 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 121.08 0.467 . . . . 0.0 110.775 -179.911 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.928 ' HB ' HD22 ' A' ' 62' ' ' LEU . 60.6 t -123.85 131.76 72.45 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 N-CA-C 108.763 -0.828 . . . . 0.0 108.763 176.76 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.446 HG11 ' CE1' ' A' ' 87' ' ' TYR . 35.6 t -106.7 126.56 62.57 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-O 120.817 0.342 . . . . 0.0 110.887 -177.679 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 46.4 tt0 -108.22 124.12 49.81 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.144 178.368 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.911 ' HB ' ' HB3' ' A' ' 95' ' ' SER . 95.1 t -97.37 121.72 48.17 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.593 -179.876 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 89.68 34.13 8.67 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.855 -0.688 . . . . 0.0 111.519 -179.64 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -81.09 14.15 2.44 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 112.432 0.53 . . . . 0.0 112.432 -173.185 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -54.41 -38.04 61.59 Favored Glycine 0 CA--C 1.519 0.32 0 C-N-CA 121.201 -0.524 . . . . 0.0 113.807 -176.887 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 46' ' ' ARG . . . . . 0.416 HH11 ' HD2' ' A' ' 46' ' ' ARG . 19.4 mtp180 -139.2 13.28 2.61 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 117.129 0.465 . . . . 0.0 111.997 -177.144 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 73.4 m-85 -112.15 29.03 8.24 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 121.254 0.55 . . . . 0.0 110.619 -177.519 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.588 HD21 HD11 ' A' ' 74' ' ' ILE . 87.0 mt -59.26 -15.66 16.89 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 114.868 -1.06 . . . . 0.0 113.074 -175.342 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 49' ' ' TYR . . . . . 0.436 ' CZ ' ' HB2' ' A' ' 19' ' ' SER . 81.5 t80 -59.13 -45.26 91.39 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.583 0.23 . . . . 0.0 111.313 -179.249 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.426 HG13 ' HB2' ' A' ' 26' ' ' ALA . 42.8 t -65.41 -54.64 26.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.672 -175.224 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 51' ' ' SER . . . . . 0.442 ' CB ' HD21 ' A' ' 64' ' ' LEU . 0.2 OUTLIER -59.52 -41.96 91.17 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.701 -179.796 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.608 ' HA ' ' HG2' ' A' ' 55' ' ' ARG . 38.7 t70 -69.08 -37.92 78.72 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 120.857 -0.337 . . . . 0.0 110.865 -179.224 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 89.4 t80 -60.26 -37.06 79.26 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.875 0.369 . . . . 0.0 110.034 177.925 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.486 HG23 HG12 ' A' ' 30' ' ' ILE . 76.0 mt -63.29 -54.78 28.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.949 -0.568 . . . . 0.0 110.673 176.044 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 55' ' ' ARG . . . . . 0.608 ' HG2' ' HA ' ' A' ' 52' ' ' ASP . 3.7 ptp180 -69.77 -16.44 63.3 Favored 'General case' 0 N--CA 1.465 0.318 0 N-CA-C 112.072 0.397 . . . . 0.0 112.072 -177.083 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 56' ' ' LYS . . . . . 0.7 ' HA ' ' HE3' ' A' ' 56' ' ' LYS . 0.0 OUTLIER -64.04 -39.24 93.66 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.693 0.282 . . . . 0.0 110.843 176.378 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 29.9 m-70 -107.27 -50.51 3.07 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.746 -178.61 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 58' ' ' SER . . . . . 0.526 ' HA ' ' HG3' ' A' ' 35' ' ' PRO . 57.6 m -88.38 132.99 34.22 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.851 -178.289 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 59' ' ' LYS . . . . . 0.562 ' N ' ' HD2' ' A' ' 59' ' ' LYS . 3.3 mptp? -80.19 57.06 2.61 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.684 0.754 . . . . 0.0 109.825 178.661 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.488 HG11 HG23 ' A' ' 39' ' ' VAL . 54.0 t -101.22 139.32 22.76 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-N 114.998 -1.001 . . . . 0.0 111.043 -178.11 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -80.02 98.61 7.28 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.866 -0.606 . . . . 0.0 109.524 174.819 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 62' ' ' LEU . . . . . 0.928 HD22 ' HB ' ' A' ' 39' ' ' VAL . 0.2 OUTLIER -87.54 121.02 29.43 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 115.934 -0.575 . . . . 0.0 109.593 -178.827 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 40.9 t -100.49 113.77 37.26 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.661 0 CA-C-N 115.738 -0.665 . . . . 0.0 109.786 -179.757 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 64' ' ' LEU . . . . . 0.75 ' HB2' ' HA ' ' A' ' 74' ' ' ILE . 54.5 mt -97.37 139.8 32.78 Favored 'General case' 0 C--N 1.312 -1.04 0 CA-C-N 115.628 -0.714 . . . . 0.0 110.338 -177.507 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.417 ' OG1' ' HA ' ' A' ' 42' ' ' VAL . 38.0 p -131.23 137.92 49.12 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.301 0.096 . . . . 0.0 110.91 178.547 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 4.7 t70 -171.19 170.81 5.93 Favored 'General case' 0 N--CA 1.466 0.33 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 175.759 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 49.5 mm -85.96 104.74 13.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 120.813 0.34 . . . . 0.0 110.865 -175.898 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 35.4 mtmt 56.21 77.52 0.42 Allowed Pre-proline 0 C--N 1.33 -0.278 0 CA-C-N 115.324 -0.853 . . . . 0.0 111.894 -179.575 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 69' ' ' PRO . . . . . 0.795 ' HD2' ' HG2' ' A' ' 76' ' ' ARG . 70.1 Cg_endo -76.57 154.96 35.63 Favored 'Trans proline' 0 N--CA 1.459 -0.505 0 C-N-CA 122.334 2.023 . . . . 0.0 112.139 175.613 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 29.5 m -140.81 0.16 1.57 Allowed 'General case' 0 C--N 1.32 -0.697 0 CA-C-O 121.171 0.51 . . . . 0.0 110.333 178.155 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 80.7 t60 -143.26 116.55 9.02 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.69 -0.686 . . . . 0.0 109.831 -179.685 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 101.52 166.34 27.46 Favored Glycine 0 N--CA 1.449 -0.488 0 C-N-CA 121.028 -0.606 . . . . 0.0 111.991 -179.248 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -81.18 60.99 4.64 Favored Glycine 0 N--CA 1.452 -0.261 0 N-CA-C 111.727 -0.549 . . . . 0.0 111.727 177.303 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.75 ' HA ' ' HB2' ' A' ' 64' ' ' LEU . 44.6 mt -96.85 135.67 30.2 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-O 120.94 0.4 . . . . 0.0 110.531 -177.844 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 97.8 t -77.53 139.04 19.3 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 CA-C-N 116.065 -0.516 . . . . 0.0 109.807 176.43 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 76' ' ' ARG . . . . . 0.795 ' HG2' ' HD2' ' A' ' 69' ' ' PRO . 65.7 mtm180 -84.62 38.77 0.71 Allowed 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 120.762 0.315 . . . . 0.0 110.807 -177.73 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 28.1 t70 -76.68 126.73 31.49 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 121.024 0.44 . . . . 0.0 110.447 -178.649 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 78' ' ' ASP . . . . . 0.508 ' HB3' HG22 ' A' ' 80' ' ' THR . 3.3 m-20 -71.13 97.28 1.47 Allowed 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.891 -0.595 . . . . 0.0 109.971 175.808 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 9.7 tp -58.56 -17.31 9.92 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.388 0 CA-C-O 121.273 0.559 . . . . 0.0 111.663 -178.255 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.508 HG22 ' HB3' ' A' ' 78' ' ' ASP . 8.8 t -66.39 -24.08 66.42 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.027 0.442 . . . . 0.0 110.442 176.246 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 36.6 m -154.42 70.18 6.08 Favored Pre-proline 0 C--N 1.329 -0.32 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 177.514 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.556 ' HB2' ' HE2' ' A' ' 87' ' ' TYR . 74.0 Cg_endo -73.27 159.28 47.37 Favored 'Trans proline' 0 C--O 1.236 0.387 0 C-N-CA 123.011 2.474 . . . . 0.0 113.516 -169.691 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 83' ' ' ARG . . . . . 0.704 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 1.9 mtm180 -93.99 126.39 39.18 Favored 'General case' 0 C--N 1.323 -0.543 0 CA-C-N 115.793 -0.639 . . . . 0.0 110.921 177.958 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 84' ' ' MET . . . . . . . . . . . . . 89.3 mmm -64.56 -23.93 67.43 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.252 -178.066 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.704 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 12.0 pt-20 -62.52 -20.53 64.72 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.607 -179.112 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 63.8 mt -86.2 -29.47 6.08 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-O 121.167 0.508 . . . . 0.0 110.541 -178.802 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 87' ' ' TYR . . . . . 0.556 ' HE2' ' HB2' ' A' ' 82' ' ' PRO . 84.6 m-85 -93.34 -30.62 15.03 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.734 -176.259 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 81.8 mtp180 -66.75 114.14 5.4 Favored 'General case' 0 CA--C 1.514 -0.416 0 CA-C-O 121.485 0.659 . . . . 0.0 111.484 -176.889 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 116.09 -17.51 14.84 Favored Glycine 0 N--CA 1.446 -0.684 0 CA-C-N 114.902 -1.044 . . . . 0.0 111.982 -177.593 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -71.86 147.71 46.87 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.769 0.318 . . . . 0.0 110.665 178.835 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -91.34 -26.37 18.96 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-O 121.035 0.445 . . . . 0.0 110.856 -179.665 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 92' ' ' LEU . . . . . 0.496 ' HG ' ' HB3' ' A' ' 116' ' ' ARG . 5.0 tt -149.55 142.71 25.03 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.653 -177.715 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.604 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 63.2 mt -131.45 123.09 51.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 N-CA-C 109.117 -0.697 . . . . 0.0 109.117 178.269 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 10.7 p90 -136.24 161.3 36.14 Favored 'General case' 0 C--N 1.321 -0.659 0 C-N-CA 120.403 -0.519 . . . . 0.0 111.375 -178.119 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 95' ' ' SER . . . . . 0.911 ' HB3' ' HB ' ' A' ' 42' ' ' VAL . 5.4 p -147.87 147.58 29.92 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.824 -0.626 . . . . 0.0 110.447 -178.268 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 96' ' ' ILE . . . . . 0.401 HD12 ' N ' ' A' ' 96' ' ' ILE . 4.3 mp -114.45 121.89 67.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-N 116.668 -0.242 . . . . 0.0 110.567 -179.184 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 50.85 67.28 4.46 Favored Pre-proline 0 N--CA 1.467 0.4 0 O-C-N 123.815 0.697 . . . . 0.0 111.201 179.328 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 98' ' ' PRO . . . . . 0.478 ' HA ' ' HD3' ' A' ' 99' ' ' PRO . 85.5 Cg_endo -87.18 143.84 6.81 Favored 'Trans proline' 0 N--CA 1.456 -0.706 0 C-N-CA 122.861 2.374 . . . . 0.0 113.19 -174.772 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.555 ' HD2' HD11 ' A' ' 102' ' ' ILE . 24.3 Cg_exo -63.7 144.51 89.47 Favored 'Trans proline' 0 C--O 1.234 0.317 0 C-N-CA 122.737 2.291 . . . . 0.0 111.573 175.611 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -78.22 44.17 0.48 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.177 0.513 . . . . 0.0 111.289 -177.708 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 101' ' ' GLU . . . . . 0.611 ' HG3' HG23 ' A' ' 102' ' ' ILE . 11.2 pt-20 -132.49 -11.4 3.15 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.439 175.795 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.611 HG23 ' HG3' ' A' ' 101' ' ' GLU . 35.1 pt -122.85 -6.86 8.25 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.449 -0.341 . . . . 0.0 111.636 -177.542 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 103' ' ' HIS . . . . . 0.739 ' HD2' ' HB ' ' A' ' 129' ' ' THR . 16.1 p-80 -62.97 -39.31 94.29 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.083 -176.256 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 32.2 t -71.78 -32.93 68.17 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 121.309 0.576 . . . . 0.0 110.086 178.487 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.602 ' O ' ' HG3' ' A' ' 108' ' ' ARG . 31.0 m -70.68 -33.28 70.75 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.314 179.898 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.512 ' HG ' ' O ' ' A' ' 102' ' ' ILE . 85.2 mt -61.34 -40.27 93.66 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.831 177.606 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 107' ' ' MET . . . . . 0.596 ' HG2' ' HD3' ' A' ' 131' ' ' ARG . 39.7 tpp -56.67 -54.4 46.54 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.344 178.036 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 108' ' ' ARG . . . . . 0.602 ' HG3' ' O ' ' A' ' 105' ' ' SER . 1.6 ptm180 -65.09 -30.94 71.93 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.492 -0.322 . . . . 0.0 111.624 -177.28 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.485 HG23 ' O ' ' A' ' 105' ' ' SER . 83.4 t -73.27 -45.86 51.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 C-N-CA 120.972 -0.291 . . . . 0.0 110.917 179.194 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -59.31 -47.74 84.26 Favored 'General case' 0 CA--C 1.516 -0.355 0 CA-C-O 120.759 0.314 . . . . 0.0 110.163 178.8 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.706 ' HA ' ' HB1' ' A' ' 148' ' ' ALA . 17.3 t70 -66.73 -29.17 69.08 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.984 -176.679 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -71.54 -43.57 66.18 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.547 178.727 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 16.2 m -88.08 -27.01 5.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.456 -0.338 . . . . 0.0 111.758 -175.7 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 89.31 46.27 4.44 Favored Glycine 0 N--CA 1.449 -0.452 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.42 179.016 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -122.5 160.92 24.6 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 121.096 0.474 . . . . 0.0 111.201 -178.233 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 116' ' ' ARG . . . . . 0.496 ' HB3' ' HG ' ' A' ' 92' ' ' LEU . 29.5 ttt180 -81.92 116.42 21.55 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.859 -0.61 . . . . 0.0 109.604 178.542 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 117' ' ' LEU . . . . . 0.604 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 56.0 tp -90.9 118.5 30.35 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.09 -179.401 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 66.3 mt -119.5 126.04 74.96 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-O 121.121 0.486 . . . . 0.0 110.362 179.07 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 119' ' ' ILE . . . . . 0.51 ' O ' ' HD3' ' A' ' 121' ' ' PRO . 63.8 mt -112.93 127.49 70.14 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.055 178.167 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 48.3 tptt -105.65 91.8 5.42 Favored Pre-proline 0 C--N 1.325 -0.463 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.067 178.507 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 121' ' ' PRO . . . . . 0.536 ' HB2' ' CG ' ' A' ' 125' ' ' GLU . 75.9 Cg_endo -92.68 -177.86 0.82 Allowed 'Trans proline' 0 N--CA 1.455 -0.751 0 C-N-CA 122.622 2.215 . . . . 0.0 111.951 175.049 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -72.81 146.02 46.59 Favored 'General case' 0 C--N 1.327 -0.37 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 173.26 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 123' ' ' THR . . . . . 0.437 HG23 ' O ' ' A' ' 123' ' ' THR . 6.2 t -68.61 96.09 0.69 Allowed 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 121.668 0.747 . . . . 0.0 109.475 175.83 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 138.13 -17.58 3.37 Favored Glycine 0 N--CA 1.449 -0.485 0 CA-C-N 115.458 -0.792 . . . . 0.0 112.482 -178.117 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 125' ' ' GLU . . . . . 0.536 ' CG ' ' HB2' ' A' ' 121' ' ' PRO . 7.5 pt-20 -97.64 164.75 12.28 Favored 'General case' 0 N--CA 1.445 -0.7 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 178.402 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -128.66 162.17 27.96 Favored 'General case' 0 C--N 1.312 -1.044 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.426 -178.71 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.456 HD13 HD12 ' A' ' 119' ' ' ILE . 19.8 mt -90.85 106.58 17.63 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.674 0 N-CA-C 108.546 -0.909 . . . . 0.0 108.546 174.464 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 14.0 m -73.76 78.9 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.825 0 CA-C-O 121.982 0.896 . . . . 0.0 110.738 -179.75 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 129' ' ' THR . . . . . 0.739 ' HB ' ' HD2' ' A' ' 103' ' ' HIS . 6.4 t -144.2 155.69 44.0 Favored 'General case' 0 N--CA 1.447 -0.596 0 CA-C-N 115.024 -0.989 . . . . 0.0 110.579 -175.821 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -88.62 -19.13 26.65 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 121.289 0.566 . . . . 0.0 109.759 172.349 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 131' ' ' ARG . . . . . 0.596 ' HD3' ' HG2' ' A' ' 107' ' ' MET . 6.1 mmp_? -61.94 141.24 58.13 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.511 -176.877 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 132' ' ' LYS . . . . . 0.504 ' HD3' ' H ' ' A' ' 132' ' ' LYS . 0.0 OUTLIER -83.89 122.9 29.34 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.816 0.817 . . . . 0.0 112.777 -171.652 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 133' ' ' MET . . . . . . . . . . . . . 85.7 mtp -139.55 170.7 15.43 Favored 'General case' 0 C--N 1.313 -1.005 0 CA-C-N 114.929 -1.032 . . . . 0.0 109.266 176.919 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 134' ' ' LYS . . . . . 0.456 ' NZ ' ' HB2' ' A' ' 134' ' ' LYS . 0.0 OUTLIER -128.29 146.01 50.88 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-O 120.988 0.423 . . . . 0.0 111.396 -178.367 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 135' ' ' LEU . . . . . 0.493 HD11 ' CD1' ' A' ' 142' ' ' TYR . 53.0 tp -80.88 139.26 36.02 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.718 -0.673 . . . . 0.0 109.554 177.165 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 136' ' ' VAL . . . . . 0.414 HG23 ' CD1' ' A' ' 143' ' ' PHE . 0.0 OUTLIER -134.66 134.46 54.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-O 120.971 0.415 . . . . 0.0 110.765 177.267 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 28.0 m-80 -107.41 114.59 28.7 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.35 178.915 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 53.2 t80 -148.75 122.28 9.14 Favored 'General case' 0 C--N 1.326 -0.445 0 C-N-CA 120.959 -0.297 . . . . 0.0 110.91 -178.766 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 139' ' ' GLY . . . . . 0.462 ' HA3' ' CB ' ' A' ' 24' ' ' ASP . . . 64.44 62.68 4.89 Favored Glycine 0 N--CA 1.452 -0.273 0 CA-C-N 115.797 -0.638 . . . . 0.0 113.231 174.867 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 35.3 mmt180 71.41 -38.28 0.42 Allowed 'General case' 0 N--CA 1.47 0.544 0 C-N-CA 123.647 0.779 . . . . 0.0 112.168 175.731 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 141' ' ' THR . . . . . 0.407 ' H ' ' C ' ' A' ' 139' ' ' GLY . 9.9 t -96.34 156.82 16.18 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 121.133 0.492 . . . . 0.0 110.831 -178.025 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 142' ' ' TYR . . . . . 0.493 ' CD1' HD11 ' A' ' 135' ' ' LEU . 44.0 p90 -121.58 154.19 37.05 Favored 'General case' 0 C--N 1.32 -0.699 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 169.415 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 143' ' ' PHE . . . . . 0.42 ' O ' HD12 ' A' ' 135' ' ' LEU . 8.9 p90 -153.37 -177.64 6.47 Favored 'General case' 0 C--N 1.316 -0.858 0 CA-C-N 116.129 -0.487 . . . . 0.0 109.777 -177.536 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 86.9 m-85 -116.41 131.97 56.8 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 116.724 -0.216 . . . . 0.0 110.699 -178.083 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 145' ' ' GLU . . . . . 0.451 ' CD ' HH21 ' A' ' 116' ' ' ARG . 17.1 pt-20 -128.91 162.3 27.86 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.044 0.45 . . . . 0.0 110.626 178.832 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 38.9 t80 -142.56 127.01 17.78 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 115.604 -0.725 . . . . 0.0 109.665 173.561 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 147' ' ' ILE . . . . . 0.427 ' N ' HD12 ' A' ' 147' ' ' ILE . 3.8 mp -95.07 100.27 10.77 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.842 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 178.854 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 148' ' ' ALA . . . . . 0.706 ' HB1' ' HA ' ' A' ' 111' ' ' ASP . . . -76.39 96.29 3.99 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.953 -0.567 . . . . 0.0 109.659 176.569 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -77.32 154.79 32.51 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-N 115.662 -0.699 . . . . 0.0 111.165 -174.929 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 59.7 t -76.79 147.66 7.4 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-N 115.411 -0.813 . . . . 0.0 109.356 178.845 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 151' ' ' ARG . . . . . . . . . . . . . 59.7 mtm-85 -67.13 152.1 46.37 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.724 0.297 . . . . 0.0 110.222 -178.976 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 18.5 m -80.78 94.78 6.48 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-O 121.181 0.515 . . . . 0.0 110.842 -176.464 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 26.9 mmm180 . . . . . 0 C--O 1.245 0.853 0 CA-C-O 118.376 -0.821 . . . . 0.0 109.809 176.729 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 2.1 mpt? . . . . . 0 N--CA 1.483 1.205 0 N-CA-C 110.222 -0.288 . . . . 0.0 110.222 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -170.04 -93.07 0.09 OUTLIER Glycine 0 N--CA 1.448 -0.547 0 N-CA-C 111.548 -0.621 . . . . 0.0 111.548 179.925 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 34.5 m 58.3 63.41 1.74 Allowed 'General case' 0 C--O 1.235 0.303 0 CA-C-O 121.21 0.528 . . . . 0.0 111.114 178.391 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 13.5 t -94.16 154.95 17.31 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.639 -0.71 . . . . 0.0 110.247 -179.487 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 19.4 t-80 -142.54 150.69 40.75 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 178.655 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 36.9 m80 -65.06 101.24 0.5 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.047 0.451 . . . . 0.0 110.397 178.473 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 51.4 t60 -148.97 136.21 20.1 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.684 -0.689 . . . . 0.0 109.766 -176.402 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 17.5 p80 -115.8 131.45 56.93 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-O 121.061 0.458 . . . . 0.0 109.89 176.917 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 45.8 m80 -75.6 153.03 37.57 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.944 -0.571 . . . . 0.0 111.197 -178.964 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 18.5 p80 -77.4 161.5 27.96 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.424 -0.807 . . . . 0.0 110.62 -179.224 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 3.9 p -107.73 106.65 17.07 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.241 175.229 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 68.3 m -142.0 169.04 18.34 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.835 -0.621 . . . . 0.0 110.449 -179.199 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -78.19 78.65 1.56 Allowed Glycine 0 N--CA 1.447 -0.581 0 C-N-CA 121.083 -0.579 . . . . 0.0 111.748 178.527 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 86.8 mt -74.52 145.37 43.53 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 120.719 0.295 . . . . 0.0 110.381 -178.702 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.415 ' HA ' ' HD3' ' A' ' 16' ' ' PRO . 45.1 t -86.72 117.31 68.47 Favored Pre-proline 0 C--N 1.325 -0.47 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.661 -178.06 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.415 ' HD3' ' HA ' ' A' ' 15' ' ' VAL . 2.8 Cg_exo -76.08 154.79 37.77 Favored 'Trans proline' 0 N--CA 1.463 -0.299 0 C-N-CA 123.063 2.508 . . . . 0.0 111.953 178.668 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -95.12 -156.19 0.5 Allowed 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.285 -0.416 . . . . 0.0 109.986 -179.361 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -77.49 167.62 54.05 Favored Glycine 0 N--CA 1.447 -0.609 0 C-N-CA 120.987 -0.625 . . . . 0.0 112.014 176.594 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 2.4 p -95.38 28.68 2.81 Favored 'General case' 0 C--N 1.321 -0.661 0 N-CA-C 111.88 0.326 . . . . 0.0 111.88 -175.709 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 40.6 t60 -53.7 -44.54 69.87 Favored 'General case' 0 N--CA 1.466 0.364 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.53 -177.394 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' MET . . . . . . . . . . . . . 67.2 mtt -71.94 -16.95 62.11 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 120.926 0.393 . . . . 0.0 111.521 -177.455 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' TRP . . . . . 0.642 ' HB3' HG22 ' A' ' 50' ' ' VAL . 77.0 m95 -96.03 -27.37 15.14 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.824 -176.888 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 6.4 m120 -56.33 -52.09 65.84 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.098 177.36 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.43 ' OD2' ' HA3' ' A' ' 139' ' ' GLY . 1.3 t70 -76.77 -28.98 55.89 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.423 -177.152 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 58.5 tp -59.29 -45.98 89.79 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-O 121.049 0.452 . . . . 0.0 109.907 174.516 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' ALA . . . . . 0.44 ' O ' HG13 ' A' ' 30' ' ' ILE . . . -56.18 -44.46 79.38 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.46 -0.791 . . . . 0.0 110.667 178.629 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 88.5 t -54.4 -46.85 70.34 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.244 0 O-C-N 123.264 0.352 . . . . 0.0 110.857 177.38 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' TYR . . . . . 0.546 ' HB2' ' CD2' ' A' ' 138' ' ' TYR . 87.2 t80 -58.48 -45.73 88.07 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.332 177.877 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.419 HG12 HD12 ' A' ' 118' ' ' ILE . 74.5 mt -63.09 -46.12 96.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.719 178.988 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.783 HG12 HG23 ' A' ' 54' ' ' ILE . 83.0 mt -57.48 -44.07 84.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 115.692 -0.685 . . . . 0.0 110.919 178.211 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 75.1 mtt180 -72.8 -21.26 61.01 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.263 -176.28 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 73.3 m -88.54 -14.01 38.75 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.345 -0.389 . . . . 0.0 111.339 177.753 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 22.0 p -126.53 -86.11 0.61 Allowed 'General case' 0 CA--C 1.534 0.328 0 CA-C-O 120.678 0.275 . . . . 0.0 111.358 179.315 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 99.77 -176.25 28.36 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 121.167 -0.539 . . . . 0.0 112.595 178.459 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -71.93 155.37 57.71 Favored 'Trans proline' 0 C--O 1.233 0.26 0 C-N-CA 122.534 2.156 . . . . 0.0 112.247 -179.35 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 98.02 -11.76 64.01 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.681 -0.771 . . . . 0.0 113.081 176.345 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 14.0 t -121.7 -166.61 1.4 Allowed 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.382 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 38' ' ' ARG . . . . . 0.675 ' HG2' ' HB2' ' A' ' 61' ' ' ASP . 84.3 mtt180 -128.03 136.36 51.13 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.891 0.377 . . . . 0.0 110.877 -179.218 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.868 ' HB ' HD22 ' A' ' 62' ' ' LEU . 20.9 t -125.47 140.63 47.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 177.182 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 40.4 t -112.41 128.93 68.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-O 120.941 0.401 . . . . 0.0 111.282 -177.469 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 41' ' ' GLU . . . . . 0.415 ' OE1' HD22 ' A' ' 64' ' ' LEU . 42.5 tt0 -105.06 110.2 22.5 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.659 -0.7 . . . . 0.0 109.549 176.887 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.438 ' HB ' ' HB3' ' A' ' 95' ' ' SER . 58.5 t -94.11 113.76 29.39 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.399 -179.462 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 103.8 42.87 1.89 Allowed Glycine 0 N--CA 1.446 -0.657 0 C-N-CA 120.524 -0.846 . . . . 0.0 111.612 -178.679 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -85.99 -127.01 0.04 OUTLIER 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 110.37 -0.233 . . . . 0.0 110.37 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 67.77 -90.23 0.2 Allowed Glycine 0 C--N 1.33 0.203 0 C-N-CA 121.281 -0.485 . . . . 0.0 112.589 177.873 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -71.9 -23.47 61.49 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 109.705 -0.479 . . . . 0.0 109.705 176.67 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 50.2 m-85 -110.18 109.59 20.14 Favored 'General case' 0 C--O 1.224 -0.277 0 CA-C-N 115.971 -0.558 . . . . 0.0 110.048 178.236 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 96.9 mt -131.35 0.81 4.11 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.706 0.289 . . . . 0.0 111.084 179.722 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 9.2 p90 -69.08 -26.97 65.21 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 112.211 0.449 . . . . 0.0 112.211 -174.936 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.642 HG22 ' HB3' ' A' ' 22' ' ' TRP . 40.9 t -76.02 -58.69 4.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-O 120.93 0.395 . . . . 0.0 110.763 179.734 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 3.3 p -60.77 -42.59 97.78 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.748 -0.66 . . . . 0.0 112.484 -176.703 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.517 ' O ' ' HG2' ' A' ' 56' ' ' LYS . 30.3 t70 -66.53 -27.54 67.84 Favored 'General case' 0 C--N 1.33 -0.256 0 C-N-CA 120.917 -0.313 . . . . 0.0 110.885 -179.359 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 88.1 t80 -70.44 -42.49 71.48 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 120.974 0.416 . . . . 0.0 110.34 175.819 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.783 HG23 HG12 ' A' ' 30' ' ' ILE . 77.3 mt -61.9 -43.58 97.66 Favored 'Isoleucine or valine' 0 C--O 1.236 0.353 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.119 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 55' ' ' ARG . . . . . 0.499 ' HG2' ' HA ' ' A' ' 52' ' ' ASP . 4.1 ptm180 -68.76 -16.09 63.7 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.952 -0.567 . . . . 0.0 111.794 -176.534 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 56' ' ' LYS . . . . . 0.517 ' HG2' ' O ' ' A' ' 52' ' ' ASP . 69.5 mmtt -65.34 -42.05 93.28 Favored 'General case' 0 C--O 1.233 0.192 0 CA-C-O 121.058 0.456 . . . . 0.0 110.349 177.401 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 33.2 m170 -94.17 -57.5 2.5 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.762 -0.654 . . . . 0.0 111.483 -174.519 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 69.0 m -102.72 130.65 49.73 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.11 0.481 . . . . 0.0 111.618 -175.589 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 59' ' ' LYS . . . . . 0.526 ' HE3' ' C ' ' A' ' 59' ' ' LYS . 0.1 OUTLIER -80.42 65.52 5.59 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 121.99 0.9 . . . . 0.0 109.224 173.676 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.574 HG21 HG23 ' A' ' 39' ' ' VAL . 7.3 p -97.16 143.5 12.37 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.025 0 CA-C-N 114.606 -1.179 . . . . 0.0 109.003 174.3 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 61' ' ' ASP . . . . . 0.675 ' HB2' ' HG2' ' A' ' 38' ' ' ARG . 19.7 m-20 -76.32 96.11 3.91 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-O 121.243 0.544 . . . . 0.0 109.68 178.081 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 62' ' ' LEU . . . . . 0.868 HD22 ' HB ' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -86.88 118.1 26.05 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 115.476 -0.784 . . . . 0.0 109.506 -178.936 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.498 HG13 HG21 ' A' ' 75' ' ' VAL . 61.9 t -97.94 114.76 36.19 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.849 0 CA-C-N 115.683 -0.689 . . . . 0.0 110.127 -179.996 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 64' ' ' LEU . . . . . 0.496 HD12 HG12 ' A' ' 74' ' ' ILE . 31.8 mt -96.77 124.0 40.63 Favored 'General case' 0 C--N 1.315 -0.93 0 CA-C-N 115.616 -0.72 . . . . 0.0 109.646 -179.915 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 33.1 p -108.34 124.96 51.16 Favored 'General case' 0 C--N 1.315 -0.924 0 CA-C-O 120.933 0.397 . . . . 0.0 110.278 177.276 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 25.6 t70 -156.17 144.58 19.98 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.202 -176.676 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.43 HG22 ' HG3' ' A' ' 68' ' ' LYS . 53.7 mt -73.42 113.71 11.78 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 116.343 -0.389 . . . . 0.0 110.208 178.676 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 68' ' ' LYS . . . . . 0.43 ' HG3' HG22 ' A' ' 67' ' ' ILE . 5.8 mtpm? 59.76 82.01 0.24 Allowed Pre-proline 0 C--O 1.233 0.212 0 CA-C-N 115.54 -0.754 . . . . 0.0 110.568 179.483 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -71.06 137.61 32.05 Favored 'Trans proline' 0 C--O 1.232 0.198 0 C-N-CA 122.742 2.295 . . . . 0.0 113.008 -175.535 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 46.3 m -85.98 -37.43 19.01 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.957 177.043 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 71.3 m-70 -96.33 132.86 41.38 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.928 -177.084 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -66.89 102.77 0.81 Allowed Glycine 0 N--CA 1.448 -0.524 0 N-CA-C 111.449 -0.66 . . . . 0.0 111.449 175.59 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 147.88 -23.13 1.46 Allowed Glycine 0 N--CA 1.446 -0.663 0 N-CA-C 110.716 -0.954 . . . . 0.0 110.716 -175.548 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.496 HG12 HD12 ' A' ' 64' ' ' LEU . 56.8 mt -83.67 140.16 16.62 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 N-CA-C 108.673 -0.862 . . . . 0.0 108.673 173.169 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.513 HG11 HD13 ' A' ' 86' ' ' ILE . 63.5 t -86.47 130.21 37.05 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.711 0 CA-C-O 120.942 0.401 . . . . 0.0 110.611 -176.539 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 76' ' ' ARG . . . . . 0.422 ' HG2' ' H ' ' A' ' 76' ' ' ARG . 15.3 ptm180 -75.15 49.19 0.44 Allowed 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.502 -0.772 . . . . 0.0 111.54 179.809 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 22.6 t70 -108.14 117.96 35.51 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 116.083 -0.508 . . . . 0.0 109.779 179.411 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 78' ' ' ASP . . . . . 0.446 ' OD2' HG23 ' A' ' 80' ' ' THR . 5.5 p-10 -92.18 132.15 36.86 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.361 -0.382 . . . . 0.0 110.548 -179.423 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 10.7 tp -62.95 -18.05 20.55 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.476 0 CA-C-N 116.155 -0.475 . . . . 0.0 112.185 -173.62 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.446 HG23 ' OD2' ' A' ' 78' ' ' ASP . 0.7 OUTLIER -77.75 -27.71 50.47 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.877 0.37 . . . . 0.0 110.66 177.483 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 22.2 t -140.81 66.42 26.65 Favored Pre-proline 0 C--N 1.326 -0.416 0 N-CA-C 109.636 -0.505 . . . . 0.0 109.636 177.996 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 76.0 Cg_endo -89.93 151.75 4.91 Favored 'Trans proline' 0 N--CA 1.456 -0.732 0 C-N-CA 122.62 2.213 . . . . 0.0 113.436 -171.817 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 83' ' ' ARG . . . . . 0.717 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 53.0 mtt-85 -93.19 115.26 27.89 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.481 174.589 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 84' ' ' MET . . . . . . . . . . . . . 93.4 mmm -62.05 -22.48 65.78 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.926 -0.579 . . . . 0.0 111.055 -178.981 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.717 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 12.9 pt-20 -62.27 -21.68 65.4 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-O 120.913 0.387 . . . . 0.0 111.137 178.692 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.513 HD13 HG11 ' A' ' 75' ' ' VAL . 82.2 mt -83.76 -43.21 17.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.621 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 70.7 m-85 -76.27 -31.5 58.3 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.841 -178.004 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 88' ' ' ARG . . . . . 0.732 ' HG3' HG12 ' A' ' 113' ' ' VAL . 31.9 mtp85 -66.91 119.86 12.62 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.615 177.737 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 115.11 -8.74 20.96 Favored Glycine 0 N--CA 1.449 -0.499 0 CA-C-N 115.737 -0.665 . . . . 0.0 111.538 -175.748 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -89.35 140.87 29.07 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 120.884 0.374 . . . . 0.0 110.633 179.227 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -88.09 -22.24 24.26 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.968 -178.927 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 92' ' ' LEU . . . . . 0.472 HD23 ' N ' ' A' ' 93' ' ' ILE . 3.3 tt -151.62 141.97 22.45 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.272 -176.733 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.549 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 65.4 mt -132.43 123.35 49.72 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-N 115.986 -0.552 . . . . 0.0 109.701 179.149 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 23.3 p90 -125.03 150.95 46.22 Favored 'General case' 0 C--N 1.322 -0.612 0 C-N-CA 120.709 -0.396 . . . . 0.0 110.402 177.906 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 95' ' ' SER . . . . . 0.438 ' HB3' ' HB ' ' A' ' 42' ' ' VAL . 11.7 p -131.52 140.58 49.54 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.692 -178.089 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 96' ' ' ILE . . . . . 0.473 HG23 ' CH2' ' A' ' 22' ' ' TRP . 81.1 mt -98.45 90.2 2.07 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-O 121.425 0.631 . . . . 0.0 110.775 -177.467 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 50.8 ttt-85 56.4 95.81 0.04 OUTLIER Pre-proline 0 N--CA 1.469 0.498 0 CA-C-N 114.304 -1.316 . . . . 0.0 111.99 -177.999 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 98' ' ' PRO . . . . . 0.408 ' HA ' ' HD3' ' A' ' 99' ' ' PRO . 96.8 Cg_endo -88.97 137.14 3.14 Favored 'Trans proline' 0 N--CA 1.455 -0.739 0 C-N-CA 122.647 2.232 . . . . 0.0 112.612 177.722 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.662 ' HD2' HD11 ' A' ' 102' ' ' ILE . 50.5 Cg_exo -53.95 156.63 12.16 Favored 'Trans proline' 0 C--O 1.236 0.393 0 C-N-CA 122.797 2.331 . . . . 0.0 112.079 175.534 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.68 ' HA ' ' CE1' ' A' ' 103' ' ' HIS . . . -75.49 29.51 0.1 Allowed 'General case' 0 C--N 1.328 -0.351 0 N-CA-C 112.57 0.582 . . . . 0.0 112.57 -172.67 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 101' ' ' GLU . . . . . 0.587 ' HG3' HG23 ' A' ' 102' ' ' ILE . 12.5 pt-20 -129.89 -23.71 2.76 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 111.937 0.347 . . . . 0.0 111.937 -178.386 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.662 HD11 ' HD2' ' A' ' 99' ' ' PRO . 41.2 pt -106.78 14.4 7.85 Favored 'Isoleucine or valine' 0 C--O 1.234 0.258 0 N-CA-C 112.45 0.537 . . . . 0.0 112.45 -172.949 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 103' ' ' HIS . . . . . 0.68 ' CE1' ' HA ' ' A' ' 100' ' ' ALA . 28.9 m170 -53.78 -54.06 43.51 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.245 0.545 . . . . 0.0 110.334 177.79 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 104' ' ' SER . . . . . 0.512 ' O ' ' HG2' ' A' ' 108' ' ' ARG . 8.8 m -59.89 -34.59 73.37 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.294 -0.866 . . . . 0.0 110.871 -177.722 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.58 ' O ' HG23 ' A' ' 109' ' ' VAL . 16.7 m -63.52 -56.07 18.97 Favored 'General case' 0 N--CA 1.452 -0.329 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.198 -177.556 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 72.2 mt -56.56 -41.16 76.42 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.657 -0.701 . . . . 0.0 111.08 -178.839 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 107' ' ' MET . . . . . . . . . . . . . 96.5 mmm -62.0 -46.89 87.22 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.889 -0.596 . . . . 0.0 111.138 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 108' ' ' ARG . . . . . 0.512 ' HG2' ' O ' ' A' ' 104' ' ' SER . 3.1 ptp180 -77.08 -22.23 53.14 Favored 'General case' 0 C--N 1.331 -0.238 0 C-N-CA 120.679 -0.409 . . . . 0.0 111.847 -178.4 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.58 HG23 ' O ' ' A' ' 105' ' ' SER . 76.2 t -68.31 -48.75 71.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 173.866 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -61.34 -37.2 82.45 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.043 177.944 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 11.2 t70 -66.01 -40.73 91.33 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.144 -0.934 . . . . 0.0 110.904 177.911 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -69.54 -43.14 73.59 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.837 -0.619 . . . . 0.0 111.987 -176.961 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.732 HG12 ' HG3' ' A' ' 88' ' ' ARG . 20.0 m -87.21 -25.16 6.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-O 120.722 0.296 . . . . 0.0 111.585 -175.561 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 82.29 59.82 2.22 Favored Glycine 0 N--CA 1.447 -0.621 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.21 179.944 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -135.43 173.96 11.14 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-O 120.854 0.359 . . . . 0.0 110.441 -179.922 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 116' ' ' ARG . . . . . 0.449 ' HD3' ' OE1' ' A' ' 145' ' ' GLU . 13.8 ttm180 -92.7 124.29 36.6 Favored 'General case' 0 C--N 1.323 -0.576 0 N-CA-C 109.66 -0.496 . . . . 0.0 109.66 175.616 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 117' ' ' LEU . . . . . 0.549 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 61.6 tp -92.66 132.75 36.63 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 116.175 -0.466 . . . . 0.0 109.803 178.945 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 118' ' ' ILE . . . . . 0.419 HD12 HG12 ' A' ' 29' ' ' ILE . 64.6 mt -126.18 122.65 62.02 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-O 121.078 0.466 . . . . 0.0 110.645 177.698 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 66.8 mt -121.43 122.9 68.43 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.016 177.599 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 23.3 ttmm -114.76 104.24 54.36 Favored Pre-proline 0 C--N 1.321 -0.645 0 CA-C-O 120.829 0.347 . . . . 0.0 110.881 176.296 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -80.63 170.78 15.34 Favored 'Trans proline' 0 N--CA 1.455 -0.78 0 C-N-CA 122.211 1.941 . . . . 0.0 110.912 169.737 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 122' ' ' LEU . . . . . 0.73 ' HB2' ' HG3' ' A' ' 125' ' ' GLU . 41.0 mt -70.17 155.29 40.83 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 116.494 -0.321 . . . . 0.0 110.378 179.473 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 123' ' ' THR . . . . . 0.698 ' HA ' ' HE1' ' A' ' 142' ' ' TYR . 46.1 m -64.8 109.9 2.22 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 109.992 -0.373 . . . . 0.0 109.992 175.629 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 107.36 -1.31 34.84 Favored Glycine 0 N--CA 1.446 -0.663 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.141 -178.536 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 125' ' ' GLU . . . . . 0.73 ' HG3' ' HB2' ' A' ' 122' ' ' LEU . 5.1 mt-10 -96.27 -169.21 1.87 Allowed 'General case' 0 N--CA 1.449 -0.501 0 CA-C-O 121.261 0.553 . . . . 0.0 110.8 177.538 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 5.8 t70 -149.35 165.43 32.03 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-N 115.193 -0.912 . . . . 0.0 109.116 -178.345 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 32.6 mt -93.54 -19.53 6.64 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 176.328 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 22.8 m 41.0 69.5 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.469 0.502 0 CA-C-O 121.988 0.899 . . . . 0.0 111.882 -175.122 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 9.8 t -146.23 -172.26 3.9 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.324 -0.853 . . . . 0.0 110.315 -175.831 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 42.9 tt0 -65.13 136.13 56.33 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 109.641 -0.503 . . . . 0.0 109.641 176.744 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 131' ' ' ARG . . . . . . . . . . . . . 97.7 mtt180 -63.54 92.32 0.06 Allowed 'General case' 0 N--CA 1.463 0.222 0 CA-C-O 121.317 0.579 . . . . 0.0 112.125 -175.105 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 90.1 mttt -148.42 -167.25 2.76 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.401 -0.818 . . . . 0.0 109.789 178.056 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 133' ' ' MET . . . . . . . . . . . . . 71.0 mtp 68.95 -178.93 0.22 Allowed 'General case' 0 N--CA 1.467 0.383 0 O-C-N 123.791 0.682 . . . . 0.0 110.668 -179.333 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 17.5 ptmt -136.85 144.07 43.41 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.95 179.9 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 135' ' ' LEU . . . . . 0.559 HD11 ' HD2' ' A' ' 142' ' ' TYR . 53.6 tp -87.63 127.77 35.28 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.655 -179.405 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -130.14 140.66 48.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.902 179.493 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 3.2 m-20 -120.13 105.5 11.05 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.04 178.001 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 138' ' ' TYR . . . . . 0.546 ' CD2' ' HB2' ' A' ' 28' ' ' TYR . 73.4 t80 -117.83 112.06 19.89 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.585 -0.524 . . . . 0.0 109.585 178.778 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 139' ' ' GLY . . . . . 0.43 ' HA3' ' OD2' ' A' ' 24' ' ' ASP . . . 81.44 26.97 49.8 Favored Glycine 0 N--CA 1.447 -0.567 0 C-N-CA 120.743 -0.741 . . . . 0.0 111.797 -178.536 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 140' ' ' ARG . . . . . 0.464 ' HD3' ' HA ' ' A' ' 140' ' ' ARG . 26.5 mmt180 67.6 8.45 6.36 Favored 'General case' 0 N--CA 1.463 0.224 0 C-N-CA 123.248 0.619 . . . . 0.0 111.927 -179.807 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 141' ' ' THR . . . . . 0.462 HG22 ' O ' ' A' ' 138' ' ' TYR . 14.0 t -107.03 135.62 48.27 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 170.926 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 142' ' ' TYR . . . . . 0.698 ' HE1' ' HA ' ' A' ' 123' ' ' THR . 6.7 p90 -101.18 147.58 26.09 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-O 121.019 0.438 . . . . 0.0 110.789 -172.947 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 20.9 p90 -156.08 170.4 22.27 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-N 115.639 -0.71 . . . . 0.0 109.321 175.962 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 96.3 m-85 -113.51 124.27 51.99 Favored 'General case' 0 C--N 1.318 -0.797 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 179.266 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 145' ' ' GLU . . . . . 0.449 ' OE1' ' HD3' ' A' ' 116' ' ' ARG . 19.1 pt-20 -112.73 161.66 16.63 Favored 'General case' 0 C--N 1.316 -0.874 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 178.4 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 146' ' ' TYR . . . . . 0.415 ' HB3' ' HB3' ' A' ' 117' ' ' LEU . 63.8 t80 -141.36 129.06 21.58 Favored 'General case' 0 C--N 1.315 -0.928 0 CA-C-N 115.938 -0.573 . . . . 0.0 109.897 175.511 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 147' ' ' ILE . . . . . 0.415 ' N ' HD12 ' A' ' 147' ' ' ILE . 3.5 mp -101.68 120.21 50.99 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.96 0 N-CA-C 107.956 -1.128 . . . . 0.0 107.956 176.327 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -63.31 92.62 0.06 Allowed 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.503 0.668 . . . . 0.0 110.377 179.112 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -81.71 171.27 14.78 Favored 'General case' 0 N--CA 1.445 -0.687 0 CA-C-N 114.675 -1.148 . . . . 0.0 111.014 -175.582 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 19.5 t -68.54 132.06 33.15 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 115.79 -0.641 . . . . 0.0 109.966 -179.943 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 151' ' ' ARG . . . . . 0.415 HH11 ' HD3' ' A' ' 151' ' ' ARG . 13.5 ptt-85 -60.19 115.53 3.56 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.899 -0.591 . . . . 0.0 111.093 179.728 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 28.1 t -113.23 143.1 44.98 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-N 115.416 -0.811 . . . . 0.0 109.419 178.912 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 153' ' ' ARG . . . . . 0.434 ' O ' ' HG3' ' A' ' 153' ' ' ARG . 32.4 ptt180 . . . . . 0 C--O 1.25 1.107 0 CA-C-O 118.865 -0.588 . . . . 0.0 110.21 178.656 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 16.2 tpt . . . . . 0 N--CA 1.48 1.072 0 CA-C-O 120.712 0.291 . . . . 0.0 110.566 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 109.63 -161.05 13.16 Favored Glycine 0 N--CA 1.451 -0.349 0 N-CA-C 111.758 -0.537 . . . . 0.0 111.758 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.0 p -88.52 96.81 10.77 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 121.244 0.545 . . . . 0.0 109.969 177.221 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 13.6 t -95.97 99.93 11.65 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.791 -0.641 . . . . 0.0 110.316 -174.361 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 26.9 m170 -111.01 110.56 21.16 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.047 179.009 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 88.7 m-70 -127.72 139.53 52.64 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 121.081 0.467 . . . . 0.0 111.095 -179.703 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 74.9 m80 -95.66 102.77 14.6 Favored 'General case' 0 C--N 1.321 -0.667 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 174.378 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 74.7 m80 -86.02 92.03 8.57 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.897 -0.592 . . . . 0.0 111.323 -172.095 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 78.1 t60 -96.86 127.2 42.6 Favored 'General case' 0 C--N 1.322 -0.612 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 173.62 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 37.9 p-80 -90.21 132.47 35.47 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 121.136 0.494 . . . . 0.0 111.146 -177.831 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 34.5 t -100.13 169.29 9.26 Favored 'General case' 0 C--N 1.32 -0.697 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 176.365 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 9.2 m -67.06 118.69 10.85 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 178.613 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -72.16 120.04 7.63 Favored Glycine 0 N--CA 1.446 -0.669 0 C-N-CA 120.375 -0.917 . . . . 0.0 112.359 -179.309 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -82.55 111.63 18.72 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 120.941 0.4 . . . . 0.0 110.409 179.644 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.443 ' HA ' ' HD3' ' A' ' 16' ' ' PRO . 28.3 m -124.32 131.68 24.22 Favored Pre-proline 0 C--N 1.324 -0.537 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.738 179.899 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.572 ' HD2' ' HD2' ' A' ' 49' ' ' TYR . 56.6 Cg_endo -89.84 141.75 3.82 Favored 'Trans proline' 0 N--CA 1.454 -0.838 0 C-N-CA 122.855 2.37 . . . . 0.0 112.403 177.013 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 17' ' ' ARG . . . . . 0.42 HH11 ' HD2' ' A' ' 17' ' ' ARG . 40.4 mtm105 -91.87 98.07 11.37 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.035 179.042 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -176.95 34.85 0.08 OUTLIER Glycine 0 N--CA 1.447 -0.604 0 C-N-CA 120.859 -0.686 . . . . 0.0 111.46 178.3 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' SER . . . . . 0.948 ' HB2' ' HB2' ' A' ' 22' ' ' TRP . 48.6 p -132.53 80.05 1.88 Allowed 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 120.668 0.27 . . . . 0.0 110.709 -175.915 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 41.9 m-70 -65.82 -62.58 1.42 Allowed 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.407 -0.36 . . . . 0.0 111.194 -177.183 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' MET . . . . . 0.741 ' HB2' ' HB ' ' A' ' 141' ' ' THR . 1.2 pmm? -66.3 -20.55 66.13 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.168 -177.456 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 22' ' ' TRP . . . . . 0.948 ' HB2' ' HB2' ' A' ' 19' ' ' SER . 61.8 m95 -76.18 -29.56 57.73 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 120.916 0.389 . . . . 0.0 110.38 178.38 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 23' ' ' ASN . . . . . 0.45 ' O ' HG23 ' A' ' 27' ' ' VAL . 88.2 m-20 -72.32 -36.03 68.76 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 174.337 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.494 ' HB3' ' HA3' ' A' ' 139' ' ' GLY . 5.4 m-20 -64.55 -38.15 90.01 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.283 174.772 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 53.8 tp -53.23 -50.31 65.01 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.161 -0.472 . . . . 0.0 109.958 173.016 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' ALA . . . . . 0.401 ' O ' HG13 ' A' ' 30' ' ' ILE . . . -58.61 -48.72 80.02 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.884 177.269 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.45 HG23 ' O ' ' A' ' 23' ' ' ASN . 79.0 t -52.52 -45.82 47.33 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.22 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.175 177.102 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 28' ' ' TYR . . . . . 0.481 ' HB2' ' CD2' ' A' ' 138' ' ' TYR . 78.1 t80 -58.03 -47.12 84.06 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.535 178.629 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.448 HG12 HD12 ' A' ' 118' ' ' ILE . 78.5 mt -60.43 -44.18 95.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.542 178.311 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.621 HD11 ' HA ' ' A' ' 54' ' ' ILE . 83.7 mt -61.99 -41.09 89.65 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 115.601 -0.727 . . . . 0.0 111.455 -179.505 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 31' ' ' ARG . . . . . 0.406 HH11 ' HD3' ' A' ' 31' ' ' ARG . 41.5 mtp-105 -71.78 -29.86 64.93 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.888 -177.541 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 76.5 m -80.92 -27.32 36.21 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.381 -0.372 . . . . 0.0 111.426 -178.999 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 14.0 p -93.77 -75.35 0.5 Allowed 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 120.752 0.31 . . . . 0.0 111.291 -177.673 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 109.43 134.6 7.03 Favored Glycine 0 N--CA 1.448 -0.543 0 C-N-CA 121.072 -0.585 . . . . 0.0 111.694 -176.399 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 32.8 Cg_exo -57.53 133.0 53.89 Favored 'Trans proline' 0 C--O 1.232 0.206 0 C-N-CA 122.925 2.417 . . . . 0.0 112.421 -179.155 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 102.24 62.76 0.73 Allowed Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.434 -0.888 . . . . 0.0 111.731 -177.948 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 15.0 t -178.31 -166.96 0.12 Allowed 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 108.545 -0.909 . . . . 0.0 108.545 -178.191 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' ARG . . . . . 0.832 ' HG2' ' HB3' ' A' ' 61' ' ' ASP . 48.5 mtt180 -124.58 136.61 54.1 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 121.045 0.45 . . . . 0.0 111.055 176.96 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.767 HG23 HG11 ' A' ' 60' ' ' VAL . 86.1 t -125.65 121.96 61.24 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 N-CA-C 109.16 -0.681 . . . . 0.0 109.16 175.342 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.419 HG22 ' HB ' ' A' ' 63' ' ' VAL . 26.4 t -101.37 132.64 46.8 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-O 120.743 0.306 . . . . 0.0 110.79 -175.261 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 41' ' ' GLU . . . . . 0.711 ' HB3' HD23 ' A' ' 64' ' ' LEU . 10.7 tt0 -108.72 126.0 52.53 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.154 -0.476 . . . . 0.0 109.972 176.252 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.739 HG13 HD11 ' A' ' 79' ' ' ILE . 64.8 t -94.12 106.62 18.29 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.774 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 174.644 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 156.75 -66.54 0.3 Allowed Glycine 0 N--CA 1.44 -1.1 0 C-N-CA 120.283 -0.96 . . . . 0.0 111.753 -178.671 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.979 ' HB1' HD13 ' A' ' 74' ' ' ILE . . . 53.38 34.36 17.87 Favored 'General case' 0 C--O 1.233 0.187 0 CA-C-O 121.132 0.491 . . . . 0.0 111.774 176.832 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -91.34 -144.85 13.52 Favored Glycine 0 N--CA 1.445 -0.742 0 C-N-CA 120.623 -0.798 . . . . 0.0 112.847 -177.541 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 39.1 mtp180 -92.6 29.81 1.67 Allowed 'General case' 0 C--N 1.321 -0.667 0 CA-C-O 121.251 0.548 . . . . 0.0 110.523 -176.026 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 5.1 p90 -129.91 30.17 4.88 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.93 -176.675 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.596 HD21 ' HA ' ' A' ' 44' ' ' ALA . 94.1 mt -72.75 7.92 1.73 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.993 -0.549 . . . . 0.0 112.147 -174.318 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 49' ' ' TYR . . . . . 0.572 ' HD2' ' HD2' ' A' ' 16' ' ' PRO . 5.7 p90 -65.95 -26.37 67.54 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.819 0.342 . . . . 0.0 110.931 177.025 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.47 ' O ' HG13 ' A' ' 54' ' ' ILE . 93.6 t -72.35 -54.37 16.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.19 175.513 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -61.86 -41.33 97.72 Favored 'General case' 0 N--CA 1.449 -0.479 0 CA-C-N 115.795 -0.638 . . . . 0.0 111.592 -179.099 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 22.1 t70 -65.49 -42.78 91.77 Favored 'General case' 0 C--N 1.329 -0.306 0 C-N-CA 121.033 -0.267 . . . . 0.0 110.756 179.128 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 89.7 t80 -59.56 -36.66 76.64 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.864 0.364 . . . . 0.0 110.533 178.64 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.621 ' HA ' HD11 ' A' ' 30' ' ' ILE . 81.3 mt -61.27 -46.85 95.79 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.386 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.017 178.205 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 36.8 ptt180 -75.33 -16.71 60.38 Favored 'General case' 0 C--O 1.234 0.25 0 CA-C-O 120.843 0.354 . . . . 0.0 111.078 -178.201 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 43.4 mmtm -75.62 -35.39 60.5 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.56 -0.291 . . . . 0.0 110.986 177.234 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 7.5 t-80 -103.94 -38.31 7.04 Favored 'General case' 0 N--CA 1.451 -0.418 0 CA-C-O 120.953 0.406 . . . . 0.0 110.75 -175.13 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 7.9 t -110.08 140.82 43.74 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 121.03 0.443 . . . . 0.0 110.302 -177.697 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 59' ' ' LYS . . . . . 0.504 ' N ' ' HD2' ' A' ' 59' ' ' LYS . 4.1 mptp? -92.22 60.59 3.74 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.783 0.802 . . . . 0.0 109.888 178.378 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.767 HG11 HG23 ' A' ' 39' ' ' VAL . 73.7 t -106.26 139.46 27.54 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-N 114.623 -1.171 . . . . 0.0 110.67 177.985 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 61' ' ' ASP . . . . . 0.832 ' HB3' ' HG2' ' A' ' 38' ' ' ARG . 18.0 t70 -74.98 90.75 2.46 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 109.168 -0.678 . . . . 0.0 109.168 175.823 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 5.5 tt -84.89 126.85 33.83 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.163 -176.529 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.419 ' HB ' HG22 ' A' ' 40' ' ' VAL . 51.5 t -106.82 127.94 61.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.828 -176.256 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 64' ' ' LEU . . . . . 0.711 HD23 ' HB3' ' A' ' 41' ' ' GLU . 82.3 mt -111.76 133.87 53.7 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 109.535 -0.543 . . . . 0.0 109.535 176.61 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 3.4 p -127.47 130.22 48.85 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 120.47 0.176 . . . . 0.0 111.024 178.566 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 66' ' ' ASP . . . . . 0.812 ' HB2' ' HB3' ' A' ' 44' ' ' ALA . 19.4 t0 -162.22 157.58 23.22 Favored 'General case' 0 C--O 1.234 0.268 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.675 -179.355 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 63.7 mt -82.58 122.01 36.55 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 116.115 -0.493 . . . . 0.0 109.79 178.926 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 18.1 ptpt 41.52 69.46 2.04 Favored Pre-proline 0 N--CA 1.474 0.77 0 O-C-N 124.003 0.814 . . . . 0.0 112.346 -175.604 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 69' ' ' PRO . . . . . 0.513 ' CB ' ' HB ' ' A' ' 74' ' ' ILE . 5.8 Cg_exo -74.51 132.61 16.32 Favored 'Trans proline' 0 N--CA 1.46 -0.467 0 C-N-CA 122.898 2.399 . . . . 0.0 111.923 179.072 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 34.0 t -78.29 -17.62 56.36 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.13 -176.759 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 64.5 m80 -80.54 -11.69 59.63 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.385 -0.371 . . . . 0.0 111.649 -176.325 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 81.24 -52.34 4.5 Favored Glycine 0 CA--C 1.52 0.401 0 C-N-CA 120.92 -0.657 . . . . 0.0 113.765 173.774 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -74.36 -3.87 67.3 Favored Glycine 0 CA--C 1.518 0.25 0 C-N-CA 121.141 -0.552 . . . . 0.0 113.23 -175.468 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.979 HD13 ' HB1' ' A' ' 44' ' ' ALA . 62.5 mt -85.91 135.51 24.84 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.713 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 178.345 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.49 HG12 ' H ' ' A' ' 77' ' ' ASP . 61.6 t -61.18 136.16 25.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-O 120.832 0.348 . . . . 0.0 110.364 -177.908 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 17.1 mmt85 -86.3 15.16 5.55 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.969 -0.559 . . . . 0.0 111.31 -171.947 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 77' ' ' ASP . . . . . 0.49 ' H ' HG12 ' A' ' 75' ' ' VAL . 26.2 t70 -77.21 136.54 38.56 Favored 'General case' 0 C--N 1.325 -0.5 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 -177.019 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -58.99 116.06 3.55 Favored 'General case' 0 C--O 1.221 -0.439 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.141 -177.145 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 79' ' ' ILE . . . . . 0.739 HD11 HG13 ' A' ' 42' ' ' VAL . 10.6 tp -69.63 -16.28 20.29 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-O 121.344 0.592 . . . . 0.0 110.399 178.551 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 9.0 t -86.99 -11.31 50.87 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.477 178.225 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 45.0 t -157.2 64.86 3.4 Favored Pre-proline 0 C--N 1.326 -0.424 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 179.879 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.562 ' HB2' ' HE2' ' A' ' 87' ' ' TYR . 90.1 Cg_endo -85.07 153.26 11.06 Favored 'Trans proline' 0 N--CA 1.458 -0.564 0 C-N-CA 122.717 2.278 . . . . 0.0 113.206 -170.187 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 83' ' ' ARG . . . . . 0.68 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 35.2 mtt180 -87.56 119.82 28.24 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.784 177.292 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 84' ' ' MET . . . . . 0.652 ' HA ' ' HD2' ' A' ' 87' ' ' TYR . 36.7 mtp -67.94 -9.32 44.24 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.567 -0.742 . . . . 0.0 112.362 -175.302 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.68 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 8.0 pt-20 -61.51 -30.13 70.43 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 121.085 0.469 . . . . 0.0 110.088 175.374 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 69.2 mt -75.07 -40.01 44.31 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 115.47 -0.786 . . . . 0.0 110.514 -179.472 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 87' ' ' TYR . . . . . 0.652 ' HD2' ' HA ' ' A' ' 84' ' ' MET . 91.5 m-85 -75.27 -34.5 61.37 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.947 -0.57 . . . . 0.0 111.216 -177.717 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 34.0 mtp180 -64.41 114.48 4.34 Favored 'General case' 0 C--O 1.235 0.328 0 CA-C-O 121.572 0.701 . . . . 0.0 110.765 177.71 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 124.21 -12.53 8.03 Favored Glycine 0 N--CA 1.443 -0.864 0 CA-C-N 114.868 -1.06 . . . . 0.0 111.492 -175.825 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -84.21 152.19 24.38 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.838 0.352 . . . . 0.0 110.872 -179.815 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -99.75 -22.16 15.48 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.407 177.546 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 92' ' ' LEU . . . . . 0.483 ' HG ' ' HB3' ' A' ' 116' ' ' ARG . 4.9 tt -152.53 142.01 21.69 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.298 -177.981 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.576 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 68.3 mt -131.89 122.96 50.48 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 178.807 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 23.4 p90 -130.61 162.33 29.59 Favored 'General case' 0 C--N 1.321 -0.643 0 C-N-CA 120.614 -0.434 . . . . 0.0 111.007 -178.023 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 95' ' ' SER . . . . . 0.569 ' OG ' ' HB ' ' A' ' 42' ' ' VAL . 4.2 m -143.73 145.41 32.39 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.768 -179.126 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 76.7 mt -116.17 111.17 34.29 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.116 177.988 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 97' ' ' ARG . . . . . 0.431 HH11 ' HD2' ' A' ' 97' ' ' ARG . 12.9 ttp180 59.17 73.49 0.68 Allowed Pre-proline 0 N--CA 1.466 0.349 0 CA-C-N 115.701 -0.681 . . . . 0.0 111.331 -177.548 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_endo -88.2 134.8 3.08 Favored 'Trans proline' 0 N--CA 1.455 -0.749 0 C-N-CA 122.826 2.35 . . . . 0.0 111.917 176.953 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.525 ' HG2' HD11 ' A' ' 102' ' ' ILE . 2.9 Cg_endo -47.48 142.49 13.09 Favored 'Trans proline' 0 C--N 1.35 0.606 0 C-N-CA 123.422 2.748 . . . . 0.0 112.807 175.659 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.813 ' HA ' ' CE1' ' A' ' 103' ' ' HIS . . . -75.09 42.84 0.19 Allowed 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.848 -0.615 . . . . 0.0 112.46 -176.168 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 101' ' ' GLU . . . . . 0.449 ' HG3' HG23 ' A' ' 102' ' ' ILE . 10.0 pt-20 -135.6 -24.56 1.35 Allowed 'General case' 0 C--N 1.326 -0.423 0 N-CA-C 112.325 0.491 . . . . 0.0 112.325 177.425 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.525 HD11 ' HG2' ' A' ' 99' ' ' PRO . 6.5 pt -114.55 3.55 7.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 N-CA-C 112.848 0.685 . . . . 0.0 112.848 -172.521 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 103' ' ' HIS . . . . . 0.813 ' CE1' ' HA ' ' A' ' 100' ' ' ALA . 35.7 m80 -47.12 -56.49 6.49 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 112.156 0.428 . . . . 0.0 112.156 179.731 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 40.1 t -66.29 -26.1 67.17 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.069 0.462 . . . . 0.0 110.771 -179.794 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.427 ' O ' HG23 ' A' ' 109' ' ' VAL . 14.2 m -67.86 -33.3 74.49 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.109 179.446 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.421 HD22 HG21 ' A' ' 42' ' ' VAL . 82.0 mt -72.13 -38.37 69.25 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.954 178.448 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 107' ' ' MET . . . . . 0.547 ' HA ' HD22 ' A' ' 117' ' ' LEU . 53.6 ttm -59.18 -43.34 92.15 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.186 -178.991 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 27.3 ptt85 -66.59 -31.58 72.37 Favored 'General case' 0 C--N 1.331 -0.207 0 C-N-CA 120.88 -0.328 . . . . 0.0 110.532 -177.704 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.427 HG23 ' O ' ' A' ' 105' ' ' SER . 94.0 t -68.94 -46.86 78.37 Favored 'Isoleucine or valine' 0 C--O 1.234 0.243 0 CA-C-N 116.549 -0.296 . . . . 0.0 110.47 179.88 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -58.74 -43.83 90.34 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.512 177.872 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.499 ' HA ' ' HB1' ' A' ' 148' ' ' ALA . 22.5 t70 -65.29 -39.94 93.21 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.012 179.629 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -66.92 -42.94 84.55 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.835 -0.621 . . . . 0.0 111.879 -178.253 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 25.8 m -87.15 -24.41 6.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 120.894 0.378 . . . . 0.0 111.486 -177.393 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 91.11 44.29 4.46 Favored Glycine 0 N--CA 1.449 -0.462 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.27 178.203 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -124.37 156.56 36.85 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 120.723 0.296 . . . . 0.0 110.834 -177.995 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 116' ' ' ARG . . . . . 0.484 ' HD3' ' OE1' ' A' ' 145' ' ' GLU . 14.3 ttm180 -78.57 127.28 31.91 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 177.015 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 117' ' ' LEU . . . . . 0.576 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 51.1 tp -95.89 121.93 38.14 Favored 'General case' 0 C--N 1.322 -0.589 0 N-CA-C 109.892 -0.411 . . . . 0.0 109.892 -179.946 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 118' ' ' ILE . . . . . 0.448 HD12 HG12 ' A' ' 29' ' ' ILE . 69.3 mt -119.77 112.69 38.07 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-O 121.023 0.439 . . . . 0.0 110.617 178.729 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 50.6 mt -111.61 121.18 63.66 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.797 0 CA-C-O 120.919 0.39 . . . . 0.0 110.32 178.94 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 63.6 tttp -111.11 103.31 54.72 Favored Pre-proline 0 C--N 1.32 -0.699 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.489 174.878 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 93.0 Cg_endo -82.9 -166.86 0.41 Allowed 'Trans proline' 0 N--CA 1.455 -0.773 0 C-N-CA 122.591 2.194 . . . . 0.0 110.829 171.185 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 7.1 mp -88.81 166.92 13.69 Favored 'General case' 0 C--N 1.319 -0.72 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 177.103 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 4.7 t -68.61 -9.39 49.5 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.153 0.501 . . . . 0.0 111.219 -177.68 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -117.49 24.7 8.99 Favored Glycine 0 N--CA 1.446 -0.676 0 N-CA-C 111.587 -0.605 . . . . 0.0 111.587 175.5 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 26.9 mm-40 -129.38 172.75 11.19 Favored 'General case' 0 N--CA 1.45 -0.46 0 CA-C-O 121.209 0.528 . . . . 0.0 110.754 -176.774 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 8.4 t70 -143.79 -170.82 3.4 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-N 115.05 -0.977 . . . . 0.0 108.58 175.358 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.602 HD11 ' HB2' ' A' ' 144' ' ' TYR . 18.3 mt -110.42 -22.61 4.91 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.764 0 CA-C-O 120.667 0.27 . . . . 0.0 110.337 179.49 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 17.4 m 46.77 24.88 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.038 0 C-N-CA 124.218 1.007 . . . . 0.0 113.044 179.401 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 129' ' ' THR . . . . . 0.437 ' O ' ' HB3' ' A' ' 130' ' ' GLU . 15.1 t -94.94 30.68 2.04 Favored 'General case' 0 C--O 1.237 0.401 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.022 179.032 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 130' ' ' GLU . . . . . 0.437 ' HB3' ' O ' ' A' ' 129' ' ' THR . 8.4 tp10 75.94 153.6 0.14 Allowed 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 115.145 -0.934 . . . . 0.0 109.758 -171.363 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 131' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -79.55 40.58 0.45 Allowed 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 120.992 0.425 . . . . 0.0 111.255 -175.139 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 28.7 mtpp -89.87 -10.2 46.17 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.399 -178.01 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 133' ' ' MET . . . . . 0.4 ' HG2' ' HB2' ' A' ' 146' ' ' TYR . 88.9 mtp -98.77 151.51 20.71 Favored 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 178.405 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 16.2 ptmt -100.42 134.62 43.1 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 121.222 0.534 . . . . 0.0 111.353 -174.795 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 135' ' ' LEU . . . . . 0.488 HD11 ' HD2' ' A' ' 142' ' ' TYR . 54.6 tp -78.58 126.7 31.11 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.334 -0.848 . . . . 0.0 110.154 177.438 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -123.43 135.12 64.32 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.712 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.909 179.869 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 20.9 m-80 -111.52 112.35 24.02 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.662 -0.699 . . . . 0.0 109.442 178.217 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 138' ' ' TYR . . . . . 0.481 ' CD2' ' HB2' ' A' ' 28' ' ' TYR . 61.1 t80 -144.73 128.77 17.55 Favored 'General case' 0 C--N 1.318 -0.773 0 N-CA-C 110.348 -0.241 . . . . 0.0 110.348 -178.001 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 139' ' ' GLY . . . . . 0.494 ' HA3' ' HB3' ' A' ' 24' ' ' ASP . . . 68.79 35.94 81.08 Favored Glycine 0 N--CA 1.447 -0.61 0 C-N-CA 120.944 -0.646 . . . . 0.0 112.907 176.169 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 140' ' ' ARG . . . . . 0.411 ' HB2' ' O ' ' A' ' 139' ' ' GLY . 69.0 mtt85 72.97 4.51 4.98 Favored 'General case' 0 N--CA 1.463 0.223 0 C-N-CA 122.772 0.429 . . . . 0.0 112.081 175.723 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 141' ' ' THR . . . . . 0.741 ' HB ' ' HB2' ' A' ' 21' ' ' MET . 14.9 t -124.57 154.09 41.15 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 176.296 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 142' ' ' TYR . . . . . 0.488 ' HD2' HD11 ' A' ' 135' ' ' LEU . 45.4 p90 -123.21 147.81 46.49 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-O 121.162 0.506 . . . . 0.0 110.653 178.539 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 14.0 p90 -154.01 179.59 8.77 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-N 115.064 -0.971 . . . . 0.0 109.056 -177.676 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 144' ' ' TYR . . . . . 0.602 ' HB2' HD11 ' A' ' 127' ' ' ILE . 97.3 m-85 -115.79 127.79 55.35 Favored 'General case' 0 C--N 1.32 -0.709 0 N-CA-C 110.19 -0.3 . . . . 0.0 110.19 179.452 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 145' ' ' GLU . . . . . 0.484 ' OE1' ' HD3' ' A' ' 116' ' ' ARG . 18.2 pt-20 -115.48 161.75 18.14 Favored 'General case' 0 C--N 1.32 -0.691 0 N-CA-C 109.715 -0.476 . . . . 0.0 109.715 176.1 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 146' ' ' TYR . . . . . 0.463 ' HB3' ' HB3' ' A' ' 117' ' ' LEU . 51.0 t80 -141.33 126.9 18.91 Favored 'General case' 0 C--N 1.313 -0.997 0 CA-C-N 115.604 -0.725 . . . . 0.0 109.741 177.532 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 3.1 mp -95.57 109.33 22.38 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.81 0 N-CA-C 109.585 -0.524 . . . . 0.0 109.585 -179.249 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 148' ' ' ALA . . . . . 0.499 ' HB1' ' HA ' ' A' ' 111' ' ' ASP . . . -63.0 111.24 2.08 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.392 -0.596 . . . . 0.0 109.392 175.114 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 -64.37 154.37 35.67 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 121.859 0.838 . . . . 0.0 111.946 -173.756 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 40.7 t -108.46 149.24 11.86 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.957 0 CA-C-N 114.77 -1.105 . . . . 0.0 108.94 179.978 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 151' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -58.01 145.65 35.42 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.667 0.27 . . . . 0.0 110.623 178.162 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 3.7 m -62.33 110.55 1.68 Allowed 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.845 -0.616 . . . . 0.0 109.853 179.477 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 10.1 ptm180 . . . . . 0 C--O 1.248 0.974 0 CA-C-O 118.133 -0.937 . . . . 0.0 110.63 -177.254 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 22.0 mmt . . . . . 0 N--CA 1.479 0.997 0 CA-C-O 120.757 0.313 . . . . 0.0 110.326 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 127.0 141.05 5.32 Favored Glycine 0 N--CA 1.445 -0.759 0 C-N-CA 120.827 -0.702 . . . . 0.0 111.815 -179.714 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 16.1 m -140.46 108.79 5.82 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 120.699 0.285 . . . . 0.0 110.313 179.838 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 33.1 m -76.44 113.98 14.64 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.386 179.322 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 2.0 p80 -111.57 101.78 10.16 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 121.555 0.693 . . . . 0.0 109.872 179.165 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 60.7 m80 -91.97 100.93 13.49 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.578 -0.737 . . . . 0.0 110.717 -176.025 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 62.4 m-70 -89.31 100.57 13.33 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 116.127 -0.488 . . . . 0.0 109.993 177.632 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 69.5 m80 -131.55 98.03 4.39 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.723 -179.886 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 56.6 t-80 -99.53 98.96 9.79 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 109.091 -0.707 . . . . 0.0 109.091 173.588 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 40.3 m80 -76.43 94.64 3.69 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.927 -0.578 . . . . 0.0 110.528 -177.815 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 19.5 m -86.3 44.33 1.13 Allowed 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.454 -0.794 . . . . 0.0 110.265 -179.716 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 22.6 t -109.07 118.34 36.52 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.732 -0.667 . . . . 0.0 109.755 -178.62 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -78.69 87.46 1.14 Allowed Glycine 0 N--CA 1.448 -0.56 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.581 -177.771 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' LEU . . . . . 0.758 HD23 ' H ' ' A' ' 14' ' ' LEU . 2.4 pt? -81.64 147.33 29.61 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 110.067 -0.346 . . . . 0.0 110.067 176.203 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 7.2 p -89.98 125.16 61.51 Favored Pre-proline 0 C--N 1.325 -0.469 0 CA-C-O 120.999 0.428 . . . . 0.0 110.272 -179.376 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -81.81 -178.89 4.44 Favored 'Trans proline' 0 N--CA 1.46 -0.468 0 C-N-CA 122.749 2.3 . . . . 0.0 112.993 -177.731 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 27.3 mmt180 -92.59 173.9 7.55 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.813 -0.631 . . . . 0.0 110.465 178.464 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -62.59 135.19 44.55 Favored Glycine 0 N--CA 1.448 -0.54 0 C-N-CA 121.191 -0.528 . . . . 0.0 112.016 178.188 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 48.9 m -74.52 78.99 1.94 Allowed 'General case' 0 C--N 1.323 -0.587 0 CA-C-O 121.275 0.56 . . . . 0.0 111.34 -178.751 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 43.1 m80 -131.62 -26.83 1.98 Allowed 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.467 -0.788 . . . . 0.0 109.698 173.236 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' MET . . . . . . . . . . . . . 25.4 ptm -69.25 -15.81 63.45 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.324 -0.853 . . . . 0.0 111.12 178.824 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' TRP . . . . . 0.584 ' HB3' HG22 ' A' ' 50' ' ' VAL . 83.1 m95 -80.71 -19.51 44.92 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.385 -176.142 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 23' ' ' ASN . . . . . 0.496 ' O ' HG23 ' A' ' 27' ' ' VAL . 2.1 m-20 -60.8 -48.79 80.22 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.811 -172.605 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -60.89 -39.55 89.7 Favored 'General case' 0 N--CA 1.468 0.44 0 CA-C-O 120.735 0.302 . . . . 0.0 111.477 -179.08 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.769 HD22 ' HD2' ' A' ' 120' ' ' LYS . 54.0 tp -58.08 -50.8 72.2 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.458 177.574 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 26' ' ' ALA . . . . . 0.468 ' O ' HG13 ' A' ' 30' ' ' ILE . . . -59.46 -46.38 88.95 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.618 -0.719 . . . . 0.0 111.18 -179.029 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.592 ' HA ' HD12 ' A' ' 30' ' ' ILE . 87.5 t -55.64 -44.29 76.25 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.915 179.912 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 72.7 t80 -59.8 -46.19 89.98 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.584 179.003 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.53 HG23 HD22 ' A' ' 92' ' ' LEU . 75.9 mt -59.69 -43.02 90.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.47 178.246 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.811 HG12 HG23 ' A' ' 54' ' ' ILE . 82.2 mt -59.05 -47.08 91.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 115.642 -0.708 . . . . 0.0 111.78 -179.622 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 31' ' ' ARG . . . . . 0.522 ' HG3' ' O ' ' A' ' 27' ' ' VAL . 35.6 mtp180 -73.44 -22.6 60.16 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 121.03 0.443 . . . . 0.0 111.02 -174.156 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 69.5 m -88.59 -8.92 53.89 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.262 -179.563 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 13.5 p -112.88 -70.01 0.83 Allowed 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.76 0.314 . . . . 0.0 111.154 -178.943 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 93.49 166.12 37.73 Favored Glycine 0 N--CA 1.449 -0.492 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.277 179.793 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 69.8 Cg_endo -75.99 156.31 38.62 Favored 'Trans proline' 0 CA--C 1.532 0.376 0 C-N-CA 122.7 2.267 . . . . 0.0 112.597 -179.831 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 84.07 39.3 9.39 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.888 178.491 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 12.5 t -164.4 -170.19 1.99 Allowed 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 177.8 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 38' ' ' ARG . . . . . 0.431 ' HA ' ' O ' ' A' ' 61' ' ' ASP . 49.0 mtm180 -119.3 136.23 54.34 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.945 0.402 . . . . 0.0 110.882 179.789 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.683 HG23 HG21 ' A' ' 60' ' ' VAL . 91.6 t -119.76 113.16 39.89 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 N-CA-C 109.034 -0.728 . . . . 0.0 109.034 173.806 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.587 ' O ' ' HA ' ' A' ' 93' ' ' ILE . 46.9 t -97.12 134.23 35.68 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.853 0 CA-C-O 120.931 0.396 . . . . 0.0 110.916 -175.703 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 41' ' ' GLU . . . . . 0.467 ' HA ' ' O ' ' A' ' 94' ' ' TYR . 0.4 OUTLIER -114.6 157.18 23.41 Favored 'General case' 0 C--N 1.318 -0.793 0 N-CA-C 109.036 -0.728 . . . . 0.0 109.036 173.521 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.559 ' HB ' ' HB3' ' A' ' 95' ' ' SER . 54.7 t -124.76 112.34 31.6 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.733 0 CA-C-N 116.512 -0.313 . . . . 0.0 110.954 178.334 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 112.3 32.82 2.26 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.665 -0.778 . . . . 0.0 113.602 173.74 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -50.44 -58.64 5.27 Favored 'General case' 0 N--CA 1.466 0.345 0 N-CA-C 112.378 0.51 . . . . 0.0 112.378 -178.24 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 63.66 -108.14 2.07 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 121.052 -0.594 . . . . 0.0 112.677 179.519 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 16.7 ptt180 -127.11 5.71 6.47 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.678 0.275 . . . . 0.0 111.333 -179.58 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.525 ' HE2' HG13 ' A' ' 96' ' ' ILE . 14.4 p90 -112.46 90.99 3.49 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.959 0.885 . . . . 0.0 110.496 179.186 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.447 HD22 HD13 ' A' ' 64' ' ' LEU . 74.6 mt -102.07 16.45 26.03 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.217 -0.901 . . . . 0.0 110.629 -175.877 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 78.0 t80 -60.69 -50.07 74.96 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.368 -0.378 . . . . 0.0 111.322 -177.054 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.584 HG22 ' HB3' ' A' ' 22' ' ' TRP . 59.6 t -62.38 -48.76 86.83 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-O 121.039 0.447 . . . . 0.0 110.726 -178.981 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 51' ' ' SER . . . . . 0.429 ' CB ' HD21 ' A' ' 64' ' ' LEU . 0.0 OUTLIER -63.98 -45.63 88.2 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.622 -177.166 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.626 ' O ' ' HG3' ' A' ' 56' ' ' LYS . 26.4 t70 -70.88 -30.32 66.65 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 120.641 0.258 . . . . 0.0 110.662 -179.042 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 45.4 t80 -61.73 -42.48 99.02 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.06 0.457 . . . . 0.0 109.961 175.97 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.811 HG23 HG12 ' A' ' 30' ' ' ILE . 80.5 mt -63.61 -48.01 88.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 115.815 -0.63 . . . . 0.0 111.437 -179.883 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 55' ' ' ARG . . . . . 0.601 ' HG2' ' HA ' ' A' ' 52' ' ' ASP . 0.1 OUTLIER -69.51 -18.88 63.72 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 111.898 0.333 . . . . 0.0 111.898 -177.149 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 56' ' ' LYS . . . . . 0.626 ' HG3' ' O ' ' A' ' 52' ' ' ASP . 56.7 mttm -67.57 -37.79 83.15 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.115 0.483 . . . . 0.0 110.575 176.084 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 8.4 t-80 -101.72 -39.42 7.44 Favored 'General case' 0 N--CA 1.444 -0.746 0 CA-C-N 115.879 -0.6 . . . . 0.0 111.034 -172.111 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 58' ' ' SER . . . . . 0.591 ' HB2' HG23 ' A' ' 30' ' ' ILE . 8.8 t -109.78 139.58 44.68 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.75 0.31 . . . . 0.0 110.393 -177.379 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 14.4 mmmm -91.35 59.99 4.04 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 121.85 0.833 . . . . 0.0 109.981 177.184 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.683 HG21 HG23 ' A' ' 39' ' ' VAL . 13.6 p -110.72 145.05 17.57 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.814 0 CA-C-N 114.817 -1.083 . . . . 0.0 110.098 177.38 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 61' ' ' ASP . . . . . 0.431 ' O ' ' HA ' ' A' ' 38' ' ' ARG . 21.6 t70 -78.79 101.63 7.71 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.062 0.458 . . . . 0.0 109.897 178.656 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 62' ' ' LEU . . . . . 0.413 ' HA ' ' O ' ' A' ' 39' ' ' VAL . 3.6 tt -91.93 119.02 31.3 Favored 'General case' 0 C--N 1.315 -0.925 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 -178.864 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.417 HG11 ' CG2' ' A' ' 86' ' ' ILE . 47.1 t -96.62 119.16 44.31 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-N 115.605 -0.725 . . . . 0.0 110.503 -176.822 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 64' ' ' LEU . . . . . 0.623 ' HB2' ' HA ' ' A' ' 74' ' ' ILE . 51.1 mt -94.39 138.34 32.46 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.553 -0.749 . . . . 0.0 109.722 179.629 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.508 ' OG1' ' HA ' ' A' ' 42' ' ' VAL . 70.2 p -128.56 130.7 47.78 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 120.875 0.369 . . . . 0.0 110.759 178.141 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 31.3 t70 -160.78 146.42 14.65 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.165 -0.47 . . . . 0.0 109.823 179.172 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.744 HD11 HG22 ' A' ' 79' ' ' ILE . 50.6 mt -75.85 106.42 5.67 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-O 121.111 0.482 . . . . 0.0 110.662 179.526 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 68' ' ' LYS . . . . . 0.431 ' N ' ' HD3' ' A' ' 69' ' ' PRO . 45.6 mtmt 65.73 65.47 0.87 Allowed Pre-proline 0 CA--C 1.533 0.307 0 CA-C-N 115.197 -0.911 . . . . 0.0 111.814 177.723 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 69' ' ' PRO . . . . . 0.984 ' HD2' ' HG3' ' A' ' 76' ' ' ARG . 2.6 Cg_exo -76.69 149.42 30.02 Favored 'Trans proline' 0 C--O 1.234 0.324 0 C-N-CA 122.976 2.45 . . . . 0.0 111.739 177.055 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 25.3 m -100.45 -1.48 35.71 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.422 -0.354 . . . . 0.0 111.248 -178.173 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 84.5 t60 -117.66 121.35 40.66 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.493 -0.321 . . . . 0.0 110.97 -175.413 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -58.24 124.89 37.8 Favored Glycine 0 N--CA 1.45 -0.431 0 CA-C-N 115.919 -0.582 . . . . 0.0 111.759 175.049 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 128.86 -24.82 4.77 Favored Glycine 0 N--CA 1.446 -0.665 0 N-CA-C 110.752 -0.939 . . . . 0.0 110.752 -174.377 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.623 ' HA ' ' HB2' ' A' ' 64' ' ' LEU . 35.5 mt -95.7 135.81 28.63 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 N-CA-C 108.892 -0.781 . . . . 0.0 108.892 174.145 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.413 HG11 HD13 ' A' ' 86' ' ' ILE . 98.7 t -78.84 136.39 23.91 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.715 0 CA-C-O 121.437 0.637 . . . . 0.0 110.178 -179.16 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 76' ' ' ARG . . . . . 0.984 ' HG3' ' HD2' ' A' ' 69' ' ' PRO . 1.3 mpp_? -90.83 34.17 0.92 Allowed 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 115.032 -0.985 . . . . 0.0 110.841 -173.0 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 22.6 t0 -89.86 136.94 32.74 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.082 -0.71 . . . . 0.0 109.082 177.888 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 7.0 p-10 -95.85 153.05 17.95 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-O 121.166 0.508 . . . . 0.0 111.353 -172.043 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 79' ' ' ILE . . . . . 0.744 HG22 HD11 ' A' ' 67' ' ' ILE . 10.4 tp -71.36 -27.09 27.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 115.648 -0.705 . . . . 0.0 112.478 -170.873 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 14.3 t -89.19 6.34 40.57 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.34 0.591 . . . . 0.0 110.326 -179.11 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 32.8 t -152.29 58.5 2.59 Favored Pre-proline 0 C--N 1.325 -0.495 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.909 174.428 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.487 ' HB2' ' HE2' ' A' ' 87' ' ' TYR . 65.4 Cg_endo -74.99 131.13 13.95 Favored 'Trans proline' 0 C--O 1.238 0.503 0 C-N-CA 122.192 1.928 . . . . 0.0 112.092 -175.105 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 83' ' ' ARG . . . . . 0.607 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 37.1 mtp85 -85.51 120.52 27.05 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.141 0.496 . . . . 0.0 111.063 -179.12 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 84' ' ' MET . . . . . 0.506 ' O ' ' HG3' ' A' ' 88' ' ' ARG . 96.1 mmm -62.5 -21.4 65.47 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.415 -0.811 . . . . 0.0 110.516 179.699 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.607 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 11.1 pt-20 -66.29 -21.62 66.27 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-O 121.195 0.522 . . . . 0.0 110.799 -178.834 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.417 ' CG2' HG11 ' A' ' 63' ' ' VAL . 66.5 mt -85.85 -31.2 6.5 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.497 -179.41 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 87' ' ' TYR . . . . . 0.487 ' HE2' ' HB2' ' A' ' 82' ' ' PRO . 79.9 m-85 -88.96 -26.06 21.72 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.432 -176.578 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 88' ' ' ARG . . . . . 0.583 ' HG2' HG12 ' A' ' 113' ' ' VAL . 81.8 mtp180 -71.97 143.82 49.09 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 121.142 0.496 . . . . 0.0 111.041 -178.912 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 80.54 11.2 84.37 Favored Glycine 0 C--N 1.319 -0.414 0 CA-C-N 115.274 -0.875 . . . . 0.0 112.042 -178.606 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -96.0 154.92 16.98 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.847 0.355 . . . . 0.0 110.355 178.627 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -98.34 -23.65 15.54 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 116.108 -0.497 . . . . 0.0 111.025 179.928 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 92' ' ' LEU . . . . . 0.53 HD22 HG23 ' A' ' 29' ' ' ILE . 4.1 tt -156.99 145.11 19.4 Favored 'General case' 0 N--CA 1.452 -0.373 0 CA-C-O 120.873 0.368 . . . . 0.0 110.81 -177.33 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.587 ' HA ' ' O ' ' A' ' 40' ' ' VAL . 61.6 mt -132.77 131.04 59.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 N-CA-C 109.031 -0.729 . . . . 0.0 109.031 178.193 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 94' ' ' TYR . . . . . 0.467 ' O ' ' HA ' ' A' ' 41' ' ' GLU . 32.4 p90 -139.68 155.74 47.21 Favored 'General case' 0 C--N 1.326 -0.414 0 C-N-CA 120.709 -0.396 . . . . 0.0 110.644 -179.508 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 95' ' ' SER . . . . . 0.559 ' HB3' ' HB ' ' A' ' 42' ' ' VAL . 10.2 p -142.48 148.16 37.24 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-O 120.748 0.309 . . . . 0.0 111.095 -176.964 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 96' ' ' ILE . . . . . 0.525 HG13 ' HE2' ' A' ' 47' ' ' PHE . 38.2 mm -99.03 92.82 2.83 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.585 -179.744 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 97' ' ' ARG . . . . . 0.589 ' NH2' ' HA ' ' A' ' 122' ' ' LEU . 98.8 mtt180 54.08 76.51 0.51 Allowed Pre-proline 0 N--CA 1.468 0.446 0 CA-C-N 115.7 -0.682 . . . . 0.0 112.429 177.995 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 98.9 Cg_endo -80.7 157.4 21.48 Favored 'Trans proline' 0 N--CA 1.46 -0.47 0 C-N-CA 122.539 2.159 . . . . 0.0 112.259 179.1 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.784 ' HD2' HD11 ' A' ' 102' ' ' ILE . 32.4 Cg_exo -57.44 142.19 95.14 Favored 'Trans proline' 0 C--N 1.345 0.394 0 C-N-CA 122.817 2.345 . . . . 0.0 111.683 174.604 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.56 ' HA ' ' NE2' ' A' ' 103' ' ' HIS . . . -63.03 -22.84 67.14 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.329 -0.396 . . . . 0.0 112.035 -175.784 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 101' ' ' GLU . . . . . 0.423 ' HG3' HG23 ' A' ' 102' ' ' ILE . 12.4 pt-20 -74.86 -10.65 59.7 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 112.072 0.397 . . . . 0.0 112.072 -176.703 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.784 HD11 ' HD2' ' A' ' 99' ' ' PRO . 45.6 pt -120.62 8.92 6.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 N-CA-C 112.502 0.556 . . . . 0.0 112.502 -177.776 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 103' ' ' HIS . . . . . 0.56 ' NE2' ' HA ' ' A' ' 100' ' ' ALA . 5.3 m-70 -53.98 -51.2 64.64 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-O 121.053 0.454 . . . . 0.0 110.902 178.04 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 41.1 t -68.25 -28.43 67.21 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.351 -179.743 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.539 ' O ' HG23 ' A' ' 109' ' ' VAL . 29.9 t -68.88 -45.52 70.76 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.962 -0.563 . . . . 0.0 109.908 -179.69 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 72.0 mt -64.37 -40.3 95.57 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.389 -0.369 . . . . 0.0 111.03 178.793 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 107' ' ' MET . . . . . 0.41 ' HG3' ' O ' ' A' ' 103' ' ' HIS . 66.3 mtp -65.54 -42.48 91.9 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.25 -179.667 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 108' ' ' ARG . . . . . 0.529 ' HG2' ' O ' ' A' ' 105' ' ' SER . 8.0 ptm180 -67.93 -31.87 71.92 Favored 'General case' 0 N--CA 1.462 0.154 0 C-N-CA 120.942 -0.303 . . . . 0.0 110.858 -178.847 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.539 HG23 ' O ' ' A' ' 105' ' ' SER . 76.1 t -66.54 -46.65 85.78 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.193 0 CA-C-O 120.71 0.29 . . . . 0.0 110.279 176.798 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -57.34 -45.84 83.89 Favored 'General case' 0 CA--C 1.514 -0.406 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.123 177.419 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.834 ' HA ' ' HB1' ' A' ' 148' ' ' ALA . 5.0 t70 -66.46 -34.09 77.16 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.668 -177.497 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -70.24 -36.29 74.4 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.94 -179.659 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.583 HG12 ' HG2' ' A' ' 88' ' ' ARG . 18.7 m -93.53 -25.96 4.76 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 116.446 -0.343 . . . . 0.0 111.509 -178.172 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 87.97 41.47 6.29 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.863 -0.684 . . . . 0.0 112.634 178.296 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -120.02 158.69 26.27 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.854 0.359 . . . . 0.0 110.918 -178.471 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 116' ' ' ARG . . . . . 0.486 ' HD3' ' OE1' ' A' ' 145' ' ' GLU . 13.2 ttm180 -78.77 123.87 27.62 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 178.434 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 117' ' ' LEU . . . . . 0.564 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 52.0 tp -97.0 123.11 40.63 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.141 179.123 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 118' ' ' ILE . . . . . 0.438 HD12 HG12 ' A' ' 29' ' ' ILE . 53.6 mt -118.39 128.78 75.34 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 CA-C-O 120.976 0.417 . . . . 0.0 110.572 179.437 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 66.0 mt -128.04 134.58 64.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.36 -179.813 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 120' ' ' LYS . . . . . 0.769 ' HD2' HD22 ' A' ' 25' ' ' LEU . 10.4 mttm -113.43 104.25 55.47 Favored Pre-proline 0 C--N 1.324 -0.516 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.481 173.163 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 121' ' ' PRO . . . . . 0.433 ' HB2' ' H ' ' A' ' 122' ' ' LEU . 58.5 Cg_endo -72.28 -146.47 0.02 OUTLIER 'Trans proline' 0 CA--C 1.535 0.547 0 C-N-CA 123.208 2.605 . . . . 0.0 112.758 176.971 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 122' ' ' LEU . . . . . 0.727 ' HB2' ' HB3' ' A' ' 125' ' ' GLU . 7.1 mp -87.59 -176.24 5.49 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.433 -0.349 . . . . 0.0 111.18 -175.884 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 21.7 m -61.23 -39.36 89.99 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.965 -0.562 . . . . 0.0 111.878 -177.533 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -145.14 42.05 1.02 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.996 -0.621 . . . . 0.0 111.602 178.477 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 125' ' ' GLU . . . . . 0.727 ' HB3' ' HB2' ' A' ' 122' ' ' LEU . 5.6 tp10 -131.98 136.17 47.1 Favored 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 -176.268 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 21.1 t70 -76.49 -179.31 5.13 Favored 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 109.838 -0.431 . . . . 0.0 109.838 178.373 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.474 ' HB ' HG22 ' A' ' 129' ' ' THR . 9.3 mt -84.59 7.25 1.82 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 N-CA-C 109.17 -0.678 . . . . 0.0 109.17 177.616 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.4 HG22 ' O ' ' A' ' 127' ' ' ILE . 15.2 m 51.58 27.98 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 C-N-CA 124.802 1.241 . . . . 0.0 112.225 178.394 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 129' ' ' THR . . . . . 0.675 HG23 ' H ' ' A' ' 131' ' ' ARG . 9.9 t -105.49 178.58 4.52 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 115.295 -0.866 . . . . 0.0 109.073 176.996 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 29.9 mt-10 -80.27 7.51 9.34 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.317 0.58 . . . . 0.0 110.131 178.741 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 131' ' ' ARG . . . . . 0.675 ' H ' HG23 ' A' ' 129' ' ' THR . 25.0 mtp180 60.19 75.63 0.4 Allowed 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 114.648 -1.16 . . . . 0.0 112.392 170.008 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 23.2 mmmt -92.77 -1.2 57.0 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.454 -0.794 . . . . 0.0 109.727 172.22 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 133' ' ' MET . . . . . 0.664 ' HG2' ' HB2' ' A' ' 146' ' ' TYR . 88.0 mtp -100.28 176.18 5.46 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.017 -0.992 . . . . 0.0 109.907 -179.543 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 14.9 ptmt -121.35 142.1 50.3 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 120.939 0.399 . . . . 0.0 110.635 -178.398 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 135' ' ' LEU . . . . . 0.73 HD11 ' HD2' ' A' ' 142' ' ' TYR . 50.1 tp -86.14 124.43 32.54 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.394 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 136' ' ' VAL . . . . . 0.437 HG23 ' CD1' ' A' ' 143' ' ' PHE . 0.0 OUTLIER -121.02 137.48 54.61 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.161 -179.724 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 2.9 m-20 -107.34 123.78 48.85 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 109.254 -0.647 . . . . 0.0 109.254 174.807 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 57.8 t80 -143.02 116.71 9.24 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 179.427 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 69.38 39.18 81.05 Favored Glycine 0 N--CA 1.447 -0.613 0 C-N-CA 120.575 -0.821 . . . . 0.0 111.95 -177.755 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 140' ' ' ARG . . . . . 0.442 HH11 ' HD3' ' A' ' 140' ' ' ARG . 22.8 ttp-105 73.24 -21.08 0.26 Allowed 'General case' 0 CA--C 1.531 0.229 0 C-N-CA 123.665 0.786 . . . . 0.0 112.561 177.802 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 6.5 t -92.15 141.71 28.29 Favored 'General case' 0 C--N 1.323 -0.562 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 177.355 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 142' ' ' TYR . . . . . 0.73 ' HD2' HD11 ' A' ' 135' ' ' LEU . 44.4 p90 -110.27 152.43 26.16 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.076 0.465 . . . . 0.0 110.917 -178.742 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 143' ' ' PHE . . . . . 0.492 ' HB3' ' HG3' ' A' ' 120' ' ' LYS . 5.4 p90 -157.7 176.22 12.88 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.837 178.632 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 73.6 m-85 -111.03 132.02 54.57 Favored 'General case' 0 C--N 1.319 -0.745 0 C-N-CA 121.011 -0.276 . . . . 0.0 110.81 -179.54 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 145' ' ' GLU . . . . . 0.486 ' OE1' ' HD3' ' A' ' 116' ' ' ARG . 21.0 pt-20 -120.72 160.85 22.48 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 109.33 -0.619 . . . . 0.0 109.33 174.288 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 146' ' ' TYR . . . . . 0.664 ' HB2' ' HG2' ' A' ' 133' ' ' MET . 32.3 t80 -140.3 124.2 17.4 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-N 116.12 -0.491 . . . . 0.0 109.742 178.017 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 147' ' ' ILE . . . . . 0.426 ' N ' HD12 ' A' ' 147' ' ' ILE . 2.8 mp -91.8 100.54 11.38 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 N-CA-C 109.624 -0.51 . . . . 0.0 109.624 179.702 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 148' ' ' ALA . . . . . 0.834 ' HB1' ' HA ' ' A' ' 111' ' ' ASP . . . -82.57 122.02 27.55 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.446 -0.797 . . . . 0.0 109.959 177.448 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 15.5 pt-20 -78.27 163.79 25.44 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-O 120.801 0.334 . . . . 0.0 110.684 -179.419 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 42.9 t -84.03 131.74 33.19 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 N-CA-C 109.426 -0.583 . . . . 0.0 109.426 175.928 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 151' ' ' ARG . . . . . . . . . . . . . 30.5 ptt85 -72.84 149.47 43.52 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.997 -176.138 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 5.3 p -79.38 132.89 36.54 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.892 -0.594 . . . . 0.0 111.05 179.773 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 153' ' ' ARG . . . . . 0.4 ' HD3' HH11 ' A' ' 153' ' ' ARG . 53.3 mtp180 . . . . . 0 C--O 1.249 1.053 0 CA-C-O 118.282 -0.866 . . . . 0.0 109.791 176.414 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 93.8 mtp . . . . . 0 N--CA 1.481 1.084 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 98.49 139.23 10.69 Favored Glycine 0 N--CA 1.444 -0.801 0 C-N-CA 120.809 -0.71 . . . . 0.0 111.892 -179.308 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 14.9 m -76.09 103.25 6.05 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-O 121.131 0.491 . . . . 0.0 109.915 179.355 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 24.5 p -101.46 34.7 2.5 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.787 -177.303 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 48.0 m80 -72.64 92.75 1.55 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.512 178.926 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 7.8 p80 -87.63 143.09 27.36 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 177.62 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 29.4 m-70 -99.63 114.15 27.02 Favored 'General case' 0 C--N 1.316 -0.851 0 CA-C-O 120.877 0.37 . . . . 0.0 110.07 179.854 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 45.0 t-80 -75.53 111.12 10.5 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.098 -179.296 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 57.0 t-80 -87.88 108.4 19.15 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.365 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 46.4 p-80 -94.91 154.29 17.28 Favored 'General case' 0 C--N 1.32 -0.712 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 172.519 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 44.7 m -66.59 95.3 0.33 Allowed 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.332 0.587 . . . . 0.0 112.316 -172.79 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 43.2 m -116.7 100.0 7.51 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.572 -0.74 . . . . 0.0 109.273 173.637 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -108.35 159.08 14.45 Favored Glycine 0 N--CA 1.446 -0.672 0 C-N-CA 120.541 -0.837 . . . . 0.0 112.608 -175.712 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -70.02 119.62 14.5 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 110.269 -0.271 . . . . 0.0 110.269 179.087 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.492 ' HA ' ' HD3' ' A' ' 16' ' ' PRO . 20.9 m -70.93 129.49 89.51 Favored Pre-proline 0 C--N 1.326 -0.435 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.506 177.638 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.492 ' HD3' ' HA ' ' A' ' 15' ' ' VAL . 16.6 Cg_exo -67.63 131.01 23.33 Favored 'Trans proline' 0 N--CA 1.463 -0.307 0 C-N-CA 122.974 2.449 . . . . 0.0 112.429 -178.296 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 27.9 mmm180 -89.72 -178.66 5.58 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.54 177.754 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -67.8 86.53 0.16 Allowed Glycine 0 C--N 1.331 0.279 0 N-CA-C 111.043 -0.823 . . . . 0.0 111.043 174.327 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 16.2 m -94.47 25.12 4.08 Favored 'General case' 0 C--N 1.323 -0.576 0 N-CA-C 111.946 0.35 . . . . 0.0 111.946 -169.608 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' HIS . . . . . 0.48 ' HA ' ' OD1' ' A' ' 23' ' ' ASN . 24.4 t-80 -62.47 -32.61 73.52 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.847 0.356 . . . . 0.0 110.324 179.474 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 21' ' ' MET . . . . . . . . . . . . . 23.8 ptp -63.2 -27.77 69.59 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.982 178.053 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 95.8 m95 -80.95 -19.37 44.31 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.967 0.413 . . . . 0.0 110.585 -178.535 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' ASN . . . . . 0.48 ' OD1' ' HA ' ' A' ' 20' ' ' HIS . 12.3 m120 -62.74 -45.82 90.94 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.813 -178.172 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 13.0 m-20 -62.85 -41.12 99.23 Favored 'General case' 0 N--CA 1.464 0.256 0 CA-C-O 120.549 0.214 . . . . 0.0 110.897 178.418 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 58.3 tp -57.43 -48.03 80.23 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 121.021 0.438 . . . . 0.0 109.993 176.423 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' ALA . . . . . 0.485 ' O ' HG13 ' A' ' 30' ' ' ILE . . . -60.82 -46.78 89.22 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.954 178.225 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.504 ' HA ' HD12 ' A' ' 30' ' ' ILE . 53.1 t -56.96 -41.62 77.31 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.199 0 CA-C-N 116.559 -0.291 . . . . 0.0 111.234 179.842 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 61.1 t80 -58.44 -42.79 88.13 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.081 0.467 . . . . 0.0 110.35 178.174 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 66.5 mt -70.2 -40.92 78.67 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.489 178.732 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.741 HG12 HG23 ' A' ' 54' ' ' ILE . 97.0 mt -57.45 -44.63 84.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 115.4 -0.818 . . . . 0.0 111.068 178.838 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 31' ' ' ARG . . . . . 0.408 ' HG3' ' O ' ' A' ' 27' ' ' VAL . 73.4 mtp180 -65.95 -28.99 69.33 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.035 -0.529 . . . . 0.0 111.614 -178.237 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 46.0 t -88.7 -20.59 24.65 Favored 'General case' 0 C--N 1.324 -0.514 0 C-N-CA 121.104 -0.238 . . . . 0.0 111.496 -176.034 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 12.6 p -100.7 -78.99 0.51 Allowed 'General case' 0 C--N 1.327 -0.398 0 C-N-CA 121.172 -0.211 . . . . 0.0 111.537 -177.386 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 106.27 164.3 22.85 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.986 -0.626 . . . . 0.0 112.267 -179.801 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 8.6 Cg_exo -71.88 144.57 43.59 Favored 'Trans proline' 0 C--O 1.234 0.296 0 C-N-CA 123.121 2.548 . . . . 0.0 112.631 -179.286 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 83.65 2.03 89.97 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 121.19 -0.528 . . . . 0.0 112.846 177.83 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 26.1 p -96.82 -172.38 2.46 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' ARG . . . . . 0.42 ' HA ' ' O ' ' A' ' 61' ' ' ASP . 20.6 mtp180 -123.92 130.66 52.96 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 110.244 -0.28 . . . . 0.0 110.244 176.764 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.543 HG23 HG21 ' A' ' 60' ' ' VAL . 83.9 t -130.09 138.53 53.75 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 178.659 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 39.8 t -111.95 121.15 63.88 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-O 120.778 0.323 . . . . 0.0 110.936 -176.275 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 41' ' ' GLU . . . . . 0.404 ' HB2' HD21 ' A' ' 62' ' ' LEU . 44.7 tt0 -99.99 108.64 20.89 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 176.053 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.509 ' HB ' ' OG ' ' A' ' 95' ' ' SER . 46.1 t -97.21 125.49 50.26 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.058 -178.681 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 100.65 20.59 14.39 Favored Glycine 0 N--CA 1.447 -0.605 0 C-N-CA 120.483 -0.865 . . . . 0.0 111.804 -176.927 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.446 ' O ' HD13 ' A' ' 74' ' ' ILE . . . -79.09 78.62 5.54 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.19 0.519 . . . . 0.0 110.044 -179.091 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -94.01 -67.85 1.06 Allowed Glycine 0 N--CA 1.443 -0.836 0 CA-C-N 115.67 -0.696 . . . . 0.0 112.907 -178.445 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 61.3 mtt85 -113.66 -45.91 3.08 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 111.778 0.288 . . . . 0.0 111.778 -174.524 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 13.3 p90 -89.1 97.83 11.42 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.549 0.69 . . . . 0.0 111.048 -177.483 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.531 HD22 HD13 ' A' ' 64' ' ' LEU . 79.9 mt -100.0 28.61 4.72 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.533 -0.758 . . . . 0.0 110.277 -179.957 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 74.2 t80 -72.52 -44.89 61.58 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.338 -175.29 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.429 ' O ' HG13 ' A' ' 54' ' ' ILE . 40.9 t -62.05 -55.56 23.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.727 0.299 . . . . 0.0 110.649 -175.459 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 51' ' ' SER . . . . . 0.415 ' CB ' HD21 ' A' ' 64' ' ' LEU . 1.6 p -54.74 -46.82 74.32 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.802 -0.636 . . . . 0.0 112.074 179.396 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.689 ' O ' ' HG2' ' A' ' 56' ' ' LYS . 33.7 t70 -68.95 -31.11 69.75 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.651 0.262 . . . . 0.0 111.127 -177.966 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 77.4 t80 -71.59 -37.11 71.02 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 120.869 0.366 . . . . 0.0 110.756 179.833 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.741 HG23 HG12 ' A' ' 30' ' ' ILE . 88.3 mt -63.73 -44.54 98.37 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-N 116.48 -0.327 . . . . 0.0 111.098 -179.559 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 55' ' ' ARG . . . . . 0.414 ' HA ' ' O ' ' A' ' 58' ' ' SER . 4.9 ptm180 -68.38 -15.56 63.6 Favored 'General case' 0 CA--C 1.533 0.319 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.321 -178.758 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 56' ' ' LYS . . . . . 0.689 ' HG2' ' O ' ' A' ' 52' ' ' ASP . 32.2 mmmt -73.77 -34.77 64.83 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.989 0.423 . . . . 0.0 110.779 177.183 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 56.7 m-70 -93.2 -47.11 7.1 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.395 -178.622 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 58' ' ' SER . . . . . 0.414 ' O ' ' HA ' ' A' ' 55' ' ' ARG . 67.2 m -121.55 135.19 55.03 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.381 179.546 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 29.3 mmmt -80.08 57.78 2.78 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.707 0.765 . . . . 0.0 110.435 -179.641 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.543 HG21 HG23 ' A' ' 39' ' ' VAL . 3.6 p -85.57 146.05 7.06 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 CA-C-N 114.89 -1.05 . . . . 0.0 109.859 176.705 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 61' ' ' ASP . . . . . 0.42 ' O ' ' HA ' ' A' ' 38' ' ' ARG . 30.4 t70 -84.72 100.27 11.38 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 177.314 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 62' ' ' LEU . . . . . 0.404 HD21 ' HB2' ' A' ' 41' ' ' GLU . 2.3 tt -99.62 129.6 45.78 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.134 -176.542 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 48.5 t -106.08 122.12 59.36 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.635 -178.633 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 64' ' ' LEU . . . . . 0.531 HD13 HD22 ' A' ' 48' ' ' LEU . 42.8 mt -94.19 135.3 35.72 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.127 -0.488 . . . . 0.0 109.746 178.055 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 18.9 p -128.44 130.8 48.13 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.593 0.235 . . . . 0.0 111.407 -178.994 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 25.3 t0 -162.89 146.87 11.29 Favored 'General case' 0 C--N 1.333 -0.142 0 CA-C-N 116.11 -0.495 . . . . 0.0 109.842 177.889 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.659 HD11 ' H ' ' A' ' 79' ' ' ILE . 48.5 mm -73.81 104.89 2.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 N-CA-C 110.169 -0.308 . . . . 0.0 110.169 179.425 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 31.4 mtmm 49.66 78.75 0.38 Allowed Pre-proline 0 N--CA 1.466 0.345 0 CA-C-N 115.576 -0.738 . . . . 0.0 111.381 -175.214 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 69' ' ' PRO . . . . . 0.707 ' HD2' ' HG2' ' A' ' 76' ' ' ARG . 11.7 Cg_endo -56.32 137.03 78.58 Favored 'Trans proline' 0 C--N 1.344 0.3 0 C-N-CA 123.294 2.662 . . . . 0.0 112.901 -178.777 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 12.8 m -97.22 -0.62 46.45 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.903 -0.59 . . . . 0.0 111.246 -178.197 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 25.0 t60 -105.38 -81.63 0.53 Allowed 'General case' 0 C--N 1.327 -0.37 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 178.206 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 156.85 163.09 12.02 Favored Glycine 0 N--CA 1.448 -0.521 0 C-N-CA 120.994 -0.622 . . . . 0.0 111.79 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 72.59 2.47 55.88 Favored Glycine 0 CA--C 1.518 0.266 0 C-N-CA 121.462 -0.399 . . . . 0.0 113.092 179.725 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.454 ' HB ' ' CB ' ' A' ' 69' ' ' PRO . 60.0 mt -100.37 142.77 14.98 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 N-CA-C 110.367 -0.234 . . . . 0.0 110.367 -176.868 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.408 HG12 ' HB2' ' A' ' 77' ' ' ASP . 98.8 t -74.03 129.09 36.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-O 120.922 0.391 . . . . 0.0 110.329 179.821 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 76' ' ' ARG . . . . . 0.707 ' HG2' ' HD2' ' A' ' 69' ' ' PRO . 88.9 mtt180 -86.68 35.0 0.66 Allowed 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.185 -175.903 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 77' ' ' ASP . . . . . 0.408 ' HB2' HG12 ' A' ' 75' ' ' VAL . 1.0 OUTLIER -77.63 173.76 11.67 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 109.711 -0.477 . . . . 0.0 109.711 -178.182 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 19.1 m-20 -103.42 122.52 45.04 Favored 'General case' 0 C--N 1.323 -0.566 0 C-N-CA 120.931 -0.307 . . . . 0.0 110.372 -173.89 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 79' ' ' ILE . . . . . 0.659 ' H ' HD11 ' A' ' 67' ' ' ILE . 10.8 tt -75.56 -26.79 18.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 CA-C-O 121.091 0.472 . . . . 0.0 111.018 178.023 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 15.0 t -84.1 -9.83 58.29 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.572 0.701 . . . . 0.0 110.386 -179.584 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 50.9 m -147.62 70.1 11.41 Favored Pre-proline 0 C--N 1.323 -0.585 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 174.421 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.711 ' HB2' ' HE2' ' A' ' 87' ' ' TYR . 72.0 Cg_endo -76.95 141.31 21.11 Favored 'Trans proline' 0 N--CA 1.461 -0.436 0 C-N-CA 122.559 2.173 . . . . 0.0 113.49 -169.092 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 83' ' ' ARG . . . . . 0.622 ' HG2' ' HG2' ' A' ' 85' ' ' GLU . 0.0 OUTLIER -79.02 117.31 19.96 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.487 -0.779 . . . . 0.0 109.328 174.11 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 84' ' ' MET . . . . . . . . . . . . . 5.4 mtp -66.08 -25.42 67.01 Favored 'General case' 0 C--N 1.324 -0.534 0 C-N-CA 120.878 -0.329 . . . . 0.0 111.243 -177.475 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.622 ' HG2' ' HG2' ' A' ' 83' ' ' ARG . 10.9 pt-20 -60.87 -26.12 67.17 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.825 0.345 . . . . 0.0 111.235 177.614 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.409 HG13 ' HB3' ' A' ' 83' ' ' ARG . 72.6 mt -74.67 -41.21 48.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.786 0.327 . . . . 0.0 110.856 178.358 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 87' ' ' TYR . . . . . 0.711 ' HE2' ' HB2' ' A' ' 82' ' ' PRO . 91.4 m-85 -82.09 -34.27 29.42 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.482 -178.359 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 88' ' ' ARG . . . . . 0.427 HH11 ' HD2' ' A' ' 88' ' ' ARG . 22.4 mtp180 -68.83 125.58 27.06 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.198 0.523 . . . . 0.0 110.398 179.296 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 101.72 3.07 52.75 Favored Glycine 0 N--CA 1.446 -0.675 0 CA-C-N 115.376 -0.829 . . . . 0.0 111.634 -176.488 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -85.63 144.05 28.08 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.084 0.468 . . . . 0.0 110.731 178.808 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -89.31 -19.62 25.07 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.594 179.215 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 92' ' ' LEU . . . . . 0.48 HD23 ' N ' ' A' ' 93' ' ' ILE . 5.6 tt -166.59 141.27 4.23 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.064 -0.517 . . . . 0.0 109.865 -178.038 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.595 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 58.6 mt -124.95 126.33 71.06 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 N-CA-C 109.433 -0.58 . . . . 0.0 109.433 177.285 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 18.8 p90 -134.21 156.18 48.82 Favored 'General case' 0 C--N 1.322 -0.619 0 C-N-CA 120.226 -0.59 . . . . 0.0 111.511 -178.877 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 95' ' ' SER . . . . . 0.509 ' OG ' ' HB ' ' A' ' 42' ' ' VAL . 14.4 m -148.06 130.52 15.77 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.457 -0.792 . . . . 0.0 110.196 -178.571 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 96' ' ' ILE . . . . . 0.435 ' N ' HD12 ' A' ' 96' ' ' ILE . 4.0 mp -87.99 103.32 13.47 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 177.123 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 97' ' ' ARG . . . . . 1.074 ' HB3' ' HA ' ' A' ' 121' ' ' PRO . 8.9 ptm180 40.11 89.61 0.08 OUTLIER Pre-proline 0 N--CA 1.475 0.809 0 C-N-CA 124.685 1.194 . . . . 0.0 113.269 -176.279 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 89.9 Cg_endo -79.96 154.33 22.69 Favored 'Trans proline' 0 N--CA 1.459 -0.525 0 C-N-CA 122.472 2.115 . . . . 0.0 112.191 178.581 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.798 ' HD2' HD11 ' A' ' 102' ' ' ILE . 51.4 Cg_exo -54.27 158.28 9.89 Favored 'Trans proline' 0 C--O 1.234 0.313 0 C-N-CA 122.8 2.334 . . . . 0.0 112.288 173.936 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -80.37 25.86 0.39 Allowed 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.147 -0.479 . . . . 0.0 112.046 -172.997 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 101' ' ' GLU . . . . . 0.666 ' HG3' HG23 ' A' ' 102' ' ' ILE . 12.2 pt-20 -124.3 -21.29 5.0 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.76 -0.2 . . . . 0.0 111.276 178.113 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.798 HD11 ' HD2' ' A' ' 99' ' ' PRO . 45.2 pt -110.38 -1.62 9.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 N-CA-C 112.031 0.382 . . . . 0.0 112.031 -174.646 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 103' ' ' HIS . . . . . 0.529 ' O ' ' HG2' ' A' ' 107' ' ' MET . 23.7 p-80 -61.68 -41.77 98.02 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.798 0.333 . . . . 0.0 110.46 -179.258 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 20.6 t -71.25 -30.21 66.04 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.16 0.505 . . . . 0.0 110.056 177.895 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.541 ' O ' HG23 ' A' ' 109' ' ' VAL . 4.6 m -68.82 -46.08 69.54 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.046 -179.626 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 92.3 mt -58.18 -40.46 81.55 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.168 179.76 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 107' ' ' MET . . . . . 0.529 ' HG2' ' O ' ' A' ' 103' ' ' HIS . 94.2 mmm -60.92 -43.85 98.0 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.43 -178.839 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 108' ' ' ARG . . . . . 0.458 ' HG2' ' O ' ' A' ' 105' ' ' SER . 13.1 ptp180 -76.9 -27.09 54.81 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.663 -0.244 . . . . 0.0 111.2 -177.786 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.541 HG23 ' O ' ' A' ' 105' ' ' SER . 73.6 t -70.9 -44.52 75.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 C-N-CA 121.158 -0.217 . . . . 0.0 110.674 177.744 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -59.46 -41.24 89.25 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 121.106 0.479 . . . . 0.0 110.323 178.466 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.467 ' HA ' ' HB1' ' A' ' 148' ' ' ALA . 16.2 t70 -65.4 -34.92 79.45 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.779 -178.565 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -72.46 -45.13 60.94 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.866 -0.606 . . . . 0.0 111.739 -178.263 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.418 HG12 ' CG ' ' A' ' 88' ' ' ARG . 31.1 m -85.88 -25.63 6.52 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-N 116.533 -0.303 . . . . 0.0 111.771 -176.102 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 84.96 59.3 1.99 Allowed Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.039 179.797 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 115' ' ' ALA . . . . . 0.455 ' O ' ' HB3' ' A' ' 148' ' ' ALA . . . -140.44 149.5 42.65 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 120.927 0.394 . . . . 0.0 110.791 -179.241 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 116' ' ' ARG . . . . . 0.529 ' HD3' ' OE1' ' A' ' 145' ' ' GLU . 14.9 ttm180 -70.98 129.75 39.8 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.893 -0.594 . . . . 0.0 109.999 177.318 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 117' ' ' LEU . . . . . 0.595 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 58.1 tp -100.16 118.66 36.97 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 116.049 -0.523 . . . . 0.0 109.709 178.645 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 60.0 mt -112.66 117.85 56.36 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-O 120.914 0.388 . . . . 0.0 110.569 179.702 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 119' ' ' ILE . . . . . 0.436 ' HA ' ' O ' ' A' ' 95' ' ' SER . 73.3 mt -120.35 120.23 62.2 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.672 -179.646 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 62.2 tttm -115.8 100.9 54.01 Favored Pre-proline 0 C--N 1.32 -0.674 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.208 175.533 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 121' ' ' PRO . . . . . 1.074 ' HA ' ' HB3' ' A' ' 97' ' ' ARG . 86.8 Cg_endo -78.96 -165.46 0.34 Allowed 'Trans proline' 0 N--CA 1.459 -0.503 0 C-N-CA 122.59 2.193 . . . . 0.0 111.792 175.696 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 122' ' ' LEU . . . . . 0.598 ' HB2' ' HB2' ' A' ' 125' ' ' GLU . 31.3 mt -66.54 152.72 44.68 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.872 175.924 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 19.9 m -64.71 106.0 1.1 Allowed 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.02 -0.536 . . . . 0.0 109.569 175.081 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 92.06 30.72 9.86 Favored Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 120.935 -0.65 . . . . 0.0 111.653 -175.118 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 125' ' ' GLU . . . . . 0.598 ' HB2' ' HB2' ' A' ' 122' ' ' LEU . 43.6 tt0 -126.6 145.19 50.64 Favored 'General case' 0 N--CA 1.448 -0.564 0 CA-C-O 121.032 0.444 . . . . 0.0 110.053 -179.408 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -101.15 167.08 10.45 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.471 -178.566 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.565 ' HB ' HG22 ' A' ' 129' ' ' THR . 6.4 mt -108.13 11.17 8.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 N-CA-C 110.02 -0.363 . . . . 0.0 110.02 -178.852 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 20.1 m 48.45 35.54 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.837 0 C-N-CA 124.147 0.979 . . . . 0.0 111.918 -179.45 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 129' ' ' THR . . . . . 0.565 HG22 ' HB ' ' A' ' 127' ' ' ILE . 13.5 t -123.16 136.97 55.0 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 114.984 -1.007 . . . . 0.0 108.94 178.082 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -88.42 101.03 13.5 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 120.76 0.314 . . . . 0.0 111.335 -173.096 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 131' ' ' ARG . . . . . . . . . . . . . 2.7 ptp180 42.02 36.76 0.71 Allowed 'General case' 0 N--CA 1.476 0.844 0 C-N-CA 124.673 1.189 . . . . 0.0 113.642 175.383 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 46.8 mmtm -84.94 -12.3 53.64 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.845 0.355 . . . . 0.0 110.899 177.795 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 133' ' ' MET . . . . . 0.491 ' HG2' ' HB2' ' A' ' 146' ' ' TYR . 85.7 mtp -133.62 170.56 15.35 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.411 -177.179 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -118.38 145.37 45.21 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.689 179.862 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 135' ' ' LEU . . . . . 0.488 HD11 ' HD2' ' A' ' 142' ' ' TYR . 57.7 tp -80.74 134.24 35.79 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.121 178.26 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -129.54 138.59 53.88 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-O 121.193 0.521 . . . . 0.0 111.577 -179.958 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 87.9 m-20 -110.23 120.17 41.6 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.005 177.323 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 59.5 t80 -148.64 123.4 9.9 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 110.201 -0.296 . . . . 0.0 110.201 177.894 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 66.79 42.72 92.89 Favored Glycine 0 N--CA 1.448 -0.563 0 C-N-CA 121.029 -0.605 . . . . 0.0 112.801 177.461 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 55.5 ttt180 73.75 -19.87 0.33 Allowed 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 123.325 0.65 . . . . 0.0 112.361 175.455 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 5.2 t -97.63 163.21 12.93 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 178.58 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 142' ' ' TYR . . . . . 0.488 ' HD2' HD11 ' A' ' 135' ' ' LEU . 37.6 p90 -131.98 148.93 52.54 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 121.237 0.541 . . . . 0.0 110.886 -179.664 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 8.7 p90 -155.23 177.69 11.06 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 115.26 -0.882 . . . . 0.0 109.4 -179.104 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -113.13 134.34 54.6 Favored 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 110.068 -0.345 . . . . 0.0 110.068 179.419 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 145' ' ' GLU . . . . . 0.529 ' OE1' ' HD3' ' A' ' 116' ' ' ARG . 20.1 pt-20 -126.8 158.47 36.51 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 121.265 0.555 . . . . 0.0 110.385 177.237 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 146' ' ' TYR . . . . . 0.491 ' HB2' ' HG2' ' A' ' 133' ' ' MET . 35.6 t80 -134.76 126.26 28.58 Favored 'General case' 0 C--N 1.316 -0.89 0 CA-C-N 115.465 -0.789 . . . . 0.0 109.265 175.241 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 147' ' ' ILE . . . . . 0.408 ' N ' HD12 ' A' ' 147' ' ' ILE . 3.1 mp -92.24 100.23 10.92 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 CA-C-O 121.19 0.519 . . . . 0.0 109.739 -178.661 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 148' ' ' ALA . . . . . 0.467 ' HB1' ' HA ' ' A' ' 111' ' ' ASP . . . -91.73 107.4 19.18 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.61 -0.723 . . . . 0.0 109.064 174.499 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -63.44 156.5 25.96 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-O 121.199 0.523 . . . . 0.0 110.28 -177.884 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 11.6 t -83.19 123.23 38.47 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.91 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 177.251 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 151' ' ' ARG . . . . . 0.401 HH21 ' HA ' ' A' ' 113' ' ' VAL . 0.0 OUTLIER -56.76 107.43 0.39 Allowed 'General case' 0 C--N 1.322 -0.595 0 O-C-N 123.599 0.562 . . . . 0.0 111.088 -178.391 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 18.1 m -61.51 119.96 9.61 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.121 -0.945 . . . . 0.0 111.084 -176.678 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 153' ' ' ARG . . . . . 0.402 ' HA ' ' NE ' ' A' ' 153' ' ' ARG . 3.5 mmp_? . . . . . 0 C--O 1.247 0.966 0 CA-C-N 115.307 -0.86 . . . . 0.0 109.916 -179.36 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 51.9 tpp . . . . . 0 N--CA 1.479 0.98 0 CA-C-O 120.685 0.279 . . . . 0.0 110.471 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -176.48 55.88 0.11 Allowed Glycine 0 N--CA 1.449 -0.466 0 N-CA-C 111.425 -0.67 . . . . 0.0 111.425 178.161 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 39.0 m -92.98 128.94 39.02 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.927 0.394 . . . . 0.0 111.245 -177.346 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 43.4 m -103.68 74.8 1.26 Allowed 'General case' 0 C--N 1.323 -0.548 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 171.237 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 56.5 p-80 -84.7 -171.45 3.64 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.897 -175.748 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 21.0 m-70 -81.98 83.77 7.16 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 121.396 0.617 . . . . 0.0 110.435 179.786 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' HIS . . . . . 0.571 ' CE1' ' HB3' ' A' ' 9' ' ' HIS . 50.9 t-80 -107.4 -70.55 0.79 Allowed 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 115.101 -0.954 . . . . 0.0 108.76 176.951 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 38.8 m80 60.5 23.73 13.38 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 115.515 -0.766 . . . . 0.0 112.4 172.657 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' HIS . . . . . 0.571 ' HB3' ' CE1' ' A' ' 7' ' ' HIS . 60.7 t60 -101.64 97.31 7.75 Favored 'General case' 0 C--N 1.32 -0.676 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 172.293 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 39.1 m80 -81.78 74.69 8.75 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 121.696 0.76 . . . . 0.0 110.69 -174.631 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 41.3 t -157.36 137.8 12.92 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 114.785 -1.098 . . . . 0.0 108.948 179.311 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 22.5 m -72.81 -19.49 61.32 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 120.9 0.381 . . . . 0.0 110.355 178.705 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 79.61 -61.33 4.26 Favored Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 120.913 -0.661 . . . . 0.0 111.489 -177.623 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' LEU . . . . . 0.402 ' O ' ' HD3' ' A' ' 16' ' ' PRO . 86.7 mt -134.4 123.51 24.2 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.51 -0.552 . . . . 0.0 109.51 175.86 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.434 ' HA ' ' HD3' ' A' ' 16' ' ' PRO . 48.6 t -87.69 108.32 19.9 Favored Pre-proline 0 C--N 1.322 -0.611 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 174.702 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.434 ' HD3' ' HA ' ' A' ' 15' ' ' VAL . 1.5 Cg_endo -84.31 -172.35 1.25 Allowed 'Trans proline' 0 N--CA 1.454 -0.837 0 C-N-CA 123.145 2.563 . . . . 0.0 111.793 -179.033 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 17' ' ' ARG . . . . . 0.404 HH11 ' HD2' ' A' ' 17' ' ' ARG . 49.4 mtp85 -83.7 79.81 9.34 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.377 0.608 . . . . 0.0 109.841 178.528 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -95.15 60.88 1.6 Allowed Glycine 0 N--CA 1.448 -0.51 0 CA-C-N 115.478 -0.783 . . . . 0.0 112.665 -177.392 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' SER . . . . . 0.675 ' HA ' ' HD1' ' A' ' 22' ' ' TRP . 2.4 p -94.49 10.46 34.49 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 121.113 0.482 . . . . 0.0 110.915 178.823 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 35.7 t60 -63.91 -52.91 57.66 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.998 -176.575 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' MET . . . . . . . . . . . . . 21.3 ptp -64.12 -20.32 65.89 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-O 120.99 0.424 . . . . 0.0 111.568 -176.296 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' TRP . . . . . 0.675 ' HD1' ' HA ' ' A' ' 19' ' ' SER . 80.6 m95 -81.89 -22.55 36.81 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.022 0.439 . . . . 0.0 110.45 -178.448 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 23' ' ' ASN . . . . . 0.419 ' O ' HG23 ' A' ' 27' ' ' VAL . 50.6 t30 -72.57 -45.23 60.2 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.118 178.752 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -59.77 -42.07 92.49 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.234 178.024 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 62.2 tp -55.76 -49.01 74.27 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.297 176.697 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' ALA . . . . . 0.508 ' HB2' HG13 ' A' ' 50' ' ' VAL . . . -58.91 -52.25 66.55 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.891 179.081 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.422 ' HA ' HD12 ' A' ' 30' ' ' ILE . 91.6 t -55.03 -43.32 69.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.321 -0.4 . . . . 0.0 111.188 -179.933 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 67.5 t80 -58.98 -47.32 85.6 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.957 0.408 . . . . 0.0 110.467 179.094 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.513 HG23 HD13 ' A' ' 92' ' ' LEU . 91.2 mt -61.89 -42.95 96.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.589 179.017 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.677 HG12 HG23 ' A' ' 54' ' ' ILE . 95.8 mt -58.23 -39.82 75.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 115.696 -0.683 . . . . 0.0 111.348 179.818 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 44.3 mtp-105 -74.55 -24.0 58.88 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.153 -178.558 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 85.0 m -88.99 -19.29 25.89 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.702 -177.926 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 13.9 p -106.6 -77.6 0.59 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.624 -177.801 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 95.36 163.33 34.43 Favored Glycine 0 N--CA 1.446 -0.635 0 C-N-CA 121.082 -0.58 . . . . 0.0 112.203 -178.467 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -66.09 143.08 70.48 Favored 'Trans proline' 0 C--O 1.233 0.26 0 C-N-CA 122.794 2.329 . . . . 0.0 112.64 -179.79 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 109.57 -32.62 6.64 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.894 177.091 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 11.3 t -98.02 -170.97 2.06 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 110.005 -0.368 . . . . 0.0 110.005 -176.467 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 38' ' ' ARG . . . . . 0.834 ' HG2' ' HB3' ' A' ' 61' ' ' ASP . 45.0 mtt180 -124.28 136.66 54.29 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.004 0.431 . . . . 0.0 111.673 -176.533 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.441 HG23 HG21 ' A' ' 60' ' ' VAL . 63.4 t -121.44 125.34 73.49 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-N 115.528 -0.76 . . . . 0.0 109.318 175.852 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 47.2 t -103.72 128.27 57.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-O 120.811 0.339 . . . . 0.0 111.406 -175.193 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 41' ' ' GLU . . . . . 0.493 ' HB3' HD23 ' A' ' 64' ' ' LEU . 34.3 tt0 -105.13 118.54 36.8 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 173.972 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.502 ' HA ' ' OG1' ' A' ' 65' ' ' THR . 58.5 t -95.54 121.05 45.73 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.362 -179.864 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 96.61 43.24 3.2 Favored Glycine 0 N--CA 1.446 -0.671 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.103 -179.817 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -77.01 82.77 3.53 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.351 0.596 . . . . 0.0 110.519 -178.292 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -69.64 -98.37 0.05 OUTLIER Glycine 0 N--CA 1.447 -0.593 0 CA-C-N 115.01 -0.995 . . . . 0.0 112.903 179.889 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 46' ' ' ARG . . . . . 0.534 ' HD2' ' O ' ' A' ' 46' ' ' ARG . 8.2 tmm_? -136.82 -7.19 1.88 Allowed 'General case' 0 C--N 1.327 -0.4 0 C-N-CA 120.904 -0.318 . . . . 0.0 111.27 -177.199 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.411 ' CZ ' ' HB ' ' A' ' 96' ' ' ILE . 9.0 p90 -61.98 -63.01 1.39 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.808 0.337 . . . . 0.0 111.011 179.688 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.417 HD22 HD13 ' A' ' 64' ' ' LEU . 59.7 mt 55.85 22.23 5.45 Favored 'General case' 0 C--N 1.323 -0.552 0 C-N-CA 123.684 0.794 . . . . 0.0 112.59 173.81 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 86.4 t80 -74.97 -56.85 4.33 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.781 0.324 . . . . 0.0 110.984 -178.075 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.508 HG13 ' HB2' ' A' ' 26' ' ' ALA . 52.5 t -63.49 -52.78 53.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.074 -175.816 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 51' ' ' SER . . . . . 0.556 ' CB ' HD21 ' A' ' 64' ' ' LEU . 0.2 OUTLIER -59.47 -46.88 87.52 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.695 -0.684 . . . . 0.0 112.491 -176.587 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 35.6 t70 -68.07 -27.2 66.29 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.729 0.3 . . . . 0.0 110.948 -177.689 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 89.3 t80 -73.81 -45.62 50.29 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 120.699 0.285 . . . . 0.0 110.798 176.916 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.677 HG23 HG12 ' A' ' 30' ' ' ILE . 78.3 mt -59.92 -43.24 91.78 Favored 'Isoleucine or valine' 0 C--O 1.234 0.253 0 CA-C-N 116.403 -0.362 . . . . 0.0 111.307 -178.079 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 2.0 ptm180 -67.83 -16.73 64.24 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.479 -178.84 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 67.2 mttm -88.05 -42.85 12.12 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.116 0.484 . . . . 0.0 110.454 177.002 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.9 OUTLIER -65.53 -41.68 92.83 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.633 -0.712 . . . . 0.0 110.932 -177.559 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 74.1 m -132.41 153.51 50.75 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.348 -179.507 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -76.71 38.84 0.2 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.908 177.846 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.441 HG21 HG23 ' A' ' 39' ' ' VAL . 7.2 p -84.03 138.76 18.66 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 CA-C-N 116.047 -0.524 . . . . 0.0 109.624 179.13 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 61' ' ' ASP . . . . . 0.834 ' HB3' ' HG2' ' A' ' 38' ' ' ARG . 13.9 t70 -84.86 93.76 8.59 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 -178.232 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 4.2 tt -90.38 127.8 36.29 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.005 -175.424 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 59.4 t -106.36 121.91 59.5 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 115.773 -0.649 . . . . 0.0 111.016 -176.674 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 64' ' ' LEU . . . . . 0.556 HD21 ' CB ' ' A' ' 51' ' ' SER . 90.5 mt -98.93 141.33 31.83 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.05 -0.523 . . . . 0.0 109.816 176.65 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.502 ' OG1' ' HA ' ' A' ' 42' ' ' VAL . 28.8 p -121.28 127.18 51.11 Favored 'General case' 0 C--O 1.238 0.487 0 CA-C-O 120.608 0.242 . . . . 0.0 111.627 -178.738 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 32.0 t70 -166.27 139.01 3.93 Favored 'General case' 0 N--CA 1.463 0.218 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.364 178.117 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 58.6 mt -75.97 112.04 13.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 N-CA-C 110.249 -0.278 . . . . 0.0 110.249 -179.511 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 47.1 mtmt 56.47 75.04 0.61 Allowed Pre-proline 0 C--N 1.33 -0.249 0 O-C-N 123.598 0.561 . . . . 0.0 109.839 -178.179 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 69' ' ' PRO . . . . . 0.574 ' CB ' ' HB ' ' A' ' 74' ' ' ILE . 8.1 Cg_exo -71.99 148.73 51.67 Favored 'Trans proline' 0 N--CA 1.465 -0.178 0 C-N-CA 123.249 2.633 . . . . 0.0 112.815 -171.195 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 23.8 p -82.88 -32.98 27.1 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.903 -179.477 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 27.7 t60 -74.62 -37.72 62.73 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.16 -177.904 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 94.85 -35.78 4.08 Favored Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 120.542 -0.837 . . . . 0.0 111.978 -177.881 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -79.8 21.34 4.76 Favored Glycine 0 C--N 1.332 0.311 0 C-N-CA 120.995 -0.622 . . . . 0.0 111.988 177.455 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.574 ' HB ' ' CB ' ' A' ' 69' ' ' PRO . 67.7 mt -117.3 147.93 20.38 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 179.652 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.541 HG12 ' H ' ' A' ' 77' ' ' ASP . 91.1 t -73.91 122.56 27.3 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 120.865 0.364 . . . . 0.0 110.24 178.858 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -78.34 16.55 0.77 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.696 -0.684 . . . . 0.0 112.645 -175.232 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 77' ' ' ASP . . . . . 0.541 ' H ' HG12 ' A' ' 75' ' ' VAL . 2.6 m-20 -76.14 155.44 34.63 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 121.496 0.665 . . . . 0.0 111.887 -175.478 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 16.9 t0 -78.88 143.78 35.57 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 114.88 -1.054 . . . . 0.0 111.276 -174.237 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 7.6 tp -96.59 -26.59 4.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.375 -177.206 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 5.0 t -78.22 -25.66 47.09 Favored 'General case' 0 C--O 1.234 0.247 0 N-CA-C 109.376 -0.602 . . . . 0.0 109.376 179.759 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 1.2 m -124.38 76.03 61.74 Favored Pre-proline 0 C--N 1.329 -0.3 0 N-CA-C 108.45 -0.944 . . . . 0.0 108.45 169.027 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -79.07 131.55 9.96 Favored 'Trans proline' 0 N--CA 1.461 -0.405 0 C-N-CA 122.671 2.247 . . . . 0.0 113.453 -170.887 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 83' ' ' ARG . . . . . 0.707 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 64.5 mtt180 -70.57 109.5 4.89 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.651 -0.704 . . . . 0.0 110.016 174.303 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 84' ' ' MET . . . . . 0.718 ' HA ' ' HD2' ' A' ' 87' ' ' TYR . 31.5 mtp -73.31 -10.23 59.53 Favored 'General case' 0 C--N 1.323 -0.572 0 C-N-CA 120.816 -0.354 . . . . 0.0 110.58 178.66 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.707 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 10.5 pt-20 -66.94 -21.98 65.96 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.542 173.908 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 71.9 mt -81.8 -34.59 12.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-O 121.351 0.596 . . . . 0.0 110.042 178.145 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 87' ' ' TYR . . . . . 0.718 ' HD2' ' HA ' ' A' ' 84' ' ' MET . 85.3 m-85 -82.39 -33.9 28.54 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.585 -0.734 . . . . 0.0 110.687 -178.487 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 50.6 mtp180 -64.07 122.46 16.61 Favored 'General case' 0 CA--C 1.516 -0.345 0 CA-C-O 121.227 0.536 . . . . 0.0 111.01 177.626 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 104.06 -12.28 52.37 Favored Glycine 0 N--CA 1.444 -0.767 0 CA-C-N 115.299 -0.864 . . . . 0.0 111.921 -178.976 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -78.79 142.5 36.91 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 110.015 -0.365 . . . . 0.0 110.015 177.767 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -90.71 -19.9 23.04 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-O 121.127 0.489 . . . . 0.0 110.453 -179.415 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 92' ' ' LEU . . . . . 0.602 ' HG ' ' HB3' ' A' ' 116' ' ' ARG . 3.4 tt -153.92 139.78 18.14 Favored 'General case' 0 N--CA 1.447 -0.596 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.929 -176.943 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.574 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 70.0 mt -131.33 124.64 55.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 177.791 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 13.9 p90 -134.72 164.9 26.48 Favored 'General case' 0 C--N 1.321 -0.661 0 C-N-CA 120.717 -0.393 . . . . 0.0 111.08 -178.809 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 6.9 p -140.58 131.14 25.46 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.523 -178.884 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 96' ' ' ILE . . . . . 0.411 ' HB ' ' CZ ' ' A' ' 47' ' ' PHE . 38.5 mm -92.03 98.31 8.23 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.098 179.262 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 63.0 mtm180 59.3 76.46 0.44 Allowed Pre-proline 0 C--N 1.332 -0.182 0 CA-C-N 115.401 -0.818 . . . . 0.0 111.54 -179.242 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 98' ' ' PRO . . . . . 0.475 ' HA ' ' HD3' ' A' ' 99' ' ' PRO . 93.4 Cg_endo -87.97 152.61 7.13 Favored 'Trans proline' 0 N--CA 1.455 -0.747 0 C-N-CA 122.593 2.195 . . . . 0.0 112.1 177.294 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.657 ' HB2' ' HG2' ' A' ' 101' ' ' GLU . 6.3 Cg_exo -73.07 148.71 45.24 Favored 'Trans proline' 0 N--CA 1.461 -0.405 0 C-N-CA 122.524 2.149 . . . . 0.0 111.461 176.019 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -76.45 39.75 0.21 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.173 0.511 . . . . 0.0 111.735 -177.475 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 101' ' ' GLU . . . . . 0.657 ' HG2' ' HB2' ' A' ' 99' ' ' PRO . 11.6 pt-20 -121.51 -28.74 4.54 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.205 177.615 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.615 HG23 ' HG3' ' A' ' 101' ' ' GLU . 34.8 pt -110.67 5.28 8.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.359 -175.976 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 103' ' ' HIS . . . . . 0.796 ' HD2' ' HB ' ' A' ' 129' ' ' THR . 9.6 p-80 -60.99 -48.17 83.07 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 115.62 -0.718 . . . . 0.0 111.392 -177.043 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 47.1 m -70.97 -23.07 62.14 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.177 0.513 . . . . 0.0 110.658 178.689 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.567 ' O ' ' HG2' ' A' ' 108' ' ' ARG . 8.7 m -73.96 -37.92 64.37 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.242 178.542 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.419 ' HG ' ' O ' ' A' ' 102' ' ' ILE . 94.0 mt -63.61 -41.08 98.34 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.722 178.014 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 107' ' ' MET . . . . . . . . . . . . . 97.7 mmm -57.33 -47.02 82.66 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.759 -0.655 . . . . 0.0 111.316 -179.281 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 108' ' ' ARG . . . . . 0.567 ' HG2' ' O ' ' A' ' 105' ' ' SER . 6.6 ptp180 -67.6 -31.48 71.55 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.505 -0.316 . . . . 0.0 111.178 -176.941 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.464 HG23 ' O ' ' A' ' 105' ' ' SER . 92.1 t -74.29 -46.0 45.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.486 -0.325 . . . . 0.0 110.659 -178.862 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -58.3 -49.99 75.2 Favored 'General case' 0 CA--C 1.516 -0.347 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 176.946 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.418 ' HA ' ' HB1' ' A' ' 148' ' ' ALA . 15.3 t70 -55.16 -40.83 71.08 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.093 -0.958 . . . . 0.0 111.028 179.565 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -68.5 -44.94 73.62 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.918 -0.583 . . . . 0.0 112.196 -176.995 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 31.1 m -84.83 -27.63 6.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 C-N-CA 120.766 -0.374 . . . . 0.0 111.759 -175.29 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 98.04 22.53 15.15 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.631 -0.795 . . . . 0.0 112.654 177.578 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -99.09 163.46 12.56 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 121.505 0.669 . . . . 0.0 111.844 -176.483 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 116' ' ' ARG . . . . . 0.602 ' HB3' ' HG ' ' A' ' 92' ' ' LEU . 23.2 ttt180 -85.08 116.23 23.34 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 115.181 -0.918 . . . . 0.0 109.591 178.181 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 117' ' ' LEU . . . . . 0.574 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 52.2 tp -90.13 128.01 36.23 Favored 'General case' 0 C--N 1.32 -0.693 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 -178.261 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 72.2 mt -129.02 119.72 50.0 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 CA-C-O 121.178 0.513 . . . . 0.0 110.891 179.683 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 64.6 mt -119.75 125.1 73.98 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.437 179.88 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 8.9 tmtm? -108.48 98.23 26.94 Favored Pre-proline 0 C--N 1.325 -0.474 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 175.22 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -77.52 -174.26 2.14 Favored 'Trans proline' 0 C--O 1.236 0.386 0 C-N-CA 122.796 2.33 . . . . 0.0 112.944 -179.507 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 122' ' ' LEU . . . . . 0.429 ' HB2' ' HB3' ' A' ' 125' ' ' GLU . 91.7 mt -75.59 176.04 8.0 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.753 -0.658 . . . . 0.0 111.463 -175.967 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 4.1 p -74.86 102.83 4.87 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.725 -0.671 . . . . 0.0 111.002 179.317 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 82.11 30.23 35.21 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.156 179.547 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 125' ' ' GLU . . . . . 0.429 ' HB3' ' HB2' ' A' ' 122' ' ' LEU . 8.8 tp10 -133.26 136.78 45.75 Favored 'General case' 0 N--CA 1.448 -0.574 0 N-CA-C 109.143 -0.688 . . . . 0.0 109.143 178.049 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -107.25 166.99 10.23 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.043 -173.481 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 45.2 mt -77.66 -21.18 13.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 115.958 -0.564 . . . . 0.0 109.998 179.642 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 28.4 m 45.86 40.19 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.604 0 C-N-CA 124.263 1.025 . . . . 0.0 112.828 176.317 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 129' ' ' THR . . . . . 0.796 ' HB ' ' HD2' ' A' ' 103' ' ' HIS . 11.9 t -95.98 169.67 9.81 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.381 -179.877 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 46.5 mt-10 -90.5 -11.28 40.71 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.111 0.481 . . . . 0.0 109.931 176.329 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 131' ' ' ARG . . . . . . . . . . . . . 19.9 mmt180 -83.02 166.84 18.45 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.434 -0.803 . . . . 0.0 109.99 -179.244 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 3.9 mppt? -106.3 130.76 54.08 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.279 0.562 . . . . 0.0 111.84 -175.497 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 133' ' ' MET . . . . . . . . . . . . . 85.0 mtp -137.77 160.63 38.73 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 115.056 -0.975 . . . . 0.0 108.971 174.405 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 134' ' ' LYS . . . . . 0.691 ' HG3' ' HG2' ' A' ' 145' ' ' GLU . 1.4 ptmt -111.93 133.07 54.36 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-O 121.039 0.447 . . . . 0.0 110.866 -178.123 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 135' ' ' LEU . . . . . 0.629 HD11 ' HD2' ' A' ' 142' ' ' TYR . 51.9 tp -81.67 121.4 26.32 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.067 179.244 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -116.21 141.95 31.7 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.65 -178.014 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 5.2 m-20 -115.33 111.35 20.74 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.737 -0.665 . . . . 0.0 109.351 176.226 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 138' ' ' TYR . . . . . 0.614 ' O ' HG22 ' A' ' 141' ' ' THR . 57.0 t80 -124.85 104.68 8.74 Favored 'General case' 0 C--N 1.319 -0.734 0 N-CA-C 109.49 -0.559 . . . . 0.0 109.49 -178.761 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 139' ' ' GLY . . . . . 0.4 ' O ' ' HB2' ' A' ' 140' ' ' ARG . . . 68.27 40.96 87.24 Favored Glycine 0 CA--C 1.519 0.299 0 C-N-CA 120.55 -0.833 . . . . 0.0 111.609 -175.575 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 140' ' ' ARG . . . . . 0.4 ' HB2' ' O ' ' A' ' 139' ' ' GLY . 0.0 OUTLIER 75.83 -25.89 0.2 Allowed 'General case' 0 N--CA 1.472 0.63 0 C-N-CA 123.681 0.792 . . . . 0.0 113.073 178.464 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 141' ' ' THR . . . . . 0.614 HG22 ' O ' ' A' ' 138' ' ' TYR . 13.9 t -75.26 142.68 43.31 Favored 'General case' 0 C--O 1.236 0.38 0 N-CA-C 109.338 -0.616 . . . . 0.0 109.338 177.262 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 142' ' ' TYR . . . . . 0.629 ' HD2' HD11 ' A' ' 135' ' ' LEU . 26.4 p90 -121.41 141.55 50.87 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 121.394 0.616 . . . . 0.0 111.229 -176.452 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 25.1 p90 -154.32 170.21 21.86 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 114.975 -1.011 . . . . 0.0 109.515 -179.968 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 75.5 m-85 -107.5 126.4 52.47 Favored 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 110.227 -0.286 . . . . 0.0 110.227 179.474 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 145' ' ' GLU . . . . . 0.691 ' HG2' ' HG3' ' A' ' 134' ' ' LYS . 10.0 pt-20 -115.41 164.12 14.74 Favored 'General case' 0 C--N 1.32 -0.677 0 N-CA-C 109.685 -0.487 . . . . 0.0 109.685 177.594 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 146' ' ' TYR . . . . . 0.563 ' HB3' ' HB3' ' A' ' 117' ' ' LEU . 50.8 t80 -147.03 127.74 14.28 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.352 177.382 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 147' ' ' ILE . . . . . 0.42 ' N ' HD12 ' A' ' 147' ' ' ILE . 3.1 mp -96.73 104.92 16.43 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.706 0 CA-C-N 115.779 -0.646 . . . . 0.0 109.366 179.506 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 148' ' ' ALA . . . . . 0.418 ' HB1' ' HA ' ' A' ' 111' ' ' ASP . . . -70.25 117.44 11.81 Favored 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 175.974 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 30.3 mt-10 -73.4 133.69 43.83 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 121.702 0.763 . . . . 0.0 111.795 -176.743 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 25.8 t -106.05 132.87 52.04 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.07 0 CA-C-N 114.442 -1.254 . . . . 0.0 108.75 176.166 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 151' ' ' ARG . . . . . . . . . . . . . 33.1 ptt180 -64.72 127.94 33.66 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 121.14 0.495 . . . . 0.0 110.37 -178.806 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 8.2 t -83.82 144.73 29.08 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.682 -0.69 . . . . 0.0 109.752 -178.604 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 23.4 mtm180 . . . . . 0 C--O 1.247 0.97 0 CA-C-O 118.365 -0.826 . . . . 0.0 110.461 -179.9 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 4.0 mpp? . . . . . 0 N--CA 1.481 1.094 0 N-CA-C 110.214 -0.291 . . . . 0.0 110.214 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -117.79 143.18 17.67 Favored Glycine 0 N--CA 1.447 -0.604 0 C-N-CA 120.886 -0.673 . . . . 0.0 112.159 179.819 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 36.9 t -97.53 -48.26 5.34 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.873 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 41.5 m -124.6 111.35 15.54 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.552 179.864 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 96.4 m-70 -94.22 94.55 8.4 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.001 0.429 . . . . 0.0 110.046 176.228 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 33.8 p-80 -101.0 168.87 9.33 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.958 -0.564 . . . . 0.0 111.218 -177.31 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 12.3 m-70 -112.14 -178.39 3.41 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.744 -0.662 . . . . 0.0 109.563 175.742 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 54.6 m80 -96.92 13.87 27.35 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 121.179 0.514 . . . . 0.0 109.955 177.152 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 29.1 m80 -115.07 150.57 35.73 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.373 -175.683 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 57.7 m80 -94.06 -28.46 15.72 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 177.67 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 13.7 p -162.98 171.55 16.36 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.088 -0.96 . . . . 0.0 109.674 178.005 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 16.4 m -63.33 109.22 1.51 Allowed 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 120.905 0.384 . . . . 0.0 110.51 178.834 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -87.43 141.45 17.4 Favored Glycine 0 N--CA 1.445 -0.743 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.444 -178.405 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 93.7 mt -96.26 -159.95 0.76 Allowed 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 109.573 -0.529 . . . . 0.0 109.573 176.078 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 15.0 m -61.14 128.61 89.69 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 120.898 0.38 . . . . 0.0 110.479 176.931 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -77.44 -176.14 3.05 Favored 'Trans proline' 0 N--CA 1.462 -0.35 0 C-N-CA 122.678 2.252 . . . . 0.0 112.25 -177.886 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' ARG . . . . . 0.467 ' O ' ' HD2' ' A' ' 17' ' ' ARG . 0.6 OUTLIER -120.18 136.57 54.58 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 121.055 0.455 . . . . 0.0 110.756 177.13 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 105.83 -42.15 1.98 Allowed Glycine 0 N--CA 1.449 -0.458 0 C-N-CA 121.017 -0.611 . . . . 0.0 112.564 -176.88 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 54.4 m -82.12 7.35 13.69 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 112.394 0.516 . . . . 0.0 112.394 -175.945 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' HIS . . . . . 0.427 ' HA ' ' OD1' ' A' ' 23' ' ' ASN . 31.7 m-70 -65.08 -16.91 63.99 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.706 0.288 . . . . 0.0 111.253 179.424 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 21' ' ' MET . . . . . . . . . . . . . 24.8 ptp -64.84 -17.48 64.29 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.174 177.679 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' TRP . . . . . 0.572 ' HB3' HG22 ' A' ' 50' ' ' VAL . 98.2 m95 -94.7 -22.31 18.2 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.675 179.854 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 23' ' ' ASN . . . . . 0.427 ' OD1' ' HA ' ' A' ' 20' ' ' HIS . 13.9 m120 -66.01 -41.0 91.58 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.987 -179.638 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 26.2 m-20 -59.17 -46.78 87.49 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.049 178.905 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 66.6 tp -59.6 -47.86 83.94 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.402 -0.817 . . . . 0.0 110.672 178.721 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' ALA . . . . . 0.411 ' O ' HG13 ' A' ' 30' ' ' ILE . . . -54.71 -51.98 63.87 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.474 -179.399 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.463 ' HA ' HD12 ' A' ' 30' ' ' ILE . 88.4 t -56.02 -43.11 74.29 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-O 120.9 0.381 . . . . 0.0 111.136 -179.717 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 83.5 t80 -59.17 -45.56 90.69 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.576 179.222 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.443 HD13 ' CD1' ' A' ' 94' ' ' TYR . 79.8 mt -65.36 -42.59 93.99 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.626 179.192 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.638 HG12 HG23 ' A' ' 54' ' ' ILE . 96.2 mt -56.62 -45.38 82.46 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-N 115.593 -0.73 . . . . 0.0 111.001 178.654 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 83.7 mtp180 -64.98 -28.27 69.4 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.629 -178.106 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 44.2 t -86.93 -24.53 24.75 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.669 0.271 . . . . 0.0 111.298 -177.316 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 11.3 p -98.48 -77.11 0.52 Allowed 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 120.745 0.307 . . . . 0.0 111.421 -176.774 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 90.57 172.22 44.1 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.943 -0.646 . . . . 0.0 112.307 -178.493 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 63.0 Cg_endo -74.29 153.68 45.71 Favored 'Trans proline' 0 C--O 1.235 0.33 0 C-N-CA 122.571 2.18 . . . . 0.0 112.121 179.391 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 82.35 30.05 34.9 Favored Glycine 0 CA--C 1.518 0.238 0 C-N-CA 120.675 -0.774 . . . . 0.0 113.073 177.772 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 14.2 t -150.07 -176.53 5.49 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 176.199 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 38' ' ' ARG . . . . . 0.544 ' HB2' ' HA ' ' A' ' 90' ' ' ALA . 17.4 mtp180 -117.34 135.56 53.77 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 120.856 0.36 . . . . 0.0 111.389 -176.697 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.442 HG12 ' OE1' ' A' ' 41' ' ' GLU . 16.7 t -123.98 125.03 70.28 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 172.843 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 47.1 t -109.71 117.59 54.94 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 121.191 0.52 . . . . 0.0 110.59 -177.887 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 41' ' ' GLU . . . . . 0.535 ' HB2' HD23 ' A' ' 64' ' ' LEU . 0.1 OUTLIER -90.98 120.32 31.88 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.309 -0.86 . . . . 0.0 110.29 -175.927 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.641 HG11 HD21 ' A' ' 106' ' ' LEU . 59.4 t -94.33 110.26 23.38 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.701 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 175.992 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 98.91 97.78 2.1 Favored Glycine 0 N--CA 1.446 -0.696 0 N-CA-C 110.988 -0.845 . . . . 0.0 110.988 -175.353 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -111.53 -53.24 2.72 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.652 0.263 . . . . 0.0 110.913 -176.256 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 48.53 -121.14 7.35 Favored Glycine 0 N--CA 1.449 -0.451 0 CA-C-N 115.788 -0.642 . . . . 0.0 112.311 -176.523 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 94.7 mtt180 -118.1 3.23 12.07 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 120.903 0.382 . . . . 0.0 110.256 175.77 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 12.4 p90 -98.05 63.34 1.6 Allowed 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.621 0.724 . . . . 0.0 111.143 -175.891 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 55.2 mt -85.33 22.74 1.44 Allowed 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.694 -0.685 . . . . 0.0 110.869 -178.713 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 80.6 t80 -63.33 -41.43 98.89 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.332 -176.512 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.572 HG22 ' HB3' ' A' ' 22' ' ' TRP . 42.6 t -75.32 -50.48 24.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.659 -178.957 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 3.0 p -62.35 -45.78 91.65 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.556 -0.747 . . . . 0.0 112.306 -174.225 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.534 ' O ' ' HG2' ' A' ' 56' ' ' LYS . 35.5 t70 -70.07 -35.67 74.4 Favored 'General case' 0 C--N 1.33 -0.275 0 C-N-CA 120.655 -0.418 . . . . 0.0 110.646 -177.011 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 88.6 t80 -58.72 -40.48 83.88 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.944 0.402 . . . . 0.0 110.299 178.079 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.638 HG23 HG12 ' A' ' 30' ' ' ILE . 79.6 mt -65.62 -49.23 79.1 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.338 -179.921 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 55' ' ' ARG . . . . . 0.453 ' HG2' ' O ' ' A' ' 52' ' ' ASP . 5.7 ptm180 -69.29 -19.98 63.9 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-N 116.476 -0.329 . . . . 0.0 111.598 -176.55 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 56' ' ' LYS . . . . . 0.534 ' HG2' ' O ' ' A' ' 52' ' ' ASP . 4.6 mmmp? -82.09 -35.61 28.44 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.713 0.292 . . . . 0.0 111.192 177.697 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 7.9 t-80 -84.55 -41.24 16.67 Favored 'General case' 0 N--CA 1.446 -0.674 0 CA-C-O 121.037 0.446 . . . . 0.0 109.966 -177.595 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 74.6 m -122.9 133.44 54.4 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.355 176.519 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -78.17 63.94 3.22 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 121.862 0.839 . . . . 0.0 110.086 179.47 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.411 HG21 HG23 ' A' ' 39' ' ' VAL . 7.1 p -94.85 149.57 4.42 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.883 0 CA-C-N 114.489 -1.232 . . . . 0.0 109.873 175.913 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 52.3 t0 -74.77 96.05 3.0 Favored 'General case' 0 C--O 1.234 0.268 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 178.093 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 62' ' ' LEU . . . . . 0.488 HD21 ' OE2' ' A' ' 41' ' ' GLU . 1.1 tm? -93.14 126.01 38.03 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 115.233 -0.894 . . . . 0.0 110.262 -173.379 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 41.7 t -125.85 119.61 55.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.043 -177.13 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 64' ' ' LEU . . . . . 0.535 HD23 ' HB2' ' A' ' 41' ' ' GLU . 12.7 mt -96.48 148.99 22.24 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 116.175 -0.466 . . . . 0.0 109.97 178.601 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.525 HG22 ' HB ' ' A' ' 75' ' ' VAL . 15.3 p -134.48 127.8 32.16 Favored 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 110.566 -0.161 . . . . 0.0 110.566 176.827 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 3.4 t70 -163.4 175.61 10.63 Favored 'General case' 0 N--CA 1.464 0.236 0 N-CA-C 110.062 -0.347 . . . . 0.0 110.062 -178.619 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 48.9 mm -88.5 107.84 18.12 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 116.652 -0.249 . . . . 0.0 110.398 -178.62 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 55.0 mtmt 60.11 90.0 0.1 OUTLIER Pre-proline 0 N--CA 1.466 0.329 0 O-C-N 123.674 0.608 . . . . 0.0 111.118 -177.987 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 69' ' ' PRO . . . . . 0.992 ' HB3' ' HB ' ' A' ' 74' ' ' ILE . 32.9 Cg_endo -66.25 141.6 63.39 Favored 'Trans proline' 0 C--O 1.233 0.268 0 C-N-CA 123.127 2.551 . . . . 0.0 113.177 -177.462 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 14.8 m -95.09 -14.78 23.93 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.693 -0.685 . . . . 0.0 110.444 175.923 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 89.7 m-70 -124.33 150.52 45.38 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.354 -179.211 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -77.42 57.59 3.73 Favored Glycine 0 CA--C 1.52 0.348 0 C-N-CA 121.421 -0.418 . . . . 0.0 112.924 179.925 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -157.85 8.12 0.2 Allowed Glycine 0 N--CA 1.449 -0.474 0 N-CA-C 111.397 -0.681 . . . . 0.0 111.397 177.373 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.992 ' HB ' ' HB3' ' A' ' 69' ' ' PRO . 40.3 mt -117.44 134.44 61.02 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 -177.78 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.617 HG11 HD13 ' A' ' 86' ' ' ILE . 55.8 t -78.12 131.17 35.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 176.959 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 76' ' ' ARG . . . . . 0.423 ' HA ' ' HD3' ' A' ' 69' ' ' PRO . 36.2 ptt180 -82.88 29.49 0.46 Allowed 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.762 -0.654 . . . . 0.0 111.939 -175.902 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 31.9 t0 -84.02 160.42 21.0 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 110.024 -0.362 . . . . 0.0 110.024 -178.944 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -79.61 104.02 9.92 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-O 120.849 0.357 . . . . 0.0 110.268 -177.646 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 79' ' ' ILE . . . . . 0.549 HD11 ' CG1' ' A' ' 42' ' ' VAL . 12.8 tt -57.67 -23.33 19.98 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.501 0 CA-C-N 115.692 -0.685 . . . . 0.0 112.478 -176.379 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 5.1 t -87.9 -6.56 58.01 Favored 'General case' 0 CA--C 1.539 0.534 0 CA-C-O 121.141 0.496 . . . . 0.0 110.869 -178.1 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 32.9 t -154.63 60.09 2.64 Favored Pre-proline 0 C--N 1.328 -0.336 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 178.177 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.794 ' HB2' ' HE2' ' A' ' 87' ' ' TYR . 84.3 Cg_endo -79.24 155.34 25.4 Favored 'Trans proline' 0 N--CA 1.461 -0.405 0 C-N-CA 122.676 2.251 . . . . 0.0 113.784 -166.01 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 83' ' ' ARG . . . . . 0.858 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 94.1 mtt180 -76.28 132.99 40.17 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.11 -0.95 . . . . 0.0 110.995 177.929 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 84' ' ' MET . . . . . . . . . . . . . 87.5 mmm -70.77 -22.42 62.39 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.119 176.812 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.858 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 10.3 pt-20 -66.0 -13.93 60.74 Favored 'General case' 0 CA--C 1.532 0.282 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.823 179.865 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.617 HD13 HG11 ' A' ' 75' ' ' VAL . 66.7 mt -93.25 -40.02 11.51 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-O 121.06 0.457 . . . . 0.0 110.846 -179.346 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 87' ' ' TYR . . . . . 0.794 ' HE2' ' HB2' ' A' ' 82' ' ' PRO . 99.0 m-85 -80.04 -28.76 39.25 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.322 -176.872 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 30.5 mtt-85 -61.7 120.75 11.24 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 121.045 0.45 . . . . 0.0 111.222 179.598 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 109.39 -2.44 31.0 Favored Glycine 0 N--CA 1.446 -0.637 0 CA-C-N 115.607 -0.724 . . . . 0.0 111.872 -177.896 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 90' ' ' ALA . . . . . 0.544 ' HA ' ' HB2' ' A' ' 38' ' ' ARG . . . -90.5 143.16 27.02 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.738 0.304 . . . . 0.0 110.594 178.162 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -88.52 -28.02 21.06 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.624 -179.505 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 92' ' ' LEU . . . . . 0.529 ' HG ' ' HB3' ' A' ' 116' ' ' ARG . 6.8 tt -149.5 143.14 25.45 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.052 -177.019 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.578 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 68.0 mt -133.36 119.42 35.02 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 N-CA-C 109.432 -0.581 . . . . 0.0 109.432 178.36 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 94' ' ' TYR . . . . . 0.443 ' CD1' HD13 ' A' ' 29' ' ' ILE . 47.7 p90 -124.58 158.59 32.65 Favored 'General case' 0 C--N 1.321 -0.664 0 C-N-CA 120.219 -0.593 . . . . 0.0 110.823 177.976 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 14.2 m -126.62 125.98 42.83 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.795 -0.638 . . . . 0.0 110.715 -176.847 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 54.2 mt -94.52 97.13 6.55 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.089 -179.672 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 97' ' ' ARG . . . . . 0.434 HH11 ' HD3' ' A' ' 97' ' ' ARG . 7.7 ttm180 59.91 73.46 0.65 Allowed Pre-proline 0 CA--C 1.533 0.295 0 CA-C-N 115.494 -0.776 . . . . 0.0 110.87 -179.028 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_endo -85.64 137.71 5.87 Favored 'Trans proline' 0 N--CA 1.458 -0.57 0 C-N-CA 122.529 2.153 . . . . 0.0 112.775 -179.302 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 32.8 Cg_endo -67.36 163.05 36.06 Favored 'Trans proline' 0 C--O 1.234 0.307 0 C-N-CA 122.685 2.256 . . . . 0.0 112.182 175.441 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -85.61 36.21 0.64 Allowed 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.959 -177.998 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 101' ' ' GLU . . . . . 0.463 ' HG3' HG23 ' A' ' 102' ' ' ILE . 11.7 pt-20 -117.63 -10.96 10.48 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 121.156 0.503 . . . . 0.0 110.47 175.482 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.581 ' O ' ' HG ' ' A' ' 106' ' ' LEU . 20.8 pt -129.49 9.11 2.48 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.96 -178.184 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 103' ' ' HIS . . . . . . . . . . . . . 8.8 p-80 -55.28 -56.39 20.62 Favored 'General case' 0 C--N 1.316 -0.851 0 CA-C-N 115.505 -0.771 . . . . 0.0 112.31 -174.969 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 31.5 t -76.23 -26.16 55.77 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 121.112 0.482 . . . . 0.0 109.999 179.128 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.556 ' O ' HG23 ' A' ' 109' ' ' VAL . 6.5 m -66.21 -42.73 88.33 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.204 -178.433 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.641 HD21 HG11 ' A' ' 42' ' ' VAL . 82.2 mt -61.32 -41.49 97.1 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.838 -0.619 . . . . 0.0 111.259 179.205 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 107' ' ' MET . . . . . 0.493 ' SD ' ' HB3' ' A' ' 131' ' ' ARG . 45.5 mtp -65.29 -42.01 93.55 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.229 -178.926 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 16.7 ptm180 -73.32 -22.94 60.21 Favored 'General case' 0 C--N 1.332 -0.183 0 C-N-CA 120.976 -0.29 . . . . 0.0 111.462 -178.907 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.556 HG23 ' O ' ' A' ' 105' ' ' SER . 73.2 t -76.15 -46.46 33.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 N-CA-C 110.235 -0.283 . . . . 0.0 110.235 175.573 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -57.18 -50.16 73.7 Favored 'General case' 0 CA--C 1.517 -0.324 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.022 176.46 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.45 ' HA ' ' HB1' ' A' ' 148' ' ' ALA . 16.3 t70 -59.54 -34.16 72.31 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.459 -0.791 . . . . 0.0 111.038 -178.565 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -70.73 -46.46 63.0 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.837 -178.708 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 33.6 m -84.67 -27.88 6.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 C-N-CA 121.0 -0.28 . . . . 0.0 111.624 -176.127 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 93.41 38.05 5.43 Favored Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 120.697 -0.764 . . . . 0.0 112.475 179.548 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -114.14 149.82 35.07 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.039 0.447 . . . . 0.0 111.093 -179.059 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 116' ' ' ARG . . . . . 0.529 ' HB3' ' HG ' ' A' ' 92' ' ' LEU . 19.8 ttt180 -71.38 116.17 11.39 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.725 -0.67 . . . . 0.0 109.803 179.321 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 117' ' ' LEU . . . . . 0.578 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 62.2 tp -88.53 120.43 29.9 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 116.034 -0.53 . . . . 0.0 109.968 -179.517 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 71.0 mt -121.52 114.94 44.99 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 CA-C-O 121.16 0.505 . . . . 0.0 110.363 179.233 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 51.0 mt -112.77 121.27 64.73 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.761 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.55 -179.379 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 120' ' ' LYS . . . . . 0.404 ' C ' ' HD3' ' A' ' 120' ' ' LYS . 1.6 tmtp? -109.99 95.33 20.51 Favored Pre-proline 0 C--N 1.322 -0.614 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 173.503 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 121' ' ' PRO . . . . . 0.428 ' HB2' ' HB3' ' A' ' 125' ' ' GLU . 88.7 Cg_endo -89.02 -161.95 0.12 Allowed 'Trans proline' 0 N--CA 1.454 -0.839 0 C-N-CA 122.998 2.465 . . . . 0.0 112.244 179.997 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 122' ' ' LEU . . . . . 0.882 ' HB2' ' HB2' ' A' ' 125' ' ' GLU . 10.3 mp -83.53 168.14 16.72 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.987 -0.552 . . . . 0.0 110.391 179.65 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 3.9 m -59.91 -32.05 70.39 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.546 -176.86 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -125.43 38.84 2.19 Favored Glycine 0 N--CA 1.452 -0.245 0 C-N-CA 120.711 -0.756 . . . . 0.0 111.844 177.756 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 125' ' ' GLU . . . . . 0.882 ' HB2' ' HB2' ' A' ' 122' ' ' LEU . 6.0 tp10 -110.5 118.01 35.11 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 120.696 0.284 . . . . 0.0 110.267 -176.104 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -84.69 167.77 15.87 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.137 0.494 . . . . 0.0 111.014 179.007 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.422 ' O ' ' HB ' ' A' ' 128' ' ' VAL . 85.7 mt -92.15 -26.47 4.91 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 CA-C-N 115.609 -0.723 . . . . 0.0 110.55 -178.407 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.422 ' HB ' ' O ' ' A' ' 127' ' ' ILE . 91.2 t 75.57 -40.1 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.471 0.582 0 C-N-CA 123.022 0.529 . . . . 0.0 110.562 178.912 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 15.3 m -56.25 -48.32 76.77 Favored 'General case' 0 N--CA 1.444 -0.748 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.277 171.282 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 19.7 mm-40 58.9 19.66 7.29 Favored 'General case' 0 CA--C 1.533 0.307 0 CA-C-N 115.068 -0.969 . . . . 0.0 111.67 178.145 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 131' ' ' ARG . . . . . 0.493 ' HB3' ' SD ' ' A' ' 107' ' ' MET . 52.3 ttt180 -76.21 161.86 28.44 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 109.349 -0.611 . . . . 0.0 109.349 177.388 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 132' ' ' LYS . . . . . 0.63 ' HD3' ' H ' ' A' ' 132' ' ' LYS . 0.0 OUTLIER -48.2 115.1 1.08 Allowed 'General case' 0 N--CA 1.465 0.313 0 CA-C-O 121.134 0.492 . . . . 0.0 112.024 -179.087 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 133' ' ' MET . . . . . 0.512 ' HG2' ' HB2' ' A' ' 146' ' ' TYR . 86.0 mtp -148.46 162.19 40.11 Favored 'General case' 0 C--N 1.314 -0.949 0 N-CA-C 107.994 -1.113 . . . . 0.0 107.994 173.272 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 134' ' ' LYS . . . . . 0.565 ' HG3' ' HG2' ' A' ' 145' ' ' GLU . 13.1 ptmm? -126.36 133.1 51.42 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-O 120.956 0.408 . . . . 0.0 111.21 -176.899 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 135' ' ' LEU . . . . . 0.775 HD11 ' HD2' ' A' ' 142' ' ' TYR . 55.6 tp -84.38 121.16 27.16 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.023 -179.662 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -116.77 149.98 18.87 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.598 -177.334 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 66.4 m-20 -116.29 125.82 52.7 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 177.584 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 34.4 t80 -138.27 130.79 29.18 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 109.565 -0.532 . . . . 0.0 109.565 176.239 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 72.03 -87.75 0.48 Allowed Glycine 0 N--CA 1.443 -0.837 0 N-CA-C 110.681 -0.967 . . . . 0.0 110.681 -174.428 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 140' ' ' ARG . . . . . 0.72 ' HA ' ' NE ' ' A' ' 140' ' ' ARG . 2.0 mmp_? -156.53 14.61 0.3 Allowed 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.423 -0.388 . . . . 0.0 110.75 174.346 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 11.2 t -113.98 154.95 26.75 Favored 'General case' 0 N--CA 1.448 -0.57 0 CA-C-N 116.33 -0.395 . . . . 0.0 109.948 179.035 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 142' ' ' TYR . . . . . 0.775 ' HD2' HD11 ' A' ' 135' ' ' LEU . 14.7 p90 -122.86 138.11 54.75 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 121.042 0.449 . . . . 0.0 110.36 -179.875 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 143' ' ' PHE . . . . . 0.423 ' O ' HD12 ' A' ' 135' ' ' LEU . 12.4 p90 -146.85 162.34 38.85 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-N 115.562 -0.745 . . . . 0.0 110.146 -177.238 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 96.3 m-85 -101.04 122.53 43.71 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 116.429 -0.351 . . . . 0.0 110.294 -179.447 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 145' ' ' GLU . . . . . 0.565 ' HG2' ' HG3' ' A' ' 134' ' ' LYS . 11.5 pt-20 -113.37 156.77 22.84 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 121.086 0.47 . . . . 0.0 110.036 177.522 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 146' ' ' TYR . . . . . 0.512 ' HB2' ' HG2' ' A' ' 133' ' ' MET . 41.7 t80 -141.91 124.47 15.83 Favored 'General case' 0 C--N 1.314 -0.969 0 CA-C-N 115.493 -0.776 . . . . 0.0 109.659 176.833 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 147' ' ' ILE . . . . . 0.409 ' N ' HD12 ' A' ' 147' ' ' ILE . 3.7 mp -93.0 101.37 12.55 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.88 0 N-CA-C 109.596 -0.52 . . . . 0.0 109.596 -177.63 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 148' ' ' ALA . . . . . 0.45 ' HB1' ' HA ' ' A' ' 111' ' ' ASP . . . -69.91 108.59 4.07 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 108.57 -0.9 . . . . 0.0 108.57 172.717 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 40.6 mt-10 -64.5 133.82 53.2 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 122.04 0.924 . . . . 0.0 112.424 -170.762 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 23.0 t -103.91 145.48 12.75 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.884 0 CA-C-N 113.888 -1.506 . . . . 0.0 109.614 179.666 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 151' ' ' ARG . . . . . . . . . . . . . 26.8 mmm180 -61.05 159.99 10.74 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 121.148 0.499 . . . . 0.0 110.898 176.729 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 1.1 p -73.2 141.2 47.34 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.553 -177.735 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.249 1.028 0 CA-C-O 118.507 -0.759 . . . . 0.0 109.426 177.067 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.479 0.983 0 CA-C-O 121.004 0.43 . . . . 0.0 110.185 . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -102.98 96.81 1.41 Allowed Glycine 0 N--CA 1.448 -0.564 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.527 -176.52 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 31.4 t -85.05 136.72 33.45 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 176.401 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 31.9 p -137.65 174.4 10.62 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.662 -0.245 . . . . 0.0 110.77 -177.209 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 66.6 m-70 -80.1 121.72 25.89 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 121.009 0.433 . . . . 0.0 110.577 -178.314 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 17.7 p80 -97.47 13.52 29.57 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-O 121.265 0.555 . . . . 0.0 110.509 179.591 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 66.4 m80 -75.68 104.4 6.21 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.617 -179.188 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 51.0 p-80 -83.81 149.77 26.2 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.456 -0.338 . . . . 0.0 110.325 177.946 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 36.8 m80 -97.54 89.81 4.81 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.432 -177.908 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 29.4 p-80 -62.04 -46.94 86.95 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.036 177.52 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 5.1 t 57.87 23.24 9.52 Favored 'General case' 0 CA--C 1.532 0.264 0 CA-C-N 115.749 -0.66 . . . . 0.0 111.249 174.47 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 5.2 p -94.01 109.4 21.14 Favored 'General case' 0 N--CA 1.448 -0.526 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.102 -177.638 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -76.53 127.39 8.63 Favored Glycine 0 N--CA 1.445 -0.732 0 C-N-CA 120.696 -0.764 . . . . 0.0 111.358 175.396 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' LEU . . . . . 0.47 HD12 ' HE2' ' A' ' 56' ' ' LYS . 88.3 mt -67.07 140.44 57.62 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.739 0.304 . . . . 0.0 110.698 -178.484 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.453 ' HA ' ' HD3' ' A' ' 16' ' ' PRO . 33.2 m -58.85 149.04 66.78 Favored Pre-proline 0 C--N 1.326 -0.456 0 CA-C-N 115.368 -0.833 . . . . 0.0 112.816 -172.855 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.453 ' HD3' ' HA ' ' A' ' 15' ' ' VAL . 3.7 Cg_exo -77.62 128.18 9.29 Favored 'Trans proline' 0 N--CA 1.457 -0.666 0 C-N-CA 123.036 2.491 . . . . 0.0 110.504 169.65 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 17' ' ' ARG . . . . . 0.652 ' HD3' ' O ' ' A' ' 17' ' ' ARG . 0.0 OUTLIER -100.13 102.68 14.06 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-O 121.17 0.51 . . . . 0.0 111.547 -172.696 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 67.32 5.25 34.31 Favored Glycine 0 CA--C 1.518 0.273 0 CA-C-N 115.787 -0.642 . . . . 0.0 113.085 176.252 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' SER . . . . . 0.535 ' O ' ' HB2' ' A' ' 23' ' ' ASN . 19.5 p -97.41 101.15 12.62 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-O 120.816 0.341 . . . . 0.0 110.583 -178.35 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 30.4 m80 -111.92 -63.64 1.39 Allowed 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 177.467 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' MET . . . . . . . . . . . . . 15.6 tmm? -73.52 -36.36 65.71 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.836 -0.62 . . . . 0.0 109.784 175.247 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 95.4 m95 -72.08 -19.39 61.82 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.899 -0.591 . . . . 0.0 110.677 177.164 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' ASN . . . . . 0.535 ' HB2' ' O ' ' A' ' 19' ' ' SER . 66.9 t30 -68.26 -37.74 81.06 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.205 -179.555 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.427 ' HB3' ' HD2' ' A' ' 138' ' ' TYR . 44.0 m-20 -61.61 -43.28 99.16 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.279 -0.418 . . . . 0.0 110.389 179.392 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.51 HD22 ' HD3' ' A' ' 120' ' ' LYS . 61.9 tp -58.16 -50.07 74.78 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.305 178.241 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -55.76 -51.78 66.22 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.876 179.049 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.435 HG23 ' O ' ' A' ' 23' ' ' ASN . 96.7 t -57.04 -43.89 81.93 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.221 179.42 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 52.2 t80 -58.18 -48.63 79.71 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.861 0.363 . . . . 0.0 110.265 178.684 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.402 HG13 ' O ' ' A' ' 25' ' ' LEU . 81.7 mt -60.81 -42.67 93.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.486 178.904 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 90.8 mt -58.15 -41.86 81.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.123 179.118 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 63.0 mtp180 -69.05 -35.07 76.16 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.076 0.465 . . . . 0.0 111.295 -179.654 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.421 ' SG ' HD12 ' A' ' 92' ' ' LEU . 48.3 t -81.37 -25.95 35.88 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.98 -0.555 . . . . 0.0 111.512 -175.509 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 20.8 p -93.56 -81.93 0.36 Allowed 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 111.851 0.315 . . . . 0.0 111.851 -174.92 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.416 ' O ' HG22 ' A' ' 37' ' ' THR . . . 107.22 168.19 22.12 Favored Glycine 0 N--CA 1.449 -0.476 0 N-CA-C 111.384 -0.686 . . . . 0.0 111.384 -175.158 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 71.0 Cg_endo -76.77 145.96 26.1 Favored 'Trans proline' 0 N--CA 1.464 -0.26 0 C-N-CA 122.32 2.013 . . . . 0.0 112.801 -178.769 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 91.75 -20.34 42.64 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.876 -0.678 . . . . 0.0 113.602 175.22 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 37' ' ' THR . . . . . 0.416 HG22 ' O ' ' A' ' 34' ' ' GLY . 14.7 t -92.06 178.85 5.75 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 117.115 0.457 . . . . 0.0 110.011 -179.08 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 38' ' ' ARG . . . . . 0.503 ' HA ' ' O ' ' A' ' 61' ' ' ASP . 0.1 OUTLIER -111.81 136.06 51.59 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-O 120.967 0.413 . . . . 0.0 111.351 -176.239 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.402 HG23 HG21 ' A' ' 60' ' ' VAL . 62.3 t -126.22 117.27 48.15 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 N-CA-C 108.997 -0.742 . . . . 0.0 108.997 173.836 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.533 HG22 ' HB ' ' A' ' 63' ' ' VAL . 40.9 t -103.13 128.86 55.73 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-O 120.999 0.428 . . . . 0.0 111.703 -173.176 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 41' ' ' GLU . . . . . 0.631 ' HB3' HD23 ' A' ' 64' ' ' LEU . 21.7 tp10 -105.22 127.41 52.91 Favored 'General case' 0 C--O 1.24 0.569 0 CA-C-N 115.606 -0.724 . . . . 0.0 109.991 174.377 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.473 ' HB ' ' OG ' ' A' ' 95' ' ' SER . 59.0 t -93.57 89.95 2.79 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 CA-C-N 115.976 -0.557 . . . . 0.0 110.235 179.816 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 121.18 120.83 2.75 Favored Glycine 0 N--CA 1.443 -0.837 0 CA-C-N 115.662 -0.699 . . . . 0.0 111.505 -175.201 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.598 ' HB1' HD21 ' A' ' 48' ' ' LEU . . . -110.59 -57.98 2.15 Favored 'General case' 0 C--N 1.321 -0.668 0 O-C-N 122.399 -0.471 . . . . 0.0 111.047 -177.198 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 52.72 -118.67 8.21 Favored Glycine 0 CA--C 1.519 0.317 0 C-N-CA 121.085 -0.579 . . . . 0.0 112.693 -178.707 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 65.2 mtp180 -134.52 14.61 3.74 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.827 0.346 . . . . 0.0 111.264 -179.669 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 21.8 p90 -103.52 35.19 2.67 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.369 0.604 . . . . 0.0 110.553 -178.298 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.598 HD21 ' HB1' ' A' ' 44' ' ' ALA . 94.5 mt -76.13 13.43 0.9 Allowed 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.484 -0.78 . . . . 0.0 112.569 -173.963 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 42.2 p90 -67.62 -26.45 66.25 Favored 'General case' 0 C--N 1.324 -0.509 0 C-N-CA 120.713 -0.395 . . . . 0.0 110.454 177.02 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.419 ' O ' HG13 ' A' ' 54' ' ' ILE . 54.0 t -68.72 -54.5 20.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.439 176.407 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 51' ' ' SER . . . . . 0.402 ' HA ' HD13 ' A' ' 62' ' ' LEU . 7.3 p -62.51 -46.78 86.85 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.847 -176.134 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -70.66 -27.55 64.13 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.569 -176.328 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 82.9 t80 -68.74 -46.65 68.33 Favored 'General case' 0 C--N 1.328 -0.346 0 C-N-CA 120.783 -0.367 . . . . 0.0 110.443 176.291 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.419 HG13 ' O ' ' A' ' 50' ' ' VAL . 77.9 mt -59.15 -45.79 92.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.385 -176.824 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 6.9 ptp180 -71.76 -16.48 62.2 Favored 'General case' 0 C--O 1.236 0.39 0 CA-C-O 120.893 0.378 . . . . 0.0 111.499 -179.111 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 56' ' ' LYS . . . . . 0.47 ' HE2' HD12 ' A' ' 14' ' ' LEU . 8.3 mtpm? -83.7 -21.8 32.24 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.861 0.362 . . . . 0.0 111.566 177.618 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 9.6 t-80 -103.16 -43.02 5.58 Favored 'General case' 0 N--CA 1.445 -0.69 0 CA-C-O 121.01 0.433 . . . . 0.0 109.863 -178.143 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 9.1 t -120.09 144.08 47.8 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 109.202 -0.666 . . . . 0.0 109.202 178.336 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 59' ' ' LYS . . . . . 0.452 ' HA ' ' HD3' ' A' ' 59' ' ' LYS . 6.1 tppt? -89.25 58.15 4.34 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 122.11 0.957 . . . . 0.0 110.332 -179.459 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.402 HG21 HG23 ' A' ' 39' ' ' VAL . 7.6 p -94.97 145.53 8.02 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.817 0 CA-C-N 114.41 -1.268 . . . . 0.0 109.677 175.564 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 61' ' ' ASP . . . . . 0.503 ' O ' ' HA ' ' A' ' 38' ' ' ARG . 25.6 t70 -84.62 93.46 8.39 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 179.278 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 62' ' ' LEU . . . . . 0.402 HD13 ' HA ' ' A' ' 51' ' ' SER . 4.6 tt -89.86 120.17 30.87 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.67 -176.192 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.533 ' HB ' HG22 ' A' ' 40' ' ' VAL . 47.8 t -103.91 122.51 56.75 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.653 0 CA-C-N 115.674 -0.694 . . . . 0.0 110.493 -174.721 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 64' ' ' LEU . . . . . 0.631 HD23 ' HB3' ' A' ' 41' ' ' GLU . 41.6 mt -99.55 133.43 43.89 Favored 'General case' 0 C--N 1.316 -0.889 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 176.575 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.436 HG22 ' HB ' ' A' ' 75' ' ' VAL . 13.0 p -125.73 124.04 40.18 Favored 'General case' 0 C--N 1.317 -0.813 0 N-CA-C 110.048 -0.353 . . . . 0.0 110.048 176.544 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 39.2 t0 -170.36 172.01 6.34 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -175.712 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.671 HG22 ' HG2' ' A' ' 68' ' ' LYS . 26.0 mm -73.67 129.83 36.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.073 -179.709 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 68' ' ' LYS . . . . . 0.671 ' HG2' HG22 ' A' ' 67' ' ' ILE . 19.6 pttp 38.71 90.32 0.07 OUTLIER Pre-proline 0 N--CA 1.476 0.837 0 O-C-N 124.247 0.967 . . . . 0.0 113.278 178.933 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 69' ' ' PRO . . . . . 0.958 ' HB3' ' HB ' ' A' ' 74' ' ' ILE . 4.9 Cg_endo -48.39 137.58 24.79 Favored 'Trans proline' 0 C--N 1.346 0.395 0 C-N-CA 123.875 3.05 . . . . 0.0 113.202 179.534 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 4.7 m -122.6 20.6 10.26 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.895 -0.593 . . . . 0.0 111.065 -178.054 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 64.4 t60 -138.75 -89.07 0.22 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.808 0.337 . . . . 0.0 110.678 -175.389 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -164.71 -72.63 0.03 OUTLIER Glycine 0 N--CA 1.447 -0.61 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.002 -179.752 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -81.04 48.65 3.82 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 121.013 -0.613 . . . . 0.0 112.665 -179.884 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.958 ' HB ' ' HB3' ' A' ' 69' ' ' PRO . 56.1 mt -113.94 123.15 69.32 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.61 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 177.069 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.543 HG11 HD13 ' A' ' 86' ' ' ILE . 91.2 t -76.04 132.09 33.72 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 176.369 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 9.8 ptp180 -79.3 21.14 0.48 Allowed 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 120.987 0.422 . . . . 0.0 111.371 -175.967 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 77' ' ' ASP . . . . . 0.496 ' HB2' HG12 ' A' ' 75' ' ' VAL . 6.1 t70 -83.48 112.49 20.01 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 109.615 -0.513 . . . . 0.0 109.615 -176.385 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 10.7 p-10 -70.87 142.21 51.2 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 121.426 0.632 . . . . 0.0 111.444 -174.055 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 79' ' ' ILE . . . . . 0.404 HD13 HG13 ' A' ' 42' ' ' VAL . 6.9 tp -66.77 -21.95 29.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.367 -0.833 . . . . 0.0 112.345 -173.66 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 10.2 t -90.05 -0.54 57.64 Favored 'General case' 0 C--N 1.322 -0.626 0 C-N-CA 120.274 -0.571 . . . . 0.0 110.492 -178.801 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 81' ' ' SER . . . . . 0.43 ' N ' ' HD3' ' A' ' 82' ' ' PRO . 4.9 m -148.24 46.58 0.46 Allowed Pre-proline 0 CA--C 1.538 0.505 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.883 177.421 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.457 ' HA ' ' OD2' ' A' ' 77' ' ' ASP . 93.3 Cg_endo -81.23 149.45 17.17 Favored 'Trans proline' 0 C--N 1.352 0.711 0 C-N-CA 122.287 1.992 . . . . 0.0 113.174 -169.01 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 83' ' ' ARG . . . . . 0.511 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 73.1 mtp85 -96.36 125.22 40.71 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.82 -0.627 . . . . 0.0 111.061 177.222 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 84' ' ' MET . . . . . 0.584 ' HE1' ' HA ' ' A' ' 109' ' ' VAL . 91.3 mmm -63.92 -20.02 65.54 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.678 -0.692 . . . . 0.0 111.296 -179.314 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.511 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 11.0 pt-20 -69.81 -16.65 63.31 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.506 -176.451 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.543 HD13 HG11 ' A' ' 75' ' ' VAL . 70.4 mt -85.23 -36.14 10.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 121.298 0.571 . . . . 0.0 109.963 178.154 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 99.2 m-85 -80.59 -31.85 36.61 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.865 -178.73 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 88' ' ' ARG . . . . . 0.441 ' HG3' HG12 ' A' ' 113' ' ' VAL . 23.3 mtp85 -64.07 119.61 10.47 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-O 121.142 0.496 . . . . 0.0 110.795 179.259 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 115.65 -17.21 16.08 Favored Glycine 0 N--CA 1.444 -0.805 0 CA-C-N 115.44 -0.8 . . . . 0.0 111.557 -177.739 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -73.38 144.55 46.39 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.83 0.348 . . . . 0.0 110.769 179.052 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -88.94 -25.66 21.95 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 121.27 0.557 . . . . 0.0 110.142 178.093 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 92' ' ' LEU . . . . . 0.483 HD23 ' N ' ' A' ' 93' ' ' ILE . 4.7 tt -150.86 141.09 22.26 Favored 'General case' 0 N--CA 1.448 -0.559 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.409 -177.136 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 93' ' ' ILE . . . . . 0.548 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 61.2 mt -130.58 128.14 63.06 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.187 177.226 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -136.88 169.69 17.35 Favored 'General case' 0 C--N 1.318 -0.781 0 C-N-CA 120.786 -0.366 . . . . 0.0 110.117 -179.074 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 95' ' ' SER . . . . . 0.635 ' HB2' ' HG3' ' A' ' 98' ' ' PRO . 7.1 m -152.07 123.08 7.57 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.346 178.901 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 96' ' ' ILE . . . . . 0.748 HG22 ' HG2' ' A' ' 97' ' ' ARG . 2.3 mp -73.37 114.94 13.6 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-N 116.3 -0.409 . . . . 0.0 109.907 174.771 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 97' ' ' ARG . . . . . 0.748 ' HG2' HG22 ' A' ' 96' ' ' ILE . 13.6 ptt180 43.54 76.27 0.55 Allowed Pre-proline 0 N--CA 1.472 0.668 0 C-N-CA 124.376 1.071 . . . . 0.0 113.17 177.41 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 98' ' ' PRO . . . . . 0.635 ' HG3' ' HB2' ' A' ' 95' ' ' SER . 12.8 Cg_endo -90.07 146.54 4.52 Favored 'Trans proline' 0 N--CA 1.453 -0.909 0 C-N-CA 122.583 2.189 . . . . 0.0 111.889 175.689 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.526 ' HD2' HD11 ' A' ' 102' ' ' ILE . 32.2 Cg_exo -61.05 140.37 89.43 Favored 'Trans proline' 0 C--N 1.344 0.34 0 C-N-CA 122.492 2.128 . . . . 0.0 111.991 177.483 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -79.74 30.85 0.25 Allowed 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 121.101 0.477 . . . . 0.0 111.805 -174.871 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 101' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -122.2 -6.89 8.84 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.812 178.614 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.526 HD11 ' HD2' ' A' ' 99' ' ' PRO . 30.8 pt -120.25 8.53 6.37 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 120.907 0.384 . . . . 0.0 111.163 -179.021 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 103' ' ' HIS . . . . . 0.465 ' O ' ' HG2' ' A' ' 107' ' ' MET . 44.7 p-80 -60.82 -40.06 91.31 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.373 -177.149 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 23.3 m -61.75 -29.58 70.22 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.861 0.362 . . . . 0.0 111.016 178.749 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.547 ' O ' HG23 ' A' ' 109' ' ' VAL . 19.3 m -75.61 -38.29 59.13 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.079 178.518 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 94.5 mt -69.14 -41.7 76.98 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.953 179.6 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 107' ' ' MET . . . . . 0.465 ' HG2' ' O ' ' A' ' 103' ' ' HIS . 94.9 mmm -57.38 -47.53 81.44 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.804 -0.634 . . . . 0.0 111.535 -179.281 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 6.7 ptp85 -66.96 -31.74 72.51 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.578 -0.283 . . . . 0.0 111.608 -178.186 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.584 ' HA ' ' HE1' ' A' ' 84' ' ' MET . 76.3 t -66.7 -47.93 81.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 C-N-CA 121.115 -0.234 . . . . 0.0 110.897 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -57.98 -46.27 85.44 Favored 'General case' 0 CA--C 1.518 -0.286 0 CA-C-N 116.515 -0.311 . . . . 0.0 110.641 179.853 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 17.8 t70 -67.73 -36.21 80.16 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.783 -178.599 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -65.43 -43.25 91.06 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.65 -179.843 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.441 HG12 ' HG3' ' A' ' 88' ' ' ARG . 18.6 m -88.22 -30.09 5.46 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.537 -175.912 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 91.41 51.63 2.5 Favored Glycine 0 N--CA 1.448 -0.554 0 C-N-CA 120.596 -0.811 . . . . 0.0 112.15 -178.856 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -132.0 157.6 43.67 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.906 0.384 . . . . 0.0 110.879 -179.424 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 116' ' ' ARG . . . . . 0.674 ' HD3' ' OE1' ' A' ' 145' ' ' GLU . 12.5 ttm180 -78.58 123.22 26.86 Favored 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 109.569 -0.53 . . . . 0.0 109.569 177.163 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 117' ' ' LEU . . . . . 0.548 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 57.3 tp -94.12 118.9 32.19 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 116.179 -0.464 . . . . 0.0 109.947 -179.553 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 59.7 mt -114.39 115.06 48.45 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 CA-C-O 121.32 0.581 . . . . 0.0 110.807 179.654 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 53.5 mt -122.52 118.62 55.77 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.953 -179.249 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 120' ' ' LYS . . . . . 0.557 ' HB3' ' HB3' ' A' ' 143' ' ' PHE . 0.6 OUTLIER -118.81 101.74 50.11 Favored Pre-proline 0 C--N 1.319 -0.722 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 169.759 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 121' ' ' PRO . . . . . 0.53 ' HA ' ' HA ' ' A' ' 97' ' ' ARG . 96.6 Cg_endo -80.04 -161.95 0.17 Allowed 'Trans proline' 0 N--CA 1.461 -0.438 0 C-N-CA 122.902 2.401 . . . . 0.0 112.425 -176.658 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 122' ' ' LEU . . . . . 0.681 ' HB2' ' HB2' ' A' ' 125' ' ' GLU . 3.0 mm? -65.31 150.08 48.87 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.929 -0.578 . . . . 0.0 109.977 178.162 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 23.2 m -68.28 -25.82 65.35 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.119 -0.491 . . . . 0.0 112.005 -171.246 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -105.67 1.64 39.25 Favored Glycine 0 N--CA 1.453 -0.233 0 C-N-CA 120.095 -1.05 . . . . 0.0 112.694 -179.563 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 125' ' ' GLU . . . . . 0.681 ' HB2' ' HB2' ' A' ' 122' ' ' LEU . 1.6 mp0 -105.79 -170.28 1.71 Allowed 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.239 0.542 . . . . 0.0 111.401 -173.595 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 16.8 t70 -143.99 171.53 14.13 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 115.147 -0.933 . . . . 0.0 108.846 179.18 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.557 ' HB ' HG22 ' A' ' 129' ' ' THR . 39.1 mt -88.83 -15.22 9.1 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-O 121.048 0.451 . . . . 0.0 110.24 179.655 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 48.9 t 73.82 -5.62 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.469 0.506 0 CA-C-O 121.346 0.593 . . . . 0.0 111.022 178.142 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 129' ' ' THR . . . . . 0.557 HG22 ' HB ' ' A' ' 127' ' ' ILE . 8.8 t -71.01 153.07 42.93 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 174.964 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 39.4 tt0 -60.19 -82.68 0.02 OUTLIER 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.819 -179.025 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 131' ' ' ARG . . . . . 0.414 HH11 ' HD2' ' A' ' 131' ' ' ARG . 0.0 OUTLIER -169.09 84.99 0.15 Allowed 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 175.561 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 30.8 mmmt -121.16 -15.92 8.09 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 115.245 -0.889 . . . . 0.0 110.1 -178.467 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 133' ' ' MET . . . . . 0.516 ' HG2' ' HB2' ' A' ' 146' ' ' TYR . 79.4 mtp -114.4 170.12 8.53 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.56 -0.746 . . . . 0.0 110.195 -176.311 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 134' ' ' LYS . . . . . 0.453 ' HG3' ' HG2' ' A' ' 145' ' ' GLU . 18.8 ptmt -121.75 134.07 54.93 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.815 -178.591 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 135' ' ' LEU . . . . . 0.539 HD11 ' HD2' ' A' ' 142' ' ' TYR . 60.0 tp -82.75 122.39 28.12 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 120.932 0.396 . . . . 0.0 110.537 178.223 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -118.16 147.04 21.87 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.355 179.84 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 13.4 m120 -124.18 96.94 5.12 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 109.416 -0.587 . . . . 0.0 109.416 -179.666 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 138' ' ' TYR . . . . . 0.427 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 64.1 t80 -104.42 109.1 20.83 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.272 -175.172 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 72.71 -82.08 0.61 Allowed Glycine 0 N--CA 1.45 -0.392 0 CA-C-N 115.768 -0.651 . . . . 0.0 111.832 179.875 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 140' ' ' ARG . . . . . 0.406 ' HD3' ' HA ' ' A' ' 140' ' ' ARG . 16.3 mmt180 -141.36 -7.43 1.01 Allowed 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 115.477 -0.362 . . . . 0.0 111.109 177.08 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 3.4 t -99.17 135.82 40.03 Favored 'General case' 0 N--CA 1.446 -0.637 0 CA-C-O 121.279 0.561 . . . . 0.0 110.083 -179.229 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 142' ' ' TYR . . . . . 0.539 ' HD2' HD11 ' A' ' 135' ' ' LEU . 27.0 p90 -114.06 144.22 43.48 Favored 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 176.193 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 143' ' ' PHE . . . . . 0.557 ' HB3' ' HB3' ' A' ' 120' ' ' LYS . 23.7 p90 -157.25 162.77 39.24 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.556 -178.854 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 87.1 m-85 -100.93 118.3 36.69 Favored 'General case' 0 C--N 1.314 -0.949 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 175.177 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 145' ' ' GLU . . . . . 0.674 ' OE1' ' HD3' ' A' ' 116' ' ' ARG . 11.5 pt-20 -110.0 155.17 22.15 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-O 121.321 0.581 . . . . 0.0 109.695 178.701 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 146' ' ' TYR . . . . . 0.516 ' HB2' ' HG2' ' A' ' 133' ' ' MET . 32.4 t80 -137.39 123.81 20.76 Favored 'General case' 0 C--N 1.307 -1.259 0 CA-C-N 115.498 -0.774 . . . . 0.0 109.382 176.493 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 147' ' ' ILE . . . . . 0.444 ' N ' HD12 ' A' ' 147' ' ' ILE . 3.3 mp -94.36 103.79 15.07 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.799 0 CA-C-N 116.111 -0.495 . . . . 0.0 109.932 -177.621 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -68.37 119.3 12.66 Favored 'General case' 0 N--CA 1.443 -0.783 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 171.358 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 -63.08 155.81 26.74 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 121.121 0.486 . . . . 0.0 110.3 -177.363 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 16.3 t -70.09 122.95 22.85 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.788 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.938 -170.401 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 151' ' ' ARG . . . . . . . . . . . . . 27.7 mmm180 -78.71 150.38 32.54 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-N 115.025 -0.989 . . . . 0.0 109.132 -179.909 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 50.0 m -71.08 91.15 0.89 Allowed 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.277 0.561 . . . . 0.0 111.36 -176.706 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 2.8 tmt_? . . . . . 0 C--O 1.249 1.056 0 CA-C-O 118.196 -0.907 . . . . 0.0 109.184 176.282 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 75.6 m95 . . . . . 0 N--CA 1.457 -0.105 0 CA-C-O 120.975 0.417 . . . . 0.0 110.457 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 23.9 t-20 -58.04 -52.74 64.29 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.354 -176.762 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.482 ' HB3' ' HD2' ' A' ' 138' ' ' TYR . 6.0 m-20 -59.14 -35.48 73.57 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.344 -179.489 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 61.6 tp -58.38 -47.63 83.25 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.331 178.481 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -61.34 -47.52 85.54 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.909 178.961 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.579 ' HA ' HD12 ' A' ' 30' ' ' ILE . 58.0 t -58.13 -43.97 86.55 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.162 0 CA-C-O 120.955 0.407 . . . . 0.0 110.83 179.82 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 68.4 t80 -56.0 -47.47 77.68 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.736 -0.665 . . . . 0.0 110.487 178.819 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.509 HG23 HD13 ' A' ' 92' ' ' LEU . 77.6 mt -63.37 -42.63 97.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.731 179.022 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.579 HD12 ' HA ' ' A' ' 27' ' ' VAL . 83.1 mt -56.26 -44.23 78.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.482 -0.781 . . . . 0.0 111.05 178.39 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . 0.468 ' HG3' ' O ' ' A' ' 27' ' ' VAL . 81.8 mtp180 -70.29 -30.34 67.31 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.959 -177.354 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 74.3 m -75.58 -29.89 59.46 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.213 -178.995 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 22.3 p -112.67 -97.4 0.43 Allowed 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.532 -0.303 . . . . 0.0 111.336 -178.876 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 113.81 -178.96 18.66 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.993 -0.622 . . . . 0.0 112.037 -178.03 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 10.6 Cg_exo -71.05 150.36 60.21 Favored 'Trans proline' 0 C--O 1.234 0.292 0 C-N-CA 122.932 2.421 . . . . 0.0 112.222 -179.412 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 84.93 41.94 7.38 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.831 -0.699 . . . . 0.0 112.86 179.257 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 14.6 t -168.65 -178.64 3.51 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 177.137 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 66.9 mtp85 -114.67 136.08 53.45 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 120.711 0.291 . . . . 0.0 111.082 -178.433 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.9 ' HB ' HD22 ' A' ' 62' ' ' LEU . 40.2 t -124.06 132.11 71.86 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 N-CA-C 108.914 -0.772 . . . . 0.0 108.914 173.47 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.423 HG11 ' CD1' ' A' ' 87' ' ' TYR . 62.0 t -105.79 124.22 60.76 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 C-N-CA 120.87 -0.332 . . . . 0.0 111.246 -175.939 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . 0.411 ' OE1' HD22 ' A' ' 64' ' ' LEU . 44.9 tt0 -103.59 109.47 21.16 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.931 -0.577 . . . . 0.0 109.852 176.583 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.573 HG11 HD21 ' A' ' 106' ' ' LEU . 47.0 t -96.65 132.99 39.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 115.947 -0.569 . . . . 0.0 109.954 179.707 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 87.12 20.48 52.81 Favored Glycine 0 N--CA 1.447 -0.613 0 C-N-CA 120.474 -0.87 . . . . 0.0 111.811 -178.637 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.452 ' HB1' ' CD2' ' A' ' 48' ' ' LEU . . . -55.81 -68.0 0.24 Allowed 'General case' 0 C--N 1.331 -0.201 0 O-C-N 123.744 0.32 . . . . 0.0 110.253 178.695 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 58.22 -93.05 0.04 OUTLIER Glycine 0 N--CA 1.452 -0.284 0 CA-C-N 115.572 -0.74 . . . . 0.0 114.1 173.06 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . 0.44 HH11 ' HD3' ' A' ' 46' ' ' ARG . 32.7 ttt-85 -126.58 11.24 7.32 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 121.351 0.596 . . . . 0.0 110.571 -172.181 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 59.0 t80 -133.04 97.96 4.15 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 109.529 -0.545 . . . . 0.0 109.529 178.995 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.72 HD22 HD13 ' A' ' 64' ' ' LEU . 67.1 mt -113.4 24.37 12.3 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.952 -172.278 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 56.8 t80 -64.65 -50.86 65.42 Favored 'General case' 0 C--N 1.329 -0.292 0 C-N-CA 120.928 -0.309 . . . . 0.0 111.781 -176.908 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.476 ' O ' HG13 ' A' ' 54' ' ' ILE . 44.1 t -60.92 -55.47 24.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.559 -0.291 . . . . 0.0 111.011 -173.013 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 10.9 p -56.93 -43.12 81.17 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.975 179.538 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.469 ' HA ' ' HG2' ' A' ' 55' ' ' ARG . 36.7 t70 -64.99 -42.88 94.12 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.728 0.299 . . . . 0.0 110.905 -179.466 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 74.6 t80 -61.11 -42.02 97.75 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.062 0.458 . . . . 0.0 110.341 177.281 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.552 HG23 HG12 ' A' ' 30' ' ' ILE . 86.3 mt -64.61 -49.13 81.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.294 179.21 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' ARG . . . . . 0.469 ' HG2' ' HA ' ' A' ' 52' ' ' ASP . 40.8 ptt180 -67.96 -18.74 64.83 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-O 120.862 0.363 . . . . 0.0 111.401 -176.05 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 84.6 mttt -84.51 -34.11 23.39 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.828 0.346 . . . . 0.0 110.971 176.104 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.6 OUTLIER -79.85 -33.6 40.05 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.253 178.76 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 70.6 m -141.78 135.95 30.2 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.5 178.063 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 7.6 tmtt? -76.15 64.77 2.03 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.888 0.852 . . . . 0.0 109.378 176.755 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.515 HG21 HG23 ' A' ' 39' ' ' VAL . 8.3 p -95.18 148.2 5.27 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.964 0 CA-C-N 114.727 -1.124 . . . . 0.0 109.118 173.834 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 25.9 t0 -78.91 88.58 4.71 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 121.34 0.59 . . . . 0.0 109.437 -179.808 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . 0.9 HD22 ' HB ' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -82.99 115.12 21.69 Favored 'General case' 0 N--CA 1.448 -0.549 0 CA-C-N 115.532 -0.758 . . . . 0.0 110.1 -177.578 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 45.3 t -103.56 114.73 43.96 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-N 115.462 -0.79 . . . . 0.0 110.081 -177.54 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . 0.72 HD13 HD22 ' A' ' 48' ' ' LEU . 20.1 mt -91.61 135.95 33.49 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-N 115.671 -0.695 . . . . 0.0 109.607 -179.696 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 14.5 p -130.76 128.96 41.83 Favored 'General case' 0 C--N 1.319 -0.723 0 C-N-CA 121.045 -0.262 . . . . 0.0 111.271 -179.074 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 5.8 t70 -171.0 155.34 4.45 Favored 'General case' 0 CA--C 1.519 -0.246 0 N-CA-C 109.371 -0.603 . . . . 0.0 109.371 175.839 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.625 HG22 ' HG2' ' A' ' 68' ' ' LYS . 58.1 mt -78.1 131.2 35.06 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 CA-C-N 116.642 -0.254 . . . . 0.0 110.606 -177.942 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' LYS . . . . . 0.625 ' HG2' HG22 ' A' ' 67' ' ' ILE . 7.9 ptmm? 42.31 71.73 1.31 Allowed Pre-proline 0 N--CA 1.471 0.586 0 O-C-N 124.152 0.908 . . . . 0.0 112.915 179.265 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo . . . . . 0 N--CA 1.463 -0.319 0 C-N-CA 122.549 2.166 . . . . 0.0 112.168 177.768 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.673 ' HA ' ' HB2' ' A' ' 64' ' ' LEU . 50.6 mt . . . . . 0 N--CA 1.452 -0.35 0 CA-C-O 120.574 0.226 . . . . 0.0 110.441 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.441 HG11 HD13 ' A' ' 86' ' ' ILE . 61.5 t -64.45 116.91 4.29 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 N-CA-C 109.631 -0.507 . . . . 0.0 109.631 176.875 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 16.2 mtt180 -84.48 53.69 2.75 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.679 -0.692 . . . . 0.0 110.432 -175.417 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . 0.421 ' HB2' HG12 ' A' ' 75' ' ' VAL . 2.0 t70 -98.83 -162.36 0.95 Allowed 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 116.307 -0.406 . . . . 0.0 109.972 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' ASP . . . . . 0.503 ' OD1' HG22 ' A' ' 80' ' ' THR . 11.8 t0 -119.38 146.17 45.57 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 120.773 0.321 . . . . 0.0 111.251 -175.475 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' ILE . . . . . 0.558 HG22 HD11 ' A' ' 67' ' ' ILE . 10.7 tp -107.96 -20.59 6.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.292 -176.266 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.503 HG22 ' OD1' ' A' ' 78' ' ' ASP . 13.3 t -79.82 -25.06 40.97 Favored 'General case' 0 CA--C 1.529 0.167 0 CA-C-O 121.616 0.722 . . . . 0.0 109.322 178.913 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 23.2 m -132.54 79.86 63.83 Favored Pre-proline 0 C--N 1.322 -0.613 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 166.048 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -74.97 146.15 32.44 Favored 'Trans proline' 0 N--CA 1.462 -0.364 0 C-N-CA 122.799 2.332 . . . . 0.0 112.991 -171.954 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' ARG . . . . . 0.537 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 82.9 mtt180 -94.58 107.92 19.89 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.542 -0.754 . . . . 0.0 110.22 175.845 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' MET . . . . . 0.554 ' HA ' ' HD2' ' A' ' 87' ' ' TYR . 95.3 mmm -59.56 -24.41 63.71 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.587 -0.733 . . . . 0.0 111.571 -176.087 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.537 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 9.4 pt-20 -55.45 -29.56 58.89 Favored 'General case' 0 C--N 1.33 -0.272 0 O-C-N 123.245 0.341 . . . . 0.0 111.415 179.465 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.441 HD13 HG11 ' A' ' 75' ' ' VAL . 64.9 mt -78.52 -35.59 19.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.81 -178.403 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . 0.554 ' HD2' ' HA ' ' A' ' 84' ' ' MET . 49.4 m-85 -85.86 -25.86 25.98 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.209 -175.327 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . 0.645 ' HG2' HG12 ' A' ' 113' ' ' VAL . 81.6 mtp180 -70.35 138.29 51.29 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 121.36 0.6 . . . . 0.0 110.666 -178.553 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 92.92 -1.19 70.51 Favored Glycine 0 C--N 1.317 -0.478 0 CA-C-N 115.11 -0.95 . . . . 0.0 111.993 -176.652 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -86.7 147.64 25.79 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.905 0.383 . . . . 0.0 110.664 178.596 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -91.05 -27.08 18.84 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.801 179.306 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . 0.509 HD13 HG23 ' A' ' 29' ' ' ILE . 6.2 tt -152.35 143.24 22.99 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.143 -177.935 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.572 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 72.3 mt -131.46 122.74 51.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 N-CA-C 109.473 -0.566 . . . . 0.0 109.473 178.547 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 15.1 p90 -129.77 157.89 40.93 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 120.917 0.389 . . . . 0.0 110.883 -178.691 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . 0.487 ' HA ' ' O ' ' A' ' 42' ' ' VAL . 16.5 m -128.04 128.37 44.85 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.958 -0.564 . . . . 0.0 110.974 -176.731 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 50.6 mm -91.71 106.67 17.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.437 -179.806 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 11.1 tpp180 57.06 69.87 1.55 Allowed Pre-proline 0 CA--C 1.535 0.389 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.071 178.821 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' PRO . . . . . 0.56 ' HG2' HG23 ' A' ' 119' ' ' ILE . 5.6 Cg_endo -87.05 135.69 3.95 Favored 'Trans proline' 0 N--CA 1.455 -0.762 0 C-N-CA 122.799 2.332 . . . . 0.0 112.31 -179.09 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . 0.559 ' HD2' HD11 ' A' ' 102' ' ' ILE . 32.3 Cg_exo -59.12 142.51 99.38 Favored 'Trans proline' 0 C--O 1.236 0.411 0 C-N-CA 122.464 2.11 . . . . 0.0 111.7 174.627 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -76.97 43.01 0.33 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.763 -176.092 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 101' ' ' GLU . . . . . 0.506 ' HG3' HG23 ' A' ' 102' ' ' ILE . 12.0 pt-20 -140.27 -34.45 0.53 Allowed 'General case' 0 N--CA 1.45 -0.472 0 CA-C-N 115.902 -0.59 . . . . 0.0 111.541 178.797 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.559 HD11 ' HD2' ' A' ' 99' ' ' PRO . 45.8 pt -95.56 -0.78 10.62 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.211 0 CA-C-O 120.837 0.351 . . . . 0.0 111.597 -176.53 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 103' ' ' HIS . . . . . 0.539 ' O ' ' HG3' ' A' ' 107' ' ' MET . 41.8 p-80 -55.92 -36.93 68.25 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.932 -0.576 . . . . 0.0 111.303 -178.863 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 6.7 m -60.93 -39.32 88.97 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.0 -179.4 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.558 ' O ' HG23 ' A' ' 109' ' ' VAL . 14.2 m -66.58 -35.37 80.05 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.976 -0.556 . . . . 0.0 109.88 -179.752 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.573 HD21 HG11 ' A' ' 42' ' ' VAL . 96.3 mt -69.91 -41.06 75.19 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.704 -0.68 . . . . 0.0 111.138 -179.676 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 107' ' ' MET . . . . . 0.539 ' HG3' ' O ' ' A' ' 103' ' ' HIS . 70.0 mtp -62.5 -42.37 99.45 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.813 -0.63 . . . . 0.0 111.487 -177.24 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 14.1 ptm180 -69.54 -29.87 67.56 Favored 'General case' 0 C--N 1.33 -0.261 0 C-N-CA 120.762 -0.375 . . . . 0.0 111.158 -179.572 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.558 HG23 ' O ' ' A' ' 105' ' ' SER . 75.4 t -66.75 -48.69 79.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 C-N-CA 120.933 -0.307 . . . . 0.0 110.56 178.399 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -57.55 -46.25 84.15 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.262 177.676 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.548 ' HA ' ' HB1' ' A' ' 148' ' ' ALA . 12.3 t70 -63.43 -34.37 77.59 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.553 -0.749 . . . . 0.0 110.729 -177.868 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -70.31 -46.97 63.19 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.801 -0.636 . . . . 0.0 111.797 -179.773 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.645 HG12 ' HG2' ' A' ' 88' ' ' ARG . 23.1 m -84.95 -26.28 6.76 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-N 116.416 -0.356 . . . . 0.0 111.811 -173.769 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 89.67 43.18 5.23 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.092 179.468 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -124.1 154.34 40.12 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.668 0.27 . . . . 0.0 110.503 -178.524 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 116' ' ' ARG . . . . . 0.463 ' HD3' ' OE1' ' A' ' 145' ' ' GLU . 14.5 ttm180 -73.95 124.48 26.27 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 178.13 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . 0.572 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 56.1 tp -93.46 121.39 34.81 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.246 -0.434 . . . . 0.0 109.977 178.562 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . 0.406 HD12 HG12 ' A' ' 29' ' ' ILE . 67.8 mt -119.12 120.18 63.1 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 CA-C-O 121.321 0.581 . . . . 0.0 110.907 179.435 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 119' ' ' ILE . . . . . 0.56 HG23 ' HG2' ' A' ' 98' ' ' PRO . 14.2 mt -112.68 130.6 66.16 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.674 178.874 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 2.6 tmtm? -106.34 94.71 10.16 Favored Pre-proline 0 C--N 1.323 -0.545 0 N-CA-C 109.287 -0.634 . . . . 0.0 109.287 174.926 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 91.1 Cg_endo -85.67 -162.69 0.16 Allowed 'Trans proline' 0 N--CA 1.46 -0.464 0 C-N-CA 122.749 2.299 . . . . 0.0 112.588 -179.539 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 122' ' ' LEU . . . . . 0.943 ' HB2' ' HB3' ' A' ' 125' ' ' GLU . 9.9 mp -86.15 159.57 19.48 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.45 179.681 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 4.0 p -64.13 -33.72 76.42 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.915 -0.584 . . . . 0.0 111.617 -178.529 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -132.18 43.74 1.26 Allowed Glycine 0 N--CA 1.447 -0.579 0 C-N-CA 120.935 -0.65 . . . . 0.0 112.135 179.824 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . 0.943 ' HB3' ' HB2' ' A' ' 122' ' ' LEU . 34.3 tt0 -145.32 129.23 17.39 Favored 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 110.044 -0.354 . . . . 0.0 110.044 179.274 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -85.41 167.59 15.38 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.605 -175.902 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 35.7 mt . . . . . 0 C--N 1.326 -0.455 0 CA-C-O 121.084 0.469 . . . . 0.0 110.218 -178.513 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 28.1 mmmt . . . . . 0 N--CA 1.453 -0.29 0 CA-C-O 121.0 0.429 . . . . 0.0 110.462 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 133' ' ' MET . . . . . . . . . . . . . 75.9 mtp -90.83 156.9 17.69 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.055 -0.521 . . . . 0.0 111.014 -175.525 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 16.1 ptmt -120.54 141.11 50.55 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 115.535 -0.757 . . . . 0.0 110.93 -175.582 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . 0.431 HD11 ' HD2' ' A' ' 142' ' ' TYR . 51.2 tp -83.12 120.65 26.03 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.108 178.042 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -119.19 146.01 24.48 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.743 -178.114 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 8.3 m120 -118.84 119.24 33.8 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.535 -0.543 . . . . 0.0 109.535 -179.233 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . 0.482 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 40.6 t80 -123.52 117.42 25.05 Favored 'General case' 0 C--N 1.321 -0.641 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 178.511 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 70.34 -87.29 0.33 Allowed Glycine 0 N--CA 1.443 -0.865 0 CA-C-N 115.604 -0.725 . . . . 0.0 111.43 -175.546 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 14.2 tpp180 -139.1 -13.09 1.21 Allowed 'General case' 0 C--N 1.317 -0.83 0 CA-C-O 121.259 0.552 . . . . 0.0 110.241 -179.147 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 5.8 t -97.99 141.17 31.29 Favored 'General case' 0 N--CA 1.448 -0.538 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.261 -176.608 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 142' ' ' TYR . . . . . 0.431 ' HD2' HD11 ' A' ' 135' ' ' LEU . 52.0 p90 -118.88 147.12 44.32 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 121.117 0.484 . . . . 0.0 110.545 177.432 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 15.2 p90 -155.24 -176.97 6.21 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.322 -0.854 . . . . 0.0 109.778 -176.292 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 31.7 m-85 -115.32 125.49 53.31 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-O 120.454 0.168 . . . . 0.0 110.76 179.699 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 145' ' ' GLU . . . . . 0.463 ' OE1' ' HD3' ' A' ' 116' ' ' ARG . 15.5 pt-20 -114.72 160.0 19.89 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 121.081 0.467 . . . . 0.0 109.813 175.847 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . 0.406 ' HB3' ' HB3' ' A' ' 117' ' ' LEU . 26.4 t80 -143.87 122.18 12.32 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-N 115.714 -0.675 . . . . 0.0 109.566 175.158 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 147' ' ' ILE . . . . . 0.439 ' N ' HD12 ' A' ' 147' ' ' ILE . 3.2 mp -90.31 102.34 13.19 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 -178.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . 0.548 ' HB1' ' HA ' ' A' ' 111' ' ' ASP . . . -72.53 114.17 10.37 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.839 -0.619 . . . . 0.0 109.903 177.381 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 8.1 pt-20 . . . . . 0 C--N 1.322 -0.62 0 CA-C-O 121.332 0.586 . . . . 0.0 110.886 -176.348 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' TRP . . . . . 0.434 ' HB3' HG22 ' A' ' 50' ' ' VAL . 50.2 m95 . . . . . 0 N--CA 1.454 -0.268 0 CA-C-O 120.884 0.373 . . . . 0.0 110.286 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 25.8 t-20 -72.57 -43.32 63.58 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.98 -0.555 . . . . 0.0 109.691 177.801 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 42.5 m-20 -57.42 -51.03 71.07 Favored 'General case' 0 N--CA 1.463 0.205 0 CA-C-N 115.949 -0.568 . . . . 0.0 109.712 176.927 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.402 ' O ' HG13 ' A' ' 29' ' ' ILE . 58.2 tp -55.01 -47.78 74.22 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.44 -0.8 . . . . 0.0 110.954 179.035 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -55.3 -52.11 64.53 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.223 179.763 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.523 ' HA ' HD12 ' A' ' 30' ' ' ILE . 98.4 t -59.51 -40.51 82.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.975 -179.523 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 84.9 t80 -60.11 -43.54 95.53 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.494 178.428 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.404 HG23 HD13 ' A' ' 92' ' ' LEU . 82.6 mt -64.84 -43.67 96.36 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.595 177.909 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.662 HG12 HG23 ' A' ' 54' ' ' ILE . 85.8 mt -56.75 -38.84 60.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.901 178.206 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 32.8 mtp85 -70.62 -35.13 72.78 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.082 179.852 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 78.9 m -87.61 0.79 55.15 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.674 -174.047 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 15.5 p -122.01 -71.73 0.72 Allowed 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 120.977 0.418 . . . . 0.0 111.175 178.026 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 97.38 145.23 18.71 Favored Glycine 0 N--CA 1.446 -0.666 0 C-N-CA 120.804 -0.712 . . . . 0.0 111.586 -177.895 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -59.18 130.55 36.7 Favored 'Trans proline' 0 C--O 1.233 0.266 0 C-N-CA 122.852 2.368 . . . . 0.0 112.671 -177.433 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 105.37 24.97 6.87 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.467 -0.873 . . . . 0.0 112.978 177.474 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 13.8 t -131.71 -171.55 2.64 Favored 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 177.312 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -119.35 131.47 55.7 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 120.897 0.379 . . . . 0.0 110.433 177.866 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.45 ' O ' ' HA ' ' A' ' 62' ' ' LEU . 95.9 t -128.14 130.44 69.62 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 176.578 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.403 HG11 ' CD1' ' A' ' 87' ' ' TYR . 46.5 t -107.21 126.04 63.36 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.674 0 CA-C-O 120.91 0.386 . . . . 0.0 111.036 -176.38 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . 0.445 ' HB3' HD23 ' A' ' 64' ' ' LEU . 39.2 tt0 -104.18 114.82 29.32 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.686 175.841 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 62.1 t -98.13 125.75 51.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.691 -177.668 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 88.03 28.66 22.63 Favored Glycine 0 N--CA 1.452 -0.261 0 CA-C-N 115.989 -0.551 . . . . 0.0 112.015 179.603 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.436 ' HB1' ' CD2' ' A' ' 48' ' ' LEU . . . -55.79 -76.58 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.35 0 C-N-CA 123.045 0.538 . . . . 0.0 112.356 -176.503 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 64.09 -102.04 0.55 Allowed Glycine 0 CA--C 1.519 0.301 0 C-N-CA 121.185 -0.531 . . . . 0.0 113.188 179.408 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -107.59 -1.89 20.79 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.655 0.264 . . . . 0.0 111.547 -178.082 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.445 ' CG ' HG21 ' A' ' 96' ' ' ILE . 99.4 m-85 -87.72 23.56 1.96 Allowed 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.933 0.397 . . . . 0.0 111.408 -174.957 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.762 HD22 HD13 ' A' ' 64' ' ' LEU . 37.8 mt -66.42 -7.74 21.29 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.691 -0.686 . . . . 0.0 112.831 -172.928 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . 0.438 ' CE2' ' HA ' ' A' ' 47' ' ' PHE . 23.4 p90 -62.0 -25.72 67.81 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.576 0.227 . . . . 0.0 111.361 -179.905 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.434 HG22 ' HB3' ' A' ' 22' ' ' TRP . 61.9 t -74.24 -54.88 13.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.924 0.393 . . . . 0.0 110.381 175.935 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -66.22 -40.13 90.08 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.9 -0.591 . . . . 0.0 112.294 -177.21 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.558 ' O ' ' HG2' ' A' ' 56' ' ' LYS . 38.7 t70 -67.23 -27.75 67.49 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.863 0.363 . . . . 0.0 110.502 -178.688 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 78.5 t80 -69.53 -41.88 75.38 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.892 0.377 . . . . 0.0 110.293 176.014 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.662 HG23 HG12 ' A' ' 30' ' ' ILE . 77.1 mt -63.65 -40.7 90.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 115.946 -0.57 . . . . 0.0 111.231 -178.493 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' ARG . . . . . 0.505 ' HG2' ' HA ' ' A' ' 52' ' ' ASP . 5.8 ptp180 -70.11 -16.57 63.13 Favored 'General case' 0 CA--C 1.534 0.365 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.985 -176.492 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . 0.558 ' HG2' ' O ' ' A' ' 52' ' ' ASP . 67.1 mmtt -72.17 -42.86 65.4 Favored 'General case' 0 N--CA 1.462 0.143 0 CA-C-O 121.186 0.517 . . . . 0.0 110.377 179.645 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 45.4 m-70 -92.36 -46.87 7.47 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.48 -0.782 . . . . 0.0 111.884 -173.002 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . 0.448 ' HB2' HG23 ' A' ' 60' ' ' VAL . 12.0 p -112.3 134.18 53.99 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 116.609 -0.269 . . . . 0.0 111.163 -176.798 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 25.4 tptp -80.24 65.85 5.53 Favored 'General case' 0 N--CA 1.448 -0.541 0 CA-C-O 122.246 1.022 . . . . 0.0 109.612 174.532 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.448 HG23 ' HB2' ' A' ' 58' ' ' SER . 92.3 t -98.39 130.86 46.58 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.192 0 CA-C-N 114.4 -1.273 . . . . 0.0 109.113 172.662 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 62.2 m-20 -75.67 86.56 2.72 Favored 'General case' 0 C--N 1.317 -0.83 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 178.981 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . 0.45 ' HA ' ' O ' ' A' ' 39' ' ' VAL . 2.8 tt -87.02 115.55 24.48 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 115.45 -0.796 . . . . 0.0 109.933 -177.054 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 48.0 t -97.54 119.16 45.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.055 -177.252 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . 0.762 HD13 HD22 ' A' ' 48' ' ' LEU . 39.2 mt -92.85 121.54 34.33 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-N 115.913 -0.585 . . . . 0.0 109.762 179.102 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 19.4 p -121.74 124.89 45.29 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-O 121.054 0.454 . . . . 0.0 110.485 178.903 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 27.3 t0 -160.72 152.29 19.49 Favored 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 109.612 -0.514 . . . . 0.0 109.612 -179.294 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.694 HG12 ' HA ' ' A' ' 78' ' ' ASP . 49.6 mt -73.12 108.9 4.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 N-CA-C 110.124 -0.325 . . . . 0.0 110.124 -177.935 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' LYS . . . . . 0.452 ' HA ' ' HD2' ' A' ' 69' ' ' PRO . 45.3 mtpt 65.2 88.86 0.11 Allowed Pre-proline 0 C--N 1.328 -0.365 0 CA-C-N 115.157 -0.929 . . . . 0.0 110.627 -178.963 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . 0.756 ' HB3' ' HB ' ' A' ' 74' ' ' ILE . 11.0 Cg_endo . . . . . 0 C--N 1.343 0.27 0 C-N-CA 123.558 2.839 . . . . 0.0 113.229 -177.498 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.756 ' HB ' ' HB3' ' A' ' 69' ' ' PRO . 53.3 mt . . . . . 0 N--CA 1.453 -0.307 0 N-CA-C 110.124 -0.324 . . . . 0.0 110.124 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 45.3 t -78.48 135.84 25.19 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.716 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 177.089 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' ARG . . . . . 0.529 ' HA ' ' HD3' ' A' ' 69' ' ' PRO . 3.3 ptm180 -79.92 25.24 0.37 Allowed 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.638 -0.256 . . . . 0.0 111.389 -176.441 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 38.2 t70 -64.59 103.8 0.72 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.37 0.605 . . . . 0.0 110.277 -177.192 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' ASP . . . . . 0.694 ' HA ' HG12 ' A' ' 67' ' ' ILE . 3.3 m-20 -68.25 123.46 20.79 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.241 -0.89 . . . . 0.0 110.201 -176.335 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 10.6 tp -64.08 -19.02 23.81 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.48 0 CA-C-O 121.132 0.492 . . . . 0.0 111.066 179.665 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 10.2 t -77.45 -14.81 59.61 Favored 'General case' 0 CA--C 1.532 0.288 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.784 178.431 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 33.6 t -158.68 70.53 3.69 Favored Pre-proline 0 C--N 1.326 -0.424 0 N-CA-C 108.353 -0.981 . . . . 0.0 108.353 177.593 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 90.0 Cg_endo -88.24 162.09 7.01 Favored 'Trans proline' 0 N--CA 1.458 -0.615 0 C-N-CA 122.956 2.437 . . . . 0.0 113.591 -168.56 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' ARG . . . . . 0.745 ' HB2' HD12 ' A' ' 86' ' ' ILE . 3.9 mmt180 -98.24 107.68 20.21 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 115.58 -0.736 . . . . 0.0 111.095 175.825 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' MET . . . . . 0.503 ' O ' ' HG3' ' A' ' 88' ' ' ARG . 91.0 mmm -62.17 -23.65 66.72 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.278 177.276 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.428 ' OE2' ' HD2' ' A' ' 83' ' ' ARG . 11.0 pt-20 -69.55 -22.58 63.54 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.638 -178.189 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.745 HD12 ' HB2' ' A' ' 83' ' ' ARG . 95.6 mt -81.04 -36.08 14.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.204 178.342 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . 0.403 ' CD1' HG11 ' A' ' 40' ' ' VAL . 22.8 m-85 -77.76 -31.21 51.92 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.72 -179.369 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . 0.503 ' HG3' ' O ' ' A' ' 84' ' ' MET . 38.2 mtp180 -63.67 123.08 17.94 Favored 'General case' 0 CA--C 1.516 -0.361 0 CA-C-O 121.331 0.586 . . . . 0.0 111.024 179.837 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 109.99 -9.5 31.71 Favored Glycine 0 N--CA 1.446 -0.639 0 CA-C-N 115.321 -0.854 . . . . 0.0 111.706 -178.506 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -81.93 143.8 31.39 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 110.349 -0.241 . . . . 0.0 110.349 178.389 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -92.89 -19.88 21.23 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 121.063 0.458 . . . . 0.0 110.627 -179.881 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . 0.45 HD23 ' N ' ' A' ' 93' ' ' ILE . 3.2 tt -152.09 140.66 20.73 Favored 'General case' 0 N--CA 1.449 -0.487 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.625 -179.062 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.467 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 72.3 mt -132.28 126.91 56.57 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 115.934 -0.576 . . . . 0.0 109.569 178.486 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' TYR . . . . . 0.4 ' HB3' ' HB ' ' A' ' 118' ' ' ILE . 8.1 p90 -134.7 162.84 31.21 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 120.812 0.339 . . . . 0.0 110.688 178.563 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 6.8 p -141.97 143.16 33.08 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.1 -176.392 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' ILE . . . . . 0.445 HG21 ' CG ' ' A' ' 47' ' ' PHE . 40.5 mm -90.47 93.11 4.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.632 179.675 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' ARG . . . . . 0.499 ' HG2' ' HA ' ' A' ' 121' ' ' PRO . 1.2 tmm_? 49.44 80.86 0.28 Allowed Pre-proline 0 N--CA 1.464 0.261 0 CA-C-N 115.18 -0.918 . . . . 0.0 111.757 178.552 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' PRO . . . . . 0.518 ' HG2' ' CD2' ' A' ' 103' ' ' HIS . 98.8 Cg_endo -84.98 152.32 11.11 Favored 'Trans proline' 0 N--CA 1.457 -0.63 0 C-N-CA 122.556 2.17 . . . . 0.0 111.874 176.195 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . 0.591 ' HD2' HD11 ' A' ' 102' ' ' ILE . 24.2 Cg_exo -64.15 155.45 64.98 Favored 'Trans proline' 0 C--N 1.343 0.28 0 C-N-CA 122.857 2.371 . . . . 0.0 112.089 175.066 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . 0.641 ' HA ' ' ND1' ' A' ' 103' ' ' HIS . . . -64.17 -16.12 61.26 Favored 'General case' 0 C--N 1.33 -0.257 0 N-CA-C 112.328 0.492 . . . . 0.0 112.328 -176.195 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 101' ' ' GLU . . . . . 0.626 ' HG3' HG23 ' A' ' 102' ' ' ILE . 12.9 pt-20 -76.14 -22.25 55.67 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.781 -0.19 . . . . 0.0 111.509 -177.519 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.626 HG23 ' HG3' ' A' ' 101' ' ' GLU . 43.1 pt -114.91 3.13 7.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 N-CA-C 112.438 0.533 . . . . 0.0 112.438 -176.177 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 103' ' ' HIS . . . . . 0.641 ' ND1' ' HA ' ' A' ' 100' ' ' ALA . 41.8 m170 -58.03 -51.57 69.13 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.002 0.43 . . . . 0.0 110.428 176.92 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 8.8 m -64.46 -29.82 70.86 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.892 -0.594 . . . . 0.0 110.59 178.03 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.554 ' O ' HG23 ' A' ' 109' ' ' VAL . 3.6 m -71.11 -43.9 66.73 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.577 -178.434 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 79.5 mt -60.77 -38.92 86.87 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.818 178.63 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 107' ' ' MET . . . . . 0.451 ' HA ' HD22 ' A' ' 117' ' ' LEU . 76.3 mtp -62.19 -45.54 92.93 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.081 179.841 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 108' ' ' ARG . . . . . 0.549 ' HG2' ' O ' ' A' ' 105' ' ' SER . 12.9 ptm180 -72.01 -22.8 61.36 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.633 -0.258 . . . . 0.0 111.073 -178.26 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.554 HG23 ' O ' ' A' ' 105' ' ' SER . 70.1 t -70.39 -49.94 49.77 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 173.985 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -58.15 -45.54 87.23 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.074 -0.512 . . . . 0.0 109.88 176.67 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.476 ' HA ' ' HB1' ' A' ' 148' ' ' ALA . 21.0 t70 -59.23 -36.15 74.92 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.329 -0.851 . . . . 0.0 111.372 179.387 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -71.95 -45.19 61.98 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.641 -0.709 . . . . 0.0 111.951 -179.269 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 23.2 m -86.94 -28.24 5.78 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 N-CA-C 111.996 0.369 . . . . 0.0 111.996 -174.627 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 87.92 58.96 1.73 Allowed Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.268 -178.65 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -137.47 162.29 34.07 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.752 0.311 . . . . 0.0 110.776 179.37 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 116' ' ' ARG . . . . . 0.446 ' HD3' ' OE1' ' A' ' 145' ' ' GLU . 12.5 ttm180 -79.72 120.27 23.78 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 175.857 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . 0.467 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 52.5 tp -91.99 125.79 36.82 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.089 178.895 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . 0.4 ' HB ' ' HB3' ' A' ' 94' ' ' TYR . 65.0 mt -118.57 115.02 46.8 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-O 121.176 0.512 . . . . 0.0 110.514 176.889 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 69.8 mt -116.62 120.73 65.87 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.144 179.55 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 120' ' ' LYS . . . . . 0.456 ' HG3' ' HB3' ' A' ' 143' ' ' PHE . 12.1 ttpp -113.58 99.94 50.82 Favored Pre-proline 0 C--N 1.324 -0.525 0 C-N-CA 120.819 -0.353 . . . . 0.0 110.27 175.928 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 121' ' ' PRO . . . . . 0.499 ' HA ' ' HG2' ' A' ' 97' ' ' ARG . 98.9 Cg_endo -81.93 -153.59 0.05 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.609 0 C-N-CA 122.594 2.196 . . . . 0.0 111.079 174.305 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 122' ' ' LEU . . . . . 0.579 ' HB2' ' HG2' ' A' ' 125' ' ' GLU . 3.6 mm? -81.49 -176.98 6.31 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 175.075 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 10.0 t -79.88 1.02 28.68 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.272 0.558 . . . . 0.0 110.602 178.491 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -156.83 71.74 0.25 Allowed Glycine 0 N--CA 1.446 -0.687 0 N-CA-C 111.325 -0.71 . . . . 0.0 111.325 178.081 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . 0.579 ' HG2' ' HB2' ' A' ' 122' ' ' LEU . 9.9 mm-40 -138.01 167.93 20.76 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 109.122 -0.695 . . . . 0.0 109.122 -177.824 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 8.7 t70 -120.68 163.22 18.4 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.046 178.128 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 20.8 mt . . . . . 0 C--N 1.326 -0.441 0 CA-C-O 120.965 0.412 . . . . 0.0 110.716 -175.724 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 46.4 mtmt . . . . . 0 CA--C 1.521 -0.16 0 CA-C-O 120.802 0.334 . . . . 0.0 111.173 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 133' ' ' MET . . . . . 0.569 ' HG2' ' HB2' ' A' ' 146' ' ' TYR . 73.5 mtp -90.12 151.29 21.66 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 179.144 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . 0.546 ' NZ ' ' HB3' ' A' ' 134' ' ' LYS . 0.3 OUTLIER -121.1 143.05 49.29 Favored 'General case' 0 C--N 1.315 -0.924 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.959 -173.655 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . 0.781 HD11 ' HD2' ' A' ' 142' ' ' TYR . 43.4 tp -86.13 119.11 26.07 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.977 -0.556 . . . . 0.0 109.694 178.98 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 136' ' ' VAL . . . . . 0.441 ' CG2' ' HG2' ' A' ' 145' ' ' GLU . 0.0 OUTLIER -117.63 144.52 25.35 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.695 -176.271 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 9.8 m120 -114.96 123.77 49.95 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.41 -179.663 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 58.3 t80 -137.57 123.36 19.99 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 109.932 -0.395 . . . . 0.0 109.932 175.213 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 72.12 -85.98 0.49 Allowed Glycine 0 N--CA 1.449 -0.476 0 N-CA-C 110.838 -0.905 . . . . 0.0 110.838 -175.051 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 7.1 mtt180 -153.73 -5.55 0.18 Allowed 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 115.443 -0.378 . . . . 0.0 111.388 173.569 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 15.3 t -87.91 143.68 26.98 Favored 'General case' 0 N--CA 1.445 -0.701 0 N-CA-C 109.039 -0.726 . . . . 0.0 109.039 176.24 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 142' ' ' TYR . . . . . 0.781 ' HD2' HD11 ' A' ' 135' ' ' LEU . 48.3 p90 -127.1 129.72 48.51 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-O 121.485 0.66 . . . . 0.0 110.214 178.506 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 143' ' ' PHE . . . . . 0.456 ' HB3' ' HG3' ' A' ' 120' ' ' LYS . 9.6 p90 -139.29 175.77 9.28 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-N 114.838 -1.074 . . . . 0.0 109.962 -173.512 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 144' ' ' TYR . . . . . 0.42 ' HA ' ' O ' ' A' ' 134' ' ' LYS . 93.9 m-85 -110.72 122.51 48.0 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.317 179.889 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 145' ' ' GLU . . . . . 0.459 ' O ' ' HG2' ' A' ' 134' ' ' LYS . 19.7 pt-20 -114.68 160.42 19.37 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-O 121.155 0.503 . . . . 0.0 109.805 175.92 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . 0.569 ' HB2' ' HG2' ' A' ' 133' ' ' MET . 46.5 t80 -142.02 125.24 16.42 Favored 'General case' 0 C--N 1.313 -0.993 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.627 175.811 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 147' ' ' ILE . . . . . 0.421 ' N ' HD12 ' A' ' 147' ' ' ILE . 3.5 mp -92.89 108.67 20.63 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.792 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 179.71 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . 0.476 ' HB1' ' HA ' ' A' ' 111' ' ' ASP . . . -74.41 128.77 36.37 Favored 'General case' 0 N--CA 1.442 -0.837 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 173.983 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 19.7 mm-40 . . . . . 0 C--N 1.319 -0.735 0 CA-C-O 121.787 0.803 . . . . 0.0 112.169 -178.23 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' TRP . . . . . 0.413 ' HB2' ' HE2' ' A' ' 49' ' ' TYR . 88.3 m95 . . . . . 0 N--CA 1.455 -0.187 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 12.8 m120 -66.06 -48.17 71.9 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.626 -0.716 . . . . 0.0 110.411 177.739 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.714 ' HB3' ' HA3' ' A' ' 139' ' ' GLY . 0.7 OUTLIER -67.51 -35.3 78.84 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.298 179.323 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.716 HD22 ' HD2' ' A' ' 120' ' ' LYS . 50.7 tp -51.79 -49.77 62.06 Favored 'General case' 0 C--O 1.231 0.131 0 CA-C-O 121.15 0.5 . . . . 0.0 109.901 173.576 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . 0.433 ' O ' HG13 ' A' ' 30' ' ' ILE . . . -60.26 -45.75 92.2 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.439 -0.8 . . . . 0.0 111.098 177.825 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.438 ' HA ' HD12 ' A' ' 30' ' ' ILE . 76.0 t -55.45 -43.7 73.09 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 CA-C-N 116.389 -0.369 . . . . 0.0 110.896 178.887 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . 0.446 ' HB2' ' CD2' ' A' ' 138' ' ' TYR . 54.3 t80 -59.49 -43.12 93.39 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.428 179.339 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 65.2 mt -65.68 -44.4 93.43 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.427 178.668 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.713 HG12 HG23 ' A' ' 54' ' ' ILE . 85.5 mt -57.63 -45.82 86.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.969 178.378 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 62.6 mtt180 -68.39 -28.59 67.23 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.193 0.521 . . . . 0.0 111.474 -177.74 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 74.6 m -88.84 -0.4 57.32 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.555 -178.566 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 24.3 p -128.11 -83.73 0.59 Allowed 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.805 0.336 . . . . 0.0 111.01 177.517 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 108.34 160.88 20.4 Favored Glycine 0 N--CA 1.449 -0.477 0 C-N-CA 120.975 -0.631 . . . . 0.0 112.228 -179.891 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 24.5 Cg_exo -63.14 146.0 94.02 Favored 'Trans proline' 0 C--O 1.233 0.269 0 C-N-CA 122.893 2.395 . . . . 0.0 112.178 178.877 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 94.1 -23.05 33.2 Favored Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 120.925 -0.655 . . . . 0.0 112.621 179.001 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 15.7 p -81.62 -171.85 3.54 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 -179.313 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' ARG . . . . . 1.085 ' HG3' ' HA ' ' A' ' 90' ' ' ALA . 17.5 ptm180 -131.2 130.77 43.39 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 121.036 0.446 . . . . 0.0 110.222 173.895 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.429 HG13 ' HB3' ' A' ' 92' ' ' LEU . 86.7 t -129.73 134.15 63.72 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 CA-C-N 115.804 -0.635 . . . . 0.0 109.351 -177.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.45 HG22 ' HB ' ' A' ' 63' ' ' VAL . 45.3 t -109.86 125.45 67.05 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-O 120.952 0.406 . . . . 0.0 111.433 -175.431 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 45.1 tt0 -101.64 120.53 40.48 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.927 -0.579 . . . . 0.0 109.711 175.091 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.484 ' HB ' ' OG ' ' A' ' 95' ' ' SER . 41.8 t -98.22 123.34 50.67 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.265 -179.418 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 97.37 27.31 9.33 Favored Glycine 0 N--CA 1.45 -0.43 0 N-CA-C 111.224 -0.751 . . . . 0.0 111.224 -176.777 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -85.25 76.43 10.16 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.09 0.471 . . . . 0.0 110.863 -177.814 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -111.0 -70.4 0.61 Allowed Glycine 0 N--CA 1.444 -0.807 0 C-N-CA 120.45 -0.881 . . . . 0.0 112.538 -179.421 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -119.03 11.17 12.38 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 120.694 0.283 . . . . 0.0 111.118 -175.872 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 42.2 t80 -130.0 70.75 1.43 Allowed 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 121.275 0.56 . . . . 0.0 109.93 178.519 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 82.1 mt -93.36 20.12 7.49 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.771 -178.656 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . 0.413 ' HE2' ' HB2' ' A' ' 22' ' ' TRP . 44.9 t80 -63.54 -39.58 94.79 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.955 -177.881 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.463 ' O ' HG13 ' A' ' 54' ' ' ILE . 59.7 t -75.58 -54.4 13.96 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.546 -179.159 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 1.5 p -60.92 -46.77 89.36 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.8 -0.636 . . . . 0.0 112.638 -175.751 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.426 ' O ' ' HG2' ' A' ' 56' ' ' LYS . 38.9 t70 -63.75 -38.1 89.82 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.847 0.356 . . . . 0.0 110.393 -178.131 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 65.6 t80 -61.21 -45.62 93.83 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.376 177.78 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.713 HG23 HG12 ' A' ' 30' ' ' ILE . 83.3 mt -58.64 -48.41 85.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 115.903 -0.59 . . . . 0.0 111.465 -179.033 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 39.1 ptt180 -72.85 -16.77 61.59 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 111.776 0.287 . . . . 0.0 111.776 -175.888 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . 0.935 ' HE2' ' HA ' ' A' ' 56' ' ' LYS . 8.1 mmpt? -73.01 -41.87 63.81 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.798 0.333 . . . . 0.0 110.27 174.882 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 31.0 m-70 -84.44 -52.52 6.11 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.213 -178.837 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 10.5 p -111.65 129.42 56.09 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.153 -178.492 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -82.39 62.34 6.02 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.991 0.901 . . . . 0.0 109.745 176.146 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.41 HG21 HG23 ' A' ' 39' ' ' VAL . 2.3 p -87.43 143.92 10.31 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.935 0 CA-C-N 114.573 -1.194 . . . . 0.0 108.357 171.442 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . 0.48 ' O ' ' HA ' ' A' ' 38' ' ' ARG . 22.8 t0 -75.57 86.99 2.67 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-O 121.647 0.737 . . . . 0.0 109.427 177.706 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 1.5 tt -85.64 122.93 30.45 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.432 -0.804 . . . . 0.0 110.027 -176.208 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.45 ' HB ' HG22 ' A' ' 40' ' ' VAL . 47.6 t -103.75 118.14 50.38 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.698 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.753 -179.276 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . 0.579 ' CB ' HG23 ' A' ' 74' ' ' ILE . 77.8 mt -95.69 133.22 40.03 Favored 'General case' 0 C--N 1.315 -0.906 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.067 -179.053 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.493 HG22 ' HB ' ' A' ' 75' ' ' VAL . 23.7 p -129.61 135.01 48.04 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 120.45 0.167 . . . . 0.0 111.188 179.704 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . 0.804 ' HB3' ' HG3' ' A' ' 69' ' ' PRO . 25.3 t70 -165.25 173.61 11.1 Favored 'General case' 0 C--O 1.234 0.278 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 178.746 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.533 HD11 HG22 ' A' ' 79' ' ' ILE . 39.2 mm -81.26 96.64 3.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-O 120.958 0.408 . . . . 0.0 110.78 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' LYS . . . . . 0.408 ' HD3' ' HB2' ' A' ' 76' ' ' ARG . 70.3 mmtt 53.1 66.9 4.25 Favored Pre-proline 0 N--CA 1.467 0.407 0 CA-C-N 115.277 -0.874 . . . . 0.0 111.513 177.481 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . 0.804 ' HG3' ' HB3' ' A' ' 66' ' ' ASP . 17.1 Cg_exo . . . . . 0 C--O 1.234 0.281 0 C-N-CA 123.164 2.576 . . . . 0.0 112.172 -178.09 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.579 HG23 ' CB ' ' A' ' 64' ' ' LEU . 39.7 mt . . . . . 0 C--O 1.233 0.187 0 N-CA-C 110.188 -0.301 . . . . 0.0 110.188 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.635 HG11 HD13 ' A' ' 86' ' ' ILE . 61.0 t -64.45 129.95 28.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 121.031 0.444 . . . . 0.0 110.563 -179.15 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' ARG . . . . . 0.454 ' HA ' ' HD3' ' A' ' 69' ' ' PRO . 5.4 ptp180 -104.12 28.97 6.29 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.655 -173.883 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . 0.5 ' H ' HG12 ' A' ' 75' ' ' VAL . 11.3 t70 -69.94 -84.74 0.03 OUTLIER 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.851 -0.613 . . . . 0.0 111.272 -172.88 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' ASP . . . . . 0.4 ' H ' ' HB3' ' A' ' 77' ' ' ASP . 7.5 t70 -163.24 -169.64 2.05 Favored 'General case' 0 C--N 1.325 -0.5 0 N-CA-C 109.091 -0.707 . . . . 0.0 109.091 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' ILE . . . . . 0.533 HG22 HD11 ' A' ' 67' ' ' ILE . 13.0 tt -144.19 -28.04 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-O 121.013 0.435 . . . . 0.0 110.749 -179.118 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.517 ' HA ' HG21 ' A' ' 102' ' ' ILE . 14.7 t -103.3 -24.52 13.51 Favored 'General case' 0 N--CA 1.45 -0.44 0 CA-C-O 121.288 0.566 . . . . 0.0 110.058 -178.047 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 68.0 m -150.13 75.17 9.0 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.27 172.871 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' PRO . . . . . 0.476 ' HB2' ' HE2' ' A' ' 87' ' ' TYR . 9.1 Cg_endo -89.64 174.04 3.53 Favored 'Trans proline' 0 N--CA 1.454 -0.824 0 C-N-CA 123.267 2.645 . . . . 0.0 112.887 -177.08 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' ARG . . . . . 0.692 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 81.6 mtt85 -78.3 118.01 20.09 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.152 176.663 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' MET . . . . . 0.463 ' HE1' ' HA ' ' A' ' 109' ' ' VAL . 91.7 mmm -61.64 -23.77 66.28 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.302 -0.863 . . . . 0.0 111.565 -178.183 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.692 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 8.6 pt-20 -56.9 -29.34 62.93 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.842 0.354 . . . . 0.0 111.417 179.692 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.635 HD13 HG11 ' A' ' 75' ' ' VAL . 54.9 mt -79.28 -24.87 12.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-O 121.199 0.523 . . . . 0.0 110.858 -176.227 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . 0.476 ' HE2' ' HB2' ' A' ' 82' ' ' PRO . 91.5 m-85 -94.51 -27.67 15.85 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.934 -0.576 . . . . 0.0 111.193 -177.159 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . 0.446 ' HG3' ' O ' ' A' ' 84' ' ' MET . 78.1 mtp180 -65.77 131.46 46.37 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.509 0.671 . . . . 0.0 111.454 -176.552 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 93.17 -5.78 75.44 Favored Glycine 0 N--CA 1.448 -0.521 0 CA-C-N 114.798 -1.092 . . . . 0.0 112.36 -179.899 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . 1.085 ' HA ' ' HG3' ' A' ' 38' ' ' ARG . . . -73.6 153.39 40.22 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.888 0.375 . . . . 0.0 110.63 179.432 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -93.85 -20.72 19.79 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.807 -179.415 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . 0.513 ' HG ' ' HB3' ' A' ' 116' ' ' ARG . 3.7 tt -160.89 142.87 12.33 Favored 'General case' 0 N--CA 1.452 -0.365 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.64 -176.809 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.533 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 66.8 mt -132.31 126.72 56.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 177.188 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 19.7 p90 -137.38 160.78 38.11 Favored 'General case' 0 C--N 1.323 -0.579 0 C-N-CA 120.52 -0.472 . . . . 0.0 111.625 -178.155 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . 0.484 ' OG ' ' HB ' ' A' ' 42' ' ' VAL . 15.7 m -146.5 140.52 26.25 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.777 -178.565 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' ILE . . . . . 0.426 ' N ' HD12 ' A' ' 96' ' ' ILE . 3.6 mp -99.31 97.1 5.52 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 N-CA-C 110.026 -0.361 . . . . 0.0 110.026 178.728 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' ARG . . . . . 0.644 ' HG2' ' HA ' ' A' ' 121' ' ' PRO . 42.8 mtm105 53.77 77.25 0.45 Allowed Pre-proline 0 N--CA 1.468 0.467 0 CA-C-N 115.413 -0.812 . . . . 0.0 111.825 179.612 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 95.7 Cg_endo -88.46 159.42 6.64 Favored 'Trans proline' 0 N--CA 1.459 -0.514 0 C-N-CA 122.733 2.288 . . . . 0.0 112.417 179.775 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . 0.626 ' HD2' HD11 ' A' ' 102' ' ' ILE . 51.1 Cg_exo -53.85 147.8 40.11 Favored 'Trans proline' 0 C--N 1.348 0.507 0 C-N-CA 122.92 2.414 . . . . 0.0 112.115 175.955 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -66.92 -19.74 65.78 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.712 -173.164 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 101' ' ' GLU . . . . . 0.586 ' HG3' HG23 ' A' ' 102' ' ' ILE . 11.7 pt-20 -73.34 -22.47 60.3 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.881 -177.334 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.626 HD11 ' HD2' ' A' ' 99' ' ' PRO . 44.1 pt -109.31 5.51 9.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 N-CA-C 112.505 0.557 . . . . 0.0 112.505 -174.711 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 103' ' ' HIS . . . . . . . . . . . . . 46.9 m170 -58.33 -45.22 88.51 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 120.998 0.427 . . . . 0.0 110.624 178.812 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 17.6 m -75.35 -27.79 59.33 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.518 177.31 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.511 ' O ' HG23 ' A' ' 109' ' ' VAL . 10.2 m -69.98 -45.15 67.95 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.896 -177.896 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 84.2 mt -56.78 -38.28 72.29 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.037 0.446 . . . . 0.0 110.822 178.717 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 107' ' ' MET . . . . . 0.408 ' HA ' HD22 ' A' ' 117' ' ' LEU . 52.0 ttm -68.4 -42.59 78.79 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.473 -178.92 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 108' ' ' ARG . . . . . 0.445 ' HG2' ' HA ' ' A' ' 105' ' ' SER . 2.5 ptm180 -68.71 -29.92 68.46 Favored 'General case' 0 N--CA 1.462 0.137 0 C-N-CA 120.471 -0.492 . . . . 0.0 110.482 179.482 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.511 HG23 ' O ' ' A' ' 105' ' ' SER . 74.5 t -66.12 -47.6 84.28 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.182 0 CA-C-N 116.453 -0.34 . . . . 0.0 110.274 176.165 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -57.74 -43.74 85.59 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.393 177.553 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.418 ' HA ' ' HB1' ' A' ' 148' ' ' ALA . 18.7 t70 -61.83 -40.43 95.24 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.625 -0.716 . . . . 0.0 110.793 179.777 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -69.4 -39.6 77.86 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.551 -0.749 . . . . 0.0 112.059 -177.859 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.462 HG21 HD11 ' A' ' 93' ' ' ILE . 15.8 m -92.39 -27.42 4.7 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 116.552 -0.294 . . . . 0.0 111.709 -174.556 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 86.47 51.56 3.45 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.827 -0.701 . . . . 0.0 112.535 -179.782 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . 0.449 ' O ' ' HB3' ' A' ' 148' ' ' ALA . . . -131.67 165.55 23.46 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.064 0.459 . . . . 0.0 111.162 -178.683 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 116' ' ' ARG . . . . . 0.513 ' HB3' ' HG ' ' A' ' 92' ' ' LEU . 15.3 ttm180 -81.87 128.74 34.35 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.037 176.485 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . 0.533 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 49.8 tp -99.18 127.85 45.22 Favored 'General case' 0 C--N 1.32 -0.704 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 177.859 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 72.4 mt -128.25 125.51 64.34 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-O 120.903 0.382 . . . . 0.0 110.591 179.347 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 61.4 mt -130.27 130.45 65.56 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-O 120.811 0.339 . . . . 0.0 110.263 178.051 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 120' ' ' LYS . . . . . 0.716 ' HD2' HD22 ' A' ' 25' ' ' LEU . 49.9 tttm -116.16 94.23 41.4 Favored Pre-proline 0 C--N 1.324 -0.51 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.227 179.176 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 121' ' ' PRO . . . . . 0.644 ' HA ' ' HG2' ' A' ' 97' ' ' ARG . 89.1 Cg_endo -89.98 -159.7 0.09 OUTLIER 'Trans proline' 0 N--CA 1.459 -0.532 0 C-N-CA 122.799 2.333 . . . . 0.0 112.694 178.101 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 122' ' ' LEU . . . . . 0.54 ' HB3' ' HB3' ' A' ' 125' ' ' GLU . 11.9 tp -76.0 164.2 26.4 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.525 -0.762 . . . . 0.0 110.354 177.365 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 11.4 t -72.73 -28.58 62.73 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.008 0.432 . . . . 0.0 110.366 178.854 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -109.34 44.56 1.47 Allowed Glycine 0 N--CA 1.449 -0.469 0 N-CA-C 110.967 -0.853 . . . . 0.0 110.967 177.105 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . 0.54 ' HB3' ' HB3' ' A' ' 122' ' ' LEU . 31.8 tt0 -147.72 139.25 23.81 Favored 'General case' 0 C--N 1.321 -0.667 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 -174.539 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 17.2 t70 -118.82 161.7 19.7 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 121.068 0.461 . . . . 0.0 111.076 -178.667 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 60.7 mt . . . . . 0 C--N 1.319 -0.717 0 CA-C-N 115.353 -0.839 . . . . 0.0 109.311 177.606 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 132' ' ' LYS . . . . . 0.414 ' HG2' ' N ' ' A' ' 133' ' ' MET . 0.0 OUTLIER . . . . . 0 N--CA 1.465 0.303 0 CA-C-O 121.614 0.721 . . . . 0.0 111.898 . . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 133' ' ' MET . . . . . 0.414 ' N ' ' HG2' ' A' ' 132' ' ' LYS . 90.2 mtp -109.58 160.74 16.0 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.458 -0.792 . . . . 0.0 109.93 -178.759 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . 0.413 ' HE3' HG13 ' A' ' 136' ' ' VAL . 0.0 OUTLIER -95.83 142.7 27.78 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.088 0.471 . . . . 0.0 110.793 -176.062 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . 0.754 HD11 ' HD2' ' A' ' 142' ' ' TYR . 43.5 tp -75.35 131.35 40.2 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-N 115.45 -0.795 . . . . 0.0 110.317 178.833 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 136' ' ' VAL . . . . . 0.413 HG13 ' HE3' ' A' ' 134' ' ' LYS . 0.0 OUTLIER -128.22 137.73 56.63 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.755 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.542 178.564 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 19.5 m-80 -112.28 106.55 15.14 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 115.652 -0.704 . . . . 0.0 110.105 -179.941 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . 0.446 ' CD2' ' HB2' ' A' ' 28' ' ' TYR . 59.8 t80 -148.77 127.62 12.61 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.909 -178.41 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . 0.714 ' HA3' ' HB3' ' A' ' 24' ' ' ASP . . . 67.78 57.8 8.41 Favored Glycine 0 N--CA 1.445 -0.745 0 CA-C-N 115.807 -0.633 . . . . 0.0 114.166 171.223 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 140' ' ' ARG . . . . . 0.52 ' HD2' ' N ' ' A' ' 140' ' ' ARG . 2.4 mpt_? 62.6 10.91 4.4 Favored 'General case' 0 N--CA 1.465 0.316 0 C-N-CA 122.692 0.397 . . . . 0.0 112.059 173.84 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 10.6 t -145.7 153.01 40.52 Favored 'General case' 0 N--CA 1.447 -0.592 0 CA-C-O 120.973 0.416 . . . . 0.0 110.326 -179.813 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 142' ' ' TYR . . . . . 0.754 ' HD2' HD11 ' A' ' 135' ' ' LEU . 5.0 p90 -122.26 137.73 54.74 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 116.052 -0.522 . . . . 0.0 109.716 174.518 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 143' ' ' PHE . . . . . 0.423 ' O ' HD12 ' A' ' 135' ' ' LEU . 21.4 p90 -145.43 -169.64 3.26 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.466 -0.788 . . . . 0.0 109.796 -174.024 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 83.4 m-85 -117.54 137.27 52.68 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 120.754 0.311 . . . . 0.0 110.932 179.903 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 145' ' ' GLU . . . . . 0.407 ' OE1' ' HD3' ' A' ' 116' ' ' ARG . 15.8 pt-20 -130.36 162.42 29.12 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.157 -0.474 . . . . 0.0 109.731 173.737 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 40.7 t80 -142.38 124.24 15.18 Favored 'General case' 0 C--N 1.317 -0.831 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 174.672 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 147' ' ' ILE . . . . . 0.417 HD12 ' N ' ' A' ' 147' ' ' ILE . 2.7 mp -93.93 98.69 8.49 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.68 0 N-CA-C 109.52 -0.548 . . . . 0.0 109.52 -179.366 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . 0.449 ' HB3' ' O ' ' A' ' 115' ' ' ALA . . . -86.89 108.74 18.91 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.625 176.663 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 . . . . . 0 C--N 1.319 -0.719 0 CA-C-O 121.136 0.493 . . . . 0.0 110.601 -179.372 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' TRP . . . . . 0.404 ' O ' ' HB3' ' A' ' 25' ' ' LEU . 89.3 m95 . . . . . 0 N--CA 1.454 -0.243 0 CA-C-O 120.626 0.25 . . . . 0.0 111.057 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 21.0 t-20 -52.34 -50.47 62.25 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.889 -178.776 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 11.3 m-20 -60.5 -33.49 72.69 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.476 -0.329 . . . . 0.0 111.42 -178.22 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.567 HD22 ' HG3' ' A' ' 120' ' ' LYS . 50.6 tp -59.17 -50.65 73.21 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.926 0.393 . . . . 0.0 110.28 176.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . 0.403 ' HB2' HG13 ' A' ' 50' ' ' VAL . . . -58.49 -49.66 76.54 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.639 179.47 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.427 ' O ' ' HG3' ' A' ' 31' ' ' ARG . 86.4 t -52.74 -46.51 50.8 Favored 'Isoleucine or valine' 0 C--O 1.233 0.209 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.949 177.893 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 86.0 t80 -56.29 -46.18 79.88 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.882 179.417 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 71.1 mt -66.78 -43.08 90.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.972 -179.484 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.422 HG12 HG23 ' A' ' 54' ' ' ILE . 88.9 mt -56.4 -48.79 79.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 115.817 -0.628 . . . . 0.0 111.067 179.216 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . 0.427 ' HG3' ' O ' ' A' ' 27' ' ' VAL . 61.9 mtp180 -63.25 -36.41 83.58 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.904 -0.589 . . . . 0.0 111.072 -178.808 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 46.6 t -77.29 -25.92 51.83 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.333 -175.338 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 13.7 p -97.03 -76.63 0.51 Allowed 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.785 0.326 . . . . 0.0 111.301 -177.865 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.505 ' O ' HG22 ' A' ' 37' ' ' THR . . . 98.22 167.54 31.54 Favored Glycine 0 N--CA 1.449 -0.452 0 C-N-CA 120.951 -0.642 . . . . 0.0 112.13 -178.601 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 6.7 Cg_exo -73.42 143.54 34.98 Favored 'Trans proline' 0 N--CA 1.462 -0.327 0 C-N-CA 122.878 2.385 . . . . 0.0 112.379 -179.36 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 97.19 -11.29 65.6 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.67 -0.776 . . . . 0.0 113.441 176.218 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . 0.505 HG22 ' O ' ' A' ' 34' ' ' GLY . 12.6 t -103.52 -179.02 3.83 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 177.501 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' ARG . . . . . 0.681 ' HB2' ' HA ' ' A' ' 90' ' ' ALA . 62.5 mtp180 -115.11 136.63 52.91 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.809 0.338 . . . . 0.0 110.763 -179.227 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.429 HG23 HG21 ' A' ' 60' ' ' VAL . 47.5 t -130.9 138.18 54.16 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 177.913 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.454 HG11 ' CE1' ' A' ' 87' ' ' TYR . 33.4 t -118.95 125.45 74.5 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 CA-C-O 120.837 0.351 . . . . 0.0 111.336 -177.254 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . 0.436 ' HB3' HD23 ' A' ' 64' ' ' LEU . 43.4 tt0 -99.57 112.15 24.4 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.954 -0.566 . . . . 0.0 109.645 175.462 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 60.5 t -97.45 121.16 47.69 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-N 116.0 -0.546 . . . . 0.0 110.385 -179.143 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 90.35 46.04 4.19 Favored Glycine 0 N--CA 1.444 -0.795 0 C-N-CA 120.539 -0.839 . . . . 0.0 111.861 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.442 ' HB1' ' CD2' ' A' ' 48' ' ' LEU . . . -59.22 -32.94 70.41 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-O 121.328 0.585 . . . . 0.0 110.932 179.292 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 63.88 -123.57 28.74 Favored Glycine 0 N--CA 1.445 -0.701 0 CA-C-N 115.714 -0.675 . . . . 0.0 112.597 177.104 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 30.5 mmt-85 -122.96 9.77 9.41 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 120.847 0.356 . . . . 0.0 110.498 -177.005 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 19.0 p90 -137.36 113.24 9.69 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 121.289 0.566 . . . . 0.0 110.82 -176.845 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.442 ' CD2' ' HB1' ' A' ' 44' ' ' ALA . 68.8 mt -104.64 60.87 0.7 Allowed 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.56 -177.164 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 72.1 t80 -75.56 -52.84 9.68 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.938 0.399 . . . . 0.0 110.88 -179.559 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.45 ' O ' HG13 ' A' ' 54' ' ' ILE . 49.1 t -67.87 -52.78 36.15 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-N 115.868 -0.606 . . . . 0.0 110.722 -176.562 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . 0.529 ' HB3' HD21 ' A' ' 64' ' ' LEU . 0.2 OUTLIER -54.84 -43.15 72.76 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.767 -0.651 . . . . 0.0 112.491 -178.933 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.417 ' O ' ' HG3' ' A' ' 56' ' ' LYS . 20.7 t70 -67.73 -42.96 81.05 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.834 0.349 . . . . 0.0 110.591 -179.104 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 75.9 t80 -63.99 -40.08 95.57 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.153 -179.009 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.45 HG13 ' O ' ' A' ' 50' ' ' VAL . 80.0 mt -63.01 -45.78 97.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.474 -0.33 . . . . 0.0 111.367 -179.709 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 33.2 ptt180 -72.04 -16.84 62.05 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.89 0.376 . . . . 0.0 110.871 -178.785 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . 0.417 ' HG3' ' O ' ' A' ' 52' ' ' ASP . 24.2 mtpp -73.08 -30.55 63.75 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.318 176.882 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 28.0 m-70 -102.51 -56.61 2.21 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.891 -177.434 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 6.8 p -100.46 135.4 41.95 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 120.982 0.42 . . . . 0.0 112.057 -174.399 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -81.39 65.05 6.36 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 122.196 0.998 . . . . 0.0 108.969 171.053 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.429 HG21 HG23 ' A' ' 39' ' ' VAL . 8.8 p -100.54 148.54 6.77 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.09 0 CA-C-N 114.322 -1.308 . . . . 0.0 110.111 178.78 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . 0.563 ' HB3' ' HG2' ' A' ' 38' ' ' ARG . 9.3 t70 -74.77 84.89 2.16 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 176.773 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . 0.425 HD23 ' HB ' ' A' ' 39' ' ' VAL . 3.1 tm? -94.57 116.83 29.24 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 115.441 -0.799 . . . . 0.0 110.287 -173.92 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 60.1 t -113.61 139.09 40.89 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 CA-C-N 115.604 -0.725 . . . . 0.0 110.561 -176.524 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . 0.529 HD21 ' HB3' ' A' ' 51' ' ' SER . 31.6 mt -112.37 136.12 52.23 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 110.171 -0.307 . . . . 0.0 110.171 178.735 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 15.9 p -118.81 125.43 49.55 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.102 0.477 . . . . 0.0 110.706 175.366 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . 0.478 ' HB3' HG21 ' A' ' 74' ' ' ILE . 23.9 t70 -154.82 140.46 17.98 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.532 -0.758 . . . . 0.0 109.247 -179.853 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.496 HG22 ' HG2' ' A' ' 68' ' ' LYS . 59.3 mt -74.44 124.17 31.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-N 116.519 -0.31 . . . . 0.0 110.315 -177.964 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' LYS . . . . . 0.496 ' HG2' HG22 ' A' ' 67' ' ' ILE . 59.8 pttt 39.72 69.72 1.66 Allowed Pre-proline 0 N--CA 1.469 0.499 0 O-C-N 124.29 0.994 . . . . 0.0 111.684 -174.296 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . 0.561 ' CB ' ' HB ' ' A' ' 74' ' ' ILE . 44.1 Cg_endo . . . . . 0 C--O 1.232 0.218 0 C-N-CA 122.856 2.371 . . . . 0.0 113.017 -174.345 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.561 ' HB ' ' CB ' ' A' ' 69' ' ' PRO . 55.3 mt . . . . . 0 N--CA 1.453 -0.291 0 N-CA-C 109.713 -0.477 . . . . 0.0 109.713 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.555 HG11 HD13 ' A' ' 86' ' ' ILE . 66.3 t -66.27 123.72 19.85 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-O 120.884 0.374 . . . . 0.0 110.266 -179.344 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 18.7 ptp180 -85.9 48.61 1.63 Allowed 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.44 0.638 . . . . 0.0 110.695 -176.251 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . 0.43 ' HB2' HG12 ' A' ' 75' ' ' VAL . 2.7 t70 -89.17 -154.56 0.31 Allowed 'General case' 0 C--N 1.321 -0.641 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 179.214 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' ASP . . . . . 0.521 ' OD1' HG22 ' A' ' 80' ' ' THR . 4.9 t70 -136.25 -176.42 4.32 Favored 'General case' 0 C--N 1.321 -0.633 0 C-N-CA 120.737 -0.385 . . . . 0.0 110.251 -178.916 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 8.9 tp -127.37 -28.18 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-O 120.822 0.344 . . . . 0.0 110.502 179.71 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.521 HG22 ' OD1' ' A' ' 78' ' ' ASP . 15.0 t -89.06 -25.75 21.77 Favored 'General case' 0 N--CA 1.451 -0.387 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 177.006 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 34.2 t -135.34 70.5 67.91 Favored Pre-proline 0 C--N 1.326 -0.442 0 CA-C-N 115.33 -0.85 . . . . 0.0 108.997 170.822 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_endo -87.32 157.01 8.11 Favored 'Trans proline' 0 N--CA 1.453 -0.909 0 C-N-CA 122.496 2.131 . . . . 0.0 112.518 -176.146 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' ARG . . . . . 0.765 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 50.0 mtt180 -89.12 111.92 22.79 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.199 173.058 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' MET . . . . . 0.523 ' HE1' ' HA ' ' A' ' 109' ' ' VAL . 95.2 mmm -66.83 -17.65 64.99 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.5 -177.62 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.765 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 9.9 pt-20 -62.35 -23.35 66.74 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.628 -0.714 . . . . 0.0 111.508 179.078 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.555 HD13 HG11 ' A' ' 75' ' ' VAL . 67.3 mt -84.36 -39.54 14.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-O 121.117 0.484 . . . . 0.0 110.363 179.724 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . 0.454 ' CE1' HG11 ' A' ' 40' ' ' VAL . 90.7 m-85 -78.86 -32.19 45.9 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.756 -0.657 . . . . 0.0 111.322 -177.881 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . 0.438 ' HG3' HG12 ' A' ' 113' ' ' VAL . 57.9 mtt180 -67.01 115.33 6.6 Favored 'General case' 0 CA--C 1.516 -0.339 0 CA-C-O 121.317 0.58 . . . . 0.0 110.633 -179.933 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 119.44 -12.05 11.23 Favored Glycine 0 N--CA 1.448 -0.522 0 CA-C-N 115.037 -0.983 . . . . 0.0 111.455 -175.213 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . 0.681 ' HA ' ' HB2' ' A' ' 38' ' ' ARG . . . -82.94 147.74 28.06 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.881 0.372 . . . . 0.0 110.898 178.346 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -96.73 -22.26 17.09 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.811 179.529 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . 0.462 ' HG ' ' HB3' ' A' ' 116' ' ' ARG . 5.3 tt -150.85 139.79 20.95 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.682 -178.442 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.569 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 67.5 mt -131.57 125.37 56.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.688 -0.687 . . . . 0.0 109.258 178.69 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 19.0 p90 -128.42 155.48 44.69 Favored 'General case' 0 C--N 1.321 -0.645 0 C-N-CA 120.618 -0.433 . . . . 0.0 110.965 -178.961 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 18.3 m -132.74 130.41 39.94 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.554 -178.436 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 65.4 mt -93.55 103.14 14.37 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.682 -178.894 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 70.6 mtp180 54.38 67.36 3.45 Favored Pre-proline 0 N--CA 1.466 0.329 0 CA-C-N 115.489 -0.778 . . . . 0.0 111.998 -178.517 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' PRO . . . . . 0.447 ' HA ' ' HD3' ' A' ' 99' ' ' PRO . 72.5 Cg_endo -76.91 140.58 20.53 Favored 'Trans proline' 0 N--CA 1.461 -0.402 0 C-N-CA 122.244 1.963 . . . . 0.0 112.251 179.615 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . 0.626 ' HD2' HD11 ' A' ' 102' ' ' ILE . 38.1 Cg_exo -60.2 147.56 93.01 Favored 'Trans proline' 0 C--O 1.235 0.331 0 C-N-CA 122.741 2.294 . . . . 0.0 111.942 176.606 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . 0.64 ' HA ' ' NE2' ' A' ' 103' ' ' HIS . . . -78.54 31.15 0.19 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.227 0.537 . . . . 0.0 111.331 -175.542 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 101' ' ' GLU . . . . . 0.565 ' HG2' ' HB2' ' A' ' 99' ' ' PRO . 7.7 pt-20 -127.55 -1.63 6.16 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-N 115.967 -0.561 . . . . 0.0 111.164 -176.908 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.626 HD11 ' HD2' ' A' ' 99' ' ' PRO . 30.9 pt -131.41 10.33 1.83 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 N-CA-C 112.118 0.414 . . . . 0.0 112.118 -178.308 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 103' ' ' HIS . . . . . 0.64 ' NE2' ' HA ' ' A' ' 100' ' ' ALA . 9.7 m-70 -54.77 -51.65 65.06 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.244 -0.435 . . . . 0.0 112.006 -176.738 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 15.5 m -62.54 -32.49 73.44 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.498 -0.319 . . . . 0.0 111.007 -177.939 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.592 ' O ' HG23 ' A' ' 109' ' ' VAL . 21.0 m -67.45 -42.3 83.32 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.329 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 73.9 mt -64.78 -43.96 91.54 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.493 179.56 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 107' ' ' MET . . . . . 0.4 ' HG3' ' O ' ' A' ' 103' ' ' HIS . 77.0 mtp -63.18 -41.8 99.27 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.55 -176.244 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 2.9 ptp180 -70.27 -30.78 67.89 Favored 'General case' 0 C--N 1.332 -0.189 0 C-N-CA 120.879 -0.329 . . . . 0.0 111.145 -178.497 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.592 HG23 ' O ' ' A' ' 105' ' ' SER . 75.3 t -63.87 -45.2 97.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.889 0.376 . . . . 0.0 110.062 177.466 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -58.42 -44.4 89.07 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.619 177.71 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.455 ' HA ' ' HB1' ' A' ' 148' ' ' ALA . 13.6 t70 -64.84 -42.48 94.88 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.059 179.586 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -64.8 -41.74 95.56 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.712 -0.676 . . . . 0.0 112.055 -177.488 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.438 HG12 ' HG3' ' A' ' 88' ' ' ARG . 12.2 m -92.57 -24.78 5.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 CA-C-N 116.506 -0.315 . . . . 0.0 111.694 -174.983 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 88.43 49.33 3.71 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.764 -0.731 . . . . 0.0 111.997 179.731 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -129.07 156.5 43.76 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 120.738 0.304 . . . . 0.0 111.142 -177.689 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 116' ' ' ARG . . . . . 0.534 ' HD3' ' OE1' ' A' ' 145' ' ' GLU . 16.4 ttm180 -80.26 125.16 29.52 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.158 -0.474 . . . . 0.0 109.728 177.549 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . 0.569 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 48.7 tp -94.47 119.31 32.99 Favored 'General case' 0 C--N 1.322 -0.619 0 N-CA-C 110.158 -0.312 . . . . 0.0 110.158 179.815 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 63.9 mt -114.91 117.97 57.31 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-O 121.183 0.516 . . . . 0.0 110.732 179.398 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 64.6 mt -112.03 132.22 61.28 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 115.923 -0.581 . . . . 0.0 110.564 179.829 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 120' ' ' LYS . . . . . 0.953 ' HD2' ' HB3' ' A' ' 143' ' ' PHE . 23.1 mmmt -102.58 99.97 14.8 Favored Pre-proline 0 C--N 1.328 -0.347 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.229 174.419 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 121' ' ' PRO . . . . . 0.425 ' HG3' ' HD2' ' A' ' 144' ' ' TYR . 88.4 Cg_endo -82.78 -158.95 0.1 OUTLIER 'Trans proline' 0 N--CA 1.459 -0.535 0 C-N-CA 122.563 2.175 . . . . 0.0 111.351 171.861 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 122' ' ' LEU . . . . . 0.829 ' HB2' ' HB2' ' A' ' 125' ' ' GLU . 3.6 mm? -99.88 -171.04 1.98 Allowed 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 110.267 -0.272 . . . . 0.0 110.267 179.916 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 8.7 t -88.76 -35.11 16.85 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.708 0.289 . . . . 0.0 111.19 -176.719 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -114.78 12.61 20.48 Favored Glycine 0 N--CA 1.449 -0.499 0 C-N-CA 120.436 -0.887 . . . . 0.0 111.296 178.53 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . 0.829 ' HB2' ' HB2' ' A' ' 122' ' ' LEU . 28.2 mt-10 -131.52 126.52 35.12 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.248 -0.476 . . . . 0.0 110.075 -176.342 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 11.3 t70 -87.01 179.28 6.71 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.679 -0.692 . . . . 0.0 109.885 -177.504 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . 0.58 HD11 ' HB2' ' A' ' 144' ' ' TYR . 56.5 mt . . . . . 0 C--N 1.326 -0.438 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 178.799 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 33.5 mttp . . . . . 0 CA--C 1.519 -0.212 0 CA-C-O 121.119 0.485 . . . . 0.0 111.03 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 133' ' ' MET . . . . . 0.55 ' HG2' ' HB2' ' A' ' 146' ' ' TYR . 84.8 mtp -111.14 165.63 11.74 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.857 -0.611 . . . . 0.0 109.405 176.144 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . 0.408 ' HE3' ' OE2' ' A' ' 145' ' ' GLU . 6.9 pttp -130.51 140.23 50.5 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.09 0.472 . . . . 0.0 111.754 -175.974 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . 0.57 HD11 ' HD2' ' A' ' 142' ' ' TYR . 39.2 tp -76.93 122.36 24.76 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.585 -0.734 . . . . 0.0 110.777 -179.645 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 136' ' ' VAL . . . . . 0.433 HG23 ' CD1' ' A' ' 143' ' ' PHE . 0.0 OUTLIER -117.95 142.25 33.23 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.761 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.437 178.426 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 137' ' ' ASN . . . . . 0.591 ' ND2' ' HB3' ' A' ' 142' ' ' TYR . 13.8 m120 -117.9 110.32 17.6 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.442 -176.022 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . 0.436 ' O ' HG22 ' A' ' 141' ' ' THR . 76.0 t80 -135.23 130.09 34.69 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.248 -0.433 . . . . 0.0 109.877 -179.434 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 63.75 26.36 69.87 Favored Glycine 0 N--CA 1.453 -0.217 0 C-N-CA 120.54 -0.838 . . . . 0.0 111.702 -176.784 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 21.2 mtp180 66.67 7.69 5.34 Favored 'General case' 0 C--N 1.33 -0.274 0 C-N-CA 123.304 0.641 . . . . 0.0 112.436 -178.731 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 141' ' ' THR . . . . . 0.436 HG22 ' O ' ' A' ' 138' ' ' TYR . 10.8 t -107.48 139.71 41.57 Favored 'General case' 0 N--CA 1.446 -0.659 0 N-CA-C 108.663 -0.866 . . . . 0.0 108.663 169.84 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 142' ' ' TYR . . . . . 0.591 ' HB3' ' ND2' ' A' ' 137' ' ' ASN . 17.0 p90 -113.86 149.08 35.59 Favored 'General case' 0 C--N 1.315 -0.892 0 CA-C-O 121.69 0.757 . . . . 0.0 111.513 -177.581 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 143' ' ' PHE . . . . . 0.953 ' HB3' ' HD2' ' A' ' 120' ' ' LYS . 3.5 p90 -151.41 178.96 8.76 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 114.238 -1.347 . . . . 0.0 108.83 -178.98 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 144' ' ' TYR . . . . . 0.58 ' HB2' HD11 ' A' ' 127' ' ' ILE . 80.6 m-85 -115.58 119.72 37.06 Favored 'General case' 0 C--N 1.313 -0.98 0 C-N-CA 120.62 -0.432 . . . . 0.0 110.529 179.82 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 145' ' ' GLU . . . . . 0.534 ' OE1' ' HD3' ' A' ' 116' ' ' ARG . 18.3 pt-20 -108.15 156.96 18.73 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 176.2 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . 0.55 ' HB2' ' HG2' ' A' ' 133' ' ' MET . 22.7 t80 -137.13 120.68 17.17 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-N 115.626 -0.715 . . . . 0.0 109.66 176.647 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 147' ' ' ILE . . . . . 0.434 ' N ' HD12 ' A' ' 147' ' ' ILE . 3.2 mp -89.05 101.5 12.05 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 -178.481 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . 0.455 ' HB1' ' HA ' ' A' ' 111' ' ' ASP . . . -74.37 96.43 2.86 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 121.225 0.536 . . . . 0.0 109.76 177.19 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 11.6 pt-20 . . . . . 0 C--N 1.314 -0.941 0 CA-C-N 115.155 -0.93 . . . . 0.0 109.752 178.89 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 40.2 m95 . . . . . 0 N--CA 1.461 0.122 0 CA-C-O 121.033 0.444 . . . . 0.0 110.533 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 25.5 t-20 -65.18 -45.55 84.39 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.553 -0.749 . . . . 0.0 110.28 -178.024 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -57.24 -46.29 83.13 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.679 -0.691 . . . . 0.0 110.255 177.953 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 62.2 tp -61.52 -46.96 87.74 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.238 -0.892 . . . . 0.0 110.958 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . 0.487 ' O ' HG13 ' A' ' 30' ' ' ILE . . . -56.19 -52.47 64.28 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.164 -179.742 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.448 ' HA ' HD12 ' A' ' 30' ' ' ILE . 84.0 t -56.12 -42.25 71.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.206 179.131 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 57.4 t80 -57.41 -45.99 83.98 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.574 179.733 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 67.0 mt -67.28 -40.23 84.48 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.785 179.783 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.576 HG12 HG23 ' A' ' 54' ' ' ILE . 95.4 mt -58.85 -38.42 72.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 115.969 -0.56 . . . . 0.0 111.125 179.401 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 40.1 mtp-105 -71.99 -30.32 65.13 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.839 -0.619 . . . . 0.0 111.332 -178.855 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 42.9 t -89.2 -17.41 29.17 Favored 'General case' 0 C--N 1.324 -0.513 0 N-CA-C 111.956 0.354 . . . . 0.0 111.956 -176.489 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 11.5 p -94.68 -79.17 0.43 Allowed 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 111.961 0.356 . . . . 0.0 111.961 -176.086 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.48 ' O ' HG22 ' A' ' 37' ' ' THR . . . 101.16 136.73 9.45 Favored Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.812 -0.709 . . . . 0.0 111.847 -176.698 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . 0.411 ' HD3' ' HA2' ' A' ' 34' ' ' GLY . 48.4 Cg_exo -55.84 126.48 22.55 Favored 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 123.076 2.518 . . . . 0.0 112.767 -176.066 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 112.73 -18.51 22.21 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.294 -0.955 . . . . 0.0 113.48 175.278 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . 0.48 HG22 ' O ' ' A' ' 34' ' ' GLY . 11.1 t -86.76 -173.6 4.56 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.995 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' ARG . . . . . 0.505 ' HG2' ' CB ' ' A' ' 61' ' ' ASP . 92.1 mtm-85 -118.45 135.2 54.5 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 120.932 0.396 . . . . 0.0 110.735 176.634 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.497 HG23 HG11 ' A' ' 60' ' ' VAL . 90.7 t -130.19 127.44 63.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 176.904 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.433 HG11 ' CE1' ' A' ' 87' ' ' TYR . 35.4 t -109.06 128.79 64.67 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-O 120.937 0.399 . . . . 0.0 111.915 -173.02 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . 0.723 ' HB3' HD23 ' A' ' 64' ' ' LEU . 6.3 tp10 -103.3 127.92 50.5 Favored 'General case' 0 C--O 1.237 0.416 0 CA-C-N 115.379 -0.828 . . . . 0.0 109.452 174.092 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.567 ' HB ' ' HB3' ' A' ' 95' ' ' SER . 35.2 t -106.05 98.91 7.49 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-O 120.974 0.416 . . . . 0.0 110.535 -179.178 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 101.08 84.8 1.83 Allowed Glycine 0 N--CA 1.451 -0.333 0 N-CA-C 111.471 -0.651 . . . . 0.0 111.471 -176.778 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.448 ' HB1' HD21 ' A' ' 48' ' ' LEU . . . -83.07 -40.83 19.35 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 112.106 0.41 . . . . 0.0 112.106 -172.107 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 57.3 -127.55 45.19 Favored Glycine 0 CA--C 1.521 0.447 0 C-N-CA 121.077 -0.582 . . . . 0.0 112.713 179.824 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 52.4 mtp180 -120.42 2.49 10.77 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.866 0.365 . . . . 0.0 111.21 179.071 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.566 ' CE1' ' HB ' ' A' ' 96' ' ' ILE . 6.3 p90 -96.85 58.29 1.61 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.379 0.609 . . . . 0.0 111.088 -176.166 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.448 HD21 ' HB1' ' A' ' 44' ' ' ALA . 83.8 mt -81.68 8.43 9.92 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.79 -0.641 . . . . 0.0 112.12 -174.425 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 75.7 t80 -57.95 -48.75 79.04 Favored 'General case' 0 N--CA 1.463 0.201 0 CA-C-O 120.589 0.233 . . . . 0.0 111.195 -179.802 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.45 ' O ' HG13 ' A' ' 54' ' ' ILE . 85.3 t -58.96 -51.73 69.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.892 -178.398 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . 0.503 ' CB ' HD21 ' A' ' 64' ' ' LEU . 3.9 p -69.79 -25.76 63.94 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.004 -0.544 . . . . 0.0 112.346 -174.418 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.522 ' O ' ' HG2' ' A' ' 55' ' ' ARG . 17.5 t70 -83.06 -41.46 18.6 Favored 'General case' 0 C--N 1.325 -0.462 0 C-N-CA 120.806 -0.358 . . . . 0.0 110.3 177.232 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 66.4 t80 -58.16 -43.75 87.55 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.545 178.839 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.576 HG23 HG12 ' A' ' 30' ' ' ILE . 89.0 mt -60.2 -47.6 91.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.192 178.326 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' ARG . . . . . 0.522 ' HG2' ' O ' ' A' ' 52' ' ' ASP . 7.9 ptp180 -71.98 -16.31 62.08 Favored 'General case' 0 CA--C 1.532 0.27 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.381 -174.725 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 44.2 mmtm -77.1 -37.57 54.03 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.839 0.352 . . . . 0.0 110.569 176.316 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 13.3 m-70 -83.79 -55.32 4.32 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.67 179.694 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 68.0 m -117.13 127.97 54.66 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.169 -179.025 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 1.3 mptm? -77.5 63.36 2.63 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-O 121.925 0.869 . . . . 0.0 110.475 176.712 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.497 HG11 HG23 ' A' ' 39' ' ' VAL . 66.1 t -82.84 142.35 13.7 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.922 0 CA-C-N 114.444 -1.253 . . . . 0.0 109.09 173.888 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . 0.505 ' CB ' ' HG2' ' A' ' 38' ' ' ARG . 0.3 OUTLIER -73.19 80.08 1.29 Allowed 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.3 0.571 . . . . 0.0 109.5 175.27 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . 0.402 ' HA ' ' O ' ' A' ' 39' ' ' VAL . 3.1 tt -84.08 114.88 22.07 Favored 'General case' 0 N--CA 1.444 -0.755 0 CA-C-N 115.598 -0.728 . . . . 0.0 109.378 -178.074 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.401 HG11 ' CG2' ' A' ' 86' ' ' ILE . 58.2 t -99.28 119.52 47.4 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.706 0 CA-C-N 115.296 -0.865 . . . . 0.0 110.229 -177.381 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . 0.723 HD23 ' HB3' ' A' ' 41' ' ' GLU . 65.8 mt -98.3 131.37 44.67 Favored 'General case' 0 C--N 1.316 -0.87 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 176.964 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.41 ' OG1' ' HA ' ' A' ' 42' ' ' VAL . 36.2 p -116.87 130.56 56.79 Favored 'General case' 0 C--N 1.318 -0.799 0 N-CA-C 109.973 -0.38 . . . . 0.0 109.973 177.021 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 5.8 t70 -157.56 161.93 38.78 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 -178.72 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.698 HD11 HG22 ' A' ' 79' ' ' ILE . 48.7 mm -76.63 95.37 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-O 120.835 0.35 . . . . 0.0 110.145 -177.716 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 56.8 mtpt 50.36 70.29 2.12 Favored Pre-proline 0 CA--C 1.535 0.373 0 CA-C-N 115.192 -0.913 . . . . 0.0 111.68 177.437 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . 0.676 ' HD2' ' HG2' ' A' ' 76' ' ' ARG . 37.0 Cg_endo . . . . . 0 C--N 1.345 0.361 0 C-N-CA 123.455 2.77 . . . . 0.0 112.865 -179.121 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.452 HG23 ' CB ' ' A' ' 64' ' ' LEU . 41.0 mt . . . . . 0 N--CA 1.449 -0.488 0 N-CA-C 109.606 -0.516 . . . . 0.0 109.606 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.526 HG12 ' H ' ' A' ' 77' ' ' ASP . 64.3 t -74.12 135.32 27.73 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-O 120.866 0.365 . . . . 0.0 110.029 179.95 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' ARG . . . . . 0.676 ' HG2' ' HD2' ' A' ' 69' ' ' PRO . 26.6 mtp85 -89.74 21.03 3.71 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.907 -0.588 . . . . 0.0 111.856 -174.096 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . 0.526 ' H ' HG12 ' A' ' 75' ' ' VAL . 1.1 m-20 -80.19 160.62 25.57 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.785 0.326 . . . . 0.0 110.843 -179.396 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' ASP . . . . . 0.406 ' HB3' ' O ' ' A' ' 81' ' ' SER . 11.0 t70 -75.22 152.93 38.29 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.934 -173.789 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' ILE . . . . . 0.698 HG22 HD11 ' A' ' 67' ' ' ILE . 12.4 tt -91.15 -31.42 5.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.883 -175.475 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 11.1 t -99.73 -24.47 14.69 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.291 0.567 . . . . 0.0 109.98 -177.184 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . 0.406 ' O ' ' HB3' ' A' ' 78' ' ' ASP . 27.9 m -126.6 74.66 74.74 Favored Pre-proline 0 C--N 1.328 -0.362 0 CA-C-N 115.942 -0.572 . . . . 0.0 109.876 172.472 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 98.1 Cg_endo -90.93 -162.27 0.11 Allowed 'Trans proline' 0 N--CA 1.459 -0.541 0 C-N-CA 123.379 2.72 . . . . 0.0 113.219 -174.071 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 94.8 mtt180 -126.2 116.45 21.33 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.348 178.319 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' MET . . . . . 0.835 ' HA ' ' HD2' ' A' ' 87' ' ' TYR . 25.3 mtp -66.14 -18.5 65.39 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 112.252 0.464 . . . . 0.0 112.252 -177.259 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.417 ' HA ' ' HD3' ' A' ' 88' ' ' ARG . 10.8 pt-20 -65.63 -25.78 67.52 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.094 0.473 . . . . 0.0 110.406 179.335 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.401 ' CG2' HG11 ' A' ' 63' ' ' VAL . 68.3 mt -73.54 -36.74 48.55 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 115.77 -0.65 . . . . 0.0 109.922 177.06 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . 0.835 ' HD2' ' HA ' ' A' ' 84' ' ' MET . 74.2 m-85 -77.92 -30.56 50.65 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.633 -0.712 . . . . 0.0 110.754 -178.242 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . 0.417 ' HD3' ' HA ' ' A' ' 85' ' ' GLU . 69.9 mtp180 -58.17 125.25 22.39 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.964 178.81 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . 0.494 ' HA3' ' NH2' ' A' ' 38' ' ' ARG . . . 97.71 -8.68 63.88 Favored Glycine 0 N--CA 1.447 -0.605 0 C-N-CA 120.821 -0.704 . . . . 0.0 112.45 179.016 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -74.82 142.63 44.19 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 120.777 0.322 . . . . 0.0 110.373 178.277 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -94.39 -18.02 21.96 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.513 179.333 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . 0.417 HD23 ' N ' ' A' ' 93' ' ' ILE . 3.6 tt -153.72 140.05 18.59 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.337 -179.154 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.574 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 71.6 mt -132.24 126.17 55.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 N-CA-C 109.032 -0.729 . . . . 0.0 109.032 178.139 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' TYR . . . . . 0.409 ' HE1' HG12 ' A' ' 39' ' ' VAL . 2.0 p90 -135.29 167.18 21.5 Favored 'General case' 0 C--N 1.32 -0.699 0 C-N-CA 120.663 -0.415 . . . . 0.0 110.535 -178.258 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . 0.633 ' HA ' ' OE1' ' A' ' 41' ' ' GLU . 4.8 p -153.93 120.32 5.47 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.632 -178.447 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' ILE . . . . . 0.566 ' HB ' ' CE1' ' A' ' 47' ' ' PHE . 46.8 mm -80.81 97.23 3.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.684 179.374 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 2.2 tmt_? 52.66 76.91 0.48 Allowed Pre-proline 0 CA--C 1.534 0.353 0 CA-C-N 114.997 -1.001 . . . . 0.0 111.393 177.921 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 69.1 Cg_endo -89.85 161.99 5.06 Favored 'Trans proline' 0 N--CA 1.457 -0.655 0 C-N-CA 122.856 2.371 . . . . 0.0 112.343 177.589 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . 0.438 ' HB2' ' HG2' ' A' ' 101' ' ' GLU . 14.6 Cg_endo -60.12 147.64 92.51 Favored 'Trans proline' 0 C--N 1.345 0.367 0 C-N-CA 122.275 1.983 . . . . 0.0 111.858 174.64 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -78.13 33.55 0.19 Allowed 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.928 -176.34 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 101' ' ' GLU . . . . . 0.663 ' HG3' HG23 ' A' ' 102' ' ' ILE . 9.7 pt-20 -116.09 -23.35 8.52 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.685 0.278 . . . . 0.0 110.712 176.549 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.663 HG23 ' HG3' ' A' ' 101' ' ' GLU . 30.1 pt -109.83 -0.26 9.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 N-CA-C 112.006 0.373 . . . . 0.0 112.006 -174.667 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 103' ' ' HIS . . . . . . . . . . . . . 22.1 p-80 -60.66 -43.4 97.67 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 121.093 0.473 . . . . 0.0 110.817 -178.228 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 4.0 p -73.78 -29.41 62.17 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.987 -0.552 . . . . 0.0 110.742 179.094 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.492 ' O ' HG23 ' A' ' 109' ' ' VAL . 2.4 m -71.49 -45.47 62.39 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.224 -179.555 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.408 ' HG ' ' O ' ' A' ' 102' ' ' ILE . 74.5 mt -60.91 -39.77 90.61 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.229 -179.846 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 107' ' ' MET . . . . . 0.457 ' HA ' HD22 ' A' ' 117' ' ' LEU . 51.7 ttm -60.45 -45.61 93.06 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.49 -179.23 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 108' ' ' ARG . . . . . 0.467 ' HG2' ' O ' ' A' ' 105' ' ' SER . 15.1 ptm180 -74.21 -24.1 59.29 Favored 'General case' 0 C--N 1.327 -0.409 0 C-N-CA 120.978 -0.289 . . . . 0.0 110.89 -177.384 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.492 HG23 ' O ' ' A' ' 105' ' ' SER . 81.1 t -72.34 -43.61 64.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 173.954 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -58.24 -42.2 85.85 Favored 'General case' 0 CA--C 1.52 -0.197 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.551 177.926 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.784 ' HA ' ' HB1' ' A' ' 148' ' ' ALA . 35.2 t70 -65.61 -40.27 92.43 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.965 -179.769 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -68.21 -37.47 80.9 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.551 -0.75 . . . . 0.0 112.12 -178.218 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 21.5 m -92.99 -22.82 5.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-O 120.794 0.33 . . . . 0.0 111.549 -177.044 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 85.91 54.41 2.77 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.971 -0.633 . . . . 0.0 112.172 178.935 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -132.73 155.87 48.07 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 120.739 0.304 . . . . 0.0 110.917 -178.975 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 23.9 ttm180 -81.53 127.6 33.01 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 176.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . 0.574 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 55.8 tp -93.3 123.94 36.93 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.022 179.348 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 66.5 mt -120.16 120.32 62.64 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 CA-C-O 120.939 0.4 . . . . 0.0 110.641 178.376 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 69.3 mt -120.13 126.57 75.42 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.165 179.331 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 120' ' ' LYS . . . . . 0.769 ' HG2' ' HB3' ' A' ' 143' ' ' PHE . 5.9 tmtt? -120.97 96.33 48.63 Favored Pre-proline 0 C--N 1.325 -0.49 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.118 178.379 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -88.8 -163.62 0.15 Allowed 'Trans proline' 0 C--O 1.238 0.497 0 C-N-CA 122.928 2.419 . . . . 0.0 112.33 177.098 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -70.54 -178.72 1.86 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.29 -0.413 . . . . 0.0 110.901 177.311 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 9.6 t -81.4 -35.26 30.96 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.904 0.383 . . . . 0.0 110.95 -176.39 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -113.74 52.54 0.64 Allowed Glycine 0 N--CA 1.448 -0.556 0 N-CA-C 110.629 -0.988 . . . . 0.0 110.629 175.852 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 36.4 tt0 -138.14 116.61 12.03 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.466 -0.367 . . . . 0.0 110.114 -173.354 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 8.1 t70 -91.71 163.19 14.18 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.987 -0.552 . . . . 0.0 110.117 -177.264 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 15.9 mt . . . . . 0 C--N 1.327 -0.398 0 N-CA-C 110.176 -0.305 . . . . 0.0 110.176 -177.716 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 8.3 tppt? . . . . . 0 N--CA 1.448 -0.527 0 CA-C-O 121.453 0.644 . . . . 0.0 109.302 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 133' ' ' MET . . . . . 0.806 ' HG2' ' HB2' ' A' ' 146' ' ' TYR . 83.4 mtp -87.17 171.75 10.44 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.247 -0.888 . . . . 0.0 110.459 -177.64 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . 0.405 ' HE2' HG13 ' A' ' 136' ' ' VAL . 14.2 ptmt -131.16 146.66 52.42 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.953 -175.268 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . 0.484 HD11 ' HD2' ' A' ' 142' ' ' TYR . 56.7 tp -79.75 129.84 34.82 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.454 176.715 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 136' ' ' VAL . . . . . 0.405 HG13 ' HE2' ' A' ' 134' ' ' LYS . 0.0 OUTLIER -127.66 129.8 70.23 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.702 0 CA-C-O 121.162 0.506 . . . . 0.0 111.162 178.811 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 15.4 m120 -109.85 122.25 47.11 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.31 -0.859 . . . . 0.0 109.234 177.739 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 61.4 t80 -137.67 125.35 22.32 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 120.535 0.207 . . . . 0.0 110.67 -177.475 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 69.26 -88.92 0.25 Allowed Glycine 0 N--CA 1.448 -0.547 0 N-CA-C 111.626 -0.589 . . . . 0.0 111.626 179.225 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 140' ' ' ARG . . . . . 0.638 ' NE ' ' HA ' ' A' ' 140' ' ' ARG . 2.1 mmp_? -143.72 9.96 1.58 Allowed 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 115.446 -0.377 . . . . 0.0 111.182 175.91 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 15.2 t -118.6 155.23 31.31 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.801 0.334 . . . . 0.0 110.611 -179.678 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 142' ' ' TYR . . . . . 0.484 ' HD2' HD11 ' A' ' 135' ' ' LEU . 32.4 p90 -133.58 141.22 47.59 Favored 'General case' 0 N--CA 1.448 -0.533 0 CA-C-O 121.086 0.469 . . . . 0.0 109.992 176.704 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 143' ' ' PHE . . . . . 0.769 ' HB3' ' HG2' ' A' ' 120' ' ' LYS . 11.6 p90 -153.89 -175.98 5.63 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 115.429 -0.805 . . . . 0.0 109.733 -177.006 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 95.7 m-85 -116.98 125.36 51.29 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 110.308 -0.256 . . . . 0.0 110.308 179.375 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 145' ' ' GLU . . . . . . . . . . . . . 21.6 pt-20 -114.05 160.92 18.36 Favored 'General case' 0 C--N 1.321 -0.649 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 176.626 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . 0.806 ' HB2' ' HG2' ' A' ' 133' ' ' MET . 42.3 t80 -141.87 123.44 15.03 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-N 115.971 -0.558 . . . . 0.0 109.693 175.617 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 147' ' ' ILE . . . . . 0.439 ' N ' HD12 ' A' ' 147' ' ' ILE . 3.1 mp -93.03 100.94 12.07 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.834 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 -178.653 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . 0.784 ' HB1' ' HA ' ' A' ' 111' ' ' ASP . . . -67.99 120.16 13.8 Favored 'General case' 0 N--CA 1.447 -0.6 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 174.378 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 . . . . . 0 C--N 1.322 -0.623 0 CA-C-O 121.27 0.557 . . . . 0.0 110.188 -176.06 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 72.5 m95 . . . . . 0 N--CA 1.453 -0.314 0 CA-C-O 120.683 0.277 . . . . 0.0 111.119 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.432 ' O ' HG23 ' A' ' 27' ' ' VAL . 14.6 m120 -60.78 -36.99 80.37 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.522 175.528 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 43.9 m-20 -64.49 -45.16 88.53 Favored 'General case' 0 CA--C 1.52 -0.2 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.38 178.907 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 61.2 tp -55.13 -50.9 68.07 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.75 179.011 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -55.55 -47.03 77.0 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.912 -0.585 . . . . 0.0 111.639 -178.702 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.576 ' HA ' HD12 ' A' ' 30' ' ' ILE . 92.2 t -58.58 -37.09 62.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.471 -179.732 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 59.8 t80 -60.01 -45.89 91.27 Favored 'General case' 0 CA--C 1.534 0.339 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.042 -178.039 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.456 HG13 HD12 ' A' ' 118' ' ' ILE . 3.2 mp -64.09 -41.56 92.83 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.17 0 CA-C-O 120.973 0.416 . . . . 0.0 110.468 176.345 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.607 HG23 ' HB2' ' A' ' 58' ' ' SER . 90.6 mt -58.42 -44.67 89.22 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 115.739 -0.664 . . . . 0.0 111.357 -177.92 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 49.7 mtp180 -66.51 -33.82 76.55 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.463 -177.617 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 44.5 t -82.29 -25.81 33.67 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.416 -174.936 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 15.4 p -95.82 -81.82 0.4 Allowed 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.85 0.357 . . . . 0.0 111.746 -174.056 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 104.56 158.34 23.75 Favored Glycine 0 N--CA 1.447 -0.597 0 C-N-CA 120.937 -0.649 . . . . 0.0 111.8 -176.666 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 15.8 Cg_exo -68.67 139.58 44.61 Favored 'Trans proline' 0 N--CA 1.465 -0.164 0 C-N-CA 122.876 2.384 . . . . 0.0 112.415 -179.426 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 96.1 -4.67 65.32 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.577 -0.821 . . . . 0.0 112.568 178.502 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 29.6 p -96.48 -170.76 2.14 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 109.983 -0.377 . . . . 0.0 109.983 -179.892 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' ARG . . . . . 0.777 ' HB2' ' HA ' ' A' ' 90' ' ' ALA . 99.3 mtt180 -123.21 129.68 51.73 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.704 0.287 . . . . 0.0 110.661 174.429 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.788 HG23 HG21 ' A' ' 60' ' ' VAL . 98.7 t -129.41 121.9 54.39 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 N-CA-C 109.203 -0.665 . . . . 0.0 109.203 175.218 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 34.0 t -106.0 130.83 56.93 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 CA-C-O 120.755 0.312 . . . . 0.0 111.502 -174.293 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . 0.749 ' HB3' HD23 ' A' ' 64' ' ' LEU . 7.8 tp10 -114.15 122.03 45.59 Favored 'General case' 0 C--O 1.239 0.5 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.012 175.24 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.495 HG11 HD21 ' A' ' 106' ' ' LEU . 24.2 t -100.8 89.0 1.55 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 115.773 -0.648 . . . . 0.0 110.489 179.842 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 148.11 55.94 0.02 OUTLIER Glycine 0 N--CA 1.448 -0.538 0 CA-C-N 115.54 -0.754 . . . . 0.0 111.366 -177.879 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.624 ' HB2' ' HB3' ' A' ' 64' ' ' LEU . . . -84.97 76.94 10.21 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.986 0.422 . . . . 0.0 111.961 -173.962 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . 0.601 ' O ' ' HG ' ' A' ' 48' ' ' LEU . . . -89.5 -157.02 32.59 Favored Glycine 0 C--O 1.226 -0.367 0 C-N-CA 120.88 -0.676 . . . . 0.0 111.781 175.823 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . 0.451 HH11 ' HD3' ' A' ' 46' ' ' ARG . 0.0 OUTLIER -74.89 -15.44 60.7 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.984 0.421 . . . . 0.0 110.811 178.802 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 32.0 p90 -85.66 41.16 0.89 Allowed 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.53 -175.122 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.757 HD11 HD11 ' A' ' 74' ' ' ILE . 94.2 mt -80.96 19.16 0.9 Allowed 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 112.379 0.511 . . . . 0.0 112.379 -176.42 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 32.7 p90 -61.29 -27.39 68.44 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.712 0.291 . . . . 0.0 110.918 179.313 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 98.6 t -69.02 -51.28 45.64 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.237 175.43 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . 0.413 ' O ' ' HG2' ' A' ' 55' ' ' ARG . 1.7 m -61.75 -45.3 94.51 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 121.384 0.612 . . . . 0.0 110.201 -179.868 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 25.6 t70 -58.8 -41.12 85.99 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 114.7 -1.137 . . . . 0.0 111.119 -179.454 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 80.6 t80 -66.99 -52.01 47.93 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.693 178.295 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.558 HG23 HG12 ' A' ' 30' ' ' ILE . 83.8 mt -58.23 -47.27 87.85 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-N 115.981 -0.554 . . . . 0.0 112.075 -176.041 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' ARG . . . . . 0.413 ' HG2' ' O ' ' A' ' 51' ' ' SER . 15.6 ptm180 -68.64 -20.7 64.48 Favored 'General case' 0 CA--C 1.533 0.289 0 N-CA-C 112.535 0.569 . . . . 0.0 112.535 -172.649 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 23.0 mtmm -84.74 -29.93 25.11 Favored 'General case' 0 C--N 1.328 -0.345 0 C-N-CA 120.705 -0.398 . . . . 0.0 111.251 179.28 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 16.4 m-70 -86.48 -54.2 4.55 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.235 0.54 . . . . 0.0 109.586 177.744 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . 0.607 ' HB2' HG23 ' A' ' 30' ' ' ILE . 10.9 t -104.22 121.63 43.7 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 115.677 -0.692 . . . . 0.0 109.532 179.052 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 3.0 mppt? -84.79 61.45 6.79 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-O 121.897 0.856 . . . . 0.0 110.241 178.951 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.788 HG21 HG23 ' A' ' 39' ' ' VAL . 2.5 p -93.62 153.34 3.39 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.792 0 CA-C-N 114.167 -1.379 . . . . 0.0 109.299 177.232 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 43.9 m-20 -73.33 82.23 1.39 Allowed 'General case' 0 CA--C 1.518 -0.254 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 172.598 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . 0.45 ' HA ' ' O ' ' A' ' 39' ' ' VAL . 2.7 tt -80.93 105.45 12.17 Favored 'General case' 0 C--N 1.321 -0.651 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 179.549 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 48.8 t -96.96 117.14 40.95 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.439 -175.829 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . 0.749 HD23 ' HB3' ' A' ' 41' ' ' GLU . 80.0 mt -99.77 130.27 45.96 Favored 'General case' 0 C--N 1.314 -0.954 0 CA-C-N 115.58 -0.737 . . . . 0.0 109.185 177.249 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 22.9 p -117.86 129.4 55.63 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 120.555 0.217 . . . . 0.0 111.047 179.334 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 25.5 t70 -165.05 153.72 12.19 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.917 -0.583 . . . . 0.0 109.931 178.527 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.475 HG22 ' HE3' ' A' ' 68' ' ' LYS . 54.3 mt -76.98 100.39 2.57 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-O 120.93 0.395 . . . . 0.0 110.605 -178.289 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' LYS . . . . . 0.581 ' NZ ' ' HB2' ' A' ' 68' ' ' LYS . 7.4 mtmp? 70.33 83.97 0.15 Allowed Pre-proline 0 C--O 1.233 0.214 0 CA-C-N 115.119 -0.946 . . . . 0.0 110.53 -179.687 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . 0.96 ' HB3' ' HB ' ' A' ' 74' ' ' ILE . 11.2 Cg_endo . . . . . 0 C--O 1.232 0.205 0 C-N-CA 123.714 2.942 . . . . 0.0 113.968 -175.653 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.96 ' HB ' ' HB3' ' A' ' 69' ' ' PRO . 55.8 mt . . . . . 0 C--O 1.234 0.263 0 CA-C-O 120.763 0.316 . . . . 0.0 110.724 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 57.3 t -85.16 126.64 40.35 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 176.126 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' ARG . . . . . 0.478 ' HB3' ' HD2' ' A' ' 69' ' ' PRO . 1.6 ppt_? -77.68 28.08 0.17 Allowed 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 112.491 0.552 . . . . 0.0 112.491 -176.344 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 16.1 t70 -75.71 157.24 33.84 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 110.117 -0.327 . . . . 0.0 110.117 -177.579 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' ASP . . . . . 0.541 ' OD1' HG22 ' A' ' 80' ' ' THR . 5.9 t70 -88.47 161.41 17.03 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 120.691 0.281 . . . . 0.0 110.875 -171.984 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 8.5 tp -98.47 -28.23 3.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-O 120.829 0.347 . . . . 0.0 111.029 -177.926 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.541 HG22 ' OD1' ' A' ' 78' ' ' ASP . 15.0 t -90.02 -1.35 57.95 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.637 0.732 . . . . 0.0 109.165 176.868 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 34.5 t -152.12 72.32 7.78 Favored Pre-proline 0 C--N 1.322 -0.594 0 CA-C-N 114.738 -1.119 . . . . 0.0 108.984 175.069 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' PRO . . . . . 0.539 ' HB2' ' HE2' ' A' ' 87' ' ' TYR . 91.1 Cg_endo -89.47 141.55 4.01 Favored 'Trans proline' 0 N--CA 1.457 -0.633 0 C-N-CA 122.829 2.353 . . . . 0.0 112.798 -177.521 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' ARG . . . . . 0.771 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 56.7 mtt-85 -83.49 113.38 20.75 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.047 178.305 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' MET . . . . . 0.71 ' HA ' ' HD2' ' A' ' 87' ' ' TYR . 29.6 mtp -68.06 -17.4 64.38 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.551 -0.295 . . . . 0.0 110.995 178.168 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.771 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 9.8 pt-20 -61.89 -23.81 66.54 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.934 0.397 . . . . 0.0 110.653 176.592 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 72.6 mt -85.11 -34.48 8.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.48 178.984 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . 0.71 ' HD2' ' HA ' ' A' ' 84' ' ' MET . 75.0 m-85 -78.23 -30.75 48.91 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.429 -177.243 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . 0.465 ' HG2' HG12 ' A' ' 113' ' ' VAL . 53.2 mtp180 -65.68 140.58 58.48 Favored 'General case' 0 CA--C 1.516 -0.362 0 CA-C-O 121.403 0.621 . . . . 0.0 110.882 178.701 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 91.08 1.73 72.29 Favored Glycine 0 N--CA 1.447 -0.61 0 CA-C-N 115.199 -0.909 . . . . 0.0 111.894 -178.044 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . 0.777 ' HA ' ' HB2' ' A' ' 38' ' ' ARG . . . -85.16 138.77 32.16 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.995 0.426 . . . . 0.0 110.75 178.88 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -89.16 -24.67 22.14 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.079 178.379 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . 0.515 HD23 ' N ' ' A' ' 93' ' ' ILE . 4.7 tt -153.49 143.15 21.85 Favored 'General case' 0 N--CA 1.45 -0.448 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.206 -178.345 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.515 ' N ' HD23 ' A' ' 92' ' ' LEU . 72.7 mt -132.03 133.73 60.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 N-CA-C 109.111 -0.7 . . . . 0.0 109.111 176.551 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' TYR . . . . . 0.453 ' O ' ' HA ' ' A' ' 41' ' ' GLU . 1.2 p90 -138.37 161.24 37.46 Favored 'General case' 0 C--N 1.321 -0.636 0 C-N-CA 120.707 -0.397 . . . . 0.0 110.119 -178.693 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . 0.639 ' HA ' ' OE2' ' A' ' 41' ' ' GLU . 19.4 m -146.87 115.65 6.82 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.058 -178.91 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 78.9 mt -77.23 94.35 1.31 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.752 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.619 179.45 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' ARG . . . . . 0.534 ' HG3' ' OE1' ' A' ' 125' ' ' GLU . 19.6 ttp85 58.61 82.64 0.23 Allowed Pre-proline 0 CA--C 1.531 0.244 0 CA-C-N 114.608 -1.178 . . . . 0.0 111.66 -177.628 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' PRO . . . . . 0.457 ' HA ' ' HD3' ' A' ' 99' ' ' PRO . 88.3 Cg_endo -83.74 136.66 7.36 Favored 'Trans proline' 0 N--CA 1.456 -0.724 0 C-N-CA 122.467 2.111 . . . . 0.0 111.638 176.136 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . 0.747 ' HB2' ' HG2' ' A' ' 101' ' ' GLU . 22.4 Cg_exo -63.32 149.94 89.9 Favored 'Trans proline' 0 C--O 1.238 0.478 0 C-N-CA 122.581 2.187 . . . . 0.0 111.733 177.951 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -73.76 42.22 0.13 Allowed 'General case' 0 N--CA 1.465 0.284 0 CA-C-O 121.304 0.573 . . . . 0.0 111.812 -178.216 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 101' ' ' GLU . . . . . 0.757 ' HG3' HG23 ' A' ' 102' ' ' ILE . 11.0 pt-20 -132.15 -26.24 1.93 Allowed 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.607 179.303 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.757 HG23 ' HG3' ' A' ' 101' ' ' GLU . 40.1 pt -119.88 -11.64 10.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.55 -175.062 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 103' ' ' HIS . . . . . 0.485 ' O ' ' HG3' ' A' ' 107' ' ' MET . 4.8 p-80 -56.72 -45.24 82.0 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.989 -0.551 . . . . 0.0 111.612 -175.147 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 8.5 m -61.35 -35.05 76.36 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.002 0.43 . . . . 0.0 110.908 179.529 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.839 ' HA ' ' HE ' ' A' ' 108' ' ' ARG . 67.1 m -73.3 -36.71 66.32 Favored 'General case' 0 N--CA 1.451 -0.408 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.39 179.703 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.495 HD21 HG11 ' A' ' 42' ' ' VAL . 85.0 mt -64.39 -42.08 96.31 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.73 178.914 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 107' ' ' MET . . . . . 0.522 ' HA ' HD22 ' A' ' 117' ' ' LEU . 81.4 mtp -60.5 -44.27 96.17 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.539 -179.292 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 108' ' ' ARG . . . . . 0.839 ' HE ' ' HA ' ' A' ' 105' ' ' SER . 31.6 ptt180 -74.73 -20.77 59.69 Favored 'General case' 0 CA--C 1.53 0.205 0 C-N-CA 121.048 -0.261 . . . . 0.0 111.555 -178.263 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.528 HG23 ' O ' ' A' ' 105' ' ' SER . 55.9 t -74.06 -43.47 51.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.749 0.309 . . . . 0.0 110.333 175.421 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -57.24 -45.66 83.73 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.972 -179.822 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.961 ' HA ' ' HB1' ' A' ' 148' ' ' ALA . 4.0 t70 -71.72 -28.71 63.87 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 121.174 0.511 . . . . 0.0 110.254 -177.284 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -74.49 -33.01 62.74 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.953 -0.567 . . . . 0.0 111.809 -179.64 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.465 HG12 ' HG2' ' A' ' 88' ' ' ARG . 34.0 m -95.52 -24.78 4.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 C-N-CA 121.088 -0.245 . . . . 0.0 111.097 179.578 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . 0.446 ' HA2' ' O ' ' A' ' 149' ' ' GLU . . . 89.87 46.5 4.2 Favored Glycine 0 N--CA 1.453 -0.226 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.993 176.303 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . 0.405 ' O ' ' HB3' ' A' ' 148' ' ' ALA . . . -124.66 150.25 46.29 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 120.533 0.206 . . . . 0.0 110.85 -178.954 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 116' ' ' ARG . . . . . 0.506 ' HD3' ' OE1' ' A' ' 145' ' ' GLU . 14.7 ttm180 -70.65 119.92 15.5 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 177.93 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . 0.522 HD22 ' HA ' ' A' ' 107' ' ' MET . 57.6 tp -90.58 118.59 30.15 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 -179.765 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . 0.456 HD12 HG13 ' A' ' 29' ' ' ILE . 61.9 mt -115.98 112.71 40.77 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.654 0 CA-C-O 121.289 0.566 . . . . 0.0 110.594 179.455 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 62.8 mt -110.97 119.03 58.71 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.845 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.029 178.474 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 120' ' ' LYS . . . . . 0.663 ' HG2' ' HB3' ' A' ' 143' ' ' PHE . 9.0 tmtm? -116.33 96.97 48.99 Favored Pre-proline 0 C--N 1.322 -0.616 0 CA-C-N 116.162 -0.472 . . . . 0.0 109.994 178.885 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 0.9 OUTLIER -77.65 -178.71 4.81 Favored 'Trans proline' 0 N--CA 1.459 -0.522 0 C-N-CA 122.652 2.235 . . . . 0.0 111.442 174.373 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 5.7 mp -63.87 177.68 0.73 Allowed 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.957 -179.439 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 15.2 m -49.45 -65.15 0.61 Allowed 'General case' 0 CA--C 1.53 0.194 0 CA-C-N 115.71 -0.677 . . . . 0.0 111.888 -175.357 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -106.54 64.86 0.27 Allowed Glycine 0 N--CA 1.448 -0.531 0 C-N-CA 120.669 -0.777 . . . . 0.0 111.173 175.452 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . 0.534 ' OE1' ' HG3' ' A' ' 97' ' ' ARG . 40.8 tt0 -140.11 145.48 37.65 Favored 'General case' 0 N--CA 1.448 -0.558 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 -174.712 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 10.3 t70 -123.02 174.67 7.05 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.356 -179.169 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 6.9 mt . . . . . 0 C--N 1.328 -0.334 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.055 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 16.5 tppt? . . . . . 0 C--O 1.232 0.155 0 CA-C-O 121.029 0.442 . . . . 0.0 110.59 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 133' ' ' MET . . . . . 0.789 ' HG2' ' HB2' ' A' ' 146' ' ' TYR . 93.4 mtp -104.86 155.76 18.63 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.578 -177.533 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 12.9 ptmt -106.12 139.73 40.19 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.446 -175.789 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . 0.838 HD11 ' HD2' ' A' ' 142' ' ' TYR . 55.2 tp -78.81 125.27 29.14 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 115.861 -0.608 . . . . 0.0 110.428 177.709 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -119.81 147.16 23.64 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.808 179.059 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 137' ' ' ASN . . . . . 0.565 ' ND2' ' HB3' ' A' ' 142' ' ' TYR . 18.2 m120 -120.72 119.1 31.82 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.92 -0.582 . . . . 0.0 109.63 178.411 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 67.7 t80 -131.74 130.98 42.6 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 109.916 -0.401 . . . . 0.0 109.916 179.289 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 71.66 -91.21 0.49 Allowed Glycine 0 N--CA 1.441 -1.0 0 N-CA-C 111.21 -0.756 . . . . 0.0 111.21 -176.821 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 140' ' ' ARG . . . . . 0.447 ' HA ' ' HD3' ' A' ' 140' ' ' ARG . 29.1 mmt180 -150.21 12.81 0.75 Allowed 'General case' 0 C--N 1.32 -0.708 0 CA-C-O 120.807 0.337 . . . . 0.0 110.556 179.308 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 7.1 t -125.15 160.64 28.67 Favored 'General case' 0 C--N 1.322 -0.606 0 N-CA-C 109.865 -0.42 . . . . 0.0 109.865 -178.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 142' ' ' TYR . . . . . 0.838 ' HD2' HD11 ' A' ' 135' ' ' LEU . 20.8 p90 -126.83 149.64 49.6 Favored 'General case' 0 N--CA 1.449 -0.523 0 CA-C-O 121.405 0.621 . . . . 0.0 111.176 179.494 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 143' ' ' PHE . . . . . 0.663 ' HB3' ' HG2' ' A' ' 120' ' ' LYS . 19.5 p90 -156.39 179.3 9.39 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 114.823 -1.08 . . . . 0.0 109.417 -177.37 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -113.2 127.85 56.3 Favored 'General case' 0 C--N 1.319 -0.752 0 C-N-CA 120.963 -0.295 . . . . 0.0 110.451 -179.738 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 145' ' ' GLU . . . . . 0.506 ' OE1' ' HD3' ' A' ' 116' ' ' ARG . 17.5 pt-20 -114.85 157.04 23.84 Favored 'General case' 0 C--N 1.32 -0.681 0 N-CA-C 109.041 -0.726 . . . . 0.0 109.041 173.189 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . 0.789 ' HB2' ' HG2' ' A' ' 133' ' ' MET . 19.5 t80 -137.77 122.75 19.01 Favored 'General case' 0 C--N 1.31 -1.133 0 CA-C-N 116.054 -0.521 . . . . 0.0 109.638 176.07 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 2.2 mp -79.49 95.76 2.18 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.813 0 N-CA-C 108.442 -0.947 . . . . 0.0 108.442 174.91 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . 0.961 ' HB1' ' HA ' ' A' ' 111' ' ' ASP . . . -74.87 130.3 39.17 Favored 'General case' 0 N--CA 1.437 -1.083 0 CA-C-N 115.462 -0.79 . . . . 0.0 109.739 178.679 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . 0.446 ' O ' ' HA2' ' A' ' 114' ' ' GLY . 74.4 mm-40 . . . . . 0 C--N 1.315 -0.904 0 CA-C-O 122.032 0.92 . . . . 0.0 111.558 178.861 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 95.5 m95 . . . . . 0 CA--C 1.528 0.122 0 N-CA-C 111.58 0.215 . . . . 0.0 111.58 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.446 ' O ' HG23 ' A' ' 27' ' ' VAL . 4.4 m-20 -66.49 -40.72 89.42 Favored 'General case' 0 C--N 1.328 -0.348 0 C-N-CA 121.224 -0.19 . . . . 0.0 111.487 -177.015 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 38.8 m-20 -61.41 -39.44 90.78 Favored 'General case' 0 N--CA 1.466 0.35 0 CA-C-O 121.071 0.462 . . . . 0.0 110.411 177.644 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.545 HD21 ' HD3' ' A' ' 120' ' ' LYS . 25.0 tp -63.33 -42.95 98.99 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.648 -0.705 . . . . 0.0 110.59 176.863 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -59.68 -46.95 87.5 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.738 178.258 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.446 HG23 ' O ' ' A' ' 23' ' ' ASN . 90.3 t -55.59 -42.26 67.9 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.192 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.069 178.803 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 69.2 t80 -59.33 -45.16 92.11 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 121.024 0.44 . . . . 0.0 110.637 179.598 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 57.9 mt -67.07 -39.91 84.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.62 179.751 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.683 HG12 HG23 ' A' ' 54' ' ' ILE . 98.1 mt -59.9 -41.87 87.35 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.453 -0.794 . . . . 0.0 110.941 178.915 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 79.2 mtp180 -66.49 -37.64 85.51 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.882 -178.407 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 81.2 m -76.76 -18.0 58.72 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.214 -176.068 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 11.9 p -104.26 -84.37 0.48 Allowed 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.433 -178.556 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.402 ' O ' HG22 ' A' ' 37' ' ' THR . . . 99.69 160.47 28.82 Favored Glycine 0 N--CA 1.447 -0.626 0 C-N-CA 121.089 -0.577 . . . . 0.0 111.902 -176.96 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 11.5 Cg_exo -70.95 152.74 63.4 Favored 'Trans proline' 0 C--O 1.235 0.33 0 C-N-CA 122.743 2.296 . . . . 0.0 111.976 179.57 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 99.61 -26.35 24.73 Favored Glycine 0 N--CA 1.453 -0.228 0 C-N-CA 120.827 -0.701 . . . . 0.0 112.752 176.624 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . 0.402 HG22 ' O ' ' A' ' 34' ' ' GLY . 14.0 t -100.5 -166.99 1.38 Allowed 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 -178.846 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' ARG . . . . . 0.995 ' HG2' ' HA ' ' A' ' 90' ' ' ALA . 0.1 OUTLIER -130.94 136.53 48.65 Favored 'General case' 0 N--CA 1.446 -0.657 0 CA-C-O 121.113 0.483 . . . . 0.0 111.021 -176.767 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.448 HG23 HG21 ' A' ' 60' ' ' VAL . 95.9 t -129.16 135.82 61.04 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.603 0 CA-C-N 115.48 -0.782 . . . . 0.0 109.486 -179.916 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.517 HG11 ' CE2' ' A' ' 87' ' ' TYR . 38.7 t -108.11 128.19 63.72 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 CA-C-O 120.927 0.394 . . . . 0.0 111.31 -176.479 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . 0.58 ' HB3' HD23 ' A' ' 64' ' ' LEU . 41.1 tt0 -106.49 118.23 36.1 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.924 -0.58 . . . . 0.0 109.778 175.826 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 62.9 t -97.21 120.48 46.6 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.671 -179.173 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 92.5 48.7 2.94 Favored Glycine 0 N--CA 1.447 -0.621 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.139 179.567 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -80.36 41.09 0.52 Allowed 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.063 0.459 . . . . 0.0 111.446 -176.861 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . 0.425 ' O ' ' HB2' ' A' ' 46' ' ' ARG . . . -81.29 81.58 1.62 Allowed Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.954 -0.641 . . . . 0.0 112.27 -178.332 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . 0.425 ' HB2' ' O ' ' A' ' 45' ' ' GLY . 82.9 mtm180 71.08 13.56 6.86 Favored 'General case' 0 N--CA 1.469 0.498 0 C-N-CA 123.238 0.615 . . . . 0.0 111.271 -179.44 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 74.6 m-85 -98.51 17.05 19.94 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.357 0.598 . . . . 0.0 109.706 176.864 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.438 HD21 HD11 ' A' ' 74' ' ' ILE . 82.2 mt -62.14 -10.1 9.44 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 114.793 -1.094 . . . . 0.0 112.388 -174.655 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 73.9 t80 -57.85 -38.35 75.53 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 120.715 0.293 . . . . 0.0 110.837 179.167 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 60.4 t -73.54 -54.63 14.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.435 -179.093 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -59.75 -38.33 81.47 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.852 -179.437 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.565 ' HA ' ' HG2' ' A' ' 55' ' ' ARG . 33.5 t70 -71.44 -35.85 71.06 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.629 0.252 . . . . 0.0 111.181 179.527 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 56.7 t80 -61.36 -49.03 78.57 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 109.503 -0.554 . . . . 0.0 109.503 175.027 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.683 HG23 HG12 ' A' ' 30' ' ' ILE . 77.6 mt -60.85 -51.83 68.61 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-N 115.727 -0.669 . . . . 0.0 111.85 -179.236 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' ARG . . . . . 0.565 ' HG2' ' HA ' ' A' ' 52' ' ' ASP . 40.1 ptt180 -65.29 -19.93 66.18 Favored 'General case' 0 N--CA 1.467 0.392 0 N-CA-C 112.382 0.512 . . . . 0.0 112.382 -173.464 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 3.1 mtmp? -87.33 -38.61 16.07 Favored 'General case' 0 C--N 1.327 -0.372 0 C-N-CA 120.723 -0.391 . . . . 0.0 111.588 178.668 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 31.0 m-70 -76.03 -32.73 59.5 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 120.662 0.268 . . . . 0.0 110.693 179.651 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 67.6 m -138.63 128.0 24.46 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 116.264 -0.425 . . . . 0.0 109.863 174.581 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . 0.409 ' HD3' ' HA ' ' A' ' 59' ' ' LYS . 1.3 tppp? -78.58 63.42 3.38 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 122.096 0.95 . . . . 0.0 110.901 -177.375 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.448 HG21 HG23 ' A' ' 39' ' ' VAL . 7.3 p -86.29 142.21 13.4 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.957 0 CA-C-N 114.349 -1.296 . . . . 0.0 109.387 172.721 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . 0.443 ' O ' ' HA ' ' A' ' 38' ' ' ARG . 33.0 t70 -76.51 89.25 3.27 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 179.228 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 2.3 tt -90.0 122.91 33.44 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.78 -0.646 . . . . 0.0 110.496 -173.93 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 43.8 t -102.29 121.76 53.74 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-N 115.523 -0.762 . . . . 0.0 109.899 -178.234 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . 0.58 HD23 ' HB3' ' A' ' 41' ' ' GLU . 50.8 mt -100.15 131.01 46.34 Favored 'General case' 0 C--N 1.316 -0.858 0 CA-C-N 116.214 -0.448 . . . . 0.0 109.919 179.766 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.549 HG22 ' HB ' ' A' ' 75' ' ' VAL . 17.0 p -132.23 137.37 47.52 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.951 0.405 . . . . 0.0 111.18 178.383 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 30.3 t70 -165.28 158.4 16.27 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.518 177.529 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 40.7 mm -72.09 96.83 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-O 120.759 0.314 . . . . 0.0 110.429 -178.76 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 65.3 mttm 63.56 90.16 0.09 OUTLIER Pre-proline 0 N--CA 1.465 0.309 0 CA-C-N 115.393 -0.821 . . . . 0.0 111.514 178.682 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . 0.415 ' HD3' ' HA ' ' A' ' 76' ' ' ARG . 97.3 Cg_endo . . . . . 0 N--CA 1.459 -0.506 0 C-N-CA 122.867 2.378 . . . . 0.0 112.726 -179.273 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.438 HD11 HD21 ' A' ' 48' ' ' LEU . 63.6 mt . . . . . 0 N--CA 1.451 -0.393 0 CA-C-O 120.756 0.312 . . . . 0.0 110.358 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.549 ' HB ' HG22 ' A' ' 65' ' ' THR . 53.8 t -72.71 133.37 31.89 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.093 179.321 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' ARG . . . . . 0.415 ' HA ' ' HD3' ' A' ' 69' ' ' PRO . 6.7 ptp180 -86.9 32.48 0.67 Allowed 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.855 -176.471 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . 0.498 ' HB2' HG12 ' A' ' 75' ' ' VAL . 1.6 t70 -77.11 -159.16 0.12 Allowed 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.653 -174.329 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' ASP . . . . . 0.457 ' OD1' HG22 ' A' ' 80' ' ' THR . 4.9 t70 -125.15 -174.16 2.98 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 120.733 0.301 . . . . 0.0 110.25 -174.374 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 9.2 tp -139.9 -30.89 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-O 120.877 0.37 . . . . 0.0 110.406 178.951 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.457 HG22 ' OD1' ' A' ' 78' ' ' ASP . 8.9 t -86.38 -20.8 27.71 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.516 0.674 . . . . 0.0 109.247 177.127 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 13.6 t -150.67 72.57 8.92 Favored Pre-proline 0 C--N 1.325 -0.489 0 CA-C-N 115.154 -0.93 . . . . 0.0 108.577 171.721 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' PRO . . . . . 0.442 ' HB3' ' O ' ' A' ' 78' ' ' ASP . 89.6 Cg_endo -89.77 171.3 4.16 Favored 'Trans proline' 0 N--CA 1.457 -0.674 0 C-N-CA 123.007 2.472 . . . . 0.0 113.149 -173.96 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' ARG . . . . . 0.597 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 63.6 mtt180 -88.9 111.36 21.99 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.671 -0.695 . . . . 0.0 109.536 171.432 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' MET . . . . . 0.522 ' O ' ' HG3' ' A' ' 88' ' ' ARG . 92.7 mmm -67.36 -20.04 65.51 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.395 -176.991 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.597 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 9.3 pt-20 -60.49 -27.29 67.47 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.309 -179.664 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 67.4 mt -79.93 -40.24 20.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-O 120.98 0.419 . . . . 0.0 111.07 -178.571 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . 0.517 ' CE2' HG11 ' A' ' 40' ' ' VAL . 73.0 m-85 -81.98 -31.14 31.29 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.632 -176.889 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . 0.744 ' HG2' HG12 ' A' ' 113' ' ' VAL . 16.1 mtp180 -69.42 116.78 10.24 Favored 'General case' 0 CA--C 1.509 -0.606 0 CA-C-O 121.906 0.86 . . . . 0.0 111.462 -175.957 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . 0.439 ' O ' ' HD3' ' A' ' 38' ' ' ARG . . . 116.38 -18.9 13.37 Favored Glycine 0 C--N 1.31 -0.897 0 CA-C-N 114.07 -1.423 . . . . 0.0 111.765 -177.727 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . 0.995 ' HA ' ' HG2' ' A' ' 38' ' ' ARG . . . -66.24 143.09 57.44 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.604 0.24 . . . . 0.0 110.553 179.075 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -82.57 -29.22 30.43 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 120.831 0.348 . . . . 0.0 110.807 -178.624 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . 0.473 ' HG ' ' HB3' ' A' ' 116' ' ' ARG . 5.8 tt -149.71 143.44 25.46 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.15 -0.477 . . . . 0.0 109.96 -177.412 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.613 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 62.8 mt -130.65 127.46 62.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 N-CA-C 109.098 -0.705 . . . . 0.0 109.098 177.019 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' TYR . . . . . 0.756 ' HD2' ' HZ3' ' A' ' 120' ' ' LYS . 20.7 p90 -138.71 142.84 38.91 Favored 'General case' 0 C--N 1.321 -0.664 0 C-N-CA 120.208 -0.597 . . . . 0.0 111.407 -179.039 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . 0.416 ' O ' ' HG2' ' A' ' 120' ' ' LYS . 8.0 m -118.08 144.96 45.19 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 115.497 -0.774 . . . . 0.0 110.047 -177.814 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' ILE . . . . . 0.819 HG12 ' HD2' ' A' ' 120' ' ' LYS . 42.9 mt -111.69 106.84 21.55 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-O 120.759 0.314 . . . . 0.0 110.46 179.804 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' ARG . . . . . 0.576 ' O ' ' HD3' ' A' ' 97' ' ' ARG . 0.0 OUTLIER 50.88 76.43 0.55 Allowed Pre-proline 0 CA--C 1.536 0.439 0 CA-C-N 115.099 -0.955 . . . . 0.0 111.173 -177.381 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_endo -96.3 159.61 1.29 Allowed 'Trans proline' 0 N--CA 1.453 -0.886 0 C-N-CA 123.211 2.607 . . . . 0.0 112.698 178.887 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . 0.677 ' HD2' HD11 ' A' ' 102' ' ' ILE . 17.5 Cg_exo -64.16 136.37 51.55 Favored 'Trans proline' 0 N--CA 1.462 -0.353 0 C-N-CA 122.32 2.014 . . . . 0.0 111.306 174.55 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . 0.572 ' HA ' ' CD2' ' A' ' 103' ' ' HIS . . . -68.98 -15.46 63.49 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 120.971 0.415 . . . . 0.0 111.833 -174.977 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 101' ' ' GLU . . . . . . . . . . . . . 1.7 pm0 -75.86 -18.51 59.4 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.888 178.582 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.677 HD11 ' HD2' ' A' ' 99' ' ' PRO . 2.6 pp -113.48 8.1 7.89 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.178 0 N-CA-C 112.567 0.58 . . . . 0.0 112.567 -177.341 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 103' ' ' HIS . . . . . 0.572 ' CD2' ' HA ' ' A' ' 100' ' ' ALA . 4.7 m-70 -57.57 -42.64 83.47 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 121.063 0.459 . . . . 0.0 110.777 176.361 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 6.9 p -69.86 -26.85 64.4 Favored 'General case' 0 C--O 1.236 0.372 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.095 -179.114 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.571 ' O ' HG23 ' A' ' 109' ' ' VAL . 74.8 m -70.52 -44.79 66.85 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 109.757 -0.461 . . . . 0.0 109.757 174.519 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 96.0 mt -56.84 -41.81 78.54 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 121.067 0.46 . . . . 0.0 110.354 175.676 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 107' ' ' MET . . . . . . . . . . . . . 46.6 tpp -55.59 -52.59 63.25 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.28 -0.873 . . . . 0.0 111.365 178.497 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 4.8 ptp180 -71.3 -22.56 61.93 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 111.889 0.329 . . . . 0.0 111.889 -177.303 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.571 HG23 ' O ' ' A' ' 105' ' ' SER . 82.5 t -70.19 -48.37 61.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 C-N-CA 120.731 -0.388 . . . . 0.0 109.981 175.012 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -60.96 -44.53 97.16 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 177.049 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 22.7 t70 -60.68 -34.06 73.77 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.36 -0.836 . . . . 0.0 111.036 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -74.75 -44.44 49.74 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.795 -0.639 . . . . 0.0 111.813 -179.271 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.744 HG12 ' HG2' ' A' ' 88' ' ' ARG . 13.1 m -87.46 -29.29 5.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.981 -172.549 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 87.32 53.77 2.71 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.852 -0.69 . . . . 0.0 112.392 -178.978 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -131.97 160.44 35.79 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.737 0.303 . . . . 0.0 111.086 -178.192 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 116' ' ' ARG . . . . . 0.473 ' HB3' ' HG ' ' A' ' 92' ' ' LEU . 13.5 ttm180 -79.0 123.88 27.72 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 109.565 -0.532 . . . . 0.0 109.565 175.923 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . 0.613 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 58.3 tp -98.14 118.32 34.49 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.181 -179.429 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 55.7 mt -117.19 115.13 47.81 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-O 121.197 0.522 . . . . 0.0 110.629 178.861 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 40.6 mt -107.78 135.78 45.3 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.631 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.032 -178.032 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 120' ' ' LYS . . . . . 0.819 ' HD2' HG12 ' A' ' 96' ' ' ILE . 4.5 ptpp? -130.51 91.96 36.47 Favored Pre-proline 0 C--N 1.324 -0.518 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.238 -179.147 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 78.5 Cg_endo -96.77 -164.28 0.09 OUTLIER 'Trans proline' 0 N--CA 1.455 -0.765 0 C-N-CA 123.308 2.672 . . . . 0.0 112.647 179.344 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 122' ' ' LEU . . . . . 0.695 ' HB2' ' HB2' ' A' ' 125' ' ' GLU . 4.2 mm? -74.67 159.32 32.23 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.481 174.796 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 27.3 m -57.96 -43.68 86.57 Favored 'General case' 0 CA--C 1.53 0.2 0 CA-C-O 120.981 0.419 . . . . 0.0 110.959 -178.948 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -100.76 38.2 3.25 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.8 -0.714 . . . . 0.0 111.595 178.288 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . 0.695 ' HB2' ' HB2' ' A' ' 122' ' ' LEU . 27.4 tt0 -123.09 116.83 24.12 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.586 -0.524 . . . . 0.0 109.586 -177.515 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -88.55 164.71 15.28 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 121.544 0.688 . . . . 0.0 111.544 -172.903 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . 0.489 ' HA ' ' CD2' ' A' ' 103' ' ' HIS . 52.1 mt . . . . . 0 C--N 1.317 -0.827 0 CA-C-N 115.06 -0.973 . . . . 0.0 108.586 172.71 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 25.6 mtpp . . . . . 0 N--CA 1.453 -0.296 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 133' ' ' MET . . . . . 0.8 ' HG2' ' HB2' ' A' ' 146' ' ' TYR . 82.1 mtp -84.05 -179.0 7.14 Favored 'General case' 0 C--O 1.232 0.176 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.294 179.874 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 19.1 ptmt -142.52 135.09 27.99 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 120.985 0.422 . . . . 0.0 111.091 -179.449 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . 0.563 HD11 ' HD2' ' A' ' 142' ' ' TYR . 50.3 tp -71.63 124.14 24.07 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.543 -0.753 . . . . 0.0 110.307 175.743 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 136' ' ' VAL . . . . . 0.42 HG23 ' CD1' ' A' ' 143' ' ' PHE . 0.0 OUTLIER -121.78 137.22 56.12 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.145 -179.818 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 12.9 m120 -110.13 126.38 54.0 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 109.136 -0.69 . . . . 0.0 109.136 177.676 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 52.8 t80 -142.12 116.72 9.72 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 121.112 0.482 . . . . 0.0 111.277 -179.39 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 77.45 -92.34 1.08 Allowed Glycine 0 N--CA 1.447 -0.618 0 CA-C-N 115.74 -0.664 . . . . 0.0 112.159 176.045 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 50.4 mtm180 -139.52 16.37 2.55 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-O 121.047 0.451 . . . . 0.0 110.831 -179.372 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 13.8 t -138.15 158.72 43.74 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.269 -179.104 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 142' ' ' TYR . . . . . 0.563 ' HD2' HD11 ' A' ' 135' ' ' LEU . 35.2 p90 -134.33 139.62 45.79 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 178.135 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 143' ' ' PHE . . . . . 0.42 ' CD1' HG23 ' A' ' 136' ' ' VAL . 9.2 p90 -148.9 -172.83 4.2 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.116 -173.185 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 99.1 m-85 -119.42 128.63 54.22 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 120.486 0.184 . . . . 0.0 110.633 -179.086 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 145' ' ' GLU . . . . . . . . . . . . . 19.1 pt-20 -120.31 159.88 24.13 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.044 0.45 . . . . 0.0 109.916 174.78 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . 0.8 ' HB2' ' HG2' ' A' ' 133' ' ' MET . 49.7 t80 -140.63 127.95 21.14 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 115.904 -0.589 . . . . 0.0 109.816 176.471 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 147' ' ' ILE . . . . . 0.433 ' N ' HD12 ' A' ' 147' ' ' ILE . 3.1 mp -94.63 100.66 11.47 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 N-CA-C 109.679 -0.489 . . . . 0.0 109.679 178.752 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -91.38 125.75 36.24 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.869 -0.605 . . . . 0.0 109.796 177.115 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 . . . . . 0 C--N 1.32 -0.696 0 CA-C-O 121.038 0.447 . . . . 0.0 110.186 -179.533 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 90.8 m95 . . . . . 0 N--CA 1.452 -0.368 0 CA-C-O 120.539 0.209 . . . . 0.0 110.696 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.412 ' O ' HG23 ' A' ' 27' ' ' VAL . 4.7 m-20 -68.99 -47.61 65.13 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.515 -0.311 . . . . 0.0 110.905 177.729 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 15.6 m-20 -60.6 -39.48 88.28 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.81 0.338 . . . . 0.0 110.579 178.59 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 60.5 tp -57.76 -49.53 76.27 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.424 176.204 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -55.71 -47.17 77.31 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.542 -0.753 . . . . 0.0 110.904 178.859 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.412 HG23 ' O ' ' A' ' 23' ' ' ASN . 84.9 t -56.73 -42.9 78.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.938 178.479 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 86.6 t80 -61.32 -45.48 94.28 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.724 0.297 . . . . 0.0 110.383 178.436 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 72.9 mt -63.21 -43.2 98.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.45 178.799 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 86.8 mt -56.83 -42.66 78.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 115.451 -0.795 . . . . 0.0 111.265 177.126 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 21.4 mtp180 -69.06 -32.37 71.79 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.804 -178.816 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 77.0 m -88.33 2.51 52.36 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.794 -0.639 . . . . 0.0 111.758 -175.874 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 22.0 p -129.7 -80.54 0.56 Allowed 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 120.816 0.341 . . . . 0.0 111.004 178.018 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 95.61 160.13 33.08 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.934 -0.65 . . . . 0.0 112.408 -179.616 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -73.25 141.68 32.62 Favored 'Trans proline' 0 N--CA 1.462 -0.347 0 C-N-CA 122.785 2.323 . . . . 0.0 111.438 178.022 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 113.13 3.71 24.39 Favored Glycine 0 N--CA 1.449 -0.452 0 C-N-CA 120.348 -0.929 . . . . 0.0 112.16 -177.226 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 14.7 t -139.42 -169.57 2.71 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 110.001 -0.37 . . . . 0.0 110.001 177.812 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' ARG . . . . . 0.41 ' HD3' HH11 ' A' ' 38' ' ' ARG . 47.0 mtp180 -121.75 135.84 54.94 Favored 'General case' 0 N--CA 1.45 -0.45 0 CA-C-O 120.906 0.384 . . . . 0.0 110.637 -178.738 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 52.3 t -122.56 134.67 65.07 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 177.463 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 50.3 t -108.04 124.36 64.21 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-O 120.733 0.301 . . . . 0.0 110.678 -177.813 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . 0.527 ' HB2' HD21 ' A' ' 62' ' ' LEU . 35.6 tt0 -102.04 106.68 17.61 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.066 179.004 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.6 ' O ' ' HA ' ' A' ' 95' ' ' SER . 60.3 t -94.04 124.39 46.49 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.603 0 CA-C-N 116.031 -0.531 . . . . 0.0 109.846 179.779 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 96.27 37.63 4.79 Favored Glycine 0 N--CA 1.445 -0.751 0 C-N-CA 120.337 -0.935 . . . . 0.0 111.297 -175.93 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -81.21 24.61 0.52 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.018 0.437 . . . . 0.0 111.413 -177.822 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -73.89 79.09 0.87 Allowed Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 121.212 -0.518 . . . . 0.0 112.08 -178.924 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 26.7 ttt180 75.67 7.72 3.8 Favored 'General case' 0 N--CA 1.468 0.436 0 C-N-CA 123.418 0.687 . . . . 0.0 110.968 177.14 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 65.8 m-85 -95.96 31.01 2.22 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.39 0.614 . . . . 0.0 110.413 178.06 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.609 HD22 HD13 ' A' ' 64' ' ' LEU . 61.6 mt -74.35 14.65 0.42 Allowed 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.075 -0.966 . . . . 0.0 112.376 -172.931 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 87.8 t80 -70.3 -37.26 74.74 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 121.068 0.461 . . . . 0.0 110.375 179.665 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 47.2 t -74.76 -48.81 32.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-N 115.936 -0.574 . . . . 0.0 110.372 -179.326 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -58.67 -39.77 81.63 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.997 -0.547 . . . . 0.0 111.369 179.526 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.425 ' O ' ' HE2' ' A' ' 56' ' ' LYS . 30.6 t70 -62.06 -45.07 95.16 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.792 0.33 . . . . 0.0 110.531 177.826 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . 0.459 ' HA ' ' HE2' ' A' ' 56' ' ' LYS . 81.5 t80 -63.53 -42.98 98.4 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.927 -179.248 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 80.8 mt -66.22 -47.73 83.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.889 -178.941 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 22.4 ptt180 -62.77 -24.57 67.78 Favored 'General case' 0 N--CA 1.467 0.401 0 N-CA-C 111.856 0.317 . . . . 0.0 111.856 -175.344 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . 0.459 ' HE2' ' HA ' ' A' ' 53' ' ' TYR . 42.2 mtmt -77.2 -31.22 55.17 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.727 0.299 . . . . 0.0 111.692 -177.611 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 20.4 t60 -99.18 -48.56 4.79 Favored 'General case' 0 N--CA 1.448 -0.562 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.518 -177.384 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 38.1 m -95.22 155.51 16.7 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.068 0.461 . . . . 0.0 111.053 -178.024 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 28.5 mmmt -105.17 19.26 20.9 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.938 -0.574 . . . . 0.0 109.704 178.242 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 15.0 p -68.63 153.27 9.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 115.404 -0.816 . . . . 0.0 110.522 -178.78 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -86.58 103.34 14.99 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 120.832 0.349 . . . . 0.0 110.16 178.521 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . 0.527 HD21 ' HB2' ' A' ' 41' ' ' GLU . 1.8 tt -101.36 119.08 38.22 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 115.942 -0.572 . . . . 0.0 109.935 -176.42 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 46.2 t -100.22 119.14 47.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.365 -179.15 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . 0.609 HD13 HD22 ' A' ' 48' ' ' LEU . 32.3 mt -95.42 122.44 38.14 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.935 -0.575 . . . . 0.0 109.73 178.785 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 37.9 p -118.34 142.27 47.69 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 120.567 0.222 . . . . 0.0 111.189 -178.374 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 30.9 t70 -165.32 154.97 12.81 Favored 'General case' 0 C--N 1.33 -0.259 0 N-CA-C 110.124 -0.325 . . . . 0.0 110.124 179.788 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.575 HD13 ' HA ' ' A' ' 78' ' ' ASP . 37.4 mm -69.61 94.33 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.853 0.359 . . . . 0.0 110.163 179.144 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' LYS . . . . . 0.722 ' HD3' ' HB2' ' A' ' 76' ' ' ARG . 40.9 mmtm 44.46 70.66 1.81 Allowed Pre-proline 0 CA--C 1.533 0.296 0 CA-C-N 115.279 -0.873 . . . . 0.0 110.835 -178.304 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . 0.742 ' HD2' ' HA ' ' A' ' 76' ' ' ARG . 10.3 Cg_endo . . . . . 0 C--N 1.344 0.341 0 C-N-CA 123.896 3.064 . . . . 0.0 113.762 -172.495 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.495 ' HB ' ' HG3' ' A' ' 69' ' ' PRO . 35.9 mt . . . . . 0 C--O 1.234 0.276 0 N-CA-C 110.38 -0.23 . . . . 0.0 110.38 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 60.3 t -68.62 128.62 32.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 178.767 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' ARG . . . . . 0.742 ' HA ' ' HD2' ' A' ' 69' ' ' PRO . 32.1 ptt180 -91.43 54.46 2.54 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.453 0.644 . . . . 0.0 110.976 -179.43 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 9.7 p-10 -83.34 -156.54 0.2 Allowed 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.039 -0.982 . . . . 0.0 109.955 178.129 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' ASP . . . . . 0.575 ' HA ' HD13 ' A' ' 67' ' ' ILE . 20.3 m-20 -143.85 108.75 4.94 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 110.297 -0.26 . . . . 0.0 110.297 -179.391 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 9.3 tp -73.66 -24.51 19.99 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.37 0 CA-C-O 120.819 0.343 . . . . 0.0 110.737 178.758 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 10.0 t -69.19 -26.95 65.09 Favored 'General case' 0 CA--C 1.531 0.241 0 CA-C-O 121.219 0.533 . . . . 0.0 110.547 178.077 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 22.7 t -134.28 78.74 57.24 Favored Pre-proline 0 C--N 1.323 -0.569 0 N-CA-C 108.153 -1.055 . . . . 0.0 108.153 173.292 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' PRO . . . . . 0.429 ' HB2' ' HE2' ' A' ' 87' ' ' TYR . 59.1 Cg_endo -71.13 133.44 23.06 Favored 'Trans proline' 0 N--CA 1.461 -0.426 0 C-N-CA 122.762 2.308 . . . . 0.0 113.625 -168.592 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' ARG . . . . . 0.537 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 70.7 mtt85 -84.98 106.27 16.36 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.453 -0.794 . . . . 0.0 109.27 171.871 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' MET . . . . . . . . . . . . . 89.5 mmm -58.21 -26.45 62.85 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.987 -0.551 . . . . 0.0 111.142 -177.235 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.537 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 11.3 pt-20 -62.14 -26.78 68.51 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.672 -179.558 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 73.6 mt -79.46 -41.11 22.16 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-O 121.04 0.447 . . . . 0.0 110.531 -179.339 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . 0.429 ' HE2' ' HB2' ' A' ' 82' ' ' PRO . 44.9 m-85 -79.65 -25.51 41.32 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.789 -176.795 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 52.0 mtp180 -66.23 131.58 46.47 Favored 'General case' 0 CA--C 1.517 -0.304 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.373 176.276 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 98.23 8.72 54.81 Favored Glycine 0 N--CA 1.444 -0.811 0 C-N-CA 120.627 -0.797 . . . . 0.0 111.699 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -100.77 144.6 29.53 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 110.204 -0.295 . . . . 0.0 110.204 177.689 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -92.78 -23.73 18.77 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.078 0.466 . . . . 0.0 110.939 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . 0.464 HD23 ' N ' ' A' ' 93' ' ' ILE . 4.6 tt -150.1 140.74 22.58 Favored 'General case' 0 N--CA 1.449 -0.516 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.434 -178.225 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.524 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 62.8 mt -130.68 119.27 45.15 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 115.784 -0.644 . . . . 0.0 109.419 177.937 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 13.2 p90 -126.18 155.21 42.11 Favored 'General case' 0 C--N 1.32 -0.701 0 C-N-CA 120.553 -0.459 . . . . 0.0 110.544 179.277 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . 0.6 ' HA ' ' O ' ' A' ' 42' ' ' VAL . 10.6 p -135.81 143.63 45.28 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.752 -0.658 . . . . 0.0 111.424 -175.189 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 74.5 mt -114.86 112.59 40.67 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 115.577 -0.738 . . . . 0.0 110.249 178.763 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 61.6 mtp180 57.59 70.36 1.34 Allowed Pre-proline 0 N--CA 1.466 0.331 0 CA-C-N 115.593 -0.73 . . . . 0.0 112.279 -178.459 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_endo -87.31 131.72 3.05 Favored 'Trans proline' 0 N--CA 1.451 -1.005 0 C-N-CA 122.536 2.157 . . . . 0.0 111.78 175.699 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . 0.635 ' HD2' HD11 ' A' ' 102' ' ' ILE . 52.2 Cg_exo -55.98 148.9 55.3 Favored 'Trans proline' 0 C--O 1.235 0.36 0 C-N-CA 122.464 2.11 . . . . 0.0 111.564 172.267 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . 0.712 ' HA ' ' ND1' ' A' ' 103' ' ' HIS . . . -60.71 -22.91 64.45 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.918 0.39 . . . . 0.0 111.763 -175.337 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 101' ' ' GLU . . . . . 0.694 ' HG3' HG23 ' A' ' 102' ' ' ILE . 10.5 pt-20 -66.65 -31.22 71.75 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.983 -179.958 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.694 HG23 ' HG3' ' A' ' 101' ' ' GLU . 48.3 pt -107.42 -1.05 9.92 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.148 0 N-CA-C 112.482 0.549 . . . . 0.0 112.482 -173.004 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 103' ' ' HIS . . . . . 0.712 ' ND1' ' HA ' ' A' ' 100' ' ' ALA . 13.1 m170 -53.54 -55.61 24.08 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 121.118 0.485 . . . . 0.0 111.162 178.235 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 19.0 m -70.2 -25.59 63.48 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 121.184 0.516 . . . . 0.0 110.689 179.503 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.705 ' O ' ' HG2' ' A' ' 108' ' ' ARG . 1.7 m -71.83 -37.65 70.27 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.502 -177.955 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 86.1 mt -63.62 -39.15 93.64 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.709 177.531 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 107' ' ' MET . . . . . . . . . . . . . 49.7 ttm -64.54 -42.33 95.78 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.208 179.447 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 108' ' ' ARG . . . . . 0.705 ' HG2' ' O ' ' A' ' 105' ' ' SER . 1.7 ptm180 -66.37 -26.84 67.45 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.836 0.35 . . . . 0.0 110.628 -178.225 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 82.2 t -75.3 -49.15 28.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.155 175.374 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -57.69 -42.63 84.05 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.494 177.458 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.492 ' HA ' ' HB1' ' A' ' 148' ' ' ALA . 16.8 t70 -62.45 -32.08 72.9 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.581 -0.736 . . . . 0.0 110.746 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -79.09 -41.74 27.97 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.585 -0.734 . . . . 0.0 111.955 -178.634 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 29.0 m -87.83 -26.14 5.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 N-CA-C 111.907 0.336 . . . . 0.0 111.907 -175.955 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 82.5 64.86 1.66 Allowed Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.884 -0.674 . . . . 0.0 112.052 -178.955 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . 0.4 ' O ' ' HB3' ' A' ' 148' ' ' ALA . . . -139.58 155.41 47.49 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 120.815 0.341 . . . . 0.0 110.702 -179.909 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 116' ' ' ARG . . . . . 0.449 ' HB3' ' HG ' ' A' ' 92' ' ' LEU . 20.0 ttm-85 -75.1 121.59 22.27 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 177.416 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . 0.524 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 65.9 tp -94.02 125.28 38.56 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.171 -179.928 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 71.4 mt -124.25 120.51 59.46 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.654 0 CA-C-O 120.899 0.38 . . . . 0.0 110.146 177.488 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 30.2 mt -114.04 131.21 66.64 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.217 -178.348 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 120' ' ' LYS . . . . . 0.616 ' HD3' ' HB3' ' A' ' 143' ' ' PHE . 10.9 mmmm -110.86 98.08 36.61 Favored Pre-proline 0 C--O 1.235 0.308 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.881 172.946 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 85.7 Cg_endo -92.42 -157.89 0.06 OUTLIER 'Trans proline' 0 N--CA 1.453 -0.889 0 C-N-CA 123.177 2.585 . . . . 0.0 111.162 173.729 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 8.0 mp -111.38 150.42 29.79 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 120.635 0.255 . . . . 0.0 110.607 178.205 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 38.1 m -65.57 110.42 2.72 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.064 0.459 . . . . 0.0 110.655 178.916 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 108.36 -10.76 36.34 Favored Glycine 0 N--CA 1.445 -0.71 0 N-CA-C 111.084 -0.806 . . . . 0.0 111.084 -176.461 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 4.7 tp10 -106.39 100.5 10.02 Favored 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 109.08 -0.711 . . . . 0.0 109.08 178.49 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 15.8 t70 -85.22 165.05 17.69 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.427 -0.351 . . . . 0.0 110.958 -174.033 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . 0.447 HG23 ' CG ' ' A' ' 103' ' ' HIS . 52.3 mt . . . . . 0 C--N 1.323 -0.548 0 CA-C-N 115.767 -0.652 . . . . 0.0 110.55 -177.628 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 132' ' ' LYS . . . . . 0.468 ' HE3' ' HB2' ' A' ' 132' ' ' LYS . 35.5 mtmt . . . . . 0 CA--C 1.52 -0.189 0 CA-C-O 120.518 0.199 . . . . 0.0 111.282 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 133' ' ' MET . . . . . . . . . . . . . 79.7 mtp -146.08 150.59 36.23 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 170.789 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 1.5 ptpp? -114.83 141.27 48.12 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 121.322 0.582 . . . . 0.0 111.301 -177.501 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . 0.558 HD11 ' HD2' ' A' ' 142' ' ' TYR . 60.0 tp -82.24 129.23 34.8 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.141 -0.936 . . . . 0.0 109.883 178.666 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -126.35 148.47 31.05 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.885 -177.852 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 13.3 m120 -124.23 125.73 44.89 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.05 -0.523 . . . . 0.0 109.865 179.827 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . 0.608 ' O ' HG22 ' A' ' 141' ' ' THR . 42.7 t80 -149.19 104.79 3.44 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.746 0.307 . . . . 0.0 111.049 177.562 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . 0.402 ' C ' ' H ' ' A' ' 141' ' ' THR . . . 59.93 67.28 2.23 Favored Glycine 0 CA--C 1.521 0.417 0 CA-C-N 116.212 -0.449 . . . . 0.0 113.736 175.878 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 21.9 mmt180 69.54 -21.64 0.16 Allowed 'General case' 0 N--CA 1.47 0.547 0 N-CA-C 113.176 0.806 . . . . 0.0 113.176 176.339 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 141' ' ' THR . . . . . 0.608 HG22 ' O ' ' A' ' 138' ' ' TYR . 1.0 OUTLIER -98.0 131.47 44.4 Favored 'General case' 0 N--CA 1.444 -0.77 0 CA-C-O 121.33 0.586 . . . . 0.0 109.91 -179.359 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 142' ' ' TYR . . . . . 0.558 ' HD2' HD11 ' A' ' 135' ' ' LEU . 21.6 p90 -115.99 147.28 41.37 Favored 'General case' 0 N--CA 1.445 -0.713 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 174.872 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 143' ' ' PHE . . . . . 0.616 ' HB3' ' HD3' ' A' ' 120' ' ' LYS . 12.2 p90 -155.81 171.82 19.38 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.61 -175.308 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -107.93 121.43 44.77 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.899 -0.591 . . . . 0.0 109.568 175.845 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 145' ' ' GLU . . . . . . . . . . . . . 15.3 pt-20 -112.32 156.06 23.06 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-O 121.267 0.556 . . . . 0.0 109.578 177.125 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 34.7 t80 -138.88 124.23 19.28 Favored 'General case' 0 C--N 1.311 -1.092 0 CA-C-N 115.646 -0.706 . . . . 0.0 109.468 176.322 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 147' ' ' ILE . . . . . 0.446 ' N ' HD12 ' A' ' 147' ' ' ILE . 3.1 mp -88.44 96.07 5.72 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.739 0 N-CA-C 109.18 -0.674 . . . . 0.0 109.18 178.078 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . 0.492 ' HB1' ' HA ' ' A' ' 111' ' ' ASP . . . -76.49 118.03 18.75 Favored 'General case' 0 C--N 1.317 -0.819 0 CA-C-N 115.369 -0.832 . . . . 0.0 109.061 177.042 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 31.3 mt-10 . . . . . 0 C--N 1.322 -0.604 0 CA-C-O 121.814 0.816 . . . . 0.0 111.094 -175.206 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 83.2 m95 . . . . . 0 N--CA 1.451 -0.407 0 N-CA-C 109.596 -0.52 . . . . 0.0 109.596 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 4.6 m-20 -62.51 -56.02 21.94 Favored 'General case' 0 CA--C 1.521 -0.171 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.508 176.418 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.549 ' HB3' ' HA3' ' A' ' 139' ' ' GLY . 44.7 m-20 -60.61 -36.64 79.09 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.617 179.766 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 64.6 tp -55.83 -49.74 72.45 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.177 175.027 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . 0.566 ' HB2' HG13 ' A' ' 50' ' ' VAL . . . -62.14 -46.69 87.89 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.582 -0.736 . . . . 0.0 111.024 179.029 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 71.4 t -53.17 -47.32 55.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 121.102 0.477 . . . . 0.0 110.664 176.8 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . 0.481 ' HB2' ' CD1' ' A' ' 138' ' ' TYR . 69.7 t80 -56.2 -41.64 75.9 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.891 178.491 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.499 HG23 HD22 ' A' ' 92' ' ' LEU . 75.8 mt -69.83 -44.81 78.63 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.82 178.88 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.621 HD11 ' HA ' ' A' ' 54' ' ' ILE . 83.6 mt -57.77 -43.77 84.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 115.891 -0.595 . . . . 0.0 111.507 -178.98 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 17.9 mtp180 -64.81 -32.76 74.6 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.902 -178.569 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 81.4 m -88.95 -18.67 26.99 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 115.501 -0.772 . . . . 0.0 111.995 -174.006 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 14.0 p -101.54 -82.1 0.47 Allowed 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 120.797 0.332 . . . . 0.0 111.556 -178.54 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 101.81 161.42 26.77 Favored Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 121.014 -0.612 . . . . 0.0 112.187 -178.328 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 7.6 Cg_exo -72.8 144.48 39.12 Favored 'Trans proline' 0 C--O 1.233 0.269 0 C-N-CA 123.083 2.522 . . . . 0.0 112.383 -179.163 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 111.89 -28.76 9.06 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.533 -0.842 . . . . 0.0 112.813 177.897 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 12.6 t -99.86 -169.45 1.74 Allowed 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 -178.551 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' ARG . . . . . 0.628 ' HB2' ' HA ' ' A' ' 90' ' ' ALA . 66.2 mtp180 -118.6 136.51 53.84 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.954 0.407 . . . . 0.0 111.134 -178.346 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.655 HG23 HG21 ' A' ' 60' ' ' VAL . 95.5 t -129.97 131.11 66.38 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-N 115.83 -0.623 . . . . 0.0 109.369 176.699 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.576 HG22 ' HB ' ' A' ' 63' ' ' VAL . 40.6 t -112.12 129.0 68.4 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 CA-C-O 120.765 0.317 . . . . 0.0 111.759 -173.178 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . 0.459 ' HB3' HD23 ' A' ' 64' ' ' LEU . 44.8 tt0 -103.11 107.76 18.7 Favored 'General case' 0 C--O 1.235 0.319 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 174.693 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 44.1 t -89.68 127.78 42.09 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.647 -178.16 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 94.14 23.98 20.82 Favored Glycine 0 N--CA 1.448 -0.523 0 N-CA-C 110.955 -0.858 . . . . 0.0 110.955 -176.375 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.608 ' HB1' HD23 ' A' ' 48' ' ' LEU . . . -93.47 80.38 4.36 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.247 -0.476 . . . . 0.0 110.858 -177.044 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -108.42 -60.61 0.54 Allowed Glycine 0 N--CA 1.446 -0.664 0 C-N-CA 120.824 -0.703 . . . . 0.0 112.015 178.607 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 57.6 mtp180 -125.47 4.44 7.63 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.933 0.397 . . . . 0.0 110.814 -179.171 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.528 ' HE2' HG23 ' A' ' 50' ' ' VAL . 64.7 t80 -86.69 -79.45 0.26 Allowed 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 176.712 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.646 HD22 HD13 ' A' ' 64' ' ' LEU . 59.4 mt 62.71 9.35 3.51 Favored 'General case' 0 N--CA 1.467 0.41 0 CA-C-N 115.156 -0.929 . . . . 0.0 112.795 171.006 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . 0.452 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 81.2 t80 -71.08 -45.42 63.77 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 111.791 0.293 . . . . 0.0 111.791 -171.431 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.566 HG13 ' HB2' ' A' ' 26' ' ' ALA . 56.2 t -69.98 -48.57 62.35 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-N 116.599 -0.273 . . . . 0.0 110.597 -177.946 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 50.9 p -58.77 -41.15 85.92 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.453 -0.339 . . . . 0.0 111.037 176.956 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.737 ' HA ' ' HE ' ' A' ' 55' ' ' ARG . 24.4 t70 -61.13 -37.97 84.72 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.8 0.333 . . . . 0.0 110.712 176.55 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 47.3 t80 -69.19 -45.6 69.55 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.308 178.041 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.621 ' HA ' HD11 ' A' ' 30' ' ' ILE . 88.0 mt -63.45 -44.83 99.02 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.823 -178.347 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' ARG . . . . . 0.748 HH22 HD11 ' A' ' 64' ' ' LEU . 12.1 ptp180 -63.37 -16.42 60.42 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-O 120.791 0.329 . . . . 0.0 111.584 -175.77 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . 0.459 ' HG3' ' O ' ' A' ' 52' ' ' ASP . 97.7 mttt -81.39 -36.04 30.03 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.599 -179.602 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 81.6 m-70 -103.67 -18.11 14.85 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.817 -175.021 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . 0.421 ' HB2' HG23 ' A' ' 30' ' ' ILE . 6.4 t -135.63 128.9 31.98 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-O 120.794 0.331 . . . . 0.0 110.566 -177.356 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -89.39 51.42 2.12 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.871 0.843 . . . . 0.0 110.126 175.532 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.655 HG21 HG23 ' A' ' 39' ' ' VAL . 8.3 p -83.59 147.21 5.96 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 CA-C-N 114.845 -1.07 . . . . 0.0 108.908 175.434 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . 0.571 ' HB3' ' HG2' ' A' ' 38' ' ' ARG . 19.0 t70 -72.68 95.52 1.88 Allowed 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 109.248 -0.649 . . . . 0.0 109.248 179.269 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . 0.411 ' HA ' ' O ' ' A' ' 39' ' ' VAL . 2.1 tt -94.77 128.45 41.49 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.407 -172.318 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.576 ' HB ' HG22 ' A' ' 40' ' ' VAL . 33.3 t -108.71 126.7 65.58 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.45 -178.92 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . 0.748 HD11 HH22 ' A' ' 55' ' ' ARG . 66.7 mt -108.61 131.18 55.13 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 116.039 -0.528 . . . . 0.0 109.63 176.4 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 49.9 p -129.3 127.91 42.11 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.721 0.296 . . . . 0.0 111.319 179.389 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 3.7 t70 -165.74 175.88 8.43 Favored 'General case' 0 C--O 1.233 0.215 0 CA-C-N 116.082 -0.508 . . . . 0.0 109.732 176.964 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 53.0 mt -87.68 114.57 26.72 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-O 120.634 0.254 . . . . 0.0 110.657 -176.391 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 55.3 mtpt 61.17 79.93 0.27 Allowed Pre-proline 0 C--N 1.331 -0.226 0 CA-C-N 115.646 -0.707 . . . . 0.0 110.9 178.287 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . 1.017 ' HB3' ' HB ' ' A' ' 74' ' ' ILE . 18.9 Cg_endo . . . . . 0 C--N 1.342 0.223 0 C-N-CA 123.281 2.654 . . . . 0.0 113.08 -176.092 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 1.017 ' HB ' ' HB3' ' A' ' 69' ' ' PRO . 65.4 mt . . . . . 0 N--CA 1.451 -0.394 0 N-CA-C 109.996 -0.372 . . . . 0.0 109.996 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.589 HG11 HD13 ' A' ' 86' ' ' ILE . 48.3 t -80.78 135.89 24.32 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 N-CA-C 109.778 -0.452 . . . . 0.0 109.778 176.805 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 11.4 ptt180 -75.98 25.71 0.12 Allowed 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.867 -0.606 . . . . 0.0 111.876 -177.177 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . 0.404 ' H ' ' C ' ' A' ' 75' ' ' VAL . 12.7 t70 -83.35 113.82 20.99 Favored 'General case' 0 C--N 1.324 -0.536 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 -177.753 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 2.2 p30 -70.67 168.97 15.37 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.033 0.444 . . . . 0.0 111.257 -172.697 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' ILE . . . . . 0.443 HD11 HD12 ' A' ' 102' ' ' ILE . 7.1 tp -83.98 -30.27 7.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 N-CA-C 112.936 0.717 . . . . 0.0 112.936 -169.569 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 12.2 t -94.23 -21.01 19.31 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.169 0.509 . . . . 0.0 110.712 -174.017 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 4.5 t -130.64 69.03 82.22 Favored Pre-proline 0 C--N 1.323 -0.585 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.05 -179.807 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -78.64 163.48 26.59 Favored 'Trans proline' 0 N--CA 1.46 -0.443 0 C-N-CA 122.98 2.453 . . . . 0.0 112.619 -175.834 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' ARG . . . . . 0.645 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 88.6 mtm180 -108.92 118.17 36.1 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.291 178.305 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' MET . . . . . 0.515 ' SD ' HG22 ' A' ' 109' ' ' VAL . 92.0 mmm -61.13 -28.61 69.23 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.267 -0.879 . . . . 0.0 111.343 -179.037 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.645 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 10.7 pt-20 -57.69 -24.27 55.9 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.711 -179.975 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.589 HD13 HG11 ' A' ' 75' ' ' VAL . 76.5 mt -86.48 -43.75 16.29 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.089 -177.478 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . 0.438 ' CE1' HG11 ' A' ' 40' ' ' VAL . 88.3 m-85 -72.13 -27.15 62.44 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.37 -178.593 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 27.0 mtp180 -66.06 116.66 7.4 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 121.409 0.623 . . . . 0.0 111.26 -179.482 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 118.61 -15.99 11.44 Favored Glycine 0 N--CA 1.447 -0.597 0 CA-C-N 115.189 -0.914 . . . . 0.0 111.243 -176.065 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . 0.628 ' HA ' ' HB2' ' A' ' 38' ' ' ARG . . . -75.48 145.63 41.25 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.897 0.379 . . . . 0.0 110.545 178.837 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -98.51 -20.76 16.89 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.125 177.659 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . 0.499 HD22 HG23 ' A' ' 29' ' ' ILE . 5.1 tt -153.33 138.24 17.17 Favored 'General case' 0 N--CA 1.447 -0.604 0 CA-C-N 115.688 -0.687 . . . . 0.0 109.967 -179.306 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.538 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 63.6 mt -130.64 131.16 64.96 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 115.987 -0.551 . . . . 0.0 109.629 -178.748 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' TYR . . . . . 0.454 ' HE1' HG12 ' A' ' 39' ' ' VAL . 26.6 p90 -134.15 156.05 49.01 Favored 'General case' 0 C--N 1.322 -0.626 0 C-N-CA 120.625 -0.43 . . . . 0.0 110.811 179.57 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 17.3 m -131.86 139.76 48.91 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.76 -177.651 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 42.3 mm -85.94 86.98 2.5 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.363 -179.259 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' ARG . . . . . 0.438 ' NH1' HD13 ' A' ' 122' ' ' LEU . 39.1 ttp180 44.32 79.56 0.33 Allowed Pre-proline 0 N--CA 1.47 0.558 0 O-C-N 124.126 0.891 . . . . 0.0 112.364 -179.313 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 91.2 Cg_endo -83.83 154.13 13.26 Favored 'Trans proline' 0 N--CA 1.456 -0.704 0 C-N-CA 122.918 2.412 . . . . 0.0 112.042 178.892 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . 0.605 ' HD2' HD11 ' A' ' 102' ' ' ILE . 51.3 Cg_exo -55.35 150.66 40.32 Favored 'Trans proline' 0 C--N 1.346 0.417 0 C-N-CA 122.605 2.204 . . . . 0.0 112.112 175.53 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -79.68 30.31 0.25 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.727 -174.205 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 101' ' ' GLU . . . . . 0.413 ' HG3' HG23 ' A' ' 102' ' ' ILE . 10.4 pt-20 -124.95 -23.46 4.26 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 120.742 0.306 . . . . 0.0 110.954 176.507 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.605 HD11 ' HD2' ' A' ' 99' ' ' PRO . 46.6 pt -98.9 -2.4 9.83 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-O 120.752 0.31 . . . . 0.0 111.316 -177.173 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 103' ' ' HIS . . . . . 0.576 ' O ' ' HG2' ' A' ' 107' ' ' MET . 31.4 p-80 -60.16 -40.09 88.71 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.138 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 8.1 p -63.21 -35.85 81.68 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.913 178.604 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.514 ' O ' HG23 ' A' ' 109' ' ' VAL . 16.3 m -67.42 -45.91 74.72 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.735 -0.666 . . . . 0.0 109.69 177.976 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 96.0 mt -59.86 -42.17 93.1 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.909 178.124 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 107' ' ' MET . . . . . 0.576 ' HG2' ' O ' ' A' ' 103' ' ' HIS . 98.2 mmm -56.71 -49.59 74.71 Favored 'General case' 0 C--O 1.233 0.234 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.537 -179.939 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 33.7 ptt85 -70.77 -30.57 67.09 Favored 'General case' 0 C--N 1.332 -0.188 0 C-N-CA 120.727 -0.389 . . . . 0.0 111.108 -177.403 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.515 HG22 ' SD ' ' A' ' 84' ' ' MET . 69.5 t -67.78 -48.49 75.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 120.575 0.226 . . . . 0.0 110.647 177.029 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -59.08 -41.64 88.5 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.708 179.626 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.679 ' HA ' ' HB1' ' A' ' 148' ' ' ALA . 23.3 t70 -65.6 -42.29 91.8 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.701 -0.682 . . . . 0.0 110.815 178.489 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -62.54 -43.46 98.77 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.964 -0.562 . . . . 0.0 111.645 -178.364 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.419 HG21 HD11 ' A' ' 93' ' ' ILE . 20.2 m -85.38 -28.14 6.42 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-O 120.928 0.394 . . . . 0.0 111.022 -177.59 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 87.35 51.85 3.2 Favored Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 120.596 -0.812 . . . . 0.0 111.918 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -130.15 155.47 46.16 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 120.831 0.348 . . . . 0.0 110.901 -178.799 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 116' ' ' ARG . . . . . 0.698 HH21 HD11 ' A' ' 118' ' ' ILE . 50.2 ttp180 -79.21 117.56 20.34 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 178.037 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . 0.538 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 60.3 tp -88.14 118.84 27.99 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.0 -0.546 . . . . 0.0 110.086 -179.535 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . 0.698 HD11 HH21 ' A' ' 116' ' ' ARG . 66.6 mt -114.52 117.42 55.54 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-O 121.28 0.562 . . . . 0.0 110.842 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 71.7 mt -116.52 116.9 53.72 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.323 179.308 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 57.6 tttp -102.76 104.4 38.78 Favored Pre-proline 0 C--N 1.322 -0.598 0 C-N-CA 120.656 -0.418 . . . . 0.0 110.005 172.351 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 121' ' ' PRO . . . . . 0.591 ' HB2' ' O ' ' A' ' 125' ' ' GLU . 70.5 Cg_endo -78.68 -139.58 0.02 OUTLIER 'Trans proline' 0 N--CA 1.457 -0.673 0 C-N-CA 122.522 2.148 . . . . 0.0 111.531 172.673 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 122' ' ' LEU . . . . . 0.888 ' HB3' ' HB3' ' A' ' 125' ' ' GLU . 14.4 tp -126.82 156.94 40.52 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.383 -178.789 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . 0.472 ' HA ' ' OH ' ' A' ' 142' ' ' TYR . 25.4 m -69.94 102.04 1.9 Allowed 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 177.368 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 100.88 2.88 55.1 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.967 -0.635 . . . . 0.0 111.737 -175.533 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . 0.888 ' HB3' ' HB3' ' A' ' 122' ' ' LEU . 37.7 tt0 -132.38 97.12 4.02 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 177.827 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 14.2 t70 -99.9 173.06 6.85 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.403 -0.817 . . . . 0.0 110.455 -170.227 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 5.3 mt . . . . . 0 C--N 1.33 -0.254 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 178.12 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 132' ' ' LYS . . . . . 0.555 ' HE3' ' HE1' ' A' ' 146' ' ' TYR . 31.7 ttpt . . . . . 0 N--CA 1.465 0.285 0 CA-C-O 121.361 0.601 . . . . 0.0 112.038 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 133' ' ' MET . . . . . . . . . . . . . 46.7 mtp -69.06 170.5 9.81 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.764 176.949 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . 0.476 ' NZ ' ' HB3' ' A' ' 134' ' ' LYS . 0.5 OUTLIER -139.68 151.65 46.09 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.942 -179.43 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . 0.436 HD11 ' HD2' ' A' ' 142' ' ' TYR . 57.4 tp -89.74 123.46 33.77 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.252 178.206 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 136' ' ' VAL . . . . . 0.452 ' CG2' ' HG2' ' A' ' 145' ' ' GLU . 0.1 OUTLIER -121.74 149.05 24.92 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.445 -179.658 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 12.3 m120 -125.86 112.62 16.2 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.2 -176.214 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . 0.481 ' CD1' ' HB2' ' A' ' 28' ' ' TYR . 53.3 t80 -147.96 123.31 10.29 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.554 0.216 . . . . 0.0 110.947 -179.723 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . 0.549 ' HA3' ' HB3' ' A' ' 24' ' ' ASP . . . 62.93 71.69 0.78 Allowed Glycine 0 N--CA 1.451 -0.317 0 CA-C-N 115.716 -0.674 . . . . 0.0 113.726 173.045 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 6.1 mpt_? 70.99 -39.5 0.45 Allowed 'General case' 0 N--CA 1.473 0.684 0 C-N-CA 123.356 0.662 . . . . 0.0 112.628 175.171 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 8.8 t -101.87 154.5 18.87 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 121.487 0.66 . . . . 0.0 111.696 -173.817 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 142' ' ' TYR . . . . . 0.472 ' OH ' ' HA ' ' A' ' 123' ' ' THR . 45.8 p90 -112.68 155.02 25.2 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 115.031 -0.986 . . . . 0.0 108.592 169.249 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 18.0 p90 -160.27 179.03 9.03 Favored 'General case' 0 C--N 1.319 -0.744 0 N-CA-C 110.151 -0.315 . . . . 0.0 110.151 -178.348 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 86.5 m-85 -116.27 125.42 52.17 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 120.724 0.297 . . . . 0.0 110.525 -179.505 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 145' ' ' GLU . . . . . 0.452 ' HG2' ' CG2' ' A' ' 136' ' ' VAL . 23.7 pt-20 -117.28 162.1 18.43 Favored 'General case' 0 C--N 1.317 -0.807 0 N-CA-C 109.557 -0.534 . . . . 0.0 109.557 175.235 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . 0.555 ' HE1' ' HE3' ' A' ' 132' ' ' LYS . 14.8 t80 -138.28 117.3 12.51 Favored 'General case' 0 C--N 1.311 -1.102 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.744 175.623 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 147' ' ' ILE . . . . . 0.42 ' N ' HD12 ' A' ' 147' ' ' ILE . 2.4 mp -85.41 99.43 7.39 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.874 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 174.643 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . 0.679 ' HB1' ' HA ' ' A' ' 111' ' ' ASP . . . -58.42 104.48 0.22 Allowed 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 108.933 -0.765 . . . . 0.0 108.933 176.432 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 36.7 mt-10 . . . . . 0 CA--C 1.506 -0.717 0 CA-C-O 122.092 0.948 . . . . 0.0 110.76 -175.329 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' TRP . . . . . 0.601 ' CH2' HG23 ' A' ' 96' ' ' ILE . 99.4 m95 . . . . . 0 C--O 1.232 0.152 0 CA-C-O 120.833 0.349 . . . . 0.0 111.677 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 24.3 t-20 -56.45 -41.06 75.86 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.765 -0.652 . . . . 0.0 111.606 -176.659 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -60.33 -50.82 72.08 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.963 -0.562 . . . . 0.0 112.042 -179.909 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 58.5 tp -56.28 -45.44 80.13 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.195 -178.474 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . 0.5 ' O ' HG13 ' A' ' 30' ' ' ILE . . . -54.74 -52.03 63.81 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.322 -179.157 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 83.2 t -51.4 -47.64 34.91 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.78 178.887 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 74.4 t80 -59.06 -44.59 91.84 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.921 0.391 . . . . 0.0 110.491 -179.054 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 72.5 mt -64.77 -45.53 94.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.918 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.607 HG12 HG23 ' A' ' 54' ' ' ILE . 85.8 mt -57.24 -44.36 83.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.88 179.911 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 55.5 mtt180 -71.36 -20.72 62.12 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.693 -0.685 . . . . 0.0 111.697 -175.224 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 72.8 m -88.98 -21.33 23.58 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.408 -0.36 . . . . 0.0 111.256 179.788 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 12.4 p -106.23 -80.16 0.56 Allowed 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 120.765 0.317 . . . . 0.0 111.255 -176.652 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 95.92 172.82 36.01 Favored Glycine 0 N--CA 1.449 -0.468 0 C-N-CA 120.822 -0.704 . . . . 0.0 112.427 -179.888 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 12.5 Cg_exo -69.68 143.39 51.08 Favored 'Trans proline' 0 N--CA 1.465 -0.189 0 C-N-CA 122.955 2.437 . . . . 0.0 112.335 -179.197 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 91.12 7.27 65.89 Favored Glycine 0 N--CA 1.454 -0.128 0 C-N-CA 120.613 -0.803 . . . . 0.0 112.694 176.413 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 29.9 p -110.43 -174.09 2.4 Favored 'General case' 0 C--N 1.321 -0.671 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 179.848 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' ARG . . . . . 0.619 ' NH2' ' HA3' ' A' ' 89' ' ' GLY . 56.6 mtm180 -129.72 126.91 39.36 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 120.771 0.319 . . . . 0.0 110.647 176.709 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.643 HG23 HG21 ' A' ' 60' ' ' VAL . 41.5 t -122.81 134.51 65.75 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 177.703 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.475 HG11 ' CE1' ' A' ' 87' ' ' TYR . 32.2 t -114.02 122.38 68.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-O 120.955 0.407 . . . . 0.0 110.436 -178.416 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . 0.815 ' HG3' HD23 ' A' ' 64' ' ' LEU . 0.1 OUTLIER -93.07 121.59 34.58 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.71 -174.706 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.508 ' O ' ' HA ' ' A' ' 95' ' ' SER . 48.5 t -102.55 113.65 39.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 N-CA-C 109.566 -0.531 . . . . 0.0 109.566 173.825 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 111.77 44.9 0.86 Allowed Glycine 0 N--CA 1.45 -0.37 0 N-CA-C 111.134 -0.786 . . . . 0.0 111.134 -176.032 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -95.85 14.73 22.41 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.102 0.477 . . . . 0.0 111.044 -175.892 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -72.74 -7.73 70.48 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.946 -0.645 . . . . 0.0 112.947 -178.153 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 74.0 ttt180 -166.18 -34.14 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.94 0.4 . . . . 0.0 110.934 -179.915 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 40.7 m-85 -82.86 83.39 7.77 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 121.116 0.484 . . . . 0.0 111.056 -175.685 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 88.2 mt -109.35 9.3 25.71 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.144 -179.514 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 39.3 t80 -72.54 -50.97 21.96 Favored 'General case' 0 C--N 1.33 -0.267 0 C-N-CA 121.023 -0.271 . . . . 0.0 110.968 178.259 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.528 ' O ' HG13 ' A' ' 54' ' ' ILE . 33.6 t -57.73 -49.0 82.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.463 -176.448 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 1.9 p -60.01 -44.07 94.81 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.93 -0.577 . . . . 0.0 111.787 -179.783 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.542 ' O ' ' HG2' ' A' ' 56' ' ' LYS . 28.8 t70 -64.99 -39.76 93.95 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 120.856 0.36 . . . . 0.0 110.601 -179.907 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 59.5 t80 -65.97 -39.47 90.41 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.563 -179.218 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.607 HG23 HG12 ' A' ' 30' ' ' ILE . 82.3 mt -64.88 -48.71 83.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.613 -179.852 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 39.7 ptt180 -67.28 -17.13 64.66 Favored 'General case' 0 N--CA 1.466 0.348 0 N-CA-C 111.586 0.217 . . . . 0.0 111.586 -175.649 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . 0.542 ' HG2' ' O ' ' A' ' 52' ' ' ASP . 33.1 mmtp -75.04 -36.07 61.87 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.822 0.344 . . . . 0.0 110.747 177.591 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 53.8 m-70 -94.6 -31.11 14.01 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.818 -175.785 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 73.3 m -136.75 132.89 35.41 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 120.759 0.314 . . . . 0.0 111.474 -178.27 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 3.1 tmtp? -81.51 60.97 4.75 Favored 'General case' 0 C--O 1.234 0.256 0 CA-C-O 121.831 0.824 . . . . 0.0 109.708 177.051 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.643 HG21 HG23 ' A' ' 39' ' ' VAL . 2.6 p -84.59 144.61 9.45 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.037 0 CA-C-N 114.975 -1.011 . . . . 0.0 108.869 172.816 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . 0.43 ' O ' ' HA ' ' A' ' 38' ' ' ARG . 24.7 m-20 -79.0 100.36 7.27 Favored 'General case' 0 CA--C 1.515 -0.378 0 CA-C-O 121.605 0.717 . . . . 0.0 109.441 176.328 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . 0.516 HD11 ' OE2' ' A' ' 41' ' ' GLU . 8.5 tt -99.28 129.14 45.48 Favored 'General case' 0 C--N 1.316 -0.854 0 CA-C-N 114.8 -1.091 . . . . 0.0 110.599 -171.653 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 57.7 t -117.45 116.06 50.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.987 -177.895 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . 0.815 HD23 ' HG3' ' A' ' 41' ' ' GLU . 33.1 mt -87.39 128.21 35.2 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 115.966 -0.561 . . . . 0.0 109.828 178.17 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.512 HG22 ' HB ' ' A' ' 75' ' ' VAL . 25.2 p -130.57 134.36 46.95 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 120.488 0.185 . . . . 0.0 110.629 178.965 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -171.74 153.73 3.43 Favored 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 178.395 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.546 HD11 HG22 ' A' ' 79' ' ' ILE . 60.8 mt -77.42 122.66 32.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 N-CA-C 110.152 -0.314 . . . . 0.0 110.152 179.483 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' LYS . . . . . 0.52 ' HG3' HG22 ' A' ' 67' ' ' ILE . 91.9 mttt 60.83 80.65 0.26 Allowed Pre-proline 0 C--O 1.234 0.267 0 O-C-N 123.734 0.646 . . . . 0.0 110.485 -177.413 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . 0.692 ' HB3' ' HB ' ' A' ' 74' ' ' ILE . 29.0 Cg_endo . . . . . 0 N--CA 1.464 -0.243 0 C-N-CA 122.799 2.333 . . . . 0.0 112.515 -178.636 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.692 ' HB ' ' HB3' ' A' ' 69' ' ' PRO . 71.2 mt . . . . . 0 N--CA 1.453 -0.301 0 N-CA-C 110.122 -0.325 . . . . 0.0 110.122 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.512 ' HB ' HG22 ' A' ' 65' ' ' THR . 61.2 t -71.28 119.18 17.16 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-O 121.199 0.523 . . . . 0.0 110.343 178.61 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' ARG . . . . . 0.41 ' H ' ' HG2' ' A' ' 76' ' ' ARG . 16.5 ptm180 -81.66 34.5 0.39 Allowed 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.379 -0.828 . . . . 0.0 111.96 -176.27 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 35.2 t70 -78.72 145.02 34.73 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 120.892 0.377 . . . . 0.0 110.392 -177.857 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' ASP . . . . . 0.51 ' HB3' HG22 ' A' ' 80' ' ' THR . 10.4 m-20 -81.15 110.86 17.05 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.696 -176.744 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' ILE . . . . . 0.546 HG22 HD11 ' A' ' 67' ' ' ILE . 10.6 tp -63.96 -19.9 25.51 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.519 0 CA-C-O 120.909 0.385 . . . . 0.0 111.022 179.75 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.51 HG22 ' HB3' ' A' ' 78' ' ' ASP . 7.0 t -68.52 -26.33 65.38 Favored 'General case' 0 CA--C 1.533 0.301 0 CA-C-O 121.13 0.49 . . . . 0.0 110.572 177.73 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 44.3 m -152.0 73.42 7.82 Favored Pre-proline 0 C--N 1.322 -0.607 0 N-CA-C 108.37 -0.974 . . . . 0.0 108.37 176.738 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' PRO . . . . . 0.469 ' HB2' ' HE2' ' A' ' 87' ' ' TYR . 75.8 Cg_endo -76.01 162.8 34.08 Favored 'Trans proline' 0 C--O 1.237 0.429 0 C-N-CA 122.817 2.344 . . . . 0.0 114.044 -166.121 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' ARG . . . . . 0.872 ' HG3' ' HG2' ' A' ' 85' ' ' GLU . 0.2 OUTLIER -81.72 99.99 9.24 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 114.855 -1.066 . . . . 0.0 109.201 174.929 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' MET . . . . . 0.401 ' O ' ' HG3' ' A' ' 88' ' ' ARG . 83.8 mmm -59.08 -31.16 68.64 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 116.596 -0.274 . . . . 0.0 111.186 -177.187 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.872 ' HG2' ' HG3' ' A' ' 83' ' ' ARG . 8.2 pt-20 -66.94 -24.72 66.1 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.495 -0.32 . . . . 0.0 111.397 -179.789 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 69.0 mt -73.62 -32.29 35.17 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 C-N-CA 120.515 -0.474 . . . . 0.0 110.429 177.282 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . 0.483 ' CB ' HG11 ' A' ' 113' ' ' VAL . 98.3 m-85 -85.91 -28.63 24.21 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.974 -0.557 . . . . 0.0 111.22 179.022 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . 0.401 ' HG3' ' O ' ' A' ' 84' ' ' MET . 69.6 mtp180 -61.72 117.95 6.49 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.33 0.586 . . . . 0.0 111.691 -177.639 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . 0.619 ' HA3' ' NH2' ' A' ' 38' ' ' ARG . . . 106.36 -5.19 38.13 Favored Glycine 0 N--CA 1.444 -0.779 0 CA-C-N 115.222 -0.899 . . . . 0.0 112.383 179.906 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -69.85 146.97 50.91 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.801 0.334 . . . . 0.0 110.495 177.733 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -91.5 -30.8 16.23 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.368 -179.766 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . 0.444 ' HG ' ' HB3' ' A' ' 116' ' ' ARG . 5.3 tt -153.25 144.19 22.88 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.182 -178.361 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.679 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 70.1 mt -133.07 129.04 57.04 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 177.31 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' TYR . . . . . 0.474 ' HE2' HD11 ' A' ' 96' ' ' ILE . 51.0 p90 -134.01 162.88 30.85 Favored 'General case' 0 C--N 1.32 -0.715 0 C-N-CA 120.053 -0.659 . . . . 0.0 111.274 179.604 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . 0.782 ' HB3' ' HG3' ' A' ' 98' ' ' PRO . 15.8 m -137.83 137.83 38.54 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.999 -175.682 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' ILE . . . . . 0.601 HG23 ' CH2' ' A' ' 22' ' ' TRP . 5.0 mp -106.74 93.87 2.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.349 177.866 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 54.1 ttp85 48.29 72.68 1.18 Allowed Pre-proline 0 CA--C 1.54 0.574 0 CA-C-N 115.527 -0.761 . . . . 0.0 112.472 177.242 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' PRO . . . . . 0.782 ' HG3' ' HB3' ' A' ' 95' ' ' SER . 14.8 Cg_endo -91.97 162.81 3.28 Favored 'Trans proline' 0 N--CA 1.454 -0.823 0 C-N-CA 123.228 2.619 . . . . 0.0 111.905 176.798 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . 0.461 ' HB2' ' HG2' ' A' ' 101' ' ' GLU . 2.4 Cg_endo -48.97 139.64 25.3 Favored 'Trans proline' 0 C--N 1.349 0.599 0 C-N-CA 123.181 2.587 . . . . 0.0 112.597 177.159 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . 0.746 ' HA ' ' CE1' ' A' ' 103' ' ' HIS . . . -79.28 19.36 0.59 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.188 -0.46 . . . . 0.0 112.098 -172.528 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 101' ' ' GLU . . . . . 0.461 ' HG2' ' HB2' ' A' ' 99' ' ' PRO . 9.3 pt-20 -115.82 -16.62 11.17 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 115.991 -0.549 . . . . 0.0 111.367 -177.572 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.634 HD11 ' HB2' ' A' ' 98' ' ' PRO . 2.5 pp -112.04 3.44 8.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 N-CA-C 112.258 0.466 . . . . 0.0 112.258 -175.546 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 103' ' ' HIS . . . . . 0.746 ' CE1' ' HA ' ' A' ' 100' ' ' ALA . 33.5 m170 -62.27 -40.79 97.4 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.181 -179.15 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 22.4 m -61.81 -31.46 71.69 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.987 0.422 . . . . 0.0 110.899 178.903 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.561 ' O ' HG23 ' A' ' 109' ' ' VAL . 14.5 m -72.84 -40.68 65.55 Favored 'General case' 0 N--CA 1.448 -0.538 0 CA-C-N 116.045 -0.525 . . . . 0.0 109.897 178.302 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 90.4 mt -61.38 -42.17 98.28 Favored 'General case' 0 C--O 1.233 0.224 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.944 178.289 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 107' ' ' MET . . . . . . . . . . . . . 91.3 mmm -55.37 -48.09 74.81 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.619 -0.719 . . . . 0.0 111.768 -179.598 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 4.1 ptp180 -74.01 -26.89 60.68 Favored 'General case' 0 C--N 1.329 -0.32 0 C-N-CA 120.875 -0.33 . . . . 0.0 111.512 -177.697 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.561 HG23 ' O ' ' A' ' 105' ' ' SER . 70.2 t -66.31 -46.87 85.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 N-CA-C 110.192 -0.299 . . . . 0.0 110.192 175.813 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -59.01 -45.57 90.36 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.292 178.527 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.504 ' HA ' ' HB1' ' A' ' 148' ' ' ALA . 24.4 t70 -64.9 -36.83 85.63 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.885 -0.598 . . . . 0.0 111.026 179.557 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -68.53 -35.56 77.64 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.717 -0.674 . . . . 0.0 112.17 -178.372 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.483 HG11 ' CB ' ' A' ' 87' ' ' TYR . 22.5 m -97.04 -23.77 4.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-O 120.745 0.307 . . . . 0.0 111.65 -177.787 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 89.43 36.4 7.5 Favored Glycine 0 N--CA 1.452 -0.235 0 C-N-CA 120.933 -0.651 . . . . 0.0 112.645 176.792 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -114.24 147.47 38.93 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 121.003 0.43 . . . . 0.0 111.416 -177.187 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 116' ' ' ARG . . . . . 0.444 ' HB3' ' HG ' ' A' ' 92' ' ' LEU . 27.8 ttt180 -70.96 120.06 15.98 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.687 -0.688 . . . . 0.0 109.836 178.876 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . 0.679 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 60.0 tp -94.72 126.83 40.28 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 -179.038 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 64.1 mt -129.02 122.79 57.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-O 120.827 0.346 . . . . 0.0 110.44 -179.223 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 119' ' ' ILE . . . . . 0.519 HG12 ' HB2' ' A' ' 95' ' ' SER . 66.7 mt -130.05 119.85 48.0 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-O 120.777 0.323 . . . . 0.0 110.755 -179.018 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 34.3 ttpt -116.27 98.38 51.31 Favored Pre-proline 0 C--N 1.326 -0.441 0 N-CA-C 109.622 -0.511 . . . . 0.0 109.622 173.085 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 89.6 Cg_endo -87.17 -156.08 0.06 OUTLIER 'Trans proline' 0 N--CA 1.457 -0.631 0 C-N-CA 122.862 2.375 . . . . 0.0 112.471 179.325 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 122' ' ' LEU . . . . . 0.441 HD12 ' HA ' ' A' ' 122' ' ' LEU . 9.3 tp -74.35 161.56 29.75 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.302 177.899 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 12.9 t -69.3 -24.65 63.97 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.064 0.459 . . . . 0.0 110.979 -177.927 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -114.32 27.14 9.17 Favored Glycine 0 N--CA 1.448 -0.519 0 C-N-CA 120.837 -0.696 . . . . 0.0 111.385 176.686 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . 0.404 ' CB ' ' HB3' ' A' ' 122' ' ' LEU . 35.6 tt0 -128.04 125.93 40.29 Favored 'General case' 0 C--N 1.319 -0.756 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 -177.167 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -108.22 166.86 10.43 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.001 -179.935 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 42.6 mt . . . . . 0 C--N 1.323 -0.551 0 CA-C-O 121.095 0.474 . . . . 0.0 110.207 -178.805 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 132' ' ' LYS . . . . . 0.406 ' HE3' ' CZ ' ' A' ' 146' ' ' TYR . 55.7 tttp . . . . . 0 CA--C 1.534 0.341 0 N-CA-C 112.836 0.68 . . . . 0.0 112.836 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 133' ' ' MET . . . . . . . . . . . . . 76.0 mtp -96.24 168.72 10.41 Favored 'General case' 0 C--N 1.328 -0.356 0 C-N-CA 120.69 -0.404 . . . . 0.0 111.098 -176.952 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . 0.461 ' HG3' ' HG2' ' A' ' 145' ' ' GLU . 15.8 ptmt -130.62 148.59 52.43 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.911 -178.088 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . 0.605 HD11 ' HD2' ' A' ' 142' ' ' TYR . 39.7 tp -94.62 126.21 39.77 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.395 -179.747 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -123.86 147.19 28.35 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.692 -179.577 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 9.8 m-80 -116.98 119.0 33.95 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.999 0.428 . . . . 0.0 110.299 177.344 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . 0.498 ' O ' HG22 ' A' ' 141' ' ' THR . 71.3 t80 -146.49 128.11 15.15 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.142 -0.481 . . . . 0.0 109.932 -177.038 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . 0.424 ' O ' ' HB2' ' A' ' 140' ' ' ARG . . . 66.37 38.9 94.0 Favored Glycine 0 N--CA 1.449 -0.469 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.238 177.904 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 140' ' ' ARG . . . . . 0.424 ' HB2' ' O ' ' A' ' 139' ' ' GLY . 13.0 mmt85 76.47 -12.54 1.02 Allowed 'General case' 0 N--CA 1.469 0.497 0 C-N-CA 123.438 0.695 . . . . 0.0 112.392 177.804 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 141' ' ' THR . . . . . 0.498 HG22 ' O ' ' A' ' 138' ' ' TYR . 4.6 t -105.21 166.1 10.64 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 120.851 0.358 . . . . 0.0 110.575 -178.972 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 142' ' ' TYR . . . . . 0.605 ' HD2' HD11 ' A' ' 135' ' ' LEU . 14.4 p90 -130.06 141.12 50.75 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.125 -0.488 . . . . 0.0 109.807 178.945 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -150.3 168.43 24.1 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.687 -177.58 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 85.8 m-85 -99.88 125.12 45.81 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 177.499 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 145' ' ' GLU . . . . . 0.461 ' HG2' ' HG3' ' A' ' 134' ' ' LYS . 7.5 pt-20 -116.26 162.84 16.88 Favored 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 109.558 -0.534 . . . . 0.0 109.558 175.596 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . 0.559 ' HB3' ' HB3' ' A' ' 117' ' ' LEU . 15.0 t80 -145.3 123.44 12.16 Favored 'General case' 0 C--N 1.314 -0.946 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.275 178.894 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 3.4 mp -91.92 100.27 10.98 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 177.545 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . 0.504 ' HB1' ' HA ' ' A' ' 111' ' ' ASP . . . -71.68 125.74 27.9 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.896 176.312 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 . . . . . 0 C--N 1.319 -0.751 0 CA-C-N 115.798 -0.637 . . . . 0.0 111.518 177.682 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 78.7 m95 . . . . . 0 CA--C 1.53 0.206 0 CA-C-O 120.854 0.359 . . . . 0.0 110.639 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 27.1 t-20 -56.35 -52.52 64.26 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.779 -0.646 . . . . 0.0 111.492 -177.514 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -63.81 -33.71 76.29 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.138 -178.901 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 56.7 tp -58.08 -49.52 76.64 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.084 175.725 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . 0.402 ' O ' HG13 ' A' ' 30' ' ' ILE . . . -58.57 -48.45 80.88 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.763 178.655 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.478 ' HA ' HD12 ' A' ' 30' ' ' ILE . 87.4 t -54.85 -44.48 72.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.177 178.553 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . 0.424 ' HB2' ' CD2' ' A' ' 138' ' ' TYR . 84.6 t80 -60.77 -46.83 88.97 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.715 179.041 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 83.1 mt -60.9 -42.83 94.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.51 178.332 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.548 HG12 HG23 ' A' ' 54' ' ' ILE . 87.7 mt -56.65 -45.32 82.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 115.704 -0.68 . . . . 0.0 111.066 177.418 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . 0.405 ' HG3' ' O ' ' A' ' 27' ' ' VAL . 81.0 mtp180 -69.33 -27.34 65.27 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 121.147 0.499 . . . . 0.0 110.899 -177.729 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 80.4 m -88.9 -2.88 58.81 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.925 -0.579 . . . . 0.0 111.639 -178.538 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 16.6 p -121.84 -76.76 0.58 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.505 0.193 . . . . 0.0 110.977 -179.387 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.512 ' O ' HG22 ' A' ' 37' ' ' THR . . . 101.03 161.82 27.58 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 121.087 -0.578 . . . . 0.0 112.409 179.597 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_exo -74.36 146.34 35.35 Favored 'Trans proline' 0 N--CA 1.462 -0.351 0 C-N-CA 122.84 2.36 . . . . 0.0 111.986 179.076 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 98.02 -15.82 61.04 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.868 -0.682 . . . . 0.0 113.046 177.357 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . 0.512 HG22 ' O ' ' A' ' 34' ' ' GLY . 13.6 t -102.42 -172.14 2.08 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 117.039 0.419 . . . . 0.0 110.544 -179.091 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' ARG . . . . . 0.53 ' HB2' ' HA ' ' A' ' 90' ' ' ALA . 68.7 mtp180 -115.42 135.8 53.74 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.565 -0.289 . . . . 0.0 110.976 -177.276 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.496 HG23 HG21 ' A' ' 60' ' ' VAL . 61.7 t -131.59 138.86 52.02 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 175.575 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.566 ' O ' ' HA ' ' A' ' 93' ' ' ILE . 23.4 t -126.92 139.13 52.76 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 178.259 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . 0.623 ' OE2' ' HA ' ' A' ' 64' ' ' LEU . 0.5 OUTLIER -116.12 156.25 26.76 Favored 'General case' 0 C--N 1.32 -0.678 0 C-N-CA 120.123 -0.631 . . . . 0.0 109.959 171.49 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.439 HG21 HD22 ' A' ' 106' ' ' LEU . 62.1 t -110.84 103.23 15.14 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.851 0 CA-C-N 115.755 -0.657 . . . . 0.0 109.79 176.385 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 115.28 56.04 0.36 Allowed Glycine 0 N--CA 1.448 -0.538 0 C-N-CA 120.309 -0.948 . . . . 0.0 112.7 178.707 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.434 ' HB2' ' OE2' ' A' ' 41' ' ' GLU . . . -80.73 77.04 7.61 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.254 0.549 . . . . 0.0 110.424 178.029 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -82.75 -154.89 16.59 Favored Glycine 0 N--CA 1.447 -0.625 0 CA-C-N 115.564 -0.744 . . . . 0.0 112.846 -179.55 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 49.9 ttt180 -70.37 -15.12 62.82 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 121.264 0.554 . . . . 0.0 110.555 -177.46 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 7.7 p90 -88.94 58.71 4.7 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.792 -0.64 . . . . 0.0 111.204 -178.707 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 95.0 mt -78.23 35.09 0.21 Allowed 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.008 -0.542 . . . . 0.0 112.15 -176.848 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 84.3 t80 -71.91 -53.83 11.92 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.602 0.239 . . . . 0.0 110.995 -179.45 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.431 ' O ' HG13 ' A' ' 54' ' ' ILE . 56.7 t -57.72 -50.8 76.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.024 -0.534 . . . . 0.0 111.134 -176.404 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 2.7 p -59.98 -42.33 93.93 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.627 -178.829 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.499 ' O ' ' HG2' ' A' ' 56' ' ' LYS . 27.5 t70 -67.73 -43.23 80.44 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.385 -0.371 . . . . 0.0 110.651 -179.647 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 61.9 t80 -63.01 -44.63 95.45 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.92 -178.405 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.548 HG23 HG12 ' A' ' 30' ' ' ILE . 84.3 mt -61.32 -46.05 97.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.864 179.508 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 2.5 ptm180 -72.92 -16.48 61.55 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.358 -176.992 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . 0.499 ' HG2' ' O ' ' A' ' 52' ' ' ASP . 36.0 mmtm -72.82 -34.82 67.1 Favored 'General case' 0 C--O 1.234 0.287 0 CA-C-O 120.848 0.356 . . . . 0.0 110.486 175.016 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 29.3 m-70 -93.55 -60.4 1.78 Allowed 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.379 -177.039 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 52.8 m -106.78 133.22 51.77 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 121.233 0.54 . . . . 0.0 111.717 -174.878 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 1.3 tmmm? -76.56 65.76 2.44 Favored 'General case' 0 N--CA 1.451 -0.38 0 CA-C-O 121.769 0.795 . . . . 0.0 108.909 174.318 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.496 HG21 HG23 ' A' ' 39' ' ' VAL . 14.9 p -97.06 147.83 6.03 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.983 0 CA-C-N 115.235 -0.893 . . . . 0.0 109.927 176.115 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 13.2 t70 -81.09 89.6 5.98 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 178.865 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 3.3 tm? -93.97 131.86 39.01 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.481 -0.781 . . . . 0.0 109.27 -178.096 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 42.4 t -115.36 117.92 57.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-O 120.457 0.17 . . . . 0.0 110.842 -177.604 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . 0.623 ' HA ' ' OE2' ' A' ' 41' ' ' GLU . 84.8 mt -86.89 128.07 35.05 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.913 -178.574 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 70.1 p -116.23 123.57 48.09 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.879 177.475 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . 0.689 ' HB3' HG21 ' A' ' 74' ' ' ILE . 17.9 t70 -149.03 136.12 19.95 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.126 -179.841 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.462 HG12 ' HB2' ' A' ' 78' ' ' ASP . 46.2 mt -69.12 110.61 2.63 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 178.189 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' LYS . . . . . 0.432 ' HG2' HG22 ' A' ' 67' ' ' ILE . 31.1 mmtp 63.25 85.37 0.17 Allowed Pre-proline 0 C--N 1.33 -0.269 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 -172.297 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . 0.655 ' HD3' ' HA ' ' A' ' 76' ' ' ARG . 4.2 Cg_endo . . . . . 0 C--N 1.351 0.698 0 C-N-CA 123.805 3.004 . . . . 0.0 112.52 -173.948 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.689 HG21 ' HB3' ' A' ' 66' ' ' ASP . 97.2 mt . . . . . 0 N--CA 1.45 -0.471 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 44.2 t -79.31 137.77 21.17 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 178.935 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' ARG . . . . . 0.655 ' HA ' ' HD3' ' A' ' 69' ' ' PRO . 0.0 OUTLIER -75.57 13.67 0.75 Allowed 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.046 -0.525 . . . . 0.0 111.75 -176.91 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . 0.473 ' OD1' ' HG2' ' A' ' 83' ' ' ARG . 12.7 t70 -70.08 121.89 18.34 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -175.893 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' ASP . . . . . 0.462 ' HB2' HG12 ' A' ' 67' ' ' ILE . 3.3 p30 -101.24 169.53 8.85 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 121.276 0.56 . . . . 0.0 111.526 -172.213 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 8.5 tt -77.46 -15.46 14.37 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 115.328 -0.851 . . . . 0.0 112.518 -171.276 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 7.8 p -93.41 -23.44 18.42 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 121.657 0.742 . . . . 0.0 109.69 -178.902 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . 0.465 ' N ' ' HD3' ' A' ' 82' ' ' PRO . 23.0 t -139.23 58.22 12.13 Favored Pre-proline 0 N--CA 1.441 -0.897 0 CA-C-N 114.677 -1.147 . . . . 0.0 110.574 -170.596 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' PRO . . . . . 0.465 ' HD3' ' N ' ' A' ' 81' ' ' SER . 5.1 Cg_exo -77.79 140.07 18.19 Favored 'Trans proline' 0 N--CA 1.458 -0.609 0 C-N-CA 122.656 2.237 . . . . 0.0 112.14 -174.736 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' ARG . . . . . 0.78 ' HB2' HD12 ' A' ' 86' ' ' ILE . 55.9 mmt-85 -80.35 113.52 18.59 Favored 'General case' 0 CA--C 1.507 -0.673 0 CA-C-O 121.14 0.495 . . . . 0.0 110.67 178.259 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' MET . . . . . 0.483 ' HA ' ' HD2' ' A' ' 87' ' ' TYR . 22.0 mtp -72.61 -13.12 61.3 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.09 178.553 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.684 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 11.3 pt-20 -70.16 -22.72 62.94 Favored 'General case' 0 C--O 1.232 0.133 0 CA-C-O 121.485 0.659 . . . . 0.0 109.579 175.259 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.78 HD12 ' HB2' ' A' ' 83' ' ' ARG . 96.3 mt -83.34 -33.94 10.47 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 115.251 -0.886 . . . . 0.0 110.172 178.859 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . 0.483 ' HD2' ' HA ' ' A' ' 84' ' ' MET . 95.3 m-85 -82.33 -37.87 25.1 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.572 -178.888 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 23.6 mtp180 -62.55 116.17 4.9 Favored 'General case' 0 CA--C 1.514 -0.44 0 CA-C-O 121.367 0.603 . . . . 0.0 111.401 -178.908 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 111.74 -10.33 27.78 Favored Glycine 0 N--CA 1.447 -0.619 0 CA-C-N 114.914 -1.039 . . . . 0.0 112.054 -178.249 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . 0.53 ' HA ' ' HB2' ' A' ' 38' ' ' ARG . . . -78.72 149.15 32.81 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.057 0.456 . . . . 0.0 110.613 179.649 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -94.38 -21.09 19.18 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.776 -179.245 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . 0.486 HD23 ' N ' ' A' ' 93' ' ' ILE . 4.7 tt -155.12 144.24 20.96 Favored 'General case' 0 N--CA 1.451 -0.376 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.719 -177.864 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.57 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 63.3 mt -130.86 127.18 61.15 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 177.203 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 94' ' ' TYR . . . . . 0.428 ' O ' ' HA ' ' A' ' 41' ' ' GLU . 32.3 p90 -129.24 161.96 28.98 Favored 'General case' 0 C--N 1.322 -0.6 0 C-N-CA 120.578 -0.449 . . . . 0.0 110.897 -179.503 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 14.2 m -144.94 145.72 31.67 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.918 0.39 . . . . 0.0 110.816 -179.333 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 72.6 mt -114.09 109.26 27.85 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.15 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 97' ' ' ARG . . . . . 0.441 HH11 ' HD2' ' A' ' 97' ' ' ARG . 42.0 ttm180 59.48 80.84 0.26 Allowed Pre-proline 0 CA--C 1.534 0.358 0 O-C-N 123.849 0.718 . . . . 0.0 111.35 -178.331 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 98' ' ' PRO . . . . . 0.421 ' HA ' ' HD3' ' A' ' 99' ' ' PRO . 96.0 Cg_endo -88.52 133.38 2.68 Favored 'Trans proline' 0 N--CA 1.456 -0.724 0 C-N-CA 122.677 2.251 . . . . 0.0 112.642 179.078 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . 0.639 ' HD2' HD11 ' A' ' 102' ' ' ILE . 32.8 Cg_exo -58.98 141.23 98.1 Favored 'Trans proline' 0 N--CA 1.464 -0.238 0 C-N-CA 122.678 2.252 . . . . 0.0 111.465 175.048 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . 0.721 ' HA ' ' NE2' ' A' ' 103' ' ' HIS . . . -72.07 4.45 3.5 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 112.154 0.428 . . . . 0.0 112.154 -173.737 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 101' ' ' GLU . . . . . 0.602 ' HG3' HG23 ' A' ' 102' ' ' ILE . 9.2 pt-20 -96.33 -21.09 18.02 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.643 -0.253 . . . . 0.0 111.64 -179.928 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.639 HD11 ' HD2' ' A' ' 99' ' ' PRO . 2.5 pp -115.68 10.49 7.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 N-CA-C 113.108 0.781 . . . . 0.0 113.108 -170.331 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 103' ' ' HIS . . . . . 0.721 ' NE2' ' HA ' ' A' ' 100' ' ' ALA . 22.1 m-70 -54.71 -50.22 68.84 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 121.042 0.449 . . . . 0.0 111.13 -179.959 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 5.1 m -64.62 -26.27 68.32 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.96 -177.296 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.526 ' O ' HG23 ' A' ' 109' ' ' VAL . 19.4 m -72.06 -38.98 69.34 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.079 -178.797 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.439 HD22 HG21 ' A' ' 42' ' ' VAL . 77.5 mt -73.42 -41.85 62.78 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.854 179.651 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 107' ' ' MET . . . . . 0.562 ' HG2' ' O ' ' A' ' 103' ' ' HIS . 90.5 mmm -56.44 -41.28 76.19 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.753 -0.658 . . . . 0.0 111.881 -177.981 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 108' ' ' ARG . . . . . 0.403 HH11 ' HD3' ' A' ' 108' ' ' ARG . 11.2 ptp180 -73.42 -29.42 62.57 Favored 'General case' 0 C--N 1.328 -0.347 0 C-N-CA 120.79 -0.364 . . . . 0.0 111.277 -178.382 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.526 HG23 ' O ' ' A' ' 105' ' ' SER . 81.0 t -68.72 -45.75 80.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 C-N-CA 121.083 -0.247 . . . . 0.0 110.515 -179.777 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -61.77 -44.5 96.76 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.274 178.717 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.708 ' HA ' ' HB1' ' A' ' 148' ' ' ALA . 17.3 t70 -63.85 -34.44 77.94 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.66 -0.7 . . . . 0.0 110.984 179.82 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -70.85 -43.36 68.64 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.825 -0.625 . . . . 0.0 111.955 -178.675 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 21.6 m -89.02 -24.05 6.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 N-CA-C 111.848 0.314 . . . . 0.0 111.848 -175.093 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 84.71 53.68 3.14 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.309 178.691 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -129.83 160.41 33.57 Favored 'General case' 0 C--N 1.323 -0.566 0 O-C-N 122.842 -0.21 . . . . 0.0 110.695 -179.227 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 116' ' ' ARG . . . . . 0.431 ' HD3' ' OE1' ' A' ' 145' ' ' GLU . 10.1 ttm180 -79.53 123.53 27.66 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 109.278 -0.638 . . . . 0.0 109.278 176.013 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . 0.57 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 58.5 tp -95.04 118.01 31.14 Favored 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 109.585 -0.524 . . . . 0.0 109.585 178.812 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 60.2 mt -115.49 114.79 47.37 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.654 0 CA-C-O 121.278 0.561 . . . . 0.0 110.696 -179.773 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 63.1 mt -115.34 123.96 71.41 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.907 0 CA-C-N 116.151 -0.477 . . . . 0.0 109.972 178.908 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 120' ' ' LYS . . . . . 0.543 ' HG2' ' HB3' ' A' ' 143' ' ' PHE . 9.5 tmtm? -110.22 97.92 32.97 Favored Pre-proline 0 C--N 1.321 -0.647 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 176.728 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 80.1 Cg_endo -87.93 -178.18 2.14 Favored 'Trans proline' 0 N--CA 1.453 -0.873 0 C-N-CA 122.794 2.329 . . . . 0.0 111.866 176.433 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 122' ' ' LEU . . . . . 0.75 ' HB2' ' HB3' ' A' ' 125' ' ' GLU . 8.1 mp -108.29 166.93 10.39 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.243 -178.85 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 24.8 m -64.19 111.97 2.82 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 120.942 0.401 . . . . 0.0 110.726 179.147 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 91.66 -32.75 5.14 Favored Glycine 0 N--CA 1.45 -0.379 0 N-CA-C 111.314 -0.714 . . . . 0.0 111.314 -176.8 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . 0.75 ' HB3' ' HB2' ' A' ' 122' ' ' LEU . 20.9 tt0 -92.09 74.68 5.49 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 176.22 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 23.6 t70 -113.62 -178.53 3.4 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 114.788 -1.096 . . . . 0.0 110.948 -166.626 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 4.7 mt . . . . . 0 C--O 1.234 0.268 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 176.201 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 30.9 mmtt . . . . . 0 CA--C 1.524 -0.051 0 N-CA-C 112.152 0.427 . . . . 0.0 112.152 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 133' ' ' MET . . . . . 0.51 ' HG2' ' HB2' ' A' ' 146' ' ' TYR . 77.2 mtp -87.89 154.03 20.85 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.15 0.5 . . . . 0.0 111.616 -173.371 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 14.8 ptmt -112.72 142.66 45.08 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 115.197 -0.91 . . . . 0.0 110.376 -177.305 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . 0.554 HD11 ' HD2' ' A' ' 142' ' ' TYR . 47.2 tp -84.33 123.05 29.76 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.428 -179.957 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -121.68 144.6 30.32 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.935 -179.516 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -111.2 130.53 55.61 Favored 'General case' 0 C--N 1.325 -0.482 0 N-CA-C 109.526 -0.546 . . . . 0.0 109.526 175.002 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . 0.424 ' CD2' ' HB2' ' A' ' 28' ' ' TYR . 57.5 t80 -148.52 111.55 4.87 Favored 'General case' 0 C--N 1.322 -0.629 0 N-CA-C 110.018 -0.364 . . . . 0.0 110.018 176.139 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 69.49 49.2 39.4 Favored Glycine 0 N--CA 1.446 -0.683 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.02 179.826 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 20.9 mmm-85 76.48 -40.66 0.39 Allowed 'General case' 0 N--CA 1.467 0.397 0 C-N-CA 123.729 0.812 . . . . 0.0 112.057 177.446 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 13.8 t -76.73 146.94 37.66 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.192 0.52 . . . . 0.0 110.64 -177.941 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 142' ' ' TYR . . . . . 0.554 ' HD2' HD11 ' A' ' 135' ' ' LEU . 47.4 p90 -117.28 142.94 46.45 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.776 179.194 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 143' ' ' PHE . . . . . 0.543 ' HB3' ' HG2' ' A' ' 120' ' ' LYS . 11.4 p90 -152.48 179.79 8.26 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.58 -0.736 . . . . 0.0 109.748 -178.476 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 89.3 m-85 -115.33 138.07 51.36 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 120.669 0.271 . . . . 0.0 110.595 -179.858 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 145' ' ' GLU . . . . . 0.431 ' OE1' ' HD3' ' A' ' 116' ' ' ARG . 17.9 pt-20 -123.81 160.05 28.22 Favored 'General case' 0 C--N 1.319 -0.737 0 N-CA-C 109.161 -0.681 . . . . 0.0 109.161 173.878 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . 0.51 ' HB2' ' HG2' ' A' ' 133' ' ' MET . 45.7 t80 -142.26 126.36 17.39 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-O 121.07 0.462 . . . . 0.0 110.374 176.78 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 2.1 mp -92.82 108.11 19.91 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.762 0 CA-C-N 115.696 -0.684 . . . . 0.0 109.389 176.683 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . 0.708 ' HB1' ' HA ' ' A' ' 111' ' ' ASP . . . -70.93 129.12 38.22 Favored 'General case' 0 N--CA 1.444 -0.774 0 CA-C-N 115.693 -0.685 . . . . 0.0 110.151 176.353 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 22.4 mm-40 . . . . . 0 C--N 1.321 -0.642 0 CA-C-O 121.768 0.794 . . . . 0.0 111.395 177.779 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 81.7 m95 . . . . . 0 C--O 1.232 0.148 0 CA-C-O 120.792 0.329 . . . . 0.0 111.145 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.504 ' O ' HG23 ' A' ' 27' ' ' VAL . 6.7 m-20 -65.5 -29.85 70.55 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.006 -179.547 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -75.04 -34.07 61.81 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 179.696 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 45.1 tp -60.31 -43.13 96.62 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 115.914 -0.585 . . . . 0.0 109.651 172.846 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -59.05 -47.33 85.62 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.458 -0.792 . . . . 0.0 110.655 176.661 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.504 HG23 ' O ' ' A' ' 23' ' ' ASN . 99.2 t -56.21 -43.25 75.86 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.188 0 CA-C-N 116.361 -0.381 . . . . 0.0 111.111 177.987 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 88.0 t80 -59.44 -48.71 80.59 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.819 0.342 . . . . 0.0 110.461 178.401 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 71.6 mt -58.48 -41.83 82.77 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.251 178.553 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.608 HG12 HG23 ' A' ' 54' ' ' ILE . 83.2 mt -60.32 -38.44 77.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 115.473 -0.785 . . . . 0.0 111.061 177.639 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 22.1 mtp180 -70.78 -30.13 66.52 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.154 -179.22 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 75.6 m -87.03 -8.91 56.67 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.576 -178.501 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 26.0 p -122.84 -80.83 0.63 Allowed 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 120.747 0.308 . . . . 0.0 111.08 179.01 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.455 ' O ' HG22 ' A' ' 37' ' ' THR . . . 88.21 168.51 44.33 Favored Glycine 0 N--CA 1.447 -0.633 0 C-N-CA 121.141 -0.552 . . . . 0.0 112.446 -179.901 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_exo -65.67 140.33 61.69 Favored 'Trans proline' 0 C--O 1.232 0.204 0 C-N-CA 122.644 2.229 . . . . 0.0 111.759 178.225 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 109.98 -8.21 31.41 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.364 -0.922 . . . . 0.0 112.507 178.978 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . 0.455 HG22 ' O ' ' A' ' 34' ' ' GLY . 11.5 t -125.04 -171.31 2.33 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.306 -0.627 . . . . 0.0 109.306 178.299 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' ARG . . . . . 0.841 ' HG3' ' HA ' ' A' ' 90' ' ' ALA . 1.7 ptm180 -132.48 136.94 47.02 Favored 'General case' 0 N--CA 1.447 -0.604 0 CA-C-O 121.075 0.464 . . . . 0.0 111.418 -179.619 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.488 ' O ' ' HA ' ' A' ' 62' ' ' LEU . 58.2 t -125.91 139.43 51.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 115.611 -0.722 . . . . 0.0 109.747 -178.223 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.475 ' HB ' HG12 ' A' ' 93' ' ' ILE . 39.6 t -116.34 134.47 59.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-O 120.854 0.359 . . . . 0.0 111.164 -178.026 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 44.1 tt0 -108.23 120.56 42.72 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.143 177.02 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.626 ' HB ' ' HB3' ' A' ' 95' ' ' SER . 85.7 t -95.91 123.49 48.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.387 -179.603 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 98.19 25.16 10.53 Favored Glycine 0 N--CA 1.447 -0.567 0 C-N-CA 120.686 -0.769 . . . . 0.0 111.789 -179.366 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -79.32 54.13 1.63 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 121.321 0.582 . . . . 0.0 111.128 -178.281 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -94.25 -64.82 1.02 Allowed Glycine 0 N--CA 1.444 -0.789 0 C-N-CA 120.854 -0.689 . . . . 0.0 111.823 178.674 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -105.07 -8.22 18.63 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.059 0.457 . . . . 0.0 110.306 175.373 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.487 ' HD1' ' HE1' ' A' ' 49' ' ' TYR . 87.4 m-85 -106.76 102.54 11.91 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.909 -0.587 . . . . 0.0 109.981 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.533 HD22 HD13 ' A' ' 64' ' ' LEU . 84.5 mt -129.7 -10.81 4.45 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.448 -0.342 . . . . 0.0 111.002 179.997 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . 0.487 ' HE1' ' HD1' ' A' ' 47' ' ' PHE . 30.6 p90 -59.06 -30.97 68.45 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 112.59 0.589 . . . . 0.0 112.59 -173.917 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 80.5 t -75.81 -58.01 5.26 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-O 120.795 0.331 . . . . 0.0 110.744 178.831 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . 0.428 ' CB ' HD21 ' A' ' 64' ' ' LEU . 15.5 p -60.32 -39.18 86.12 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.939 -177.983 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.499 ' O ' ' HG3' ' A' ' 56' ' ' LYS . 29.7 t70 -65.11 -33.65 76.53 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.64 -178.38 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 71.0 t80 -71.25 -44.71 64.77 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.545 177.499 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.608 HG23 HG12 ' A' ' 30' ' ' ILE . 79.2 mt -57.48 -46.42 85.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.868 -176.602 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' ARG . . . . . 0.512 HH12 HD11 ' A' ' 64' ' ' LEU . 9.0 ptp85 -69.03 -16.12 63.63 Favored 'General case' 0 N--CA 1.467 0.383 0 N-CA-C 112.164 0.431 . . . . 0.0 112.164 -176.889 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . 0.499 ' HG3' ' O ' ' A' ' 52' ' ' ASP . 67.9 mttm -82.54 -33.08 28.31 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 120.807 0.337 . . . . 0.0 111.392 -179.753 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 13.9 t60 -95.11 -39.65 10.02 Favored 'General case' 0 N--CA 1.448 -0.529 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.357 -177.699 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 8.1 p -118.51 132.07 56.23 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.449 -0.341 . . . . 0.0 111.13 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . 0.463 ' HD2' ' HA ' ' A' ' 59' ' ' LYS . 26.9 mmmt -80.97 61.2 4.47 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.696 0.76 . . . . 0.0 110.603 176.062 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 7.7 p -98.07 144.65 10.92 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.725 0 CA-C-N 114.901 -1.045 . . . . 0.0 109.509 175.508 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -73.12 89.61 1.5 Allowed 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 177.561 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . 0.488 ' HA ' ' O ' ' A' ' 39' ' ' VAL . 3.5 tt -96.39 118.4 32.84 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.014 0.435 . . . . 0.0 110.363 -176.611 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 58.1 t -102.19 128.98 54.31 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.463 0 CA-C-N 115.588 -0.733 . . . . 0.0 110.72 -176.141 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . 0.533 HD13 HD22 ' A' ' 48' ' ' LEU . 66.1 mt -108.66 133.26 52.99 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.936 -0.574 . . . . 0.0 109.999 176.404 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 12.5 p -119.12 132.03 55.96 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.724 0.297 . . . . 0.0 110.71 176.194 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . 0.448 ' HB3' HG21 ' A' ' 74' ' ' ILE . 24.5 t70 -156.96 146.85 20.81 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.426 -177.843 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.614 HG12 ' HB2' ' A' ' 78' ' ' ASP . 34.5 mt -73.9 103.91 2.44 Favored 'Isoleucine or valine' 0 C--O 1.238 0.491 0 N-CA-C 110.114 -0.328 . . . . 0.0 110.114 179.419 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' LYS . . . . . 0.401 ' HE2' ' HB3' ' A' ' 68' ' ' LYS . 30.7 mtpt 56.92 80.08 0.3 Allowed Pre-proline 0 C--N 1.33 -0.276 0 CA-C-N 115.191 -0.913 . . . . 0.0 109.798 -177.091 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . 0.877 ' HB3' ' HB ' ' A' ' 74' ' ' ILE . 9.1 Cg_endo . . . . . 0 C--O 1.234 0.275 0 C-N-CA 123.895 3.064 . . . . 0.0 113.7 -173.077 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.877 ' HB ' ' HB3' ' A' ' 69' ' ' PRO . 43.4 mt . . . . . 0 N--CA 1.453 -0.318 0 N-CA-C 110.164 -0.31 . . . . 0.0 110.164 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.525 HG12 ' H ' ' A' ' 77' ' ' ASP . 63.3 t -79.41 141.94 14.66 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.093 178.764 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' ARG . . . . . 0.566 ' HG2' ' HD2' ' A' ' 69' ' ' PRO . 89.1 mtm180 -82.87 16.41 2.28 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.913 -176.148 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . 0.525 ' H ' HG12 ' A' ' 75' ' ' VAL . 35.9 t70 -87.03 138.01 31.86 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 179.001 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' ASP . . . . . 0.614 ' HB2' HG12 ' A' ' 67' ' ' ILE . 0.7 OUTLIER -103.32 177.92 4.7 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.73 0.3 . . . . 0.0 111.257 -173.362 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 9.3 tp -94.03 -24.66 4.95 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.444 0 N-CA-C 112.601 0.593 . . . . 0.0 112.601 -170.401 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.51 HG22 ' OD1' ' A' ' 78' ' ' ASP . 6.3 t -91.1 -20.5 21.96 Favored 'General case' 0 C--N 1.325 -0.47 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 -178.319 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . 0.495 ' HB2' ' OD2' ' A' ' 78' ' ' ASP . 34.0 m -129.42 62.85 65.23 Favored Pre-proline 0 CA--C 1.535 0.391 0 CA-C-N 115.48 -0.782 . . . . 0.0 110.081 172.822 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 87.9 Cg_endo -85.7 150.28 9.98 Favored 'Trans proline' 0 N--CA 1.459 -0.515 0 C-N-CA 122.375 2.05 . . . . 0.0 113.525 -171.847 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 77.8 mtt-85 -88.95 112.51 23.41 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.416 -0.811 . . . . 0.0 110.413 175.147 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' MET . . . . . . . . . . . . . 93.6 mmm -66.05 -23.38 66.53 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.449 -0.341 . . . . 0.0 111.057 -179.264 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 6.7 pm0 -67.62 -19.32 65.21 Favored 'General case' 0 N--CA 1.464 0.246 0 CA-C-O 120.889 0.376 . . . . 0.0 111.01 179.61 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.404 HD13 HG11 ' A' ' 75' ' ' VAL . 62.1 mt -83.81 -39.34 14.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.345 179.017 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . 0.417 ' CB ' HG11 ' A' ' 113' ' ' VAL . 93.3 m-85 -80.65 -34.07 35.17 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.209 -178.557 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . 0.525 ' HA ' ' HB ' ' A' ' 113' ' ' VAL . 62.2 mtp85 -65.15 132.93 50.42 Favored 'General case' 0 CA--C 1.515 -0.384 0 CA-C-O 121.329 0.585 . . . . 0.0 110.856 -178.509 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 102.4 -19.41 48.33 Favored Glycine 0 N--CA 1.446 -0.683 0 CA-C-N 115.053 -0.976 . . . . 0.0 111.641 -176.803 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . 0.841 ' HA ' ' HG3' ' A' ' 38' ' ' ARG . . . -71.46 145.3 49.32 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.837 0.351 . . . . 0.0 110.705 -179.772 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -92.52 -21.98 19.81 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.041 -179.188 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . 0.525 ' HG ' ' HB3' ' A' ' 116' ' ' ARG . 3.5 tt -150.81 138.4 19.68 Favored 'General case' 0 N--CA 1.449 -0.497 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.912 -176.28 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.643 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 85.5 mt -133.03 124.05 49.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 115.719 -0.673 . . . . 0.0 109.326 176.955 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 94' ' ' TYR . . . . . 0.437 ' HB3' ' HB ' ' A' ' 118' ' ' ILE . 10.2 p90 -130.01 158.84 38.49 Favored 'General case' 0 C--N 1.32 -0.696 0 C-N-CA 120.808 -0.357 . . . . 0.0 110.802 -179.524 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . 0.626 ' HB3' ' HB ' ' A' ' 42' ' ' VAL . 11.5 p -145.07 137.71 26.18 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.594 -177.749 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 63.7 mt -104.7 111.51 34.55 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.293 -179.212 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 6.1 tpm_? 61.32 75.67 0.44 Allowed Pre-proline 0 CA--C 1.534 0.355 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.188 -179.763 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 98' ' ' PRO . . . . . 0.42 ' HA ' ' HD3' ' A' ' 99' ' ' PRO . 0.9 OUTLIER -84.32 150.86 12.01 Favored 'Trans proline' 0 N--CA 1.457 -0.629 0 C-N-CA 122.788 2.325 . . . . 0.0 111.589 176.449 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . 0.42 ' HD3' ' HA ' ' A' ' 98' ' ' PRO . 31.2 Cg_exo -59.39 155.16 42.64 Favored 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.703 2.269 . . . . 0.0 111.619 175.727 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . 0.651 ' HA ' ' CE1' ' A' ' 103' ' ' HIS . . . -79.26 7.19 8.17 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 112.144 0.424 . . . . 0.0 112.144 -174.118 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 101' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -111.75 -14.03 13.64 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 111.804 0.298 . . . . 0.0 111.804 179.597 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.42 ' O ' HG13 ' A' ' 102' ' ' ILE . 32.2 pt -123.51 77.46 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 121.821 0.82 . . . . 0.0 111.661 -179.281 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 103' ' ' HIS . . . . . 0.651 ' CE1' ' HA ' ' A' ' 100' ' ' ALA . 44.9 m80 -112.99 -50.25 2.89 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.418 -0.81 . . . . 0.0 109.331 174.983 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 18.9 t -74.9 -23.76 58.42 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 176.353 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.546 ' O ' ' HG2' ' A' ' 108' ' ' ARG . 3.3 m -67.87 -38.96 83.76 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.459 -0.791 . . . . 0.0 109.754 177.272 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 69.2 mt -73.2 -38.76 65.99 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.129 175.701 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 107' ' ' MET . . . . . . . . . . . . . 47.9 ttm -62.1 -39.82 93.75 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.685 -0.689 . . . . 0.0 111.129 -179.819 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 108' ' ' ARG . . . . . 0.546 ' HG2' ' O ' ' A' ' 105' ' ' SER . 7.9 ptp180 -68.56 -25.35 64.86 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.629 0.252 . . . . 0.0 110.795 -179.816 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.489 HG23 ' O ' ' A' ' 105' ' ' SER . 94.2 t -72.32 -48.18 49.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 175.697 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -59.63 -41.59 90.8 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.167 176.164 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 18.0 t70 -61.95 -38.28 87.89 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.412 -0.813 . . . . 0.0 111.164 178.232 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -72.74 -40.37 66.11 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.612 -0.722 . . . . 0.0 111.957 -178.377 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.525 ' HB ' ' HA ' ' A' ' 88' ' ' ARG . 13.7 m -91.01 -24.57 5.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-O 120.895 0.378 . . . . 0.0 111.741 -174.339 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 88.69 42.13 5.83 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 121.009 -0.615 . . . . 0.0 112.421 178.916 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -119.41 156.5 30.03 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 121.101 0.477 . . . . 0.0 111.407 -177.177 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 116' ' ' ARG . . . . . 0.525 ' HB3' ' HG ' ' A' ' 92' ' ' LEU . 21.5 ttm180 -79.59 121.37 25.18 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.793 -0.639 . . . . 0.0 109.654 176.793 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . 0.643 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 53.3 tp -92.71 118.83 31.47 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.383 -178.579 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . 0.437 ' HB ' ' HB3' ' A' ' 94' ' ' TYR . 64.1 mt -113.38 121.72 66.12 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.61 0 CA-C-O 121.024 0.44 . . . . 0.0 110.425 178.101 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 56.4 mt -120.46 134.31 64.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.375 -179.809 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 45.2 tptt -110.14 98.2 33.94 Favored Pre-proline 0 C--N 1.323 -0.549 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.524 175.43 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 82.0 Cg_endo -91.47 174.62 2.42 Favored 'Trans proline' 0 N--CA 1.456 -0.721 0 C-N-CA 123.068 2.512 . . . . 0.0 112.005 173.961 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -99.01 163.79 12.44 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.467 178.984 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 14.5 t -65.06 -21.78 66.88 Favored 'General case' 0 CA--C 1.534 0.363 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.429 -179.162 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -104.13 18.04 46.74 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.308 179.871 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 22.7 mm-40 -119.6 -173.84 2.62 Favored 'General case' 0 N--CA 1.449 -0.487 0 CA-C-O 121.209 0.528 . . . . 0.0 110.334 -178.489 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -148.87 170.01 19.25 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 115.381 -0.827 . . . . 0.0 108.791 176.548 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 7.5 mt . . . . . 0 C--N 1.322 -0.591 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 179.484 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 29.5 mmmt . . . . . 0 N--CA 1.456 -0.125 0 CA-C-O 120.845 0.355 . . . . 0.0 111.447 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 133' ' ' MET . . . . . 0.737 ' HG2' ' HB2' ' A' ' 146' ' ' TYR . 82.5 mtp -92.38 164.94 13.31 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.929 -174.431 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 13.2 ptmm? -127.08 140.47 52.26 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.971 -177.503 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . 0.512 HD11 ' HD2' ' A' ' 142' ' ' TYR . 51.6 tp -80.7 129.19 34.38 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.338 -179.091 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -123.3 139.04 51.18 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.68 178.751 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 16.8 m120 -114.83 108.25 16.5 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 115.801 -0.636 . . . . 0.0 109.868 179.557 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . 0.4 ' O ' HG22 ' A' ' 141' ' ' THR . 54.1 t80 -131.65 106.01 7.89 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-O 120.929 0.395 . . . . 0.0 110.323 -178.275 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . 0.468 ' O ' ' HB2' ' A' ' 140' ' ' ARG . . . 80.0 34.16 31.07 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.094 178.922 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 140' ' ' ARG . . . . . 0.468 ' HB2' ' O ' ' A' ' 139' ' ' GLY . 0.0 OUTLIER 75.32 -14.57 0.75 Allowed 'General case' 0 N--CA 1.468 0.471 0 C-N-CA 123.279 0.632 . . . . 0.0 111.921 178.097 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 141' ' ' THR . . . . . 0.4 HG22 ' O ' ' A' ' 138' ' ' TYR . 8.3 t -93.9 141.62 28.31 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 175.562 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 142' ' ' TYR . . . . . 0.512 ' HD2' HD11 ' A' ' 135' ' ' LEU . 43.0 p90 -119.07 143.54 47.07 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 121.364 0.602 . . . . 0.0 110.825 -176.052 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 15.0 p90 -152.01 173.88 14.34 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 115.119 -0.946 . . . . 0.0 109.413 -178.512 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 76.8 m-85 -112.94 129.47 56.46 Favored 'General case' 0 C--N 1.322 -0.611 0 C-N-CA 121.058 -0.257 . . . . 0.0 110.691 -179.624 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 145' ' ' GLU . . . . . 0.495 ' OE1' ' HD3' ' A' ' 116' ' ' ARG . 19.2 pt-20 -115.33 157.19 24.18 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 174.667 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . 0.737 ' HB2' ' HG2' ' A' ' 133' ' ' MET . 32.9 t80 -139.24 124.19 18.77 Favored 'General case' 0 C--N 1.315 -0.913 0 CA-C-N 115.752 -0.658 . . . . 0.0 109.904 176.656 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 3.1 mp -93.54 105.93 17.41 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.859 0 N-CA-C 109.726 -0.472 . . . . 0.0 109.726 -179.168 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -62.3 114.94 3.76 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-O 121.139 0.495 . . . . 0.0 110.756 178.054 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 8.1 mm-40 . . . . . 0 C--N 1.32 -0.683 0 CA-C-N 115.346 -0.843 . . . . 0.0 111.194 179.22 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 51.4 m95 . . . . . 0 C--O 1.232 0.167 0 CA-C-O 120.677 0.275 . . . . 0.0 111.22 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.43 ' O ' HG23 ' A' ' 27' ' ' VAL . 25.1 t-20 -66.19 -58.96 4.26 Favored 'General case' 0 N--CA 1.463 0.198 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.674 -172.285 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.462 ' CB ' ' HA3' ' A' ' 139' ' ' GLY . 4.5 m-20 -58.12 -32.68 68.36 Favored 'General case' 0 N--CA 1.464 0.27 0 CA-C-O 120.631 0.253 . . . . 0.0 111.333 -178.892 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 45.7 tp -57.16 -51.22 70.2 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-O 120.932 0.396 . . . . 0.0 110.262 175.291 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . 0.426 ' HB2' HG13 ' A' ' 50' ' ' VAL . . . -63.48 -43.56 96.94 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.601 179.887 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.43 HG23 ' O ' ' A' ' 23' ' ' ASN . 95.5 t -52.13 -47.85 43.09 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.153 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.076 177.454 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 56.4 t80 -57.81 -43.31 85.62 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.539 179.88 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.414 HG23 HD13 ' A' ' 92' ' ' LEU . 70.8 mt -67.91 -43.97 85.51 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.791 179.247 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.486 HG12 HG23 ' A' ' 54' ' ' ILE . 92.1 mt -58.27 -45.54 89.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 115.61 -0.723 . . . . 0.0 111.0 178.303 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 84.0 mtt-85 -65.56 -27.72 68.63 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.666 -0.697 . . . . 0.0 111.761 -177.848 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 53.5 t -84.79 -27.35 26.9 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.596 -0.275 . . . . 0.0 111.186 -179.011 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 12.4 p -94.21 -76.96 0.47 Allowed 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 120.797 0.332 . . . . 0.0 111.202 -177.041 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.402 ' HA2' ' HD3' ' A' ' 35' ' ' PRO . . . 95.75 142.81 13.42 Favored Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 120.85 -0.69 . . . . 0.0 112.162 -178.843 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . 0.526 ' HG3' ' HA ' ' A' ' 58' ' ' SER . 58.1 Cg_exo -51.68 126.4 19.6 Favored 'Trans proline' 0 C--N 1.343 0.284 0 C-N-CA 123.283 2.655 . . . . 0.0 113.001 -176.795 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 104.32 53.93 0.81 Allowed Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.514 179.517 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 15.1 t -166.74 -175.84 3.27 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 179.624 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 63.1 mtt85 -122.11 132.51 54.51 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 121.08 0.467 . . . . 0.0 110.775 -179.911 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.928 ' HB ' HD22 ' A' ' 62' ' ' LEU . 60.6 t -123.85 131.76 72.45 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 N-CA-C 108.763 -0.828 . . . . 0.0 108.763 176.76 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.446 HG11 ' CE1' ' A' ' 87' ' ' TYR . 35.6 t -106.7 126.56 62.57 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-O 120.817 0.342 . . . . 0.0 110.887 -177.679 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 46.4 tt0 -108.22 124.12 49.81 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.144 178.368 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.911 ' HB ' ' HB3' ' A' ' 95' ' ' SER . 95.1 t -97.37 121.72 48.17 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.593 -179.876 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 89.68 34.13 8.67 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.855 -0.688 . . . . 0.0 111.519 -179.64 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -81.09 14.15 2.44 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 112.432 0.53 . . . . 0.0 112.432 -173.185 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -54.41 -38.04 61.59 Favored Glycine 0 CA--C 1.519 0.32 0 C-N-CA 121.201 -0.524 . . . . 0.0 113.807 -176.887 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . 0.416 HH11 ' HD2' ' A' ' 46' ' ' ARG . 19.4 mtp180 -139.2 13.28 2.61 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 117.129 0.465 . . . . 0.0 111.997 -177.144 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 73.4 m-85 -112.15 29.03 8.24 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 121.254 0.55 . . . . 0.0 110.619 -177.519 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.588 HD21 HD11 ' A' ' 74' ' ' ILE . 87.0 mt -59.26 -15.66 16.89 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 114.868 -1.06 . . . . 0.0 113.074 -175.342 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 81.5 t80 -59.13 -45.26 91.39 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.583 0.23 . . . . 0.0 111.313 -179.249 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.426 HG13 ' HB2' ' A' ' 26' ' ' ALA . 42.8 t -65.41 -54.64 26.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.672 -175.224 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . 0.442 ' CB ' HD21 ' A' ' 64' ' ' LEU . 0.2 OUTLIER -59.52 -41.96 91.17 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.701 -179.796 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.608 ' HA ' ' HG2' ' A' ' 55' ' ' ARG . 38.7 t70 -69.08 -37.92 78.72 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 120.857 -0.337 . . . . 0.0 110.865 -179.224 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 89.4 t80 -60.26 -37.06 79.26 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.875 0.369 . . . . 0.0 110.034 177.925 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.486 HG23 HG12 ' A' ' 30' ' ' ILE . 76.0 mt -63.29 -54.78 28.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.949 -0.568 . . . . 0.0 110.673 176.044 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' ARG . . . . . 0.608 ' HG2' ' HA ' ' A' ' 52' ' ' ASP . 3.7 ptp180 -69.77 -16.44 63.3 Favored 'General case' 0 N--CA 1.465 0.318 0 N-CA-C 112.072 0.397 . . . . 0.0 112.072 -177.083 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . 0.7 ' HA ' ' HE3' ' A' ' 56' ' ' LYS . 0.0 OUTLIER -64.04 -39.24 93.66 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.693 0.282 . . . . 0.0 110.843 176.378 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 29.9 m-70 -107.27 -50.51 3.07 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.746 -178.61 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . 0.526 ' HA ' ' HG3' ' A' ' 35' ' ' PRO . 57.6 m -88.38 132.99 34.22 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.851 -178.289 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . 0.562 ' HD2' ' N ' ' A' ' 59' ' ' LYS . 3.3 mptp? -80.19 57.06 2.61 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.684 0.754 . . . . 0.0 109.825 178.661 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.488 HG11 HG23 ' A' ' 39' ' ' VAL . 54.0 t -101.22 139.32 22.76 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-N 114.998 -1.001 . . . . 0.0 111.043 -178.11 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -80.02 98.61 7.28 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.866 -0.606 . . . . 0.0 109.524 174.819 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . 0.928 HD22 ' HB ' ' A' ' 39' ' ' VAL . 0.2 OUTLIER -87.54 121.02 29.43 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 115.934 -0.575 . . . . 0.0 109.593 -178.827 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 40.9 t -100.49 113.77 37.26 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.661 0 CA-C-N 115.738 -0.665 . . . . 0.0 109.786 -179.757 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . 0.75 ' HB2' ' HA ' ' A' ' 74' ' ' ILE . 54.5 mt -97.37 139.8 32.78 Favored 'General case' 0 C--N 1.312 -1.04 0 CA-C-N 115.628 -0.714 . . . . 0.0 110.338 -177.507 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.417 ' OG1' ' HA ' ' A' ' 42' ' ' VAL . 38.0 p -131.23 137.92 49.12 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.301 0.096 . . . . 0.0 110.91 178.547 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 4.7 t70 -171.19 170.81 5.93 Favored 'General case' 0 N--CA 1.466 0.33 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 175.759 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 49.5 mm -85.96 104.74 13.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 120.813 0.34 . . . . 0.0 110.865 -175.898 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 35.4 mtmt 56.21 77.52 0.42 Allowed Pre-proline 0 C--N 1.33 -0.278 0 CA-C-N 115.324 -0.853 . . . . 0.0 111.894 -179.575 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . 0.795 ' HD2' ' HG2' ' A' ' 76' ' ' ARG . 70.1 Cg_endo . . . . . 0 N--CA 1.459 -0.505 0 C-N-CA 122.334 2.023 . . . . 0.0 112.139 175.613 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.75 ' HA ' ' HB2' ' A' ' 64' ' ' LEU . 44.6 mt . . . . . 0 N--CA 1.451 -0.415 0 CA-C-O 120.94 0.4 . . . . 0.0 110.531 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 97.8 t -77.53 139.04 19.3 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 CA-C-N 116.065 -0.516 . . . . 0.0 109.807 176.43 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' ARG . . . . . 0.795 ' HG2' ' HD2' ' A' ' 69' ' ' PRO . 65.7 mtm180 -84.62 38.77 0.71 Allowed 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 120.762 0.315 . . . . 0.0 110.807 -177.73 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 28.1 t70 -76.68 126.73 31.49 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 121.024 0.44 . . . . 0.0 110.447 -178.649 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' ASP . . . . . 0.508 ' HB3' HG22 ' A' ' 80' ' ' THR . 3.3 m-20 -71.13 97.28 1.47 Allowed 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.891 -0.595 . . . . 0.0 109.971 175.808 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 9.7 tp -58.56 -17.31 9.92 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.388 0 CA-C-O 121.273 0.559 . . . . 0.0 111.663 -178.255 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.508 HG22 ' HB3' ' A' ' 78' ' ' ASP . 8.8 t -66.39 -24.08 66.42 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.027 0.442 . . . . 0.0 110.442 176.246 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 36.6 m -154.42 70.18 6.08 Favored Pre-proline 0 C--N 1.329 -0.32 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 177.514 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' PRO . . . . . 0.556 ' HB2' ' HE2' ' A' ' 87' ' ' TYR . 74.0 Cg_endo -73.27 159.28 47.37 Favored 'Trans proline' 0 C--O 1.236 0.387 0 C-N-CA 123.011 2.474 . . . . 0.0 113.516 -169.691 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' ARG . . . . . 0.704 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 1.9 mtm180 -93.99 126.39 39.18 Favored 'General case' 0 C--N 1.323 -0.543 0 CA-C-N 115.793 -0.639 . . . . 0.0 110.921 177.958 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' MET . . . . . . . . . . . . . 89.3 mmm -64.56 -23.93 67.43 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.252 -178.066 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.704 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 12.0 pt-20 -62.52 -20.53 64.72 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.607 -179.112 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 63.8 mt -86.2 -29.47 6.08 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-O 121.167 0.508 . . . . 0.0 110.541 -178.802 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . 0.556 ' HE2' ' HB2' ' A' ' 82' ' ' PRO . 84.6 m-85 -93.34 -30.62 15.03 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.734 -176.259 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 81.8 mtp180 -66.75 114.14 5.4 Favored 'General case' 0 CA--C 1.514 -0.416 0 CA-C-O 121.485 0.659 . . . . 0.0 111.484 -176.889 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 116.09 -17.51 14.84 Favored Glycine 0 N--CA 1.446 -0.684 0 CA-C-N 114.902 -1.044 . . . . 0.0 111.982 -177.593 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -71.86 147.71 46.87 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.769 0.318 . . . . 0.0 110.665 178.835 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -91.34 -26.37 18.96 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-O 121.035 0.445 . . . . 0.0 110.856 -179.665 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . 0.496 ' HG ' ' HB3' ' A' ' 116' ' ' ARG . 5.0 tt -149.55 142.71 25.03 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.653 -177.715 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.604 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 63.2 mt -131.45 123.09 51.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 N-CA-C 109.117 -0.697 . . . . 0.0 109.117 178.269 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 10.7 p90 -136.24 161.3 36.14 Favored 'General case' 0 C--N 1.321 -0.659 0 C-N-CA 120.403 -0.519 . . . . 0.0 111.375 -178.119 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . 0.911 ' HB3' ' HB ' ' A' ' 42' ' ' VAL . 5.4 p -147.87 147.58 29.92 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.824 -0.626 . . . . 0.0 110.447 -178.268 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 96' ' ' ILE . . . . . 0.401 HD12 ' N ' ' A' ' 96' ' ' ILE . 4.3 mp -114.45 121.89 67.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-N 116.668 -0.242 . . . . 0.0 110.567 -179.184 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 50.85 67.28 4.46 Favored Pre-proline 0 N--CA 1.467 0.4 0 O-C-N 123.815 0.697 . . . . 0.0 111.201 179.328 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 98' ' ' PRO . . . . . 0.478 ' HA ' ' HD3' ' A' ' 99' ' ' PRO . 85.5 Cg_endo -87.18 143.84 6.81 Favored 'Trans proline' 0 N--CA 1.456 -0.706 0 C-N-CA 122.861 2.374 . . . . 0.0 113.19 -174.772 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . 0.555 ' HD2' HD11 ' A' ' 102' ' ' ILE . 24.3 Cg_exo -63.7 144.51 89.47 Favored 'Trans proline' 0 C--O 1.234 0.317 0 C-N-CA 122.737 2.291 . . . . 0.0 111.573 175.611 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -78.22 44.17 0.48 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.177 0.513 . . . . 0.0 111.289 -177.708 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 101' ' ' GLU . . . . . 0.611 ' HG3' HG23 ' A' ' 102' ' ' ILE . 11.2 pt-20 -132.49 -11.4 3.15 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.439 175.795 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.611 HG23 ' HG3' ' A' ' 101' ' ' GLU . 35.1 pt -122.85 -6.86 8.25 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.449 -0.341 . . . . 0.0 111.636 -177.542 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 103' ' ' HIS . . . . . . . . . . . . . 16.1 p-80 -62.97 -39.31 94.29 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.083 -176.256 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 32.2 t -71.78 -32.93 68.17 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 121.309 0.576 . . . . 0.0 110.086 178.487 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.602 ' O ' ' HG3' ' A' ' 108' ' ' ARG . 31.0 m -70.68 -33.28 70.75 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.314 179.898 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.512 ' HG ' ' O ' ' A' ' 102' ' ' ILE . 85.2 mt -61.34 -40.27 93.66 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.831 177.606 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 107' ' ' MET . . . . . . . . . . . . . 39.7 tpp -56.67 -54.4 46.54 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.344 178.036 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 108' ' ' ARG . . . . . 0.602 ' HG3' ' O ' ' A' ' 105' ' ' SER . 1.6 ptm180 -65.09 -30.94 71.93 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.492 -0.322 . . . . 0.0 111.624 -177.28 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.485 HG23 ' O ' ' A' ' 105' ' ' SER . 83.4 t -73.27 -45.86 51.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 C-N-CA 120.972 -0.291 . . . . 0.0 110.917 179.194 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -59.31 -47.74 84.26 Favored 'General case' 0 CA--C 1.516 -0.355 0 CA-C-O 120.759 0.314 . . . . 0.0 110.163 178.8 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.706 ' HA ' ' HB1' ' A' ' 148' ' ' ALA . 17.3 t70 -66.73 -29.17 69.08 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.984 -176.679 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -71.54 -43.57 66.18 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.547 178.727 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 16.2 m -88.08 -27.01 5.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.456 -0.338 . . . . 0.0 111.758 -175.7 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 89.31 46.27 4.44 Favored Glycine 0 N--CA 1.449 -0.452 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.42 179.016 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -122.5 160.92 24.6 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 121.096 0.474 . . . . 0.0 111.201 -178.233 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 116' ' ' ARG . . . . . 0.496 ' HB3' ' HG ' ' A' ' 92' ' ' LEU . 29.5 ttt180 -81.92 116.42 21.55 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.859 -0.61 . . . . 0.0 109.604 178.542 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . 0.604 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 56.0 tp -90.9 118.5 30.35 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.09 -179.401 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 66.3 mt -119.5 126.04 74.96 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-O 121.121 0.486 . . . . 0.0 110.362 179.07 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 119' ' ' ILE . . . . . 0.51 ' O ' ' HD3' ' A' ' 121' ' ' PRO . 63.8 mt -112.93 127.49 70.14 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.055 178.167 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 48.3 tptt -105.65 91.8 5.42 Favored Pre-proline 0 C--N 1.325 -0.463 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.067 178.507 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 121' ' ' PRO . . . . . 0.536 ' HB2' ' CG ' ' A' ' 125' ' ' GLU . 75.9 Cg_endo -92.68 -177.86 0.82 Allowed 'Trans proline' 0 N--CA 1.455 -0.751 0 C-N-CA 122.622 2.215 . . . . 0.0 111.951 175.049 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -72.81 146.02 46.59 Favored 'General case' 0 C--N 1.327 -0.37 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 173.26 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . 0.437 ' O ' HG23 ' A' ' 123' ' ' THR . 6.2 t -68.61 96.09 0.69 Allowed 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 121.668 0.747 . . . . 0.0 109.475 175.83 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 138.13 -17.58 3.37 Favored Glycine 0 N--CA 1.449 -0.485 0 CA-C-N 115.458 -0.792 . . . . 0.0 112.482 -178.117 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . 0.536 ' CG ' ' HB2' ' A' ' 121' ' ' PRO . 7.5 pt-20 -97.64 164.75 12.28 Favored 'General case' 0 N--CA 1.445 -0.7 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 178.402 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -128.66 162.17 27.96 Favored 'General case' 0 C--N 1.312 -1.044 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.426 -178.71 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . 0.456 HD13 HD12 ' A' ' 119' ' ' ILE . 19.8 mt . . . . . 0 C--N 1.321 -0.674 0 N-CA-C 108.546 -0.909 . . . . 0.0 108.546 174.464 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.457 -0.125 0 CA-C-O 121.816 0.817 . . . . 0.0 112.777 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 133' ' ' MET . . . . . . . . . . . . . 85.7 mtp -139.55 170.7 15.43 Favored 'General case' 0 C--N 1.313 -1.005 0 CA-C-N 114.929 -1.032 . . . . 0.0 109.266 176.919 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . 0.456 ' HB2' ' NZ ' ' A' ' 134' ' ' LYS . 0.0 OUTLIER -128.29 146.01 50.88 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-O 120.988 0.423 . . . . 0.0 111.396 -178.367 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . 0.493 HD11 ' CD1' ' A' ' 142' ' ' TYR . 53.0 tp -80.88 139.26 36.02 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.718 -0.673 . . . . 0.0 109.554 177.165 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 136' ' ' VAL . . . . . 0.414 HG23 ' CD1' ' A' ' 143' ' ' PHE . 0.0 OUTLIER -134.66 134.46 54.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-O 120.971 0.415 . . . . 0.0 110.765 177.267 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 137' ' ' ASN . . . . . 0.44 ' ND2' ' HB3' ' A' ' 142' ' ' TYR . 16.0 m120 -107.41 114.59 28.7 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.35 178.915 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 53.2 t80 -148.75 122.28 9.14 Favored 'General case' 0 C--N 1.326 -0.445 0 C-N-CA 120.959 -0.297 . . . . 0.0 110.91 -178.766 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . 0.462 ' HA3' ' CB ' ' A' ' 24' ' ' ASP . . . 64.44 62.68 4.89 Favored Glycine 0 N--CA 1.452 -0.273 0 CA-C-N 115.797 -0.638 . . . . 0.0 113.231 174.867 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 35.3 mmt180 71.41 -38.28 0.42 Allowed 'General case' 0 N--CA 1.47 0.544 0 C-N-CA 123.647 0.779 . . . . 0.0 112.168 175.731 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 141' ' ' THR . . . . . 0.407 ' H ' ' C ' ' A' ' 139' ' ' GLY . 9.9 t -96.34 156.82 16.18 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 121.133 0.492 . . . . 0.0 110.831 -178.025 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 142' ' ' TYR . . . . . 0.493 ' CD1' HD11 ' A' ' 135' ' ' LEU . 44.0 p90 -121.58 154.19 37.05 Favored 'General case' 0 C--N 1.32 -0.699 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 169.415 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 143' ' ' PHE . . . . . 0.42 ' O ' HD12 ' A' ' 135' ' ' LEU . 8.9 p90 -153.37 -177.64 6.47 Favored 'General case' 0 C--N 1.316 -0.858 0 CA-C-N 116.129 -0.487 . . . . 0.0 109.777 -177.536 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 86.9 m-85 -116.41 131.97 56.8 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 116.724 -0.216 . . . . 0.0 110.699 -178.083 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 145' ' ' GLU . . . . . 0.451 ' CD ' HH21 ' A' ' 116' ' ' ARG . 17.1 pt-20 -128.91 162.3 27.86 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.044 0.45 . . . . 0.0 110.626 178.832 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 38.9 t80 -142.56 127.01 17.78 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 115.604 -0.725 . . . . 0.0 109.665 173.561 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 147' ' ' ILE . . . . . 0.427 ' N ' HD12 ' A' ' 147' ' ' ILE . 3.8 mp -95.07 100.27 10.77 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.842 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 178.854 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . 0.706 ' HB1' ' HA ' ' A' ' 111' ' ' ASP . . . -76.39 96.29 3.99 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.953 -0.567 . . . . 0.0 109.659 176.569 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 . . . . . 0 C--N 1.314 -0.966 0 CA-C-N 115.662 -0.699 . . . . 0.0 111.165 -174.929 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' TRP . . . . . 0.642 ' HB3' HG22 ' A' ' 50' ' ' VAL . 77.0 m95 . . . . . 0 N--CA 1.452 -0.335 0 CA-C-O 120.57 0.224 . . . . 0.0 110.824 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 6.4 m120 -56.33 -52.09 65.84 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.098 177.36 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.43 ' OD2' ' HA3' ' A' ' 139' ' ' GLY . 1.3 t70 -76.77 -28.98 55.89 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.423 -177.152 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 58.5 tp -59.29 -45.98 89.79 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-O 121.049 0.452 . . . . 0.0 109.907 174.516 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . 0.44 ' O ' HG13 ' A' ' 30' ' ' ILE . . . -56.18 -44.46 79.38 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.46 -0.791 . . . . 0.0 110.667 178.629 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 88.5 t -54.4 -46.85 70.34 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.244 0 O-C-N 123.264 0.352 . . . . 0.0 110.857 177.38 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . 0.546 ' HB2' ' CD2' ' A' ' 138' ' ' TYR . 87.2 t80 -58.48 -45.73 88.07 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.332 177.877 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.419 HG12 HD12 ' A' ' 118' ' ' ILE . 74.5 mt -63.09 -46.12 96.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.719 178.988 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.783 HG12 HG23 ' A' ' 54' ' ' ILE . 83.0 mt -57.48 -44.07 84.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 115.692 -0.685 . . . . 0.0 110.919 178.211 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 75.1 mtt180 -72.8 -21.26 61.01 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.263 -176.28 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 73.3 m -88.54 -14.01 38.75 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.345 -0.389 . . . . 0.0 111.339 177.753 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 22.0 p -126.53 -86.11 0.61 Allowed 'General case' 0 CA--C 1.534 0.328 0 CA-C-O 120.678 0.275 . . . . 0.0 111.358 179.315 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 99.77 -176.25 28.36 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 121.167 -0.539 . . . . 0.0 112.595 178.459 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -71.93 155.37 57.71 Favored 'Trans proline' 0 C--O 1.233 0.26 0 C-N-CA 122.534 2.156 . . . . 0.0 112.247 -179.35 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 98.02 -11.76 64.01 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.681 -0.771 . . . . 0.0 113.081 176.345 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 14.0 t -121.7 -166.61 1.4 Allowed 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.382 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' ARG . . . . . 0.675 ' HG2' ' HB2' ' A' ' 61' ' ' ASP . 84.3 mtt180 -128.03 136.36 51.13 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.891 0.377 . . . . 0.0 110.877 -179.218 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.868 ' HB ' HD22 ' A' ' 62' ' ' LEU . 20.9 t -125.47 140.63 47.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 177.182 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 40.4 t -112.41 128.93 68.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-O 120.941 0.401 . . . . 0.0 111.282 -177.469 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . 0.415 ' OE1' HD22 ' A' ' 64' ' ' LEU . 42.5 tt0 -105.06 110.2 22.5 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.659 -0.7 . . . . 0.0 109.549 176.887 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.438 ' HB ' ' HB3' ' A' ' 95' ' ' SER . 58.5 t -94.11 113.76 29.39 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.399 -179.462 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 103.8 42.87 1.89 Allowed Glycine 0 N--CA 1.446 -0.657 0 C-N-CA 120.524 -0.846 . . . . 0.0 111.612 -178.679 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -85.99 -127.01 0.04 OUTLIER 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 110.37 -0.233 . . . . 0.0 110.37 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 67.77 -90.23 0.2 Allowed Glycine 0 C--N 1.33 0.203 0 C-N-CA 121.281 -0.485 . . . . 0.0 112.589 177.873 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -71.9 -23.47 61.49 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 109.705 -0.479 . . . . 0.0 109.705 176.67 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 50.2 m-85 -110.18 109.59 20.14 Favored 'General case' 0 C--O 1.224 -0.277 0 CA-C-N 115.971 -0.558 . . . . 0.0 110.048 178.236 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 96.9 mt -131.35 0.81 4.11 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.706 0.289 . . . . 0.0 111.084 179.722 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 9.2 p90 -69.08 -26.97 65.21 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 112.211 0.449 . . . . 0.0 112.211 -174.936 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.642 HG22 ' HB3' ' A' ' 22' ' ' TRP . 40.9 t -76.02 -58.69 4.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-O 120.93 0.395 . . . . 0.0 110.763 179.734 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 3.3 p -60.77 -42.59 97.78 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.748 -0.66 . . . . 0.0 112.484 -176.703 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.517 ' O ' ' HG2' ' A' ' 56' ' ' LYS . 30.3 t70 -66.53 -27.54 67.84 Favored 'General case' 0 C--N 1.33 -0.256 0 C-N-CA 120.917 -0.313 . . . . 0.0 110.885 -179.359 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 88.1 t80 -70.44 -42.49 71.48 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 120.974 0.416 . . . . 0.0 110.34 175.819 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.783 HG23 HG12 ' A' ' 30' ' ' ILE . 77.3 mt -61.9 -43.58 97.66 Favored 'Isoleucine or valine' 0 C--O 1.236 0.353 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.119 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' ARG . . . . . 0.499 ' HG2' ' HA ' ' A' ' 52' ' ' ASP . 4.1 ptm180 -68.76 -16.09 63.7 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.952 -0.567 . . . . 0.0 111.794 -176.534 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . 0.517 ' HG2' ' O ' ' A' ' 52' ' ' ASP . 69.5 mmtt -65.34 -42.05 93.28 Favored 'General case' 0 C--O 1.233 0.192 0 CA-C-O 121.058 0.456 . . . . 0.0 110.349 177.401 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 33.2 m170 -94.17 -57.5 2.5 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.762 -0.654 . . . . 0.0 111.483 -174.519 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 69.0 m -102.72 130.65 49.73 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.11 0.481 . . . . 0.0 111.618 -175.589 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . 0.526 ' C ' ' HE3' ' A' ' 59' ' ' LYS . 0.1 OUTLIER -80.42 65.52 5.59 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 121.99 0.9 . . . . 0.0 109.224 173.676 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.574 HG21 HG23 ' A' ' 39' ' ' VAL . 7.3 p -97.16 143.5 12.37 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.025 0 CA-C-N 114.606 -1.179 . . . . 0.0 109.003 174.3 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . 0.675 ' HB2' ' HG2' ' A' ' 38' ' ' ARG . 19.7 m-20 -76.32 96.11 3.91 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-O 121.243 0.544 . . . . 0.0 109.68 178.081 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . 0.868 HD22 ' HB ' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -86.88 118.1 26.05 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 115.476 -0.784 . . . . 0.0 109.506 -178.936 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.498 HG13 HG21 ' A' ' 75' ' ' VAL . 61.9 t -97.94 114.76 36.19 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.849 0 CA-C-N 115.683 -0.689 . . . . 0.0 110.127 -179.996 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . 0.496 HD12 HG12 ' A' ' 74' ' ' ILE . 31.8 mt -96.77 124.0 40.63 Favored 'General case' 0 C--N 1.315 -0.93 0 CA-C-N 115.616 -0.72 . . . . 0.0 109.646 -179.915 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 33.1 p -108.34 124.96 51.16 Favored 'General case' 0 C--N 1.315 -0.924 0 CA-C-O 120.933 0.397 . . . . 0.0 110.278 177.276 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 25.6 t70 -156.17 144.58 19.98 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.202 -176.676 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.43 HG22 ' HG3' ' A' ' 68' ' ' LYS . 53.7 mt -73.42 113.71 11.78 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 116.343 -0.389 . . . . 0.0 110.208 178.676 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' LYS . . . . . 0.43 ' HG3' HG22 ' A' ' 67' ' ' ILE . 5.8 mtpm? 59.76 82.01 0.24 Allowed Pre-proline 0 C--O 1.233 0.212 0 CA-C-N 115.54 -0.754 . . . . 0.0 110.568 179.483 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo . . . . . 0 C--O 1.232 0.198 0 C-N-CA 122.742 2.295 . . . . 0.0 113.008 -175.535 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.496 HG12 HD12 ' A' ' 64' ' ' LEU . 56.8 mt . . . . . 0 N--CA 1.45 -0.445 0 N-CA-C 108.673 -0.862 . . . . 0.0 108.673 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.513 HG11 HD13 ' A' ' 86' ' ' ILE . 63.5 t -86.47 130.21 37.05 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.711 0 CA-C-O 120.942 0.401 . . . . 0.0 110.611 -176.539 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' ARG . . . . . 0.422 ' HG2' ' H ' ' A' ' 76' ' ' ARG . 15.3 ptm180 -75.15 49.19 0.44 Allowed 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.502 -0.772 . . . . 0.0 111.54 179.809 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 22.6 t70 -108.14 117.96 35.51 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 116.083 -0.508 . . . . 0.0 109.779 179.411 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' ASP . . . . . 0.446 ' OD2' HG23 ' A' ' 80' ' ' THR . 5.5 p-10 -92.18 132.15 36.86 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.361 -0.382 . . . . 0.0 110.548 -179.423 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 10.7 tp -62.95 -18.05 20.55 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.476 0 CA-C-N 116.155 -0.475 . . . . 0.0 112.185 -173.62 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.446 HG23 ' OD2' ' A' ' 78' ' ' ASP . 0.7 OUTLIER -77.75 -27.71 50.47 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.877 0.37 . . . . 0.0 110.66 177.483 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 22.2 t -140.81 66.42 26.65 Favored Pre-proline 0 C--N 1.326 -0.416 0 N-CA-C 109.636 -0.505 . . . . 0.0 109.636 177.996 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 76.0 Cg_endo -89.93 151.75 4.91 Favored 'Trans proline' 0 N--CA 1.456 -0.732 0 C-N-CA 122.62 2.213 . . . . 0.0 113.436 -171.817 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' ARG . . . . . 0.717 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 53.0 mtt-85 -93.19 115.26 27.89 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.481 174.589 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' MET . . . . . . . . . . . . . 93.4 mmm -62.05 -22.48 65.78 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.926 -0.579 . . . . 0.0 111.055 -178.981 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.717 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 12.9 pt-20 -62.27 -21.68 65.4 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-O 120.913 0.387 . . . . 0.0 111.137 178.692 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.513 HD13 HG11 ' A' ' 75' ' ' VAL . 82.2 mt -83.76 -43.21 17.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.621 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 70.7 m-85 -76.27 -31.5 58.3 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.841 -178.004 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . 0.732 ' HG3' HG12 ' A' ' 113' ' ' VAL . 31.9 mtp85 -66.91 119.86 12.62 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.615 177.737 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 115.11 -8.74 20.96 Favored Glycine 0 N--CA 1.449 -0.499 0 CA-C-N 115.737 -0.665 . . . . 0.0 111.538 -175.748 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -89.35 140.87 29.07 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 120.884 0.374 . . . . 0.0 110.633 179.227 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -88.09 -22.24 24.26 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.968 -178.927 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . 0.472 HD23 ' N ' ' A' ' 93' ' ' ILE . 3.3 tt -151.62 141.97 22.45 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.272 -176.733 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.549 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 65.4 mt -132.43 123.35 49.72 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-N 115.986 -0.552 . . . . 0.0 109.701 179.149 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 23.3 p90 -125.03 150.95 46.22 Favored 'General case' 0 C--N 1.322 -0.612 0 C-N-CA 120.709 -0.396 . . . . 0.0 110.402 177.906 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . 0.438 ' HB3' ' HB ' ' A' ' 42' ' ' VAL . 11.7 p -131.52 140.58 49.54 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.692 -178.089 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 96' ' ' ILE . . . . . 0.473 HG23 ' CH2' ' A' ' 22' ' ' TRP . 81.1 mt -98.45 90.2 2.07 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-O 121.425 0.631 . . . . 0.0 110.775 -177.467 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 50.8 ttt-85 56.4 95.81 0.04 OUTLIER Pre-proline 0 N--CA 1.469 0.498 0 CA-C-N 114.304 -1.316 . . . . 0.0 111.99 -177.999 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 98' ' ' PRO . . . . . 0.408 ' HA ' ' HD3' ' A' ' 99' ' ' PRO . 96.8 Cg_endo -88.97 137.14 3.14 Favored 'Trans proline' 0 N--CA 1.455 -0.739 0 C-N-CA 122.647 2.232 . . . . 0.0 112.612 177.722 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . 0.662 ' HD2' HD11 ' A' ' 102' ' ' ILE . 50.5 Cg_exo -53.95 156.63 12.16 Favored 'Trans proline' 0 C--O 1.236 0.393 0 C-N-CA 122.797 2.331 . . . . 0.0 112.079 175.534 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . 0.68 ' HA ' ' CE1' ' A' ' 103' ' ' HIS . . . -75.49 29.51 0.1 Allowed 'General case' 0 C--N 1.328 -0.351 0 N-CA-C 112.57 0.582 . . . . 0.0 112.57 -172.67 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 101' ' ' GLU . . . . . 0.587 ' HG3' HG23 ' A' ' 102' ' ' ILE . 12.5 pt-20 -129.89 -23.71 2.76 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 111.937 0.347 . . . . 0.0 111.937 -178.386 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.662 HD11 ' HD2' ' A' ' 99' ' ' PRO . 41.2 pt -106.78 14.4 7.85 Favored 'Isoleucine or valine' 0 C--O 1.234 0.258 0 N-CA-C 112.45 0.537 . . . . 0.0 112.45 -172.949 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 103' ' ' HIS . . . . . 0.68 ' CE1' ' HA ' ' A' ' 100' ' ' ALA . 28.9 m170 -53.78 -54.06 43.51 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.245 0.545 . . . . 0.0 110.334 177.79 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . 0.512 ' O ' ' HG2' ' A' ' 108' ' ' ARG . 8.8 m -59.89 -34.59 73.37 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.294 -0.866 . . . . 0.0 110.871 -177.722 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.58 ' O ' HG23 ' A' ' 109' ' ' VAL . 16.7 m -63.52 -56.07 18.97 Favored 'General case' 0 N--CA 1.452 -0.329 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.198 -177.556 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 72.2 mt -56.56 -41.16 76.42 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.657 -0.701 . . . . 0.0 111.08 -178.839 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 107' ' ' MET . . . . . . . . . . . . . 96.5 mmm -62.0 -46.89 87.22 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.889 -0.596 . . . . 0.0 111.138 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 108' ' ' ARG . . . . . 0.512 ' HG2' ' O ' ' A' ' 104' ' ' SER . 3.1 ptp180 -77.08 -22.23 53.14 Favored 'General case' 0 C--N 1.331 -0.238 0 C-N-CA 120.679 -0.409 . . . . 0.0 111.847 -178.4 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.58 HG23 ' O ' ' A' ' 105' ' ' SER . 76.2 t -68.31 -48.75 71.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 173.866 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -61.34 -37.2 82.45 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.043 177.944 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 11.2 t70 -66.01 -40.73 91.33 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.144 -0.934 . . . . 0.0 110.904 177.911 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -69.54 -43.14 73.59 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.837 -0.619 . . . . 0.0 111.987 -176.961 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.732 HG12 ' HG3' ' A' ' 88' ' ' ARG . 20.0 m -87.21 -25.16 6.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-O 120.722 0.296 . . . . 0.0 111.585 -175.561 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 82.29 59.82 2.22 Favored Glycine 0 N--CA 1.447 -0.621 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.21 179.944 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -135.43 173.96 11.14 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-O 120.854 0.359 . . . . 0.0 110.441 -179.922 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 116' ' ' ARG . . . . . 0.449 ' HD3' ' OE1' ' A' ' 145' ' ' GLU . 13.8 ttm180 -92.7 124.29 36.6 Favored 'General case' 0 C--N 1.323 -0.576 0 N-CA-C 109.66 -0.496 . . . . 0.0 109.66 175.616 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . 0.549 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 61.6 tp -92.66 132.75 36.63 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 116.175 -0.466 . . . . 0.0 109.803 178.945 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . 0.419 HD12 HG12 ' A' ' 29' ' ' ILE . 64.6 mt -126.18 122.65 62.02 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-O 121.078 0.466 . . . . 0.0 110.645 177.698 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 66.8 mt -121.43 122.9 68.43 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.016 177.599 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 23.3 ttmm -114.76 104.24 54.36 Favored Pre-proline 0 C--N 1.321 -0.645 0 CA-C-O 120.829 0.347 . . . . 0.0 110.881 176.296 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -80.63 170.78 15.34 Favored 'Trans proline' 0 N--CA 1.455 -0.78 0 C-N-CA 122.211 1.941 . . . . 0.0 110.912 169.737 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 122' ' ' LEU . . . . . 0.73 ' HB2' ' HG3' ' A' ' 125' ' ' GLU . 41.0 mt -70.17 155.29 40.83 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 116.494 -0.321 . . . . 0.0 110.378 179.473 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . 0.698 ' HA ' ' HE1' ' A' ' 142' ' ' TYR . 46.1 m -64.8 109.9 2.22 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 109.992 -0.373 . . . . 0.0 109.992 175.629 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 107.36 -1.31 34.84 Favored Glycine 0 N--CA 1.446 -0.663 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.141 -178.536 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . 0.73 ' HG3' ' HB2' ' A' ' 122' ' ' LEU . 5.1 mt-10 -96.27 -169.21 1.87 Allowed 'General case' 0 N--CA 1.449 -0.501 0 CA-C-O 121.261 0.553 . . . . 0.0 110.8 177.538 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 5.8 t70 -149.35 165.43 32.03 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-N 115.193 -0.912 . . . . 0.0 109.116 -178.345 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 32.6 mt . . . . . 0 C--N 1.325 -0.475 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 176.328 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 90.1 mttt . . . . . 0 N--CA 1.454 -0.236 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 133' ' ' MET . . . . . . . . . . . . . 71.0 mtp 68.95 -178.93 0.22 Allowed 'General case' 0 N--CA 1.467 0.383 0 O-C-N 123.791 0.682 . . . . 0.0 110.668 -179.333 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 17.5 ptmt -136.85 144.07 43.41 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.95 179.9 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . 0.559 HD11 ' HD2' ' A' ' 142' ' ' TYR . 53.6 tp -87.63 127.77 35.28 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.655 -179.405 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 136' ' ' VAL . . . . . 0.461 ' C ' HD22 ' A' ' 137' ' ' ASN . 0.0 OUTLIER -130.14 140.66 48.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.902 179.493 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 137' ' ' ASN . . . . . 0.461 HD22 ' C ' ' A' ' 136' ' ' VAL . 0.9 OUTLIER -120.13 105.5 11.05 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.04 178.001 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . 0.546 ' CD2' ' HB2' ' A' ' 28' ' ' TYR . 73.4 t80 -117.83 112.06 19.89 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.585 -0.524 . . . . 0.0 109.585 178.778 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . 0.43 ' HA3' ' OD2' ' A' ' 24' ' ' ASP . . . 81.44 26.97 49.8 Favored Glycine 0 N--CA 1.447 -0.567 0 C-N-CA 120.743 -0.741 . . . . 0.0 111.797 -178.536 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 140' ' ' ARG . . . . . 0.464 ' HD3' ' HA ' ' A' ' 140' ' ' ARG . 26.5 mmt180 67.6 8.45 6.36 Favored 'General case' 0 N--CA 1.463 0.224 0 C-N-CA 123.248 0.619 . . . . 0.0 111.927 -179.807 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 141' ' ' THR . . . . . 0.462 HG22 ' O ' ' A' ' 138' ' ' TYR . 14.0 t -107.03 135.62 48.27 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 170.926 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 142' ' ' TYR . . . . . 0.698 ' HE1' ' HA ' ' A' ' 123' ' ' THR . 6.7 p90 -101.18 147.58 26.09 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-O 121.019 0.438 . . . . 0.0 110.789 -172.947 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 20.9 p90 -156.08 170.4 22.27 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-N 115.639 -0.71 . . . . 0.0 109.321 175.962 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 96.3 m-85 -113.51 124.27 51.99 Favored 'General case' 0 C--N 1.318 -0.797 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 179.266 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 145' ' ' GLU . . . . . 0.449 ' OE1' ' HD3' ' A' ' 116' ' ' ARG . 19.1 pt-20 -112.73 161.66 16.63 Favored 'General case' 0 C--N 1.316 -0.874 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 178.4 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . 0.415 ' HB3' ' HB3' ' A' ' 117' ' ' LEU . 63.8 t80 -141.36 129.06 21.58 Favored 'General case' 0 C--N 1.315 -0.928 0 CA-C-N 115.938 -0.573 . . . . 0.0 109.897 175.511 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 147' ' ' ILE . . . . . 0.415 ' N ' HD12 ' A' ' 147' ' ' ILE . 3.5 mp -101.68 120.21 50.99 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.96 0 N-CA-C 107.956 -1.128 . . . . 0.0 107.956 176.327 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -63.31 92.62 0.06 Allowed 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.503 0.668 . . . . 0.0 110.377 179.112 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 . . . . . 0 N--CA 1.445 -0.687 0 CA-C-N 114.675 -1.148 . . . . 0.0 111.014 -175.582 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 61.8 m95 . . . . . 0 N--CA 1.455 -0.19 0 CA-C-O 120.916 0.389 . . . . 0.0 110.38 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.45 ' O ' HG23 ' A' ' 27' ' ' VAL . 9.6 m120 -72.32 -36.03 68.76 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 174.337 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.494 ' HB3' ' HA3' ' A' ' 139' ' ' GLY . 5.4 m-20 -64.55 -38.15 90.01 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.283 174.772 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 53.8 tp -53.23 -50.31 65.01 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.161 -0.472 . . . . 0.0 109.958 173.016 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . 0.401 ' O ' HG13 ' A' ' 30' ' ' ILE . . . -58.61 -48.72 80.02 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.884 177.269 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.45 HG23 ' O ' ' A' ' 23' ' ' ASN . 79.0 t -52.52 -45.82 47.33 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.22 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.175 177.102 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . 0.481 ' HB2' ' CD2' ' A' ' 138' ' ' TYR . 78.1 t80 -58.03 -47.12 84.06 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.535 178.629 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.448 HG12 HD12 ' A' ' 118' ' ' ILE . 78.5 mt -60.43 -44.18 95.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.542 178.311 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.621 HD11 ' HA ' ' A' ' 54' ' ' ILE . 83.7 mt -61.99 -41.09 89.65 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 115.601 -0.727 . . . . 0.0 111.455 -179.505 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . 0.406 HH11 ' HD3' ' A' ' 31' ' ' ARG . 41.5 mtp-105 -71.78 -29.86 64.93 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.888 -177.541 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 76.5 m -80.92 -27.32 36.21 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.381 -0.372 . . . . 0.0 111.426 -178.999 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 14.0 p -93.77 -75.35 0.5 Allowed 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 120.752 0.31 . . . . 0.0 111.291 -177.673 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 109.43 134.6 7.03 Favored Glycine 0 N--CA 1.448 -0.543 0 C-N-CA 121.072 -0.585 . . . . 0.0 111.694 -176.399 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 32.8 Cg_exo -57.53 133.0 53.89 Favored 'Trans proline' 0 C--O 1.232 0.206 0 C-N-CA 122.925 2.417 . . . . 0.0 112.421 -179.155 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 102.24 62.76 0.73 Allowed Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.434 -0.888 . . . . 0.0 111.731 -177.948 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 15.0 t -178.31 -166.96 0.12 Allowed 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 108.545 -0.909 . . . . 0.0 108.545 -178.191 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' ARG . . . . . 0.832 ' HG2' ' HB3' ' A' ' 61' ' ' ASP . 48.5 mtt180 -124.58 136.61 54.1 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 121.045 0.45 . . . . 0.0 111.055 176.96 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.767 HG23 HG11 ' A' ' 60' ' ' VAL . 86.1 t -125.65 121.96 61.24 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 N-CA-C 109.16 -0.681 . . . . 0.0 109.16 175.342 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.419 HG22 ' HB ' ' A' ' 63' ' ' VAL . 26.4 t -101.37 132.64 46.8 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-O 120.743 0.306 . . . . 0.0 110.79 -175.261 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . 0.711 ' HB3' HD23 ' A' ' 64' ' ' LEU . 10.7 tt0 -108.72 126.0 52.53 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.154 -0.476 . . . . 0.0 109.972 176.252 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.739 HG13 HD11 ' A' ' 79' ' ' ILE . 64.8 t -94.12 106.62 18.29 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.774 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 174.644 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 156.75 -66.54 0.3 Allowed Glycine 0 N--CA 1.44 -1.1 0 C-N-CA 120.283 -0.96 . . . . 0.0 111.753 -178.671 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.979 ' HB1' HD13 ' A' ' 74' ' ' ILE . . . 53.38 34.36 17.87 Favored 'General case' 0 C--O 1.233 0.187 0 CA-C-O 121.132 0.491 . . . . 0.0 111.774 176.832 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -91.34 -144.85 13.52 Favored Glycine 0 N--CA 1.445 -0.742 0 C-N-CA 120.623 -0.798 . . . . 0.0 112.847 -177.541 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 39.1 mtp180 -92.6 29.81 1.67 Allowed 'General case' 0 C--N 1.321 -0.667 0 CA-C-O 121.251 0.548 . . . . 0.0 110.523 -176.026 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 5.1 p90 -129.91 30.17 4.88 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.93 -176.675 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.596 HD21 ' HA ' ' A' ' 44' ' ' ALA . 94.1 mt -72.75 7.92 1.73 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.993 -0.549 . . . . 0.0 112.147 -174.318 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 5.7 p90 -65.95 -26.37 67.54 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.819 0.342 . . . . 0.0 110.931 177.025 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.47 ' O ' HG13 ' A' ' 54' ' ' ILE . 93.6 t -72.35 -54.37 16.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.19 175.513 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -61.86 -41.33 97.72 Favored 'General case' 0 N--CA 1.449 -0.479 0 CA-C-N 115.795 -0.638 . . . . 0.0 111.592 -179.099 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 22.1 t70 -65.49 -42.78 91.77 Favored 'General case' 0 C--N 1.329 -0.306 0 C-N-CA 121.033 -0.267 . . . . 0.0 110.756 179.128 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 89.7 t80 -59.56 -36.66 76.64 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.864 0.364 . . . . 0.0 110.533 178.64 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.621 ' HA ' HD11 ' A' ' 30' ' ' ILE . 81.3 mt -61.27 -46.85 95.79 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.386 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.017 178.205 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 36.8 ptt180 -75.33 -16.71 60.38 Favored 'General case' 0 C--O 1.234 0.25 0 CA-C-O 120.843 0.354 . . . . 0.0 111.078 -178.201 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 43.4 mmtm -75.62 -35.39 60.5 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.56 -0.291 . . . . 0.0 110.986 177.234 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . 0.469 ' CD2' HG21 ' A' ' 30' ' ' ILE . 13.1 t60 -103.94 -38.31 7.04 Favored 'General case' 0 N--CA 1.451 -0.418 0 CA-C-O 120.953 0.406 . . . . 0.0 110.75 -175.13 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 7.9 t -110.08 140.82 43.74 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 121.03 0.443 . . . . 0.0 110.302 -177.697 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . 0.504 ' HD2' ' N ' ' A' ' 59' ' ' LYS . 4.1 mptp? -92.22 60.59 3.74 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.783 0.802 . . . . 0.0 109.888 178.378 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.767 HG11 HG23 ' A' ' 39' ' ' VAL . 73.7 t -106.26 139.46 27.54 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-N 114.623 -1.171 . . . . 0.0 110.67 177.985 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . 0.832 ' HB3' ' HG2' ' A' ' 38' ' ' ARG . 18.0 t70 -74.98 90.75 2.46 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 109.168 -0.678 . . . . 0.0 109.168 175.823 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 5.5 tt -84.89 126.85 33.83 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.163 -176.529 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.419 ' HB ' HG22 ' A' ' 40' ' ' VAL . 51.5 t -106.82 127.94 61.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.828 -176.256 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . 0.711 HD23 ' HB3' ' A' ' 41' ' ' GLU . 82.3 mt -111.76 133.87 53.7 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 109.535 -0.543 . . . . 0.0 109.535 176.61 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 3.4 p -127.47 130.22 48.85 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 120.47 0.176 . . . . 0.0 111.024 178.566 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . 0.812 ' HB2' ' HB3' ' A' ' 44' ' ' ALA . 19.4 t0 -162.22 157.58 23.22 Favored 'General case' 0 C--O 1.234 0.268 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.675 -179.355 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 63.7 mt -82.58 122.01 36.55 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 116.115 -0.493 . . . . 0.0 109.79 178.926 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 18.1 ptpt 41.52 69.46 2.04 Favored Pre-proline 0 N--CA 1.474 0.77 0 O-C-N 124.003 0.814 . . . . 0.0 112.346 -175.604 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . 0.513 ' CB ' ' HB ' ' A' ' 74' ' ' ILE . 5.8 Cg_exo . . . . . 0 N--CA 1.46 -0.467 0 C-N-CA 122.898 2.399 . . . . 0.0 111.923 179.072 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.979 HD13 ' HB1' ' A' ' 44' ' ' ALA . 62.5 mt . . . . . 0 C--O 1.235 0.33 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.49 HG12 ' H ' ' A' ' 77' ' ' ASP . 61.6 t -61.18 136.16 25.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-O 120.832 0.348 . . . . 0.0 110.364 -177.908 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 17.1 mmt85 -86.3 15.16 5.55 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.969 -0.559 . . . . 0.0 111.31 -171.947 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . 0.49 ' H ' HG12 ' A' ' 75' ' ' VAL . 26.2 t70 -77.21 136.54 38.56 Favored 'General case' 0 C--N 1.325 -0.5 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 -177.019 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -58.99 116.06 3.55 Favored 'General case' 0 C--O 1.221 -0.439 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.141 -177.145 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' ILE . . . . . 0.739 HD11 HG13 ' A' ' 42' ' ' VAL . 10.6 tp -69.63 -16.28 20.29 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-O 121.344 0.592 . . . . 0.0 110.399 178.551 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 9.0 t -86.99 -11.31 50.87 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.477 178.225 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 45.0 t -157.2 64.86 3.4 Favored Pre-proline 0 C--N 1.326 -0.424 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 179.879 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' PRO . . . . . 0.562 ' HB2' ' HE2' ' A' ' 87' ' ' TYR . 90.1 Cg_endo -85.07 153.26 11.06 Favored 'Trans proline' 0 N--CA 1.458 -0.564 0 C-N-CA 122.717 2.278 . . . . 0.0 113.206 -170.187 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' ARG . . . . . 0.68 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 35.2 mtt180 -87.56 119.82 28.24 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.784 177.292 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' MET . . . . . 0.652 ' HA ' ' HD2' ' A' ' 87' ' ' TYR . 36.7 mtp -67.94 -9.32 44.24 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.567 -0.742 . . . . 0.0 112.362 -175.302 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.68 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 8.0 pt-20 -61.51 -30.13 70.43 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 121.085 0.469 . . . . 0.0 110.088 175.374 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 69.2 mt -75.07 -40.01 44.31 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 115.47 -0.786 . . . . 0.0 110.514 -179.472 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . 0.652 ' HD2' ' HA ' ' A' ' 84' ' ' MET . 91.5 m-85 -75.27 -34.5 61.37 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.947 -0.57 . . . . 0.0 111.216 -177.717 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 34.0 mtp180 -64.41 114.48 4.34 Favored 'General case' 0 C--O 1.235 0.328 0 CA-C-O 121.572 0.701 . . . . 0.0 110.765 177.71 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 124.21 -12.53 8.03 Favored Glycine 0 N--CA 1.443 -0.864 0 CA-C-N 114.868 -1.06 . . . . 0.0 111.492 -175.825 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -84.21 152.19 24.38 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.838 0.352 . . . . 0.0 110.872 -179.815 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -99.75 -22.16 15.48 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.407 177.546 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . 0.483 ' HG ' ' HB3' ' A' ' 116' ' ' ARG . 4.9 tt -152.53 142.01 21.69 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.298 -177.981 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.576 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 68.3 mt -131.89 122.96 50.48 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 178.807 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 23.4 p90 -130.61 162.33 29.59 Favored 'General case' 0 C--N 1.321 -0.643 0 C-N-CA 120.614 -0.434 . . . . 0.0 111.007 -178.023 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . 0.569 ' OG ' ' HB ' ' A' ' 42' ' ' VAL . 4.2 m -143.73 145.41 32.39 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.768 -179.126 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 76.7 mt -116.17 111.17 34.29 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.116 177.988 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 97' ' ' ARG . . . . . 0.431 HH11 ' HD2' ' A' ' 97' ' ' ARG . 12.9 ttp180 59.17 73.49 0.68 Allowed Pre-proline 0 N--CA 1.466 0.349 0 CA-C-N 115.701 -0.681 . . . . 0.0 111.331 -177.548 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_endo -88.2 134.8 3.08 Favored 'Trans proline' 0 N--CA 1.455 -0.749 0 C-N-CA 122.826 2.35 . . . . 0.0 111.917 176.953 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . 0.525 ' HG2' HD11 ' A' ' 102' ' ' ILE . 2.9 Cg_endo -47.48 142.49 13.09 Favored 'Trans proline' 0 C--N 1.35 0.606 0 C-N-CA 123.422 2.748 . . . . 0.0 112.807 175.659 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . 0.813 ' HA ' ' CE1' ' A' ' 103' ' ' HIS . . . -75.09 42.84 0.19 Allowed 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.848 -0.615 . . . . 0.0 112.46 -176.168 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 101' ' ' GLU . . . . . 0.449 ' HG3' HG23 ' A' ' 102' ' ' ILE . 10.0 pt-20 -135.6 -24.56 1.35 Allowed 'General case' 0 C--N 1.326 -0.423 0 N-CA-C 112.325 0.491 . . . . 0.0 112.325 177.425 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.525 HD11 ' HG2' ' A' ' 99' ' ' PRO . 6.5 pt -114.55 3.55 7.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 N-CA-C 112.848 0.685 . . . . 0.0 112.848 -172.521 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 103' ' ' HIS . . . . . 0.813 ' CE1' ' HA ' ' A' ' 100' ' ' ALA . 35.7 m80 -47.12 -56.49 6.49 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 112.156 0.428 . . . . 0.0 112.156 179.731 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 40.1 t -66.29 -26.1 67.17 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.069 0.462 . . . . 0.0 110.771 -179.794 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.427 ' O ' HG23 ' A' ' 109' ' ' VAL . 14.2 m -67.86 -33.3 74.49 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.109 179.446 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.421 HD22 HG21 ' A' ' 42' ' ' VAL . 82.0 mt -72.13 -38.37 69.25 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.954 178.448 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 107' ' ' MET . . . . . 0.547 ' HA ' HD22 ' A' ' 117' ' ' LEU . 53.6 ttm -59.18 -43.34 92.15 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.186 -178.991 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 27.3 ptt85 -66.59 -31.58 72.37 Favored 'General case' 0 C--N 1.331 -0.207 0 C-N-CA 120.88 -0.328 . . . . 0.0 110.532 -177.704 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.427 HG23 ' O ' ' A' ' 105' ' ' SER . 94.0 t -68.94 -46.86 78.37 Favored 'Isoleucine or valine' 0 C--O 1.234 0.243 0 CA-C-N 116.549 -0.296 . . . . 0.0 110.47 179.88 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -58.74 -43.83 90.34 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.512 177.872 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.499 ' HA ' ' HB1' ' A' ' 148' ' ' ALA . 22.5 t70 -65.29 -39.94 93.21 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.012 179.629 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -66.92 -42.94 84.55 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.835 -0.621 . . . . 0.0 111.879 -178.253 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 25.8 m -87.15 -24.41 6.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 120.894 0.378 . . . . 0.0 111.486 -177.393 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 91.11 44.29 4.46 Favored Glycine 0 N--CA 1.449 -0.462 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.27 178.203 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -124.37 156.56 36.85 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 120.723 0.296 . . . . 0.0 110.834 -177.995 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 116' ' ' ARG . . . . . 0.484 ' HD3' ' OE1' ' A' ' 145' ' ' GLU . 14.3 ttm180 -78.57 127.28 31.91 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 177.015 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . 0.576 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 51.1 tp -95.89 121.93 38.14 Favored 'General case' 0 C--N 1.322 -0.589 0 N-CA-C 109.892 -0.411 . . . . 0.0 109.892 -179.946 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . 0.448 HD12 HG12 ' A' ' 29' ' ' ILE . 69.3 mt -119.77 112.69 38.07 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-O 121.023 0.439 . . . . 0.0 110.617 178.729 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 50.6 mt -111.61 121.18 63.66 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.797 0 CA-C-O 120.919 0.39 . . . . 0.0 110.32 178.94 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 63.6 tttp -111.11 103.31 54.72 Favored Pre-proline 0 C--N 1.32 -0.699 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.489 174.878 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 93.0 Cg_endo -82.9 -166.86 0.41 Allowed 'Trans proline' 0 N--CA 1.455 -0.773 0 C-N-CA 122.591 2.194 . . . . 0.0 110.829 171.185 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 7.1 mp -88.81 166.92 13.69 Favored 'General case' 0 C--N 1.319 -0.72 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 177.103 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 4.7 t -68.61 -9.39 49.5 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.153 0.501 . . . . 0.0 111.219 -177.68 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -117.49 24.7 8.99 Favored Glycine 0 N--CA 1.446 -0.676 0 N-CA-C 111.587 -0.605 . . . . 0.0 111.587 175.5 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 26.9 mm-40 -129.38 172.75 11.19 Favored 'General case' 0 N--CA 1.45 -0.46 0 CA-C-O 121.209 0.528 . . . . 0.0 110.754 -176.774 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 8.4 t70 -143.79 -170.82 3.4 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-N 115.05 -0.977 . . . . 0.0 108.58 175.358 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . 0.602 HD11 ' HB2' ' A' ' 144' ' ' TYR . 18.3 mt . . . . . 0 C--N 1.318 -0.764 0 CA-C-O 120.667 0.27 . . . . 0.0 110.337 179.49 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 28.7 mtpp . . . . . 0 C--O 1.23 0.059 0 CA-C-O 120.838 0.351 . . . . 0.0 111.399 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 133' ' ' MET . . . . . 0.4 ' HG2' ' HB2' ' A' ' 146' ' ' TYR . 88.9 mtp -98.77 151.51 20.71 Favored 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 178.405 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 16.2 ptmt -100.42 134.62 43.1 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 121.222 0.534 . . . . 0.0 111.353 -174.795 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . 0.488 HD11 ' HD2' ' A' ' 142' ' ' TYR . 54.6 tp -78.58 126.7 31.11 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.334 -0.848 . . . . 0.0 110.154 177.438 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -123.43 135.12 64.32 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.712 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.909 179.869 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 137' ' ' ASN . . . . . 0.512 ' ND2' ' HB3' ' A' ' 142' ' ' TYR . 14.5 m120 -111.52 112.35 24.02 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.662 -0.699 . . . . 0.0 109.442 178.217 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . 0.481 ' CD2' ' HB2' ' A' ' 28' ' ' TYR . 61.1 t80 -144.73 128.77 17.55 Favored 'General case' 0 C--N 1.318 -0.773 0 N-CA-C 110.348 -0.241 . . . . 0.0 110.348 -178.001 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . 0.494 ' HA3' ' HB3' ' A' ' 24' ' ' ASP . . . 68.79 35.94 81.08 Favored Glycine 0 N--CA 1.447 -0.61 0 C-N-CA 120.944 -0.646 . . . . 0.0 112.907 176.169 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 140' ' ' ARG . . . . . 0.411 ' HB2' ' O ' ' A' ' 139' ' ' GLY . 69.0 mtt85 72.97 4.51 4.98 Favored 'General case' 0 N--CA 1.463 0.223 0 C-N-CA 122.772 0.429 . . . . 0.0 112.081 175.723 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 14.9 t -124.57 154.09 41.15 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 176.296 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 142' ' ' TYR . . . . . 0.512 ' HB3' ' ND2' ' A' ' 137' ' ' ASN . 45.4 p90 -123.21 147.81 46.49 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-O 121.162 0.506 . . . . 0.0 110.653 178.539 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 14.0 p90 -154.01 179.59 8.77 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-N 115.064 -0.971 . . . . 0.0 109.056 -177.676 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 144' ' ' TYR . . . . . 0.602 ' HB2' HD11 ' A' ' 127' ' ' ILE . 97.3 m-85 -115.79 127.79 55.35 Favored 'General case' 0 C--N 1.32 -0.709 0 N-CA-C 110.19 -0.3 . . . . 0.0 110.19 179.452 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 145' ' ' GLU . . . . . 0.484 ' OE1' ' HD3' ' A' ' 116' ' ' ARG . 18.2 pt-20 -115.48 161.75 18.14 Favored 'General case' 0 C--N 1.32 -0.691 0 N-CA-C 109.715 -0.476 . . . . 0.0 109.715 176.1 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . 0.463 ' HB3' ' HB3' ' A' ' 117' ' ' LEU . 51.0 t80 -141.33 126.9 18.91 Favored 'General case' 0 C--N 1.313 -0.997 0 CA-C-N 115.604 -0.725 . . . . 0.0 109.741 177.532 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 3.1 mp -95.57 109.33 22.38 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.81 0 N-CA-C 109.585 -0.524 . . . . 0.0 109.585 -179.249 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . 0.499 ' HB1' ' HA ' ' A' ' 111' ' ' ASP . . . -63.0 111.24 2.08 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.392 -0.596 . . . . 0.0 109.392 175.114 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 . . . . . 0 C--N 1.322 -0.595 0 CA-C-O 121.859 0.838 . . . . 0.0 111.946 -173.756 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' TRP . . . . . 0.584 ' HB3' HG22 ' A' ' 50' ' ' VAL . 83.1 m95 . . . . . 0 N--CA 1.456 -0.157 0 CA-C-O 120.528 0.204 . . . . 0.0 111.385 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.496 ' O ' HG23 ' A' ' 27' ' ' VAL . 2.1 m-20 -60.8 -48.79 80.22 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.811 -172.605 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -60.89 -39.55 89.7 Favored 'General case' 0 N--CA 1.468 0.44 0 CA-C-O 120.735 0.302 . . . . 0.0 111.477 -179.08 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.769 HD22 ' HD2' ' A' ' 120' ' ' LYS . 54.0 tp -58.08 -50.8 72.2 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.458 177.574 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . 0.468 ' O ' HG13 ' A' ' 30' ' ' ILE . . . -59.46 -46.38 88.95 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.618 -0.719 . . . . 0.0 111.18 -179.029 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.592 ' HA ' HD12 ' A' ' 30' ' ' ILE . 87.5 t -55.64 -44.29 76.25 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.915 179.912 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 72.7 t80 -59.8 -46.19 89.98 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.584 179.003 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.53 HG23 HD22 ' A' ' 92' ' ' LEU . 75.9 mt -59.69 -43.02 90.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.47 178.246 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.811 HG12 HG23 ' A' ' 54' ' ' ILE . 82.2 mt -59.05 -47.08 91.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 115.642 -0.708 . . . . 0.0 111.78 -179.622 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . 0.522 ' HG3' ' O ' ' A' ' 27' ' ' VAL . 35.6 mtp180 -73.44 -22.6 60.16 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 121.03 0.443 . . . . 0.0 111.02 -174.156 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 69.5 m -88.59 -8.92 53.89 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.262 -179.563 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 13.5 p -112.88 -70.01 0.83 Allowed 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.76 0.314 . . . . 0.0 111.154 -178.943 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 93.49 166.12 37.73 Favored Glycine 0 N--CA 1.449 -0.492 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.277 179.793 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 69.8 Cg_endo -75.99 156.31 38.62 Favored 'Trans proline' 0 CA--C 1.532 0.376 0 C-N-CA 122.7 2.267 . . . . 0.0 112.597 -179.831 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 84.07 39.3 9.39 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.888 178.491 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 12.5 t -164.4 -170.19 1.99 Allowed 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 177.8 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' ARG . . . . . 0.431 ' HA ' ' O ' ' A' ' 61' ' ' ASP . 49.0 mtm180 -119.3 136.23 54.34 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.945 0.402 . . . . 0.0 110.882 179.789 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.683 HG23 HG21 ' A' ' 60' ' ' VAL . 91.6 t -119.76 113.16 39.89 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 N-CA-C 109.034 -0.728 . . . . 0.0 109.034 173.806 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.587 ' O ' ' HA ' ' A' ' 93' ' ' ILE . 46.9 t -97.12 134.23 35.68 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.853 0 CA-C-O 120.931 0.396 . . . . 0.0 110.916 -175.703 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . 0.467 ' HA ' ' O ' ' A' ' 94' ' ' TYR . 0.4 OUTLIER -114.6 157.18 23.41 Favored 'General case' 0 C--N 1.318 -0.793 0 N-CA-C 109.036 -0.728 . . . . 0.0 109.036 173.521 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.559 ' HB ' ' HB3' ' A' ' 95' ' ' SER . 54.7 t -124.76 112.34 31.6 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.733 0 CA-C-N 116.512 -0.313 . . . . 0.0 110.954 178.334 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 112.3 32.82 2.26 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.665 -0.778 . . . . 0.0 113.602 173.74 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -50.44 -58.64 5.27 Favored 'General case' 0 N--CA 1.466 0.345 0 N-CA-C 112.378 0.51 . . . . 0.0 112.378 -178.24 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 63.66 -108.14 2.07 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 121.052 -0.594 . . . . 0.0 112.677 179.519 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 16.7 ptt180 -127.11 5.71 6.47 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.678 0.275 . . . . 0.0 111.333 -179.58 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.525 ' HE2' HG13 ' A' ' 96' ' ' ILE . 14.4 p90 -112.46 90.99 3.49 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.959 0.885 . . . . 0.0 110.496 179.186 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.447 HD22 HD13 ' A' ' 64' ' ' LEU . 74.6 mt -102.07 16.45 26.03 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.217 -0.901 . . . . 0.0 110.629 -175.877 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 78.0 t80 -60.69 -50.07 74.96 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.368 -0.378 . . . . 0.0 111.322 -177.054 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.584 HG22 ' HB3' ' A' ' 22' ' ' TRP . 59.6 t -62.38 -48.76 86.83 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-O 121.039 0.447 . . . . 0.0 110.726 -178.981 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . 0.429 ' CB ' HD21 ' A' ' 64' ' ' LEU . 0.0 OUTLIER -63.98 -45.63 88.2 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.622 -177.166 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.626 ' O ' ' HG3' ' A' ' 56' ' ' LYS . 26.4 t70 -70.88 -30.32 66.65 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 120.641 0.258 . . . . 0.0 110.662 -179.042 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 45.4 t80 -61.73 -42.48 99.02 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.06 0.457 . . . . 0.0 109.961 175.97 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.811 HG23 HG12 ' A' ' 30' ' ' ILE . 80.5 mt -63.61 -48.01 88.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 115.815 -0.63 . . . . 0.0 111.437 -179.883 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' ARG . . . . . 0.601 ' HG2' ' HA ' ' A' ' 52' ' ' ASP . 0.1 OUTLIER -69.51 -18.88 63.72 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 111.898 0.333 . . . . 0.0 111.898 -177.149 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . 0.626 ' HG3' ' O ' ' A' ' 52' ' ' ASP . 56.7 mttm -67.57 -37.79 83.15 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.115 0.483 . . . . 0.0 110.575 176.084 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . 0.505 ' CD2' HG21 ' A' ' 30' ' ' ILE . 16.8 t60 -101.72 -39.42 7.44 Favored 'General case' 0 N--CA 1.444 -0.746 0 CA-C-N 115.879 -0.6 . . . . 0.0 111.034 -172.111 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . 0.591 ' HB2' HG23 ' A' ' 30' ' ' ILE . 8.8 t -109.78 139.58 44.68 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.75 0.31 . . . . 0.0 110.393 -177.379 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 14.4 mmmm -91.35 59.99 4.04 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 121.85 0.833 . . . . 0.0 109.981 177.184 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.683 HG21 HG23 ' A' ' 39' ' ' VAL . 13.6 p -110.72 145.05 17.57 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.814 0 CA-C-N 114.817 -1.083 . . . . 0.0 110.098 177.38 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . 0.431 ' O ' ' HA ' ' A' ' 38' ' ' ARG . 21.6 t70 -78.79 101.63 7.71 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.062 0.458 . . . . 0.0 109.897 178.656 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . 0.413 ' HA ' ' O ' ' A' ' 39' ' ' VAL . 3.6 tt -91.93 119.02 31.3 Favored 'General case' 0 C--N 1.315 -0.925 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 -178.864 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.417 HG11 ' CG2' ' A' ' 86' ' ' ILE . 47.1 t -96.62 119.16 44.31 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-N 115.605 -0.725 . . . . 0.0 110.503 -176.822 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . 0.623 ' HB2' ' HA ' ' A' ' 74' ' ' ILE . 51.1 mt -94.39 138.34 32.46 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.553 -0.749 . . . . 0.0 109.722 179.629 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.508 ' OG1' ' HA ' ' A' ' 42' ' ' VAL . 70.2 p -128.56 130.7 47.78 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 120.875 0.369 . . . . 0.0 110.759 178.141 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 31.3 t70 -160.78 146.42 14.65 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.165 -0.47 . . . . 0.0 109.823 179.172 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.744 HD11 HG22 ' A' ' 79' ' ' ILE . 50.6 mt -75.85 106.42 5.67 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-O 121.111 0.482 . . . . 0.0 110.662 179.526 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' LYS . . . . . 0.431 ' N ' ' HD3' ' A' ' 69' ' ' PRO . 45.6 mtmt 65.73 65.47 0.87 Allowed Pre-proline 0 CA--C 1.533 0.307 0 CA-C-N 115.197 -0.911 . . . . 0.0 111.814 177.723 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . 0.984 ' HD2' ' HG3' ' A' ' 76' ' ' ARG . 2.6 Cg_exo . . . . . 0 C--O 1.234 0.324 0 C-N-CA 122.976 2.45 . . . . 0.0 111.739 177.055 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.623 ' HA ' ' HB2' ' A' ' 64' ' ' LEU . 35.5 mt . . . . . 0 N--CA 1.449 -0.486 0 N-CA-C 108.892 -0.781 . . . . 0.0 108.892 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.413 HG11 HD13 ' A' ' 86' ' ' ILE . 98.7 t -78.84 136.39 23.91 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.715 0 CA-C-O 121.437 0.637 . . . . 0.0 110.178 -179.16 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' ARG . . . . . 0.984 ' HG3' ' HD2' ' A' ' 69' ' ' PRO . 1.3 mpp_? -90.83 34.17 0.92 Allowed 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 115.032 -0.985 . . . . 0.0 110.841 -173.0 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 22.6 t0 -89.86 136.94 32.74 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.082 -0.71 . . . . 0.0 109.082 177.888 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 7.0 p-10 -95.85 153.05 17.95 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-O 121.166 0.508 . . . . 0.0 111.353 -172.043 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' ILE . . . . . 0.744 HG22 HD11 ' A' ' 67' ' ' ILE . 10.4 tp -71.36 -27.09 27.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 115.648 -0.705 . . . . 0.0 112.478 -170.873 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 14.3 t -89.19 6.34 40.57 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.34 0.591 . . . . 0.0 110.326 -179.11 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 32.8 t -152.29 58.5 2.59 Favored Pre-proline 0 C--N 1.325 -0.495 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.909 174.428 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' PRO . . . . . 0.487 ' HB2' ' HE2' ' A' ' 87' ' ' TYR . 65.4 Cg_endo -74.99 131.13 13.95 Favored 'Trans proline' 0 C--O 1.238 0.503 0 C-N-CA 122.192 1.928 . . . . 0.0 112.092 -175.105 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' ARG . . . . . 0.607 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 37.1 mtp85 -85.51 120.52 27.05 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.141 0.496 . . . . 0.0 111.063 -179.12 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' MET . . . . . 0.506 ' O ' ' HG3' ' A' ' 88' ' ' ARG . 96.1 mmm -62.5 -21.4 65.47 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.415 -0.811 . . . . 0.0 110.516 179.699 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.607 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 11.1 pt-20 -66.29 -21.62 66.27 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-O 121.195 0.522 . . . . 0.0 110.799 -178.834 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.417 ' CG2' HG11 ' A' ' 63' ' ' VAL . 66.5 mt -85.85 -31.2 6.5 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.497 -179.41 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . 0.487 ' HE2' ' HB2' ' A' ' 82' ' ' PRO . 79.9 m-85 -88.96 -26.06 21.72 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.432 -176.578 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . 0.583 ' HG2' HG12 ' A' ' 113' ' ' VAL . 81.8 mtp180 -71.97 143.82 49.09 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 121.142 0.496 . . . . 0.0 111.041 -178.912 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 80.54 11.2 84.37 Favored Glycine 0 C--N 1.319 -0.414 0 CA-C-N 115.274 -0.875 . . . . 0.0 112.042 -178.606 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -96.0 154.92 16.98 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.847 0.355 . . . . 0.0 110.355 178.627 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -98.34 -23.65 15.54 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 116.108 -0.497 . . . . 0.0 111.025 179.928 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . 0.53 HD22 HG23 ' A' ' 29' ' ' ILE . 4.1 tt -156.99 145.11 19.4 Favored 'General case' 0 N--CA 1.452 -0.373 0 CA-C-O 120.873 0.368 . . . . 0.0 110.81 -177.33 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.587 ' HA ' ' O ' ' A' ' 40' ' ' VAL . 61.6 mt -132.77 131.04 59.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 N-CA-C 109.031 -0.729 . . . . 0.0 109.031 178.193 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 94' ' ' TYR . . . . . 0.467 ' O ' ' HA ' ' A' ' 41' ' ' GLU . 32.4 p90 -139.68 155.74 47.21 Favored 'General case' 0 C--N 1.326 -0.414 0 C-N-CA 120.709 -0.396 . . . . 0.0 110.644 -179.508 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . 0.559 ' HB3' ' HB ' ' A' ' 42' ' ' VAL . 10.2 p -142.48 148.16 37.24 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-O 120.748 0.309 . . . . 0.0 111.095 -176.964 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 96' ' ' ILE . . . . . 0.525 HG13 ' HE2' ' A' ' 47' ' ' PHE . 38.2 mm -99.03 92.82 2.83 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.585 -179.744 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 97' ' ' ARG . . . . . 0.589 ' NH2' ' HA ' ' A' ' 122' ' ' LEU . 98.8 mtt180 54.08 76.51 0.51 Allowed Pre-proline 0 N--CA 1.468 0.446 0 CA-C-N 115.7 -0.682 . . . . 0.0 112.429 177.995 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 98.9 Cg_endo -80.7 157.4 21.48 Favored 'Trans proline' 0 N--CA 1.46 -0.47 0 C-N-CA 122.539 2.159 . . . . 0.0 112.259 179.1 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . 0.784 ' HD2' HD11 ' A' ' 102' ' ' ILE . 32.4 Cg_exo -57.44 142.19 95.14 Favored 'Trans proline' 0 C--N 1.345 0.394 0 C-N-CA 122.817 2.345 . . . . 0.0 111.683 174.604 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . 0.56 ' HA ' ' NE2' ' A' ' 103' ' ' HIS . . . -63.03 -22.84 67.14 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.329 -0.396 . . . . 0.0 112.035 -175.784 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 101' ' ' GLU . . . . . 0.423 ' HG3' HG23 ' A' ' 102' ' ' ILE . 12.4 pt-20 -74.86 -10.65 59.7 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 112.072 0.397 . . . . 0.0 112.072 -176.703 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.784 HD11 ' HD2' ' A' ' 99' ' ' PRO . 45.6 pt -120.62 8.92 6.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 N-CA-C 112.502 0.556 . . . . 0.0 112.502 -177.776 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 103' ' ' HIS . . . . . 0.56 ' NE2' ' HA ' ' A' ' 100' ' ' ALA . 5.3 m-70 -53.98 -51.2 64.64 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-O 121.053 0.454 . . . . 0.0 110.902 178.04 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 41.1 t -68.25 -28.43 67.21 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.351 -179.743 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.539 ' O ' HG23 ' A' ' 109' ' ' VAL . 29.9 t -68.88 -45.52 70.76 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.962 -0.563 . . . . 0.0 109.908 -179.69 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 72.0 mt -64.37 -40.3 95.57 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.389 -0.369 . . . . 0.0 111.03 178.793 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 107' ' ' MET . . . . . 0.41 ' HG3' ' O ' ' A' ' 103' ' ' HIS . 66.3 mtp -65.54 -42.48 91.9 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.25 -179.667 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 108' ' ' ARG . . . . . 0.529 ' HG2' ' O ' ' A' ' 105' ' ' SER . 8.0 ptm180 -67.93 -31.87 71.92 Favored 'General case' 0 N--CA 1.462 0.154 0 C-N-CA 120.942 -0.303 . . . . 0.0 110.858 -178.847 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.539 HG23 ' O ' ' A' ' 105' ' ' SER . 76.1 t -66.54 -46.65 85.78 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.193 0 CA-C-O 120.71 0.29 . . . . 0.0 110.279 176.798 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -57.34 -45.84 83.89 Favored 'General case' 0 CA--C 1.514 -0.406 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.123 177.419 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.834 ' HA ' ' HB1' ' A' ' 148' ' ' ALA . 5.0 t70 -66.46 -34.09 77.16 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.668 -177.497 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -70.24 -36.29 74.4 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.94 -179.659 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.583 HG12 ' HG2' ' A' ' 88' ' ' ARG . 18.7 m -93.53 -25.96 4.76 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 116.446 -0.343 . . . . 0.0 111.509 -178.172 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 87.97 41.47 6.29 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.863 -0.684 . . . . 0.0 112.634 178.296 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -120.02 158.69 26.27 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.854 0.359 . . . . 0.0 110.918 -178.471 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 116' ' ' ARG . . . . . 0.486 ' HD3' ' OE1' ' A' ' 145' ' ' GLU . 13.2 ttm180 -78.77 123.87 27.62 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 178.434 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . 0.564 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 52.0 tp -97.0 123.11 40.63 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.141 179.123 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . 0.438 HD12 HG12 ' A' ' 29' ' ' ILE . 53.6 mt -118.39 128.78 75.34 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 CA-C-O 120.976 0.417 . . . . 0.0 110.572 179.437 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 66.0 mt -128.04 134.58 64.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.36 -179.813 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 120' ' ' LYS . . . . . 0.769 ' HD2' HD22 ' A' ' 25' ' ' LEU . 10.4 mttm -113.43 104.25 55.47 Favored Pre-proline 0 C--N 1.324 -0.516 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.481 173.163 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 121' ' ' PRO . . . . . 0.433 ' HB2' ' H ' ' A' ' 122' ' ' LEU . 58.5 Cg_endo -72.28 -146.47 0.02 OUTLIER 'Trans proline' 0 CA--C 1.535 0.547 0 C-N-CA 123.208 2.605 . . . . 0.0 112.758 176.971 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 122' ' ' LEU . . . . . 0.727 ' HB2' ' HB3' ' A' ' 125' ' ' GLU . 7.1 mp -87.59 -176.24 5.49 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.433 -0.349 . . . . 0.0 111.18 -175.884 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 21.7 m -61.23 -39.36 89.99 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.965 -0.562 . . . . 0.0 111.878 -177.533 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -145.14 42.05 1.02 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.996 -0.621 . . . . 0.0 111.602 178.477 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . 0.727 ' HB3' ' HB2' ' A' ' 122' ' ' LEU . 5.6 tp10 -131.98 136.17 47.1 Favored 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 -176.268 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 21.1 t70 -76.49 -179.31 5.13 Favored 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 109.838 -0.431 . . . . 0.0 109.838 178.373 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 9.3 mt . . . . . 0 C--N 1.325 -0.499 0 N-CA-C 109.17 -0.678 . . . . 0.0 109.17 177.616 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 23.2 mmmt . . . . . 0 CA--C 1.52 -0.201 0 CA-C-O 121.454 0.645 . . . . 0.0 109.727 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 133' ' ' MET . . . . . 0.664 ' HG2' ' HB2' ' A' ' 146' ' ' TYR . 88.0 mtp -100.28 176.18 5.46 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.017 -0.992 . . . . 0.0 109.907 -179.543 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 14.9 ptmt -121.35 142.1 50.3 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 120.939 0.399 . . . . 0.0 110.635 -178.398 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . 0.73 HD11 ' HD2' ' A' ' 142' ' ' TYR . 50.1 tp -86.14 124.43 32.54 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.394 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 136' ' ' VAL . . . . . 0.437 HG23 ' CD1' ' A' ' 143' ' ' PHE . 0.0 OUTLIER -121.02 137.48 54.61 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.161 -179.724 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 137' ' ' ASN . . . . . 0.478 HD22 ' N ' ' A' ' 137' ' ' ASN . 0.9 OUTLIER -107.34 123.78 48.85 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 109.254 -0.647 . . . . 0.0 109.254 174.807 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 57.8 t80 -143.02 116.71 9.24 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 179.427 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 69.38 39.18 81.05 Favored Glycine 0 N--CA 1.447 -0.613 0 C-N-CA 120.575 -0.821 . . . . 0.0 111.95 -177.755 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 140' ' ' ARG . . . . . 0.442 HH11 ' HD3' ' A' ' 140' ' ' ARG . 22.8 ttp-105 73.24 -21.08 0.26 Allowed 'General case' 0 CA--C 1.531 0.229 0 C-N-CA 123.665 0.786 . . . . 0.0 112.561 177.802 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 6.5 t -92.15 141.71 28.29 Favored 'General case' 0 C--N 1.323 -0.562 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 177.355 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 142' ' ' TYR . . . . . 0.73 ' HD2' HD11 ' A' ' 135' ' ' LEU . 44.4 p90 -110.27 152.43 26.16 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.076 0.465 . . . . 0.0 110.917 -178.742 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 143' ' ' PHE . . . . . 0.492 ' HB3' ' HG3' ' A' ' 120' ' ' LYS . 5.4 p90 -157.7 176.22 12.88 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.837 178.632 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 73.6 m-85 -111.03 132.02 54.57 Favored 'General case' 0 C--N 1.319 -0.745 0 C-N-CA 121.011 -0.276 . . . . 0.0 110.81 -179.54 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 145' ' ' GLU . . . . . 0.486 ' OE1' ' HD3' ' A' ' 116' ' ' ARG . 21.0 pt-20 -120.72 160.85 22.48 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 109.33 -0.619 . . . . 0.0 109.33 174.288 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . 0.664 ' HB2' ' HG2' ' A' ' 133' ' ' MET . 32.3 t80 -140.3 124.2 17.4 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-N 116.12 -0.491 . . . . 0.0 109.742 178.017 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 147' ' ' ILE . . . . . 0.426 ' N ' HD12 ' A' ' 147' ' ' ILE . 2.8 mp -91.8 100.54 11.38 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 N-CA-C 109.624 -0.51 . . . . 0.0 109.624 179.702 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . 0.834 ' HB1' ' HA ' ' A' ' 111' ' ' ASP . . . -82.57 122.02 27.55 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.446 -0.797 . . . . 0.0 109.959 177.448 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 15.5 pt-20 . . . . . 0 C--N 1.321 -0.667 0 CA-C-O 120.801 0.334 . . . . 0.0 110.684 -179.419 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 95.8 m95 . . . . . 0 CA--C 1.522 -0.127 0 CA-C-O 120.967 0.413 . . . . 0.0 110.585 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.464 ' O ' HG23 ' A' ' 27' ' ' VAL . 12.3 m120 -62.74 -45.82 90.94 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.813 -178.172 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 13.0 m-20 -62.85 -41.12 99.23 Favored 'General case' 0 N--CA 1.464 0.256 0 CA-C-O 120.549 0.214 . . . . 0.0 110.897 178.418 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 58.3 tp -57.43 -48.03 80.23 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 121.021 0.438 . . . . 0.0 109.993 176.423 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . 0.485 ' O ' HG13 ' A' ' 30' ' ' ILE . . . -60.82 -46.78 89.22 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.954 178.225 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.504 ' HA ' HD12 ' A' ' 30' ' ' ILE . 53.1 t -56.96 -41.62 77.31 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.199 0 CA-C-N 116.559 -0.291 . . . . 0.0 111.234 179.842 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 61.1 t80 -58.44 -42.79 88.13 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.081 0.467 . . . . 0.0 110.35 178.174 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 66.5 mt -70.2 -40.92 78.67 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.489 178.732 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.741 HG12 HG23 ' A' ' 54' ' ' ILE . 97.0 mt -57.45 -44.63 84.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 115.4 -0.818 . . . . 0.0 111.068 178.838 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . 0.408 ' HG3' ' O ' ' A' ' 27' ' ' VAL . 73.4 mtp180 -65.95 -28.99 69.33 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.035 -0.529 . . . . 0.0 111.614 -178.237 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 46.0 t -88.7 -20.59 24.65 Favored 'General case' 0 C--N 1.324 -0.514 0 C-N-CA 121.104 -0.238 . . . . 0.0 111.496 -176.034 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 12.6 p -100.7 -78.99 0.51 Allowed 'General case' 0 C--N 1.327 -0.398 0 C-N-CA 121.172 -0.211 . . . . 0.0 111.537 -177.386 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 106.27 164.3 22.85 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.986 -0.626 . . . . 0.0 112.267 -179.801 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 8.6 Cg_exo -71.88 144.57 43.59 Favored 'Trans proline' 0 C--O 1.234 0.296 0 C-N-CA 123.121 2.548 . . . . 0.0 112.631 -179.286 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 83.65 2.03 89.97 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 121.19 -0.528 . . . . 0.0 112.846 177.83 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 26.1 p -96.82 -172.38 2.46 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' ARG . . . . . 0.42 ' HA ' ' O ' ' A' ' 61' ' ' ASP . 20.6 mtp180 -123.92 130.66 52.96 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 110.244 -0.28 . . . . 0.0 110.244 176.764 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.543 HG23 HG21 ' A' ' 60' ' ' VAL . 83.9 t -130.09 138.53 53.75 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 178.659 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 39.8 t -111.95 121.15 63.88 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-O 120.778 0.323 . . . . 0.0 110.936 -176.275 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . 0.404 ' HB2' HD21 ' A' ' 62' ' ' LEU . 44.7 tt0 -99.99 108.64 20.89 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 176.053 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.509 ' HB ' ' OG ' ' A' ' 95' ' ' SER . 46.1 t -97.21 125.49 50.26 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.058 -178.681 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 100.65 20.59 14.39 Favored Glycine 0 N--CA 1.447 -0.605 0 C-N-CA 120.483 -0.865 . . . . 0.0 111.804 -176.927 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.446 ' O ' HD13 ' A' ' 74' ' ' ILE . . . -79.09 78.62 5.54 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.19 0.519 . . . . 0.0 110.044 -179.091 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -94.01 -67.85 1.06 Allowed Glycine 0 N--CA 1.443 -0.836 0 CA-C-N 115.67 -0.696 . . . . 0.0 112.907 -178.445 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 61.3 mtt85 -113.66 -45.91 3.08 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 111.778 0.288 . . . . 0.0 111.778 -174.524 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 13.3 p90 -89.1 97.83 11.42 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.549 0.69 . . . . 0.0 111.048 -177.483 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.531 HD22 HD13 ' A' ' 64' ' ' LEU . 79.9 mt -100.0 28.61 4.72 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.533 -0.758 . . . . 0.0 110.277 -179.957 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 74.2 t80 -72.52 -44.89 61.58 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.338 -175.29 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.429 ' O ' HG13 ' A' ' 54' ' ' ILE . 40.9 t -62.05 -55.56 23.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.727 0.299 . . . . 0.0 110.649 -175.459 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . 0.415 ' CB ' HD21 ' A' ' 64' ' ' LEU . 1.6 p -54.74 -46.82 74.32 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.802 -0.636 . . . . 0.0 112.074 179.396 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.689 ' O ' ' HG2' ' A' ' 56' ' ' LYS . 33.7 t70 -68.95 -31.11 69.75 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.651 0.262 . . . . 0.0 111.127 -177.966 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 77.4 t80 -71.59 -37.11 71.02 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 120.869 0.366 . . . . 0.0 110.756 179.833 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.741 HG23 HG12 ' A' ' 30' ' ' ILE . 88.3 mt -63.73 -44.54 98.37 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-N 116.48 -0.327 . . . . 0.0 111.098 -179.559 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' ARG . . . . . 0.414 ' HA ' ' O ' ' A' ' 58' ' ' SER . 4.9 ptm180 -68.38 -15.56 63.6 Favored 'General case' 0 CA--C 1.533 0.319 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.321 -178.758 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . 0.689 ' HG2' ' O ' ' A' ' 52' ' ' ASP . 32.2 mmmt -73.77 -34.77 64.83 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.989 0.423 . . . . 0.0 110.779 177.183 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 56.7 m-70 -93.2 -47.11 7.1 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.395 -178.622 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . 0.414 ' O ' ' HA ' ' A' ' 55' ' ' ARG . 67.2 m -121.55 135.19 55.03 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.381 179.546 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 29.3 mmmt -80.08 57.78 2.78 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.707 0.765 . . . . 0.0 110.435 -179.641 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.543 HG21 HG23 ' A' ' 39' ' ' VAL . 3.6 p -85.57 146.05 7.06 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 CA-C-N 114.89 -1.05 . . . . 0.0 109.859 176.705 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . 0.42 ' O ' ' HA ' ' A' ' 38' ' ' ARG . 30.4 t70 -84.72 100.27 11.38 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 177.314 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . 0.404 HD21 ' HB2' ' A' ' 41' ' ' GLU . 2.3 tt -99.62 129.6 45.78 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.134 -176.542 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 48.5 t -106.08 122.12 59.36 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.635 -178.633 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . 0.531 HD13 HD22 ' A' ' 48' ' ' LEU . 42.8 mt -94.19 135.3 35.72 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.127 -0.488 . . . . 0.0 109.746 178.055 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 18.9 p -128.44 130.8 48.13 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.593 0.235 . . . . 0.0 111.407 -178.994 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 25.3 t0 -162.89 146.87 11.29 Favored 'General case' 0 C--N 1.333 -0.142 0 CA-C-N 116.11 -0.495 . . . . 0.0 109.842 177.889 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.659 HD11 ' H ' ' A' ' 79' ' ' ILE . 48.5 mm -73.81 104.89 2.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 N-CA-C 110.169 -0.308 . . . . 0.0 110.169 179.425 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 31.4 mtmm 49.66 78.75 0.38 Allowed Pre-proline 0 N--CA 1.466 0.345 0 CA-C-N 115.576 -0.738 . . . . 0.0 111.381 -175.214 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . 0.707 ' HD2' ' HG2' ' A' ' 76' ' ' ARG . 11.7 Cg_endo . . . . . 0 C--N 1.344 0.3 0 C-N-CA 123.294 2.662 . . . . 0.0 112.901 -178.777 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.454 ' HB ' ' CB ' ' A' ' 69' ' ' PRO . 60.0 mt . . . . . 0 N--CA 1.454 -0.25 0 N-CA-C 110.367 -0.234 . . . . 0.0 110.367 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.408 HG12 ' HB2' ' A' ' 77' ' ' ASP . 98.8 t -74.03 129.09 36.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-O 120.922 0.391 . . . . 0.0 110.329 179.821 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' ARG . . . . . 0.707 ' HG2' ' HD2' ' A' ' 69' ' ' PRO . 88.9 mtt180 -86.68 35.0 0.66 Allowed 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.185 -175.903 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . 0.408 ' HB2' HG12 ' A' ' 75' ' ' VAL . 1.0 OUTLIER -77.63 173.76 11.67 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 109.711 -0.477 . . . . 0.0 109.711 -178.182 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 19.1 m-20 -103.42 122.52 45.04 Favored 'General case' 0 C--N 1.323 -0.566 0 C-N-CA 120.931 -0.307 . . . . 0.0 110.372 -173.89 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' ILE . . . . . 0.659 ' H ' HD11 ' A' ' 67' ' ' ILE . 10.8 tt -75.56 -26.79 18.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 CA-C-O 121.091 0.472 . . . . 0.0 111.018 178.023 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 15.0 t -84.1 -9.83 58.29 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.572 0.701 . . . . 0.0 110.386 -179.584 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 50.9 m -147.62 70.1 11.41 Favored Pre-proline 0 C--N 1.323 -0.585 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 174.421 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' PRO . . . . . 0.711 ' HB2' ' HE2' ' A' ' 87' ' ' TYR . 72.0 Cg_endo -76.95 141.31 21.11 Favored 'Trans proline' 0 N--CA 1.461 -0.436 0 C-N-CA 122.559 2.173 . . . . 0.0 113.49 -169.092 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 83' ' ' ARG . . . . . 0.622 ' HG2' ' HG2' ' A' ' 85' ' ' GLU . 0.0 OUTLIER -79.02 117.31 19.96 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.487 -0.779 . . . . 0.0 109.328 174.11 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' MET . . . . . . . . . . . . . 5.4 mtp -66.08 -25.42 67.01 Favored 'General case' 0 C--N 1.324 -0.534 0 C-N-CA 120.878 -0.329 . . . . 0.0 111.243 -177.475 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.622 ' HG2' ' HG2' ' A' ' 83' ' ' ARG . 10.9 pt-20 -60.87 -26.12 67.17 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.825 0.345 . . . . 0.0 111.235 177.614 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.409 HG13 ' HB3' ' A' ' 83' ' ' ARG . 72.6 mt -74.67 -41.21 48.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.786 0.327 . . . . 0.0 110.856 178.358 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . 0.711 ' HE2' ' HB2' ' A' ' 82' ' ' PRO . 91.4 m-85 -82.09 -34.27 29.42 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.482 -178.359 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . 0.427 HH11 ' HD2' ' A' ' 88' ' ' ARG . 22.4 mtp180 -68.83 125.58 27.06 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.198 0.523 . . . . 0.0 110.398 179.296 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 101.72 3.07 52.75 Favored Glycine 0 N--CA 1.446 -0.675 0 CA-C-N 115.376 -0.829 . . . . 0.0 111.634 -176.488 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -85.63 144.05 28.08 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.084 0.468 . . . . 0.0 110.731 178.808 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -89.31 -19.62 25.07 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.594 179.215 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . 0.48 HD23 ' N ' ' A' ' 93' ' ' ILE . 5.6 tt -166.59 141.27 4.23 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.064 -0.517 . . . . 0.0 109.865 -178.038 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.595 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 58.6 mt -124.95 126.33 71.06 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 N-CA-C 109.433 -0.58 . . . . 0.0 109.433 177.285 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 18.8 p90 -134.21 156.18 48.82 Favored 'General case' 0 C--N 1.322 -0.619 0 C-N-CA 120.226 -0.59 . . . . 0.0 111.511 -178.877 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . 0.509 ' OG ' ' HB ' ' A' ' 42' ' ' VAL . 14.4 m -148.06 130.52 15.77 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.457 -0.792 . . . . 0.0 110.196 -178.571 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 96' ' ' ILE . . . . . 0.435 ' N ' HD12 ' A' ' 96' ' ' ILE . 4.0 mp -87.99 103.32 13.47 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 177.123 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 97' ' ' ARG . . . . . 1.074 ' HB3' ' HA ' ' A' ' 121' ' ' PRO . 8.9 ptm180 40.11 89.61 0.08 OUTLIER Pre-proline 0 N--CA 1.475 0.809 0 C-N-CA 124.685 1.194 . . . . 0.0 113.269 -176.279 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 89.9 Cg_endo -79.96 154.33 22.69 Favored 'Trans proline' 0 N--CA 1.459 -0.525 0 C-N-CA 122.472 2.115 . . . . 0.0 112.191 178.581 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . 0.798 ' HD2' HD11 ' A' ' 102' ' ' ILE . 51.4 Cg_exo -54.27 158.28 9.89 Favored 'Trans proline' 0 C--O 1.234 0.313 0 C-N-CA 122.8 2.334 . . . . 0.0 112.288 173.936 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -80.37 25.86 0.39 Allowed 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.147 -0.479 . . . . 0.0 112.046 -172.997 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 101' ' ' GLU . . . . . 0.666 ' HG3' HG23 ' A' ' 102' ' ' ILE . 12.2 pt-20 -124.3 -21.29 5.0 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.76 -0.2 . . . . 0.0 111.276 178.113 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.798 HD11 ' HD2' ' A' ' 99' ' ' PRO . 45.2 pt -110.38 -1.62 9.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 N-CA-C 112.031 0.382 . . . . 0.0 112.031 -174.646 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 103' ' ' HIS . . . . . 0.529 ' O ' ' HG2' ' A' ' 107' ' ' MET . 23.7 p-80 -61.68 -41.77 98.02 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.798 0.333 . . . . 0.0 110.46 -179.258 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 20.6 t -71.25 -30.21 66.04 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.16 0.505 . . . . 0.0 110.056 177.895 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.541 ' O ' HG23 ' A' ' 109' ' ' VAL . 4.6 m -68.82 -46.08 69.54 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.046 -179.626 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 92.3 mt -58.18 -40.46 81.55 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.168 179.76 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 107' ' ' MET . . . . . 0.529 ' HG2' ' O ' ' A' ' 103' ' ' HIS . 94.2 mmm -60.92 -43.85 98.0 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.43 -178.839 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 108' ' ' ARG . . . . . 0.458 ' HG2' ' O ' ' A' ' 105' ' ' SER . 13.1 ptp180 -76.9 -27.09 54.81 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.663 -0.244 . . . . 0.0 111.2 -177.786 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.541 HG23 ' O ' ' A' ' 105' ' ' SER . 73.6 t -70.9 -44.52 75.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 C-N-CA 121.158 -0.217 . . . . 0.0 110.674 177.744 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -59.46 -41.24 89.25 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 121.106 0.479 . . . . 0.0 110.323 178.466 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.467 ' HA ' ' HB1' ' A' ' 148' ' ' ALA . 16.2 t70 -65.4 -34.92 79.45 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.779 -178.565 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -72.46 -45.13 60.94 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.866 -0.606 . . . . 0.0 111.739 -178.263 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.418 HG12 ' CG ' ' A' ' 88' ' ' ARG . 31.1 m -85.88 -25.63 6.52 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-N 116.533 -0.303 . . . . 0.0 111.771 -176.102 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 84.96 59.3 1.99 Allowed Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.039 179.797 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . 0.455 ' O ' ' HB3' ' A' ' 148' ' ' ALA . . . -140.44 149.5 42.65 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 120.927 0.394 . . . . 0.0 110.791 -179.241 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 116' ' ' ARG . . . . . 0.529 ' HD3' ' OE1' ' A' ' 145' ' ' GLU . 14.9 ttm180 -70.98 129.75 39.8 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.893 -0.594 . . . . 0.0 109.999 177.318 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . 0.595 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 58.1 tp -100.16 118.66 36.97 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 116.049 -0.523 . . . . 0.0 109.709 178.645 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 60.0 mt -112.66 117.85 56.36 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-O 120.914 0.388 . . . . 0.0 110.569 179.702 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 119' ' ' ILE . . . . . 0.436 ' HA ' ' O ' ' A' ' 95' ' ' SER . 73.3 mt -120.35 120.23 62.2 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.672 -179.646 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 62.2 tttm -115.8 100.9 54.01 Favored Pre-proline 0 C--N 1.32 -0.674 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.208 175.533 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 121' ' ' PRO . . . . . 1.074 ' HA ' ' HB3' ' A' ' 97' ' ' ARG . 86.8 Cg_endo -78.96 -165.46 0.34 Allowed 'Trans proline' 0 N--CA 1.459 -0.503 0 C-N-CA 122.59 2.193 . . . . 0.0 111.792 175.696 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 122' ' ' LEU . . . . . 0.598 ' HB2' ' HB2' ' A' ' 125' ' ' GLU . 31.3 mt -66.54 152.72 44.68 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.872 175.924 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 19.9 m -64.71 106.0 1.1 Allowed 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.02 -0.536 . . . . 0.0 109.569 175.081 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 92.06 30.72 9.86 Favored Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 120.935 -0.65 . . . . 0.0 111.653 -175.118 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . 0.598 ' HB2' ' HB2' ' A' ' 122' ' ' LEU . 43.6 tt0 -126.6 145.19 50.64 Favored 'General case' 0 N--CA 1.448 -0.564 0 CA-C-O 121.032 0.444 . . . . 0.0 110.053 -179.408 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -101.15 167.08 10.45 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.471 -178.566 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 6.4 mt . . . . . 0 C--N 1.328 -0.341 0 N-CA-C 110.02 -0.363 . . . . 0.0 110.02 -178.852 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 46.8 mmtm . . . . . 0 N--CA 1.458 -0.068 0 CA-C-O 120.845 0.355 . . . . 0.0 110.899 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 133' ' ' MET . . . . . 0.491 ' HG2' ' HB2' ' A' ' 146' ' ' TYR . 85.7 mtp -133.62 170.56 15.35 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.411 -177.179 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -118.38 145.37 45.21 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.689 179.862 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . 0.488 HD11 ' HD2' ' A' ' 142' ' ' TYR . 57.7 tp -80.74 134.24 35.79 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.121 178.26 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -129.54 138.59 53.88 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-O 121.193 0.521 . . . . 0.0 111.577 -179.958 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 14.3 m120 -110.23 120.17 41.6 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.005 177.323 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 59.5 t80 -148.64 123.4 9.9 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 110.201 -0.296 . . . . 0.0 110.201 177.894 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 66.79 42.72 92.89 Favored Glycine 0 N--CA 1.448 -0.563 0 C-N-CA 121.029 -0.605 . . . . 0.0 112.801 177.461 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 55.5 ttt180 73.75 -19.87 0.33 Allowed 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 123.325 0.65 . . . . 0.0 112.361 175.455 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 5.2 t -97.63 163.21 12.93 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 178.58 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 142' ' ' TYR . . . . . 0.488 ' HD2' HD11 ' A' ' 135' ' ' LEU . 37.6 p90 -131.98 148.93 52.54 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 121.237 0.541 . . . . 0.0 110.886 -179.664 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 8.7 p90 -155.23 177.69 11.06 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 115.26 -0.882 . . . . 0.0 109.4 -179.104 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -113.13 134.34 54.6 Favored 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 110.068 -0.345 . . . . 0.0 110.068 179.419 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 145' ' ' GLU . . . . . 0.529 ' OE1' ' HD3' ' A' ' 116' ' ' ARG . 20.1 pt-20 -126.8 158.47 36.51 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 121.265 0.555 . . . . 0.0 110.385 177.237 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . 0.491 ' HB2' ' HG2' ' A' ' 133' ' ' MET . 35.6 t80 -134.76 126.26 28.58 Favored 'General case' 0 C--N 1.316 -0.89 0 CA-C-N 115.465 -0.789 . . . . 0.0 109.265 175.241 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 147' ' ' ILE . . . . . 0.408 ' N ' HD12 ' A' ' 147' ' ' ILE . 3.1 mp -92.24 100.23 10.92 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 CA-C-O 121.19 0.519 . . . . 0.0 109.739 -178.661 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . 0.467 ' HB1' ' HA ' ' A' ' 111' ' ' ASP . . . -91.73 107.4 19.18 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.61 -0.723 . . . . 0.0 109.064 174.499 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 . . . . . 0 C--O 1.236 0.368 0 CA-C-O 121.199 0.523 . . . . 0.0 110.28 -177.884 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 80.6 m95 . . . . . 0 N--CA 1.453 -0.297 0 CA-C-O 121.022 0.439 . . . . 0.0 110.45 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.419 ' O ' HG23 ' A' ' 27' ' ' VAL . 2.7 t-20 -72.57 -45.23 60.2 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.118 178.752 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -59.77 -42.07 92.49 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.234 178.024 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 62.2 tp -55.76 -49.01 74.27 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.297 176.697 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . 0.508 ' HB2' HG13 ' A' ' 50' ' ' VAL . . . -58.91 -52.25 66.55 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.891 179.081 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.422 ' HA ' HD12 ' A' ' 30' ' ' ILE . 91.6 t -55.03 -43.32 69.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.321 -0.4 . . . . 0.0 111.188 -179.933 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 67.5 t80 -58.98 -47.32 85.6 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.957 0.408 . . . . 0.0 110.467 179.094 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.513 HG23 HD13 ' A' ' 92' ' ' LEU . 91.2 mt -61.89 -42.95 96.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.589 179.017 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.677 HG12 HG23 ' A' ' 54' ' ' ILE . 95.8 mt -58.23 -39.82 75.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 115.696 -0.683 . . . . 0.0 111.348 179.818 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 44.3 mtp-105 -74.55 -24.0 58.88 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.153 -178.558 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 85.0 m -88.99 -19.29 25.89 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.702 -177.926 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 13.9 p -106.6 -77.6 0.59 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.624 -177.801 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 95.36 163.33 34.43 Favored Glycine 0 N--CA 1.446 -0.635 0 C-N-CA 121.082 -0.58 . . . . 0.0 112.203 -178.467 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -66.09 143.08 70.48 Favored 'Trans proline' 0 C--O 1.233 0.26 0 C-N-CA 122.794 2.329 . . . . 0.0 112.64 -179.79 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 109.57 -32.62 6.64 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.894 177.091 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 11.3 t -98.02 -170.97 2.06 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 110.005 -0.368 . . . . 0.0 110.005 -176.467 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' ARG . . . . . 0.834 ' HG2' ' HB3' ' A' ' 61' ' ' ASP . 45.0 mtt180 -124.28 136.66 54.29 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.004 0.431 . . . . 0.0 111.673 -176.533 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.441 HG23 HG21 ' A' ' 60' ' ' VAL . 63.4 t -121.44 125.34 73.49 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-N 115.528 -0.76 . . . . 0.0 109.318 175.852 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 47.2 t -103.72 128.27 57.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-O 120.811 0.339 . . . . 0.0 111.406 -175.193 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . 0.493 ' HB3' HD23 ' A' ' 64' ' ' LEU . 34.3 tt0 -105.13 118.54 36.8 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 173.972 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.502 ' HA ' ' OG1' ' A' ' 65' ' ' THR . 58.5 t -95.54 121.05 45.73 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.362 -179.864 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 96.61 43.24 3.2 Favored Glycine 0 N--CA 1.446 -0.671 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.103 -179.817 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -77.01 82.77 3.53 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.351 0.596 . . . . 0.0 110.519 -178.292 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -69.64 -98.37 0.05 OUTLIER Glycine 0 N--CA 1.447 -0.593 0 CA-C-N 115.01 -0.995 . . . . 0.0 112.903 179.889 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . 0.534 ' O ' ' HD2' ' A' ' 46' ' ' ARG . 8.2 tmm_? -136.82 -7.19 1.88 Allowed 'General case' 0 C--N 1.327 -0.4 0 C-N-CA 120.904 -0.318 . . . . 0.0 111.27 -177.199 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.411 ' CZ ' ' HB ' ' A' ' 96' ' ' ILE . 9.0 p90 -61.98 -63.01 1.39 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.808 0.337 . . . . 0.0 111.011 179.688 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.417 HD22 HD13 ' A' ' 64' ' ' LEU . 59.7 mt 55.85 22.23 5.45 Favored 'General case' 0 C--N 1.323 -0.552 0 C-N-CA 123.684 0.794 . . . . 0.0 112.59 173.81 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 86.4 t80 -74.97 -56.85 4.33 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.781 0.324 . . . . 0.0 110.984 -178.075 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.508 HG13 ' HB2' ' A' ' 26' ' ' ALA . 52.5 t -63.49 -52.78 53.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.074 -175.816 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . 0.556 ' CB ' HD21 ' A' ' 64' ' ' LEU . 0.2 OUTLIER -59.47 -46.88 87.52 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.695 -0.684 . . . . 0.0 112.491 -176.587 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 35.6 t70 -68.07 -27.2 66.29 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.729 0.3 . . . . 0.0 110.948 -177.689 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 89.3 t80 -73.81 -45.62 50.29 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 120.699 0.285 . . . . 0.0 110.798 176.916 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.677 HG23 HG12 ' A' ' 30' ' ' ILE . 78.3 mt -59.92 -43.24 91.78 Favored 'Isoleucine or valine' 0 C--O 1.234 0.253 0 CA-C-N 116.403 -0.362 . . . . 0.0 111.307 -178.079 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 2.0 ptm180 -67.83 -16.73 64.24 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.479 -178.84 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 67.2 mttm -88.05 -42.85 12.12 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.116 0.484 . . . . 0.0 110.454 177.002 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.9 OUTLIER -65.53 -41.68 92.83 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.633 -0.712 . . . . 0.0 110.932 -177.559 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 74.1 m -132.41 153.51 50.75 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.348 -179.507 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -76.71 38.84 0.2 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.908 177.846 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.441 HG21 HG23 ' A' ' 39' ' ' VAL . 7.2 p -84.03 138.76 18.66 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 CA-C-N 116.047 -0.524 . . . . 0.0 109.624 179.13 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . 0.834 ' HB3' ' HG2' ' A' ' 38' ' ' ARG . 13.9 t70 -84.86 93.76 8.59 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 -178.232 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 4.2 tt -90.38 127.8 36.29 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.005 -175.424 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 59.4 t -106.36 121.91 59.5 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 115.773 -0.649 . . . . 0.0 111.016 -176.674 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . 0.556 HD21 ' CB ' ' A' ' 51' ' ' SER . 90.5 mt -98.93 141.33 31.83 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.05 -0.523 . . . . 0.0 109.816 176.65 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.502 ' OG1' ' HA ' ' A' ' 42' ' ' VAL . 28.8 p -121.28 127.18 51.11 Favored 'General case' 0 C--O 1.238 0.487 0 CA-C-O 120.608 0.242 . . . . 0.0 111.627 -178.738 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 32.0 t70 -166.27 139.01 3.93 Favored 'General case' 0 N--CA 1.463 0.218 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.364 178.117 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 58.6 mt -75.97 112.04 13.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 N-CA-C 110.249 -0.278 . . . . 0.0 110.249 -179.511 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 47.1 mtmt 56.47 75.04 0.61 Allowed Pre-proline 0 C--N 1.33 -0.249 0 O-C-N 123.598 0.561 . . . . 0.0 109.839 -178.179 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . 0.574 ' CB ' ' HB ' ' A' ' 74' ' ' ILE . 8.1 Cg_exo . . . . . 0 N--CA 1.465 -0.178 0 C-N-CA 123.249 2.633 . . . . 0.0 112.815 -171.195 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.574 ' HB ' ' CB ' ' A' ' 69' ' ' PRO . 67.7 mt . . . . . 0 N--CA 1.45 -0.461 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.541 HG12 ' H ' ' A' ' 77' ' ' ASP . 91.1 t -73.91 122.56 27.3 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 120.865 0.364 . . . . 0.0 110.24 178.858 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -78.34 16.55 0.77 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.696 -0.684 . . . . 0.0 112.645 -175.232 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . 0.541 ' H ' HG12 ' A' ' 75' ' ' VAL . 2.6 m-20 -76.14 155.44 34.63 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 121.496 0.665 . . . . 0.0 111.887 -175.478 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 16.9 t0 -78.88 143.78 35.57 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 114.88 -1.054 . . . . 0.0 111.276 -174.237 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 7.6 tp -96.59 -26.59 4.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.375 -177.206 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 5.0 t -78.22 -25.66 47.09 Favored 'General case' 0 C--O 1.234 0.247 0 N-CA-C 109.376 -0.602 . . . . 0.0 109.376 179.759 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 1.2 m -124.38 76.03 61.74 Favored Pre-proline 0 C--N 1.329 -0.3 0 N-CA-C 108.45 -0.944 . . . . 0.0 108.45 169.027 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -79.07 131.55 9.96 Favored 'Trans proline' 0 N--CA 1.461 -0.405 0 C-N-CA 122.671 2.247 . . . . 0.0 113.453 -170.887 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 83' ' ' ARG . . . . . 0.707 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 64.5 mtt180 -70.57 109.5 4.89 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.651 -0.704 . . . . 0.0 110.016 174.303 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' MET . . . . . 0.718 ' HA ' ' HD2' ' A' ' 87' ' ' TYR . 31.5 mtp -73.31 -10.23 59.53 Favored 'General case' 0 C--N 1.323 -0.572 0 C-N-CA 120.816 -0.354 . . . . 0.0 110.58 178.66 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.707 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 10.5 pt-20 -66.94 -21.98 65.96 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.542 173.908 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 71.9 mt -81.8 -34.59 12.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-O 121.351 0.596 . . . . 0.0 110.042 178.145 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . 0.718 ' HD2' ' HA ' ' A' ' 84' ' ' MET . 85.3 m-85 -82.39 -33.9 28.54 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.585 -0.734 . . . . 0.0 110.687 -178.487 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 50.6 mtp180 -64.07 122.46 16.61 Favored 'General case' 0 CA--C 1.516 -0.345 0 CA-C-O 121.227 0.536 . . . . 0.0 111.01 177.626 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 104.06 -12.28 52.37 Favored Glycine 0 N--CA 1.444 -0.767 0 CA-C-N 115.299 -0.864 . . . . 0.0 111.921 -178.976 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -78.79 142.5 36.91 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 110.015 -0.365 . . . . 0.0 110.015 177.767 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -90.71 -19.9 23.04 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-O 121.127 0.489 . . . . 0.0 110.453 -179.415 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . 0.602 ' HG ' ' HB3' ' A' ' 116' ' ' ARG . 3.4 tt -153.92 139.78 18.14 Favored 'General case' 0 N--CA 1.447 -0.596 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.929 -176.943 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.574 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 70.0 mt -131.33 124.64 55.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 177.791 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 13.9 p90 -134.72 164.9 26.48 Favored 'General case' 0 C--N 1.321 -0.661 0 C-N-CA 120.717 -0.393 . . . . 0.0 111.08 -178.809 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 6.9 p -140.58 131.14 25.46 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.523 -178.884 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 96' ' ' ILE . . . . . 0.411 ' HB ' ' CZ ' ' A' ' 47' ' ' PHE . 38.5 mm -92.03 98.31 8.23 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.098 179.262 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 63.0 mtm180 59.3 76.46 0.44 Allowed Pre-proline 0 C--N 1.332 -0.182 0 CA-C-N 115.401 -0.818 . . . . 0.0 111.54 -179.242 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 98' ' ' PRO . . . . . 0.475 ' HA ' ' HD3' ' A' ' 99' ' ' PRO . 93.4 Cg_endo -87.97 152.61 7.13 Favored 'Trans proline' 0 N--CA 1.455 -0.747 0 C-N-CA 122.593 2.195 . . . . 0.0 112.1 177.294 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . 0.657 ' HB2' ' HG2' ' A' ' 101' ' ' GLU . 6.3 Cg_exo -73.07 148.71 45.24 Favored 'Trans proline' 0 N--CA 1.461 -0.405 0 C-N-CA 122.524 2.149 . . . . 0.0 111.461 176.019 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -76.45 39.75 0.21 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.173 0.511 . . . . 0.0 111.735 -177.475 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 101' ' ' GLU . . . . . 0.657 ' HG2' ' HB2' ' A' ' 99' ' ' PRO . 11.6 pt-20 -121.51 -28.74 4.54 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.205 177.615 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.615 HG23 ' HG3' ' A' ' 101' ' ' GLU . 34.8 pt -110.67 5.28 8.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.359 -175.976 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 103' ' ' HIS . . . . . . . . . . . . . 9.6 p-80 -60.99 -48.17 83.07 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 115.62 -0.718 . . . . 0.0 111.392 -177.043 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 47.1 m -70.97 -23.07 62.14 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.177 0.513 . . . . 0.0 110.658 178.689 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.567 ' O ' ' HG2' ' A' ' 108' ' ' ARG . 8.7 m -73.96 -37.92 64.37 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.242 178.542 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.419 ' HG ' ' O ' ' A' ' 102' ' ' ILE . 94.0 mt -63.61 -41.08 98.34 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.722 178.014 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 107' ' ' MET . . . . . . . . . . . . . 97.7 mmm -57.33 -47.02 82.66 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.759 -0.655 . . . . 0.0 111.316 -179.281 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 108' ' ' ARG . . . . . 0.567 ' HG2' ' O ' ' A' ' 105' ' ' SER . 6.6 ptp180 -67.6 -31.48 71.55 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.505 -0.316 . . . . 0.0 111.178 -176.941 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.464 HG23 ' O ' ' A' ' 105' ' ' SER . 92.1 t -74.29 -46.0 45.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.486 -0.325 . . . . 0.0 110.659 -178.862 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -58.3 -49.99 75.2 Favored 'General case' 0 CA--C 1.516 -0.347 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 176.946 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.418 ' HA ' ' HB1' ' A' ' 148' ' ' ALA . 15.3 t70 -55.16 -40.83 71.08 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.093 -0.958 . . . . 0.0 111.028 179.565 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -68.5 -44.94 73.62 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.918 -0.583 . . . . 0.0 112.196 -176.995 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 31.1 m -84.83 -27.63 6.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 C-N-CA 120.766 -0.374 . . . . 0.0 111.759 -175.29 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 98.04 22.53 15.15 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.631 -0.795 . . . . 0.0 112.654 177.578 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -99.09 163.46 12.56 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 121.505 0.669 . . . . 0.0 111.844 -176.483 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 116' ' ' ARG . . . . . 0.602 ' HB3' ' HG ' ' A' ' 92' ' ' LEU . 23.2 ttt180 -85.08 116.23 23.34 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 115.181 -0.918 . . . . 0.0 109.591 178.181 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . 0.574 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 52.2 tp -90.13 128.01 36.23 Favored 'General case' 0 C--N 1.32 -0.693 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 -178.261 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 72.2 mt -129.02 119.72 50.0 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 CA-C-O 121.178 0.513 . . . . 0.0 110.891 179.683 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 64.6 mt -119.75 125.1 73.98 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.437 179.88 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 8.9 tmtm? -108.48 98.23 26.94 Favored Pre-proline 0 C--N 1.325 -0.474 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 175.22 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -77.52 -174.26 2.14 Favored 'Trans proline' 0 C--O 1.236 0.386 0 C-N-CA 122.796 2.33 . . . . 0.0 112.944 -179.507 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 122' ' ' LEU . . . . . 0.429 ' HB2' ' HB3' ' A' ' 125' ' ' GLU . 91.7 mt -75.59 176.04 8.0 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.753 -0.658 . . . . 0.0 111.463 -175.967 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 4.1 p -74.86 102.83 4.87 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.725 -0.671 . . . . 0.0 111.002 179.317 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 82.11 30.23 35.21 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.156 179.547 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . 0.429 ' HB3' ' HB2' ' A' ' 122' ' ' LEU . 8.8 tp10 -133.26 136.78 45.75 Favored 'General case' 0 N--CA 1.448 -0.574 0 N-CA-C 109.143 -0.688 . . . . 0.0 109.143 178.049 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -107.25 166.99 10.23 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.043 -173.481 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 45.2 mt . . . . . 0 C--N 1.327 -0.378 0 CA-C-N 115.958 -0.564 . . . . 0.0 109.998 179.642 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 3.9 mppt? . . . . . 0 CA--C 1.515 -0.399 0 CA-C-O 121.279 0.562 . . . . 0.0 111.84 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 133' ' ' MET . . . . . . . . . . . . . 85.0 mtp -137.77 160.63 38.73 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 115.056 -0.975 . . . . 0.0 108.971 174.405 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . 0.691 ' HG3' ' HG2' ' A' ' 145' ' ' GLU . 1.4 ptmt -111.93 133.07 54.36 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-O 121.039 0.447 . . . . 0.0 110.866 -178.123 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . 0.629 HD11 ' HD2' ' A' ' 142' ' ' TYR . 51.9 tp -81.67 121.4 26.32 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.067 179.244 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 136' ' ' VAL . . . . . 0.413 ' C ' HD22 ' A' ' 137' ' ' ASN . 0.0 OUTLIER -116.21 141.95 31.7 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.65 -178.014 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 137' ' ' ASN . . . . . 0.413 HD22 ' C ' ' A' ' 136' ' ' VAL . 0.9 OUTLIER -115.33 111.35 20.74 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.737 -0.665 . . . . 0.0 109.351 176.226 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . 0.614 ' O ' HG22 ' A' ' 141' ' ' THR . 57.0 t80 -124.85 104.68 8.74 Favored 'General case' 0 C--N 1.319 -0.734 0 N-CA-C 109.49 -0.559 . . . . 0.0 109.49 -178.761 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . 0.4 ' O ' ' HB2' ' A' ' 140' ' ' ARG . . . 68.27 40.96 87.24 Favored Glycine 0 CA--C 1.519 0.299 0 C-N-CA 120.55 -0.833 . . . . 0.0 111.609 -175.575 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 140' ' ' ARG . . . . . 0.4 ' HB2' ' O ' ' A' ' 139' ' ' GLY . 0.0 OUTLIER 75.83 -25.89 0.2 Allowed 'General case' 0 N--CA 1.472 0.63 0 C-N-CA 123.681 0.792 . . . . 0.0 113.073 178.464 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 141' ' ' THR . . . . . 0.614 HG22 ' O ' ' A' ' 138' ' ' TYR . 13.9 t -75.26 142.68 43.31 Favored 'General case' 0 C--O 1.236 0.38 0 N-CA-C 109.338 -0.616 . . . . 0.0 109.338 177.262 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 142' ' ' TYR . . . . . 0.629 ' HD2' HD11 ' A' ' 135' ' ' LEU . 26.4 p90 -121.41 141.55 50.87 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 121.394 0.616 . . . . 0.0 111.229 -176.452 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 25.1 p90 -154.32 170.21 21.86 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 114.975 -1.011 . . . . 0.0 109.515 -179.968 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 75.5 m-85 -107.5 126.4 52.47 Favored 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 110.227 -0.286 . . . . 0.0 110.227 179.474 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 145' ' ' GLU . . . . . 0.691 ' HG2' ' HG3' ' A' ' 134' ' ' LYS . 10.0 pt-20 -115.41 164.12 14.74 Favored 'General case' 0 C--N 1.32 -0.677 0 N-CA-C 109.685 -0.487 . . . . 0.0 109.685 177.594 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . 0.563 ' HB3' ' HB3' ' A' ' 117' ' ' LEU . 50.8 t80 -147.03 127.74 14.28 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.352 177.382 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 147' ' ' ILE . . . . . 0.42 ' N ' HD12 ' A' ' 147' ' ' ILE . 3.1 mp -96.73 104.92 16.43 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.706 0 CA-C-N 115.779 -0.646 . . . . 0.0 109.366 179.506 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . 0.418 ' HB1' ' HA ' ' A' ' 111' ' ' ASP . . . -70.25 117.44 11.81 Favored 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 175.974 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 30.3 mt-10 . . . . . 0 C--N 1.32 -0.692 0 CA-C-O 121.702 0.763 . . . . 0.0 111.795 -176.743 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' TRP . . . . . 0.572 ' HB3' HG22 ' A' ' 50' ' ' VAL . 98.2 m95 . . . . . 0 N--CA 1.454 -0.229 0 CA-C-O 120.836 0.35 . . . . 0.0 110.675 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.404 ' O ' HG23 ' A' ' 27' ' ' VAL . 13.9 m120 -66.01 -41.0 91.58 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.987 -179.638 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 26.2 m-20 -59.17 -46.78 87.49 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.049 178.905 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 66.6 tp -59.6 -47.86 83.94 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.402 -0.817 . . . . 0.0 110.672 178.721 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . 0.411 ' O ' HG13 ' A' ' 30' ' ' ILE . . . -54.71 -51.98 63.87 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.474 -179.399 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.463 ' HA ' HD12 ' A' ' 30' ' ' ILE . 88.4 t -56.02 -43.11 74.29 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-O 120.9 0.381 . . . . 0.0 111.136 -179.717 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 83.5 t80 -59.17 -45.56 90.69 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.576 179.222 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.443 HD13 ' CD1' ' A' ' 94' ' ' TYR . 79.8 mt -65.36 -42.59 93.99 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.626 179.192 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.638 HG12 HG23 ' A' ' 54' ' ' ILE . 96.2 mt -56.62 -45.38 82.46 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-N 115.593 -0.73 . . . . 0.0 111.001 178.654 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 83.7 mtp180 -64.98 -28.27 69.4 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.629 -178.106 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 44.2 t -86.93 -24.53 24.75 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.669 0.271 . . . . 0.0 111.298 -177.316 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 11.3 p -98.48 -77.11 0.52 Allowed 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 120.745 0.307 . . . . 0.0 111.421 -176.774 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 90.57 172.22 44.1 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.943 -0.646 . . . . 0.0 112.307 -178.493 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 63.0 Cg_endo -74.29 153.68 45.71 Favored 'Trans proline' 0 C--O 1.235 0.33 0 C-N-CA 122.571 2.18 . . . . 0.0 112.121 179.391 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 82.35 30.05 34.9 Favored Glycine 0 CA--C 1.518 0.238 0 C-N-CA 120.675 -0.774 . . . . 0.0 113.073 177.772 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 14.2 t -150.07 -176.53 5.49 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 176.199 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' ARG . . . . . 0.544 ' HB2' ' HA ' ' A' ' 90' ' ' ALA . 17.4 mtp180 -117.34 135.56 53.77 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 120.856 0.36 . . . . 0.0 111.389 -176.697 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.442 HG12 ' OE1' ' A' ' 41' ' ' GLU . 16.7 t -123.98 125.03 70.28 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 172.843 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 47.1 t -109.71 117.59 54.94 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 121.191 0.52 . . . . 0.0 110.59 -177.887 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . 0.535 ' HB2' HD23 ' A' ' 64' ' ' LEU . 0.1 OUTLIER -90.98 120.32 31.88 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.309 -0.86 . . . . 0.0 110.29 -175.927 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.641 HG11 HD21 ' A' ' 106' ' ' LEU . 59.4 t -94.33 110.26 23.38 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.701 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 175.992 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 98.91 97.78 2.1 Favored Glycine 0 N--CA 1.446 -0.696 0 N-CA-C 110.988 -0.845 . . . . 0.0 110.988 -175.353 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -111.53 -53.24 2.72 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.652 0.263 . . . . 0.0 110.913 -176.256 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 48.53 -121.14 7.35 Favored Glycine 0 N--CA 1.449 -0.451 0 CA-C-N 115.788 -0.642 . . . . 0.0 112.311 -176.523 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 94.7 mtt180 -118.1 3.23 12.07 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 120.903 0.382 . . . . 0.0 110.256 175.77 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 12.4 p90 -98.05 63.34 1.6 Allowed 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.621 0.724 . . . . 0.0 111.143 -175.891 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 55.2 mt -85.33 22.74 1.44 Allowed 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.694 -0.685 . . . . 0.0 110.869 -178.713 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 80.6 t80 -63.33 -41.43 98.89 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.332 -176.512 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.572 HG22 ' HB3' ' A' ' 22' ' ' TRP . 42.6 t -75.32 -50.48 24.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.659 -178.957 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 3.0 p -62.35 -45.78 91.65 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.556 -0.747 . . . . 0.0 112.306 -174.225 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.534 ' O ' ' HG2' ' A' ' 56' ' ' LYS . 35.5 t70 -70.07 -35.67 74.4 Favored 'General case' 0 C--N 1.33 -0.275 0 C-N-CA 120.655 -0.418 . . . . 0.0 110.646 -177.011 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 88.6 t80 -58.72 -40.48 83.88 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.944 0.402 . . . . 0.0 110.299 178.079 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.638 HG23 HG12 ' A' ' 30' ' ' ILE . 79.6 mt -65.62 -49.23 79.1 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.338 -179.921 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' ARG . . . . . 0.453 ' HG2' ' O ' ' A' ' 52' ' ' ASP . 5.7 ptm180 -69.29 -19.98 63.9 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-N 116.476 -0.329 . . . . 0.0 111.598 -176.55 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . 0.534 ' HG2' ' O ' ' A' ' 52' ' ' ASP . 4.6 mmmp? -82.09 -35.61 28.44 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.713 0.292 . . . . 0.0 111.192 177.697 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 14.4 t60 -84.55 -41.24 16.67 Favored 'General case' 0 N--CA 1.446 -0.674 0 CA-C-O 121.037 0.446 . . . . 0.0 109.966 -177.595 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 74.6 m -122.9 133.44 54.4 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.355 176.519 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -78.17 63.94 3.22 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 121.862 0.839 . . . . 0.0 110.086 179.47 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.411 HG21 HG23 ' A' ' 39' ' ' VAL . 7.1 p -94.85 149.57 4.42 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.883 0 CA-C-N 114.489 -1.232 . . . . 0.0 109.873 175.913 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 52.3 t0 -74.77 96.05 3.0 Favored 'General case' 0 C--O 1.234 0.268 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 178.093 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . 0.488 HD21 ' OE2' ' A' ' 41' ' ' GLU . 1.1 tm? -93.14 126.01 38.03 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 115.233 -0.894 . . . . 0.0 110.262 -173.379 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 41.7 t -125.85 119.61 55.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.043 -177.13 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . 0.535 HD23 ' HB2' ' A' ' 41' ' ' GLU . 12.7 mt -96.48 148.99 22.24 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 116.175 -0.466 . . . . 0.0 109.97 178.601 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.525 HG22 ' HB ' ' A' ' 75' ' ' VAL . 15.3 p -134.48 127.8 32.16 Favored 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 110.566 -0.161 . . . . 0.0 110.566 176.827 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 3.4 t70 -163.4 175.61 10.63 Favored 'General case' 0 N--CA 1.464 0.236 0 N-CA-C 110.062 -0.347 . . . . 0.0 110.062 -178.619 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 48.9 mm -88.5 107.84 18.12 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 116.652 -0.249 . . . . 0.0 110.398 -178.62 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 55.0 mtmt 60.11 90.0 0.1 OUTLIER Pre-proline 0 N--CA 1.466 0.329 0 O-C-N 123.674 0.608 . . . . 0.0 111.118 -177.987 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . 0.992 ' HB3' ' HB ' ' A' ' 74' ' ' ILE . 32.9 Cg_endo . . . . . 0 C--O 1.233 0.268 0 C-N-CA 123.127 2.551 . . . . 0.0 113.177 -177.462 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.992 ' HB ' ' HB3' ' A' ' 69' ' ' PRO . 40.3 mt . . . . . 0 N--CA 1.449 -0.478 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.617 HG11 HD13 ' A' ' 86' ' ' ILE . 55.8 t -78.12 131.17 35.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 176.959 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' ARG . . . . . 0.423 ' HA ' ' HD3' ' A' ' 69' ' ' PRO . 36.2 ptt180 -82.88 29.49 0.46 Allowed 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.762 -0.654 . . . . 0.0 111.939 -175.902 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 31.9 t0 -84.02 160.42 21.0 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 110.024 -0.362 . . . . 0.0 110.024 -178.944 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -79.61 104.02 9.92 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-O 120.849 0.357 . . . . 0.0 110.268 -177.646 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' ILE . . . . . 0.549 HD11 ' CG1' ' A' ' 42' ' ' VAL . 12.8 tt -57.67 -23.33 19.98 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.501 0 CA-C-N 115.692 -0.685 . . . . 0.0 112.478 -176.379 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 5.1 t -87.9 -6.56 58.01 Favored 'General case' 0 CA--C 1.539 0.534 0 CA-C-O 121.141 0.496 . . . . 0.0 110.869 -178.1 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 32.9 t -154.63 60.09 2.64 Favored Pre-proline 0 C--N 1.328 -0.336 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 178.177 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' PRO . . . . . 0.794 ' HB2' ' HE2' ' A' ' 87' ' ' TYR . 84.3 Cg_endo -79.24 155.34 25.4 Favored 'Trans proline' 0 N--CA 1.461 -0.405 0 C-N-CA 122.676 2.251 . . . . 0.0 113.784 -166.01 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 83' ' ' ARG . . . . . 0.858 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 94.1 mtt180 -76.28 132.99 40.17 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.11 -0.95 . . . . 0.0 110.995 177.929 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' MET . . . . . . . . . . . . . 87.5 mmm -70.77 -22.42 62.39 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.119 176.812 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.858 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 10.3 pt-20 -66.0 -13.93 60.74 Favored 'General case' 0 CA--C 1.532 0.282 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.823 179.865 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.617 HD13 HG11 ' A' ' 75' ' ' VAL . 66.7 mt -93.25 -40.02 11.51 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-O 121.06 0.457 . . . . 0.0 110.846 -179.346 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . 0.794 ' HE2' ' HB2' ' A' ' 82' ' ' PRO . 99.0 m-85 -80.04 -28.76 39.25 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.322 -176.872 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 30.5 mtt-85 -61.7 120.75 11.24 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 121.045 0.45 . . . . 0.0 111.222 179.598 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 109.39 -2.44 31.0 Favored Glycine 0 N--CA 1.446 -0.637 0 CA-C-N 115.607 -0.724 . . . . 0.0 111.872 -177.896 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . 0.544 ' HA ' ' HB2' ' A' ' 38' ' ' ARG . . . -90.5 143.16 27.02 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.738 0.304 . . . . 0.0 110.594 178.162 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -88.52 -28.02 21.06 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.624 -179.505 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . 0.529 ' HG ' ' HB3' ' A' ' 116' ' ' ARG . 6.8 tt -149.5 143.14 25.45 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.052 -177.019 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.578 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 68.0 mt -133.36 119.42 35.02 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 N-CA-C 109.432 -0.581 . . . . 0.0 109.432 178.36 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 94' ' ' TYR . . . . . 0.443 ' CD1' HD13 ' A' ' 29' ' ' ILE . 47.7 p90 -124.58 158.59 32.65 Favored 'General case' 0 C--N 1.321 -0.664 0 C-N-CA 120.219 -0.593 . . . . 0.0 110.823 177.976 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 14.2 m -126.62 125.98 42.83 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.795 -0.638 . . . . 0.0 110.715 -176.847 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 54.2 mt -94.52 97.13 6.55 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.089 -179.672 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 97' ' ' ARG . . . . . 0.434 HH11 ' HD3' ' A' ' 97' ' ' ARG . 7.7 ttm180 59.91 73.46 0.65 Allowed Pre-proline 0 CA--C 1.533 0.295 0 CA-C-N 115.494 -0.776 . . . . 0.0 110.87 -179.028 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_endo -85.64 137.71 5.87 Favored 'Trans proline' 0 N--CA 1.458 -0.57 0 C-N-CA 122.529 2.153 . . . . 0.0 112.775 -179.302 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 32.8 Cg_endo -67.36 163.05 36.06 Favored 'Trans proline' 0 C--O 1.234 0.307 0 C-N-CA 122.685 2.256 . . . . 0.0 112.182 175.441 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -85.61 36.21 0.64 Allowed 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.959 -177.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 101' ' ' GLU . . . . . 0.463 ' HG3' HG23 ' A' ' 102' ' ' ILE . 11.7 pt-20 -117.63 -10.96 10.48 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 121.156 0.503 . . . . 0.0 110.47 175.482 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.581 ' O ' ' HG ' ' A' ' 106' ' ' LEU . 20.8 pt -129.49 9.11 2.48 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.96 -178.184 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 103' ' ' HIS . . . . . . . . . . . . . 8.8 p-80 -55.28 -56.39 20.62 Favored 'General case' 0 C--N 1.316 -0.851 0 CA-C-N 115.505 -0.771 . . . . 0.0 112.31 -174.969 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 31.5 t -76.23 -26.16 55.77 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 121.112 0.482 . . . . 0.0 109.999 179.128 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.556 ' O ' HG23 ' A' ' 109' ' ' VAL . 6.5 m -66.21 -42.73 88.33 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.204 -178.433 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.641 HD21 HG11 ' A' ' 42' ' ' VAL . 82.2 mt -61.32 -41.49 97.1 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.838 -0.619 . . . . 0.0 111.259 179.205 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 107' ' ' MET . . . . . 0.425 ' HA ' HD22 ' A' ' 117' ' ' LEU . 45.5 mtp -65.29 -42.01 93.55 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.229 -178.926 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 16.7 ptm180 -73.32 -22.94 60.21 Favored 'General case' 0 C--N 1.332 -0.183 0 C-N-CA 120.976 -0.29 . . . . 0.0 111.462 -178.907 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.556 HG23 ' O ' ' A' ' 105' ' ' SER . 73.2 t -76.15 -46.46 33.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 N-CA-C 110.235 -0.283 . . . . 0.0 110.235 175.573 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -57.18 -50.16 73.7 Favored 'General case' 0 CA--C 1.517 -0.324 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.022 176.46 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.45 ' HA ' ' HB1' ' A' ' 148' ' ' ALA . 16.3 t70 -59.54 -34.16 72.31 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.459 -0.791 . . . . 0.0 111.038 -178.565 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -70.73 -46.46 63.0 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.837 -178.708 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 33.6 m -84.67 -27.88 6.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 C-N-CA 121.0 -0.28 . . . . 0.0 111.624 -176.127 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 93.41 38.05 5.43 Favored Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 120.697 -0.764 . . . . 0.0 112.475 179.548 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -114.14 149.82 35.07 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.039 0.447 . . . . 0.0 111.093 -179.059 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 116' ' ' ARG . . . . . 0.529 ' HB3' ' HG ' ' A' ' 92' ' ' LEU . 19.8 ttt180 -71.38 116.17 11.39 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.725 -0.67 . . . . 0.0 109.803 179.321 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . 0.578 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 62.2 tp -88.53 120.43 29.9 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 116.034 -0.53 . . . . 0.0 109.968 -179.517 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 71.0 mt -121.52 114.94 44.99 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 CA-C-O 121.16 0.505 . . . . 0.0 110.363 179.233 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 51.0 mt -112.77 121.27 64.73 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.761 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.55 -179.379 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 120' ' ' LYS . . . . . 0.404 ' C ' ' HD3' ' A' ' 120' ' ' LYS . 1.6 tmtp? -109.99 95.33 20.51 Favored Pre-proline 0 C--N 1.322 -0.614 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 173.503 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 121' ' ' PRO . . . . . 0.428 ' HB2' ' HB3' ' A' ' 125' ' ' GLU . 88.7 Cg_endo -89.02 -161.95 0.12 Allowed 'Trans proline' 0 N--CA 1.454 -0.839 0 C-N-CA 122.998 2.465 . . . . 0.0 112.244 179.997 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 122' ' ' LEU . . . . . 0.882 ' HB2' ' HB2' ' A' ' 125' ' ' GLU . 10.3 mp -83.53 168.14 16.72 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.987 -0.552 . . . . 0.0 110.391 179.65 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 3.9 m -59.91 -32.05 70.39 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.546 -176.86 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -125.43 38.84 2.19 Favored Glycine 0 N--CA 1.452 -0.245 0 C-N-CA 120.711 -0.756 . . . . 0.0 111.844 177.756 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . 0.882 ' HB2' ' HB2' ' A' ' 122' ' ' LEU . 6.0 tp10 -110.5 118.01 35.11 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 120.696 0.284 . . . . 0.0 110.267 -176.104 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -84.69 167.77 15.87 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.137 0.494 . . . . 0.0 111.014 179.007 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 85.7 mt . . . . . 0 C--N 1.325 -0.477 0 CA-C-N 115.609 -0.723 . . . . 0.0 110.55 -178.407 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 132' ' ' LYS . . . . . 0.436 ' HE3' ' HB2' ' A' ' 132' ' ' LYS . 0.0 OUTLIER . . . . . 0 N--CA 1.465 0.313 0 CA-C-O 121.134 0.492 . . . . 0.0 112.024 . . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 133' ' ' MET . . . . . 0.512 ' HG2' ' HB2' ' A' ' 146' ' ' TYR . 86.0 mtp -148.46 162.19 40.11 Favored 'General case' 0 C--N 1.314 -0.949 0 N-CA-C 107.994 -1.113 . . . . 0.0 107.994 173.272 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . 0.565 ' HG3' ' HG2' ' A' ' 145' ' ' GLU . 13.1 ptmm? -126.36 133.1 51.42 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-O 120.956 0.408 . . . . 0.0 111.21 -176.899 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . 0.775 HD11 ' HD2' ' A' ' 142' ' ' TYR . 55.6 tp -84.38 121.16 27.16 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.023 -179.662 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -116.77 149.98 18.87 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.598 -177.334 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 10.5 m120 -116.29 125.82 52.7 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 177.584 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 34.4 t80 -138.27 130.79 29.18 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 109.565 -0.532 . . . . 0.0 109.565 176.239 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 72.03 -87.75 0.48 Allowed Glycine 0 N--CA 1.443 -0.837 0 N-CA-C 110.681 -0.967 . . . . 0.0 110.681 -174.428 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 140' ' ' ARG . . . . . 0.72 ' NE ' ' HA ' ' A' ' 140' ' ' ARG . 2.0 mmp_? -156.53 14.61 0.3 Allowed 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.423 -0.388 . . . . 0.0 110.75 174.346 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 11.2 t -113.98 154.95 26.75 Favored 'General case' 0 N--CA 1.448 -0.57 0 CA-C-N 116.33 -0.395 . . . . 0.0 109.948 179.035 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 142' ' ' TYR . . . . . 0.775 ' HD2' HD11 ' A' ' 135' ' ' LEU . 14.7 p90 -122.86 138.11 54.75 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 121.042 0.449 . . . . 0.0 110.36 -179.875 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 143' ' ' PHE . . . . . 0.423 ' O ' HD12 ' A' ' 135' ' ' LEU . 12.4 p90 -146.85 162.34 38.85 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-N 115.562 -0.745 . . . . 0.0 110.146 -177.238 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 96.3 m-85 -101.04 122.53 43.71 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 116.429 -0.351 . . . . 0.0 110.294 -179.447 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 145' ' ' GLU . . . . . 0.565 ' HG2' ' HG3' ' A' ' 134' ' ' LYS . 11.5 pt-20 -113.37 156.77 22.84 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 121.086 0.47 . . . . 0.0 110.036 177.522 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . 0.512 ' HB2' ' HG2' ' A' ' 133' ' ' MET . 41.7 t80 -141.91 124.47 15.83 Favored 'General case' 0 C--N 1.314 -0.969 0 CA-C-N 115.493 -0.776 . . . . 0.0 109.659 176.833 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 147' ' ' ILE . . . . . 0.409 ' N ' HD12 ' A' ' 147' ' ' ILE . 3.7 mp -93.0 101.37 12.55 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.88 0 N-CA-C 109.596 -0.52 . . . . 0.0 109.596 -177.63 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . 0.45 ' HB1' ' HA ' ' A' ' 111' ' ' ASP . . . -69.91 108.59 4.07 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 108.57 -0.9 . . . . 0.0 108.57 172.717 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 40.6 mt-10 . . . . . 0 C--N 1.321 -0.661 0 CA-C-O 122.04 0.924 . . . . 0.0 112.424 -170.762 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 95.4 m95 . . . . . 0 C--O 1.232 0.175 0 CA-C-O 121.046 0.45 . . . . 0.0 110.677 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.435 ' O ' HG23 ' A' ' 27' ' ' VAL . 2.7 t-20 -68.26 -37.74 81.06 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.205 -179.555 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.427 ' HB3' ' HD2' ' A' ' 138' ' ' TYR . 44.0 m-20 -61.61 -43.28 99.16 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.279 -0.418 . . . . 0.0 110.389 179.392 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.51 HD22 ' HD3' ' A' ' 120' ' ' LYS . 61.9 tp -58.16 -50.07 74.78 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.305 178.241 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -55.76 -51.78 66.22 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.876 179.049 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.435 HG23 ' O ' ' A' ' 23' ' ' ASN . 96.7 t -57.04 -43.89 81.93 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.221 179.42 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 52.2 t80 -58.18 -48.63 79.71 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.861 0.363 . . . . 0.0 110.265 178.684 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.402 HG13 ' O ' ' A' ' 25' ' ' LEU . 81.7 mt -60.81 -42.67 93.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.486 178.904 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.429 HD13 ' CD2' ' A' ' 57' ' ' HIS . 90.8 mt -58.15 -41.86 81.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.123 179.118 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 63.0 mtp180 -69.05 -35.07 76.16 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.076 0.465 . . . . 0.0 111.295 -179.654 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.421 ' SG ' HD12 ' A' ' 92' ' ' LEU . 48.3 t -81.37 -25.95 35.88 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.98 -0.555 . . . . 0.0 111.512 -175.509 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 20.8 p -93.56 -81.93 0.36 Allowed 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 111.851 0.315 . . . . 0.0 111.851 -174.92 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.416 ' O ' HG22 ' A' ' 37' ' ' THR . . . 107.22 168.19 22.12 Favored Glycine 0 N--CA 1.449 -0.476 0 N-CA-C 111.384 -0.686 . . . . 0.0 111.384 -175.158 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 71.0 Cg_endo -76.77 145.96 26.1 Favored 'Trans proline' 0 N--CA 1.464 -0.26 0 C-N-CA 122.32 2.013 . . . . 0.0 112.801 -178.769 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 91.75 -20.34 42.64 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.876 -0.678 . . . . 0.0 113.602 175.22 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . 0.416 HG22 ' O ' ' A' ' 34' ' ' GLY . 14.7 t -92.06 178.85 5.75 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 117.115 0.457 . . . . 0.0 110.011 -179.08 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' ARG . . . . . 0.503 ' HA ' ' O ' ' A' ' 61' ' ' ASP . 0.1 OUTLIER -111.81 136.06 51.59 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-O 120.967 0.413 . . . . 0.0 111.351 -176.239 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.402 HG23 HG21 ' A' ' 60' ' ' VAL . 62.3 t -126.22 117.27 48.15 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 N-CA-C 108.997 -0.742 . . . . 0.0 108.997 173.836 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.533 HG22 ' HB ' ' A' ' 63' ' ' VAL . 40.9 t -103.13 128.86 55.73 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-O 120.999 0.428 . . . . 0.0 111.703 -173.176 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . 0.631 ' HB3' HD23 ' A' ' 64' ' ' LEU . 21.7 tp10 -105.22 127.41 52.91 Favored 'General case' 0 C--O 1.24 0.569 0 CA-C-N 115.606 -0.724 . . . . 0.0 109.991 174.377 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.473 ' HB ' ' OG ' ' A' ' 95' ' ' SER . 59.0 t -93.57 89.95 2.79 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 CA-C-N 115.976 -0.557 . . . . 0.0 110.235 179.816 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 121.18 120.83 2.75 Favored Glycine 0 N--CA 1.443 -0.837 0 CA-C-N 115.662 -0.699 . . . . 0.0 111.505 -175.201 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.598 ' HB1' HD21 ' A' ' 48' ' ' LEU . . . -110.59 -57.98 2.15 Favored 'General case' 0 C--N 1.321 -0.668 0 O-C-N 122.399 -0.471 . . . . 0.0 111.047 -177.198 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 52.72 -118.67 8.21 Favored Glycine 0 CA--C 1.519 0.317 0 C-N-CA 121.085 -0.579 . . . . 0.0 112.693 -178.707 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 65.2 mtp180 -134.52 14.61 3.74 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.827 0.346 . . . . 0.0 111.264 -179.669 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 21.8 p90 -103.52 35.19 2.67 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.369 0.604 . . . . 0.0 110.553 -178.298 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.598 HD21 ' HB1' ' A' ' 44' ' ' ALA . 94.5 mt -76.13 13.43 0.9 Allowed 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.484 -0.78 . . . . 0.0 112.569 -173.963 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 42.2 p90 -67.62 -26.45 66.25 Favored 'General case' 0 C--N 1.324 -0.509 0 C-N-CA 120.713 -0.395 . . . . 0.0 110.454 177.02 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.419 ' O ' HG13 ' A' ' 54' ' ' ILE . 54.0 t -68.72 -54.5 20.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.439 176.407 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . 0.402 ' HA ' HD13 ' A' ' 62' ' ' LEU . 7.3 p -62.51 -46.78 86.85 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.847 -176.134 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -70.66 -27.55 64.13 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.569 -176.328 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 82.9 t80 -68.74 -46.65 68.33 Favored 'General case' 0 C--N 1.328 -0.346 0 C-N-CA 120.783 -0.367 . . . . 0.0 110.443 176.291 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.419 HG13 ' O ' ' A' ' 50' ' ' VAL . 77.9 mt -59.15 -45.79 92.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.385 -176.824 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 6.9 ptp180 -71.76 -16.48 62.2 Favored 'General case' 0 C--O 1.236 0.39 0 CA-C-O 120.893 0.378 . . . . 0.0 111.499 -179.111 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 8.3 mtpm? -83.7 -21.8 32.24 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.861 0.362 . . . . 0.0 111.566 177.618 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . 0.429 ' CD2' HD13 ' A' ' 30' ' ' ILE . 11.8 t60 -103.16 -43.02 5.58 Favored 'General case' 0 N--CA 1.445 -0.69 0 CA-C-O 121.01 0.433 . . . . 0.0 109.863 -178.143 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 9.1 t -120.09 144.08 47.8 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 109.202 -0.666 . . . . 0.0 109.202 178.336 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . 0.452 ' HD3' ' HA ' ' A' ' 59' ' ' LYS . 6.1 tppt? -89.25 58.15 4.34 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 122.11 0.957 . . . . 0.0 110.332 -179.459 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.402 HG21 HG23 ' A' ' 39' ' ' VAL . 7.6 p -94.97 145.53 8.02 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.817 0 CA-C-N 114.41 -1.268 . . . . 0.0 109.677 175.564 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . 0.503 ' O ' ' HA ' ' A' ' 38' ' ' ARG . 25.6 t70 -84.62 93.46 8.39 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 179.278 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . 0.402 HD13 ' HA ' ' A' ' 51' ' ' SER . 4.6 tt -89.86 120.17 30.87 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.67 -176.192 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.533 ' HB ' HG22 ' A' ' 40' ' ' VAL . 47.8 t -103.91 122.51 56.75 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.653 0 CA-C-N 115.674 -0.694 . . . . 0.0 110.493 -174.721 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . 0.631 HD23 ' HB3' ' A' ' 41' ' ' GLU . 41.6 mt -99.55 133.43 43.89 Favored 'General case' 0 C--N 1.316 -0.889 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 176.575 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.436 HG22 ' HB ' ' A' ' 75' ' ' VAL . 13.0 p -125.73 124.04 40.18 Favored 'General case' 0 C--N 1.317 -0.813 0 N-CA-C 110.048 -0.353 . . . . 0.0 110.048 176.544 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 39.2 t0 -170.36 172.01 6.34 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -175.712 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.671 HG22 ' HG2' ' A' ' 68' ' ' LYS . 26.0 mm -73.67 129.83 36.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.073 -179.709 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' LYS . . . . . 0.671 ' HG2' HG22 ' A' ' 67' ' ' ILE . 19.6 pttp 38.71 90.32 0.07 OUTLIER Pre-proline 0 N--CA 1.476 0.837 0 O-C-N 124.247 0.967 . . . . 0.0 113.278 178.933 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . 0.958 ' HB3' ' HB ' ' A' ' 74' ' ' ILE . 4.9 Cg_endo . . . . . 0 C--N 1.346 0.395 0 C-N-CA 123.875 3.05 . . . . 0.0 113.202 179.534 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.958 ' HB ' ' HB3' ' A' ' 69' ' ' PRO . 56.1 mt . . . . . 0 N--CA 1.447 -0.61 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.543 HG11 HD13 ' A' ' 86' ' ' ILE . 91.2 t -76.04 132.09 33.72 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 176.369 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 9.8 ptp180 -79.3 21.14 0.48 Allowed 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 120.987 0.422 . . . . 0.0 111.371 -175.967 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . 0.496 ' HB2' HG12 ' A' ' 75' ' ' VAL . 6.1 t70 -83.48 112.49 20.01 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 109.615 -0.513 . . . . 0.0 109.615 -176.385 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 10.7 p-10 -70.87 142.21 51.2 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 121.426 0.632 . . . . 0.0 111.444 -174.055 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' ILE . . . . . 0.404 HD13 HG13 ' A' ' 42' ' ' VAL . 6.9 tp -66.77 -21.95 29.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.367 -0.833 . . . . 0.0 112.345 -173.66 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 10.2 t -90.05 -0.54 57.64 Favored 'General case' 0 C--N 1.322 -0.626 0 C-N-CA 120.274 -0.571 . . . . 0.0 110.492 -178.801 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . 0.43 ' N ' ' HD3' ' A' ' 82' ' ' PRO . 4.9 m -148.24 46.58 0.46 Allowed Pre-proline 0 CA--C 1.538 0.505 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.883 177.421 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' PRO . . . . . 0.457 ' HA ' ' OD2' ' A' ' 77' ' ' ASP . 93.3 Cg_endo -81.23 149.45 17.17 Favored 'Trans proline' 0 C--N 1.352 0.711 0 C-N-CA 122.287 1.992 . . . . 0.0 113.174 -169.01 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 83' ' ' ARG . . . . . 0.511 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 73.1 mtp85 -96.36 125.22 40.71 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.82 -0.627 . . . . 0.0 111.061 177.222 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 84' ' ' MET . . . . . 0.584 ' HE1' ' HA ' ' A' ' 109' ' ' VAL . 91.3 mmm -63.92 -20.02 65.54 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.678 -0.692 . . . . 0.0 111.296 -179.314 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.511 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 11.0 pt-20 -69.81 -16.65 63.31 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.506 -176.451 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.543 HD13 HG11 ' A' ' 75' ' ' VAL . 70.4 mt -85.23 -36.14 10.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 121.298 0.571 . . . . 0.0 109.963 178.154 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 99.2 m-85 -80.59 -31.85 36.61 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.865 -178.73 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . 0.441 ' HG3' HG12 ' A' ' 113' ' ' VAL . 23.3 mtp85 -64.07 119.61 10.47 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-O 121.142 0.496 . . . . 0.0 110.795 179.259 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 115.65 -17.21 16.08 Favored Glycine 0 N--CA 1.444 -0.805 0 CA-C-N 115.44 -0.8 . . . . 0.0 111.557 -177.739 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -73.38 144.55 46.39 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.83 0.348 . . . . 0.0 110.769 179.052 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -88.94 -25.66 21.95 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 121.27 0.557 . . . . 0.0 110.142 178.093 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . 0.483 HD23 ' N ' ' A' ' 93' ' ' ILE . 4.7 tt -150.86 141.09 22.26 Favored 'General case' 0 N--CA 1.448 -0.559 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.409 -177.136 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 93' ' ' ILE . . . . . 0.548 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 61.2 mt -130.58 128.14 63.06 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.187 177.226 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -136.88 169.69 17.35 Favored 'General case' 0 C--N 1.318 -0.781 0 C-N-CA 120.786 -0.366 . . . . 0.0 110.117 -179.074 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . 0.635 ' HB2' ' HG3' ' A' ' 98' ' ' PRO . 7.1 m -152.07 123.08 7.57 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.346 178.901 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 96' ' ' ILE . . . . . 0.748 HG22 ' HG2' ' A' ' 97' ' ' ARG . 2.3 mp -73.37 114.94 13.6 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-N 116.3 -0.409 . . . . 0.0 109.907 174.771 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 97' ' ' ARG . . . . . 0.748 ' HG2' HG22 ' A' ' 96' ' ' ILE . 13.6 ptt180 43.54 76.27 0.55 Allowed Pre-proline 0 N--CA 1.472 0.668 0 C-N-CA 124.376 1.071 . . . . 0.0 113.17 177.41 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 98' ' ' PRO . . . . . 0.635 ' HG3' ' HB2' ' A' ' 95' ' ' SER . 12.8 Cg_endo -90.07 146.54 4.52 Favored 'Trans proline' 0 N--CA 1.453 -0.909 0 C-N-CA 122.583 2.189 . . . . 0.0 111.889 175.689 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . 0.526 ' HD2' HD11 ' A' ' 102' ' ' ILE . 32.2 Cg_exo -61.05 140.37 89.43 Favored 'Trans proline' 0 C--N 1.344 0.34 0 C-N-CA 122.492 2.128 . . . . 0.0 111.991 177.483 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -79.74 30.85 0.25 Allowed 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 121.101 0.477 . . . . 0.0 111.805 -174.871 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 101' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -122.2 -6.89 8.84 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.812 178.614 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.526 HD11 ' HD2' ' A' ' 99' ' ' PRO . 30.8 pt -120.25 8.53 6.37 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 120.907 0.384 . . . . 0.0 111.163 -179.021 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 103' ' ' HIS . . . . . 0.465 ' O ' ' HG2' ' A' ' 107' ' ' MET . 44.7 p-80 -60.82 -40.06 91.31 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.373 -177.149 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 23.3 m -61.75 -29.58 70.22 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.861 0.362 . . . . 0.0 111.016 178.749 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.547 ' O ' HG23 ' A' ' 109' ' ' VAL . 19.3 m -75.61 -38.29 59.13 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.079 178.518 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 94.5 mt -69.14 -41.7 76.98 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.953 179.6 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 107' ' ' MET . . . . . 0.465 ' HG2' ' O ' ' A' ' 103' ' ' HIS . 94.9 mmm -57.38 -47.53 81.44 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.804 -0.634 . . . . 0.0 111.535 -179.281 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 6.7 ptp85 -66.96 -31.74 72.51 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.578 -0.283 . . . . 0.0 111.608 -178.186 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.584 ' HA ' ' HE1' ' A' ' 84' ' ' MET . 76.3 t -66.7 -47.93 81.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 C-N-CA 121.115 -0.234 . . . . 0.0 110.897 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -57.98 -46.27 85.44 Favored 'General case' 0 CA--C 1.518 -0.286 0 CA-C-N 116.515 -0.311 . . . . 0.0 110.641 179.853 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 17.8 t70 -67.73 -36.21 80.16 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.783 -178.599 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -65.43 -43.25 91.06 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.65 -179.843 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.441 HG12 ' HG3' ' A' ' 88' ' ' ARG . 18.6 m -88.22 -30.09 5.46 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.537 -175.912 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 91.41 51.63 2.5 Favored Glycine 0 N--CA 1.448 -0.554 0 C-N-CA 120.596 -0.811 . . . . 0.0 112.15 -178.856 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -132.0 157.6 43.67 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.906 0.384 . . . . 0.0 110.879 -179.424 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 116' ' ' ARG . . . . . 0.674 ' HD3' ' OE1' ' A' ' 145' ' ' GLU . 12.5 ttm180 -78.58 123.22 26.86 Favored 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 109.569 -0.53 . . . . 0.0 109.569 177.163 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . 0.548 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 57.3 tp -94.12 118.9 32.19 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 116.179 -0.464 . . . . 0.0 109.947 -179.553 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 59.7 mt -114.39 115.06 48.45 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 CA-C-O 121.32 0.581 . . . . 0.0 110.807 179.654 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 53.5 mt -122.52 118.62 55.77 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.953 -179.249 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 120' ' ' LYS . . . . . 0.557 ' HB3' ' HB3' ' A' ' 143' ' ' PHE . 0.6 OUTLIER -118.81 101.74 50.11 Favored Pre-proline 0 C--N 1.319 -0.722 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 169.759 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 121' ' ' PRO . . . . . 0.53 ' HA ' ' HA ' ' A' ' 97' ' ' ARG . 96.6 Cg_endo -80.04 -161.95 0.17 Allowed 'Trans proline' 0 N--CA 1.461 -0.438 0 C-N-CA 122.902 2.401 . . . . 0.0 112.425 -176.658 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 122' ' ' LEU . . . . . 0.681 ' HB2' ' HB2' ' A' ' 125' ' ' GLU . 3.0 mm? -65.31 150.08 48.87 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.929 -0.578 . . . . 0.0 109.977 178.162 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 23.2 m -68.28 -25.82 65.35 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.119 -0.491 . . . . 0.0 112.005 -171.246 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -105.67 1.64 39.25 Favored Glycine 0 N--CA 1.453 -0.233 0 C-N-CA 120.095 -1.05 . . . . 0.0 112.694 -179.563 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . 0.681 ' HB2' ' HB2' ' A' ' 122' ' ' LEU . 1.6 mp0 -105.79 -170.28 1.71 Allowed 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.239 0.542 . . . . 0.0 111.401 -173.595 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 16.8 t70 -143.99 171.53 14.13 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 115.147 -0.933 . . . . 0.0 108.846 179.18 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 39.1 mt . . . . . 0 C--N 1.325 -0.488 0 CA-C-O 121.048 0.451 . . . . 0.0 110.24 179.655 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 30.8 mmmt . . . . . 0 N--CA 1.454 -0.24 0 CA-C-O 121.122 0.487 . . . . 0.0 110.1 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 133' ' ' MET . . . . . 0.516 ' HG2' ' HB2' ' A' ' 146' ' ' TYR . 79.4 mtp -114.4 170.12 8.53 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.56 -0.746 . . . . 0.0 110.195 -176.311 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 134' ' ' LYS . . . . . 0.453 ' HG3' ' HG2' ' A' ' 145' ' ' GLU . 18.8 ptmt -121.75 134.07 54.93 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.815 -178.591 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . 0.539 HD11 ' HD2' ' A' ' 142' ' ' TYR . 60.0 tp -82.75 122.39 28.12 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 120.932 0.396 . . . . 0.0 110.537 178.223 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -118.16 147.04 21.87 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.355 179.84 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 13.4 m120 -124.18 96.94 5.12 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 109.416 -0.587 . . . . 0.0 109.416 -179.666 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . 0.427 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 64.1 t80 -104.42 109.1 20.83 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.272 -175.172 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 72.71 -82.08 0.61 Allowed Glycine 0 N--CA 1.45 -0.392 0 CA-C-N 115.768 -0.651 . . . . 0.0 111.832 179.875 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 140' ' ' ARG . . . . . 0.406 ' HD3' ' HA ' ' A' ' 140' ' ' ARG . 16.3 mmt180 -141.36 -7.43 1.01 Allowed 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 115.477 -0.362 . . . . 0.0 111.109 177.08 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 3.4 t -99.17 135.82 40.03 Favored 'General case' 0 N--CA 1.446 -0.637 0 CA-C-O 121.279 0.561 . . . . 0.0 110.083 -179.229 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 142' ' ' TYR . . . . . 0.539 ' HD2' HD11 ' A' ' 135' ' ' LEU . 27.0 p90 -114.06 144.22 43.48 Favored 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 176.193 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 143' ' ' PHE . . . . . 0.557 ' HB3' ' HB3' ' A' ' 120' ' ' LYS . 23.7 p90 -157.25 162.77 39.24 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.556 -178.854 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 87.1 m-85 -100.93 118.3 36.69 Favored 'General case' 0 C--N 1.314 -0.949 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 175.177 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 145' ' ' GLU . . . . . 0.674 ' OE1' ' HD3' ' A' ' 116' ' ' ARG . 11.5 pt-20 -110.0 155.17 22.15 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-O 121.321 0.581 . . . . 0.0 109.695 178.701 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . 0.516 ' HB2' ' HG2' ' A' ' 133' ' ' MET . 32.4 t80 -137.39 123.81 20.76 Favored 'General case' 0 C--N 1.307 -1.259 0 CA-C-N 115.498 -0.774 . . . . 0.0 109.382 176.493 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 147' ' ' ILE . . . . . 0.444 ' N ' HD12 ' A' ' 147' ' ' ILE . 3.3 mp -94.36 103.79 15.07 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.799 0 CA-C-N 116.111 -0.495 . . . . 0.0 109.932 -177.621 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -68.37 119.3 12.66 Favored 'General case' 0 N--CA 1.443 -0.783 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 171.358 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 . . . . . 0 C--N 1.322 -0.593 0 CA-C-O 121.121 0.486 . . . . 0.0 110.3 -177.363 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.7 mpt? . . . . . 0 N--CA 1.479 1.014 0 N-CA-C 110.453 -0.203 . . . . 0.0 110.453 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 79.56 165.05 29.89 Favored Glycine 0 N--CA 1.448 -0.559 0 C-N-CA 120.846 -0.693 . . . . 0.0 113.045 176.857 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 58.7 m -132.79 128.1 36.02 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 120.901 0.381 . . . . 0.0 110.167 175.436 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 21.6 m -102.99 23.45 12.26 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 121.291 0.567 . . . . 0.0 110.538 -178.345 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 48.8 m80 -95.9 80.45 3.34 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.722 177.879 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 30.2 p-80 -100.9 107.13 18.57 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.887 -0.597 . . . . 0.0 109.719 174.66 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 95.6 m-70 -88.35 88.91 7.78 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 121.296 0.569 . . . . 0.0 110.814 -175.818 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 35.2 m-70 -108.9 112.27 24.41 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.219 -0.9 . . . . 0.0 109.869 176.486 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 4.4 p-80 -141.35 46.01 1.72 Allowed 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.304 -179.507 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 81.6 m-70 -67.76 98.44 0.71 Allowed 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.662 -0.699 . . . . 0.0 109.873 179.586 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 11.3 p -158.83 127.38 5.3 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.764 -174.669 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 17.3 t -84.95 107.29 17.02 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 109.365 -0.605 . . . . 0.0 109.365 177.216 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -80.77 72.22 2.74 Favored Glycine 0 N--CA 1.448 -0.564 0 C-N-CA 121.173 -0.537 . . . . 0.0 112.973 -175.456 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 87.4 mt -105.14 105.16 15.08 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-O 121.164 0.507 . . . . 0.0 109.773 174.644 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 7.7 m -118.6 116.27 35.0 Favored Pre-proline 0 C--N 1.317 -0.812 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.796 -177.684 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -62.32 126.79 19.33 Favored 'Trans proline' 0 N--CA 1.461 -0.433 0 C-N-CA 122.528 2.152 . . . . 0.0 112.693 -179.026 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 18.3 ptt180 -91.19 -176.36 4.56 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 115.131 -0.94 . . . . 0.0 110.066 -179.626 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 82.17 0.85 90.1 Favored Glycine 0 N--CA 1.449 -0.487 0 C-N-CA 120.396 -0.907 . . . . 0.0 111.074 -176.299 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 1.9 p -85.3 45.03 1.14 Allowed 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 121.324 0.583 . . . . 0.0 110.649 -179.701 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 71.8 m-70 -60.95 -37.97 84.24 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.482 -0.781 . . . . 0.0 110.576 -177.822 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' MET . . . . . . . . . . . . . 66.2 mtt -70.66 -15.57 62.74 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.821 -179.318 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 75.6 m95 -95.63 -18.84 20.21 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.457 178.738 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 23.9 t-20 -58.04 -52.74 64.29 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.354 -176.762 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.482 ' HB3' ' HD2' ' A' ' 138' ' ' TYR . 6.0 m-20 -59.14 -35.48 73.57 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.344 -179.489 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 61.6 tp -58.38 -47.63 83.25 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.331 178.481 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -61.34 -47.52 85.54 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.909 178.961 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.579 ' HA ' HD12 ' A' ' 30' ' ' ILE . 58.0 t -58.13 -43.97 86.55 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.162 0 CA-C-O 120.955 0.407 . . . . 0.0 110.83 179.82 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 68.4 t80 -56.0 -47.47 77.68 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.736 -0.665 . . . . 0.0 110.487 178.819 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.509 HG23 HD13 ' A' ' 92' ' ' LEU . 77.6 mt -63.37 -42.63 97.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.731 179.022 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.579 HD12 ' HA ' ' A' ' 27' ' ' VAL . 83.1 mt -56.26 -44.23 78.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.482 -0.781 . . . . 0.0 111.05 178.39 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . 0.468 ' HG3' ' O ' ' A' ' 27' ' ' VAL . 81.8 mtp180 -70.29 -30.34 67.31 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.959 -177.354 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 74.3 m -75.58 -29.89 59.46 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.213 -178.995 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 22.3 p -112.67 -97.4 0.43 Allowed 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.532 -0.303 . . . . 0.0 111.336 -178.876 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 113.81 -178.96 18.66 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.993 -0.622 . . . . 0.0 112.037 -178.03 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 10.6 Cg_exo -71.05 150.36 60.21 Favored 'Trans proline' 0 C--O 1.234 0.292 0 C-N-CA 122.932 2.421 . . . . 0.0 112.222 -179.412 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 84.93 41.94 7.38 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.831 -0.699 . . . . 0.0 112.86 179.257 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 14.6 t -168.65 -178.64 3.51 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 177.137 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 66.9 mtp85 -114.67 136.08 53.45 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 120.711 0.291 . . . . 0.0 111.082 -178.433 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.9 ' HB ' HD22 ' A' ' 62' ' ' LEU . 40.2 t -124.06 132.11 71.86 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 N-CA-C 108.914 -0.772 . . . . 0.0 108.914 173.47 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.423 HG11 ' CD1' ' A' ' 87' ' ' TYR . 62.0 t -105.79 124.22 60.76 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 C-N-CA 120.87 -0.332 . . . . 0.0 111.246 -175.939 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . 0.411 ' OE1' HD22 ' A' ' 64' ' ' LEU . 44.9 tt0 -103.59 109.47 21.16 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.931 -0.577 . . . . 0.0 109.852 176.583 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.573 HG11 HD21 ' A' ' 106' ' ' LEU . 47.0 t -96.65 132.99 39.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 115.947 -0.569 . . . . 0.0 109.954 179.707 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 87.12 20.48 52.81 Favored Glycine 0 N--CA 1.447 -0.613 0 C-N-CA 120.474 -0.87 . . . . 0.0 111.811 -178.637 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.452 ' HB1' ' CD2' ' A' ' 48' ' ' LEU . . . -55.81 -68.0 0.24 Allowed 'General case' 0 C--N 1.331 -0.201 0 O-C-N 123.744 0.32 . . . . 0.0 110.253 178.695 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 58.22 -93.05 0.04 OUTLIER Glycine 0 N--CA 1.452 -0.284 0 CA-C-N 115.572 -0.74 . . . . 0.0 114.1 173.06 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . 0.44 HH11 ' HD3' ' A' ' 46' ' ' ARG . 32.7 ttt-85 -126.58 11.24 7.32 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 121.351 0.596 . . . . 0.0 110.571 -172.181 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 59.0 t80 -133.04 97.96 4.15 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 109.529 -0.545 . . . . 0.0 109.529 178.995 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.72 HD22 HD13 ' A' ' 64' ' ' LEU . 67.1 mt -113.4 24.37 12.3 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.952 -172.278 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 56.8 t80 -64.65 -50.86 65.42 Favored 'General case' 0 C--N 1.329 -0.292 0 C-N-CA 120.928 -0.309 . . . . 0.0 111.781 -176.908 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.476 ' O ' HG13 ' A' ' 54' ' ' ILE . 44.1 t -60.92 -55.47 24.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.559 -0.291 . . . . 0.0 111.011 -173.013 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 10.9 p -56.93 -43.12 81.17 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.975 179.538 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.469 ' HA ' ' HG2' ' A' ' 55' ' ' ARG . 36.7 t70 -64.99 -42.88 94.12 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.728 0.299 . . . . 0.0 110.905 -179.466 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 74.6 t80 -61.11 -42.02 97.75 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.062 0.458 . . . . 0.0 110.341 177.281 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.552 HG23 HG12 ' A' ' 30' ' ' ILE . 86.3 mt -64.61 -49.13 81.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.294 179.21 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . 0.469 ' HG2' ' HA ' ' A' ' 52' ' ' ASP . 40.8 ptt180 -67.96 -18.74 64.83 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-O 120.862 0.363 . . . . 0.0 111.401 -176.05 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 84.6 mttt -84.51 -34.11 23.39 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.828 0.346 . . . . 0.0 110.971 176.104 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.6 OUTLIER -79.85 -33.6 40.05 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.253 178.76 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 70.6 m -141.78 135.95 30.2 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.5 178.063 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 7.6 tmtt? -76.15 64.77 2.03 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.888 0.852 . . . . 0.0 109.378 176.755 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.515 HG21 HG23 ' A' ' 39' ' ' VAL . 8.3 p -95.18 148.2 5.27 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.964 0 CA-C-N 114.727 -1.124 . . . . 0.0 109.118 173.834 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 25.9 t0 -78.91 88.58 4.71 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 121.34 0.59 . . . . 0.0 109.437 -179.808 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . 0.9 HD22 ' HB ' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -82.99 115.12 21.69 Favored 'General case' 0 N--CA 1.448 -0.549 0 CA-C-N 115.532 -0.758 . . . . 0.0 110.1 -177.578 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 45.3 t -103.56 114.73 43.96 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-N 115.462 -0.79 . . . . 0.0 110.081 -177.54 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . 0.72 HD13 HD22 ' A' ' 48' ' ' LEU . 20.1 mt -91.61 135.95 33.49 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-N 115.671 -0.695 . . . . 0.0 109.607 -179.696 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 14.5 p -130.76 128.96 41.83 Favored 'General case' 0 C--N 1.319 -0.723 0 C-N-CA 121.045 -0.262 . . . . 0.0 111.271 -179.074 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 5.8 t70 -171.0 155.34 4.45 Favored 'General case' 0 CA--C 1.519 -0.246 0 N-CA-C 109.371 -0.603 . . . . 0.0 109.371 175.839 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.625 HG22 ' HG2' ' A' ' 68' ' ' LYS . 58.1 mt -78.1 131.2 35.06 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 CA-C-N 116.642 -0.254 . . . . 0.0 110.606 -177.942 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' LYS . . . . . 0.625 ' HG2' HG22 ' A' ' 67' ' ' ILE . 7.9 ptmm? 42.31 71.73 1.31 Allowed Pre-proline 0 N--CA 1.471 0.586 0 O-C-N 124.152 0.908 . . . . 0.0 112.915 179.265 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -78.91 167.15 22.5 Favored 'Trans proline' 0 N--CA 1.463 -0.319 0 C-N-CA 122.549 2.166 . . . . 0.0 112.168 177.768 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 12.6 t -120.49 6.7 10.58 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 121.359 0.599 . . . . 0.0 109.629 179.009 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 79.1 m80 -117.99 131.76 56.45 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.641 -0.709 . . . . 0.0 110.747 -175.504 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -68.12 107.75 2.18 Favored Glycine 0 N--CA 1.45 -0.386 0 CA-C-N 115.822 -0.627 . . . . 0.0 112.223 179.836 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 142.62 -24.65 2.31 Favored Glycine 0 N--CA 1.448 -0.534 0 C-N-CA 120.954 -0.641 . . . . 0.0 111.928 -179.456 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.673 ' HA ' ' HB2' ' A' ' 64' ' ' LEU . 50.6 mt -84.92 125.84 40.33 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-O 120.574 0.226 . . . . 0.0 110.441 -179.823 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.441 HG11 HD13 ' A' ' 86' ' ' ILE . 61.5 t -64.45 116.91 4.29 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 N-CA-C 109.631 -0.507 . . . . 0.0 109.631 176.875 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 16.2 mtt180 -84.48 53.69 2.75 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.679 -0.692 . . . . 0.0 110.432 -175.417 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . 0.421 ' HB2' HG12 ' A' ' 75' ' ' VAL . 2.0 t70 -98.83 -162.36 0.95 Allowed 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 116.307 -0.406 . . . . 0.0 109.972 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . 0.503 ' OD1' HG22 ' A' ' 80' ' ' THR . 11.8 t0 -119.38 146.17 45.57 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 120.773 0.321 . . . . 0.0 111.251 -175.475 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . 0.558 HG22 HD11 ' A' ' 67' ' ' ILE . 10.7 tp -107.96 -20.59 6.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.292 -176.266 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.503 HG22 ' OD1' ' A' ' 78' ' ' ASP . 13.3 t -79.82 -25.06 40.97 Favored 'General case' 0 CA--C 1.529 0.167 0 CA-C-O 121.616 0.722 . . . . 0.0 109.322 178.913 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 23.2 m -132.54 79.86 63.83 Favored Pre-proline 0 C--N 1.322 -0.613 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 166.048 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -74.97 146.15 32.44 Favored 'Trans proline' 0 N--CA 1.462 -0.364 0 C-N-CA 122.799 2.332 . . . . 0.0 112.991 -171.954 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' ARG . . . . . 0.537 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 82.9 mtt180 -94.58 107.92 19.89 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.542 -0.754 . . . . 0.0 110.22 175.845 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' MET . . . . . 0.554 ' HA ' ' HD2' ' A' ' 87' ' ' TYR . 95.3 mmm -59.56 -24.41 63.71 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.587 -0.733 . . . . 0.0 111.571 -176.087 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.537 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 9.4 pt-20 -55.45 -29.56 58.89 Favored 'General case' 0 C--N 1.33 -0.272 0 O-C-N 123.245 0.341 . . . . 0.0 111.415 179.465 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.441 HD13 HG11 ' A' ' 75' ' ' VAL . 64.9 mt -78.52 -35.59 19.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.81 -178.403 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . 0.554 ' HD2' ' HA ' ' A' ' 84' ' ' MET . 49.4 m-85 -85.86 -25.86 25.98 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.209 -175.327 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . 0.645 ' HG2' HG12 ' A' ' 113' ' ' VAL . 81.6 mtp180 -70.35 138.29 51.29 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 121.36 0.6 . . . . 0.0 110.666 -178.553 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 92.92 -1.19 70.51 Favored Glycine 0 C--N 1.317 -0.478 0 CA-C-N 115.11 -0.95 . . . . 0.0 111.993 -176.652 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -86.7 147.64 25.79 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.905 0.383 . . . . 0.0 110.664 178.596 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -91.05 -27.08 18.84 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.801 179.306 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . 0.509 HD13 HG23 ' A' ' 29' ' ' ILE . 6.2 tt -152.35 143.24 22.99 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.143 -177.935 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.572 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 72.3 mt -131.46 122.74 51.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 N-CA-C 109.473 -0.566 . . . . 0.0 109.473 178.547 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 15.1 p90 -129.77 157.89 40.93 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 120.917 0.389 . . . . 0.0 110.883 -178.691 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . 0.487 ' HA ' ' O ' ' A' ' 42' ' ' VAL . 16.5 m -128.04 128.37 44.85 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.958 -0.564 . . . . 0.0 110.974 -176.731 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 50.6 mm -91.71 106.67 17.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.437 -179.806 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 11.1 tpp180 57.06 69.87 1.55 Allowed Pre-proline 0 CA--C 1.535 0.389 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.071 178.821 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' PRO . . . . . 0.56 ' HG2' HG23 ' A' ' 119' ' ' ILE . 5.6 Cg_endo -87.05 135.69 3.95 Favored 'Trans proline' 0 N--CA 1.455 -0.762 0 C-N-CA 122.799 2.332 . . . . 0.0 112.31 -179.09 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.559 ' HD2' HD11 ' A' ' 102' ' ' ILE . 32.3 Cg_exo -59.12 142.51 99.38 Favored 'Trans proline' 0 C--O 1.236 0.411 0 C-N-CA 122.464 2.11 . . . . 0.0 111.7 174.627 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -76.97 43.01 0.33 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.763 -176.092 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' GLU . . . . . 0.506 ' HG3' HG23 ' A' ' 102' ' ' ILE . 12.0 pt-20 -140.27 -34.45 0.53 Allowed 'General case' 0 N--CA 1.45 -0.472 0 CA-C-N 115.902 -0.59 . . . . 0.0 111.541 178.797 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.559 HD11 ' HD2' ' A' ' 99' ' ' PRO . 45.8 pt -95.56 -0.78 10.62 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.211 0 CA-C-O 120.837 0.351 . . . . 0.0 111.597 -176.53 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' HIS . . . . . 0.539 ' O ' ' HG3' ' A' ' 107' ' ' MET . 41.8 p-80 -55.92 -36.93 68.25 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.932 -0.576 . . . . 0.0 111.303 -178.863 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 6.7 m -60.93 -39.32 88.97 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.0 -179.4 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.558 ' O ' HG23 ' A' ' 109' ' ' VAL . 14.2 m -66.58 -35.37 80.05 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.976 -0.556 . . . . 0.0 109.88 -179.752 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.573 HD21 HG11 ' A' ' 42' ' ' VAL . 96.3 mt -69.91 -41.06 75.19 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.704 -0.68 . . . . 0.0 111.138 -179.676 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' MET . . . . . 0.539 ' HG3' ' O ' ' A' ' 103' ' ' HIS . 70.0 mtp -62.5 -42.37 99.45 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.813 -0.63 . . . . 0.0 111.487 -177.24 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 14.1 ptm180 -69.54 -29.87 67.56 Favored 'General case' 0 C--N 1.33 -0.261 0 C-N-CA 120.762 -0.375 . . . . 0.0 111.158 -179.572 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.558 HG23 ' O ' ' A' ' 105' ' ' SER . 75.4 t -66.75 -48.69 79.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 C-N-CA 120.933 -0.307 . . . . 0.0 110.56 178.399 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -57.55 -46.25 84.15 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.262 177.676 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.548 ' HA ' ' HB1' ' A' ' 148' ' ' ALA . 12.3 t70 -63.43 -34.37 77.59 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.553 -0.749 . . . . 0.0 110.729 -177.868 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -70.31 -46.97 63.19 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.801 -0.636 . . . . 0.0 111.797 -179.773 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.645 HG12 ' HG2' ' A' ' 88' ' ' ARG . 23.1 m -84.95 -26.28 6.76 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-N 116.416 -0.356 . . . . 0.0 111.811 -173.769 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 89.67 43.18 5.23 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.092 179.468 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -124.1 154.34 40.12 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.668 0.27 . . . . 0.0 110.503 -178.524 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' ARG . . . . . 0.463 ' HD3' ' OE1' ' A' ' 145' ' ' GLU . 14.5 ttm180 -73.95 124.48 26.27 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 178.13 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . 0.572 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 56.1 tp -93.46 121.39 34.81 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.246 -0.434 . . . . 0.0 109.977 178.562 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . 0.406 HD12 HG12 ' A' ' 29' ' ' ILE . 67.8 mt -119.12 120.18 63.1 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 CA-C-O 121.321 0.581 . . . . 0.0 110.907 179.435 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 119' ' ' ILE . . . . . 0.56 HG23 ' HG2' ' A' ' 98' ' ' PRO . 14.2 mt -112.68 130.6 66.16 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.674 178.874 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 2.6 tmtm? -106.34 94.71 10.16 Favored Pre-proline 0 C--N 1.323 -0.545 0 N-CA-C 109.287 -0.634 . . . . 0.0 109.287 174.926 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 91.1 Cg_endo -85.67 -162.69 0.16 Allowed 'Trans proline' 0 N--CA 1.46 -0.464 0 C-N-CA 122.749 2.299 . . . . 0.0 112.588 -179.539 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 122' ' ' LEU . . . . . 0.943 ' HB2' ' HB3' ' A' ' 125' ' ' GLU . 9.9 mp -86.15 159.57 19.48 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.45 179.681 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 4.0 p -64.13 -33.72 76.42 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.915 -0.584 . . . . 0.0 111.617 -178.529 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -132.18 43.74 1.26 Allowed Glycine 0 N--CA 1.447 -0.579 0 C-N-CA 120.935 -0.65 . . . . 0.0 112.135 179.824 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . 0.943 ' HB3' ' HB2' ' A' ' 122' ' ' LEU . 34.3 tt0 -145.32 129.23 17.39 Favored 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 110.044 -0.354 . . . . 0.0 110.044 179.274 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -85.41 167.59 15.38 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.605 -175.902 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 35.7 mt -87.0 -21.64 7.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-O 121.084 0.469 . . . . 0.0 110.218 -178.513 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 19.8 t 60.21 65.22 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.233 0 CA-C-O 122.11 0.957 . . . . 0.0 110.126 -177.256 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . 0.536 ' HB ' ' CD2' ' A' ' 103' ' ' HIS . 12.9 t -138.65 -179.25 5.71 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 115.128 -0.942 . . . . 0.0 109.558 -178.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 3.0 mp0 -74.24 161.29 30.07 Favored 'General case' 0 C--N 1.319 -0.72 0 N-CA-C 109.492 -0.559 . . . . 0.0 109.492 176.894 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 131' ' ' ARG . . . . . . . . . . . . . 34.9 ttm180 -74.39 82.26 1.92 Allowed 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 121.402 0.62 . . . . 0.0 110.176 -179.181 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 28.1 mmmt -126.98 -38.99 1.98 Allowed 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.231 -0.895 . . . . 0.0 110.462 -176.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 133' ' ' MET . . . . . . . . . . . . . 75.9 mtp -90.83 156.9 17.69 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.055 -0.521 . . . . 0.0 111.014 -175.525 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 16.1 ptmt -120.54 141.11 50.55 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 115.535 -0.757 . . . . 0.0 110.93 -175.582 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . 0.431 HD11 ' HD2' ' A' ' 142' ' ' TYR . 51.2 tp -83.12 120.65 26.03 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.108 178.042 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -119.19 146.01 24.48 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.743 -178.114 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 8.3 m120 -118.84 119.24 33.8 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.535 -0.543 . . . . 0.0 109.535 -179.233 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . 0.482 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 40.6 t80 -123.52 117.42 25.05 Favored 'General case' 0 C--N 1.321 -0.641 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 178.511 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 70.34 -87.29 0.33 Allowed Glycine 0 N--CA 1.443 -0.865 0 CA-C-N 115.604 -0.725 . . . . 0.0 111.43 -175.546 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 14.2 tpp180 -139.1 -13.09 1.21 Allowed 'General case' 0 C--N 1.317 -0.83 0 CA-C-O 121.259 0.552 . . . . 0.0 110.241 -179.147 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 5.8 t -97.99 141.17 31.29 Favored 'General case' 0 N--CA 1.448 -0.538 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.261 -176.608 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 142' ' ' TYR . . . . . 0.431 ' HD2' HD11 ' A' ' 135' ' ' LEU . 52.0 p90 -118.88 147.12 44.32 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 121.117 0.484 . . . . 0.0 110.545 177.432 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 15.2 p90 -155.24 -176.97 6.21 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.322 -0.854 . . . . 0.0 109.778 -176.292 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 31.7 m-85 -115.32 125.49 53.31 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-O 120.454 0.168 . . . . 0.0 110.76 179.699 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 145' ' ' GLU . . . . . 0.463 ' OE1' ' HD3' ' A' ' 116' ' ' ARG . 15.5 pt-20 -114.72 160.0 19.89 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 121.081 0.467 . . . . 0.0 109.813 175.847 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . 0.406 ' HB3' ' HB3' ' A' ' 117' ' ' LEU . 26.4 t80 -143.87 122.18 12.32 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-N 115.714 -0.675 . . . . 0.0 109.566 175.158 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 147' ' ' ILE . . . . . 0.439 ' N ' HD12 ' A' ' 147' ' ' ILE . 3.2 mp -90.31 102.34 13.19 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 -178.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . 0.548 ' HB1' ' HA ' ' A' ' 111' ' ' ASP . . . -72.53 114.17 10.37 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.839 -0.619 . . . . 0.0 109.903 177.381 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 8.1 pt-20 -72.63 150.19 43.25 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.332 0.586 . . . . 0.0 110.886 -176.348 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 26.3 t -86.19 150.74 3.79 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.818 0 CA-C-N 115.464 -0.789 . . . . 0.0 109.434 -177.599 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 151' ' ' ARG . . . . . . . . . . . . . 5.6 mmp_? -69.56 154.2 42.35 Favored 'General case' 0 C--N 1.328 -0.334 0 N-CA-C 110.346 -0.242 . . . . 0.0 110.346 -179.805 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 23.1 t -63.36 149.34 46.05 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 176.21 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 99.1 mtt180 . . . . . 0 C--O 1.249 1.04 0 CA-C-O 118.506 -0.759 . . . . 0.0 110.171 -177.869 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.6 mpt? . . . . . 0 N--CA 1.481 1.11 0 CA-C-O 120.666 0.27 . . . . 0.0 110.44 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -138.63 44.89 1.07 Allowed Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.201 -178.804 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 20.1 m -85.11 41.88 0.9 Allowed 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 121.251 0.548 . . . . 0.0 111.003 -179.204 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 6.1 p -101.34 -169.66 1.72 Allowed 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.202 177.865 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 54.7 p-80 -134.84 133.86 40.18 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.02 0.438 . . . . 0.0 110.618 177.353 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 30.4 t60 -156.42 165.4 36.45 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 -178.714 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 94.1 m-70 67.75 14.82 9.57 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 123.065 0.546 . . . . 0.0 110.874 -177.136 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 9.6 m-70 -81.35 60.84 4.59 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-O 121.209 0.528 . . . . 0.0 112.189 -175.911 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 29.1 m80 -136.1 99.67 4.2 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.808 -0.633 . . . . 0.0 109.831 174.915 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 13.8 p80 -79.48 163.71 24.52 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 116.013 -0.539 . . . . 0.0 110.363 -178.641 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 4.1 t -154.96 44.11 0.49 Allowed 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 108.477 -0.935 . . . . 0.0 108.477 178.735 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 38.1 t -78.13 92.87 4.46 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.316 -0.856 . . . . 0.0 110.966 -175.375 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -138.46 42.19 1.29 Allowed Glycine 0 N--CA 1.448 -0.536 0 C-N-CA 120.807 -0.711 . . . . 0.0 111.761 177.532 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . 0.749 ' H ' HD23 ' A' ' 14' ' ' LEU . 2.5 pt? -106.78 153.77 21.97 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 120.806 0.336 . . . . 0.0 110.783 -177.52 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 29.9 m -91.71 136.76 26.09 Favored Pre-proline 0 C--N 1.323 -0.55 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.948 178.423 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -77.23 156.99 33.55 Favored 'Trans proline' 0 C--O 1.236 0.4 0 C-N-CA 122.839 2.36 . . . . 0.0 112.189 -179.893 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 33.7 mtp180 -108.9 141.79 40.46 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.937 -179.671 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -76.95 104.05 1.86 Allowed Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 121.201 -0.524 . . . . 0.0 112.939 -176.606 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . 0.412 ' CB ' ' HB2' ' A' ' 22' ' ' TRP . 12.6 p -99.74 164.86 11.86 Favored 'General case' 0 C--N 1.323 -0.548 0 C-N-CA 122.399 0.28 . . . . 0.0 110.475 177.961 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 37.8 t-80 -95.6 -83.85 0.35 Allowed 'General case' 0 C--N 1.325 -0.466 0 C-N-CA 120.973 -0.291 . . . . 0.0 110.775 -178.878 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' MET . . . . . . . . . . . . . 56.7 mtt -64.14 -29.52 70.64 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-O 121.089 0.471 . . . . 0.0 111.214 -178.688 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' TRP . . . . . 0.434 ' HB3' HG22 ' A' ' 50' ' ' VAL . 50.2 m95 -69.28 -26.79 64.92 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.286 -178.611 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 25.8 t-20 -72.57 -43.32 63.58 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.98 -0.555 . . . . 0.0 109.691 177.801 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 42.5 m-20 -57.42 -51.03 71.07 Favored 'General case' 0 N--CA 1.463 0.205 0 CA-C-N 115.949 -0.568 . . . . 0.0 109.712 176.927 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.402 ' O ' HG13 ' A' ' 29' ' ' ILE . 58.2 tp -55.01 -47.78 74.22 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.44 -0.8 . . . . 0.0 110.954 179.035 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -55.3 -52.11 64.53 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.223 179.763 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.523 ' HA ' HD12 ' A' ' 30' ' ' ILE . 98.4 t -59.51 -40.51 82.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.975 -179.523 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 84.9 t80 -60.11 -43.54 95.53 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.494 178.428 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.404 HG23 HD13 ' A' ' 92' ' ' LEU . 82.6 mt -64.84 -43.67 96.36 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.595 177.909 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.662 HG12 HG23 ' A' ' 54' ' ' ILE . 85.8 mt -56.75 -38.84 60.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.901 178.206 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 32.8 mtp85 -70.62 -35.13 72.78 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.082 179.852 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 78.9 m -87.61 0.79 55.15 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.674 -174.047 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 15.5 p -122.01 -71.73 0.72 Allowed 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 120.977 0.418 . . . . 0.0 111.175 178.026 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 97.38 145.23 18.71 Favored Glycine 0 N--CA 1.446 -0.666 0 C-N-CA 120.804 -0.712 . . . . 0.0 111.586 -177.895 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -59.18 130.55 36.7 Favored 'Trans proline' 0 C--O 1.233 0.266 0 C-N-CA 122.852 2.368 . . . . 0.0 112.671 -177.433 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 105.37 24.97 6.87 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.467 -0.873 . . . . 0.0 112.978 177.474 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 13.8 t -131.71 -171.55 2.64 Favored 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 177.312 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -119.35 131.47 55.7 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 120.897 0.379 . . . . 0.0 110.433 177.866 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.45 ' O ' ' HA ' ' A' ' 62' ' ' LEU . 95.9 t -128.14 130.44 69.62 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 176.578 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.403 HG11 ' CD1' ' A' ' 87' ' ' TYR . 46.5 t -107.21 126.04 63.36 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.674 0 CA-C-O 120.91 0.386 . . . . 0.0 111.036 -176.38 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . 0.445 ' HB3' HD23 ' A' ' 64' ' ' LEU . 39.2 tt0 -104.18 114.82 29.32 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.686 175.841 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 62.1 t -98.13 125.75 51.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.691 -177.668 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 88.03 28.66 22.63 Favored Glycine 0 N--CA 1.452 -0.261 0 CA-C-N 115.989 -0.551 . . . . 0.0 112.015 179.603 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.436 ' HB1' ' CD2' ' A' ' 48' ' ' LEU . . . -55.79 -76.58 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.35 0 C-N-CA 123.045 0.538 . . . . 0.0 112.356 -176.503 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 64.09 -102.04 0.55 Allowed Glycine 0 CA--C 1.519 0.301 0 C-N-CA 121.185 -0.531 . . . . 0.0 113.188 179.408 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -107.59 -1.89 20.79 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.655 0.264 . . . . 0.0 111.547 -178.082 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.445 ' CG ' HG21 ' A' ' 96' ' ' ILE . 99.4 m-85 -87.72 23.56 1.96 Allowed 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.933 0.397 . . . . 0.0 111.408 -174.957 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.762 HD22 HD13 ' A' ' 64' ' ' LEU . 37.8 mt -66.42 -7.74 21.29 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.691 -0.686 . . . . 0.0 112.831 -172.928 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . 0.438 ' CE2' ' HA ' ' A' ' 47' ' ' PHE . 23.4 p90 -62.0 -25.72 67.81 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.576 0.227 . . . . 0.0 111.361 -179.905 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.434 HG22 ' HB3' ' A' ' 22' ' ' TRP . 61.9 t -74.24 -54.88 13.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.924 0.393 . . . . 0.0 110.381 175.935 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -66.22 -40.13 90.08 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.9 -0.591 . . . . 0.0 112.294 -177.21 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.558 ' O ' ' HG2' ' A' ' 56' ' ' LYS . 38.7 t70 -67.23 -27.75 67.49 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.863 0.363 . . . . 0.0 110.502 -178.688 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 78.5 t80 -69.53 -41.88 75.38 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.892 0.377 . . . . 0.0 110.293 176.014 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.662 HG23 HG12 ' A' ' 30' ' ' ILE . 77.1 mt -63.65 -40.7 90.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 115.946 -0.57 . . . . 0.0 111.231 -178.493 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . 0.505 ' HG2' ' HA ' ' A' ' 52' ' ' ASP . 5.8 ptp180 -70.11 -16.57 63.13 Favored 'General case' 0 CA--C 1.534 0.365 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.985 -176.492 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . 0.558 ' HG2' ' O ' ' A' ' 52' ' ' ASP . 67.1 mmtt -72.17 -42.86 65.4 Favored 'General case' 0 N--CA 1.462 0.143 0 CA-C-O 121.186 0.517 . . . . 0.0 110.377 179.645 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 45.4 m-70 -92.36 -46.87 7.47 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.48 -0.782 . . . . 0.0 111.884 -173.002 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . 0.448 ' HB2' HG23 ' A' ' 60' ' ' VAL . 12.0 p -112.3 134.18 53.99 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 116.609 -0.269 . . . . 0.0 111.163 -176.798 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 25.4 tptp -80.24 65.85 5.53 Favored 'General case' 0 N--CA 1.448 -0.541 0 CA-C-O 122.246 1.022 . . . . 0.0 109.612 174.532 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.448 HG23 ' HB2' ' A' ' 58' ' ' SER . 92.3 t -98.39 130.86 46.58 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.192 0 CA-C-N 114.4 -1.273 . . . . 0.0 109.113 172.662 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 62.2 m-20 -75.67 86.56 2.72 Favored 'General case' 0 C--N 1.317 -0.83 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 178.981 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . 0.45 ' HA ' ' O ' ' A' ' 39' ' ' VAL . 2.8 tt -87.02 115.55 24.48 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 115.45 -0.796 . . . . 0.0 109.933 -177.054 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 48.0 t -97.54 119.16 45.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.055 -177.252 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . 0.762 HD13 HD22 ' A' ' 48' ' ' LEU . 39.2 mt -92.85 121.54 34.33 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-N 115.913 -0.585 . . . . 0.0 109.762 179.102 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 19.4 p -121.74 124.89 45.29 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-O 121.054 0.454 . . . . 0.0 110.485 178.903 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 27.3 t0 -160.72 152.29 19.49 Favored 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 109.612 -0.514 . . . . 0.0 109.612 -179.294 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.694 HG12 ' HA ' ' A' ' 78' ' ' ASP . 49.6 mt -73.12 108.9 4.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 N-CA-C 110.124 -0.325 . . . . 0.0 110.124 -177.935 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' LYS . . . . . 0.452 ' HA ' ' HD2' ' A' ' 69' ' ' PRO . 45.3 mtpt 65.2 88.86 0.11 Allowed Pre-proline 0 C--N 1.328 -0.365 0 CA-C-N 115.157 -0.929 . . . . 0.0 110.627 -178.963 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . 0.756 ' HB3' ' HB ' ' A' ' 74' ' ' ILE . 11.0 Cg_endo -57.44 140.08 92.09 Favored 'Trans proline' 0 C--N 1.343 0.27 0 C-N-CA 123.558 2.839 . . . . 0.0 113.229 -177.498 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 35.8 m -97.48 -12.16 22.96 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.695 -0.684 . . . . 0.0 111.156 178.716 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . 0.496 ' HB2' HD11 ' A' ' 48' ' ' LEU . 38.0 m-70 -135.23 179.85 6.07 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.368 -179.83 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -88.62 144.33 18.24 Favored Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 120.92 -0.657 . . . . 0.0 111.931 178.593 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 95.21 1.03 62.94 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.131 -179.797 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.756 ' HB ' ' HB3' ' A' ' 69' ' ' PRO . 53.3 mt -100.72 128.0 53.27 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 N-CA-C 110.124 -0.324 . . . . 0.0 110.124 179.177 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 45.3 t -78.48 135.84 25.19 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.716 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 177.089 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' ARG . . . . . 0.529 ' HA ' ' HD3' ' A' ' 69' ' ' PRO . 3.3 ptm180 -79.92 25.24 0.37 Allowed 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.638 -0.256 . . . . 0.0 111.389 -176.441 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 38.2 t70 -64.59 103.8 0.72 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.37 0.605 . . . . 0.0 110.277 -177.192 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . 0.694 ' HA ' HG12 ' A' ' 67' ' ' ILE . 3.3 m-20 -68.25 123.46 20.79 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.241 -0.89 . . . . 0.0 110.201 -176.335 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 10.6 tp -64.08 -19.02 23.81 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.48 0 CA-C-O 121.132 0.492 . . . . 0.0 111.066 179.665 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 10.2 t -77.45 -14.81 59.61 Favored 'General case' 0 CA--C 1.532 0.288 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.784 178.431 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 33.6 t -158.68 70.53 3.69 Favored Pre-proline 0 C--N 1.326 -0.424 0 N-CA-C 108.353 -0.981 . . . . 0.0 108.353 177.593 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 90.0 Cg_endo -88.24 162.09 7.01 Favored 'Trans proline' 0 N--CA 1.458 -0.615 0 C-N-CA 122.956 2.437 . . . . 0.0 113.591 -168.56 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' ARG . . . . . 0.745 ' HB2' HD12 ' A' ' 86' ' ' ILE . 3.9 mmt180 -98.24 107.68 20.21 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 115.58 -0.736 . . . . 0.0 111.095 175.825 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' MET . . . . . 0.503 ' O ' ' HG3' ' A' ' 88' ' ' ARG . 91.0 mmm -62.17 -23.65 66.72 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.278 177.276 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.428 ' OE2' ' HD2' ' A' ' 83' ' ' ARG . 11.0 pt-20 -69.55 -22.58 63.54 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.638 -178.189 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.745 HD12 ' HB2' ' A' ' 83' ' ' ARG . 95.6 mt -81.04 -36.08 14.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.204 178.342 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . 0.403 ' CD1' HG11 ' A' ' 40' ' ' VAL . 22.8 m-85 -77.76 -31.21 51.92 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.72 -179.369 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . 0.503 ' HG3' ' O ' ' A' ' 84' ' ' MET . 38.2 mtp180 -63.67 123.08 17.94 Favored 'General case' 0 CA--C 1.516 -0.361 0 CA-C-O 121.331 0.586 . . . . 0.0 111.024 179.837 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 109.99 -9.5 31.71 Favored Glycine 0 N--CA 1.446 -0.639 0 CA-C-N 115.321 -0.854 . . . . 0.0 111.706 -178.506 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -81.93 143.8 31.39 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 110.349 -0.241 . . . . 0.0 110.349 178.389 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -92.89 -19.88 21.23 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 121.063 0.458 . . . . 0.0 110.627 -179.881 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . 0.45 HD23 ' N ' ' A' ' 93' ' ' ILE . 3.2 tt -152.09 140.66 20.73 Favored 'General case' 0 N--CA 1.449 -0.487 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.625 -179.062 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.467 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 72.3 mt -132.28 126.91 56.57 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 115.934 -0.576 . . . . 0.0 109.569 178.486 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' TYR . . . . . 0.4 ' HB3' ' HB ' ' A' ' 118' ' ' ILE . 8.1 p90 -134.7 162.84 31.21 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 120.812 0.339 . . . . 0.0 110.688 178.563 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 6.8 p -141.97 143.16 33.08 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.1 -176.392 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' ILE . . . . . 0.445 HG21 ' CG ' ' A' ' 47' ' ' PHE . 40.5 mm -90.47 93.11 4.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.632 179.675 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . 0.499 ' HG2' ' HA ' ' A' ' 121' ' ' PRO . 1.2 tmm_? 49.44 80.86 0.28 Allowed Pre-proline 0 N--CA 1.464 0.261 0 CA-C-N 115.18 -0.918 . . . . 0.0 111.757 178.552 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' PRO . . . . . 0.518 ' HG2' ' CD2' ' A' ' 103' ' ' HIS . 98.8 Cg_endo -84.98 152.32 11.11 Favored 'Trans proline' 0 N--CA 1.457 -0.63 0 C-N-CA 122.556 2.17 . . . . 0.0 111.874 176.195 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.591 ' HD2' HD11 ' A' ' 102' ' ' ILE . 24.2 Cg_exo -64.15 155.45 64.98 Favored 'Trans proline' 0 C--N 1.343 0.28 0 C-N-CA 122.857 2.371 . . . . 0.0 112.089 175.066 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.641 ' HA ' ' ND1' ' A' ' 103' ' ' HIS . . . -64.17 -16.12 61.26 Favored 'General case' 0 C--N 1.33 -0.257 0 N-CA-C 112.328 0.492 . . . . 0.0 112.328 -176.195 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' GLU . . . . . 0.626 ' HG3' HG23 ' A' ' 102' ' ' ILE . 12.9 pt-20 -76.14 -22.25 55.67 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.781 -0.19 . . . . 0.0 111.509 -177.519 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.626 HG23 ' HG3' ' A' ' 101' ' ' GLU . 43.1 pt -114.91 3.13 7.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 N-CA-C 112.438 0.533 . . . . 0.0 112.438 -176.177 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' HIS . . . . . 0.641 ' ND1' ' HA ' ' A' ' 100' ' ' ALA . 41.8 m170 -58.03 -51.57 69.13 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.002 0.43 . . . . 0.0 110.428 176.92 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 8.8 m -64.46 -29.82 70.86 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.892 -0.594 . . . . 0.0 110.59 178.03 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.554 ' O ' HG23 ' A' ' 109' ' ' VAL . 3.6 m -71.11 -43.9 66.73 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.577 -178.434 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 79.5 mt -60.77 -38.92 86.87 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.818 178.63 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' MET . . . . . 0.451 ' HA ' HD22 ' A' ' 117' ' ' LEU . 76.3 mtp -62.19 -45.54 92.93 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.081 179.841 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' ARG . . . . . 0.549 ' HG2' ' O ' ' A' ' 105' ' ' SER . 12.9 ptm180 -72.01 -22.8 61.36 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.633 -0.258 . . . . 0.0 111.073 -178.26 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.554 HG23 ' O ' ' A' ' 105' ' ' SER . 70.1 t -70.39 -49.94 49.77 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 173.985 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -58.15 -45.54 87.23 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.074 -0.512 . . . . 0.0 109.88 176.67 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.476 ' HA ' ' HB1' ' A' ' 148' ' ' ALA . 21.0 t70 -59.23 -36.15 74.92 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.329 -0.851 . . . . 0.0 111.372 179.387 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -71.95 -45.19 61.98 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.641 -0.709 . . . . 0.0 111.951 -179.269 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 23.2 m -86.94 -28.24 5.78 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 N-CA-C 111.996 0.369 . . . . 0.0 111.996 -174.627 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 87.92 58.96 1.73 Allowed Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.268 -178.65 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -137.47 162.29 34.07 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.752 0.311 . . . . 0.0 110.776 179.37 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 116' ' ' ARG . . . . . 0.446 ' HD3' ' OE1' ' A' ' 145' ' ' GLU . 12.5 ttm180 -79.72 120.27 23.78 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 175.857 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . 0.467 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 52.5 tp -91.99 125.79 36.82 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.089 178.895 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . 0.4 ' HB ' ' HB3' ' A' ' 94' ' ' TYR . 65.0 mt -118.57 115.02 46.8 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-O 121.176 0.512 . . . . 0.0 110.514 176.889 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 69.8 mt -116.62 120.73 65.87 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.144 179.55 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 120' ' ' LYS . . . . . 0.456 ' HG3' ' HB3' ' A' ' 143' ' ' PHE . 12.1 ttpp -113.58 99.94 50.82 Favored Pre-proline 0 C--N 1.324 -0.525 0 C-N-CA 120.819 -0.353 . . . . 0.0 110.27 175.928 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 121' ' ' PRO . . . . . 0.499 ' HA ' ' HG2' ' A' ' 97' ' ' ARG . 98.9 Cg_endo -81.93 -153.59 0.05 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.609 0 C-N-CA 122.594 2.196 . . . . 0.0 111.079 174.305 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 122' ' ' LEU . . . . . 0.579 ' HB2' ' HG2' ' A' ' 125' ' ' GLU . 3.6 mm? -81.49 -176.98 6.31 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 175.075 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 10.0 t -79.88 1.02 28.68 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.272 0.558 . . . . 0.0 110.602 178.491 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -156.83 71.74 0.25 Allowed Glycine 0 N--CA 1.446 -0.687 0 N-CA-C 111.325 -0.71 . . . . 0.0 111.325 178.081 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . 0.579 ' HG2' ' HB2' ' A' ' 122' ' ' LEU . 9.9 mm-40 -138.01 167.93 20.76 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 109.122 -0.695 . . . . 0.0 109.122 -177.824 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 8.7 t70 -120.68 163.22 18.4 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.046 178.128 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.508 ' HB ' HG22 ' A' ' 129' ' ' THR . 20.8 mt -109.86 -15.4 9.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-O 120.965 0.412 . . . . 0.0 110.716 -175.724 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 18.3 t 51.87 65.06 0.18 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.285 0 CA-C-O 121.651 0.739 . . . . 0.0 110.215 -176.065 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . 0.508 HG22 ' HB ' ' A' ' 127' ' ' ILE . 9.0 t -144.04 177.21 8.73 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.876 -176.125 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 130' ' ' GLU . . . . . 0.669 ' HG3' ' HG3' ' A' ' 132' ' ' LYS . 9.8 pt-20 -88.86 28.54 1.15 Allowed 'General case' 0 CA--C 1.532 0.26 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.648 -175.158 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 131' ' ' ARG . . . . . . . . . . . . . 86.0 mtt180 63.8 24.31 13.74 Favored 'General case' 0 N--CA 1.47 0.535 0 N-CA-C 112.718 0.636 . . . . 0.0 112.718 171.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 132' ' ' LYS . . . . . 0.669 ' HG3' ' HG3' ' A' ' 130' ' ' GLU . 46.4 mtmt -83.36 -9.35 59.11 Favored 'General case' 0 C--N 1.327 -0.383 0 C-N-CA 120.667 -0.413 . . . . 0.0 111.173 177.845 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 133' ' ' MET . . . . . 0.569 ' HG2' ' HB2' ' A' ' 146' ' ' TYR . 73.5 mtp -90.12 151.29 21.66 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 179.144 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . 0.546 ' NZ ' ' HB3' ' A' ' 134' ' ' LYS . 0.3 OUTLIER -121.1 143.05 49.29 Favored 'General case' 0 C--N 1.315 -0.924 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.959 -173.655 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . 0.781 HD11 ' HD2' ' A' ' 142' ' ' TYR . 43.4 tp -86.13 119.11 26.07 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.977 -0.556 . . . . 0.0 109.694 178.98 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 136' ' ' VAL . . . . . 0.441 ' CG2' ' HG2' ' A' ' 145' ' ' GLU . 0.0 OUTLIER -117.63 144.52 25.35 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.695 -176.271 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 9.8 m120 -114.96 123.77 49.95 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.41 -179.663 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 58.3 t80 -137.57 123.36 19.99 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 109.932 -0.395 . . . . 0.0 109.932 175.213 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 72.12 -85.98 0.49 Allowed Glycine 0 N--CA 1.449 -0.476 0 N-CA-C 110.838 -0.905 . . . . 0.0 110.838 -175.051 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 7.1 mtt180 -153.73 -5.55 0.18 Allowed 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 115.443 -0.378 . . . . 0.0 111.388 173.569 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 15.3 t -87.91 143.68 26.98 Favored 'General case' 0 N--CA 1.445 -0.701 0 N-CA-C 109.039 -0.726 . . . . 0.0 109.039 176.24 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 142' ' ' TYR . . . . . 0.781 ' HD2' HD11 ' A' ' 135' ' ' LEU . 48.3 p90 -127.1 129.72 48.51 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-O 121.485 0.66 . . . . 0.0 110.214 178.506 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 143' ' ' PHE . . . . . 0.456 ' HB3' ' HG3' ' A' ' 120' ' ' LYS . 9.6 p90 -139.29 175.77 9.28 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-N 114.838 -1.074 . . . . 0.0 109.962 -173.512 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 144' ' ' TYR . . . . . 0.42 ' HA ' ' O ' ' A' ' 134' ' ' LYS . 93.9 m-85 -110.72 122.51 48.0 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.317 179.889 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 145' ' ' GLU . . . . . 0.459 ' O ' ' HG2' ' A' ' 134' ' ' LYS . 19.7 pt-20 -114.68 160.42 19.37 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-O 121.155 0.503 . . . . 0.0 109.805 175.92 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . 0.569 ' HB2' ' HG2' ' A' ' 133' ' ' MET . 46.5 t80 -142.02 125.24 16.42 Favored 'General case' 0 C--N 1.313 -0.993 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.627 175.811 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 147' ' ' ILE . . . . . 0.421 ' N ' HD12 ' A' ' 147' ' ' ILE . 3.5 mp -92.89 108.67 20.63 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.792 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 179.71 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . 0.476 ' HB1' ' HA ' ' A' ' 111' ' ' ASP . . . -74.41 128.77 36.37 Favored 'General case' 0 N--CA 1.442 -0.837 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 173.983 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 19.7 mm-40 -61.12 165.74 4.12 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-O 121.787 0.803 . . . . 0.0 112.169 -178.23 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 41.1 t -71.94 131.47 34.61 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.8 0 CA-C-N 114.621 -1.172 . . . . 0.0 109.772 -178.644 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 151' ' ' ARG . . . . . 0.501 ' HD3' ' HA ' ' A' ' 151' ' ' ARG . 23.7 mmt180 -92.73 164.49 13.36 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.548 -176.115 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 42.1 t -88.56 150.2 23.2 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.564 -0.743 . . . . 0.0 110.873 -174.387 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 7.9 tpm_? . . . . . 0 C--O 1.249 1.047 0 CA-C-O 118.298 -0.858 . . . . 0.0 109.512 177.326 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 17.1 tpt . . . . . 0 N--CA 1.479 1.016 0 N-CA-C 110.313 -0.254 . . . . 0.0 110.313 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 139.95 -93.22 0.19 Allowed Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 120.637 -0.792 . . . . 0.0 112.466 177.67 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 33.4 t -78.27 123.39 26.89 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 120.925 0.393 . . . . 0.0 110.592 -178.21 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 19.4 m -103.35 117.58 34.81 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.236 -0.438 . . . . 0.0 109.965 178.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 85.4 m-70 -102.55 141.63 35.06 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.497 -177.224 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 79.2 m-70 -99.0 122.35 42.14 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.751 -179.829 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 83.2 t60 -76.31 -39.15 54.84 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.385 178.053 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 22.7 t60 -116.12 132.51 56.64 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.245 -177.943 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 56.8 m-70 -120.73 159.89 24.46 Favored 'General case' 0 C--N 1.324 -0.513 0 N-CA-C 109.449 -0.574 . . . . 0.0 109.449 -179.715 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 17.9 p80 -126.04 172.54 9.88 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.034 0.445 . . . . 0.0 111.134 -175.119 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 35.8 t -134.61 100.67 4.7 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.612 -0.722 . . . . 0.0 109.512 177.735 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 14.8 m -59.69 -36.4 76.41 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.135 -179.018 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -87.16 110.1 3.52 Favored Glycine 0 N--CA 1.443 -0.896 0 C-N-CA 120.574 -0.822 . . . . 0.0 111.12 176.107 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . 0.674 ' H ' HD23 ' A' ' 14' ' ' LEU . 2.3 pt? -70.25 138.65 51.83 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 120.9 0.381 . . . . 0.0 110.371 179.142 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 27.3 m -87.22 152.92 53.53 Favored Pre-proline 0 C--N 1.323 -0.572 0 CA-C-N 116.037 -0.528 . . . . 0.0 110.259 179.476 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -68.36 157.59 61.19 Favored 'Trans proline' 0 C--O 1.236 0.398 0 C-N-CA 122.438 2.092 . . . . 0.0 111.834 178.67 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 0.537 ' H ' ' HD2' ' A' ' 17' ' ' ARG . 1.1 mpt_? -79.36 75.92 5.95 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.385 0.612 . . . . 0.0 109.946 179.544 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . 0.415 ' O ' ' HG2' ' A' ' 21' ' ' MET . . . -96.83 89.91 1.1 Allowed Glycine 0 N--CA 1.443 -0.874 0 CA-C-N 115.474 -0.785 . . . . 0.0 112.377 -177.907 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 13.0 m -87.96 -28.34 21.53 Favored 'General case' 0 C--N 1.32 -0.71 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 175.57 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 19.2 t-160 -61.38 -30.62 70.65 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 114.867 -1.06 . . . . 0.0 111.162 -177.679 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' MET . . . . . 0.709 ' HB2' ' HB ' ' A' ' 141' ' ' THR . 21.2 ptt? -67.28 -17.2 64.69 Favored 'General case' 0 CA--C 1.53 0.21 0 CA-C-O 120.681 0.277 . . . . 0.0 111.436 -178.4 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' TRP . . . . . 0.413 ' HB2' ' HE2' ' A' ' 49' ' ' TYR . 88.3 m95 -87.42 -32.55 19.47 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 176.97 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 12.8 m120 -66.06 -48.17 71.9 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.626 -0.716 . . . . 0.0 110.411 177.739 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.714 ' HB3' ' HA3' ' A' ' 139' ' ' GLY . 0.7 OUTLIER -67.51 -35.3 78.84 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.298 179.323 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.716 HD22 ' HD2' ' A' ' 120' ' ' LYS . 50.7 tp -51.79 -49.77 62.06 Favored 'General case' 0 C--O 1.231 0.131 0 CA-C-O 121.15 0.5 . . . . 0.0 109.901 173.576 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . 0.433 ' O ' HG13 ' A' ' 30' ' ' ILE . . . -60.26 -45.75 92.2 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.439 -0.8 . . . . 0.0 111.098 177.825 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.438 ' HA ' HD12 ' A' ' 30' ' ' ILE . 76.0 t -55.45 -43.7 73.09 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 CA-C-N 116.389 -0.369 . . . . 0.0 110.896 178.887 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . 0.446 ' HB2' ' CD2' ' A' ' 138' ' ' TYR . 54.3 t80 -59.49 -43.12 93.39 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.428 179.339 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 65.2 mt -65.68 -44.4 93.43 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.427 178.668 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.713 HG12 HG23 ' A' ' 54' ' ' ILE . 85.5 mt -57.63 -45.82 86.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.969 178.378 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 62.6 mtt180 -68.39 -28.59 67.23 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.193 0.521 . . . . 0.0 111.474 -177.74 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 74.6 m -88.84 -0.4 57.32 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.555 -178.566 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 24.3 p -128.11 -83.73 0.59 Allowed 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.805 0.336 . . . . 0.0 111.01 177.517 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 108.34 160.88 20.4 Favored Glycine 0 N--CA 1.449 -0.477 0 C-N-CA 120.975 -0.631 . . . . 0.0 112.228 -179.891 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 24.5 Cg_exo -63.14 146.0 94.02 Favored 'Trans proline' 0 C--O 1.233 0.269 0 C-N-CA 122.893 2.395 . . . . 0.0 112.178 178.877 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 94.1 -23.05 33.2 Favored Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 120.925 -0.655 . . . . 0.0 112.621 179.001 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 15.7 p -81.62 -171.85 3.54 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 -179.313 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . 1.085 ' HG3' ' HA ' ' A' ' 90' ' ' ALA . 17.5 ptm180 -131.2 130.77 43.39 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 121.036 0.446 . . . . 0.0 110.222 173.895 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.429 HG13 ' HB3' ' A' ' 92' ' ' LEU . 86.7 t -129.73 134.15 63.72 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 CA-C-N 115.804 -0.635 . . . . 0.0 109.351 -177.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.45 HG22 ' HB ' ' A' ' 63' ' ' VAL . 45.3 t -109.86 125.45 67.05 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-O 120.952 0.406 . . . . 0.0 111.433 -175.431 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 45.1 tt0 -101.64 120.53 40.48 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.927 -0.579 . . . . 0.0 109.711 175.091 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.484 ' HB ' ' OG ' ' A' ' 95' ' ' SER . 41.8 t -98.22 123.34 50.67 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.265 -179.418 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 97.37 27.31 9.33 Favored Glycine 0 N--CA 1.45 -0.43 0 N-CA-C 111.224 -0.751 . . . . 0.0 111.224 -176.777 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -85.25 76.43 10.16 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.09 0.471 . . . . 0.0 110.863 -177.814 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -111.0 -70.4 0.61 Allowed Glycine 0 N--CA 1.444 -0.807 0 C-N-CA 120.45 -0.881 . . . . 0.0 112.538 -179.421 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -119.03 11.17 12.38 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 120.694 0.283 . . . . 0.0 111.118 -175.872 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 42.2 t80 -130.0 70.75 1.43 Allowed 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 121.275 0.56 . . . . 0.0 109.93 178.519 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 82.1 mt -93.36 20.12 7.49 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.771 -178.656 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . 0.413 ' HE2' ' HB2' ' A' ' 22' ' ' TRP . 44.9 t80 -63.54 -39.58 94.79 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.955 -177.881 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.463 ' O ' HG13 ' A' ' 54' ' ' ILE . 59.7 t -75.58 -54.4 13.96 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.546 -179.159 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 1.5 p -60.92 -46.77 89.36 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.8 -0.636 . . . . 0.0 112.638 -175.751 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.426 ' O ' ' HG2' ' A' ' 56' ' ' LYS . 38.9 t70 -63.75 -38.1 89.82 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.847 0.356 . . . . 0.0 110.393 -178.131 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 65.6 t80 -61.21 -45.62 93.83 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.376 177.78 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.713 HG23 HG12 ' A' ' 30' ' ' ILE . 83.3 mt -58.64 -48.41 85.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 115.903 -0.59 . . . . 0.0 111.465 -179.033 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 39.1 ptt180 -72.85 -16.77 61.59 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 111.776 0.287 . . . . 0.0 111.776 -175.888 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . 0.935 ' HE2' ' HA ' ' A' ' 56' ' ' LYS . 8.1 mmpt? -73.01 -41.87 63.81 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.798 0.333 . . . . 0.0 110.27 174.882 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 31.0 m-70 -84.44 -52.52 6.11 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.213 -178.837 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 10.5 p -111.65 129.42 56.09 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.153 -178.492 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -82.39 62.34 6.02 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.991 0.901 . . . . 0.0 109.745 176.146 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.41 HG21 HG23 ' A' ' 39' ' ' VAL . 2.3 p -87.43 143.92 10.31 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.935 0 CA-C-N 114.573 -1.194 . . . . 0.0 108.357 171.442 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . 0.48 ' O ' ' HA ' ' A' ' 38' ' ' ARG . 22.8 t0 -75.57 86.99 2.67 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-O 121.647 0.737 . . . . 0.0 109.427 177.706 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 1.5 tt -85.64 122.93 30.45 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.432 -0.804 . . . . 0.0 110.027 -176.208 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.45 ' HB ' HG22 ' A' ' 40' ' ' VAL . 47.6 t -103.75 118.14 50.38 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.698 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.753 -179.276 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . 0.579 ' CB ' HG23 ' A' ' 74' ' ' ILE . 77.8 mt -95.69 133.22 40.03 Favored 'General case' 0 C--N 1.315 -0.906 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.067 -179.053 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.493 HG22 ' HB ' ' A' ' 75' ' ' VAL . 23.7 p -129.61 135.01 48.04 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 120.45 0.167 . . . . 0.0 111.188 179.704 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . 0.804 ' HB3' ' HG3' ' A' ' 69' ' ' PRO . 25.3 t70 -165.25 173.61 11.1 Favored 'General case' 0 C--O 1.234 0.278 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 178.746 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.533 HD11 HG22 ' A' ' 79' ' ' ILE . 39.2 mm -81.26 96.64 3.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-O 120.958 0.408 . . . . 0.0 110.78 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' LYS . . . . . 0.408 ' HD3' ' HB2' ' A' ' 76' ' ' ARG . 70.3 mmtt 53.1 66.9 4.25 Favored Pre-proline 0 N--CA 1.467 0.407 0 CA-C-N 115.277 -0.874 . . . . 0.0 111.513 177.481 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . 0.804 ' HG3' ' HB3' ' A' ' 66' ' ' ASP . 17.1 Cg_exo -69.34 146.62 63.38 Favored 'Trans proline' 0 C--O 1.234 0.281 0 C-N-CA 123.164 2.576 . . . . 0.0 112.172 -178.09 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 12.3 p -95.7 11.25 34.08 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.782 -175.477 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 27.6 t60 -99.8 11.32 39.55 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 121.009 0.433 . . . . 0.0 110.233 -178.954 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 78.63 -78.04 1.69 Allowed Glycine 0 CA--C 1.518 0.256 0 C-N-CA 121.278 -0.487 . . . . 0.0 114.004 172.152 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -70.19 -11.15 66.94 Favored Glycine 0 CA--C 1.519 0.305 0 C-N-CA 121.4 -0.428 . . . . 0.0 114.04 -171.852 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.579 HG23 ' CB ' ' A' ' 64' ' ' LEU . 39.7 mt -72.37 138.16 22.08 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 116.939 0.369 . . . . 0.0 110.188 179.917 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.635 HG11 HD13 ' A' ' 86' ' ' ILE . 61.0 t -64.45 129.95 28.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 121.031 0.444 . . . . 0.0 110.563 -179.15 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' ARG . . . . . 0.454 ' HA ' ' HD3' ' A' ' 69' ' ' PRO . 5.4 ptp180 -104.12 28.97 6.29 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.655 -173.883 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . 0.5 ' H ' HG12 ' A' ' 75' ' ' VAL . 11.3 t70 -69.94 -84.74 0.03 OUTLIER 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.851 -0.613 . . . . 0.0 111.272 -172.88 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . 0.4 ' H ' ' HB3' ' A' ' 77' ' ' ASP . 7.5 t70 -163.24 -169.64 2.05 Favored 'General case' 0 C--N 1.325 -0.5 0 N-CA-C 109.091 -0.707 . . . . 0.0 109.091 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . 0.533 HG22 HD11 ' A' ' 67' ' ' ILE . 13.0 tt -144.19 -28.04 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-O 121.013 0.435 . . . . 0.0 110.749 -179.118 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.517 ' HA ' HG21 ' A' ' 102' ' ' ILE . 14.7 t -103.3 -24.52 13.51 Favored 'General case' 0 N--CA 1.45 -0.44 0 CA-C-O 121.288 0.566 . . . . 0.0 110.058 -178.047 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 68.0 m -150.13 75.17 9.0 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.27 172.871 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.476 ' HB2' ' HE2' ' A' ' 87' ' ' TYR . 9.1 Cg_endo -89.64 174.04 3.53 Favored 'Trans proline' 0 N--CA 1.454 -0.824 0 C-N-CA 123.267 2.645 . . . . 0.0 112.887 -177.08 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' ARG . . . . . 0.692 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 81.6 mtt85 -78.3 118.01 20.09 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.152 176.663 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' MET . . . . . 0.463 ' HE1' ' HA ' ' A' ' 109' ' ' VAL . 91.7 mmm -61.64 -23.77 66.28 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.302 -0.863 . . . . 0.0 111.565 -178.183 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.692 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 8.6 pt-20 -56.9 -29.34 62.93 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.842 0.354 . . . . 0.0 111.417 179.692 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.635 HD13 HG11 ' A' ' 75' ' ' VAL . 54.9 mt -79.28 -24.87 12.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-O 121.199 0.523 . . . . 0.0 110.858 -176.227 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . 0.476 ' HE2' ' HB2' ' A' ' 82' ' ' PRO . 91.5 m-85 -94.51 -27.67 15.85 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.934 -0.576 . . . . 0.0 111.193 -177.159 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . 0.446 ' HG3' ' O ' ' A' ' 84' ' ' MET . 78.1 mtp180 -65.77 131.46 46.37 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.509 0.671 . . . . 0.0 111.454 -176.552 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 93.17 -5.78 75.44 Favored Glycine 0 N--CA 1.448 -0.521 0 CA-C-N 114.798 -1.092 . . . . 0.0 112.36 -179.899 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . 1.085 ' HA ' ' HG3' ' A' ' 38' ' ' ARG . . . -73.6 153.39 40.22 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.888 0.375 . . . . 0.0 110.63 179.432 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -93.85 -20.72 19.79 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.807 -179.415 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . 0.513 ' HG ' ' HB3' ' A' ' 116' ' ' ARG . 3.7 tt -160.89 142.87 12.33 Favored 'General case' 0 N--CA 1.452 -0.365 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.64 -176.809 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.533 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 66.8 mt -132.31 126.72 56.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 177.188 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 19.7 p90 -137.38 160.78 38.11 Favored 'General case' 0 C--N 1.323 -0.579 0 C-N-CA 120.52 -0.472 . . . . 0.0 111.625 -178.155 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . 0.484 ' OG ' ' HB ' ' A' ' 42' ' ' VAL . 15.7 m -146.5 140.52 26.25 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.777 -178.565 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' ILE . . . . . 0.426 ' N ' HD12 ' A' ' 96' ' ' ILE . 3.6 mp -99.31 97.1 5.52 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 N-CA-C 110.026 -0.361 . . . . 0.0 110.026 178.728 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . 0.644 ' HG2' ' HA ' ' A' ' 121' ' ' PRO . 42.8 mtm105 53.77 77.25 0.45 Allowed Pre-proline 0 N--CA 1.468 0.467 0 CA-C-N 115.413 -0.812 . . . . 0.0 111.825 179.612 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 95.7 Cg_endo -88.46 159.42 6.64 Favored 'Trans proline' 0 N--CA 1.459 -0.514 0 C-N-CA 122.733 2.288 . . . . 0.0 112.417 179.775 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.626 ' HD2' HD11 ' A' ' 102' ' ' ILE . 51.1 Cg_exo -53.85 147.8 40.11 Favored 'Trans proline' 0 C--N 1.348 0.507 0 C-N-CA 122.92 2.414 . . . . 0.0 112.115 175.955 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -66.92 -19.74 65.78 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.712 -173.164 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' GLU . . . . . 0.586 ' HG3' HG23 ' A' ' 102' ' ' ILE . 11.7 pt-20 -73.34 -22.47 60.3 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.881 -177.334 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.626 HD11 ' HD2' ' A' ' 99' ' ' PRO . 44.1 pt -109.31 5.51 9.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 N-CA-C 112.505 0.557 . . . . 0.0 112.505 -174.711 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' HIS . . . . . . . . . . . . . 46.9 m170 -58.33 -45.22 88.51 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 120.998 0.427 . . . . 0.0 110.624 178.812 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 17.6 m -75.35 -27.79 59.33 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.518 177.31 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.511 ' O ' HG23 ' A' ' 109' ' ' VAL . 10.2 m -69.98 -45.15 67.95 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.896 -177.896 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 84.2 mt -56.78 -38.28 72.29 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.037 0.446 . . . . 0.0 110.822 178.717 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' MET . . . . . 0.556 ' SD ' ' HB2' ' A' ' 131' ' ' ARG . 52.0 ttm -68.4 -42.59 78.79 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.473 -178.92 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' ARG . . . . . 0.445 ' HG2' ' HA ' ' A' ' 105' ' ' SER . 2.5 ptm180 -68.71 -29.92 68.46 Favored 'General case' 0 N--CA 1.462 0.137 0 C-N-CA 120.471 -0.492 . . . . 0.0 110.482 179.482 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.511 HG23 ' O ' ' A' ' 105' ' ' SER . 74.5 t -66.12 -47.6 84.28 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.182 0 CA-C-N 116.453 -0.34 . . . . 0.0 110.274 176.165 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -57.74 -43.74 85.59 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.393 177.553 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.418 ' HA ' ' HB1' ' A' ' 148' ' ' ALA . 18.7 t70 -61.83 -40.43 95.24 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.625 -0.716 . . . . 0.0 110.793 179.777 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -69.4 -39.6 77.86 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.551 -0.749 . . . . 0.0 112.059 -177.859 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.462 HG21 HD11 ' A' ' 93' ' ' ILE . 15.8 m -92.39 -27.42 4.7 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 116.552 -0.294 . . . . 0.0 111.709 -174.556 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . 0.655 ' HA3' HG22 ' A' ' 150' ' ' VAL . . . 86.47 51.56 3.45 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.827 -0.701 . . . . 0.0 112.535 -179.782 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . 0.449 ' O ' ' HB3' ' A' ' 148' ' ' ALA . . . -131.67 165.55 23.46 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.064 0.459 . . . . 0.0 111.162 -178.683 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 116' ' ' ARG . . . . . 0.513 ' HB3' ' HG ' ' A' ' 92' ' ' LEU . 15.3 ttm180 -81.87 128.74 34.35 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.037 176.485 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . 0.533 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 49.8 tp -99.18 127.85 45.22 Favored 'General case' 0 C--N 1.32 -0.704 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 177.859 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 72.4 mt -128.25 125.51 64.34 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-O 120.903 0.382 . . . . 0.0 110.591 179.347 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 61.4 mt -130.27 130.45 65.56 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-O 120.811 0.339 . . . . 0.0 110.263 178.051 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 120' ' ' LYS . . . . . 0.716 ' HD2' HD22 ' A' ' 25' ' ' LEU . 49.9 tttm -116.16 94.23 41.4 Favored Pre-proline 0 C--N 1.324 -0.51 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.227 179.176 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 121' ' ' PRO . . . . . 0.644 ' HA ' ' HG2' ' A' ' 97' ' ' ARG . 89.1 Cg_endo -89.98 -159.7 0.09 OUTLIER 'Trans proline' 0 N--CA 1.459 -0.532 0 C-N-CA 122.799 2.333 . . . . 0.0 112.694 178.101 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 122' ' ' LEU . . . . . 0.54 ' HB3' ' HB3' ' A' ' 125' ' ' GLU . 11.9 tp -76.0 164.2 26.4 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.525 -0.762 . . . . 0.0 110.354 177.365 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 11.4 t -72.73 -28.58 62.73 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.008 0.432 . . . . 0.0 110.366 178.854 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -109.34 44.56 1.47 Allowed Glycine 0 N--CA 1.449 -0.469 0 N-CA-C 110.967 -0.853 . . . . 0.0 110.967 177.105 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . 0.54 ' HB3' ' HB3' ' A' ' 122' ' ' LEU . 31.8 tt0 -147.72 139.25 23.81 Favored 'General case' 0 C--N 1.321 -0.667 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 -174.539 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 17.2 t70 -118.82 161.7 19.7 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 121.068 0.461 . . . . 0.0 111.076 -178.667 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 60.7 mt -97.42 109.33 23.16 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.717 0 CA-C-N 115.353 -0.839 . . . . 0.0 109.311 177.606 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 17.3 m -83.08 47.7 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-O 121.737 0.779 . . . . 0.0 111.015 -176.108 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . 0.527 HG21 ' HG3' ' A' ' 133' ' ' MET . 12.1 t -78.08 -179.85 6.38 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 114.868 -1.06 . . . . 0.0 110.722 -178.075 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 7.9 tp10 -79.67 -63.75 1.34 Allowed 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 112.254 0.465 . . . . 0.0 112.254 -169.093 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 131' ' ' ARG . . . . . 0.556 ' HB2' ' SD ' ' A' ' 107' ' ' MET . 94.7 mtt180 -89.26 -2.49 58.49 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.776 -0.193 . . . . 0.0 111.183 -175.469 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 132' ' ' LYS . . . . . 0.414 ' HG2' ' N ' ' A' ' 133' ' ' MET . 0.0 OUTLIER 71.77 147.79 0.08 Allowed 'General case' 0 N--CA 1.465 0.303 0 O-C-N 123.89 0.743 . . . . 0.0 111.898 -178.026 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 133' ' ' MET . . . . . 0.527 ' HG3' HG21 ' A' ' 129' ' ' THR . 90.2 mtp -109.58 160.74 16.0 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.458 -0.792 . . . . 0.0 109.93 -178.759 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . 0.413 ' HE3' HG13 ' A' ' 136' ' ' VAL . 0.0 OUTLIER -95.83 142.7 27.78 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.088 0.471 . . . . 0.0 110.793 -176.062 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . 0.754 HD11 ' HD2' ' A' ' 142' ' ' TYR . 43.5 tp -75.35 131.35 40.2 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-N 115.45 -0.795 . . . . 0.0 110.317 178.833 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 136' ' ' VAL . . . . . 0.413 HG13 ' HE3' ' A' ' 134' ' ' LYS . 0.0 OUTLIER -128.22 137.73 56.63 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.755 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.542 178.564 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 19.5 m-80 -112.28 106.55 15.14 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 115.652 -0.704 . . . . 0.0 110.105 -179.941 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . 0.446 ' CD2' ' HB2' ' A' ' 28' ' ' TYR . 59.8 t80 -148.77 127.62 12.61 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.909 -178.41 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . 0.714 ' HA3' ' HB3' ' A' ' 24' ' ' ASP . . . 67.78 57.8 8.41 Favored Glycine 0 N--CA 1.445 -0.745 0 CA-C-N 115.807 -0.633 . . . . 0.0 114.166 171.223 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 140' ' ' ARG . . . . . 0.52 ' HD2' ' N ' ' A' ' 140' ' ' ARG . 2.4 mpt_? 62.6 10.91 4.4 Favored 'General case' 0 N--CA 1.465 0.316 0 C-N-CA 122.692 0.397 . . . . 0.0 112.059 173.84 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 141' ' ' THR . . . . . 0.709 ' HB ' ' HB2' ' A' ' 21' ' ' MET . 10.6 t -145.7 153.01 40.52 Favored 'General case' 0 N--CA 1.447 -0.592 0 CA-C-O 120.973 0.416 . . . . 0.0 110.326 -179.813 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 142' ' ' TYR . . . . . 0.754 ' HD2' HD11 ' A' ' 135' ' ' LEU . 5.0 p90 -122.26 137.73 54.74 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 116.052 -0.522 . . . . 0.0 109.716 174.518 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 143' ' ' PHE . . . . . 0.423 ' O ' HD12 ' A' ' 135' ' ' LEU . 21.4 p90 -145.43 -169.64 3.26 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.466 -0.788 . . . . 0.0 109.796 -174.024 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 83.4 m-85 -117.54 137.27 52.68 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 120.754 0.311 . . . . 0.0 110.932 179.903 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 145' ' ' GLU . . . . . 0.407 ' OE1' ' HD3' ' A' ' 116' ' ' ARG . 15.8 pt-20 -130.36 162.42 29.12 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.157 -0.474 . . . . 0.0 109.731 173.737 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 40.7 t80 -142.38 124.24 15.18 Favored 'General case' 0 C--N 1.317 -0.831 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 174.672 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 147' ' ' ILE . . . . . 0.417 HD12 ' N ' ' A' ' 147' ' ' ILE . 2.7 mp -93.93 98.69 8.49 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.68 0 N-CA-C 109.52 -0.548 . . . . 0.0 109.52 -179.366 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . 0.449 ' HB3' ' O ' ' A' ' 115' ' ' ALA . . . -86.89 108.74 18.91 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.625 176.663 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -75.15 166.06 24.24 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 121.136 0.493 . . . . 0.0 110.601 -179.372 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 150' ' ' VAL . . . . . 0.655 HG22 ' HA3' ' A' ' 114' ' ' GLY . 14.6 t -104.01 126.2 58.64 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.878 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 175.851 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 151' ' ' ARG . . . . . . . . . . . . . 48.0 mtp180 -77.07 94.24 3.99 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-O 121.155 0.502 . . . . 0.0 110.525 -178.678 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 12.3 p -101.16 99.42 9.83 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 115.651 -0.704 . . . . 0.0 110.316 178.261 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.247 0.955 0 CA-C-O 118.829 -0.605 . . . . 0.0 109.539 178.488 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 4.2 mpp? . . . . . 0 N--CA 1.481 1.11 0 CA-C-O 120.727 0.299 . . . . 0.0 110.281 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 171.29 46.23 0.04 OUTLIER Glycine 0 N--CA 1.448 -0.538 0 C-N-CA 120.847 -0.692 . . . . 0.0 111.972 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 13.0 m -122.86 10.12 9.51 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.13 0.49 . . . . 0.0 110.425 -179.85 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 14.5 m -97.74 -50.27 4.52 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.914 -0.584 . . . . 0.0 109.907 179.774 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 28.3 m80 -100.38 164.68 11.82 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.694 -0.685 . . . . 0.0 110.071 -178.148 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 22.0 m-70 -108.04 101.79 11.01 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 120.906 0.384 . . . . 0.0 110.745 -179.753 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . 0.421 ' CG ' ' H ' ' A' ' 8' ' ' HIS . 35.8 t-80 -160.69 -177.28 6.07 Favored 'General case' 0 C--N 1.325 -0.482 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 179.353 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . 0.421 ' H ' ' CG ' ' A' ' 7' ' ' HIS . 56.1 m80 63.92 27.35 14.4 Favored 'General case' 0 N--CA 1.468 0.466 0 C-N-CA 122.796 0.438 . . . . 0.0 111.505 179.061 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 52.7 m80 -73.49 130.35 39.92 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.49 178.079 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' HIS . . . . . 0.415 ' CD2' ' HA3' ' A' ' 73' ' ' GLY . 54.9 p-80 -104.55 164.91 11.42 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.254 0.55 . . . . 0.0 111.012 -178.18 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 17.8 m -114.16 130.64 56.6 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.652 -0.704 . . . . 0.0 109.525 175.453 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 29.5 p -153.37 96.53 2.05 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.984 0.421 . . . . 0.0 111.305 -178.018 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -106.1 82.56 0.33 Allowed Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 120.678 -0.772 . . . . 0.0 112.022 178.499 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 93.1 mt -97.88 169.93 9.31 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 120.756 0.312 . . . . 0.0 110.836 -178.085 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 4.4 p -151.38 104.84 2.93 Favored Pre-proline 0 C--N 1.323 -0.547 0 CA-C-O 121.381 0.61 . . . . 0.0 110.027 177.036 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.478 ' HB2' ' HD1' ' A' ' 49' ' ' TYR . 93.6 Cg_endo -85.85 145.96 9.04 Favored 'Trans proline' 0 N--CA 1.456 -0.687 0 C-N-CA 122.614 2.209 . . . . 0.0 113.128 -177.994 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -127.39 156.38 42.13 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.726 174.051 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 65.94 -161.71 43.53 Favored Glycine 0 N--CA 1.45 -0.43 0 C-N-CA 120.463 -0.875 . . . . 0.0 110.983 -173.932 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 35.1 t 63.07 26.72 15.53 Favored 'General case' 0 CA--C 1.534 0.338 0 CA-C-O 121.105 0.479 . . . . 0.0 110.689 175.67 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 33.9 m-70 -63.65 -24.3 67.73 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-N 115.975 -0.557 . . . . 0.0 111.573 -174.717 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' MET . . . . . . . . . . . . . 28.1 ttt -66.68 -20.18 65.92 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 121.166 0.508 . . . . 0.0 110.992 179.712 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' TRP . . . . . 0.404 ' O ' ' HB3' ' A' ' 25' ' ' LEU . 89.3 m95 -88.72 -16.8 31.33 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.974 -0.557 . . . . 0.0 111.057 -179.538 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 21.0 t-20 -52.34 -50.47 62.25 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.889 -178.776 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 11.3 m-20 -60.5 -33.49 72.69 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.476 -0.329 . . . . 0.0 111.42 -178.22 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.567 HD22 ' HG3' ' A' ' 120' ' ' LYS . 50.6 tp -59.17 -50.65 73.21 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.926 0.393 . . . . 0.0 110.28 176.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . 0.403 ' HB2' HG13 ' A' ' 50' ' ' VAL . . . -58.49 -49.66 76.54 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.639 179.47 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.427 ' O ' ' HG3' ' A' ' 31' ' ' ARG . 86.4 t -52.74 -46.51 50.8 Favored 'Isoleucine or valine' 0 C--O 1.233 0.209 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.949 177.893 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 86.0 t80 -56.29 -46.18 79.88 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.882 179.417 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 71.1 mt -66.78 -43.08 90.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.972 -179.484 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.422 HG12 HG23 ' A' ' 54' ' ' ILE . 88.9 mt -56.4 -48.79 79.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 115.817 -0.628 . . . . 0.0 111.067 179.216 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . 0.427 ' HG3' ' O ' ' A' ' 27' ' ' VAL . 61.9 mtp180 -63.25 -36.41 83.58 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.904 -0.589 . . . . 0.0 111.072 -178.808 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 46.6 t -77.29 -25.92 51.83 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.333 -175.338 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 13.7 p -97.03 -76.63 0.51 Allowed 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.785 0.326 . . . . 0.0 111.301 -177.865 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.505 ' O ' HG22 ' A' ' 37' ' ' THR . . . 98.22 167.54 31.54 Favored Glycine 0 N--CA 1.449 -0.452 0 C-N-CA 120.951 -0.642 . . . . 0.0 112.13 -178.601 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 6.7 Cg_exo -73.42 143.54 34.98 Favored 'Trans proline' 0 N--CA 1.462 -0.327 0 C-N-CA 122.878 2.385 . . . . 0.0 112.379 -179.36 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 97.19 -11.29 65.6 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.67 -0.776 . . . . 0.0 113.441 176.218 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . 0.505 HG22 ' O ' ' A' ' 34' ' ' GLY . 12.6 t -103.52 -179.02 3.83 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 177.501 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . 0.681 ' HB2' ' HA ' ' A' ' 90' ' ' ALA . 62.5 mtp180 -115.11 136.63 52.91 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.809 0.338 . . . . 0.0 110.763 -179.227 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.429 HG23 HG21 ' A' ' 60' ' ' VAL . 47.5 t -130.9 138.18 54.16 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 177.913 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.454 HG11 ' CE1' ' A' ' 87' ' ' TYR . 33.4 t -118.95 125.45 74.5 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 CA-C-O 120.837 0.351 . . . . 0.0 111.336 -177.254 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . 0.436 ' HB3' HD23 ' A' ' 64' ' ' LEU . 43.4 tt0 -99.57 112.15 24.4 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.954 -0.566 . . . . 0.0 109.645 175.462 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 60.5 t -97.45 121.16 47.69 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-N 116.0 -0.546 . . . . 0.0 110.385 -179.143 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 90.35 46.04 4.19 Favored Glycine 0 N--CA 1.444 -0.795 0 C-N-CA 120.539 -0.839 . . . . 0.0 111.861 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.442 ' HB1' ' CD2' ' A' ' 48' ' ' LEU . . . -59.22 -32.94 70.41 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-O 121.328 0.585 . . . . 0.0 110.932 179.292 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 63.88 -123.57 28.74 Favored Glycine 0 N--CA 1.445 -0.701 0 CA-C-N 115.714 -0.675 . . . . 0.0 112.597 177.104 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . 0.473 ' HA ' ' HE1' ' A' ' 71' ' ' HIS . 30.5 mmt-85 -122.96 9.77 9.41 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 120.847 0.356 . . . . 0.0 110.498 -177.005 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 19.0 p90 -137.36 113.24 9.69 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 121.289 0.566 . . . . 0.0 110.82 -176.845 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.442 ' CD2' ' HB1' ' A' ' 44' ' ' ALA . 68.8 mt -104.64 60.87 0.7 Allowed 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.56 -177.164 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . 0.478 ' HD1' ' HB2' ' A' ' 16' ' ' PRO . 72.1 t80 -75.56 -52.84 9.68 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.938 0.399 . . . . 0.0 110.88 -179.559 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.45 ' O ' HG13 ' A' ' 54' ' ' ILE . 49.1 t -67.87 -52.78 36.15 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-N 115.868 -0.606 . . . . 0.0 110.722 -176.562 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . 0.529 ' HB3' HD21 ' A' ' 64' ' ' LEU . 0.2 OUTLIER -54.84 -43.15 72.76 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.767 -0.651 . . . . 0.0 112.491 -178.933 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.417 ' O ' ' HG3' ' A' ' 56' ' ' LYS . 20.7 t70 -67.73 -42.96 81.05 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.834 0.349 . . . . 0.0 110.591 -179.104 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 75.9 t80 -63.99 -40.08 95.57 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.153 -179.009 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.45 HG13 ' O ' ' A' ' 50' ' ' VAL . 80.0 mt -63.01 -45.78 97.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.474 -0.33 . . . . 0.0 111.367 -179.709 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 33.2 ptt180 -72.04 -16.84 62.05 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.89 0.376 . . . . 0.0 110.871 -178.785 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . 0.417 ' HG3' ' O ' ' A' ' 52' ' ' ASP . 24.2 mtpp -73.08 -30.55 63.75 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.318 176.882 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 28.0 m-70 -102.51 -56.61 2.21 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.891 -177.434 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 6.8 p -100.46 135.4 41.95 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 120.982 0.42 . . . . 0.0 112.057 -174.399 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -81.39 65.05 6.36 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 122.196 0.998 . . . . 0.0 108.969 171.053 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.429 HG21 HG23 ' A' ' 39' ' ' VAL . 8.8 p -100.54 148.54 6.77 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.09 0 CA-C-N 114.322 -1.308 . . . . 0.0 110.111 178.78 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . 0.563 ' HB3' ' HG2' ' A' ' 38' ' ' ARG . 9.3 t70 -74.77 84.89 2.16 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 176.773 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . 0.425 HD23 ' HB ' ' A' ' 39' ' ' VAL . 3.1 tm? -94.57 116.83 29.24 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 115.441 -0.799 . . . . 0.0 110.287 -173.92 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 60.1 t -113.61 139.09 40.89 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 CA-C-N 115.604 -0.725 . . . . 0.0 110.561 -176.524 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . 0.529 HD21 ' HB3' ' A' ' 51' ' ' SER . 31.6 mt -112.37 136.12 52.23 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 110.171 -0.307 . . . . 0.0 110.171 178.735 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 15.9 p -118.81 125.43 49.55 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.102 0.477 . . . . 0.0 110.706 175.366 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . 0.478 ' HB3' HG21 ' A' ' 74' ' ' ILE . 23.9 t70 -154.82 140.46 17.98 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.532 -0.758 . . . . 0.0 109.247 -179.853 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.496 HG22 ' HG2' ' A' ' 68' ' ' LYS . 59.3 mt -74.44 124.17 31.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-N 116.519 -0.31 . . . . 0.0 110.315 -177.964 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' LYS . . . . . 0.496 ' HG2' HG22 ' A' ' 67' ' ' ILE . 59.8 pttt 39.72 69.72 1.66 Allowed Pre-proline 0 N--CA 1.469 0.499 0 O-C-N 124.29 0.994 . . . . 0.0 111.684 -174.296 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . 0.561 ' CB ' ' HB ' ' A' ' 74' ' ' ILE . 44.1 Cg_endo -67.64 141.88 56.56 Favored 'Trans proline' 0 C--O 1.232 0.218 0 C-N-CA 122.856 2.371 . . . . 0.0 113.017 -174.345 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 11.7 t -88.37 -16.19 33.6 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.27 -178.874 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . 0.473 ' HE1' ' HA ' ' A' ' 46' ' ' ARG . 71.6 m80 -80.52 -12.29 59.55 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.883 -179.604 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 80.98 -53.1 4.58 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 121.039 -0.601 . . . . 0.0 113.419 175.926 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.415 ' HA3' ' CD2' ' A' ' 10' ' ' HIS . . . -76.21 -10.26 85.43 Favored Glycine 0 C--O 1.228 -0.259 0 C-N-CA 121.348 -0.453 . . . . 0.0 113.585 -175.957 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.561 ' HB ' ' CB ' ' A' ' 69' ' ' PRO . 55.3 mt -75.3 142.3 14.73 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 N-CA-C 109.713 -0.477 . . . . 0.0 109.713 177.254 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.555 HG11 HD13 ' A' ' 86' ' ' ILE . 66.3 t -66.27 123.72 19.85 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-O 120.884 0.374 . . . . 0.0 110.266 -179.344 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 18.7 ptp180 -85.9 48.61 1.63 Allowed 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.44 0.638 . . . . 0.0 110.695 -176.251 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . 0.43 ' HB2' HG12 ' A' ' 75' ' ' VAL . 2.7 t70 -89.17 -154.56 0.31 Allowed 'General case' 0 C--N 1.321 -0.641 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 179.214 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . 0.521 ' OD1' HG22 ' A' ' 80' ' ' THR . 4.9 t70 -136.25 -176.42 4.32 Favored 'General case' 0 C--N 1.321 -0.633 0 C-N-CA 120.737 -0.385 . . . . 0.0 110.251 -178.916 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 8.9 tp -127.37 -28.18 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-O 120.822 0.344 . . . . 0.0 110.502 179.71 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.521 HG22 ' OD1' ' A' ' 78' ' ' ASP . 15.0 t -89.06 -25.75 21.77 Favored 'General case' 0 N--CA 1.451 -0.387 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 177.006 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 34.2 t -135.34 70.5 67.91 Favored Pre-proline 0 C--N 1.326 -0.442 0 CA-C-N 115.33 -0.85 . . . . 0.0 108.997 170.822 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_endo -87.32 157.01 8.11 Favored 'Trans proline' 0 N--CA 1.453 -0.909 0 C-N-CA 122.496 2.131 . . . . 0.0 112.518 -176.146 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' ARG . . . . . 0.765 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 50.0 mtt180 -89.12 111.92 22.79 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.199 173.058 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' MET . . . . . 0.523 ' HE1' ' HA ' ' A' ' 109' ' ' VAL . 95.2 mmm -66.83 -17.65 64.99 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.5 -177.62 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.765 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 9.9 pt-20 -62.35 -23.35 66.74 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.628 -0.714 . . . . 0.0 111.508 179.078 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.555 HD13 HG11 ' A' ' 75' ' ' VAL . 67.3 mt -84.36 -39.54 14.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-O 121.117 0.484 . . . . 0.0 110.363 179.724 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . 0.454 ' CE1' HG11 ' A' ' 40' ' ' VAL . 90.7 m-85 -78.86 -32.19 45.9 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.756 -0.657 . . . . 0.0 111.322 -177.881 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . 0.438 ' HG3' HG12 ' A' ' 113' ' ' VAL . 57.9 mtt180 -67.01 115.33 6.6 Favored 'General case' 0 CA--C 1.516 -0.339 0 CA-C-O 121.317 0.58 . . . . 0.0 110.633 -179.933 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 119.44 -12.05 11.23 Favored Glycine 0 N--CA 1.448 -0.522 0 CA-C-N 115.037 -0.983 . . . . 0.0 111.455 -175.213 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . 0.681 ' HA ' ' HB2' ' A' ' 38' ' ' ARG . . . -82.94 147.74 28.06 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.881 0.372 . . . . 0.0 110.898 178.346 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -96.73 -22.26 17.09 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.811 179.529 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . 0.462 ' HG ' ' HB3' ' A' ' 116' ' ' ARG . 5.3 tt -150.85 139.79 20.95 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.682 -178.442 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.569 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 67.5 mt -131.57 125.37 56.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.688 -0.687 . . . . 0.0 109.258 178.69 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 19.0 p90 -128.42 155.48 44.69 Favored 'General case' 0 C--N 1.321 -0.645 0 C-N-CA 120.618 -0.433 . . . . 0.0 110.965 -178.961 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 18.3 m -132.74 130.41 39.94 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.554 -178.436 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 65.4 mt -93.55 103.14 14.37 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.682 -178.894 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 70.6 mtp180 54.38 67.36 3.45 Favored Pre-proline 0 N--CA 1.466 0.329 0 CA-C-N 115.489 -0.778 . . . . 0.0 111.998 -178.517 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' PRO . . . . . 0.447 ' HA ' ' HD3' ' A' ' 99' ' ' PRO . 72.5 Cg_endo -76.91 140.58 20.53 Favored 'Trans proline' 0 N--CA 1.461 -0.402 0 C-N-CA 122.244 1.963 . . . . 0.0 112.251 179.615 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.626 ' HD2' HD11 ' A' ' 102' ' ' ILE . 38.1 Cg_exo -60.2 147.56 93.01 Favored 'Trans proline' 0 C--O 1.235 0.331 0 C-N-CA 122.741 2.294 . . . . 0.0 111.942 176.606 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.64 ' HA ' ' NE2' ' A' ' 103' ' ' HIS . . . -78.54 31.15 0.19 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.227 0.537 . . . . 0.0 111.331 -175.542 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' GLU . . . . . 0.565 ' HG2' ' HB2' ' A' ' 99' ' ' PRO . 7.7 pt-20 -127.55 -1.63 6.16 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-N 115.967 -0.561 . . . . 0.0 111.164 -176.908 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.626 HD11 ' HD2' ' A' ' 99' ' ' PRO . 30.9 pt -131.41 10.33 1.83 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 N-CA-C 112.118 0.414 . . . . 0.0 112.118 -178.308 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' HIS . . . . . 0.64 ' NE2' ' HA ' ' A' ' 100' ' ' ALA . 9.7 m-70 -54.77 -51.65 65.06 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.244 -0.435 . . . . 0.0 112.006 -176.738 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 15.5 m -62.54 -32.49 73.44 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.498 -0.319 . . . . 0.0 111.007 -177.939 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.592 ' O ' HG23 ' A' ' 109' ' ' VAL . 21.0 m -67.45 -42.3 83.32 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.329 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 73.9 mt -64.78 -43.96 91.54 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.493 179.56 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' MET . . . . . 0.4 ' HG3' ' O ' ' A' ' 103' ' ' HIS . 77.0 mtp -63.18 -41.8 99.27 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.55 -176.244 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 2.9 ptp180 -70.27 -30.78 67.89 Favored 'General case' 0 C--N 1.332 -0.189 0 C-N-CA 120.879 -0.329 . . . . 0.0 111.145 -178.497 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.592 HG23 ' O ' ' A' ' 105' ' ' SER . 75.3 t -63.87 -45.2 97.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.889 0.376 . . . . 0.0 110.062 177.466 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -58.42 -44.4 89.07 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.619 177.71 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.455 ' HA ' ' HB1' ' A' ' 148' ' ' ALA . 13.6 t70 -64.84 -42.48 94.88 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.059 179.586 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -64.8 -41.74 95.56 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.712 -0.676 . . . . 0.0 112.055 -177.488 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.438 HG12 ' HG3' ' A' ' 88' ' ' ARG . 12.2 m -92.57 -24.78 5.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 CA-C-N 116.506 -0.315 . . . . 0.0 111.694 -174.983 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 88.43 49.33 3.71 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.764 -0.731 . . . . 0.0 111.997 179.731 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -129.07 156.5 43.76 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 120.738 0.304 . . . . 0.0 111.142 -177.689 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 116' ' ' ARG . . . . . 0.534 ' HD3' ' OE1' ' A' ' 145' ' ' GLU . 16.4 ttm180 -80.26 125.16 29.52 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.158 -0.474 . . . . 0.0 109.728 177.549 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . 0.569 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 48.7 tp -94.47 119.31 32.99 Favored 'General case' 0 C--N 1.322 -0.619 0 N-CA-C 110.158 -0.312 . . . . 0.0 110.158 179.815 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 63.9 mt -114.91 117.97 57.31 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-O 121.183 0.516 . . . . 0.0 110.732 179.398 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 64.6 mt -112.03 132.22 61.28 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 115.923 -0.581 . . . . 0.0 110.564 179.829 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 120' ' ' LYS . . . . . 0.953 ' HD2' ' HB3' ' A' ' 143' ' ' PHE . 23.1 mmmt -102.58 99.97 14.8 Favored Pre-proline 0 C--N 1.328 -0.347 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.229 174.419 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 121' ' ' PRO . . . . . 0.425 ' HG3' ' HD2' ' A' ' 144' ' ' TYR . 88.4 Cg_endo -82.78 -158.95 0.1 OUTLIER 'Trans proline' 0 N--CA 1.459 -0.535 0 C-N-CA 122.563 2.175 . . . . 0.0 111.351 171.861 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 122' ' ' LEU . . . . . 0.829 ' HB2' ' HB2' ' A' ' 125' ' ' GLU . 3.6 mm? -99.88 -171.04 1.98 Allowed 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 110.267 -0.272 . . . . 0.0 110.267 179.916 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 8.7 t -88.76 -35.11 16.85 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.708 0.289 . . . . 0.0 111.19 -176.719 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -114.78 12.61 20.48 Favored Glycine 0 N--CA 1.449 -0.499 0 C-N-CA 120.436 -0.887 . . . . 0.0 111.296 178.53 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . 0.829 ' HB2' ' HB2' ' A' ' 122' ' ' LEU . 28.2 mt-10 -131.52 126.52 35.12 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.248 -0.476 . . . . 0.0 110.075 -176.342 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 11.3 t70 -87.01 179.28 6.71 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.679 -0.692 . . . . 0.0 109.885 -177.504 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.58 HD11 ' HB2' ' A' ' 144' ' ' TYR . 56.5 mt -71.64 -33.72 49.92 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 178.799 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 55.6 t 68.71 79.53 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.333 -0.148 0 CA-C-N 115.313 -0.858 . . . . 0.0 109.582 -174.991 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 13.2 t -165.65 -168.95 1.43 Allowed 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.438 -0.801 . . . . 0.0 109.635 -176.514 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -73.92 148.86 41.84 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 110.01 -0.367 . . . . 0.0 110.01 179.452 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 131' ' ' ARG . . . . . 0.405 ' HD3' HH11 ' A' ' 131' ' ' ARG . 10.0 mmm180 -79.24 63.63 3.93 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.222 0.534 . . . . 0.0 110.881 -177.699 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 33.5 mttp -117.36 -1.25 11.8 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.03 179.92 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 133' ' ' MET . . . . . 0.55 ' HG2' ' HB2' ' A' ' 146' ' ' TYR . 84.8 mtp -111.14 165.63 11.74 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.857 -0.611 . . . . 0.0 109.405 176.144 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . 0.408 ' HE3' ' OE2' ' A' ' 145' ' ' GLU . 6.9 pttp -130.51 140.23 50.5 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.09 0.472 . . . . 0.0 111.754 -175.974 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . 0.57 HD11 ' HD2' ' A' ' 142' ' ' TYR . 39.2 tp -76.93 122.36 24.76 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.585 -0.734 . . . . 0.0 110.777 -179.645 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 136' ' ' VAL . . . . . 0.433 HG23 ' CD1' ' A' ' 143' ' ' PHE . 0.0 OUTLIER -117.95 142.25 33.23 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.761 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.437 178.426 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 137' ' ' ASN . . . . . 0.591 ' ND2' ' HB3' ' A' ' 142' ' ' TYR . 13.8 m120 -117.9 110.32 17.6 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.442 -176.022 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . 0.436 ' O ' HG22 ' A' ' 141' ' ' THR . 76.0 t80 -135.23 130.09 34.69 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.248 -0.433 . . . . 0.0 109.877 -179.434 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 63.75 26.36 69.87 Favored Glycine 0 N--CA 1.453 -0.217 0 C-N-CA 120.54 -0.838 . . . . 0.0 111.702 -176.784 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 21.2 mtp180 66.67 7.69 5.34 Favored 'General case' 0 C--N 1.33 -0.274 0 C-N-CA 123.304 0.641 . . . . 0.0 112.436 -178.731 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 141' ' ' THR . . . . . 0.436 HG22 ' O ' ' A' ' 138' ' ' TYR . 10.8 t -107.48 139.71 41.57 Favored 'General case' 0 N--CA 1.446 -0.659 0 N-CA-C 108.663 -0.866 . . . . 0.0 108.663 169.84 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 142' ' ' TYR . . . . . 0.591 ' HB3' ' ND2' ' A' ' 137' ' ' ASN . 17.0 p90 -113.86 149.08 35.59 Favored 'General case' 0 C--N 1.315 -0.892 0 CA-C-O 121.69 0.757 . . . . 0.0 111.513 -177.581 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 143' ' ' PHE . . . . . 0.953 ' HB3' ' HD2' ' A' ' 120' ' ' LYS . 3.5 p90 -151.41 178.96 8.76 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 114.238 -1.347 . . . . 0.0 108.83 -178.98 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 144' ' ' TYR . . . . . 0.58 ' HB2' HD11 ' A' ' 127' ' ' ILE . 80.6 m-85 -115.58 119.72 37.06 Favored 'General case' 0 C--N 1.313 -0.98 0 C-N-CA 120.62 -0.432 . . . . 0.0 110.529 179.82 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 145' ' ' GLU . . . . . 0.534 ' OE1' ' HD3' ' A' ' 116' ' ' ARG . 18.3 pt-20 -108.15 156.96 18.73 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 176.2 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . 0.55 ' HB2' ' HG2' ' A' ' 133' ' ' MET . 22.7 t80 -137.13 120.68 17.17 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-N 115.626 -0.715 . . . . 0.0 109.66 176.647 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 147' ' ' ILE . . . . . 0.434 ' N ' HD12 ' A' ' 147' ' ' ILE . 3.2 mp -89.05 101.5 12.05 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 -178.481 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . 0.455 ' HB1' ' HA ' ' A' ' 111' ' ' ASP . . . -74.37 96.43 2.86 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 121.225 0.536 . . . . 0.0 109.76 177.19 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 11.6 pt-20 -75.54 164.67 26.1 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-N 115.155 -0.93 . . . . 0.0 109.752 178.89 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 34.5 t -68.18 127.58 30.15 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 N-CA-C 109.248 -0.649 . . . . 0.0 109.248 177.846 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 151' ' ' ARG . . . . . 0.406 HH11 ' HD2' ' A' ' 151' ' ' ARG . 13.6 ptt180 -81.44 66.93 7.2 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-O 121.691 0.757 . . . . 0.0 110.633 -176.597 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 10.8 t -164.7 -176.28 4.2 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 114.912 -1.04 . . . . 0.0 108.918 179.008 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.247 0.933 0 CA-C-O 118.503 -0.761 . . . . 0.0 109.714 178.847 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.402 ' HG3' ' O ' ' A' ' 1' ' ' MET . 23.9 ptt? . . . . . 0 N--CA 1.479 1.002 0 CA-C-O 121.498 0.666 . . . . 0.0 110.545 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 157.36 135.22 1.88 Allowed Glycine 0 N--CA 1.444 -0.829 0 CA-C-N 115.556 -0.747 . . . . 0.0 111.479 179.687 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 27.6 m -66.63 98.0 0.48 Allowed 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.301 0.572 . . . . 0.0 111.025 -177.353 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 15.5 m -94.32 53.0 1.64 Allowed 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.73 -0.668 . . . . 0.0 109.322 178.412 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 8.5 p80 -74.16 162.98 28.41 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.243 -0.889 . . . . 0.0 111.084 -175.238 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 27.1 m-70 -98.36 118.78 35.8 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.91 -0.587 . . . . 0.0 110.517 -179.624 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 70.3 m80 -69.13 -28.83 66.81 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 121.396 0.617 . . . . 0.0 109.388 175.016 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 26.9 m-70 -116.03 115.53 26.29 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.226 -0.897 . . . . 0.0 109.61 173.718 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 74.9 t60 -71.28 -33.82 70.1 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 107.845 -1.168 . . . . 0.0 107.845 173.094 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 32.1 p-80 -129.85 122.48 28.78 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 114.457 -1.247 . . . . 0.0 108.427 169.303 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 10.7 t -66.64 98.6 0.53 Allowed 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.098 0.475 . . . . 0.0 110.748 -177.265 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 33.6 t -128.95 132.35 47.6 Favored 'General case' 0 N--CA 1.45 -0.445 0 CA-C-N 115.724 -0.671 . . . . 0.0 110.081 -179.015 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 153.5 -177.31 31.12 Favored Glycine 0 N--CA 1.446 -0.691 0 C-N-CA 121.028 -0.606 . . . . 0.0 111.916 -179.813 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . 0.72 ' H ' HD23 ' A' ' 14' ' ' LEU . 2.4 pt? -112.37 147.34 36.6 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 110.238 -0.282 . . . . 0.0 110.238 179.241 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 16.3 m -93.21 114.58 63.18 Favored Pre-proline 0 C--N 1.326 -0.455 0 CA-C-O 121.112 0.482 . . . . 0.0 110.563 178.13 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 89.5 Cg_endo -80.07 166.77 20.58 Favored 'Trans proline' 0 N--CA 1.459 -0.54 0 C-N-CA 122.62 2.213 . . . . 0.0 112.406 -179.173 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 23.0 mmt180 -87.13 -15.35 38.68 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.926 178.21 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 72.88 35.64 58.11 Favored Glycine 0 N--CA 1.448 -0.534 0 C-N-CA 120.75 -0.738 . . . . 0.0 111.941 179.847 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 12.7 p -83.61 108.26 16.59 Favored 'General case' 0 N--CA 1.447 -0.601 0 CA-C-O 121.307 0.575 . . . . 0.0 110.495 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' HIS . . . . . 0.571 ' CD2' ' H ' ' A' ' 21' ' ' MET . 58.0 t60 -164.35 -152.26 0.18 Allowed 'General case' 0 C--N 1.32 -0.68 0 N-CA-C 107.302 -1.37 . . . . 0.0 107.302 -176.322 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' MET . . . . . 0.571 ' H ' ' CD2' ' A' ' 20' ' ' HIS . 0.0 OUTLIER -56.87 -14.68 3.68 Favored 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 112.212 0.449 . . . . 0.0 112.212 178.06 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' TRP . . . . . 0.538 ' CD1' ' HB3' ' A' ' 20' ' ' HIS . 40.2 m95 -54.63 -33.35 60.44 Favored 'General case' 0 N--CA 1.461 0.122 0 CA-C-O 121.033 0.444 . . . . 0.0 110.533 175.321 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 25.5 t-20 -65.18 -45.55 84.39 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.553 -0.749 . . . . 0.0 110.28 -178.024 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -57.24 -46.29 83.13 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.679 -0.691 . . . . 0.0 110.255 177.953 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 62.2 tp -61.52 -46.96 87.74 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.238 -0.892 . . . . 0.0 110.958 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . 0.487 ' O ' HG13 ' A' ' 30' ' ' ILE . . . -56.19 -52.47 64.28 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.164 -179.742 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.448 ' HA ' HD12 ' A' ' 30' ' ' ILE . 84.0 t -56.12 -42.25 71.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.206 179.131 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 57.4 t80 -57.41 -45.99 83.98 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.574 179.733 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 67.0 mt -67.28 -40.23 84.48 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.785 179.783 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.576 HG12 HG23 ' A' ' 54' ' ' ILE . 95.4 mt -58.85 -38.42 72.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 115.969 -0.56 . . . . 0.0 111.125 179.401 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 40.1 mtp-105 -71.99 -30.32 65.13 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.839 -0.619 . . . . 0.0 111.332 -178.855 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 42.9 t -89.2 -17.41 29.17 Favored 'General case' 0 C--N 1.324 -0.513 0 N-CA-C 111.956 0.354 . . . . 0.0 111.956 -176.489 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 11.5 p -94.68 -79.17 0.43 Allowed 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 111.961 0.356 . . . . 0.0 111.961 -176.086 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.48 ' O ' HG22 ' A' ' 37' ' ' THR . . . 101.16 136.73 9.45 Favored Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.812 -0.709 . . . . 0.0 111.847 -176.698 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . 0.411 ' HD3' ' HA2' ' A' ' 34' ' ' GLY . 48.4 Cg_exo -55.84 126.48 22.55 Favored 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 123.076 2.518 . . . . 0.0 112.767 -176.066 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 112.73 -18.51 22.21 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.294 -0.955 . . . . 0.0 113.48 175.278 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . 0.48 HG22 ' O ' ' A' ' 34' ' ' GLY . 11.1 t -86.76 -173.6 4.56 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.995 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . 0.505 ' HG2' ' CB ' ' A' ' 61' ' ' ASP . 92.1 mtm-85 -118.45 135.2 54.5 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 120.932 0.396 . . . . 0.0 110.735 176.634 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.497 HG23 HG11 ' A' ' 60' ' ' VAL . 90.7 t -130.19 127.44 63.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 176.904 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.433 HG11 ' CE1' ' A' ' 87' ' ' TYR . 35.4 t -109.06 128.79 64.67 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-O 120.937 0.399 . . . . 0.0 111.915 -173.02 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . 0.723 ' HB3' HD23 ' A' ' 64' ' ' LEU . 6.3 tp10 -103.3 127.92 50.5 Favored 'General case' 0 C--O 1.237 0.416 0 CA-C-N 115.379 -0.828 . . . . 0.0 109.452 174.092 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.567 ' HB ' ' HB3' ' A' ' 95' ' ' SER . 35.2 t -106.05 98.91 7.49 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-O 120.974 0.416 . . . . 0.0 110.535 -179.178 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 101.08 84.8 1.83 Allowed Glycine 0 N--CA 1.451 -0.333 0 N-CA-C 111.471 -0.651 . . . . 0.0 111.471 -176.778 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.448 ' HB1' HD21 ' A' ' 48' ' ' LEU . . . -83.07 -40.83 19.35 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 112.106 0.41 . . . . 0.0 112.106 -172.107 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 57.3 -127.55 45.19 Favored Glycine 0 CA--C 1.521 0.447 0 C-N-CA 121.077 -0.582 . . . . 0.0 112.713 179.824 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 52.4 mtp180 -120.42 2.49 10.77 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.866 0.365 . . . . 0.0 111.21 179.071 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.566 ' CE1' ' HB ' ' A' ' 96' ' ' ILE . 6.3 p90 -96.85 58.29 1.61 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.379 0.609 . . . . 0.0 111.088 -176.166 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.448 HD21 ' HB1' ' A' ' 44' ' ' ALA . 83.8 mt -81.68 8.43 9.92 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.79 -0.641 . . . . 0.0 112.12 -174.425 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 75.7 t80 -57.95 -48.75 79.04 Favored 'General case' 0 N--CA 1.463 0.201 0 CA-C-O 120.589 0.233 . . . . 0.0 111.195 -179.802 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.45 ' O ' HG13 ' A' ' 54' ' ' ILE . 85.3 t -58.96 -51.73 69.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.892 -178.398 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . 0.503 ' CB ' HD21 ' A' ' 64' ' ' LEU . 3.9 p -69.79 -25.76 63.94 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.004 -0.544 . . . . 0.0 112.346 -174.418 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.522 ' O ' ' HG2' ' A' ' 55' ' ' ARG . 17.5 t70 -83.06 -41.46 18.6 Favored 'General case' 0 C--N 1.325 -0.462 0 C-N-CA 120.806 -0.358 . . . . 0.0 110.3 177.232 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 66.4 t80 -58.16 -43.75 87.55 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.545 178.839 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.576 HG23 HG12 ' A' ' 30' ' ' ILE . 89.0 mt -60.2 -47.6 91.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.192 178.326 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . 0.522 ' HG2' ' O ' ' A' ' 52' ' ' ASP . 7.9 ptp180 -71.98 -16.31 62.08 Favored 'General case' 0 CA--C 1.532 0.27 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.381 -174.725 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 44.2 mmtm -77.1 -37.57 54.03 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.839 0.352 . . . . 0.0 110.569 176.316 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 13.3 m-70 -83.79 -55.32 4.32 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.67 179.694 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 68.0 m -117.13 127.97 54.66 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.169 -179.025 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 1.3 mptm? -77.5 63.36 2.63 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-O 121.925 0.869 . . . . 0.0 110.475 176.712 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.497 HG11 HG23 ' A' ' 39' ' ' VAL . 66.1 t -82.84 142.35 13.7 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.922 0 CA-C-N 114.444 -1.253 . . . . 0.0 109.09 173.888 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . 0.505 ' CB ' ' HG2' ' A' ' 38' ' ' ARG . 0.3 OUTLIER -73.19 80.08 1.29 Allowed 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.3 0.571 . . . . 0.0 109.5 175.27 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . 0.402 ' HA ' ' O ' ' A' ' 39' ' ' VAL . 3.1 tt -84.08 114.88 22.07 Favored 'General case' 0 N--CA 1.444 -0.755 0 CA-C-N 115.598 -0.728 . . . . 0.0 109.378 -178.074 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.401 HG11 ' CG2' ' A' ' 86' ' ' ILE . 58.2 t -99.28 119.52 47.4 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.706 0 CA-C-N 115.296 -0.865 . . . . 0.0 110.229 -177.381 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . 0.723 HD23 ' HB3' ' A' ' 41' ' ' GLU . 65.8 mt -98.3 131.37 44.67 Favored 'General case' 0 C--N 1.316 -0.87 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 176.964 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.41 ' OG1' ' HA ' ' A' ' 42' ' ' VAL . 36.2 p -116.87 130.56 56.79 Favored 'General case' 0 C--N 1.318 -0.799 0 N-CA-C 109.973 -0.38 . . . . 0.0 109.973 177.021 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 5.8 t70 -157.56 161.93 38.78 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 -178.72 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.698 HD11 HG22 ' A' ' 79' ' ' ILE . 48.7 mm -76.63 95.37 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-O 120.835 0.35 . . . . 0.0 110.145 -177.716 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 56.8 mtpt 50.36 70.29 2.12 Favored Pre-proline 0 CA--C 1.535 0.373 0 CA-C-N 115.192 -0.913 . . . . 0.0 111.68 177.437 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . 0.676 ' HD2' ' HG2' ' A' ' 76' ' ' ARG . 37.0 Cg_endo -64.76 155.61 66.32 Favored 'Trans proline' 0 C--N 1.345 0.361 0 C-N-CA 123.455 2.77 . . . . 0.0 112.865 -179.121 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 11.4 p -89.52 -34.37 16.42 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.705 -0.679 . . . . 0.0 110.742 177.792 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 88.8 m-70 -81.09 131.27 35.29 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.376 -177.902 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -68.46 128.05 24.08 Favored Glycine 0 N--CA 1.449 -0.473 0 CA-C-N 115.763 -0.653 . . . . 0.0 111.483 176.121 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 127.22 -23.36 5.5 Favored Glycine 0 N--CA 1.447 -0.614 0 N-CA-C 111.248 -0.741 . . . . 0.0 111.248 -176.632 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.452 HG23 ' CB ' ' A' ' 64' ' ' LEU . 41.0 mt -93.83 136.62 24.89 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 N-CA-C 109.606 -0.516 . . . . 0.0 109.606 176.64 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.526 HG12 ' H ' ' A' ' 77' ' ' ASP . 64.3 t -74.12 135.32 27.73 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-O 120.866 0.365 . . . . 0.0 110.029 179.95 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' ARG . . . . . 0.676 ' HG2' ' HD2' ' A' ' 69' ' ' PRO . 26.6 mtp85 -89.74 21.03 3.71 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.907 -0.588 . . . . 0.0 111.856 -174.096 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . 0.526 ' H ' HG12 ' A' ' 75' ' ' VAL . 1.1 m-20 -80.19 160.62 25.57 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.785 0.326 . . . . 0.0 110.843 -179.396 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . 0.406 ' HB3' ' O ' ' A' ' 81' ' ' SER . 11.0 t70 -75.22 152.93 38.29 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.934 -173.789 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . 0.698 HG22 HD11 ' A' ' 67' ' ' ILE . 12.4 tt -91.15 -31.42 5.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.883 -175.475 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 11.1 t -99.73 -24.47 14.69 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.291 0.567 . . . . 0.0 109.98 -177.184 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . 0.406 ' O ' ' HB3' ' A' ' 78' ' ' ASP . 27.9 m -126.6 74.66 74.74 Favored Pre-proline 0 C--N 1.328 -0.362 0 CA-C-N 115.942 -0.572 . . . . 0.0 109.876 172.472 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 98.1 Cg_endo -90.93 -162.27 0.11 Allowed 'Trans proline' 0 N--CA 1.459 -0.541 0 C-N-CA 123.379 2.72 . . . . 0.0 113.219 -174.071 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 94.8 mtt180 -126.2 116.45 21.33 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.348 178.319 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' MET . . . . . 0.835 ' HA ' ' HD2' ' A' ' 87' ' ' TYR . 25.3 mtp -66.14 -18.5 65.39 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 112.252 0.464 . . . . 0.0 112.252 -177.259 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.417 ' HA ' ' HD3' ' A' ' 88' ' ' ARG . 10.8 pt-20 -65.63 -25.78 67.52 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.094 0.473 . . . . 0.0 110.406 179.335 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.401 ' CG2' HG11 ' A' ' 63' ' ' VAL . 68.3 mt -73.54 -36.74 48.55 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 115.77 -0.65 . . . . 0.0 109.922 177.06 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . 0.835 ' HD2' ' HA ' ' A' ' 84' ' ' MET . 74.2 m-85 -77.92 -30.56 50.65 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.633 -0.712 . . . . 0.0 110.754 -178.242 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . 0.417 ' HD3' ' HA ' ' A' ' 85' ' ' GLU . 69.9 mtp180 -58.17 125.25 22.39 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.964 178.81 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . 0.494 ' HA3' ' NH2' ' A' ' 38' ' ' ARG . . . 97.71 -8.68 63.88 Favored Glycine 0 N--CA 1.447 -0.605 0 C-N-CA 120.821 -0.704 . . . . 0.0 112.45 179.016 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -74.82 142.63 44.19 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 120.777 0.322 . . . . 0.0 110.373 178.277 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -94.39 -18.02 21.96 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.513 179.333 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . 0.417 HD23 ' N ' ' A' ' 93' ' ' ILE . 3.6 tt -153.72 140.05 18.59 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.337 -179.154 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.574 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 71.6 mt -132.24 126.17 55.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 N-CA-C 109.032 -0.729 . . . . 0.0 109.032 178.139 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' TYR . . . . . 0.409 ' HE1' HG12 ' A' ' 39' ' ' VAL . 2.0 p90 -135.29 167.18 21.5 Favored 'General case' 0 C--N 1.32 -0.699 0 C-N-CA 120.663 -0.415 . . . . 0.0 110.535 -178.258 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . 0.633 ' HA ' ' OE1' ' A' ' 41' ' ' GLU . 4.8 p -153.93 120.32 5.47 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.632 -178.447 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' ILE . . . . . 0.566 ' HB ' ' CE1' ' A' ' 47' ' ' PHE . 46.8 mm -80.81 97.23 3.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.684 179.374 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 2.2 tmt_? 52.66 76.91 0.48 Allowed Pre-proline 0 CA--C 1.534 0.353 0 CA-C-N 114.997 -1.001 . . . . 0.0 111.393 177.921 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 69.1 Cg_endo -89.85 161.99 5.06 Favored 'Trans proline' 0 N--CA 1.457 -0.655 0 C-N-CA 122.856 2.371 . . . . 0.0 112.343 177.589 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.438 ' HB2' ' HG2' ' A' ' 101' ' ' GLU . 14.6 Cg_endo -60.12 147.64 92.51 Favored 'Trans proline' 0 C--N 1.345 0.367 0 C-N-CA 122.275 1.983 . . . . 0.0 111.858 174.64 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -78.13 33.55 0.19 Allowed 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.928 -176.34 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' GLU . . . . . 0.663 ' HG3' HG23 ' A' ' 102' ' ' ILE . 9.7 pt-20 -116.09 -23.35 8.52 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.685 0.278 . . . . 0.0 110.712 176.549 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.663 HG23 ' HG3' ' A' ' 101' ' ' GLU . 30.1 pt -109.83 -0.26 9.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 N-CA-C 112.006 0.373 . . . . 0.0 112.006 -174.667 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' HIS . . . . . 0.713 ' HD2' ' HB ' ' A' ' 129' ' ' THR . 22.1 p-80 -60.66 -43.4 97.67 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 121.093 0.473 . . . . 0.0 110.817 -178.228 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 4.0 p -73.78 -29.41 62.17 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.987 -0.552 . . . . 0.0 110.742 179.094 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.492 ' O ' HG23 ' A' ' 109' ' ' VAL . 2.4 m -71.49 -45.47 62.39 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.224 -179.555 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.408 ' HG ' ' O ' ' A' ' 102' ' ' ILE . 74.5 mt -60.91 -39.77 90.61 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.229 -179.846 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' MET . . . . . 0.457 ' HA ' HD22 ' A' ' 117' ' ' LEU . 51.7 ttm -60.45 -45.61 93.06 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.49 -179.23 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' ARG . . . . . 0.467 ' HG2' ' O ' ' A' ' 105' ' ' SER . 15.1 ptm180 -74.21 -24.1 59.29 Favored 'General case' 0 C--N 1.327 -0.409 0 C-N-CA 120.978 -0.289 . . . . 0.0 110.89 -177.384 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.492 HG23 ' O ' ' A' ' 105' ' ' SER . 81.1 t -72.34 -43.61 64.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 173.954 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -58.24 -42.2 85.85 Favored 'General case' 0 CA--C 1.52 -0.197 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.551 177.926 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.784 ' HA ' ' HB1' ' A' ' 148' ' ' ALA . 35.2 t70 -65.61 -40.27 92.43 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.965 -179.769 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -68.21 -37.47 80.9 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.551 -0.75 . . . . 0.0 112.12 -178.218 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 21.5 m -92.99 -22.82 5.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-O 120.794 0.33 . . . . 0.0 111.549 -177.044 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 85.91 54.41 2.77 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.971 -0.633 . . . . 0.0 112.172 178.935 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -132.73 155.87 48.07 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 120.739 0.304 . . . . 0.0 110.917 -178.975 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 23.9 ttm180 -81.53 127.6 33.01 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 176.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . 0.574 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 55.8 tp -93.3 123.94 36.93 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.022 179.348 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 66.5 mt -120.16 120.32 62.64 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 CA-C-O 120.939 0.4 . . . . 0.0 110.641 178.376 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 69.3 mt -120.13 126.57 75.42 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.165 179.331 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 120' ' ' LYS . . . . . 0.769 ' HG2' ' HB3' ' A' ' 143' ' ' PHE . 5.9 tmtt? -120.97 96.33 48.63 Favored Pre-proline 0 C--N 1.325 -0.49 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.118 178.379 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -88.8 -163.62 0.15 Allowed 'Trans proline' 0 C--O 1.238 0.497 0 C-N-CA 122.928 2.419 . . . . 0.0 112.33 177.098 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -70.54 -178.72 1.86 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.29 -0.413 . . . . 0.0 110.901 177.311 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 9.6 t -81.4 -35.26 30.96 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.904 0.383 . . . . 0.0 110.95 -176.39 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -113.74 52.54 0.64 Allowed Glycine 0 N--CA 1.448 -0.556 0 N-CA-C 110.629 -0.988 . . . . 0.0 110.629 175.852 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 36.4 tt0 -138.14 116.61 12.03 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.466 -0.367 . . . . 0.0 110.114 -173.354 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 8.1 t70 -91.71 163.19 14.18 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.987 -0.552 . . . . 0.0 110.117 -177.264 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 15.9 mt -93.2 -10.98 9.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 N-CA-C 110.176 -0.305 . . . . 0.0 110.176 -177.716 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 19.2 m 47.41 32.08 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.764 0 C-N-CA 124.167 0.987 . . . . 0.0 112.533 179.664 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . 0.713 ' HB ' ' HD2' ' A' ' 103' ' ' HIS . 14.9 t -109.05 157.99 18.17 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.405 -179.843 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 130' ' ' GLU . . . . . 0.416 ' OE2' ' HD2' ' A' ' 131' ' ' ARG . 1.1 tm-20 -58.08 122.75 13.83 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 108.763 -0.829 . . . . 0.0 108.763 176.086 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 131' ' ' ARG . . . . . 0.425 ' CD ' ' H ' ' A' ' 131' ' ' ARG . 0.0 OUTLIER -52.87 112.11 0.79 Allowed 'General case' 0 N--CA 1.464 0.24 0 CA-C-O 122.148 0.975 . . . . 0.0 111.921 -171.848 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 8.3 tppt? -144.13 -32.8 0.42 Allowed 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 114.582 -1.19 . . . . 0.0 109.302 -177.734 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 133' ' ' MET . . . . . 0.806 ' HG2' ' HB2' ' A' ' 146' ' ' TYR . 83.4 mtp -87.17 171.75 10.44 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.247 -0.888 . . . . 0.0 110.459 -177.64 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . 0.405 ' HE2' HG13 ' A' ' 136' ' ' VAL . 14.2 ptmt -131.16 146.66 52.42 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.953 -175.268 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . 0.484 HD11 ' HD2' ' A' ' 142' ' ' TYR . 56.7 tp -79.75 129.84 34.82 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.454 176.715 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 136' ' ' VAL . . . . . 0.405 HG13 ' HE2' ' A' ' 134' ' ' LYS . 0.0 OUTLIER -127.66 129.8 70.23 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.702 0 CA-C-O 121.162 0.506 . . . . 0.0 111.162 178.811 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 15.4 m120 -109.85 122.25 47.11 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.31 -0.859 . . . . 0.0 109.234 177.739 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 61.4 t80 -137.67 125.35 22.32 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 120.535 0.207 . . . . 0.0 110.67 -177.475 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 69.26 -88.92 0.25 Allowed Glycine 0 N--CA 1.448 -0.547 0 N-CA-C 111.626 -0.589 . . . . 0.0 111.626 179.225 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 140' ' ' ARG . . . . . 0.638 ' NE ' ' HA ' ' A' ' 140' ' ' ARG . 2.1 mmp_? -143.72 9.96 1.58 Allowed 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 115.446 -0.377 . . . . 0.0 111.182 175.91 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 141' ' ' THR . . . . . 0.568 ' HB ' ' HB3' ' A' ' 21' ' ' MET . 15.2 t -118.6 155.23 31.31 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.801 0.334 . . . . 0.0 110.611 -179.678 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 142' ' ' TYR . . . . . 0.484 ' HD2' HD11 ' A' ' 135' ' ' LEU . 32.4 p90 -133.58 141.22 47.59 Favored 'General case' 0 N--CA 1.448 -0.533 0 CA-C-O 121.086 0.469 . . . . 0.0 109.992 176.704 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 143' ' ' PHE . . . . . 0.769 ' HB3' ' HG2' ' A' ' 120' ' ' LYS . 11.6 p90 -153.89 -175.98 5.63 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 115.429 -0.805 . . . . 0.0 109.733 -177.006 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 95.7 m-85 -116.98 125.36 51.29 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 110.308 -0.256 . . . . 0.0 110.308 179.375 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 145' ' ' GLU . . . . . . . . . . . . . 21.6 pt-20 -114.05 160.92 18.36 Favored 'General case' 0 C--N 1.321 -0.649 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 176.626 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . 0.806 ' HB2' ' HG2' ' A' ' 133' ' ' MET . 42.3 t80 -141.87 123.44 15.03 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-N 115.971 -0.558 . . . . 0.0 109.693 175.617 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 147' ' ' ILE . . . . . 0.439 ' N ' HD12 ' A' ' 147' ' ' ILE . 3.1 mp -93.03 100.94 12.07 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.834 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 -178.653 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . 0.784 ' HB1' ' HA ' ' A' ' 111' ' ' ASP . . . -67.99 120.16 13.8 Favored 'General case' 0 N--CA 1.447 -0.6 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 174.378 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -62.03 143.1 57.06 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.27 0.557 . . . . 0.0 110.188 -176.06 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 8.2 t -96.15 126.34 48.78 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.901 0 CA-C-N 115.608 -0.723 . . . . 0.0 110.339 -174.779 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 151' ' ' ARG . . . . . . . . . . . . . 12.5 ptm180 -72.52 163.41 28.08 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 115.518 -0.764 . . . . 0.0 110.656 177.728 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 3.8 p -72.9 161.68 30.42 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 115.976 -0.557 . . . . 0.0 110.207 173.48 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 11.9 mmt180 . . . . . 0 C--O 1.25 1.08 0 CA-C-O 118.511 -0.756 . . . . 0.0 111.007 -178.046 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 13.5 tpt . . . . . 0 N--CA 1.478 0.967 0 N-CA-C 110.044 -0.354 . . . . 0.0 110.044 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -172.0 -117.45 0.44 Allowed Glycine 0 N--CA 1.447 -0.595 0 N-CA-C 111.179 -0.768 . . . . 0.0 111.179 179.684 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 48.7 m 53.6 37.42 25.9 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.156 0.503 . . . . 0.0 111.525 177.113 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 16.2 m -94.31 125.56 39.02 Favored 'General case' 0 N--CA 1.45 -0.465 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.148 179.786 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 71.4 m-70 -86.45 85.87 7.33 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.209 0.528 . . . . 0.0 110.315 -178.929 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 26.7 t-80 -114.66 86.13 2.38 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.506 -0.77 . . . . 0.0 109.942 -179.874 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 11.3 p-80 -154.63 172.81 17.26 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.838 -0.619 . . . . 0.0 109.718 177.522 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 46.0 m80 -103.71 116.69 32.79 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 120.912 0.387 . . . . 0.0 110.749 -175.455 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 20.0 p80 -105.95 164.64 11.8 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.133 179.968 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 47.6 t-80 64.35 101.98 0.04 OUTLIER 'General case' 0 N--CA 1.466 0.332 0 O-C-N 123.878 0.736 . . . . 0.0 111.635 179.109 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 10.1 t -107.04 138.83 42.46 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.026 -0.534 . . . . 0.0 109.561 176.241 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 3.8 p -73.03 128.99 37.09 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 120.735 0.303 . . . . 0.0 110.529 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -90.88 151.55 21.24 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.878 -0.677 . . . . 0.0 112.526 -178.188 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 96.3 mt -125.17 115.27 20.17 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 110.034 -0.358 . . . . 0.0 110.034 179.493 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.408 ' HA ' ' HD3' ' A' ' 16' ' ' PRO . 31.7 m -92.48 145.49 30.63 Favored Pre-proline 0 C--N 1.32 -0.681 0 CA-C-N 116.53 -0.305 . . . . 0.0 111.039 -179.295 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.408 ' HD3' ' HA ' ' A' ' 15' ' ' VAL . 16.6 Cg_exo -68.61 156.8 64.32 Favored 'Trans proline' 0 C--O 1.234 0.279 0 C-N-CA 122.716 2.278 . . . . 0.0 111.661 176.03 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -141.74 59.95 1.48 Allowed 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 121.225 0.536 . . . . 0.0 110.894 -177.085 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -89.92 0.94 80.03 Favored Glycine 0 N--CA 1.451 -0.305 0 CA-C-N 115.698 -0.683 . . . . 0.0 111.868 178.265 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . 0.661 ' HB3' ' CD1' ' A' ' 22' ' ' TRP . 51.0 m -86.06 76.48 9.79 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.147 0.499 . . . . 0.0 110.119 177.405 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 54.7 m80 -62.98 -31.38 72.49 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.469 -0.787 . . . . 0.0 112.039 -174.022 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' MET . . . . . 0.458 ' CG ' ' HB ' ' A' ' 141' ' ' THR . 50.1 ttm -69.96 -28.54 65.63 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.239 0.543 . . . . 0.0 110.469 179.605 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' TRP . . . . . 0.661 ' CD1' ' HB3' ' A' ' 19' ' ' SER . 72.5 m95 -82.61 -19.25 38.71 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.748 -0.66 . . . . 0.0 111.119 -174.928 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.432 ' O ' HG23 ' A' ' 27' ' ' VAL . 14.6 m120 -60.78 -36.99 80.37 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.522 175.528 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 43.9 m-20 -64.49 -45.16 88.53 Favored 'General case' 0 CA--C 1.52 -0.2 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.38 178.907 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 61.2 tp -55.13 -50.9 68.07 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.75 179.011 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -55.55 -47.03 77.0 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.912 -0.585 . . . . 0.0 111.639 -178.702 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.576 ' HA ' HD12 ' A' ' 30' ' ' ILE . 92.2 t -58.58 -37.09 62.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.471 -179.732 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 59.8 t80 -60.01 -45.89 91.27 Favored 'General case' 0 CA--C 1.534 0.339 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.042 -178.039 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.456 HG13 HD12 ' A' ' 118' ' ' ILE . 3.2 mp -64.09 -41.56 92.83 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.17 0 CA-C-O 120.973 0.416 . . . . 0.0 110.468 176.345 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.607 HG23 ' HB2' ' A' ' 58' ' ' SER . 90.6 mt -58.42 -44.67 89.22 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 115.739 -0.664 . . . . 0.0 111.357 -177.92 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 49.7 mtp180 -66.51 -33.82 76.55 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.463 -177.617 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 44.5 t -82.29 -25.81 33.67 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.416 -174.936 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 15.4 p -95.82 -81.82 0.4 Allowed 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.85 0.357 . . . . 0.0 111.746 -174.056 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 104.56 158.34 23.75 Favored Glycine 0 N--CA 1.447 -0.597 0 C-N-CA 120.937 -0.649 . . . . 0.0 111.8 -176.666 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 15.8 Cg_exo -68.67 139.58 44.61 Favored 'Trans proline' 0 N--CA 1.465 -0.164 0 C-N-CA 122.876 2.384 . . . . 0.0 112.415 -179.426 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 96.1 -4.67 65.32 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.577 -0.821 . . . . 0.0 112.568 178.502 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 29.6 p -96.48 -170.76 2.14 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 109.983 -0.377 . . . . 0.0 109.983 -179.892 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . 0.777 ' HB2' ' HA ' ' A' ' 90' ' ' ALA . 99.3 mtt180 -123.21 129.68 51.73 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.704 0.287 . . . . 0.0 110.661 174.429 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.788 HG23 HG21 ' A' ' 60' ' ' VAL . 98.7 t -129.41 121.9 54.39 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 N-CA-C 109.203 -0.665 . . . . 0.0 109.203 175.218 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 34.0 t -106.0 130.83 56.93 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 CA-C-O 120.755 0.312 . . . . 0.0 111.502 -174.293 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . 0.749 ' HB3' HD23 ' A' ' 64' ' ' LEU . 7.8 tp10 -114.15 122.03 45.59 Favored 'General case' 0 C--O 1.239 0.5 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.012 175.24 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.495 HG11 HD21 ' A' ' 106' ' ' LEU . 24.2 t -100.8 89.0 1.55 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 115.773 -0.648 . . . . 0.0 110.489 179.842 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 148.11 55.94 0.02 OUTLIER Glycine 0 N--CA 1.448 -0.538 0 CA-C-N 115.54 -0.754 . . . . 0.0 111.366 -177.879 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.624 ' HB2' ' HB3' ' A' ' 64' ' ' LEU . . . -84.97 76.94 10.21 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.986 0.422 . . . . 0.0 111.961 -173.962 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . 0.601 ' O ' ' HG ' ' A' ' 48' ' ' LEU . . . -89.5 -157.02 32.59 Favored Glycine 0 C--O 1.226 -0.367 0 C-N-CA 120.88 -0.676 . . . . 0.0 111.781 175.823 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . 0.451 HH11 ' HD3' ' A' ' 46' ' ' ARG . 0.0 OUTLIER -74.89 -15.44 60.7 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.984 0.421 . . . . 0.0 110.811 178.802 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 32.0 p90 -85.66 41.16 0.89 Allowed 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.53 -175.122 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.757 HD11 HD11 ' A' ' 74' ' ' ILE . 94.2 mt -80.96 19.16 0.9 Allowed 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 112.379 0.511 . . . . 0.0 112.379 -176.42 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 32.7 p90 -61.29 -27.39 68.44 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.712 0.291 . . . . 0.0 110.918 179.313 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 98.6 t -69.02 -51.28 45.64 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.237 175.43 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . 0.413 ' O ' ' HG2' ' A' ' 55' ' ' ARG . 1.7 m -61.75 -45.3 94.51 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 121.384 0.612 . . . . 0.0 110.201 -179.868 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 25.6 t70 -58.8 -41.12 85.99 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 114.7 -1.137 . . . . 0.0 111.119 -179.454 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 80.6 t80 -66.99 -52.01 47.93 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.693 178.295 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.558 HG23 HG12 ' A' ' 30' ' ' ILE . 83.8 mt -58.23 -47.27 87.85 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-N 115.981 -0.554 . . . . 0.0 112.075 -176.041 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . 0.413 ' HG2' ' O ' ' A' ' 51' ' ' SER . 15.6 ptm180 -68.64 -20.7 64.48 Favored 'General case' 0 CA--C 1.533 0.289 0 N-CA-C 112.535 0.569 . . . . 0.0 112.535 -172.649 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 23.0 mtmm -84.74 -29.93 25.11 Favored 'General case' 0 C--N 1.328 -0.345 0 C-N-CA 120.705 -0.398 . . . . 0.0 111.251 179.28 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 16.4 m-70 -86.48 -54.2 4.55 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.235 0.54 . . . . 0.0 109.586 177.744 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . 0.607 ' HB2' HG23 ' A' ' 30' ' ' ILE . 10.9 t -104.22 121.63 43.7 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 115.677 -0.692 . . . . 0.0 109.532 179.052 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 3.0 mppt? -84.79 61.45 6.79 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-O 121.897 0.856 . . . . 0.0 110.241 178.951 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.788 HG21 HG23 ' A' ' 39' ' ' VAL . 2.5 p -93.62 153.34 3.39 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.792 0 CA-C-N 114.167 -1.379 . . . . 0.0 109.299 177.232 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 43.9 m-20 -73.33 82.23 1.39 Allowed 'General case' 0 CA--C 1.518 -0.254 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 172.598 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . 0.45 ' HA ' ' O ' ' A' ' 39' ' ' VAL . 2.7 tt -80.93 105.45 12.17 Favored 'General case' 0 C--N 1.321 -0.651 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 179.549 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 48.8 t -96.96 117.14 40.95 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.439 -175.829 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . 0.749 HD23 ' HB3' ' A' ' 41' ' ' GLU . 80.0 mt -99.77 130.27 45.96 Favored 'General case' 0 C--N 1.314 -0.954 0 CA-C-N 115.58 -0.737 . . . . 0.0 109.185 177.249 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 22.9 p -117.86 129.4 55.63 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 120.555 0.217 . . . . 0.0 111.047 179.334 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 25.5 t70 -165.05 153.72 12.19 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.917 -0.583 . . . . 0.0 109.931 178.527 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.475 HG22 ' HE3' ' A' ' 68' ' ' LYS . 54.3 mt -76.98 100.39 2.57 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-O 120.93 0.395 . . . . 0.0 110.605 -178.289 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' LYS . . . . . 0.581 ' NZ ' ' HB2' ' A' ' 68' ' ' LYS . 7.4 mtmp? 70.33 83.97 0.15 Allowed Pre-proline 0 C--O 1.233 0.214 0 CA-C-N 115.119 -0.946 . . . . 0.0 110.53 -179.687 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . 0.96 ' HB3' ' HB ' ' A' ' 74' ' ' ILE . 11.2 Cg_endo -56.78 140.09 90.35 Favored 'Trans proline' 0 C--O 1.232 0.205 0 C-N-CA 123.714 2.942 . . . . 0.0 113.968 -175.653 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 28.6 m -103.12 16.88 25.43 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.483 -0.78 . . . . 0.0 110.267 174.837 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 22.3 t-80 -146.35 174.44 11.36 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 -179.279 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -99.89 119.14 6.4 Favored Glycine 0 N--CA 1.449 -0.457 0 C-N-CA 120.823 -0.703 . . . . 0.0 112.535 -175.837 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 120.86 -13.62 9.81 Favored Glycine 0 N--CA 1.454 -0.136 0 C-N-CA 120.904 -0.665 . . . . 0.0 112.004 179.393 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.96 ' HB ' ' HB3' ' A' ' 69' ' ' PRO . 55.8 mt -79.09 139.4 18.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-O 120.763 0.316 . . . . 0.0 110.724 -179.746 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 57.3 t -85.16 126.64 40.35 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 176.126 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' ARG . . . . . 0.478 ' HB3' ' HD2' ' A' ' 69' ' ' PRO . 1.6 ppt_? -77.68 28.08 0.17 Allowed 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 112.491 0.552 . . . . 0.0 112.491 -176.344 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 16.1 t70 -75.71 157.24 33.84 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 110.117 -0.327 . . . . 0.0 110.117 -177.579 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . 0.541 ' OD1' HG22 ' A' ' 80' ' ' THR . 5.9 t70 -88.47 161.41 17.03 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 120.691 0.281 . . . . 0.0 110.875 -171.984 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 8.5 tp -98.47 -28.23 3.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-O 120.829 0.347 . . . . 0.0 111.029 -177.926 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.541 HG22 ' OD1' ' A' ' 78' ' ' ASP . 15.0 t -90.02 -1.35 57.95 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.637 0.732 . . . . 0.0 109.165 176.868 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 34.5 t -152.12 72.32 7.78 Favored Pre-proline 0 C--N 1.322 -0.594 0 CA-C-N 114.738 -1.119 . . . . 0.0 108.984 175.069 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.539 ' HB2' ' HE2' ' A' ' 87' ' ' TYR . 91.1 Cg_endo -89.47 141.55 4.01 Favored 'Trans proline' 0 N--CA 1.457 -0.633 0 C-N-CA 122.829 2.353 . . . . 0.0 112.798 -177.521 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' ARG . . . . . 0.771 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 56.7 mtt-85 -83.49 113.38 20.75 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.047 178.305 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' MET . . . . . 0.71 ' HA ' ' HD2' ' A' ' 87' ' ' TYR . 29.6 mtp -68.06 -17.4 64.38 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.551 -0.295 . . . . 0.0 110.995 178.168 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.771 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 9.8 pt-20 -61.89 -23.81 66.54 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.934 0.397 . . . . 0.0 110.653 176.592 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 72.6 mt -85.11 -34.48 8.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.48 178.984 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . 0.71 ' HD2' ' HA ' ' A' ' 84' ' ' MET . 75.0 m-85 -78.23 -30.75 48.91 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.429 -177.243 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . 0.465 ' HG2' HG12 ' A' ' 113' ' ' VAL . 53.2 mtp180 -65.68 140.58 58.48 Favored 'General case' 0 CA--C 1.516 -0.362 0 CA-C-O 121.403 0.621 . . . . 0.0 110.882 178.701 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 91.08 1.73 72.29 Favored Glycine 0 N--CA 1.447 -0.61 0 CA-C-N 115.199 -0.909 . . . . 0.0 111.894 -178.044 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . 0.777 ' HA ' ' HB2' ' A' ' 38' ' ' ARG . . . -85.16 138.77 32.16 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.995 0.426 . . . . 0.0 110.75 178.88 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -89.16 -24.67 22.14 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.079 178.379 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . 0.515 HD23 ' N ' ' A' ' 93' ' ' ILE . 4.7 tt -153.49 143.15 21.85 Favored 'General case' 0 N--CA 1.45 -0.448 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.206 -178.345 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.515 ' N ' HD23 ' A' ' 92' ' ' LEU . 72.7 mt -132.03 133.73 60.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 N-CA-C 109.111 -0.7 . . . . 0.0 109.111 176.551 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' TYR . . . . . 0.453 ' O ' ' HA ' ' A' ' 41' ' ' GLU . 1.2 p90 -138.37 161.24 37.46 Favored 'General case' 0 C--N 1.321 -0.636 0 C-N-CA 120.707 -0.397 . . . . 0.0 110.119 -178.693 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . 0.639 ' HA ' ' OE2' ' A' ' 41' ' ' GLU . 19.4 m -146.87 115.65 6.82 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.058 -178.91 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 78.9 mt -77.23 94.35 1.31 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.752 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.619 179.45 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . 0.534 ' HG3' ' OE1' ' A' ' 125' ' ' GLU . 19.6 ttp85 58.61 82.64 0.23 Allowed Pre-proline 0 CA--C 1.531 0.244 0 CA-C-N 114.608 -1.178 . . . . 0.0 111.66 -177.628 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' PRO . . . . . 0.457 ' HA ' ' HD3' ' A' ' 99' ' ' PRO . 88.3 Cg_endo -83.74 136.66 7.36 Favored 'Trans proline' 0 N--CA 1.456 -0.724 0 C-N-CA 122.467 2.111 . . . . 0.0 111.638 176.136 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.747 ' HB2' ' HG2' ' A' ' 101' ' ' GLU . 22.4 Cg_exo -63.32 149.94 89.9 Favored 'Trans proline' 0 C--O 1.238 0.478 0 C-N-CA 122.581 2.187 . . . . 0.0 111.733 177.951 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -73.76 42.22 0.13 Allowed 'General case' 0 N--CA 1.465 0.284 0 CA-C-O 121.304 0.573 . . . . 0.0 111.812 -178.216 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' GLU . . . . . 0.757 ' HG3' HG23 ' A' ' 102' ' ' ILE . 11.0 pt-20 -132.15 -26.24 1.93 Allowed 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.607 179.303 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.757 HG23 ' HG3' ' A' ' 101' ' ' GLU . 40.1 pt -119.88 -11.64 10.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.55 -175.062 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' HIS . . . . . 0.73 ' HD2' ' HB ' ' A' ' 129' ' ' THR . 4.8 p-80 -56.72 -45.24 82.0 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.989 -0.551 . . . . 0.0 111.612 -175.147 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 8.5 m -61.35 -35.05 76.36 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.002 0.43 . . . . 0.0 110.908 179.529 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.839 ' HA ' ' HE ' ' A' ' 108' ' ' ARG . 67.1 m -73.3 -36.71 66.32 Favored 'General case' 0 N--CA 1.451 -0.408 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.39 179.703 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.495 HD21 HG11 ' A' ' 42' ' ' VAL . 85.0 mt -64.39 -42.08 96.31 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.73 178.914 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' MET . . . . . 0.522 ' HA ' HD22 ' A' ' 117' ' ' LEU . 81.4 mtp -60.5 -44.27 96.17 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.539 -179.292 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' ARG . . . . . 0.839 ' HE ' ' HA ' ' A' ' 105' ' ' SER . 31.6 ptt180 -74.73 -20.77 59.69 Favored 'General case' 0 CA--C 1.53 0.205 0 C-N-CA 121.048 -0.261 . . . . 0.0 111.555 -178.263 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.528 HG23 ' O ' ' A' ' 105' ' ' SER . 55.9 t -74.06 -43.47 51.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.749 0.309 . . . . 0.0 110.333 175.421 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -57.24 -45.66 83.73 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.972 -179.822 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.961 ' HA ' ' HB1' ' A' ' 148' ' ' ALA . 4.0 t70 -71.72 -28.71 63.87 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 121.174 0.511 . . . . 0.0 110.254 -177.284 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -74.49 -33.01 62.74 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.953 -0.567 . . . . 0.0 111.809 -179.64 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.465 HG12 ' HG2' ' A' ' 88' ' ' ARG . 34.0 m -95.52 -24.78 4.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 C-N-CA 121.088 -0.245 . . . . 0.0 111.097 179.578 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . 0.446 ' HA2' ' O ' ' A' ' 149' ' ' GLU . . . 89.87 46.5 4.2 Favored Glycine 0 N--CA 1.453 -0.226 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.993 176.303 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . 0.405 ' O ' ' HB3' ' A' ' 148' ' ' ALA . . . -124.66 150.25 46.29 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 120.533 0.206 . . . . 0.0 110.85 -178.954 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 116' ' ' ARG . . . . . 0.506 ' HD3' ' OE1' ' A' ' 145' ' ' GLU . 14.7 ttm180 -70.65 119.92 15.5 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 177.93 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . 0.522 HD22 ' HA ' ' A' ' 107' ' ' MET . 57.6 tp -90.58 118.59 30.15 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 -179.765 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . 0.456 HD12 HG13 ' A' ' 29' ' ' ILE . 61.9 mt -115.98 112.71 40.77 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.654 0 CA-C-O 121.289 0.566 . . . . 0.0 110.594 179.455 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 62.8 mt -110.97 119.03 58.71 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.845 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.029 178.474 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 120' ' ' LYS . . . . . 0.663 ' HG2' ' HB3' ' A' ' 143' ' ' PHE . 9.0 tmtm? -116.33 96.97 48.99 Favored Pre-proline 0 C--N 1.322 -0.616 0 CA-C-N 116.162 -0.472 . . . . 0.0 109.994 178.885 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 0.9 OUTLIER -77.65 -178.71 4.81 Favored 'Trans proline' 0 N--CA 1.459 -0.522 0 C-N-CA 122.652 2.235 . . . . 0.0 111.442 174.373 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 5.7 mp -63.87 177.68 0.73 Allowed 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.957 -179.439 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 15.2 m -49.45 -65.15 0.61 Allowed 'General case' 0 CA--C 1.53 0.194 0 CA-C-N 115.71 -0.677 . . . . 0.0 111.888 -175.357 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -106.54 64.86 0.27 Allowed Glycine 0 N--CA 1.448 -0.531 0 C-N-CA 120.669 -0.777 . . . . 0.0 111.173 175.452 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . 0.534 ' OE1' ' HG3' ' A' ' 97' ' ' ARG . 40.8 tt0 -140.11 145.48 37.65 Favored 'General case' 0 N--CA 1.448 -0.558 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 -174.712 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 10.3 t70 -123.02 174.67 7.05 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.356 -179.169 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.54 ' HB ' HG22 ' A' ' 129' ' ' THR . 6.9 mt -93.6 -19.85 6.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 -179.055 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.448 HG22 ' O ' ' A' ' 127' ' ' ILE . 5.9 m 53.22 24.07 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.666 0 C-N-CA 124.628 1.171 . . . . 0.0 112.686 179.179 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . 0.779 HG23 ' H ' ' A' ' 130' ' ' GLU . 1.7 t -82.07 -69.68 0.6 Allowed 'General case' 0 CA--C 1.536 0.412 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.139 174.747 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 130' ' ' GLU . . . . . 0.779 ' H ' HG23 ' A' ' 129' ' ' THR . 6.9 pt-20 -176.78 -174.68 0.57 Allowed 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 108.6 -0.889 . . . . 0.0 108.6 174.637 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 131' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -91.91 27.07 2.21 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 121.213 0.53 . . . . 0.0 110.699 -177.299 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 132' ' ' LYS . . . . . 0.581 ' H ' ' HG3' ' A' ' 130' ' ' GLU . 16.5 tppt? -66.99 -24.49 66.04 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.59 178.045 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 133' ' ' MET . . . . . 0.789 ' HG2' ' HB2' ' A' ' 146' ' ' TYR . 93.4 mtp -104.86 155.76 18.63 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.578 -177.533 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 12.9 ptmt -106.12 139.73 40.19 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.446 -175.789 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . 0.838 HD11 ' HD2' ' A' ' 142' ' ' TYR . 55.2 tp -78.81 125.27 29.14 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 115.861 -0.608 . . . . 0.0 110.428 177.709 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -119.81 147.16 23.64 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.808 179.059 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 137' ' ' ASN . . . . . 0.565 ' ND2' ' HB3' ' A' ' 142' ' ' TYR . 18.2 m120 -120.72 119.1 31.82 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.92 -0.582 . . . . 0.0 109.63 178.411 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 67.7 t80 -131.74 130.98 42.6 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 109.916 -0.401 . . . . 0.0 109.916 179.289 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 71.66 -91.21 0.49 Allowed Glycine 0 N--CA 1.441 -1.0 0 N-CA-C 111.21 -0.756 . . . . 0.0 111.21 -176.821 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 140' ' ' ARG . . . . . 0.447 ' HA ' ' HD3' ' A' ' 140' ' ' ARG . 29.1 mmt180 -150.21 12.81 0.75 Allowed 'General case' 0 C--N 1.32 -0.708 0 CA-C-O 120.807 0.337 . . . . 0.0 110.556 179.308 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 141' ' ' THR . . . . . 0.458 ' HB ' ' CG ' ' A' ' 21' ' ' MET . 7.1 t -125.15 160.64 28.67 Favored 'General case' 0 C--N 1.322 -0.606 0 N-CA-C 109.865 -0.42 . . . . 0.0 109.865 -178.991 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 142' ' ' TYR . . . . . 0.838 ' HD2' HD11 ' A' ' 135' ' ' LEU . 20.8 p90 -126.83 149.64 49.6 Favored 'General case' 0 N--CA 1.449 -0.523 0 CA-C-O 121.405 0.621 . . . . 0.0 111.176 179.494 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 143' ' ' PHE . . . . . 0.663 ' HB3' ' HG2' ' A' ' 120' ' ' LYS . 19.5 p90 -156.39 179.3 9.39 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 114.823 -1.08 . . . . 0.0 109.417 -177.37 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -113.2 127.85 56.3 Favored 'General case' 0 C--N 1.319 -0.752 0 C-N-CA 120.963 -0.295 . . . . 0.0 110.451 -179.738 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 145' ' ' GLU . . . . . 0.506 ' OE1' ' HD3' ' A' ' 116' ' ' ARG . 17.5 pt-20 -114.85 157.04 23.84 Favored 'General case' 0 C--N 1.32 -0.681 0 N-CA-C 109.041 -0.726 . . . . 0.0 109.041 173.189 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . 0.789 ' HB2' ' HG2' ' A' ' 133' ' ' MET . 19.5 t80 -137.77 122.75 19.01 Favored 'General case' 0 C--N 1.31 -1.133 0 CA-C-N 116.054 -0.521 . . . . 0.0 109.638 176.07 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 2.2 mp -79.49 95.76 2.18 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.813 0 N-CA-C 108.442 -0.947 . . . . 0.0 108.442 174.91 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . 0.961 ' HB1' ' HA ' ' A' ' 111' ' ' ASP . . . -74.87 130.3 39.17 Favored 'General case' 0 N--CA 1.437 -1.083 0 CA-C-N 115.462 -0.79 . . . . 0.0 109.739 178.679 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . 0.584 ' OE1' ' HD3' ' A' ' 153' ' ' ARG . 74.4 mm-40 -65.16 179.56 0.7 Allowed 'General case' 0 C--N 1.315 -0.904 0 CA-C-O 122.032 0.92 . . . . 0.0 111.558 178.861 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 150' ' ' VAL . . . . . 0.614 ' HB ' ' HA ' ' A' ' 153' ' ' ARG . 39.2 t -116.08 135.27 56.78 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.111 0 CA-C-N 114.511 -1.222 . . . . 0.0 107.95 176.144 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 151' ' ' ARG . . . . . . . . . . . . . 26.3 mtp180 -62.49 106.74 0.81 Allowed 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 120.827 0.346 . . . . 0.0 110.077 -176.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 16.2 m 67.79 24.09 8.34 Favored 'General case' 0 C--N 1.333 -0.151 0 CA-C-N 115.001 -0.999 . . . . 0.0 110.811 -177.801 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 153' ' ' ARG . . . . . 0.614 ' HA ' ' HB ' ' A' ' 150' ' ' VAL . 21.1 mtm180 . . . . . 0 C--O 1.25 1.106 0 O-C-N 125.088 1.493 . . . . 0.0 114.247 -178.674 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 66.1 mtt . . . . . 0 N--CA 1.479 1.001 0 N-CA-C 110.097 -0.334 . . . . 0.0 110.097 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 81.01 -142.77 23.57 Favored Glycine 0 N--CA 1.448 -0.54 0 C-N-CA 120.933 -0.651 . . . . 0.0 111.932 178.281 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 43.0 t -132.78 135.35 45.65 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-O 121.025 0.44 . . . . 0.0 110.597 177.657 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 24.2 m -95.16 6.4 49.17 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 121.475 0.655 . . . . 0.0 109.555 176.503 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 62.0 t60 -112.8 110.32 20.35 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.185 -0.916 . . . . 0.0 110.142 179.401 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 48.5 t-80 -94.44 122.25 36.81 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 109.721 -0.474 . . . . 0.0 109.721 176.475 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 81.2 t60 -127.9 117.81 22.47 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.316 -177.405 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 5.9 p80 -76.37 128.18 34.32 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.169 -0.469 . . . . 0.0 109.893 176.598 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 20.1 t-80 -77.05 153.83 34.0 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.216 -177.577 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 15.6 p-80 -68.77 105.29 2.27 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.6 0.714 . . . . 0.0 109.809 175.855 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 23.1 t -145.04 162.05 37.91 Favored 'General case' 0 N--CA 1.446 -0.63 0 CA-C-N 115.393 -0.821 . . . . 0.0 110.192 -173.068 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 27.8 t -108.66 121.25 44.63 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 177.352 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -82.98 179.45 52.96 Favored Glycine 0 N--CA 1.446 -0.685 0 C-N-CA 120.618 -0.801 . . . . 0.0 112.223 -178.394 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . 0.497 HD12 HH12 ' A' ' 17' ' ' ARG . 2.7 pt? -71.49 152.94 42.59 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 120.665 0.269 . . . . 0.0 110.457 178.633 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 24.5 m -83.33 127.51 68.32 Favored Pre-proline 0 C--N 1.323 -0.558 0 CA-C-O 121.027 0.441 . . . . 0.0 110.859 179.291 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 30.7 Cg_endo -66.54 133.34 31.82 Favored 'Trans proline' 0 N--CA 1.46 -0.464 0 C-N-CA 121.951 1.767 . . . . 0.0 111.51 176.628 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 0.569 ' HB2' ' CE1' ' A' ' 20' ' ' HIS . 11.1 mpt_? -81.01 63.09 5.24 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 116.421 -0.354 . . . . 0.0 111.028 -178.432 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . 0.491 ' O ' ' HG2' ' A' ' 21' ' ' MET . . . 64.62 -93.2 0.14 Allowed Glycine 0 C--N 1.331 0.266 0 CA-C-N 115.773 -0.649 . . . . 0.0 113.716 175.352 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . 0.401 ' HB3' ' OH ' ' A' ' 49' ' ' TYR . 19.9 m -54.83 -24.92 25.22 Favored 'General case' 0 C--N 1.326 -0.431 0 N-CA-C 112.957 0.725 . . . . 0.0 112.957 -172.982 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' HIS . . . . . 0.569 ' CE1' ' HB2' ' A' ' 17' ' ' ARG . 51.6 m170 -54.52 -40.07 68.25 Favored 'General case' 0 N--CA 1.465 0.302 0 N-CA-C 111.784 0.29 . . . . 0.0 111.784 -177.668 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' MET . . . . . 0.491 ' HG2' ' O ' ' A' ' 18' ' ' GLY . 27.2 ptm -83.73 -16.75 43.68 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 120.746 0.307 . . . . 0.0 111.38 -177.513 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 95.5 m95 -91.19 -31.56 16.14 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.545 -0.298 . . . . 0.0 111.58 -176.943 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.446 ' O ' HG23 ' A' ' 27' ' ' VAL . 4.4 m-20 -66.49 -40.72 89.42 Favored 'General case' 0 C--N 1.328 -0.348 0 C-N-CA 121.224 -0.19 . . . . 0.0 111.487 -177.015 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 38.8 m-20 -61.41 -39.44 90.78 Favored 'General case' 0 N--CA 1.466 0.35 0 CA-C-O 121.071 0.462 . . . . 0.0 110.411 177.644 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.545 HD21 ' HD3' ' A' ' 120' ' ' LYS . 25.0 tp -63.33 -42.95 98.99 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.648 -0.705 . . . . 0.0 110.59 176.863 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -59.68 -46.95 87.5 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.738 178.258 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.446 HG23 ' O ' ' A' ' 23' ' ' ASN . 90.3 t -55.59 -42.26 67.9 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.192 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.069 178.803 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 69.2 t80 -59.33 -45.16 92.11 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 121.024 0.44 . . . . 0.0 110.637 179.598 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 57.9 mt -67.07 -39.91 84.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.62 179.751 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.683 HG12 HG23 ' A' ' 54' ' ' ILE . 98.1 mt -59.9 -41.87 87.35 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.453 -0.794 . . . . 0.0 110.941 178.915 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 79.2 mtp180 -66.49 -37.64 85.51 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.882 -178.407 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 81.2 m -76.76 -18.0 58.72 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.214 -176.068 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 11.9 p -104.26 -84.37 0.48 Allowed 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.433 -178.556 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.402 ' O ' HG22 ' A' ' 37' ' ' THR . . . 99.69 160.47 28.82 Favored Glycine 0 N--CA 1.447 -0.626 0 C-N-CA 121.089 -0.577 . . . . 0.0 111.902 -176.96 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 11.5 Cg_exo -70.95 152.74 63.4 Favored 'Trans proline' 0 C--O 1.235 0.33 0 C-N-CA 122.743 2.296 . . . . 0.0 111.976 179.57 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 99.61 -26.35 24.73 Favored Glycine 0 N--CA 1.453 -0.228 0 C-N-CA 120.827 -0.701 . . . . 0.0 112.752 176.624 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . 0.402 HG22 ' O ' ' A' ' 34' ' ' GLY . 14.0 t -100.5 -166.99 1.38 Allowed 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 -178.846 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . 0.995 ' HG2' ' HA ' ' A' ' 90' ' ' ALA . 0.1 OUTLIER -130.94 136.53 48.65 Favored 'General case' 0 N--CA 1.446 -0.657 0 CA-C-O 121.113 0.483 . . . . 0.0 111.021 -176.767 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.448 HG23 HG21 ' A' ' 60' ' ' VAL . 95.9 t -129.16 135.82 61.04 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.603 0 CA-C-N 115.48 -0.782 . . . . 0.0 109.486 -179.916 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.517 HG11 ' CE2' ' A' ' 87' ' ' TYR . 38.7 t -108.11 128.19 63.72 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 CA-C-O 120.927 0.394 . . . . 0.0 111.31 -176.479 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . 0.58 ' HB3' HD23 ' A' ' 64' ' ' LEU . 41.1 tt0 -106.49 118.23 36.1 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.924 -0.58 . . . . 0.0 109.778 175.826 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 62.9 t -97.21 120.48 46.6 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.671 -179.173 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 92.5 48.7 2.94 Favored Glycine 0 N--CA 1.447 -0.621 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.139 179.567 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -80.36 41.09 0.52 Allowed 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.063 0.459 . . . . 0.0 111.446 -176.861 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . 0.425 ' O ' ' HB2' ' A' ' 46' ' ' ARG . . . -81.29 81.58 1.62 Allowed Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.954 -0.641 . . . . 0.0 112.27 -178.332 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . 0.425 ' HB2' ' O ' ' A' ' 45' ' ' GLY . 82.9 mtm180 71.08 13.56 6.86 Favored 'General case' 0 N--CA 1.469 0.498 0 C-N-CA 123.238 0.615 . . . . 0.0 111.271 -179.44 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 74.6 m-85 -98.51 17.05 19.94 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.357 0.598 . . . . 0.0 109.706 176.864 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.473 HD11 ' HB3' ' A' ' 71' ' ' HIS . 82.2 mt -62.14 -10.1 9.44 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 114.793 -1.094 . . . . 0.0 112.388 -174.655 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . 0.401 ' OH ' ' HB3' ' A' ' 19' ' ' SER . 73.9 t80 -57.85 -38.35 75.53 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 120.715 0.293 . . . . 0.0 110.837 179.167 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 60.4 t -73.54 -54.63 14.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.435 -179.093 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -59.75 -38.33 81.47 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.852 -179.437 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.565 ' HA ' ' HG2' ' A' ' 55' ' ' ARG . 33.5 t70 -71.44 -35.85 71.06 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.629 0.252 . . . . 0.0 111.181 179.527 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 56.7 t80 -61.36 -49.03 78.57 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 109.503 -0.554 . . . . 0.0 109.503 175.027 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.683 HG23 HG12 ' A' ' 30' ' ' ILE . 77.6 mt -60.85 -51.83 68.61 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-N 115.727 -0.669 . . . . 0.0 111.85 -179.236 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . 0.565 ' HG2' ' HA ' ' A' ' 52' ' ' ASP . 40.1 ptt180 -65.29 -19.93 66.18 Favored 'General case' 0 N--CA 1.467 0.392 0 N-CA-C 112.382 0.512 . . . . 0.0 112.382 -173.464 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 3.1 mtmp? -87.33 -38.61 16.07 Favored 'General case' 0 C--N 1.327 -0.372 0 C-N-CA 120.723 -0.391 . . . . 0.0 111.588 178.668 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 31.0 m-70 -76.03 -32.73 59.5 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 120.662 0.268 . . . . 0.0 110.693 179.651 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 67.6 m -138.63 128.0 24.46 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 116.264 -0.425 . . . . 0.0 109.863 174.581 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . 0.409 ' HD3' ' HA ' ' A' ' 59' ' ' LYS . 1.3 tppp? -78.58 63.42 3.38 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 122.096 0.95 . . . . 0.0 110.901 -177.375 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.448 HG21 HG23 ' A' ' 39' ' ' VAL . 7.3 p -86.29 142.21 13.4 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.957 0 CA-C-N 114.349 -1.296 . . . . 0.0 109.387 172.721 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . 0.443 ' O ' ' HA ' ' A' ' 38' ' ' ARG . 33.0 t70 -76.51 89.25 3.27 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 179.228 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 2.3 tt -90.0 122.91 33.44 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.78 -0.646 . . . . 0.0 110.496 -173.93 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 43.8 t -102.29 121.76 53.74 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-N 115.523 -0.762 . . . . 0.0 109.899 -178.234 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . 0.58 HD23 ' HB3' ' A' ' 41' ' ' GLU . 50.8 mt -100.15 131.01 46.34 Favored 'General case' 0 C--N 1.316 -0.858 0 CA-C-N 116.214 -0.448 . . . . 0.0 109.919 179.766 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.549 HG22 ' HB ' ' A' ' 75' ' ' VAL . 17.0 p -132.23 137.37 47.52 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.951 0.405 . . . . 0.0 111.18 178.383 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 30.3 t70 -165.28 158.4 16.27 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.518 177.529 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 40.7 mm -72.09 96.83 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-O 120.759 0.314 . . . . 0.0 110.429 -178.76 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 65.3 mttm 63.56 90.16 0.09 OUTLIER Pre-proline 0 N--CA 1.465 0.309 0 CA-C-N 115.393 -0.821 . . . . 0.0 111.514 178.682 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . 0.415 ' HD3' ' HA ' ' A' ' 76' ' ' ARG . 97.3 Cg_endo -83.84 170.35 11.32 Favored 'Trans proline' 0 N--CA 1.459 -0.506 0 C-N-CA 122.867 2.378 . . . . 0.0 112.726 -179.273 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 14.8 t -156.64 34.48 0.31 Allowed 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.844 0.831 . . . . 0.0 108.868 178.686 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . 0.473 ' HB3' HD11 ' A' ' 48' ' ' LEU . 20.2 m80 -115.88 -66.58 1.07 Allowed 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.114 -0.948 . . . . 0.0 110.883 -173.11 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -160.16 -126.7 0.85 Allowed Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.1 -179.154 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -81.93 61.4 4.67 Favored Glycine 0 N--CA 1.452 -0.241 0 C-N-CA 121.076 -0.583 . . . . 0.0 112.273 -178.572 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.438 HD11 HD21 ' A' ' 48' ' ' LEU . 63.6 mt -107.53 134.83 48.1 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-O 120.756 0.312 . . . . 0.0 110.358 179.299 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.549 ' HB ' HG22 ' A' ' 65' ' ' THR . 53.8 t -72.71 133.37 31.89 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.093 179.321 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' ARG . . . . . 0.415 ' HA ' ' HD3' ' A' ' 69' ' ' PRO . 6.7 ptp180 -86.9 32.48 0.67 Allowed 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.855 -176.471 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . 0.498 ' HB2' HG12 ' A' ' 75' ' ' VAL . 1.6 t70 -77.11 -159.16 0.12 Allowed 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.653 -174.329 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . 0.457 ' OD1' HG22 ' A' ' 80' ' ' THR . 4.9 t70 -125.15 -174.16 2.98 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 120.733 0.301 . . . . 0.0 110.25 -174.374 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 9.2 tp -139.9 -30.89 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-O 120.877 0.37 . . . . 0.0 110.406 178.951 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.457 HG22 ' OD1' ' A' ' 78' ' ' ASP . 8.9 t -86.38 -20.8 27.71 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.516 0.674 . . . . 0.0 109.247 177.127 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 13.6 t -150.67 72.57 8.92 Favored Pre-proline 0 C--N 1.325 -0.489 0 CA-C-N 115.154 -0.93 . . . . 0.0 108.577 171.721 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.442 ' HB3' ' O ' ' A' ' 78' ' ' ASP . 89.6 Cg_endo -89.77 171.3 4.16 Favored 'Trans proline' 0 N--CA 1.457 -0.674 0 C-N-CA 123.007 2.472 . . . . 0.0 113.149 -173.96 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' ARG . . . . . 0.597 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 63.6 mtt180 -88.9 111.36 21.99 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.671 -0.695 . . . . 0.0 109.536 171.432 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' MET . . . . . 0.522 ' O ' ' HG3' ' A' ' 88' ' ' ARG . 92.7 mmm -67.36 -20.04 65.51 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.395 -176.991 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.597 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 9.3 pt-20 -60.49 -27.29 67.47 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.309 -179.664 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 67.4 mt -79.93 -40.24 20.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-O 120.98 0.419 . . . . 0.0 111.07 -178.571 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . 0.517 ' CE2' HG11 ' A' ' 40' ' ' VAL . 73.0 m-85 -81.98 -31.14 31.29 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.632 -176.889 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . 0.744 ' HG2' HG12 ' A' ' 113' ' ' VAL . 16.1 mtp180 -69.42 116.78 10.24 Favored 'General case' 0 CA--C 1.509 -0.606 0 CA-C-O 121.906 0.86 . . . . 0.0 111.462 -175.957 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . 0.439 ' O ' ' HD3' ' A' ' 38' ' ' ARG . . . 116.38 -18.9 13.37 Favored Glycine 0 C--N 1.31 -0.897 0 CA-C-N 114.07 -1.423 . . . . 0.0 111.765 -177.727 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . 0.995 ' HA ' ' HG2' ' A' ' 38' ' ' ARG . . . -66.24 143.09 57.44 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.604 0.24 . . . . 0.0 110.553 179.075 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -82.57 -29.22 30.43 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 120.831 0.348 . . . . 0.0 110.807 -178.624 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . 0.473 ' HG ' ' HB3' ' A' ' 116' ' ' ARG . 5.8 tt -149.71 143.44 25.46 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.15 -0.477 . . . . 0.0 109.96 -177.412 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.613 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 62.8 mt -130.65 127.46 62.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 N-CA-C 109.098 -0.705 . . . . 0.0 109.098 177.019 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' TYR . . . . . 0.756 ' HD2' ' HZ3' ' A' ' 120' ' ' LYS . 20.7 p90 -138.71 142.84 38.91 Favored 'General case' 0 C--N 1.321 -0.664 0 C-N-CA 120.208 -0.597 . . . . 0.0 111.407 -179.039 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . 0.416 ' O ' ' HG2' ' A' ' 120' ' ' LYS . 8.0 m -118.08 144.96 45.19 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 115.497 -0.774 . . . . 0.0 110.047 -177.814 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' ILE . . . . . 0.819 HG12 ' HD2' ' A' ' 120' ' ' LYS . 42.9 mt -111.69 106.84 21.55 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-O 120.759 0.314 . . . . 0.0 110.46 179.804 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . 0.576 ' O ' ' HD3' ' A' ' 97' ' ' ARG . 0.0 OUTLIER 50.88 76.43 0.55 Allowed Pre-proline 0 CA--C 1.536 0.439 0 CA-C-N 115.099 -0.955 . . . . 0.0 111.173 -177.381 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_endo -96.3 159.61 1.29 Allowed 'Trans proline' 0 N--CA 1.453 -0.886 0 C-N-CA 123.211 2.607 . . . . 0.0 112.698 178.887 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.677 ' HD2' HD11 ' A' ' 102' ' ' ILE . 17.5 Cg_exo -64.16 136.37 51.55 Favored 'Trans proline' 0 N--CA 1.462 -0.353 0 C-N-CA 122.32 2.014 . . . . 0.0 111.306 174.55 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.572 ' HA ' ' CD2' ' A' ' 103' ' ' HIS . . . -68.98 -15.46 63.49 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 120.971 0.415 . . . . 0.0 111.833 -174.977 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' GLU . . . . . . . . . . . . . 1.7 pm0 -75.86 -18.51 59.4 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.888 178.582 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.677 HD11 ' HD2' ' A' ' 99' ' ' PRO . 2.6 pp -113.48 8.1 7.89 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.178 0 N-CA-C 112.567 0.58 . . . . 0.0 112.567 -177.341 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' HIS . . . . . 0.572 ' CD2' ' HA ' ' A' ' 100' ' ' ALA . 4.7 m-70 -57.57 -42.64 83.47 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 121.063 0.459 . . . . 0.0 110.777 176.361 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 6.9 p -69.86 -26.85 64.4 Favored 'General case' 0 C--O 1.236 0.372 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.095 -179.114 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.571 ' O ' HG23 ' A' ' 109' ' ' VAL . 74.8 m -70.52 -44.79 66.85 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 109.757 -0.461 . . . . 0.0 109.757 174.519 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 96.0 mt -56.84 -41.81 78.54 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 121.067 0.46 . . . . 0.0 110.354 175.676 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' MET . . . . . . . . . . . . . 46.6 tpp -55.59 -52.59 63.25 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.28 -0.873 . . . . 0.0 111.365 178.497 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 4.8 ptp180 -71.3 -22.56 61.93 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 111.889 0.329 . . . . 0.0 111.889 -177.303 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.571 HG23 ' O ' ' A' ' 105' ' ' SER . 82.5 t -70.19 -48.37 61.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 C-N-CA 120.731 -0.388 . . . . 0.0 109.981 175.012 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -60.96 -44.53 97.16 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 177.049 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 22.7 t70 -60.68 -34.06 73.77 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.36 -0.836 . . . . 0.0 111.036 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -74.75 -44.44 49.74 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.795 -0.639 . . . . 0.0 111.813 -179.271 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.744 HG12 ' HG2' ' A' ' 88' ' ' ARG . 13.1 m -87.46 -29.29 5.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.981 -172.549 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 87.32 53.77 2.71 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.852 -0.69 . . . . 0.0 112.392 -178.978 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -131.97 160.44 35.79 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.737 0.303 . . . . 0.0 111.086 -178.192 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 116' ' ' ARG . . . . . 0.473 ' HB3' ' HG ' ' A' ' 92' ' ' LEU . 13.5 ttm180 -79.0 123.88 27.72 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 109.565 -0.532 . . . . 0.0 109.565 175.923 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . 0.613 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 58.3 tp -98.14 118.32 34.49 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.181 -179.429 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 55.7 mt -117.19 115.13 47.81 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-O 121.197 0.522 . . . . 0.0 110.629 178.861 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 40.6 mt -107.78 135.78 45.3 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.631 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.032 -178.032 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 120' ' ' LYS . . . . . 0.819 ' HD2' HG12 ' A' ' 96' ' ' ILE . 4.5 ptpp? -130.51 91.96 36.47 Favored Pre-proline 0 C--N 1.324 -0.518 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.238 -179.147 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 78.5 Cg_endo -96.77 -164.28 0.09 OUTLIER 'Trans proline' 0 N--CA 1.455 -0.765 0 C-N-CA 123.308 2.672 . . . . 0.0 112.647 179.344 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 122' ' ' LEU . . . . . 0.695 ' HB2' ' HB2' ' A' ' 125' ' ' GLU . 4.2 mm? -74.67 159.32 32.23 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.481 174.796 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 27.3 m -57.96 -43.68 86.57 Favored 'General case' 0 CA--C 1.53 0.2 0 CA-C-O 120.981 0.419 . . . . 0.0 110.959 -178.948 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -100.76 38.2 3.25 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.8 -0.714 . . . . 0.0 111.595 178.288 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . 0.695 ' HB2' ' HB2' ' A' ' 122' ' ' LEU . 27.4 tt0 -123.09 116.83 24.12 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.586 -0.524 . . . . 0.0 109.586 -177.515 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -88.55 164.71 15.28 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 121.544 0.688 . . . . 0.0 111.544 -172.903 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.557 HG22 ' HB ' ' A' ' 129' ' ' THR . 52.1 mt -101.6 103.25 14.65 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.827 0 CA-C-N 115.06 -0.973 . . . . 0.0 108.586 172.71 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 39.0 t -73.72 72.99 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 121.994 0.902 . . . . 0.0 109.754 -179.49 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . 0.557 ' HB ' HG22 ' A' ' 127' ' ' ILE . 2.8 m -160.9 133.46 6.16 Favored 'General case' 0 N--CA 1.434 -1.256 0 CA-C-N 114.275 -1.33 . . . . 0.0 108.275 -179.179 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 6.3 mt-10 -58.69 156.87 10.22 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.947 0.403 . . . . 0.0 111.818 -176.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 131' ' ' ARG . . . . . . . . . . . . . 62.4 mtm-85 -61.47 106.15 0.61 Allowed 'General case' 0 C--O 1.234 0.289 0 CA-C-N 115.412 -0.813 . . . . 0.0 113.114 -169.197 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 25.6 mtpp -137.33 -29.0 0.9 Allowed 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 114.404 -1.271 . . . . 0.0 109.759 172.816 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 133' ' ' MET . . . . . 0.8 ' HG2' ' HB2' ' A' ' 146' ' ' TYR . 82.1 mtp -84.05 -179.0 7.14 Favored 'General case' 0 C--O 1.232 0.176 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.294 179.874 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 19.1 ptmt -142.52 135.09 27.99 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 120.985 0.422 . . . . 0.0 111.091 -179.449 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . 0.563 HD11 ' HD2' ' A' ' 142' ' ' TYR . 50.3 tp -71.63 124.14 24.07 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.543 -0.753 . . . . 0.0 110.307 175.743 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 136' ' ' VAL . . . . . 0.42 HG23 ' CD1' ' A' ' 143' ' ' PHE . 0.0 OUTLIER -121.78 137.22 56.12 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.145 -179.818 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 12.9 m120 -110.13 126.38 54.0 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 109.136 -0.69 . . . . 0.0 109.136 177.676 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 52.8 t80 -142.12 116.72 9.72 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 121.112 0.482 . . . . 0.0 111.277 -179.39 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 77.45 -92.34 1.08 Allowed Glycine 0 N--CA 1.447 -0.618 0 CA-C-N 115.74 -0.664 . . . . 0.0 112.159 176.045 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 50.4 mtm180 -139.52 16.37 2.55 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-O 121.047 0.451 . . . . 0.0 110.831 -179.372 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 13.8 t -138.15 158.72 43.74 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.269 -179.104 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 142' ' ' TYR . . . . . 0.563 ' HD2' HD11 ' A' ' 135' ' ' LEU . 35.2 p90 -134.33 139.62 45.79 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 178.135 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 143' ' ' PHE . . . . . 0.42 ' CD1' HG23 ' A' ' 136' ' ' VAL . 9.2 p90 -148.9 -172.83 4.2 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.116 -173.185 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 99.1 m-85 -119.42 128.63 54.22 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 120.486 0.184 . . . . 0.0 110.633 -179.086 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 145' ' ' GLU . . . . . . . . . . . . . 19.1 pt-20 -120.31 159.88 24.13 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.044 0.45 . . . . 0.0 109.916 174.78 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . 0.8 ' HB2' ' HG2' ' A' ' 133' ' ' MET . 49.7 t80 -140.63 127.95 21.14 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 115.904 -0.589 . . . . 0.0 109.816 176.471 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 147' ' ' ILE . . . . . 0.433 ' N ' HD12 ' A' ' 147' ' ' ILE . 3.1 mp -94.63 100.66 11.47 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 N-CA-C 109.679 -0.489 . . . . 0.0 109.679 178.752 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -91.38 125.75 36.24 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.869 -0.605 . . . . 0.0 109.796 177.115 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 -79.69 160.89 26.12 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-O 121.038 0.447 . . . . 0.0 110.186 -179.533 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 40.5 t -84.3 140.65 15.81 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-N 116.0 -0.545 . . . . 0.0 109.555 179.783 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 151' ' ' ARG . . . . . 0.501 ' O ' ' HD3' ' A' ' 151' ' ' ARG . 0.1 OUTLIER -56.68 131.25 48.51 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.967 0.413 . . . . 0.0 110.237 178.67 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 4.9 m -60.93 122.43 14.87 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.618 -0.719 . . . . 0.0 112.028 -171.859 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 153' ' ' ARG . . . . . 0.436 ' HB2' HH11 ' A' ' 151' ' ' ARG . 50.4 ttp85 . . . . . 0 C--O 1.249 1.052 0 CA-C-O 118.289 -0.862 . . . . 0.0 109.103 173.14 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 26.6 ptt? . . . . . 0 N--CA 1.483 1.222 0 N-CA-C 111.525 0.194 . . . . 0.0 111.525 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 75.85 -157.88 49.3 Favored Glycine 0 N--CA 1.449 -0.495 0 C-N-CA 120.631 -0.795 . . . . 0.0 112.322 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 29.4 m -97.99 174.34 6.61 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 120.961 0.41 . . . . 0.0 110.733 -178.036 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 10.7 t -141.78 75.3 1.49 Allowed 'General case' 0 C--N 1.322 -0.612 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 175.106 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 28.6 t-80 -146.91 153.7 40.43 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.436 -173.281 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 2.0 t-80 71.77 20.56 4.54 Favored 'General case' 0 N--CA 1.464 0.264 0 O-C-N 124.089 0.868 . . . . 0.0 109.79 -177.955 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 80.7 m80 -92.49 6.32 47.55 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.304 -0.862 . . . . 0.0 109.472 172.928 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 62.9 m80 -73.93 142.38 45.93 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.248 -0.887 . . . . 0.0 110.497 -178.107 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 20.5 m80 -89.66 84.99 6.35 Favored 'General case' 0 C--N 1.32 -0.683 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 -178.072 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 52.0 p-80 -95.24 126.07 40.31 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 121.185 0.516 . . . . 0.0 110.552 178.55 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 21.4 m -149.26 111.53 4.68 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.907 -0.588 . . . . 0.0 109.777 179.042 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 5.3 t -108.43 179.37 4.22 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 116.455 -0.339 . . . . 0.0 110.465 -176.678 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -131.04 166.42 22.71 Favored Glycine 0 N--CA 1.446 -0.661 0 N-CA-C 111.276 -0.73 . . . . 0.0 111.276 177.548 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . 0.421 HD12 ' O ' ' A' ' 14' ' ' LEU . 2.9 pp -136.46 152.61 50.76 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.863 0.331 . . . . 0.0 110.785 178.97 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.488 ' HA ' ' HD3' ' A' ' 16' ' ' PRO . 14.2 m -115.46 115.48 42.12 Favored Pre-proline 0 C--N 1.322 -0.624 0 CA-C-O 121.296 0.569 . . . . 0.0 111.027 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.488 ' HD3' ' HA ' ' A' ' 15' ' ' VAL . 3.9 Cg_exo -82.33 142.04 11.73 Favored 'Trans proline' 0 N--CA 1.458 -0.587 0 C-N-CA 123.245 2.63 . . . . 0.0 112.101 178.663 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 34.4 mmt180 -87.2 -33.26 19.4 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 121.354 0.597 . . . . 0.0 109.939 177.276 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 123.54 99.7 1.4 Allowed Glycine 0 N--CA 1.446 -0.669 0 N-CA-C 110.716 -0.954 . . . . 0.0 110.716 -174.897 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . 0.784 ' HB3' ' HD1' ' A' ' 22' ' ' TRP . 37.6 m -119.21 94.94 4.6 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-O 121.111 0.482 . . . . 0.0 111.274 -173.936 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 9.7 m80 -60.32 -45.84 92.01 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.506 -0.77 . . . . 0.0 110.491 -178.55 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -65.62 -15.52 62.82 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.43 -0.805 . . . . 0.0 111.763 -177.028 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' TRP . . . . . 0.784 ' HD1' ' HB3' ' A' ' 19' ' ' SER . 90.8 m95 -94.83 -29.55 14.67 Favored 'General case' 0 C--N 1.322 -0.598 0 C-N-CA 121.013 -0.275 . . . . 0.0 110.696 177.891 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.412 ' O ' HG23 ' A' ' 27' ' ' VAL . 4.7 m-20 -68.99 -47.61 65.13 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.515 -0.311 . . . . 0.0 110.905 177.729 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 15.6 m-20 -60.6 -39.48 88.28 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.81 0.338 . . . . 0.0 110.579 178.59 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 60.5 tp -57.76 -49.53 76.27 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.424 176.204 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -55.71 -47.17 77.31 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.542 -0.753 . . . . 0.0 110.904 178.859 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.412 HG23 ' O ' ' A' ' 23' ' ' ASN . 84.9 t -56.73 -42.9 78.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.938 178.479 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 86.6 t80 -61.32 -45.48 94.28 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.724 0.297 . . . . 0.0 110.383 178.436 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 72.9 mt -63.21 -43.2 98.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.45 178.799 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 86.8 mt -56.83 -42.66 78.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 115.451 -0.795 . . . . 0.0 111.265 177.126 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 21.4 mtp180 -69.06 -32.37 71.79 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.804 -178.816 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 77.0 m -88.33 2.51 52.36 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.794 -0.639 . . . . 0.0 111.758 -175.874 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 22.0 p -129.7 -80.54 0.56 Allowed 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 120.816 0.341 . . . . 0.0 111.004 178.018 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 95.61 160.13 33.08 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.934 -0.65 . . . . 0.0 112.408 -179.616 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -73.25 141.68 32.62 Favored 'Trans proline' 0 N--CA 1.462 -0.347 0 C-N-CA 122.785 2.323 . . . . 0.0 111.438 178.022 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 113.13 3.71 24.39 Favored Glycine 0 N--CA 1.449 -0.452 0 C-N-CA 120.348 -0.929 . . . . 0.0 112.16 -177.226 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 14.7 t -139.42 -169.57 2.71 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 110.001 -0.37 . . . . 0.0 110.001 177.812 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . 0.41 ' HD3' HH11 ' A' ' 38' ' ' ARG . 47.0 mtp180 -121.75 135.84 54.94 Favored 'General case' 0 N--CA 1.45 -0.45 0 CA-C-O 120.906 0.384 . . . . 0.0 110.637 -178.738 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 52.3 t -122.56 134.67 65.07 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 177.463 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 50.3 t -108.04 124.36 64.21 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-O 120.733 0.301 . . . . 0.0 110.678 -177.813 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . 0.527 ' HB2' HD21 ' A' ' 62' ' ' LEU . 35.6 tt0 -102.04 106.68 17.61 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.066 179.004 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.6 ' O ' ' HA ' ' A' ' 95' ' ' SER . 60.3 t -94.04 124.39 46.49 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.603 0 CA-C-N 116.031 -0.531 . . . . 0.0 109.846 179.779 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 96.27 37.63 4.79 Favored Glycine 0 N--CA 1.445 -0.751 0 C-N-CA 120.337 -0.935 . . . . 0.0 111.297 -175.93 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -81.21 24.61 0.52 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.018 0.437 . . . . 0.0 111.413 -177.822 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -73.89 79.09 0.87 Allowed Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 121.212 -0.518 . . . . 0.0 112.08 -178.924 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 26.7 ttt180 75.67 7.72 3.8 Favored 'General case' 0 N--CA 1.468 0.436 0 C-N-CA 123.418 0.687 . . . . 0.0 110.968 177.14 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 65.8 m-85 -95.96 31.01 2.22 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.39 0.614 . . . . 0.0 110.413 178.06 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.609 HD22 HD13 ' A' ' 64' ' ' LEU . 61.6 mt -74.35 14.65 0.42 Allowed 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.075 -0.966 . . . . 0.0 112.376 -172.931 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . 0.481 ' CE2' ' HB2' ' A' ' 19' ' ' SER . 87.8 t80 -70.3 -37.26 74.74 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 121.068 0.461 . . . . 0.0 110.375 179.665 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 47.2 t -74.76 -48.81 32.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-N 115.936 -0.574 . . . . 0.0 110.372 -179.326 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -58.67 -39.77 81.63 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.997 -0.547 . . . . 0.0 111.369 179.526 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.425 ' O ' ' HE2' ' A' ' 56' ' ' LYS . 30.6 t70 -62.06 -45.07 95.16 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.792 0.33 . . . . 0.0 110.531 177.826 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . 0.459 ' HA ' ' HE2' ' A' ' 56' ' ' LYS . 81.5 t80 -63.53 -42.98 98.4 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.927 -179.248 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 80.8 mt -66.22 -47.73 83.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.889 -178.941 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 22.4 ptt180 -62.77 -24.57 67.78 Favored 'General case' 0 N--CA 1.467 0.401 0 N-CA-C 111.856 0.317 . . . . 0.0 111.856 -175.344 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . 0.459 ' HE2' ' HA ' ' A' ' 53' ' ' TYR . 42.2 mtmt -77.2 -31.22 55.17 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.727 0.299 . . . . 0.0 111.692 -177.611 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 20.4 t60 -99.18 -48.56 4.79 Favored 'General case' 0 N--CA 1.448 -0.562 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.518 -177.384 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 38.1 m -95.22 155.51 16.7 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.068 0.461 . . . . 0.0 111.053 -178.024 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 28.5 mmmt -105.17 19.26 20.9 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.938 -0.574 . . . . 0.0 109.704 178.242 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 15.0 p -68.63 153.27 9.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 115.404 -0.816 . . . . 0.0 110.522 -178.78 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -86.58 103.34 14.99 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 120.832 0.349 . . . . 0.0 110.16 178.521 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . 0.527 HD21 ' HB2' ' A' ' 41' ' ' GLU . 1.8 tt -101.36 119.08 38.22 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 115.942 -0.572 . . . . 0.0 109.935 -176.42 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 46.2 t -100.22 119.14 47.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.365 -179.15 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . 0.609 HD13 HD22 ' A' ' 48' ' ' LEU . 32.3 mt -95.42 122.44 38.14 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.935 -0.575 . . . . 0.0 109.73 178.785 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 37.9 p -118.34 142.27 47.69 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 120.567 0.222 . . . . 0.0 111.189 -178.374 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 30.9 t70 -165.32 154.97 12.81 Favored 'General case' 0 C--N 1.33 -0.259 0 N-CA-C 110.124 -0.325 . . . . 0.0 110.124 179.788 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.575 HD13 ' HA ' ' A' ' 78' ' ' ASP . 37.4 mm -69.61 94.33 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.853 0.359 . . . . 0.0 110.163 179.144 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' LYS . . . . . 0.722 ' HD3' ' HB2' ' A' ' 76' ' ' ARG . 40.9 mmtm 44.46 70.66 1.81 Allowed Pre-proline 0 CA--C 1.533 0.296 0 CA-C-N 115.279 -0.873 . . . . 0.0 110.835 -178.304 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . 0.742 ' HD2' ' HA ' ' A' ' 76' ' ' ARG . 10.3 Cg_endo -51.45 142.25 39.03 Favored 'Trans proline' 0 C--N 1.344 0.341 0 C-N-CA 123.896 3.064 . . . . 0.0 113.762 -172.495 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 22.6 t -96.82 -8.4 31.14 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 114.961 -1.018 . . . . 0.0 109.944 -178.769 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 60.5 t-80 -79.79 -46.46 16.93 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.204 -178.443 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 109.37 144.09 10.41 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.96 -0.638 . . . . 0.0 111.918 -177.842 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 86.95 -41.11 3.08 Favored Glycine 0 CA--C 1.516 0.148 0 C-N-CA 120.901 -0.666 . . . . 0.0 112.187 179.493 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.495 ' HB ' ' HG3' ' A' ' 69' ' ' PRO . 35.9 mt -58.76 149.08 5.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 C-N-CA 122.809 0.444 . . . . 0.0 110.38 177.072 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 60.3 t -68.62 128.62 32.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 178.767 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' ARG . . . . . 0.742 ' HA ' ' HD2' ' A' ' 69' ' ' PRO . 32.1 ptt180 -91.43 54.46 2.54 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.453 0.644 . . . . 0.0 110.976 -179.43 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 9.7 p-10 -83.34 -156.54 0.2 Allowed 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.039 -0.982 . . . . 0.0 109.955 178.129 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . 0.575 ' HA ' HD13 ' A' ' 67' ' ' ILE . 20.3 m-20 -143.85 108.75 4.94 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 110.297 -0.26 . . . . 0.0 110.297 -179.391 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 9.3 tp -73.66 -24.51 19.99 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.37 0 CA-C-O 120.819 0.343 . . . . 0.0 110.737 178.758 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 10.0 t -69.19 -26.95 65.09 Favored 'General case' 0 CA--C 1.531 0.241 0 CA-C-O 121.219 0.533 . . . . 0.0 110.547 178.077 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 22.7 t -134.28 78.74 57.24 Favored Pre-proline 0 C--N 1.323 -0.569 0 N-CA-C 108.153 -1.055 . . . . 0.0 108.153 173.292 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.429 ' HB2' ' HE2' ' A' ' 87' ' ' TYR . 59.1 Cg_endo -71.13 133.44 23.06 Favored 'Trans proline' 0 N--CA 1.461 -0.426 0 C-N-CA 122.762 2.308 . . . . 0.0 113.625 -168.592 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' ARG . . . . . 0.537 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 70.7 mtt85 -84.98 106.27 16.36 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.453 -0.794 . . . . 0.0 109.27 171.871 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' MET . . . . . . . . . . . . . 89.5 mmm -58.21 -26.45 62.85 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.987 -0.551 . . . . 0.0 111.142 -177.235 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.537 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 11.3 pt-20 -62.14 -26.78 68.51 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.672 -179.558 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 73.6 mt -79.46 -41.11 22.16 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-O 121.04 0.447 . . . . 0.0 110.531 -179.339 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . 0.429 ' HE2' ' HB2' ' A' ' 82' ' ' PRO . 44.9 m-85 -79.65 -25.51 41.32 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.789 -176.795 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 52.0 mtp180 -66.23 131.58 46.47 Favored 'General case' 0 CA--C 1.517 -0.304 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.373 176.276 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 98.23 8.72 54.81 Favored Glycine 0 N--CA 1.444 -0.811 0 C-N-CA 120.627 -0.797 . . . . 0.0 111.699 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -100.77 144.6 29.53 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 110.204 -0.295 . . . . 0.0 110.204 177.689 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -92.78 -23.73 18.77 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.078 0.466 . . . . 0.0 110.939 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . 0.464 HD23 ' N ' ' A' ' 93' ' ' ILE . 4.6 tt -150.1 140.74 22.58 Favored 'General case' 0 N--CA 1.449 -0.516 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.434 -178.225 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.524 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 62.8 mt -130.68 119.27 45.15 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 115.784 -0.644 . . . . 0.0 109.419 177.937 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 13.2 p90 -126.18 155.21 42.11 Favored 'General case' 0 C--N 1.32 -0.701 0 C-N-CA 120.553 -0.459 . . . . 0.0 110.544 179.277 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . 0.6 ' HA ' ' O ' ' A' ' 42' ' ' VAL . 10.6 p -135.81 143.63 45.28 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.752 -0.658 . . . . 0.0 111.424 -175.189 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 74.5 mt -114.86 112.59 40.67 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 115.577 -0.738 . . . . 0.0 110.249 178.763 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 61.6 mtp180 57.59 70.36 1.34 Allowed Pre-proline 0 N--CA 1.466 0.331 0 CA-C-N 115.593 -0.73 . . . . 0.0 112.279 -178.459 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_endo -87.31 131.72 3.05 Favored 'Trans proline' 0 N--CA 1.451 -1.005 0 C-N-CA 122.536 2.157 . . . . 0.0 111.78 175.699 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.635 ' HD2' HD11 ' A' ' 102' ' ' ILE . 52.2 Cg_exo -55.98 148.9 55.3 Favored 'Trans proline' 0 C--O 1.235 0.36 0 C-N-CA 122.464 2.11 . . . . 0.0 111.564 172.267 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.712 ' HA ' ' ND1' ' A' ' 103' ' ' HIS . . . -60.71 -22.91 64.45 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.918 0.39 . . . . 0.0 111.763 -175.337 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' GLU . . . . . 0.694 ' HG3' HG23 ' A' ' 102' ' ' ILE . 10.5 pt-20 -66.65 -31.22 71.75 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.983 -179.958 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.694 HG23 ' HG3' ' A' ' 101' ' ' GLU . 48.3 pt -107.42 -1.05 9.92 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.148 0 N-CA-C 112.482 0.549 . . . . 0.0 112.482 -173.004 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' HIS . . . . . 0.712 ' ND1' ' HA ' ' A' ' 100' ' ' ALA . 13.1 m170 -53.54 -55.61 24.08 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 121.118 0.485 . . . . 0.0 111.162 178.235 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 19.0 m -70.2 -25.59 63.48 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 121.184 0.516 . . . . 0.0 110.689 179.503 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.705 ' O ' ' HG2' ' A' ' 108' ' ' ARG . 1.7 m -71.83 -37.65 70.27 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.502 -177.955 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 86.1 mt -63.62 -39.15 93.64 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.709 177.531 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' MET . . . . . 0.447 ' SD ' ' HB3' ' A' ' 131' ' ' ARG . 49.7 ttm -64.54 -42.33 95.78 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.208 179.447 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' ARG . . . . . 0.705 ' HG2' ' O ' ' A' ' 105' ' ' SER . 1.7 ptm180 -66.37 -26.84 67.45 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.836 0.35 . . . . 0.0 110.628 -178.225 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 82.2 t -75.3 -49.15 28.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.155 175.374 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -57.69 -42.63 84.05 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.494 177.458 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.492 ' HA ' ' HB1' ' A' ' 148' ' ' ALA . 16.8 t70 -62.45 -32.08 72.9 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.581 -0.736 . . . . 0.0 110.746 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -79.09 -41.74 27.97 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.585 -0.734 . . . . 0.0 111.955 -178.634 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 29.0 m -87.83 -26.14 5.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 N-CA-C 111.907 0.336 . . . . 0.0 111.907 -175.955 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . 0.412 ' HA3' ' HA ' ' A' ' 150' ' ' VAL . . . 82.5 64.86 1.66 Allowed Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.884 -0.674 . . . . 0.0 112.052 -178.955 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . 0.4 ' O ' ' HB3' ' A' ' 148' ' ' ALA . . . -139.58 155.41 47.49 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 120.815 0.341 . . . . 0.0 110.702 -179.909 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 116' ' ' ARG . . . . . 0.449 ' HB3' ' HG ' ' A' ' 92' ' ' LEU . 20.0 ttm-85 -75.1 121.59 22.27 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 177.416 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . 0.524 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 65.9 tp -94.02 125.28 38.56 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.171 -179.928 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 71.4 mt -124.25 120.51 59.46 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.654 0 CA-C-O 120.899 0.38 . . . . 0.0 110.146 177.488 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 30.2 mt -114.04 131.21 66.64 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.217 -178.348 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 120' ' ' LYS . . . . . 0.616 ' HD3' ' HB3' ' A' ' 143' ' ' PHE . 10.9 mmmm -110.86 98.08 36.61 Favored Pre-proline 0 C--O 1.235 0.308 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.881 172.946 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 85.7 Cg_endo -92.42 -157.89 0.06 OUTLIER 'Trans proline' 0 N--CA 1.453 -0.889 0 C-N-CA 123.177 2.585 . . . . 0.0 111.162 173.729 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 8.0 mp -111.38 150.42 29.79 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 120.635 0.255 . . . . 0.0 110.607 178.205 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 38.1 m -65.57 110.42 2.72 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.064 0.459 . . . . 0.0 110.655 178.916 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 108.36 -10.76 36.34 Favored Glycine 0 N--CA 1.445 -0.71 0 N-CA-C 111.084 -0.806 . . . . 0.0 111.084 -176.461 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 4.7 tp10 -106.39 100.5 10.02 Favored 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 109.08 -0.711 . . . . 0.0 109.08 178.49 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 15.8 t70 -85.22 165.05 17.69 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.427 -0.351 . . . . 0.0 110.958 -174.033 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.447 HG23 ' CG ' ' A' ' 103' ' ' HIS . 52.3 mt -83.2 -21.72 8.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-N 115.767 -0.652 . . . . 0.0 110.55 -177.628 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 17.4 m 47.6 26.87 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.931 0 C-N-CA 124.444 1.098 . . . . 0.0 112.926 179.77 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 13.7 t -92.89 145.44 24.38 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 109.97 -0.381 . . . . 0.0 109.97 177.831 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -91.08 32.02 1.05 Allowed 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.271 0.558 . . . . 0.0 109.915 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 131' ' ' ARG . . . . . 0.447 ' HB3' ' SD ' ' A' ' 107' ' ' MET . 4.0 mmp_? -110.65 -177.8 3.32 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.579 -178.272 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 132' ' ' LYS . . . . . 0.468 ' HE3' ' HB2' ' A' ' 132' ' ' LYS . 35.5 mtmt -99.49 124.32 44.56 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.282 -178.918 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 133' ' ' MET . . . . . . . . . . . . . 79.7 mtp -146.08 150.59 36.23 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 170.789 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 1.5 ptpp? -114.83 141.27 48.12 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 121.322 0.582 . . . . 0.0 111.301 -177.501 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . 0.558 HD11 ' HD2' ' A' ' 142' ' ' TYR . 60.0 tp -82.24 129.23 34.8 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.141 -0.936 . . . . 0.0 109.883 178.666 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -126.35 148.47 31.05 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.885 -177.852 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 13.3 m120 -124.23 125.73 44.89 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.05 -0.523 . . . . 0.0 109.865 179.827 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . 0.608 ' O ' HG22 ' A' ' 141' ' ' THR . 42.7 t80 -149.19 104.79 3.44 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.746 0.307 . . . . 0.0 111.049 177.562 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . 0.402 ' C ' ' H ' ' A' ' 141' ' ' THR . . . 59.93 67.28 2.23 Favored Glycine 0 CA--C 1.521 0.417 0 CA-C-N 116.212 -0.449 . . . . 0.0 113.736 175.878 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 21.9 mmt180 69.54 -21.64 0.16 Allowed 'General case' 0 N--CA 1.47 0.547 0 N-CA-C 113.176 0.806 . . . . 0.0 113.176 176.339 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 141' ' ' THR . . . . . 0.608 HG22 ' O ' ' A' ' 138' ' ' TYR . 1.0 OUTLIER -98.0 131.47 44.4 Favored 'General case' 0 N--CA 1.444 -0.77 0 CA-C-O 121.33 0.586 . . . . 0.0 109.91 -179.359 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 142' ' ' TYR . . . . . 0.558 ' HD2' HD11 ' A' ' 135' ' ' LEU . 21.6 p90 -115.99 147.28 41.37 Favored 'General case' 0 N--CA 1.445 -0.713 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 174.872 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 143' ' ' PHE . . . . . 0.616 ' HB3' ' HD3' ' A' ' 120' ' ' LYS . 12.2 p90 -155.81 171.82 19.38 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.61 -175.308 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -107.93 121.43 44.77 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.899 -0.591 . . . . 0.0 109.568 175.845 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 145' ' ' GLU . . . . . . . . . . . . . 15.3 pt-20 -112.32 156.06 23.06 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-O 121.267 0.556 . . . . 0.0 109.578 177.125 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 34.7 t80 -138.88 124.23 19.28 Favored 'General case' 0 C--N 1.311 -1.092 0 CA-C-N 115.646 -0.706 . . . . 0.0 109.468 176.322 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 147' ' ' ILE . . . . . 0.446 ' N ' HD12 ' A' ' 147' ' ' ILE . 3.1 mp -88.44 96.07 5.72 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.739 0 N-CA-C 109.18 -0.674 . . . . 0.0 109.18 178.078 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . 0.492 ' HB1' ' HA ' ' A' ' 111' ' ' ASP . . . -76.49 118.03 18.75 Favored 'General case' 0 C--N 1.317 -0.819 0 CA-C-N 115.369 -0.832 . . . . 0.0 109.061 177.042 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 31.3 mt-10 -61.48 129.59 41.92 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 121.814 0.816 . . . . 0.0 111.094 -175.206 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 150' ' ' VAL . . . . . 0.412 ' HA ' ' HA3' ' A' ' 114' ' ' GLY . 9.3 t -83.49 118.28 30.73 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.008 0 CA-C-N 114.387 -1.279 . . . . 0.0 110.557 -171.98 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 151' ' ' ARG . . . . . . . . . . . . . 13.0 ptp180 -87.54 80.56 8.01 Favored 'General case' 0 C--N 1.314 -0.961 0 CA-C-N 115.174 -0.921 . . . . 0.0 109.379 177.701 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 44.7 t -140.4 151.15 44.7 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.547 -0.751 . . . . 0.0 110.986 -173.846 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 37.2 tpt85 . . . . . 0 N--CA 1.44 -0.932 0 CA-C-O 118.266 -0.873 . . . . 0.0 109.055 172.78 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.479 0.985 0 N-CA-C 109.702 -0.481 . . . . 0.0 109.702 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -82.88 100.48 2.2 Favored Glycine 0 N--CA 1.446 -0.683 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.481 -178.685 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 27.9 t -65.59 126.95 29.95 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 109.36 -0.607 . . . . 0.0 109.36 177.192 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 8.6 p -80.92 49.77 1.27 Allowed 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 112.264 0.468 . . . . 0.0 112.264 -172.156 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 26.1 t-80 -121.61 85.87 2.48 Favored 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 171.813 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 7.6 p-80 -136.62 17.13 3.11 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.518 -0.764 . . . . 0.0 110.632 -177.407 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 10.7 p80 -101.44 17.48 22.61 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 121.387 0.613 . . . . 0.0 110.105 178.617 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 43.0 p-80 -74.6 -7.25 52.56 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.506 -0.77 . . . . 0.0 112.048 -175.123 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 15.7 p-80 -79.69 163.36 24.59 Favored 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 176.119 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 54.3 p-80 -132.41 169.33 16.68 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 121.015 0.436 . . . . 0.0 111.331 -175.901 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 42.9 t -133.7 156.03 48.67 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.585 -0.734 . . . . 0.0 109.644 175.303 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 20.8 m -127.82 0.92 6.04 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 120.782 0.325 . . . . 0.0 110.592 178.688 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 68.27 82.35 0.17 Allowed Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 120.837 -0.697 . . . . 0.0 112.26 -177.277 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . 0.734 ' H ' HD23 ' A' ' 14' ' ' LEU . 2.5 pt? -84.37 142.06 30.43 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 120.872 0.368 . . . . 0.0 110.422 -178.607 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.434 ' HA ' ' HD3' ' A' ' 16' ' ' PRO . 46.4 t -117.65 106.68 45.84 Favored Pre-proline 0 C--N 1.32 -0.698 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.06 179.372 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.434 ' HD3' ' HA ' ' A' ' 15' ' ' VAL . 2.7 Cg_endo -81.58 163.51 18.97 Favored 'Trans proline' 0 N--CA 1.456 -0.7 0 C-N-CA 122.983 2.455 . . . . 0.0 112.038 179.225 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 0.487 ' NE ' ' HA ' ' A' ' 17' ' ' ARG . 5.0 mmp_? -110.92 143.71 41.13 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.261 178.381 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 140.58 -165.69 26.05 Favored Glycine 0 N--CA 1.448 -0.505 0 C-N-CA 120.68 -0.772 . . . . 0.0 112.241 178.81 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . 0.487 ' HB3' ' HD1' ' A' ' 22' ' ' TRP . 15.3 m -80.89 44.83 0.77 Allowed 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 120.757 0.313 . . . . 0.0 111.237 -178.532 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' HIS . . . . . 0.43 ' HA ' ' HB2' ' A' ' 23' ' ' ASN . 61.8 m-70 -66.68 -20.39 65.97 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 111.83 0.307 . . . . 0.0 111.83 -177.023 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' MET . . . . . . . . . . . . . 56.9 mtt -68.22 -18.05 64.47 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.214 0.531 . . . . 0.0 110.271 174.737 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' TRP . . . . . 0.487 ' HD1' ' HB3' ' A' ' 19' ' ' SER . 83.2 m95 -96.54 -30.38 13.34 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.914 -0.585 . . . . 0.0 109.596 175.431 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.43 ' HB2' ' HA ' ' A' ' 20' ' ' HIS . 4.6 m-20 -62.51 -56.02 21.94 Favored 'General case' 0 CA--C 1.521 -0.171 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.508 176.418 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.549 ' HB3' ' HA3' ' A' ' 139' ' ' GLY . 44.7 m-20 -60.61 -36.64 79.09 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.617 179.766 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 64.6 tp -55.83 -49.74 72.45 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.177 175.027 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . 0.566 ' HB2' HG13 ' A' ' 50' ' ' VAL . . . -62.14 -46.69 87.89 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.582 -0.736 . . . . 0.0 111.024 179.029 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 71.4 t -53.17 -47.32 55.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 121.102 0.477 . . . . 0.0 110.664 176.8 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . 0.481 ' HB2' ' CD1' ' A' ' 138' ' ' TYR . 69.7 t80 -56.2 -41.64 75.9 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.891 178.491 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.499 HG23 HD22 ' A' ' 92' ' ' LEU . 75.8 mt -69.83 -44.81 78.63 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.82 178.88 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.621 HD11 ' HA ' ' A' ' 54' ' ' ILE . 83.6 mt -57.77 -43.77 84.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 115.891 -0.595 . . . . 0.0 111.507 -178.98 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 17.9 mtp180 -64.81 -32.76 74.6 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.902 -178.569 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 81.4 m -88.95 -18.67 26.99 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 115.501 -0.772 . . . . 0.0 111.995 -174.006 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 14.0 p -101.54 -82.1 0.47 Allowed 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 120.797 0.332 . . . . 0.0 111.556 -178.54 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 101.81 161.42 26.77 Favored Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 121.014 -0.612 . . . . 0.0 112.187 -178.328 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 7.6 Cg_exo -72.8 144.48 39.12 Favored 'Trans proline' 0 C--O 1.233 0.269 0 C-N-CA 123.083 2.522 . . . . 0.0 112.383 -179.163 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 111.89 -28.76 9.06 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.533 -0.842 . . . . 0.0 112.813 177.897 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 12.6 t -99.86 -169.45 1.74 Allowed 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 -178.551 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . 0.628 ' HB2' ' HA ' ' A' ' 90' ' ' ALA . 66.2 mtp180 -118.6 136.51 53.84 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.954 0.407 . . . . 0.0 111.134 -178.346 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.655 HG23 HG21 ' A' ' 60' ' ' VAL . 95.5 t -129.97 131.11 66.38 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-N 115.83 -0.623 . . . . 0.0 109.369 176.699 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.576 HG22 ' HB ' ' A' ' 63' ' ' VAL . 40.6 t -112.12 129.0 68.4 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 CA-C-O 120.765 0.317 . . . . 0.0 111.759 -173.178 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . 0.459 ' HB3' HD23 ' A' ' 64' ' ' LEU . 44.8 tt0 -103.11 107.76 18.7 Favored 'General case' 0 C--O 1.235 0.319 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 174.693 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 44.1 t -89.68 127.78 42.09 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.647 -178.16 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 94.14 23.98 20.82 Favored Glycine 0 N--CA 1.448 -0.523 0 N-CA-C 110.955 -0.858 . . . . 0.0 110.955 -176.375 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.608 ' HB1' HD23 ' A' ' 48' ' ' LEU . . . -93.47 80.38 4.36 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.247 -0.476 . . . . 0.0 110.858 -177.044 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -108.42 -60.61 0.54 Allowed Glycine 0 N--CA 1.446 -0.664 0 C-N-CA 120.824 -0.703 . . . . 0.0 112.015 178.607 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 57.6 mtp180 -125.47 4.44 7.63 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.933 0.397 . . . . 0.0 110.814 -179.171 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.528 ' HE2' HG23 ' A' ' 50' ' ' VAL . 64.7 t80 -86.69 -79.45 0.26 Allowed 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 176.712 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.646 HD22 HD13 ' A' ' 64' ' ' LEU . 59.4 mt 62.71 9.35 3.51 Favored 'General case' 0 N--CA 1.467 0.41 0 CA-C-N 115.156 -0.929 . . . . 0.0 112.795 171.006 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . 0.452 ' HB3' ' CE2' ' A' ' 47' ' ' PHE . 81.2 t80 -71.08 -45.42 63.77 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 111.791 0.293 . . . . 0.0 111.791 -171.431 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.566 HG13 ' HB2' ' A' ' 26' ' ' ALA . 56.2 t -69.98 -48.57 62.35 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-N 116.599 -0.273 . . . . 0.0 110.597 -177.946 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 50.9 p -58.77 -41.15 85.92 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.453 -0.339 . . . . 0.0 111.037 176.956 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.737 ' HA ' ' HE ' ' A' ' 55' ' ' ARG . 24.4 t70 -61.13 -37.97 84.72 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.8 0.333 . . . . 0.0 110.712 176.55 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 47.3 t80 -69.19 -45.6 69.55 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.308 178.041 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.621 ' HA ' HD11 ' A' ' 30' ' ' ILE . 88.0 mt -63.45 -44.83 99.02 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.823 -178.347 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . 0.748 HH22 HD11 ' A' ' 64' ' ' LEU . 12.1 ptp180 -63.37 -16.42 60.42 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-O 120.791 0.329 . . . . 0.0 111.584 -175.77 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . 0.459 ' HG3' ' O ' ' A' ' 52' ' ' ASP . 97.7 mttt -81.39 -36.04 30.03 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.599 -179.602 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 81.6 m-70 -103.67 -18.11 14.85 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.817 -175.021 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . 0.421 ' HB2' HG23 ' A' ' 30' ' ' ILE . 6.4 t -135.63 128.9 31.98 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-O 120.794 0.331 . . . . 0.0 110.566 -177.356 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -89.39 51.42 2.12 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.871 0.843 . . . . 0.0 110.126 175.532 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.655 HG21 HG23 ' A' ' 39' ' ' VAL . 8.3 p -83.59 147.21 5.96 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 CA-C-N 114.845 -1.07 . . . . 0.0 108.908 175.434 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . 0.571 ' HB3' ' HG2' ' A' ' 38' ' ' ARG . 19.0 t70 -72.68 95.52 1.88 Allowed 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 109.248 -0.649 . . . . 0.0 109.248 179.269 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . 0.411 ' HA ' ' O ' ' A' ' 39' ' ' VAL . 2.1 tt -94.77 128.45 41.49 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.407 -172.318 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.576 ' HB ' HG22 ' A' ' 40' ' ' VAL . 33.3 t -108.71 126.7 65.58 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.45 -178.92 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . 0.748 HD11 HH22 ' A' ' 55' ' ' ARG . 66.7 mt -108.61 131.18 55.13 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 116.039 -0.528 . . . . 0.0 109.63 176.4 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 49.9 p -129.3 127.91 42.11 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.721 0.296 . . . . 0.0 111.319 179.389 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 3.7 t70 -165.74 175.88 8.43 Favored 'General case' 0 C--O 1.233 0.215 0 CA-C-N 116.082 -0.508 . . . . 0.0 109.732 176.964 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 53.0 mt -87.68 114.57 26.72 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-O 120.634 0.254 . . . . 0.0 110.657 -176.391 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 55.3 mtpt 61.17 79.93 0.27 Allowed Pre-proline 0 C--N 1.331 -0.226 0 CA-C-N 115.646 -0.707 . . . . 0.0 110.9 178.287 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . 1.017 ' HB3' ' HB ' ' A' ' 74' ' ' ILE . 18.9 Cg_endo -58.21 114.84 2.15 Favored 'Trans proline' 0 C--N 1.342 0.223 0 C-N-CA 123.281 2.654 . . . . 0.0 113.08 -176.092 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 5.9 p -80.56 -30.54 37.04 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.932 178.911 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 46.1 t-80 -64.5 -59.11 4.7 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.797 178.826 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 132.33 -41.58 1.48 Allowed Glycine 0 N--CA 1.447 -0.575 0 C-N-CA 120.877 -0.678 . . . . 0.0 111.992 -179.164 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -93.6 24.54 25.37 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 121.004 -0.617 . . . . 0.0 112.031 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 1.017 ' HB ' ' HB3' ' A' ' 69' ' ' PRO . 65.4 mt -104.91 146.47 12.06 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 N-CA-C 109.996 -0.372 . . . . 0.0 109.996 -179.71 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.589 HG11 HD13 ' A' ' 86' ' ' ILE . 48.3 t -80.78 135.89 24.32 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 N-CA-C 109.778 -0.452 . . . . 0.0 109.778 176.805 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 11.4 ptt180 -75.98 25.71 0.12 Allowed 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.867 -0.606 . . . . 0.0 111.876 -177.177 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . 0.404 ' H ' ' C ' ' A' ' 75' ' ' VAL . 12.7 t70 -83.35 113.82 20.99 Favored 'General case' 0 C--N 1.324 -0.536 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 -177.753 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 2.2 p30 -70.67 168.97 15.37 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.033 0.444 . . . . 0.0 111.257 -172.697 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . 0.443 HD11 HD12 ' A' ' 102' ' ' ILE . 7.1 tp -83.98 -30.27 7.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 N-CA-C 112.936 0.717 . . . . 0.0 112.936 -169.569 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 12.2 t -94.23 -21.01 19.31 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.169 0.509 . . . . 0.0 110.712 -174.017 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 4.5 t -130.64 69.03 82.22 Favored Pre-proline 0 C--N 1.323 -0.585 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.05 -179.807 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -78.64 163.48 26.59 Favored 'Trans proline' 0 N--CA 1.46 -0.443 0 C-N-CA 122.98 2.453 . . . . 0.0 112.619 -175.834 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' ARG . . . . . 0.645 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 88.6 mtm180 -108.92 118.17 36.1 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.291 178.305 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' MET . . . . . 0.515 ' SD ' HG22 ' A' ' 109' ' ' VAL . 92.0 mmm -61.13 -28.61 69.23 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.267 -0.879 . . . . 0.0 111.343 -179.037 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.645 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 10.7 pt-20 -57.69 -24.27 55.9 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.711 -179.975 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.589 HD13 HG11 ' A' ' 75' ' ' VAL . 76.5 mt -86.48 -43.75 16.29 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.089 -177.478 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . 0.438 ' CE1' HG11 ' A' ' 40' ' ' VAL . 88.3 m-85 -72.13 -27.15 62.44 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.37 -178.593 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 27.0 mtp180 -66.06 116.66 7.4 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 121.409 0.623 . . . . 0.0 111.26 -179.482 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 118.61 -15.99 11.44 Favored Glycine 0 N--CA 1.447 -0.597 0 CA-C-N 115.189 -0.914 . . . . 0.0 111.243 -176.065 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . 0.628 ' HA ' ' HB2' ' A' ' 38' ' ' ARG . . . -75.48 145.63 41.25 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.897 0.379 . . . . 0.0 110.545 178.837 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -98.51 -20.76 16.89 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.125 177.659 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . 0.499 HD22 HG23 ' A' ' 29' ' ' ILE . 5.1 tt -153.33 138.24 17.17 Favored 'General case' 0 N--CA 1.447 -0.604 0 CA-C-N 115.688 -0.687 . . . . 0.0 109.967 -179.306 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.538 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 63.6 mt -130.64 131.16 64.96 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 115.987 -0.551 . . . . 0.0 109.629 -178.748 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' TYR . . . . . 0.454 ' HE1' HG12 ' A' ' 39' ' ' VAL . 26.6 p90 -134.15 156.05 49.01 Favored 'General case' 0 C--N 1.322 -0.626 0 C-N-CA 120.625 -0.43 . . . . 0.0 110.811 179.57 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 17.3 m -131.86 139.76 48.91 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.76 -177.651 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 42.3 mm -85.94 86.98 2.5 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.363 -179.259 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . 0.438 ' NH1' HD13 ' A' ' 122' ' ' LEU . 39.1 ttp180 44.32 79.56 0.33 Allowed Pre-proline 0 N--CA 1.47 0.558 0 O-C-N 124.126 0.891 . . . . 0.0 112.364 -179.313 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 91.2 Cg_endo -83.83 154.13 13.26 Favored 'Trans proline' 0 N--CA 1.456 -0.704 0 C-N-CA 122.918 2.412 . . . . 0.0 112.042 178.892 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.605 ' HD2' HD11 ' A' ' 102' ' ' ILE . 51.3 Cg_exo -55.35 150.66 40.32 Favored 'Trans proline' 0 C--N 1.346 0.417 0 C-N-CA 122.605 2.204 . . . . 0.0 112.112 175.53 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -79.68 30.31 0.25 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.727 -174.205 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' GLU . . . . . 0.413 ' HG3' HG23 ' A' ' 102' ' ' ILE . 10.4 pt-20 -124.95 -23.46 4.26 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 120.742 0.306 . . . . 0.0 110.954 176.507 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.605 HD11 ' HD2' ' A' ' 99' ' ' PRO . 46.6 pt -98.9 -2.4 9.83 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-O 120.752 0.31 . . . . 0.0 111.316 -177.173 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' HIS . . . . . 0.576 ' O ' ' HG2' ' A' ' 107' ' ' MET . 31.4 p-80 -60.16 -40.09 88.71 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.138 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 8.1 p -63.21 -35.85 81.68 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.913 178.604 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.514 ' O ' HG23 ' A' ' 109' ' ' VAL . 16.3 m -67.42 -45.91 74.72 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.735 -0.666 . . . . 0.0 109.69 177.976 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 96.0 mt -59.86 -42.17 93.1 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.909 178.124 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' MET . . . . . 0.576 ' HG2' ' O ' ' A' ' 103' ' ' HIS . 98.2 mmm -56.71 -49.59 74.71 Favored 'General case' 0 C--O 1.233 0.234 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.537 -179.939 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 33.7 ptt85 -70.77 -30.57 67.09 Favored 'General case' 0 C--N 1.332 -0.188 0 C-N-CA 120.727 -0.389 . . . . 0.0 111.108 -177.403 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.515 HG22 ' SD ' ' A' ' 84' ' ' MET . 69.5 t -67.78 -48.49 75.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 120.575 0.226 . . . . 0.0 110.647 177.029 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -59.08 -41.64 88.5 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.708 179.626 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.679 ' HA ' ' HB1' ' A' ' 148' ' ' ALA . 23.3 t70 -65.6 -42.29 91.8 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.701 -0.682 . . . . 0.0 110.815 178.489 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -62.54 -43.46 98.77 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.964 -0.562 . . . . 0.0 111.645 -178.364 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.419 HG21 HD11 ' A' ' 93' ' ' ILE . 20.2 m -85.38 -28.14 6.42 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-O 120.928 0.394 . . . . 0.0 111.022 -177.59 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 87.35 51.85 3.2 Favored Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 120.596 -0.812 . . . . 0.0 111.918 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -130.15 155.47 46.16 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 120.831 0.348 . . . . 0.0 110.901 -178.799 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 116' ' ' ARG . . . . . 0.698 HH21 HD11 ' A' ' 118' ' ' ILE . 50.2 ttp180 -79.21 117.56 20.34 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 178.037 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . 0.538 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 60.3 tp -88.14 118.84 27.99 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.0 -0.546 . . . . 0.0 110.086 -179.535 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . 0.698 HD11 HH21 ' A' ' 116' ' ' ARG . 66.6 mt -114.52 117.42 55.54 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-O 121.28 0.562 . . . . 0.0 110.842 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 71.7 mt -116.52 116.9 53.72 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.323 179.308 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 57.6 tttp -102.76 104.4 38.78 Favored Pre-proline 0 C--N 1.322 -0.598 0 C-N-CA 120.656 -0.418 . . . . 0.0 110.005 172.351 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 121' ' ' PRO . . . . . 0.591 ' HB2' ' O ' ' A' ' 125' ' ' GLU . 70.5 Cg_endo -78.68 -139.58 0.02 OUTLIER 'Trans proline' 0 N--CA 1.457 -0.673 0 C-N-CA 122.522 2.148 . . . . 0.0 111.531 172.673 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 122' ' ' LEU . . . . . 0.888 ' HB3' ' HB3' ' A' ' 125' ' ' GLU . 14.4 tp -126.82 156.94 40.52 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.383 -178.789 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . 0.472 ' HA ' ' OH ' ' A' ' 142' ' ' TYR . 25.4 m -69.94 102.04 1.9 Allowed 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 177.368 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 100.88 2.88 55.1 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.967 -0.635 . . . . 0.0 111.737 -175.533 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . 0.888 ' HB3' ' HB3' ' A' ' 122' ' ' LEU . 37.7 tt0 -132.38 97.12 4.02 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 177.827 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 14.2 t70 -99.9 173.06 6.85 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.403 -0.817 . . . . 0.0 110.455 -170.227 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.403 ' HB ' HG22 ' A' ' 129' ' ' THR . 5.3 mt -78.62 -14.98 13.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 178.12 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 27.6 m 48.21 35.7 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.556 0 C-N-CA 124.669 1.188 . . . . 0.0 112.263 -178.962 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . 0.403 HG22 ' HB ' ' A' ' 127' ' ' ILE . 15.2 t -115.19 144.03 44.32 Favored 'General case' 0 N--CA 1.452 -0.33 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.743 179.393 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 6.9 mp0 -102.19 63.75 0.91 Allowed 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 121.021 0.439 . . . . 0.0 109.923 177.893 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 131' ' ' ARG . . . . . 0.505 ' HE ' ' HA ' ' A' ' 131' ' ' ARG . 0.0 OUTLIER -108.96 -170.16 1.61 Allowed 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.38 -176.569 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 132' ' ' LYS . . . . . 0.555 ' HE3' ' HE1' ' A' ' 146' ' ' TYR . 31.7 ttpt -84.72 11.0 9.83 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-O 121.361 0.601 . . . . 0.0 112.038 -172.165 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 133' ' ' MET . . . . . . . . . . . . . 46.7 mtp -69.06 170.5 9.81 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.764 176.949 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . 0.476 ' NZ ' ' HB3' ' A' ' 134' ' ' LYS . 0.5 OUTLIER -139.68 151.65 46.09 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.942 -179.43 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . 0.436 HD11 ' HD2' ' A' ' 142' ' ' TYR . 57.4 tp -89.74 123.46 33.77 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.252 178.206 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 136' ' ' VAL . . . . . 0.452 ' CG2' ' HG2' ' A' ' 145' ' ' GLU . 0.1 OUTLIER -121.74 149.05 24.92 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.445 -179.658 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 12.3 m120 -125.86 112.62 16.2 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.2 -176.214 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . 0.481 ' CD1' ' HB2' ' A' ' 28' ' ' TYR . 53.3 t80 -147.96 123.31 10.29 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.554 0.216 . . . . 0.0 110.947 -179.723 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . 0.549 ' HA3' ' HB3' ' A' ' 24' ' ' ASP . . . 62.93 71.69 0.78 Allowed Glycine 0 N--CA 1.451 -0.317 0 CA-C-N 115.716 -0.674 . . . . 0.0 113.726 173.045 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 6.1 mpt_? 70.99 -39.5 0.45 Allowed 'General case' 0 N--CA 1.473 0.684 0 C-N-CA 123.356 0.662 . . . . 0.0 112.628 175.171 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 8.8 t -101.87 154.5 18.87 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 121.487 0.66 . . . . 0.0 111.696 -173.817 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 142' ' ' TYR . . . . . 0.472 ' OH ' ' HA ' ' A' ' 123' ' ' THR . 45.8 p90 -112.68 155.02 25.2 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 115.031 -0.986 . . . . 0.0 108.592 169.249 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 18.0 p90 -160.27 179.03 9.03 Favored 'General case' 0 C--N 1.319 -0.744 0 N-CA-C 110.151 -0.315 . . . . 0.0 110.151 -178.348 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 86.5 m-85 -116.27 125.42 52.17 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 120.724 0.297 . . . . 0.0 110.525 -179.505 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 145' ' ' GLU . . . . . 0.452 ' HG2' ' CG2' ' A' ' 136' ' ' VAL . 23.7 pt-20 -117.28 162.1 18.43 Favored 'General case' 0 C--N 1.317 -0.807 0 N-CA-C 109.557 -0.534 . . . . 0.0 109.557 175.235 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . 0.555 ' HE1' ' HE3' ' A' ' 132' ' ' LYS . 14.8 t80 -138.28 117.3 12.51 Favored 'General case' 0 C--N 1.311 -1.102 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.744 175.623 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 147' ' ' ILE . . . . . 0.42 ' N ' HD12 ' A' ' 147' ' ' ILE . 2.4 mp -85.41 99.43 7.39 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.874 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 174.643 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . 0.679 ' HB1' ' HA ' ' A' ' 111' ' ' ASP . . . -58.42 104.48 0.22 Allowed 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 108.933 -0.765 . . . . 0.0 108.933 176.432 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 36.7 mt-10 -50.91 121.32 5.81 Favored 'General case' 0 CA--C 1.506 -0.717 0 CA-C-O 122.092 0.948 . . . . 0.0 110.76 -175.329 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 150' ' ' VAL . . . . . 0.595 HG12 ' H ' ' A' ' 152' ' ' SER . 3.5 t -64.64 118.35 6.78 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.12 0 CA-C-N 113.326 -1.761 . . . . 0.0 111.425 -164.226 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 151' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.31 25.48 2.21 Favored 'General case' 0 C--N 1.315 -0.906 0 CA-C-N 114.786 -1.097 . . . . 0.0 110.152 176.432 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 152' ' ' SER . . . . . 0.595 ' H ' HG12 ' A' ' 150' ' ' VAL . 15.6 m -138.84 157.6 45.76 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 114.747 -1.115 . . . . 0.0 108.907 177.632 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 99.1 mtt180 . . . . . 0 C--O 1.246 0.889 0 CA-C-O 118.718 -0.658 . . . . 0.0 110.246 178.525 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 27.5 ttt . . . . . 0 N--CA 1.478 0.943 0 CA-C-O 120.747 0.308 . . . . 0.0 110.447 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 87.52 -69.27 2.98 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.584 176.17 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 15.1 m -72.38 85.05 1.1 Allowed 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.975 0.417 . . . . 0.0 110.465 179.774 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 48.8 m -154.23 86.12 1.16 Allowed 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.238 177.879 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 49.4 m80 -92.31 118.99 31.45 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 109.503 -0.554 . . . . 0.0 109.503 179.17 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 88.0 m-70 -91.76 81.83 5.23 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.504 0.669 . . . . 0.0 111.121 -173.806 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 52.6 t-80 -135.49 100.41 4.5 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.188 -0.915 . . . . 0.0 109.222 175.414 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 8.6 p-80 -119.77 34.46 5.21 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.113 -178.249 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 38.2 t60 -60.16 126.48 27.69 Favored 'General case' 0 C--N 1.327 -0.388 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 176.989 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 30.7 m170 -69.04 145.02 53.86 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.922 -177.607 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 33.9 t -124.68 144.21 50.33 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 116.076 -0.511 . . . . 0.0 109.922 -179.069 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 71.2 m -100.22 100.37 11.18 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 120.959 0.409 . . . . 0.0 110.683 178.264 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -118.52 151.33 17.84 Favored Glycine 0 N--CA 1.446 -0.699 0 C-N-CA 120.8 -0.715 . . . . 0.0 111.656 179.502 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 94.6 mt -99.54 167.2 10.75 Favored 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 110.172 -0.307 . . . . 0.0 110.172 -179.86 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.41 ' HA ' ' HD3' ' A' ' 16' ' ' PRO . 7.6 p -83.83 127.95 65.25 Favored Pre-proline 0 C--N 1.322 -0.605 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 176.997 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.41 ' HD3' ' HA ' ' A' ' 15' ' ' VAL . 23.1 Cg_exo -63.63 125.88 16.4 Favored 'Trans proline' 0 N--CA 1.461 -0.416 0 C-N-CA 122.323 2.015 . . . . 0.0 112.135 179.146 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -97.54 150.92 20.57 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-N 115.463 -0.79 . . . . 0.0 109.938 -179.313 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 80.6 28.47 47.28 Favored Glycine 0 N--CA 1.446 -0.692 0 N-CA-C 110.798 -0.921 . . . . 0.0 110.798 -171.526 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 11.7 p -104.56 17.16 24.66 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 120.891 0.377 . . . . 0.0 111.17 -175.062 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 36.7 m-70 -58.89 -24.41 62.23 Favored 'General case' 0 N--CA 1.464 0.268 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.325 179.664 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' MET . . . . . . . . . . . . . 22.8 mmt -77.13 -16.91 58.99 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.966 -178.933 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' TRP . . . . . 0.601 ' CH2' HG23 ' A' ' 96' ' ' ILE . 99.4 m95 -98.81 -18.1 18.11 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.351 -0.386 . . . . 0.0 111.677 -179.882 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 24.3 t-20 -56.45 -41.06 75.86 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.765 -0.652 . . . . 0.0 111.606 -176.659 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -60.33 -50.82 72.08 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.963 -0.562 . . . . 0.0 112.042 -179.909 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 58.5 tp -56.28 -45.44 80.13 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.195 -178.474 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . 0.5 ' O ' HG13 ' A' ' 30' ' ' ILE . . . -54.74 -52.03 63.81 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.322 -179.157 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 83.2 t -51.4 -47.64 34.91 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.78 178.887 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 74.4 t80 -59.06 -44.59 91.84 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.921 0.391 . . . . 0.0 110.491 -179.054 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 72.5 mt -64.77 -45.53 94.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.918 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.607 HG12 HG23 ' A' ' 54' ' ' ILE . 85.8 mt -57.24 -44.36 83.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.88 179.911 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 55.5 mtt180 -71.36 -20.72 62.12 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.693 -0.685 . . . . 0.0 111.697 -175.224 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 72.8 m -88.98 -21.33 23.58 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.408 -0.36 . . . . 0.0 111.256 179.788 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 12.4 p -106.23 -80.16 0.56 Allowed 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 120.765 0.317 . . . . 0.0 111.255 -176.652 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 95.92 172.82 36.01 Favored Glycine 0 N--CA 1.449 -0.468 0 C-N-CA 120.822 -0.704 . . . . 0.0 112.427 -179.888 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 12.5 Cg_exo -69.68 143.39 51.08 Favored 'Trans proline' 0 N--CA 1.465 -0.189 0 C-N-CA 122.955 2.437 . . . . 0.0 112.335 -179.197 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 91.12 7.27 65.89 Favored Glycine 0 N--CA 1.454 -0.128 0 C-N-CA 120.613 -0.803 . . . . 0.0 112.694 176.413 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 29.9 p -110.43 -174.09 2.4 Favored 'General case' 0 C--N 1.321 -0.671 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 179.848 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . 0.619 ' NH2' ' HA3' ' A' ' 89' ' ' GLY . 56.6 mtm180 -129.72 126.91 39.36 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 120.771 0.319 . . . . 0.0 110.647 176.709 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.643 HG23 HG21 ' A' ' 60' ' ' VAL . 41.5 t -122.81 134.51 65.75 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 177.703 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.475 HG11 ' CE1' ' A' ' 87' ' ' TYR . 32.2 t -114.02 122.38 68.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-O 120.955 0.407 . . . . 0.0 110.436 -178.416 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . 0.815 ' HG3' HD23 ' A' ' 64' ' ' LEU . 0.1 OUTLIER -93.07 121.59 34.58 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.71 -174.706 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.508 ' O ' ' HA ' ' A' ' 95' ' ' SER . 48.5 t -102.55 113.65 39.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 N-CA-C 109.566 -0.531 . . . . 0.0 109.566 173.825 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 111.77 44.9 0.86 Allowed Glycine 0 N--CA 1.45 -0.37 0 N-CA-C 111.134 -0.786 . . . . 0.0 111.134 -176.032 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -95.85 14.73 22.41 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.102 0.477 . . . . 0.0 111.044 -175.892 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -72.74 -7.73 70.48 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.946 -0.645 . . . . 0.0 112.947 -178.153 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 74.0 ttt180 -166.18 -34.14 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.94 0.4 . . . . 0.0 110.934 -179.915 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 40.7 m-85 -82.86 83.39 7.77 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 121.116 0.484 . . . . 0.0 111.056 -175.685 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 88.2 mt -109.35 9.3 25.71 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.144 -179.514 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 39.3 t80 -72.54 -50.97 21.96 Favored 'General case' 0 C--N 1.33 -0.267 0 C-N-CA 121.023 -0.271 . . . . 0.0 110.968 178.259 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.528 ' O ' HG13 ' A' ' 54' ' ' ILE . 33.6 t -57.73 -49.0 82.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.463 -176.448 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 1.9 p -60.01 -44.07 94.81 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.93 -0.577 . . . . 0.0 111.787 -179.783 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.542 ' O ' ' HG2' ' A' ' 56' ' ' LYS . 28.8 t70 -64.99 -39.76 93.95 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 120.856 0.36 . . . . 0.0 110.601 -179.907 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 59.5 t80 -65.97 -39.47 90.41 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.563 -179.218 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.607 HG23 HG12 ' A' ' 30' ' ' ILE . 82.3 mt -64.88 -48.71 83.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.613 -179.852 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 39.7 ptt180 -67.28 -17.13 64.66 Favored 'General case' 0 N--CA 1.466 0.348 0 N-CA-C 111.586 0.217 . . . . 0.0 111.586 -175.649 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . 0.542 ' HG2' ' O ' ' A' ' 52' ' ' ASP . 33.1 mmtp -75.04 -36.07 61.87 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.822 0.344 . . . . 0.0 110.747 177.591 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 53.8 m-70 -94.6 -31.11 14.01 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.818 -175.785 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 73.3 m -136.75 132.89 35.41 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 120.759 0.314 . . . . 0.0 111.474 -178.27 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 3.1 tmtp? -81.51 60.97 4.75 Favored 'General case' 0 C--O 1.234 0.256 0 CA-C-O 121.831 0.824 . . . . 0.0 109.708 177.051 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.643 HG21 HG23 ' A' ' 39' ' ' VAL . 2.6 p -84.59 144.61 9.45 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.037 0 CA-C-N 114.975 -1.011 . . . . 0.0 108.869 172.816 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . 0.43 ' O ' ' HA ' ' A' ' 38' ' ' ARG . 24.7 m-20 -79.0 100.36 7.27 Favored 'General case' 0 CA--C 1.515 -0.378 0 CA-C-O 121.605 0.717 . . . . 0.0 109.441 176.328 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . 0.516 HD11 ' OE2' ' A' ' 41' ' ' GLU . 8.5 tt -99.28 129.14 45.48 Favored 'General case' 0 C--N 1.316 -0.854 0 CA-C-N 114.8 -1.091 . . . . 0.0 110.599 -171.653 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 57.7 t -117.45 116.06 50.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.987 -177.895 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . 0.815 HD23 ' HG3' ' A' ' 41' ' ' GLU . 33.1 mt -87.39 128.21 35.2 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 115.966 -0.561 . . . . 0.0 109.828 178.17 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.512 HG22 ' HB ' ' A' ' 75' ' ' VAL . 25.2 p -130.57 134.36 46.95 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 120.488 0.185 . . . . 0.0 110.629 178.965 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -171.74 153.73 3.43 Favored 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 178.395 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.546 HD11 HG22 ' A' ' 79' ' ' ILE . 60.8 mt -77.42 122.66 32.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 N-CA-C 110.152 -0.314 . . . . 0.0 110.152 179.483 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' LYS . . . . . 0.52 ' HG3' HG22 ' A' ' 67' ' ' ILE . 91.9 mttt 60.83 80.65 0.26 Allowed Pre-proline 0 C--O 1.234 0.267 0 O-C-N 123.734 0.646 . . . . 0.0 110.485 -177.413 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . 0.692 ' HB3' ' HB ' ' A' ' 74' ' ' ILE . 29.0 Cg_endo -64.71 122.39 10.23 Favored 'Trans proline' 0 N--CA 1.464 -0.243 0 C-N-CA 122.799 2.333 . . . . 0.0 112.515 -178.636 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 8.0 t -87.96 7.07 32.77 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.914 -178.266 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 50.7 t-80 -112.43 -73.43 0.67 Allowed 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.46 -179.758 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 145.32 -35.15 1.47 Allowed Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.01 -179.534 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -92.55 23.23 29.01 Favored Glycine 0 C--O 1.228 -0.238 0 C-N-CA 120.979 -0.629 . . . . 0.0 111.825 177.899 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.692 ' HB ' ' HB3' ' A' ' 69' ' ' PRO . 71.2 mt -109.99 140.34 29.39 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-N 115.518 -0.341 . . . . 0.0 110.122 -178.478 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.512 ' HB ' HG22 ' A' ' 65' ' ' THR . 61.2 t -71.28 119.18 17.16 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-O 121.199 0.523 . . . . 0.0 110.343 178.61 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' ARG . . . . . 0.41 ' H ' ' HG2' ' A' ' 76' ' ' ARG . 16.5 ptm180 -81.66 34.5 0.39 Allowed 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.379 -0.828 . . . . 0.0 111.96 -176.27 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 35.2 t70 -78.72 145.02 34.73 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 120.892 0.377 . . . . 0.0 110.392 -177.857 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . 0.51 ' HB3' HG22 ' A' ' 80' ' ' THR . 10.4 m-20 -81.15 110.86 17.05 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.696 -176.744 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . 0.546 HG22 HD11 ' A' ' 67' ' ' ILE . 10.6 tp -63.96 -19.9 25.51 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.519 0 CA-C-O 120.909 0.385 . . . . 0.0 111.022 179.75 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.51 HG22 ' HB3' ' A' ' 78' ' ' ASP . 7.0 t -68.52 -26.33 65.38 Favored 'General case' 0 CA--C 1.533 0.301 0 CA-C-O 121.13 0.49 . . . . 0.0 110.572 177.73 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 44.3 m -152.0 73.42 7.82 Favored Pre-proline 0 C--N 1.322 -0.607 0 N-CA-C 108.37 -0.974 . . . . 0.0 108.37 176.738 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.469 ' HB2' ' HE2' ' A' ' 87' ' ' TYR . 75.8 Cg_endo -76.01 162.8 34.08 Favored 'Trans proline' 0 C--O 1.237 0.429 0 C-N-CA 122.817 2.344 . . . . 0.0 114.044 -166.121 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' ARG . . . . . 0.872 ' HG3' ' HG2' ' A' ' 85' ' ' GLU . 0.2 OUTLIER -81.72 99.99 9.24 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 114.855 -1.066 . . . . 0.0 109.201 174.929 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' MET . . . . . 0.401 ' O ' ' HG3' ' A' ' 88' ' ' ARG . 83.8 mmm -59.08 -31.16 68.64 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 116.596 -0.274 . . . . 0.0 111.186 -177.187 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.872 ' HG2' ' HG3' ' A' ' 83' ' ' ARG . 8.2 pt-20 -66.94 -24.72 66.1 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.495 -0.32 . . . . 0.0 111.397 -179.789 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 69.0 mt -73.62 -32.29 35.17 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 C-N-CA 120.515 -0.474 . . . . 0.0 110.429 177.282 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . 0.483 ' CB ' HG11 ' A' ' 113' ' ' VAL . 98.3 m-85 -85.91 -28.63 24.21 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.974 -0.557 . . . . 0.0 111.22 179.022 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . 0.401 ' HG3' ' O ' ' A' ' 84' ' ' MET . 69.6 mtp180 -61.72 117.95 6.49 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.33 0.586 . . . . 0.0 111.691 -177.639 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . 0.619 ' HA3' ' NH2' ' A' ' 38' ' ' ARG . . . 106.36 -5.19 38.13 Favored Glycine 0 N--CA 1.444 -0.779 0 CA-C-N 115.222 -0.899 . . . . 0.0 112.383 179.906 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -69.85 146.97 50.91 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.801 0.334 . . . . 0.0 110.495 177.733 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -91.5 -30.8 16.23 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.368 -179.766 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . 0.444 ' HG ' ' HB3' ' A' ' 116' ' ' ARG . 5.3 tt -153.25 144.19 22.88 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.182 -178.361 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.679 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 70.1 mt -133.07 129.04 57.04 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 177.31 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' TYR . . . . . 0.474 ' HE2' HD11 ' A' ' 96' ' ' ILE . 51.0 p90 -134.01 162.88 30.85 Favored 'General case' 0 C--N 1.32 -0.715 0 C-N-CA 120.053 -0.659 . . . . 0.0 111.274 179.604 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . 0.782 ' HB3' ' HG3' ' A' ' 98' ' ' PRO . 15.8 m -137.83 137.83 38.54 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.999 -175.682 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' ILE . . . . . 0.601 HG23 ' CH2' ' A' ' 22' ' ' TRP . 5.0 mp -106.74 93.87 2.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.349 177.866 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 54.1 ttp85 48.29 72.68 1.18 Allowed Pre-proline 0 CA--C 1.54 0.574 0 CA-C-N 115.527 -0.761 . . . . 0.0 112.472 177.242 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' PRO . . . . . 0.782 ' HG3' ' HB3' ' A' ' 95' ' ' SER . 14.8 Cg_endo -91.97 162.81 3.28 Favored 'Trans proline' 0 N--CA 1.454 -0.823 0 C-N-CA 123.228 2.619 . . . . 0.0 111.905 176.798 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.461 ' HB2' ' HG2' ' A' ' 101' ' ' GLU . 2.4 Cg_endo -48.97 139.64 25.3 Favored 'Trans proline' 0 C--N 1.349 0.599 0 C-N-CA 123.181 2.587 . . . . 0.0 112.597 177.159 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.746 ' HA ' ' CE1' ' A' ' 103' ' ' HIS . . . -79.28 19.36 0.59 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.188 -0.46 . . . . 0.0 112.098 -172.528 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' GLU . . . . . 0.461 ' HG2' ' HB2' ' A' ' 99' ' ' PRO . 9.3 pt-20 -115.82 -16.62 11.17 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 115.991 -0.549 . . . . 0.0 111.367 -177.572 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.634 HD11 ' HB2' ' A' ' 98' ' ' PRO . 2.5 pp -112.04 3.44 8.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 N-CA-C 112.258 0.466 . . . . 0.0 112.258 -175.546 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' HIS . . . . . 0.746 ' CE1' ' HA ' ' A' ' 100' ' ' ALA . 33.5 m170 -62.27 -40.79 97.4 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.181 -179.15 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 22.4 m -61.81 -31.46 71.69 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.987 0.422 . . . . 0.0 110.899 178.903 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.561 ' O ' HG23 ' A' ' 109' ' ' VAL . 14.5 m -72.84 -40.68 65.55 Favored 'General case' 0 N--CA 1.448 -0.538 0 CA-C-N 116.045 -0.525 . . . . 0.0 109.897 178.302 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 90.4 mt -61.38 -42.17 98.28 Favored 'General case' 0 C--O 1.233 0.224 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.944 178.289 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' MET . . . . . . . . . . . . . 91.3 mmm -55.37 -48.09 74.81 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.619 -0.719 . . . . 0.0 111.768 -179.598 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 4.1 ptp180 -74.01 -26.89 60.68 Favored 'General case' 0 C--N 1.329 -0.32 0 C-N-CA 120.875 -0.33 . . . . 0.0 111.512 -177.697 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.561 HG23 ' O ' ' A' ' 105' ' ' SER . 70.2 t -66.31 -46.87 85.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 N-CA-C 110.192 -0.299 . . . . 0.0 110.192 175.813 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -59.01 -45.57 90.36 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.292 178.527 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.504 ' HA ' ' HB1' ' A' ' 148' ' ' ALA . 24.4 t70 -64.9 -36.83 85.63 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.885 -0.598 . . . . 0.0 111.026 179.557 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -68.53 -35.56 77.64 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.717 -0.674 . . . . 0.0 112.17 -178.372 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.483 HG11 ' CB ' ' A' ' 87' ' ' TYR . 22.5 m -97.04 -23.77 4.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-O 120.745 0.307 . . . . 0.0 111.65 -177.787 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 89.43 36.4 7.5 Favored Glycine 0 N--CA 1.452 -0.235 0 C-N-CA 120.933 -0.651 . . . . 0.0 112.645 176.792 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -114.24 147.47 38.93 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 121.003 0.43 . . . . 0.0 111.416 -177.187 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 116' ' ' ARG . . . . . 0.444 ' HB3' ' HG ' ' A' ' 92' ' ' LEU . 27.8 ttt180 -70.96 120.06 15.98 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.687 -0.688 . . . . 0.0 109.836 178.876 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . 0.679 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 60.0 tp -94.72 126.83 40.28 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 -179.038 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 64.1 mt -129.02 122.79 57.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-O 120.827 0.346 . . . . 0.0 110.44 -179.223 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 119' ' ' ILE . . . . . 0.519 HG12 ' HB2' ' A' ' 95' ' ' SER . 66.7 mt -130.05 119.85 48.0 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-O 120.777 0.323 . . . . 0.0 110.755 -179.018 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 34.3 ttpt -116.27 98.38 51.31 Favored Pre-proline 0 C--N 1.326 -0.441 0 N-CA-C 109.622 -0.511 . . . . 0.0 109.622 173.085 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 89.6 Cg_endo -87.17 -156.08 0.06 OUTLIER 'Trans proline' 0 N--CA 1.457 -0.631 0 C-N-CA 122.862 2.375 . . . . 0.0 112.471 179.325 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 122' ' ' LEU . . . . . 0.441 HD12 ' HA ' ' A' ' 122' ' ' LEU . 9.3 tp -74.35 161.56 29.75 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.302 177.899 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 12.9 t -69.3 -24.65 63.97 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.064 0.459 . . . . 0.0 110.979 -177.927 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -114.32 27.14 9.17 Favored Glycine 0 N--CA 1.448 -0.519 0 C-N-CA 120.837 -0.696 . . . . 0.0 111.385 176.686 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . 0.404 ' CB ' ' HB3' ' A' ' 122' ' ' LEU . 35.6 tt0 -128.04 125.93 40.29 Favored 'General case' 0 C--N 1.319 -0.756 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 -177.167 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -108.22 166.86 10.43 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.001 -179.935 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 42.6 mt -83.83 -22.78 8.15 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-O 121.095 0.474 . . . . 0.0 110.207 -178.805 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 11.1 t 61.75 39.12 0.18 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.228 0 CA-C-O 122.027 0.917 . . . . 0.0 109.714 -178.908 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 6.1 t -131.02 20.91 4.92 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.417 -0.811 . . . . 0.0 108.939 176.134 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 6.0 tp10 -54.34 105.41 0.15 Allowed 'General case' 0 C--O 1.233 0.212 0 CA-C-N 114.797 -1.092 . . . . 0.0 111.131 -173.183 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 131' ' ' ARG . . . . . . . . . . . . . 5.2 ttm105 179.53 -37.38 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.47 -0.786 . . . . 0.0 110.942 -172.901 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 132' ' ' LYS . . . . . 0.406 ' HE3' ' CZ ' ' A' ' 146' ' ' TYR . 55.7 tttp -134.65 -17.57 1.96 Allowed 'General case' 0 CA--C 1.534 0.341 0 N-CA-C 112.836 0.68 . . . . 0.0 112.836 -165.698 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 133' ' ' MET . . . . . . . . . . . . . 76.0 mtp -96.24 168.72 10.41 Favored 'General case' 0 C--N 1.328 -0.356 0 C-N-CA 120.69 -0.404 . . . . 0.0 111.098 -176.952 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . 0.461 ' HG3' ' HG2' ' A' ' 145' ' ' GLU . 15.8 ptmt -130.62 148.59 52.43 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.911 -178.088 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . 0.605 HD11 ' HD2' ' A' ' 142' ' ' TYR . 39.7 tp -94.62 126.21 39.77 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.395 -179.747 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -123.86 147.19 28.35 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.692 -179.577 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 9.8 m-80 -116.98 119.0 33.95 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.999 0.428 . . . . 0.0 110.299 177.344 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . 0.498 ' O ' HG22 ' A' ' 141' ' ' THR . 71.3 t80 -146.49 128.11 15.15 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.142 -0.481 . . . . 0.0 109.932 -177.038 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . 0.424 ' O ' ' HB2' ' A' ' 140' ' ' ARG . . . 66.37 38.9 94.0 Favored Glycine 0 N--CA 1.449 -0.469 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.238 177.904 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 140' ' ' ARG . . . . . 0.424 ' HB2' ' O ' ' A' ' 139' ' ' GLY . 13.0 mmt85 76.47 -12.54 1.02 Allowed 'General case' 0 N--CA 1.469 0.497 0 C-N-CA 123.438 0.695 . . . . 0.0 112.392 177.804 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 141' ' ' THR . . . . . 0.498 HG22 ' O ' ' A' ' 138' ' ' TYR . 4.6 t -105.21 166.1 10.64 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 120.851 0.358 . . . . 0.0 110.575 -178.972 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 142' ' ' TYR . . . . . 0.605 ' HD2' HD11 ' A' ' 135' ' ' LEU . 14.4 p90 -130.06 141.12 50.75 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.125 -0.488 . . . . 0.0 109.807 178.945 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -150.3 168.43 24.1 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.687 -177.58 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 85.8 m-85 -99.88 125.12 45.81 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 177.499 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 145' ' ' GLU . . . . . 0.461 ' HG2' ' HG3' ' A' ' 134' ' ' LYS . 7.5 pt-20 -116.26 162.84 16.88 Favored 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 109.558 -0.534 . . . . 0.0 109.558 175.596 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . 0.559 ' HB3' ' HB3' ' A' ' 117' ' ' LEU . 15.0 t80 -145.3 123.44 12.16 Favored 'General case' 0 C--N 1.314 -0.946 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.275 178.894 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 3.4 mp -91.92 100.27 10.98 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 177.545 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . 0.504 ' HB1' ' HA ' ' A' ' 111' ' ' ASP . . . -71.68 125.74 27.9 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.896 176.312 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -59.4 149.95 27.82 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.798 -0.637 . . . . 0.0 111.518 177.682 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 25.1 t -85.0 128.85 38.61 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.911 0 CA-C-N 115.021 -0.991 . . . . 0.0 109.404 179.268 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 151' ' ' ARG . . . . . . . . . . . . . 44.7 mtp85 -78.69 152.28 31.7 Favored 'General case' 0 C--N 1.317 -0.848 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.369 -178.222 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 18.8 t -80.67 147.07 30.8 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.624 -174.828 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 153' ' ' ARG . . . . . 0.412 HH11 ' HD3' ' A' ' 153' ' ' ARG . 8.6 ptt180 . . . . . 0 C--O 1.248 1.025 0 CA-C-O 118.165 -0.922 . . . . 0.0 110.044 178.998 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 25.0 mmt . . . . . 0 N--CA 1.48 1.062 0 N-CA-C 110.192 -0.299 . . . . 0.0 110.192 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -54.84 110.99 1.92 Allowed Glycine 0 C--N 1.332 0.321 0 C-N-CA 121.361 -0.447 . . . . 0.0 112.688 -177.822 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 16.1 m -115.87 123.14 47.39 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 120.727 0.299 . . . . 0.0 110.239 -179.2 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 15.9 m -90.58 131.47 36.28 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.495 -178.365 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 51.2 p-80 -99.85 146.11 26.99 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 109.962 -0.384 . . . . 0.0 109.962 178.621 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 38.9 m80 -104.52 178.26 4.61 Favored 'General case' 0 C--N 1.316 -0.878 0 CA-C-N 116.173 -0.467 . . . . 0.0 109.77 177.928 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 41.8 m80 -80.49 94.51 6.24 Favored 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 109.377 -0.601 . . . . 0.0 109.377 179.191 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 12.3 t-80 -111.22 126.42 54.85 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.347 -0.842 . . . . 0.0 110.076 -173.667 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 29.9 m170 61.84 77.94 0.31 Allowed 'General case' 0 N--CA 1.464 0.244 0 CA-C-O 121.453 0.644 . . . . 0.0 110.992 -176.552 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 56.3 t-80 -139.77 146.97 40.16 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.505 -0.771 . . . . 0.0 109.284 178.029 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 21.6 t -160.96 172.54 16.74 Favored 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 178.441 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 32.5 t -154.33 161.73 41.59 Favored 'General case' 0 C--N 1.32 -0.705 0 N-CA-C 109.557 -0.534 . . . . 0.0 109.557 -179.069 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -94.54 100.66 2.62 Favored Glycine 0 N--CA 1.447 -0.608 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.037 -179.298 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 94.1 mt -73.21 136.37 44.68 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.052 0.454 . . . . 0.0 110.319 -179.416 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 28.9 m -93.32 152.75 41.35 Favored Pre-proline 0 C--N 1.321 -0.655 0 CA-C-N 115.979 -0.555 . . . . 0.0 111.015 -178.911 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -70.41 159.09 54.09 Favored 'Trans proline' 0 C--O 1.234 0.3 0 C-N-CA 122.427 2.085 . . . . 0.0 111.465 175.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 0.607 ' H ' ' HD3' ' A' ' 17' ' ' ARG . 0.0 OUTLIER -111.29 114.13 27.09 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 121.126 0.488 . . . . 0.0 110.694 -177.869 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -65.17 101.94 0.61 Allowed Glycine 0 N--CA 1.449 -0.453 0 CA-C-N 115.674 -0.694 . . . . 0.0 111.964 179.31 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 3.3 p -160.84 118.54 2.42 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 120.801 0.334 . . . . 0.0 110.215 -177.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 91.2 m-70 -125.04 -52.48 1.65 Allowed 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.463 -0.335 . . . . 0.0 111.234 -176.646 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -72.83 -15.8 61.61 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 121.039 0.447 . . . . 0.0 111.175 -177.303 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 78.7 m95 -66.59 -18.45 65.37 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.639 176.655 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 27.1 t-20 -56.35 -52.52 64.26 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.779 -0.646 . . . . 0.0 111.492 -177.514 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -63.81 -33.71 76.29 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.138 -178.901 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 56.7 tp -58.08 -49.52 76.64 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.084 175.725 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . 0.402 ' O ' HG13 ' A' ' 30' ' ' ILE . . . -58.57 -48.45 80.88 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.763 178.655 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.478 ' HA ' HD12 ' A' ' 30' ' ' ILE . 87.4 t -54.85 -44.48 72.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.177 178.553 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . 0.424 ' HB2' ' CD2' ' A' ' 138' ' ' TYR . 84.6 t80 -60.77 -46.83 88.97 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.715 179.041 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 83.1 mt -60.9 -42.83 94.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.51 178.332 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.548 HG12 HG23 ' A' ' 54' ' ' ILE . 87.7 mt -56.65 -45.32 82.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 115.704 -0.68 . . . . 0.0 111.066 177.418 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . 0.405 ' HG3' ' O ' ' A' ' 27' ' ' VAL . 81.0 mtp180 -69.33 -27.34 65.27 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 121.147 0.499 . . . . 0.0 110.899 -177.729 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 80.4 m -88.9 -2.88 58.81 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.925 -0.579 . . . . 0.0 111.639 -178.538 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 16.6 p -121.84 -76.76 0.58 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.505 0.193 . . . . 0.0 110.977 -179.387 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.512 ' O ' HG22 ' A' ' 37' ' ' THR . . . 101.03 161.82 27.58 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 121.087 -0.578 . . . . 0.0 112.409 179.597 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_exo -74.36 146.34 35.35 Favored 'Trans proline' 0 N--CA 1.462 -0.351 0 C-N-CA 122.84 2.36 . . . . 0.0 111.986 179.076 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 98.02 -15.82 61.04 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.868 -0.682 . . . . 0.0 113.046 177.357 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . 0.512 HG22 ' O ' ' A' ' 34' ' ' GLY . 13.6 t -102.42 -172.14 2.08 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 117.039 0.419 . . . . 0.0 110.544 -179.091 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . 0.53 ' HB2' ' HA ' ' A' ' 90' ' ' ALA . 68.7 mtp180 -115.42 135.8 53.74 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.565 -0.289 . . . . 0.0 110.976 -177.276 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.496 HG23 HG21 ' A' ' 60' ' ' VAL . 61.7 t -131.59 138.86 52.02 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 175.575 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.566 ' O ' ' HA ' ' A' ' 93' ' ' ILE . 23.4 t -126.92 139.13 52.76 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 178.259 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . 0.623 ' OE2' ' HA ' ' A' ' 64' ' ' LEU . 0.5 OUTLIER -116.12 156.25 26.76 Favored 'General case' 0 C--N 1.32 -0.678 0 C-N-CA 120.123 -0.631 . . . . 0.0 109.959 171.49 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.439 HG21 HD22 ' A' ' 106' ' ' LEU . 62.1 t -110.84 103.23 15.14 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.851 0 CA-C-N 115.755 -0.657 . . . . 0.0 109.79 176.385 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 115.28 56.04 0.36 Allowed Glycine 0 N--CA 1.448 -0.538 0 C-N-CA 120.309 -0.948 . . . . 0.0 112.7 178.707 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.434 ' HB2' ' OE2' ' A' ' 41' ' ' GLU . . . -80.73 77.04 7.61 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.254 0.549 . . . . 0.0 110.424 178.029 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -82.75 -154.89 16.59 Favored Glycine 0 N--CA 1.447 -0.625 0 CA-C-N 115.564 -0.744 . . . . 0.0 112.846 -179.55 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 49.9 ttt180 -70.37 -15.12 62.82 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 121.264 0.554 . . . . 0.0 110.555 -177.46 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 7.7 p90 -88.94 58.71 4.7 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.792 -0.64 . . . . 0.0 111.204 -178.707 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 95.0 mt -78.23 35.09 0.21 Allowed 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.008 -0.542 . . . . 0.0 112.15 -176.848 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . 0.543 ' HB2' ' HG3' ' A' ' 17' ' ' ARG . 84.3 t80 -71.91 -53.83 11.92 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.602 0.239 . . . . 0.0 110.995 -179.45 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.431 ' O ' HG13 ' A' ' 54' ' ' ILE . 56.7 t -57.72 -50.8 76.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.024 -0.534 . . . . 0.0 111.134 -176.404 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 2.7 p -59.98 -42.33 93.93 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.627 -178.829 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.499 ' O ' ' HG2' ' A' ' 56' ' ' LYS . 27.5 t70 -67.73 -43.23 80.44 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.385 -0.371 . . . . 0.0 110.651 -179.647 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 61.9 t80 -63.01 -44.63 95.45 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.92 -178.405 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.548 HG23 HG12 ' A' ' 30' ' ' ILE . 84.3 mt -61.32 -46.05 97.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.864 179.508 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 2.5 ptm180 -72.92 -16.48 61.55 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.358 -176.992 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . 0.499 ' HG2' ' O ' ' A' ' 52' ' ' ASP . 36.0 mmtm -72.82 -34.82 67.1 Favored 'General case' 0 C--O 1.234 0.287 0 CA-C-O 120.848 0.356 . . . . 0.0 110.486 175.016 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 29.3 m-70 -93.55 -60.4 1.78 Allowed 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.379 -177.039 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 52.8 m -106.78 133.22 51.77 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 121.233 0.54 . . . . 0.0 111.717 -174.878 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 1.3 tmmm? -76.56 65.76 2.44 Favored 'General case' 0 N--CA 1.451 -0.38 0 CA-C-O 121.769 0.795 . . . . 0.0 108.909 174.318 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.496 HG21 HG23 ' A' ' 39' ' ' VAL . 14.9 p -97.06 147.83 6.03 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.983 0 CA-C-N 115.235 -0.893 . . . . 0.0 109.927 176.115 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 13.2 t70 -81.09 89.6 5.98 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 178.865 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 3.3 tm? -93.97 131.86 39.01 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.481 -0.781 . . . . 0.0 109.27 -178.096 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 42.4 t -115.36 117.92 57.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-O 120.457 0.17 . . . . 0.0 110.842 -177.604 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . 0.623 ' HA ' ' OE2' ' A' ' 41' ' ' GLU . 84.8 mt -86.89 128.07 35.05 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.913 -178.574 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 70.1 p -116.23 123.57 48.09 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.879 177.475 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . 0.689 ' HB3' HG21 ' A' ' 74' ' ' ILE . 17.9 t70 -149.03 136.12 19.95 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.126 -179.841 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.462 HG12 ' HB2' ' A' ' 78' ' ' ASP . 46.2 mt -69.12 110.61 2.63 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 178.189 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' LYS . . . . . 0.432 ' HG2' HG22 ' A' ' 67' ' ' ILE . 31.1 mmtp 63.25 85.37 0.17 Allowed Pre-proline 0 C--N 1.33 -0.269 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 -172.297 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . 0.655 ' HD3' ' HA ' ' A' ' 76' ' ' ARG . 4.2 Cg_endo -44.47 108.01 0.12 Allowed 'Trans proline' 0 C--N 1.351 0.698 0 C-N-CA 123.805 3.004 . . . . 0.0 112.52 -173.948 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 17.4 m -65.77 -33.24 75.41 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 114.835 -1.075 . . . . 0.0 111.801 -176.482 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . 0.564 ' H ' HD12 ' A' ' 74' ' ' ILE . 71.7 t60 -141.87 96.59 2.99 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 112.942 0.719 . . . . 0.0 112.942 -170.574 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 57.74 -113.13 4.34 Favored Glycine 0 CA--C 1.519 0.313 0 CA-C-N 115.553 -0.749 . . . . 0.0 114.799 167.454 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -82.35 58.72 4.96 Favored Glycine 0 C--N 1.332 0.361 0 C-N-CA 121.615 -0.326 . . . . 0.0 113.772 -170.9 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.689 HG21 ' HB3' ' A' ' 66' ' ' ASP . 97.2 mt -115.83 141.89 31.32 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 174.403 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 44.2 t -79.31 137.77 21.17 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 178.935 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' ARG . . . . . 0.655 ' HA ' ' HD3' ' A' ' 69' ' ' PRO . 0.0 OUTLIER -75.57 13.67 0.75 Allowed 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.046 -0.525 . . . . 0.0 111.75 -176.91 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . 0.473 ' OD1' ' HG2' ' A' ' 83' ' ' ARG . 12.7 t70 -70.08 121.89 18.34 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 -175.893 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . 0.462 ' HB2' HG12 ' A' ' 67' ' ' ILE . 3.3 p30 -101.24 169.53 8.85 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 121.276 0.56 . . . . 0.0 111.526 -172.213 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 8.5 tt -77.46 -15.46 14.37 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 115.328 -0.851 . . . . 0.0 112.518 -171.276 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 7.8 p -93.41 -23.44 18.42 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 121.657 0.742 . . . . 0.0 109.69 -178.902 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . 0.465 ' N ' ' HD3' ' A' ' 82' ' ' PRO . 23.0 t -139.23 58.22 12.13 Favored Pre-proline 0 N--CA 1.441 -0.897 0 CA-C-N 114.677 -1.147 . . . . 0.0 110.574 -170.596 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.465 ' HD3' ' N ' ' A' ' 81' ' ' SER . 5.1 Cg_exo -77.79 140.07 18.19 Favored 'Trans proline' 0 N--CA 1.458 -0.609 0 C-N-CA 122.656 2.237 . . . . 0.0 112.14 -174.736 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' ARG . . . . . 0.78 ' HB2' HD12 ' A' ' 86' ' ' ILE . 55.9 mmt-85 -80.35 113.52 18.59 Favored 'General case' 0 CA--C 1.507 -0.673 0 CA-C-O 121.14 0.495 . . . . 0.0 110.67 178.259 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' MET . . . . . 0.483 ' HA ' ' HD2' ' A' ' 87' ' ' TYR . 22.0 mtp -72.61 -13.12 61.3 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.09 178.553 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.684 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 11.3 pt-20 -70.16 -22.72 62.94 Favored 'General case' 0 C--O 1.232 0.133 0 CA-C-O 121.485 0.659 . . . . 0.0 109.579 175.259 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.78 HD12 ' HB2' ' A' ' 83' ' ' ARG . 96.3 mt -83.34 -33.94 10.47 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 115.251 -0.886 . . . . 0.0 110.172 178.859 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . 0.483 ' HD2' ' HA ' ' A' ' 84' ' ' MET . 95.3 m-85 -82.33 -37.87 25.1 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.572 -178.888 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 23.6 mtp180 -62.55 116.17 4.9 Favored 'General case' 0 CA--C 1.514 -0.44 0 CA-C-O 121.367 0.603 . . . . 0.0 111.401 -178.908 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 111.74 -10.33 27.78 Favored Glycine 0 N--CA 1.447 -0.619 0 CA-C-N 114.914 -1.039 . . . . 0.0 112.054 -178.249 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . 0.53 ' HA ' ' HB2' ' A' ' 38' ' ' ARG . . . -78.72 149.15 32.81 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.057 0.456 . . . . 0.0 110.613 179.649 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -94.38 -21.09 19.18 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.776 -179.245 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . 0.486 HD23 ' N ' ' A' ' 93' ' ' ILE . 4.7 tt -155.12 144.24 20.96 Favored 'General case' 0 N--CA 1.451 -0.376 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.719 -177.864 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.57 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 63.3 mt -130.86 127.18 61.15 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 177.203 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' TYR . . . . . 0.428 ' O ' ' HA ' ' A' ' 41' ' ' GLU . 32.3 p90 -129.24 161.96 28.98 Favored 'General case' 0 C--N 1.322 -0.6 0 C-N-CA 120.578 -0.449 . . . . 0.0 110.897 -179.503 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 14.2 m -144.94 145.72 31.67 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.918 0.39 . . . . 0.0 110.816 -179.333 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 72.6 mt -114.09 109.26 27.85 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.15 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . 0.441 HH11 ' HD2' ' A' ' 97' ' ' ARG . 42.0 ttm180 59.48 80.84 0.26 Allowed Pre-proline 0 CA--C 1.534 0.358 0 O-C-N 123.849 0.718 . . . . 0.0 111.35 -178.331 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' PRO . . . . . 0.421 ' HA ' ' HD3' ' A' ' 99' ' ' PRO . 96.0 Cg_endo -88.52 133.38 2.68 Favored 'Trans proline' 0 N--CA 1.456 -0.724 0 C-N-CA 122.677 2.251 . . . . 0.0 112.642 179.078 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.639 ' HD2' HD11 ' A' ' 102' ' ' ILE . 32.8 Cg_exo -58.98 141.23 98.1 Favored 'Trans proline' 0 N--CA 1.464 -0.238 0 C-N-CA 122.678 2.252 . . . . 0.0 111.465 175.048 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.721 ' HA ' ' NE2' ' A' ' 103' ' ' HIS . . . -72.07 4.45 3.5 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 112.154 0.428 . . . . 0.0 112.154 -173.737 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' GLU . . . . . 0.602 ' HG3' HG23 ' A' ' 102' ' ' ILE . 9.2 pt-20 -96.33 -21.09 18.02 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.643 -0.253 . . . . 0.0 111.64 -179.928 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.639 HD11 ' HD2' ' A' ' 99' ' ' PRO . 2.5 pp -115.68 10.49 7.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 N-CA-C 113.108 0.781 . . . . 0.0 113.108 -170.331 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 103' ' ' HIS . . . . . 0.721 ' NE2' ' HA ' ' A' ' 100' ' ' ALA . 22.1 m-70 -54.71 -50.22 68.84 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 121.042 0.449 . . . . 0.0 111.13 -179.959 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 5.1 m -64.62 -26.27 68.32 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.96 -177.296 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.526 ' O ' HG23 ' A' ' 109' ' ' VAL . 19.4 m -72.06 -38.98 69.34 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.079 -178.797 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.439 HD22 HG21 ' A' ' 42' ' ' VAL . 77.5 mt -73.42 -41.85 62.78 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.854 179.651 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 107' ' ' MET . . . . . 0.562 ' HG2' ' O ' ' A' ' 103' ' ' HIS . 90.5 mmm -56.44 -41.28 76.19 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.753 -0.658 . . . . 0.0 111.881 -177.981 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 108' ' ' ARG . . . . . 0.403 HH11 ' HD3' ' A' ' 108' ' ' ARG . 11.2 ptp180 -73.42 -29.42 62.57 Favored 'General case' 0 C--N 1.328 -0.347 0 C-N-CA 120.79 -0.364 . . . . 0.0 111.277 -178.382 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.526 HG23 ' O ' ' A' ' 105' ' ' SER . 81.0 t -68.72 -45.75 80.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 C-N-CA 121.083 -0.247 . . . . 0.0 110.515 -179.777 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -61.77 -44.5 96.76 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.274 178.717 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.708 ' HA ' ' HB1' ' A' ' 148' ' ' ALA . 17.3 t70 -63.85 -34.44 77.94 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.66 -0.7 . . . . 0.0 110.984 179.82 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -70.85 -43.36 68.64 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.825 -0.625 . . . . 0.0 111.955 -178.675 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 21.6 m -89.02 -24.05 6.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 N-CA-C 111.848 0.314 . . . . 0.0 111.848 -175.093 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 84.71 53.68 3.14 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.309 178.691 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -129.83 160.41 33.57 Favored 'General case' 0 C--N 1.323 -0.566 0 O-C-N 122.842 -0.21 . . . . 0.0 110.695 -179.227 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 116' ' ' ARG . . . . . 0.431 ' HD3' ' OE1' ' A' ' 145' ' ' GLU . 10.1 ttm180 -79.53 123.53 27.66 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 109.278 -0.638 . . . . 0.0 109.278 176.013 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . 0.57 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 58.5 tp -95.04 118.01 31.14 Favored 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 109.585 -0.524 . . . . 0.0 109.585 178.812 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 60.2 mt -115.49 114.79 47.37 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.654 0 CA-C-O 121.278 0.561 . . . . 0.0 110.696 -179.773 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 63.1 mt -115.34 123.96 71.41 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.907 0 CA-C-N 116.151 -0.477 . . . . 0.0 109.972 178.908 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 120' ' ' LYS . . . . . 0.543 ' HG2' ' HB3' ' A' ' 143' ' ' PHE . 9.5 tmtm? -110.22 97.92 32.97 Favored Pre-proline 0 C--N 1.321 -0.647 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 176.728 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 80.1 Cg_endo -87.93 -178.18 2.14 Favored 'Trans proline' 0 N--CA 1.453 -0.873 0 C-N-CA 122.794 2.329 . . . . 0.0 111.866 176.433 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 122' ' ' LEU . . . . . 0.75 ' HB2' ' HB3' ' A' ' 125' ' ' GLU . 8.1 mp -108.29 166.93 10.39 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.243 -178.85 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 24.8 m -64.19 111.97 2.82 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 120.942 0.401 . . . . 0.0 110.726 179.147 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 91.66 -32.75 5.14 Favored Glycine 0 N--CA 1.45 -0.379 0 N-CA-C 111.314 -0.714 . . . . 0.0 111.314 -176.8 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . 0.75 ' HB3' ' HB2' ' A' ' 122' ' ' LEU . 20.9 tt0 -92.09 74.68 5.49 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 176.22 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 23.6 t70 -113.62 -178.53 3.4 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 114.788 -1.096 . . . . 0.0 110.948 -166.626 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 4.7 mt -71.51 -27.28 28.14 Favored 'Isoleucine or valine' 0 C--O 1.234 0.268 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 176.201 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 3.3 t 63.35 33.92 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.261 0 CA-C-O 121.911 0.862 . . . . 0.0 109.453 -179.158 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 20.2 p -117.66 -72.63 0.68 Allowed 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.482 -0.781 . . . . 0.0 111.822 -173.482 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 58.8 80.4 0.19 Allowed 'General case' 0 C--O 1.233 0.215 0 O-C-N 123.682 0.614 . . . . 0.0 110.535 -176.571 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 131' ' ' ARG . . . . . . . . . . . . . 19.1 tpp180 -165.68 -71.97 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.213 0.53 . . . . 0.0 110.412 -177.672 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 30.9 mmtt -77.89 -49.9 13.29 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.45 -0.795 . . . . 0.0 112.152 -176.699 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 133' ' ' MET . . . . . 0.51 ' HG2' ' HB2' ' A' ' 146' ' ' TYR . 77.2 mtp -87.89 154.03 20.85 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.15 0.5 . . . . 0.0 111.616 -173.371 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 14.8 ptmt -112.72 142.66 45.08 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 115.197 -0.91 . . . . 0.0 110.376 -177.305 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . 0.554 HD11 ' HD2' ' A' ' 142' ' ' TYR . 47.2 tp -84.33 123.05 29.76 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.428 -179.957 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -121.68 144.6 30.32 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.935 -179.516 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -111.2 130.53 55.61 Favored 'General case' 0 C--N 1.325 -0.482 0 N-CA-C 109.526 -0.546 . . . . 0.0 109.526 175.002 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . 0.424 ' CD2' ' HB2' ' A' ' 28' ' ' TYR . 57.5 t80 -148.52 111.55 4.87 Favored 'General case' 0 C--N 1.322 -0.629 0 N-CA-C 110.018 -0.364 . . . . 0.0 110.018 176.139 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 69.49 49.2 39.4 Favored Glycine 0 N--CA 1.446 -0.683 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.02 179.826 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 20.9 mmm-85 76.48 -40.66 0.39 Allowed 'General case' 0 N--CA 1.467 0.397 0 C-N-CA 123.729 0.812 . . . . 0.0 112.057 177.446 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 13.8 t -76.73 146.94 37.66 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.192 0.52 . . . . 0.0 110.64 -177.941 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 142' ' ' TYR . . . . . 0.554 ' HD2' HD11 ' A' ' 135' ' ' LEU . 47.4 p90 -117.28 142.94 46.45 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.776 179.194 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 143' ' ' PHE . . . . . 0.543 ' HB3' ' HG2' ' A' ' 120' ' ' LYS . 11.4 p90 -152.48 179.79 8.26 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.58 -0.736 . . . . 0.0 109.748 -178.476 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 89.3 m-85 -115.33 138.07 51.36 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 120.669 0.271 . . . . 0.0 110.595 -179.858 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 145' ' ' GLU . . . . . 0.431 ' OE1' ' HD3' ' A' ' 116' ' ' ARG . 17.9 pt-20 -123.81 160.05 28.22 Favored 'General case' 0 C--N 1.319 -0.737 0 N-CA-C 109.161 -0.681 . . . . 0.0 109.161 173.878 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . 0.51 ' HB2' ' HG2' ' A' ' 133' ' ' MET . 45.7 t80 -142.26 126.36 17.39 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-O 121.07 0.462 . . . . 0.0 110.374 176.78 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 2.1 mp -92.82 108.11 19.91 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.762 0 CA-C-N 115.696 -0.684 . . . . 0.0 109.389 176.683 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . 0.708 ' HB1' ' HA ' ' A' ' 111' ' ' ASP . . . -70.93 129.12 38.22 Favored 'General case' 0 N--CA 1.444 -0.774 0 CA-C-N 115.693 -0.685 . . . . 0.0 110.151 176.353 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 22.4 mm-40 -64.18 167.95 6.01 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 121.768 0.794 . . . . 0.0 111.395 177.779 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 16.5 t -90.4 117.7 34.2 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.953 0 CA-C-N 114.836 -1.074 . . . . 0.0 109.525 179.346 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 151' ' ' ARG . . . . . . . . . . . . . 30.2 mmm180 -87.59 90.04 8.22 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 115.727 -0.67 . . . . 0.0 109.979 -179.499 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 20.9 t -143.19 148.07 35.9 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.508 -178.662 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 9.2 tpt180 . . . . . 0 C--O 1.251 1.153 0 CA-C-O 118.293 -0.861 . . . . 0.0 109.114 178.278 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 22.0 ptm . . . . . 0 N--CA 1.482 1.163 0 N-CA-C 110.032 -0.359 . . . . 0.0 110.032 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -79.63 53.18 4.25 Favored Glycine 0 N--CA 1.453 -0.216 0 C-N-CA 121.265 -0.493 . . . . 0.0 113.195 -174.045 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 16.3 m -79.68 -20.77 45.8 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.162 0.506 . . . . 0.0 110.243 177.236 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 33.9 m -114.98 89.05 3.01 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.94 -0.573 . . . . 0.0 109.997 176.504 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 41.1 p-80 -93.12 7.6 43.53 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.406 0.622 . . . . 0.0 110.239 178.484 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 21.1 m-70 -92.01 35.51 0.98 Allowed 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.328 178.214 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 28.1 p-80 -81.29 137.67 35.78 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.681 178.835 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 76.5 t60 -129.34 128.48 43.2 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 109.563 -0.532 . . . . 0.0 109.563 -179.078 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 81.6 t60 -81.39 -32.38 32.83 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.46 -172.578 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 94.1 m-70 -87.23 16.76 4.87 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.793 0.33 . . . . 0.0 111.302 -175.979 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 19.6 m -65.8 111.01 3.04 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.144 177.112 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 19.7 t -94.09 -47.32 6.73 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 115.915 -0.584 . . . . 0.0 109.757 -178.791 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 83.22 113.47 0.53 Allowed Glycine 0 N--CA 1.448 -0.512 0 CA-C-N 115.739 -0.664 . . . . 0.0 112.175 -178.921 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -77.48 126.02 30.25 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-O 120.919 0.39 . . . . 0.0 110.54 -178.73 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 60.9 t -102.83 111.11 64.65 Favored Pre-proline 0 C--N 1.323 -0.55 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.709 -178.107 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -79.51 179.26 6.51 Favored 'Trans proline' 0 N--CA 1.46 -0.467 0 C-N-CA 123.051 2.5 . . . . 0.0 111.117 174.932 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 35.2 ptt180 -81.0 -19.18 44.55 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.267 0.556 . . . . 0.0 110.241 -179.86 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -179.0 164.37 32.61 Favored Glycine 0 N--CA 1.444 -0.783 0 CA-C-N 115.689 -0.687 . . . . 0.0 111.507 178.297 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 12.2 p -87.81 148.24 24.77 Favored 'General case' 0 C--N 1.32 -0.704 0 N-CA-C 110.095 -0.335 . . . . 0.0 110.095 177.77 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 64.1 m80 -131.1 -46.49 1.01 Allowed 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.974 0.416 . . . . 0.0 110.393 179.498 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' MET . . . . . . . . . . . . . 65.5 mtt -71.5 -40.79 69.94 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.022 179.394 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 81.7 m95 -69.57 -19.99 63.66 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.497 -0.774 . . . . 0.0 111.145 -178.567 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.504 ' O ' HG23 ' A' ' 27' ' ' VAL . 6.7 m-20 -65.5 -29.85 70.55 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.006 -179.547 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -75.04 -34.07 61.81 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 179.696 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 45.1 tp -60.31 -43.13 96.62 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 115.914 -0.585 . . . . 0.0 109.651 172.846 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -59.05 -47.33 85.62 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.458 -0.792 . . . . 0.0 110.655 176.661 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.504 HG23 ' O ' ' A' ' 23' ' ' ASN . 99.2 t -56.21 -43.25 75.86 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.188 0 CA-C-N 116.361 -0.381 . . . . 0.0 111.111 177.987 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 88.0 t80 -59.44 -48.71 80.59 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.819 0.342 . . . . 0.0 110.461 178.401 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 71.6 mt -58.48 -41.83 82.77 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.251 178.553 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.608 HG12 HG23 ' A' ' 54' ' ' ILE . 83.2 mt -60.32 -38.44 77.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 115.473 -0.785 . . . . 0.0 111.061 177.639 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 22.1 mtp180 -70.78 -30.13 66.52 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.154 -179.22 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 75.6 m -87.03 -8.91 56.67 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.576 -178.501 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 26.0 p -122.84 -80.83 0.63 Allowed 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 120.747 0.308 . . . . 0.0 111.08 179.01 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.455 ' O ' HG22 ' A' ' 37' ' ' THR . . . 88.21 168.51 44.33 Favored Glycine 0 N--CA 1.447 -0.633 0 C-N-CA 121.141 -0.552 . . . . 0.0 112.446 -179.901 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_exo -65.67 140.33 61.69 Favored 'Trans proline' 0 C--O 1.232 0.204 0 C-N-CA 122.644 2.229 . . . . 0.0 111.759 178.225 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 109.98 -8.21 31.41 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.364 -0.922 . . . . 0.0 112.507 178.978 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . 0.455 HG22 ' O ' ' A' ' 34' ' ' GLY . 11.5 t -125.04 -171.31 2.33 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.306 -0.627 . . . . 0.0 109.306 178.299 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . 0.841 ' HG3' ' HA ' ' A' ' 90' ' ' ALA . 1.7 ptm180 -132.48 136.94 47.02 Favored 'General case' 0 N--CA 1.447 -0.604 0 CA-C-O 121.075 0.464 . . . . 0.0 111.418 -179.619 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.488 ' O ' ' HA ' ' A' ' 62' ' ' LEU . 58.2 t -125.91 139.43 51.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 115.611 -0.722 . . . . 0.0 109.747 -178.223 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.475 ' HB ' HG12 ' A' ' 93' ' ' ILE . 39.6 t -116.34 134.47 59.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-O 120.854 0.359 . . . . 0.0 111.164 -178.026 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 44.1 tt0 -108.23 120.56 42.72 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.143 177.02 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.626 ' HB ' ' HB3' ' A' ' 95' ' ' SER . 85.7 t -95.91 123.49 48.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.387 -179.603 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 98.19 25.16 10.53 Favored Glycine 0 N--CA 1.447 -0.567 0 C-N-CA 120.686 -0.769 . . . . 0.0 111.789 -179.366 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -79.32 54.13 1.63 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 121.321 0.582 . . . . 0.0 111.128 -178.281 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -94.25 -64.82 1.02 Allowed Glycine 0 N--CA 1.444 -0.789 0 C-N-CA 120.854 -0.689 . . . . 0.0 111.823 178.674 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -105.07 -8.22 18.63 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.059 0.457 . . . . 0.0 110.306 175.373 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.487 ' HD1' ' HE1' ' A' ' 49' ' ' TYR . 87.4 m-85 -106.76 102.54 11.91 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.909 -0.587 . . . . 0.0 109.981 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.533 HD22 HD13 ' A' ' 64' ' ' LEU . 84.5 mt -129.7 -10.81 4.45 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.448 -0.342 . . . . 0.0 111.002 179.997 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . 0.487 ' HE1' ' HD1' ' A' ' 47' ' ' PHE . 30.6 p90 -59.06 -30.97 68.45 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 112.59 0.589 . . . . 0.0 112.59 -173.917 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 80.5 t -75.81 -58.01 5.26 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-O 120.795 0.331 . . . . 0.0 110.744 178.831 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . 0.428 ' CB ' HD21 ' A' ' 64' ' ' LEU . 15.5 p -60.32 -39.18 86.12 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.939 -177.983 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.499 ' O ' ' HG3' ' A' ' 56' ' ' LYS . 29.7 t70 -65.11 -33.65 76.53 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.64 -178.38 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 71.0 t80 -71.25 -44.71 64.77 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.545 177.499 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.608 HG23 HG12 ' A' ' 30' ' ' ILE . 79.2 mt -57.48 -46.42 85.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.868 -176.602 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . 0.512 HH12 HD11 ' A' ' 64' ' ' LEU . 9.0 ptp85 -69.03 -16.12 63.63 Favored 'General case' 0 N--CA 1.467 0.383 0 N-CA-C 112.164 0.431 . . . . 0.0 112.164 -176.889 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . 0.499 ' HG3' ' O ' ' A' ' 52' ' ' ASP . 67.9 mttm -82.54 -33.08 28.31 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 120.807 0.337 . . . . 0.0 111.392 -179.753 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 13.9 t60 -95.11 -39.65 10.02 Favored 'General case' 0 N--CA 1.448 -0.529 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.357 -177.699 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 8.1 p -118.51 132.07 56.23 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.449 -0.341 . . . . 0.0 111.13 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . 0.463 ' HD2' ' HA ' ' A' ' 59' ' ' LYS . 26.9 mmmt -80.97 61.2 4.47 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.696 0.76 . . . . 0.0 110.603 176.062 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 7.7 p -98.07 144.65 10.92 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.725 0 CA-C-N 114.901 -1.045 . . . . 0.0 109.509 175.508 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -73.12 89.61 1.5 Allowed 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 177.561 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . 0.488 ' HA ' ' O ' ' A' ' 39' ' ' VAL . 3.5 tt -96.39 118.4 32.84 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.014 0.435 . . . . 0.0 110.363 -176.611 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 58.1 t -102.19 128.98 54.31 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.463 0 CA-C-N 115.588 -0.733 . . . . 0.0 110.72 -176.141 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . 0.533 HD13 HD22 ' A' ' 48' ' ' LEU . 66.1 mt -108.66 133.26 52.99 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.936 -0.574 . . . . 0.0 109.999 176.404 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 12.5 p -119.12 132.03 55.96 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.724 0.297 . . . . 0.0 110.71 176.194 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . 0.448 ' HB3' HG21 ' A' ' 74' ' ' ILE . 24.5 t70 -156.96 146.85 20.81 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.426 -177.843 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.614 HG12 ' HB2' ' A' ' 78' ' ' ASP . 34.5 mt -73.9 103.91 2.44 Favored 'Isoleucine or valine' 0 C--O 1.238 0.491 0 N-CA-C 110.114 -0.328 . . . . 0.0 110.114 179.419 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' LYS . . . . . 0.401 ' HE2' ' HB3' ' A' ' 68' ' ' LYS . 30.7 mtpt 56.92 80.08 0.3 Allowed Pre-proline 0 C--N 1.33 -0.276 0 CA-C-N 115.191 -0.913 . . . . 0.0 109.798 -177.091 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . 0.877 ' HB3' ' HB ' ' A' ' 74' ' ' ILE . 9.1 Cg_endo -49.8 133.16 33.0 Favored 'Trans proline' 0 C--O 1.234 0.275 0 C-N-CA 123.895 3.064 . . . . 0.0 113.7 -173.077 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 39.5 t -87.75 -5.7 58.53 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.438 -0.801 . . . . 0.0 110.053 177.51 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 68.7 m-70 -136.43 165.53 25.59 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.354 -179.559 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -86.53 138.76 16.02 Favored Glycine 0 N--CA 1.448 -0.558 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.263 -179.131 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 106.55 -2.26 36.76 Favored Glycine 0 N--CA 1.449 -0.456 0 C-N-CA 120.76 -0.733 . . . . 0.0 111.753 179.303 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.877 ' HB ' ' HB3' ' A' ' 69' ' ' PRO . 43.4 mt -98.91 140.28 18.83 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 N-CA-C 110.164 -0.31 . . . . 0.0 110.164 -179.754 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.525 HG12 ' H ' ' A' ' 77' ' ' ASP . 63.3 t -79.41 141.94 14.66 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.093 178.764 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' ARG . . . . . 0.566 ' HG2' ' HD2' ' A' ' 69' ' ' PRO . 89.1 mtm180 -82.87 16.41 2.28 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.913 -176.148 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . 0.525 ' H ' HG12 ' A' ' 75' ' ' VAL . 35.9 t70 -87.03 138.01 31.86 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 179.001 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . 0.614 ' HB2' HG12 ' A' ' 67' ' ' ILE . 0.7 OUTLIER -103.32 177.92 4.7 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.73 0.3 . . . . 0.0 111.257 -173.362 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 9.3 tp -94.03 -24.66 4.95 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.444 0 N-CA-C 112.601 0.593 . . . . 0.0 112.601 -170.401 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.51 HG22 ' OD1' ' A' ' 78' ' ' ASP . 6.3 t -91.1 -20.5 21.96 Favored 'General case' 0 C--N 1.325 -0.47 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 -178.319 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . 0.495 ' HB2' ' OD2' ' A' ' 78' ' ' ASP . 34.0 m -129.42 62.85 65.23 Favored Pre-proline 0 CA--C 1.535 0.391 0 CA-C-N 115.48 -0.782 . . . . 0.0 110.081 172.822 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 87.9 Cg_endo -85.7 150.28 9.98 Favored 'Trans proline' 0 N--CA 1.459 -0.515 0 C-N-CA 122.375 2.05 . . . . 0.0 113.525 -171.847 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' ARG . . . . . . . . . . . . . 77.8 mtt-85 -88.95 112.51 23.41 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.416 -0.811 . . . . 0.0 110.413 175.147 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' MET . . . . . . . . . . . . . 93.6 mmm -66.05 -23.38 66.53 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.449 -0.341 . . . . 0.0 111.057 -179.264 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 6.7 pm0 -67.62 -19.32 65.21 Favored 'General case' 0 N--CA 1.464 0.246 0 CA-C-O 120.889 0.376 . . . . 0.0 111.01 179.61 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.404 HD13 HG11 ' A' ' 75' ' ' VAL . 62.1 mt -83.81 -39.34 14.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.345 179.017 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . 0.417 ' CB ' HG11 ' A' ' 113' ' ' VAL . 93.3 m-85 -80.65 -34.07 35.17 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.209 -178.557 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . 0.525 ' HA ' ' HB ' ' A' ' 113' ' ' VAL . 62.2 mtp85 -65.15 132.93 50.42 Favored 'General case' 0 CA--C 1.515 -0.384 0 CA-C-O 121.329 0.585 . . . . 0.0 110.856 -178.509 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 102.4 -19.41 48.33 Favored Glycine 0 N--CA 1.446 -0.683 0 CA-C-N 115.053 -0.976 . . . . 0.0 111.641 -176.803 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . 0.841 ' HA ' ' HG3' ' A' ' 38' ' ' ARG . . . -71.46 145.3 49.32 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.837 0.351 . . . . 0.0 110.705 -179.772 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -92.52 -21.98 19.81 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.041 -179.188 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . 0.525 ' HG ' ' HB3' ' A' ' 116' ' ' ARG . 3.5 tt -150.81 138.4 19.68 Favored 'General case' 0 N--CA 1.449 -0.497 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.912 -176.28 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.643 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 85.5 mt -133.03 124.05 49.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 115.719 -0.673 . . . . 0.0 109.326 176.955 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' TYR . . . . . 0.437 ' HB3' ' HB ' ' A' ' 118' ' ' ILE . 10.2 p90 -130.01 158.84 38.49 Favored 'General case' 0 C--N 1.32 -0.696 0 C-N-CA 120.808 -0.357 . . . . 0.0 110.802 -179.524 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . 0.626 ' HB3' ' HB ' ' A' ' 42' ' ' VAL . 11.5 p -145.07 137.71 26.18 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.594 -177.749 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 63.7 mt -104.7 111.51 34.55 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.293 -179.212 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 6.1 tpm_? 61.32 75.67 0.44 Allowed Pre-proline 0 CA--C 1.534 0.355 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.188 -179.763 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' PRO . . . . . 0.42 ' HA ' ' HD3' ' A' ' 99' ' ' PRO . 0.9 OUTLIER -84.32 150.86 12.01 Favored 'Trans proline' 0 N--CA 1.457 -0.629 0 C-N-CA 122.788 2.325 . . . . 0.0 111.589 176.449 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.42 ' HD3' ' HA ' ' A' ' 98' ' ' PRO . 31.2 Cg_exo -59.39 155.16 42.64 Favored 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.703 2.269 . . . . 0.0 111.619 175.727 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.651 ' HA ' ' CE1' ' A' ' 103' ' ' HIS . . . -79.26 7.19 8.17 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 112.144 0.424 . . . . 0.0 112.144 -174.118 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -111.75 -14.03 13.64 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 111.804 0.298 . . . . 0.0 111.804 179.597 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.42 ' O ' HG13 ' A' ' 102' ' ' ILE . 32.2 pt -123.51 77.46 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 121.821 0.82 . . . . 0.0 111.661 -179.281 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 103' ' ' HIS . . . . . 0.651 ' CE1' ' HA ' ' A' ' 100' ' ' ALA . 44.9 m80 -112.99 -50.25 2.89 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.418 -0.81 . . . . 0.0 109.331 174.983 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 18.9 t -74.9 -23.76 58.42 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 176.353 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.546 ' O ' ' HG2' ' A' ' 108' ' ' ARG . 3.3 m -67.87 -38.96 83.76 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.459 -0.791 . . . . 0.0 109.754 177.272 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 69.2 mt -73.2 -38.76 65.99 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.129 175.701 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 107' ' ' MET . . . . . . . . . . . . . 47.9 ttm -62.1 -39.82 93.75 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.685 -0.689 . . . . 0.0 111.129 -179.819 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 108' ' ' ARG . . . . . 0.546 ' HG2' ' O ' ' A' ' 105' ' ' SER . 7.9 ptp180 -68.56 -25.35 64.86 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.629 0.252 . . . . 0.0 110.795 -179.816 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.489 HG23 ' O ' ' A' ' 105' ' ' SER . 94.2 t -72.32 -48.18 49.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 175.697 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -59.63 -41.59 90.8 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.167 176.164 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 18.0 t70 -61.95 -38.28 87.89 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.412 -0.813 . . . . 0.0 111.164 178.232 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -72.74 -40.37 66.11 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.612 -0.722 . . . . 0.0 111.957 -178.377 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.525 ' HB ' ' HA ' ' A' ' 88' ' ' ARG . 13.7 m -91.01 -24.57 5.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-O 120.895 0.378 . . . . 0.0 111.741 -174.339 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 88.69 42.13 5.83 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 121.009 -0.615 . . . . 0.0 112.421 178.916 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -119.41 156.5 30.03 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 121.101 0.477 . . . . 0.0 111.407 -177.177 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 116' ' ' ARG . . . . . 0.525 ' HB3' ' HG ' ' A' ' 92' ' ' LEU . 21.5 ttm180 -79.59 121.37 25.18 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.793 -0.639 . . . . 0.0 109.654 176.793 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . 0.643 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 53.3 tp -92.71 118.83 31.47 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.383 -178.579 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . 0.437 ' HB ' ' HB3' ' A' ' 94' ' ' TYR . 64.1 mt -113.38 121.72 66.12 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.61 0 CA-C-O 121.024 0.44 . . . . 0.0 110.425 178.101 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 56.4 mt -120.46 134.31 64.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.375 -179.809 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 45.2 tptt -110.14 98.2 33.94 Favored Pre-proline 0 C--N 1.323 -0.549 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.524 175.43 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 82.0 Cg_endo -91.47 174.62 2.42 Favored 'Trans proline' 0 N--CA 1.456 -0.721 0 C-N-CA 123.068 2.512 . . . . 0.0 112.005 173.961 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -99.01 163.79 12.44 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.467 178.984 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 14.5 t -65.06 -21.78 66.88 Favored 'General case' 0 CA--C 1.534 0.363 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.429 -179.162 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -104.13 18.04 46.74 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.308 179.871 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 22.7 mm-40 -119.6 -173.84 2.62 Favored 'General case' 0 N--CA 1.449 -0.487 0 CA-C-O 121.209 0.528 . . . . 0.0 110.334 -178.489 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -148.87 170.01 19.25 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 115.381 -0.827 . . . . 0.0 108.791 176.548 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.443 ' C ' ' H ' ' A' ' 129' ' ' THR . 7.5 mt -101.1 -18.19 6.47 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 179.484 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 27.8 t 68.72 -13.32 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.541 0.611 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.572 179.213 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . 0.443 ' H ' ' C ' ' A' ' 127' ' ' ILE . 7.7 t -79.47 -176.97 5.54 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.931 0.396 . . . . 0.0 110.582 179.915 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 130' ' ' GLU . . . . . 0.515 ' HB2' ' HG2' ' A' ' 132' ' ' LYS . 33.2 mt-10 -87.22 -166.6 1.62 Allowed 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.982 -0.553 . . . . 0.0 110.537 -178.89 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 131' ' ' ARG . . . . . 0.811 ' HD2' ' H ' ' A' ' 131' ' ' ARG . 0.0 OUTLIER -77.55 37.67 0.23 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 121.107 0.48 . . . . 0.0 110.598 177.609 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 132' ' ' LYS . . . . . 0.515 ' HG2' ' HB2' ' A' ' 130' ' ' GLU . 29.5 mmmt -79.27 -41.29 28.49 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.844 -0.616 . . . . 0.0 111.447 -176.03 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 133' ' ' MET . . . . . 0.737 ' HG2' ' HB2' ' A' ' 146' ' ' TYR . 82.5 mtp -92.38 164.94 13.31 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.929 -174.431 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 13.2 ptmm? -127.08 140.47 52.26 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.971 -177.503 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . 0.512 HD11 ' HD2' ' A' ' 142' ' ' TYR . 51.6 tp -80.7 129.19 34.38 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.338 -179.091 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -123.3 139.04 51.18 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.68 178.751 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 16.8 m120 -114.83 108.25 16.5 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 115.801 -0.636 . . . . 0.0 109.868 179.557 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . 0.4 ' O ' HG22 ' A' ' 141' ' ' THR . 54.1 t80 -131.65 106.01 7.89 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-O 120.929 0.395 . . . . 0.0 110.323 -178.275 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . 0.468 ' O ' ' HB2' ' A' ' 140' ' ' ARG . . . 80.0 34.16 31.07 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.094 178.922 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 140' ' ' ARG . . . . . 0.468 ' HB2' ' O ' ' A' ' 139' ' ' GLY . 0.0 OUTLIER 75.32 -14.57 0.75 Allowed 'General case' 0 N--CA 1.468 0.471 0 C-N-CA 123.279 0.632 . . . . 0.0 111.921 178.097 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 141' ' ' THR . . . . . 0.4 HG22 ' O ' ' A' ' 138' ' ' TYR . 8.3 t -93.9 141.62 28.31 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 175.562 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 142' ' ' TYR . . . . . 0.512 ' HD2' HD11 ' A' ' 135' ' ' LEU . 43.0 p90 -119.07 143.54 47.07 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 121.364 0.602 . . . . 0.0 110.825 -176.052 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 15.0 p90 -152.01 173.88 14.34 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 115.119 -0.946 . . . . 0.0 109.413 -178.512 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 76.8 m-85 -112.94 129.47 56.46 Favored 'General case' 0 C--N 1.322 -0.611 0 C-N-CA 121.058 -0.257 . . . . 0.0 110.691 -179.624 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 145' ' ' GLU . . . . . 0.495 ' OE1' ' HD3' ' A' ' 116' ' ' ARG . 19.2 pt-20 -115.33 157.19 24.18 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 174.667 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . 0.737 ' HB2' ' HG2' ' A' ' 133' ' ' MET . 32.9 t80 -139.24 124.19 18.77 Favored 'General case' 0 C--N 1.315 -0.913 0 CA-C-N 115.752 -0.658 . . . . 0.0 109.904 176.656 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 3.1 mp -93.54 105.93 17.41 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.859 0 N-CA-C 109.726 -0.472 . . . . 0.0 109.726 -179.168 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -62.3 114.94 3.76 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-O 121.139 0.495 . . . . 0.0 110.756 178.054 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 8.1 mm-40 -76.28 -175.53 3.24 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.346 -0.843 . . . . 0.0 111.194 179.22 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 21.5 t -87.55 135.55 25.11 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.92 0 CA-C-N 114.824 -1.08 . . . . 0.0 109.07 177.591 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 151' ' ' ARG . . . . . . . . . . . . . 3.9 ppt_? -59.37 135.92 57.81 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.872 0.368 . . . . 0.0 110.198 -178.474 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 34.8 m -128.95 114.7 16.78 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.786 -176.935 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 62.0 ttt-85 . . . . . 0 C--O 1.245 0.856 0 CA-C-O 118.519 -0.753 . . . . 0.0 109.707 179.588 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 64.9 mtt . . . . . 0 N--CA 1.482 1.134 0 N-CA-C 110.108 -0.331 . . . . 0.0 110.108 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -129.58 -164.24 11.37 Favored Glycine 0 N--CA 1.446 -0.69 0 C-N-CA 120.852 -0.69 . . . . 0.0 111.835 178.388 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 22.7 m -128.11 -174.57 3.25 Favored 'General case' 0 C--N 1.32 -0.68 0 N-CA-C 109.708 -0.479 . . . . 0.0 109.708 177.588 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 33.0 m -67.15 135.69 53.92 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.871 0.367 . . . . 0.0 110.618 179.257 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 37.6 p-80 -122.92 144.82 48.97 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.526 179.467 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 8.1 p80 -140.69 117.73 11.19 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 115.953 -0.567 . . . . 0.0 109.705 176.058 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 18.2 m-70 -120.12 117.11 27.08 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.349 -173.344 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 43.6 m80 56.74 43.34 25.39 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-N 115.733 -0.667 . . . . 0.0 112.214 173.908 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 45.5 t60 -132.92 23.87 4.25 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 122.162 0.982 . . . . 0.0 108.433 174.549 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 22.5 p-80 -98.73 158.21 15.77 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 114.799 -1.091 . . . . 0.0 111.169 -177.421 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 38.7 m 65.51 18.72 11.37 Favored 'General case' 0 CA--C 1.533 0.311 0 CA-C-N 115.492 -0.776 . . . . 0.0 112.144 174.676 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 14.6 p -82.13 77.37 8.94 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.572 0.701 . . . . 0.0 111.06 -179.345 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -165.59 69.01 0.19 Allowed Glycine 0 N--CA 1.448 -0.561 0 CA-C-N 115.436 -0.802 . . . . 0.0 111.222 179.252 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 82.8 mt -81.49 138.67 35.46 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.901 0.381 . . . . 0.0 111.137 -175.666 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 47.3 t -112.27 98.84 44.6 Favored Pre-proline 0 C--N 1.323 -0.564 0 CA-C-N 115.824 -0.626 . . . . 0.0 109.65 176.363 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 77.1 Cg_endo -86.36 -175.12 1.65 Allowed 'Trans proline' 0 N--CA 1.458 -0.592 0 C-N-CA 123.138 2.558 . . . . 0.0 112.94 -176.602 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 0.463 ' HA ' ' HB2' ' A' ' 20' ' ' HIS . 16.0 mtt-85 -92.21 -166.02 1.46 Allowed 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.779 -0.646 . . . . 0.0 111.287 179.185 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 92.55 -54.67 2.72 Favored Glycine 0 N--CA 1.446 -0.664 0 N-CA-C 111.178 -0.769 . . . . 0.0 111.178 -174.704 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . 0.436 ' HB2' ' CZ ' ' A' ' 49' ' ' TYR . 36.5 p -110.42 8.45 23.21 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 121.065 0.46 . . . . 0.0 110.21 176.793 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' HIS . . . . . 0.463 ' HB2' ' HA ' ' A' ' 17' ' ' ARG . 21.7 t-80 -57.37 -42.22 81.67 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.525 -0.762 . . . . 0.0 111.433 -178.244 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -60.33 -24.95 65.44 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 121.342 0.591 . . . . 0.0 110.738 -177.829 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 51.4 m95 -97.29 -19.35 18.61 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.22 -178.764 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.43 ' O ' HG23 ' A' ' 27' ' ' VAL . 25.1 t-20 -66.19 -58.96 4.26 Favored 'General case' 0 N--CA 1.463 0.198 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.674 -172.285 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.462 ' CB ' ' HA3' ' A' ' 139' ' ' GLY . 4.5 m-20 -58.12 -32.68 68.36 Favored 'General case' 0 N--CA 1.464 0.27 0 CA-C-O 120.631 0.253 . . . . 0.0 111.333 -178.892 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 45.7 tp -57.16 -51.22 70.2 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-O 120.932 0.396 . . . . 0.0 110.262 175.291 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . 0.426 ' HB2' HG13 ' A' ' 50' ' ' VAL . . . -63.48 -43.56 96.94 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.601 179.887 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.43 HG23 ' O ' ' A' ' 23' ' ' ASN . 95.5 t -52.13 -47.85 43.09 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.153 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.076 177.454 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 56.4 t80 -57.81 -43.31 85.62 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.539 179.88 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.414 HG23 HD13 ' A' ' 92' ' ' LEU . 70.8 mt -67.91 -43.97 85.51 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.791 179.247 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.486 HG12 HG23 ' A' ' 54' ' ' ILE . 92.1 mt -58.27 -45.54 89.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 115.61 -0.723 . . . . 0.0 111.0 178.303 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 84.0 mtt-85 -65.56 -27.72 68.63 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.666 -0.697 . . . . 0.0 111.761 -177.848 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 53.5 t -84.79 -27.35 26.9 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.596 -0.275 . . . . 0.0 111.186 -179.011 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 12.4 p -94.21 -76.96 0.47 Allowed 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 120.797 0.332 . . . . 0.0 111.202 -177.041 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.402 ' HA2' ' HD3' ' A' ' 35' ' ' PRO . . . 95.75 142.81 13.42 Favored Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 120.85 -0.69 . . . . 0.0 112.162 -178.843 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . 0.526 ' HG3' ' HA ' ' A' ' 58' ' ' SER . 58.1 Cg_exo -51.68 126.4 19.6 Favored 'Trans proline' 0 C--N 1.343 0.284 0 C-N-CA 123.283 2.655 . . . . 0.0 113.001 -176.795 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 104.32 53.93 0.81 Allowed Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.514 179.517 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 15.1 t -166.74 -175.84 3.27 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 179.624 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . . . . . . . . . 63.1 mtt85 -122.11 132.51 54.51 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 121.08 0.467 . . . . 0.0 110.775 -179.911 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.928 ' HB ' HD22 ' A' ' 62' ' ' LEU . 60.6 t -123.85 131.76 72.45 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 N-CA-C 108.763 -0.828 . . . . 0.0 108.763 176.76 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.446 HG11 ' CE1' ' A' ' 87' ' ' TYR . 35.6 t -106.7 126.56 62.57 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-O 120.817 0.342 . . . . 0.0 110.887 -177.679 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 46.4 tt0 -108.22 124.12 49.81 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.144 178.368 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.911 ' HB ' ' HB3' ' A' ' 95' ' ' SER . 95.1 t -97.37 121.72 48.17 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.593 -179.876 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 89.68 34.13 8.67 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.855 -0.688 . . . . 0.0 111.519 -179.64 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -81.09 14.15 2.44 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 112.432 0.53 . . . . 0.0 112.432 -173.185 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -54.41 -38.04 61.59 Favored Glycine 0 CA--C 1.519 0.32 0 C-N-CA 121.201 -0.524 . . . . 0.0 113.807 -176.887 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . 0.416 HH11 ' HD2' ' A' ' 46' ' ' ARG . 19.4 mtp180 -139.2 13.28 2.61 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 117.129 0.465 . . . . 0.0 111.997 -177.144 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 73.4 m-85 -112.15 29.03 8.24 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 121.254 0.55 . . . . 0.0 110.619 -177.519 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.588 HD21 HD11 ' A' ' 74' ' ' ILE . 87.0 mt -59.26 -15.66 16.89 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 114.868 -1.06 . . . . 0.0 113.074 -175.342 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . 0.436 ' CZ ' ' HB2' ' A' ' 19' ' ' SER . 81.5 t80 -59.13 -45.26 91.39 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.583 0.23 . . . . 0.0 111.313 -179.249 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.426 HG13 ' HB2' ' A' ' 26' ' ' ALA . 42.8 t -65.41 -54.64 26.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.672 -175.224 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . 0.442 ' CB ' HD21 ' A' ' 64' ' ' LEU . 0.2 OUTLIER -59.52 -41.96 91.17 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.701 -179.796 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.608 ' HA ' ' HG2' ' A' ' 55' ' ' ARG . 38.7 t70 -69.08 -37.92 78.72 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 120.857 -0.337 . . . . 0.0 110.865 -179.224 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 89.4 t80 -60.26 -37.06 79.26 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.875 0.369 . . . . 0.0 110.034 177.925 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.486 HG23 HG12 ' A' ' 30' ' ' ILE . 76.0 mt -63.29 -54.78 28.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.949 -0.568 . . . . 0.0 110.673 176.044 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . 0.608 ' HG2' ' HA ' ' A' ' 52' ' ' ASP . 3.7 ptp180 -69.77 -16.44 63.3 Favored 'General case' 0 N--CA 1.465 0.318 0 N-CA-C 112.072 0.397 . . . . 0.0 112.072 -177.083 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . 0.7 ' HA ' ' HE3' ' A' ' 56' ' ' LYS . 0.0 OUTLIER -64.04 -39.24 93.66 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.693 0.282 . . . . 0.0 110.843 176.378 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 29.9 m-70 -107.27 -50.51 3.07 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.746 -178.61 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . 0.526 ' HA ' ' HG3' ' A' ' 35' ' ' PRO . 57.6 m -88.38 132.99 34.22 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.851 -178.289 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . 0.562 ' HD2' ' N ' ' A' ' 59' ' ' LYS . 3.3 mptp? -80.19 57.06 2.61 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.684 0.754 . . . . 0.0 109.825 178.661 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.488 HG11 HG23 ' A' ' 39' ' ' VAL . 54.0 t -101.22 139.32 22.76 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-N 114.998 -1.001 . . . . 0.0 111.043 -178.11 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -80.02 98.61 7.28 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.866 -0.606 . . . . 0.0 109.524 174.819 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . 0.928 HD22 ' HB ' ' A' ' 39' ' ' VAL . 0.2 OUTLIER -87.54 121.02 29.43 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 115.934 -0.575 . . . . 0.0 109.593 -178.827 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 40.9 t -100.49 113.77 37.26 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.661 0 CA-C-N 115.738 -0.665 . . . . 0.0 109.786 -179.757 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . 0.75 ' HB2' ' HA ' ' A' ' 74' ' ' ILE . 54.5 mt -97.37 139.8 32.78 Favored 'General case' 0 C--N 1.312 -1.04 0 CA-C-N 115.628 -0.714 . . . . 0.0 110.338 -177.507 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.417 ' OG1' ' HA ' ' A' ' 42' ' ' VAL . 38.0 p -131.23 137.92 49.12 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.301 0.096 . . . . 0.0 110.91 178.547 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 4.7 t70 -171.19 170.81 5.93 Favored 'General case' 0 N--CA 1.466 0.33 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 175.759 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 49.5 mm -85.96 104.74 13.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 120.813 0.34 . . . . 0.0 110.865 -175.898 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 35.4 mtmt 56.21 77.52 0.42 Allowed Pre-proline 0 C--N 1.33 -0.278 0 CA-C-N 115.324 -0.853 . . . . 0.0 111.894 -179.575 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . 0.795 ' HD2' ' HG2' ' A' ' 76' ' ' ARG . 70.1 Cg_endo -76.57 154.96 35.63 Favored 'Trans proline' 0 N--CA 1.459 -0.505 0 C-N-CA 122.334 2.023 . . . . 0.0 112.139 175.613 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 29.5 m -140.81 0.16 1.57 Allowed 'General case' 0 C--N 1.32 -0.697 0 CA-C-O 121.171 0.51 . . . . 0.0 110.333 178.155 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 80.7 t60 -143.26 116.55 9.02 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.69 -0.686 . . . . 0.0 109.831 -179.685 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 101.52 166.34 27.46 Favored Glycine 0 N--CA 1.449 -0.488 0 C-N-CA 121.028 -0.606 . . . . 0.0 111.991 -179.248 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -81.18 60.99 4.64 Favored Glycine 0 N--CA 1.452 -0.261 0 N-CA-C 111.727 -0.549 . . . . 0.0 111.727 177.303 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.75 ' HA ' ' HB2' ' A' ' 64' ' ' LEU . 44.6 mt -96.85 135.67 30.2 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-O 120.94 0.4 . . . . 0.0 110.531 -177.844 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 97.8 t -77.53 139.04 19.3 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 CA-C-N 116.065 -0.516 . . . . 0.0 109.807 176.43 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' ARG . . . . . 0.795 ' HG2' ' HD2' ' A' ' 69' ' ' PRO . 65.7 mtm180 -84.62 38.77 0.71 Allowed 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 120.762 0.315 . . . . 0.0 110.807 -177.73 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 28.1 t70 -76.68 126.73 31.49 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 121.024 0.44 . . . . 0.0 110.447 -178.649 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . 0.508 ' HB3' HG22 ' A' ' 80' ' ' THR . 3.3 m-20 -71.13 97.28 1.47 Allowed 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.891 -0.595 . . . . 0.0 109.971 175.808 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 9.7 tp -58.56 -17.31 9.92 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.388 0 CA-C-O 121.273 0.559 . . . . 0.0 111.663 -178.255 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.508 HG22 ' HB3' ' A' ' 78' ' ' ASP . 8.8 t -66.39 -24.08 66.42 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.027 0.442 . . . . 0.0 110.442 176.246 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 36.6 m -154.42 70.18 6.08 Favored Pre-proline 0 C--N 1.329 -0.32 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 177.514 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.556 ' HB2' ' HE2' ' A' ' 87' ' ' TYR . 74.0 Cg_endo -73.27 159.28 47.37 Favored 'Trans proline' 0 C--O 1.236 0.387 0 C-N-CA 123.011 2.474 . . . . 0.0 113.516 -169.691 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' ARG . . . . . 0.704 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 1.9 mtm180 -93.99 126.39 39.18 Favored 'General case' 0 C--N 1.323 -0.543 0 CA-C-N 115.793 -0.639 . . . . 0.0 110.921 177.958 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' MET . . . . . . . . . . . . . 89.3 mmm -64.56 -23.93 67.43 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.252 -178.066 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.704 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 12.0 pt-20 -62.52 -20.53 64.72 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.607 -179.112 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 63.8 mt -86.2 -29.47 6.08 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-O 121.167 0.508 . . . . 0.0 110.541 -178.802 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . 0.556 ' HE2' ' HB2' ' A' ' 82' ' ' PRO . 84.6 m-85 -93.34 -30.62 15.03 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.734 -176.259 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 81.8 mtp180 -66.75 114.14 5.4 Favored 'General case' 0 CA--C 1.514 -0.416 0 CA-C-O 121.485 0.659 . . . . 0.0 111.484 -176.889 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 116.09 -17.51 14.84 Favored Glycine 0 N--CA 1.446 -0.684 0 CA-C-N 114.902 -1.044 . . . . 0.0 111.982 -177.593 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -71.86 147.71 46.87 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.769 0.318 . . . . 0.0 110.665 178.835 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -91.34 -26.37 18.96 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-O 121.035 0.445 . . . . 0.0 110.856 -179.665 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . 0.496 ' HG ' ' HB3' ' A' ' 116' ' ' ARG . 5.0 tt -149.55 142.71 25.03 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.653 -177.715 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.604 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 63.2 mt -131.45 123.09 51.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 N-CA-C 109.117 -0.697 . . . . 0.0 109.117 178.269 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 10.7 p90 -136.24 161.3 36.14 Favored 'General case' 0 C--N 1.321 -0.659 0 C-N-CA 120.403 -0.519 . . . . 0.0 111.375 -178.119 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . 0.911 ' HB3' ' HB ' ' A' ' 42' ' ' VAL . 5.4 p -147.87 147.58 29.92 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.824 -0.626 . . . . 0.0 110.447 -178.268 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' ILE . . . . . 0.401 HD12 ' N ' ' A' ' 96' ' ' ILE . 4.3 mp -114.45 121.89 67.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-N 116.668 -0.242 . . . . 0.0 110.567 -179.184 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 50.85 67.28 4.46 Favored Pre-proline 0 N--CA 1.467 0.4 0 O-C-N 123.815 0.697 . . . . 0.0 111.201 179.328 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' PRO . . . . . 0.478 ' HA ' ' HD3' ' A' ' 99' ' ' PRO . 85.5 Cg_endo -87.18 143.84 6.81 Favored 'Trans proline' 0 N--CA 1.456 -0.706 0 C-N-CA 122.861 2.374 . . . . 0.0 113.19 -174.772 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.555 ' HD2' HD11 ' A' ' 102' ' ' ILE . 24.3 Cg_exo -63.7 144.51 89.47 Favored 'Trans proline' 0 C--O 1.234 0.317 0 C-N-CA 122.737 2.291 . . . . 0.0 111.573 175.611 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -78.22 44.17 0.48 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.177 0.513 . . . . 0.0 111.289 -177.708 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' GLU . . . . . 0.611 ' HG3' HG23 ' A' ' 102' ' ' ILE . 11.2 pt-20 -132.49 -11.4 3.15 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.439 175.795 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.611 HG23 ' HG3' ' A' ' 101' ' ' GLU . 35.1 pt -122.85 -6.86 8.25 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.449 -0.341 . . . . 0.0 111.636 -177.542 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 103' ' ' HIS . . . . . 0.739 ' HD2' ' HB ' ' A' ' 129' ' ' THR . 16.1 p-80 -62.97 -39.31 94.29 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.083 -176.256 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 32.2 t -71.78 -32.93 68.17 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 121.309 0.576 . . . . 0.0 110.086 178.487 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.602 ' O ' ' HG3' ' A' ' 108' ' ' ARG . 31.0 m -70.68 -33.28 70.75 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.314 179.898 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.512 ' HG ' ' O ' ' A' ' 102' ' ' ILE . 85.2 mt -61.34 -40.27 93.66 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.831 177.606 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 107' ' ' MET . . . . . 0.596 ' HG2' ' HD3' ' A' ' 131' ' ' ARG . 39.7 tpp -56.67 -54.4 46.54 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.344 178.036 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 108' ' ' ARG . . . . . 0.602 ' HG3' ' O ' ' A' ' 105' ' ' SER . 1.6 ptm180 -65.09 -30.94 71.93 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.492 -0.322 . . . . 0.0 111.624 -177.28 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.485 HG23 ' O ' ' A' ' 105' ' ' SER . 83.4 t -73.27 -45.86 51.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 C-N-CA 120.972 -0.291 . . . . 0.0 110.917 179.194 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -59.31 -47.74 84.26 Favored 'General case' 0 CA--C 1.516 -0.355 0 CA-C-O 120.759 0.314 . . . . 0.0 110.163 178.8 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.706 ' HA ' ' HB1' ' A' ' 148' ' ' ALA . 17.3 t70 -66.73 -29.17 69.08 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.984 -176.679 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -71.54 -43.57 66.18 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.547 178.727 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 16.2 m -88.08 -27.01 5.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.456 -0.338 . . . . 0.0 111.758 -175.7 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 89.31 46.27 4.44 Favored Glycine 0 N--CA 1.449 -0.452 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.42 179.016 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -122.5 160.92 24.6 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 121.096 0.474 . . . . 0.0 111.201 -178.233 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 116' ' ' ARG . . . . . 0.496 ' HB3' ' HG ' ' A' ' 92' ' ' LEU . 29.5 ttt180 -81.92 116.42 21.55 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.859 -0.61 . . . . 0.0 109.604 178.542 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . 0.604 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 56.0 tp -90.9 118.5 30.35 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.09 -179.401 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 66.3 mt -119.5 126.04 74.96 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-O 121.121 0.486 . . . . 0.0 110.362 179.07 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 119' ' ' ILE . . . . . 0.51 ' O ' ' HD3' ' A' ' 121' ' ' PRO . 63.8 mt -112.93 127.49 70.14 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.055 178.167 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 48.3 tptt -105.65 91.8 5.42 Favored Pre-proline 0 C--N 1.325 -0.463 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.067 178.507 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 121' ' ' PRO . . . . . 0.536 ' HB2' ' CG ' ' A' ' 125' ' ' GLU . 75.9 Cg_endo -92.68 -177.86 0.82 Allowed 'Trans proline' 0 N--CA 1.455 -0.751 0 C-N-CA 122.622 2.215 . . . . 0.0 111.951 175.049 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -72.81 146.02 46.59 Favored 'General case' 0 C--N 1.327 -0.37 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 173.26 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . 0.437 ' O ' HG23 ' A' ' 123' ' ' THR . 6.2 t -68.61 96.09 0.69 Allowed 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 121.668 0.747 . . . . 0.0 109.475 175.83 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 138.13 -17.58 3.37 Favored Glycine 0 N--CA 1.449 -0.485 0 CA-C-N 115.458 -0.792 . . . . 0.0 112.482 -178.117 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . 0.536 ' CG ' ' HB2' ' A' ' 121' ' ' PRO . 7.5 pt-20 -97.64 164.75 12.28 Favored 'General case' 0 N--CA 1.445 -0.7 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 178.402 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -128.66 162.17 27.96 Favored 'General case' 0 C--N 1.312 -1.044 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.426 -178.71 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.456 HD13 HD12 ' A' ' 119' ' ' ILE . 19.8 mt -90.85 106.58 17.63 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.674 0 N-CA-C 108.546 -0.909 . . . . 0.0 108.546 174.464 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 14.0 m -73.76 78.9 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.825 0 CA-C-O 121.982 0.896 . . . . 0.0 110.738 -179.75 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . 0.739 ' HB ' ' HD2' ' A' ' 103' ' ' HIS . 6.4 t -144.2 155.69 44.0 Favored 'General case' 0 N--CA 1.447 -0.596 0 CA-C-N 115.024 -0.989 . . . . 0.0 110.579 -175.821 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -88.62 -19.13 26.65 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 121.289 0.566 . . . . 0.0 109.759 172.349 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 131' ' ' ARG . . . . . 0.596 ' HD3' ' HG2' ' A' ' 107' ' ' MET . 6.1 mmp_? -61.94 141.24 58.13 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.511 -176.877 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 132' ' ' LYS . . . . . 0.504 ' HD3' ' H ' ' A' ' 132' ' ' LYS . 0.0 OUTLIER -83.89 122.9 29.34 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.816 0.817 . . . . 0.0 112.777 -171.652 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 133' ' ' MET . . . . . . . . . . . . . 85.7 mtp -139.55 170.7 15.43 Favored 'General case' 0 C--N 1.313 -1.005 0 CA-C-N 114.929 -1.032 . . . . 0.0 109.266 176.919 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . 0.456 ' HB2' ' NZ ' ' A' ' 134' ' ' LYS . 0.0 OUTLIER -128.29 146.01 50.88 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-O 120.988 0.423 . . . . 0.0 111.396 -178.367 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . 0.493 HD11 ' CD1' ' A' ' 142' ' ' TYR . 53.0 tp -80.88 139.26 36.02 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.718 -0.673 . . . . 0.0 109.554 177.165 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 136' ' ' VAL . . . . . 0.414 HG23 ' CD1' ' A' ' 143' ' ' PHE . 0.0 OUTLIER -134.66 134.46 54.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-O 120.971 0.415 . . . . 0.0 110.765 177.267 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 137' ' ' ASN . . . . . 0.44 ' ND2' ' HB3' ' A' ' 142' ' ' TYR . 16.0 m120 -107.41 114.59 28.7 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.35 178.915 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 53.2 t80 -148.75 122.28 9.14 Favored 'General case' 0 C--N 1.326 -0.445 0 C-N-CA 120.959 -0.297 . . . . 0.0 110.91 -178.766 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . 0.462 ' HA3' ' CB ' ' A' ' 24' ' ' ASP . . . 64.44 62.68 4.89 Favored Glycine 0 N--CA 1.452 -0.273 0 CA-C-N 115.797 -0.638 . . . . 0.0 113.231 174.867 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 35.3 mmt180 71.41 -38.28 0.42 Allowed 'General case' 0 N--CA 1.47 0.544 0 C-N-CA 123.647 0.779 . . . . 0.0 112.168 175.731 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 141' ' ' THR . . . . . 0.407 ' H ' ' C ' ' A' ' 139' ' ' GLY . 9.9 t -96.34 156.82 16.18 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 121.133 0.492 . . . . 0.0 110.831 -178.025 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 142' ' ' TYR . . . . . 0.493 ' CD1' HD11 ' A' ' 135' ' ' LEU . 44.0 p90 -121.58 154.19 37.05 Favored 'General case' 0 C--N 1.32 -0.699 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 169.415 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 143' ' ' PHE . . . . . 0.42 ' O ' HD12 ' A' ' 135' ' ' LEU . 8.9 p90 -153.37 -177.64 6.47 Favored 'General case' 0 C--N 1.316 -0.858 0 CA-C-N 116.129 -0.487 . . . . 0.0 109.777 -177.536 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 86.9 m-85 -116.41 131.97 56.8 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 116.724 -0.216 . . . . 0.0 110.699 -178.083 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 145' ' ' GLU . . . . . 0.451 ' CD ' HH21 ' A' ' 116' ' ' ARG . 17.1 pt-20 -128.91 162.3 27.86 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.044 0.45 . . . . 0.0 110.626 178.832 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 38.9 t80 -142.56 127.01 17.78 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 115.604 -0.725 . . . . 0.0 109.665 173.561 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 147' ' ' ILE . . . . . 0.427 ' N ' HD12 ' A' ' 147' ' ' ILE . 3.8 mp -95.07 100.27 10.77 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.842 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 178.854 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . 0.706 ' HB1' ' HA ' ' A' ' 111' ' ' ASP . . . -76.39 96.29 3.99 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.953 -0.567 . . . . 0.0 109.659 176.569 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -77.32 154.79 32.51 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-N 115.662 -0.699 . . . . 0.0 111.165 -174.929 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 59.7 t -76.79 147.66 7.4 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-N 115.411 -0.813 . . . . 0.0 109.356 178.845 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 151' ' ' ARG . . . . . . . . . . . . . 59.7 mtm-85 -67.13 152.1 46.37 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.724 0.297 . . . . 0.0 110.222 -178.976 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 18.5 m -80.78 94.78 6.48 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-O 121.181 0.515 . . . . 0.0 110.842 -176.464 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 26.9 mmm180 . . . . . 0 C--O 1.245 0.853 0 CA-C-O 118.376 -0.821 . . . . 0.0 109.809 176.729 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 2.1 mpt? . . . . . 0 N--CA 1.483 1.205 0 N-CA-C 110.222 -0.288 . . . . 0.0 110.222 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -170.04 -93.07 0.09 OUTLIER Glycine 0 N--CA 1.448 -0.547 0 N-CA-C 111.548 -0.621 . . . . 0.0 111.548 179.925 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 34.5 m 58.3 63.41 1.74 Allowed 'General case' 0 C--O 1.235 0.303 0 CA-C-O 121.21 0.528 . . . . 0.0 111.114 178.391 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 13.5 t -94.16 154.95 17.31 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.639 -0.71 . . . . 0.0 110.247 -179.487 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 19.4 t-80 -142.54 150.69 40.75 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 178.655 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 36.9 m80 -65.06 101.24 0.5 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.047 0.451 . . . . 0.0 110.397 178.473 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 51.4 t60 -148.97 136.21 20.1 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.684 -0.689 . . . . 0.0 109.766 -176.402 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 17.5 p80 -115.8 131.45 56.93 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-O 121.061 0.458 . . . . 0.0 109.89 176.917 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 45.8 m80 -75.6 153.03 37.57 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.944 -0.571 . . . . 0.0 111.197 -178.964 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 18.5 p80 -77.4 161.5 27.96 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.424 -0.807 . . . . 0.0 110.62 -179.224 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 3.9 p -107.73 106.65 17.07 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.241 175.229 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 68.3 m -142.0 169.04 18.34 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.835 -0.621 . . . . 0.0 110.449 -179.199 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -78.19 78.65 1.56 Allowed Glycine 0 N--CA 1.447 -0.581 0 C-N-CA 121.083 -0.579 . . . . 0.0 111.748 178.527 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 86.8 mt -74.52 145.37 43.53 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 120.719 0.295 . . . . 0.0 110.381 -178.702 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.415 ' HA ' ' HD3' ' A' ' 16' ' ' PRO . 45.1 t -86.72 117.31 68.47 Favored Pre-proline 0 C--N 1.325 -0.47 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.661 -178.06 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.415 ' HD3' ' HA ' ' A' ' 15' ' ' VAL . 2.8 Cg_exo -76.08 154.79 37.77 Favored 'Trans proline' 0 N--CA 1.463 -0.299 0 C-N-CA 123.063 2.508 . . . . 0.0 111.953 178.668 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -95.12 -156.19 0.5 Allowed 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.285 -0.416 . . . . 0.0 109.986 -179.361 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -77.49 167.62 54.05 Favored Glycine 0 N--CA 1.447 -0.609 0 C-N-CA 120.987 -0.625 . . . . 0.0 112.014 176.594 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 2.4 p -95.38 28.68 2.81 Favored 'General case' 0 C--N 1.321 -0.661 0 N-CA-C 111.88 0.326 . . . . 0.0 111.88 -175.709 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 40.6 t60 -53.7 -44.54 69.87 Favored 'General case' 0 N--CA 1.466 0.364 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.53 -177.394 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' MET . . . . . . . . . . . . . 67.2 mtt -71.94 -16.95 62.11 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 120.926 0.393 . . . . 0.0 111.521 -177.455 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' TRP . . . . . 0.642 ' HB3' HG22 ' A' ' 50' ' ' VAL . 77.0 m95 -96.03 -27.37 15.14 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.824 -176.888 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 6.4 m120 -56.33 -52.09 65.84 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.098 177.36 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.43 ' OD2' ' HA3' ' A' ' 139' ' ' GLY . 1.3 t70 -76.77 -28.98 55.89 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.423 -177.152 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 58.5 tp -59.29 -45.98 89.79 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-O 121.049 0.452 . . . . 0.0 109.907 174.516 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . 0.44 ' O ' HG13 ' A' ' 30' ' ' ILE . . . -56.18 -44.46 79.38 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.46 -0.791 . . . . 0.0 110.667 178.629 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 88.5 t -54.4 -46.85 70.34 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.244 0 O-C-N 123.264 0.352 . . . . 0.0 110.857 177.38 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . 0.546 ' HB2' ' CD2' ' A' ' 138' ' ' TYR . 87.2 t80 -58.48 -45.73 88.07 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.332 177.877 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.419 HG12 HD12 ' A' ' 118' ' ' ILE . 74.5 mt -63.09 -46.12 96.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.719 178.988 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.783 HG12 HG23 ' A' ' 54' ' ' ILE . 83.0 mt -57.48 -44.07 84.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 115.692 -0.685 . . . . 0.0 110.919 178.211 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 75.1 mtt180 -72.8 -21.26 61.01 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.263 -176.28 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 73.3 m -88.54 -14.01 38.75 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.345 -0.389 . . . . 0.0 111.339 177.753 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 22.0 p -126.53 -86.11 0.61 Allowed 'General case' 0 CA--C 1.534 0.328 0 CA-C-O 120.678 0.275 . . . . 0.0 111.358 179.315 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 99.77 -176.25 28.36 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 121.167 -0.539 . . . . 0.0 112.595 178.459 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -71.93 155.37 57.71 Favored 'Trans proline' 0 C--O 1.233 0.26 0 C-N-CA 122.534 2.156 . . . . 0.0 112.247 -179.35 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 98.02 -11.76 64.01 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.681 -0.771 . . . . 0.0 113.081 176.345 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 14.0 t -121.7 -166.61 1.4 Allowed 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -179.382 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . 0.675 ' HG2' ' HB2' ' A' ' 61' ' ' ASP . 84.3 mtt180 -128.03 136.36 51.13 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.891 0.377 . . . . 0.0 110.877 -179.218 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.868 ' HB ' HD22 ' A' ' 62' ' ' LEU . 20.9 t -125.47 140.63 47.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 177.182 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 40.4 t -112.41 128.93 68.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-O 120.941 0.401 . . . . 0.0 111.282 -177.469 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . 0.415 ' OE1' HD22 ' A' ' 64' ' ' LEU . 42.5 tt0 -105.06 110.2 22.5 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.659 -0.7 . . . . 0.0 109.549 176.887 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.438 ' HB ' ' HB3' ' A' ' 95' ' ' SER . 58.5 t -94.11 113.76 29.39 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.399 -179.462 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 103.8 42.87 1.89 Allowed Glycine 0 N--CA 1.446 -0.657 0 C-N-CA 120.524 -0.846 . . . . 0.0 111.612 -178.679 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -85.99 -127.01 0.04 OUTLIER 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 110.37 -0.233 . . . . 0.0 110.37 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 67.77 -90.23 0.2 Allowed Glycine 0 C--N 1.33 0.203 0 C-N-CA 121.281 -0.485 . . . . 0.0 112.589 177.873 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -71.9 -23.47 61.49 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 109.705 -0.479 . . . . 0.0 109.705 176.67 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 50.2 m-85 -110.18 109.59 20.14 Favored 'General case' 0 C--O 1.224 -0.277 0 CA-C-N 115.971 -0.558 . . . . 0.0 110.048 178.236 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 96.9 mt -131.35 0.81 4.11 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.706 0.289 . . . . 0.0 111.084 179.722 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 9.2 p90 -69.08 -26.97 65.21 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 112.211 0.449 . . . . 0.0 112.211 -174.936 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.642 HG22 ' HB3' ' A' ' 22' ' ' TRP . 40.9 t -76.02 -58.69 4.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-O 120.93 0.395 . . . . 0.0 110.763 179.734 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 3.3 p -60.77 -42.59 97.78 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.748 -0.66 . . . . 0.0 112.484 -176.703 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.517 ' O ' ' HG2' ' A' ' 56' ' ' LYS . 30.3 t70 -66.53 -27.54 67.84 Favored 'General case' 0 C--N 1.33 -0.256 0 C-N-CA 120.917 -0.313 . . . . 0.0 110.885 -179.359 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 88.1 t80 -70.44 -42.49 71.48 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 120.974 0.416 . . . . 0.0 110.34 175.819 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.783 HG23 HG12 ' A' ' 30' ' ' ILE . 77.3 mt -61.9 -43.58 97.66 Favored 'Isoleucine or valine' 0 C--O 1.236 0.353 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.119 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . 0.499 ' HG2' ' HA ' ' A' ' 52' ' ' ASP . 4.1 ptm180 -68.76 -16.09 63.7 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.952 -0.567 . . . . 0.0 111.794 -176.534 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . 0.517 ' HG2' ' O ' ' A' ' 52' ' ' ASP . 69.5 mmtt -65.34 -42.05 93.28 Favored 'General case' 0 C--O 1.233 0.192 0 CA-C-O 121.058 0.456 . . . . 0.0 110.349 177.401 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 33.2 m170 -94.17 -57.5 2.5 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.762 -0.654 . . . . 0.0 111.483 -174.519 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 69.0 m -102.72 130.65 49.73 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.11 0.481 . . . . 0.0 111.618 -175.589 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . 0.526 ' C ' ' HE3' ' A' ' 59' ' ' LYS . 0.1 OUTLIER -80.42 65.52 5.59 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 121.99 0.9 . . . . 0.0 109.224 173.676 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.574 HG21 HG23 ' A' ' 39' ' ' VAL . 7.3 p -97.16 143.5 12.37 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.025 0 CA-C-N 114.606 -1.179 . . . . 0.0 109.003 174.3 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . 0.675 ' HB2' ' HG2' ' A' ' 38' ' ' ARG . 19.7 m-20 -76.32 96.11 3.91 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-O 121.243 0.544 . . . . 0.0 109.68 178.081 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . 0.868 HD22 ' HB ' ' A' ' 39' ' ' VAL . 0.1 OUTLIER -86.88 118.1 26.05 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 115.476 -0.784 . . . . 0.0 109.506 -178.936 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.498 HG13 HG21 ' A' ' 75' ' ' VAL . 61.9 t -97.94 114.76 36.19 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.849 0 CA-C-N 115.683 -0.689 . . . . 0.0 110.127 -179.996 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . 0.496 HD12 HG12 ' A' ' 74' ' ' ILE . 31.8 mt -96.77 124.0 40.63 Favored 'General case' 0 C--N 1.315 -0.93 0 CA-C-N 115.616 -0.72 . . . . 0.0 109.646 -179.915 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 33.1 p -108.34 124.96 51.16 Favored 'General case' 0 C--N 1.315 -0.924 0 CA-C-O 120.933 0.397 . . . . 0.0 110.278 177.276 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 25.6 t70 -156.17 144.58 19.98 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.202 -176.676 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.43 HG22 ' HG3' ' A' ' 68' ' ' LYS . 53.7 mt -73.42 113.71 11.78 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 116.343 -0.389 . . . . 0.0 110.208 178.676 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' LYS . . . . . 0.43 ' HG3' HG22 ' A' ' 67' ' ' ILE . 5.8 mtpm? 59.76 82.01 0.24 Allowed Pre-proline 0 C--O 1.233 0.212 0 CA-C-N 115.54 -0.754 . . . . 0.0 110.568 179.483 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -71.06 137.61 32.05 Favored 'Trans proline' 0 C--O 1.232 0.198 0 C-N-CA 122.742 2.295 . . . . 0.0 113.008 -175.535 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 46.3 m -85.98 -37.43 19.01 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.957 177.043 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 71.3 m-70 -96.33 132.86 41.38 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.928 -177.084 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -66.89 102.77 0.81 Allowed Glycine 0 N--CA 1.448 -0.524 0 N-CA-C 111.449 -0.66 . . . . 0.0 111.449 175.59 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 147.88 -23.13 1.46 Allowed Glycine 0 N--CA 1.446 -0.663 0 N-CA-C 110.716 -0.954 . . . . 0.0 110.716 -175.548 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.496 HG12 HD12 ' A' ' 64' ' ' LEU . 56.8 mt -83.67 140.16 16.62 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 N-CA-C 108.673 -0.862 . . . . 0.0 108.673 173.169 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.513 HG11 HD13 ' A' ' 86' ' ' ILE . 63.5 t -86.47 130.21 37.05 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.711 0 CA-C-O 120.942 0.401 . . . . 0.0 110.611 -176.539 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' ARG . . . . . 0.422 ' HG2' ' H ' ' A' ' 76' ' ' ARG . 15.3 ptm180 -75.15 49.19 0.44 Allowed 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.502 -0.772 . . . . 0.0 111.54 179.809 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 22.6 t70 -108.14 117.96 35.51 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 116.083 -0.508 . . . . 0.0 109.779 179.411 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . 0.446 ' OD2' HG23 ' A' ' 80' ' ' THR . 5.5 p-10 -92.18 132.15 36.86 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.361 -0.382 . . . . 0.0 110.548 -179.423 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 10.7 tp -62.95 -18.05 20.55 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.476 0 CA-C-N 116.155 -0.475 . . . . 0.0 112.185 -173.62 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.446 HG23 ' OD2' ' A' ' 78' ' ' ASP . 0.7 OUTLIER -77.75 -27.71 50.47 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.877 0.37 . . . . 0.0 110.66 177.483 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 22.2 t -140.81 66.42 26.65 Favored Pre-proline 0 C--N 1.326 -0.416 0 N-CA-C 109.636 -0.505 . . . . 0.0 109.636 177.996 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 76.0 Cg_endo -89.93 151.75 4.91 Favored 'Trans proline' 0 N--CA 1.456 -0.732 0 C-N-CA 122.62 2.213 . . . . 0.0 113.436 -171.817 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' ARG . . . . . 0.717 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 53.0 mtt-85 -93.19 115.26 27.89 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.481 174.589 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' MET . . . . . . . . . . . . . 93.4 mmm -62.05 -22.48 65.78 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.926 -0.579 . . . . 0.0 111.055 -178.981 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.717 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 12.9 pt-20 -62.27 -21.68 65.4 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-O 120.913 0.387 . . . . 0.0 111.137 178.692 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.513 HD13 HG11 ' A' ' 75' ' ' VAL . 82.2 mt -83.76 -43.21 17.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.621 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 70.7 m-85 -76.27 -31.5 58.3 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.841 -178.004 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . 0.732 ' HG3' HG12 ' A' ' 113' ' ' VAL . 31.9 mtp85 -66.91 119.86 12.62 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.615 177.737 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 115.11 -8.74 20.96 Favored Glycine 0 N--CA 1.449 -0.499 0 CA-C-N 115.737 -0.665 . . . . 0.0 111.538 -175.748 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -89.35 140.87 29.07 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 120.884 0.374 . . . . 0.0 110.633 179.227 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -88.09 -22.24 24.26 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.968 -178.927 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . 0.472 HD23 ' N ' ' A' ' 93' ' ' ILE . 3.3 tt -151.62 141.97 22.45 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.272 -176.733 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.549 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 65.4 mt -132.43 123.35 49.72 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-N 115.986 -0.552 . . . . 0.0 109.701 179.149 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 23.3 p90 -125.03 150.95 46.22 Favored 'General case' 0 C--N 1.322 -0.612 0 C-N-CA 120.709 -0.396 . . . . 0.0 110.402 177.906 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . 0.438 ' HB3' ' HB ' ' A' ' 42' ' ' VAL . 11.7 p -131.52 140.58 49.54 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.692 -178.089 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' ILE . . . . . 0.473 HG23 ' CH2' ' A' ' 22' ' ' TRP . 81.1 mt -98.45 90.2 2.07 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-O 121.425 0.631 . . . . 0.0 110.775 -177.467 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 50.8 ttt-85 56.4 95.81 0.04 OUTLIER Pre-proline 0 N--CA 1.469 0.498 0 CA-C-N 114.304 -1.316 . . . . 0.0 111.99 -177.999 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' PRO . . . . . 0.408 ' HA ' ' HD3' ' A' ' 99' ' ' PRO . 96.8 Cg_endo -88.97 137.14 3.14 Favored 'Trans proline' 0 N--CA 1.455 -0.739 0 C-N-CA 122.647 2.232 . . . . 0.0 112.612 177.722 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.662 ' HD2' HD11 ' A' ' 102' ' ' ILE . 50.5 Cg_exo -53.95 156.63 12.16 Favored 'Trans proline' 0 C--O 1.236 0.393 0 C-N-CA 122.797 2.331 . . . . 0.0 112.079 175.534 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.68 ' HA ' ' CE1' ' A' ' 103' ' ' HIS . . . -75.49 29.51 0.1 Allowed 'General case' 0 C--N 1.328 -0.351 0 N-CA-C 112.57 0.582 . . . . 0.0 112.57 -172.67 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' GLU . . . . . 0.587 ' HG3' HG23 ' A' ' 102' ' ' ILE . 12.5 pt-20 -129.89 -23.71 2.76 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 111.937 0.347 . . . . 0.0 111.937 -178.386 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.662 HD11 ' HD2' ' A' ' 99' ' ' PRO . 41.2 pt -106.78 14.4 7.85 Favored 'Isoleucine or valine' 0 C--O 1.234 0.258 0 N-CA-C 112.45 0.537 . . . . 0.0 112.45 -172.949 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 103' ' ' HIS . . . . . 0.68 ' CE1' ' HA ' ' A' ' 100' ' ' ALA . 28.9 m170 -53.78 -54.06 43.51 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.245 0.545 . . . . 0.0 110.334 177.79 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . 0.512 ' O ' ' HG2' ' A' ' 108' ' ' ARG . 8.8 m -59.89 -34.59 73.37 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.294 -0.866 . . . . 0.0 110.871 -177.722 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.58 ' O ' HG23 ' A' ' 109' ' ' VAL . 16.7 m -63.52 -56.07 18.97 Favored 'General case' 0 N--CA 1.452 -0.329 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.198 -177.556 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 72.2 mt -56.56 -41.16 76.42 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.657 -0.701 . . . . 0.0 111.08 -178.839 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 107' ' ' MET . . . . . . . . . . . . . 96.5 mmm -62.0 -46.89 87.22 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.889 -0.596 . . . . 0.0 111.138 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 108' ' ' ARG . . . . . 0.512 ' HG2' ' O ' ' A' ' 104' ' ' SER . 3.1 ptp180 -77.08 -22.23 53.14 Favored 'General case' 0 C--N 1.331 -0.238 0 C-N-CA 120.679 -0.409 . . . . 0.0 111.847 -178.4 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.58 HG23 ' O ' ' A' ' 105' ' ' SER . 76.2 t -68.31 -48.75 71.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 173.866 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -61.34 -37.2 82.45 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.043 177.944 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 11.2 t70 -66.01 -40.73 91.33 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.144 -0.934 . . . . 0.0 110.904 177.911 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -69.54 -43.14 73.59 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.837 -0.619 . . . . 0.0 111.987 -176.961 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.732 HG12 ' HG3' ' A' ' 88' ' ' ARG . 20.0 m -87.21 -25.16 6.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-O 120.722 0.296 . . . . 0.0 111.585 -175.561 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 82.29 59.82 2.22 Favored Glycine 0 N--CA 1.447 -0.621 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.21 179.944 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -135.43 173.96 11.14 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-O 120.854 0.359 . . . . 0.0 110.441 -179.922 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 116' ' ' ARG . . . . . 0.449 ' HD3' ' OE1' ' A' ' 145' ' ' GLU . 13.8 ttm180 -92.7 124.29 36.6 Favored 'General case' 0 C--N 1.323 -0.576 0 N-CA-C 109.66 -0.496 . . . . 0.0 109.66 175.616 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . 0.549 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 61.6 tp -92.66 132.75 36.63 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 116.175 -0.466 . . . . 0.0 109.803 178.945 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . 0.419 HD12 HG12 ' A' ' 29' ' ' ILE . 64.6 mt -126.18 122.65 62.02 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-O 121.078 0.466 . . . . 0.0 110.645 177.698 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 66.8 mt -121.43 122.9 68.43 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.016 177.599 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 23.3 ttmm -114.76 104.24 54.36 Favored Pre-proline 0 C--N 1.321 -0.645 0 CA-C-O 120.829 0.347 . . . . 0.0 110.881 176.296 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -80.63 170.78 15.34 Favored 'Trans proline' 0 N--CA 1.455 -0.78 0 C-N-CA 122.211 1.941 . . . . 0.0 110.912 169.737 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 122' ' ' LEU . . . . . 0.73 ' HB2' ' HG3' ' A' ' 125' ' ' GLU . 41.0 mt -70.17 155.29 40.83 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 116.494 -0.321 . . . . 0.0 110.378 179.473 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . 0.698 ' HA ' ' HE1' ' A' ' 142' ' ' TYR . 46.1 m -64.8 109.9 2.22 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 109.992 -0.373 . . . . 0.0 109.992 175.629 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 107.36 -1.31 34.84 Favored Glycine 0 N--CA 1.446 -0.663 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.141 -178.536 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . 0.73 ' HG3' ' HB2' ' A' ' 122' ' ' LEU . 5.1 mt-10 -96.27 -169.21 1.87 Allowed 'General case' 0 N--CA 1.449 -0.501 0 CA-C-O 121.261 0.553 . . . . 0.0 110.8 177.538 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 5.8 t70 -149.35 165.43 32.03 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-N 115.193 -0.912 . . . . 0.0 109.116 -178.345 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 32.6 mt -93.54 -19.53 6.64 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 176.328 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 22.8 m 41.0 69.5 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.469 0.502 0 CA-C-O 121.988 0.899 . . . . 0.0 111.882 -175.122 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 9.8 t -146.23 -172.26 3.9 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.324 -0.853 . . . . 0.0 110.315 -175.831 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 42.9 tt0 -65.13 136.13 56.33 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 109.641 -0.503 . . . . 0.0 109.641 176.744 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 131' ' ' ARG . . . . . . . . . . . . . 97.7 mtt180 -63.54 92.32 0.06 Allowed 'General case' 0 N--CA 1.463 0.222 0 CA-C-O 121.317 0.579 . . . . 0.0 112.125 -175.105 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 90.1 mttt -148.42 -167.25 2.76 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.401 -0.818 . . . . 0.0 109.789 178.056 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 133' ' ' MET . . . . . . . . . . . . . 71.0 mtp 68.95 -178.93 0.22 Allowed 'General case' 0 N--CA 1.467 0.383 0 O-C-N 123.791 0.682 . . . . 0.0 110.668 -179.333 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 17.5 ptmt -136.85 144.07 43.41 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.95 179.9 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . 0.559 HD11 ' HD2' ' A' ' 142' ' ' TYR . 53.6 tp -87.63 127.77 35.28 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.655 -179.405 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 136' ' ' VAL . . . . . 0.461 ' C ' HD22 ' A' ' 137' ' ' ASN . 0.0 OUTLIER -130.14 140.66 48.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.902 179.493 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 137' ' ' ASN . . . . . 0.461 HD22 ' C ' ' A' ' 136' ' ' VAL . 0.9 OUTLIER -120.13 105.5 11.05 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.04 178.001 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . 0.546 ' CD2' ' HB2' ' A' ' 28' ' ' TYR . 73.4 t80 -117.83 112.06 19.89 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.585 -0.524 . . . . 0.0 109.585 178.778 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . 0.43 ' HA3' ' OD2' ' A' ' 24' ' ' ASP . . . 81.44 26.97 49.8 Favored Glycine 0 N--CA 1.447 -0.567 0 C-N-CA 120.743 -0.741 . . . . 0.0 111.797 -178.536 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 140' ' ' ARG . . . . . 0.464 ' HD3' ' HA ' ' A' ' 140' ' ' ARG . 26.5 mmt180 67.6 8.45 6.36 Favored 'General case' 0 N--CA 1.463 0.224 0 C-N-CA 123.248 0.619 . . . . 0.0 111.927 -179.807 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 141' ' ' THR . . . . . 0.462 HG22 ' O ' ' A' ' 138' ' ' TYR . 14.0 t -107.03 135.62 48.27 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 170.926 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 142' ' ' TYR . . . . . 0.698 ' HE1' ' HA ' ' A' ' 123' ' ' THR . 6.7 p90 -101.18 147.58 26.09 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-O 121.019 0.438 . . . . 0.0 110.789 -172.947 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 20.9 p90 -156.08 170.4 22.27 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-N 115.639 -0.71 . . . . 0.0 109.321 175.962 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 96.3 m-85 -113.51 124.27 51.99 Favored 'General case' 0 C--N 1.318 -0.797 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 179.266 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 145' ' ' GLU . . . . . 0.449 ' OE1' ' HD3' ' A' ' 116' ' ' ARG . 19.1 pt-20 -112.73 161.66 16.63 Favored 'General case' 0 C--N 1.316 -0.874 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 178.4 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . 0.415 ' HB3' ' HB3' ' A' ' 117' ' ' LEU . 63.8 t80 -141.36 129.06 21.58 Favored 'General case' 0 C--N 1.315 -0.928 0 CA-C-N 115.938 -0.573 . . . . 0.0 109.897 175.511 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 147' ' ' ILE . . . . . 0.415 ' N ' HD12 ' A' ' 147' ' ' ILE . 3.5 mp -101.68 120.21 50.99 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.96 0 N-CA-C 107.956 -1.128 . . . . 0.0 107.956 176.327 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -63.31 92.62 0.06 Allowed 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.503 0.668 . . . . 0.0 110.377 179.112 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -81.71 171.27 14.78 Favored 'General case' 0 N--CA 1.445 -0.687 0 CA-C-N 114.675 -1.148 . . . . 0.0 111.014 -175.582 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 19.5 t -68.54 132.06 33.15 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 115.79 -0.641 . . . . 0.0 109.966 -179.943 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 151' ' ' ARG . . . . . 0.415 HH11 ' HD3' ' A' ' 151' ' ' ARG . 13.5 ptt-85 -60.19 115.53 3.56 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.899 -0.591 . . . . 0.0 111.093 179.728 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 28.1 t -113.23 143.1 44.98 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-N 115.416 -0.811 . . . . 0.0 109.419 178.912 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 153' ' ' ARG . . . . . 0.434 ' O ' ' HG3' ' A' ' 153' ' ' ARG . 32.4 ptt180 . . . . . 0 C--O 1.25 1.107 0 CA-C-O 118.865 -0.588 . . . . 0.0 110.21 178.656 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 16.2 tpt . . . . . 0 N--CA 1.48 1.072 0 CA-C-O 120.712 0.291 . . . . 0.0 110.566 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 109.63 -161.05 13.16 Favored Glycine 0 N--CA 1.451 -0.349 0 N-CA-C 111.758 -0.537 . . . . 0.0 111.758 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.0 p -88.52 96.81 10.77 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 121.244 0.545 . . . . 0.0 109.969 177.221 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 13.6 t -95.97 99.93 11.65 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.791 -0.641 . . . . 0.0 110.316 -174.361 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 26.9 m170 -111.01 110.56 21.16 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.047 179.009 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 88.7 m-70 -127.72 139.53 52.64 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 121.081 0.467 . . . . 0.0 111.095 -179.703 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 74.9 m80 -95.66 102.77 14.6 Favored 'General case' 0 C--N 1.321 -0.667 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 174.378 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 86.9 m-70 -86.02 92.03 8.57 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.897 -0.592 . . . . 0.0 111.323 -172.095 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 78.1 t60 -96.86 127.2 42.6 Favored 'General case' 0 C--N 1.322 -0.612 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 173.62 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 37.9 p-80 -90.21 132.47 35.47 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 121.136 0.494 . . . . 0.0 111.146 -177.831 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 34.5 t -100.13 169.29 9.26 Favored 'General case' 0 C--N 1.32 -0.697 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 176.365 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 9.2 m -67.06 118.69 10.85 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 178.613 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -72.16 120.04 7.63 Favored Glycine 0 N--CA 1.446 -0.669 0 C-N-CA 120.375 -0.917 . . . . 0.0 112.359 -179.309 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -82.55 111.63 18.72 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 120.941 0.4 . . . . 0.0 110.409 179.644 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.443 ' HA ' ' HD3' ' A' ' 16' ' ' PRO . 28.3 m -124.32 131.68 24.22 Favored Pre-proline 0 C--N 1.324 -0.537 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.738 179.899 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.572 ' HD2' ' HD2' ' A' ' 49' ' ' TYR . 56.6 Cg_endo -89.84 141.75 3.82 Favored 'Trans proline' 0 N--CA 1.454 -0.838 0 C-N-CA 122.855 2.37 . . . . 0.0 112.403 177.013 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 0.42 HH11 ' HD2' ' A' ' 17' ' ' ARG . 40.4 mtm105 -91.87 98.07 11.37 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.035 179.042 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -176.95 34.85 0.08 OUTLIER Glycine 0 N--CA 1.447 -0.604 0 C-N-CA 120.859 -0.686 . . . . 0.0 111.46 178.3 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . 0.948 ' HB2' ' HB2' ' A' ' 22' ' ' TRP . 48.6 p -132.53 80.05 1.88 Allowed 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 120.668 0.27 . . . . 0.0 110.709 -175.915 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 41.9 m-70 -65.82 -62.58 1.42 Allowed 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.407 -0.36 . . . . 0.0 111.194 -177.183 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' MET . . . . . 0.741 ' HB2' ' HB ' ' A' ' 141' ' ' THR . 1.2 pmm? -66.3 -20.55 66.13 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.168 -177.456 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' TRP . . . . . 0.948 ' HB2' ' HB2' ' A' ' 19' ' ' SER . 61.8 m95 -76.18 -29.56 57.73 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 120.916 0.389 . . . . 0.0 110.38 178.38 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.45 ' O ' HG23 ' A' ' 27' ' ' VAL . 9.6 m120 -72.32 -36.03 68.76 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 174.337 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.494 ' HB3' ' HA3' ' A' ' 139' ' ' GLY . 5.4 m-20 -64.55 -38.15 90.01 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.283 174.772 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 53.8 tp -53.23 -50.31 65.01 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.161 -0.472 . . . . 0.0 109.958 173.016 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . 0.401 ' O ' HG13 ' A' ' 30' ' ' ILE . . . -58.61 -48.72 80.02 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.884 177.269 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.45 HG23 ' O ' ' A' ' 23' ' ' ASN . 79.0 t -52.52 -45.82 47.33 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.22 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.175 177.102 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . 0.481 ' HB2' ' CD2' ' A' ' 138' ' ' TYR . 78.1 t80 -58.03 -47.12 84.06 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.535 178.629 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.448 HG12 HD12 ' A' ' 118' ' ' ILE . 78.5 mt -60.43 -44.18 95.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.542 178.311 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.621 HD11 ' HA ' ' A' ' 54' ' ' ILE . 83.7 mt -61.99 -41.09 89.65 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 115.601 -0.727 . . . . 0.0 111.455 -179.505 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . 0.406 HH11 ' HD3' ' A' ' 31' ' ' ARG . 41.5 mtp-105 -71.78 -29.86 64.93 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.888 -177.541 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 76.5 m -80.92 -27.32 36.21 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.381 -0.372 . . . . 0.0 111.426 -178.999 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 14.0 p -93.77 -75.35 0.5 Allowed 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 120.752 0.31 . . . . 0.0 111.291 -177.673 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 109.43 134.6 7.03 Favored Glycine 0 N--CA 1.448 -0.543 0 C-N-CA 121.072 -0.585 . . . . 0.0 111.694 -176.399 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 32.8 Cg_exo -57.53 133.0 53.89 Favored 'Trans proline' 0 C--O 1.232 0.206 0 C-N-CA 122.925 2.417 . . . . 0.0 112.421 -179.155 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 102.24 62.76 0.73 Allowed Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.434 -0.888 . . . . 0.0 111.731 -177.948 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 15.0 t -178.31 -166.96 0.12 Allowed 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 108.545 -0.909 . . . . 0.0 108.545 -178.191 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . 0.832 ' HG2' ' HB3' ' A' ' 61' ' ' ASP . 48.5 mtt180 -124.58 136.61 54.1 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 121.045 0.45 . . . . 0.0 111.055 176.96 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.767 HG23 HG11 ' A' ' 60' ' ' VAL . 86.1 t -125.65 121.96 61.24 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 N-CA-C 109.16 -0.681 . . . . 0.0 109.16 175.342 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.419 HG22 ' HB ' ' A' ' 63' ' ' VAL . 26.4 t -101.37 132.64 46.8 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-O 120.743 0.306 . . . . 0.0 110.79 -175.261 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . 0.711 ' HB3' HD23 ' A' ' 64' ' ' LEU . 10.7 tt0 -108.72 126.0 52.53 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.154 -0.476 . . . . 0.0 109.972 176.252 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.739 HG13 HD11 ' A' ' 79' ' ' ILE . 64.8 t -94.12 106.62 18.29 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.774 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 174.644 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 156.75 -66.54 0.3 Allowed Glycine 0 N--CA 1.44 -1.1 0 C-N-CA 120.283 -0.96 . . . . 0.0 111.753 -178.671 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.979 ' HB1' HD13 ' A' ' 74' ' ' ILE . . . 53.38 34.36 17.87 Favored 'General case' 0 C--O 1.233 0.187 0 CA-C-O 121.132 0.491 . . . . 0.0 111.774 176.832 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -91.34 -144.85 13.52 Favored Glycine 0 N--CA 1.445 -0.742 0 C-N-CA 120.623 -0.798 . . . . 0.0 112.847 -177.541 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 39.1 mtp180 -92.6 29.81 1.67 Allowed 'General case' 0 C--N 1.321 -0.667 0 CA-C-O 121.251 0.548 . . . . 0.0 110.523 -176.026 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 5.1 p90 -129.91 30.17 4.88 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.93 -176.675 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.596 HD21 ' HA ' ' A' ' 44' ' ' ALA . 94.1 mt -72.75 7.92 1.73 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.993 -0.549 . . . . 0.0 112.147 -174.318 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . 0.572 ' HD2' ' HD2' ' A' ' 16' ' ' PRO . 5.7 p90 -65.95 -26.37 67.54 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.819 0.342 . . . . 0.0 110.931 177.025 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.47 ' O ' HG13 ' A' ' 54' ' ' ILE . 93.6 t -72.35 -54.37 16.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.19 175.513 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -61.86 -41.33 97.72 Favored 'General case' 0 N--CA 1.449 -0.479 0 CA-C-N 115.795 -0.638 . . . . 0.0 111.592 -179.099 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 22.1 t70 -65.49 -42.78 91.77 Favored 'General case' 0 C--N 1.329 -0.306 0 C-N-CA 121.033 -0.267 . . . . 0.0 110.756 179.128 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 89.7 t80 -59.56 -36.66 76.64 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.864 0.364 . . . . 0.0 110.533 178.64 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.621 ' HA ' HD11 ' A' ' 30' ' ' ILE . 81.3 mt -61.27 -46.85 95.79 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.386 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.017 178.205 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 36.8 ptt180 -75.33 -16.71 60.38 Favored 'General case' 0 C--O 1.234 0.25 0 CA-C-O 120.843 0.354 . . . . 0.0 111.078 -178.201 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 43.4 mmtm -75.62 -35.39 60.5 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.56 -0.291 . . . . 0.0 110.986 177.234 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . 0.469 ' CD2' HG21 ' A' ' 30' ' ' ILE . 13.1 t60 -103.94 -38.31 7.04 Favored 'General case' 0 N--CA 1.451 -0.418 0 CA-C-O 120.953 0.406 . . . . 0.0 110.75 -175.13 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 7.9 t -110.08 140.82 43.74 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 121.03 0.443 . . . . 0.0 110.302 -177.697 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . 0.504 ' HD2' ' N ' ' A' ' 59' ' ' LYS . 4.1 mptp? -92.22 60.59 3.74 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.783 0.802 . . . . 0.0 109.888 178.378 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.767 HG11 HG23 ' A' ' 39' ' ' VAL . 73.7 t -106.26 139.46 27.54 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-N 114.623 -1.171 . . . . 0.0 110.67 177.985 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . 0.832 ' HB3' ' HG2' ' A' ' 38' ' ' ARG . 18.0 t70 -74.98 90.75 2.46 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 109.168 -0.678 . . . . 0.0 109.168 175.823 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 5.5 tt -84.89 126.85 33.83 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.163 -176.529 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.419 ' HB ' HG22 ' A' ' 40' ' ' VAL . 51.5 t -106.82 127.94 61.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.828 -176.256 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . 0.711 HD23 ' HB3' ' A' ' 41' ' ' GLU . 82.3 mt -111.76 133.87 53.7 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 109.535 -0.543 . . . . 0.0 109.535 176.61 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 3.4 p -127.47 130.22 48.85 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 120.47 0.176 . . . . 0.0 111.024 178.566 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . 0.812 ' HB2' ' HB3' ' A' ' 44' ' ' ALA . 19.4 t0 -162.22 157.58 23.22 Favored 'General case' 0 C--O 1.234 0.268 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.675 -179.355 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 63.7 mt -82.58 122.01 36.55 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 116.115 -0.493 . . . . 0.0 109.79 178.926 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 18.1 ptpt 41.52 69.46 2.04 Favored Pre-proline 0 N--CA 1.474 0.77 0 O-C-N 124.003 0.814 . . . . 0.0 112.346 -175.604 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . 0.513 ' CB ' ' HB ' ' A' ' 74' ' ' ILE . 5.8 Cg_exo -74.51 132.61 16.32 Favored 'Trans proline' 0 N--CA 1.46 -0.467 0 C-N-CA 122.898 2.399 . . . . 0.0 111.923 179.072 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 34.0 t -78.29 -17.62 56.36 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.13 -176.759 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 64.5 m80 -80.54 -11.69 59.63 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.385 -0.371 . . . . 0.0 111.649 -176.325 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 81.24 -52.34 4.5 Favored Glycine 0 CA--C 1.52 0.401 0 C-N-CA 120.92 -0.657 . . . . 0.0 113.765 173.774 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -74.36 -3.87 67.3 Favored Glycine 0 CA--C 1.518 0.25 0 C-N-CA 121.141 -0.552 . . . . 0.0 113.23 -175.468 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.979 HD13 ' HB1' ' A' ' 44' ' ' ALA . 62.5 mt -85.91 135.51 24.84 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.713 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 178.345 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.49 HG12 ' H ' ' A' ' 77' ' ' ASP . 61.6 t -61.18 136.16 25.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-O 120.832 0.348 . . . . 0.0 110.364 -177.908 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 17.1 mmt85 -86.3 15.16 5.55 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.969 -0.559 . . . . 0.0 111.31 -171.947 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . 0.49 ' H ' HG12 ' A' ' 75' ' ' VAL . 26.2 t70 -77.21 136.54 38.56 Favored 'General case' 0 C--N 1.325 -0.5 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 -177.019 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -58.99 116.06 3.55 Favored 'General case' 0 C--O 1.221 -0.439 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.141 -177.145 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . 0.739 HD11 HG13 ' A' ' 42' ' ' VAL . 10.6 tp -69.63 -16.28 20.29 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-O 121.344 0.592 . . . . 0.0 110.399 178.551 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 9.0 t -86.99 -11.31 50.87 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.477 178.225 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 45.0 t -157.2 64.86 3.4 Favored Pre-proline 0 C--N 1.326 -0.424 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 179.879 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.562 ' HB2' ' HE2' ' A' ' 87' ' ' TYR . 90.1 Cg_endo -85.07 153.26 11.06 Favored 'Trans proline' 0 N--CA 1.458 -0.564 0 C-N-CA 122.717 2.278 . . . . 0.0 113.206 -170.187 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' ARG . . . . . 0.68 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 35.2 mtt180 -87.56 119.82 28.24 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.784 177.292 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' MET . . . . . 0.652 ' HA ' ' HD2' ' A' ' 87' ' ' TYR . 36.7 mtp -67.94 -9.32 44.24 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.567 -0.742 . . . . 0.0 112.362 -175.302 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.68 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 8.0 pt-20 -61.51 -30.13 70.43 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 121.085 0.469 . . . . 0.0 110.088 175.374 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 69.2 mt -75.07 -40.01 44.31 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 115.47 -0.786 . . . . 0.0 110.514 -179.472 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . 0.652 ' HD2' ' HA ' ' A' ' 84' ' ' MET . 91.5 m-85 -75.27 -34.5 61.37 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.947 -0.57 . . . . 0.0 111.216 -177.717 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 34.0 mtp180 -64.41 114.48 4.34 Favored 'General case' 0 C--O 1.235 0.328 0 CA-C-O 121.572 0.701 . . . . 0.0 110.765 177.71 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 124.21 -12.53 8.03 Favored Glycine 0 N--CA 1.443 -0.864 0 CA-C-N 114.868 -1.06 . . . . 0.0 111.492 -175.825 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -84.21 152.19 24.38 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.838 0.352 . . . . 0.0 110.872 -179.815 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -99.75 -22.16 15.48 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.407 177.546 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . 0.483 ' HG ' ' HB3' ' A' ' 116' ' ' ARG . 4.9 tt -152.53 142.01 21.69 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.298 -177.981 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.576 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 68.3 mt -131.89 122.96 50.48 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 178.807 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 23.4 p90 -130.61 162.33 29.59 Favored 'General case' 0 C--N 1.321 -0.643 0 C-N-CA 120.614 -0.434 . . . . 0.0 111.007 -178.023 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . 0.569 ' OG ' ' HB ' ' A' ' 42' ' ' VAL . 4.2 m -143.73 145.41 32.39 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.768 -179.126 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 76.7 mt -116.17 111.17 34.29 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.116 177.988 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . 0.431 HH11 ' HD2' ' A' ' 97' ' ' ARG . 12.9 ttp180 59.17 73.49 0.68 Allowed Pre-proline 0 N--CA 1.466 0.349 0 CA-C-N 115.701 -0.681 . . . . 0.0 111.331 -177.548 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_endo -88.2 134.8 3.08 Favored 'Trans proline' 0 N--CA 1.455 -0.749 0 C-N-CA 122.826 2.35 . . . . 0.0 111.917 176.953 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.525 ' HG2' HD11 ' A' ' 102' ' ' ILE . 2.9 Cg_endo -47.48 142.49 13.09 Favored 'Trans proline' 0 C--N 1.35 0.606 0 C-N-CA 123.422 2.748 . . . . 0.0 112.807 175.659 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.813 ' HA ' ' CE1' ' A' ' 103' ' ' HIS . . . -75.09 42.84 0.19 Allowed 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.848 -0.615 . . . . 0.0 112.46 -176.168 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' GLU . . . . . 0.449 ' HG3' HG23 ' A' ' 102' ' ' ILE . 10.0 pt-20 -135.6 -24.56 1.35 Allowed 'General case' 0 C--N 1.326 -0.423 0 N-CA-C 112.325 0.491 . . . . 0.0 112.325 177.425 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.525 HD11 ' HG2' ' A' ' 99' ' ' PRO . 6.5 pt -114.55 3.55 7.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 N-CA-C 112.848 0.685 . . . . 0.0 112.848 -172.521 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 103' ' ' HIS . . . . . 0.813 ' CE1' ' HA ' ' A' ' 100' ' ' ALA . 35.7 m80 -47.12 -56.49 6.49 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 112.156 0.428 . . . . 0.0 112.156 179.731 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 40.1 t -66.29 -26.1 67.17 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.069 0.462 . . . . 0.0 110.771 -179.794 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.427 ' O ' HG23 ' A' ' 109' ' ' VAL . 14.2 m -67.86 -33.3 74.49 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.109 179.446 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.421 HD22 HG21 ' A' ' 42' ' ' VAL . 82.0 mt -72.13 -38.37 69.25 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.954 178.448 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 107' ' ' MET . . . . . 0.547 ' HA ' HD22 ' A' ' 117' ' ' LEU . 53.6 ttm -59.18 -43.34 92.15 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.186 -178.991 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 27.3 ptt85 -66.59 -31.58 72.37 Favored 'General case' 0 C--N 1.331 -0.207 0 C-N-CA 120.88 -0.328 . . . . 0.0 110.532 -177.704 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.427 HG23 ' O ' ' A' ' 105' ' ' SER . 94.0 t -68.94 -46.86 78.37 Favored 'Isoleucine or valine' 0 C--O 1.234 0.243 0 CA-C-N 116.549 -0.296 . . . . 0.0 110.47 179.88 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -58.74 -43.83 90.34 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.512 177.872 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.499 ' HA ' ' HB1' ' A' ' 148' ' ' ALA . 22.5 t70 -65.29 -39.94 93.21 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.012 179.629 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -66.92 -42.94 84.55 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.835 -0.621 . . . . 0.0 111.879 -178.253 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 25.8 m -87.15 -24.41 6.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 120.894 0.378 . . . . 0.0 111.486 -177.393 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 91.11 44.29 4.46 Favored Glycine 0 N--CA 1.449 -0.462 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.27 178.203 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -124.37 156.56 36.85 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 120.723 0.296 . . . . 0.0 110.834 -177.995 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 116' ' ' ARG . . . . . 0.484 ' HD3' ' OE1' ' A' ' 145' ' ' GLU . 14.3 ttm180 -78.57 127.28 31.91 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 177.015 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . 0.576 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 51.1 tp -95.89 121.93 38.14 Favored 'General case' 0 C--N 1.322 -0.589 0 N-CA-C 109.892 -0.411 . . . . 0.0 109.892 -179.946 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . 0.448 HD12 HG12 ' A' ' 29' ' ' ILE . 69.3 mt -119.77 112.69 38.07 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-O 121.023 0.439 . . . . 0.0 110.617 178.729 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 50.6 mt -111.61 121.18 63.66 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.797 0 CA-C-O 120.919 0.39 . . . . 0.0 110.32 178.94 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 63.6 tttp -111.11 103.31 54.72 Favored Pre-proline 0 C--N 1.32 -0.699 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.489 174.878 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 93.0 Cg_endo -82.9 -166.86 0.41 Allowed 'Trans proline' 0 N--CA 1.455 -0.773 0 C-N-CA 122.591 2.194 . . . . 0.0 110.829 171.185 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 7.1 mp -88.81 166.92 13.69 Favored 'General case' 0 C--N 1.319 -0.72 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 177.103 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 4.7 t -68.61 -9.39 49.5 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.153 0.501 . . . . 0.0 111.219 -177.68 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -117.49 24.7 8.99 Favored Glycine 0 N--CA 1.446 -0.676 0 N-CA-C 111.587 -0.605 . . . . 0.0 111.587 175.5 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 26.9 mm-40 -129.38 172.75 11.19 Favored 'General case' 0 N--CA 1.45 -0.46 0 CA-C-O 121.209 0.528 . . . . 0.0 110.754 -176.774 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 8.4 t70 -143.79 -170.82 3.4 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-N 115.05 -0.977 . . . . 0.0 108.58 175.358 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.602 HD11 ' HB2' ' A' ' 144' ' ' TYR . 18.3 mt -110.42 -22.61 4.91 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.764 0 CA-C-O 120.667 0.27 . . . . 0.0 110.337 179.49 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 17.4 m 46.77 24.88 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.038 0 C-N-CA 124.218 1.007 . . . . 0.0 113.044 179.401 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . 0.437 ' O ' ' HB3' ' A' ' 130' ' ' GLU . 15.1 t -94.94 30.68 2.04 Favored 'General case' 0 C--O 1.237 0.401 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.022 179.032 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 130' ' ' GLU . . . . . 0.437 ' HB3' ' O ' ' A' ' 129' ' ' THR . 8.4 tp10 75.94 153.6 0.14 Allowed 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 115.145 -0.934 . . . . 0.0 109.758 -171.363 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 131' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -79.55 40.58 0.45 Allowed 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 120.992 0.425 . . . . 0.0 111.255 -175.139 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 28.7 mtpp -89.87 -10.2 46.17 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.399 -178.01 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 133' ' ' MET . . . . . 0.4 ' HG2' ' HB2' ' A' ' 146' ' ' TYR . 88.9 mtp -98.77 151.51 20.71 Favored 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 178.405 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 16.2 ptmt -100.42 134.62 43.1 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 121.222 0.534 . . . . 0.0 111.353 -174.795 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . 0.488 HD11 ' HD2' ' A' ' 142' ' ' TYR . 54.6 tp -78.58 126.7 31.11 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.334 -0.848 . . . . 0.0 110.154 177.438 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -123.43 135.12 64.32 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.712 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.909 179.869 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 137' ' ' ASN . . . . . 0.512 ' ND2' ' HB3' ' A' ' 142' ' ' TYR . 14.5 m120 -111.52 112.35 24.02 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.662 -0.699 . . . . 0.0 109.442 178.217 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . 0.481 ' CD2' ' HB2' ' A' ' 28' ' ' TYR . 61.1 t80 -144.73 128.77 17.55 Favored 'General case' 0 C--N 1.318 -0.773 0 N-CA-C 110.348 -0.241 . . . . 0.0 110.348 -178.001 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . 0.494 ' HA3' ' HB3' ' A' ' 24' ' ' ASP . . . 68.79 35.94 81.08 Favored Glycine 0 N--CA 1.447 -0.61 0 C-N-CA 120.944 -0.646 . . . . 0.0 112.907 176.169 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 140' ' ' ARG . . . . . 0.411 ' HB2' ' O ' ' A' ' 139' ' ' GLY . 69.0 mtt85 72.97 4.51 4.98 Favored 'General case' 0 N--CA 1.463 0.223 0 C-N-CA 122.772 0.429 . . . . 0.0 112.081 175.723 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 141' ' ' THR . . . . . 0.741 ' HB ' ' HB2' ' A' ' 21' ' ' MET . 14.9 t -124.57 154.09 41.15 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 176.296 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 142' ' ' TYR . . . . . 0.512 ' HB3' ' ND2' ' A' ' 137' ' ' ASN . 45.4 p90 -123.21 147.81 46.49 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-O 121.162 0.506 . . . . 0.0 110.653 178.539 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 14.0 p90 -154.01 179.59 8.77 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-N 115.064 -0.971 . . . . 0.0 109.056 -177.676 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 144' ' ' TYR . . . . . 0.602 ' HB2' HD11 ' A' ' 127' ' ' ILE . 97.3 m-85 -115.79 127.79 55.35 Favored 'General case' 0 C--N 1.32 -0.709 0 N-CA-C 110.19 -0.3 . . . . 0.0 110.19 179.452 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 145' ' ' GLU . . . . . 0.484 ' OE1' ' HD3' ' A' ' 116' ' ' ARG . 18.2 pt-20 -115.48 161.75 18.14 Favored 'General case' 0 C--N 1.32 -0.691 0 N-CA-C 109.715 -0.476 . . . . 0.0 109.715 176.1 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . 0.463 ' HB3' ' HB3' ' A' ' 117' ' ' LEU . 51.0 t80 -141.33 126.9 18.91 Favored 'General case' 0 C--N 1.313 -0.997 0 CA-C-N 115.604 -0.725 . . . . 0.0 109.741 177.532 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 147' ' ' ILE . . . . . . . . . . . . . 3.1 mp -95.57 109.33 22.38 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.81 0 N-CA-C 109.585 -0.524 . . . . 0.0 109.585 -179.249 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . 0.499 ' HB1' ' HA ' ' A' ' 111' ' ' ASP . . . -63.0 111.24 2.08 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 109.392 -0.596 . . . . 0.0 109.392 175.114 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 -64.37 154.37 35.67 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 121.859 0.838 . . . . 0.0 111.946 -173.756 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 40.7 t -108.46 149.24 11.86 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.957 0 CA-C-N 114.77 -1.105 . . . . 0.0 108.94 179.978 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 151' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -58.01 145.65 35.42 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.667 0.27 . . . . 0.0 110.623 178.162 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 3.7 m -62.33 110.55 1.68 Allowed 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.845 -0.616 . . . . 0.0 109.853 179.477 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 10.1 ptm180 . . . . . 0 C--O 1.248 0.974 0 CA-C-O 118.133 -0.937 . . . . 0.0 110.63 -177.254 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 22.0 mmt . . . . . 0 N--CA 1.479 0.997 0 CA-C-O 120.757 0.313 . . . . 0.0 110.326 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 127.0 141.05 5.32 Favored Glycine 0 N--CA 1.445 -0.759 0 C-N-CA 120.827 -0.702 . . . . 0.0 111.815 -179.714 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 16.1 m -140.46 108.79 5.82 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 120.699 0.285 . . . . 0.0 110.313 179.838 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 33.1 m -76.44 113.98 14.64 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.386 179.322 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 2.0 p80 -111.57 101.78 10.16 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 121.555 0.693 . . . . 0.0 109.872 179.165 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . 0.464 ' HB3' ' CD2' ' A' ' 8' ' ' HIS . 60.7 m80 -91.97 100.93 13.49 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.578 -0.737 . . . . 0.0 110.717 -176.025 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 62.4 m-70 -89.31 100.57 13.33 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 116.127 -0.488 . . . . 0.0 109.993 177.632 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . 0.464 ' CD2' ' HB3' ' A' ' 6' ' ' HIS . 97.2 m-70 -131.55 98.03 4.39 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.723 -179.886 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 56.6 t-80 -99.53 98.96 9.79 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 109.091 -0.707 . . . . 0.0 109.091 173.588 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 40.3 m80 -76.43 94.64 3.69 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.927 -0.578 . . . . 0.0 110.528 -177.815 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 19.5 m -86.3 44.33 1.13 Allowed 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.454 -0.794 . . . . 0.0 110.265 -179.716 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 22.6 t -109.07 118.34 36.52 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.732 -0.667 . . . . 0.0 109.755 -178.62 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -78.69 87.46 1.14 Allowed Glycine 0 N--CA 1.448 -0.56 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.581 -177.771 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . 0.758 ' H ' HD23 ' A' ' 14' ' ' LEU . 2.4 pt? -81.64 147.33 29.61 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 110.067 -0.346 . . . . 0.0 110.067 176.203 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 7.2 p -89.98 125.16 61.51 Favored Pre-proline 0 C--N 1.325 -0.469 0 CA-C-O 120.999 0.428 . . . . 0.0 110.272 -179.376 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -81.81 -178.89 4.44 Favored 'Trans proline' 0 N--CA 1.46 -0.468 0 C-N-CA 122.749 2.3 . . . . 0.0 112.993 -177.731 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 27.3 mmt180 -92.59 173.9 7.55 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.813 -0.631 . . . . 0.0 110.465 178.464 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -62.59 135.19 44.55 Favored Glycine 0 N--CA 1.448 -0.54 0 C-N-CA 121.191 -0.528 . . . . 0.0 112.016 178.188 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 48.9 m -74.52 78.99 1.94 Allowed 'General case' 0 C--N 1.323 -0.587 0 CA-C-O 121.275 0.56 . . . . 0.0 111.34 -178.751 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 43.1 m80 -131.62 -26.83 1.98 Allowed 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.467 -0.788 . . . . 0.0 109.698 173.236 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' MET . . . . . . . . . . . . . 25.4 ptm -69.25 -15.81 63.45 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.324 -0.853 . . . . 0.0 111.12 178.824 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' TRP . . . . . 0.584 ' HB3' HG22 ' A' ' 50' ' ' VAL . 83.1 m95 -80.71 -19.51 44.92 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.385 -176.142 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.496 ' O ' HG23 ' A' ' 27' ' ' VAL . 2.1 m-20 -60.8 -48.79 80.22 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.811 -172.605 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -60.89 -39.55 89.7 Favored 'General case' 0 N--CA 1.468 0.44 0 CA-C-O 120.735 0.302 . . . . 0.0 111.477 -179.08 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.769 HD22 ' HD2' ' A' ' 120' ' ' LYS . 54.0 tp -58.08 -50.8 72.2 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.458 177.574 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . 0.468 ' O ' HG13 ' A' ' 30' ' ' ILE . . . -59.46 -46.38 88.95 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.618 -0.719 . . . . 0.0 111.18 -179.029 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.592 ' HA ' HD12 ' A' ' 30' ' ' ILE . 87.5 t -55.64 -44.29 76.25 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.915 179.912 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 72.7 t80 -59.8 -46.19 89.98 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.584 179.003 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.53 HG23 HD22 ' A' ' 92' ' ' LEU . 75.9 mt -59.69 -43.02 90.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.47 178.246 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.811 HG12 HG23 ' A' ' 54' ' ' ILE . 82.2 mt -59.05 -47.08 91.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 115.642 -0.708 . . . . 0.0 111.78 -179.622 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . 0.522 ' HG3' ' O ' ' A' ' 27' ' ' VAL . 35.6 mtp180 -73.44 -22.6 60.16 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 121.03 0.443 . . . . 0.0 111.02 -174.156 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 69.5 m -88.59 -8.92 53.89 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.262 -179.563 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 13.5 p -112.88 -70.01 0.83 Allowed 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.76 0.314 . . . . 0.0 111.154 -178.943 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 93.49 166.12 37.73 Favored Glycine 0 N--CA 1.449 -0.492 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.277 179.793 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 69.8 Cg_endo -75.99 156.31 38.62 Favored 'Trans proline' 0 CA--C 1.532 0.376 0 C-N-CA 122.7 2.267 . . . . 0.0 112.597 -179.831 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 84.07 39.3 9.39 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.888 178.491 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 12.5 t -164.4 -170.19 1.99 Allowed 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 177.8 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . 0.431 ' HA ' ' O ' ' A' ' 61' ' ' ASP . 49.0 mtm180 -119.3 136.23 54.34 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.945 0.402 . . . . 0.0 110.882 179.789 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.683 HG23 HG21 ' A' ' 60' ' ' VAL . 91.6 t -119.76 113.16 39.89 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 N-CA-C 109.034 -0.728 . . . . 0.0 109.034 173.806 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.587 ' O ' ' HA ' ' A' ' 93' ' ' ILE . 46.9 t -97.12 134.23 35.68 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.853 0 CA-C-O 120.931 0.396 . . . . 0.0 110.916 -175.703 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . 0.467 ' HA ' ' O ' ' A' ' 94' ' ' TYR . 0.4 OUTLIER -114.6 157.18 23.41 Favored 'General case' 0 C--N 1.318 -0.793 0 N-CA-C 109.036 -0.728 . . . . 0.0 109.036 173.521 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.559 ' HB ' ' HB3' ' A' ' 95' ' ' SER . 54.7 t -124.76 112.34 31.6 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.733 0 CA-C-N 116.512 -0.313 . . . . 0.0 110.954 178.334 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 112.3 32.82 2.26 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.665 -0.778 . . . . 0.0 113.602 173.74 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -50.44 -58.64 5.27 Favored 'General case' 0 N--CA 1.466 0.345 0 N-CA-C 112.378 0.51 . . . . 0.0 112.378 -178.24 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 63.66 -108.14 2.07 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 121.052 -0.594 . . . . 0.0 112.677 179.519 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 16.7 ptt180 -127.11 5.71 6.47 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.678 0.275 . . . . 0.0 111.333 -179.58 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.525 ' HE2' HG13 ' A' ' 96' ' ' ILE . 14.4 p90 -112.46 90.99 3.49 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.959 0.885 . . . . 0.0 110.496 179.186 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.447 HD22 HD13 ' A' ' 64' ' ' LEU . 74.6 mt -102.07 16.45 26.03 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.217 -0.901 . . . . 0.0 110.629 -175.877 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 78.0 t80 -60.69 -50.07 74.96 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.368 -0.378 . . . . 0.0 111.322 -177.054 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.584 HG22 ' HB3' ' A' ' 22' ' ' TRP . 59.6 t -62.38 -48.76 86.83 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-O 121.039 0.447 . . . . 0.0 110.726 -178.981 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . 0.429 ' CB ' HD21 ' A' ' 64' ' ' LEU . 0.0 OUTLIER -63.98 -45.63 88.2 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.622 -177.166 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.626 ' O ' ' HG3' ' A' ' 56' ' ' LYS . 26.4 t70 -70.88 -30.32 66.65 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 120.641 0.258 . . . . 0.0 110.662 -179.042 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 45.4 t80 -61.73 -42.48 99.02 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.06 0.457 . . . . 0.0 109.961 175.97 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.811 HG23 HG12 ' A' ' 30' ' ' ILE . 80.5 mt -63.61 -48.01 88.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 115.815 -0.63 . . . . 0.0 111.437 -179.883 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . 0.601 ' HG2' ' HA ' ' A' ' 52' ' ' ASP . 0.1 OUTLIER -69.51 -18.88 63.72 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 111.898 0.333 . . . . 0.0 111.898 -177.149 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . 0.626 ' HG3' ' O ' ' A' ' 52' ' ' ASP . 56.7 mttm -67.57 -37.79 83.15 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.115 0.483 . . . . 0.0 110.575 176.084 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . 0.505 ' CD2' HG21 ' A' ' 30' ' ' ILE . 16.8 t60 -101.72 -39.42 7.44 Favored 'General case' 0 N--CA 1.444 -0.746 0 CA-C-N 115.879 -0.6 . . . . 0.0 111.034 -172.111 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . 0.591 ' HB2' HG23 ' A' ' 30' ' ' ILE . 8.8 t -109.78 139.58 44.68 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.75 0.31 . . . . 0.0 110.393 -177.379 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 14.4 mmmm -91.35 59.99 4.04 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 121.85 0.833 . . . . 0.0 109.981 177.184 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.683 HG21 HG23 ' A' ' 39' ' ' VAL . 13.6 p -110.72 145.05 17.57 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.814 0 CA-C-N 114.817 -1.083 . . . . 0.0 110.098 177.38 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . 0.431 ' O ' ' HA ' ' A' ' 38' ' ' ARG . 21.6 t70 -78.79 101.63 7.71 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.062 0.458 . . . . 0.0 109.897 178.656 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . 0.413 ' HA ' ' O ' ' A' ' 39' ' ' VAL . 3.6 tt -91.93 119.02 31.3 Favored 'General case' 0 C--N 1.315 -0.925 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 -178.864 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.417 HG11 ' CG2' ' A' ' 86' ' ' ILE . 47.1 t -96.62 119.16 44.31 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-N 115.605 -0.725 . . . . 0.0 110.503 -176.822 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . 0.623 ' HB2' ' HA ' ' A' ' 74' ' ' ILE . 51.1 mt -94.39 138.34 32.46 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.553 -0.749 . . . . 0.0 109.722 179.629 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.508 ' OG1' ' HA ' ' A' ' 42' ' ' VAL . 70.2 p -128.56 130.7 47.78 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 120.875 0.369 . . . . 0.0 110.759 178.141 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 31.3 t70 -160.78 146.42 14.65 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.165 -0.47 . . . . 0.0 109.823 179.172 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.744 HD11 HG22 ' A' ' 79' ' ' ILE . 50.6 mt -75.85 106.42 5.67 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-O 121.111 0.482 . . . . 0.0 110.662 179.526 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' LYS . . . . . 0.431 ' N ' ' HD3' ' A' ' 69' ' ' PRO . 45.6 mtmt 65.73 65.47 0.87 Allowed Pre-proline 0 CA--C 1.533 0.307 0 CA-C-N 115.197 -0.911 . . . . 0.0 111.814 177.723 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . 0.984 ' HD2' ' HG3' ' A' ' 76' ' ' ARG . 2.6 Cg_exo -76.69 149.42 30.02 Favored 'Trans proline' 0 C--O 1.234 0.324 0 C-N-CA 122.976 2.45 . . . . 0.0 111.739 177.055 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 25.3 m -100.45 -1.48 35.71 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.422 -0.354 . . . . 0.0 111.248 -178.173 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 84.5 t60 -117.66 121.35 40.66 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.493 -0.321 . . . . 0.0 110.97 -175.413 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -58.24 124.89 37.8 Favored Glycine 0 N--CA 1.45 -0.431 0 CA-C-N 115.919 -0.582 . . . . 0.0 111.759 175.049 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 128.86 -24.82 4.77 Favored Glycine 0 N--CA 1.446 -0.665 0 N-CA-C 110.752 -0.939 . . . . 0.0 110.752 -174.377 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.623 ' HA ' ' HB2' ' A' ' 64' ' ' LEU . 35.5 mt -95.7 135.81 28.63 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 N-CA-C 108.892 -0.781 . . . . 0.0 108.892 174.145 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.413 HG11 HD13 ' A' ' 86' ' ' ILE . 98.7 t -78.84 136.39 23.91 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.715 0 CA-C-O 121.437 0.637 . . . . 0.0 110.178 -179.16 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' ARG . . . . . 0.984 ' HG3' ' HD2' ' A' ' 69' ' ' PRO . 1.3 mpp_? -90.83 34.17 0.92 Allowed 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 115.032 -0.985 . . . . 0.0 110.841 -173.0 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 22.6 t0 -89.86 136.94 32.74 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.082 -0.71 . . . . 0.0 109.082 177.888 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 7.0 p-10 -95.85 153.05 17.95 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-O 121.166 0.508 . . . . 0.0 111.353 -172.043 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . 0.744 HG22 HD11 ' A' ' 67' ' ' ILE . 10.4 tp -71.36 -27.09 27.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 115.648 -0.705 . . . . 0.0 112.478 -170.873 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 14.3 t -89.19 6.34 40.57 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.34 0.591 . . . . 0.0 110.326 -179.11 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 32.8 t -152.29 58.5 2.59 Favored Pre-proline 0 C--N 1.325 -0.495 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.909 174.428 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.487 ' HB2' ' HE2' ' A' ' 87' ' ' TYR . 65.4 Cg_endo -74.99 131.13 13.95 Favored 'Trans proline' 0 C--O 1.238 0.503 0 C-N-CA 122.192 1.928 . . . . 0.0 112.092 -175.105 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' ARG . . . . . 0.607 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 37.1 mtp85 -85.51 120.52 27.05 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.141 0.496 . . . . 0.0 111.063 -179.12 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' MET . . . . . 0.506 ' O ' ' HG3' ' A' ' 88' ' ' ARG . 96.1 mmm -62.5 -21.4 65.47 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.415 -0.811 . . . . 0.0 110.516 179.699 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.607 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 11.1 pt-20 -66.29 -21.62 66.27 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-O 121.195 0.522 . . . . 0.0 110.799 -178.834 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.417 ' CG2' HG11 ' A' ' 63' ' ' VAL . 66.5 mt -85.85 -31.2 6.5 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.497 -179.41 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . 0.487 ' HE2' ' HB2' ' A' ' 82' ' ' PRO . 79.9 m-85 -88.96 -26.06 21.72 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.432 -176.578 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . 0.583 ' HG2' HG12 ' A' ' 113' ' ' VAL . 81.8 mtp180 -71.97 143.82 49.09 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 121.142 0.496 . . . . 0.0 111.041 -178.912 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 80.54 11.2 84.37 Favored Glycine 0 C--N 1.319 -0.414 0 CA-C-N 115.274 -0.875 . . . . 0.0 112.042 -178.606 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -96.0 154.92 16.98 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.847 0.355 . . . . 0.0 110.355 178.627 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -98.34 -23.65 15.54 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 116.108 -0.497 . . . . 0.0 111.025 179.928 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . 0.53 HD22 HG23 ' A' ' 29' ' ' ILE . 4.1 tt -156.99 145.11 19.4 Favored 'General case' 0 N--CA 1.452 -0.373 0 CA-C-O 120.873 0.368 . . . . 0.0 110.81 -177.33 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.587 ' HA ' ' O ' ' A' ' 40' ' ' VAL . 61.6 mt -132.77 131.04 59.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 N-CA-C 109.031 -0.729 . . . . 0.0 109.031 178.193 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' TYR . . . . . 0.467 ' O ' ' HA ' ' A' ' 41' ' ' GLU . 32.4 p90 -139.68 155.74 47.21 Favored 'General case' 0 C--N 1.326 -0.414 0 C-N-CA 120.709 -0.396 . . . . 0.0 110.644 -179.508 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . 0.559 ' HB3' ' HB ' ' A' ' 42' ' ' VAL . 10.2 p -142.48 148.16 37.24 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-O 120.748 0.309 . . . . 0.0 111.095 -176.964 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' ILE . . . . . 0.525 HG13 ' HE2' ' A' ' 47' ' ' PHE . 38.2 mm -99.03 92.82 2.83 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.585 -179.744 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . 0.589 ' NH2' ' HA ' ' A' ' 122' ' ' LEU . 98.8 mtt180 54.08 76.51 0.51 Allowed Pre-proline 0 N--CA 1.468 0.446 0 CA-C-N 115.7 -0.682 . . . . 0.0 112.429 177.995 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 98.9 Cg_endo -80.7 157.4 21.48 Favored 'Trans proline' 0 N--CA 1.46 -0.47 0 C-N-CA 122.539 2.159 . . . . 0.0 112.259 179.1 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.784 ' HD2' HD11 ' A' ' 102' ' ' ILE . 32.4 Cg_exo -57.44 142.19 95.14 Favored 'Trans proline' 0 C--N 1.345 0.394 0 C-N-CA 122.817 2.345 . . . . 0.0 111.683 174.604 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.56 ' HA ' ' NE2' ' A' ' 103' ' ' HIS . . . -63.03 -22.84 67.14 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.329 -0.396 . . . . 0.0 112.035 -175.784 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 101' ' ' GLU . . . . . 0.423 ' HG3' HG23 ' A' ' 102' ' ' ILE . 12.4 pt-20 -74.86 -10.65 59.7 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 112.072 0.397 . . . . 0.0 112.072 -176.703 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.784 HD11 ' HD2' ' A' ' 99' ' ' PRO . 45.6 pt -120.62 8.92 6.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 N-CA-C 112.502 0.556 . . . . 0.0 112.502 -177.776 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 103' ' ' HIS . . . . . 0.56 ' NE2' ' HA ' ' A' ' 100' ' ' ALA . 5.3 m-70 -53.98 -51.2 64.64 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-O 121.053 0.454 . . . . 0.0 110.902 178.04 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 41.1 t -68.25 -28.43 67.21 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.351 -179.743 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.539 ' O ' HG23 ' A' ' 109' ' ' VAL . 29.9 t -68.88 -45.52 70.76 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.962 -0.563 . . . . 0.0 109.908 -179.69 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 72.0 mt -64.37 -40.3 95.57 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.389 -0.369 . . . . 0.0 111.03 178.793 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 107' ' ' MET . . . . . 0.41 ' HG3' ' O ' ' A' ' 103' ' ' HIS . 66.3 mtp -65.54 -42.48 91.9 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.25 -179.667 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 108' ' ' ARG . . . . . 0.529 ' HG2' ' O ' ' A' ' 105' ' ' SER . 8.0 ptm180 -67.93 -31.87 71.92 Favored 'General case' 0 N--CA 1.462 0.154 0 C-N-CA 120.942 -0.303 . . . . 0.0 110.858 -178.847 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.539 HG23 ' O ' ' A' ' 105' ' ' SER . 76.1 t -66.54 -46.65 85.78 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.193 0 CA-C-O 120.71 0.29 . . . . 0.0 110.279 176.798 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -57.34 -45.84 83.89 Favored 'General case' 0 CA--C 1.514 -0.406 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.123 177.419 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.834 ' HA ' ' HB1' ' A' ' 148' ' ' ALA . 5.0 t70 -66.46 -34.09 77.16 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.668 -177.497 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -70.24 -36.29 74.4 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.94 -179.659 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.583 HG12 ' HG2' ' A' ' 88' ' ' ARG . 18.7 m -93.53 -25.96 4.76 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 116.446 -0.343 . . . . 0.0 111.509 -178.172 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 87.97 41.47 6.29 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.863 -0.684 . . . . 0.0 112.634 178.296 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -120.02 158.69 26.27 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.854 0.359 . . . . 0.0 110.918 -178.471 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 116' ' ' ARG . . . . . 0.486 ' HD3' ' OE1' ' A' ' 145' ' ' GLU . 13.2 ttm180 -78.77 123.87 27.62 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 178.434 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . 0.564 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 52.0 tp -97.0 123.11 40.63 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.141 179.123 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . 0.438 HD12 HG12 ' A' ' 29' ' ' ILE . 53.6 mt -118.39 128.78 75.34 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 CA-C-O 120.976 0.417 . . . . 0.0 110.572 179.437 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 66.0 mt -128.04 134.58 64.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.36 -179.813 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 120' ' ' LYS . . . . . 0.769 ' HD2' HD22 ' A' ' 25' ' ' LEU . 10.4 mttm -113.43 104.25 55.47 Favored Pre-proline 0 C--N 1.324 -0.516 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.481 173.163 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 121' ' ' PRO . . . . . 0.433 ' HB2' ' H ' ' A' ' 122' ' ' LEU . 58.5 Cg_endo -72.28 -146.47 0.02 OUTLIER 'Trans proline' 0 CA--C 1.535 0.547 0 C-N-CA 123.208 2.605 . . . . 0.0 112.758 176.971 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 122' ' ' LEU . . . . . 0.727 ' HB2' ' HB3' ' A' ' 125' ' ' GLU . 7.1 mp -87.59 -176.24 5.49 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.433 -0.349 . . . . 0.0 111.18 -175.884 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 21.7 m -61.23 -39.36 89.99 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.965 -0.562 . . . . 0.0 111.878 -177.533 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -145.14 42.05 1.02 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.996 -0.621 . . . . 0.0 111.602 178.477 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . 0.727 ' HB3' ' HB2' ' A' ' 122' ' ' LEU . 5.6 tp10 -131.98 136.17 47.1 Favored 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 -176.268 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 21.1 t70 -76.49 -179.31 5.13 Favored 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 109.838 -0.431 . . . . 0.0 109.838 178.373 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.474 ' HB ' HG22 ' A' ' 129' ' ' THR . 9.3 mt -84.59 7.25 1.82 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 N-CA-C 109.17 -0.678 . . . . 0.0 109.17 177.616 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.4 HG22 ' O ' ' A' ' 127' ' ' ILE . 15.2 m 51.58 27.98 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 C-N-CA 124.802 1.241 . . . . 0.0 112.225 178.394 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . 0.675 HG23 ' H ' ' A' ' 131' ' ' ARG . 9.9 t -105.49 178.58 4.52 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 115.295 -0.866 . . . . 0.0 109.073 176.996 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 29.9 mt-10 -80.27 7.51 9.34 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.317 0.58 . . . . 0.0 110.131 178.741 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 131' ' ' ARG . . . . . 0.675 ' H ' HG23 ' A' ' 129' ' ' THR . 25.0 mtp180 60.19 75.63 0.4 Allowed 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 114.648 -1.16 . . . . 0.0 112.392 170.008 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 23.2 mmmt -92.77 -1.2 57.0 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.454 -0.794 . . . . 0.0 109.727 172.22 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 133' ' ' MET . . . . . 0.664 ' HG2' ' HB2' ' A' ' 146' ' ' TYR . 88.0 mtp -100.28 176.18 5.46 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.017 -0.992 . . . . 0.0 109.907 -179.543 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 14.9 ptmt -121.35 142.1 50.3 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 120.939 0.399 . . . . 0.0 110.635 -178.398 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . 0.73 HD11 ' HD2' ' A' ' 142' ' ' TYR . 50.1 tp -86.14 124.43 32.54 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.394 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 136' ' ' VAL . . . . . 0.437 HG23 ' CD1' ' A' ' 143' ' ' PHE . 0.0 OUTLIER -121.02 137.48 54.61 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.161 -179.724 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 137' ' ' ASN . . . . . 0.478 HD22 ' N ' ' A' ' 137' ' ' ASN . 0.9 OUTLIER -107.34 123.78 48.85 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 109.254 -0.647 . . . . 0.0 109.254 174.807 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 57.8 t80 -143.02 116.71 9.24 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 179.427 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 69.38 39.18 81.05 Favored Glycine 0 N--CA 1.447 -0.613 0 C-N-CA 120.575 -0.821 . . . . 0.0 111.95 -177.755 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 140' ' ' ARG . . . . . 0.442 HH11 ' HD3' ' A' ' 140' ' ' ARG . 22.8 ttp-105 73.24 -21.08 0.26 Allowed 'General case' 0 CA--C 1.531 0.229 0 C-N-CA 123.665 0.786 . . . . 0.0 112.561 177.802 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 6.5 t -92.15 141.71 28.29 Favored 'General case' 0 C--N 1.323 -0.562 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 177.355 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 142' ' ' TYR . . . . . 0.73 ' HD2' HD11 ' A' ' 135' ' ' LEU . 44.4 p90 -110.27 152.43 26.16 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.076 0.465 . . . . 0.0 110.917 -178.742 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 143' ' ' PHE . . . . . 0.492 ' HB3' ' HG3' ' A' ' 120' ' ' LYS . 5.4 p90 -157.7 176.22 12.88 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.837 178.632 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 73.6 m-85 -111.03 132.02 54.57 Favored 'General case' 0 C--N 1.319 -0.745 0 C-N-CA 121.011 -0.276 . . . . 0.0 110.81 -179.54 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 145' ' ' GLU . . . . . 0.486 ' OE1' ' HD3' ' A' ' 116' ' ' ARG . 21.0 pt-20 -120.72 160.85 22.48 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 109.33 -0.619 . . . . 0.0 109.33 174.288 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . 0.664 ' HB2' ' HG2' ' A' ' 133' ' ' MET . 32.3 t80 -140.3 124.2 17.4 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-N 116.12 -0.491 . . . . 0.0 109.742 178.017 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 147' ' ' ILE . . . . . 0.426 ' N ' HD12 ' A' ' 147' ' ' ILE . 2.8 mp -91.8 100.54 11.38 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 N-CA-C 109.624 -0.51 . . . . 0.0 109.624 179.702 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . 0.834 ' HB1' ' HA ' ' A' ' 111' ' ' ASP . . . -82.57 122.02 27.55 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.446 -0.797 . . . . 0.0 109.959 177.448 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 15.5 pt-20 -78.27 163.79 25.44 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-O 120.801 0.334 . . . . 0.0 110.684 -179.419 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 42.9 t -84.03 131.74 33.19 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 N-CA-C 109.426 -0.583 . . . . 0.0 109.426 175.928 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 151' ' ' ARG . . . . . . . . . . . . . 30.5 ptt85 -72.84 149.47 43.52 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.997 -176.138 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 5.3 p -79.38 132.89 36.54 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.892 -0.594 . . . . 0.0 111.05 179.773 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 153' ' ' ARG . . . . . 0.4 ' HD3' HH11 ' A' ' 153' ' ' ARG . 53.3 mtp180 . . . . . 0 C--O 1.249 1.053 0 CA-C-O 118.282 -0.866 . . . . 0.0 109.791 176.414 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 93.8 mtp . . . . . 0 N--CA 1.481 1.084 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 98.49 139.23 10.69 Favored Glycine 0 N--CA 1.444 -0.801 0 C-N-CA 120.809 -0.71 . . . . 0.0 111.892 -179.308 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 14.9 m -76.09 103.25 6.05 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-O 121.131 0.491 . . . . 0.0 109.915 179.355 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 24.5 p -101.46 34.7 2.5 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.787 -177.303 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 48.0 m80 -72.64 92.75 1.55 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.512 178.926 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 7.8 p80 -87.63 143.09 27.36 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 177.62 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 29.4 m-70 -99.63 114.15 27.02 Favored 'General case' 0 C--N 1.316 -0.851 0 CA-C-O 120.877 0.37 . . . . 0.0 110.07 179.854 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 45.0 t-80 -75.53 111.12 10.5 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.098 -179.296 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 57.0 t-80 -87.88 108.4 19.15 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.365 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 10.2 p80 -94.91 154.29 17.28 Favored 'General case' 0 C--N 1.32 -0.712 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 172.519 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 44.7 m -66.59 95.3 0.33 Allowed 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.332 0.587 . . . . 0.0 112.316 -172.79 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 43.2 m -116.7 100.0 7.51 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.572 -0.74 . . . . 0.0 109.273 173.637 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -108.35 159.08 14.45 Favored Glycine 0 N--CA 1.446 -0.672 0 C-N-CA 120.541 -0.837 . . . . 0.0 112.608 -175.712 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -70.02 119.62 14.5 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 110.269 -0.271 . . . . 0.0 110.269 179.087 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.492 ' HA ' ' HD3' ' A' ' 16' ' ' PRO . 20.9 m -70.93 129.49 89.51 Favored Pre-proline 0 C--N 1.326 -0.435 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.506 177.638 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.492 ' HD3' ' HA ' ' A' ' 15' ' ' VAL . 16.6 Cg_exo -67.63 131.01 23.33 Favored 'Trans proline' 0 N--CA 1.463 -0.307 0 C-N-CA 122.974 2.449 . . . . 0.0 112.429 -178.296 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 27.9 mmm180 -89.72 -178.66 5.58 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.54 177.754 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -67.8 86.53 0.16 Allowed Glycine 0 C--N 1.331 0.279 0 N-CA-C 111.043 -0.823 . . . . 0.0 111.043 174.327 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 16.2 m -94.47 25.12 4.08 Favored 'General case' 0 C--N 1.323 -0.576 0 N-CA-C 111.946 0.35 . . . . 0.0 111.946 -169.608 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' HIS . . . . . 0.48 ' HA ' ' OD1' ' A' ' 23' ' ' ASN . 24.4 t-80 -62.47 -32.61 73.52 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.847 0.356 . . . . 0.0 110.324 179.474 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' MET . . . . . . . . . . . . . 23.8 ptp -63.2 -27.77 69.59 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.982 178.053 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 95.8 m95 -80.95 -19.37 44.31 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.967 0.413 . . . . 0.0 110.585 -178.535 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.48 ' OD1' ' HA ' ' A' ' 20' ' ' HIS . 12.3 m120 -62.74 -45.82 90.94 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.813 -178.172 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 13.0 m-20 -62.85 -41.12 99.23 Favored 'General case' 0 N--CA 1.464 0.256 0 CA-C-O 120.549 0.214 . . . . 0.0 110.897 178.418 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 58.3 tp -57.43 -48.03 80.23 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 121.021 0.438 . . . . 0.0 109.993 176.423 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . 0.485 ' O ' HG13 ' A' ' 30' ' ' ILE . . . -60.82 -46.78 89.22 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.954 178.225 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.504 ' HA ' HD12 ' A' ' 30' ' ' ILE . 53.1 t -56.96 -41.62 77.31 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.199 0 CA-C-N 116.559 -0.291 . . . . 0.0 111.234 179.842 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 61.1 t80 -58.44 -42.79 88.13 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.081 0.467 . . . . 0.0 110.35 178.174 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 66.5 mt -70.2 -40.92 78.67 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.489 178.732 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.741 HG12 HG23 ' A' ' 54' ' ' ILE . 97.0 mt -57.45 -44.63 84.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 115.4 -0.818 . . . . 0.0 111.068 178.838 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . 0.408 ' HG3' ' O ' ' A' ' 27' ' ' VAL . 73.4 mtp180 -65.95 -28.99 69.33 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.035 -0.529 . . . . 0.0 111.614 -178.237 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 46.0 t -88.7 -20.59 24.65 Favored 'General case' 0 C--N 1.324 -0.514 0 C-N-CA 121.104 -0.238 . . . . 0.0 111.496 -176.034 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 12.6 p -100.7 -78.99 0.51 Allowed 'General case' 0 C--N 1.327 -0.398 0 C-N-CA 121.172 -0.211 . . . . 0.0 111.537 -177.386 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 106.27 164.3 22.85 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.986 -0.626 . . . . 0.0 112.267 -179.801 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 8.6 Cg_exo -71.88 144.57 43.59 Favored 'Trans proline' 0 C--O 1.234 0.296 0 C-N-CA 123.121 2.548 . . . . 0.0 112.631 -179.286 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 83.65 2.03 89.97 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 121.19 -0.528 . . . . 0.0 112.846 177.83 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 26.1 p -96.82 -172.38 2.46 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . 0.42 ' HA ' ' O ' ' A' ' 61' ' ' ASP . 20.6 mtp180 -123.92 130.66 52.96 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 110.244 -0.28 . . . . 0.0 110.244 176.764 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.543 HG23 HG21 ' A' ' 60' ' ' VAL . 83.9 t -130.09 138.53 53.75 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 178.659 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 39.8 t -111.95 121.15 63.88 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-O 120.778 0.323 . . . . 0.0 110.936 -176.275 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . 0.404 ' HB2' HD21 ' A' ' 62' ' ' LEU . 44.7 tt0 -99.99 108.64 20.89 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 176.053 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.509 ' HB ' ' OG ' ' A' ' 95' ' ' SER . 46.1 t -97.21 125.49 50.26 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.058 -178.681 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 100.65 20.59 14.39 Favored Glycine 0 N--CA 1.447 -0.605 0 C-N-CA 120.483 -0.865 . . . . 0.0 111.804 -176.927 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.446 ' O ' HD13 ' A' ' 74' ' ' ILE . . . -79.09 78.62 5.54 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.19 0.519 . . . . 0.0 110.044 -179.091 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -94.01 -67.85 1.06 Allowed Glycine 0 N--CA 1.443 -0.836 0 CA-C-N 115.67 -0.696 . . . . 0.0 112.907 -178.445 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 61.3 mtt85 -113.66 -45.91 3.08 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 111.778 0.288 . . . . 0.0 111.778 -174.524 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 13.3 p90 -89.1 97.83 11.42 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.549 0.69 . . . . 0.0 111.048 -177.483 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.531 HD22 HD13 ' A' ' 64' ' ' LEU . 79.9 mt -100.0 28.61 4.72 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.533 -0.758 . . . . 0.0 110.277 -179.957 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 74.2 t80 -72.52 -44.89 61.58 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.338 -175.29 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.429 ' O ' HG13 ' A' ' 54' ' ' ILE . 40.9 t -62.05 -55.56 23.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.727 0.299 . . . . 0.0 110.649 -175.459 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . 0.415 ' CB ' HD21 ' A' ' 64' ' ' LEU . 1.6 p -54.74 -46.82 74.32 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.802 -0.636 . . . . 0.0 112.074 179.396 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.689 ' O ' ' HG2' ' A' ' 56' ' ' LYS . 33.7 t70 -68.95 -31.11 69.75 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.651 0.262 . . . . 0.0 111.127 -177.966 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 77.4 t80 -71.59 -37.11 71.02 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 120.869 0.366 . . . . 0.0 110.756 179.833 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.741 HG23 HG12 ' A' ' 30' ' ' ILE . 88.3 mt -63.73 -44.54 98.37 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-N 116.48 -0.327 . . . . 0.0 111.098 -179.559 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . 0.414 ' HA ' ' O ' ' A' ' 58' ' ' SER . 4.9 ptm180 -68.38 -15.56 63.6 Favored 'General case' 0 CA--C 1.533 0.319 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.321 -178.758 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . 0.689 ' HG2' ' O ' ' A' ' 52' ' ' ASP . 32.2 mmmt -73.77 -34.77 64.83 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.989 0.423 . . . . 0.0 110.779 177.183 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 56.7 m-70 -93.2 -47.11 7.1 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.395 -178.622 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . 0.414 ' O ' ' HA ' ' A' ' 55' ' ' ARG . 67.2 m -121.55 135.19 55.03 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.381 179.546 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 29.3 mmmt -80.08 57.78 2.78 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.707 0.765 . . . . 0.0 110.435 -179.641 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.543 HG21 HG23 ' A' ' 39' ' ' VAL . 3.6 p -85.57 146.05 7.06 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 CA-C-N 114.89 -1.05 . . . . 0.0 109.859 176.705 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . 0.42 ' O ' ' HA ' ' A' ' 38' ' ' ARG . 30.4 t70 -84.72 100.27 11.38 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 177.314 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . 0.404 HD21 ' HB2' ' A' ' 41' ' ' GLU . 2.3 tt -99.62 129.6 45.78 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.134 -176.542 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 48.5 t -106.08 122.12 59.36 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.635 -178.633 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . 0.531 HD13 HD22 ' A' ' 48' ' ' LEU . 42.8 mt -94.19 135.3 35.72 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.127 -0.488 . . . . 0.0 109.746 178.055 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 18.9 p -128.44 130.8 48.13 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.593 0.235 . . . . 0.0 111.407 -178.994 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 25.3 t0 -162.89 146.87 11.29 Favored 'General case' 0 C--N 1.333 -0.142 0 CA-C-N 116.11 -0.495 . . . . 0.0 109.842 177.889 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.659 HD11 ' H ' ' A' ' 79' ' ' ILE . 48.5 mm -73.81 104.89 2.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 N-CA-C 110.169 -0.308 . . . . 0.0 110.169 179.425 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 31.4 mtmm 49.66 78.75 0.38 Allowed Pre-proline 0 N--CA 1.466 0.345 0 CA-C-N 115.576 -0.738 . . . . 0.0 111.381 -175.214 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . 0.707 ' HD2' ' HG2' ' A' ' 76' ' ' ARG . 11.7 Cg_endo -56.32 137.03 78.58 Favored 'Trans proline' 0 C--N 1.344 0.3 0 C-N-CA 123.294 2.662 . . . . 0.0 112.901 -178.777 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 12.8 m -97.22 -0.62 46.45 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.903 -0.59 . . . . 0.0 111.246 -178.197 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 25.0 t60 -105.38 -81.63 0.53 Allowed 'General case' 0 C--N 1.327 -0.37 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 178.206 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 156.85 163.09 12.02 Favored Glycine 0 N--CA 1.448 -0.521 0 C-N-CA 120.994 -0.622 . . . . 0.0 111.79 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 72.59 2.47 55.88 Favored Glycine 0 CA--C 1.518 0.266 0 C-N-CA 121.462 -0.399 . . . . 0.0 113.092 179.725 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.454 ' HB ' ' CB ' ' A' ' 69' ' ' PRO . 60.0 mt -100.37 142.77 14.98 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 N-CA-C 110.367 -0.234 . . . . 0.0 110.367 -176.868 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.408 HG12 ' HB2' ' A' ' 77' ' ' ASP . 98.8 t -74.03 129.09 36.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-O 120.922 0.391 . . . . 0.0 110.329 179.821 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' ARG . . . . . 0.707 ' HG2' ' HD2' ' A' ' 69' ' ' PRO . 88.9 mtt180 -86.68 35.0 0.66 Allowed 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.185 -175.903 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . 0.408 ' HB2' HG12 ' A' ' 75' ' ' VAL . 1.0 OUTLIER -77.63 173.76 11.67 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 109.711 -0.477 . . . . 0.0 109.711 -178.182 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 19.1 m-20 -103.42 122.52 45.04 Favored 'General case' 0 C--N 1.323 -0.566 0 C-N-CA 120.931 -0.307 . . . . 0.0 110.372 -173.89 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . 0.659 ' H ' HD11 ' A' ' 67' ' ' ILE . 10.8 tt -75.56 -26.79 18.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 CA-C-O 121.091 0.472 . . . . 0.0 111.018 178.023 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 15.0 t -84.1 -9.83 58.29 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.572 0.701 . . . . 0.0 110.386 -179.584 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 50.9 m -147.62 70.1 11.41 Favored Pre-proline 0 C--N 1.323 -0.585 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 174.421 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.711 ' HB2' ' HE2' ' A' ' 87' ' ' TYR . 72.0 Cg_endo -76.95 141.31 21.11 Favored 'Trans proline' 0 N--CA 1.461 -0.436 0 C-N-CA 122.559 2.173 . . . . 0.0 113.49 -169.092 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' ARG . . . . . 0.622 ' HG2' ' HG2' ' A' ' 85' ' ' GLU . 0.0 OUTLIER -79.02 117.31 19.96 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.487 -0.779 . . . . 0.0 109.328 174.11 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' MET . . . . . . . . . . . . . 5.4 mtp -66.08 -25.42 67.01 Favored 'General case' 0 C--N 1.324 -0.534 0 C-N-CA 120.878 -0.329 . . . . 0.0 111.243 -177.475 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.622 ' HG2' ' HG2' ' A' ' 83' ' ' ARG . 10.9 pt-20 -60.87 -26.12 67.17 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.825 0.345 . . . . 0.0 111.235 177.614 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.409 HG13 ' HB3' ' A' ' 83' ' ' ARG . 72.6 mt -74.67 -41.21 48.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.786 0.327 . . . . 0.0 110.856 178.358 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . 0.711 ' HE2' ' HB2' ' A' ' 82' ' ' PRO . 91.4 m-85 -82.09 -34.27 29.42 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.482 -178.359 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . 0.427 HH11 ' HD2' ' A' ' 88' ' ' ARG . 22.4 mtp180 -68.83 125.58 27.06 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.198 0.523 . . . . 0.0 110.398 179.296 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 101.72 3.07 52.75 Favored Glycine 0 N--CA 1.446 -0.675 0 CA-C-N 115.376 -0.829 . . . . 0.0 111.634 -176.488 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -85.63 144.05 28.08 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.084 0.468 . . . . 0.0 110.731 178.808 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -89.31 -19.62 25.07 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.594 179.215 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . 0.48 HD23 ' N ' ' A' ' 93' ' ' ILE . 5.6 tt -166.59 141.27 4.23 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.064 -0.517 . . . . 0.0 109.865 -178.038 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.595 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 58.6 mt -124.95 126.33 71.06 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 N-CA-C 109.433 -0.58 . . . . 0.0 109.433 177.285 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 18.8 p90 -134.21 156.18 48.82 Favored 'General case' 0 C--N 1.322 -0.619 0 C-N-CA 120.226 -0.59 . . . . 0.0 111.511 -178.877 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . 0.509 ' OG ' ' HB ' ' A' ' 42' ' ' VAL . 14.4 m -148.06 130.52 15.77 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.457 -0.792 . . . . 0.0 110.196 -178.571 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' ILE . . . . . 0.435 ' N ' HD12 ' A' ' 96' ' ' ILE . 4.0 mp -87.99 103.32 13.47 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 177.123 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . 1.074 ' HB3' ' HA ' ' A' ' 121' ' ' PRO . 8.9 ptm180 40.11 89.61 0.08 OUTLIER Pre-proline 0 N--CA 1.475 0.809 0 C-N-CA 124.685 1.194 . . . . 0.0 113.269 -176.279 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 89.9 Cg_endo -79.96 154.33 22.69 Favored 'Trans proline' 0 N--CA 1.459 -0.525 0 C-N-CA 122.472 2.115 . . . . 0.0 112.191 178.581 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.798 ' HD2' HD11 ' A' ' 102' ' ' ILE . 51.4 Cg_exo -54.27 158.28 9.89 Favored 'Trans proline' 0 C--O 1.234 0.313 0 C-N-CA 122.8 2.334 . . . . 0.0 112.288 173.936 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -80.37 25.86 0.39 Allowed 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.147 -0.479 . . . . 0.0 112.046 -172.997 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 101' ' ' GLU . . . . . 0.666 ' HG3' HG23 ' A' ' 102' ' ' ILE . 12.2 pt-20 -124.3 -21.29 5.0 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.76 -0.2 . . . . 0.0 111.276 178.113 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.798 HD11 ' HD2' ' A' ' 99' ' ' PRO . 45.2 pt -110.38 -1.62 9.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 N-CA-C 112.031 0.382 . . . . 0.0 112.031 -174.646 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 103' ' ' HIS . . . . . 0.529 ' O ' ' HG2' ' A' ' 107' ' ' MET . 23.7 p-80 -61.68 -41.77 98.02 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.798 0.333 . . . . 0.0 110.46 -179.258 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 20.6 t -71.25 -30.21 66.04 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.16 0.505 . . . . 0.0 110.056 177.895 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.541 ' O ' HG23 ' A' ' 109' ' ' VAL . 4.6 m -68.82 -46.08 69.54 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.046 -179.626 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 92.3 mt -58.18 -40.46 81.55 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.168 179.76 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 107' ' ' MET . . . . . 0.529 ' HG2' ' O ' ' A' ' 103' ' ' HIS . 94.2 mmm -60.92 -43.85 98.0 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.43 -178.839 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 108' ' ' ARG . . . . . 0.458 ' HG2' ' O ' ' A' ' 105' ' ' SER . 13.1 ptp180 -76.9 -27.09 54.81 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.663 -0.244 . . . . 0.0 111.2 -177.786 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.541 HG23 ' O ' ' A' ' 105' ' ' SER . 73.6 t -70.9 -44.52 75.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 C-N-CA 121.158 -0.217 . . . . 0.0 110.674 177.744 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -59.46 -41.24 89.25 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 121.106 0.479 . . . . 0.0 110.323 178.466 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.467 ' HA ' ' HB1' ' A' ' 148' ' ' ALA . 16.2 t70 -65.4 -34.92 79.45 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.779 -178.565 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -72.46 -45.13 60.94 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.866 -0.606 . . . . 0.0 111.739 -178.263 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.418 HG12 ' CG ' ' A' ' 88' ' ' ARG . 31.1 m -85.88 -25.63 6.52 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-N 116.533 -0.303 . . . . 0.0 111.771 -176.102 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 84.96 59.3 1.99 Allowed Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.039 179.797 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . 0.455 ' O ' ' HB3' ' A' ' 148' ' ' ALA . . . -140.44 149.5 42.65 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 120.927 0.394 . . . . 0.0 110.791 -179.241 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 116' ' ' ARG . . . . . 0.529 ' HD3' ' OE1' ' A' ' 145' ' ' GLU . 14.9 ttm180 -70.98 129.75 39.8 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.893 -0.594 . . . . 0.0 109.999 177.318 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . 0.595 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 58.1 tp -100.16 118.66 36.97 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 116.049 -0.523 . . . . 0.0 109.709 178.645 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 60.0 mt -112.66 117.85 56.36 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-O 120.914 0.388 . . . . 0.0 110.569 179.702 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 119' ' ' ILE . . . . . 0.436 ' HA ' ' O ' ' A' ' 95' ' ' SER . 73.3 mt -120.35 120.23 62.2 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.672 -179.646 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 62.2 tttm -115.8 100.9 54.01 Favored Pre-proline 0 C--N 1.32 -0.674 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.208 175.533 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 121' ' ' PRO . . . . . 1.074 ' HA ' ' HB3' ' A' ' 97' ' ' ARG . 86.8 Cg_endo -78.96 -165.46 0.34 Allowed 'Trans proline' 0 N--CA 1.459 -0.503 0 C-N-CA 122.59 2.193 . . . . 0.0 111.792 175.696 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 122' ' ' LEU . . . . . 0.598 ' HB2' ' HB2' ' A' ' 125' ' ' GLU . 31.3 mt -66.54 152.72 44.68 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.872 175.924 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 19.9 m -64.71 106.0 1.1 Allowed 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.02 -0.536 . . . . 0.0 109.569 175.081 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 92.06 30.72 9.86 Favored Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 120.935 -0.65 . . . . 0.0 111.653 -175.118 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . 0.598 ' HB2' ' HB2' ' A' ' 122' ' ' LEU . 43.6 tt0 -126.6 145.19 50.64 Favored 'General case' 0 N--CA 1.448 -0.564 0 CA-C-O 121.032 0.444 . . . . 0.0 110.053 -179.408 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -101.15 167.08 10.45 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.471 -178.566 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.565 ' HB ' HG22 ' A' ' 129' ' ' THR . 6.4 mt -108.13 11.17 8.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 N-CA-C 110.02 -0.363 . . . . 0.0 110.02 -178.852 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 20.1 m 48.45 35.54 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.837 0 C-N-CA 124.147 0.979 . . . . 0.0 111.918 -179.45 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . 0.565 HG22 ' HB ' ' A' ' 127' ' ' ILE . 13.5 t -123.16 136.97 55.0 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 114.984 -1.007 . . . . 0.0 108.94 178.082 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -88.42 101.03 13.5 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 120.76 0.314 . . . . 0.0 111.335 -173.096 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 131' ' ' ARG . . . . . . . . . . . . . 2.7 ptp180 42.02 36.76 0.71 Allowed 'General case' 0 N--CA 1.476 0.844 0 C-N-CA 124.673 1.189 . . . . 0.0 113.642 175.383 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 46.8 mmtm -84.94 -12.3 53.64 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.845 0.355 . . . . 0.0 110.899 177.795 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 133' ' ' MET . . . . . 0.491 ' HG2' ' HB2' ' A' ' 146' ' ' TYR . 85.7 mtp -133.62 170.56 15.35 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.411 -177.179 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -118.38 145.37 45.21 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.689 179.862 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . 0.488 HD11 ' HD2' ' A' ' 142' ' ' TYR . 57.7 tp -80.74 134.24 35.79 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.121 178.26 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -129.54 138.59 53.88 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-O 121.193 0.521 . . . . 0.0 111.577 -179.958 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 14.3 m120 -110.23 120.17 41.6 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.005 177.323 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 59.5 t80 -148.64 123.4 9.9 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 110.201 -0.296 . . . . 0.0 110.201 177.894 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 66.79 42.72 92.89 Favored Glycine 0 N--CA 1.448 -0.563 0 C-N-CA 121.029 -0.605 . . . . 0.0 112.801 177.461 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 140' ' ' ARG . . . . . . . . . . . . . 55.5 ttt180 73.75 -19.87 0.33 Allowed 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 123.325 0.65 . . . . 0.0 112.361 175.455 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 5.2 t -97.63 163.21 12.93 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 178.58 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 142' ' ' TYR . . . . . 0.488 ' HD2' HD11 ' A' ' 135' ' ' LEU . 37.6 p90 -131.98 148.93 52.54 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 121.237 0.541 . . . . 0.0 110.886 -179.664 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 8.7 p90 -155.23 177.69 11.06 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 115.26 -0.882 . . . . 0.0 109.4 -179.104 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -113.13 134.34 54.6 Favored 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 110.068 -0.345 . . . . 0.0 110.068 179.419 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 145' ' ' GLU . . . . . 0.529 ' OE1' ' HD3' ' A' ' 116' ' ' ARG . 20.1 pt-20 -126.8 158.47 36.51 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 121.265 0.555 . . . . 0.0 110.385 177.237 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . 0.491 ' HB2' ' HG2' ' A' ' 133' ' ' MET . 35.6 t80 -134.76 126.26 28.58 Favored 'General case' 0 C--N 1.316 -0.89 0 CA-C-N 115.465 -0.789 . . . . 0.0 109.265 175.241 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 147' ' ' ILE . . . . . 0.408 ' N ' HD12 ' A' ' 147' ' ' ILE . 3.1 mp -92.24 100.23 10.92 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 CA-C-O 121.19 0.519 . . . . 0.0 109.739 -178.661 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . 0.467 ' HB1' ' HA ' ' A' ' 111' ' ' ASP . . . -91.73 107.4 19.18 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.61 -0.723 . . . . 0.0 109.064 174.499 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -63.44 156.5 25.96 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-O 121.199 0.523 . . . . 0.0 110.28 -177.884 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 11.6 t -83.19 123.23 38.47 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.91 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 177.251 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 151' ' ' ARG . . . . . 0.401 HH21 ' HA ' ' A' ' 113' ' ' VAL . 0.0 OUTLIER -56.76 107.43 0.39 Allowed 'General case' 0 C--N 1.322 -0.595 0 O-C-N 123.599 0.562 . . . . 0.0 111.088 -178.391 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 18.1 m -61.51 119.96 9.61 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.121 -0.945 . . . . 0.0 111.084 -176.678 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 153' ' ' ARG . . . . . 0.402 ' HA ' ' NE ' ' A' ' 153' ' ' ARG . 3.5 mmp_? . . . . . 0 C--O 1.247 0.966 0 CA-C-N 115.307 -0.86 . . . . 0.0 109.916 -179.36 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 51.9 tpp . . . . . 0 N--CA 1.479 0.98 0 CA-C-O 120.685 0.279 . . . . 0.0 110.471 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -176.48 55.88 0.11 Allowed Glycine 0 N--CA 1.449 -0.466 0 N-CA-C 111.425 -0.67 . . . . 0.0 111.425 178.161 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 39.0 m -92.98 128.94 39.02 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.927 0.394 . . . . 0.0 111.245 -177.346 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 43.4 m -103.68 74.8 1.26 Allowed 'General case' 0 C--N 1.323 -0.548 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 171.237 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 56.5 p-80 -84.7 -171.45 3.64 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.897 -175.748 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 21.0 m-70 -81.98 83.77 7.16 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 121.396 0.617 . . . . 0.0 110.435 179.786 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . 0.571 ' CE1' ' HB3' ' A' ' 9' ' ' HIS . 50.9 t-80 -107.4 -70.55 0.79 Allowed 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 115.101 -0.954 . . . . 0.0 108.76 176.951 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 38.8 m80 60.5 23.73 13.38 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 115.515 -0.766 . . . . 0.0 112.4 172.657 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . 0.571 ' HB3' ' CE1' ' A' ' 7' ' ' HIS . 15.6 t-80 -101.64 97.31 7.75 Favored 'General case' 0 C--N 1.32 -0.676 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 172.293 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 39.1 m80 -81.78 74.69 8.75 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 121.696 0.76 . . . . 0.0 110.69 -174.631 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.4 ' HB3' ' CE1' ' A' ' 9' ' ' HIS . 41.3 t -157.36 137.8 12.92 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 114.785 -1.098 . . . . 0.0 108.948 179.311 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 22.5 m -72.81 -19.49 61.32 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 120.9 0.381 . . . . 0.0 110.355 178.705 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 79.61 -61.33 4.26 Favored Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 120.913 -0.661 . . . . 0.0 111.489 -177.623 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . 0.402 ' O ' ' HD3' ' A' ' 16' ' ' PRO . 86.7 mt -134.4 123.51 24.2 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.51 -0.552 . . . . 0.0 109.51 175.86 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.434 ' HA ' ' HD3' ' A' ' 16' ' ' PRO . 48.6 t -87.69 108.32 19.9 Favored Pre-proline 0 C--N 1.322 -0.611 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 174.702 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.434 ' HD3' ' HA ' ' A' ' 15' ' ' VAL . 1.5 Cg_endo -84.31 -172.35 1.25 Allowed 'Trans proline' 0 N--CA 1.454 -0.837 0 C-N-CA 123.145 2.563 . . . . 0.0 111.793 -179.033 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 0.404 HH11 ' HD2' ' A' ' 17' ' ' ARG . 49.4 mtp85 -83.7 79.81 9.34 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.377 0.608 . . . . 0.0 109.841 178.528 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -95.15 60.88 1.6 Allowed Glycine 0 N--CA 1.448 -0.51 0 CA-C-N 115.478 -0.783 . . . . 0.0 112.665 -177.392 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . 0.675 ' HA ' ' HD1' ' A' ' 22' ' ' TRP . 2.4 p -94.49 10.46 34.49 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 121.113 0.482 . . . . 0.0 110.915 178.823 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 35.7 t60 -63.91 -52.91 57.66 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.998 -176.575 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' MET . . . . . . . . . . . . . 21.3 ptp -64.12 -20.32 65.89 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-O 120.99 0.424 . . . . 0.0 111.568 -176.296 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' TRP . . . . . 0.675 ' HD1' ' HA ' ' A' ' 19' ' ' SER . 80.6 m95 -81.89 -22.55 36.81 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.022 0.439 . . . . 0.0 110.45 -178.448 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.419 ' O ' HG23 ' A' ' 27' ' ' VAL . 2.7 t-20 -72.57 -45.23 60.2 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.118 178.752 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -59.77 -42.07 92.49 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.234 178.024 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 62.2 tp -55.76 -49.01 74.27 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.297 176.697 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . 0.508 ' HB2' HG13 ' A' ' 50' ' ' VAL . . . -58.91 -52.25 66.55 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.891 179.081 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.422 ' HA ' HD12 ' A' ' 30' ' ' ILE . 91.6 t -55.03 -43.32 69.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.321 -0.4 . . . . 0.0 111.188 -179.933 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 67.5 t80 -58.98 -47.32 85.6 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.957 0.408 . . . . 0.0 110.467 179.094 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.513 HG23 HD13 ' A' ' 92' ' ' LEU . 91.2 mt -61.89 -42.95 96.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.589 179.017 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.677 HG12 HG23 ' A' ' 54' ' ' ILE . 95.8 mt -58.23 -39.82 75.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 115.696 -0.683 . . . . 0.0 111.348 179.818 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 44.3 mtp-105 -74.55 -24.0 58.88 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.153 -178.558 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 85.0 m -88.99 -19.29 25.89 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.702 -177.926 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 13.9 p -106.6 -77.6 0.59 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.624 -177.801 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 95.36 163.33 34.43 Favored Glycine 0 N--CA 1.446 -0.635 0 C-N-CA 121.082 -0.58 . . . . 0.0 112.203 -178.467 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -66.09 143.08 70.48 Favored 'Trans proline' 0 C--O 1.233 0.26 0 C-N-CA 122.794 2.329 . . . . 0.0 112.64 -179.79 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 109.57 -32.62 6.64 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.894 177.091 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 11.3 t -98.02 -170.97 2.06 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 110.005 -0.368 . . . . 0.0 110.005 -176.467 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . 0.834 ' HG2' ' HB3' ' A' ' 61' ' ' ASP . 45.0 mtt180 -124.28 136.66 54.29 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.004 0.431 . . . . 0.0 111.673 -176.533 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.441 HG23 HG21 ' A' ' 60' ' ' VAL . 63.4 t -121.44 125.34 73.49 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-N 115.528 -0.76 . . . . 0.0 109.318 175.852 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 47.2 t -103.72 128.27 57.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-O 120.811 0.339 . . . . 0.0 111.406 -175.193 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . 0.493 ' HB3' HD23 ' A' ' 64' ' ' LEU . 34.3 tt0 -105.13 118.54 36.8 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 173.972 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.502 ' HA ' ' OG1' ' A' ' 65' ' ' THR . 58.5 t -95.54 121.05 45.73 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.362 -179.864 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 96.61 43.24 3.2 Favored Glycine 0 N--CA 1.446 -0.671 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.103 -179.817 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -77.01 82.77 3.53 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.351 0.596 . . . . 0.0 110.519 -178.292 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -69.64 -98.37 0.05 OUTLIER Glycine 0 N--CA 1.447 -0.593 0 CA-C-N 115.01 -0.995 . . . . 0.0 112.903 179.889 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . 0.534 ' O ' ' HD2' ' A' ' 46' ' ' ARG . 8.2 tmm_? -136.82 -7.19 1.88 Allowed 'General case' 0 C--N 1.327 -0.4 0 C-N-CA 120.904 -0.318 . . . . 0.0 111.27 -177.199 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.411 ' CZ ' ' HB ' ' A' ' 96' ' ' ILE . 9.0 p90 -61.98 -63.01 1.39 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.808 0.337 . . . . 0.0 111.011 179.688 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.417 HD22 HD13 ' A' ' 64' ' ' LEU . 59.7 mt 55.85 22.23 5.45 Favored 'General case' 0 C--N 1.323 -0.552 0 C-N-CA 123.684 0.794 . . . . 0.0 112.59 173.81 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 86.4 t80 -74.97 -56.85 4.33 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.781 0.324 . . . . 0.0 110.984 -178.075 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.508 HG13 ' HB2' ' A' ' 26' ' ' ALA . 52.5 t -63.49 -52.78 53.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.074 -175.816 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . 0.556 ' CB ' HD21 ' A' ' 64' ' ' LEU . 0.2 OUTLIER -59.47 -46.88 87.52 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.695 -0.684 . . . . 0.0 112.491 -176.587 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 35.6 t70 -68.07 -27.2 66.29 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.729 0.3 . . . . 0.0 110.948 -177.689 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 89.3 t80 -73.81 -45.62 50.29 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 120.699 0.285 . . . . 0.0 110.798 176.916 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.677 HG23 HG12 ' A' ' 30' ' ' ILE . 78.3 mt -59.92 -43.24 91.78 Favored 'Isoleucine or valine' 0 C--O 1.234 0.253 0 CA-C-N 116.403 -0.362 . . . . 0.0 111.307 -178.079 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 2.0 ptm180 -67.83 -16.73 64.24 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.479 -178.84 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 67.2 mttm -88.05 -42.85 12.12 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.116 0.484 . . . . 0.0 110.454 177.002 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.9 OUTLIER -65.53 -41.68 92.83 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.633 -0.712 . . . . 0.0 110.932 -177.559 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 74.1 m -132.41 153.51 50.75 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.348 -179.507 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -76.71 38.84 0.2 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.908 177.846 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.441 HG21 HG23 ' A' ' 39' ' ' VAL . 7.2 p -84.03 138.76 18.66 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 CA-C-N 116.047 -0.524 . . . . 0.0 109.624 179.13 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . 0.834 ' HB3' ' HG2' ' A' ' 38' ' ' ARG . 13.9 t70 -84.86 93.76 8.59 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 -178.232 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 4.2 tt -90.38 127.8 36.29 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.005 -175.424 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 59.4 t -106.36 121.91 59.5 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 115.773 -0.649 . . . . 0.0 111.016 -176.674 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . 0.556 HD21 ' CB ' ' A' ' 51' ' ' SER . 90.5 mt -98.93 141.33 31.83 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.05 -0.523 . . . . 0.0 109.816 176.65 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.502 ' OG1' ' HA ' ' A' ' 42' ' ' VAL . 28.8 p -121.28 127.18 51.11 Favored 'General case' 0 C--O 1.238 0.487 0 CA-C-O 120.608 0.242 . . . . 0.0 111.627 -178.738 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 32.0 t70 -166.27 139.01 3.93 Favored 'General case' 0 N--CA 1.463 0.218 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.364 178.117 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 58.6 mt -75.97 112.04 13.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 N-CA-C 110.249 -0.278 . . . . 0.0 110.249 -179.511 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 47.1 mtmt 56.47 75.04 0.61 Allowed Pre-proline 0 C--N 1.33 -0.249 0 O-C-N 123.598 0.561 . . . . 0.0 109.839 -178.179 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . 0.574 ' CB ' ' HB ' ' A' ' 74' ' ' ILE . 8.1 Cg_exo -71.99 148.73 51.67 Favored 'Trans proline' 0 N--CA 1.465 -0.178 0 C-N-CA 123.249 2.633 . . . . 0.0 112.815 -171.195 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 23.8 p -82.88 -32.98 27.1 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.903 -179.477 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 27.7 t60 -74.62 -37.72 62.73 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.16 -177.904 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 94.85 -35.78 4.08 Favored Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 120.542 -0.837 . . . . 0.0 111.978 -177.881 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -79.8 21.34 4.76 Favored Glycine 0 C--N 1.332 0.311 0 C-N-CA 120.995 -0.622 . . . . 0.0 111.988 177.455 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.574 ' HB ' ' CB ' ' A' ' 69' ' ' PRO . 67.7 mt -117.3 147.93 20.38 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 179.652 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.541 HG12 ' H ' ' A' ' 77' ' ' ASP . 91.1 t -73.91 122.56 27.3 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 120.865 0.364 . . . . 0.0 110.24 178.858 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -78.34 16.55 0.77 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.696 -0.684 . . . . 0.0 112.645 -175.232 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . 0.541 ' H ' HG12 ' A' ' 75' ' ' VAL . 2.6 m-20 -76.14 155.44 34.63 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 121.496 0.665 . . . . 0.0 111.887 -175.478 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 16.9 t0 -78.88 143.78 35.57 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 114.88 -1.054 . . . . 0.0 111.276 -174.237 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 7.6 tp -96.59 -26.59 4.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.375 -177.206 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 5.0 t -78.22 -25.66 47.09 Favored 'General case' 0 C--O 1.234 0.247 0 N-CA-C 109.376 -0.602 . . . . 0.0 109.376 179.759 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 1.2 m -124.38 76.03 61.74 Favored Pre-proline 0 C--N 1.329 -0.3 0 N-CA-C 108.45 -0.944 . . . . 0.0 108.45 169.027 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -79.07 131.55 9.96 Favored 'Trans proline' 0 N--CA 1.461 -0.405 0 C-N-CA 122.671 2.247 . . . . 0.0 113.453 -170.887 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' ARG . . . . . 0.707 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 64.5 mtt180 -70.57 109.5 4.89 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.651 -0.704 . . . . 0.0 110.016 174.303 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' MET . . . . . 0.718 ' HA ' ' HD2' ' A' ' 87' ' ' TYR . 31.5 mtp -73.31 -10.23 59.53 Favored 'General case' 0 C--N 1.323 -0.572 0 C-N-CA 120.816 -0.354 . . . . 0.0 110.58 178.66 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.707 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 10.5 pt-20 -66.94 -21.98 65.96 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.542 173.908 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 71.9 mt -81.8 -34.59 12.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-O 121.351 0.596 . . . . 0.0 110.042 178.145 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . 0.718 ' HD2' ' HA ' ' A' ' 84' ' ' MET . 85.3 m-85 -82.39 -33.9 28.54 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.585 -0.734 . . . . 0.0 110.687 -178.487 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 50.6 mtp180 -64.07 122.46 16.61 Favored 'General case' 0 CA--C 1.516 -0.345 0 CA-C-O 121.227 0.536 . . . . 0.0 111.01 177.626 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 104.06 -12.28 52.37 Favored Glycine 0 N--CA 1.444 -0.767 0 CA-C-N 115.299 -0.864 . . . . 0.0 111.921 -178.976 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -78.79 142.5 36.91 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 110.015 -0.365 . . . . 0.0 110.015 177.767 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -90.71 -19.9 23.04 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-O 121.127 0.489 . . . . 0.0 110.453 -179.415 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . 0.602 ' HG ' ' HB3' ' A' ' 116' ' ' ARG . 3.4 tt -153.92 139.78 18.14 Favored 'General case' 0 N--CA 1.447 -0.596 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.929 -176.943 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.574 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 70.0 mt -131.33 124.64 55.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 177.791 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 13.9 p90 -134.72 164.9 26.48 Favored 'General case' 0 C--N 1.321 -0.661 0 C-N-CA 120.717 -0.393 . . . . 0.0 111.08 -178.809 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 6.9 p -140.58 131.14 25.46 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.523 -178.884 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' ILE . . . . . 0.411 ' HB ' ' CZ ' ' A' ' 47' ' ' PHE . 38.5 mm -92.03 98.31 8.23 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.098 179.262 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 63.0 mtm180 59.3 76.46 0.44 Allowed Pre-proline 0 C--N 1.332 -0.182 0 CA-C-N 115.401 -0.818 . . . . 0.0 111.54 -179.242 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' PRO . . . . . 0.475 ' HA ' ' HD3' ' A' ' 99' ' ' PRO . 93.4 Cg_endo -87.97 152.61 7.13 Favored 'Trans proline' 0 N--CA 1.455 -0.747 0 C-N-CA 122.593 2.195 . . . . 0.0 112.1 177.294 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.657 ' HB2' ' HG2' ' A' ' 101' ' ' GLU . 6.3 Cg_exo -73.07 148.71 45.24 Favored 'Trans proline' 0 N--CA 1.461 -0.405 0 C-N-CA 122.524 2.149 . . . . 0.0 111.461 176.019 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -76.45 39.75 0.21 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.173 0.511 . . . . 0.0 111.735 -177.475 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 101' ' ' GLU . . . . . 0.657 ' HG2' ' HB2' ' A' ' 99' ' ' PRO . 11.6 pt-20 -121.51 -28.74 4.54 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.205 177.615 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.615 HG23 ' HG3' ' A' ' 101' ' ' GLU . 34.8 pt -110.67 5.28 8.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.359 -175.976 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 103' ' ' HIS . . . . . 0.796 ' HD2' ' HB ' ' A' ' 129' ' ' THR . 9.6 p-80 -60.99 -48.17 83.07 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 115.62 -0.718 . . . . 0.0 111.392 -177.043 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 47.1 m -70.97 -23.07 62.14 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.177 0.513 . . . . 0.0 110.658 178.689 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.567 ' O ' ' HG2' ' A' ' 108' ' ' ARG . 8.7 m -73.96 -37.92 64.37 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.242 178.542 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.419 ' HG ' ' O ' ' A' ' 102' ' ' ILE . 94.0 mt -63.61 -41.08 98.34 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.722 178.014 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 107' ' ' MET . . . . . . . . . . . . . 97.7 mmm -57.33 -47.02 82.66 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.759 -0.655 . . . . 0.0 111.316 -179.281 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 108' ' ' ARG . . . . . 0.567 ' HG2' ' O ' ' A' ' 105' ' ' SER . 6.6 ptp180 -67.6 -31.48 71.55 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.505 -0.316 . . . . 0.0 111.178 -176.941 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.464 HG23 ' O ' ' A' ' 105' ' ' SER . 92.1 t -74.29 -46.0 45.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.486 -0.325 . . . . 0.0 110.659 -178.862 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -58.3 -49.99 75.2 Favored 'General case' 0 CA--C 1.516 -0.347 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 176.946 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.418 ' HA ' ' HB1' ' A' ' 148' ' ' ALA . 15.3 t70 -55.16 -40.83 71.08 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.093 -0.958 . . . . 0.0 111.028 179.565 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -68.5 -44.94 73.62 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.918 -0.583 . . . . 0.0 112.196 -176.995 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 31.1 m -84.83 -27.63 6.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 C-N-CA 120.766 -0.374 . . . . 0.0 111.759 -175.29 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 98.04 22.53 15.15 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.631 -0.795 . . . . 0.0 112.654 177.578 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -99.09 163.46 12.56 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 121.505 0.669 . . . . 0.0 111.844 -176.483 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 116' ' ' ARG . . . . . 0.602 ' HB3' ' HG ' ' A' ' 92' ' ' LEU . 23.2 ttt180 -85.08 116.23 23.34 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 115.181 -0.918 . . . . 0.0 109.591 178.181 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . 0.574 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 52.2 tp -90.13 128.01 36.23 Favored 'General case' 0 C--N 1.32 -0.693 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 -178.261 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 72.2 mt -129.02 119.72 50.0 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 CA-C-O 121.178 0.513 . . . . 0.0 110.891 179.683 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 64.6 mt -119.75 125.1 73.98 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.437 179.88 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 8.9 tmtm? -108.48 98.23 26.94 Favored Pre-proline 0 C--N 1.325 -0.474 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 175.22 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -77.52 -174.26 2.14 Favored 'Trans proline' 0 C--O 1.236 0.386 0 C-N-CA 122.796 2.33 . . . . 0.0 112.944 -179.507 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 122' ' ' LEU . . . . . 0.429 ' HB2' ' HB3' ' A' ' 125' ' ' GLU . 91.7 mt -75.59 176.04 8.0 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.753 -0.658 . . . . 0.0 111.463 -175.967 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 4.1 p -74.86 102.83 4.87 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.725 -0.671 . . . . 0.0 111.002 179.317 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 82.11 30.23 35.21 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.156 179.547 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . 0.429 ' HB3' ' HB2' ' A' ' 122' ' ' LEU . 8.8 tp10 -133.26 136.78 45.75 Favored 'General case' 0 N--CA 1.448 -0.574 0 N-CA-C 109.143 -0.688 . . . . 0.0 109.143 178.049 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -107.25 166.99 10.23 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.043 -173.481 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 45.2 mt -77.66 -21.18 13.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 115.958 -0.564 . . . . 0.0 109.998 179.642 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 28.4 m 45.86 40.19 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.604 0 C-N-CA 124.263 1.025 . . . . 0.0 112.828 176.317 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . 0.796 ' HB ' ' HD2' ' A' ' 103' ' ' HIS . 11.9 t -95.98 169.67 9.81 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.381 -179.877 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 46.5 mt-10 -90.5 -11.28 40.71 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.111 0.481 . . . . 0.0 109.931 176.329 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 131' ' ' ARG . . . . . . . . . . . . . 19.9 mmt180 -83.02 166.84 18.45 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.434 -0.803 . . . . 0.0 109.99 -179.244 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 3.9 mppt? -106.3 130.76 54.08 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.279 0.562 . . . . 0.0 111.84 -175.497 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 133' ' ' MET . . . . . . . . . . . . . 85.0 mtp -137.77 160.63 38.73 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 115.056 -0.975 . . . . 0.0 108.971 174.405 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . 0.691 ' HG3' ' HG2' ' A' ' 145' ' ' GLU . 1.4 ptmt -111.93 133.07 54.36 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-O 121.039 0.447 . . . . 0.0 110.866 -178.123 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . 0.629 HD11 ' HD2' ' A' ' 142' ' ' TYR . 51.9 tp -81.67 121.4 26.32 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.067 179.244 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 136' ' ' VAL . . . . . 0.413 ' C ' HD22 ' A' ' 137' ' ' ASN . 0.0 OUTLIER -116.21 141.95 31.7 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.65 -178.014 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 137' ' ' ASN . . . . . 0.413 HD22 ' C ' ' A' ' 136' ' ' VAL . 0.9 OUTLIER -115.33 111.35 20.74 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.737 -0.665 . . . . 0.0 109.351 176.226 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . 0.614 ' O ' HG22 ' A' ' 141' ' ' THR . 57.0 t80 -124.85 104.68 8.74 Favored 'General case' 0 C--N 1.319 -0.734 0 N-CA-C 109.49 -0.559 . . . . 0.0 109.49 -178.761 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . 0.4 ' O ' ' HB2' ' A' ' 140' ' ' ARG . . . 68.27 40.96 87.24 Favored Glycine 0 CA--C 1.519 0.299 0 C-N-CA 120.55 -0.833 . . . . 0.0 111.609 -175.575 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 140' ' ' ARG . . . . . 0.4 ' HB2' ' O ' ' A' ' 139' ' ' GLY . 0.0 OUTLIER 75.83 -25.89 0.2 Allowed 'General case' 0 N--CA 1.472 0.63 0 C-N-CA 123.681 0.792 . . . . 0.0 113.073 178.464 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 141' ' ' THR . . . . . 0.614 HG22 ' O ' ' A' ' 138' ' ' TYR . 13.9 t -75.26 142.68 43.31 Favored 'General case' 0 C--O 1.236 0.38 0 N-CA-C 109.338 -0.616 . . . . 0.0 109.338 177.262 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 142' ' ' TYR . . . . . 0.629 ' HD2' HD11 ' A' ' 135' ' ' LEU . 26.4 p90 -121.41 141.55 50.87 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 121.394 0.616 . . . . 0.0 111.229 -176.452 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 25.1 p90 -154.32 170.21 21.86 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 114.975 -1.011 . . . . 0.0 109.515 -179.968 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 75.5 m-85 -107.5 126.4 52.47 Favored 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 110.227 -0.286 . . . . 0.0 110.227 179.474 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 145' ' ' GLU . . . . . 0.691 ' HG2' ' HG3' ' A' ' 134' ' ' LYS . 10.0 pt-20 -115.41 164.12 14.74 Favored 'General case' 0 C--N 1.32 -0.677 0 N-CA-C 109.685 -0.487 . . . . 0.0 109.685 177.594 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . 0.563 ' HB3' ' HB3' ' A' ' 117' ' ' LEU . 50.8 t80 -147.03 127.74 14.28 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.352 177.382 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 147' ' ' ILE . . . . . 0.42 ' N ' HD12 ' A' ' 147' ' ' ILE . 3.1 mp -96.73 104.92 16.43 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.706 0 CA-C-N 115.779 -0.646 . . . . 0.0 109.366 179.506 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . 0.418 ' HB1' ' HA ' ' A' ' 111' ' ' ASP . . . -70.25 117.44 11.81 Favored 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 175.974 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 30.3 mt-10 -73.4 133.69 43.83 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 121.702 0.763 . . . . 0.0 111.795 -176.743 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 25.8 t -106.05 132.87 52.04 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.07 0 CA-C-N 114.442 -1.254 . . . . 0.0 108.75 176.166 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 151' ' ' ARG . . . . . . . . . . . . . 33.1 ptt180 -64.72 127.94 33.66 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 121.14 0.495 . . . . 0.0 110.37 -178.806 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 8.2 t -83.82 144.73 29.08 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.682 -0.69 . . . . 0.0 109.752 -178.604 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 23.4 mtm180 . . . . . 0 C--O 1.247 0.97 0 CA-C-O 118.365 -0.826 . . . . 0.0 110.461 -179.9 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 4.0 mpp? . . . . . 0 N--CA 1.481 1.094 0 N-CA-C 110.214 -0.291 . . . . 0.0 110.214 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -117.79 143.18 17.67 Favored Glycine 0 N--CA 1.447 -0.604 0 C-N-CA 120.886 -0.673 . . . . 0.0 112.159 179.819 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 36.9 t -97.53 -48.26 5.34 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.873 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 41.5 m -124.6 111.35 15.54 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.552 179.864 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 96.4 m-70 -94.22 94.55 8.4 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.001 0.429 . . . . 0.0 110.046 176.228 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 33.8 p-80 -101.0 168.87 9.33 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.958 -0.564 . . . . 0.0 111.218 -177.31 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 12.3 m-70 -112.14 -178.39 3.41 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.744 -0.662 . . . . 0.0 109.563 175.742 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 54.6 m80 -96.92 13.87 27.35 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 121.179 0.514 . . . . 0.0 109.955 177.152 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 29.1 m80 -115.07 150.57 35.73 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.373 -175.683 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 57.7 m80 -94.06 -28.46 15.72 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 177.67 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 13.7 p -162.98 171.55 16.36 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.088 -0.96 . . . . 0.0 109.674 178.005 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 16.4 m -63.33 109.22 1.51 Allowed 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 120.905 0.384 . . . . 0.0 110.51 178.834 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -87.43 141.45 17.4 Favored Glycine 0 N--CA 1.445 -0.743 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.444 -178.405 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 93.7 mt -96.26 -159.95 0.76 Allowed 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 109.573 -0.529 . . . . 0.0 109.573 176.078 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 15.0 m -61.14 128.61 89.69 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 120.898 0.38 . . . . 0.0 110.479 176.931 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -77.44 -176.14 3.05 Favored 'Trans proline' 0 N--CA 1.462 -0.35 0 C-N-CA 122.678 2.252 . . . . 0.0 112.25 -177.886 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 0.467 ' O ' ' HD2' ' A' ' 17' ' ' ARG . 0.6 OUTLIER -120.18 136.57 54.58 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 121.055 0.455 . . . . 0.0 110.756 177.13 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 105.83 -42.15 1.98 Allowed Glycine 0 N--CA 1.449 -0.458 0 C-N-CA 121.017 -0.611 . . . . 0.0 112.564 -176.88 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 54.4 m -82.12 7.35 13.69 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 112.394 0.516 . . . . 0.0 112.394 -175.945 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' HIS . . . . . 0.427 ' HA ' ' OD1' ' A' ' 23' ' ' ASN . 31.7 m-70 -65.08 -16.91 63.99 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.706 0.288 . . . . 0.0 111.253 179.424 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' MET . . . . . . . . . . . . . 24.8 ptp -64.84 -17.48 64.29 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.174 177.679 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' TRP . . . . . 0.572 ' HB3' HG22 ' A' ' 50' ' ' VAL . 98.2 m95 -94.7 -22.31 18.2 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.675 179.854 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.427 ' OD1' ' HA ' ' A' ' 20' ' ' HIS . 13.9 m120 -66.01 -41.0 91.58 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.987 -179.638 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 26.2 m-20 -59.17 -46.78 87.49 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.049 178.905 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . . . . . . . . . 66.6 tp -59.6 -47.86 83.94 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.402 -0.817 . . . . 0.0 110.672 178.721 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . 0.411 ' O ' HG13 ' A' ' 30' ' ' ILE . . . -54.71 -51.98 63.87 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.474 -179.399 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.463 ' HA ' HD12 ' A' ' 30' ' ' ILE . 88.4 t -56.02 -43.11 74.29 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-O 120.9 0.381 . . . . 0.0 111.136 -179.717 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 83.5 t80 -59.17 -45.56 90.69 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.576 179.222 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.443 HD13 ' CD1' ' A' ' 94' ' ' TYR . 79.8 mt -65.36 -42.59 93.99 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.626 179.192 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.638 HG12 HG23 ' A' ' 54' ' ' ILE . 96.2 mt -56.62 -45.38 82.46 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-N 115.593 -0.73 . . . . 0.0 111.001 178.654 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 83.7 mtp180 -64.98 -28.27 69.4 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.629 -178.106 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 44.2 t -86.93 -24.53 24.75 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.669 0.271 . . . . 0.0 111.298 -177.316 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 11.3 p -98.48 -77.11 0.52 Allowed 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 120.745 0.307 . . . . 0.0 111.421 -176.774 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 90.57 172.22 44.1 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.943 -0.646 . . . . 0.0 112.307 -178.493 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 63.0 Cg_endo -74.29 153.68 45.71 Favored 'Trans proline' 0 C--O 1.235 0.33 0 C-N-CA 122.571 2.18 . . . . 0.0 112.121 179.391 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 82.35 30.05 34.9 Favored Glycine 0 CA--C 1.518 0.238 0 C-N-CA 120.675 -0.774 . . . . 0.0 113.073 177.772 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 14.2 t -150.07 -176.53 5.49 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 176.199 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . 0.544 ' HB2' ' HA ' ' A' ' 90' ' ' ALA . 17.4 mtp180 -117.34 135.56 53.77 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 120.856 0.36 . . . . 0.0 111.389 -176.697 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.442 HG12 ' OE1' ' A' ' 41' ' ' GLU . 16.7 t -123.98 125.03 70.28 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 172.843 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 47.1 t -109.71 117.59 54.94 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 121.191 0.52 . . . . 0.0 110.59 -177.887 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . 0.535 ' HB2' HD23 ' A' ' 64' ' ' LEU . 0.1 OUTLIER -90.98 120.32 31.88 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.309 -0.86 . . . . 0.0 110.29 -175.927 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.641 HG11 HD21 ' A' ' 106' ' ' LEU . 59.4 t -94.33 110.26 23.38 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.701 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 175.992 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 98.91 97.78 2.1 Favored Glycine 0 N--CA 1.446 -0.696 0 N-CA-C 110.988 -0.845 . . . . 0.0 110.988 -175.353 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -111.53 -53.24 2.72 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.652 0.263 . . . . 0.0 110.913 -176.256 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 48.53 -121.14 7.35 Favored Glycine 0 N--CA 1.449 -0.451 0 CA-C-N 115.788 -0.642 . . . . 0.0 112.311 -176.523 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 94.7 mtt180 -118.1 3.23 12.07 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 120.903 0.382 . . . . 0.0 110.256 175.77 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 12.4 p90 -98.05 63.34 1.6 Allowed 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.621 0.724 . . . . 0.0 111.143 -175.891 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 55.2 mt -85.33 22.74 1.44 Allowed 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.694 -0.685 . . . . 0.0 110.869 -178.713 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 80.6 t80 -63.33 -41.43 98.89 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.332 -176.512 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.572 HG22 ' HB3' ' A' ' 22' ' ' TRP . 42.6 t -75.32 -50.48 24.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.659 -178.957 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 3.0 p -62.35 -45.78 91.65 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.556 -0.747 . . . . 0.0 112.306 -174.225 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.534 ' O ' ' HG2' ' A' ' 56' ' ' LYS . 35.5 t70 -70.07 -35.67 74.4 Favored 'General case' 0 C--N 1.33 -0.275 0 C-N-CA 120.655 -0.418 . . . . 0.0 110.646 -177.011 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 88.6 t80 -58.72 -40.48 83.88 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.944 0.402 . . . . 0.0 110.299 178.079 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.638 HG23 HG12 ' A' ' 30' ' ' ILE . 79.6 mt -65.62 -49.23 79.1 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.338 -179.921 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . 0.453 ' HG2' ' O ' ' A' ' 52' ' ' ASP . 5.7 ptm180 -69.29 -19.98 63.9 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-N 116.476 -0.329 . . . . 0.0 111.598 -176.55 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . 0.534 ' HG2' ' O ' ' A' ' 52' ' ' ASP . 4.6 mmmp? -82.09 -35.61 28.44 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.713 0.292 . . . . 0.0 111.192 177.697 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 14.4 t60 -84.55 -41.24 16.67 Favored 'General case' 0 N--CA 1.446 -0.674 0 CA-C-O 121.037 0.446 . . . . 0.0 109.966 -177.595 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 74.6 m -122.9 133.44 54.4 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.355 176.519 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -78.17 63.94 3.22 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 121.862 0.839 . . . . 0.0 110.086 179.47 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.411 HG21 HG23 ' A' ' 39' ' ' VAL . 7.1 p -94.85 149.57 4.42 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.883 0 CA-C-N 114.489 -1.232 . . . . 0.0 109.873 175.913 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 52.3 t0 -74.77 96.05 3.0 Favored 'General case' 0 C--O 1.234 0.268 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 178.093 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . 0.488 HD21 ' OE2' ' A' ' 41' ' ' GLU . 1.1 tm? -93.14 126.01 38.03 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 115.233 -0.894 . . . . 0.0 110.262 -173.379 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 41.7 t -125.85 119.61 55.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.043 -177.13 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . 0.535 HD23 ' HB2' ' A' ' 41' ' ' GLU . 12.7 mt -96.48 148.99 22.24 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 116.175 -0.466 . . . . 0.0 109.97 178.601 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.525 HG22 ' HB ' ' A' ' 75' ' ' VAL . 15.3 p -134.48 127.8 32.16 Favored 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 110.566 -0.161 . . . . 0.0 110.566 176.827 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 3.4 t70 -163.4 175.61 10.63 Favored 'General case' 0 N--CA 1.464 0.236 0 N-CA-C 110.062 -0.347 . . . . 0.0 110.062 -178.619 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 48.9 mm -88.5 107.84 18.12 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 116.652 -0.249 . . . . 0.0 110.398 -178.62 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 55.0 mtmt 60.11 90.0 0.1 OUTLIER Pre-proline 0 N--CA 1.466 0.329 0 O-C-N 123.674 0.608 . . . . 0.0 111.118 -177.987 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . 0.992 ' HB3' ' HB ' ' A' ' 74' ' ' ILE . 32.9 Cg_endo -66.25 141.6 63.39 Favored 'Trans proline' 0 C--O 1.233 0.268 0 C-N-CA 123.127 2.551 . . . . 0.0 113.177 -177.462 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 14.8 m -95.09 -14.78 23.93 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.693 -0.685 . . . . 0.0 110.444 175.923 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 89.7 m-70 -124.33 150.52 45.38 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.354 -179.211 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -77.42 57.59 3.73 Favored Glycine 0 CA--C 1.52 0.348 0 C-N-CA 121.421 -0.418 . . . . 0.0 112.924 179.925 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -157.85 8.12 0.2 Allowed Glycine 0 N--CA 1.449 -0.474 0 N-CA-C 111.397 -0.681 . . . . 0.0 111.397 177.373 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.992 ' HB ' ' HB3' ' A' ' 69' ' ' PRO . 40.3 mt -117.44 134.44 61.02 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 -177.78 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.617 HG11 HD13 ' A' ' 86' ' ' ILE . 55.8 t -78.12 131.17 35.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 176.959 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' ARG . . . . . 0.423 ' HA ' ' HD3' ' A' ' 69' ' ' PRO . 36.2 ptt180 -82.88 29.49 0.46 Allowed 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.762 -0.654 . . . . 0.0 111.939 -175.902 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 31.9 t0 -84.02 160.42 21.0 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 110.024 -0.362 . . . . 0.0 110.024 -178.944 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -79.61 104.02 9.92 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-O 120.849 0.357 . . . . 0.0 110.268 -177.646 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . 0.549 HD11 ' CG1' ' A' ' 42' ' ' VAL . 12.8 tt -57.67 -23.33 19.98 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.501 0 CA-C-N 115.692 -0.685 . . . . 0.0 112.478 -176.379 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 5.1 t -87.9 -6.56 58.01 Favored 'General case' 0 CA--C 1.539 0.534 0 CA-C-O 121.141 0.496 . . . . 0.0 110.869 -178.1 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 32.9 t -154.63 60.09 2.64 Favored Pre-proline 0 C--N 1.328 -0.336 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 178.177 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.794 ' HB2' ' HE2' ' A' ' 87' ' ' TYR . 84.3 Cg_endo -79.24 155.34 25.4 Favored 'Trans proline' 0 N--CA 1.461 -0.405 0 C-N-CA 122.676 2.251 . . . . 0.0 113.784 -166.01 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' ARG . . . . . 0.858 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 94.1 mtt180 -76.28 132.99 40.17 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.11 -0.95 . . . . 0.0 110.995 177.929 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' MET . . . . . . . . . . . . . 87.5 mmm -70.77 -22.42 62.39 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.119 176.812 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.858 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 10.3 pt-20 -66.0 -13.93 60.74 Favored 'General case' 0 CA--C 1.532 0.282 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.823 179.865 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.617 HD13 HG11 ' A' ' 75' ' ' VAL . 66.7 mt -93.25 -40.02 11.51 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-O 121.06 0.457 . . . . 0.0 110.846 -179.346 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . 0.794 ' HE2' ' HB2' ' A' ' 82' ' ' PRO . 99.0 m-85 -80.04 -28.76 39.25 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.322 -176.872 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 30.5 mtt-85 -61.7 120.75 11.24 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 121.045 0.45 . . . . 0.0 111.222 179.598 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 109.39 -2.44 31.0 Favored Glycine 0 N--CA 1.446 -0.637 0 CA-C-N 115.607 -0.724 . . . . 0.0 111.872 -177.896 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . 0.544 ' HA ' ' HB2' ' A' ' 38' ' ' ARG . . . -90.5 143.16 27.02 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.738 0.304 . . . . 0.0 110.594 178.162 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -88.52 -28.02 21.06 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.624 -179.505 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . 0.529 ' HG ' ' HB3' ' A' ' 116' ' ' ARG . 6.8 tt -149.5 143.14 25.45 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.052 -177.019 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.578 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 68.0 mt -133.36 119.42 35.02 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 N-CA-C 109.432 -0.581 . . . . 0.0 109.432 178.36 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' TYR . . . . . 0.443 ' CD1' HD13 ' A' ' 29' ' ' ILE . 47.7 p90 -124.58 158.59 32.65 Favored 'General case' 0 C--N 1.321 -0.664 0 C-N-CA 120.219 -0.593 . . . . 0.0 110.823 177.976 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 14.2 m -126.62 125.98 42.83 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.795 -0.638 . . . . 0.0 110.715 -176.847 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' ILE . . . . . . . . . . . . . 54.2 mt -94.52 97.13 6.55 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.089 -179.672 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . 0.434 HH11 ' HD3' ' A' ' 97' ' ' ARG . 7.7 ttm180 59.91 73.46 0.65 Allowed Pre-proline 0 CA--C 1.533 0.295 0 CA-C-N 115.494 -0.776 . . . . 0.0 110.87 -179.028 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_endo -85.64 137.71 5.87 Favored 'Trans proline' 0 N--CA 1.458 -0.57 0 C-N-CA 122.529 2.153 . . . . 0.0 112.775 -179.302 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 32.8 Cg_endo -67.36 163.05 36.06 Favored 'Trans proline' 0 C--O 1.234 0.307 0 C-N-CA 122.685 2.256 . . . . 0.0 112.182 175.441 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -85.61 36.21 0.64 Allowed 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.959 -177.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 101' ' ' GLU . . . . . 0.463 ' HG3' HG23 ' A' ' 102' ' ' ILE . 11.7 pt-20 -117.63 -10.96 10.48 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 121.156 0.503 . . . . 0.0 110.47 175.482 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.581 ' O ' ' HG ' ' A' ' 106' ' ' LEU . 20.8 pt -129.49 9.11 2.48 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.96 -178.184 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 103' ' ' HIS . . . . . . . . . . . . . 8.8 p-80 -55.28 -56.39 20.62 Favored 'General case' 0 C--N 1.316 -0.851 0 CA-C-N 115.505 -0.771 . . . . 0.0 112.31 -174.969 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 31.5 t -76.23 -26.16 55.77 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 121.112 0.482 . . . . 0.0 109.999 179.128 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.556 ' O ' HG23 ' A' ' 109' ' ' VAL . 6.5 m -66.21 -42.73 88.33 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.204 -178.433 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.641 HD21 HG11 ' A' ' 42' ' ' VAL . 82.2 mt -61.32 -41.49 97.1 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.838 -0.619 . . . . 0.0 111.259 179.205 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 107' ' ' MET . . . . . 0.493 ' SD ' ' HB3' ' A' ' 131' ' ' ARG . 45.5 mtp -65.29 -42.01 93.55 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.229 -178.926 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 16.7 ptm180 -73.32 -22.94 60.21 Favored 'General case' 0 C--N 1.332 -0.183 0 C-N-CA 120.976 -0.29 . . . . 0.0 111.462 -178.907 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.556 HG23 ' O ' ' A' ' 105' ' ' SER . 73.2 t -76.15 -46.46 33.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 N-CA-C 110.235 -0.283 . . . . 0.0 110.235 175.573 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -57.18 -50.16 73.7 Favored 'General case' 0 CA--C 1.517 -0.324 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.022 176.46 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.45 ' HA ' ' HB1' ' A' ' 148' ' ' ALA . 16.3 t70 -59.54 -34.16 72.31 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.459 -0.791 . . . . 0.0 111.038 -178.565 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -70.73 -46.46 63.0 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.837 -178.708 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 33.6 m -84.67 -27.88 6.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 C-N-CA 121.0 -0.28 . . . . 0.0 111.624 -176.127 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 93.41 38.05 5.43 Favored Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 120.697 -0.764 . . . . 0.0 112.475 179.548 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -114.14 149.82 35.07 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.039 0.447 . . . . 0.0 111.093 -179.059 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 116' ' ' ARG . . . . . 0.529 ' HB3' ' HG ' ' A' ' 92' ' ' LEU . 19.8 ttt180 -71.38 116.17 11.39 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.725 -0.67 . . . . 0.0 109.803 179.321 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . 0.578 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 62.2 tp -88.53 120.43 29.9 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 116.034 -0.53 . . . . 0.0 109.968 -179.517 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 71.0 mt -121.52 114.94 44.99 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 CA-C-O 121.16 0.505 . . . . 0.0 110.363 179.233 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 51.0 mt -112.77 121.27 64.73 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.761 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.55 -179.379 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 120' ' ' LYS . . . . . 0.404 ' C ' ' HD3' ' A' ' 120' ' ' LYS . 1.6 tmtp? -109.99 95.33 20.51 Favored Pre-proline 0 C--N 1.322 -0.614 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 173.503 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 121' ' ' PRO . . . . . 0.428 ' HB2' ' HB3' ' A' ' 125' ' ' GLU . 88.7 Cg_endo -89.02 -161.95 0.12 Allowed 'Trans proline' 0 N--CA 1.454 -0.839 0 C-N-CA 122.998 2.465 . . . . 0.0 112.244 179.997 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 122' ' ' LEU . . . . . 0.882 ' HB2' ' HB2' ' A' ' 125' ' ' GLU . 10.3 mp -83.53 168.14 16.72 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.987 -0.552 . . . . 0.0 110.391 179.65 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 3.9 m -59.91 -32.05 70.39 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.546 -176.86 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -125.43 38.84 2.19 Favored Glycine 0 N--CA 1.452 -0.245 0 C-N-CA 120.711 -0.756 . . . . 0.0 111.844 177.756 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . 0.882 ' HB2' ' HB2' ' A' ' 122' ' ' LEU . 6.0 tp10 -110.5 118.01 35.11 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 120.696 0.284 . . . . 0.0 110.267 -176.104 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -84.69 167.77 15.87 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.137 0.494 . . . . 0.0 111.014 179.007 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.422 ' O ' ' HB ' ' A' ' 128' ' ' VAL . 85.7 mt -92.15 -26.47 4.91 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 CA-C-N 115.609 -0.723 . . . . 0.0 110.55 -178.407 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.422 ' HB ' ' O ' ' A' ' 127' ' ' ILE . 91.2 t 75.57 -40.1 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.471 0.582 0 C-N-CA 123.022 0.529 . . . . 0.0 110.562 178.912 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 15.3 m -56.25 -48.32 76.77 Favored 'General case' 0 N--CA 1.444 -0.748 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.277 171.282 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 19.7 mm-40 58.9 19.66 7.29 Favored 'General case' 0 CA--C 1.533 0.307 0 CA-C-N 115.068 -0.969 . . . . 0.0 111.67 178.145 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 131' ' ' ARG . . . . . 0.493 ' HB3' ' SD ' ' A' ' 107' ' ' MET . 52.3 ttt180 -76.21 161.86 28.44 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 109.349 -0.611 . . . . 0.0 109.349 177.388 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 132' ' ' LYS . . . . . 0.63 ' HD3' ' H ' ' A' ' 132' ' ' LYS . 0.0 OUTLIER -48.2 115.1 1.08 Allowed 'General case' 0 N--CA 1.465 0.313 0 CA-C-O 121.134 0.492 . . . . 0.0 112.024 -179.087 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 133' ' ' MET . . . . . 0.512 ' HG2' ' HB2' ' A' ' 146' ' ' TYR . 86.0 mtp -148.46 162.19 40.11 Favored 'General case' 0 C--N 1.314 -0.949 0 N-CA-C 107.994 -1.113 . . . . 0.0 107.994 173.272 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . 0.565 ' HG3' ' HG2' ' A' ' 145' ' ' GLU . 13.1 ptmm? -126.36 133.1 51.42 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-O 120.956 0.408 . . . . 0.0 111.21 -176.899 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . 0.775 HD11 ' HD2' ' A' ' 142' ' ' TYR . 55.6 tp -84.38 121.16 27.16 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.023 -179.662 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -116.77 149.98 18.87 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.598 -177.334 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 10.5 m120 -116.29 125.82 52.7 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 177.584 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 34.4 t80 -138.27 130.79 29.18 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 109.565 -0.532 . . . . 0.0 109.565 176.239 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 72.03 -87.75 0.48 Allowed Glycine 0 N--CA 1.443 -0.837 0 N-CA-C 110.681 -0.967 . . . . 0.0 110.681 -174.428 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 140' ' ' ARG . . . . . 0.72 ' NE ' ' HA ' ' A' ' 140' ' ' ARG . 2.0 mmp_? -156.53 14.61 0.3 Allowed 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.423 -0.388 . . . . 0.0 110.75 174.346 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 11.2 t -113.98 154.95 26.75 Favored 'General case' 0 N--CA 1.448 -0.57 0 CA-C-N 116.33 -0.395 . . . . 0.0 109.948 179.035 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 142' ' ' TYR . . . . . 0.775 ' HD2' HD11 ' A' ' 135' ' ' LEU . 14.7 p90 -122.86 138.11 54.75 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 121.042 0.449 . . . . 0.0 110.36 -179.875 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 143' ' ' PHE . . . . . 0.423 ' O ' HD12 ' A' ' 135' ' ' LEU . 12.4 p90 -146.85 162.34 38.85 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-N 115.562 -0.745 . . . . 0.0 110.146 -177.238 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 96.3 m-85 -101.04 122.53 43.71 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 116.429 -0.351 . . . . 0.0 110.294 -179.447 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 145' ' ' GLU . . . . . 0.565 ' HG2' ' HG3' ' A' ' 134' ' ' LYS . 11.5 pt-20 -113.37 156.77 22.84 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 121.086 0.47 . . . . 0.0 110.036 177.522 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . 0.512 ' HB2' ' HG2' ' A' ' 133' ' ' MET . 41.7 t80 -141.91 124.47 15.83 Favored 'General case' 0 C--N 1.314 -0.969 0 CA-C-N 115.493 -0.776 . . . . 0.0 109.659 176.833 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 147' ' ' ILE . . . . . 0.409 ' N ' HD12 ' A' ' 147' ' ' ILE . 3.7 mp -93.0 101.37 12.55 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.88 0 N-CA-C 109.596 -0.52 . . . . 0.0 109.596 -177.63 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . 0.45 ' HB1' ' HA ' ' A' ' 111' ' ' ASP . . . -69.91 108.59 4.07 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 108.57 -0.9 . . . . 0.0 108.57 172.717 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 40.6 mt-10 -64.5 133.82 53.2 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 122.04 0.924 . . . . 0.0 112.424 -170.762 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 23.0 t -103.91 145.48 12.75 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.884 0 CA-C-N 113.888 -1.506 . . . . 0.0 109.614 179.666 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 151' ' ' ARG . . . . . . . . . . . . . 26.8 mmm180 -61.05 159.99 10.74 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 121.148 0.499 . . . . 0.0 110.898 176.729 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 1.1 p -73.2 141.2 47.34 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.553 -177.735 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.249 1.028 0 CA-C-O 118.507 -0.759 . . . . 0.0 109.426 177.067 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.479 0.983 0 CA-C-O 121.004 0.43 . . . . 0.0 110.185 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -102.98 96.81 1.41 Allowed Glycine 0 N--CA 1.448 -0.564 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.527 -176.52 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 31.4 t -85.05 136.72 33.45 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 176.401 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 31.9 p -137.65 174.4 10.62 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.662 -0.245 . . . . 0.0 110.77 -177.209 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 66.6 m-70 -80.1 121.72 25.89 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 121.009 0.433 . . . . 0.0 110.577 -178.314 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 17.7 p80 -97.47 13.52 29.57 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-O 121.265 0.555 . . . . 0.0 110.509 179.591 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 66.4 m80 -75.68 104.4 6.21 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.617 -179.188 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 51.0 p-80 -83.81 149.77 26.2 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.456 -0.338 . . . . 0.0 110.325 177.946 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 36.8 m80 -97.54 89.81 4.81 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.432 -177.908 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 29.4 p-80 -62.04 -46.94 86.95 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.036 177.52 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 5.1 t 57.87 23.24 9.52 Favored 'General case' 0 CA--C 1.532 0.264 0 CA-C-N 115.749 -0.66 . . . . 0.0 111.249 174.47 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 5.2 p -94.01 109.4 21.14 Favored 'General case' 0 N--CA 1.448 -0.526 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.102 -177.638 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -76.53 127.39 8.63 Favored Glycine 0 N--CA 1.445 -0.732 0 C-N-CA 120.696 -0.764 . . . . 0.0 111.358 175.396 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . 0.47 HD12 ' HE2' ' A' ' 56' ' ' LYS . 88.3 mt -67.07 140.44 57.62 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.739 0.304 . . . . 0.0 110.698 -178.484 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.453 ' HA ' ' HD3' ' A' ' 16' ' ' PRO . 33.2 m -58.85 149.04 66.78 Favored Pre-proline 0 C--N 1.326 -0.456 0 CA-C-N 115.368 -0.833 . . . . 0.0 112.816 -172.855 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.453 ' HD3' ' HA ' ' A' ' 15' ' ' VAL . 3.7 Cg_exo -77.62 128.18 9.29 Favored 'Trans proline' 0 N--CA 1.457 -0.666 0 C-N-CA 123.036 2.491 . . . . 0.0 110.504 169.65 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 0.652 ' HD3' ' O ' ' A' ' 17' ' ' ARG . 0.0 OUTLIER -100.13 102.68 14.06 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-O 121.17 0.51 . . . . 0.0 111.547 -172.696 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 67.32 5.25 34.31 Favored Glycine 0 CA--C 1.518 0.273 0 CA-C-N 115.787 -0.642 . . . . 0.0 113.085 176.252 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . 0.535 ' O ' ' HB2' ' A' ' 23' ' ' ASN . 19.5 p -97.41 101.15 12.62 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-O 120.816 0.341 . . . . 0.0 110.583 -178.35 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 30.4 m80 -111.92 -63.64 1.39 Allowed 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 177.467 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' MET . . . . . . . . . . . . . 15.6 tmm? -73.52 -36.36 65.71 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.836 -0.62 . . . . 0.0 109.784 175.247 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 95.4 m95 -72.08 -19.39 61.82 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.899 -0.591 . . . . 0.0 110.677 177.164 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.535 ' HB2' ' O ' ' A' ' 19' ' ' SER . 2.7 t-20 -68.26 -37.74 81.06 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.205 -179.555 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.427 ' HB3' ' HD2' ' A' ' 138' ' ' TYR . 44.0 m-20 -61.61 -43.28 99.16 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.279 -0.418 . . . . 0.0 110.389 179.392 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.51 HD22 ' HD3' ' A' ' 120' ' ' LYS . 61.9 tp -58.16 -50.07 74.78 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.305 178.241 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -55.76 -51.78 66.22 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.876 179.049 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.435 HG23 ' O ' ' A' ' 23' ' ' ASN . 96.7 t -57.04 -43.89 81.93 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.194 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.221 179.42 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 52.2 t80 -58.18 -48.63 79.71 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.861 0.363 . . . . 0.0 110.265 178.684 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.402 HG13 ' O ' ' A' ' 25' ' ' LEU . 81.7 mt -60.81 -42.67 93.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.486 178.904 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.429 HD13 ' CD2' ' A' ' 57' ' ' HIS . 90.8 mt -58.15 -41.86 81.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.123 179.118 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 63.0 mtp180 -69.05 -35.07 76.16 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.076 0.465 . . . . 0.0 111.295 -179.654 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.421 ' SG ' HD12 ' A' ' 92' ' ' LEU . 48.3 t -81.37 -25.95 35.88 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.98 -0.555 . . . . 0.0 111.512 -175.509 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 20.8 p -93.56 -81.93 0.36 Allowed 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 111.851 0.315 . . . . 0.0 111.851 -174.92 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.416 ' O ' HG22 ' A' ' 37' ' ' THR . . . 107.22 168.19 22.12 Favored Glycine 0 N--CA 1.449 -0.476 0 N-CA-C 111.384 -0.686 . . . . 0.0 111.384 -175.158 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 71.0 Cg_endo -76.77 145.96 26.1 Favored 'Trans proline' 0 N--CA 1.464 -0.26 0 C-N-CA 122.32 2.013 . . . . 0.0 112.801 -178.769 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 91.75 -20.34 42.64 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.876 -0.678 . . . . 0.0 113.602 175.22 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . 0.416 HG22 ' O ' ' A' ' 34' ' ' GLY . 14.7 t -92.06 178.85 5.75 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 117.115 0.457 . . . . 0.0 110.011 -179.08 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' ARG . . . . . 0.503 ' HA ' ' O ' ' A' ' 61' ' ' ASP . 0.1 OUTLIER -111.81 136.06 51.59 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-O 120.967 0.413 . . . . 0.0 111.351 -176.239 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.402 HG23 HG21 ' A' ' 60' ' ' VAL . 62.3 t -126.22 117.27 48.15 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 N-CA-C 108.997 -0.742 . . . . 0.0 108.997 173.836 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.533 HG22 ' HB ' ' A' ' 63' ' ' VAL . 40.9 t -103.13 128.86 55.73 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-O 120.999 0.428 . . . . 0.0 111.703 -173.176 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . 0.631 ' HB3' HD23 ' A' ' 64' ' ' LEU . 21.7 tp10 -105.22 127.41 52.91 Favored 'General case' 0 C--O 1.24 0.569 0 CA-C-N 115.606 -0.724 . . . . 0.0 109.991 174.377 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.473 ' HB ' ' OG ' ' A' ' 95' ' ' SER . 59.0 t -93.57 89.95 2.79 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 CA-C-N 115.976 -0.557 . . . . 0.0 110.235 179.816 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 121.18 120.83 2.75 Favored Glycine 0 N--CA 1.443 -0.837 0 CA-C-N 115.662 -0.699 . . . . 0.0 111.505 -175.201 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.598 ' HB1' HD21 ' A' ' 48' ' ' LEU . . . -110.59 -57.98 2.15 Favored 'General case' 0 C--N 1.321 -0.668 0 O-C-N 122.399 -0.471 . . . . 0.0 111.047 -177.198 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 52.72 -118.67 8.21 Favored Glycine 0 CA--C 1.519 0.317 0 C-N-CA 121.085 -0.579 . . . . 0.0 112.693 -178.707 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 65.2 mtp180 -134.52 14.61 3.74 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.827 0.346 . . . . 0.0 111.264 -179.669 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 21.8 p90 -103.52 35.19 2.67 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.369 0.604 . . . . 0.0 110.553 -178.298 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.598 HD21 ' HB1' ' A' ' 44' ' ' ALA . 94.5 mt -76.13 13.43 0.9 Allowed 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.484 -0.78 . . . . 0.0 112.569 -173.963 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 42.2 p90 -67.62 -26.45 66.25 Favored 'General case' 0 C--N 1.324 -0.509 0 C-N-CA 120.713 -0.395 . . . . 0.0 110.454 177.02 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.419 ' O ' HG13 ' A' ' 54' ' ' ILE . 54.0 t -68.72 -54.5 20.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.439 176.407 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . 0.402 ' HA ' HD13 ' A' ' 62' ' ' LEU . 7.3 p -62.51 -46.78 86.85 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.847 -176.134 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -70.66 -27.55 64.13 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.569 -176.328 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 82.9 t80 -68.74 -46.65 68.33 Favored 'General case' 0 C--N 1.328 -0.346 0 C-N-CA 120.783 -0.367 . . . . 0.0 110.443 176.291 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.419 HG13 ' O ' ' A' ' 50' ' ' VAL . 77.9 mt -59.15 -45.79 92.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.385 -176.824 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 6.9 ptp180 -71.76 -16.48 62.2 Favored 'General case' 0 C--O 1.236 0.39 0 CA-C-O 120.893 0.378 . . . . 0.0 111.499 -179.111 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . 0.47 ' HE2' HD12 ' A' ' 14' ' ' LEU . 8.3 mtpm? -83.7 -21.8 32.24 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.861 0.362 . . . . 0.0 111.566 177.618 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . 0.429 ' CD2' HD13 ' A' ' 30' ' ' ILE . 11.8 t60 -103.16 -43.02 5.58 Favored 'General case' 0 N--CA 1.445 -0.69 0 CA-C-O 121.01 0.433 . . . . 0.0 109.863 -178.143 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 9.1 t -120.09 144.08 47.8 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 109.202 -0.666 . . . . 0.0 109.202 178.336 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . 0.452 ' HD3' ' HA ' ' A' ' 59' ' ' LYS . 6.1 tppt? -89.25 58.15 4.34 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 122.11 0.957 . . . . 0.0 110.332 -179.459 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.402 HG21 HG23 ' A' ' 39' ' ' VAL . 7.6 p -94.97 145.53 8.02 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.817 0 CA-C-N 114.41 -1.268 . . . . 0.0 109.677 175.564 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . 0.503 ' O ' ' HA ' ' A' ' 38' ' ' ARG . 25.6 t70 -84.62 93.46 8.39 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 179.278 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . 0.402 HD13 ' HA ' ' A' ' 51' ' ' SER . 4.6 tt -89.86 120.17 30.87 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.67 -176.192 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.533 ' HB ' HG22 ' A' ' 40' ' ' VAL . 47.8 t -103.91 122.51 56.75 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.653 0 CA-C-N 115.674 -0.694 . . . . 0.0 110.493 -174.721 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . 0.631 HD23 ' HB3' ' A' ' 41' ' ' GLU . 41.6 mt -99.55 133.43 43.89 Favored 'General case' 0 C--N 1.316 -0.889 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 176.575 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.436 HG22 ' HB ' ' A' ' 75' ' ' VAL . 13.0 p -125.73 124.04 40.18 Favored 'General case' 0 C--N 1.317 -0.813 0 N-CA-C 110.048 -0.353 . . . . 0.0 110.048 176.544 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 39.2 t0 -170.36 172.01 6.34 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -175.712 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.671 HG22 ' HG2' ' A' ' 68' ' ' LYS . 26.0 mm -73.67 129.83 36.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.073 -179.709 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' LYS . . . . . 0.671 ' HG2' HG22 ' A' ' 67' ' ' ILE . 19.6 pttp 38.71 90.32 0.07 OUTLIER Pre-proline 0 N--CA 1.476 0.837 0 O-C-N 124.247 0.967 . . . . 0.0 113.278 178.933 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . 0.958 ' HB3' ' HB ' ' A' ' 74' ' ' ILE . 4.9 Cg_endo -48.39 137.58 24.79 Favored 'Trans proline' 0 C--N 1.346 0.395 0 C-N-CA 123.875 3.05 . . . . 0.0 113.202 179.534 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 4.7 m -122.6 20.6 10.26 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.895 -0.593 . . . . 0.0 111.065 -178.054 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 64.4 t60 -138.75 -89.07 0.22 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.808 0.337 . . . . 0.0 110.678 -175.389 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -164.71 -72.63 0.03 OUTLIER Glycine 0 N--CA 1.447 -0.61 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.002 -179.752 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -81.04 48.65 3.82 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 121.013 -0.613 . . . . 0.0 112.665 -179.884 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.958 ' HB ' ' HB3' ' A' ' 69' ' ' PRO . 56.1 mt -113.94 123.15 69.32 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.61 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 177.069 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.543 HG11 HD13 ' A' ' 86' ' ' ILE . 91.2 t -76.04 132.09 33.72 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 176.369 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 9.8 ptp180 -79.3 21.14 0.48 Allowed 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 120.987 0.422 . . . . 0.0 111.371 -175.967 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . 0.496 ' HB2' HG12 ' A' ' 75' ' ' VAL . 6.1 t70 -83.48 112.49 20.01 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 109.615 -0.513 . . . . 0.0 109.615 -176.385 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 10.7 p-10 -70.87 142.21 51.2 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 121.426 0.632 . . . . 0.0 111.444 -174.055 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . 0.404 HD13 HG13 ' A' ' 42' ' ' VAL . 6.9 tp -66.77 -21.95 29.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.367 -0.833 . . . . 0.0 112.345 -173.66 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 10.2 t -90.05 -0.54 57.64 Favored 'General case' 0 C--N 1.322 -0.626 0 C-N-CA 120.274 -0.571 . . . . 0.0 110.492 -178.801 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . 0.43 ' N ' ' HD3' ' A' ' 82' ' ' PRO . 4.9 m -148.24 46.58 0.46 Allowed Pre-proline 0 CA--C 1.538 0.505 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.883 177.421 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.457 ' HA ' ' OD2' ' A' ' 77' ' ' ASP . 93.3 Cg_endo -81.23 149.45 17.17 Favored 'Trans proline' 0 C--N 1.352 0.711 0 C-N-CA 122.287 1.992 . . . . 0.0 113.174 -169.01 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' ARG . . . . . 0.511 ' HB3' ' HG2' ' A' ' 85' ' ' GLU . 73.1 mtp85 -96.36 125.22 40.71 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.82 -0.627 . . . . 0.0 111.061 177.222 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' MET . . . . . 0.584 ' HE1' ' HA ' ' A' ' 109' ' ' VAL . 91.3 mmm -63.92 -20.02 65.54 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.678 -0.692 . . . . 0.0 111.296 -179.314 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.511 ' HG2' ' HB3' ' A' ' 83' ' ' ARG . 11.0 pt-20 -69.81 -16.65 63.31 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.506 -176.451 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.543 HD13 HG11 ' A' ' 75' ' ' VAL . 70.4 mt -85.23 -36.14 10.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 121.298 0.571 . . . . 0.0 109.963 178.154 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' TYR . . . . . . . . . . . . . 99.2 m-85 -80.59 -31.85 36.61 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.865 -178.73 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . 0.441 ' HG3' HG12 ' A' ' 113' ' ' VAL . 23.3 mtp85 -64.07 119.61 10.47 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-O 121.142 0.496 . . . . 0.0 110.795 179.259 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 115.65 -17.21 16.08 Favored Glycine 0 N--CA 1.444 -0.805 0 CA-C-N 115.44 -0.8 . . . . 0.0 111.557 -177.739 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -73.38 144.55 46.39 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.83 0.348 . . . . 0.0 110.769 179.052 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -88.94 -25.66 21.95 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 121.27 0.557 . . . . 0.0 110.142 178.093 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . 0.483 HD23 ' N ' ' A' ' 93' ' ' ILE . 4.7 tt -150.86 141.09 22.26 Favored 'General case' 0 N--CA 1.448 -0.559 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.409 -177.136 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' ILE . . . . . 0.548 ' O ' ' HA ' ' A' ' 117' ' ' LEU . 61.2 mt -130.58 128.14 63.06 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.187 177.226 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -136.88 169.69 17.35 Favored 'General case' 0 C--N 1.318 -0.781 0 C-N-CA 120.786 -0.366 . . . . 0.0 110.117 -179.074 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . 0.635 ' HB2' ' HG3' ' A' ' 98' ' ' PRO . 7.1 m -152.07 123.08 7.57 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.346 178.901 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 96' ' ' ILE . . . . . 0.748 HG22 ' HG2' ' A' ' 97' ' ' ARG . 2.3 mp -73.37 114.94 13.6 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-N 116.3 -0.409 . . . . 0.0 109.907 174.771 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . 0.748 ' HG2' HG22 ' A' ' 96' ' ' ILE . 13.6 ptt180 43.54 76.27 0.55 Allowed Pre-proline 0 N--CA 1.472 0.668 0 C-N-CA 124.376 1.071 . . . . 0.0 113.17 177.41 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 98' ' ' PRO . . . . . 0.635 ' HG3' ' HB2' ' A' ' 95' ' ' SER . 12.8 Cg_endo -90.07 146.54 4.52 Favored 'Trans proline' 0 N--CA 1.453 -0.909 0 C-N-CA 122.583 2.189 . . . . 0.0 111.889 175.689 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.526 ' HD2' HD11 ' A' ' 102' ' ' ILE . 32.2 Cg_exo -61.05 140.37 89.43 Favored 'Trans proline' 0 C--N 1.344 0.34 0 C-N-CA 122.492 2.128 . . . . 0.0 111.991 177.483 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -79.74 30.85 0.25 Allowed 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 121.101 0.477 . . . . 0.0 111.805 -174.871 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 101' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -122.2 -6.89 8.84 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.812 178.614 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.526 HD11 ' HD2' ' A' ' 99' ' ' PRO . 30.8 pt -120.25 8.53 6.37 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 120.907 0.384 . . . . 0.0 111.163 -179.021 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 103' ' ' HIS . . . . . 0.465 ' O ' ' HG2' ' A' ' 107' ' ' MET . 44.7 p-80 -60.82 -40.06 91.31 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.373 -177.149 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 23.3 m -61.75 -29.58 70.22 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.861 0.362 . . . . 0.0 111.016 178.749 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.547 ' O ' HG23 ' A' ' 109' ' ' VAL . 19.3 m -75.61 -38.29 59.13 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.079 178.518 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 94.5 mt -69.14 -41.7 76.98 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.953 179.6 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 107' ' ' MET . . . . . 0.465 ' HG2' ' O ' ' A' ' 103' ' ' HIS . 94.9 mmm -57.38 -47.53 81.44 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.804 -0.634 . . . . 0.0 111.535 -179.281 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 6.7 ptp85 -66.96 -31.74 72.51 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.578 -0.283 . . . . 0.0 111.608 -178.186 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.584 ' HA ' ' HE1' ' A' ' 84' ' ' MET . 76.3 t -66.7 -47.93 81.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 C-N-CA 121.115 -0.234 . . . . 0.0 110.897 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -57.98 -46.27 85.44 Favored 'General case' 0 CA--C 1.518 -0.286 0 CA-C-N 116.515 -0.311 . . . . 0.0 110.641 179.853 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 17.8 t70 -67.73 -36.21 80.16 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.783 -178.599 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -65.43 -43.25 91.06 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.65 -179.843 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.441 HG12 ' HG3' ' A' ' 88' ' ' ARG . 18.6 m -88.22 -30.09 5.46 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.537 -175.912 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 91.41 51.63 2.5 Favored Glycine 0 N--CA 1.448 -0.554 0 C-N-CA 120.596 -0.811 . . . . 0.0 112.15 -178.856 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -132.0 157.6 43.67 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.906 0.384 . . . . 0.0 110.879 -179.424 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 116' ' ' ARG . . . . . 0.674 ' HD3' ' OE1' ' A' ' 145' ' ' GLU . 12.5 ttm180 -78.58 123.22 26.86 Favored 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 109.569 -0.53 . . . . 0.0 109.569 177.163 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . 0.548 ' HA ' ' O ' ' A' ' 93' ' ' ILE . 57.3 tp -94.12 118.9 32.19 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 116.179 -0.464 . . . . 0.0 109.947 -179.553 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 118' ' ' ILE . . . . . . . . . . . . . 59.7 mt -114.39 115.06 48.45 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 CA-C-O 121.32 0.581 . . . . 0.0 110.807 179.654 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 53.5 mt -122.52 118.62 55.77 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.953 -179.249 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 120' ' ' LYS . . . . . 0.557 ' HB3' ' HB3' ' A' ' 143' ' ' PHE . 0.6 OUTLIER -118.81 101.74 50.11 Favored Pre-proline 0 C--N 1.319 -0.722 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 169.759 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 121' ' ' PRO . . . . . 0.53 ' HA ' ' HA ' ' A' ' 97' ' ' ARG . 96.6 Cg_endo -80.04 -161.95 0.17 Allowed 'Trans proline' 0 N--CA 1.461 -0.438 0 C-N-CA 122.902 2.401 . . . . 0.0 112.425 -176.658 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 122' ' ' LEU . . . . . 0.681 ' HB2' ' HB2' ' A' ' 125' ' ' GLU . 3.0 mm? -65.31 150.08 48.87 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.929 -0.578 . . . . 0.0 109.977 178.162 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 123' ' ' THR . . . . . . . . . . . . . 23.2 m -68.28 -25.82 65.35 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.119 -0.491 . . . . 0.0 112.005 -171.246 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -105.67 1.64 39.25 Favored Glycine 0 N--CA 1.453 -0.233 0 C-N-CA 120.095 -1.05 . . . . 0.0 112.694 -179.563 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . 0.681 ' HB2' ' HB2' ' A' ' 122' ' ' LEU . 1.6 mp0 -105.79 -170.28 1.71 Allowed 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.239 0.542 . . . . 0.0 111.401 -173.595 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 126' ' ' ASP . . . . . . . . . . . . . 16.8 t70 -143.99 171.53 14.13 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 115.147 -0.933 . . . . 0.0 108.846 179.18 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.557 ' HB ' HG22 ' A' ' 129' ' ' THR . 39.1 mt -88.83 -15.22 9.1 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-O 121.048 0.451 . . . . 0.0 110.24 179.655 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 48.9 t 73.82 -5.62 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.469 0.506 0 CA-C-O 121.346 0.593 . . . . 0.0 111.022 178.142 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . 0.557 HG22 ' HB ' ' A' ' 127' ' ' ILE . 8.8 t -71.01 153.07 42.93 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 174.964 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 130' ' ' GLU . . . . . . . . . . . . . 39.4 tt0 -60.19 -82.68 0.02 OUTLIER 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.819 -179.025 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 131' ' ' ARG . . . . . 0.414 HH11 ' HD2' ' A' ' 131' ' ' ARG . 0.0 OUTLIER -169.09 84.99 0.15 Allowed 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 175.561 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 132' ' ' LYS . . . . . . . . . . . . . 30.8 mmmt -121.16 -15.92 8.09 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 115.245 -0.889 . . . . 0.0 110.1 -178.467 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 133' ' ' MET . . . . . 0.516 ' HG2' ' HB2' ' A' ' 146' ' ' TYR . 79.4 mtp -114.4 170.12 8.53 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.56 -0.746 . . . . 0.0 110.195 -176.311 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 134' ' ' LYS . . . . . 0.453 ' HG3' ' HG2' ' A' ' 145' ' ' GLU . 18.8 ptmt -121.75 134.07 54.93 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.815 -178.591 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . 0.539 HD11 ' HD2' ' A' ' 142' ' ' TYR . 60.0 tp -82.75 122.39 28.12 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 120.932 0.396 . . . . 0.0 110.537 178.223 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -118.16 147.04 21.87 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.355 179.84 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 13.4 m120 -124.18 96.94 5.12 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 109.416 -0.587 . . . . 0.0 109.416 -179.666 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . 0.427 ' HD2' ' HB3' ' A' ' 24' ' ' ASP . 64.1 t80 -104.42 109.1 20.83 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.272 -175.172 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 72.71 -82.08 0.61 Allowed Glycine 0 N--CA 1.45 -0.392 0 CA-C-N 115.768 -0.651 . . . . 0.0 111.832 179.875 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 140' ' ' ARG . . . . . 0.406 ' HD3' ' HA ' ' A' ' 140' ' ' ARG . 16.3 mmt180 -141.36 -7.43 1.01 Allowed 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 115.477 -0.362 . . . . 0.0 111.109 177.08 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 3.4 t -99.17 135.82 40.03 Favored 'General case' 0 N--CA 1.446 -0.637 0 CA-C-O 121.279 0.561 . . . . 0.0 110.083 -179.229 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 142' ' ' TYR . . . . . 0.539 ' HD2' HD11 ' A' ' 135' ' ' LEU . 27.0 p90 -114.06 144.22 43.48 Favored 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 176.193 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 143' ' ' PHE . . . . . 0.557 ' HB3' ' HB3' ' A' ' 120' ' ' LYS . 23.7 p90 -157.25 162.77 39.24 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.556 -178.854 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 144' ' ' TYR . . . . . . . . . . . . . 87.1 m-85 -100.93 118.3 36.69 Favored 'General case' 0 C--N 1.314 -0.949 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 175.177 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 145' ' ' GLU . . . . . 0.674 ' OE1' ' HD3' ' A' ' 116' ' ' ARG . 11.5 pt-20 -110.0 155.17 22.15 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-O 121.321 0.581 . . . . 0.0 109.695 178.701 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . 0.516 ' HB2' ' HG2' ' A' ' 133' ' ' MET . 32.4 t80 -137.39 123.81 20.76 Favored 'General case' 0 C--N 1.307 -1.259 0 CA-C-N 115.498 -0.774 . . . . 0.0 109.382 176.493 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 147' ' ' ILE . . . . . 0.444 ' N ' HD12 ' A' ' 147' ' ' ILE . 3.3 mp -94.36 103.79 15.07 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.799 0 CA-C-N 116.111 -0.495 . . . . 0.0 109.932 -177.621 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -68.37 119.3 12.66 Favored 'General case' 0 N--CA 1.443 -0.783 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 171.358 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 -63.08 155.81 26.74 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 121.121 0.486 . . . . 0.0 110.3 -177.363 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 16.3 t -70.09 122.95 22.85 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.788 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.938 -170.401 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 151' ' ' ARG . . . . . . . . . . . . . 27.7 mmm180 -78.71 150.38 32.54 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-N 115.025 -0.989 . . . . 0.0 109.132 -179.909 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 50.0 m -71.08 91.15 0.89 Allowed 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.277 0.561 . . . . 0.0 111.36 -176.706 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 2.8 tmt_? . . . . . 0 C--O 1.249 1.056 0 CA-C-O 118.196 -0.907 . . . . 0.0 109.184 176.282 . . . . . . . . 0 0 . 1 stop_ save_